PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sponne, I; Fifre, A; Kriem, B; Koziel, V; Bihain, B; Oster, T; Olivier, JL; Pillot, T				Sponne, I; Fifre, A; Kriem, B; Koziel, V; Bihain, B; Oster, T; Olivier, JL; Pillot, T			Membrane cholesterol interferes with neuronal apoptosis induced by soluble oligomers but not fibrils of the amyloid-beta peptide	FASEB JOURNAL			English	Article						Alzheimer's disease; membrane fluidity; oxidative stress; cytoskeleton	PROTEIN TRANSGENIC MICE; C-TERMINAL DOMAIN; ALZHEIMERS-DISEASE; A-BETA; DEPENDENT MODULATION; FUSOGENIC PROPERTIES; FIBRILLOGENESIS; ALPHA; NEURODEGENERATION; PHOSPHORYLATION	Neuronal cell death in Alzheimer's disease (AD) is partly induced by the interaction of the amyloid-P peptide (Abeta) with the plasma membrane of target cells. Accordingly, recent studies have suggested that cholesterol, an important component of membranes that controls their physical properties and functions, plays a critical role in neurodegenerative diseases. We report here that the enrichment of the neuronal plasma membrane with cholesterol protects cortical neurons from apoptosis induced by soluble oligomers of the Abeta(1-40) peptide. Conversely, cholesterol depletion using cyclodextrin renders cells more vulnerable to the cytotoxic effects of the Abeta-soluble oligomers. Increasing the cholesterol content of small unilamellar liposomes also decreases Abeta-dependent liposome fusion. We clearly demonstrate that cholesterol protection is specific to the soluble conformation of Abeta, because we observed no protective effects on cortical neurons treated by amyloid fibrils of the Abeta(1-40) peptide. This may provide a new opportunity for the development of an effective AD therapy as well as elucidate the impact of the cholesterol level during AD development.	Univ Nancy 1, INSERM, EMI 0014, F-54505 Vandoeuvre Les Nancy, France; Lab Med & Therapeut Mol, F-54505 Vandoeuvre Les Nancy, France; Univ Metz, EA3472, LIMBP, F-57000 Metz, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lorraine; Universite de Lorraine	Pillot, T (corresponding author), Univ Nancy 1, INSERM, EMI 0014, 9 Ave Foret Haye,BP 184, F-54505 Vandoeuvre Les Nancy, France.	Thierry.Pillot@bcmn.facmed.u-nancy.fr	Olivier, Jean luc/AAQ-2721-2021					Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; Arispe N, 2002, FASEB J, V16, P1526, DOI 10.1096/fj.02-0829com; BI X, 2001, SOC NEUR ABSTR, V27; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Curtain CC, 2003, J BIOL CHEM, V278, P2977, DOI 10.1074/jbc.M205455200; DEA D, 2001, SOC NEUR ABSTR, V27; Drouet B, 2000, CELL MOL LIFE SCI, V57, P705, DOI 10.1007/s000180050035; Drouet B, 2001, J NEUROCHEM, V76, P117, DOI 10.1046/j.1471-4159.2001.00047.x; Eckert GP, 2000, DEMENT GERIATR COGN, V11, P181, DOI 10.1159/000017234; Estus S, 1997, J NEUROSCI, V17, P7736; Fan QW, 2002, J NEUROCHEM, V80, P178, DOI 10.1046/j.0022-3042.2001.00686.x; Fan QW, 2001, J NEUROCHEM, V76, P391, DOI 10.1046/j.1471-4159.2001.00063.x; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; Favit A, 1998, P NATL ACAD SCI USA, V95, P5562, DOI 10.1073/pnas.95.10.5562; Gong JS, 2002, J NEUROSCI RES, V70, P438, DOI 10.1002/jnr.10347; Haley RW, 2000, ARCH NEUROL-CHICAGO, V57, P1410, DOI 10.1001/archneur.57.10.1410; Hartmann T, 2001, TRENDS NEUROSCI, V24, pS45, DOI 10.1016/S0166-2236(00)01990-1; HEIDER JG, 1978, J LIPID RES, V19, P514; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Inoue S, 1999, BRAIN RES REV, V29, P218, DOI 10.1016/S0165-0173(98)00055-1; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Jick H, 2000, LANCET, V356, P1627, DOI 10.1016/S0140-6736(00)03155-X; Kim HJ, 2002, FASEB J, V16, P118, DOI 10.1096/fj.01-0987fje; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Koistinaho M, 2002, P NATL ACAD SCI USA, V99, P1610, DOI 10.1073/pnas.032670899; Koistinaho M, 2001, P NATL ACAD SCI USA, V98, P14675, DOI 10.1073/pnas.261562998; Kojro E, 2001, P NATL ACAD SCI USA, V98, P5815, DOI 10.1073/pnas.081612998; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Launer LJ, 2001, NEUROLOGY, V57, P1447, DOI 10.1212/WNL.57.8.1447; Lin H, 2001, FASEB J, V15, P2433, DOI 10.1096/fj.01-0377com; Michikawa M, 2001, J NEUROSCI, V21, P7226, DOI 10.1523/JNEUROSCI.21-18-07226.2001; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Mudher A, 2002, TRENDS NEUROSCI, V25, P22, DOI 10.1016/S0166-2236(00)02031-2; Nilsberth C, 2001, NAT NEUROSCI, V4, P887, DOI 10.1038/nn0901-887; Pillot T, 1999, J NEUROCHEM, V73, P1626, DOI 10.1046/j.1471-4159.1999.0731626.x; Pillot T, 1996, J BIOL CHEM, V271, P28757, DOI 10.1074/jbc.271.46.28757; Pillot T, 1997, EUR J BIOCHEM, V243, P650, DOI 10.1111/j.1432-1033.1997.00650.x; Rhee SK, 1998, J BIOL CHEM, V273, P13379, DOI 10.1074/jbc.273.22.13379; Sawamura N, 2001, J BIOL CHEM, V276, P10314, DOI 10.1074/jbc.M009733200; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; Shogomori H, 2001, J NEUROCHEM, V78, P991, DOI 10.1046/j.1471-4159.2001.00489.x; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Sponne I, 2003, J BIOL CHEM, V278, P3437, DOI 10.1074/jbc.M206745200; Stuve O, 2003, CURR OPIN NEUROL, V16, P393, DOI 10.1097/01.wco.0000073942.19076.d1; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P1439, DOI 10.1001/archneur.57.10.1439; Wolozin B, 2001, P NATL ACAD SCI USA, V98, P5371, DOI 10.1073/pnas.101123198; Yankner BA, 1996, NEURON, V16, P921, DOI 10.1016/S0896-6273(00)80115-4; Yip CM, 2001, J MOL BIOL, V311, P723, DOI 10.1006/jmbi.2001.4881; Zhou Y, 1996, NEUROREPORT, V7, P2487	57	76	78	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					836	+		10.1096/fj.03-0372fje	http://dx.doi.org/10.1096/fj.03-0372fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001562				2022-12-28	WOS:000220522800027
J	Gonzales, C; Voirol, MJ; Giacomini, M; Gaillard, RC; Pedrazzini, T; Pralong, FP				Gonzales, C; Voirol, MJ; Giacomini, M; Gaillard, RC; Pedrazzini, T; Pralong, FP			The neuropeptide Y Y1 receptor mediates NPY-induced inhibition of the gonadotrope axis under poor metabolic conditions	FASEB JOURNAL			English	Article						feeding; puberty; reproduction; hypothalamus; leptin	AMPHETAMINE-REGULATED TRANSCRIPT; LUTEINIZING-HORMONE SECRETION; CONGENITAL LEPTIN DEFICIENCY; OBESE GENE-PRODUCT; NORMAL FEMALE MICE; LATERAL VENTRICLE; PARAVENTRICULAR NUCLEUS; SEXUAL-MATURATION; OB/OB MICE; PUBERTAL DEVELOPMENT	Hypothalamic neuropeptide Y (NPY) plays a central role in the control of food intake, energy balance, and modulation of neuroendocrine functions. In particular, an increase in NPY expression participates in the inhibition of the reproductive activity under poor nutritional conditions. The present study was designed to evaluate further the involvement of the Y1 subtype of NPY receptors in these effects. Food intake, body weight gain, and the onset of puberty were studied in groups of wild-type and Y1 deficient mice that were either fed ad libitum or subjected to a 30% restriction in food intake. This moderate feeding restriction induced a similar deficit in body weight gain in wild-type and in Y1 knockout mice. However, although wild-type mice experienced the expected delay of puberty, all mice in the food restriction group and lacking Y1 could go through puberty over the time of the experiment despite decreases in circulating leptin levels and increases in hypothalamic NPY expression. This observation demonstrates that the absence of Y1 impairs the perception of decreasing energy stores by the gonadotrope axis, demonstrating a physiological role for Y1 in the sensing of endogenous metabolic parameters by the hypothalamus.	Univ Hosp, Div Endocrinol Diabetol & Metab, CH-1011 Lausanne, Switzerland; Univ Hosp, Div Hypertens, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Pralong, FP (corresponding author), Univ Hosp, Div Endocrinol, CH-1011 Lausanne, Switzerland.	Francois.Pralong@chuv.hospvd.ch	Giacomini, Mauro/D-3194-2013	Giacomini, Mauro/0000-0001-5646-2034	Swiss national science foundation [32-00B0-100858/1]; Novartis Foundation	Swiss national science foundation(Swiss National Science Foundation (SNSF)European Commission); Novartis Foundation(Novartis)	This work was supported by grants from the Swiss national science foundation (#32-00B0-100858/1) and the Novartis Foundation. The authors wish to thank Michel L. Aubert for his precious comments and suggestions during the revision of the manuscript.	Adam CL, 2002, NEUROENDOCRINOLOGY, V75, P250, DOI 10.1159/000054716; Ahima RS, 1997, J CLIN INVEST, V99, P391, DOI 10.1172/JCI119172; Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; ALLEN YS, 1983, SCIENCE, V221, P877, DOI 10.1126/science.6136091; BAUERDANTOIN AC, 1993, ENDOCRINOLOGY, V133, P2413, DOI 10.1210/en.133.6.2413; Bergonzelli GE, 2001, DIABETES, V50, P2666, DOI 10.2337/diabetes.50.12.2666; Blomqvist AG, 1997, TRENDS NEUROSCI, V20, P294, DOI 10.1016/S0166-2236(96)01057-0; BRADY LS, 1990, NEUROENDOCRINOLOGY, V52, P441, DOI 10.1159/000125626; BRONSON FH, 1986, ENDOCRINOLOGY, V118, P2483, DOI 10.1210/endo-118-6-2483; Cabrele C, 2000, J PEPT SCI, V6, P97, DOI 10.1002/(SICI)1099-1387(200003)6:3<97::AID-PSC236>3.0.CO;2-E; Campbell RE, 2001, NEUROENDOCRINOLOGY, V74, P106, DOI 10.1159/000054676; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Chehab FE, 1996, NAT GENET, V12, P318, DOI 10.1038/ng0396-318; Chehab FF, 1997, SCIENCE, V275, P88, DOI 10.1126/science.275.5296.88; Cheung CC, 1997, ENDOCRINOLOGY, V138, P855, DOI 10.1210/en.138.2.855; Edwards CMB, 1999, J ENDOCRINOL, V160, pR7, DOI 10.1677/joe.0.160R007; El Majdoubi M, 2000, P NATL ACAD SCI USA, V97, P6179; Farooqi IS, 2002, J CLIN INVEST, V110, P1093, DOI 10.1172/JCI200215693; Fekete C, 2002, ENDOCRINOLOGY, V143, P4513, DOI 10.1210/en.2002-220574; GARTHWAITE TL, 1980, ENDOCRINOLOGY, V107, P671, DOI 10.1210/endo-107-3-671; Gehlert DR, 1998, P SOC EXP BIOL MED, V218, P7; GRUAZ NM, 1993, ENDOCRINOLOGY, V133, P1891, DOI 10.1210/en.133.4.1891; Gruaz NM, 1998, J NEUROENDOCRINOL, V10, P627, DOI 10.1046/j.1365-2826.1998.00247.x; HAAS DA, 1987, LIFE SCI, V41, P2725, DOI 10.1016/0024-3205(87)90465-6; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; HAMILTON GD, 1986, AM J PHYSIOL, V250, pR370, DOI 10.1152/ajpregu.1986.250.3.R370; Jain MR, 1999, ENDOCRINOLOGY, V140, P5171, DOI 10.1210/en.140.11.5171; KALRA SP, 1984, LIFE SCI, V35, P1173, DOI 10.1016/0024-3205(84)90187-5; KALRA SP, 1992, ENDOCRINOLOGY, V130, P3323, DOI 10.1210/en.130.6.3323; KALRA SP, 1991, P NATL ACAD SCI USA, V88, P10931, DOI 10.1073/pnas.88.23.10931; Lebrethon MC, 2000, ENDOCRINOLOGY, V141, P1464, DOI 10.1210/en.141.4.1464; Li C, 1999, ENDOCRINOLOGY, V140, P5382, DOI 10.1210/en.140.11.5382; MCDONALD JK, 1989, ENDOCRINOLOGY, V125, P186, DOI 10.1210/endo-125-1-186; MINAMI S, 1990, NEUROENDOCRINOLOGY, V52, P112, DOI 10.1159/000125548; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Parent AS, 2000, REGUL PEPTIDES, V92, P17, DOI 10.1016/S0167-0115(00)00144-0; Pedrazzini T, 1998, NAT MED, V4, P722, DOI 10.1038/nm0698-722; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PIERROZ DD, 1995, NEUROENDOCRINOLOGY, V61, P293, DOI 10.1159/000126851; Plant TM, 2001, FRONT NEUROENDOCRIN, V22, P107, DOI 10.1006/frne.2001.0211; Pralong FP, 2000, REGUL PEPTIDES, V95, P47, DOI 10.1016/S0167-0115(00)00130-0; Pralong FP, 2002, FASEB J, V16, P712, DOI 10.1096/fj.01-0754fje; Raposinho PD, 2000, NEUROENDOCRINOLOGY, V71, P2, DOI 10.1159/000054514; Raposinho PD, 2001, MOL CELL ENDOCRINOL, V185, P195, DOI 10.1016/S0303-7207(01)00620-7; Raposinho PD, 1999, ENDOCRINOLOGY, V140, P4046, DOI 10.1210/en.140.9.4046; SAHU A, 1987, PEPTIDES, V8, P921, DOI 10.1016/0196-9781(87)90081-7; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sainsbury A, 2001, PEPTIDES, V22, P467, DOI 10.1016/S0196-9781(01)00342-4; Sainsbury A, 2002, GENE DEV, V16, P1077, DOI 10.1101/gad.979102; SCHWARTZ MW, 1993, BRAIN RES BULL, V31, P361, DOI 10.1016/0361-9230(93)90228-4; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUTTON SW, 1988, ENDOCRINOLOGY, V123, P2152, DOI 10.1210/endo-123-4-2152; Toufexis DJ, 2002, J NEUROENDOCRINOL, V14, P492, DOI 10.1046/j.1365-2826.2002.00805.x; WADE GN, 1992, NEUROSCI BIOBEHAV R, V16, P235, DOI 10.1016/S0149-7634(05)80183-6; WAHLESTEDT C, 1987, BRAIN RES, V417, P33, DOI 10.1016/0006-8993(87)90176-4; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	58	36	39	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					137	139		10.1096/fj.03-0189fje	http://dx.doi.org/10.1096/fj.03-0189fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597564				2022-12-28	WOS:000188829300052
J	Hashikawa, T; Hooker, SW; Maj, JG; Knott-Craig, CJ; Takedachi, M; Murakami, S; Thompson, LF				Hashikawa, T; Hooker, SW; Maj, JG; Knott-Craig, CJ; Takedachi, M; Murakami, S; Thompson, LF			Regulation of adenosine receptor engagement by ecto-adenosine deaminase	FASEB JOURNAL			English	Article						CD26; cAMP; CD73	T-CELL-ACTIVATION; DIPEPTIDYL PEPTIDASE-IV; SURFACE EXPRESSION; HUMAN CD26; BINDING; LYMPHOCYTES; DEFICIENCY; CD73; PROTEIN; ASSOCIATION	Adenosine deaminase (ADA) can localize to the cell surface through its interaction with CD26. Using CD26-transfected cells, we demonstrate that cell surface ADA (ecto-ADA) can regulate adenosine receptor engagement by degrading extracellular adenosine (Ado) to inosine. This ability was dependent upon CD26 expression, the extent of CD26 saturation with ecto-ADA, and the kinetics of the cAMP response. Thus, the cAMP response was markedly decreased when CD26-transfected cells were incubated with an exogenous source of ADA to increase ecto-ADA expression. The ability of ecto-ADA to inhibit the cAMP response was demonstrated by treatment with the specific ADA inhibitor 2'-deoxycoformycin. This inhibited the ability of ecto-ADA to degrade Ado and increased the cAMP response. Although CD26 expression on human thymocytes was low compared with that of CD26-transfected cells, it was saturated with ecto-ADA. When thymocytes incubated at high densities (to mimic the situation in tissues) were exposed to exogenous adenosine, the cAMP response was dramatically decreased by ecto-ADA. We conclude that ecto-ADA has the potential to regulate adenosine receptor-mediated cAMP responses in vivo in tissues with CD26(+) cells and sufficient cell death caused by apoptosis or inflammation to provide a source of ADA to bind to CD26.	Oklahoma Med Res Fdn, Immunobiol & Canc Res Program, Oklahoma City, OK 73104 USA; Osaka Univ, Grad Sch Dent, Dept Periodontol, Suita, Osaka 5650871, Japan; Oklahoma Univ Hlth Sci Ctr, Dept Surg, Oklahoma City, OK USA	Oklahoma Medical Research Foundation; Osaka University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Thompson, LF (corresponding author), Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.	Linda-Thompson@omrf.ouhsc.edu	Takedachi, Masahide/GVS-6539-2022		NIH [AI18220, HD36044, AI45864]; Japan Society for the Promotion of Science [15659498]	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Michael Hershfield for human recombinant ADA and helpful discussions and Kerry Humphrey for manuscript preparation. This work was supported by NIH grants AI18220, HD36044, and AI45864 and grant No.15659498 from the Japan Society for the Promotion of Science. L.F.T. holds the Putnam City Schools Chair in Cancer Research.	ABBOTT CA, 1994, IMMUNOGENETICS, V40, P331, DOI 10.1007/BF01246674; AGARWAL RP, 1977, BIOCHEM PHARMACOL, V26, P359, DOI 10.1016/0006-2952(77)90192-7; BOSS GR, 1981, CLIN IMMUNOL IMMUNOP, V19, P1, DOI 10.1016/0090-1229(81)90042-8; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHECHIK BE, 1981, J IMMUNOL, V126, P1003; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; DANG NH, 1990, J IMMUNOL, V144, P4092; Dong RP, 1997, J IMMUNOL, V159, P6070; Dong RP, 1996, J IMMUNOL, V156, P1349; FOX RI, 1981, J IMMUNOL, V126, P2062; GIBLETT ER, 1972, LANCET, V2, P1067; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hasko G, 2000, FASEB J, V14, P2065, DOI 10.1096/fj.99-0508com; Hegen M, 1997, IMMUNOLOGY, V90, P257, DOI 10.1046/j.1365-2567.1997.00053.x; Herrera C, 2001, MOL PHARMACOL, V59, P127, DOI 10.1124/mol.59.1.127; IwakiEgawa S, 1997, CELL IMMUNOL, V178, P180, DOI 10.1006/cimm.1997.1123; KAMEOKA J, 1993, SCIENCE, V261, P466, DOI 10.1126/science.8101391; MA DDF, 1982, J IMMUNOL, V129, P1430; MARTIN M, 1993, CLIN EXP IMMUNOL, V93, P286; MARTIN M, 1995, J IMMUNOL, V155, P4630; Matsuoka I, 2002, MOL PHARMACOL, V61, P606, DOI 10.1124/mol.61.3.606; Morabito L, 1998, J CLIN INVEST, V101, P295, DOI 10.1172/JCI1554; MORRISON ME, 1993, J EXP MED, V177, P1135, DOI 10.1084/jem.177.4.1135; OLSSON RA, 1990, PHYSIOL REV, V70, P761, DOI 10.1152/physrev.1990.70.3.761; Oravecz T, 1997, J EXP MED, V186, P1865, DOI 10.1084/jem.186.11.1865; PALMER TM, 1995, NEUROPHARMACOLOGY, V34, P683, DOI 10.1016/0028-3908(95)00044-7; Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com; Proost P, 1998, FEBS LETT, V432, P73, DOI 10.1016/S0014-5793(98)00830-8; Proost P, 1998, J BIOL CHEM, V273, P7222, DOI 10.1074/jbc.273.13.7222; Ramkumar V, 1988, Prog Drug Res, V32, P195; RESTA R, 1994, J IMMUNOL, V153, P1046; Resta R, 1997, J CLIN INVEST, V99, P676, DOI 10.1172/JCI119211; Richard E, 2000, J EXP MED, V192, P1223, DOI 10.1084/jem.192.9.1223; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; STILES GL, 1992, J BIOL CHEM, V267, P6451; Strohmeier GR, 1997, J CLIN INVEST, V99, P2588, DOI 10.1172/JCI119447; VANDERWEYDEN MB, 1976, J BIOL CHEM, V251, P5448; Yamashita Y, 1998, EUR J IMMUNOL, V28, P2981, DOI 10.1002/(SICI)1521-4141(199810)28:10<2981::AID-IMMU2981>3.0.CO;2-D; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	40	50	51	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					131	133		10.1096/fj.03-0011fje	http://dx.doi.org/10.1096/fj.03-0011fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630704				2022-12-28	WOS:000188829300050
J	Iwanaga, Y; Gu, Y; Dieterle, T; Presotto, C; Del Soldato, P; Peterson, KL; Ongini, E; Condorelli, G; Ross, J				Iwanaga, Y; Gu, Y; Dieterle, T; Presotto, C; Del Soldato, P; Peterson, KL; Ongini, E; Condorelli, G; Ross, J			A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure	FASEB JOURNAL			English	Article						ACE inhibition; cardiomyopathy; cardiac function	CONVERTING ENZYME-INHIBITION; DEPENDENT PROTEIN-KINASE; CARDIOMYOPATHIC HAMSTERS; CONTRACTILE RESPONSE; VENTRICULAR MYOCYTES; ORGANIC NITRATES; ACE-INHIBITION; IN-VIVO; CGMP; NITROSYLATION	Nitric oxide (NO) production is known to be impaired in heart failure. A new compound (NCX 899), a NO-releasing derivative of enalapril was characterized, and its actions were evaluated in Bio 14.6 cardioMyopathic (CM) hamsters with heart failure. The hamsters were randomized to oral treatment for 4 weeks with vehicle (n=11), NCX 899 (NCX, 25 mg/kg, n=10), or enalapril (25 mg/kg, n=10). In the vehicle group, fractional shortening by echocardiography decreased (-23.6+/-2.0%) and LV end-diastolic dimension) increased (+10.9+/-1.0%), whereas fractional shortening increased (+17.5+/-4.4%) in NCX and was unchanged in the enalapril group (both P<0.01 vs. vehicle). End-diastolic dimension decreased only in NCX. LV contractility (LVdP/dt(max) and E-max) was significantly greater in NCX than in enalapril or vehicle, while relaxation (Tau) was shortened in both NCX and enalapril vs. vehicle. ACE activity was inhibited equally by NCX and enalapril in the CM hamster, and plasma nitrate levels were increased only in NCX (P<0.05 vs. enalapril and vehicle). In aortic strips endothelium-independent relaxation occurred only with NCX. The superior effects of NO-releasing enalapril (NCX) vs. enalapril alone to enhance vascular effects, increase LV contractility and prevent unfavorable remodeling and are consistent with vascular delivery of exogenous NO. NCX 899 may hold promise for the future treatment of heart failure.	Univ Calif San Diego, Dept Med, Inst Mol Med, La Jolla, CA 92093 USA; Nicox Res Inst, Bresso, MI, Italy; Univ Roma La Sapienza, Mol Cardiol Lab, I-00128 Rome, Italy	University of California System; University of California San Diego; Sapienza University Rome	Ross, J (corresponding author), Univ Calif San Diego, Dept Med, Inst Mol Med, 9500 Gilman Dr 0641, La Jolla, CA 92093 USA.	jross@ucsd.edu	Condorelli, Gerolama/AAC-3472-2022; Dieterle, Thomas/AAG-3619-2019; Dieterle, Thomas/CAA-2532-2022; Condorelli, Gianluigi/Q-6736-2017	Condorelli, Gerolama/0000-0003-0177-8829; Dieterle, Thomas/0000-0002-3740-1903; Condorelli, Gianluigi/0000-0003-0481-6843				Agnoletti L, 1999, CIRCULATION, V100, P1983, DOI 10.1161/01.CIR.100.19.1983; Barouch LA, 2002, NATURE, V416, P337, DOI 10.1038/416337a; Bastien NR, 1999, CARDIOVASC RES, V43, P77, DOI 10.1016/S0008-6363(99)00015-2; Brown NJ, 1998, CIRCULATION, V97, P1411, DOI 10.1161/01.CIR.97.14.1411; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Cohn RD, 2001, J CLIN INVEST, V107, pR1, DOI 10.1172/JCI11642; Elkayam U, 1999, CIRCULATION, V99, P2652, DOI 10.1161/01.CIR.99.20.2652; ELKAYAM U, 1991, CIRCULATION, V84, P2040, DOI 10.1161/01.CIR.84.5.2040; FACTOR SM, 1982, CIRCULATION, V66, P342, DOI 10.1161/01.CIR.66.2.342; Fang ZY, 2002, AM HEART J, V143, P383, DOI 10.1067/mhj.2002.120780; Fiorucci S, 2002, FASEB J, V16, P1645, DOI 10.1096/fj.02-0297fje; Galle J, 1999, BRIT J PHARMACOL, V127, P195, DOI 10.1038/sj.bjp.0702495; HALEEN SJ, 1991, CIRC RES, V68, P1302, DOI 10.1161/01.RES.68.5.1302; Hare JM, 2003, J MOL CELL CARDIOL, V35, P719, DOI 10.1016/S0022-2828(03)00143-3; Ikeda Y, 2000, AM J PHYSIOL-HEART C, V278, pH1362, DOI 10.1152/ajpheart.2000.278.4.H1362; Ito H, 1996, AM J PHYSIOL-HEART C, V270, pH1509, DOI 10.1152/ajpheart.1996.270.4.H1509; Keeble JE, 2002, BRIT J PHARMACOL, V137, P295, DOI 10.1038/sj.bjp.0704876; Kojda G, 1996, CIRC RES, V78, P91, DOI 10.1161/01.RES.78.1.91; Layland J, 2002, J PHYSIOL-LONDON, V540, P457, DOI 10.1113/jphysiol.2001.014126; LEVINE TB, 1980, CIRCULATION, V62, P35, DOI 10.1161/01.CIR.62.1.35; Linz W, 1999, CARDIOVASC RES, V43, P549, DOI 10.1016/S0008-6363(99)00091-7; Loke KE, 2000, J MOL CELL CARDIOL, V32, P2299, DOI 10.1006/jmcc.2000.1258; Mansoor AM, 1996, CLIN EXP PHARMACOL P, V23, P43; Masutomo K, 1996, JPN CIRC J, V60, P50, DOI 10.1253/jcj.60.50; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; Mohan P, 1996, CIRCULATION, V93, P1223, DOI 10.1161/01.CIR.93.6.1223; Mombouli JV, 1999, J MOL CELL CARDIOL, V31, P61, DOI 10.1006/jmcc.1998.0844; Muller-Strahl G, 2000, J PHYSIOL-LONDON, V522, P311, DOI 10.1111/j.1469-7793.2000.00311.x; Muscara MN, 2001, BRIT J PHARMACOL, V133, P1314, DOI 10.1038/sj.bjp.0704209; NASCIMBEN L, 1995, CIRCULATION, V91, P1824, DOI 10.1161/01.CIR.91.6.1824; Oh JK, 1994, ECHO MANUAL MAYO CLI; Pieper GM, 2002, FREE RADICAL BIO MED, V32, P1143, DOI 10.1016/S0891-5849(02)00832-8; Rossoni G, 2002, BRIT J PHARMACOL, V135, P1540, DOI 10.1038/sj.bjp.0704585; Ryoke T, 1999, CIRCULATION, V100, P1734, DOI 10.1161/01.CIR.100.16.1734; Senzaki H, 2001, FASEB J, V15, P1718, DOI 10.1096/fj.00-0538com; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Surks HK, 1999, SCIENCE, V286, P1583, DOI 10.1126/science.286.5444.1583; Wallace JL, 2003, FUND CLIN PHARMACOL, V17, P11, DOI 10.1046/j.1472-8206.2003.00125.x; Wanstall JC, 2001, BRIT J PHARMACOL, V134, P463, DOI 10.1038/sj.bjp.0704269; Watanabe M, 1998, J CARDIOVASC PHARM, V32, P248, DOI 10.1097/00005344-199808000-00012; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zieman SJ, 2001, CIRC RES, V88, P97, DOI 10.1161/01.RES.88.1.97; Ziolo MT, 2001, AM J PHYSIOL-HEART C, V281, pH2295, DOI 10.1152/ajpheart.2001.281.6.H2295	43	16	18	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					587	+		10.1096/fj.03-0872fje	http://dx.doi.org/10.1096/fj.03-0872fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734637				2022-12-28	WOS:000188829300006
J	Kammanadiminti, SJ; Mann, BJ; Dutil, L; Chadee, K				Kammanadiminti, SJ; Mann, BJ; Dutil, L; Chadee, K			Regulation of Toll-like receptor-2 expression by the Gal-lectin of Entamoeba histolytica	FASEB JOURNAL			English	Article						galactose lectin; TLR-2; macrophage		The Gal/GalNAc lectin (Gal-lectin) of Entamoeba histolytica is a surface molecule involved in parasite adherence to host cells and is the most promising subunit vaccine candidate against amoebiasis. As macrophages are the major effector cells in host defense against amoebas, we studied the molecular mechanisms by which Gal-lectin activates macrophage. Microarray analysis showed that Gal-lectin up-regulated mRNAs of several cytokines and receptor genes involved in proinflammatory responses. The mechanism whereby the Gal-lectin regulates Toll-like receptor 2 (TLR-2) expression in macrophages was studied. Native Gal-lectin increased TLR-2 mRNA expression in a dose- and time-dependent fashion; peak response occurred with 1 mu g/ml after 2 h stimulation. By immunoflourescence, enhanced surface expression of TLR-2 was observed after 12 h. With the use of nonoverlapping anti-Gal-lectin monoclonal antibodies that map to the carbohydrate recognition domain, amino acid 596-1082 was identified as the TLR-2 stimulating region. The Gal-lectin increased TLR-2 gene transcription, and the half-life of the mRNA transcripts was 1.4 h. Inhibition of nuclear factor (NF)-kappa B suppressed TLR-2 mRNA induction by the Gal-lectin. Moreover, cells pretreated with an inhibitor of p38 kinase (SB 208530) inhibited Gal-lectin induced TLR-2 mRNA expression by 40%. We conclude that the Gal-lectin activates NF-kappaB and MAP kinase-signaling pathways in macrophages culminating in the induction of several genes including TLR-2 and hypothesize that this could have a significant impact on macrophage activation and contribute to amoebic pathogenesis.	McGill Univ, Inst Parasitol, Ste Anne De Bellevue, PQ, Canada; Univ Virginia, Charlottesville, VA USA	McGill University; University of Virginia	Chadee, K (corresponding author), McGill Univ, Inst Parasitol, Macdonald Campus,21,111 Lakeshore Rd, Ste Anne De Bellevue, PQ, Canada.	kris.chadee@mcgill.ca			Canadian Institutes of Health Research; Natural Sciences and Engineering Research Council of Canada; Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec; McGill University Graduate Fellowship	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR); Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec; McGill University Graduate Fellowship	This study was supported in part by grants from the Canadian Institutes of Health Research and the Natural Sciences and Engineering Research Council of Canada. Research at the Institute of Parasitology was partially funded by the Fonds pour la Formation de Chercheurs et l' Aide a la recherche du Quebec. S. Kammanadiminti was the recipient of a McGill University Graduate Fellowship.	Abreu MT, 2002, J BIOL CHEM, V277, P20431, DOI 10.1074/jbc.M110333200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Campbell D, 2000, EUR J IMMUNOL, V30, P423, DOI 10.1002/1521-4141(200002)30:2&lt;423::AID-IMMU423&gt;3.0.CO;2-0; Campos MA, 2001, J IMMUNOL, V167, P416, DOI 10.4049/jimmunol.167.1.416; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Cario E, 2002, AM J PATHOL, V160, P165, DOI 10.1016/S0002-9440(10)64360-X; CHADEE K, 1984, AM J PATHOL, V117, P71; Chaussabel D, 2003, BLOOD, V102, P672, DOI 10.1182/blood-2002-10-3232; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Clerk A, 1999, J MOL CELL CARDIOL, V31, P2087, DOI 10.1006/jmcc.1999.1040; Dhiman N, 2001, VACCINE, V20, P22, DOI 10.1016/S0264-410X(01)00319-X; Dodson JM, 1999, J INFECT DIS, V179, P460, DOI 10.1086/314610; Eskra L, 2003, INFECT IMMUN, V71, P1125, DOI 10.1128/IAI.71.3.1125-1133.2003; Gewirtz AT, 2001, J IMMUNOL, V167, P1882, DOI 10.4049/jimmunol.167.4.1882; Hamilton JA, 1998, INT J BIOCHEM CELL B, V30, P271, DOI 10.1016/S1357-2725(97)00111-8; Hausmann M, 2002, GASTROENTEROLOGY, V122, P1987, DOI 10.1053/gast.2002.33662; Hecker M, 1996, BRIT J PHARMACOL, V118, P2178, DOI 10.1111/j.1476-5381.1996.tb15660.x; Kaisho T, 2002, BBA-MOL CELL RES, V1589, P1, DOI 10.1016/S0167-4889(01)00182-3; KARIN M, 1992, FASEB J, V6, P2581, DOI 10.1096/fasebj.6.8.1317309; KYRIAKIS JM, 2000, SCI STKE; Lockhart BP, 1998, BRIT J PHARMACOL, V123, P879, DOI 10.1038/sj.bjp.0701664; MANN BJ, 1993, INFECT IMMUN, V61, P1772, DOI 10.1128/IAI.61.5.1772-1778.1993; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767; MCCOY JJ, 1994, INFECT IMMUN, V62, P3045, DOI 10.1128/IAI.62.8.3045-3050.1994; McCubrey JA, 2000, LEUKEMIA, V14, P9, DOI 10.1038/sj.leu.2401657; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Neurath MF, 1997, IMMUNOBIOLOGY, V198, P91, DOI 10.1016/S0171-2985(97)80030-7; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Orlicek SL, 1999, SHOCK, V12, P350, DOI 10.1097/00024382-199911000-00004; Ouaissi A, 2002, J IMMUNOL, V168, P6366, DOI 10.4049/jimmunol.168.12.6366; Park SJ, 2002, CELL BIOL TOXICOL, V18, P121, DOI 10.1023/A:1015384201785; PETRI WA, 1987, J CLIN INVEST, V80, P1238, DOI 10.1172/JCI113198; PETRI WA, 1990, J IMMUNOL, V144, P4803; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; SEGUIN R, 1995, IMMUNOLOGY, V86, P49; Seguin R, 1995, P NATL ACAD SCI USA, V92, P12175, DOI 10.1073/pnas.92.26.12175; Seguin R, 1997, INFECT IMMUN, V65, P2522; Seydel KB, 1998, GASTROENTEROLOGY, V115, P1446, DOI 10.1016/S0016-5085(98)70023-X; Shimizu H, 2002, GASTROENTEROLOGY, V123, P1265, DOI 10.1053/gast.2002.36006; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Stanley SL, 2001, J INFECT DIS, V184, P504, DOI 10.1086/322046; Tengku-Muhammad TS, 1999, CYTOKINE, V11, P463, DOI 10.1006/cyto.1998.0460; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Wang TY, 2001, J IMMUNOL, V167, P6924, DOI 10.4049/jimmunol.167.12.6924; WHO (World Health Organization), 1998, WORLD HLTH REP 1998	47	50	51	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					155	157		10.1096/fj.03-0578fje	http://dx.doi.org/10.1096/fj.03-0578fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630697				2022-12-28	WOS:000188829300059
J	McKiernan, S; Bua, E; McGorray, J; Aiken, J				McKiernan, S; Bua, E; McGorray, J; Aiken, J			Early-onset calorie restriction conserves fiber number in aging rat skeletal muscle	FASEB JOURNAL			English	Article						sarcopenia; muscle fibers	VASTUS LATERALIS MUSCLE; DNA DELETION MUTATIONS; MITOCHONDRIAL ABNORMALITIES; OXIDATIVE DAMAGE; FOOD RESTRICTION; AGE; ATROPHY; PROPORTION; SARCOPENIA; APOPTOSIS	The purpose of this work was to determine the effect of early-onset calorie restriction on sarcopenia in the aging rat. Ad libitum (AL) fed animals were examined at 5, 18, 21, and 36 months of age. Calorie-restricted (CR) rats, 40% restricted since 4 months of age, were examined at 21 and 36 months of age. By 36 months, vastus lateralis, rectus femoris and soleus muscles, from AL-fed rats, had significant muscle mass and fiber loss, and reduced muscle cross-sectional area. Mean fiber diameter decreased with age in the vastus lateralis and rectus femoris but not the soleus of AL-fed rats. The number of Type I fibers significantly increased in the vastus lateralis with age. Calorie restriction did not prevent muscle mass loss with age; however, it significantly reduced muscle mass loss between 21 and 36 months of age compared with age-matched AL cohorts. Calorie restriction prevented fiber loss with age, and this conservation of fiber number reduced muscle mass loss with age.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Aiken, J (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	aiken@svm.vetmed.wisc.edu	Kozbakova, Ainur/K-5077-2018; Ballester, Javier/E-7310-2012; Smolarz, Andrzej/A-5491-2013	Kozbakova, Ainur/0000-0002-5213-4882; Smolarz, Andrzej/0000-0002-6473-9627; Aiken, Judd/0000-0001-6119-4521				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; Balagopal P, 1997, AM J PHYSIOL-ENDOC M, V272, pE45, DOI 10.1152/ajpendo.1997.272.1.E45; Borisov AB, 2001, ANAT REC, V264, P203, DOI 10.1002/ar.1155; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; CARMELI E, 1994, P SOC EXP BIOL MED, V206, P103; Cartee G D, 1994, Exerc Sport Sci Rev, V22, P91; CARTEE GD, 1995, J GERONTOL A-BIOL, V50, P137; Carter CS, 2001, EXP AGING RES, V27, P271, DOI 10.1080/036107301300208709; Dirks A, 2002, AM J PHYSIOL-REG I, V282, pR519, DOI 10.1152/ajpregu.00458.2001; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Dubowitz V., 1973, MUSCLE BIOPSY MODERN; Dutta C, 1997, J NUTR, V127, pS992, DOI 10.1093/jn/127.5.992S; HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S; HAVENITH MG, 1990, HISTOCHEMISTRY, V93, P497, DOI 10.1007/BF00266407; Higami Y, 2000, CELL TISSUE RES, V301, P125, DOI 10.1007/s004419900156; HOLLOSZY JO, 1991, MECH AGEING DEV, V60, P199, DOI 10.1016/0047-6374(91)90131-I; ISHIHARA A, 1988, MECH AGEING DEV, V45, P213, DOI 10.1016/0047-6374(88)90003-6; Kanda K, 2002, MICROSC RES TECHNIQ, V59, P301, DOI 10.1002/jemt.10208; Kirkendall DT, 1998, AM J SPORT MED, V26, P598, DOI 10.1177/03635465980260042401; Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2; Lu DX, 1997, ANAT REC, V248, P355; MCCARTER R, 1978, NUTR REP INT, V17, P339; McCarter RJM, 1997, AGING-CLIN EXP RES, V9, P73, DOI 10.1007/BF03340130; MCCARTER RJM, 1982, AM J PHYSIOL, V242, pR89, DOI 10.1152/ajpregu.1982.242.1.R89; NAVARRO A, 2001, FRONT BIOSCI, V6, P26; PARK JHY, 1982, FED PROC, V41, P464; Proctor DN, 1998, J NUTR, V128, p351S, DOI 10.1093/jn/128.2.351S; Rosenberg IH, 1997, J NUTR, V127, pS990, DOI 10.1093/jn/127.5.990S; SAS, 1989, SAS US GUID; Sheehan D.C., 1980, THEORY PRACTICE HIST; SIECK GC, 1989, J APPL PHYSIOL, V66, P2196, DOI 10.1152/jappl.1989.66.5.2196; SJOSTROM M, 1992, ANAT REC, V234, P183, DOI 10.1002/ar.1092340205; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; SOHAL RS, 1994, MECH AGEING DEV, V76, P215, DOI 10.1016/0047-6374(94)91595-4; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; Thompson LV, 2002, J ORTHOP SPORT PHYS, V32, P44, DOI 10.2519/jospt.2002.32.2.44; Turturro A, 1999, J GERONTOL A-BIOL, V54, pB492, DOI 10.1093/gerona/54.11.B492; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Weindruch R, 2001, J NUTR, V131, p918S, DOI 10.1093/jn/131.3.918S; Weindruch R., 1988, RETARDATION AGING DI; WINEINGER MA, 1995, GROWTH DEVELOP AGING, V59, P107; YU BP, 1982, J GERONTOL, V37, P130, DOI 10.1093/geronj/37.2.130; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657	46	62	64	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					580	+		10.1096/fj.03-0667fje	http://dx.doi.org/10.1096/fj.03-0667fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734642				2022-12-28	WOS:000188829300002
J	Bernhard, D; Pfister, G; Huck, CW; Kind, M; Salvenmoser, W; Bonn, GK; Wick, G				Bernhard, D; Pfister, G; Huck, CW; Kind, M; Salvenmoser, W; Bonn, GK; Wick, G			Disruption of vascular endothelial homeostasis by tobacco smoke - impact on atherosclerosis	FASEB JOURNAL			English	Article						smoking; cell death; statin; aging	POLYCYCLIC AROMATIC-HYDROCARBONS; CIGARETTE-SMOKING; APOPTOSIS; CELL; MECHANISMS; NICOTINE; INHIBITION; EXPRESSION; NECROSIS; DISEASE	The World Health Organization (WHO) predicts that by 2020 tobacco will become the largest single health problem worldwide and will cause an estimated 8.4 million deaths annually (http://www5.who.int/tobacco/). Although the impact of smoking on human health is well defined from the medical point of view, surprisingly little is known about the mechanisms by which tobacco smoke mediates its disastrous effects. Here, we demonstrate that tobacco smoke dramatically changes vascular endothelial cell and tissue morphology, leading to a loss of endothelial barrier function within minutes. Long-term exposure of endothelial cells to tobacco smoke extracts induces necrosis that may trigger a pro-inflammatory status of the vessel wall. Pre-incubation of the extracts without cells for 6 h at 37degreesC led to a complete loss of activity. Further, the endothelium could be rescued by changing to fresh medium even at times when the extracts had lost their activity. Finally, we show that N-acetyl cysteine and statins inhibit the adverse tobacco smoke effects.	Austrian Acad Sci, Inst Biomed Aging Res, A-6020 Innsbruck, Austria; Leopold Franzens Univ Innsbruck, Inst Analyt Chem & Radiochem, A-6020 Innsbruck, Austria; Leopold Franzens Univ Innsbruck, Inst Zool & Limnol, A-6020 Innsbruck, Austria	Austrian Academy of Sciences; University of Innsbruck; University of Innsbruck	Bernhard, D (corresponding author), Univ Innsbruck, Inst Pathophysiol, Fritz Pregel Str 3-4OG, A-6020 Innsbruck, Austria.	David.Bernhard@uibk.ac.at		Bernhard, David/0000-0002-2383-6607; Pfister, Gerald/0000-0003-4928-6612; Huck, Christian/0000-0002-6272-3242				Amberger A, 1997, CELL STRESS CHAPERON, V2, P94, DOI 10.1379/1466-1268(1997)002<0094:CEOIVE>2.3.CO;2; American Hospital Association, 2002, HEART DIS STROK STAT, P1; BAKKER S, 2000, CARIOVASC RES, V45, P486; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bernhard D, 2001, CELL DEATH DIFFER, V8, P1014, DOI 10.1038/sj.cdd.4400914; Bernhard D, 2003, CANCER LETT, V195, P193, DOI 10.1016/S0304-3835(03)00157-5; Bialous SA, 2001, TOB CONTROL, V10, P96, DOI 10.1136/tc.10.2.96; DAVIS JW, 1990, ADV EXP MED BIOL, V273, P107; DAWBER TR, 1960, CIRCULATION, V22, P164; DJORDJEVIC MV, 1995, CARCINOGENESIS, V16, P2627, DOI 10.1093/carcin/16.11.2627; Hansson GK, 2001, ARTERIOSCL THROM VAS, V21, P1876, DOI 10.1161/hq1201.100220; Hoshino Y, 2001, AM J PHYSIOL-LUNG C, V281, pL509, DOI 10.1152/ajplung.2001.281.2.L509; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Ishii T, 2001, AM J PHYSIOL-LUNG C, V280, pL1189, DOI 10.1152/ajplung.2001.280.6.L1189; Jarvis MJ, 2001, JNCI-J NATL CANCER I, V93, P134, DOI 10.1093/jnci/93.2.134; Jousilahti P, 1996, CIRCULATION, V93, P1372, DOI 10.1161/01.CIR.93.7.1372; Kita T, 2001, ANN NY ACAD SCI, V947, P199; LEHR HA, 1993, ANN NY ACAD SCI, V686, P112, DOI 10.1111/j.1749-6632.1993.tb39163.x; Libby P, 2002, NATURE, V420, P868, DOI 10.1161/ATVBAHA.108.179705; Milionis HJ, 2001, ANGIOLOGY, V52, P575, DOI 10.1177/000331970105200901; Nagy J, 1997, ENDOTHELIUM-J ENDOTH, V5, P251, DOI 10.3109/10623329709052590; Nathe TJ, 2002, ARTERIOSCL THROM VAS, V22, P1293, DOI 10.1161/01.ATV.0000023428.69244.49; Nia AB, 2002, BIOMARKERS, V7, P209, DOI 10.1080/13547500110120000; NORONHADUTRA AA, 1993, CARDIOVASC RES, V27, P774, DOI 10.1093/cvr/27.5.774; Penn A, 1996, ENVIRON HEALTH PERSP, V104, P1108, DOI 10.2307/3433125; Pfeifer GP, 2002, ONCOGENE, V21, P7435, DOI 10.1038/sj.onc.1205803; PITTILO RM, 1990, INT J EXP PATHOL, V71, P573; Proskuryakov SY, 2003, EXP CELL RES, V283, P1, DOI 10.1016/S0014-4827(02)00027-7; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rubin H, 2002, ONCOGENE, V21, P7392, DOI 10.1038/sj.onc.1205800; Rubin H, 2001, CARCINOGENESIS, V22, P1903, DOI 10.1093/carcin/22.12.1903; Shen YM, 1996, AM J PHYSIOL-HEART C, V270, pH1624, DOI 10.1152/ajpheart.1996.270.5.H1624; Stone PCW, 2002, BIOCHEM BIOPH RES CO, V295, P1150, DOI 10.1016/S0006-291X(02)00800-8; Tithof PK, 2002, FASEB J, V16, P1463, DOI 10.1096/fj.02-0092fje; Tithof PK, 2001, AM J PHYSIOL-HEART C, V281, pH1946, DOI 10.1152/ajpheart.2001.281.5.H1946; Vayssier M, 1998, AM J PHYSIOL-LUNG C, V275, pL771, DOI 10.1152/ajplung.1998.275.4.L771; Vayssier-Taussat M, 2001, AM J PHYSIOL-HEART C, V280, pH1293, DOI 10.1152/ajpheart.2001.280.3.H1293; Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081; Wick G, 2001, TRENDS IMMUNOL, V22, P665, DOI 10.1016/S1471-4906(01)02089-0; Zafarullah M, 2003, CELL MOL LIFE SCI, V60, P6, DOI 10.1007/s000180300001; ZUCCARO P, 1993, J CHROMATOGR-BIOMED, V621, P257, DOI 10.1016/0378-4347(93)80103-B	41	75	77	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2302	+		10.1096/fj.03-0312fje	http://dx.doi.org/10.1096/fj.03-0312fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525940				2022-12-28	WOS:000186343300003
J	Lavenburg, KR; Ivey, J; Hsu, T; Muise-Helmericks, RC				Lavenburg, KR; Ivey, J; Hsu, T; Muise-Helmericks, RC			Coordinated functions of Akt/PKB and ETS1 in tubule formation	FASEB JOURNAL			English	Article						angiogenesis; Drosophila; tubulogenesis; tracheal development	ENDOTHELIAL GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; GENETIC-CONTROL; CELL-MIGRATION; AKT; ANGIOGENESIS; PROTEIN; EXPRESSION; PATHWAY	We investigated the inter-relationship between two downstream effectors of vascular endothelial growth factor (VEGF), the serine threonine kinase Akt (also known as protein kinase B) and the transcription factor ETS1, during tubulogenesis. Human endothelial cell culture and the in vivo Drosophila tracheal systems are employed in comparative analysis. We show that VEGF stimulates the expression of ETS1 through a phosphatidylinositol-3-kinase (PI3K)/Akt-dependent pathway in primary endothelial cells. Activation of Akt results in vessel formation in vitro, a process that is blocked by expression of antisense ETS1. The functional relationship between ETS and Akt was then tested in the homologous tubular system in Drosophila. Contrary to expectation, ETS1 and Akt did not form a linear positive regulatory pathway in vivo. Instead, genetic analyses suggest that the Drosophila ETS 1 homologue Pointed is required for cell motility per se while Drosophila Akt (Dakt1) is responsible for organized and restricted cell movement that is essential for tubule formation. Taken together, our results show that ETS1 and Akt control different aspects of cell motility that are integrated in the precise regulation of vascular tubule formation.	Med Univ S Carolina, Lab Canc Genom, Hollings Canc Ctr, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Cell Biol & Anat, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hsu, T (corresponding author), Med Univ S Carolina, Lab Canc Genom, Hollings Canc Ctr, Rm 333,86 Jonathon Lucas St, Charleston, SC 29425 USA.	hsut@musc.edu; musehelm@musc.edu		Hsu, Tien/0000-0003-2308-4297	NCI NIH HHS [P01 CA078582-080005, R01 CA109860, P01 CA078582, R21 CA095888, R01 CA109860-04] Funding Source: Medline; NCRR NIH HHS [P20 RR016434] Funding Source: Medline; NIGMS NIH HHS [R01 GM057843, R01 GM057843-08] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA078582, R01CA109860, R21CA095888] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016434] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057843] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Affolter M, 2000, CURR OPIN CELL BIOL, V12, P731, DOI 10.1016/S0955-0674(00)00160-5; Arias A.M., 1993, DEV DROSOPHILA, P609; Bagni C, 2002, MECH DEVELOP, V117, P265, DOI 10.1016/S0925-4773(02)00176-4; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Chen ZQ, 1997, CANCER RES, V57, P2013; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Gao XS, 2000, DEV BIOL, V221, P404, DOI 10.1006/dbio.2000.9680; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Higuchi M, 2001, CURR BIOL, V11, P1958, DOI 10.1016/S0960-9822(01)00599-1; Iwasaka C, 1996, J CELL PHYSIOL, V169, P522, DOI 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.3.CO;2-Q; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jin J, 2001, DEV CELL, V1, P817, DOI 10.1016/S1534-5807(01)00090-9; Kennedy SG, 1997, GENE DEV, V11, P701, DOI 10.1101/gad.11.6.701; Kwon T, 2000, J BIOL CHEM, V275, P423, DOI 10.1074/jbc.275.1.423; Merenmies J, 1997, CELL GROWTH DIFFER, V8, P3; Metzger RJ, 1999, SCIENCE, V284, P1635, DOI 10.1126/science.284.5420.1635; Morales-Ruiz M, 2000, CIRC RES, V86, P892, DOI 10.1161/01.RES.86.8.892; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; MUISEHELMERICKS RC, 1995, J BIOL CHEM, V270, P27538, DOI 10.1074/jbc.270.46.27538; Nakano T, 2000, J CELL PHYSIOL, V184, P255, DOI 10.1002/1097-4652(200008)184:2<255::AID-JCP14>3.0.CO;2-J; NEHLS V, 1995, MICROVASC RES, V50, P311, DOI 10.1006/mvre.1995.1061; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; PERRIMON N, 1991, DEV GENET, V12, P238, DOI 10.1002/dvg.1020120309; Perrimon N, 1996, GENETICS, V144, P1681; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Radimerski T, 2002, NAT CELL BIOL, V4, P251, DOI 10.1038/ncb763; Ribeiro C, 2002, DEV CELL, V2, P677, DOI 10.1016/S1534-5807(02)00171-5; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Samakovlis C, 1996, DEVELOPMENT, V122, P1395; Scanga SE, 2000, ONCOGENE, V19, P3971, DOI 10.1038/sj.onc.1203739; Sementchenko VI, 2000, ONCOGENE, V19, P6533, DOI 10.1038/sj.onc.1204034; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Staveley BE, 1998, CURR BIOL, V8, P599, DOI 10.1016/S0960-9822(98)70231-3; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Veikkola T, 2000, CANCER RES, V60, P203; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Wilk R, 1996, GENE DEV, V10, P93, DOI 10.1101/gad.10.1.93; Yordy JS, 2000, ONCOGENE, V19, P6503, DOI 10.1038/sj.onc.1204036	39	21	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2278	+		10.1096/fj.03-0040fje	http://dx.doi.org/10.1096/fj.03-0040fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525946	Green Accepted			2022-12-28	WOS:000186343300013
J	Scarlatti, F; Sala, G; Somenzi, G; Signorelli, P; Sacchi, N; Ghidoni, R				Scarlatti, F; Sala, G; Somenzi, G; Signorelli, P; Sacchi, N; Ghidoni, R			Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling	FASEB JOURNAL			English	Article						polyphenol; serine palmitoyltransferase; sphingomyelin; neutral sphingomyelinase	SERINE PALMITOYLTRANSFERASE; EPITHELIAL-CELLS; IN-VITRO; EXPRESSION; LINES; KINASE; WINE; ACID; INDUCTION; SUBSTRATE	Resveratrol (3,4',5-trans-trihydroxystilbene), a phytoalexin present in grapes and red wine, is emerging as a natural compound with potential anticancer properties. Here we show that resveratrol can induce growth inhibition and apoptosis in MDA-MB-231, a highly invasive and metastatic breast cancer cell line, in concomitance with a dramatic endogenous increase of growth inhibitory/proapoptotic ceramide. We found that accumulation of ceramide derives from both de novo ceramide synthesis and sphingomyelin hydrolysis. More specifically we demonstrated that ceramide accumulation induced by resveratrol can be traced to the activation of serine palmitoyltransferase (SPT), the key enzyme of de novo ceramide biosynthetic pathway, and neutral sphingomyelinase (nSMase), a main enzyme involved in the sphingomyelin/ceramide pathway. However, by using specific inhibitors of SPT, myriocin and L-cycloserine, and nSMase, gluthatione and manumycin, we found that only the SPT inhibitors could counteract the biological effects induced by resveratrol. Thus, resveratrol seems to exert its growth inhibitory/apoptotic effect on the metastatic breast cancer cell line MDA-MB-231 by activating the de novo ceramide synthesis pathway.	Univ Milan, Sch Med, San Paolo Univ Hosp, Biochem & Mol Biol Lab, I-20142 Milan, Italy	University of Milan	Ghidoni, R (corresponding author), Univ Milan, Sch Med, San Paolo Univ Hosp, Biochem & Mol Biol Lab, Via A di Rudini 8, I-20142 Milan, Italy.	riccardo.ghidoni@unimi.it		GHIDONI, RICCARDO/0000-0002-6300-5867; signorelli, paola/0000-0003-2368-2393				AMES BN, 1960, J BIOL CHEM, V235, P769; Aoudjit F, 2001, ONCOGENE, V20, P4995, DOI 10.1038/sj.onc.1204554; Bhat KPL, 2001, CANCER RES, V61, P7456; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bove K, 2002, BIOCHEM BIOPH RES CO, V291, P1001, DOI 10.1006/bbrc.2002.6554; Brownson DM, 2002, J NUTR, V132, p3482S, DOI 10.1093/jn/132.11.3482S; Cai YJ, 2003, BBA-MOL BASIS DIS, V1637, P31, DOI 10.1016/S0925-4439(02)00174-6; Damianaki A, 2000, J CELL BIOCHEM, V78, P429, DOI 10.1002/1097-4644(20000901)78:3<429::AID-JCB8>3.0.CO;2-M; del Pulgar TG, 2002, BIOCHEM J, V363, P183, DOI 10.1042/0264-6021:3630183; Ferrero ME, 1998, AM J CLIN NUTR, V68, P1208, DOI 10.1093/ajcn/68.6.1208; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Freyberger A, 2001, ARCH TOXICOL, V74, P709, DOI 10.1007/s002040000186; Gaziano JM, 1999, AM J CARDIOL, V83, P52, DOI 10.1016/S0002-9149(98)00782-6; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hsieh TC, 1999, INT J ONCOL, V15, P245; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Joe AK, 2002, CLIN CANCER RES, V8, P893; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; Liu B, 2000, METHOD ENZYMOL, V311, P164; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Nakagawa H, 2001, J CANCER RES CLIN, V127, P258, DOI 10.1007/s004320000190; Narayanan BA, 2003, INT J CANCER, V104, P204, DOI 10.1002/ijc.10932; Perry DK, 2000, J BIOL CHEM, V275, P9078, DOI 10.1074/jbc.275.12.9078; Perry DK, 1999, TRENDS BIOCHEM SCI, V24, P226, DOI 10.1016/S0968-0004(99)01407-3; PREISS J, 1986, J BIOL CHEM, V261, P8597; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; Spiegel S, 1996, CURR OPIN CELL BIOL, V8, P159, DOI 10.1016/S0955-0674(96)80061-5; Stewart JR, 1999, BIOCHEMISTRY-US, V38, P13244, DOI 10.1021/bi990875u; STROBL JS, 1992, J PHARMACOL EXP THER, V263, P186; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Sumitomo M, 2002, J CLIN INVEST, V109, P827, DOI 10.1172/JCI200214146; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; Vitrac X, 2003, LIFE SCI, V72, P2219, DOI 10.1016/S0024-3205(03)00096-1; Wang HT, 2001, CANCER RES, V61, P5102; Worm J, 2001, J BIOL CHEM, V276, P39990, DOI 10.1074/jbc.M103181200; Wu Q, 1997, MOL CELL BIOL, V17, P6598, DOI 10.1128/MCB.17.11.6598; Xu J, 1998, J BIOL CHEM, V273, P16521, DOI 10.1074/jbc.273.26.16521; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381	45	144	149	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2339	+		10.1096/fj.03-0292fje	http://dx.doi.org/10.1096/fj.03-0292fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563682				2022-12-28	WOS:000186343300027
J	Chung, JH; Han, JH; Hwang, EJ; Seo, JY; Cho, KH; Kim, KH; Youn, JI; Eun, HC				Chung, JH; Han, JH; Hwang, EJ; Seo, JY; Cho, KH; Kim, KH; Youn, JI; Eun, HC			Dual mechanisms of green tea extract-induced cell survival in human epidermal keratinocytes	FASEB JOURNAL			English	Article						EGCG; keratinocytes; proliferation; apoptosis	HAIRLESS MICE; GROWTH; INDUCTION; APOPTOSIS; PHOSPHORYLATION; PROTECTION; DEATH; SKIN; BAD; (-)-EPIGALLOCATECHIN-3-GALLATE	Beneficial effects attributed to green tea, such as its anticancer and antioxidant properties, may be mediated by (-)-epigallocatechin-3-gallate ( EGCG). In this study, the effects of EGCG on cell proliferation and UV-induced apoptosis were investigated in normal epidermal keratinocytes. When topically applied to aged human skin, EGCG stimulated the proliferation of epidermal keratinocytes, which increased the epidermal thickness. In addition, this topical application also inhibited the UV-induced apoptosis of epidermal keratinocytes. EGCG was found to increase the phosphorylation of Bad protein at the Ser112 and Ser136. Moreover, EGCG-induced Erk phosphorylation was found to be critical for the phosphorylation of Ser112 in Bad protein, and the EGCG-induced activation of the Akt pathway was found to be involved in the phosphorylation of Ser136. Furthermore, EGCG increased Bcl-2 expression but decreased Bax expression, causing an increase in the Bcl-2-to-Bax ratio. In addition, we demonstrate the differential growth inhibitory effects of EGCG on cancer cells. In conclusion, this study demonstrates that EGCG promotes keratinocyte survival and inhibits the UV-induced apoptosis via two mechanisms: by phosphorylating Ser112 and Ser136 of Bad protein through Erk and Akt pathways, respectively, and by increasing the Bcl-2-to-Bax ratio. Moreover, these two proposed mechanisms of EGCG-induced cell proliferation may differ kinetically to promote keratinocyte survival.	Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul 110744, South Korea; Seoul Natl Univ Hosp, Clin Res Inst, Lab Cutaneous Aging Res, Seoul 110744, South Korea	Seoul National University (SNU); Seoul National University (SNU); Seoul National University Hospital	Eun, HC (corresponding author), Seoul Natl Univ, Coll Med, Dept Dermatol, 28 Yongon Dong, Seoul 110744, South Korea.	hceun@snu.ac.kr	Chung, Jin Ho/C-3604-2011; Kim, Kyu Han/E-7814-2012; Eun, Hee Chul/J-5568-2012; Cho, Kwang Hyun/J-5661-2012					Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; AGARWAL R, 1993, PHOTOCHEM PHOTOBIOL, V58, P695, DOI 10.1111/j.1751-1097.1993.tb04954.x; Ahmad N, 1997, JNCI-J NATL CANCER I, V89, P1881, DOI 10.1093/jnci/89.24.1881; Bergmann A, 1998, CELL, V95, P331, DOI 10.1016/S0092-8674(00)81765-1; Blot WJ, 1997, CRIT REV FOOD SCI, V37, P739, DOI 10.1080/10408399709527800; Blume-Jensen P, 1998, CURR BIOL, V8, P779, DOI 10.1016/S0960-9822(98)70302-1; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BOYCE ST, 1983, J INVEST DERMATOL, V81, pS33, DOI 10.1111/1523-1747.ep12540422; Bushman JL, 1998, NUTR CANCER, V31, P151, DOI 10.1080/01635589809514697; Chen ZP, 1998, CANCER LETT, V129, P173, DOI 10.1016/S0304-3835(98)00108-6; Chung JH, 2000, J INVEST DERMATOL, V115, P177, DOI 10.1046/j.1523-1747.2000.00009.x; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; delPeso L, 1997, SCIENCE, V278, P687; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gupta S, 2000, TOXICOL APPL PHARM, V164, P82, DOI 10.1006/taap.1999.8885; HENGARTNER MO, 1994, CURR OPIN GENET DEV, V4, P581, DOI 10.1016/0959-437X(94)90076-F; Isoherranen K, 1999, ARCH DERMATOL RES, V291, P212, DOI 10.1007/s004030050396; KATIYAR SK, 1995, PHOTOCHEM PHOTOBIOL, V62, P855; Katiyar SK, 1999, PHOTOCHEM PHOTOBIOL, V69, P148, DOI 10.1111/j.1751-1097.1999.tb03267.x; Kim YG, 2000, PIGM CELL RES, V13, P352, DOI 10.1034/j.1600-0749.2000.130508.x; Kohlmeier L, 1997, NUTR CANCER, V27, P1, DOI 10.1080/01635589709514494; Kurada P, 1998, CELL, V95, P319, DOI 10.1016/S0092-8674(00)81764-X; LEE MJ, 1995, CANCER EPIDEM BIOMAR, V4, P393; Liang YC, 1999, CARCINOGENESIS, V20, P733, DOI 10.1093/carcin/20.4.733; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Meier P, 1998, CELL, V95, P295, DOI 10.1016/S0092-8674(00)81760-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; SALAH N, 1995, ARCH BIOCHEM BIOPHYS, V322, P339, DOI 10.1006/abbi.1995.1473; Seo JY, 2001, J INVEST DERMATOL, V116, P915, DOI 10.1046/j.1523-1747.2001.01358.x; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Valcic S, 1996, ANTI-CANCER DRUG, V7, P461, DOI 10.1097/00001813-199606000-00011; WANG ZY, 1991, CARCINOGENESIS, V12, P1527, DOI 10.1093/carcin/12.8.1527; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang CS, 2000, J NUTR, V130, P2409, DOI 10.1093/jn/130.10.2409; Yang GY, 1998, CARCINOGENESIS, V19, P611, DOI 10.1093/carcin/19.4.611; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	40	124	138	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1913	+		10.1096/fj.02-0914fje	http://dx.doi.org/10.1096/fj.02-0914fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897059				2022-12-28	WOS:000185345100017
J	Damy, T; Ratajczak, P; Robidel, E; Bendall, JK; Oliviero, P; Boczkowski, J; Ebrahimian, T; Marotte, F; Samuel, JL; Heymes, C				Damy, T; Ratajczak, P; Robidel, E; Bendall, JK; Oliviero, P; Boczkowski, J; Ebrahimian, T; Marotte, F; Samuel, JL; Heymes, C			Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats	FASEB JOURNAL			English	Article						NOS1; caveolin; aging; cardiac dysfunction	HUMAN HEART-FAILURE; SKELETAL-MUSCLE; VENTRICULAR MYOCYTES; CALCIUM CURRENT; IN-VIVO; EXPRESSION; DYSFUNCTION; CAVEOLIN-3; RELEASE; BASAL	Nitric oxide ( NO) has been implicated in the development of heart failure, although the source, significance, and functional role of the different NO synthase (NOS) isoforms in this pathology are controversial. The presence of a neuronal-type NOS isoform (NOS1) in the cardiac sarcoplasmic reticulum has been recently discovered, leading to the hypothesis that NOS1-derived NO may notably alter myocardial inotropy. However, the regulation and role(s) of NOS1 in cardiac diseases remain to be determined. Using an experimental model of myocardial infarction (MI) in senescent rats, we demonstrated a significant increase in cardiac NOS1 expression and activity in MI, coupled with the translocation of this enzyme to the sarcolemma through interactions with caveolin-3. The enhanced NOS1 activity counteracts the decrease in cardiac NOS3 expression and activity observed in heart failure. We demonstrated an increased interaction between NOS1 and its regulatory protein HSP90 in post-MI hearts, a potential mechanism for the higher NOS1 activity in this setting. Finally, preferential in vivo inhibition of NOS1 activity enhanced basal post-MI left ventricular dysfunction in senescent rats. These results provide the first evidence that increased NOS1-derived NO production may play a significant role in the autocrine regulation of myocardial contractility after MI in aging rats.	Univ Paris 07, Hop Lariboisiere, INSERM, U572,IFR J Marrey, F-75475 Paris 10, France; Hop Bichat Claude Bernard, INSERM, U408, F-75877 Paris, France; Univ Paris 07, Hop Lariboisiere, INSERM, U541,IFR J Marrey, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Heymes, C (corresponding author), Univ Paris 07, Hop Lariboisiere, INSERM, U572,IFR J Marrey, 41 Blvd Chapelle, F-75475 Paris 10, France.	Christophe.Heymes@larib.inserm.fr	Boczkowski, Jorge/S-7474-2018; Ratajczak, Philippe/H-5398-2012; Heymes, Christophe/Y-9368-2019	Boczkowski, Jorge/0000-0001-6619-5785; Heymes, Christophe/0000-0002-6666-6193				Andries LJ, 1998, CIRC RES, V82, P195; Ashley EA, 2002, CIRCULATION, V105, P3011, DOI 10.1161/01.CIR.0000019516.31040.2D; Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Bing RJ, 1996, MOL CELL BIOCHEM, V161, P303, DOI 10.1007/BF00240063; Brahmajothi MV, 1999, CIRC RES, V85, P575, DOI 10.1161/01.RES.85.7.575; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Cohn JN, 2000, J AM COLL CARDIOL, V35, P569, DOI 10.1016/S0735-1097(99)00630-0; Dittrich M, 2001, J PHYSIOL-LONDON, V534, P109, DOI 10.1111/j.1469-7793.2001.00109.x; Drexler H, 1999, J MOL CELL CARDIOL, V31, P51, DOI 10.1006/jmcc.1998.0843; DUDEK RR, 1994, BIOCHEM BIOPH RES CO, V205, P1671, DOI 10.1006/bbrc.1994.2860; FINKEL MS, 1995, J PHARMACOL EXP THER, V272, P945; Gallo MP, 2001, PFLUG ARCH EUR J PHY, V441, P621, DOI 10.1007/s004240000475; GROCOTTMASON R, 1994, AM J PHYSIOL-HEART C, V267, pH1804, DOI 10.1152/ajpheart.1994.267.5.H1804; Gyurko R, 2000, AM J PHYSIOL-HEART C, V278, pH971, DOI 10.1152/ajpheart.2000.278.3.H971; Hare JM, 2000, CIRC RES, V86, P1085, DOI 10.1161/01.RES.86.10.1085; Hare JM, 1998, CIRCULATION, V97, P161, DOI 10.1161/01.CIR.97.2.161; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; Heymes C, 1999, CIRCULATION, V99, P3009, DOI 10.1161/01.CIR.99.23.3009; Kaye DM, 2002, CIRC RES, V91, P1198, DOI 10.1161/01.RES.0000047506.52381.90; Keita H, 2000, BRAIN RES, V881, P237, DOI 10.1016/S0006-8993(00)02820-1; Kelm M, 1997, CARDIOVASC RES, V36, P185, DOI 10.1016/S0008-6363(97)00149-1; KOBZIK L, 1994, NATURE, V372, P546, DOI 10.1038/372546a0; Lanone S, 2001, CRIT CARE MED, V29, P1720, DOI 10.1097/00003246-200109000-00011; MISKO TP, 1993, ANAL BIOCHEM, V214, P11, DOI 10.1006/abio.1993.1449; Mohri M, 1997, HYPERTENSION, V30, P50, DOI 10.1161/01.HYP.30.1.50; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Paulus W J, 2001, Heart Fail Rev, V6, P105; PAULUS WJ, 1995, CIRCULATION, V92, P2119, DOI 10.1161/01.CIR.92.8.2119; Paulus WJ, 2001, CIRCULATION, V104, P2260, DOI 10.1161/circ.104.19.2260; PAULUS WJ, 1994, CIRCULATION, V89, P2070, DOI 10.1161/01.CIR.89.5.2070; PFEFFER MA, 1988, NEW ENGL J MED, V319, P80, DOI 10.1056/NEJM198807143190204; Piech A, 2002, AM J PHYSIOL-HEART C, V282, pH219, DOI 10.1152/ajpheart.2002.282.1.H219; Prabhu SD, 2000, CIRCULATION, V101, P2103, DOI 10.1161/01.CIR.101.17.2103; Ratajczak P, 2003, CARDIOVASC RES, V57, P358, DOI 10.1016/S0008-6363(02)00660-0; Raya TE, 1997, AM J PHYSIOL-HEART C, V273, pH2652, DOI 10.1152/ajpheart.1997.273.6.H2652; Sears CE, 2003, CIRC RES, V92, pE52, DOI 10.1161/01.RES.0000064585.95749.6D; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Shah AM, 1999, CARDIOVASC RES, V43, P507, DOI 10.1016/S0008-6363(99)00181-9; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; SHAH VP, 1991, PHARMACEUT RES, V8, P55, DOI 10.1023/A:1015826205930; Silvagno F, 1996, J BIOL CHEM, V271, P11204, DOI 10.1074/jbc.271.19.11204; Silvestre JS, 1999, CIRCULATION, V99, P2694, DOI 10.1161/01.CIR.99.20.2694; Smith CJ, 1996, CIRC RES, V78, P58, DOI 10.1161/01.RES.78.1.58; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Stamler JS, 2001, PHYSIOL REV, V81, P209, DOI 10.1152/physrev.2001.81.1.209; Stoyanovsky D, 1997, CELL CALCIUM, V21, P19, DOI 10.1016/S0143-4160(97)90093-2; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Vejlstrup NG, 1998, J MOL CELL CARDIOL, V30, P1215, DOI 10.1006/jmcc.1998.0686; Venema VJ, 1997, J BIOL CHEM, V272, P28187, DOI 10.1074/jbc.272.45.28187; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234	54	97	98	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1934	+		10.1096/fj.02-1208fje	http://dx.doi.org/10.1096/fj.02-1208fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897062				2022-12-28	WOS:000185345100020
J	Merker, K; Ullrich, O; Schmidt, H; Sitte, N; Grune, T				Merker, K; Ullrich, O; Schmidt, H; Sitte, N; Grune, T			Stability of the nuclear protein turnover during cellular senescence of human fibroblasts	FASEB JOURNAL			English	Article						protein oxidation; proteasome; proliferative senescence; nucleus; cytosol	HUMAN BJ FIBROBLASTS; GLUTAMINE-SYNTHETASE; OXIDIZED PROTEINS; OXIDATION; DEGRADATION; PROTEASOME; PROTEOLYSIS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; INHIBITION; COMPLEX	The accumulation of oxidized proteins is one of the highlights of age-related changes of cellular metabolism and happens at least partially as a result of a decline in the activity of intracellular proteases (e.g., the proteasome). Because the proteasome is located in numerous cellular compartments, we tested whether and to which extent the proteasome and the protein turnover changes in the cytosolic compartment and in the nucleus of proliferating fibroblasts. We demonstrated that the activity of the proteasomal system declines during proliferative senescence of human fibroblasts in the cytosol dramatically, whereas it is stable within the nucleus. It could be demonstrated in both compartments that an accumulation of oxidized proteins occurs. After oxidative stress, a short timed activation of the proteasomal system in the nucleus occurs. This activation was accompanied by an increase in the protein turnover in response to oxidative stress, which was also present in the nucleus of senescent cells. Taking into account that the nuclear/cytosol ratio of the proteasome content declines during proliferative senescence, we postulated that the senescence-related changes in the cytosolic proteasomal system are more pronounced and that the nuclear proteasomal system is only marginally affected by the senescence process.	Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, D-10117 Berlin, Germany; Humboldt Univ, Fac Med Charite, Inst Anat, D-10117 Berlin, Germany; Humboldt Univ, Fac Med Charite, Clin Gastroenterol & Hepatol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Grune, T (corresponding author), Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, Schumannstr 20-21, D-10117 Berlin, Germany.	tilman.grune@charite.de		Grune, Tilman/0000-0003-4775-9973				AGARWAL S, 1994, MECH AGEING DEV, V75, P11, DOI 10.1016/0047-6374(94)90024-8; Burkle A, 2000, BIOGERONTOLOGY, V1, P41, DOI 10.1023/A:1010089924898; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; CARNEY JM, 1991, P NATL ACAD SCI USA, V88, P3633, DOI 10.1073/pnas.88.9.3633; Chao CC, 1997, P NATL ACAD SCI USA, V94, P2969, DOI 10.1073/pnas.94.7.2969; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FRIGUET B, 1994, ARCH BIOCHEM BIOPHYS, V311, P168, DOI 10.1006/abbi.1994.1222; Friguet B, 1997, FEBS LETT, V405, P21, DOI 10.1016/S0014-5793(97)00148-8; FRIGUET B, 1994, J BIOL CHEM, V269, P21639; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; Grune T, 1996, J BIOL CHEM, V271, P15504, DOI 10.1074/jbc.271.26.15504; Grune T, 1998, J BIOL CHEM, V273, P10857, DOI 10.1074/jbc.273.18.10857; Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459; GRUNE T, 2001, HDB BIOL AGING, P25; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; HOLLIDAY R, 1972, NATURE, V238, P26, DOI 10.1038/238026a0; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; Sitte N, 2000, FASEB J, V14, P1490, DOI 10.1096/fj.14.11.1490; Sitte N, 2000, FASEB J, V14, P2503, DOI 10.1096/fj.00-0210com; Sitte N, 2000, FASEB J, V14, P2495, DOI 10.1096/fj.00-0209com; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Sitte N, 2000, FREE RADICAL BIO MED, V28, P701, DOI 10.1016/S0891-5849(99)00279-8; Stadtman E R, 1988, Basic Life Sci, V49, P331; Stadtman E R, 1992, EXS, V62, P64; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; Ullrich O, 1999, P NATL ACAD SCI USA, V96, P6223, DOI 10.1073/pnas.96.11.6223; Waterborg JH, 2001, BIOCHEMISTRY-US, V40, P2599, DOI 10.1021/bi002480c; Yin DZ, 1996, FREE RADICAL BIO MED, V21, P871, DOI 10.1016/0891-5849(96)00175-X	36	29	29	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1963	+		10.1096/fj.03-0177fje	http://dx.doi.org/10.1096/fj.03-0177fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897070				2022-12-28	WOS:000185345100028
J	Shankar, K; Vaidya, VS; Corton, JC; Bucci, TJ; Liu, J; Waalkes, MP; Mehendale, HM				Shankar, K; Vaidya, VS; Corton, JC; Bucci, TJ; Liu, J; Waalkes, MP; Mehendale, HM			Activation of PPAR-alpha in streptozotocin-induced diabetes is essential for resistance against acetaminophen toxicity	FASEB JOURNAL			English	Article						cell proliferation; microarray; real-time PCR; tissue repair	HEAT-SHOCK-PROTEIN; PEROXISOME PROLIFERATOR CIPROFIBRATE; ANTIMITOTIC AGENT COLCHICINE; AMELIORATES LIVER-INJURY; CARBON-TETRACHLORIDE; RECEPTOR-ALPHA; COVALENT BINDING; N-ACETYLCYSTEINE; KAPPA-B; THIOACETAMIDE	Diabetic (DB) mice exhibit significant resistance to hepatotoxicants. The role of peroxisome proliferator receptor (PPAR)-alpha activation in diabetes, in protection against lethal acetaminophen (APAP) challenge, was investigated. Upon treatment with APAP (600 mg/kg, i.p., a LD100 dose in wild-type [WT] non-DB mice), WT-DB mice showed only 30% mortality and 40% less liver injury as measured by alanine aminotransferase and histopathology. In contrast, diabetes in PPAR knockout (PPAR-alpha(-/-)) mice failed to protect against APAP toxicity, suggesting the importance of PPAR-alpha in diabetes-induced protection. S-phase DNA synthesis and PCNA immunohistochemical staining after injury showed early and robust tissue repair in WT-DB mice, but not in the PPAR-alpha(-/-) DB mice. Microarray analyses were performed on livers from non-DB and DB (WT and PPAR-alpha(-/-)) mice at 0 and 12 h after APAP. Microarray data were confirmed via real-time polymerase chain reaction analysis of several genes, including stress response, immediate early genes, DNA damage, heat shock proteins, and cell cycle regulators, followed by Western analyses of selected proteins. Gel shift assays revealed higher activation of nuclear factor-kappaB in WT-DB mice after APAP treatment. These findings suggest PPAR-alpha activation as a hepatoprotective adaptive response mediating protection against APAP in diabetes.	Univ Louisiana Monroe, Dept Toxicol, Sch Pharm, Coll Hlth Sci, Monroe, LA 71209 USA; Toxicogenomics, Chapel Hill, NC USA; Natl Ctr Toxicol Res, Pathol Associates Int, Jefferson, AR 72079 USA; NIEHS, Inorgan Carcinogenesis Sect, NCI, Res Triangle Pk, NC 27709 USA	University of Louisiana System; University of Louisiana Monroe; US Food & Drug Administration (FDA); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); NIH National Institute of Environmental Health Sciences (NIEHS)	Mehendale, HM (corresponding author), Univ Louisiana Monroe, Dept Toxicol, Sch Pharm, Coll Hlth Sci, 700 Univ Ave,Sugar Hall 306, Monroe, LA 71209 USA.	mehendale@ulm.edu		Shankar, Kartik/0000-0002-7964-9026				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; Anderson SP, 2002, HEPATOLOGY, V36, P544, DOI 10.1053/jhep.2002.35276; Asayama K, 1999, MOL CELL BIOCHEM, V194, P227, DOI 10.1023/A:1006930513476; Awad MM, 2000, CELL GROWTH DIFFER, V11, P325; Awad MM, 2000, J BIOL CHEM, V275, P38716, DOI 10.1074/jbc.M008040200; BARTOLONE JB, 1988, BIOCHEM PHARMACOL, V37, P4763, DOI 10.1016/0006-2952(88)90350-4; Blazka ME, 1996, J INFLAMM, V47, P138; Calfee KG, 1998, FASEB J, V12, pA563; CHANDA S, 1995, HEPATOLOGY, V21, P477, DOI 10.1002/hep.1840210232; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Cosulich S, 2000, CARCINOGENESIS, V21, P579, DOI 10.1093/carcin/21.4.579; Dalu A, 1998, ENVIRON HEALTH PERSP, V106, P597, DOI 10.2307/3434235; Dharaney S, 2002, HEPATOLOGY, V36, p264A; Engels W, 1999, MOL CELL BIOCHEM, V192, P53, DOI 10.1023/A:1006855214237; Fujimori S, 1997, DIGEST DIS SCI, V42, P1987, DOI 10.1023/A:1018892000606; GAYNES BI, 1989, COMP BIOCHEM PHYS B, V94, P213, DOI 10.1016/0305-0491(89)90036-9; GREENWELL A, 1991, CANCER LETT, V59, P251, DOI 10.1016/0304-3835(91)90149-C; HERBER B, 1994, ONCOGENE, V9, P1295; Holden PR, 2000, CELL MOL BIOL, V46, P29; JEFFERY EH, 1991, ADV EXP MED BIOL, V283, P249; Kirschner M W, 1978, Int Rev Cytol, V54, P1, DOI 10.1016/S0074-7696(08)60164-3; Kroetz DL, 1998, J BIOL CHEM, V273, P31581, DOI 10.1074/jbc.273.47.31581; Kulkarni SG, 1997, TOXICOLOGY, V120, P79, DOI 10.1016/S0300-483X(97)03627-5; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Li YX, 2000, BIOCHEM PHARMACOL, V59, P427, DOI 10.1016/S0006-2952(99)00339-1; Manautou JE, 1998, TOXICOLOGY, V127, P1, DOI 10.1016/S0300-483X(98)00013-4; Manautou JE, 1996, FUND APPL TOXICOL, V29, P229, DOI 10.1006/faat.1996.0026; MANAUTOU JE, 1994, TOXICOL APPL PHARM, V129, P252, DOI 10.1006/taap.1994.1250; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MANGIPUDY RS, 1995, PHARMACOL TOXICOL, V77, P182, DOI 10.1111/j.1600-0773.1995.tb01010.x; Mangipudy RS, 1996, ENVIRON HEALTH PERSP, V104, P744, DOI 10.2307/3433220; Michalik L, 2001, J CELL BIOL, V154, P799, DOI 10.1083/jcb.200011148; Nicholls-Grzemski FA, 2000, TOXICOL SCI, V56, P220, DOI 10.1093/toxsci/56.1.220; NICHOLLSGRZEMSKI FA, 1992, BIOCHEM PHARMACOL, V43, P1395, DOI 10.1016/0006-2952(92)90193-M; Nilakantan V, 1998, FREE RADICAL BIO MED, V24, P1430, DOI 10.1016/S0891-5849(98)00007-0; O'Brien ML, 2002, TOXICOL SCI, V69, P139, DOI 10.1093/toxsci/69.1.139; Parrish AR, 1999, TOXICOL SCI, V50, P98, DOI 10.1093/toxsci/50.1.98; Pestell RG, 1999, ENDOCR REV, V20, P501, DOI 10.1210/er.20.4.501; RAO CV, 1991, BIOCHEM PHARMACOL, V42, P2323, DOI 10.1016/0006-2952(91)90237-Y; Rao PS, 1996, TOXICOL APPL PHARM, V140, P235, DOI 10.1006/taap.1996.0218; RAO VC, 1993, ARCH TOXICOL, V67, P392, DOI 10.1007/BF01977400; RAO VC, 1991, TOXICOL PATHOL, V19, P597, DOI 10.1177/019262339101900405; Rauscher FM, 2001, J BIOCHEM MOL TOXIC, V15, P41, DOI 10.1002/1099-0461(2001)15:1<41::AID-JBT5>3.3.CO;2-Q; REINKE LA, 1985, DRUG METAB DISPOS, V13, P548; Roberts RA, 2002, TOXICOL SCI, V68, P270, DOI 10.1093/toxsci/68.2.270; Salminen WF, 1998, J PHARMACOL EXP THER, V286, P519; Salminen WF, 1997, TOXICOL APPL PHARM, V147, P247, DOI 10.1006/taap.1997.8290; Shankar K, 2003, TOXICOL SCI, V73, P220, DOI 10.1093/toxsci/kfg059; Shankar K, 2003, TOXICOL APPL PHARM, V188, P122, DOI 10.1016/S0041-008X(02)00037-6; TSUKAMOTO I, 1989, BIOCHIM BIOPHYS ACTA, V1009, P191, DOI 10.1016/0167-4781(89)90101-2; Vanden Heuvel JP, 1999, TOXICOL SCI, V47, P1, DOI 10.1093/toxsci/47.1.1; Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557; Walker NJ, 2001, J BIOCHEM MOL TOXIC, V15, P121, DOI 10.1002/jbt.8; Wang J, 2001, J CERAM PROCESS RES, V2, P27; Wang T, 2000, TOXICOL APPL PHARM, V166, P92, DOI 10.1006/taap.2000.8952; Wang T, 2000, J PHARMACOL EXP THER, V294, P473; Yamagami K, 1998, J SURG RES, V79, P47, DOI 10.1006/jsre.1998.5403; Yamagishi N, 2001, LIFE SCI, V69, P2603, DOI 10.1016/S0024-3205(01)01337-6; Yamamoto H, 2000, RES EXP MED, V199, P309, DOI 10.1007/s004339900040; Zaher H, 1998, TOXICOL APPL PHARM, V152, P193, DOI 10.1006/taap.1998.8501	61	48	48	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1748	+		10.1096/fj.02-1186fje	http://dx.doi.org/10.1096/fj.02-1186fje			33	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958197				2022-12-28	WOS:000184471600016
J	Heidbreder, M; Frohlich, F; Johren, O; Dendorfer, A; Qadri, F; Dominiak, P				Heidbreder, M; Frohlich, F; Johren, O; Dendorfer, A; Qadri, F; Dominiak, P			Hypoxia rapidly activates HIF-3a mRNA expression	FASEB JOURNAL			English	Article						hypoxia-inducible factors; systemic hypoxia; PAS proteins	INDUCIBLE FACTOR-I; PAS DOMAIN PROTEIN; FACTOR 1-ALPHA; TARGET GENES; NUCLEAR TRANSLOCATION; CEREBRAL-ISCHEMIA; ALPHA-SUBUNITS; RAT; TRANSCRIPTION; CELLS	The role of the hypoxia-inducible factor (HIF) subunits 1alpha and 1beta in cellular response to hypoxia is well established, whereas little is known about HIF-2alpha and HIF-3alpha with respect to organ distribution and transcriptional regulation by hypoxia. We investigated mRNA levels of all HIF subunits and of their target genes erythropoietin (EPO) and glucose-transporter 1 (GLUT1) in rats undergoing systemic hypoxia for 30 or 120 min by quantitative real-time RT-PCR. In normoxia, persistently high mRNA levels of all HIF subunits were detected in cerebral cortex, hippocampus, and lung; the heart contained the lowest amounts. Hypoxia did not affect mRNA levels of HIF-1alpha, -1beta, and -2alpha. HIF-3alpha mRNA levels increased in all organs examined after 2 h of hypoxia. A significant rise of EPO and GLUT1 mRNA levels occurred in cortex, heart, liver, and kidney after 2 h of hypoxia, indicating activation of the HIF system. Protein levels of all HIF subunits, determined in brain and lung by immunoblotting, showed a marked increase corresponding to the duration of hypoxia. Our results suggest that induction at the transcriptional level is a unique feature of HIF-3alpha, which therefore may represent a rapidly reacting component of the HIF system in protection against hypoxic damage.	Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany	University of Lubeck	Heidbreder, M (corresponding author), Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, Ratzeburger Allee 160, D-23538 Lubeck, Germany.	heidbred@medinf.mu-luebeck.de	Jöhren, Olaf/G-6967-2011; Bader, Michael/K-2124-2013	Joehren, Olaf/0000-0002-0532-5133				Ambrosini G, 2002, J BIOL CHEM, V277, P34601, DOI 10.1074/jbc.M205172200; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Bernaudin M, 2002, J CEREBR BLOOD F MET, V22, P393, DOI 10.1097/00004647-200204000-00003; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Brusselmans K, 2001, J BIOL CHEM, V276, P39192, DOI 10.1074/jbc.C100428200; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Drutel G, 1996, BIOCHEM BIOPH RES CO, V225, P333, DOI 10.1006/bbrc.1996.1176; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gorlach A, 2000, BBA-GENE STRUCT EXPR, V1493, P125, DOI 10.1016/S0167-4781(00)00172-X; Gu YZ, 1998, GENE EXPRESSION, V7, P205; Hara S, 2001, BIOCHEM BIOPH RES CO, V287, P808, DOI 10.1006/bbrc.2001.5659; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Johren O, 2001, ENDOCRINOLOGY, V142, P3324, DOI 10.1210/en.142.8.3324; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kawata H, 2001, CIRC RES, V88, P696, DOI 10.1161/hh0701.088842; Kietzmann T, 2001, BIOCHEM J, V354, P531, DOI 10.1042/0264-6021:3540531; Kotch LE, 1999, DEV BIOL, V209, P254, DOI 10.1006/dbio.1999.9253; Madan A, 2002, MOL GENET METAB, V75, P244, DOI 10.1006/mgme.2001.3293; Makino Y, 2002, J BIOL CHEM, V277, P32405, DOI 10.1074/jbc.C200328200; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; NAGAO M, 1992, BIOCHIM BIOPHYS ACTA, V1171, P99, DOI 10.1016/0167-4781(92)90146-Q; Page EL, 2002, J BIOL CHEM, V277, P48403, DOI 10.1074/jbc.M209114200; Pugh CW, 1997, J BIOL CHEM, V272, P11205; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; Stroka DM, 2001, FASEB J, V15, P2445, DOI 10.1096/fj.01-0125com; Tajima H, 1999, NEUROREPORT, V10, P2029, DOI 10.1097/00001756-199907130-00007; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; TSO JY, 1985, NUCLEIC ACIDS RES, V13, P2485, DOI 10.1093/nar/13.7.2485; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; Wenger RH, 2002, FASEB J, V16, DOI 10.1096/fj.01-0944rev; Wiener CM, 1996, BIOCHEM BIOPH RES CO, V225, P485, DOI 10.1006/bbrc.1996.1199; Wolfrum S, 2002, CARDIOVASC RES, V55, P583, DOI 10.1016/S0008-6363(02)00408-X; Yu AY, 1999, J CLIN INVEST, V103, P691, DOI 10.1172/JCI5912; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 1999, CANCER RES, V59, P5830; Zhong H, 2000, CANCER RES, V60, P1541; Zou AP, 2001, PHYSIOL GENOMICS, V6, P159, DOI 10.1152/physiolgenomics.2001.6.3.159	55	148	168	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1541	+		10.1096/fj.02-0963fje	http://dx.doi.org/10.1096/fj.02-0963fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824304				2022-12-28	WOS:000183818000034
J	Kimes, AS; Horti, AG; London, ED; Chefer, SI; Contoreggi, C; Ernst, M; Friello, P; Koren, AO; Kurian, V; Matochik, JA; Pavlova, O; Vaupel, DB; Mukhin, AG				Kimes, AS; Horti, AG; London, ED; Chefer, SI; Contoreggi, C; Ernst, M; Friello, P; Koren, AO; Kurian, V; Matochik, JA; Pavlova, O; Vaupel, DB; Mukhin, AG			2-[F-18]F-A85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans	FASEB JOURNAL			English	Article						dosimetry; smoking; Alzheimer's disease; Parkinson's disease; non-invasive imaging	ALZHEIMERS-DISEASE; BINDING-SITES; C-11 NICOTINE; PARKINSONS; TRACER; RADIOLIGAND; POSTMORTEM; AFFINITY; SUBUNIT; SMOKING	Noninvasive imaging of nicotinic acetylcholine receptors (nAChRs) in the human brain in vivo is critical for elucidating the role of these receptors in normal brain function and in the pathogenesis of brain disorders. Here we report the first in vivo visualization of human brain areas containing nAChRs by using PET and 2-[F-18]fluoro-3-(2(S)azetidinylmethoxy)pyridine (2-[F-18]FA). We acquired scans from six healthy non-smoking volunteers after i.v. bolus administration of 2-[F-18]FA (1.6 MBq/kg or 0.043 +/- 0.002 mCi/kg). This dose was sufficient for visualizing nAChRs in the thalamus up to 5 h after injection. There were no adverse effects associated with administration of no-carrier-added 2-[F-18]FA (1.3-10 pmol/kg). Consistent with the distribution of nAChRs in human brain, accumulated radioactivity was greatest in thalamus, intermediate in the midbrain, pons, cerebellum, and cortex; and least in white matter. As similar to90% of the injected radioactivity was eliminated via the urine (biological half-life ca. 4 h), the urinary bladder wall received the highest radiation dose. The estimate of radiation dose equivalent to the urinary bladder wall (ca. 180 +/- 30 mSv/MBq or 0.7 rem/mCi with a 2.4 h void interval) suggests that multiple studies could be performed in a single subject. The results predict that quantitative PET imaging of nAChRs in human brain with 2-[F-18]FA is feasible.	NIDA, Intramural Res Program, Neuroimaging Res Branch, Baltimore, MD 21224 USA; Univ Calif Los Angeles, David Geffen Sch Med, Inst Neuropsychiat, Los Angeles, CA USA; NIMH, Intramural Res Program, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Kimes, AS (corresponding author), NIDA, Intramural Res Program, Neuroimaging Res Branch, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	akimes@intra.nida.nih.gov			NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000405, Z01DA000405] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abreo MA, 1996, J MED CHEM, V39, P817, DOI 10.1021/jm9506884; BERNIER DR, 1994, NUCL MED TECHNOLOGY; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; CHANGEUX JP, 1984, SCIENCE, V225, P1335, DOI 10.1126/science.6382611; Chefer SI, 2003, SYNAPSE, V48, P25, DOI 10.1002/syn.10180; Chefer SI, 2000, METMBS'00: PROCEEDINGS OF THE INTERNATIONAL CONFERENCE ON MATHEMATICS AND ENGINEERING TECHNIQUES IN MEDICINE AND BIOLOGICAL SCIENCES, VOLS I AND II, P409; Chefer SI, 1999, NEUROREPORT, V10, P2715, DOI 10.1097/00001756-199909090-00005; Chefer SI, 1998, LIFE SCI, V63, pPL355, DOI 10.1016/S0024-3205(98)00514-1; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; Court JA, 2000, J CHEM NEUROANAT, V20, P281, DOI 10.1016/S0891-0618(00)00110-1; DEROGATIS L R, 1973, Psychopharmacology Bulletin, V9, P13; Ding YS, 2000, NUCL MED BIOL, V27, P381, DOI 10.1016/S0969-8051(00)00094-9; Dolle F, 1999, J MED CHEM, V42, P2251, DOI 10.1021/jm9910223; Dolle F, 1998, J LABELLED COMPD RAD, V41, P451, DOI 10.1002/(SICI)1099-1344(199805)41:5<451::AID-JLCR111>3.0.CO;2-R; Epping-Jordan MP, 1999, PSYCHOPHARMACOLOGY, V147, P25, DOI 10.1007/s002130051135; Fujita M, 2002, EUR J NUCL MED MOL I, V29, P183, DOI 10.1007/s00259-001-0695-z; Fujita M, 2000, J NUCL MED, V41, P1552; HELLSTROMLINDAH.E, 1994, MOL BRAIN RES, V66, P94; Horti AG, 1998, J LABELLED COMPD RAD, V41, P309, DOI 10.1002/(SICI)1099-1344(199804)41:4<309::AID-JLCR78>3.0.CO;2-I; Horti AG, 1998, NUCL MED BIOL, V25, P599, DOI 10.1016/S0969-8051(98)00031-6; Koren AO, 1998, J MED CHEM, V41, P3690, DOI 10.1021/jm980170a; Loevinger R, 1991, MIRD PRIMER ABSORBED; Lundqvist H, 1998, ALZ DIS ASSOC DIS, V12, P238, DOI 10.1097/00002093-199809000-00018; Marubio LM, 1999, NATURE, V398, P805, DOI 10.1038/19756; MAZIERE M, 1995, BRAIN IMAGING NICOTI, P13; Mukhin AG, 2000, MOL PHARMACOL, V57, P642, DOI 10.1124/mol.57.3.642; Muzic RF, 1998, J NUCL MED, V39, P2048; Newhouse PA, 1997, DRUG AGING, V11, P206, DOI 10.2165/00002512-199711030-00005; NORDBERG A, 1990, J NEURAL TRANSM-PARK, V2, P215, DOI 10.1007/BF02257652; Nordberg A, 1997, DEMENT GERIATR COGN, V8, P78, DOI 10.1159/000106611; NORDBERG A, 1986, NEUROSCI LETT, V72, P115, DOI 10.1016/0304-3940(86)90629-4; OLSON L, 1992, J NEURAL TRANSM-PARK, V4, P79, DOI 10.1007/BF02257624; PAVLOVA OA, 2000, SOC NEUR ABSTR, V26, P627; Perry DC, 1999, J PHARMACOL EXP THER, V289, P1545; PERRY EK, 1995, NEUROSCIENCE, V64, P385, DOI 10.1016/0306-4522(94)00410-7; Picciotto MR, 1998, NATURE, V391, P173, DOI 10.1038/34413; Picciotto MR, 2002, J NEUROSCI, V22, P3338; Rasmussen T, 1998, PHARMACOL BIOCHEM BE, V60, P567, DOI 10.1016/S0091-3057(98)00003-3; RINNE JO, 1991, BRAIN RES, V547, P167; Robins L, 1995, DIAGNOSTIC INTERVIEW; Sihver W, 2000, BEHAV BRAIN RES, V113, P143, DOI 10.1016/S0166-4328(00)00209-6; Valette H, 1998, LIFE SCI, V64, pPL93, DOI 10.1016/S0024-3205(98)00573-6; Valette H, 2003, J NEUROCHEM, V84, P105, DOI 10.1046/j.1471-4159.2003.01502.x; Valette H, 1999, J NUCL MED, V40, P1374; VAUPEL DB, 2002, DRUG ALCOHOL DEPEN S, V1, pS187; Warpman U, 1995, NEUROREPORT, V6, P2419, DOI 10.1097/00001756-199511270-00033; Zachary R., 1986, SHIPLEY I LIVING SCA	47	96	97	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1331	+		10.1096/fj.02-0492fje	http://dx.doi.org/10.1096/fj.02-0492fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759330				2022-12-28	WOS:000183165000015
J	Cariou, B; Capitaine, N; Le Marcis, V; Vega, N; Bereziat, V; Kergoat, M; Laville, M; Girard, J; Vidal, H; Burnol, AF				Cariou, B; Capitaine, N; Le Marcis, V; Vega, N; Bereziat, V; Kergoat, M; Laville, M; Girard, J; Vidal, H; Burnol, AF			Increased adipose tissue expression of Grb14 in several models of insulin resistance	FASEB JOURNAL			English	Article						thiazolidinediones; zeta interacting protein; Goto-Kakizaki rats; insulin signaling	ACTIVATED RECEPTOR-GAMMA; HUMAN SKELETAL-MUSCLE; KINASE-C-ZETA; PHOSPHATIDYLINOSITOL 3-KINASE; GENE-EXPRESSION; DIFFERENTIAL REGULATION; HUMAN ADIPOCYTES; ADAPTER GRB14; PROTEINS; THIAZOLIDINEDIONES	Grb14 is an effector of insulin signaling, which directly inhibits insulin receptor catalytic activity in vitro. Here, we investigated whether the expression of Grb14 and its binding partner ZIP (PKC zeta interacting protein) is regulated during insulin resistance in type 2 diabetic rodents and humans. Grb14 expression was increased in adipose tissue of both ob/ob mice and Goto-Kakizaki ( GK) rats, whereas there was no difference in liver. An increase was also observed in subcutaneous adipose tissue of type 2 diabetic subjects when compared with controls. ZIP expression was increased in adipose tissue of ob/ob mice and type 2 diabetic patients, but it did not vary in GK rats. Hormonal regulation of Grb14 and ZIP expression was then investigated in 3T3-F442A adipocytes. In this model, insulin stimulated Grb14 expression, while TNF-alpha increased ZIP expression. Moreover, the insulin-sensitizing drugs thiazolidinediones (TZDs) decreased Grb14 expression in 3T3-F442A adipocytes. Finally, we investigated the dynamic regulation of Grb14 expression in ob/ob mice in several conditions improving their insulin sensitivity. Prolonged fasting and treatment with metformin significantly decreased Grb14 expression in peri-epidydimal adipose tissue, while there was only a trend to a diminution after TZD treatment. Taken together, these results suggest that the regulation of Grb14 expression in adipose tissue may play a physiological role in insulin sensitivity.	Univ Paris 05, CNRS, UMR 8104, INSERM,U567,Inst Cochin,Dept Endocrinol, F-75674 Paris, France; Fac Med R Laennec, Ctr Rech & Nutr Humaine Lyon, Lyon, France; Hop Edouard Herriot, Serv Endocrinol Diabetol & Nutr, Lyon, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; CHU Lyon	Burnol, AF (corresponding author), Univ Paris 05, CNRS, UMR 8104, INSERM,U567,Inst Cochin,Dept Endocrinol, F-75674 Paris, France.	burnol@cochin.inserm.fr	Vidal, Hubert/M-6674-2017; Díaz, Nicanor Vega/R-4903-2019; Burnol, Anne-Francoise/P-2181-2017	Vidal, Hubert/0000-0002-9467-0317; Cariou, Bertrand/0000-0002-1580-8040; BEREZIAT, Veronique/0000-0002-9795-549X				Adams M, 1997, J CLIN INVEST, V100, P3149, DOI 10.1172/JCI119870; Bereziat V, 2002, J BIOL CHEM, V277, P4845, DOI 10.1074/jbc.M106574200; Cariou B, 2002, MOL CELL BIOL, V22, P6959, DOI 10.1128/MCB.22.20.6959-6970.2002; Chua SC, 1996, SCIENCE, V271, P994, DOI 10.1126/science.271.5251.994; COONEY GJ, 2004, IN PRESS EMBO J; Daly RJ, 1998, CELL SIGNAL, V10, P613, DOI 10.1016/S0898-6568(98)00022-9; Daly RJ, 1996, J BIOL CHEM, V271, P12502, DOI 10.1074/jbc.271.21.12502; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; GARVEY WT, 1992, DIABETES, V41, P465, DOI 10.2337/diabetes.41.4.465; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Han DC, 2001, ONCOGENE, V20, P6315, DOI 10.1038/sj.onc.1204775; Hemming R, 2001, BIOCHEM CELL BIOL, V79, P21, DOI 10.1139/bcb-79-1-21; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Jiang GQ, 2002, DIABETES, V51, P2412, DOI 10.2337/diabetes.51.8.2412; Joung I, 1996, P NATL ACAD SCI USA, V93, P5991, DOI 10.1073/pnas.93.12.5991; Kasus-Jacobi A, 1998, J BIOL CHEM, V273, P26026, DOI 10.1074/jbc.273.40.26026; Kerouz NJ, 1997, J CLIN INVEST, V100, P3164, DOI 10.1172/JCI119872; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Motoshima H, 2002, J CLIN ENDOCR METAB, V87, P5662, DOI 10.1210/JC.2002-020635; ORourke CM, 1997, METABOLISM, V46, P192, DOI 10.1016/S0026-0495(97)90301-2; OSTMAN J, 1979, METABOLISM, V28, P1198, DOI 10.1016/0026-0495(79)90131-8; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Ribon V, 1998, P NATL ACAD SCI USA, V95, P14751, DOI 10.1073/pnas.95.25.14751; Rieusset J, 2001, DIABETOLOGIA, V44, P544, DOI 10.1007/s001250051660; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Sanz L, 1999, EMBO J, V18, P3044, DOI 10.1093/emboj/18.11.3044; SHAFRIR E, 1992, DIABETES METAB REV, V8, P179, DOI 10.1002/dmr.5610080302; Smith U, 2002, INT J OBESITY, V26, P897, DOI 10.1038/sj.ijo.0802028; Smith U, 2001, FASEB J, V15, P215, DOI 10.1096/fj.00-0020com; Wick KR, 2003, J BIOL CHEM, V278, P8460, DOI 10.1074/jbc.M208518200; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	36	50	52	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					965	+		10.1096/fj.03-0824fje	http://dx.doi.org/10.1096/fj.03-0824fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059968				2022-12-28	WOS:000221108800019
J	Yamashita, K; McDaid, J; Ollinger, R; Tsui, TY; Berberat, PO; Usheva, A; Csizmadia, E; Smith, RN; Soares, MP; Bach, FH				Yamashita, K; McDaid, J; Ollinger, R; Tsui, TY; Berberat, PO; Usheva, A; Csizmadia, E; Smith, RN; Soares, MP; Bach, FH			Biliverdin, a natural product of heme catabolism, induces tolerance to cardiac allografts	FASEB JOURNAL			English	Article						heme oxygenase-1; heart transplantation; tolerance; T cells	ALLOREACTIVE T-CELLS; BILIRUBIN; OXYGENASE-1; ACTIVATION; PROTEIN; PREVENTS; DISEASE; PROLIFERATION; ASSOCIATION; EXPRESSION	Biliverdin, a product of heme oxygenase-1 (HO-1) enzymatic action, is converted into bilirubin, which has been considered a waste product in the past. We now show that administration of biliverdin has a salutary effect in organ transplantation. A brief course of treatment with biliverdin leads to long-term survival of H-2 incompatible heart allografts. Furthermore, those recipients harboring long-surviving (>100 days) allografts were tolerant to donor antigens indicated by the acceptance of second donor strain hearts but not third-party grafts. Treatment with biliverdin decreased intragraft leukocyte infiltration and inhibited T cell proliferation. Likely related to tolerance induction, biliverdin interferes with T cell signaling by inhibiting activation of nuclear factor of activated T cells (NEAT) and nuclear factor kappaB (NF-kappaB), two transcription factors involved in interleukin-2 (IL-2) transcription and T cell proliferation, as well as suppressing Th1 interferon-gamma (IFN-gamma) production in vitro. These findings support the potential use of biliverdin, a natural product, in transplantation and other T cell mediated immune disorders.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Immunobiol Res Ctr, Boston, MA 02215 USA; Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg, Hong Kong, Hong Kong, Peoples R China; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of Hong Kong; Harvard University; Harvard Medical School; Massachusetts General Hospital; Instituto Gulbenkian de Ciencia	Yamashita, K (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	kyamashi@bidmc.harvard.edu	Öllinger, Robert/D-1538-2009; Soares, Miguel P/G-4188-2011	Ollinger, Robert/0000-0002-4499-1673; Soares, Miguel/0000-0002-9314-4833				Ahmad Z, 2002, J BIOL CHEM, V277, P9226, DOI 10.1074/jbc.M108239200; Bach FH, 1997, NAT MED, V3, P196, DOI 10.1038/nm0297-196; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Clark JE, 2003, CIRC RES, V93, pE2, DOI 10.1161/01.RES.0000084381.86567.08; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; CORRY RJ, 1973, TRANSPLANTATION, V16, P343, DOI 10.1097/00007890-197310000-00010; Djousse L, 2001, AM J CARDIOL, V87, P1196, DOI 10.1016/S0002-9149(01)01494-1; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Finn PW, 2001, J IMMUNOL, V167, P5994, DOI 10.4049/jimmunol.167.10.5994; Haga Y, 1996, DIGEST DIS SCI, V41, P1468, DOI 10.1007/BF02088574; Haga Y, 1996, BBA-MOL BASIS DIS, V1317, P65, DOI 10.1016/0925-4439(96)00039-7; HALL BM, 1984, TRANSPLANTATION, V37, P595, DOI 10.1097/00007890-198406000-00014; Hansen TWR, 1996, PEDIATR RES, V39, P1072, DOI 10.1203/00006450-199606000-00023; KUPIECWEGLINSKI JW, 1985, CELL IMMUNOL, V93, P168, DOI 10.1016/0008-8749(85)90397-1; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Ozkaynak E, 2001, NAT IMMUNOL, V2, P591, DOI 10.1038/89731; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Sanchez-Fueyo A, 2002, J IMMUNOL, V168, P2274, DOI 10.4049/jimmunol.168.5.2274; SANO K, 1985, PEDIATR RES, V19, P587, DOI 10.1203/00006450-198506000-00017; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; SCHWERTNER HA, 1994, CLIN CHEM, V40, P18; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Suchin EJ, 2001, J IMMUNOL, V166, P973, DOI 10.4049/jimmunol.166.2.973; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; VACHHARAJANI TJ, 2000, AM J PHYSL HEART CIR, V278; Vitek L, 2002, ATHEROSCLEROSIS, V160, P449, DOI 10.1016/S0021-9150(01)00601-3; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; Woo J, 2000, TRANSPLANTATION, V69, P623, DOI 10.1097/00007890-200002270-00026; YASUURA K, 1991, TRANSPLANTATION, V51, P896, DOI 10.1097/00007890-199104000-00031	36	159	168	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					765	+		10.1096/fj.03-0839fje	http://dx.doi.org/10.1096/fj.03-0839fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977878				2022-12-28	WOS:000220425000018
J	Bua, EA; McKiernan, SH; Aiken, JM				Bua, EA; McKiernan, SH; Aiken, JM			Calorie restriction limits the generation but not the progression of mitochondrial abnormalities in aging skeletal muscle	FASEB JOURNAL			English	Article						age; skeletal muscle; atrophy	DNA DELETION MUTATIONS; DIETARY RESTRICTION; RAT MUSCLE; SARCOPENIA; ATROPHY; STRESS; DAMAGE; LIVER	The effect of early-onset calorie restriction and aging on the accumulation of electron transport system (ETS) abnormalities was studied in rat skeletal muscle. Rectus femoris and vastus lateralis muscle fibers were analyzed for cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) enzyme activities. Fibers displaying COX negative and SDH hyper reactive (COX-/SDH++) phenotype were followed through 1000-2000 micrometers to determine the frequency and length of these abnormalities as well as the physiological impact on fiber structure. Calorie restricted rats had fewer ETS abnormal muscle fibers. The mean length of ETS abnormal regions in ad libitum rat muscle fibers was similar to calorie restricted rat muscles. ETS abnormal fibers from both diet groups exhibited intra-fiber atrophy. A negative correlation between ETS abnormality length and fiber cross-sectional area (CSA) ratio was observed in both ad libitum and calorie-restricted rats. Although calorie restriction reduced the number of ETS abnormalities, it did not affect the length or associated fiber atrophy of ETS abnormal regions once the abnormality was established. Thus, calorie restriction affects the onset but not the progression of electron transport system abnormalities, thereby, limiting a process that ultimately results in fiber breakage and fiber loss.	Univ Wisconsin, Dept Anim Hlth & Biomed Sci, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Aiken, JM (corresponding author), Univ Wisconsin, Dept Anim Hlth & Biomed Sci, 1656 Linden Dr, Madison, WI 53706 USA.	jma@svm.vetmed.wisc.edu		Aiken, Judd/0000-0001-6119-4521				Aspnes LE, 1997, FASEB J, V11, P573, DOI 10.1096/fasebj.11.7.9212081; BENJAMIN IJ, 1989, CIRC RES, V65, P657, DOI 10.1161/01.RES.65.3.657; Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001; Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502; Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0; Cortopassi GA, 2002, MECH AGEING DEV, V123, P851, DOI 10.1016/S0047-6374(02)00022-2; Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100; Cottrell DA, 2001, NEUROPATH APPL NEURO, V27, P206, DOI 10.1046/j.1365-2990.2001.00315.x; Dubowitz V, 1985, MUSCLE BIOPSY PRACTI, P19; Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7; HART RW, 1990, EFFECTS CALORIC REST, P351; Kapahi P, 1999, FREE RADICAL BIO MED, V26, P495, DOI 10.1016/S0891-5849(98)00323-2; LARSSON L, 1995, PROG NEUROBIOL, V45, P397, DOI 10.1016/0301-0082(95)98601-Z; Lee CM, 1998, ANN NY ACAD SCI, V854, P182, DOI 10.1111/j.1749-6632.1998.tb09901.x; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; Lopez ME, 2000, MUTAT RES-FUND MOL M, V452, P123, DOI 10.1016/S0027-5107(00)00059-2; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; MCKIERNAN SH, IN PRESS EARLY ONSET; Merry BJ, 2002, INT J BIOCHEM CELL B, V34, P1340, DOI 10.1016/S1357-2725(02)00038-9; Morley JE, 2001, J LAB CLIN MED, V137, P231, DOI 10.1067/mlc.2001.113504; Nair K S, 2000, Mayo Clin Proc, V75 Suppl, pS14; Nikolic M, 2001, COLLEGIUM ANTROPOL, V25, P545; RAO G, 1990, J NUTR, V120, P602, DOI 10.1093/jn/120.6.602; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sreekumar R, 2002, AM J PHYSIOL-ENDOC M, V283, pE38, DOI 10.1152/ajpendo.00387.2001; VANZEELAND N, 1999, J ANTI-AGING MED, V2, P231; WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Welle S, 2002, CAN J APPL PHYSIOL, V27, P19, DOI 10.1139/h02-002; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6	31	36	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					582	+		10.1096/fj.03-0668fje	http://dx.doi.org/10.1096/fj.03-0668fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734641				2022-12-28	WOS:000188829300003
J	Mair, GR; Niciu, MJ; Stewart, MT; Brennan, G; Omar, H; Halton, DW; Mains, R; Eipper, BA; Maule, AG; Day, TA				Mair, GR; Niciu, MJ; Stewart, MT; Brennan, G; Omar, H; Halton, DW; Mains, R; Eipper, BA; Maule, AG; Day, TA			A functionally atypical amidating enzyme from the human parasite Schistosoma mansoni	FASEB JOURNAL			English	Article						peptidylglycine alpha-hydroxylating monooxygenase; neuropeptide F; FMRFamide; schistosome; helminth	ALPHA-HYDROXYLATING MONOOXYGENASE; FMRFAMIDE-RELATED PEPTIDES; HUMAN BLOOD FLUKE; NEUROPEPTIDE-F; PROCESSING ENZYME; MONIEZIA-EXPANSA; NERVOUS-SYSTEM; CLONING; PROTEIN; MUSCLE	Many neuropeptide transmitters require the presence of a carboxy-terminal alpha-amide group for biological activity. Amidation requires conversion of a glycine-extended peptide intermediate into a C-terminally amidated product. This post-translational modification depends on the sequential action of two enzymes (peptidylglycine alpha-hydroxylating monooxygenase or PHM, and peptidyl-alpha-hydroxyglycine alpha-amidating lyase or PAL) that in most eukaryotes are expressed as separate domains of a single protein (peptidylglycine alpha-amidating monooxygenase or PAM). We identified a cDNA encoding PHM in the human parasite Schistosoma mansoni. Transient expression of schistosome PHM (smPHM) revealed functional properties that are different from other PHM proteins; smPHM displays a lower pH-optimum and, when expressed in mammalian cells, is heavily N-glycosylated. In adult worms, PHM is found in the trans-Golgi network and secretory vesicles of both central and peripheral nerves. The widespread occurrence of PHM in the nervous system confirms the important role of amidated neuropeptides in these parasitic flatworms. The differences between schistosome and mammalian PHM suggest that it could be a target for new chemotherapeutics.	Iowa State Univ, Dept Biomed Sci, Ames, IA 50011 USA; Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Parasitol Res Grp, Belfast BT9 7BL, Antrim, North Ireland; Univ Connecticut, Ctr Hlth, Dept Neurosci, Farmington, CT 06030 USA	Iowa State University; Queens University Belfast; University of Connecticut	Day, TA (corresponding author), Iowa State Univ, Dept Biomed Sci, 2036 Vet Med Bldg, Ames, IA 50011 USA.	day@iastate.edu	Niciu, Mark J/J-1766-2014	Niciu, Mark J/0000-0002-5612-3021; Mair, Gunnar/0000-0002-5187-3691; Day, Tim/0000-0002-9037-6540; Maule, Aaron/0000-0003-0862-2667	NIAID NIH HHS [R01-AI49162, N01-AI-55270] Funding Source: Medline; NIDDK NIH HHS [DK-32949] Funding Source: Medline; NIGMS NIH HHS [GM08607] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI055270, R01AI049162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032949, R01DK032949, R56DK032949] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; Armstrong EP, 1997, J COMP NEUROL, V377, P41, DOI 10.1002/(SICI)1096-9861(19970106)377:1&lt;41::AID-CNE5&gt;3.0.CO;2-J; Bolkenius FN, 1998, GEN PHARMACOL, V31, P655, DOI 10.1016/S0306-3623(98)00192-X; Caldwell BD, 1999, J BIOL CHEM, V274, P34646, DOI 10.1074/jbc.274.49.34646; Cioli D, 2000, CURR OPIN INFECT DIS, V13, P659, DOI 10.1097/00001432-200012000-00014; CURRY WJ, 1992, COMP BIOCHEM PHYS C, V101, P269, DOI 10.1016/0742-8413(92)90272-9; Day TA, 1997, PEPTIDES, V18, P917, DOI 10.1016/S0196-9781(97)00073-9; DAY TA, 1994, PARASITOLOGY, V109, P455, DOI 10.1017/S0031182000080707; Day TA, 1999, PEPTIDES, V20, P999, DOI 10.1016/S0196-9781(99)00093-5; Dougan PM, 2002, J COMP NEUROL, V454, P58, DOI 10.1002/cne.10440; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Fairweather I, 1995, ACTA BIOL HUNG, V46, P211; Fan XM, 2000, MOL BRAIN RES, V82, P25, DOI 10.1016/S0169-328X(00)00173-X; Geary TG, 1999, ANN NY ACAD SCI, V897, P212, DOI 10.1111/j.1749-6632.1999.tb07893.x; GUAN JL, 1985, CELL, V42, P489, DOI 10.1016/0092-8674(85)90106-0; Hauser F, 1997, BIOCHEM BIOPH RES CO, V241, P509, DOI 10.1006/bbrc.1997.7854; HUSTEN EJ, 1994, ARCH BIOCHEM BIOPHYS, V312, P487, DOI 10.1006/abbi.1994.1336; Ismail M, 1999, AM J TROP MED HYG, V60, P932, DOI 10.4269/ajtmh.1999.60.932; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; Johnston RN, 1996, J NEUROCHEM, V67, P814; JOHNSTON RN, 1995, BIOCHEM BIOPH RES CO, V209, P689, DOI 10.1006/bbrc.1995.1554; Kolhekar AS, 1997, BIOCHEMISTRY-US, V36, P10901, DOI 10.1021/bi9708747; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Kolhekar AS, 1998, J BIOL CHEM, V273, P23012, DOI 10.1074/jbc.273.36.23012; LACKEY DB, 1992, J BIOL CHEM, V267, P17508; Mair GR, 1998, PARASITOL TODAY, V14, P73, DOI 10.1016/S0169-4758(97)01182-4; Mair GR, 2000, PARASITOLOGY, V121, P163, DOI 10.1017/S0031182099006174; Mair GR, 2000, PARASITOLOGY, V120, P71, DOI 10.1017/S0031182099005296; MARKS NJ, 1995, PARASITOLOGY, V110, P371, DOI 10.1017/S0031182000064714; Maule Aaron G., 2002, Current Topics in Medicinal Chemistry, V2, P733, DOI 10.2174/1568026023393697; MAULE AG, 1991, PARASITOLOGY, V102, P309, DOI 10.1017/S0031182000062648; Milgram SL, 1997, J CELL SCI, V110, P695; MIYAZONO K, 1992, J BIOL CHEM, V267, P5668; NAIR PM, 1985, INDIAN J BIOCHEM BIO, V22, P339; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Oyarce AM, 2000, J BIOL CHEM, V275, P3270, DOI 10.1074/jbc.275.5.3270; Prigge ST, 1999, NAT STRUCT BIOL, V6, P976; Prigge ST, 2000, CELL MOL LIFE SCI, V57, P1236, DOI 10.1007/PL00000763; Remme JHF, 2002, TRENDS PARASITOL, V18, P421, DOI 10.1016/S1471-4922(02)02387-5; Skelly PJ, 2001, PARASITOLOGY, V123, P277, DOI 10.1017/S0031182001008484; SKUCE PJ, 1990, CELL TISSUE RES, V261, P573, DOI 10.1007/BF00313537; SKUCE PJ, 1990, PARASITOLOGY, V101, P227, DOI 10.1017/S0031182000063277; SOLISSOTO JM, 1994, PARASITOLOGY, V108, P301, DOI 10.1017/S0031182000076149; Spijker S, 1999, FASEB J, V13, P735, DOI 10.1096/fasebj.13.6.735	45	31	31	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					114	121		10.1096/fj.03-0429com	http://dx.doi.org/10.1096/fj.03-0429com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718392				2022-12-28	WOS:000188829300045
J	Wang, YC; Ho, CC				Wang, YC; Ho, CC			Micropatterning of proteins and mammalian cells on biomaterials	FASEB JOURNAL			English	Article						microcontact printing; chitosan; scaffold; microfabrication	IN-VITRO; TISSUE; GROWTH; FABRICATION; MATRIX; VIVO; ATTACHMENT; SURFACES; CHITOSAN	Controlling the spatial organization of cells is vital in engineering tissues that require precisely defined cellular architectures. For example, functional nerves or blood vessels form only when groups of cells are organized and aligned in very specific geometries. Yet, scaffold designs incorporating spatially defined physical cues such as microscale surface topographies or spatial patterns of extracellular matrix to guide the spatial organization and behavior of cells cultured in vitro remain largely unexplored. Here we demonstrate a new approach for controlling the spatial organization, spreading, and orientation of cells on two micropatterned biomaterials: chitosan and gelatin. Biomaterials with grooves of defined width and depth were fabricated using a two-step soft lithography process. Selective attachment and spreading of cells within the grooves was ensured by covalently modifying the plateau regions with commercially available protein resistant triblock copolymers. Precise spatial control over cell spreading and orientation has been observed when human microvascular endothelial cells are cultured on these patterned biomaterials, suggesting the potential of this technique in creating tissue culture scaffolds with defined chemical and topographical features.	Univ Cincinnati, Dept Chem & Mat Engn, Cincinnati, OH 45221 USA	University System of Ohio; University of Cincinnati	Ho, CC (corresponding author), Univ Cincinnati, Dept Chem & Mat Engn, Cincinnati, OH 45221 USA.	cho@alpha.che.uc.edu						Arevalo-Silva CA, 2001, TISSUE ENG, V7, P81, DOI 10.1089/107632700300003314; Badylak SF, 2002, ANN NY ACAD SCI, V961, P302, DOI 10.1111/j.1749-6632.2002.tb03107.x; BELLAMKONDA R, 1995, J BIOMED MATER RES, V29, P663, DOI 10.1002/jbm.820290514; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.3.CO;2-4; Brunette DM, 1999, J BIOMECH ENG-T ASME, V121, P49, DOI 10.1115/1.2798042; CIMA LG, 1994, J CELL BIOCHEM, V56, P155, DOI 10.1002/jcb.240560206; Deutsch J, 2000, J BIOMED MATER RES, V53, P267, DOI 10.1002/(SICI)1097-4636(2000)53:3<267::AID-JBM12>3.0.CO;2-J; DIGENIS GA, 1994, J PHARM SCI, V83, P915, DOI 10.1002/jps.2600830702; Dike LE, 1999, IN VITRO CELL DEV-AN, V35, P441; Esposito E, 1996, BIOMATERIALS, V17, P2009, DOI 10.1016/0142-9612(95)00325-8; Germain L, 2002, ANN NY ACAD SCI, V961, P268, DOI 10.1111/j.1749-6632.2002.tb03099.x; Griffith LG, 1997, ANN NY ACAD SCI, V831, P382; Hirschi KK, 2002, ANN NY ACAD SCI, V961, P223, DOI 10.1111/j.1749-6632.2002.tb03090.x; HUBBELL JA, 1995, BIO-TECHNOL, V13, P565, DOI 10.1038/nbt0695-565; Hutmacher DW, 2001, J BIOMAT SCI-POLYM E, V12, P107, DOI 10.1163/156856201744489; Huynh T, 1999, NAT BIOTECHNOL, V17, P1083, DOI 10.1038/15062; Illum L, 1998, PHARM RES-DORDR, V15, P1326; Jasmund Inka, 2002, Adv Biochem Eng Biotechnol, V74, P99; Kirkpatrick CJ, 2002, BIOMOL ENG, V19, P211, DOI 10.1016/S1389-0344(02)00019-9; KLEINFELD D, 1988, J NEUROSCI, V8, P4098; Lu LC, 2001, BIOMATERIALS, V22, P291, DOI 10.1016/S0142-9612(00)00179-4; Mata A, 2002, J BIOMED MATER RES, V62, P499, DOI 10.1002/jbm.10353; MATSUDA T, 1995, J BIOMED MATER RES, V29, P749, DOI 10.1002/jbm.820290611; McIntire LV, 2002, ANN NY ACAD SCI, V961, P246, DOI 10.1111/j.1749-6632.2002.tb03092.x; McPherson TB, 1997, J BIOMED MATER RES, V38, P289; Mrksich M, 1996, P NATL ACAD SCI USA, V93, P10775, DOI 10.1073/pnas.93.20.10775; Murray MM, 2003, J ORTHOPAED RES, V21, P238, DOI 10.1016/S0736-0266(02)00142-0; Parikh S N, 2002, J Postgrad Med, V48, P142; Risbud MV, 2002, TRENDS BIOTECHNOL, V20, P351, DOI 10.1016/S0167-7799(02)02016-4; SINGHVI R, 1994, SCIENCE, V264, P696, DOI 10.1126/science.8171320; Thompson DM, 2001, TISSUE ENG, V7, P247, DOI 10.1089/10763270152044125; Wang YC, 2003, BIOMATERIALS, V24, P1047, DOI 10.1016/S0142-9612(02)00434-9; Warren SM, 2002, J NEUROSURG, V97, P481, DOI 10.3171/spi.2002.97.4.0481; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899	35	51	56	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					525	+		10.1096/fj.03-0490fje	http://dx.doi.org/10.1096/fj.03-0490fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715699				2022-12-28	WOS:000188829300032
J	Brunelli, R; Greco, G; Barteri, M; Krasnowska, EK; Mei, G; Natella, F; Pala, A; Rotella, S; Ursini, F; Zichella, L; Parasassi, T				Brunelli, R; Greco, G; Barteri, M; Krasnowska, EK; Mei, G; Natella, F; Pala, A; Rotella, S; Ursini, F; Zichella, L; Parasassi, T			One site on the apoB-100 specifically binds 17-beta-estradiol and regulates the overall structure of LDL	FASEB JOURNAL			English	Article						electronegative LDL; equilibrium dialysis; circular dichroism; SAXS	LOW-DENSITY-LIPOPROTEIN; APOLIPOPROTEIN B-100; OXIDATION; RECEPTOR; EXPRESSION; PARTICLES; AROMATASE; ESTROGEN; BEHAVIOR	The major protein component (apoB-100) of low-density lipoprotein (LDL) is known as a multipotential molecule the several functional regions of which can all be affected by key structural modifications driven by specific domains. Based on our previous report on structural and conformational modifications of apoB-100 in the presence of 17-beta-estradiol (E-2), we characterized the interaction between E-2 and the apoB-100 and further explored the induced alterations in terms of the structural arrangement of the whole LDL particle. We report evidence for the existence on apoB-100 of a single specific and saturable binding site for E-2, the occupancy of which modifies the overall structure of the protein, inducing an increase in the alpha-helix fraction. As a consequence, the structure of the LDL particle is deeply perturbed, with a change in the arrangement of both the outer shell and lipid core and an overall volume shrinkage. The evidence of a regulation of apoB-100 structure by a physiological ligand opens new perspectives in the study of the biological addressing of the LDL particle and suggests a novel rationale in the search for mechanisms underlying the beneficial role of E-2 in decreasing the risk of early lesions in atherosclerosis.	CNR, Ist Neurobiol & Med Mol, I-00137 Rome, Italy; Univ Roma La Sapienza, Dipartimento Sci Ginecol Perinatol & Puericultura, Rome, Italy; Univ Roma La Sapienza, Dipartimento Chim, I-00185 Rome, Italy; Univ Roma Tor Vergata, Dipartimento Med Sperimentale & Sci Biochim, Rome, Italy; Ist Nazl Ric Alimenti & Nutr, Rome, Italy; Univ Padua, Dipartimento Chim Biol, Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; Sapienza University Rome; University of Rome Tor Vergata; Consiglio per la Ricerca in Agricoltura e L'analisi Dell'economia Agraria (CREA); University of Padua	Parasassi, T (corresponding author), CNR, Ist Neurobiol & Med Mol, Viale Marx 15-43, I-00137 Rome, Italy.	t.parasassi@in.rm.cnr.it	fausta, natella/AGR-5829-2022	fausta, natella/0000-0002-1999-9817; Parasassi, Tiziana/0000-0002-9795-0568				BENVENGA S, 1990, ENDOCRINOLOGY, V127, P2241, DOI 10.1210/endo-127-5-2241; BENVENGA S, 1988, J CLIN ENDOCR METAB, V67, P6, DOI 10.1210/jcem-67-1-6; Boren J, 1998, J CLIN INVEST, V101, P2658, DOI 10.1172/JCI2265; Brunelli R, 2000, BIOCHEMISTRY-US, V39, P13897, DOI 10.1021/bi000341p; Cantor C. R., 1980, BIOPHYSICAL CHEM 3; CHATTERTON JE, 1995, J LIPID RES, V36, P2027; Ettelaie C, 1997, BBA-LIPID LIPID MET, V1345, P237, DOI 10.1016/S0005-2760(96)00185-3; Glatter O., 1982, SMALL ANGLE XRAYS SC; Guevara J, 1996, J PROTEIN CHEM, V15, P17, DOI 10.1007/BF01886807; Guevara JG, 1999, J PROTEIN CHEM, V18, P845, DOI 10.1023/A:1020627212272; Harada N, 1999, CIRC RES, V84, P1285, DOI 10.1161/01.RES.84.11.1285; Harada N, 1999, ONCOLOGY-BASEL, V57, P7, DOI 10.1159/000055270; Hevonoja T, 2000, BBA-MOL CELL BIOL L, V1488, P189, DOI 10.1016/S1388-1981(00)00123-2; HOFF HF, 1995, CURR OPIN LIPIDOL, V6, P317, DOI 10.1097/00041433-199510000-00012; LESZCZYNSKI D E, 1989, Steroids, V54, P37, DOI 10.1016/0039-128X(89)90074-3; LOSORDO DW, 1994, CIRCULATION, V89, P1501, DOI 10.1161/01.CIR.89.4.1501; Lund-Katz S, 1998, BIOCHEMISTRY-US, V37, P12867, DOI 10.1021/bi980828m; Meyer DF, 1996, BIOCHEM J, V319, P217, DOI 10.1042/bj3190217; MULLER K, 1978, EUR J BIOCHEM, V82, P73, DOI 10.1111/j.1432-1033.1978.tb11998.x; Nielsen LB, 1996, ATHEROSCLEROSIS, V123, P1, DOI 10.1016/0021-9150(96)05802-9; OLSSON U, 1993, BIOCHEMISTRY-US, V32, P1858, DOI 10.1021/bi00058a020; Parasassi T, 2000, FREE RADICAL BIO MED, V28, P1589, DOI 10.1016/S0891-5849(00)00275-6; Pentikainen MO, 2001, J LIPID RES, V42, P916; PRASSL R, 1995, BIOCHEMISTRY-US, V34, P3795, DOI 10.1021/bi00011a037; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; Rutledge JC, 1997, CIRC RES, V80, P819; SCHUMAKER VN, 1994, ADV PROTEIN CHEM, V45, P205; Segrest JP, 2001, J LIPID RES, V42, P1346; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Shwaery GT, 1998, ATHEROSCLEROSIS, V138, P255, DOI 10.1016/S0021-9150(98)00020-3; SINGH S, 1986, BIOCHIM BIOPHYS ACTA, V876, P460, DOI 10.1016/0005-2760(86)90032-9; Stafforini DM, 1999, J BIOL CHEM, V274, P7018, DOI 10.1074/jbc.274.11.7018; Tang M, 1997, J LAB CLIN MED, V129, P447, DOI 10.1016/S0022-2143(97)90078-0; Ursini F, 2002, TRENDS MOL MED, V8, P370, DOI 10.1016/S1471-4914(02)02382-1; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; Xu SH, 1998, BIOCHEMISTRY-US, V37, P9284, DOI 10.1021/bi9729662	36	13	13	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2127	+		10.1096/fj.02-1181fje	http://dx.doi.org/10.1096/fj.02-1181fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500554				2022-12-28	WOS:000185925100001
J	Namazi, MR				Namazi, MR			Nicotinamide: a potential addition to the anti-psoriatic weaponry	FASEB JOURNAL			English	Article						AIDS; interleukin 12; nicotinamide; PARP; psoriasis; protein kinase C; T helper cell; treatment; tumor necrosis factor-alpha	CELL-DIFFERENTIATION; HISTAMINE-RELEASE; INDUCED ARTHRITIS; MAST-CELLS; PSORIASIS; METHOTREXATE; INHIBITION; BLOOD; MICE	Psoriasis is an inflammatory disorder characterized by a T helper type 1 cell cytokine pattern. Increased expression of adhesion molecules, prominent neutrophil accumulation, and increased production of nitric oxide are characteristics of this disorder. Moreover, histamine and proteases are supposed to participate in the pathogenesis of psoriasis. Nicotinamide is an inhibitor of poly (ADP-ribose) polymerase-1 (PARP-1) that, through enhancement of nuclear kappa B-mediated transcription, plays a pivotal role in the expression of inflammatory cytokines, chemokines, adhesion molecules, and inflammatory mediators. Through interaction with CD38 and inhibition of IL-1, IL-12, and TNF-alpha production, nicotinamide produces a mild TH2 bias. Nicotinamide is a potent phosphodiesterase inhibitor and suppresses neutrophil chemotaxis and mast cell histamine release. It inhibits nitric oxide synthase mRNA induction and suppresses antigen-induced lymphocyte transformation. Nicotinamide increases the biosynthesis of ceramides, which upon degradation produce sphingosine. Sphingosine inhibits protein kinase C (PKC) and decreases basal cell proliferation dependent on PKC. Taken together, it can be reasoned that nicotinamide could be a useful addition to anti-psoriatic armamentarium. The combination of nicotinamide and thalidomide or methotrexate provided a powerful synergistic inhibition of murine collagen-induced arthritis. Nicotinamide decreased the methotrexate-induced hepatotoxicity. The above combinations may prove to have a powerful anti-psoriatic effect as well. As PARP inhibitors could exert anti-retroviral effect, nicotinamide could also be of special value in the treatment of HIV-infected psoriatics.	Shiraz Univ Med Sci, Dept Dermatol, Shiraz, Iran	Shiraz University of Medical Science	Namazi, MR (corresponding author), POB 71955687, Shiraz, Iran.	namazi_mr@yahoo.com	namazi, mohammad reza/E-3197-2018	namazi, mohammad reza/0000-0002-7409-7437				BERK MA, 1986, ARCH DERMATOL, V122, P670, DOI 10.1001/archderm.122.6.670; BURGER DR, 1976, J IMMUNOL, V117, P797; Cather Jennifer, 2002, Am J Clin Dermatol, V3, P159, DOI 10.2165/00128071-200203030-00003; CHRISTOPHERS E, 1999, FITZPATRICKS DERMATO, V1, P495; FRAKI JE, 1983, BRIT J DERMATOL, V108, P39, DOI 10.1111/j.1365-2133.1983.tb04577.x; HIROMATSU Y, 1993, IMMUNOLOGY, V80, P330; Kolb H, 1999, DIABETES CARE, V22, pB16; Kretowski A, 2000, DIABETES RES CLIN PR, V47, P81, DOI 10.1016/S0168-8227(99)00122-9; Kroger H, 1998, INFLAMMATION, V22, P277, DOI 10.1023/A:1022348132132; Kroger H, 1999, GEN PHARMACOL, V33, P203, DOI 10.1016/S0306-3623(98)00232-8; Kroger H, 1996, INFLAMMATION, V20, P203, DOI 10.1007/BF01487406; Krueger JG, 2002, J AM ACAD DERMATOL, V46, P1, DOI 10.1067/mjd.2002.120568; MAOQIANG M, 1992, INT J DERMATOL, V31, P370; MEISEL M, 1995, INFLAMMATION, V19, P379; NAMAZI MR, 2003, IN PRESS IMMUNOL LET; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Ortonne JP, 1999, BRIT J DERMATOL, V140, P1; PELLATDECEUNYNCK C, 1994, BIOCHEM J, V297, P53, DOI 10.1042/bj2970053; Petersen LJ, 1998, ACTA DERM-VENEREOL, V78, P190; RAYNAUD F, 1994, BRIT J DERMATOL, V131, P740, DOI 10.1111/j.1365-2133.1994.tb05003.x; STRATFORD MRL, 1992, RADIOTHER ONCOL, V25, P37, DOI 10.1016/0167-8140(92)90193-X; Tanno O, 2000, BRIT J DERMATOL, V143, P524; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Weller R., 1996, British Journal of Dermatology, V134, P569; WELLER R, 1997, BRIT J DERMATOL, V136, P132; WERTZ PW, 1990, J INVEST DERMATOL, V94, P159, DOI 10.1111/1523-1747.ep12874122; WYCZOLKOWSKA J, 1975, INT ARCH ALLER A IMM, V49, P285, DOI 10.1159/000231409	28	40	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1377	1379		10.1096/fj.03-0002hyp	http://dx.doi.org/10.1096/fj.03-0002hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890690				2022-12-28	WOS:000185345100029
J	Plenz, G; Eschert, H; Beissert, S; Arps, V; Sindermann, JR; Robenek, H; Volker, W				Plenz, G; Eschert, H; Beissert, S; Arps, V; Sindermann, JR; Robenek, H; Volker, W			Alterations in the vascular extracellular matrix of granulocyte macrophage colony-stimulating factor (GM-CSF)-deficient mice	FASEB JOURNAL			English	Article						GM-CSF deficiency; vascular collagens; remodeling; atherogenesis	SMOOTH-MUSCLE-CELLS; TUMOR-NECROSIS-FACTOR; COLLAGEN TYPES-I; VIII COLLAGEN; MESSENGER-RNA; GM-CSF; CHOLESTEROL; EXPRESSION; PROLIFERATION; INTERLEUKIN-1	GM-CSF takes part in the cytokine network regulating the metabolism of extracellular matrix (ECM) during atherogenesis. Since data also point to an effect of GM-CSF on the vascular ECM in general, the vascular collagenous matrix was studied in wild-type and GM-CSF-deficient mice. Histological examination revealed a disorganized vascular ECM in GM-CSF-deficient mice involving the collagenous matrix and elastic fiber system. As shown by electron microscopy, collagen bundles were disrupted and reduced. The diameter of fibrils varied widely. mRNA expression of collagens and related molecules was studied. Fibrillar collagens were markedly reduced, alpha1 (I) procollagen to 16.5% of control levels alpha1 (III) procollagen was abolished whereas the expression level of network-forming alpha1 (VIII) procollagen was not altered. As shown by in situ hybridization, the number of collagen-expressing cells was reduced. Matrix metalloproteinases and their inhibitor 1 were not affected by GM-CSF deficiency. Our studies demonstrate that GM-CSF plays a major role in the cytokine network regulating the metabolism of vascular collagens. GM-CSF deficiency leads to an altered composition of the vascular collagenous matrix, i.e., reduced amount of fibrillar collagen, altered ratio of fibrillar and network-forming collagen, and failures in the fibrillogenesis. We suggest that GM-CSF is a basic requirement for the maintenance of vessel wall integrity and resilience.	Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Hosp Munster, Dept Thorac & Cardiovasc Surg, D-48149 Munster, Germany; Univ Hosp Munster, Dept Dermatol, D-48149 Munster, Germany; Univ Hosp Munster, Dept Cardiol & Angiol, D-48149 Munster, Germany	University of Munster; University of Munster; University of Munster	Plenz, G (corresponding author), Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.	plenz@uni-muenster.de						Brandt T, 2001, NEUROLOGY, V57, P24, DOI 10.1212/WNL.57.1.24; Canturk NZ, 1999, ENDOCR RES, V25, P105, DOI 10.3109/07435809909066133; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; FILONZI EL, 1993, ATHEROSCLEROSIS, V99, P241, DOI 10.1016/0021-9150(93)90026-Q; George SJ, 2000, EXPERT OPIN INV DRUG, V9, P993, DOI 10.1517/13543784.9.5.993; ISHIBASHI S, 1990, J BIOL CHEM, V265, P14109; ISHIBASHI T, 1995, ANN NY ACAD SCI, V748, P630; Liu X, 1997, P NATL ACAD SCI USA, V94, P1852, DOI 10.1073/pnas.94.5.1852; MacBeath JRE, 1996, BIOCHEM J, V319, P993, DOI 10.1042/bj3190993; MCCULLAGH KG, 1980, J PATHOL, V130, P45, DOI 10.1002/path.1711300107; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; METCALF D, 1993, CR ACAD SCI III-VIE, V316, P866; MORTON LF, 1982, ATHEROSCLEROSIS, V42, P41, DOI 10.1016/0021-9150(82)90124-1; NAKAO K, 1995, J DENT RES, V74, P1072, DOI 10.1177/00220345950740040701; NAKATA K, 1991, J IMMUNOL, V147, P1266; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; NEWBY AC, 1994, BASIC RES CARDIOL, V89, P59; NIMER SD, 1988, JAMA-J AM MED ASSOC, V260, P3297, DOI 10.1001/jama.260.22.3297; Ottani V, 2001, MICRON, V32, P251, DOI 10.1016/S0968-4328(00)00042-1; PIGUET PF, 1993, EXP LUNG RES, V19, P579, DOI 10.3109/01902149309031729; Plenz G, 1999, ARTERIOSCL THROM VAS, V19, P1658, DOI 10.1161/01.ATV.19.7.1658; Plenz G, 1997, ARTERIOSCL THROM VAS, V17, P2489, DOI 10.1161/01.ATV.17.11.2489; Plenz G, 1999, ARTERIOSCL THROM VAS, V19, P1201, DOI 10.1161/01.ATV.19.5.1201; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; ROMANIC AM, 1991, J BIOL CHEM, V266, P12703; SEELENTAG W, 1989, EUR J IMMUNOL, V19, P209, DOI 10.1002/eji.1830190135; Shindo J, 1999, CIRCULATION, V99, P2150, DOI 10.1161/01.CIR.99.16.2150; SIEFF CA, 1988, BLOOD, V72, P1316; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Tomita T, 2000, CANCER LETT, V156, P83, DOI 10.1016/S0304-3835(00)00446-8; VOSS B, 1986, PATHOL RES PRACT, V181, P568, DOI 10.1016/S0344-0338(86)80151-0; WANG J, 1994, EXP MOL PATHOL, V61, P109, DOI 10.1006/exmp.1994.1030; Zhang YH, 1998, J IMMUNOL, V161, P3071	34	15	16	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1451	1457		10.1096/fj.02-1035com	http://dx.doi.org/10.1096/fj.02-1035com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890699				2022-12-28	WOS:000185345100038
J	Bublin, M; Radauer, C; Wilson, IBH; Kraft, D; Scheiner, O; Breiteneder, H; Hoffmann-Sommergruber, K				Bublin, M; Radauer, C; Wilson, IBH; Kraft, D; Scheiner, O; Breiteneder, H; Hoffmann-Sommergruber, K			Cross-reactive N-glycans of Api g 5, a high molecular weight glycoprotein allergen from celery, are required for immunoglobulin E binding and activation of effector cells from allergic patients	FASEB JOURNAL			English	Article						type I hypersensitivity; food allergy; pollen allergy; berberine bridge enzyme	CORE ALPHA-1,3-LINKED FUCOSE; CARBOHYDRATE DETERMINANTS; MAJOR ALLERGEN; LINKED OLIGOSACCHARIDES; APIUM-GRAVEOLENS; BIRCH POLLEN; IGE-BINDING; TREE POLLEN; MUGWORT; EPITOPE	Allergy diagnosis relying on the determination of specific IgE is frequently complicated by the presence of cross-reacting IgE of unclear clinical relevance. Particularly, the anaphylactogenic activity of IgE directed to cross-reactive carbohydrate moieties of glycoproteins from plants and invertebrates has been a matter of debate. In this study, we present the biochemical and immunological characterization of Api g 5, a glycoprotein allergen from celery with homology to FAD containing oxidases. Carbohydrate analysis of the allergen revealed the presence of glycans carrying fucosyl and xylosyl residues, structures previously shown to bind IgE. Chemical deglycosylation of the protein completely abolished binding of serum IgE from all 14 patients tested. Likewise, basophils from a patient allergic to mugwort pollen and celery were stimulated only by native Api g 5, whereas the deglycosylated allergen did not trigger release of histamine. IgE inhibition immunoblots showed that native Api g 5 other than the deglycosylated protein completely inhibited IgE binding to high molecular weight allergens in protein extracts from birch pollen, mugwort pollen, and celery. A similar inhibition was accomplished using the IgE binding oligosaccharide, MUXF, coupled to bovine serum albumin. All these observations taken together confer convincing evidence that IgE directed to cross-reactive carbohydrates is capable of eliciting allergic reactions in vivo.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Agr Univ Vienna, Inst Chem, A-1190 Vienna, Austria	University of Vienna; University of Natural Resources & Life Sciences, Vienna	Hoffmann-Sommergruber, K (corresponding author), AKH EBO, 3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Karin.Hoffmann@akh-wien.ac.at	Wilson, Iain/B-3326-2009; Radauer, Christian/AAN-6260-2021	Wilson, Iain/0000-0001-8996-1518; Radauer, Christian/0000-0001-9920-4449; Bublin, Merima/0000-0002-7191-9431; Hoffmann-Sommergruber, Karin/0000-0002-8830-058X				AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Aalberse RC, 1998, ALLERGY, V53, P54, DOI 10.1111/j.1398-9995.1998.tb04940.x; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Chardin H, 2001, INT ARCH ALLERGY IMM, V125, P128, DOI 10.1159/000053806; DITTRICH H, 1991, P NATL ACAD SCI USA, V88, P9969, DOI 10.1073/pnas.88.22.9969; FORSBECK M, 1979, CONTACT DERMATITIS, V5, P191, DOI 10.1111/j.1600-0536.1979.tb04839.x; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Ganglberger E, 2000, CLIN EXP ALLERGY, V30, P566, DOI 10.1046/j.1365-2222.2000.00773.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; Iacovacci P., 2002, Clinical and Experimental Allergy, V32, P1620, DOI 10.1046/j.1365-2222.2002.01516.x; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; Kolarich D, 2000, ANAL BIOCHEM, V285, P64, DOI 10.1006/abio.2000.4737; KUROSAKA A, 1991, J BIOL CHEM, V266, P4168; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Liaw SH, 2001, BIOCHEM BIOPH RES CO, V280, P738, DOI 10.1006/bbrc.2000.4203; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; RINK E, 1975, FEBS LETT, V49, P396, DOI 10.1016/0014-5793(75)80794-0; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; SOJAR HT, 1987, ARCH BIOCHEM BIOPHYS, V259, P52, DOI 10.1016/0003-9861(87)90469-3; Su SN, 1996, J ALLERGY CLIN IMMUN, V98, P486, DOI 10.1016/S0091-6749(96)70080-5; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259, DOI 10.1159/000236534; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Vieths S, 2002, ALLERGY, V57, P100, DOI 10.1034/j.1398-9995.57.s72.20.x; VIETHS S, 1997, ARBEITEN P EHRLICH I, V91, P250; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; WUTHRICH B, 1985, SCHWEIZ MED WSCHR, V115, P358; WUTHRICH B, 1990, ALLERGY, V45, P566, DOI 10.1111/j.1398-9995.1990.tb00941.x; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280	40	91	95	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1697	+		10.1096/fj.02-0872fje	http://dx.doi.org/10.1096/fj.02-0872fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958180				2022-12-28	WOS:000184471600009
J	Cooke, MS; Evans, MD; Dizdaroglu, M; Lunec, J				Cooke, MS; Evans, MD; Dizdaroglu, M; Lunec, J			Oxidative DNA damage: mechanisms, mutation, and disease	FASEB JOURNAL			English	Review						reactive oxygen species; repair	BASE EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; COLI ENDONUCLEASE-III; SYSTEMIC-LUPUS-ERYTHEMATOSUS; RADICAL-INDUCED FORMATION; CYTOSINE-DERIVED LESIONS; SINGLE-STRANDED-DNA; HUMAN CELL-EXTRACTS; HUMAN MUTY HOMOLOG; ESCHERICHIA-COLI	Oxidative DNA damage is an inevitable consequence of cellular metabolism, with a propensity for increased levels following toxic insult. Although more than 20 base lesions have been identified, only a fraction of these have received appreciable study, most notably 8-oxo-2' deoxyguanosine. This lesion has been the focus of intense research interest and been ascribed much importance, largely to the detriment of other lesions. The present work reviews the basis for the biological significance of oxidative DNA damage, drawing attention to the multiplicity of proteins with repair activities along with a number of poorly considered effects of damage. Given the plethora of ( often contradictory) reports describing pathological conditions in which levels of oxidative DNA damage have been measured, this review critically addresses the extent to which the in vitro significance of such damage has relevance for the pathogenesis of disease. It is suggested that some shortcomings associated with biomarkers, along with gaps in our knowledge, may be responsible for the failure to produce consistent and definitive results when applied to understanding the role of DNA damage in disease, highlighting the need for further studies.	Univ Leicester, Leicester Royal Infirm, Univ Hosp Leicester NHS Trust, Dept Clin Biochem,Oxidat Stress Grp, Leicester LE2 7LX, Leics, England; NIST, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA	University Hospitals of Leicester NHS Trust; University of Leicester; National Institute of Standards & Technology (NIST) - USA	Cooke, MS (corresponding author), Univ Leicester, Leicester Royal Infirm, Univ Hosp Leicester NHS Trust, Dept Clin Biochem,Oxidat Stress Grp, Leicester LE2 7LX, Leics, England.	msc5@1e.ac.uk	Cooke, Marcus/ABI-1501-2020; Evans, Mark/P-2305-2018; Cooke, Marcus S/D-4517-2013	Cooke, Marcus/0000-0003-0369-862X; Evans, Mark/0000-0003-3673-8501; 				Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Alam ZI, 2000, J NEUROCHEM, V75, P840, DOI 10.1046/j.1471-4159.2000.0750840.x; Asagoshi K, 2000, J BIOL CHEM, V275, P24781, DOI 10.1074/jbc.M000576200; Audebert M, 2000, CANCER RES, V60, P4740; Baker D, 2002, CHEM RES TOXICOL, V15, P33, DOI 10.1021/tx010113b; Bandaru V, 2002, DNA REPAIR, V1, P517, DOI 10.1016/S1568-7864(02)00036-8; BARNETT YA, 1995, MUTAT RES-DNAGING G, V338, P115, DOI 10.1016/0921-8734(95)00017-Z; BASHIR S, 1993, ANN RHEUM DIS, V52, P659, DOI 10.1136/ard.52.9.659; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BESSHO T, 1993, J BIOL CHEM, V268, P19416; Bogdanov M, 2000, FREE RADICAL BIO MED, V29, P652, DOI 10.1016/S0891-5849(00)00349-X; BOHR VA, 1995, MUTAT RES-DNAGING G, V338, P25, DOI 10.1016/0921-8734(95)00008-T; BOITEUX S, 1992, BIOCHEMISTRY-US, V31, P106, DOI 10.1021/bi00116a016; Boiteux S, 2000, ARCH BIOCHEM BIOPHYS, V377, P1, DOI 10.1006/abbi.2000.1773; Boldogh I, 2001, NUCLEIC ACIDS RES, V29, P2802, DOI 10.1093/nar/29.13.2802; Boorstein RJ, 2001, J BIOL CHEM, V276, P41991, DOI 10.1074/jbc.M106953200; BREEN AP, 1995, FREE RADICAL BIO MED, V18, P1033, DOI 10.1016/0891-5849(94)00209-3; Brooks PJ, 2000, J BIOL CHEM, V275, P22355, DOI 10.1074/jbc.M002259200; Bruner SD, 2000, NATURE, V403, P859, DOI 10.1038/35002510; CADET J, 1991, J CHIM PHYS PCB, V88, P1021, DOI 10.1051/jcp/1991881021; CADET J, 1994, J AM CHEM SOC, V116, P7403, DOI 10.1021/ja00095a052; CANNONCARLSON SV, 1989, J BIOL CHEM, V264, P13306; Cardin R, 2001, J HEPATOL, V34, P587, DOI 10.1016/S0168-8278(00)00098-2; CARMICHAEL PL, 1995, MUTAT RES-FUND MOL M, V326, P235, DOI 10.1016/0027-5107(94)00177-7; Chaung WR, 1997, MUTAT RES-FUND MOL M, V373, P125, DOI 10.1016/S0027-5107(96)00197-2; CHENG KC, 1992, J BIOL CHEM, V267, P166; Cheng L, 2000, CARCINOGENESIS, V21, P1527, DOI 10.1093/carcin/21.8.1527; Chevillard S, 1998, ONCOGENE, V16, P3083, DOI 10.1038/sj.onc.1202096; Collins AR, 1998, FASEB J, V12, P1397, DOI 10.1096/fasebj.12.13.1397; Cooke M. S., 2002, Giornale Italiano di Dermatologia e Venereologia, V137, P239; Cooke MS, 2001, BIOCHEM BIOPH RES CO, V284, P232, DOI 10.1006/bbrc.2001.4954; Cooke MS, 1997, FREE RADICAL BIO MED, V22, P151, DOI 10.1016/S0891-5849(96)00283-3; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; Dandona P, 1996, LANCET, V347, P444, DOI 10.1016/S0140-6736(96)90013-6; David-Cordonnier MH, 2001, BIOCHEMISTRY-US, V40, P11811, DOI 10.1021/bi0112356; de Boer J, 2000, CARCINOGENESIS, V21, P453, DOI 10.1093/carcin/21.3.453; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; Dherin C, 1999, NUCLEIC ACIDS RES, V27, P4001, DOI 10.1093/nar/27.20.4001; Dianov GL, 2000, J BIOL CHEM, V275, P11809, DOI 10.1074/jbc.275.16.11809; DIRKSEN ML, 1988, INT J RADIAT BIOL, V54, P195, DOI 10.1080/09553008814551631; Dizdaroglu M, 2000, BIOCHEMISTRY-US, V39, P5586, DOI 10.1021/bi9927787; Dizdaroglu M, 1999, BIOCHEMISTRY-US, V38, P243, DOI 10.1021/bi9819071; Dizdaroglu M, 1998, DNA AND FREE RADICALS: TECHNIQUES, MECHANISMS & APPLICATIONS, P3; DIZDAROGLU M, 1986, BIOCHEM J, V238, P247, DOI 10.1042/bj2380247; DIZDAROGLU M, 1986, BIOCHEM J, V235, P531, DOI 10.1042/bj2350531; DIZDAROGLU M, 1993, FEBS LETT, V315, P1, DOI 10.1016/0014-5793(93)81120-O; DIZDAROGLU M, 1992, MUTAT RES, V275, P331, DOI 10.1016/0921-8734(92)90036-O; Dizdaroglu M, 1996, NUCLEIC ACIDS RES, V24, P418, DOI 10.1093/nar/24.3.418; DIZDAROGLU M, 1993, BIOCHEMISTRY-US, V32, P12105, DOI 10.1021/bi00096a022; DIZDAROGLU M, 1987, BIOCHEM J, V241, P929, DOI 10.1042/bj2410929; DOETSCH PW, 1995, BIOCHEMISTRY-US, V34, P737, DOI 10.1021/bi00003a005; Drury JA, 1998, FREE RADICAL RES, V28, P423, DOI 10.3109/10715769809070811; Duarte V, 2000, NUCLEIC ACIDS RES, V28, P1555, DOI 10.1093/nar/28.7.1555; Duell EJ, 2000, CARCINOGENESIS, V21, P965, DOI 10.1093/carcin/21.5.965; Eide L, 2001, BIOCHEMISTRY-US, V40, P6653, DOI 10.1021/bi0028901; EVANS MD, 1997, ADV MOL CEL, V20, P25; Farinati F, 1999, FREE RADICAL BIO MED, V27, P1284, DOI 10.1016/S0891-5849(99)00161-6; Farinati F, 1998, GUT, V42, P351, DOI 10.1136/gut.42.3.351; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; Frelon S, 2002, FREE RADICAL RES, V36, P499, DOI 10.1080/10715760290025889; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; Frenkel K, 1998, CANCER EPIDEM BIOMAR, V7, P49; FRENKEL K, 1993, FREE RADICAL BIO MED, V14, P483, DOI 10.1016/0891-5849(93)90105-4; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; Fujimoto J, 1997, CHEM RES TOXICOL, V10, P1254, DOI 10.1021/tx970102b; GALLOWAY AM, 1994, J BIOL CHEM, V269, P974; Ghosh R, 1999, NUCLEIC ACIDS RES, V27, P3213, DOI 10.1093/nar/27.15.3213; Graziewicz MA, 2000, FREE RADICAL BIO MED, V28, P75, DOI 10.1016/S0891-5849(99)00208-7; Griffiths HR, 2002, MOL ASPECTS MED, V23, P101, DOI 10.1016/S0098-2997(02)00017-1; Gu YS, 2002, J BIOL CHEM, V277, P11135, DOI 10.1074/jbc.M108618200; HAHM KB, 1998, DIG DIS SCI S, V43, P72; Halliwell B.A.G.J., 1996, FREE RADICALS BIOL M; Hamilton ML, 2001, P NATL ACAD SCI USA, V98, P10469, DOI 10.1073/pnas.171202698; Hanaoka T, 2001, CANCER LETT, V170, P53, DOI 10.1016/S0304-3835(01)00565-1; Hardie LJ, 2000, CARCINOGENESIS, V21, P167, DOI 10.1093/carcin/21.2.167; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Hazra IK, 1998, NUCLEIC ACIDS RES, V26, P5116, DOI 10.1093/nar/26.22.5116; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Holliday R, 2000, MUTAT RES-REV MUTAT, V463, P173, DOI 10.1016/S1383-5742(00)00048-X; Honda M, 2000, LEUKEMIA RES, V24, P461, DOI 10.1016/S0145-2126(00)00006-0; HU JJ, 1995, MUTAT RES-DNA REPAIR, V336, P193, DOI 10.1016/0921-8777(94)00054-A; Ikeda H, 2001, MED PEDIATR ONCOL, V37, P505, DOI 10.1002/mpo.1243; Ikeda S, 1998, J BIOL CHEM, V273, P21585, DOI 10.1074/jbc.273.34.21585; Inoue M, 1998, JPN J CANCER RES, V89, P691, DOI 10.1111/j.1349-7006.1998.tb03272.x; Izzotti A, 2001, FASEB J, V15, P752, DOI 10.1096/fj.00-0312com; Jackson AL, 1998, P NATL ACAD SCI USA, V95, P12468, DOI 10.1073/pnas.95.21.12468; JARUGA P, 1994, FEBS LETT, V341, P59, DOI 10.1016/0014-5793(94)80240-8; KASAI H, 1992, J AM CHEM SOC, V114, P9692, DOI 10.1021/ja00050a078; Kato J, 2001, CANCER RES, V61, P8697; Kavli B, 2002, J BIOL CHEM, V277, P39926, DOI 10.1074/jbc.M207107200; Kitada T, 2001, J HEPATOL, V35, P613, DOI 10.1016/S0168-8278(01)00171-4; Kohno T, 1998, ONCOGENE, V16, P3219, DOI 10.1038/sj.onc.1201872; Koppele JMT, 1996, NEUROBIOL AGING, V17, P819; Krapfenbauer K, 1998, CLIN SCI, V95, P331, DOI 10.1042/CS19970302; Kuraoka I, 2000, P NATL ACAD SCI USA, V97, P3832, DOI 10.1073/pnas.070471597; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le Page F, 1998, NUCLEIC ACIDS RES, V26, P1276, DOI 10.1093/nar/26.5.1276; Lee BM, 1998, CANCER LETT, V125, P61, DOI 10.1016/S0304-3835(97)00520-X; Lee SH, 2001, TRENDS CARDIOVAS MED, V11, P148, DOI 10.1016/S1050-1738(01)00094-9; Lezza A.M.S., 1999, J ANTI-AGING MED, V2, P209, DOI [10.1089/rej.1.1999.2.209, DOI 10.1089/REJ.1.1999.2.209]; Lipinski LJ, 1999, NUCLEIC ACIDS RES, V27, P3153, DOI 10.1093/nar/27.15.3153; LOFT S, 1995, TRANSPLANTATION, V59, P16, DOI 10.1097/00007890-199501150-00004; Lovell MA, 1999, J NEUROCHEM, V72, P771, DOI 10.1046/j.1471-4159.1999.0720771.x; Luna L, 2000, MUTAT RES-DNA REPAIR, V460, P95, DOI 10.1016/S0921-8777(00)00015-X; LUNEC J, 1994, FEBS LETT, V348, P131, DOI 10.1016/0014-5793(94)00583-4; Lyras L, 1998, J NEUROCHEM, V71, P302; MALINS DC, 1991, CANCER RES, V51, P5430; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Martinet W, 2001, CIRC RES, V88, P733, DOI 10.1161/hh0701.088684; Matsui A, 2000, CANCER LETT, V151, P87, DOI 10.1016/S0304-3835(99)00424-3; Matsui M, 1999, J INVEST DERMATOL, V113, P26, DOI 10.1046/j.1523-1747.1999.00630.x; Mazurek A, 2002, J BIOL CHEM, V277, P8260, DOI 10.1074/jbc.M111269200; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; Mecocci P, 1998, NEUROLOGY, V51, P1014, DOI 10.1212/WNL.51.4.1014; Melvin T, 1996, J AM CHEM SOC, V118, P10031, DOI 10.1021/ja961722m; Miyabe I, 2002, NUCLEIC ACIDS RES, V30, P3443, DOI 10.1093/nar/gkf460; Musarrat J, 1996, EUR J CANCER, V32A, P1209, DOI 10.1016/0959-8049(96)00031-7; NACKERDIEN Z, 1991, CANCER RES, V51, P5837; NAGASHIMA M, 1995, CANCER LETT, V90, P157, DOI 10.1016/0304-3835(95)03698-V; Nilsen H, 2000, MOL CELL, V5, P1059, DOI 10.1016/S1097-2765(00)80271-3; Nilsen H, 2001, EMBO J, V20, P4278, DOI 10.1093/emboj/20.15.4278; Ohtsubo T, 2000, NUCLEIC ACIDS RES, V28, P1355, DOI 10.1093/nar/28.6.1355; OKAMOTO K, 1994, INT J CANCER, V58, P825, DOI 10.1002/ijc.2910580613; OLINSKI R, 1992, FEBS LETT, V309, P193, DOI 10.1016/0014-5793(92)81093-2; Oliva MR, 1997, MOL CARCINOGEN, V18, P232, DOI 10.1002/(SICI)1098-2744(199704)18:4<232::AID-MC7>3.0.CO;2-F; ONEILL P, 1985, INT J RADIAT BIOL, V47, P71, DOI 10.1080/09553008514550101; Osterod M, 2001, CARCINOGENESIS, V22, P1459, DOI 10.1093/carcin/22.9.1459; Parker A, 2001, J BIOL CHEM, V276, P5547, DOI 10.1074/jbc.M008463200; Pascucci B, 2002, NUCLEIC ACIDS RES, V30, P2124, DOI 10.1093/nar/30.10.2124; Ramon O, 1999, FREE RADICAL RES, V31, P217, DOI 10.1080/10715769900300781; RAOUL S, 1996, J CHEM SOC PERK T, V23, P371; RATTAN SIS, 1995, MED SCI RES, V23, P469; Reardon JT, 1997, P NATL ACAD SCI USA, V94, P9463, DOI 10.1073/pnas.94.17.9463; Rehman A, 1999, FEBS LETT, V448, P120, DOI 10.1016/S0014-5793(99)00339-7; Romano G, 2000, CARCINOGENESIS, V21, P1143, DOI 10.1093/carcin/21.6.1143; Rossman TG, 1998, MUTAT RES-FUND MOL M, V402, P103, DOI 10.1016/S0027-5107(97)00287-X; Rusmintratip V, 2000, P NATL ACAD SCI USA, V97, P14183, DOI 10.1073/pnas.97.26.14183; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Schwarz KB, 2001, DIGEST DIS SCI, V46, P2173, DOI 10.1023/A:1011958814371; Seidl R, 1997, NEUROSCI LETT, V235, P137, DOI 10.1016/S0304-3940(97)00748-9; SHIMODA R, 1994, CANCER RES, V54, P3171; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; SOHAL RS, 1994, MECH AGEING DEV, V74, P121, DOI 10.1016/0047-6374(94)90104-X; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; SPENCER JPE, 1994, FEBS LETT, V353, P246, DOI 10.1016/0014-5793(94)01056-0; STEENKEN S, 1987, J CHEM SOC FARAD T 1, V83, P113, DOI 10.1039/f19878300113; STENTURKER S, 1997, FEBS LETT, V416, P286; Sultan SM, 2000, RHEUMATOLOGY, V39, P1147, DOI 10.1093/rheumatology/39.10.1147; Suzuki S, 1999, DIABETES RES CLIN PR, V45, P161, DOI 10.1016/S0168-8227(99)00046-7; Takao M, 2002, J BIOL CHEM, V277, P42205, DOI 10.1074/jbc.M206884200; TEOULE R, 1987, INT J RADIAT BIOL, V51, P573, DOI 10.1080/09553008414552111; Thier R, 1999, ARCH TOXICOL, V73, P479, DOI 10.1007/s002040050638; Thorslund T, 2002, DNA REPAIR, V1, P261, DOI 10.1016/S1568-7864(02)00003-4; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Tuo JS, 2002, J BIOL CHEM, V277, P30832, DOI 10.1074/jbc.M204814200; Turker MS, 1999, CANCER RES, V59, P1837; VIEIRA AJSC, 1990, J AM CHEM SOC, V112, P6986, DOI 10.1021/ja00175a036; Vladimirova O, 1998, MULT SCLER, V4, P413, DOI 10.1191/135245898678919456; VONSONNTAG, 1987, CHEM BASIS RAD BIOL; Vulimiri SV, 2000, MOL CARCINOGEN, V27, P34, DOI 10.1002/(SICI)1098-2744(200001)27:1<34::AID-MC6>3.3.CO;2-7; WAGNER JR, 1994, J AM CHEM SOC, V116, P2235, DOI 10.1021/ja00085a001; Wagner JR, 1996, ANAL BIOCHEM, V233, P76, DOI 10.1006/abio.1996.0010; WAGNER JR, 1994, J CHIM PHYS PCB, V91, P1280, DOI 10.1051/jcp/1994911280; WARD JF, 1994, RADIAT RES, V138, pS85, DOI 10.2307/3578769; WEITZMAN SA, 1990, BLOOD, V76, P655; Willy C, 2000, FREE RADICAL BIO MED, V28, P1, DOI 10.1016/S0891-5849(99)00211-7; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Wrona MZ, 1998, CHEM RES TOXICOL, V11, P639, DOI 10.1021/tx970185w; Zhang J, 1999, AM J PATHOL, V154, P1423, DOI 10.1016/S0002-9440(10)65396-5	175	2195	2300	9	359	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1195	1214		10.1096/fj.02-0752rev	http://dx.doi.org/10.1096/fj.02-0752rev			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832285				2022-12-28	WOS:000184471600032
J	Imagawa, S; Nakano, Y; Obara, N; Suzuki, N; Doi, T; Kodama, T; Nagasawa, T; Yamamoto, M				Imagawa, S; Nakano, Y; Obara, N; Suzuki, N; Doi, T; Kodama, T; Nagasawa, T; Yamamoto, M			A GATA-specific inhibitor (K-7174) rescues anemia induced by IL-1 beta, TNF-alpha, or L-NMMA	FASEB JOURNAL			English	Article						interleukin-1 beta; N-G-monomethyl-L-arginine; tumor necrosis factor-alpha; erythropoietin	TUMOR-NECROSIS-FACTOR; RECOMBINANT-HUMAN-ERYTHROPOIETIN; SERUM IMMUNOREACTIVE ERYTHROPOIETIN; MONOMETHYL-L-ARGININE; RHEUMATOID-ARTHRITIS; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; CHRONIC DISORDERS; INTERLEUKIN-1; SUPPRESSION	Interleukin-1beta (IL-1beta), tumor necrosis factor-alpha (TNF-alpha), or N-G-monomethyl-L-arginine (L-NMMA) are increased in patients with chronic disease-related anemia. They increase the binding activity of GATA and inhibit erythropoietin (Epo) promoter activity. In this study, we examined the ability of K-7174 (a GATA-specific inhibitor) to improve Epo production when inhibited by treatment with IL-1beta, TNF-alpha, or L-NMMA. Epo protein production and promoter activity were induced in Hep3B cells with 1% O-2. However, 15 U/ml IL-1beta, 220 U/ml TNF-alpha, or 10(-3) M L-NMMA inhibited Epo protein production and promoter activity, respectively. Addition of 10 muM K-7174 rescued these inhibitions of Epo protein production and promoter activity induced by IL-1beta, TNF-alpha, or L-NMMA, respectively. Electrophoretic mobility shift assays revealed that addition of K-7174 decreased GATA binding activity, which was increased with the addition of IL-1beta, TNF-alpha, or L-NMMA. Furthermore, intraperitoneal injection of mice with IL-1beta or TNF-alpha decreased the hemoglobin concentrations and reticulocyte counts. However, the addition of K-7174 reversed these effects. These results raise the possibility of using K-7174 as therapy to treat anemia.	Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 3058577, Japan; Kowa Co Ltd, Kowa Res Inst, Tokyo 1038433, Japan; Univ Tokyo, Lab Syst Biol, Tokyo 1538904, Japan; Univ Tokyo, Med Res Ctr Adv Sci & Technol, Tokyo 1538904, Japan	University of Tsukuba; University of Tsukuba; University of Tsukuba; Kowa Company, Ltd.; University of Tokyo; University of Tokyo	Imagawa, S (corresponding author), Univ Tsukuba, Div Hematol, Inst Clin Med, Tsukuba, Ibaraki 3058575, Japan.	simagawa@md.tsukuba.ac.jp	Suzuki, Norio/AAZ-9458-2021; Yamamoto, Masayuki/A-4873-2010; Suzuki, Norio/F-3456-2010	Suzuki, Norio/0000-0001-6100-3350; Yamamoto, Masayuki/0000-0002-9073-9436; 				BAER AN, 1987, BRIT J HAEMATOL, V66, P559, DOI 10.1111/j.1365-2141.1987.tb01344.x; BENDTZEN K, 1988, IMMUNOL LETT, V19, P183, DOI 10.1016/0165-2478(88)90141-1; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; BORDER WA, 1990, NATURE, V346, P371, DOI 10.1038/346371a0; Boyes J, 1998, NATURE, V396, P594, DOI 10.1038/25166; CLINBON U, 1990, EXP HEMATOL, V18, P438; DINARELLO CA, 1989, CYTOKINES, V1, P105; DOUGLAS SW, 1975, BLOOD, V45, P55; DOWTON SB, 1988, SEMIN HEMATOL, V25, P84; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; FAQUIN W C, 1992, Blood, V79, P1987; FISCHL M, 1990, NEW ENGL J MED, V322, P1488, DOI 10.1056/NEJM199005243222103; GALSON DL, 1995, MOL CELL BIOL, V15, P2135; HOCHBERG MC, 1988, ARTHRITIS RHEUM, V31, P1318, DOI 10.1002/art.1780311016; IMAGAWA S, 1991, BLOOD, V77, P278; Imagawa S, 1997, BLOOD, V89, P1430, DOI 10.1182/blood.V89.4.1430; JELKMANN W, 1992, LIFE SCI, V50, P301, DOI 10.1016/0024-3205(92)90338-P; JOHANNSEN H, 1989, EUR J HAEMATOL, V43, P201; JOHNSON CS, 1990, EXP HEMATOL, V18, P109; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; La Ferla K, 2002, FASEB J, V16, P1811, DOI 10.1096/fj.02-0168fje; LEE GR, 1983, SEMIN HEMATOL, V20, P61; LEVINE B, 1990, NEW ENGL J MED, V323, P236, DOI 10.1056/NEJM199007263230405; LUDWIG H, 1990, NEW ENGL J MED, V322, P1693, DOI 10.1056/NEJM199006143222402; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; MEANS RT, 1989, ARTHRITIS RHEUM-US, V32, P638, DOI 10.1002/anr.1780320519; MEANS RT, 1990, J CLIN INVEST, V86, P538, DOI 10.1172/JCI114741; MERIKA M, 1993, MOL CELL BIOL, V13, P3999, DOI 10.1128/MCB.13.7.3999; MILLER CB, 1990, NEW ENGL J MED, V322, P1689, DOI 10.1056/NEJM199006143222401; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Papadaki HA, 2002, BLOOD, V100, P474, DOI 10.1182/blood-2002-01-0136; PINCUS T, 1990, AM J MED, V89, P161, DOI 10.1016/0002-9343(90)90294-N; REIFF RH, 1958, AM J CLIN PATHOL, V30, P199, DOI 10.1093/ajcp/30.3.199; Ribeiro ACM, 1996, EXP PHYSIOL, V81, P475, DOI 10.1113/expphysiol.1996.sp003950; RUDNICK S, 1990, P AN M AM SOC CLIN, V9, P182; Sano Y, 2001, J BIOL CHEM, V276, P3674, DOI 10.1074/jbc.M006896200; SCHOOLEY JC, 1987, BRIT J HAEMATOL, V67, P11, DOI 10.1111/j.1365-2141.1987.tb02289.x; Shivdasani RA, 1996, BLOOD, V87, P4025, DOI 10.1182/blood.V87.10.4025.bloodjournal87104025; Silva Maite, 1996, Blood, V88, P1576; SPIVAK JL, 1989, JAMA-J AM MED ASSOC, V261, P3104, DOI 10.1001/jama.261.21.3104; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; ULICH TR, 1990, EXP HEMATOL, V18, P311; Umetani M, 2000, BIOCHEM BIOPH RES CO, V272, P370, DOI 10.1006/bbrc.2000.2784; Whyatt D, 2000, NATURE, V406, P519, DOI 10.1038/35020086; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; ZARRABI MH, 1977, BRIT J HAEMATOL, V35, P647, DOI 10.1111/j.1365-2141.1977.tb00628.x	46	55	57	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1742	+		10.1096/fj.02-1134fje	http://dx.doi.org/10.1096/fj.02-1134fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958195				2022-12-28	WOS:000184471600012
J	Battista, S; Pentimalli, F; Baldassarre, G; Fedele, M; Fidanza, V; Croce, CM; Fusco, A				Battista, S; Pentimalli, F; Baldassarre, G; Fedele, M; Fidanza, V; Croce, CM; Fusco, A			Loss of Hmga1 gene function affects embryonic stem cell lymphohematopoietic differentiation	FASEB JOURNAL			English	Article						HMGA1; homologous recombination; T lymphocytes; interleukin; ES cells	IN-VITRO DIFFERENTIATION; C GENE; EXPRESSION; TRANSCRIPTION; PROTEINS; BINDING; IL-2; PRECURSORS; CYTOKINE; ELEMENTS	By interacting with transcription machinery, high-mobility group A 1 (HMGA1) proteins alter the chromatin structure and thereby regulate the transcriptional activity of several genes. To assess their role in development, we studied the in vitro differentiation of embryonic stem (ES) cells that bear one or both disrupted Hmga1 alleles. Here, we report that Hmga1 null ES cells generate fewer T-cell precursors than do wild-type ES cells. Indeed, they preferentially differentiate to B cells, probably consequent to decreased interleukin 2 expression and increased interleukin 6 expression. Moreover, a lack of HMGA1 expression induces changes in hemopoietic differentiation, i.e., a reduced monocyte/macrophage population and an increase in megakaryocyte precursor numbers, erythropoiesis, and globin gene expression. Re-expression of the Hmga1 gene in Hmga1 null ES cells restores the wild-type phenotype. The effect on megakaryocyte/erythrocyte lineages seems, at least in part, mediated by the GATA-1 transcription factor, a key regulator of red blood cell differentiation. In fact, we found that Hmga1-/- ES cells overexpress GATA-1 and that HMGA1 proteins directly control GATA-1 transcription. Taken together, these data indicate that HMGA1 proteins play a prime role in lymphohematopoietic differentiation.	Univ Naples Federico II, Fac Med & Chirurg, CNR,Dipartimento Biol & Patol Cellulaire & Mol, Ctr Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Thomas Jefferson Univ, Jefferson Med Coll, Kimmel Canc Inst, Philadelphia, PA 19107 USA	Consiglio Nazionale delle Ricerche (CNR); University of Naples Federico II; Jefferson University	Fusco, A (corresponding author), Univ Naples Federico II, Fac Med & Chirurg, CNR,Dipartimento Biol & Patol Cellulaire & Mol, Ctr Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	afusco@napoli.com	Battista, Sabrina/AAY-2981-2020; Baldassarre, Gustavo/K-1350-2016; Fedele, Monica/C-1417-2015; Pentimalli, Francesca/K-4936-2014; Young, Richard A/F-6495-2012	Battista, Sabrina/0000-0001-5899-9759; Baldassarre, Gustavo/0000-0002-9750-8825; Fedele, Monica/0000-0002-9171-1312; Pentimalli, Francesca/0000-0003-4740-6801; Young, Richard A/0000-0001-8855-8647; Fusco, Alfredo/0000-0003-3332-5197				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Baldassarre G, 2003, MOL CELL BIOL, V23, P2225, DOI 10.1128/MCB.23.7.2225-2238.2003; Baldassarre G, 2001, P NATL ACAD SCI USA, V98, P7970, DOI 10.1073/pnas.141224998; Battista S, 1999, CANCER RES, V59, P4793; BLOBEL GA, 1995, MOL CELL BIOL, V15, P626; Bustin M, 1996, PROG NUCLEIC ACID RE, V54, P35, DOI 10.1016/S0079-6603(08)60360-8; Chase MB, 1999, AM J HEMATOL, V60, P27, DOI 10.1002/(SICI)1096-8652(199901)60:1<27::AID-AJH6>3.0.CO;2-0; CHEN U, 1992, P NATL ACAD SCI USA, V89, P2541, DOI 10.1073/pnas.89.7.2541; Chiappetta G, 1996, ONCOGENE, V13, P2439; CRIPPA MP, 1991, J BIOL CHEM, V266, P2712; Dani C, 1999, CELLS TISSUES ORGANS, V165, P173, DOI 10.1159/000016697; Fantuzzi G, 2000, J LEUKOCYTE BIOL, V68, P437; Fedele M, 2001, CARCINOGENESIS, V22, P1583, DOI 10.1093/carcin/22.10.1583; GUTIERREZRAMOS JC, 1992, P NATL ACAD SCI USA, V89, P9171, DOI 10.1073/pnas.89.19.9171; Himes SR, 1996, IMMUNITY, V5, P479, DOI 10.1016/S1074-7613(00)80503-8; Himes SR, 2000, J IMMUNOL, V164, P3157, DOI 10.4049/jimmunol.164.6.3157; JOHN S, 1995, MOL CELL BIOL, V15, P1786; JOHNSON KR, 1989, MOL CELL BIOL, V9, P2114, DOI 10.1128/MCB.9.5.2114; Kondo M, 1997, CELL, V91, P661, DOI 10.1016/S0092-8674(00)80453-5; LEONARD M, 1993, BLOOD, V82, P1071; Lewis RT, 2001, J BIOL CHEM, V276, P9550, DOI 10.1074/jbc.M008726200; MAGIS W, 1995, BIOCHEM BIOPH RES CO, V214, P927, DOI 10.1006/bbrc.1995.2375; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; McDevitt MA, 1997, P NATL ACAD SCI USA, V94, P6781, DOI 10.1073/pnas.94.13.6781; Melillo RM, 2001, MOL CELL BIOL, V21, P2485, DOI 10.1128/MCB.21.7.2485-2495.2001; Meng AM, 1999, BLOOD, V93, P500, DOI 10.1182/blood.V93.2.500.402k09_500_508; Nishimura S, 2000, MOL CELL BIOL, V20, P713, DOI 10.1128/MCB.20.2.713-723.2000; OGAWA M, 1991, J EXP MED, V174, P63, DOI 10.1084/jem.174.1.63; POTOCNIK AJ, 1994, EMBO J, V13, P5274, DOI 10.1002/j.1460-2075.1994.tb06861.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; Rohwedel J, 1998, DEV BIOL, V201, P167, DOI 10.1006/dbio.1998.9002; Rolink A, 1996, J EXP MED, V183, P187, DOI 10.1084/jem.183.1.187; SCHMITT RM, 1991, GENE DEV, V5, P728, DOI 10.1101/gad.5.5.728; SCHOENMAKERS EFPM, 1995, NAT GENET, V10, P436, DOI 10.1038/ng0895-436; Shannon MF, 1998, IMMUNOL CELL BIOL, V76, P461, DOI 10.1046/j.1440-1711.1998.00770.x; SHIVDASANI RA, 1995, CELL, V81, P695, DOI 10.1016/0092-8674(95)90531-6; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; Takatsu K, 1997, P SOC EXP BIOL MED, V215, P121; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Wang ZB, 1999, EMBO J, V18, P2218, DOI 10.1093/emboj/18.8.2218; WEISS MJ, 1994, GENE DEV, V8, P1184, DOI 10.1101/gad.8.10.1184; WILES MV, 1991, DEVELOPMENT, V111, P259; ZHOU XJ, 1995, NATURE, V376, P771, DOI 10.1038/376771a0	44	60	65	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1496	+		10.1096/fj.02-0977fje	http://dx.doi.org/10.1096/fj.02-0977fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824305				2022-12-28	WOS:000183818000027
J	Geiszt, M; Witta, J; Baffi, J; Lekstrom, K; Leto, TL				Geiszt, M; Witta, J; Baffi, J; Lekstrom, K; Leto, TL			Dual oxidases represent novel hydrogen peroxide sources supporting mucosal surface host defense	FASEB JOURNAL			English	Article						ThOx1 protein; ThOx2 protein; duox protein; lactoperoxidase; reactive oxygen species	NADPH OXIDASE; IDENTIFICATION; THIOCYANATE; CEPACIA; CLONING; SYSTEM; SALIVA; THOX2; GENE	Lactoperoxidase (LPO) is an enzyme with antimicrobial properties present in saliva, milk, tears, and airway secretions. Although the formation of microbial oxidants by LPO has been recognized for some time, the source of hydrogen peroxide (H2O2) for LPO-catalyzed reactions remains unknown. Reactive oxygen species produced by the phagocyte NADPH oxidase (phox) play a critical role in host defense against pathogens; however, analogous oxidant-generating systems in other tissues have not been associated with antimicrobial activity. Several homologues of gp91(phox), the catalytic core of this enzyme, were described recently; dual oxidase (Duox)1/thyroid oxidase 1 and Duox2/thyroid oxidase 2 were identified in the thyroid gland and characterized as H2O2 donors for thyroxin biosynthesis. We examined Duox1 and Duox2 expression in secretory glands and on mucosal surfaces and give evidence for their presence and activity in salivary glands, rectum, trachea, and bronchium. Epithelium cells in salivary excretory ducts and rectal glands express Duox2, whereas tracheal and bronchial epithelial cells express Duox1. Furthermore, we detected Duox1-dependent H2O2 release by cultured human bronchial epithelial cells. Our observations suggest that Duox1 and Duox2 are novel H2O2 sources that can support LPO-mediated antimicrobial defense mechanisms on mucosal surfaces.	NIAID, Host Def Lab, NIH, Bethesda, MD 20892 USA; Semmelweis Univ, Fac Med, Dept Physiol, H-1444 Budapest, Hungary; Uniformed Serv Univ Hlth Sci, Dept Pharmacol, Bethesda, MD 20814 USA; NEI, Ocular Gene Therapy Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Semmelweis University; Uniformed Services University of the Health Sciences - USA; National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Leto, TL (corresponding author), NIAID, Host Def Lab, NIH, Bldg 10,Rm 11N106, Bethesda, MD 20892 USA.	tleto@nih.gov			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000614, ZIAAI000614] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; Boucher R C, 2001, Trans Am Clin Climatol Assoc, V112, P99; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; Dupuy C, 2000, BIOCHEM BIOPH RES CO, V277, P287, DOI 10.1006/bbrc.2000.3671; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; DUPUY C, 1991, J BIOL CHEM, V266, P3739; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; ELLIS JA, 1988, BIOCHEM J, V251, P887, DOI 10.1042/bj2510887; FOX CH, 1993, CURRENT PROTOCOLS IM; Ganz T, 2002, J CLIN INVEST, V109, P693, DOI 10.1172/JCI200215218; Geiszt M, 2000, P NATL ACAD SCI USA, V97, P8010, DOI 10.1073/pnas.130135897; Gerson C, 2000, AM J RESP CELL MOL, V22, P665, DOI 10.1165/ajrcmb.22.6.3980; Hoidal JR, 2001, AM J RESP CELL MOL, V25, P661, DOI 10.1165/ajrcmb.25.6.f213; KINNULA VL, 1992, AM J PHYSIOL, V262, pL708, DOI 10.1152/ajplung.1992.262.6.L708; Klebanoff S.J., 1999, INFLAMMATION BASIC P, P721; KLEBANOFF SJ, 1966, BIOCHIM BIOPHYS ACTA, V117, P63, DOI 10.1016/0304-4165(66)90152-8; KLEBANOFF SJ, 1965, P SOC EXP BIOL MED, V118, P483, DOI 10.3181/00379727-118-29882; KONTOGHIORGHES GJ, 1995, BLOOD REV, V9, P33, DOI 10.1016/0268-960X(95)90038-1; LAVIGNE MCH, CIRCULATION, V104, P79; Leto TL., 1999, INFLAMMATION BASIC P, P769; Linsdell P, 1998, J GEN PHYSIOL, V111, P601, DOI 10.1085/jgp.111.4.601; LiPuma JJ, 1998, CLIN CHEST MED, V19, P473, DOI 10.1016/S0272-5231(05)70094-0; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; PILEWSKI JM, 1999, PHYSL REV S, V1, pS215; REITER B, 1963, J GEN MICROBIOL, V33, P12; Riedel C, 2001, TRENDS BIOCHEM SCI, V26, P490, DOI 10.1016/S0968-0004(01)01904-1; Segal BH, 2000, MEDICINE, V79, P170, DOI 10.1097/00005792-200005000-00004; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SPEERT DP, 1994, J INFECT DIS, V170, P1524, DOI 10.1093/infdis/170.6.1524; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; ZELDOW BJ, 1963, J IMMUNOL, V90, P12	33	404	424	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1502	+		10.1096/fj.02-1104fje	http://dx.doi.org/10.1096/fj.02-1104fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824283				2022-12-28	WOS:000183818000030
J	Jendrossek, V; Handrick, R; Belka, C				Jendrossek, V; Handrick, R; Belka, C			Celecoxib activates a novel mitochondrial apoptosis signaling pathway	FASEB JOURNAL			English	Article						Bcl-2; caspase; Apaf-1; mitochondria; FADD	DRUG-INDUCED APOPTOSIS; PROSTATE-CANCER CELLS; TYROSINE KINASE LCK; BCL-2 FAMILY; CYTOCHROME-C; CYCLOOXYGENASE-2 INHIBITOR; IONIZING-RADIATION; DISTINCT PATHWAYS; LYMPHOMA-CELLS; BREAST-CANCER	The cyclooxygenase (COX)-2 inhibitor Celecoxib may inhibit cancer cell growth independently of its capacity to block the COX-2 enzyme. The growth inhibitory effect had been attributed to its pro-apoptotic effects. However, the molecular details of Celecoxib-induced apoptosis have not been analyzed yet. To differentiate between death receptor and mitochondrial signaling pathways, induction of apoptosis upon treatment with Celecoxib was tested in Jurkat T- and BJAB B-lymphoma cell lines with defects in either pathway. Celecoxib-induced dose- and time-dependent apoptosis in Jurkat and BJAB cells involving i) activation of caspases-9, -8, and -3, ii) cleavage of poly(ADP-ribose) polymerase and inhibitor of caspase-activated DNAase, iii) breakdown of the mitochondrial membrane potential, and iv) release of cytochrome c. Lack of Fas-associated death domain protein (FADD), overexpression of a dominant negative FADD, lack of caspase-8, and treatment with caspase-8-specific inhibitors had no influence on Celecoxib-induced apoptosis. In contrast, overexpression of a dominant negative caspase-9 or pharmacological inhibition of caspase-9 strongly interfered with Celecoxib-induced cell death. Furthermore, expression of Apaf-1 was required for Celecoxib-induced apoptosis. Importantly, Bcl-2 overexpression did not abrogate caspase activation, mitochondrial alterations, and apoptosis upon Celecoxib treatment while inhibiting radiation induced apoptosis. In conclusion, Celecoxib induces apoptosis via a novel apoptosome-dependent but Bcl-2-independent mitochondrial pathway.	Univ Tubingen, Dept Radiat Oncol, Expt Radiotherapy Grp, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Belka, C (corresponding author), Univ Tubingen, Dept Radiat Oncol, Expt Radiotherapy Grp, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	claus.belka@uni-tuebingen.de	Jendrossek, Verena/AAH-4967-2019	Jendrossek, Verena/0000-0003-1058-2107				Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Belka C, 2003, ONCOGENE, V22, P176, DOI 10.1038/sj.onc.1206103; Belka C, 2002, INT J RADIAT BIOL, V78, P643, DOI 10.1080/09553000210137680; Belka C, 1999, ONCOGENE, V18, P4983, DOI 10.1038/sj.onc.1202878; Belka C, 2001, ONCOGENE, V20, P2190, DOI 10.1038/sj.onc.1204318; Belka C, 2000, ONCOGENE, V19, P1181, DOI 10.1038/sj.onc.1203401; Cheng EHY, 1996, NATURE, V379, P554, DOI 10.1038/379554a0; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Del Bello B, 2001, ONCOGENE, V20, P4591, DOI 10.1038/sj.onc.1204618; Engels IH, 2000, ONCOGENE, V19, P4563, DOI 10.1038/sj.onc.1203824; FLETCHER BS, 1992, J BIOL CHEM, V267, P4338; Fulda S, 2002, ONCOGENE, V21, P2283, DOI 10.1038/sj.onc.1205258; Furlong IJ, 1998, CELL DEATH DIFFER, V5, P214, DOI 10.1038/sj.cdd.4400335; Grassme H, 2000, SCIENCE, V290, P527, DOI 10.1126/science.290.5491.527; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Guenal I, 1997, ONCOGENE, V15, P347, DOI 10.1038/sj.onc.1201182; Gupta S, 2000, PROSTATE, V42, P73, DOI 10.1002/(SICI)1097-0045(20000101)42:1<73::AID-PROS9>3.0.CO;2-G; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Hemmati PG, 2002, ONCOGENE, V21, P3149, DOI 10.1038/sj.onc.1205458; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Jendrossek V, 2003, ONCOGENE, V22, P2621, DOI 10.1038/sj.onc.1206355; Jiang XH, 2002, ONCOGENE, V21, P6113, DOI 10.1038/sj.onc.1205778; Juo P, 1998, CURR BIOL, V8, P1001, DOI 10.1016/S0960-9822(07)00420-4; Komhoff M, 2000, AM J PATHOL, V157, P29, DOI 10.1016/S0002-9440(10)64513-0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Li XY, 2001, CANCER RES, V61, P1699; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MILAS L, 1991, INT J RADIAT BIOL, V60, P65, DOI 10.1080/09553009114551561; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; MIYASHITA T, 1995, CELL, V80, P293; Muller M, 1997, J CLIN INVEST, V99, P403, DOI 10.1172/JCI119174; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Newton K, 2000, J EXP MED, V191, P195, DOI 10.1084/jem.191.1.195; Ochs K, 2000, CANCER RES, V60, P5815; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Real PJ, 2002, ONCOGENE, V21, P7611, DOI 10.1038/sj.onc.1206004; Renz A, 2001, BLOOD, V98, P1542, DOI 10.1182/blood.V98.5.1542; Rudner J, 2001, J CELL SCI, V114, P4161; Rudner J, 2001, INT J RADIAT BIOL, V77, P1, DOI 10.1080/095530001453069; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; SANO H, 1995, CANCER RES, V55, P3785; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; SEDLAK TW, 1995, P NATL ACAD SCI USA, V92, P7834, DOI 10.1073/pnas.92.17.7834; Seno H, 2002, CANCER RES, V62, P506; SHIFF SJ, 1995, J CLIN INVEST, V96, P491, DOI 10.1172/JCI118060; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, P NATL ACAD SCI USA, V97, P3100, DOI 10.1073/pnas.97.7.3100; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Song XQ, 2002, J NATL CANCER I, V94, P585; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stepczynska A, 2001, ONCOGENE, V20, P1193, DOI 10.1038/sj.onc.1204221; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; von Haefen C, 2002, ONCOGENE, V21, P4009, DOI 10.1038/sj.onc.1205497; Waskewich C, 2002, CANCER RES, V62, P2029; Wesselborg S, 1999, BLOOD, V93, P3053, DOI 10.1182/blood.V93.9.3053; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469	71	126	129	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1547	+		10.1096/fj.02-0947fje	http://dx.doi.org/10.1096/fj.02-0947fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824303				2022-12-28	WOS:000183818000024
J	Zanin-Zhorov, A; Nussbaum, G; Franitza, S; Cohen, IR; Lider, O				Zanin-Zhorov, A; Nussbaum, G; Franitza, S; Cohen, IR; Lider, O			T cells respond to heat shock protein 60 via TLR2: activation of adhesion and inhibition of chemokine receptors	FASEB JOURNAL			English	Article						chemotaxis; extracellular matrix; HSP; inflammation; SDF-1 alpha	HEAT-SHOCK-PROTEIN; TOLL-LIKE RECEPTORS; EXTRACELLULAR-MATRIX; INNATE; HSP60; MIGRATION; ATHEROSCLEROSIS; EXPRESSION; ANTIBODIES; BACTERIAL	Soluble 60 kDa heat shock protein (HSP60) activates macrophages via TLR4. We now report that soluble HSP60 activates T cells via the innate receptor TLR2. HSP60 activated T cell adhesion to fibronectin to a degree similar to other activators: IL-2, SDF-1alpha, and RANTES. T cell type and state of activation was important; nonactivated CD45RA(+) and IL-2-activated CD45RO(+) T cells responded optimally (1 h) at low concentrations (0.1-1 ng/ml), but nonactivated CD45RO(+) T cells required higher concentrations (similar to1 mug/ml) of HSP60. T cell HSP60 signaling was inhibited specifically by monoclonal antibodies (mAb) to TLR2 but not by a mAb to TLR4. Indeed, T cells from mice with mutated TLR4 could still respond to HSP60, whereas Chinese hamster T cells with mutated TLR2 did not respond. The human T cell response to soluble HSP60 depended on phosphatidylinositol 3-kinase and protein kinase C signaling and involved the phosphorylation of Pyk-2. Soluble HSP60 also inhibited actin polymerization and T cell chemotaxis through extracellular matrix-like gels toward the chemokines SDF-1alpha (CXCL12) or ELC (CCL19). Exposure to HSP60 for longer times (18 h) down-regulated chemokine receptor expression: CXCR4 and CCR7. These results suggest that soluble HSP60, through TLR2-dependent interactions, can regulate T cell behavior in inflammation.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Cohen, IR (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	irun.cohen@weizmann.ac.il	Cohen, Irun R/B-3542-2009					Abulafia-Lapid R, 1999, J AUTOIMMUN, V12, P121, DOI 10.1006/jaut.1998.0262; Ariel A, 1998, J IMMUNOL, V161, P2465; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Christians ES, 2002, CRIT CARE MED, V30, pS43, DOI 10.1097/00003246-200201001-00006; Cohen I. R., 2000, TENDING ADAMS GARDEN; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; DEGRAEFFMEEDER ER, 1990, AM J PATHOL, V137, P1013; DELOGU C, 2002, CURR OPIN CRIT CARE, V8, P411; Direskeneli H, 2000, J RHEUMATOL, V27, P708; ELIAS D, 1990, P NATL ACAD SCI USA, V87, P1576, DOI 10.1073/pnas.87.4.1576; Franitza S, 2002, EUR J IMMUNOL, V32, P193, DOI 10.1002/1521-4141(200201)32:1<193::AID-IMMU193>3.0.CO;2-H; Franitza S, 2000, J IMMUNOL, V165, P2738, DOI 10.4049/jimmunol.165.5.2738; Habich C, 2002, J IMMUNOL, V168, P569, DOI 10.4049/jimmunol.168.2.569; Heine H, 1999, J IMMUNOL, V162, P6971; HELDWEIN KA, 2001, MOD ASP IMMUNOBIOL, V1, P249; Hu W, 1998, EUR J IMMUNOL, V28, P2444, DOI 10.1002/(SICI)1521-4141(199808)28:08<2444::AID-IMMU2444>3.0.CO;2-N; JINDAL S, 1989, MOL CELL BIOL, V9, P2279, DOI 10.1128/MCB.9.5.2279; Kol A, 1998, CIRCULATION, V98, P300, DOI 10.1161/01.CIR.98.4.300; Kol A, 2000, J IMMUNOL, V164, P13, DOI 10.4049/jimmunol.164.1.13; Kol A, 1999, J CLIN INVEST, V103, P571, DOI 10.1172/JCI5310; Konen-Waisman S, 1999, J INFECT DIS, V179, P403, DOI 10.1086/314590; Laplante AF, 1998, J HISTOCHEM CYTOCHEM, V46, P1291, DOI 10.1177/002215549804601109; Lau SS, 2000, AM J PHYSIOL-HEART C, V278, pH1439, DOI 10.1152/ajpheart.2000.278.5.H1439; Matsuguchi T, 2000, BLOOD, V95, P1378, DOI 10.1182/blood.V95.4.1378.004k08_1378_1385; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; MOR F, 1992, J CLIN INVEST, V90, P2447, DOI 10.1172/JCI116136; More SH, 2001, INT IMMUNOL, V13, P1121, DOI 10.1093/intimm/13.9.1121; Musikacharoen T, 2001, J IMMUNOL, V166, P4516, DOI 10.4049/jimmunol.166.7.4516; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Ramage JM, 1999, J IMMUNOL, V162, P704; Raz I, 2001, LANCET, V358, P1749, DOI 10.1016/S0140-6736(01)06801-5; SCHER HP, 1992, EUR J IMMUNOL, V22, P1667; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Srivastava P, 2002, NAT REV IMMUNOL, V2, P185, DOI 10.1038/nri749; Vaday GG, 2000, J LEUKOCYTE BIOL, V67, P149, DOI 10.1002/jlb.67.2.149; van Seventer GA, 1998, EUR J IMMUNOL, V28, P3867, DOI 10.1002/(SICI)1521-4141(199811)28:11<3867::AID-IMMU3867>3.3.CO;2-B; VANEDEN W, 1988, NATURE, V331, P171, DOI 10.1038/331171a0; Wallin RPA, 2002, TRENDS IMMUNOL, V23, P130, DOI 10.1016/S1471-4906(01)02168-8; Weiss YG, 2002, J CLIN INVEST, V110, P801, DOI 10.1172/JCI200215888; Wick G, 2000, HERZ, V25, P87, DOI 10.1007/PL00001957; Xu QB, 2000, CIRCULATION, V102, P14, DOI 10.1161/01.CIR.102.1.14; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yokota S, 2000, CELL STRESS CHAPERON, V5, P337, DOI 10.1379/1466-1268(2000)005<0337:AACCIH>2.0.CO;2; YOUNG DB, 1987, IMMUNOL TODAY, V8, P215, DOI 10.1016/0167-5699(87)90168-X; Zrihan-Licht S, 2000, ONCOGENE, V19, P1318, DOI 10.1038/sj.onc.1203422	51	147	156	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1567	+		10.1096/fj.02-1139fje	http://dx.doi.org/10.1096/fj.02-1139fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824285				2022-12-28	WOS:000183818000014
J	Jackson, DN; Foster, DA				Jackson, DN; Foster, DA			The enigmatic protein kinase C delta: complex roles in cell proliferatin and survival	FASEB JOURNAL			English	Review						cell cycle; tumor promotion; tumor suppressor; tyrosine kinase	GROWTH-FACTOR-I; BREAST-CANCER CELLS; CAPILLARY ENDOTHELIAL-CELLS; TUMOR-SUPPRESSOR GENES; HIGH-AFFINITY RECEPTOR; ABL TYROSINE KINASE; SMOOTH-MUSCLE-CELLS; SRC FAMILY KINASES; PKC-DELTA; PHORBOL ESTER	Protein kinase C delta (PKC delta) has been implicated both as a tumor suppressor and a positive regulator of cell cycle progression. PKC delta has also been reported to positively and negatively regulate apoptotic programs. This has led to conflicting hypotheses on the role of PKC delta in the control of cell proliferation and survival. Surprisingly, PKC delta mice develop normally and are fertile, indicating that PKC delta is not critical for normal cell proliferation during development. However, PKC delta may play important roles in neoplastic cell proliferation. In this review, we have summarized the apparent multifunctional properties of this enigmatic protein with regard to its role in the regulation of cell cycle progression and cell survival. It is proposed that PKC delta has both tumor suppressor and proliferation capabilities that can be recruited as a backup kinase for both gatekeeper tumor suppression and as an activator of the Ras/Raf/MEK/MAP kinase signaling pathway in cell proliferation.	CUNY Hunter Coll, Dept Biol Sci, New York, NY 10021 USA	City University of New York (CUNY) System; Hunter College (CUNY)	Foster, DA (corresponding author), CUNY Hunter Coll, Dept Biol Sci, 695 Park Ave, New York, NY 10021 USA.	foster@genectr.hunter.cuny.edu						ABBAS T, 2004, IN PRESS J BIOL CHEM, V279; Accili D, 1996, NAT GENET, V12, P106, DOI 10.1038/ng0196-106; Acs P, 2000, CARCINOGENESIS, V21, P887, DOI 10.1093/carcin/21.5.887; Ashton AW, 1999, J BIOL CHEM, V274, P20805, DOI 10.1074/jbc.274.30.20805; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Blake RA, 1999, CELL GROWTH DIFFER, V10, P231; Blass M, 2002, MOL CELL BIOL, V22, P182, DOI 10.1128/MCB.22.1.182-195.2002; Braun MU, 2003, J MOL CELL CARDIOL, V35, P895, DOI 10.1016/S0022-2828(03)00142-1; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Clark AS, 2003, CANCER RES, V63, P780; Corbit KC, 1999, MOL CELL BIOL, V19, P4209; Crosby D, 2003, J BIOL CHEM, V278, P24533, DOI 10.1074/jbc.M301847200; Datta K, 2000, J BIOL CHEM, V275, P20700, DOI 10.1074/jbc.M909970199; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOTTO GP, 1985, NATURE, V318, P472; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Foncea R, 2000, BIOCHEM BIOPH RES CO, V273, P736, DOI 10.1006/bbrc.2000.3008; Fukumoto S, 1997, J BIOL CHEM, V272, P13816, DOI 10.1074/jbc.272.21.13816; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Griffiths G, 1996, BIOCHEM BIOPH RES CO, V222, P802, DOI 10.1006/bbrc.1996.0830; GSCHWENDT M, 1995, CARCINOGENESIS, V16, P107, DOI 10.1093/carcin/16.1.107; GSCHWENDT M, 1994, FEBS LETT, V347, P85, DOI 10.1016/0014-5793(94)00514-1; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P63; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Harrington EO, 1997, J BIOL CHEM, V272, P7390, DOI 10.1074/jbc.272.11.7390; Heit I, 2001, ONCOGENE, V20, P5143, DOI 10.1038/sj.onc.1204657; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; Ho A, 2002, CURR OPIN GENET DEV, V12, P47, DOI 10.1016/S0959-437X(01)00263-5; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Hulleman E, 2001, CELL MOL LIFE SCI, V58, P80, DOI 10.1007/PL00000780; HUPPI K, 1994, GENOMICS, V19, P161, DOI 10.1006/geno.1994.1028; Jackson TA, 2001, MOL ENDOCRINOL, V15, P1517, DOI 10.1210/me.15.9.1517; Joseloff E, 2002, J BIOL CHEM, V277, P12318, DOI 10.1074/jbc.M111618200; Kambhampati S, 2003, J BIOL CHEM, V278, P32544, DOI 10.1074/jbc.M301523200; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kitamura K, 2003, GENES CELLS, V8, P311, DOI 10.1046/j.1365-2443.2003.00635.x; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kumar V, 2000, EMBO J, V19, P1087, DOI 10.1093/emboj/19.5.1087; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Leitges M, 2001, J CLIN INVEST, V108, P1505; LI C, 2003, FASEB J; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; LI WQ, 1994, J BIOL CHEM, V269, P2349; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; LIAO L, 1994, CELL GROWTH DIFFER, V5, P1185; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Lu ZM, 1998, MOL CELL BIOL, V18, P839, DOI 10.1128/MCB.18.2.839; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; McCracken MA, 2003, MOL CANCER THER, V2, P273; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Ni HY, 2003, BRIT J HAEMATOL, V121, P849, DOI 10.1046/j.1365-2141.2003.04368.x; Page K, 2002, AM J RESP CELL MOL, V27, P204, DOI 10.1165/ajrcmb.27.2.20010016oc; Pal S, 1997, J BIOL CHEM, V272, P27509, DOI 10.1074/jbc.272.44.27509; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Perletti GP, 1999, ONCOGENE, V18, P1251, DOI 10.1038/sj.onc.1202408; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Reddig PJ, 1999, CANCER RES, V59, P5710; Ren J, 2002, J BIOL CHEM, V277, P17616, DOI 10.1074/jbc.M200436200; Ren J, 2002, J BIOL CHEM, V277, P33758, DOI 10.1074/jbc.M110667200; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Shanmugam M, 2001, CANCER LETT, V172, P43, DOI 10.1016/S0304-3835(01)00602-4; Soh JW, 2003, J BIOL CHEM, V278, P34709, DOI 10.1074/jbc.M302016200; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Stetak A, 2001, BIOCHEM BIOPH RES CO, V285, P483, DOI 10.1006/bbrc.2001.5199; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; SZALLASI Z, 1995, BIOCHEM BIOPH RES CO, V214, P888, DOI 10.1006/bbrc.1995.2370; Toyoda M, 1998, BIOCHEM BIOPH RES CO, V250, P430, DOI 10.1006/bbrc.1998.9332; Ueda Y, 1996, J BIOL CHEM, V271, P23512, DOI 10.1074/jbc.271.38.23512; Wakino S, 2001, J BIOL CHEM, V276, P47650, DOI 10.1074/jbc.M108719200; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Watters D, 1998, BIOCHEM PHARMACOL, V55, P1691, DOI 10.1016/S0006-2952(97)00680-1; YANG Q, 2000, J HUM GENET, V47, P453; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; YUPSA SH, 1988, CANCER RES, V50, P25; Zabarovsky ER, 2002, ONCOGENE, V21, P6915, DOI 10.1038/sj.onc.1205835; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275; ZETTERBERG A, 1995, CURR OPIN CELL BIOL, V7, P835, DOI 10.1016/0955-0674(95)80067-0; Zhong MH, 2002, ONCOGENE, V21, P1071, DOI 10.1038/sj/onc/1205165; Zhong MH, 2001, CELL GROWTH DIFFER, V12, P187	96	166	178	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					627	636		10.1096/fj.03-0979rev	http://dx.doi.org/10.1096/fj.03-0979rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054085				2022-12-28	WOS:000221108800033
J	Lin, KM; Hollander, JM; Kao, VY; Lin, B; Macpherson, L; Dillmann, WH				Lin, KM; Hollander, JM; Kao, VY; Lin, B; Macpherson, L; Dillmann, WH			Myocyte protection by 10 kD heat shock protein (Hsp10) involves the mobile loop and attenuation of the Ras GTP-ase pathway	FASEB JOURNAL			English	Article						ischemia reperfusion injury; temperature-sensitive mutant; chaperonin; electron transport chain	HYDROGEN EXCHANGE INHIBITION; MYOCARDIAL PROTECTION; SIGNALING PATHWAYS; HSP60; EXPRESSION; ISCHEMIA; INJURY; CELLS; CARDIOMYOCYTES; HYPERTROPHY	Heat shock proteins (hsp), hsp60 and hsp10, are involved in the folding of imported mitochondrial proteins and the refolding of denatured proteins after stress. We examined whether hsp10 can reduce myocyte death by its mitochondrial function or by interacting with cytoplasmic signaling pathways. Overexpression of hsp10 by adenoviral infection decreased myocyte death induced by hydrogen peroxide, sodium cyanide, and simulated ischemia and reoxygenation (SI/RO). We generated an adenoviral vector coding for a temperature-sensitive mutant hsp10 protein (P34H), incapable of cooperatively refolding denatured malate dehydrogenase with hsp60. Overexpression of the hsp10 mutant potentiated SI/RO-induced myocyte death. Analysis of electron transport chain function revealed increased Complex I capacity with hsp10 overexpression, whereas hsp10( P34H) overexpression decreased Complex II capacity. Hsp10 overexpression preserved both Complex I and II function after SI/RO. Examination of the Ras GTP-ase signaling pathway indicated that inhibition of Ras was required for protection by hsp10. Constitutive activation of Ras abolished the effects afforded by hsp10 and hsp10(P34H). Hsp10 overexpression inactivated Raf, ERK, and p90Ribosomal kinase (p90RSK) before and after SI/RO. Our results suggest that complex mechanisms are involved in the protection by hsp10 against SI/RO-induced myocyte death. This mechanism may involve the hsp10 mobile loop and attenuation of the Ras GTP-ase signaling pathway.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Natl Hlth Res Inst, Div Med Engn Res, Taipei, Taiwan	University of California System; University of California San Diego; National Health Research Institutes - Taiwan	Dillmann, WH (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	wdillmann@ucsd.edu	Lin, Kurt Ming-Chao/E-3975-2010	Lin, Kurt/0000-0003-1371-5569; Macpherson, Lindsey/0000-0002-1089-3733	NHLBI NIH HHS [HL49434] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL049434, R01HL049434] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anversa P, 2000, J HEART LUNG TRANSPL, V19, pS1, DOI 10.1016/S1053-2498(99)00111-4; Avkiran M, 2002, J AM COLL CARDIOL, V39, P747, DOI 10.1016/S0735-1097(02)01693-5; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; Buerke M, 1999, AM J CARDIOL, V83, p19G; Carmicle S, 2002, J BIOL CHEM, V277, P155, DOI 10.1074/jbc.M107624200; Cicconi S, 2003, J CELL PHYSIOL, V195, P27, DOI 10.1002/jcp.10219; Dillmann W H, 1999, Infect Dis Obstet Gynecol, V7, P55, DOI 10.1002/(SICI)1098-0997(1999)7:1/2<55::AID-IDOG11>3.0.CO;2-M; Dubaquie Y, 1997, P NATL ACAD SCI USA, V94, P9011, DOI 10.1073/pnas.94.17.9011; Dubaquie Y, 1998, EMBO J, V17, P5868, DOI 10.1093/emboj/17.20.5868; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FLAMENG W, 1995, CURR OPIN CARDIOL, V10, P577, DOI 10.1097/00001573-199511000-00005; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; Hefti MA, 1997, J MOL CELL CARDIOL, V29, P2873, DOI 10.1006/jmcc.1997.0523; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOHFELD J, 1994, J CELL BIOL, V126, P305, DOI 10.1083/jcb.126.2.305; HUNTER JJ, 1995, J BIOL CHEM, V270, P23173, DOI 10.1074/jbc.270.39.23173; Hurtado C, 2001, BASIC RES CARDIOL, V96, P312, DOI 10.1007/s003950170038; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Jin G, 2000, J SURG RES, V94, P124, DOI 10.1006/jsre.2000.6014; Karmazyn M, 1999, CIRC RES, V85, P777, DOI 10.1161/01.RES.85.9.777; Landry S J, 1999, Pac Symp Biocomput, P520; Landry SJ, 1997, BIOCHEMISTRY-US, V36, P10975, DOI 10.1021/bi971141p; Lau S, 1997, CIRCULATION, V96, P2287; Li YS, 1996, MOL CELL BIOL, V16, P5947; Lin KM, 2001, CIRCULATION, V103, P1787, DOI 10.1161/01.CIR.103.13.1787; Mentzer RM, 2003, ANN THORAC SURG, V75, pS700, DOI 10.1016/S0003-4975(02)04700-8; Richardson A, 1998, TRENDS BIOCHEM SCI, V23, P138, DOI 10.1016/S0968-0004(98)01193-1; Richardson A, 2001, J BIOL CHEM, V276, P4981, DOI 10.1074/jbc.M008628200; SINGH B, 1990, BIOCHEM BIOPH RES CO, V169, P391, DOI 10.1016/0006-291X(90)90344-M; Sorescu Dan, 2002, Congest Heart Fail, V8, P132, DOI 10.1111/j.1527-5299.2002.00717.x; STANIFORTH RA, 1994, FEBS LETT, V344, P129, DOI 10.1016/0014-5793(94)00348-3; Wang QD, 2002, CARDIOVASC RES, V55, P25, DOI 10.1016/S0008-6363(02)00261-4; Yifrach O, 2000, P NATL ACAD SCI USA, V97, P1521, DOI 10.1073/pnas.040449997	33	29	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1004	+		10.1096/fj.03-0348fje	http://dx.doi.org/10.1096/fj.03-0348fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059967				2022-12-28	WOS:000221108800018
J	Aguiari, G; Banzi, M; Gessi, S; Cai, YQ; Zeggio, E; Manzati, E; Piva, R; Lambertini, E; Ferrari, L; Peters, DJ; Lanza, F; Harris, PC; Borea, PA; Somlo, S; del Senno, L				Aguiari, G; Banzi, M; Gessi, S; Cai, YQ; Zeggio, E; Manzati, E; Piva, R; Lambertini, E; Ferrari, L; Peters, DJ; Lanza, F; Harris, PC; Borea, PA; Somlo, S; del Senno, L			Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells	FASEB JOURNAL			English	Article						PKD2 and PKD1 gene expression; real-time RT-PCR; PAF-induced calcium release; PKD mutations; aminoglycoside antibiotics	C-TERMINAL FRAGMENT; KIDNEY-DISEASE; GENE-PRODUCT; DEPENDENT ACTIVATION; PLASMA-MEMBRANE; PROTEIN PRODUCT; CATION CHANNEL; PKD2 PROTEIN; EXPRESSION; INTERACTS	Polycystin-2 (PC2), encoded by the PKD2 gene, mutated in 10-15% of autosomal-dominant polycystic kidney disease (ADPKD) patients, is a Ca2+-permeable cation channel present in kidney epithelia and other tissues. As PC2 was found expressed in B-lymphoblastoid cells (LCLs) and Ca2+ signaling pathways are important regulators of B cell function activities, we investigated whether PC2 plays some role in B-LCLs. In LCLs, PC2 was found mainly in ER membranes but similar to8 times less than in kidney HEK293 cells. The same reductions were found in PKD2 and PKD1 RNA; thus, PKD genes maintained, in LCLs, the same reciprocal proportion as they do in kidney cells. In LCLs obtained from subjects carrying PKD2 mutations (PKD2-LCLs) and showing reduced PC2 levels, intracellular Ca2+ concentrations evoked by platelet-activating factor (PAF), were significantly lower than in non-PKD-LCLs. This reduction was also found in PKD1-LCLs but without PC2 reductions. Likewise, cell proliferation, which is controlled by Ca2+, was reduced in PKD2- and PKD1-LCLs. Moreover, in LCLs with PKD2 nonsense mutations, aminoglycoside antibiotics reduced the PC2 defect by promoting readthrough of stop codons. Therefore, PC2 and PC1 are functionally expressed in LCLs, which provide a model, easily obtainable from ADPKD patients, to study PKD gene expression and function.	Univ Ferrara, Dept Biochem & Mol Biol, I-44100 Ferrara, Italy; Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Ferrara, Dept Biomed Sci & Adv Therapies, Haematol Unit, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Leiden Univ, Med Ctr, Dept Human & Clin Genet, Leiden, Netherlands; Mayo Clin & Mayo Fdn, Dept Pathol, Rochester, MN 55905 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA	University of Ferrara; University of Ferrara; University of Ferrara; University of Ferrara; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Mayo Clinic; Yale University; Yale University	del Senno, L (corresponding author), Univ Ferrara, Dept Biochem & Mol Biol, Via L Borsari 46, I-44100 Ferrara, Italy.	sen@unife.it	Peters, Dorien/AFH-8507-2022; Gessi, Stefania/AAS-3844-2020; Aguiari, Gianluca/AAA-4514-2019; Lanza, Francesco/AAN-2879-2021	Peters, Dorien/0000-0001-6974-7143; Gessi, Stefania/0000-0002-2197-5611	Telethon [E.1250] Funding Source: Medline	Telethon(Fondazione Telethon)		Aguiari G, 2003, BIOCHEM BIOPH RES CO, V301, P657, DOI 10.1016/S0006-291X(02)03011-5; Aguiari G, 2000, Hum Mutat, V16, P444, DOI 10.1002/1098-1004(200011)16:5<444::AID-HUMU11>3.0.CO;2-C; Aguiari G, 1999, AM J KIDNEY DIS, V33, P880, DOI 10.1016/S0272-6386(99)70420-8; Aguiari G, 1998, EXP CELL RES, V244, P259, DOI 10.1006/excr.1998.4198; Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Bedwell DM, 1997, NAT MED, V3, P1280, DOI 10.1038/nm1197-1280; Boletta A, 2000, MOL CELL, V6, P1267, DOI 10.1016/S1097-2765(00)00123-4; Cai ZQ, 1999, J BIOL CHEM, V274, P28557, DOI 10.1074/jbc.274.40.28557; Chauvet V, 2002, AM J PATHOL, V160, P973, DOI 10.1016/S0002-9440(10)64919-X; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Farrell Paul J., 1995, Trends in Microbiology, V3, P105, DOI 10.1016/S0966-842X(00)88891-5; Foggensteiner L, 2000, J AM SOC NEPHROL, V11, P814, DOI 10.1681/ASN.V115814; GABOW PA, 1993, NEW ENGL J MED, V329, P332, DOI 10.1056/NEJM199307293290508; Gessi S, 2002, MOL PHARMACOL, V61, P415, DOI 10.1124/mol.61.2.415; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Harris PC, 1999, HUM MOL GENET, V8, P1861, DOI 10.1093/hmg/8.10.1861; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ibraghimov-Beskrovnaya O, 2000, HUM MOL GENET, V9, P1641, DOI 10.1093/hmg/9.11.1641; Kaletta T, 2003, NEPHRON EXP NEPHROL, V93, pE9, DOI 10.1159/000066650; Kaplan Jean-Claude, 1992, Human Mutation, V1, P357, DOI 10.1002/humu.1380010502; Keeling KM, 2001, HUM MOL GENET, V10, P291, DOI 10.1093/hmg/10.3.291; Kim E, 1999, J BIOL CHEM, V274, P4947, DOI 10.1074/jbc.274.8.4947; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Kurosaki T, 2000, IMMUNOL REV, V176, P19; Lambertini E, 2002, BIOCHEM BIOPH RES CO, V292, P761, DOI 10.1006/bbrc.2002.6708; Li Q, 2003, BIOCHEMISTRY-US, V42, P450, DOI 10.1021/bi0267792; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Mori Y, 2002, J EXP MED, V195, P673, DOI 10.1084/jem.20011758; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Nickel C, 2002, J CLIN INVEST, V109, P481, DOI 10.1172/JC1200212867; Obermuller N, 1999, AM J PHYSIOL-RENAL, V277, pF914, DOI 10.1152/ajprenal.1999.277.6.F914; Ong ACM, 1999, AM J PATHOL, V154, P1721, DOI 10.1016/S0002-9440(10)65428-4; Parnell SC, 1998, BIOCHEM BIOPH RES CO, V251, P625, DOI 10.1006/bbrc.1998.9514; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Qian Q, 2003, HUM MOL GENET, V12, P1875, DOI 10.1093/hmg/ddg190; Reynolds DM, 1999, J AM SOC NEPHROL, V10, P2342; Rezaul K, 1997, BIOCHEM BIOPH RES CO, V239, P23, DOI 10.1006/bbrc.1997.7419; Rossignol MJ, 2001, EUR STUD AMER HIST, V1, P63; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Scheffers MS, 2002, HUM MOL GENET, V11, P59, DOI 10.1093/hmg/11.1.59; SCHULAM PG, 1990, BIOCHEM BIOPH RES CO, V166, P1047, DOI 10.1016/0006-291X(90)90916-B; SNYDER F, 1990, AM J PHYSIOL, V259, pC697, DOI 10.1152/ajpcell.1990.259.5.C697; Stayner C, 2001, TRENDS PHARMACOL SCI, V22, P543, DOI 10.1016/S0165-6147(00)01832-0; Sutters M, 2003, J LAB CLIN MED, V141, P91, DOI 10.1067/mlc.2003.13; Torres VE, 2001, J AM SOC NEPHROL, V12, P1, DOI 10.1681/ASN.V1211; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vandorpe DH, 2001, J BIOL CHEM, V276, P4093, DOI 10.1074/jbc.M006252200; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Weston BS, 2001, BBA-MOL BASIS DIS, V1536, P161, DOI 10.1016/S0925-4439(01)00046-1; Winslow MM, 2003, CURR OPIN IMMUNOL, V15, P299, DOI 10.1016/S0952-7915(03)00050-5; Xu GM, 2001, J BIOL CHEM, V276, P46544, DOI 10.1074/jbc.M107828200; YAMADA H, 1993, J EXP MED, V177, P1613, DOI 10.1084/jem.177.6.1613	57	52	52	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					884	+		10.1096/fj.03-0687fje	http://dx.doi.org/10.1096/fj.03-0687fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001556				2022-12-28	WOS:000220522800022
J	Schildknecht, S; Bachschmid, M; Baumann, A; Ullrich, V				Schildknecht, S; Bachschmid, M; Baumann, A; Ullrich, V			COX-2 inhibitors selectively block prostacyclin synthesis in endotoxin exposed vascular smooth muscle cells	FASEB JOURNAL			English	Article						prostaglandin-endoperoxide synthase epoprostenol; septic shock; dinoprostone; cyclooxygenase inhibitors	NITRIC-OXIDE SYNTHASE; GASTROINTESTINAL TOXICITY; CARDIOVASCULAR EVENTS; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS; MESSENGER-RNA; SEPTIC SHOCK; IN-VIVO; CYCLOOXYGENASE-2; PEROXYNITRITE	High levels of prostacyclin (PGI(2); measured as 6-keto-PGF(1alpha)) have been reported in patients under septic shock. Because this was at variance with our previous findings of nitration and inhibition of PGI(2) synthase by endotoxin (LPS) in the endothelium, we examined the role of vascular smooth muscle as an alternative source of PGI(2). Bovine aortic smooth muscle cells (SMC) in passage 1 contained high levels of PGI(2) synthase but no activity and no detectable levels of COX-1 or COX-2. LPS exposure for 3 h caused COX-2 mRNA and protein levels to rise during 8 h together with a large increase in PGI(2) synthase activity. In contrast, cytokines lead to only a moderate increase of both PGI(2) and PGE(2). Specific COX-2 inhibitors completely blocked PGI(2) formation but PGF(2) synthesis only partially. Unexpectedly, (NO)-N-. formation remained low over 6-8 h, which may be a reason for the lack of nitration and inhibition of prostacyclin synthase in LPS exposed SMC. Our results can explain the clinical observation of severe hypotension in progressive stages of septic shock as a mechanism to compensate endothelial dysfunction. According to our data, the use of COX-2-specific inhibitors may not be advisable in septic patients. In contrast, administration of COX-1-specific blockers could prevent platelet aggregation during progressed stages of endotoxic shock.	Univ Konstanz, Fak Biol, Dept Biol, Fach Sonnenbuhl X910, D-78457 Constance, Germany	University of Konstanz	Ullrich, V (corresponding author), Univ Konstanz, Fak Biol, Dept Biol, Fach Sonnenbuhl X910, D-78457 Constance, Germany.	volker.ullrich@uni-konstanz.de		Bachschmid, Markus Michael/0000-0002-0748-5528				Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BERMAN RS, 1993, BRIT J PHARMACOL, V110, P1282, DOI 10.1111/j.1476-5381.1993.tb13956.x; Bing RJ, 2002, J AM COLL CARDIOL, V39, P521, DOI 10.1016/S0735-1097(01)01749-1; BISHOPBAILEY D, METHODS NITRIC OXIDE, V3, P41; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Brock TG, 1999, J BIOL CHEM, V274, P11660, DOI 10.1074/jbc.274.17.11660; Catella-Lawson F, 2001, NEW ENGL J MED, V345, P1809, DOI 10.1056/NEJMoa003199; Caughey GE, 2001, J IMMUNOL, V167, P2831, DOI 10.4049/jimmunol.167.5.2831; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Connolly E, 2002, J PHARMACOL EXP THER, V300, P393, DOI 10.1124/jpet.300.2.393; DAVENPECK KL, 1994, AM J PHYSIOL, V267, pH622, DOI 10.1152/ajpheart.1994.267.2.H622; Deitch EA, 1998, SHOCK, V9, P1, DOI 10.1097/00024382-199801000-00001; DEWITT DL, 1983, J CLIN INVEST, V72, P1882, DOI 10.1172/JCI111151; ELDOR A, 1981, J CLIN INVEST, V67, P735, DOI 10.1172/JCI110090; Ersoy Y, 2002, ANN RHEUM DIS, V61, P76, DOI 10.1136/ard.61.1.76; Fierro IM, 2001, BRAZ J MED BIOL RES, V34, P555, DOI 10.1590/S0100-879X2001000500002; GAYNOR E, 1970, SCIENCE, V170, P986, DOI 10.1126/science.170.3961.986; GRIFFITHS MJD, 1995, AM J PHYSIOL-LUNG C, V268, pL509, DOI 10.1152/ajplung.1995.268.3.L509; HALUSHKA PV, 1985, CRIT CARE MED, V13, P451, DOI 10.1097/00003246-198506000-00001; HARRIS RC, 1994, J CLIN INVEST, V94, P2504, DOI 10.1172/JCI117620; Kalgutkar AS, 1998, SCIENCE, V280, P1268, DOI 10.1126/science.280.5367.1268; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Kurumbail RG, 1996, NATURE, V384, P644, DOI 10.1038/384644a0; Liou JY, 2000, J BIOL CHEM, V275, P15314, DOI 10.1074/jbc.275.20.15314; MAEDA K, 1995, SHOCK, V3, P46, DOI 10.1097/00024382-199503010-00007; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P418; MAROTTA P, 1992, BRIT J PHARMACOL, V107, P640, DOI 10.1111/j.1476-5381.1992.tb14499.x; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Mukherjee D, 2002, BIOCHEM PHARMACOL, V63, P817, DOI 10.1016/S0006-2952(02)00842-0; Mukherjee D, 2001, JAMA-J AM MED ASSOC, V286, P954, DOI 10.1001/jama.286.8.954; Neubert K, 1997, PROSTAGLANDINS, V54, P447, DOI 10.1016/S0090-6980(97)00063-4; OBANION MK, 1991, J BIOL CHEM, V266, P23261; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006-2952(02)01422-3; RIMARACHIN JA, 1994, ARTERIOSCLER THROMB, V14, P1021, DOI 10.1161/01.ATV.14.7.1021; RISTIMAKI A, 1994, J BIOL CHEM, V269, P11769; Schonbeck U, 1999, AM J PATHOL, V155, P1281, DOI 10.1016/S0002-9440(10)65230-3; Schultz MJ, 2002, ANN MED, V34, P573, DOI 10.1080/078538902321117797; Sengupta S., 1999, Indian Journal of Pharmacology, V31, P322; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; SIMMONS DL, 1993, J LIPID MEDIATOR, V6, P113; SIRSJO A, 1994, FEBS LETT, V338, P191, DOI 10.1016/0014-5793(94)80363-3; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Stoclet JC, 1999, CIRCULATION, V100, P107, DOI 10.1161/01.CIR.100.2.107; Ullrich V, 2001, BBA-MOL CELL BIOL L, V1532, P1, DOI 10.1016/S1388-1981(01)00126-3; Uracz W, 2002, J PHYSIOL PHARMACOL, V53, P643; Vallance P, 1997, LANCET, V349, P1391, DOI 10.1016/S0140-6736(96)09424-X; Vane JR, 2002, SCIENCE, V296, P474, DOI 10.1126/science.1071702; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; Wright JM, 2002, CAN MED ASSOC J, V167, P1131; Zou MH, 1999, AM J PATHOL, V154, P1359, DOI 10.1016/S0002-9440(10)65390-4; Zou MH, 1998, BIOCHEM J, V336, P507, DOI 10.1042/bj3360507; Zou MH, 1996, FEBS LETT, V382, P101, DOI 10.1016/0014-5793(96)00160-3	59	37	38	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					757	+		10.1096/fj.03-0609fje	http://dx.doi.org/10.1096/fj.03-0609fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977876				2022-12-28	WOS:000220425000016
J	Ahmad, N				Ahmad, N			Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer	FASEB JOURNAL			English	Article						Plk inhibitor; gene therapy; apoptosis; cell cycle	CYCLIN B1; CELLS; CENTROSOMES; INHIBITION; MARKER	Second only to skin cancer, cancer of the prostate gland (CaP) is the most commonly occurring cancer in American men. Existing treatment approaches and surgical intervention have been unable to effectively manage this dreaded cancer; therefore, efforts are ongoing to explore novel targets and strategies for the management of CaP. A complete understanding of the genetic control of the processes of cellular proliferation and programmed cell death, or "apoptosis," may provide the basis for the rational design of novel therapeutic strategies against CaP. Key regulators for the mitotic progression in mammalian cells are the polo-like kinases (Plks). The activity of Plk1 is elevated in tissues and cells with a high mitotic index, including cancer cells. An increasing body of evidence suggests that the level of Plk1 expression has prognostic value for predicting outcomes in patients with some cancers such as lung cancer, squamous cell carcinomas of the head and neck, melanomas, and ovarian and endometrial carcinomas. However, the role of Plk1 in CaP is not known. Here, a hypothesis is put forward that Plk1 plays a critical role in the development of Prostate cancer; and the silencing of Plk1 will result in elimination of human CaP cells via an inactivation of cyclin-dependent kinase 1 (Cdc2)/cyclin B 1-mediated mitotic arrest followed by apoptosis. A corollary to this hypothesis is that Plk1 could serve as a target for the intervention of CaP in humans. Therefore, if the hypothesis is tested to be true, it is conceivable that gene therapeutic approaches aimed at Plk1 or the pharmacological inhibitors of Plk1 may be developed for the treatment/management of CaP.	Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, Madison, WI 53706 USA; Univ Wisconsin, Mol & Environm Toxicol Ctr, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Ahmad, N (corresponding author), Univ Wisconsin, Med Sci Ctr, Dept Dermatol, Ctr Comprehens Canc, 1300 Univ Ave, Madison, WI 53706 USA.	nahmad@wisc.edu	Ahmad, Nihal/AAR-4249-2021	Ahmad, Nihal/0000-0002-4239-9887				Brinkley BR, 2001, TRENDS CELL BIOL, V11, P18, DOI 10.1016/S0962-8924(00)01872-9; Donaldson MM, 2001, J CELL SCI, V114, P2357; Doxsey SJ, 2001, NAT CELL BIOL, V3, pE105, DOI 10.1038/35074618; Jemal A, 2003, CA-CANCER J CLIN, V53, P5, DOI 10.3322/canjclin.53.1.5; Kneisel L, 2002, J CUTAN PATHOL, V29, P354, DOI 10.1034/j.1600-0560.2002.290605.x; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Liu XQ, 2002, P NATL ACAD SCI USA, V99, P8672, DOI 10.1073/pnas.132269599; Pihan GA, 2001, CANCER RES, V61, P2212; Smits VAJ, 2000, NAT CELL BIOL, V2, P672, DOI 10.1038/35023629; Spankuch-Schmitt B, 2002, JNCI-J NATL CANCER I, V94, P1863, DOI 10.1093/jnci/94.24.1863; Spankuch-Schmitt B, 2002, ONCOGENE, V21, P3162, DOI 10.1038/sj.onc.1205412; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Yuan JP, 2002, ONCOGENE, V21, P8282, DOI 10.1038/sj.onc.1206011; Yuan JP, 1997, AM J PATHOL, V150, P1165	14	28	51	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					5	7		10.1096/fj.03-0848hyp	http://dx.doi.org/10.1096/fj.03-0848hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718382				2022-12-28	WOS:000188829300035
J	Andoh, T; Kuraishi, Y				Andoh, T; Kuraishi, Y			Direct action of immunoglobulin G on primary sensory neurons through Fc gamma receptor I	FASEB JOURNAL			English	Article						IgG; Fc gamma RI; substance P; calcium channel	ITCH-ASSOCIATED RESPONSE; SUBSTANCE-P RELEASE; MOUSE MAST-CELLS; IFN-GAMMA; CONDUCTION-VELOCITY; HERPES-ZOSTER; IGG; MICE; HISTAMINE; CAPSAICIN	Immunoglobulin G (IgG) binds specific antigens, and IgG-antigen complexes primarily activate immune cells and the complement system. These immune reactions are known to affect neural functions through the production and release of mediators such as cytokines. The high affinity IgG receptor FcgammaRI, but not the low affinity receptors Fc gamma RII and Fc gamma RIII, was expressed on the mouse dorsal root ganglion (DRG) neurons, especially small- or medium-sized neurons. IgG bound to DRG neurons and made a complex with antigen there. Ragweed pollen bound to nerve fibers in the skin of sensitized mouse in situ. The formation of IgG-ragweed pollen complex increased the concentration of Ca2+ ions in the DRG neurons. This increase was inhibited by a Ca2+ chelator, L- and N-type voltage-dependent Ca2+ channel blockers, and anti-FcgammaRI antibody. IgG-antigen complex released substance P from DRG neurons, which was inhibited by L- and N-type Ca2+ channel blockers. Thus, IgG and antigen combine on primary sensory neurons to directly activate them, which may be a novel type of immune-neuron linkage.	Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, Toyama 9300194, Japan	University of Toyama	Kuraishi, Y (corresponding author), Toyama Med & Pharmaceut Univ, Fac Pharmaceut Sci, Dept Appl Pharmacol, 2630 Sugitani, Toyama 9300194, Japan.	kuraisiy@ms.toyama-mpu.ac.jp						Andoh T, 1998, J PHARMACOL EXP THER, V286, P1140; CARPENTER SE, 1981, BRIT J PHARMACOL, V73, P755, DOI 10.1111/j.1476-5381.1981.tb16812.x; Chen YL, 1998, INT ARCH ALLERGY IMM, V116, P269, DOI 10.1159/000023955; DISCLAFANI A, 1983, CUTIS, V31, P523; FERGUSON AC, 1984, J ALLERGY CLIN IMMUN, V74, P678, DOI 10.1016/0091-6749(84)90229-X; Haanpaa M, 1998, NEUROLOGY, V51, P1405, DOI 10.1212/WNL.51.5.1405; HANDWERKER HO, 1991, J NEUROPHYSIOL, V66, P307, DOI 10.1152/jn.1991.66.1.307; Harding LM, 1999, PROG NEURO-PSYCHOPH, V23, P1103, DOI 10.1016/S0278-5846(99)00049-4; HARPER AA, 1985, J PHYSIOL-LONDON, V359, P31, DOI 10.1113/jphysiol.1985.sp015573; HAYWARD A, 1991, J INFECT DIS, V163, P873, DOI 10.1093/infdis/163.4.873; HILL PB, 1995, VET IMMUNOL IMMUNOP, V44, P105, DOI 10.1016/0165-2427(94)05298-7; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; JONAKAIT GM, 1991, ANN NY ACAD SCI, V632, P19, DOI 10.1111/j.1749-6632.1991.tb33090.x; Kumazawa T, 1996, PROG BRAIN RES, V113, P3, DOI 10.1016/S0079-6123(08)61078-X; KURAISHI Y, 1995, EUR J PHARMACOL, V275, P229, DOI 10.1016/0014-2999(94)00780-B; KURAISHI Y, 1985, BRAIN RES, V325, P294, DOI 10.1016/0006-8993(85)90326-9; LEE KH, 1986, J COMP NEUROL, V243, P335, DOI 10.1002/cne.902430305; MAGGI CA, 1990, NEUROSCI LETT, V114, P203, DOI 10.1016/0304-3940(90)90072-H; Morioka N, 2002, J NEUROCHEM, V80, P989, DOI 10.1046/j.0022-3042.2002.00722.x; Ohtsuka E, 2003, J PHARMACOL SCI, V91, P263, DOI 10.1254/jphs.91.263; Ohtsuka E, 2001, JPN J PHARMACOL, V86, P97, DOI 10.1254/jjp.86.97; OVARY Z, 1971, J IMMUNOL, V107, P1795; PETRONI KC, 1988, J IMMUNOL, V140, P3467; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; Takahashi T, 2001, INT ARCH ALLERGY IMM, V125, P228, DOI 10.1159/000053820; TIGELAAR RE, 1971, J IMMUNOL, V106, P661; Uciechowski P, 1998, EUR J IMMUNOL, V28, P2928, DOI 10.1002/(SICI)1521-4141(199809)28:09<2928::AID-IMMU2928>3.0.CO;2-8; UEDA M, 1994, NEUROSCI RES, V20, P231, DOI 10.1016/0168-0102(94)90092-2; VANDEWINKEL JGJ, 1990, SCAND J IMMUNOL, V31, P315	29	73	78	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					182	184		10.1096/fj.02-1169fje	http://dx.doi.org/10.1096/fj.02-1169fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630707				2022-12-28	WOS:000188829300067
J	Cuzzocrea, S; Mazzon, E; Dugo, L; Di Paola, R; Caputi, AP; Salvemini, D				Cuzzocrea, S; Mazzon, E; Dugo, L; Di Paola, R; Caputi, AP; Salvemini, D			Superoxide: a key player in hypertension	FASEB JOURNAL			English	Article						superoxide dismutase; M40403; F-2-isoprostane	NITRIC-OXIDE SYNTHESIS; PEROXYNITRITE DECOMPOSITION CATALYSTS; SPLANCHNIC ARTERY-OCCLUSION; BLOOD-PRESSURE; RAT MODEL; IN-VIVO; ENDOTHELIUM; DISMUTASE; ACETYLCHOLINE; ACTIVATION	Superoxide is increased in the vessel wall of spontaneously hypertensive rats (SHR) where, if "blocked," potentiates endothelium-dependent vasodilation. The purpose of this study was to determine the role of superoxide anion in hypertension and its interaction with nitric oxide (NO). For this purpose we used a low molecular weight synthetic superoxide dismutase mimetic (M40403), known to remove selectively superoxide anion. Baseline mean arterial pressure (MAP) was significantly elevated in the SHR compared with its normal counterpart, Wistar Kyoto (WKY). M40403 at a dose (2 mg.kg(-1).h(-1)), which had no effect in the WKY, significantly decreased MAP in SHR rats. To determine whether superoxide anion increases MAP by inactivating NO, NO synthesis was blocked with N-G nitroarginine methyl ester (L-NAME, 3 mg/kg i.v.), a nonselective nitric oxide synthase inhibitor. L-NAME (3 mg/kg, i.v) blocked the anti-hypertensive effect of M40403 (2 mg/kg over 30 min). When used at a dose that yielded similar increases in MAP, norepinephrine (2.1 mug/kg) failed to alter the anti-hypertensive effects of M40403 in the SHR. To investigate whether the antihypertensive effect of M40403 was associated with an improvement of the alterations in vascular reactivity, a separate group of experiments was carried out ex vivo. Endothelium-dependent vasorelaxation to acetylcholine (10 nM-10 muM), an index of endothelial function, was reduced in aortic rings taken from SHR rats when compared with WKY rats. In vivo treatment with M40403 caused an improvement of the degree of the endothelial dysfunction in SHR rats. Furthermore, immunohistochemical analysis for nitrotyrosine (the product formed from the interaction of nitric oxide with superoxide) revealed a positive staining in aorta from SHR rats. The degree of staining for nitrotyrosine was markedly reduced in tissue sections obtained from SHR rats treated with M40403. Our data suggest that overt production of superoxide in SHR couples with nitric oxide, reducing its function and leading to a loss of blood vessel tone and hypertension. Another important effect appears to be at the level of endothelial cellular integrity, where by interacting with nitric oxide, superoxide anion forms peroxynitrite and subsequent endothelial cell dysfunction. By removing superoxide, M40403 restores blood pressure to near-to-normal values.	MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, St Louis, MO 63114 USA; Univ Messina, Inst Pharmacol, I-98100 Messina, Italy; Univ Messina, Sch Med, Dept Biomorphol, I-98100 Messina, Italy	University of Messina; University of Messina	Salvemini, D (corresponding author), MetaPhore Pharmaceut, Dept Biol & Pharmacol Res, 1910 Innerbelt Business Ctr Dr, St Louis, MO 63114 USA.	dsalvemini@metaphore.com	di paola, rosanna/U-4356-2019; Mazzon, Emanuela/AAL-4334-2020	di paola, rosanna/0000-0001-6725-8581; mazzon, emanuela/0000-0002-5073-717X; Dugo, Laura/0000-0001-5527-0364				ANGUS JA, 1992, KIDNEY INT, V41, pS73; Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; BAYLIS C, 1992, J CLIN INVEST, V90, P278, DOI 10.1172/JCI115849; Beckman JS, 1996, CHEM RES TOXICOL, V9, P836, DOI 10.1021/tx9501445; Bouloumie A, 1997, HYPERTENSION, V30, P934, DOI 10.1161/01.HYP.30.4.934; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CARLOS R, 1999, HYPERTENSION, V34, P943; COCKCROFT JR, 1994, NEW ENGL J MED, V330, P1036, DOI 10.1056/NEJM199404143301502; Cosentino F, 1998, J CLIN INVEST, V101, P1530, DOI 10.1172/JCI650; Cuzzocrea S, 1997, BRIT J PHARMACOL, V121, P1065, DOI 10.1038/sj.bjp.0701234; Cuzzocrea S, 2001, BRIT J PHARMACOL, V132, P19, DOI 10.1038/sj.bjp.0703775; Cuzzocrea S, 2001, PHARMACOL REV, V53, P135; Davidson C. A., 1997, AM J PHYSIOL, V273, P437; DOHI Y, 1995, HYPERTENSION, V15, P170; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; GRANGER JP, 1992, J CARDIOVASC PHARM, V20, pS160, DOI 10.1097/00005344-199204002-00045; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Grover AK, 2003, AM J PHYSIOL-CELL PH, V284, pC294, DOI 10.1152/ajpcell.00297.2002; GRUNFELD S, 1995, HYPERTENSION, V26, P854, DOI 10.1161/01.HYP.26.6.854; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HAYNES WG, 1993, J HYPERTENS, V11, P1375, DOI 10.1097/00004872-199312000-00009; HU LF, 1994, HYPERTENSION, V23, P185, DOI 10.1161/01.HYP.23.2.185; Kerr S, 1999, HYPERTENSION, V33, P1353, DOI 10.1161/01.HYP.33.6.1353; KOOY NW, 1994, ARCH BIOCHEM BIOPHYS, V310, P352, DOI 10.1006/abbi.1994.1178; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; LAURENT S, 1990, AM J PHYSIOL, V258, pH1004, DOI 10.1152/ajpheart.1990.258.4.H1004; Laursen JB, 1997, CIRCULATION, V95, P588, DOI 10.1161/01.CIR.95.3.588; LINDER L, 1990, CIRCULATION, V81, P1762, DOI 10.1161/01.CIR.81.6.1762; MALINSKI T, 1993, BIOCHEM BIOPH RES CO, V194, P654, DOI 10.1006/bbrc.1993.1871; MARUYAMA J, 1994, AM J PHYSIOL, V266, pH2476, DOI 10.1152/ajpheart.1994.266.6.H2476; McIntyre M, 1999, HYPERTENSION, V34, P539, DOI 10.1161/01.HYP.34.4.539; McIntyre M, 1997, HYPERTENSION, V30, P1517, DOI 10.1161/01.HYP.30.6.1517; Miyamoto Y, 1996, P SOC EXP BIOL MED, V211, P366; MIYAMOTO Y, 1991, P SOC EXP BIOL MED, V21, P366; NAKAZONO K, 1991, P NATL ACAD SCI USA, V88, P10045, DOI 10.1073/pnas.88.22.10045; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRITCHARD KA, 1995, CIRC RES, V77, P510, DOI 10.1161/01.RES.77.3.510; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rees D, 1996, HYPERTENSION, V28, P367, DOI 10.1161/01.HYP.28.3.367; RIBEIRO MO, 1992, HYPERTENSION, V20, P298, DOI 10.1161/01.HYP.20.3.298; Riley DP, 1996, INORG CHEM, V35, P5213, DOI 10.1021/ic960262v; Riley L, 1997, INFECT DIS CLIN N AM, V11, P119, DOI 10.1016/S0891-5520(05)70346-9; RUBANYI GM, 1986, AM J PHYSIOL, V250, pH822, DOI 10.1152/ajpheart.1986.250.5.H822; Salvemini D, 1999, SCIENCE, V286, P304, DOI 10.1126/science.286.5438.304; Salvemini D, 1999, BRIT J PHARMACOL, V127, P685, DOI 10.1038/sj.bjp.0702604; Salvemini D, 1998, P NATL ACAD SCI USA, V95, P2659, DOI 10.1073/pnas.95.5.2659; Salvemini D, 2001, ARTHRITIS RHEUM, V44, P2909, DOI 10.1002/1529-0131(200112)44:12<2909::AID-ART479>3.0.CO;2-#; Salvemini D, 1996, EUR J PHARMACOL, V303, P217, DOI 10.1016/0014-2999(96)00140-9; Salvemini D, 2001, BRIT J PHARMACOL, V132, P815, DOI 10.1038/sj.bjp.0703841; SAMUNI A, 1991, J CLIN INVEST, V87, P1526, DOI 10.1172/JCI115163; Schnackenberg CG, 1998, HYPERTENSION, V32, P59, DOI 10.1161/01.HYP.32.1.59; SUZUKI H, 1995, HYPERTENSION, V25, P1083, DOI 10.1161/01.HYP.25.5.1083; Szabo C, 1997, J CLIN INVEST, V100, P723, DOI 10.1172/JCI119585; Szabo C, 1996, CIRC RES, V78, P1051, DOI 10.1161/01.RES.78.6.1051; TADDEI S, 1993, HYPERTENSION, V21, P929, DOI 10.1161/01.HYP.21.6.929; TREASURE CB, 1992, CIRC RES, V71, P776, DOI 10.1161/01.RES.71.4.776; Tschudi MR, 1996, HYPERTENSION, V27, P32, DOI 10.1161/01.HYP.27.1.32; VALLANCE P, 1989, LANCET, V2, P997; VILLA LM, 1994, P NATL ACAD SCI USA, V91, P12383, DOI 10.1073/pnas.91.26.12383; WEI EP, 1985, CIRC RES, V57, P781, DOI 10.1161/01.RES.57.5.781	60	73	77	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					94	101		10.1096/fj.03-0428com	http://dx.doi.org/10.1096/fj.03-0428com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718390				2022-12-28	WOS:000188829300043
J	Dye, JF; Vause, S; Johnston, T; Clark, P; Firth, JA; D'Souza, SW; Sibley, CP; Glazier, JD				Dye, JF; Vause, S; Johnston, T; Clark, P; Firth, JA; D'Souza, SW; Sibley, CP; Glazier, JD			Characterization of cationic amino acid transporters and expression of endothelial nitric oxide synthase in human placental microvascular endothelial cells	FASEB JOURNAL			English	Article						placenta; arginine; transport; endothelium; eNOS	MEMBRANE-PROTEIN; SYSTEM Y(+); LOCALIZATION; SPECIFICITY; ACTIVATION; DEPENDENCE; RELEASE; CLONING	We investigated the expression and activity of arginine transporters and endothelial nitric oxide synthase (eNOS) in human placental microvascular endothelial cells (HPMEC). Using RT-PCR amplification products for eNOS, CAT1, CAT2A, CAT2B, CAT4, 4F2hc (CD98), rBAT and the light chains y(+)LAT1, y(+)LAT2, and b(0+)AT1 were detected in HPMEC, but not B0+. Immunohistochemistry and Western blotting confirmed the presence of 4F2hc and CAT1 protein in HPMEC. 4F2hc-light chain dimers were indicated by a shift in molecular mass detected under nonreducing conditions. L-Arginine transport into HPMEC was independent of Na+ or Cl- and was inhibited by the neutral amino acid glutamine, but not by cystine. The K-i for glutamine inhibition was greater in the absence of Na+. Kinetic analysis supported a two-transporter model attributed to system y(+)L and system y(+). Expression of eNOS in HPMEC was detectable by immunohistochemistry and ELISA but not by Western blotting. Activity of eNOS in HPMEC, measured over 48 h, either as the basal production of nitric oxide (NO) or as the accumulation of intracellular cGMP was not detectable. We conclude that HPMEC transport cationic amino acids by systems y(+) and y(+)L and that basal eNOS expression and activity in these cells is low.	Imperial Coll Sch Med, Div Biomed Sci, London SW7 2AZ, England; Univ Manchester, St Marys Hosp, Acad Unit Child Hlth, Manchester M13 0JH, Lancs, England	Imperial College London; University of Manchester	Glazier, JD (corresponding author), Univ Manchester, St Marys Hosp, Acad Unit Child Hlth, Hathersage Rd, Manchester M13 0JH, Lancs, England.	jglazier@fs3.scg.man.ac.uk	Dye, Julian/U-3396-2019		British Heart Foundation	British Heart Foundation(British Heart Foundation)	We gratefully acknowledge the generous donation of human CAT1 antibody from Dr. Sergey Zharikov (University of Florida, Gainesville) and Dr. Edward Block (Veterans Affairs Medical Center, Gainesville, FL). We would like to thank Dr. S. Greenwood for her helpful technical advice and discussions, Ms. L. Laurence and Ms. M. Cretney for their excellent laboratory assistance, Dr. W. G. Bardsley for his advice and training in regard to the use of the SIMFIT computer program, and the staff at the Central Delivery Units of St. Mary's Hospitals in Manchester and London for their assistance in obtaining placentas. This work was supported by the British Heart Foundation.	ANGELO S, 1994, J MEMBRANE BIOL, V141, P183; Ayuk PTY, 2000, AM J PHYSIOL-CELL PH, V278, pC1162, DOI 10.1152/ajpcell.2000.278.6.C1162; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BUSSOLATI O, 1993, AM J PHYSIOL, V265, pC1006, DOI 10.1152/ajpcell.1993.265.4.C1006; BUTTERY LDK, 1994, PLACENTA, V15, P257, DOI 10.1016/0143-4004(94)90017-5; CETIN I, 1990, AM J OBSTET GYNECOL, V162, P253, DOI 10.1016/0002-9378(90)90860-A; Chillaron J, 2001, AM J PHYSIOL-RENAL, V281, pF995, DOI 10.1152/ajprenal.2001.281.6.F995; CLOSS EI, 1999, MEMBRANE TRANSPORTER, P229; Deves R, 2000, J MEMBRANE BIOL, V173, P165, DOI 10.1007/s002320001017; Deves R, 1998, PHYSIOL REV, V78, P487, DOI 10.1152/physrev.1998.78.2.487; Dye JF, 2001, MICROVASC RES, V62, P94, DOI 10.1006/mvre.2001.2333; Dye JF, 2001, PLACENTA, V22, P32, DOI 10.1053/plac.2000.0579; Feron O, 1999, CURR OPIN NEPHROL HY, V8, P55, DOI 10.1097/00041552-199901000-00010; Firth JA, 1996, PLACENTA, V17, P89, DOI 10.1016/S0143-4004(96)80001-4; Goligorsky MS, 2002, AM J PHYSIOL-RENAL, V283, pF1, DOI 10.1152/ajprenal.00377.2001; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Graf P, 2001, BRIT J PHARMACOL, V132, P1193, DOI 10.1038/sj.bjp.0703921; JAFFE EA, 1973, J CLIN INVEST, V71, P974; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRISHNAKUMAR K, 2003, AM J PHYSIOL-CELL PH, V284, pC1784; McDonald KK, 1997, J BIOL CHEM, V272, P31213, DOI 10.1074/jbc.272.50.31213; MITCHELL JA, 1990, EUR J PHARMACOL, V182, P573, DOI 10.1016/0014-2999(90)90058-E; MYATT L, 1993, PLACENTA, V14, P487, DOI 10.1016/S0143-4004(05)80202-4; Orpana AK, 1996, AM J OBSTET GYNECOL, V174, P1056, DOI 10.1016/S0002-9378(96)70350-2; Ou W, 2003, VIROLOGY, V308, P101, DOI 10.1016/S0042-6822(02)00086-7; Ranta VH, 1998, HYPERTENS PREGNANCY, V17, P307, DOI 10.3109/10641959809009604; Rojas AM, 1999, J MEMBRANE BIOL, V168, P199, DOI 10.1007/s002329900509; Sala R, 2002, AM J PHYSIOL-CELL PH, V282, pC134, DOI 10.1152/ajpcell.2002.282.1.C134; Sladek SM, 1997, AM J PHYSIOL-REG I, V272, pR441, DOI 10.1152/ajpregu.1997.272.2.R441; Sloan JL, 1999, J BIOL CHEM, V274, P23740, DOI 10.1074/jbc.274.34.23740; SOBREVIA L, 1995, J PHYSIOL-LONDON, V489, P183, DOI 10.1113/jphysiol.1995.sp021040; Torrents D, 1998, J BIOL CHEM, V273, P32437, DOI 10.1074/jbc.273.49.32437; TSUKAHARA H, 1993, BIOCHEM BIOPH RES CO, V193, P722, DOI 10.1006/bbrc.1993.1685; Verrey F, 1999, J MEMBRANE BIOL, V172, P181, DOI 10.1007/s002329900595; Wagner CA, 2001, AM J PHYSIOL-CELL PH, V281, pC1077, DOI 10.1152/ajpcell.2001.281.4.C1077; Wolf S, 2002, BIOCHEM J, V364, P767, DOI 10.1042/BJ20020084; Zarlingo TJ, 1997, PLACENTA, V18, P511, DOI 10.1016/0143-4004(77)90004-2; Zharikov SI, 2001, AM J PHYSIOL-LUNG C, V280, pL465, DOI 10.1152/ajplung.2001.280.3.L465	38	41	43	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					125	127		10.1096/fj.02-0916fje	http://dx.doi.org/10.1096/fj.02-0916fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597568				2022-12-28	WOS:000188829300048
J	Graler, MH; Goetzl, EJ				Graler, MH; Goetzl, EJ			The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors	FASEB JOURNAL			English	Article						receptor internalization; calcium signaling; lymphocyte; immunity; transplantation	CIRCULATING MATURE LYMPHOCYTES; ALLOGRAFT SURVIVAL; INDUCED ARTHRITIS; SEQUESTRATION; ACCELERATION; RATS; TRANSPLANTATION; TRAFFICKING; INDUCTION; DRUG	FTY720 is an immunosuppressant that reduces circulating levels of naive lymphocytes by increasing their localization and sequestration in secondary lymphoid organs. It is considered to be an agonist for sphingosine 1-phosphate (S1P) G protein-coupled receptors (GPCRs) after phosphorylation at micromolar concentrations. We now describe its nonagonist and noncompetitive inhibitory activity at low nanomolar concentrations for types 1 and 5 S1P-GPCRs and of moderate potency for type 2 S1P-GPCRs. FTY720 blocks S1P signaling through S1P(1,2,5) by inducing their internalization and intracellular partial degradation without affecting S1P(3) or S1P(4). S1P-R internalization is maximal several hours after only seconds of incubation with FTY720 at 37degreesC and washing, and continues for days before recovery of surface expression and functions. The timing and extent of S1P-R internalization are highly dependent on FTY720 concentration. FTY720 is therefore an S1P-GPCR-selective and noncompetitive inhibitor with a unique mechanism of action.	Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Graler, MH (corresponding author), Univ Calif San Francisco, Dept Med, Room UB-8B,UC Box 0711,533 Parnassus Ave, San Francisco, CA 94143 USA.	graeler@itsa.ucsf.edu	Gräler, Markus/ABH-1905-2021	Gräler, Markus/0000-0001-6650-7849				An SZ, 1998, J CELL BIOCHEM, P147; Bohler T, 2000, Transpl Int, V13 Suppl 1, pS311, DOI 10.1007/s001470050350; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C200176200; Brinkmann V, 2001, TRANSPLANT P, V33, P3078, DOI 10.1016/S0041-1345(01)02312-0; Brinkmann V, 2002, CURR OPIN IMMUNOL, V14, P569, DOI 10.1016/S0952-7915(02)00374-6; Brinkmann V, 2001, TRANSPLANTATION, V72, P764, DOI 10.1097/00007890-200109150-00002; Budde K, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V1341073; Chen S, 2001, TRANSPLANT P, V33, P3057, DOI 10.1016/S0041-1345(01)02306-5; Chiba K, 1999, TRANSPLANT P, V31, P1230, DOI 10.1016/S0041-1345(98)01975-7; Chiba K, 1998, J IMMUNOL, V160, P5037; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Fujino M, 2003, J PHARMACOL EXP THER, V305, P70, DOI 10.1124/jpet.102.045658; FUJITA T, 1994, J ANTIBIOT, V47, P208, DOI 10.7164/antibiotics.47.208; Graeler M, 2002, FASEB J, V16, P1874, DOI 10.1096/fj.02-0548com; Graeler M, 2002, J IMMUNOL, V169, P4084, DOI 10.4049/jimmunol.169.8.4084; Graeler MH, 2003, J BIOL CHEM, V278, P27737, DOI 10.1074/jbc.C300147200; Graler MH, 2003, J CELL BIOCHEM, V89, P507, DOI 10.1002/jcb.10537; Honig SM, 2003, J CLIN INVEST, V111, P627, DOI 10.1172/JCI200316200; Hozumi Y, 1999, LIFE SCI, V65, P1739, DOI 10.1016/S0024-3205(99)00426-9; Kitabayashi H, 2000, J CARDIOVASC PHARM, V35, P410, DOI 10.1097/00005344-200003000-00010; Kiuchi M, 2000, J MED CHEM, V43, P2946, DOI 10.1021/jm000173z; Kiuchi M, 1998, BIOORG MED CHEM LETT, V8, P101, DOI 10.1016/S0960-894X(97)10188-3; KLUEPFEL D, 1972, J ANTIBIOT, V25, P109, DOI 10.7164/antibiotics.25.109; Kurose S, 2000, EXP EYE RES, V70, P7, DOI 10.1006/exer.1999.0777; Li HS, 2002, J PHARMACOL EXP THER, V301, P519, DOI 10.1124/jpet.301.2.519; Luo ZJ, 1999, IMMUNOPHARMACOLOGY, V41, P199, DOI 10.1016/S0162-3109(99)00004-1; Maki T, 2002, TRANSPLANTATION, V74, P1684, DOI 10.1097/01.TP.0000038969.72218.0F; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Matsuura M, 2000, INFLAMM RES, V49, P404, DOI 10.1007/s000110050608; Matsuura M, 2000, INT J IMMUNOPHARMACO, V22, P323, DOI 10.1016/S0192-0561(99)00088-0; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; Okazaki H, 2002, J RHEUMATOL, V29, P707; Olivera A, 2000, METHOD ENZYMOL, V311, P215; Pinschewer DD, 2000, J IMMUNOL, V164, P5761, DOI 10.4049/jimmunol.164.11.5761; Suzuki S, 1996, TRANSPLANT P, V28, P2049; Welsch CA, 2003, J BIOL CHEM, V278, P26976, DOI 10.1074/jbc.M213144200; Yan H, 1998, TRANSPLANT P, V30, P3436, DOI 10.1016/S0041-1345(98)01092-6; Yanagawa Y, 1998, J IMMUNOL, V160, P5493; Yanagawa Y, 1998, IMMUNOLOGY, V95, P591; Yang ZD, 2003, CLIN IMMUNOL, V107, P30, DOI 10.1016/S1521-6616(02)00054-2; Yatomi Y, 1997, J BIOCHEM, V121, P969	41	433	461	0	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					551	+		10.1096/fj.03-0910fje	http://dx.doi.org/10.1096/fj.03-0910fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715694				2022-12-28	WOS:000188829300033
J	Marquez, S; Crespo, P; Carlini, V; Garbarino-Pico, E; Baler, R; Caputto, BL; Guido, ME				Marquez, S; Crespo, P; Carlini, V; Garbarino-Pico, E; Baler, R; Caputto, BL; Guido, ME			The metabolism of phospholipids oscillates rhythmically in cultures of fibroblasts and is regulated by the clock protein PERIOD 1	FASEB JOURNAL			English	Article						circadian rhythms; phospholipid synthesis; cell cultures; Per1; CLOCK/CLOCK mutants	CIRCADIAN GENE-EXPRESSION; NIH 3T3 FIBROBLASTS; SUPRACHIASMATIC NUCLEUS; PERIPHERAL-TISSUES; RAT-1 FIBROBLASTS; MESSENGER-RNA; BIOLOGICAL CLOCK; GANGLION-CELLS; LIGHT; RHYTHMS	The mammalian circadian timing system is composed of countless cell oscillators distributed throughout the body and central pacemakers regulating temporal physiology and behavior. Peripheral clocks display circadian rhythms in gene expression both in vivo and in culture. We examined the biosynthesis of phospholipids as well as the expression of the clock gene period 1 (Per1) and its potential involvement in the regulation of the phospholipid metabolism in cultured quiescent NIH 3T3 cells synchronized by a 2 h serum shock. A 30 min pulse of radiolabeled precursor was given at phases ranging from 0.5 to 62 h after serum treatment. We observed a daily rhythm in the phospholipid labeling that persisted at least for two cycles, with levels significantly decreasing 29 and 58 h after treatment. Per1 expression exhibited a rapid and transient induction and a daily rhythmicity in antiphase to the lipid labeling. After Per1 expression knockdown, the rhythm of phospholipid labeling was lost. Furthermore, in cultures of CLOCK mutant fibroblasts-cells with a clock mechanism impairment-PERI was equally expressed at all times examined and the phospholipid labeling did not oscillate. The results demonstrate that the biosynthesis of phospholipids oscillates daily in cultured fibroblasts by an endogenous clock mechanism involving Per1 expression.	Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, RA-5000 Cordoba, Argentina; NIMH, Unit Temporal Gene Express, Lab Cellular & Mol Regulat, NIH, Bethesda, MD 20892 USA	National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Guido, ME (corresponding author), Univ Nacl Cordoba, Fac Ciencias Quim, Dept Quim Biol, CIQUIBIC,CONICET, Ciudad Univ, RA-5000 Cordoba, Argentina.	mguido@dqb.fcq.unc.edu.ar		Garbarino Pico, Eduardo/0000-0002-2931-2038				Akiyama M, 1999, J NEUROSCI, V19, P1115; Albrecht U, 2001, J BIOL RHYTHM, V16, P100, DOI 10.1177/074873001129001791; Allen G, 2001, J NEUROSCI, V21, P7937, DOI 10.1523/JNEUROSCI.21-20-07937.2001; ASCHOFF J, 1976, FED PROC, V35, P2326; Balsalobre A, 2000, CURR BIOL, V10, P1291, DOI 10.1016/S0960-9822(00)00758-2; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 2002, CELL TISSUE RES, V309, P193, DOI 10.1007/s00441-002-0585-0; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown SA, 2002, CURR BIOL, V12, P1574, DOI 10.1016/S0960-9822(02)01145-4; Bussolino DF, 2001, FASEB J, V15, P556; Bussolino DF, 1998, MOL BRAIN RES, V58, P10, DOI 10.1016/S0169-328X(98)00065-5; Caputto BL, 2002, BBA-MOL CELL BIOL L, V1583, P1, DOI 10.1016/S1388-1981(02)00209-3; Caputto BL, 2000, NEUROCHEM RES, V25, P153, DOI 10.1023/A:1007508020173; CUNNINGHAM TW, 1991, BIOCHEM BIOPH RES CO, V175, P568, DOI 10.1016/0006-291X(91)91603-A; Deguchi A, 2002, JPN J CANCER RES, V93, P157, DOI 10.1111/j.1349-7006.2002.tb01254.x; Duffield GE, 2002, CURR BIOL, V12, P551, DOI 10.1016/S0960-9822(02)00765-0; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Grundschober C, 2001, J BIOL CHEM, V276, P46751, DOI 10.1074/jbc.M107499200; Guido ME, 1999, NEUROSCIENCE, V90, P555, DOI 10.1016/S0306-4522(98)00467-9; Guido ME, 2001, J NEUROCHEM, V76, P835, DOI 10.1046/j.1471-4159.2001.00081.x; GUIDO ME, 1990, J NEUROCHEM, V55, P1855, DOI 10.1111/j.1471-4159.1990.tb05768.x; Guido ME, 1996, J NEUROSCI RES, V43, P93, DOI 10.1002/jnr.490430112; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; Hirota T, 2002, J BIOL CHEM, V277, P44244, DOI 10.1074/jbc.M206233200; Jackowski S, 1996, J BIOL CHEM, V271, P20219, DOI 10.1074/jbc.271.34.20219; JAY TM, 1985, BRAIN RES, V342, P297, DOI 10.1016/0006-8993(85)91129-1; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; KISS Z, 1992, ARCH BIOCHEM BIOPHYS, V296, P457, DOI 10.1016/0003-9861(92)90597-P; Le Minh N, 2001, EMBO J, V20, P7128, DOI 10.1093/emboj/20.24.7128; Leloup JC, 2003, P NATL ACAD SCI USA, V100, P7051, DOI 10.1073/pnas.1132112100; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Momchilova A, 1999, CELL BIOL INT, V23, P603, DOI 10.1006/cbir.1999.0430; Morre DJ, 2002, BIOCHEMISTRY-US, V41, P11941, DOI 10.1021/bi020392h; Oishi K, 2000, BIOCHEM BIOPH RES CO, V268, P164, DOI 10.1006/bbrc.1999.2054; Okamura H, 2002, CELL TISSUE RES, V309, P47, DOI 10.1007/s00441-002-0572-5; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; Preitner N, 2002, CELL, V110, P251, DOI 10.1016/S0092-8674(02)00825-5; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Schibler U, 2002, CELL, V111, P919, DOI 10.1016/S0092-8674(02)01225-4; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Tei H, 1997, NATURE, V389, P512, DOI 10.1038/39086; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; WEISS SJ, 1982, BIOCHEM J, V204, P587, DOI 10.1042/bj2040587; Yagita K, 2000, FEBS LETT, V465, P79, DOI 10.1016/S0014-5793(99)01724-X; Yagita K, 2001, SCIENCE, V292, P278, DOI 10.1126/science.1059542; Yamaguchi S, 2000, MOL CELL BIOL, V20, P4773, DOI 10.1128/MCB.20.13.4773-4781.2000; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zerpa GAD, 1999, J NEUROCHEM, V73, P1228, DOI 10.1046/j.1471-4159.1999.0731228.x; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4	56	31	31	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					519	+		10.1096/fj.03-0417fje	http://dx.doi.org/10.1096/fj.03-0417fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715703				2022-12-28	WOS:000188829300021
J	Huang, SS; Ling, TY; Tseng, WF; Huang, YH; Tang, FM; Leal, SM; Huang, JS				Huang, SS; Ling, TY; Tseng, WF; Huang, YH; Tang, FM; Leal, SM; Huang, JS			Cellular growth inhibition by IGFBP-3 and TGF-beta(1) requires LRP-1	FASEB JOURNAL			English	Article						type V TGF-beta receptor; IGFBP-3 receptor; growth inhibition; epithelial cells; carcinogenesis	LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; FACTOR-BETA RECEPTOR; TGF-BETA; ALPHA-2-MACROGLOBULIN RECEPTOR; V RECEPTOR; FUNCTIONAL MODULATION; HIGH-AFFINITY; TUMOR-CELLS; EXPRESSION	The type V TGF-beta receptor (TbetaR-V)/ IGFBP-3 receptor mediates the IGF-independent growth inhibition induced by IGFBP-3. It also mediates the growth inhibitory response to TGF-beta(1), in concert with other TGF-beta receptor types, and its loss may contribute to the malignant phenotype of human carcinoma cells. Here we demonstrate that TbetaR-V is identical to LRP-1/alpha(2)M receptor as shown by MALDI-TOF analysis of tryptic peptides of TbetaR-V purified from bovine liver. In addition, I-125-IGFBP-3 affinity-labeled TbetaR-V in MvlLu cells is immunoprecipitated by antibodies to LRP-l and TbetaR-V. RAP, an LRP-l antagonist, inhibits binding of I-125-TGF-beta(1) and I-125-IGFBP-3 to TbetaR-V and diminishes IGFBP-3-induced growth inhibition in MvlLu cells. Absent or low levels of LRP-1, as with TbetaR-V, have been linked to the malignant phenotype of carcinoma cells. Mutagenized Mv1Lu cells selected for reduced expression of LRP-l have an attenuated growth inhibitory response to TGF-beta(1), and IGFBP-3. LRP-l -deficient mouse embryonic fibroblasts lack a growth inhibitory response to TGF-beta(1), and IGFBP-3. On the other hand, stable transfection of H1299 human lung carcinoma cells with LRP-l cDNA restores the growth inhibitory response. These results suggest that the LRP-1/TbetaR-V/IGFBP-3 receptor is required for the growth inhibitory response to IGFBP-3 and TGF-beta(1).	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Taipei Med Univ, Dept Biochem, Taipei, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Taipei Medical University	Huang, SS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangss@slu.edu; huangjs@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X	NATIONAL CANCER INSTITUTE [R01CA038808] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38808] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; Blobe GC, 2001, J BIOL CHEM, V276, P39608, DOI 10.1074/jbc.M106831200; Boensch C, 1999, J BIOL CHEM, V274, P10582, DOI 10.1074/jbc.274.15.10582; Bu GJ, 1998, CURR OPIN LIPIDOL, V9, P149, DOI 10.1097/00041433-199804000-00012; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Eickelberg O, 2002, J BIOL CHEM, V277, P823, DOI 10.1074/jbc.M105110200; Fink SP, 2001, CANCER RES, V61, P256; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; GONIAS SL, 1994, ANN NY ACAD SCI, V737, P273, DOI 10.1111/j.1749-6632.1994.tb44318.x; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Heldin NE, 1999, MOL CELL ENDOCRINOL, V153, P79, DOI 10.1016/S0303-7207(99)00086-6; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hocevar BA, 1998, MINER ELECTROL METAB, V24, P131, DOI 10.1159/000057360; Howell BW, 2001, CURR OPIN NEUROBIOL, V11, P74, DOI 10.1016/S0959-4388(00)00176-8; Huang SS, 1997, J BIOL CHEM, V272, P27155, DOI 10.1074/jbc.272.43.27155; HUANG SS, 1988, J BIOL CHEM, V263, P1535; Koong AC, 2000, CANCER RES, V60, P883; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAIHO M, 1990, J BIOL CHEM, V265, P18518; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Leal SM, 1999, J BIOL CHEM, V274, P6711, DOI 10.1074/jbc.274.10.6711; Li YH, 1997, CANCER LETT, V111, P199, DOI 10.1016/S0304-3835(96)04520-X; Liu CX, 2000, CANCER RES, V60, P1961; Liu QJ, 1997, J BIOL CHEM, V272, P18891, DOI 10.1074/jbc.272.30.18891; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MOUSTAKAS A, 1995, J BIOL CHEM, V270, P765, DOI 10.1074/jbc.270.2.765; Moustakas A, 2002, IMMUNOL LETT, V82, P85, DOI 10.1016/S0165-2478(02)00023-8; OGRADY P, 1992, J BIOL CHEM, V267, P21033; OGRADY P, 1991, J BIOL CHEM, V266, P8583; OGRADY P, 1991, BIOCHEM BIOPH RES CO, V179, P378, DOI 10.1016/0006-291X(91)91381-L; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Ravitz MJ, 1997, ADV CANCER RES, V71, P165, DOI 10.1016/S0065-230X(08)60099-8; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Strickland DK, 2002, TRENDS ENDOCRIN MET, V13, P66, DOI 10.1016/S1043-2760(01)00526-4; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Taipale J, 1996, J BIOL CHEM, V271, P4342; VANLEUVEN F, 1979, J BIOL CHEM, V254, P5155; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WILLNOW TE, 1994, J CELL SCI, V107, P719; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yamamoto M, 1997, CANCER RES, V57, P2799; YAMASHITA H, 1995, J BIOL CHEM, V270, P770, DOI 10.1074/jbc.270.2.770; YINGLING JM, 1995, BBA-REV CANCER, V1242, P115, DOI 10.1016/0304-419X(95)00007-2; Ziere GJ, 1996, EUR J BIOCHEM, V242, P703, DOI 10.1111/j.1432-1033.1996.0703r.x	52	126	129	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2068	2081		10.1096/fj.03-0256com	http://dx.doi.org/10.1096/fj.03-0256com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597676				2022-12-28	WOS:000186961200043
J	Jost, MM; Ninci, E; Meder, B; Kempf, C; van Royen, N; Hua, J; Berger, B; Hoefer, I; Modolell, M; Buschmann, N				Jost, MM; Ninci, E; Meder, B; Kempf, C; van Royen, N; Hua, J; Berger, B; Hoefer, I; Modolell, M; Buschmann, N			Divergent effects of GM-CSF and TGF beta(1) on bone marrow-derived macrophage arginase-1 activity, MCP-1 expression, and matrix-metalloproteinase-12: a potential role during arteriogenesis	FASEB JOURNAL			English	Article						blood vessels; bone marrow cells; cell adhesion; cytokines; gene expression	COLONY-STIMULATING FACTOR; L-ARGININE TRANSPORT; COLLATERAL GROWTH; IN-VIVO; CELLS; ARTERY; ANGIOGENESIS; GENE; TRANSPLANTATION; PROTEOLYSIS	Granulocyte/macrophage-colony stimulating factor (GM-CSF) and transforming growth factor (TGF)beta(1) induce arteriogenesis in a nonischemic model of femoral artery ligation. Moreover, clinical trials demonstrated an improved collateralization after injection of bone marrow cells. In the present study, the expression of arteriogenic factors in bone marrow-derived macrophages (BMDM) was measured to verify the potential of these cells to influence collateral artery growth. GM-CSF induced in BMDM the expression of monocyte chemoattractive protein (MCP)-1, matrix-metalloproteinase (MMP)-12, and arginase-1-the latter also showing a remarkable increase in activity. During in vivo induced arteriogenesis, the accumulation rate of macrophages around proliferating collaterals was significantly increased. We also show that MCP-1 is found to be mainly expressed in the media of the vessel wall, MMP-12 in macrophages of the adventitia, and arginase at both locations. This study provides for the first time a comprehensive analysis of GM-CSF/TGFbeta(1)-regulated arteriogenic factors in BMDM and supports the hypothesis that arteriogenesis is a multistage mechanism, including monocyte/macrophage adhesion and transmigration, pro-arteriogenic cytokine expression, degradation of connective tissue, and collagen synthesis regulation. Selective modulation of these mechanisms as well as cell-based therapies supplying arteriogenic factors in vivo point toward new strategies to influence collateral artery growth.	Univ Freiburg, Dept Internal Med Cardiol & Angiol 3, Res Grp Expt & Clin Arteriogenesis, D-79106 Freiburg, Germany; Max Planck Inst Immunobiol, D-79108 Freiburg, Germany	University of Freiburg; Max Planck Society	Jost, MM (corresponding author), Univ Freiburg, Dept Internal Med 3, Res Grp Expt & Clin Arteriogenesis, Breisacher Str 66 ZKF, D-79106 Freiburg, Germany.	meyer@med1.ukl.uni-freiburg.de	van Royen, Niels/Q-1097-2017					Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Ballermann BJ, 1998, KIDNEY INT, V54, pS100, DOI 10.1046/j.1523-1755.1998.06720.x; Buschmann IR, 2001, ATHEROSCLEROSIS, V159, P343, DOI 10.1016/S0021-9150(01)00637-2; Buschmann IR, 2003, CIRCULATION, V108, P610, DOI 10.1161/01.CIR.0000074209.17561.99; Buschmann Ivo, 1999, Journal of the American College of Cardiology, V33, p318A; Cai WJ, 2000, J MOL CELL CARDIOL, V32, P997, DOI 10.1006/jmcc.2000.1137; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; Durante W, 2000, FASEB J, V14, P1775, DOI 10.1096/fj.99-0960com; Durante W, 2001, CIRCULATION, V103, P1121, DOI 10.1161/01.CIR.103.8.1121; Edelberg JM, 2002, CIRC RES, V90, pE89, DOI 10.1161/01.RES.0000020861.20064.7E; Epstein SE, 2001, CARDIOVASC RES, V49, P532, DOI 10.1016/S0008-6363(00)00217-0; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; Greaves DR, 2002, TRENDS IMMUNOL, V23, P535, DOI 10.1016/S1471-4906(02)02331-1; Gu L, 1997, J LEUKOCYTE BIOL, V62, P577, DOI 10.1002/jlb.62.5.577; Heil M, 2002, AM J PHYSIOL-HEART C, V283, pH2411, DOI 10.1152/ajpheart.01098.2001; Heil M, 2000, EUR J CELL BIOL, V79, P850, DOI 10.1078/0171-9335-00113; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; Hoefer IE, 2002, CIRCULATION, V105, P1639, DOI 10.1161/01.CIR.0000014987.32865.8E; Iba O, 2002, CIRCULATION, V106, P2019, DOI 10.1161/01.CIR.0000031332.45480.79; Kim I, 1999, J BIOL CHEM, V274, P26523, DOI 10.1074/jbc.274.37.26523; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Kosaki K, 1998, CIRC RES, V82, P794, DOI 10.1161/01.RES.82.7.794; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Li H, 2002, AM J PHYSIOL-REG I, V282, pR64, DOI 10.1152/ajpregu.2002.282.1.R64; Lijnen HR, 1999, THROMB HAEMOSTASIS, V81, P799; LIN EY, 1993, J IMMUNOL, V151, P1979; Makinen K, 2002, MOL THER, V6, P127, DOI 10.1006/mthe.2002.0638; Malik N, 1996, J IMMUNOL, V156, P3952; Munder M, 1998, J EXP MED, V187, P2103, DOI 10.1084/jem.187.12.2103; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; Rafii S, 2002, GENE THER, V9, P631, DOI 10.1038/sj.gt.3301723; Rozen S, 1998, PRIMER3; Sarafi MN, 1997, J EXP MED, V185, P99, DOI 10.1084/jem.185.1.99; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; Scholz D, 2000, VIRCHOWS ARCH, V436, P257, DOI 10.1007/s004280050039; Seiler C, 2001, CIRCULATION, V104, P2012, DOI 10.1161/hc4201.097835; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Tateishi-Yuyama E, 2002, LANCET, V360, P427, DOI 10.1016/S0140-6736(02)09670-8; van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje; van Royen N, 2003, CIRC RES, V92, P218, DOI 10.1161/01.RES.0000052313.23087.3F	41	51	54	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2281	+		10.1096/fj.03-0071fje	http://dx.doi.org/10.1096/fj.03-0071fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525945				2022-12-28	WOS:000186343300007
J	Park, KH; Kwok, SM; Sharon, C; Baerga, R; Sesti, F				Park, KH; Kwok, SM; Sharon, C; Baerga, R; Sesti, F			N-glycosylation-dependent block is a novel mechanism for drug-induced cardiac arrhythmia	FASEB JOURNAL			English	Article						HERG; MiRP1; KCNE2; sulfamethoxazole; LQTs	LONG-QT SYNDROME; ION-CHANNEL; POTASSIUM CHANNELS; IN-VITRO; HERG; MUTATION; TRIMETHOPRIM; PROLONGATION; KCNE2; SULFAMETHOXAZOLE	Voltage-gated potassium channels formed with the cardiac subunit HERG and a polymorphic variant of MinK-related peptide (MiRP1) exhibit increased susceptibility to the antibiotic sulfamethoxazole (SMX) compared with channels formed with wild-type (WT) subunits. Here the molecular bases for SMX high-affinity block are investigated. The polymorphism causes a benign T to A amino acid mutation at position 8 (T8A) that destroys an N-glycosylation site of MiRP1. In vitro disruption of glycosylation by mutagenesis or in vivo by treatment with neuraminidase is associated with increased susceptibility to SMX and to other elementary agents such as divalent cations. Defective glycosylation does not affect the ability of T8A to form stable complexes with HERG, but rather it increases drug susceptibility through structural modifications in the channel complex. We conclude that N-glycosylation may play a key role in the etiology of life-threatening arrhythmia.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Sesti, F (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Physiol & Biophys, 675 Hoes Lane, Piscataway, NJ 08854 USA.	sestife@umdnj.edu	Park, Ki Ho/E-8921-2011; Park, Ki Ho/N-8153-2017	Park, Ki Ho/0000-0002-6193-9826				Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Anantharam A, 2003, J BIOL CHEM, V278, P11739, DOI 10.1074/jbc.M212751200; BENNETT PB, 1995, NATURE, V376, P683, DOI 10.1038/376683a0; Bianchi L, 2003, J BIOL CHEM, V278, P12415, DOI 10.1074/jbc.M212788200; BLASER J, 1993, INFECTION, V21, P206, DOI 10.1007/BF01728888; Burton DY, 2003, HUM GENE THER, V14, P907, DOI 10.1089/104303403765701196; CASSIDY JT, 1965, J BIOL CHEM, V240, P3501; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Freeman LC, 2000, J MEMBRANE BIOL, V177, P65, DOI 10.1007/s002320001100; Gehle VM, 1997, MOL BRAIN RES, V45, P219, DOI 10.1016/S0169-328X(96)00256-2; Gong QM, 2002, AM J PHYSIOL-HEART C, V283, pH77, DOI 10.1152/ajpheart.00008.2002; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Ho WK, 1998, J PHYSIOL-LONDON, V507, P631, DOI 10.1111/j.1469-7793.1998.631bs.x; Ho WK, 1999, BIOPHYS J, V76, P1959, DOI 10.1016/S0006-3495(99)77355-8; Isbrandt D, 2002, J MOL MED-JMM, V80, P524, DOI 10.1007/s00109-002-0364-0; Johnson JP, 1999, BIOPHYS J, V77, P2534, DOI 10.1016/S0006-3495(99)77088-8; JOOS B, 1995, ANTIMICROB AGENTS CH, V39, P2661, DOI 10.1128/AAC.39.12.2661; Keating MT, 2001, CELL, V104, P569, DOI 10.1016/S0092-8674(01)00243-4; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Larsen LA, 2001, CLIN CHEM, V47, P1390; LOPEZ JA, 1987, AM J CARDIOL, V59, P376, DOI 10.1016/0002-9149(87)90824-1; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; Mazhari R, 2001, CIRC RES, V89, P33, DOI 10.1161/hh1301.093633; MCDONAGH JC, 1990, J MOL CELL CARDIOL, V22, P1305, DOI 10.1016/0022-2828(90)90066-B; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; MINARDO J, 1998, NEW ENGL J MED, V319, P257; Moreno I, 2003, J PHARMACOL EXP THER, V304, P862, DOI 10.1124/jpet.102.042325; Napolitano C, 2000, J CARDIOVASC ELECTR, V11, P691, DOI 10.1111/j.1540-8167.2000.tb00033.x; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; Schulze-Bahr E, 2001, J MOL MED-JMM, V79, P504, DOI 10.1007/s001090100249; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Shimizu H, 2003, JPN J PHYSIOL, V53, P25, DOI 10.2170/jjphysiol.53.25; SUMIKAWA K, 1988, MOL BRAIN RES, V4, P191, DOI 10.1016/0169-328X(88)90025-3; Viskin S, 1999, LANCET, V354, P1625, DOI 10.1016/S0140-6736(99)02107-8; WIENER I, 1981, MT SINAI J MED, V48, P53; Zitron E, 2002, BRIT J PHARMACOL, V137, P221, DOI 10.1038/sj.bjp.0704859	41	31	33	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13								10.1096/fj.03-0577fje	http://dx.doi.org/10.1096/fj.03-0577fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563681				2022-12-28	WOS:000186343300031
J	Rosenfeldt, HM; Amrani, Y; Watterson, KR; Murthy, KS; Panettieri, RA; Spiegel, S				Rosenfeldt, HM; Amrani, Y; Watterson, KR; Murthy, KS; Panettieri, RA; Spiegel, S			Sphingosine-l-phosphate stimulates contraction of human airway smooth muscle cells	FASEB JOURNAL			English	Article						asthma; airway smooth muscle cells; sphingosine-1-phosphate; contractility	COLLAGEN-MATRIX CONTRACTION; SIGNAL-TRANSDUCTION; RECEPTOR EDG-1; STRESS FIBERS; RHO-KINASE; G-PROTEINS; IN-VITRO; 1-PHOSPHATE; SPHINGOSINE-1-PHOSPHATE; PHOSPHORYLATION	The bioactive sphingolipid sphingosine-1-phosphate (SIP) that is increased in airways of asthmatic subjects markedly induced contraction of human airway smooth muscle (HASM) cells embedded in collagen matrices in a G; independent manner. Dihydro-S1P, which binds to SIP receptors, also stimulated contractility. SIP induced formation of stress fibers, contraction of individual HASM cells, and stimulated myosin light chain phosphorylation, which was inhibited by the Rho-associated kinase inhibitor Y-27632. S1P-stimulated HASM cell contractility was independent of the ERK1/2 and PKC signaling pathways, important regulators of airway smooth muscle contraction. However, removal of extracellular calcium completely blocked S1P-mediated contraction and Y-27632 reduced it. SIP also induced calcium mobilization that was not desensitized by repeated additions. Pretreatment with thapsigargin to deplete InsP3 sensitive calcium stores partially blocked increases in [Ca2+](i) induced by SIP, yet did not inhibit S1P-stimulated contraction. In sharp contrast, the L-type calcium channel blocker verapamil markedly decreased S1P-induced HASM cell contraction, supporting a role for calcium influx from extracellular sources. Collectively, our results suggest that SIP may regulate HASM contractility, important in the pathobiology of asthma.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Univ Penn, Dept Med, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA; Virginia Commonwealth Univ, Dept Physiol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Med, Richmond, VA 23298 USA	Virginia Commonwealth University; University of Pennsylvania; Virginia Commonwealth University; Virginia Commonwealth University	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Med Coll Virginia Campus,2-011 Sanger Hall,1101 E, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Amrani, Yassine/A-1826-2013; panettieri, reynold/AAG-9485-2019; Amrani, Yassine/Q-6323-2019	Amrani, Yassine/0000-0002-7042-6926	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067663, P50HL067663] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050094] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67663, P01 HL067663, P50 HL067663] Funding Source: Medline; NIAID NIH HHS [AI50094, R01 AI050094] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Amrani Y, 2002, CURR OPIN ALLERGY CL, V2, P39, DOI 10.1097/00130832-200202000-00007; Bischoff A, 2000, BRIT J PHARMACOL, V130, P1871, DOI 10.1038/sj.bjp.0703515; BORNFELDT KE, 1995, J CELL BIOL, V130, P193, DOI 10.1083/jcb.130.1.193; BURRIDGE K, 1981, NATURE, V294, P691, DOI 10.1038/294691a0; Cain AE, 2002, HYPERTENSION, V39, P543, DOI 10.1161/hy0202.103129; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Coussin F, 2002, CIRC RES, V91, P151, DOI 10.1161/01.RES.0000028150.51130.36; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; Formigli L, 2002, AM J PHYSIOL-CELL PH, V282, pC1361, DOI 10.1152/ajpcell.00378.2001; Goetzl EJ, 2001, PROSTAG OTH LIPID M, V64, P11, DOI 10.1016/S0090-6980(01)00104-6; Grinnell F, 2000, TRENDS CELL BIOL, V10, P362, DOI 10.1016/S0962-8924(00)01802-X; Hedges JC, 2000, AM J PHYSIOL-CELL PH, V278, pC718, DOI 10.1152/ajpcell.2000.278.4.C718; Heringdorf DMZ, 1997, FEBS LETT, V410, P34, DOI 10.1016/S0014-5793(97)00320-7; Hirshman CA, 1999, LIFE SCI, V64, P443, DOI 10.1016/S0024-3205(98)00586-4; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Hori M, 1998, LIFE SCI, V62, P1629, DOI 10.1016/S0024-3205(98)00119-2; Ishihata A, 2002, EUR J PHARMACOL, V445, P247, DOI 10.1016/S0014-2999(02)01790-9; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kamm KE, 2001, J BIOL CHEM, V276, P4527, DOI 10.1074/jbc.R000028200; Katoh K, 2001, J CELL BIOL, V153, P569, DOI 10.1083/jcb.153.3.569; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; LEE RT, 1995, CIRC RES, V76, P209, DOI 10.1161/01.RES.76.2.209; Malek RL, 2001, J BIOL CHEM, V276, P5692, DOI 10.1074/jbc.M003964200; Meacci E, 2002, BIOCHEM J, V362, P349, DOI 10.1042/0264-6021:3620349; MURTHY KS, 1991, AM J PHYSIOL, V261, pG937, DOI 10.1152/ajpgi.1991.261.6.G937; Oishi K, 2000, AM J PHYSIOL-CELL PH, V279, pC1432, DOI 10.1152/ajpcell.2000.279.5.C1432; Pyne S, 2000, BIOCHEM J, V349, P385, DOI 10.1042/0264-6021:3490385; Roux E, 1998, GEN PHARMACOL, V31, P349, DOI 10.1016/S0306-3623(98)00007-X; Ryu Y, 2002, CIRC RES, V90, P325, DOI 10.1161/hh0302.104455; Skuta G, 1999, J BIOL CHEM, V274, P30163, DOI 10.1074/jbc.274.42.30163; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200; Tamama K, 2001, BIOCHEM J, V353, P139, DOI 10.1042/bj3530139; Tornquist K, 1997, ENDOCRINOLOGY, V138, P4049, DOI 10.1210/en.138.10.4049; Tosaka M, 2001, STROKE, V32, P2913, DOI 10.1161/hs1201.099525; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; vanKoppen CJ, 1996, J BIOL CHEM, V271, P2082, DOI 10.1074/jbc.271.4.2082; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; Windh RT, 1999, J BIOL CHEM, V274, P27351, DOI 10.1074/jbc.274.39.27351; Zhong JM, 2001, J PHYSIOL-LONDON, V531, P105, DOI 10.1111/j.1469-7793.2001.0105j.x	41	104	108	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1789	1799		10.1096/fj.02-0836com	http://dx.doi.org/10.1096/fj.02-0836com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519658				2022-12-28	WOS:000186343300033
J	Engvall, E; Wewer, UM				Engvall, E; Wewer, UM			The new frontier in muscular dystrophy research: booster genes	FASEB JOURNAL			English	Review						integrin alpha 7 beta 1; myostatin; gene therapy	12 MELTRIN ALPHA; GALNAC TRANSFERASE; MDX MICE; IN-VIVO; MUSCLE; EXPRESSION; MYOSTATIN; OVEREXPRESSION; THERAPY; GROWTH	More than 30 different forms of muscular dystrophy ( MD) have been molecularly characterized and can be diagnosed, but progress toward treatment has been slow. Gene replacement therapy has met with great difficulty because of the large size of the defective genes and because of difficulties in delivering a gene to all muscle groups. Cell replacement therapy has also been difficult to realize. Will it even be possible to design specific therapy protocols for all MDs? Or is a more realistic goal to treat some of the secondary manifestations that are common to several forms of MD, such as membrane instability, necrosis, and inflammation, and to promote regeneration? As reviewed here, enhanced expression of a range of proteins provides a boost for degenerating dystrophic muscle in mouse models. Expression of a mini-agrin promotes basement membrane formation instead of laminin alpha2; integrin alpha7, GalNac transferase, and ADAM12 promote cell adhesion and muscle stability in the absence of dystrophin; calpastatin prevents muscle necrosis; and nitric oxide synthase prevents inflammation. ADAM12, IGF-I, and myostatin blockade promote regeneration and reduce fibrosis. One can envision numerous other candidate booster genes which encode proteins that promote survival and/or regeneration of the compromised muscle or proteins that affect post-translational modifications of critical proteins. Finally, fibrosis, which is the curse of many human diseases, may also be attacked. Once the mechanisms of the boosters are better understood, drugs may be developed to provide the boost to muscle. Some of the experiences in models of muscular dystrophy may inspire new approaches in other genetic degenerative diseases as well.	Burnham Inst, La Jolla, CA 92037 USA; Univ Copenhagen, Inst Mol Pathol, DK-2100 Copenhagen, Denmark	Sanford Burnham Prebys Medical Discovery Institute; University of Copenhagen	Engvall, E (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	eengvall@burnham.org						Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bertoni C, 2002, HUM GENE THER, V13, P707, DOI 10.1089/104303402317322276; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; Bornemann A, 2000, BRAIN PATHOL, V10, P193, DOI 10.1111/j.1750-3639.2000.tb00254.x; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Cohn RD, 2000, MUSCLE NERVE, V23, P1456, DOI 10.1002/1097-4598(200010)23:10<1456::AID-MUS2>3.0.CO;2-T; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Dubowitz Victor, 2002, Neuromuscul Disord, V12, P421, DOI 10.1016/S0960-8966(02)00006-8; Eto K, 2002, J BIOL CHEM, V277, P17804, DOI 10.1074/jbc.M200086200; Freeze HH, 1999, BIOCHEM BIOPH RES CO, V255, P189, DOI 10.1006/bbrc.1998.9945; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Harper SQ, 2002, NAT MED, V8, P253, DOI 10.1038/nm0302-253; Hartigan-O'Connor D, 2000, MICROSC RES TECHNIQ, V48, P223, DOI 10.1002/(SICI)1097-0029(20000201/15)48:3/4<223::AID-JEMT10>3.0.CO;2-L; Hill JJ, 2002, J BIOL CHEM, V277, P40735, DOI 10.1074/jbc.M206379200; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; Iba K, 2000, J CELL BIOL, V149, P1143, DOI 10.1083/jcb.149.5.1143; Kawaguchi N, 2002, AM J PATHOL, V160, P1895, DOI 10.1016/S0002-9440(10)61136-4; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kronqvist P, 2002, AM J PATHOL, V161, P1535, DOI 10.1016/S0002-9440(10)64431-8; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; LEE CC, 1993, HUM GENE THER, V4, P273, DOI 10.1089/hum.1993.4.3-273; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lilla J, 2002, AM J PATHOL, V160, P1551, DOI 10.1016/S0002-9440(10)61100-5; Loechel F, 1998, J BIOL CHEM, V273, P16993, DOI 10.1074/jbc.273.27.16993; Marshall E, 2002, SCIENCE, V298, P510, DOI 10.1126/science.298.5593.510; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; Michele DE, 2002, NATURE, V418, P417, DOI 10.1038/nature00837; Moll J, 2001, NATURE, V413, P302, DOI 10.1038/35095054; Muntoni F, 2002, LANCET, V360, P1419, DOI 10.1016/S0140-6736(02)11397-3; Nguyen HH, 2002, P NATL ACAD SCI USA, V99, P5616, DOI 10.1073/pnas.082613599; Partridge T, 2000, NEUROL SCI, V21, pS939; Sakamoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1265, DOI 10.1016/S0006-291X(02)00362-5; Smith PL, 2002, J CELL BIOL, V158, P801, DOI 10.1083/jcb.200203125; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; Spencer MJ, 2002, P NATL ACAD SCI USA, V99, P8874, DOI 10.1073/pnas.132269299; Spencer MJ, 2001, NEUROMUSCULAR DISORD, V11, P556, DOI 10.1016/S0960-8966(01)00198-5; Squire S, 2002, HUM MOL GENET, V11, P3333, DOI 10.1093/hmg/11.26.3333; Stracher A, 1999, ANN NY ACAD SCI, V884, P52, DOI 10.1111/j.1749-6632.1999.tb08635.x; Takeda S, 2001, BIODRUGS, V15, P635, DOI 10.2165/00063030-200115100-00001; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Wehling M, 2001, J CELL BIOL, V155, P123, DOI 10.1083/jcb.200105110; WELLS DJ, 1992, HUM MOL GENET, V1, P35; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306; Xia B, 2002, DEV BIOL, V242, P58, DOI 10.1006/dbio.2001.0530; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Zhu XL, 2001, J BIOL CHEM, V276, P21785, DOI 10.1074/jbc.M101877200; Zimmers TA, 2002, SCIENCE, V296, P1486, DOI 10.1126/science.1069525	50	72	80	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1579	1584		10.1096/fj.02-1215rev	http://dx.doi.org/10.1096/fj.02-1215rev			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958164				2022-12-28	WOS:000185925100032
J	Bishop-Bailey, D; Warner, TD				Bishop-Bailey, D; Warner, TD			PPAR gamma ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-gamma antagonist	FASEB JOURNAL			English	Article						restenosis; inflammation; nuclear receptor; NSAID	CYCLOOXYGENASE-2 EXPRESSION; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; APOPTOSIS; THERAPY; CYCLO-OXYGENASE-2; RELEASE; TARGET; GENE; RAT	Peroxisome proliferator-activated receptor (PPAR)gamma and inducible cyclooxygenase-2 (COX-2) are expressed in atherosclerotic lesions, particularly in the intimal monocytic and vascular smooth muscle cells. We have therefore studied the interaction between PPAR. and inducible cyclo-oxygenase (COX-2) in rat aortic vascular smooth muscle cells (RASMC)s. The synthetic PPARgamma ligand rosiglitazone induced prostaglandin (PG) release from RASMCs, including that of PGD(2), the precursor of the putative endogenous PPARgamma ligand 15-deoxy-Delta(12,14)-prostaglandin J(2). Moreover, rosiglitazone both synergized with IL-1beta to further induce prostaglandin release and affected the expression of phospholipase A(2) and COX-2. Rosiglitazone-induced prostaglandin release was inhibited by the PPARgamma partial agonist GW0072 and the PPARgamma antagonist GW9662. Rosiglitazone also induced RASMC apoptosis, an effect not explained as an autocrine effect of the induced-prostanoids, but on arachidonic acid release, as cell death was unaffected by either the nonselective COX inhibitor piroxicam or the selective COX-2 inhibitor DFP, but by inhibitors of either secretory or cytosolic phospholipase A(2). In contrast, indomethacin, an alternative inhibitor of cyclooxygenase activity, inhibited both rosiglitazone-induced cell death, and rosiglitazone-induced PPAR reporter gene activation.	Barts & London, Queen Marys Sch Med & Dent, Dept Cardiac Vasc & Inflammat Res, William Harvey Res Inst, London EC1M 6BQ, England	University of London; Queen Mary University London	Bishop-Bailey, D (corresponding author), Barts & London, Queen Marys Sch Med & Dent, Dept Cardiac Vasc & Inflammat Res, William Harvey Res Inst, Charterhouse Sq, London EC1M 6BQ, England.	d.bishop-bailey@qmul.ac.uk	Warner, Timothy D/A-1980-2009	Warner, Timothy D/0000-0003-3988-4408; Bishop-Bailey, David/0000-0003-2455-596X				Adamson DJA, 2002, MOL PHARMACOL, V61, P7, DOI 10.1124/mol.61.1.7; Bishop-Bailey D, 1999, INT J MOL MED, V3, P41; Bishop-Bailey D, 2000, BRIT J PHARMACOL, V129, P823, DOI 10.1038/sj.bjp.0703149; Bishop-Bailey D, 2002, CIRC RES, V91, P210, DOI 10.1161/01.RES.0000029080.15742.85; Bishop-Bailey D, 1999, J BIOL CHEM, V274, P17042, DOI 10.1074/jbc.274.24.17042; Bishop-Bailey D, 1998, ARTERIOSCL THROM VAS, V18, P1655, DOI 10.1161/01.ATV.18.10.1655; BishopBailey D, 1997, BRIT J PHARMACOL, V121, P125, DOI 10.1038/sj.bjp.0701100; Burleigh ME, 2002, CIRCULATION, V105, P1816, DOI 10.1161/01.CIR.0000014927.74465.7F; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Couturier C, 1999, J BIOL CHEM, V274, P23085, DOI 10.1074/jbc.274.33.23085; Dubois RN, 2000, ALIMENT PHARM THERAP, V14, P64, DOI 10.1046/j.1365-2036.2000.014s1064.x; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Inoue H, 2000, J BIOL CHEM, V275, P28028; INSEL PA, 1996, GOODMAN GILMANS PHAR, P633; Jiang YJ, 2001, J LIPID RES, V42, P716; Kawahito Y, 2000, J CLIN INVEST, V106, P189, DOI 10.1172/JCI9652; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Leblanc Y, 1999, BIOORG MED CHEM LETT, V9, P2207, DOI 10.1016/S0960-894X(99)00365-0; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Levine L, 2003, FASEB J, V17, P800, DOI 10.1096/fj.02-0906hyp; Levine L, 2001, PROSTAG LEUKOTR ESS, V65, P229, DOI 10.1054/plef.2001.0316; Meade EA, 1999, J BIOL CHEM, V274, P8328, DOI 10.1074/jbc.274.12.8328; Mitchell JA, 1999, BRIT J PHARMACOL, V128, P1121, DOI 10.1038/sj.bjp.0702897; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Taketo MM, 2002, BBA-MOL CELL BIOL L, V1585, P72, DOI 10.1016/S1388-1981(02)00326-8	29	62	67	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1925	+		10.1096/fj.02-1075fje	http://dx.doi.org/10.1096/fj.02-1075fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897060				2022-12-28	WOS:000185345100018
J	Gratzinger, D; Canosa, S; Engelhardt, B; Madri, JA				Gratzinger, D; Canosa, S; Engelhardt, B; Madri, JA			Platelet endothelial cell adhesion molecule-1 modulates endothelial cell motility through the small G-protein Rho	FASEB JOURNAL			English	Article						CD31; vascular endothelium; cell movement; small G-protein; sphingosine-1-phosphate	HETEROTRIMERIC G-PROTEINS; TYROSINE PHOSPHORYLATION; SPHINGOSINE 1-PHOSPHATE; LIPID RAFTS; IN-VITRO; C-SRC; CYTOPLASMIC DOMAIN; MIGRATORY BEHAVIOR; MEMBRANE DOMAINS; VASCULAR SYSTEM	Platelet endothelial cell adhesion molecule-1 (PECAM-1), an immunoglobulin family vascular adhesion molecule, is involved in endothelial cell migration and angiogenesis (1, 2). We found that endothelial cells lacking PECAM-1 exhibit increased single cell motility and extension formation but poor wound healing migration, reminiscent of cells in which Rho activity has been suppressed by overexpressing a GTPase-activating protein (3). The ability of PECAM-1 to restore wound healing migration to PECAM-1-deficient cells was independent of its extracellular domain or signaling via its immunoreceptor tyrosine-based inhibitory motif. PECAM-1-deficient endothelial cells had a selective defect in RhoGTP loading, and inhibition of Rho activity mimicked the PECAM-1-deficient phenotype of increased chemokinetic single cell motility at the expense of coordinated wound healing migration. The wound healing advantage of PECAM-1-positive endothelial cells was not only Rho mediated but pertussis toxin inhibitable, characteristic of migration mediated by heterotrimeric G-protein-linked seven-transmembrane receptor signaling such as signaling in response to the serum sphingolipid sphingosine-1-phosphate (S1P) (4, 5). Indeed, we found that the wound healing defect of PECAM-1 null endothelial cells is minimized in sphingolipid-depleted media; moreover, PECAM-1 null endothelial cells fail to increase their migration in response to S1P. We have also found that PECAM-1 localizes to rafts and that in its absence heterotrimeric G-protein components are differentially recruited to rafts, providing a potential mechanism for PECAM-1-mediated coordination of S1P signaling. PECAM-1 may thus support the effective S1P/RhoGTP signaling required for wound healing endothelial migration by allowing for the spatially directed, coordinated activation of Galpha signaling pathways.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Max Planck Inst Vasc Biol, Munster, Germany	Yale University; Max Planck Society	Madri, JA (corresponding author), Yale Univ, Sch Med, Dept Pathol, Lauder Hall 115, New Haven, CT 06510 USA.	joseph.madri@yale.edu	Engelhardt, Britta/K-7267-2014	Engelhardt, Britta/0000-0003-3059-9846; Gratzinger, Dita/0000-0002-9182-8123	NHLBI NIH HHS [R37-HL-28373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL028373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aepfelbacher M, 1997, ARTERIOSCL THROM VAS, V17, P1623, DOI 10.1161/01.ATV.17.9.1623; ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Belperio JA, 2000, J LEUKOCYTE BIOL, V68, P1; BERNANKE DH, 1982, DEV BIOL, V91, P235, DOI 10.1016/0012-1606(82)90030-6; BUHL AM, 1995, J BIOL CHEM, V270, P24631, DOI 10.1074/jbc.270.42.24631; Cao GY, 2002, AM J PHYSIOL-CELL PH, V282, pC1181, DOI 10.1152/ajpcell.00524.2001; Chiba R, 1999, BLOOD, V94, P1319, DOI 10.1182/blood.V94.4.1319.416k28_1319_1329; COTRAN RS, 1994, PATHOLOGIC BASIS DIS; DeLisser HM, 1997, AM J PATHOL, V151, P671; Duncan GS, 1999, J IMMUNOL, V162, P3022; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Enciso JM, 2003, J CELL BIOL, V160, P605, DOI 10.1083/jcb.200209014; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; English D, 2000, FASEB J, V14, P2255, DOI 10.1096/fj.00-0134com; Essler M, 1998, J BIOL CHEM, V273, P21867, DOI 10.1074/jbc.273.34.21867; Galbiati F, 2000, J BIOL CHEM, V275, P23368, DOI 10.1074/jbc.M002020200; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Haskell MD, 2001, J CELL SCI, V114, P1699; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Jackson DE, 1997, J BIOL CHEM, V272, P6986, DOI 10.1074/jbc.272.11.6986; Kim CS, 1998, LAB INVEST, V78, P583; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; Kurz H, 1996, DEV BIOL, V173, P133, DOI 10.1006/dbio.1996.0012; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee OH, 1999, BIOCHEM BIOPH RES CO, V264, P743, DOI 10.1006/bbrc.1999.1586; LEURS R, 1995, PHARMACOL THERAPEUT, V66, P413, DOI 10.1016/0163-7258(95)00006-3; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; Lu TT, 1997, J BIOL CHEM, V272, P14442, DOI 10.1074/jbc.272.22.14442; Lu TT, 1996, P NATL ACAD SCI USA, V93, P11808, DOI 10.1073/pnas.93.21.11808; MADRI JA, 1988, AM J PATHOL, V132, P18; Mahooti S, 2000, AM J PATHOL, V157, P75, DOI 10.1016/S0002-9440(10)64519-1; Maragoudakis ME, 2002, BIOCHEM SOC T, V30, P173, DOI 10.1042/bst0300173; Mettouchi A, 2001, MOL CELL, V8, P115, DOI 10.1016/S1097-2765(01)00285-4; Murthy KS, 2000, J BIOL CHEM, V275, P30211, DOI 10.1074/jbc.M002194200; Nakamura K, 2000, J BIOL CHEM, V275, P27155; NEWMAN PJ, 1990, SCIENCE, V247, P1219, DOI 10.1126/science.1690453; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Nusrat A, 2000, J CELL SCI, V113, P1771; Offermanns S, 1997, SCIENCE, V275, P533, DOI 10.1126/science.275.5299.533; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Osawa M, 1997, EUR J CELL BIOL, V72, P229; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Pinter E, 1997, AM J PATHOL, V150, P1523; Pintucci G, 2002, FASEB J, V16, P598, DOI 10.1096/fj.01-0815fje; Ren XD, 2000, METHOD ENZYMOL, V325, P264; Richard DE, 2001, ONCOGENE, V20, P1556, DOI 10.1038/sj.onc.1204193; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Salvucci O, 2002, BLOOD, V99, P2703, DOI 10.1182/blood.V99.8.2703; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Santiago FS, 1999, AM J PATHOL, V154, P937, DOI 10.1016/S0002-9440(10)65341-2; SCHIMMENTI LA, 1992, J CELL PHYSIOL, V153, P417, DOI 10.1002/jcp.1041530222; Schubert AL, 2002, BIOCHEMISTRY-US, V41, P5754, DOI 10.1021/bi0121656; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Solowiej A, 2003, AM J PATHOL, V162, P953, DOI 10.1016/S0002-9440(10)63890-4; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sun BW, 2001, CHEM LETT, P2, DOI 10.1246/cl.2001.2; Sun J, 1996, J BIOL CHEM, V271, P18561, DOI 10.1074/jbc.271.31.18561; Uchida S, 2000, BIOCHEM BIOPH RES CO, V269, P633, DOI 10.1006/bbrc.2000.2315; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Wong CWY, 2000, MOL BIOL CELL, V11, P3109, DOI 10.1091/mbc.11.9.3109; Yano Y, 1996, BIOCHEM BIOPH RES CO, V224, P508, DOI 10.1006/bbrc.1996.1057; Yatomi Y, 1997, J BIOCHEM, V121, P969	74	67	70	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1458	1469		10.1096/fj.02-1040com	http://dx.doi.org/10.1096/fj.02-1040com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890700				2022-12-28	WOS:000185345100039
J	Jauslin, ML; Meier, T; Smith, RAJ; Murphy, MP				Jauslin, ML; Meier, T; Smith, RAJ; Murphy, MP			Mitochondria-targeted antioxidants protect Friedreich Ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants	FASEB JOURNAL			English	Article						idebenone; mitochondrial oxidative stress; MitoQ; frataxin	IN-VIVO; DEFICIENCY; FRATAXIN; DELIVERY; HOMOLOG; DNA	Friedreich Ataxia ( FRDA), the most common inherited ataxia, arises from defective expression of the mitochondrial protein frataxin, which leads to increased mitochondrial oxidative damage. Therefore, antioxidants targeted to mitochondria should be particularly effective at slowing disease progression. To test this hypothesis, we compared the efficacy of mitochondria-targeted and untargeted antioxidants derived from coenzyme Q(10) and from vitamin E at preventing cell death due to endogenous oxidative stress in cultured fibroblasts from FRDA patients in which glutathione synthesis was blocked. The mitochondria- targeted antioxidant MitoQ was several hundredfold more potent than the untargeted analog idebenone. The mitochondria- targeted antioxidant MitoVit E was 350-fold more potent than the water soluble analog Trolox. This is the first demonstration that mitochondria- targeted antioxidants prevent cell death that arises in response to endogenous oxidative damage. Targeted antioxidants may have therapeutic potential in FRDA and in other disorders involving mitochondrial oxidative damage.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; MyoContract Ltd, CH-4410 Liestal, Switzerland; Univ Otago, Dept Chem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 2XY, England.	mpm@mrc-dunn.cam.ac.uk	Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618				Babcock M, 1997, SCIENCE, V276, P1709, DOI 10.1126/science.276.5319.1709; Campuzano V, 1996, SCIENCE, V271, P1423, DOI 10.1126/science.271.5254.1423; Hausse AO, 2002, HEART, V87, P346, DOI 10.1136/heart.87.4.346; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jauslin ML, 2002, HUM MOL GENET, V11, P3055, DOI 10.1093/hmg/11.24.3055; Kaplan J, 1999, P NATL ACAD SCI USA, V96, P10948, DOI 10.1073/pnas.96.20.10948; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Kelso GF, 2002, ANN NY ACAD SCI, V959, P263, DOI 10.1111/j.1749-6632.2002.tb02098.x; LEVESQUE A, 1995, CYTOMETRY, V20, P181, DOI 10.1002/cyto.990200211; Lodi R, 1999, P NATL ACAD SCI USA, V96, P11492, DOI 10.1073/pnas.96.20.11492; Lodi R, 2001, ANN NEUROL, V49, P590; Murphy MP, 2000, ADV DRUG DELIVER REV, V41, P235, DOI 10.1016/S0169-409X(99)00069-1; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Murphy MP, 2001, EXPERT OPIN BIOL TH, V1, P753, DOI 10.1517/14712598.1.5.753; Puccio H, 2000, HUM MOL GENET, V9, P887, DOI 10.1093/hmg/9.6.887; Puccio H, 2002, CURR OPIN GENET DEV, V12, P272, DOI 10.1016/S0959-437X(02)00298-8; Puccio H, 2001, NAT GENET, V27, P181, DOI 10.1038/84818; Schulz JB, 2000, NEUROLOGY, V55, P1719, DOI 10.1212/WNL.55.11.1719; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Smith RAJ, 2003, P NATL ACAD SCI USA, V100, P5407, DOI 10.1073/pnas.0931245100; Wilson RB, 1997, NAT GENET, V16, P352, DOI 10.1038/ng0897-352	21	302	337	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1972	+		10.1096/fj.03-0240fje	http://dx.doi.org/10.1096/fj.03-0240fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923074				2022-12-28	WOS:000185345100001
J	Liu, GJ; Simpson, AM; Swan, MA; Tao, C; Tuch, BE; Crawford, RM; Jovanovic, A; Martin, DK				Liu, GJ; Simpson, AM; Swan, MA; Tao, C; Tuch, BE; Crawford, RM; Jovanovic, A; Martin, DK			ATP-sensitive potassium channels induced in liver cells after transfection with insulin cDNA and the GLUT2 transporter regulate glucose-stimulated insulin secretion	FASEB JOURNAL			English	Article						HEPG2ins/g; patch-clamp electrophysiology; Western blotting; confocal laser scanning microscopy; radioimmunoassay	FUNCTIONAL EXPRESSION; K+ CHANNELS; LINE; CALCIUM; CLONING; SINGLE; PATHWAYS; GENE	As part of our research into the liver-directed gene therapy of Type I diabetes, we have engineered a human hepatoma cell line (HEPG2ins/g cells) to store and secrete insulin to a glucose stimulus. The aim of the present study was to determine whether HEPG2ins/g cells respond to glucose via signaling pathways that depend on ATP-sensitive potassium channels (K-ATP). Using patch-clamp electrophysiology with symmetrical KCl solutions, the single-channel conductance of K-ATP was 61pS. K-ATP was inhibited by ATP (1 mM) or cAMP (50 muM) applied to the cytosolic side of the membrane. Single K-ATP channels and macroscopic whole-cell currents were inhibited by glucose (20 mM) and glibenclamide (20 muM) and were activated by diazoxide (150 muM). Immunoprecipitation and Western blot analysis confirmed the presence of Kir6.2 K-ATP channel subunit protein in HEPG2ins/g and HEPG2ins cells. Using radioimmunoassay techniques, we report that exposure of the cells to tolbutamide (100 muM) resulted in an increase in insulin secretion from 0.3 +/- 0.05 to 1.8 +/- 0.2 pmol insulin/10(6) cells and glibenclamide (20 muM) from 0.4 +/- 0.06 to 2.1 +/- 0.3 (n=4), similar to what is seen on glucose (20 mM) stimulation. Diazoxide (150 muM) completely inhibited glucose-stimulated insulin release. Glucose 20 mM and glibenclamide 100 muM increased intracellular Ca2+ level in the HEPG2ins/g cells. However, glucose 20 mM did not stimulate a rise in intracellular Ca2+ in the un-transfected parent cell-line HEPG2. We used confocal microscopy to confirm that glucose (20 mM) stimulated the release of insulin from the fluorescently labeled secretion granules in the cells. Furthermore, glibenclamide (20 muM) also stimulated the release of insulin from fluorescently labeled secretion granules, and diazoxide (150 muM) blocked that stimulated release of insulin. Our results suggest that HEPG2ins/g cells respond to glucose via signaling pathways that depend on K-ATP, similar to a normal pancreatic beta cell.	Univ Technol Sydney, Dept Hlth Sci, Broadway, NSW 2007, Australia; Univ Technol Sydney, Dept Cell & Mol Biol, Broadway, NSW 2007, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia; Univ Sydney, Inst Biomed Res, Sydney, NSW 2006, Australia; Prince Wales Hosp, Diabet Transplant Unit, Randwick, NSW 2031, Australia; Univ New S Wales, Randwick, NSW, Australia; Univ Dundee, Ninewells Hosp & Med Sch, Tayside Inst Child Hlth, Dundee DD1 9SY, Scotland; Univ Technol Sydney, Inst Nanoscale Technol, Sydney, NSW, Australia	University of Technology Sydney; University of Technology Sydney; University of Sydney; University of Sydney; University of New South Wales Sydney; University of Dundee; University of Technology Sydney	Martin, DK (corresponding author), Univ Technol Sydney, Dept Hlth Sci, POB 123, Broadway, NSW 2007, Australia.	donm@uts.edu.au	Tuch, Bernard E/D-8041-2013; Jovanovic, Aleksandar/A-4482-2008	Jovanovic, Aleksandar/0000-0002-1214-9318; Liu, Guo-Jun/0000-0002-4278-8372; Martin, Donald/0000-0001-5913-2372	Biotechnology and Biological Sciences Research Council [C15048] Funding Source: Medline; British Heart Foundation [PG/02/091/14227] Funding Source: Medline; Wellcome Trust [059528/Z/99/Z/JMW/CP/JF] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); British Heart Foundation(British Heart Foundation); Wellcome Trust(Wellcome TrustEuropean Commission)		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BABENKO AP, 1998, ANNU REV PHYSIOL, V60, P308; CAPIOD T, 1989, J PHYSIOL-LONDON, V409, P285, DOI 10.1113/jphysiol.1989.sp017497; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; EISENBARTH GS, 1986, NEW ENGL J MED, V314, P1360; Ferber S, 2000, NAT MED, V6, P568, DOI 10.1038/75050; HENDERSON RM, 1989, AM J PHYSIOL, V256, pG1028, DOI 10.1152/ajpgi.1989.256.6.G1028; Henquin JC, 2000, DIABETES, V49, P1751, DOI 10.2337/diabetes.49.11.1751; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Lee K, 1998, J PHYSIOL-LONDON, V510, P441, DOI 10.1111/j.1469-7793.1998.441bk.x; LIDOFSKY SD, 1995, P NATL ACAD SCI USA, V92, P7115, DOI 10.1073/pnas.92.15.7115; Malhi H, 2000, J BIOL CHEM, V275, P26050, DOI 10.1074/jbc.M001576200; NOMA A, 1983, NATURE, V305, P147, DOI 10.1038/305147a0; PERMUTT MA, 1989, P NATL ACAD SCI USA, V86, P8688, DOI 10.1073/pnas.86.22.8688; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; Ranki HJ, 2001, J AM COLL CARDIOL, V38, P906, DOI 10.1016/S0735-1097(01)01428-0; Reimann F, 2001, DIABETES, V50, P2253, DOI 10.2337/diabetes.50.10.2253; Russ U, 1999, J PHYSIOL-LONDON, V517, P781, DOI 10.1111/j.1469-7793.1999.0781s.x; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; SAKURADA M, 1993, ENDOCRINOLOGY, V132, P2659, DOI 10.1210/en.132.6.2659; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Simpson AM, 1999, TRANSPLANT P, V31, P812, DOI 10.1016/S0041-1345(98)01782-5; SIMPSON AM, 1995, GENE THER, V2, P223; Simpson AM, 1997, GENE THER, V4, P1202, DOI 10.1038/sj.gt.3300527; Soria B, 2000, DIABETES, V49, P157, DOI 10.2337/diabetes.49.2.157; SPRUCE AE, 1985, NATURE, V316, P736, DOI 10.1038/316736a0; Straub SG, 1998, DIABETES, V47, P758, DOI 10.2337/diabetes.47.5.758; Tuch BE, 2003, GENE THER, V10, P490, DOI 10.1038/sj.gt.3301911; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Weinhouse S, 1976, CURRENT TOPICS CELLU, P1; Wellman GC, 1999, BRIT J PHARMACOL, V128, P909, DOI 10.1038/sj.bjp.0702868; Yamada K, 2000, J BIOL CHEM, V275, P22278, DOI 10.1074/jbc.M908048199; ZALEWSKI PD, 1994, J HISTOCHEM CYTOCHEM, V42, P877, DOI 10.1177/42.7.8014471	34	12	12	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1682	+		10.1096/fj.02-0051fje	http://dx.doi.org/10.1096/fj.02-0051fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958175	Green Accepted			2022-12-28	WOS:000184471600002
J	Khanna, S; Merriam, AP; Gong, B; Leahy, P; Porter, JD				Khanna, S; Merriam, AP; Gong, B; Leahy, P; Porter, JD			Comprehensive expression profiling by muscle tissue class and identification of the molecular niche of extraocular muscle	FASEB JOURNAL			English	Article						skeletal muscle; cardiac muscle; smooth muscle; DNA microarray; proteomics	SKELETAL-MUSCLE; GENE-EXPRESSION; MUSCULAR-DYSTROPHY; SERIAL ANALYSIS; DEFICIENCY; MUTATIONS; DIAPHRAGM; MYOPATHY; PATTERNS; FIBERS	Muscle tissue is an elegant model for biologic integration of structure with function and is frequently affected by a variety of inherited diseases. Traditional muscle classes-skeletal, cardiac, and smooth-share basic aspects of contractile and energetics mechanisms but also have distinctive role-specific adaptations. We used large-scale oligonucleotide microarrays to broaden knowledge of the adaptive expression patterns underlying muscle tissue differences and to identify transcript subsets that are most likely to represent candidate disease genes. Using stringent analysis criteria, we found 95 transcripts, which were preferentially expressed by each muscle class and were validated by inclusion of known muscle class-specific and inherited disease-related genes. Differentially expressed transcripts not previously identified as class-specific extend understanding of muscle class transcriptomes and may represent novel muscle-specific disease genes. We also analyzed the expression profile of extraocular muscle, which is divergent from other skeletal muscles, in the broader context of all major muscle classes. Data show that the extraocular muscle phenotype results from the combination of tissue-specific transcripts, novel expression levels of skeletal muscle transcripts, and partial sharing of gene expression patterns with cardiac and smooth muscle. These, and additional proteomic data, establish that extraocular muscle does not constitute a distinctive muscle class but that it does occupy a novel niche within the skeletal muscle class.	Case Western Reserve Univ, Dept Ophthalmol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Ctr Comprehens Canc, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Neurosci, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Res Inst, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; University Hospitals of Cleveland	Khanna, S (corresponding author), Univ Hosp Cleveland, Dept Ophthalmol, 11100 Euclid Ave, Cleveland, OH 44106 USA.	sxk128@po.cwru.edu						Bakay M, 2002, NEUROMUSCULAR DISORD, V12, pS125, DOI 10.1016/S0960-8966(02)00093-7; Blackshaw S, 2001, CELL, V107, P579, DOI 10.1016/S0092-8674(01)00574-8; Boer JM, 2002, NEUROMUSCULAR DISORD, V12, pS118, DOI 10.1016/S0960-8966(02)00092-5; Boppart MD, 1999, J APPL PHYSIOL, V87, P1668, DOI 10.1152/jappl.1999.87.5.1668; BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010; BURKE RE, 1971, SCIENCE, V174, P709, DOI 10.1126/science.174.4010.709; Campbell WG, 2001, AM J PHYSIOL-CELL PH, V280, pC763, DOI 10.1152/ajpcell.2001.280.4.C763; Carlson CJ, 2001, J APPL PHYSIOL, V91, P2079, DOI 10.1152/jappl.2001.91.5.2079; Chen YW, 2000, J CELL BIOL, V151, P1321, DOI 10.1083/jcb.151.6.1321; Cheng G, 2002, INVEST OPHTH VIS SCI, V43, P1048; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Chockalingam PS, 2002, AM J PHYSIOL-CELL PH, V283, pC500, DOI 10.1152/ajpcell.00529.2001; Comi GP, 2001, ANN NEUROL, V50, P202, DOI 10.1002/ana.1095; Enard W, 2002, SCIENCE, V296, P340, DOI 10.1126/science.1068996; Engel A., 1994, MYOLOGY; Engle EC, 2002, ANN NY ACAD SCI, V956, P55, DOI 10.1111/j.1749-6632.2002.tb02808.x; Engle Elizabeth C, 2002, Strabismus, V10, P125, DOI 10.1076/stra.10.2.125.8142; Finn SG, 2001, BIOCHEM J, V358, P489, DOI 10.1042/0264-6021:3580489; Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001; Fluck M, 1999, AM J PHYSIOL-CELL PH, V277, pC152, DOI 10.1152/ajpcell.1999.277.1.C152; Genetta T, 2001, J BIOL CHEM, V276, P25589, DOI 10.1074/jbc.M011637200; Greenberg SA, 2002, NEUROLOGY, V59, P1170, DOI 10.1212/WNL.59.8.1170; Haslett JN, 2002, INT J DEV NEUROSCI, V20, P359, DOI 10.1016/S0736-5748(02)00041-2; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; JACOBY J, 1990, J MUSCLE RES CELL M, V11, P25, DOI 10.1007/BF01833323; Juel C, 2000, ACTA PHYSIOL SCAND, V170, P59; KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418; Kaplan JC, 2002, NEUROMUSCULAR DISORD, V12, P777; KARPATI G, 1986, AM J MED GENET, V25, P653, DOI 10.1002/ajmg.1320250407; Kerst B, 2000, NEUROMUSCULAR DISORD, V10, P572, DOI 10.1016/S0960-8966(00)00150-4; KHANNA S, IN PRESS INVEST OPHT; KHURANA TS, 1995, J EXP MED, V182, P467, DOI 10.1084/jem.182.2.467; Kitamura K, 1999, DEVELOPMENT, V126, P5749; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; Lahat H, 2001, AM J HUM GENET, V69, P1378, DOI 10.1086/324565; Mitchell PO, 2002, AM J PHYSIOL-CELL PH, V282, pC984, DOI 10.1152/ajpcell.00483.2001; Pallafacchina G, 2002, P NATL ACAD SCI USA, V99, P9213, DOI 10.1073/pnas.142166599; PETER JB, 1972, BIOCHEMISTRY-US, V11, P2627, DOI 10.1021/bi00764a013; Porter JD, 2001, P NATL ACAD SCI USA, V98, P12062, DOI 10.1073/pnas.211257298; Porter JD, 2002, ANN NY ACAD SCI, V956, P7, DOI 10.1111/j.1749-6632.2002.tb02804.x; Porter JD, 1998, J CELL SCI, V111, P1801; PORTER JD, 1995, SURV OPHTHALMOL, V39, P451, DOI 10.1016/S0039-6257(05)80055-4; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Porter JD, 1996, NEUROLOGY, V46, P30, DOI 10.1212/WNL.46.1.30; PORTER JD, IN PRESS PERSPECTIVE; PTACEK LJ, 1994, CELL, V77, P863; Ragusa RJ, 1996, J NEUROL SCI, V139, P180; RICHARD I, 1995, CELL, V81, P27, DOI 10.1016/0092-8674(95)90368-2; Rouger K, 2002, AM J PHYSIOL-CELL PH, V283, pC773, DOI 10.1152/ajpcell.00112.2002; Saraiva MJM, 2001, HUM MUTAT, V17, P493, DOI 10.1002/humu.1132; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sharon D, 2002, P NATL ACAD SCI USA, V99, P315, DOI 10.1073/pnas.012582799; Spencer R F, 1988, Rev Oculomot Res, V2, P33; Tanaka T, 1997, J MOL CELL CARDIOL, V29, P121, DOI 10.1006/jmcc.1996.0257; Tseng BS, 2002, J APPL PHYSIOL, V93, P537, DOI 10.1152/japplphysiol.00202.2002; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WIECZOREK DF, 1985, J CELL BIOL, V101, P618, DOI 10.1083/jcb.101.2.618	57	27	29	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1370	+		10.1096/fj.02-1108fje	http://dx.doi.org/10.1096/fj.02-1108fje			53	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12832294				2022-12-28	WOS:000183165000042
J	Di Gennaro, A; Carnini, C; Buccellati, C; Ballerio, R; Zarini, S; Fumagalli, F; Viappiani, S; Librizzi, L; Hernandez, A; Murphy, RC; Constantin, G; de Curtis, M; Folco, G; Sala, A				Di Gennaro, A; Carnini, C; Buccellati, C; Ballerio, R; Zarini, S; Fumagalli, F; Viappiani, S; Librizzi, L; Hernandez, A; Murphy, RC; Constantin, G; de Curtis, M; Folco, G; Sala, A			Cysteinyl-leukotriene receptor activation in brain inflammatory reactions and cerebral edema formation: a role for transcellular biosynthesis of cysteinyl leukotrienes	FASEB JOURNAL			English	Article						neutrophils; endothelium; paracrine communication; lipoxygenase inhibitors; leukotriene antagonists	COLONY-STIMULATING FACTOR; VEIN ENDOTHELIAL-CELLS; IN-VITRO; POLYMORPHONUCLEAR LEUKOCYTES; SULFIDOPEPTIDE-LEUKOTRIENES; NEUTROPHIL ADHESION; CYSLT(2) RECEPTOR; BASILAR ARTERY; ISCHEMIA; MEDIATORS	We studied the effect of intravascular activation of human neutrophils on the synthesis of cysteinyl leukotrienes (cysLT) and the formation of cerebral edema in guinea-pig brains. Challenge with the chemotactic formylated tripeptide fMLP (0.1 muM) of neutrophil-perfused brain in vitro resulted in blood-brain barrier disruption associated with a significant increase of cysLT. Both events were completely prevented by neutrophil pretreatment with a specific 5-lipoxygenase (5-LO) inhibitor. Perfusion with the 5-LO metabolite leukotriene B-4 (10 nM), together with neutrophils treated with the 5-LO inhibitor, did not restore the alteration in permeability observed upon perfusion with untreated and activated neutrophils. The dual cysLT1-cysLT2 receptor antagonist BAYu9773 was more potent and more effective than a selective cysLT1 antagonist in preventing the brain permeability alteration induced by neutrophil activation. RT-PCR showed significant expression of cysLT2 receptor mRNA in human umbilical vein endothelial cells. Intravital microscopy in mice showed that inhibition of leukotriene synthesis significantly reduced firm adhesion of neutrophils to cerebral vessels without affecting rolling. These data support the hypothesis that neutrophil and endothelial cells cooperate toward the local synthesis of cysLT within the brain vasculature and, acting via the cysLT2 receptor on endothelial cells, may represent a contributing pathogenic mechanism in the development of cerebral inflammation and edema.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Cardiopulm Pharmacol, I-20133 Milan, Italy; Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Ist Neurol Besta, I-20133 Milan, Italy; Univ Verona, Dept Pathol, I-37134 Verona, Italy	University of Milan; University of Milan; National Jewish Health; IRCCS Istituto Neurologico Besta; University of Verona	Sala, A (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	angelo.sala@unimi.it	Murphy, Robert/AAO-5349-2020; de Curtis, Marco M/J-8704-2016; Librizzi, Laura/J-7889-2016; Sala, Angelo/H-5478-2019	Murphy, Robert/0000-0002-9430-6515; de Curtis, Marco M/0000-0001-7443-6737; Librizzi, Laura/0000-0002-2741-4452; Constantin, Gabriela/0000-0001-8978-3539; de Curtis, Marco/0000-0002-5608-929X; Sala, Angelo/0000-0001-9290-0257; Zarini, Simona/0000-0002-7460-3299				Akopov S, 1996, CEREBROVAS BRAIN MET, V8, P11; AKOPOV SE, 1995, J VASC RES, V32, P49, DOI 10.1159/000159077; BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; Bandeira-Melo C, 2002, J EXP MED, V196, P841, DOI 10.1084/jem.20020516; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; BRADY HR, 1992, BIOCHEM BIOPH RES CO, V186, P1307, DOI 10.1016/S0006-291X(05)81548-7; BRADY HR, 1990, AM J PHYSIOL, V259, pF809, DOI 10.1152/ajprenal.1990.259.5.F809; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; BUNTING S, 1976, PROSTAG OTH LIPID M, V12, P897, DOI 10.1016/0090-6980(76)90125-8; Capra V, 1998, BRIT J PHARMACOL, V123, P590, DOI 10.1038/sj.bjp.0701636; CHEN H, 1994, ANN NEUROL, V35, P458, DOI 10.1002/ana.410350414; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Connolly ES, 1996, J CLIN INVEST, V97, P209, DOI 10.1172/JCI118392; DAHINDEN CA, 1988, J EXP MED, V167, P1281, DOI 10.1084/jem.167.4.1281; de Curtis M, 1991, Hippocampus, V1, P341, DOI 10.1002/hipo.450010402; de Curtis M, 1998, BRAIN RES PROTOC, V3, P221, DOI 10.1016/S1385-299X(98)00044-0; Evans JF, 2002, PROSTAG OTH LIPID M, V68-9, P587, DOI 10.1016/S0090-6980(02)00057-6; FIORE S, 1990, J EXP MED, V172, P1451, DOI 10.1084/jem.172.5.1451; Folco G, 2000, AM J RESP CRIT CARE, V161, pS112, DOI 10.1164/ajrccm.161.supplement_1.ltta-22; GRIMMINGER F, 1990, J EXP MED, V172, P1115, DOI 10.1084/jem.172.4.1115; GUIDOT DM, 1994, P NATL ACAD SCI USA, V91, P8156, DOI 10.1073/pnas.91.17.8156; Hartl R, 1996, J CEREBR BLOOD F MET, V16, P1108; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Karim S, 1996, J BIOL CHEM, V271, P12042, DOI 10.1074/jbc.271.20.12042; Laudanna C, 2003, J IMMUNOL METHODS, V273, P115, DOI 10.1016/S0022-1759(02)00421-0; Lynch KR, 1999, NATURE, V399, P789; MACLOUF J, 1982, P NATL ACAD SCI-BIOL, V79, P6042, DOI 10.1073/pnas.79.19.6042; Maclouf J, 1996, HAEMOSTASIS, V26, P28; MACLOUF J, 1989, BLOOD, V74, P703; MARCUS AJ, 1982, BIOCHEM BIOPH RES CO, V109, P130, DOI 10.1016/0006-291X(82)91575-3; MCINTYRE TM, 1986, P NATL ACAD SCI USA, V83, P2204, DOI 10.1073/pnas.83.7.2204; MILLER DK, 1990, NATURE, V343, P278, DOI 10.1038/343278a0; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; NISHIYE E, 1988, BRIT J PHARMACOL, V93, P591, DOI 10.1111/j.1476-5381.1988.tb10315.x; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601, DOI 10.1124/mol.58.6.1601; Sala A, 1996, J BIOL CHEM, V271, P17944, DOI 10.1074/jbc.271.30.17944; SALA A, 1993, BRIT J PHARMACOL, V110, P1206, DOI 10.1111/j.1476-5381.1993.tb13943.x; Sala A, 1996, BLOOD, V87, P1824; Sala A, 2000, CIRCULATION, V101, P1436, DOI 10.1161/01.CIR.101.12.1436; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Sjostrom M, 2003, ARTERIOSCL THROM VAS, V23, pE37, DOI 10.1161/01.ATV.0000082689.46538.DF; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; Takasaki J, 2000, BIOCHEM BIOPH RES CO, V274, P316, DOI 10.1006/bbrc.2000.3140; VOELKEL NF, 1992, AM REV RESPIR DIS, V145, P701, DOI 10.1164/ajrccm/145.3.701	46	62	63	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					842	+		10.1096/fj.03-0599fje	http://dx.doi.org/10.1096/fj.03-0599fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001558				2022-12-28	WOS:000220522800021
J	Quan, XX; Rassadi, R; Rabie, B; Matusiewicz, N; Stochaj, U				Quan, XX; Rassadi, R; Rabie, B; Matusiewicz, N; Stochaj, U			Regulated nuclear accumulation of the yeast hsp70 Ssa4p in ethanol-stressed cells is mediated by the N-terminal domain, requires the nuclear carrier Nmd5p and protein kinase C	FASEB JOURNAL			English	Article						stress; heat shock proteins; nuclear transport; PKC	SACCHAROMYCES-CEREVISIAE; HEAT-SHOCK; NUCLEOCYTOPLASMIC TRANSPORT; TARGETING SEQUENCES; POLY(A)(+) RNA; IMPORTIN-BETA; RAN; INTEGRITY; LOCALIZATION; PATHWAY	Cytoplasmic proteins of the hsp70/hsc70 family redistribute in cells that have been exposed to stress. As such, the hsp70 Ssa4p of the budding yeast S. cerevisiae accumulates in nuclei when cells are treated with ethanol, whereas classical nuclear import is inhibited under these conditions. The N-terminal domain of Ssa4p, which is lacking a classical NLS, mediates nuclear accumulation upon ethanol exposure. Concentration of the Ssa4p N-terminal segment in nuclei is reversible, as the protein relocates to the cytoplasm when cells recover. Mutant analysis demonstrates that the small GTPase Gsp1p and GTPase-modulating factors are required to accumulate Ssa4p in nuclei upon ethanol stress. Moreover, we have identified the importin-beta family member Nmd5p as the nuclear carrier for Ssa4p. Ethanol treatment significantly increases the formation of import complexes containing Nmd5p and the N-terminal Ssa4p domain. Likewise, docking of the carrier Nmd5p at the nuclear pore is enhanced by ethanol. Furthermore, we show that the stressed-induced nuclear accumulation of Ssa4p depends on signaling through protein kinase C and requires sensors of the cell integrity pathway.	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Stochaj, U (corresponding author), McGill Univ, Dept Physiol, 3655 Promenade Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	ursula.stochaj@mcgill.ca	stochaj, ursula/AAC-1865-2021					BENJAMIN IJ, 1994, BIOL HEAT SHOCK PROT, P533; Chu A, 2001, FASEB J, V15, P1478, DOI 10.1096/fj.00-0680fje; Chughtai ZS, 2001, J BIOL CHEM, V276, P20261, DOI 10.1074/jbc.M100364200; Corbett AH, 1997, MICROBIOL MOL BIOL R, V61, P193, DOI 10.1128/.61.2.193-211.1997; CORBETT AH, 1995, J CELL BIOL, V130, P1017, DOI 10.1083/jcb.130.5.1017; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DANG CV, 1989, J BIOL CHEM, V264, P18019; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Ferrigno P, 1998, EMBO J, V17, P5606, DOI 10.1093/emboj/17.19.5606; Gao HH, 2003, J BIOL CHEM, V278, P25331, DOI 10.1074/jbc.M301607200; Gray JV, 1997, EMBO J, V16, P4924, DOI 10.1093/emboj/16.16.4924; Heinisch JJ, 1999, MOL MICROBIOL, V32, P671, DOI 10.1046/j.1365-2958.1999.01375.x; KAMADA Y, 1995, GENE DEV, V9, P1559, DOI 10.1101/gad.9.13.1559; Ketela T, 1999, J BACTERIOL, V181, P3330, DOI 10.1128/JB.181.11.3330-3340.1999; Koepp DM, 1996, J CELL BIOL, V133, P1163, DOI 10.1083/jcb.133.6.1163; Kose S, 1999, J BIOL CHEM, V274, P3946, DOI 10.1074/jbc.274.7.3946; Kose S, 1997, J CELL BIOL, V139, P841, DOI 10.1083/jcb.139.4.841; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Lamian V, 1996, EXP CELL RES, V228, P84, DOI 10.1006/excr.1996.0302; LEVIN DE, 1995, CURR OPIN CELL BIOL, V7, P197, DOI 10.1016/0955-0674(95)80028-X; Liu Y, 1996, EMBO J, V15, P6750, DOI 10.1002/j.1460-2075.1996.tb01064.x; Madhani HD, 1998, TRENDS GENET, V14, P151, DOI 10.1016/S0168-9525(98)01425-5; MANDELL RB, 1990, J CELL BIOL, V111, P1775, DOI 10.1083/jcb.111.5.1775; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Molina M, 1998, METHOD MICROBIOL, V26, P375; MORIMOTO RI, 1994, BIOL HEAT SHOCK PROT, P1; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Nanduri J, 2001, MOL BIOL CELL, V12, P1835, DOI 10.1091/mbc.12.6.1835; NOWAK TS, 1994, BIOL HEAT SHOCK PROT, P553; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; OKUNO Y, 1993, EXP CELL RES, V206, P134, DOI 10.1006/excr.1993.1129; Perez P, 2002, J BIOCHEM, V132, P513, DOI 10.1093/oxfordjournals.jbchem.a003250; Philip B, 2001, MOL CELL BIOL, V21, P271, DOI 10.1128/MCB.21.1.271-280.2001; PIPER PW, 1995, FEMS MICROBIOL LETT, V134, P121, DOI 10.1016/0378-1097(95)00431-9; Rajavel M, 1999, MOL CELL BIOL, V19, P3969; Reiser V, 1999, MOL BIOL CELL, V10, P1147, DOI 10.1091/mbc.10.4.1147; Ribbeck K, 1999, CURR BIOL, V9, P47, DOI 10.1016/S0960-9822(99)80046-3; Rudt F, 2001, EUR J CELL BIOL, V80, P661, DOI 10.1078/0171-9335-00212; SAAVEDRA C, 1999, GENE DEV, V10, P1608; Saavedra CA, 1997, GENE DEV, V11, P2845, DOI 10.1101/gad.11.21.2845; SCHLENSTEDT G, 1995, P NATL ACAD SCI USA, V92, P225, DOI 10.1073/pnas.92.1.225; SHI YG, 1992, MOL CELL BIOL, V12, P2186, DOI 10.1128/MCB.12.5.2186; Shulga N, 1999, J BIOL CHEM, V274, P16501, DOI 10.1074/jbc.274.23.16501; Shulga N, 2003, MOL CELL BIOL, V23, P534, DOI 10.1128/MCB.23.2.534-542.2003; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Stochaj U, 1999, BIOESSAYS, V21, P579, DOI 10.1002/(SICI)1521-1878(199907)21:7<579::AID-BIES6>3.0.CO;2-E; Stochaj U, 2000, FASEB J, V14, P2130, DOI 10.1096/fj.99-0751fje; Strom AC, 2001, GENOME BIOL, V2; TANI T, 1995, MOL BIOL CELL, V6, P1515, DOI 10.1091/mbc.6.11.1515; Van Wuytswinkel O, 2000, MOL MICROBIOL, V37, P382, DOI 10.1046/j.1365-2958.2000.02002.x; Wong DH, 1997, MOL CELL BIOL, V17, P3755, DOI 10.1128/MCB.17.7.3755; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; [No title captured]	53	15	15	3	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					899	+		10.1096/fj.03-0947fje	http://dx.doi.org/10.1096/fj.03-0947fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001563				2022-12-28	WOS:000220522800028
J	Zuber, C; Fan, JY; Guhl, B; Roth, J				Zuber, C; Fan, JY; Guhl, B; Roth, J			Misfolded proinsulin accumulates in expanded pre-Golgi intermediates and endoplasmic reticulum subdomains in pancreatic beta cells of Akita mice	FASEB JOURNAL			English	Article						electron microscopy; protein quality control; protein folding disease; ERAD	UNFOLDED-PROTEIN-RESPONSE; CLASS-I MOLECULES; QUALITY-CONTROL; ER DEGRADATION; SACCHAROMYCES-CEREVISIAE; SECRETORY PATHWAY; GENE; COMPARTMENT; PROTEASOME; RETENTION	A missense mutation of the insulin 2 gene (Cys96Tyr) in Akita mice disrupting one of the two interchain disulfide bonds results in intracellular accumulation of misfolded proinsulin. We analyzed the secretory pathway of pancreatic beta cells by electron microscopy and morphometry and identified sites of proinsulin accumulation by quantitative immunogold electron microscopy in this protein-folding disease. In Akita mice beta cells, the volume density of dilated endoplasmic reticulum subdomains was increased by 2.9- fold, resulting in a 1.7-fold increased volume density of the entire rough endoplasmic reticulum. The volume density of pre-Golgi intermediates was increased by 4.9-fold, and that of the Golgi apparatus was increase by 3.4-fold. The relative labeling intensity for proinsulin was 2.1-fold higher in dilated endoplasmic reticulum subdomains and 2.9- fold higher in pre-Golgi intermediates as compared with narrow endoplasmic reticulum, resulting in a significantly different distribution pattern between Akita and control mice beta cells (X-2= 29.97, P < 0.001). The numerical density of insulin secretory granules was equal in Akita and control mice beta cells. However, their volume density and average volume were reduced to 20% and their average diameter to 58% in Akita mice. Together, these data demonstrate that misfolded proinsulin accumulates mainly in pre-Golgi intermediates and to a lesser extent in dilated endoplasmic reticulum subdomains, providing evidence for the importance of pre-Golgi intermediates in a protein folding disease.	Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, CH-8091 Zurich, Switzerland	University of Zurich	Roth, J (corresponding author), Univ Zurich, Dept Pathol, Div Cell & Mol Pathol, Schmelzbergstr 12, CH-8091 Zurich, Switzerland.	juergen.roth@usz.ch						ALANEN A, 1985, EUR J IMMUNOL, V15, P235, DOI 10.1002/eji.1830150306; Aridor M, 2001, J CELL BIOL, V152, P213, DOI 10.1083/jcb.152.1.213; Bannykh SI, 1996, J CELL BIOL, V135, P19, DOI 10.1083/jcb.135.1.19; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BUNZLI HF, 1972, H-S Z PHYSIOL CHEM, V353, P451, DOI 10.1515/bchm2.1972.353.1.451; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Fan JY, 2003, HISTOCHEM CELL BIOL, V120, P455, DOI 10.1007/s00418-003-0597-1; FARQUHAR M, 1907, GOLGI APPARTUS, P63; Greenfield JJA, 1999, J CELL SCI, V112, P1477; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Hauri HP, 2000, J CELL SCI, V113, P587; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Izumi T, 2003, DIABETES, V52, P409, DOI 10.2337/diabetes.52.2.409; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; Kayo T, 1998, J CLIN INVEST, V101, P2112, DOI 10.1172/JCI1842; Kim PS, 1998, ENDOCR REV, V19, P173, DOI 10.1210/er.19.2.173; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; Menzel R, 1997, YEAST, V13, P1211, DOI 10.1002/(SICI)1097-0061(199710)13:13<1211::AID-YEA168>3.0.CO;2-8; Mezzacasa A, 2002, TRAFFIC, V3, P833, DOI 10.1034/j.1600-0854.2002.31108.x; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; ORCI L, 1987, CELL, V49, P865, DOI 10.1016/0092-8674(87)90624-6; Oyadomari S, 2002, J CLIN INVEST, V109, P525, DOI 10.1172/JCI200214550; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; PALADE GE, 1956, J BIOPHYS BIOCHEM CY, V2, P417, DOI 10.1083/jcb.2.4.417; Parodi AJ, 2000, ANNU REV BIOCHEM, V69, P69, DOI 10.1146/annurev.biochem.69.1.69; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; RAPOSO G, 1995, J CELL BIOL, V131, P1403, DOI 10.1083/jcb.131.6.1403; ROTH J, 1978, J HISTOCHEM CYTOCHEM, V26, P1074, DOI 10.1177/26.12.366014; ROTH J, 2000, ANTIGEN RETRIEVAL TE, P275; Saraste J, 1992, Semin Cell Biol, V3, P343, DOI 10.1016/1043-4682(92)90020-V; SARASTE J, 1991, J CELL SCI, V100, P415; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; Spiliotis ET, 2002, MOL BIOL CELL, V13, P1566, DOI 10.1091/mbc.01-07-0322; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; Takewaka T, 1999, J BIOCHEM-TOKYO, V125, P507, DOI 10.1093/oxfordjournals.jbchem.a022314; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; TOKUYASU KT, 1986, J MICROSC-OXFORD, V143, P139, DOI 10.1111/j.1365-2818.1986.tb02772.x; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; VALETTI C, 1991, J CELL BIOL, V115, P983, DOI 10.1083/jcb.115.4.983; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Wang J, 1999, J CLIN INVEST, V103, P27, DOI 10.1172/JCI4431; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wojcik C, 1996, EUR J CELL BIOL, V71, P311; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Yoshioka M, 1997, DIABETES, V46, P887, DOI 10.2337/diabetes.46.5.887; Zuber C, 2001, P NATL ACAD SCI USA, V98, P10710, DOI 10.1073/pnas.191359198	64	57	57	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					917	+		10.1096/fj.03-1210fje	http://dx.doi.org/10.1096/fj.03-1210fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033933				2022-12-28	WOS:000220522800018
J	Takei, Y; Maruyama, A; Ferdous, A; Nishimura, Y; Kawano, S; Ikejima, K; Okumura, S; Asayama, S; Nogawa, M; Hashimoto, M; Makino, Y; Kinoshita, M; Watanabe, S; Akaike, T; Lemasters, JJ; Sato, N				Takei, Y; Maruyama, A; Ferdous, A; Nishimura, Y; Kawano, S; Ikejima, K; Okumura, S; Asayama, S; Nogawa, M; Hashimoto, M; Makino, Y; Kinoshita, M; Watanabe, S; Akaike, T; Lemasters, JJ; Sato, N			Targeted gene delivery to sinusoidal endothelial cells: DNA nanoassociate bearing hyaluronan-glycocalyx	FASEB JOURNAL			English	Article						hyaluronic acid receptor; receptor-mediated gene transfer; glycocalyx; stealth property; DNA triplex	RECEPTOR-MEDIATED ENDOCYTOSIS; ORTHOTOPIC LIVER-TRANSPLANTATION; ETHANOL-INDUCED VASOCONSTRICTION; COMB-TYPE COPOLYMERS; IN-VIVO; PARTIAL-HEPATECTOMY; SIDE-CHAINS; RAT-LIVER; EXPRESSION; COMPLEXES	Liver sinusoidal endothelial cells (SECs) possess unique receptors that recognize and internalize hyaluronic acid (HA). To develop a system for targeting foreign DNA to SECs, comb-type polycations having HA side chains were prepared by coupling HA to poly(L-lysine) (PLL). The HA-grafted-PLL copolymer (PLL-g-HA) thus formed was mixed with DNA in 154 mM NaCl to form soluble nanoassociates bearing hydrated hyaluronate shells. Agarose gel retardation assays revealed selective interaction of the PLL backbone with DNA despite the presence of polyanionic HA side chains. To determine whether the PLL-g-HA/DNA complexes were recognized by SEC HA receptors in vivo, we injected Wistar rats i.v. via the tail vein with PLL-g-HA complexed to a beta-galactosidase expression plasmid (pSV beta-Gal) labeled with P-32. One hour postinjection, >90% of the injected radioactivity remained in the liver. Administration of the PLL-g-HA complexed to an FITC-labeled DNA revealed that the carrier-DNA complex was distributed exclusively in SECs. A large number of SECs expressing beta-galactosidase was detected along the sinusoidal lining after transfection with PLL-g-HA/pSV beta-Gal. Moreover, PLL-g-HA effectively stabilized DNA triplex formation. In conclusion, the new PLL-g-HA/DNA carrier system permits targeted transfer of exogenous genes selectively to the SECs.	Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138421, Japan; Tokyo Inst Technol, Fac Biosci & Biotechnol, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Osaka Univ, Sch Med, Dept Med 1, Suita, Osaka 5650871, Japan; Akita Univ, Sch Med, Dept Internal Med 1, Akita 0108543, Japan; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA	Juntendo University; Tokyo Institute of Technology; Osaka University; Akita University; University of North Carolina; University of North Carolina Chapel Hill	Sato, N (corresponding author), Juntendo Univ, Sch Med, Dept Gastroenterol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	nsato@med.juntendo.ac.jp	Maruyama, Atsushi/C-9186-2015	Maruyama, Atsushi/0000-0002-7495-2974; Nogawa, Masayuki/0000-0002-4835-2545				ALLEN TM, 1988, BIOCHIM BIOPHYS ACTA, V981, P27; Asayama S, 1998, BIOCONJUGATE CHEM, V9, P476, DOI 10.1021/bc970213m; BACH FH, 1994, IMMUNOL REV, V141, P5, DOI 10.1111/j.1600-065X.1994.tb00870.x; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOWDHURY NR, 1993, J BIOL CHEM, V268, P11265; Ferdous A, 1998, J PHARM SCI-US, V87, P1400, DOI 10.1021/js980066g; FUJIMOTO K, 1993, J BIOMED MATER RES, V27, P1559, DOI 10.1002/jbm.820271213; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; GERRITSEN ME, 1993, FASEB J, V7, P523, DOI 10.1096/fasebj.7.6.8472891; Holland NB, 1998, NATURE, V392, P799, DOI 10.1038/33894; Kircheis R, 1999, J GENE MED, V1, P111; Limmer A, 2000, NAT MED, V6, P1348, DOI 10.1038/82161; Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P3, DOI 10.1021/bc960071g; Maruyama A, 1997, BIOCONJUGATE CHEM, V8, P735, DOI 10.1021/bc9701048; Maruyama A, 1998, BIOCONJUGATE CHEM, V9, P292, DOI 10.1021/bc9701510; McLean JW, 1997, AM J PHYSIOL-HEART C, V273, pH387, DOI 10.1152/ajpheart.1997.273.1.H387; MICHAEL SI, 1994, GENE THER, V1, P223; MILNER ST, 1991, SCIENCE, V251, P905, DOI 10.1126/science.251.4996.905; MOCHIDA S, 1990, GASTROENTEROLOGY, V99, P771, DOI 10.1016/0016-5085(90)90967-6; Naito M, 1996, J LEUKOCYTE BIOL, V60, P337, DOI 10.1002/jlb.60.3.337; Nishimura Y, 1996, TRANSPLANTATION, V61, P99, DOI 10.1097/00007890-199601150-00020; Nishimura Y, 1998, HEPATOLOGY, V27, P1039, DOI 10.1002/hep.510270420; OSHITA M, 1993, J CLIN INVEST, V91, P1337, DOI 10.1172/JCI116334; OSHITA M, 1992, HEPATOLOGY, V16, P1007, DOI 10.1002/hep.1840160425; PERALES JC, 1994, P NATL ACAD SCI USA, V91, P4086, DOI 10.1073/pnas.91.9.4086; PLANK C, 1992, BIOCONJUGATE CHEM, V3, P533, DOI 10.1021/bc00018a012; POBER JS, 1990, TRANSPLANTATION, V50, P537, DOI 10.1097/00007890-199010000-00001; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Sambrook J., 2002, MOL CLONING LAB MANU; Seternes T, 2002, P NATL ACAD SCI USA, V99, P7594, DOI 10.1073/pnas.102173299; SMEDSROD B, 1990, BIOCHEM J, V266, P313, DOI 10.1042/bj2660313; SMMEDSROD B, 1984, BIOCHEM J, V22, P617; TAKEI Y, 1991, TRANSPLANTATION, V51, P959, DOI 10.1097/00007890-199105000-00005; TAKEI Y, 2000, METHODS MOL MED NONV, V65, P123; VERRECCHIA T, 1994, SCIENCE, V263, P1600; WAGNER E, 1990, P NATL ACAD SCI USA, V87, P3410, DOI 10.1073/pnas.87.9.3410; WU GY, 1988, J BIOL CHEM, V263, P14621; Wu J, 1998, HEPATOLOGY, V27, P772, DOI 10.1002/hep.510270319; YOKOYAMA M, 1991, CANCER RES, V51, P3229; ZHANG YZ, 1991, FASEB J, V5, P3108, DOI 10.1096/fasebj.5.15.1720751; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048	42	66	71	1	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					699	+		10.1096/fj.03-0494fje	http://dx.doi.org/10.1096/fj.03-0494fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977882				2022-12-28	WOS:000220425000022
J	Carrillo-Vico, A; Calvo, JR; Abreu, P; Lardone, PJ; Garcia-Maurino, S; Reiter, RJ; Guerrero, JM				Carrillo-Vico, A; Calvo, JR; Abreu, P; Lardone, PJ; Garcia-Maurino, S; Reiter, RJ; Guerrero, JM			Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance	FASEB JOURNAL			English	Article						neuroimmunology; NAT; HIOMT; IL-2	BLOOD MONONUCLEAR-CELLS; NATURAL-KILLER ACTIVITY; RAT PINEAL-GLAND; LYMPHOID-CELLS; INTERFERON-GAMMA; HUMAN MONOCYTES; BONE-MARROW; IFN-GAMMA; IN-VITRO; PROLIFERATION	It has been historically assumed that the pineal gland is the major source of melatonin (N-acetyl-5-methoxytryptamine) in vertebrates. Melatonin plays a central role in fine-tuning circadian rhythms in vertebrate physiology. In addition, melatonin shows a remarkable functional versatility exhibiting antioxidant, oncostatic, antiaging, and immunomodulatory properties. Melatonin has been identified in a wide range of organisms from bacteria to human beings. Its biosynthesis from tryptophan involves four well-defined intracellular steps catalyzed by tryptophan hydroxylase, aromatic amino acid decarboxylase, serotonin-N-acetyltransferase, and hydroxyndole-O-methyltransferase. Here, for the first time, we document that both resting and phytohemagglutinin-stimulated human lymphocytes synthesize and release large amounts of melatonin, with the melatonin concentration in the medium increasing up to five times the nocturnal physiological levels in human serum. Moreover, we show that the necessary machinery to synthesize melatonin is present in human lymphocytes. Furthermore, melatonin released to the culture medium is synthesized in the cells, because blocking the enzymes required for its biosynthesis or inhibiting protein synthesis in general produced a significant reduction in melatonin release. Moreover, this inhibition caused a decrease in IL-2 production, which was restored by adding exogenous melatonin. These findings indicate that in addition to pineal gland, human lymphoid cells are an important physiological source of melatonin and that this melatonin could be involved in the regulation of the human immune system, possibly by acting as an intracrine, autocrine, and/or paracrine substance.	Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, E-41009 Seville, Spain; Virgen Macarena Hosp, Seville, Spain; Univ La Laguna, Sch Med, Dept Physiol, Tenerife, Spain; Univ Texas, Hlth Sci Ctr, Dept Cellular & Struct Biol, San Antonio, TX 78284 USA	University of Sevilla; Hospital Universitario Virgen Macarena; Universidad de la Laguna; University of Texas System; University of Texas Health San Antonio	Guerrero, JM (corresponding author), Univ Seville, Sch Med, Dept Med Biochem & Mol Biol, Avda Sanchez Pizjuan 4, E-41009 Seville, Spain.	guerrero@us.es	Carrillo-Vico, Antonio/K-5265-2014; IBIS, NEUROINMUNO/O-9306-2015; Calvo, Juan R./A-7338-2017; García-Mauriño, Sofía/E-6707-2010; Lardone, Patricia J/H-1959-2015	Carrillo-Vico, Antonio/0000-0002-8516-0999; Calvo, Juan R./0000-0002-4854-2963; García-Mauriño, Sofía/0000-0002-7698-5112; Lardone, Patricia J/0000-0003-1793-3985; Guerrero, Juan Miguel/0000-0001-7553-0119				ARZT ES, 1988, J CLIN IMMUNOL, V8, P513, DOI 10.1007/BF00916958; Barjavel MJ, 1998, J IMMUNOL, V160, P1191; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bubenik GA, 1997, BIOL SIGNAL, V6, P40; Butcher NJ, 2000, MOL PHARMACOL, V57, P468, DOI 10.1124/mol.57.3.468; CALVO JR, 1995, J PINEAL RES, V18, P119, DOI 10.1111/j.1600-079X.1995.tb00149.x; Carrillo-Vico A, 2003, FASEB J, V17, P755, DOI 10.1096/fj.02-0501fje; CHAMPNEY TH, 1984, J NEUROSCI RES, V11, P59, DOI 10.1002/jnr.490110107; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLOMBO LL, 1992, IMMUNOL LETT, V33, P123, DOI 10.1016/0165-2478(92)90035-M; Conti A, 2000, J PINEAL RES, V28, P193, DOI 10.1034/j.1600-079X.2000.280401.x; Cos S, 1998, CANCER RES, V58, P4383; CSABA G, 1975, ENDOCRINOL EXP, V9, P59; DELGOBBO V, 1989, INT J IMMUNOPHARMACO, V11, P567, DOI 10.1016/0192-0561(89)90187-2; DISTEFANO A, 1994, J PINEAL RES, V17, P164; FINOCCHIARO LME, 1991, BIOCHEM J, V280, P727, DOI 10.1042/bj2800727; FINOCCHIARO LME, 1988, J INTERFERON RES, V8, P705, DOI 10.1089/jir.1988.8.705; Garcia-Chaumont C, 2000, PHARMACOL THERAPEUT, V87, P255, DOI 10.1016/S0163-7258(00)00062-0; Garcia-Maurino S, 1999, LIFE SCI, V65, P2143, DOI 10.1016/S0024-3205(99)00479-8; GarciaMaurino S, 1997, J IMMUNOL, V159, P574; GarciaPerganeda A, 1997, J IMMUNOL, V159, P3774; GIORDANO M, 1991, J PINEAL RES, V10, P117, DOI 10.1111/j.1600-079X.1991.tb00827.x; GONZALEZHABA MG, 1995, FASEB J, V9, P1331, DOI 10.1096/fasebj.9.13.7557023; GUERRERO JM, 1992, ENDOCR RES, V18, P91, DOI 10.1080/07435809209035401; Guerrero JM, 2002, CURR TOP MED CHEM, V2, P67; JANKOVIC BD, 1970, IMMUNOLOGY, V18, P1; Konakchieva R, 1995, J NEUROIMMUNOL, V63, P125, DOI 10.1016/0165-5728(95)00135-2; Kronenwett R, 1998, BLOOD, V91, P852, DOI 10.1182/blood.V91.3.852.852_852_862; LEWINSKI A, 1989, J PINEAL RES, V7, P153, DOI 10.1111/j.1600-079X.1989.tb00663.x; Manchester LC, 1995, CELL MOL BIOL RES, V41, P391; Markowska M, 2001, J PINEAL RES, V30, P220, DOI 10.1034/j.1600-079X.2001.300405.x; MORREY KM, 1994, J IMMUNOL, V153, P2671; Nelson RJ, 2000, ANN NY ACAD SCI, V917, P404; Pahlavani MA, 1997, IMMUNOPHARM IMMUNOT, V19, P327, DOI 10.3109/08923979709046979; PERSENGIEV SP, 1993, INT J BIOCHEM, V25, P441, DOI 10.1016/0020-711X(93)90637-T; Reiter RJ, 1998, PROG NEUROBIOL, V56, P359, DOI 10.1016/S0301-0082(98)00052-5; REITER RJ, 1991, ENDOCR REV, V12, P151, DOI 10.1210/edrv-12-2-151; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; RODRIGUEZ IR, 1994, J BIOL CHEM, V269, P31969; RUBIO A, 1993, ENDOCRINOLOGY, V132, P393, DOI 10.1210/en.132.1.393; Simonneaux V, 2003, PHARMACOL REV, V55, P325, DOI 10.1124/pr.55.2.2; SUGDEN D, 1989, EXPERIENTIA, V45, P922, DOI 10.1007/BF01953049; Tan DX, 1999, BBA-GEN SUBJECTS, V1472, P206, DOI 10.1016/S0304-4165(99)00125-7; WAKABAYASHI H, 1986, J CHROMATOGR, V381, P21, DOI 10.1016/S0378-4347(00)83561-6; Wiechmann AF, 1999, J PINEAL RES, V27, P116, DOI 10.1111/j.1600-079X.1999.tb00605.x; Wolfler A, 1998, LIFE SCI, V63, P835, DOI 10.1016/S0024-3205(98)00340-3; YOUNG MRI, 1993, IMMUNOLOGY, V80, P395	48	335	354	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					537	+		10.1096/fj.03-0694fje	http://dx.doi.org/10.1096/fj.03-0694fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715696				2022-12-28	WOS:000188829300026
J	Warskulat, U; Flogel, U; Jacoby, C; Hartwig, HG; Thewissen, M; Merx, MW; Molojavyi, A; Heller-Stilb, B; Schrader, J; Haussinger, D				Warskulat, U; Flogel, U; Jacoby, C; Hartwig, HG; Thewissen, M; Merx, MW; Molojavyi, A; Heller-Stilb, B; Schrader, J; Haussinger, D			Taurine transporter knockout depletes muscle taurine levels and results in severe skeletal muscle impairment but leaves cardiac function uncompromised	FASEB JOURNAL			English	Article						gene disruption; knockout mice; compatible organic osmolytes	AMINO-ACID TRANSPORTER; POTASSIUM CHANNELS; ION CHANNELS; RAT-LIVER; EXERCISE; DEFICIENCY; FIBERS; INJURY; CELLS; CARDIOMYOPATHY	Taurine is the most abundant free amino acid in heart and skeletal muscle. In the present study, the effects of hereditary taurine deficiency on muscle function were examined in taurine transporter knockout (taut-/-) mice. These mice show an almost complete depletion of heart and skeletal muscle taurine levels. Treadmill experiments demonstrated that total exercise capacity of taut-/- mice was reduced by >80% compared with wild-type controls. The decreased performance of taut-/- mice correlated with increased lactate levels in serum during exercise. Surprisingly, cardiac function of taut-/- mice as assessed by magnetic resonance imaging, echocardiography, and isolated heart studies showed a largely normal phenotype under both control and stimulated conditions. However, analysis of taut-/- skeletal muscle revealed electromyographic abnormalities. H-1 nuclear magnetic resonance spectroscopy of tissue extracts showed that in the heart of taut-/- mice the lack of taurine was compensated by the upregulation of various organic solutes. In contrast, a deficit of >10 mM in total organic osmolyte concentration was found in skeletal muscle. The present study identifies taurine transport as a crucial factor for the maintenance of skeletal muscle function and total exercise capacity, while cardiac muscle apparently can compensate for the loss of taurine.	Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Physiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Anat 2, D-40225 Dusseldorf, Germany; Rhein Westfal TH Aachen, Univ Hosp, Med Clin 1, D-5100 Aachen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; RWTH Aachen University; RWTH Aachen University Hospital	Haussinger, D (corresponding author), Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, Moorenstr 5, D-40225 Dusseldorf, Germany.	haeussin@uni-duesseldorf.de						BAGNASCO S, 1986, J BIOL CHEM, V261, P5872; Bakker AJ, 2002, J PHYSIOL-LONDON, V538, P185, DOI 10.1113/jphysiol.2001.012872; Baum M, 2001, AMINO ACIDS, V20, P75, DOI 10.1007/s007260170067; BEREGI E, 1988, Z GERONTOL, V21, P83; CHAPMAN RA, 1993, CARDIOVASC RES, V27, P358, DOI 10.1093/cvr/27.3.358; Crosbie RH, 2002, FASEB J, V16, P943, DOI 10.1096/fj.01-0327com; Cuisinier C, 2002, EUR J APPL PHYSIOL, V87, P489, DOI 10.1007/s00421-002-0679-0; Dawson R, 2002, AMINO ACIDS, V22, P309; De Luca A, 2000, ADV EXP MED BIOL, V483, P45; Flogel U, 1999, J MOL CELL CARDIOL, V31, P827, DOI 10.1006/jmcc.1998.0921; Graf D, 2002, HEPATOLOGY, V36, P829, DOI 10.1053/jhep.2002.35536; GREEN TR, 1991, BIOCHIM BIOPHYS ACTA, V1073, P91, DOI 10.1016/0304-4165(91)90187-L; Gu SM, 2000, P NATL ACAD SCI USA, V97, P3230, DOI 10.1073/pnas.050318197; Haussinger D, 1996, BIOCHEM J, V313, P697; Heger J, 2002, CIRC RES, V90, P93, DOI 10.1161/hh0102.102757; HEILIG CW, 1989, AM J PHYSIOL, V257, pF1108, DOI 10.1152/ajprenal.1989.257.6.F1108; Heller-Stilb B, 2001, FASEB J, V15, P231, DOI 10.1096/fj.01-0691fje; HUXTABLE RJ, 1992, PHYSIOL REV, V72, P101, DOI 10.1152/physrev.1992.72.1.101; Hyde R, 2001, BIOCHEM J, V355, P563, DOI 10.1042/bj3550563; Kurz AK, 1998, HEPATOLOGY, V28, P774, DOI 10.1002/hep.510280326; LAKE N, 1993, AM J PHYSIOL, V264, pH1323; Lang F, 1998, PFLUG ARCH EUR J PHY, V436, P377, DOI 10.1007/s004240050646; Lang PA, 2003, CELL PHYSIOL BIOCHEM, V13, P337, DOI 10.1159/000075121; Matsuzaki Y, 2002, MED SCI SPORT EXER, V34, P793, DOI 10.1097/00005768-200205000-00011; McVeigh KE, 2000, CYTOGENET CELL GENET, V88, P153, DOI 10.1159/000015509; MOISE NS, 1991, AM HEART J, V121, P541, DOI 10.1016/0002-8703(91)90724-V; NOVOTNY MJ, 1991, AM J PHYSIOL, V261, pH121, DOI 10.1152/ajpheart.1991.261.1.H121; PION PD, 1987, SCIENCE, V237, P764, DOI 10.1126/science.3616607; PION PD, 1992, J AM VET MED ASSOC, V201, P267; ROBITAILLE PML, 1991, J MAGN RESON, V92, P73, DOI 10.1016/0022-2364(91)90248-R; Satoh H, 1998, GEN PHARMACOL-VASC S, V30, P451, DOI 10.1016/S0306-3623(97)00309-1; SAWAMURA A, 1990, CELL CALCIUM, V11, P251, DOI 10.1016/0143-4160(90)90001-B; SCHAFFER SW, 1992, ADV EXP MED BIOL, V315, P105; SZE DY, 1990, BIOCHIM BIOPHYS ACTA, V1054, P181, DOI 10.1016/0167-4889(90)90240-E; TIMBRELL JA, 1995, GEN PHARMACOL-VASC S, V26, P453, DOI 10.1016/0306-3623(94)00203-Y; Tricarico D, 2001, J PHARMACOL EXP THER, V298, P1167; Tricarico D, 2000, BRIT J PHARMACOL, V130, P827, DOI 10.1038/sj.bjp.0703385; Varoqui H, 2000, J BIOL CHEM, V275, P4049, DOI 10.1074/jbc.275.6.4049; Welch WJ, 1996, CELL STRESS CHAPERON, V1, P109, DOI 10.1379/1466-1268(1996)001<0109:IOMACC>2.3.CO;2; Wettstein M, 1997, HEPATOLOGY, V26, P1560	40	120	124	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					577	+		10.1096/fj.03-0496fje	http://dx.doi.org/10.1096/fj.03-0496fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734644				2022-12-28	WOS:000188829300013
J	Gingras, M; Bergeron, J; Dery, J; Durham, HD; Berthod, F				Gingras, M; Bergeron, J; Dery, J; Durham, HD; Berthod, F			In vitro development of a tissue-engineered model of peripheral nerve regeneration to study neurite growth	FASEB JOURNAL			English	Article						axon guidance; biomaterial; peripheral nervous system; keratinocytes; NGF	SCHWANN-CELL INVASION; LONG-TERM CULTURE; NEUROTROPHIC FACTOR; SENSORY NEURONS; COLLAGEN SPONGE; SKIN EQUIVALENT; AXONAL GROWTH; FIBROBLASTS; OUTGROWTH; EXPRESSION	A unique tissue-engineered model of peripheral nerve regeneration was developed in vitro to study neurite outgrowth. Mouse dorsal root ganglia neurons were seeded on a collagen sponge populated with human endothelial cells and/or human fibroblasts. Addition of nerve growth factor (NGF; 10 ng/ml) was not required for sensory neurons survival but was necessary to promote neurite outgrowth, as assessed by immunostaining of the 150 kDa neurofilament. A vigorous neurite elongation was detected inside the reconstructed tissue after 14 and 31 days of neurons culture, reaching up to 770 mum from day 14. Axons were often observed closely associated with the capillary-like tubes reconstructed in the model, in a similar pattern as in the human dermis. The presence of endothelial cells induced a significant increase of the neurite elongation after 14 days of culture. The addition of human keratinocytes totally avoided the twofold decrease in the amount of neurites observed between 14 and 31 days in controls. Besides the addition of NGF, axonal growth did not necessitate B27 supplement or glial cell coculture to be promoted and stabilized for long-term culture. Thus, this model might be a valuable tool to study the effect of various cells and/or attractive or repulsive molecules on neurite outgrowth in vitro.	Univ Laval, CHA, Hop St Sacrement, Lab Organogenese Expt, Quebec City, PQ G1S 4L8, Canada; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada	Laval University; McGill University	Berthod, F (corresponding author), Univ Laval, CHA, Hop St Sacrement, Lab Organogenese Expt, 1050 Chemin St Foy, Quebec City, PQ G1S 4L8, Canada.	berthod@chg.ulaval.ca		Berthod, Francois/0000-0003-3580-0297				ACHESON A, 1991, NEURON, V7, P265, DOI 10.1016/0896-6273(91)90265-2; AUGER FA, 1995, IN VITRO CELL DEV-AN, V31, P432; Backstrom E, 2000, J IMMUNOL, V165, P4895, DOI 10.4049/jimmunol.165.9.4895; Balgude AP, 2001, BIOMATERIALS, V22, P1077, DOI 10.1016/S0142-9612(00)00350-1; Becq H, 1999, J NEUROSCI RES, V58, P553, DOI 10.1002/(SICI)1097-4547(19991115)58:4<553::AID-JNR8>3.0.CO;2-8; Berthod F, 1996, J BIOMED MATER RES, V32, P87, DOI 10.1002/(SICI)1097-4636(199609)32:1<87::AID-JBM10>3.0.CO;2-F; Berthod F, 1997, J INVEST DERMATOL, V108, P737, DOI 10.1111/1523-1747.ep12292122; BERTHOD F, 1993, BIOMATERIALS, V14, P749, DOI 10.1016/0142-9612(93)90039-5; BERTHOD F, 1994, CLIN MATER, V15, P259, DOI 10.1016/0267-6605(94)90055-8; Berthod F, 1997, SKIN SUBSTITUTE PROD, P23; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; Borkenhagen M, 1998, J BIOMED MATER RES, V40, P392, DOI 10.1002/(SICI)1097-4636(19980603)40:3<392::AID-JBM8>3.3.CO;2-4; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Byers MR, 1992, GROWTH FACTORS, V6, DOI 10.3109/08977199209008870; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Cao X, 2001, NEUROSCIENCE, V103, P831, DOI 10.1016/S0306-4522(01)00029-X; Cheng B, 2002, MICROSURG, V22, P133, DOI 10.1002/micr.21740; D'Arcangelo D, 2000, CIRC RES, V86, P312, DOI 10.1161/01.RES.86.3.312; DANIELSEN N, 1988, J NEUROSCI RES, V20, P320, DOI 10.1002/jnr.490200306; Doroudchi MM, 1996, J NEUROPATH EXP NEUR, V55, P246, DOI 10.1097/00005072-199602000-00013; Dubey N, 1999, EXP NEUROL, V158, P338, DOI 10.1006/exnr.1999.7095; Durham HD, 1997, J NEUROPATH EXP NEUR, V56, P523, DOI 10.1097/00005072-199705000-00008; Edoff K, 2002, J NEUROSCI RES, V67, P255, DOI 10.1002/jnr.10092; GERMAIN L, 1993, BURNS, V19, P99, DOI 10.1016/0305-4179(93)90028-7; Gotz ME, 2002, J NEURAL TRANSM, V109, P597, DOI 10.1007/s007020200049; Hudon V, 2003, BRIT J DERMATOL, V148, P1094, DOI 10.1046/j.1365-2133.2003.05298.x; Jerregard H, 2001, J NEUROCYTOL, V30, P327, DOI 10.1023/A:1014460413884; KNOOPS B, 1991, BRAIN RES, V540, P183, DOI 10.1016/0006-8993(91)90506-Q; Lee YS, 2002, J NEUROTRAUM, V19, P357, DOI 10.1089/089771502753594927; Lesuisse C, 2002, J NEUROBIOL, V51, P9, DOI 10.1002/neu.10037; Lillesaar C, 2001, NEUROSCI LETT, V308, P161, DOI 10.1016/S0304-3940(01)01997-8; Luo FR, 1999, CANCER CHEMOTH PHARM, V44, P29, DOI 10.1007/s002800050941; Ma MY, 2000, J NEUROCYTOL, V29, P249, DOI 10.1023/A:1026519720352; Miller C, 2001, TISSUE ENG, V7, P705, DOI 10.1089/107632701753337663; Mukouyama Y, 2002, CELL, V109, P693, DOI 10.1016/S0092-8674(02)00757-2; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; Padilla F, 1999, J NEUROSCI RES, V58, P270; Patel TD, 2000, NEURON, V25, P345, DOI 10.1016/S0896-6273(00)80899-5; Pincelli C, 1997, J INVEST DERMATOL, V109, P757, DOI 10.1111/1523-1747.ep12340768; Pinney E, 2000, J CELL PHYSIOL, V183, P74, DOI 10.1002/(SICI)1097-4652(200004)183:1<74::AID-JCP9>3.0.CO;2-G; Rangappa N, 2000, J BIOMED MATER RES, V51, P625, DOI 10.1002/1097-4636(20000915)51:4<625::AID-JBM10>3.0.CO;2-U; Ruscheweyh R, 2001, NEUROSCIENCE, V107, P275, DOI 10.1016/S0306-4522(01)00354-2; Snider WD, 1996, PHILOS T ROY SOC B, V351, P395, DOI 10.1098/rstb.1996.0034; Snow DM, 2002, J NEUROBIOL, V51, P285, DOI 10.1002/neu.10060; SODERSTROM S, 1995, TOXICOL LETT, V75, P133, DOI 10.1016/0378-4274(94)03176-8; Sondell M, 1999, BRAIN RES, V846, P219, DOI 10.1016/S0006-8993(99)02056-9; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; Steinbrech DS, 1999, ANN PLAS SURG, V42, P514, DOI 10.1097/00000637-199905000-00009; Terman GW, 2001, J NEUROPHYSIOL, V85, P485, DOI 10.1152/jn.2001.85.2.485; Vikman KS, 2001, J NEUROSCI METH, V105, P175, DOI 10.1016/S0165-0270(00)00360-5; Yip PM, 1998, MOL BIOL CELL, V9, P277, DOI 10.1091/mbc.9.2.277; Young RC, 2002, BRIT J PLAST SURG, V55, P235, DOI 10.1054/bjps.2002.3798; Yu XJ, 2001, J NEUROSCI RES, V66, P303, DOI 10.1002/jnr.1225	53	40	41	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2124	+		10.1096/fj.02-1180fje	http://dx.doi.org/10.1096/fj.02-1180fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958159				2022-12-28	WOS:000185925100022
J	Gao, HM; Liu, B; Zhang, WQ; Hong, JS				Gao, HM; Liu, B; Zhang, WQ; Hong, JS			Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease	FASEB JOURNAL			English	Article						inflammation; microglia; NADPH oxidase; synergistic neurotoxicity	NITRIC-OXIDE SYNTHASE; ENVIRONMENTAL RISK-FACTORS; SUBSTANTIA-NIGRA; NADPH OXIDASE; GLIAL-CELLS; MICROGLIAL ACTIVATION; INTRANIGRAL INJECTION; INFLAMMATORY REACTION; ALZHEIMERS-DISEASE; PESTICIDE EXPOSURE	Parkinson's disease (PD) is a profound movement disorder resulting from progressive degeneration of the nigrostriatal dopaminergic pathway. Although its etiology remains unknown, increasing evidence suggests the involvement of multiple factors such as environmental toxins and genetic susceptibilities in the pathogenesis of PD. In this study using mesencephalic neuronglia cultures as an in vitro PD model, we demonstrated that the neurotoxin 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP, 0.1-0.5 muM) and an inflammogen lipopolysaccharide (LPS, 0.5 ng/ml) synergistically induced a progressive and selective degeneration of dopaminergic neurons. The synergistic neurotoxicity was observed when both agents were applied either simultaneously or in tandem. The synergistic neurotoxicity was more prominent when lower doses of both agents were applied for a longer period of time. Mechanistically, microglial NADPH oxidase-mediated generation of reactive oxygen species played a pivotal role in the synergistic neurotoxicity: MPTP and LPS synergistically stimulated the NADPH oxidase-mediated release of superoxide free radical; pharmacological inhibition and genetic inactivation of NADPH oxidase prevented superoxide production and the synergistic neurotoxicity. Additionally, inhibition of nitric oxide synthase afforded significant neuroprotection, suggesting the involvement of nitric oxide in the synergistic neurotoxicity. This study lends strong support for a multifactorial etiology of PD and provides clues for therapeutic interventions.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Gao, HM (corresponding author), NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, POB 12233,F1-01, Res Triangle Pk, NC 27709 USA.	gao@niehs.nih.gov	liu, Bin/A-7695-2009; gao, huiming/C-8454-2012; Hong, Jau-shyong/F-1920-2019	Hong, Jau-shyong/0000-0002-3056-8401				AKIYAMA H, 1989, BRAIN RES, V489, P247, DOI 10.1016/0006-8993(89)90857-3; Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Casals J, 1998, J NEURAL TRANSM, V105, P645, DOI 10.1007/s007020050086; Cassarino DS, 1997, BBA-MOL BASIS DIS, V1362, P77, DOI 10.1016/S0925-4439(97)00070-7; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; Cicchetti F, 2002, EUR J NEUROSCI, V15, P991, DOI 10.1046/j.1460-9568.2002.01938.x; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Hanson GR, 1998, ANN NY ACAD SCI, V844, P103, DOI 10.1111/j.1749-6632.1998.tb08225.x; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Herishanu YO, 2001, CAN J NEUROL SCI, V28, P144, DOI 10.1017/S0317167100052835; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1997, P NATL ACAD SCI USA, V94, P7531, DOI 10.1073/pnas.94.14.7531; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kidd P M, 2000, Altern Med Rev, V5, P502; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Kurkowska-Jastrzebska I, 1999, EXP NEUROL, V156, P50, DOI 10.1006/exnr.1998.6993; LANGSTON JW, 1985, LIFE SCI, V36, P201; Langston JW, 1999, ANN NEUROL, V46, P598, DOI 10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; Liberatore GT, 1999, NAT MED, V5, P1403; Ling ZD, 2002, MOVEMENT DISORD, V17, P116, DOI 10.1002/mds.10078; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; MCGEER PL, 1988, NEUROLOGY, V38, P1285, DOI 10.1212/WNL.38.8.1285; Nagatsu T, 2000, J NEURAL TRANSM-SUPP, P143; Nagatsu T, 2000, ADV RES NEURODEGENER, V8, P277; Noh KM, 2000, J NEUROSCI, V20; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Park SU, 2002, J NEUROSCI, V22, P4399, DOI 10.1523/JNEUROSCI.22-11-04399.2002; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; RAJPUT AH, 1987, NEUROLOGY, V37, P1820, DOI 10.1212/WNL.37.11.1820; RAVENHOLT RT, 1982, LANCET, V2, P860; Ritz B, 2000, INT J EPIDEMIOL, V29, P323, DOI 10.1093/ije/29.2.323; SCHULZ JB, 1995, J NEUROCHEM, V64, P936, DOI 10.1046/j.1471-4159.1995.64020936.x; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328, DOI 10.1212/WNL.42.7.1328; SNYDER SH, 1985, NATURE, V317, P198, DOI 10.1038/317198a0; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; SUZUKI K, 1990, ADV NEUROL, V53, P215; SUZUKI K, 1992, J NEUROL SCI, V109, P219, DOI 10.1016/0022-510X(92)90172-H; Tammariello SP, 2000, J NEUROSCI, V20; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; WILLIAMS DB, 1991, NEUROLOGY, V41, P1554, DOI 10.1212/WNL.41.10.1554; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Xie Z, 2002, J NEUROSCI, V22, P3484	67	131	135	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1957	+		10.1096/fj.03-0203fje	http://dx.doi.org/10.1096/fj.03-0203fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923073				2022-12-28	WOS:000185345100007
J	Wheeler, YRY; Kute, TE; Willingham, MC; Chen, SY; Sane, DC				Wheeler, YRY; Kute, TE; Willingham, MC; Chen, SY; Sane, DC			Intrabody-based strategies for inhibition of vascular endothelial growth factor receptor-2: effects on apoptosis, cell growth, and angiogenesis	FASEB JOURNAL			English	Article						adenovirus; KDR; tube formation; HUVEC	PERMEABILITY FACTOR; TUMOR-GROWTH; FACTOR VEGF; TYROSINE KINASE; QUALITY-CONTROL; KDEL RECEPTOR; FACTOR GENE; EXPRESSION; PROTEINS; PROLIFERATION	VEGF, an endothelial-specific mitogen, is an important tumor angiogenesis growth factor. The major receptor for VEGF on endothelial cells is KDR. We hypothesized that an intrabody could bind newly synthesized KDR and block receptor transport to the cell surface, thereby inhibiting important VEGF effects. We expressed a single chain antibody (p3S5) to KDR with or without the endoplasmic reticulum ( ER) retention signal ( KDEL), using either a plasmid (p3S5-HAK) or a tet-off adenoviral system (Ad-HAK). Plasmid-mediated expression of the tethered intrabody significantly reduced KDR expression ( from 82.5 +/- 12.5% to 27.9 +/- 13.6% of cells; P< 0.01) and thymidine incorporation in successfully transfected cells. Ad-HAK infection resulted in intrabody expression in >90% of human umbilical vein endothelial cells ( HUVECs), producing marked (80%) apoptosis at 48 h postinfection. The intrabody was essential for these effects, as confirmed by inhibiting its expression with doxycycline or by expressing irrelevant genes (lacZ, GFP). Cell death was dependent on KDR, because Ad-HAK infection of cell lines with minimal or no KDR had little effect on cell viability. Infected HUVECs were unable to form tubes on Engelbreth Holm-Swarm (EHS) tumor gel matrix. These results demonstrate the potential for development of an intrabody-based strategy to block angiogenesis and prevent tumor growth.	Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Canc Biol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Pathol, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Internal Med, Winston Salem, NC 27157 USA; Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center; Baylor College of Medicine	Sane, DC (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Cardiol Sect, Dept Canc Biol, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dsane@wfubmc.edu						ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Alvarez RD, 2000, CLIN CANCER RES, V6, P3081; Anan K, 1996, SURGERY, V119, P333, DOI 10.1016/S0039-6060(96)80120-6; BEJAMIN LE, 1999, J CLIN INVEST, V103, P159; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; BERKMAN RA, 1993, J CLIN INVEST, V91, P153, DOI 10.1172/JCI116165; BLOOD CH, 1990, BIOCHIM BIOPHYS ACTA, V1032, P89, DOI 10.1016/0304-419X(90)90014-R; Brekken RA, 1998, CANCER RES, V58, P1952; BREM S, 1976, CANCER RES, V36, P2807; BROWN LF, 1995, HUM PATHOL, V26, P86, DOI 10.1016/0046-8177(95)90119-1; Bu GJ, 1997, J CELL SCI, V110, P65; Chen JD, 1997, NAT MED, V3, P1110, DOI 10.1038/nm1097-1110; Chen SY, 1999, GENE THERAPY OF CANCER, P389; Cheng SY, 1996, P NATL ACAD SCI USA, V93, P8502, DOI 10.1073/pnas.93.16.8502; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Crew JP, 1997, CANCER RES, V57, P5281; Cunningham SA, 1999, J BIOL CHEM, V274, P18421, DOI 10.1074/jbc.274.26.18421; der Maur AA, 2001, FEBS LETT, V508, P407, DOI 10.1016/S0014-5793(01)03101-5; Deshane J, 1995, J CLIN INVEST, V96, P2980, DOI 10.1172/JCI118370; Engel BC, 2000, MOL THER, V1, P165, DOI 10.1006/mthe.2000.0026; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gerber HP, 2003, J MOL MED, V81, P20, DOI 10.1007/s00109-002-0397-4; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Hunt S, 2001, CURR OPIN MOL THER, V3, P418; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; KONDO S, 1993, BIOCHEM BIOPH RES CO, V194, P1234, DOI 10.1006/bbrc.1993.1955; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; LEWIS MJ, 1990, NATURE, V348, P162, DOI 10.1038/348162a0; LEWIS MJ, 1992, J MOL BIOL, V226, P913, DOI 10.1016/0022-2836(92)91039-R; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; Llewellyn DH, 1997, BIOCHEM BIOPH RES CO, V240, P36, DOI 10.1006/bbrc.1997.7607; Lu D, 1999, J IMMUNOL METHODS, V230, P159, DOI 10.1016/S0022-1759(99)00135-0; Marasco WA, 1997, GENE THER, V4, P11, DOI 10.1038/sj.gt.3300346; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; OLSON TA, 1994, CANCER RES, V54, P276; Orlando JS, 2002, J VIROL, V76, P1475, DOI 10.1128/JVI.76.3.1475-1487.2002; PARANGI S, 1995, CANCER RES, V55, P6071; Parry TJ, 1999, NUCLEIC ACIDS RES, V27, P2569, DOI 10.1093/nar/27.13.2569; PETERS KG, 1993, P NATL ACAD SCI USA, V90, P8915, DOI 10.1073/pnas.90.19.8915; PIHLAJANIEMI T, 1987, EMBO J, V6, P643, DOI 10.1002/j.1460-2075.1987.tb04803.x; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; PLATE KH, 1993, CANCER RES, V53, P5822; Rajpal A, 2001, J BIOL CHEM, V276, P33139, DOI 10.1074/jbc.M101332200; Ramakrishnan S, 1996, CANCER RES, V56, P1324; RICHARDSON JH, 1995, P NATL ACAD SCI USA, V92, P3137, DOI 10.1073/pnas.92.8.3137; Robinson CJ, 2001, J CELL SCI, V114, P853; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Saleh M, 1996, CANCER RES, V56, P393; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Shaheen RM, 1999, CANCER RES, V59, P5412; Siemeister G, 1998, P NATL ACAD SCI USA, V95, P4625, DOI 10.1073/pnas.95.8.4625; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Steinberger P, 2000, P NATL ACAD SCI USA, V97, P805, DOI 10.1073/pnas.97.2.805; Sukbuntherng J, 2001, J PHARM PHARMACOL, V53, P1629, DOI 10.1211/0022357011778232; TOWNSLEY FM, 1993, EMBO J, V12, P2821, DOI 10.1002/j.1460-2075.1993.tb05943.x; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; ZHANG HT, 1995, J NATL CANCER I, V87, P213, DOI 10.1093/jnci/87.3.213	69	27	46	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1733	+		10.1096/fj.02-0942fje	http://dx.doi.org/10.1096/fj.02-0942fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958192				2022-12-28	WOS:000184471600027
J	Melo, LG; Pachori, AS; Kong, D; Gnecchi, M; Wang, K; Pratt, RE; Dzau, VJ				Melo, LG; Pachori, AS; Kong, D; Gnecchi, M; Wang, K; Pratt, RE; Dzau, VJ			Gene and cell-based therapies for heart disease	FASEB JOURNAL			English	Review						coronary artery disease; AAV; mycardial protection; contractile function	ENDOTHELIAL PROGENITOR CELLS; ISCHEMIA-REPERFUSION INJURY; MARROW STROMAL CELLS; CARDIAC STEM-CELLS; GROWTH-FACTOR; ANTISENSE OLIGODEOXYNUCLEOTIDES; BETA(2)-ADRENERGIC RECEPTOR; CONTRACTILE FUNCTION; MYOCARDIAL-ISCHEMIA; MEDIATED DELIVERY	Heart disease remains the prevalent cause of premature death and accounts for a significant proportion of all hospital admissions. Recent developments in understanding the molecular mechanisms of myocardial disease have led to the identification of new therapeutic targets, and the availability of vectors with enhanced myocardial tropism offers the opportunity for the design of gene therapies for both protection and rescue of the myocardium. Genetic therapies have been devised to treat complex diseases such as myocardial ischemia, heart failure, and inherited myopathies in various animal models. Some of these experimental therapies have made a successful transition to clinical trial and are being considered for use in human patients. The recent isolation of endothelial and cardiomyocyte precursor cells from adult bone marrow may permit the design of strategies for repair of the damaged heart. Cell-based therapies may have potential application in neovascularization and regeneration of ischemic and infarcted myocardium, in blood vessel reconstruction, and in bioengineering of artificial organs and prostheses. We expect that advances in the field will lead to the development of safer and more efficient vectors. The advent of genomic screening technology should allow the identification of novel therapeutic targets and facilitate the detection of disease-causing polymorphisms that may lead to the design of individualized gene and cell-based therapies.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Brigham & Womens Hosp, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Queens University - Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Melo, LG (corresponding author), Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada.	melo@post.queensu.ca	Gnecchi, Massimiliano/X-7095-2019; Gnecchi, Massimiliano/J-8609-2018	Gnecchi, Massimiliano/0000-0001-7435-4328; Gnecchi, Massimiliano/0000-0001-7435-4328	NHLBI NIH HHS [HL 073219, HL 072010, HL 35610, HL 058316] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035610, R01HL035610, R01HL072010, R01HL073219] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata J, 2002, HYPERTENSION, V40, P653, DOI 10.1161/01.HYP.0000036035.41122.99; AGRAWAL RS, 2001, MOL THER, V3, pA837; Akhtar S, 2000, ADV DRUG DELIVER REV, V44, P3, DOI 10.1016/S0169-409X(00)00080-6; Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Alexander MY, 1999, CLIN EXP PHARMACOL P, V26, P661, DOI 10.1046/j.1440-1681.1999.03117.x; Asahara T, 1997, SCIENCE, V275, P964, DOI 10.1126/science.275.5302.964; Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Assmus B, 2002, CIRCULATION, V106, P3009, DOI 10.1161/01.CIR.0000043246.74879.CD; Baartscheer A, 2001, CARDIOVASC RES, V49, P249, DOI 10.1016/S0008-6363(00)00275-3; BASHIR R, 2002, KIDNEY INT S1, V61, P110; Beltrami AP, 2001, NEW ENGL J MED, V344, P1750, DOI 10.1056/NEJM200106073442303; Beltrami AP, 2003, CELL, V114, P763, DOI 10.1016/S0092-8674(03)00687-1; Brauner R, 1997, J THORAC CARDIOV SUR, V114, P923, DOI 10.1016/S0022-5223(97)70006-0; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; Cartier R, 2002, GENE THER, V9, P157, DOI 10.1038/sj.gt.3301635; Celletti FL, 2001, NAT MED, V7, P425, DOI 10.1038/86490; Chatterjee S, 2002, CIRCULATION, V106, pI212, DOI 10.1161/01.cir.0000032907.33237.55; D'Agostino RB, 2000, AM HEART J, V139, P272, DOI 10.1016/S0002-8703(00)90236-9; Deb A, 2003, CIRCULATION, V107, P1247, DOI 10.1161/01.CIR.0000061910.39145.F0; del Monte F, 1999, CIRCULATION, V100, P2308, DOI 10.1161/01.CIR.100.23.2308; del Monte F, 2002, CIRCULATION, V105, P904, DOI 10.1161/hc0802.105564; del Monte F, 2001, CIRCULATION, V104, P1424, DOI 10.1161/hc3601.095574; Donahue JK, 2000, NAT MED, V6, P1395; Doudna JA, 2002, NATURE, V418, P222, DOI 10.1038/418222a; Fukui T, 2001, BIOCHEM BIOPH RES CO, V281, P1200, DOI 10.1006/bbrc.2001.4493; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; Giordano FJ, 1996, NAT MED, V2, P534, DOI 10.1038/nm0596-534; Givertz MM, 1998, LANCET, V352, P34; Grines CL, 2002, CIRCULATION, V105, P1291, DOI 10.1161/hc1102.105595; Hajjar RJ, 2000, CIRC RES, V86, P616, DOI 10.1161/01.RES.86.6.616; Hajjar RJ, 1997, CIRCULATION, V95, P423; Hakuno D, 2002, CIRCULATION, V105, P380, DOI 10.1161/hc0302.102593; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; HERTTUALA SY, 2000, LANCET, V355, P213; HERTTUALA Y, 2003, NAT MED, V9, P694; Holly TA, 1999, J MOL CELL CARDIOL, V31, P1709, DOI 10.1006/jmcc.1999.1006; Hristov M, 2003, ARTERIOSCL THROM VAS, V23, P1185, DOI 10.1161/01.ATV.0000073832.49290.B5; Ikeda Y, 2002, CIRCULATION, V105, P502, DOI 10.1161/hc0402.102953; Ikenaga S, 2001, J SURG RES, V96, P277, DOI 10.1006/jsre.2000.6080; Isner JM, 2002, NATURE, V415, P234, DOI 10.1038/415234a; Iwaguro H, 2002, CIRCULATION, V105, P732, DOI 10.1161/hc0602.103673; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Jessup M, 2003, NEW ENGL J MED, V348, P2007, DOI 10.1056/NEJMra021498; Jiang YH, 2002, NATURE, V418, P41, DOI 10.1038/nature00870; Kajstura J, 1998, P NATL ACAD SCI USA, V95, P8801, DOI 10.1073/pnas.95.15.8801; Kalka C, 2000, CIRC RES, V86, P1198, DOI 10.1161/01.RES.86.12.1198; Kalka C, 2000, P NATL ACAD SCI USA, V97, P3422, DOI 10.1073/pnas.070046397; KANNEL WB, 1991, AM HEART J, V121, P951, DOI 10.1016/0002-8703(91)90225-7; Kawada T, 2002, P NATL ACAD SCI USA, V99, P901, DOI 10.1073/pnas.022641799; Kawamoto A, 2003, CIRCULATION, V107, P461, DOI 10.1161/01.CIR.0000046450.89986.50; Kawamoto A, 2001, CIRCULATION, V103, P634; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Laham RJ, 2001, ANNU REV MED, V52, P485, DOI 10.1146/annurev.med.52.1.485; Lee LY, 2000, ANN THORAC SURG, V69, P14, DOI 10.1016/S0003-4975(99)01102-9; Lee RJ, 2000, CIRCULATION, V102, P898; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; Leor J, 2000, CIRCULATION, V102, P56; Li QH, 2001, CIRCULATION, V103, P1893; Li RK, 1999, CIRCULATION, V100, P63; Li S, 2000, GENE THER, V7, P31, DOI 10.1038/sj.gt.3301110; Losordo DW, 1998, CIRCULATION, V98, P2800, DOI 10.1161/01.CIR.98.25.2800; Mack CA, 1998, J THORAC CARDIOV SUR, V115, P168, DOI 10.1016/S0022-5223(98)70455-6; Mah C, 2002, CLIN PHARMACOKINET, V41, P901, DOI 10.2165/00003088-200241120-00001; Makino S, 1999, J CLIN INVEST, V103, P697, DOI 10.1172/JCI5298; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; Mann BK, 2001, ANAT RECORD, V263, P367, DOI 10.1002/ar.1116; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Maurice JP, 1999, J CLIN INVEST, V104, P21, DOI 10.1172/JCI6026; McDevitt TC, 2002, J BIOMED MATER RES, V60, P472, DOI 10.1002/jbm.1292; McMurray J, 2002, CIRCULATION, V105, P2099, DOI 10.1161/01.CIR.0000014763.63528.9D; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; Miao WF, 2000, J MOL CELL CARDIOL, V32, P2397, DOI 10.1006/jmcc.2000.1283; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Monahan PE, 2000, MOL MED TODAY, V6, P433, DOI 10.1016/S1357-4310(00)01810-4; Morishita R, 1997, NAT MED, V3, P894, DOI 10.1038/nm0897-894; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Nuss HB, 1999, J CLIN INVEST, V103, P889, DOI 10.1172/JCI5073; Oh H, 2003, P NATL ACAD SCI USA, V100, P12313, DOI 10.1073/pnas.2132126100; OKUDO S, 2001, CIRCULATION, V103, P877; Orlic D, 2002, CIRC RES, V91, P1092, DOI 10.1161/01.RES.0000046045.00846.B0; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Park JL, 1999, ANN THORAC SURG, V68, P1905, DOI 10.1016/S0003-4975(99)01073-5; Perin EC, 2003, CIRCULATION, V107, P2294, DOI 10.1161/01.CIR.0000070596.30552.8B; Poston RS, 1999, TRANSPLANTATION, V68, P825, DOI 10.1097/00007890-199909270-00015; Prentice H, 1997, CARDIOVASC RES, V35, P567, DOI 10.1016/S0008-6363(97)00158-2; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; Rebar EJ, 2002, NAT MED, V8, P1427, DOI 10.1038/nm795; Reinlib L, 2000, CIRCULATION, V101, pE182; Robbins PD, 1998, PHARMACOL THERAPEUT, V80, P35, DOI 10.1016/S0163-7258(98)00020-5; Rockman HA, 2002, NATURE, V415, P206, DOI 10.1038/415206a; Rosengart TK, 1999, CIRCULATION, V100, P468, DOI 10.1161/01.CIR.100.5.468; Roth DM, 2002, CIRCULATION, V105, P1989, DOI 10.1161/01.CIR.0000014968.54967.D3; Roth DM, 1999, CIRCULATION, V99, P3099, DOI 10.1161/01.CIR.99.24.3099; Shah AS, 2001, CIRCULATION, V103, P1311; Shah AS, 2000, CIRCULATION, V101, P408, DOI 10.1161/01.CIR.101.4.408; Shintani S, 2001, CIRCULATION, V103, P897, DOI 10.1161/01.CIR.103.6.897; Sodian R, 2000, CIRCULATION, V102, P22; Spinale FG, 2002, CIRC RES, V90, P520, DOI 10.1161/01.RES.0000013290.12884.A3; Srivastava D, 2000, NATURE, V407, P221, DOI 10.1038/35025190; Stamm C, 2003, LANCET, V361, P45, DOI 10.1016/S0140-6736(03)12110-1; Stein CA, 2001, J CLIN INVEST, V108, P641, DOI 10.1172/JCI13885; Stein EA, 2002, AM J MED, V112, p3s; Stepkowski SM, 2000, CURR OPIN MOL THER, V2, P304; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Su H, 2002, P NATL ACAD SCI USA, V99, P9480, DOI 10.1073/pnas.132275299; Suzuki K, 1997, J CLIN INVEST, V99, P1645, DOI 10.1172/JCI119327; Sylven Christer, 2002, J Interv Cardiol, V15, P7, DOI 10.1111/j.1540-8183.2002.tb01026.x; Symes JF, 1999, ANN THORAC SURG, V68, P830, DOI 10.1016/S0003-4975(99)00807-3; Takahashi T, 1999, NAT MED, V5, P434, DOI 10.1038/7434; Taylor DA, 2002, CIRCULATION, V106, P2, DOI 10.1161/01.CIR.0000024386.99599.4A; Toma C, 2002, CIRCULATION, V105, P93, DOI 10.1161/hc0102.101442; Tomita S, 1999, CIRCULATION, V100, P247, DOI 10.1161/01.cir.100.suppl_2.ii-247; Towbin JA, 2002, NATURE, V415, P227, DOI 10.1038/415227a; Tse HF, 2003, LANCET, V361, P47, DOI 10.1016/S0140-6736(03)12111-3; Ueda H, 1999, ANN THORAC SURG, V67, P1726, DOI 10.1016/S0003-4975(99)00279-9; Urbanek K, 2003, P NATL ACAD SCI USA, V100, P10440, DOI 10.1073/pnas.1832855100; Vale PR, 2001, CIRCULATION, V103, P2138; Wang JS, 2001, J THORAC CARDIOV SUR, V122, P699, DOI 10.1067/mtc.2001.116317; Watson RDS, 2002, BMJ-BRIT MED J, V325, P1348, DOI 10.1136/bmj.325.7376.1348; White RR, 2000, J CLIN INVEST, V106, P929, DOI 10.1172/JCI11325; Woo YJ, 1998, CIRCULATION, V98, pII255; Wright MJ, 2001, BASIC RES CARDIOL, V96, P227, DOI 10.1007/s003950170053; Yang ZQ, 2002, AM J PHYSIOL-HEART C, V282, pH949, DOI 10.1152/ajpheart.00741.2001; Yoshida T, 1996, J MOL CELL CARDIOL, V28, P1759, DOI 10.1006/jmcc.1996.0165; ZELTINGER J, 2 INT C CELLULAR ENG; Zhu HL, 2000, MOL THER, V2, P470, DOI 10.1006/mthe.2000.0193	129	53	61	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					648	663		10.1096/fj.03-1171rev	http://dx.doi.org/10.1096/fj.03-1171rev			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054087				2022-12-28	WOS:000221108800035
J	Hans, A; Bajramovic, JJ; Syan, S; Perret, E; Dunia, I; Brahic, M; Gonzalez-Dunia, D				Hans, A; Bajramovic, JJ; Syan, S; Perret, E; Dunia, I; Brahic, M; Gonzalez-Dunia, D			Persistent, non-cytolytic infection of neurons by Borna disease virus interferes with ERK 1/2 signaling and abrogates BDNF-induced synaptogenesis	FASEB JOURNAL			English	Article						neurotrophin; mitogen-activated protein kinase (MAPK)	ACTIVATED PROTEIN-KINASE; ALZHEIMERS-DISEASE; NEUROPSYCHIATRIC DISEASE; NEUROTRANSMITTER RELEASE; HIPPOCAMPAL-NEURONS; BIPOLAR DISORDER; GENE-EXPRESSION; NEUROTROPHINS; SCHIZOPHRENIA; TRANSMISSION	Infection of the central nervous system by Borna disease virus (BDV) provides a unique model to study the mechanisms whereby a persistent viral infection can impair neuronal function and cause behavioral diseases reminiscent of mood disorders, schizophrenia, or autism in humans. In the present work, we studied the effect of BDV infection on the response of hippocampal neurons, the main target for this virus, to the neurotrophin BDNF. We showed that persistent infection did not affect neuronal survival or morphology. However, it blocked BDNF-induced ERK 1/2 phosphorylation, despite normal expression of the TrkB BDNF receptor. In addition, BDNF-induced expression of synaptic vesicle proteins was abrogated, which resulted in severely impaired synaptogenesis and defects in synaptic organization. Thus, we provide the first evidence that a virus can interfere specifically with neurotrophin-regulated neuroplasticity, thereby hampering proper neuronal connectivity. These results may help to understand the behavioral disorders associated with BDV infection.	CHU Purpan, INSERM, U563, F-31059 Toulouse 3, France; Inst Pasteur, CNRS, URA 1930, Unite Virus Lents, Paris, France; Inst Pasteur, Ctr Imagerie Dynam, Paris, France; Univ Paris 07, CNRS, Inst Jacques Monod, Paris, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite	Gonzalez-Dunia, D (corresponding author), CHU Purpan, INSERM, U563, CPTP Bat B,Pl Dr Baylac, F-31059 Toulouse 3, France.	Daniel.Dunia@toulouse.inserm.fr	Bajramovic, Jeffrey/AAF-6695-2020; Dunia, Daniel/K-1090-2014	Dunia, Daniel/0000-0002-2837-7120; Bajramovic, Jeffrey/0000-0002-6504-3437				Aakalu G, 2001, NEURON, V30, P489, DOI 10.1016/S0896-6273(01)00295-1; Bajramovic JJ, 2003, J VIROL, V77, P12222, DOI 10.1128/JVI.77.22.12222-12231.2003; Bajramovic JJ, 2002, J VIROL, V76, P6268, DOI 10.1128/JVI.76.12.6268-6286.2002; Bode L, 2003, CLIN MICROBIOL REV, V16, P534, DOI 10.1128/CMR.16.3.534-545.2003; BODE L, 1995, NAT MED, V1, P232, DOI 10.1038/nm0395-232; Bode L, 2001, MOL PSYCHIATR, V6, P481, DOI 10.1038/sj.mp.4000909; CARBONE KM, 1993, J VIROL, V67, P1453, DOI 10.1128/JVI.67.3.1453-1460.1993; Carbone KM, 2001, CLIN MICROBIOL REV, V14, P513, DOI 10.1128/CMR.14.3.513-527.2001; DELATORRE JC, 1994, J VIROL, V68, P7669, DOI 10.1128/JVI.68.12.7669-7675.1994; Dietrich DE, 1998, PHARMACOPSYCHIATRY, V31, P77, DOI 10.1055/s-2007-979305; Dunia I, 1996, J CELL BIOL, V132, P701, DOI 10.1083/jcb.132.4.701; GonzalezDunia D, 1997, BRAIN RES BULL, V44, P647, DOI 10.1016/S0361-9230(97)00276-1; GonzalezDunia D, 1997, J VIROL, V71, P3208, DOI 10.1128/JVI.71.4.3208-3218.1997; GOSZTONYI G, 1995, BORNA DIS, P39; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hans A, 2001, J BIOL CHEM, V276, P7258, DOI 10.1074/jbc.M005107200; Hornig M, 1999, P NATL ACAD SCI USA, V96, P12102, DOI 10.1073/pnas.96.21.12102; Hornig M, 2001, CURR TOP MICROBIOL, V253, P157; Huang EJ, 2001, ANNU REV NEUROSCI, V24, P677, DOI 10.1146/annurev.neuro.24.1.677; Ikuta Kazuyoshi, 2002, P87; Jovanovic JN, 2000, NAT NEUROSCI, V3, P323, DOI 10.1038/73888; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; Lewin GR, 1996, ANNU REV NEUROSCI, V19, P289, DOI 10.1146/annurev.ne.19.030196.001445; Lipkin WI, 2001, TRENDS MICROBIOL, V9, P295, DOI 10.1016/S0966-842X(01)02071-6; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Masliah E, 2001, NEUROLOGY, V56, P127, DOI 10.1212/WNL.56.1.127; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Mirnics K, 2000, NEURON, V28, P53, DOI 10.1016/S0896-6273(00)00085-4; Planz O, 2001, J VIROL, V75, P4871, DOI 10.1128/JVI.75.10.4871-4877.2001; Planz Oliver, 2002, P179; Pletnikov Mikhail V., 2002, P125; Poo MM, 2001, NAT REV NEUROSCI, V2, P24, DOI 10.1038/35049004; Pozzo-Miller LD, 1999, J NEUROSCI, V19, P4972; Rizo J, 2002, NAT REV NEUROSCI, V3, P641, DOI 10.1038/nrn898; ROTT R, 1985, SCIENCE, V228, P755, DOI 10.1126/science.3922055; ROTT R, 1995, BORNA DIS, P17; SCHNEEMANN A, 1995, VIROLOGY, V210, P1, DOI 10.1006/viro.1995.1311; Schwemmle M, 1997, J BIOL CHEM, V272, P21818, DOI 10.1074/jbc.272.35.21818; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Small DH, 2001, NAT REV NEUROSCI, V2, P595, DOI 10.1038/35086072; Takei N, 1997, J NEUROCHEM, V68, P370; Tyler WJ, 2001, J NEUROSCI, V21, P4249, DOI 10.1523/JNEUROSCI.21-12-04249.2001; Vawter MP, 2002, MOL PSYCHIATR, V7, P571, DOI 10.1038/sj.mp.4001158; Vicario-Abejon C, 1998, J NEUROSCI, V18, P7256; Wu GY, 2001, NAT NEUROSCI, V4, P151, DOI 10.1038/83976; YOLKEN RH, 1995, CLIN MICROBIOL REV, V8, P131, DOI 10.1128/CMR.8.1.131; Zocher M, 2000, J NEUROVIROL, V6, P462, DOI 10.3109/13550280009091947	48	52	60	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					863	+		10.1096/fj.03-0764fje	http://dx.doi.org/10.1096/fj.03-0764fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033926				2022-12-28	WOS:000220522800010
J	Liu, YQ; Senger, DR				Liu, YQ; Senger, DR			Matrix-specific activation of Src and Rho initiates capillary morphogenesis of endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; collagen; laminin; beta 1 integrins; VE-cadherin	BINDING PROTEIN RHO; GROWTH-FACTOR; IN-VITRO; VASCULAR-PERMEABILITY; TUBE FORMATION; ALPHA(2)BETA(1) INTEGRINS; ACTIN CYTOSKELETON; EPITHELIAL-CELLS; FOCAL ADHESIONS; FAMILY KINASES	Interstitial collagen I stimulates microvascular endothelial cells to form solid cords that imitate precapillary structures found during angiogenesis. Time-lapse microscopy identified cell retraction and disruption of cell-cell contacts as early critical steps in collagen I-induced capillary morphogenesis. These early stages paralleled collagen I activation of Src kinase and GTPase Rho through beta1 integrins. The Src inhibitor PP2, dominant-negative Src, and Rho inhibitor exoenzyme C3 transferase each inhibited collagen I induction of actin stress fibers that mediate cell retraction and each inhibited capillary morphogenesis. Collagen I also disrupted VE-cadherin from intercellular junctions through a Src-dependent mechanism; both the Src inhibitor PP2 and dominant-negative Src preserved VE-cadherin localization to regions of cell-cell contact. An active Src mutant disrupted VE-cadherin and cell-cell contacts similarly to collagen I. In sharp contrast, laminin-1 did not induce capillary morphogenesis, and laminin-1 did not induce activation of Src or Rho. Rather, laminin-1 induced persistent activation of the GTPase Rac. Thus, these studies identify activation of Src and Rho as key mechanisms by which collagen I provokes capillary morphogenesis of microvascular endothelial cells, and they define marked differences between the functions of collagen I and laminin-1 in regulating endothelial cell morphogenesis.	Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Senger, DR (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Div Canc Biol & Angiogenesis, Res North,99 Brookline Ave, Boston, MA 02215 USA.	dsenger@caregroup.harvard.edu			NCI NIH HHS [CA77357] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077357] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALOISI M, 1971, VIRCHOWS ARCH B, V8, P328; ChrzanowskaWodnicka M, 1996, J CELL BIOL, V133, P1403, DOI 10.1083/jcb.133.6.1403; DELVOS U, 1982, LAB INVEST, V46, P61; Drake CJ, 1999, J HISTOCHEM CYTOCHEM, V47, P1351, DOI 10.1177/002215549904701101; Drake CJ, 1998, ANN NY ACAD SCI, V857, P155, DOI 10.1111/j.1749-6632.1998.tb10115.x; Drake CJ, 1997, DEV BIOL, V192, P17, DOI 10.1006/dbio.1997.8751; Drake CJ, 2000, BLOOD, V95, P1671, DOI 10.1182/blood.V95.5.1671.005k39_1671_1679; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Feng D, 1996, J EXP MED, V183, P1981, DOI 10.1084/jem.183.5.1981; FOUSER L, 1991, J BIOL CHEM, V266, P18345; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Ilan N, 1998, J CELL SCI, V111, P3621; Irby RB, 2002, CANCER RES, V62, P2669; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; JACKSON CJ, 1994, CELL BIOL INT, V18, P859, DOI 10.1006/cbir.1994.1122; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Le Doux JM, 2001, HUM GENE THER, V12, P1611, DOI 10.1089/10430340152528110; MONTESANO R, 1983, J CELL BIOL, V97, P1648, DOI 10.1083/jcb.97.5.1648; MONTESANO R, 2001, BAS CLIN ON, V24, P111; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Obergfell A, 2002, J CELL BIOL, V157, P265, DOI 10.1083/jcb.200112113; Owens DW, 2000, MOL BIOL CELL, V11, P51, DOI 10.1091/mbc.11.1.51; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schmidt A, 1998, ANNU REV CELL DEV BI, V14, P305, DOI 10.1146/annurev.cellbio.14.1.305; Senger DR, 2002, AM J PATHOL, V160, P195, DOI 10.1016/S0002-9440(10)64363-5; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Sweeney SM, 1998, P NATL ACAD SCI USA, V95, P7275, DOI 10.1073/pnas.95.13.7275; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; VERNON RB, 1995, AM J PATHOL, V147, P873; Whelan MC, 2003, J BIOL CHEM, V278, P327, DOI 10.1074/jbc.M207554200; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; [No title captured]	44	87	91	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					457	468		10.1096/fj.03-0948com	http://dx.doi.org/10.1096/fj.03-0948com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003991				2022-12-28	WOS:000220522800038
J	Kuwano, T; Nakao, S; Yamamoto, H; Tsuneyoshi, M; Yamamoto, T; Kuwano, M; Ono, M				Kuwano, T; Nakao, S; Yamamoto, H; Tsuneyoshi, M; Yamamoto, T; Kuwano, M; Ono, M			Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis	FASEB JOURNAL			English	Article						COX2; vascular endothelial growth factor; prostanoid; inflammatory disease	ENDOTHELIAL GROWTH-FACTOR; ACTIVATED PROTEIN-KINASE; PROSTAGLANDIN E-2; TRANSCRIPTIONAL REGULATION; NUCLEAR-FACTOR; COLON-CANCER; IN-VIVO; MACROPHAGE INFILTRATION; INTESTINAL POLYPOSIS; TUMOR-GROWTH	Cyclooxygenase1 (COX1) and COX2 mediate the rate-limiting step in arachidonic acid metabolism. Expression of COX2 mRNA and protein is often enhanced in various human cell types by inflammatory cytokines such as interleukin-1beta (IL-1beta) and tumor necrosis factor alpha (TNFalpha). IL-1beta enhanced expression of various prostanoids and this expression was blocked by COX2 selective inhibitors. IL-1beta markedly induced angiogenesis in vitro and in vivo, which was significantly inhibited by COX2 selective inhibitors but not by a vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor. In contrast, COX2 selective inhibitors only partially blocked VEGF-induced angiogenesis. EP2, EP4 (prostaglandin E2 receptors) agonists and thromboxane A2 (TXA2) receptor agonists induced angiogenesis in vitro and in vivo; IL-1beta-induced angiogenesis was blocked by an EP4 antagonist and a TXA2 receptor antagonist. IL-1beta induced much less angiogenesis in cornea of COX2 knockout mice than that of wild-type mice. This is the first report that COX2 and some prostanoids play a key role in IL-1beta-induced angiogenesis.	Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Anat Pathol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Pathol Sci, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Otorhinolaryngol, Higashi Ku, Fukuoka 8128582, Japan; Kurume Univ, Res Ctr Innovat Canc Therapy, Fukuoka 8300011, Japan	Kyushu University; Kyushu University; Kyushu University; Kyushu University; Kurume University	Ono, M (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Med Biochem, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	mayumi@biochem1.med.kyushu-u.ac.jp						Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Arslan A, 1996, PROSTAGLANDINS, V52, P463, DOI 10.1016/S0090-6980(96)00125-6; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; BENAV P, 1995, FEBS LETT, V372, P83, DOI 10.1016/0014-5793(95)00956-A; Bol DK, 2002, CANCER RES, V62, P2516; Caivano M, 2000, J IMMUNOL, V164, P3018, DOI 10.4049/jimmunol.164.6.3018; Cheng T, 1998, INVEST OPHTH VIS SCI, V39, P581; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Crofford LJ, 1997, ARTHRITIS RHEUM-US, V40, P226, DOI 10.1002/art.1780400207; Daniel TO, 1999, CANCER RES, V59, P4574; Davis BJ, 1999, ENDOCRINOLOGY, V140, P2685, DOI 10.1210/en.140.6.2685; Dequeker J, 1998, BRIT J RHEUMATOL, V37, P946; Fiebich BL, 2000, J NEUROCHEM, V75, P2020, DOI 10.1046/j.1471-4159.2000.0752020.x; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; GRAEBER JE, 1990, PROSTAGLANDINS, V39, P665, DOI 10.1016/0090-6980(90)90026-R; He H, 1999, J BIOL CHEM, V274, P25130, DOI 10.1074/jbc.274.35.25130; Hirata A, 2002, CANCER RES, V62, P2554; INOUE H, 1995, J BIOL CHEM, V270, P24965, DOI 10.1074/jbc.270.42.24965; Itokawa T, 2002, MOL CANCER THER, V1, P295; Kakiuchi Y, 2002, CANCER RES, V62, P1567; Kawai S, 1998, Nihon Rinsho, V56, P782; Kirtikara K, 2000, MOL CELL BIOCHEM, V203, P41, DOI 10.1023/A:1007045600664; Majima M, 2000, BRIT J PHARMACOL, V130, P641, DOI 10.1038/sj.bjp.0703327; Masferrer JL, 1999, ANN NY ACAD SCI, V889, P84, DOI 10.1111/j.1749-6632.1999.tb08726.x; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Murata H, 1999, AM J GASTROENTEROL, V94, P451; Nakao S, 2003, J IMMUNOL, V170, P5704, DOI 10.4049/jimmunol.170.11.5704; Ogawa S, 1999, Angiogenesis, V3, P327, DOI 10.1023/A:1026554404941; Ono M, 1999, CANCER CHEMOTH PHARM, V43, pS69, DOI 10.1007/s002800051101; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Reddy BS, 2000, DRUG AGING, V16, P329, DOI 10.2165/00002512-200016050-00002; RICHARDS RG, 1994, INFLAMMATION, V18, P203, DOI 10.1007/BF01534561; Riendeau D, 1997, BRIT J PHARMACOL, V121, P105, DOI 10.1038/sj.bjp.0701076; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; SANO H, 1995, CANCER RES, V55, P3785; Sawaoka H, 1999, LAB INVEST, V79, P1469; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Tanaka Y, 1997, BIOL PHARM BULL, V20, P322; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.3.CO;2-D; Tsuji S, 1998, Nihon Rinsho, V56, P2247; Tsuji S, 2001, J EXP CLIN CANC RES, V20, P117; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Wadleigh DJ, 1999, BIOCHEM BIOPH RES CO, V264, P865, DOI 10.1006/bbrc.1999.1606; Wakitani K, 1998, JPN J PHARMACOL, V78, P365, DOI 10.1254/jjp.78.365; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Williams CS, 1996, AM J PHYSIOL-GASTR L, V270, pG393; Xue YW, 2003, WORLD J GASTROENTERO, V9, P250, DOI 10.3748/wjg.v9.i2.250; Yano S, 2003, CANCER SCI, V94, P244, DOI 10.1111/j.1349-7006.2003.tb01428.x; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang XP, 1999, J EXP MED, V190, P451, DOI 10.1084/jem.190.4.451	53	234	249	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					300	310		10.1096/fj.03-0473com	http://dx.doi.org/10.1096/fj.03-0473com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769824				2022-12-28	WOS:000220425000010
J	Mackenzie, GG; Carrasquedo, F; Delfino, JM; Keen, CL; Fraga, CG; Oteiza, PI				Mackenzie, GG; Carrasquedo, F; Delfino, JM; Keen, CL; Fraga, CG; Oteiza, PI			Epicatechin, catechin, and dimeric procyanidins inhibit PMA-induced NF-kappa B activation at multiple steps in Jurkat T cells	FASEB JOURNAL			English	Article						(-)-epicatechin; (+)-catechin; dimeric procyanidin; immune response; IL-2	GENE-EXPRESSION; ANTIOXIDANT ACTIVITY; COCOA PROCYANIDINS; HUMAN PLASMA; KINASE-BETA; TRANSCRIPTION; POLYPHENOLS; CHOCOLATE; INTERLEUKIN-2; ALPHA	The capacity of the flavan-3-ols [(-)-epicatechin (EC) and (+)-catechin (CT)] and a B dimeric procyanidin (DP-B) to modulate phorbol 12-myristate 13-acetate (PMA)-induced NF-kappa B activation in Jurkat T cells was investigated. The classic PMA-triggered increase in cell oxidants was prevented when cells were preincubated for 24 h with EC, CT, or DP-B (1.7-17.2 mu M). PMA induced the phosphorylation of IKK beta and the subsequent degradation Of I kappa B alpha: These events were inhibited in cells pretreated with the flavonoids. PMA induced a 4.6-fold increase in NF-kappa B nuclear binding activity in control cells. Pretreatment with EC, CT, or DP-B decreased PMA-induced NF-kappa B binding activity and the transactivation of the NF-kappa B-driven gene IL-2. EC, CT, and DP-B inhibited, in vitro, NF-kappa B binding to its DNA consensus sequence, but they had no effect on the binding activity of CREB or OCT-1. Thus, EC, CT, or DP-B can influence the immune response by modulating NF-kappa B activation. This modulation can occur at early (regulation of oxidant levels, IKK activation) as well as late (binding of NF-kappa B to DNA) stages of the NF-kappa B activation cascade. A model is presented for possible interactions between DP-B and NF-kappa B proteins, which could lead to the inhibition of NF-kappa B binding to kappa B sites.	Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Univ Calif Davis, Dept Environm Toxicol, Davis, CA 95616 USA; Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA; Univ Buenos Aires, Fac Farm & Bioquim, Consejo Nacl Invest Cient & Tecn, Programa Rad Libres, RA-1113 Buenos Aires, DF, Argentina; Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, Inst Quim & Fisicoquim Biol, RA-1113 Buenos Aires, DF, Argentina	University of California System; University of California Davis; University of California System; University of California Davis; University of California System; University of California Davis; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires	Oteiza, PI (corresponding author), Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.	poteiza@ucdavis.edu	Fraga, Cesar/Q-8161-2019; Mackenzie, Gerardo G/AAW-5114-2020		University of Buenos Aires, Argentina [B054, BO42]; Mars, Inc., Hackettstown, NJ; National Institutes of Health, Bethesda, MD [DK35747]	University of Buenos Aires, Argentina(University of Buenos Aires); Mars, Inc., Hackettstown, NJ; National Institutes of Health, Bethesda, MD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by grants (B054 and BO42) from the University of Buenos Aires, Argentina; Mars, Inc., Hackettstown, NJ; the National Institutes of Health (DK35747), Bethesda, MD. G. G. Mackenzie is a fellow from the University of Buenos Aires, Argentina.	Adamson GE, 1999, J AGR FOOD CHEM, V47, P4184, DOI 10.1021/jf990317m; Arighi CN, 1998, BIOCHEMISTRY-US, V37, P16802, DOI 10.1021/bi981827x; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Bowie A, 2000, BIOCHEM PHARMACOL, V59, P13, DOI 10.1016/S0006-2952(99)00296-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHANG G, 1989, J AM CHEM SOC, V111, P4379, DOI 10.1021/ja00194a035; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Chen YC, 2000, BIOCHEM PHARMACOL, V59, P1445, DOI 10.1016/S0006-2952(00)00255-0; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Dhanalakshmi S, 2002, ONCOGENE, V21, P1759, DOI 10.1038/sj.onc.1205240; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ginn-Pease ME, 1998, FREE RADICAL BIO MED, V25, P346, DOI 10.1016/S0891-5849(98)00067-7; Hammerstone JF, 2000, J NUTR, V130, p2086S, DOI 10.1093/jn/130.8.2086S; Han SH, 1998, J PHARMACOL EXP THER, V287, P1105; Heiss C, 2003, JAMA-J AM MED ASSOC, V290, P1030, DOI 10.1001/jama.290.8.1030; Holt RR, 2002, AM J CLIN NUTR, V76, P798, DOI 10.1093/ajcn/76.4.798; Holt RR, 2002, JAMA-J AM MED ASSOC, V287, P2212, DOI 10.1001/jama.287.17.2212; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Kondo K, 1996, LANCET, V348, P1514, DOI 10.1016/S0140-6736(05)65927-2; Kris-Etherton PM, 2002, CURR OPIN LIPIDOL, V13, P41, DOI 10.1097/00041433-200202000-00007; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; LEONARD WJ, 1985, P NATL ACAD SCI USA, V82, P6281, DOI 10.1073/pnas.82.18.6281; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Lotito SB, 2000, BIOCHEM BIOPH RES CO, V276, P945, DOI 10.1006/bbrc.2000.3571; Lotito SB, 1998, FREE RADICAL BIO MED, V24, P435, DOI 10.1016/S0891-5849(97)00276-1; Mackenzie GG, 2002, J BIOL CHEM, V277, P34610, DOI 10.1074/jbc.M203616200; Mao T, 2000, J MED FOOD, V3, P107, DOI DOI 10.1089/; Mao TK, 1999, INT J IMMUNOTHER, V15, P23; Mao TK, 2000, LIFE SCI, V66, P1377, DOI 10.1016/S0024-3205(00)00449-5; MOHAMADI F, 1990, J COMPUT CHEM, V11, P440, DOI 10.1002/jcc.540110405; Moran LK, 2001, CURR MED CHEM, V8, P763, DOI 10.2174/0929867013372904; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park YC, 2000, FEBS LETT, V465, P93, DOI 10.1016/S0014-5793(99)01735-4; Rein D, 2000, J NUTR, V130, p2109S, DOI 10.1093/jn/130.8.2109S; Ren H, 2002, J IMMUNOL, V168, P3721, DOI 10.4049/jimmunol.168.8.3721; Rice-Evans C, 2001, CURR MED CHEM, V8, P797, DOI 10.2174/0929867013373011; ROSETTE C, 1995, J CELL BIOL, V128, P1111, DOI 10.1083/jcb.128.6.1111; Saliou C, 2001, METHOD ENZYMOL, V335, P380; Sanbongi C, 1997, CELL IMMUNOL, V177, P129, DOI 10.1006/cimm.1997.1109; Santos-Buelga C, 2000, J SCI FOOD AGR, V80, P1094, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;1094::AID-JSFA569&gt;3.0.CO;2-1, 10.1002/(SICI)1097-0010(20000515)80:7<1094::AID-JSFA569>3.3.CO;2-T]; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Singh R, 2002, ARTHRITIS RHEUM, V46, P2079, DOI 10.1002/art.10443; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STILL WC, 1990, J AM CHEM SOC, V112, P6127, DOI 10.1021/ja00172a038; Taubert D, 2003, JAMA-J AM MED ASSOC, V290, P1029, DOI 10.1001/jama.290.8.1029; Waterhouse AL, 1996, LANCET, V348, P834, DOI 10.1016/S0140-6736(05)65262-2; Weisburger JH, 2001, EXP BIOL MED, V226, P891, DOI 10.1177/153537020122601003; Yang FJ, 1998, J NUTR, V128, P2334, DOI 10.1093/jn/128.12.2334; Zhao W, 1999, TOXICOL APPL PHARM, V154, P153, DOI 10.1006/taap.1998.8545	54	155	165	2	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					167	169		10.1096/fj.03-0402fje	http://dx.doi.org/10.1096/fj.03-0402fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630700				2022-12-28	WOS:000188829300063
J	Belevych, AE; Juranek, I; Harvey, RD				Belevych, AE; Juranek, I; Harvey, RD			Protein kinase C regulates functional coupling of beta(1)-adrenergic receptors to G(i/o)-mediated responses in cardiac myocytes	FASEB JOURNAL			English	Article						inhibitory G(i/o) proteins; L-type Ca2+ channels; dual coupling; beta-adrenergic regulation	PERTUSSIS-TOXIN; BETA(2)-ADRENERGIC RECEPTORS; VENTRICULAR MYOCYTES; ACTIVATION; EXPRESSION; ISOFORMS; PHOSPHORYLATION; DESENSITIZATION; MECHANISM; CHANNELS	The effect of protein kinase C (PKC) activation on beta(1)-adrenergic receptor (beta(1)-AR) regulation of the cardiac L-type Ca2+ current (I-Ca,I-L) was studied using the whole-cell patch clamp technique. Treatment of guinea pig ventricular myocytes with phorbol-12,13-dibutyrate (PDBu) caused a significant decrease in I-Ca,I-L sensitivity to stimulation by submaximal beta(1)-AR activation using isoproterenol (Iso). This decrease in sensitivity was also associated with the ability of higher concentrations of Iso to directly inhibit the stimulatory response. PDBu treatment produced similar effects on H-2 histamine receptor-mediated I-Ca,I-L responses. In the presence of PDBu, higher concentrations of Iso inhibited the histamine stimulated I-Ca,I-L, and this effect was blocked by a selective beta(1)-AR antagonist. Higher concentrations of histamine also inhibited the Iso stimulated I-Ca,I-L, and this effect was blocked by a selective H-2 receptor antagonist. The effects of PDBu were blocked by the PKC inhibitor bisindolylmaleimide I, and they were not mimicked by the inactive phorbol ester 4alpha-phorbol-12,13-didecanoate. The inhibitory effects of Iso and histamine were significantly reduced when G(i/o) mediated responses were blocked with pertussis toxin. These results suggest that PKC promotes coupling of cardiac beta(1)-adrenergic and H-2 histamine receptors to G(i/o) mediated inhibitory responses.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Harvey, RD (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 2109 Adelbert Rd, Cleveland, OH 44106 USA.	rdh3@cwru.edu	Harvey, Robert D/L-8496-2016	Harvey, Robert D/0000-0002-8499-8765; Belevych, Andriy/0000-0002-1272-5784				Akaishi Y, 1997, J MOL CELL CARDIOL, V29, P765, DOI 10.1006/jmcc.1996.0315; Belevych AE, 2003, BIOPHYS J, V84, p538A; Belevych AE, 2002, MOL PHARMACOL, V62, P554, DOI 10.1124/mol.62.3.554; Belevych AE, 2001, J PHYSIOL-LONDON, V536, P677, DOI 10.1111/j.1469-7793.2001.00677.x; BOHM M, 1992, BASIC RES CARDIOL, V87, P37; Bowling N, 1999, CIRCULATION, V99, P384, DOI 10.1161/01.CIR.99.3.384; Brodde OE, 1999, PHARMACOL REV, V51, P651; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Cai JJ, 1996, MOL PHARMACOL, V49, P81; Chakraborti S, 2000, CELL SIGNAL, V12, P499, DOI 10.1016/S0898-6568(00)00087-5; Chen XW, 2002, CIRC RES, V91, P517, DOI 10.1161/01.RES.0000033988.13062.7C; CHUANG TT, 1995, J BIOL CHEM, V270, P18660, DOI 10.1074/jbc.270.31.18660; Communal C, 1999, CIRCULATION, V100, P2210, DOI 10.1161/01.CIR.100.22.2210; Daaka Y, 1997, NATURE, V390, P88, DOI 10.1038/36362; Dzimiri N, 1999, PHARMACOL REV, V51, P465; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Gauthier C, 2000, TRENDS PHARMACOL SCI, V21, P426, DOI 10.1016/S0165-6147(00)01562-5; Gauthier C, 1996, J CLIN INVEST, V98, P556, DOI 10.1172/JCI118823; Goldberg M, 1997, J CLIN INVEST, V99, P55, DOI 10.1172/JCI119133; Hemmings HC, 1998, TOXICOL LETT, V101, P89, DOI 10.1016/S0378-4274(98)00170-2; HESCHELER J, 1987, PFLUG ARCH EUR J PHY, V410, P23, DOI 10.1007/BF00581891; HESCHELER J, 1986, PFLUG ARCH EUR J PHY, V407, P182, DOI 10.1007/BF00580674; Hool LC, 1997, AM J PHYSIOL-HEART C, V273, pH1669, DOI 10.1152/ajpheart.1997.273.4.H1669; Kamp TJ, 2000, CIRC RES, V87, P1095, DOI 10.1161/01.RES.87.12.1095; Kaumann AJ, 1997, TRENDS PHARMACOL SCI, V18, P70, DOI 10.1016/S0165-6147(96)01033-4; Kilts JD, 2000, CIRC RES, V87, P705, DOI 10.1161/01.RES.87.8.705; Koch WJ, 1996, CIRC RES, V78, P511, DOI 10.1161/01.RES.78.4.511; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; NEUMANN J, 1988, LANCET, V2, P936; OUADID H, 1995, J CARDIOVASC PHARM, V25, P282, DOI 10.1097/00005344-199502000-00014; Paul K, 1997, CIRC RES, V81, P643; Richard S, 1998, CARDIOVASC RES, V37, P300, DOI 10.1016/S0008-6363(97)00273-3; Rohde S, 2000, J MOL CELL CARDIOL, V32, P1193, DOI 10.1006/jmcc.2000.1153; Schwartz DD, 1997, J CARDIOVASC PHARM, V29, P257, DOI 10.1097/00005344-199702000-00015; Shin HG, 2000, CARDIOVASC RES, V48, P285, DOI 10.1016/S0008-6363(00)00185-1; Takeishi Y, 1999, CIRC RES, V85, P264, DOI 10.1161/01.RES.85.3.264; UNGERER M, 1993, CIRCULATION, V87, P454, DOI 10.1161/01.CIR.87.2.454; van der Goot H, 2000, EUR J MED CHEM, V35, P5, DOI 10.1016/S0223-5234(00)00101-X; Wang JW, 1999, CAN J CARDIOL, V15, P683; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105; Xiao RP, 1999, CIRC RES, V84, P43; XIAO RP, 1995, MOL PHARMACOL, V47, P322; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	43	14	15	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					367	+		10.1096/fj.03-0647fje	http://dx.doi.org/10.1096/fj.03-0647fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688202				2022-12-28	WOS:000188067500008
J	Schechner, JS; Crane, SK; Wang, FY; Szeglin, AM; Tellides, G; Lorber, MI; Bothwell, ALM; Pober, JS				Schechner, JS; Crane, SK; Wang, FY; Szeglin, AM; Tellides, G; Lorber, MI; Bothwell, ALM; Pober, JS			Engraftment of a vascularized human skin equivalent	FASEB JOURNAL			English	Article						transplantation; HUVEC; vascularization	ENDOTHELIAL GROWTH-FACTOR; CULTURED KERATINOCYTES; FULL-THICKNESS; VENOUS ULCERS; ATHYMIC MICE; IN-VITRO; ANGIOGENESIS; SUBSTITUTES; GRAFTS; TISSUE	Clinical performance of currently available human skin equivalents is limited by failure to develop perfusion. To address this problem we have developed a method of endothelial cell transplantation that promotes vascularization of human skin equivalents in vivo. Enhancement of vascularization by Bcl-2 overexpression was demonstrated by seeding human acellular dermis grafts with human umbilical vein endothelial cells (HUVEC) transduced with the survival gene Bcl-2 or an EGFP control transgene, and subcutaneous implantation in immunodeficient mice (n=18). After 1 month the grafts with Bcl-2-transduced cells contained a significantly greater density of perfused HUVEC-lined microvessels (55.0/mm(3)) than controls (25.4/mm(3), P= 0.026). Vascularized skin equivalents were then constructed by sequentially seeding the apical and basal surfaces of acellular dermis with cultured human keratinocytes and Bcl-2-transduced HUVEC, respectively. Two weeks after orthotopic implantation onto mice, 75% of grafts (n=16) displayed both a differentiated human epidermis and perfusion through HUVEC-lined microvessels. These vessels, which showed evidence of progressive maturation, accelerated the rate of graft vascularization. Successful transplantation of such vascularized human skin equivalents should enhance clinical utility, especially in recipients with impaired angiogenesis.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Interdepartmental Program Vasc Biol, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Schechner, JS (corresponding author), Yale Univ, Sch Med, Dept Dermatol, POB 208059, New Haven, CT 06520 USA.	jeffrey.schechner@yale.edu			NHLBI NIH HHS [HL51014] Funding Source: Medline; NIAMS NIH HHS [AR02134, P30 AR4192] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K08AR002134] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; Balasubramani M, 2001, BURNS, V27, P534, DOI 10.1016/S0305-4179(01)00018-3; BELL E, 1981, SCIENCE, V211, P1052, DOI 10.1126/science.7008197; Black AF, 1998, FASEB J, V12, P1331, DOI 10.1096/fasebj.12.13.1331; BOYCE ST, 1995, ANN SURG, V222, P743, DOI 10.1097/00000658-199512000-00008; Brem H, 2000, ARCH SURG-CHICAGO, V135, P627, DOI 10.1001/archsurg.135.6.627; Carmeliet P, 2000, NAT MED, V6, P1102, DOI 10.1038/80430; DEMARCHEZ M, 1992, TRANSPLANTATION, V54, P317, DOI 10.1097/00007890-199208000-00023; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; EAGLSTEIN WH, 1995, DERMATOL SURG, V21, P839, DOI 10.1111/j.1524-4725.1995.tb00709.x; Erdag G, 2002, TRANSPLANTATION, V73, P519, DOI 10.1097/00007890-200202270-00005; Falabella AF, 2000, ARCH DERMATOL, V136, P1225, DOI 10.1001/archderm.136.10.1225; Falanga V, 1998, ARCH DERMATOL, V134, P293, DOI 10.1001/archderm.134.3.293; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; KREJCI NC, 1991, J INVEST DERMATOL, V97, P843, DOI 10.1111/1523-1747.ep12491522; LANGDON RC, 1988, J INVEST DERMATOL, V91, P478, DOI 10.1111/1523-1747.ep12476623; Medalie DA, 1996, J INVEST DERMATOL, V107, P121, DOI 10.1111/1523-1747.ep12298363; Medalie DA, 1997, TRANSPLANTATION, V64, P454, DOI 10.1097/00007890-199708150-00015; Nor JE, 1999, AM J PATHOL, V154, P375, DOI 10.1016/S0002-9440(10)65284-4; Phillips T, 2002, ARCH DERMATOL, V138, P1079, DOI 10.1001/archderm.138.8.1079; Pollman MJ, 1999, J CELL PHYSIOL, V178, P359, DOI 10.1002/(SICI)1097-4652(199903)178:3<359::AID-JCP10>3.3.CO;2-F; Schechner JS, 2000, P NATL ACAD SCI USA, V97, P9191, DOI 10.1073/pnas.150242297; Sheridan RL, 2001, BURNS, V27, P421, DOI 10.1016/S0305-4179(00)00156-X; Supp DM, 2000, J INVEST DERMATOL, V114, P5, DOI 10.1046/j.1523-1747.2000.00824.x; Supp DM, 2002, FASEB J, V16, DOI 10.1096/fj.01-0868com; Supp Dorothy M., 2002, Journal of Burn Care & Rehabilitation, V23, P10, DOI 10.1097/00004630-200201000-00004; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANNAS IV, 1982, SCIENCE, V215, P174, DOI 10.1126/science.7031899; Young D. M., 1996, Journal of Burn Care and Rehabilitation, V17, P305, DOI 10.1097/00004630-199607000-00005	32	66	72	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2250	2256		10.1096/fj.03-0257com	http://dx.doi.org/10.1096/fj.03-0257com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656987				2022-12-28	WOS:000188067500046
J	Cadet, JL; Jayanthi, S; Deng, XL				Cadet, JL; Jayanthi, S; Deng, XL			Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis	FASEB JOURNAL			English	Review						Bcl-2 family proteins; cDNA array; IEGs; mitochondria; endoplasmic reticulum; neurodegeneration; terminal apoptosis	INDUCED DOPAMINERGIC NEUROTOXICITY; NITRIC-OXIDE SYNTHASE; TRYPTOPHAN-HYDROXYLASE ACTIVITY; PERMEABILITY TRANSITION PORE; ZINC SUPEROXIDE-DISMUTASE; BCL-2 FAMILY PROTEINS; RAT-BRAIN; C-FOS; CYTOCHROME-C; MOUSE-BRAIN	Methamphetamine (METH) is a drug of abuse that has long been known to damage monoaminergic systems in the mammalian brain. Recent reports have provided conclusive evidence that METH can cause neuropathological changes in the rodent brain via apoptotic mechanisms akin to those reported in various models of neuronal death. The purpose of this review is to provide an interim account for a role of oxygen-based radicals and the participation of transcription factors and the involvement of cell death genes in METH-induced neurodegeneration. We discuss data suggesting the participation of endoplasmic reticulum and mitochondria-mediated activation of caspase-dependent and -independent cascades in the manifestation of METH-induced apoptosis. Studies that use more comprehensive approaches to gene expression profiling should allow us to draw more instructive molecular portraits of the complex plastic and degenerative effects of this drug.	NIDA, Mol Neuropsychiat Branch, NIH, Intramural Res Program,DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Branch, NIH, Intramural Res Program,DHHS, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	jcadet@intra.nida.nih.gov	Jayanthi, Subramaniam/ABI-4023-2020	Jayanthi, Subramaniam/0000-0002-5209-303X	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000174, Z01DA000153, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Albers DS, 1995, J PHARMACOL EXP THER, V275, P1104; ALI SF, 1993, DEV BRAIN RES, V73, P25, DOI 10.1016/0165-3806(93)90042-9; Allen RT, 1998, CELL MOL LIFE SCI, V54, P427, DOI 10.1007/s000180050171; Asanuma M, 2000, MOL BRAIN RES, V80, P237, DOI 10.1016/S0169-328X(00)00128-5; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; AXT KJ, 1991, SYNAPSE, V9, P302, DOI 10.1002/syn.890090405; BAKHIT C, 1981, NEUROPHARMACOLOGY, V20, P1135, DOI 10.1016/0028-3908(81)90053-8; BALDWIN HA, 1993, BRIT J PHARMACOL, V108, P590, DOI 10.1111/j.1476-5381.1993.tb12847.x; BECKMAN JS, 1991, J DEV PHYSIOL, V15, P53; Bhattacharya R, 2002, DNA REPAIR, V1, P955, DOI 10.1016/S1568-7864(02)00147-7; Bokemeyer D, 1996, J BIOL CHEM, V271, P639, DOI 10.1074/jbc.271.2.639; BOWYER JF, 1994, J PHARMACOL EXP THER, V268, P1571; BOYD JM, 1995, ONCOGENE, V11, P1921; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; CADET JL, 1994, ANN NY ACAD SCI, V738, P388; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2002, SYNAPSE, V44, P211, DOI 10.1002/syn.10074; CADET JL, 1994, J NEUROCHEM, V62, P380; Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cadet JL, 2003, GLUTAMATE ADDICTION, P201; Caldwell MA, 2001, NAT BIOTECHNOL, V19, P475, DOI 10.1038/88158; Callahan BT, 2001, J NEUROCHEM, V77, P1348, DOI 10.1046/j.1471-4159.2001.00341.x; Cappon GD, 2000, BRAIN RES, V863, P106, DOI 10.1016/S0006-8993(00)02107-7; Cass WA, 1999, J NEUROSCI, V19, P7653, DOI 10.1523/JNEUROSCI.19-17-07653.1999; Cass WA, 1996, J NEUROSCI, V16, P8132; Cass WA, 2000, ANN NY ACAD SCI, V914, P127, DOI 10.1111/j.1749-6632.2000.tb05190.x; CHAN P, 1994, J NEUROCHEM, V62, P2484, DOI 10.1046/j.1471-4159.1994.62062484.x; Chapman DE, 2001, J PHARMACOL EXP THER, V296, P520; Cho AK, 2001, SYNAPSE, V39, P161, DOI 10.1002/1098-2396(200102)39:2<161::AID-SYN7>3.0.CO;2-E; Chynn K Y, 1968, Invest Radiol, V3, P275; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; CONCI F, 1988, ITAL J NEUROL SCI, V9, P77, DOI 10.1007/BF02334412; CONNELL PH, 1968, P ROY SOC MED, V61, P178, DOI 10.1177/003591576806100228; CUBELLS JF, 1994, J NEUROSCI, V14, P2260, DOI 10.1523/jneurosci.14-04-02260.1994; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; DAWSON VL, 1993, J NEUROSCI, V13, P2651; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; DERLET R W, 1989, Journal of Emergency Medicine, V7, P157, DOI 10.1016/0736-4679(89)90263-1; DEVITO MJ, 1989, NEUROPHARMACOLOGY, V28, P1145, DOI 10.1016/0028-3908(89)90130-5; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Eisch AJ, 1998, SYNAPSE, V30, P433, DOI 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.3.CO;2-F; ELLINWOO.EH, 1971, SCIENCE, V171, P420, DOI 10.1126/science.171.3969.420; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; Everitt BJ, 2002, J NEUROSCI, V22, P3312; FARFEL GM, 1995, J PHARMACOL EXP THER, V272, P868; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Figueredo-Cardenas G, 1998, EXP NEUROL, V149, P356, DOI 10.1006/exnr.1997.6724; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V282, P834; Fleckenstein AE, 1999, EUR J PHARMACOL, V382, P45, DOI 10.1016/S0014-2999(99)00588-9; Fleckenstein AE, 1997, J PHARMACOL EXP THER, V283, P281; Fleckenstein AE, 1997, EUR J PHARMACOL, V324, P179, DOI 10.1016/S0014-2999(97)00081-2; FORNACE AJ, 1989, MOL CELL BIOL, V9, P851, DOI 10.1128/MCB.9.2.851; Frey K, 1997, EUR J PHARMACOL, V334, P273, DOI 10.1016/S0014-2999(97)01152-7; Fridovich I, 1997, J BIOL CHEM, V272, P18515, DOI 10.1074/jbc.272.30.18515; Friedman SD, 1998, PHARMACOL BIOCHEM BE, V61, P35, DOI 10.1016/S0091-3057(98)00066-5; FUKUI K, 1989, BRAIN RES, V482, P198, DOI 10.1016/0006-8993(89)90562-3; Fukumura M, 1998, BRAIN RES, V806, P1, DOI 10.1016/S0006-8993(98)00656-8; Fukunaga K, 1998, MOL NEUROBIOL, V16, P79, DOI 10.1007/BF02740604; Fumagalli F, 1998, J NEUROSCI, V18, P4861; Fumagalli F, 1999, J NEUROSCI, V19, P2424; Gamaley IA, 1999, INT REV CYTOL, V188, P203; GIOVANNI A, 1995, J NEUROCHEM, V64, P1819; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; GU H, 1994, J BIOL CHEM, V269, P7124; Hall W, 1996, ADDICTION, V91, P81, DOI 10.1046/j.1360-0443.1996.9118110.x; Harvey DC, 2000, BRAIN RES, V871, P259, DOI 10.1016/S0006-8993(00)02439-2; Hayashi T, 2001, SYNAPSE, V39, P305, DOI 10.1002/1098-2396(20010315)39:4<305::AID-SYN1013>3.0.CO;2-E; Hebert MA, 2000, ANN NY ACAD SCI, V914, P238, DOI 10.1111/j.1749-6632.2000.tb05200.x; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Hirata H, 1996, BRAIN RES, V714, P95, DOI 10.1016/0006-8993(95)01502-7; Hirata H, 1998, MOL BRAIN RES, V58, P209, DOI 10.1016/S0169-328X(98)00055-2; HOTCHKISS A, 1980, EUR J PHARMACOL, V66, P201, DOI 10.1016/0014-2999(80)90143-0; HOTCHKISS AJ, 1980, J PHARMACOL EXP THER, V214, P257; Imam SZ, 2001, J NEUROCHEM, V78, P952, DOI 10.1046/j.1471-4159.2001.00477.x; Imam SZ, 2001, J NEUROCHEM, V76, P745, DOI 10.1046/j.1471-4159.2001.00029.x; Itzhak Y, 2002, ANN NY ACAD SCI, V965, P127; Itzhak Y, 2002, PROG NEURO-PSYCHOPH, V26, P1177, DOI 10.1016/S0278-5846(02)00257-9; Itzhak Y, 2000, ANN NY ACAD SCI, V914, P104, DOI 10.1111/j.1749-6632.2000.tb05188.x; Itzhak Y, 1998, J PHARMACOL EXP THER, V284, P1040; Itzhak Y, 2000, NEUROREPORT, V11, P2943, DOI 10.1097/00001756-200009110-00022; Janicke RU, 1998, J BIOL CHEM, V273, P15540, DOI 10.1074/jbc.273.25.15540; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; Jayanthi S, 1999, NEUROSCIENCE, V91, P1379, DOI 10.1016/S0306-4522(98)00698-8; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jayanthi S, 2002, MOL PHARMACOL, V61, P1124, DOI 10.1124/mol.61.5.1124; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; Jones SR, 1998, J NEUROSCI, V18, P1979; Kaina B, 1997, CANCER RES, V57, P2721; KALANT H, 1975, CAN MED ASSOC J, V112, P299; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Kelekar A, 1997, MOL CELL BIOL, V17, P7040, DOI 10.1128/MCB.17.12.7040; KIRKSEY DF, 1979, BRIT J PHARMACOL, V67, P387, DOI 10.1111/j.1476-5381.1979.tb08692.x; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOCH RA, 1994, J NEUROSCI, V14, P2585; KOGAN FJ, 1976, EUR J PHARMACOL, V36, P363, DOI 10.1016/0014-2999(76)90090-X; Kokoshka JM, 2000, J NEUROCHEM, V75, P2095, DOI 10.1046/j.1471-4159.2000.0752095.x; Kokoshka JM, 1998, BRAIN RES, V799, P78, DOI 10.1016/S0006-8993(98)00472-7; Kokoshka JM, 1998, EUR J PHARMACOL, V361, P269, DOI 10.1016/S0014-2999(98)00741-9; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAMER JC, 1967, J AMER MED ASSOC, V201, P305, DOI 10.1001/jama.201.5.305; KRUEGER BK, 1990, J NEUROCHEM, V55, P260, DOI 10.1111/j.1471-4159.1990.tb08847.x; Lackinger D, 2001, MUTAGENESIS, V16, P233, DOI 10.1093/mutage/16.3.233; Lan KC, 1998, J FORMOS MED ASSOC, V97, P528; LaVoie MJ, 1999, J NEUROSCI, V19, P1484, DOI 10.1523/jneurosci.19-04-01484.1999; Logan BK, 2001, J ANAL TOXICOL, V25, P400, DOI 10.1093/jat/25.5.400; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; MAREK GJ, 1990, BRAIN RES, V516, P1, DOI 10.1016/0006-8993(90)90889-J; MAREK GJ, 1990, PHARMACOL BIOCHEM BE, V36, P187, DOI 10.1016/0091-3057(90)90147-A; MAREK GJ, 1990, BRAIN RES, V513, P274, DOI 10.1016/0006-8993(90)90467-P; MARSHALL JF, 1993, J NEURAL TRANSM-GEN, V91, P241, DOI 10.1007/BF01245234; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Mashima T, 1999, ONCOGENE, V18, P2423, DOI 10.1038/sj.onc.1202558; McCann UD, 1998, J NEUROSCI, V18, P8417; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; Melega WP, 1997, BRAIN RES, V766, P113, DOI 10.1016/S0006-8993(97)00548-9; Melega WP, 2000, SYNAPSE, V35, P243, DOI 10.1002/(SICI)1098-2396(20000315)35:4<243::AID-SYN1>3.0.CO;2-N; Miller DB, 2000, ANN NY ACAD SCI, V914, P194, DOI 10.1111/j.1749-6632.2000.tb05196.x; MILLER DB, 1994, J PHARMACOL EXP THER, V270, P752; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Mogi M, 1999, NEUROSCI LETT, V270, P45, DOI 10.1016/S0304-3940(99)00463-2; MONTECUCCO A, 1995, NUCLEIC ACIDS RES, V23, P962, DOI 10.1093/nar/23.6.962; Moriguchi T, 1997, EMBO J, V16, P7045, DOI 10.1093/emboj/16.23.7045; Murachi T, 1980, Adv Enzyme Regul, V19, P407; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NAKAYAMA M, 1993, BRAIN RES, V601, P209, DOI 10.1016/0006-8993(93)91712-2; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nilsen H, 2001, CARCINOGENESIS, V22, P987, DOI 10.1093/carcin/22.7.987; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; OCALLAGHAN JP, 1994, J PHARMACOL EXP THER, V270, P741; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; Paschen W, 2001, CELL CALCIUM, V29, P1, DOI 10.1054/ceca.2000.0162; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Perez JA, 1999, J EMERG MED, V17, P469, DOI 10.1016/S0736-4679(99)00009-8; Petit C, 1999, BIOCHIMIE, V81, P15, DOI 10.1016/S0300-9084(99)80034-0; PU CF, 1993, DEV BRAIN RES, V72, P325; Pu CF, 1996, SYNAPSE, V23, P328, DOI 10.1002/(SICI)1098-2396(199608)23:4<328::AID-SYN11>3.0.CO;2-T; PUDER KS, 1988, AM J DRUG ALCOHOL AB, V14, P463, DOI 10.3109/00952998809001564; RADI R, 1991, J BIOL CHEM, V266, P4244; Ramana CV, 1998, P NATL ACAD SCI USA, V95, P5061, DOI 10.1073/pnas.95.9.5061; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed J C, 1996, Behring Inst Mitt, P72; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; RICAURTE GA, 1992, ANN NY ACAD SCI, V648, P371; RICAURTE GA, 1980, BRAIN RES, V193, P153, DOI 10.1016/0006-8993(80)90952-X; RICAURTE GA, 1983, NEUROPHARMACOLOGY, V22, P1383, DOI 10.1016/0028-3908(83)90228-9; RICAURTE GA, 1983, NEUROPHARMACOLOGY, V22, P1165, DOI 10.1016/0028-3908(83)90075-8; RICAURTE GA, 1982, BRAIN RES, V235, P93, DOI 10.1016/0006-8993(82)90198-6; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SALANOVA V, 1984, POSTGRAD MED J, V60, P429, DOI 10.1136/pgmj.60.704.429; Salehi A, 2003, TRENDS NEUROSCI, V26, P73, DOI 10.1016/S0166-2236(02)00038-3; Sanchez V, 2003, J NEUROCHEM, V85, P515, DOI 10.1046/j.1471-4159.2003.01714.x; SATOH MS, 1992, NATURE, V356, P356, DOI 10.1038/356356a0; Schepens PJ, 1998, ANN EMERG MED, V31, P633, DOI 10.1016/S0196-0644(98)70210-0; Schmued LC, 1997, BRAIN RES, V759, P135, DOI 10.1016/S0006-8993(97)00173-X; SCHREIBER M, 1995, EMBO J, V14, P5338, DOI 10.1002/j.1460-2075.1995.tb00218.x; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; Seiden L.S., 1995, HDB NEUROTOXICOLOGY, P825; SEIDEN LS, 1984, PHARMACOL BIOCHEM BE, V21, P29, DOI 10.1016/0091-3057(84)90125-4; Sheng PL, 1996, SYNAPSE, V24, P213; Sheng PL, 1996, ANN NY ACAD SCI, V801, P174, DOI 10.1111/j.1749-6632.1996.tb17440.x; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 1996, AM J PHYSIOL-GASTR L, V271, pG949, DOI 10.1152/ajpgi.1996.271.6.G949; Simon SL, 2000, AM J ADDICTION, V9, P222; Sonders MS, 1997, J NEUROSCI, V17, P960; SONSALLA PK, 1988, PROG NEURO-PSYCHOPH, V12, P345, DOI 10.1016/0278-5846(88)90054-1; SONSALLA PK, 1986, J PHARMACOL EXP THER, V238, P932; SONSALLA PK, 1986, NEUROPHARMACOLOGY, V25, P1221, DOI 10.1016/0028-3908(86)90139-5; SONSALLA PK, 1991, J PHARMACOL EXP THER, V256, P506; STERANKA LR, 1980, EUR J PHARMACOL, V65, P439, DOI 10.1016/0014-2999(80)90351-9; Stewart JL, 1997, J ANAL TOXICOL, V21, P515, DOI 10.1093/jat/21.6.515; Stokes AH, 1999, J NEUROSCI RES, V55, P659, DOI 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Sullivan AM, 1997, NEUROSCI LETT, V233, P73, DOI 10.1016/S0304-3940(97)00623-X; SULZER D, 1995, J NEUROSCI, V15, P4102; Susin SA, 1996, J EXP MED, V184, P1331, DOI 10.1084/jem.184.4.1331; Tabner Brian J., 2001, Current Topics in Medicinal Chemistry, V1, P507, DOI 10.2174/1568026013394822; Takai N, 1998, J NEUROSCI RES, V54, P214, DOI 10.1002/(SICI)1097-4547(19981015)54:2<214::AID-JNR9>3.0.CO;2-H; Takaki M, 2001, J NEUROCHEM, V79, P679, DOI 10.1046/j.1471-4159.2001.00615.x; TEUCHERTNOODT G, 1991, NEUROPHARMACOLOGY, V30, P733, DOI 10.1016/0028-3908(91)90181-A; Tournier C, 1997, P NATL ACAD SCI USA, V94, P7337, DOI 10.1073/pnas.94.14.7337; TRULSON ME, 1982, NEUROPHARMACOLOGY, V21, P521, DOI 10.1016/0028-3908(82)90042-9; Ujike H, 2002, ANN NY ACAD SCI, V965, P55; Utz PJ, 2000, CELL DEATH DIFFER, V7, P589, DOI 10.1038/sj.cdd.4400696; VEGA WA, 1993, SUICIDE LIFE-THREAT, V23, P110; Villemagne V, 1998, J NEUROSCI, V18, P419; Volkow ND, 2001, AM J PSYCHIAT, V158, P377, DOI 10.1176/appi.ajp.158.3.377; Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001; Volkow ND, 2001, AM J PSYCHIAT, V158, P383, DOI 10.1176/appi.ajp.158.3.383; WAGNER GC, 1985, RES COMMUN CHEM PATH, V47, P221; WAGNER GC, 1980, NEUROLOGY, V30, P547; Watson A, 1998, J NEUROSCI, V18, P751; Wilson JM, 1996, NAT MED, V2, P699, DOI 10.1038/nm0696-699; WOOLVERTON WL, 1989, BRAIN RES, V486, P73, DOI 10.1016/0006-8993(89)91279-1; YANG E, 1995, CELL, V80, P285, DOI 10.1016/0092-8674(95)90411-5; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Yui K, 1999, MOL PSYCHIATR, V4, P512, DOI 10.1038/sj.mp.4000575; YurkoMauro KA, 1996, J NEUROSCI RES, V43, P476; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	208	242	253	0	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1775	1788		10.1096/fj.03-0073rev	http://dx.doi.org/10.1096/fj.03-0073rev			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519657				2022-12-28	WOS:000186343300032
J	Nistri, S; Chiappini, L; Sassoli, C; Bani, D				Nistri, S; Chiappini, L; Sassoli, C; Bani, D			Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism	FASEB JOURNAL			English	Article						P-selectin; VCAM-1; ICAM-1	LEUKOCYTE ADHESION; TISSUE-INJURY; EXPRESSION; DISEASE; INFLAMMATION; ACTIVATION; RECEPTORS; HORMONE; WOMEN; HEART	Neutrophil margination within blood vessels is an early finding during myocardial ischemia and can result in myocardial tissue injury. This phenomenon depends on the endothelial expression of adhesion molecules, which allow leukocyte extravasation. The hormone relaxin (RLX) was found to protect against experimental myocardial injury and to reduce neutrophil extravasation into the inflamed tissues. This study addresses the role of RLX in down-regulating endothelial adhesiveness to neutrophils and the possible involvement of NO, an anti-adhesive molecule, in the mechanism of action of RLX. Lipopolysaccharide (LPS)-primed rat coronary endothelial (RCE) cells and neutrophils were co-cultured and their adhesion was quantified in the absence and presence of RLX, alone or together with the NO-synthase inhibitor L-NMMA. Inactivated RLX was used as control for specificity of the RLX effect. A 24-h incubation of LPS-primed RCE cells with RLX (60 and 600 ng/ml) caused a significant reduction of adherent neutrophils and of endothelial expression of the adhesion molecules P-selectin and VCAM-1 protein and mRNA, evaluated by immunohistochemistry, Western blot, and RT-PCR. These effects of RLX were blunted by L-NMMA and were not reproduced by inactivated RLX. These findings suggest that RLX has anti-inflammatory properties that could be of benefit in ischemic heart disease.	Univ Florence, Sect Histol, Dept Anat Histol & Forens Med, I-50139 Florence, Italy; Univ Florence, Sect Anat, Dept Anat Histol & Forens Med, I-50139 Florence, Italy	University of Florence; University of Florence	Bani, D (corresponding author), Univ Florence, Sect Histol, Dept Anat Histol & Forens Med, Vle G Pieraccini 6, I-50139 Florence, Italy.	daniele.bani@unifi.it	SASSOLI, CHIARA/AAC-4023-2019	SASSOLI, CHIARA/0000-0002-1337-0938; Bani, Daniele/0000-0001-6302-901X				ANDERSON BO, 1991, J SURG RES, V51, P170, DOI 10.1016/0022-4804(91)90090-9; Bachschmid M, 2003, FASEB J, V17, P914, DOI 10.1096/fj.02-0530fje; Bani D, 1997, GEN PHARMACOL-VASC S, V28, P13, DOI 10.1016/S0306-3623(96)00171-1; Bani D, 1997, ENDOCRINOLOGY, V138, P1909, DOI 10.1210/en.138.5.1909; Bani D, 1998, AM J PATHOL, V152, P1367; BULLESBACH EE, 1988, INT J PEPT PROT RES, V32, P361; DAVENPECK KL, 1994, GASTROENTEROLOGY, V107, P1050, DOI 10.1016/0016-5085(94)90229-1; DE CR, 1995, J CLIN INVEST, V96, P60; ENGLER RL, 1986, AM J PHYSIOL, V251, P314; FAILLI P, 1996, FASEB J         1214; Hsu SY, 2002, SCIENCE, V295, P671, DOI 10.1126/science.1065654; Hu FB, 2000, NEW ENGL J MED, V343, P530, DOI 10.1056/NEJM200008243430802; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Laroux FS, 2000, ANTIOXID REDOX SIGN, V2, P391, DOI 10.1089/15230860050192161; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Nistri Silvia, 2002, Biological Procedures Online, V4, P32, DOI 10.1251/bpo31; OSHEROFF PL, 1993, J BIOL CHEM, V268, P15193; Peng HB, 1998, J IMMUNOL, V161, P1970; PIETERSMA A, 1994, AM J PHYSIOL, V267, pH874, DOI 10.1152/ajpheart.1994.267.3.H874; SLUITER W, 1993, J CARDIOVASC PHARM, V22, pS37, DOI 10.1097/00005344-199322004-00006; Spiecker M, 1999, METHOD ENZYMOL, V300, P374; WENGER NK, 1993, NEW ENGL J MED, V329, P247, DOI 10.1056/NEJM199307223290406	23	50	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2109	+		10.1096/fj.03-0216fje	http://dx.doi.org/10.1096/fj.03-0216fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500542	Green Submitted			2022-12-28	WOS:000185925100015
J	El-Agnaf, OMA; Salem, SA; Paleologou, KE; Cooper, LJ; Fullwood, NJ; Gibson, MJ; Curran, MD; Court, JA; Mann, DMA; Ikeda, S; Cookson, MR; Hardy, J; Allsop, D				El-Agnaf, OMA; Salem, SA; Paleologou, KE; Cooper, LJ; Fullwood, NJ; Gibson, MJ; Curran, MD; Court, JA; Mann, DMA; Ikeda, S; Cookson, MR; Hardy, J; Allsop, D			alpha-synuclein implicated in Parkinson's disease is present in extracellular biological fluids, including human plasma	FASEB JOURNAL			English	Article						amyloid; dementia with Lewy bodies; neurodegeneration	MULTIPLE-SYSTEM ATROPHY; ALZHEIMERS-DISEASE; LEWY BODIES; HUMAN BRAIN; CEREBROSPINAL-FLUID; MESSENGER-RNA; MOUSE MODEL; FATTY-ACIDS; PROTEIN; MUTATIONS	Parkinson's disease (PD) and other related disorders are characterized by the accumulation of fibrillar aggregates of alpha-synuclein protein (alpha-syn) inside brain cells. It is likely that the formation of alpha-syn aggregates plays a seminal role in the pathogenesis of at least some of these diseases, because two different mutations in the gene encoding alpha-syn have been found in inherited forms of PD. alpha-Syn is mainly expressed by neuronal cells and is generally considered to exist as a cytoplasmic protein. Here, we report the unexpected identification of alpha-syn in conditioned culture media from untransfected and alpha-syn-transfected human neuroblastoma cells, as well as in human cerebrospinal fluid and blood plasma. The method used was immunocapture by using anti-alpha-syn antibodies coupled to magnetic beads, followed by detection on Western blots. In all cases, alpha-syn was identified as a single 15 kDa band, which co-migrated with a recombinant form of the protein and reacted with five different antibodies to alpha-syn. Our findings suggest that cells normally secrete alpha-syn into their surrounding media, both in vitro and in vivo. The detection of extracellular alpha-syn and/or its modified forms in body fluids, particularly in human plasma, offers new opportunities for the development of diagnostic tests for PD and related diseases.	Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England; Belfast City Hosp, Movement Disorders Clin, Belfast BT9 7AD, Antrim, North Ireland; Belfast City Hosp, No Ireland Reg Histocompatibil & Immunogenet Lab, Belfast BT9 7AD, Antrim, North Ireland; Newcastle Gen Hosp, Joint MRC Newcastle Univ Dev Clin Brain Ageing, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; Hope Hosp, Clin Neurosci Res Grp, Greater Manchester Neurosci Ctr, Salford M6 8HD, Lancs, England; Shinshu Univ, Sch Med, Nagano, Japan; NIA, Neurogenet Lab, Bethesda, MD 20892 USA	Lancaster University; Belfast City Hospital; Belfast City Hospital; Newcastle General Hospital; Shinshu University; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	El-Agnaf, OMA (corresponding author), Univ Lancaster, Div Biol Sci, Lancaster LA1 4YQ, England.	o.el-agnaf@lancaster.ac.uk	Allsop, David/B-9725-2008; Resource Center, NINDS Human Genetics/AGF-2474-2022; Hardy, John/C-2451-2009; Sander-Effron, Samuel/AAX-2231-2020; Cookson, Mark/AAW-2516-2021	Allsop, David/0000-0002-0513-5575; Hardy, John/0000-0002-3122-0423; Cookson, Mark/0000-0002-1058-3831; Fullwood, Nigel James/0000-0002-9405-8515	NATIONAL INSTITUTE ON AGING [Z01AG000952] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Baba M, 1998, AM J PATHOL, V152, P879; Barlowe C, 2002, CURR OPIN CELL BIOL, V14, P417, DOI 10.1016/S0955-0674(02)00348-4; Borghi R, 2000, NEUROSCI LETT, V287, P65, DOI 10.1016/S0304-3940(00)01153-8; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; DeMattos RB, 2002, J NEUROCHEM, V81, P229, DOI 10.1046/j.1471-4159.2002.00889.x; DeMattos RB, 2002, SCIENCE, V295, P2264, DOI 10.1126/science.1067568; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; El-Agnaf OMA, 1998, FEBS LETT, V440, P71, DOI 10.1016/S0014-5793(98)01418-5; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hashimoto M, 1997, BIOCHEM BIOPH RES CO, V237, P611, DOI 10.1006/bbrc.1997.6978; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakowec MW, 1998, NEUROSCI LETT, V253, P13, DOI 10.1016/S0304-3940(98)00599-0; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Li QX, 2002, J ALZHEIMERS DIS, V4, P309, DOI 10.3233/JAD-2002-4406; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mor-Vaknin N, 2003, NAT CELL BIOL, V5, P59, DOI 10.1038/ncb898; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nickel W, 2003, EUR J BIOCHEM, V270, P2109, DOI 10.1046/j.1432-1033.2003.03577.x; Nishimura N, 1999, J BIOL CHEM, V274, P15937, DOI 10.1074/jbc.274.22.15937; Nishimura N, 2002, P NATL ACAD SCI USA, V99, P6755, DOI 10.1073/pnas.092150699; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Sharon R, 2003, NEURON, V37, P583, DOI 10.1016/S0896-6273(03)00024-2; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Solano SM, 2000, ANN NEUROL, V47, P201, DOI 10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F; Souza JM, 2000, FEBS LETT, V474, P116, DOI 10.1016/S0014-5793(00)01563-5; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stefanis L, 2001, J NEUROCHEM, V76, P1165, DOI 10.1046/j.1471-4159.2001.00114.x; Turnbull S, 2001, FREE RADICAL BIO MED, V30, P1163, DOI 10.1016/S0891-5849(01)00513-5; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; van der Putten H, 2000, J NEUROSCI, V20, P6021, DOI 10.1523/JNEUROSCI.20-16-06021.2000; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353	44	453	480	1	39	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1945	+		10.1096/fj.03-0098fje	http://dx.doi.org/10.1096/fj.03-0098fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519670				2022-12-28	WOS:000185345100012
J	Deininger, MH; Wybranietz, WA; Graepler, FTC; Lauer, UM; Meyermann, R; Schluesener, HJ				Deininger, MH; Wybranietz, WA; Graepler, FTC; Lauer, UM; Meyermann, R; Schluesener, HJ			Endothelial endostatin release is induced by general cell stress and modulated by the nitric oxide/cGMP pathway	FASEB JOURNAL			English	Article						anti-angiogenic therapy; glioblastoma pathology; nitric oxide synthase	ANGIOGENESIS INHIBITORS ENDOSTATIN; GROWTH-FACTOR; TUMOR-GROWTH; SYNTHASE EXPRESSION; NUCLEAR ANTIGEN; ZINC-BINDING; APOPTOSIS; COLLAGEN; THERAPY; CANCER	Endostatin is a 20 kDa carboxyl-terminal fragment of collagen XVIII that, when added exogenously, inhibits endothelial proliferation and migration in vitro and angiogenesis and tumor growth in vivo. Previous results showed endostatin/collagen XVIII labeling in few endothelial cells in human glioblastoma multiforme. We have now observed constitutive release of endostatin from one of four endothelial cell lines. Induction of endostatin release was observed after H2O2, an in vitro model of cell stress, CoCl2, a model of hypoxia, and by IFN-gamma challenge. Endostatin expression and release was reduced by the nitric oxide synthase inhibitors aminoguanidine and L-NAME and induced by the NO synthase-independent NO donors sodium nitroprusside ( SNP) and spermine-NONO-ate. SNP-mediated endostatin induction was abrogated by the soluble guanylate cyclase inhibitor 1H-(1.2.4) oxadiazolo (4,3-A) quinoxalin-1-one. Adenoviral endostatin transduction resulted in the release of endostatin from endothelial cells and in down-regulation of iNOS (NOS2) and eNOS (NOS3), and surprisingly in a 10% induction of PCNA. These results describe the modulation of endostatin release by the NO signaling cascade and provide important new pharmacological information for the systemic induction of endogenous endostatin release by common NO donor pharmacotherapy.	Univ Tubingen, Sch Med, Inst Brain Res, D-72076 Tubingen, Germany; Med Univ Clin Tubingen, Dept Internal Med 1, Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Deininger, MH (corresponding author), Univ Tubingen, Sch Med, Inst Brain Res, Calwer Str 3, D-72076 Tubingen, Germany.	martin.deininger@uni-tuebingen.de						Bartlett SR, 1999, J PHYSIOL-LONDON, V521, P705, DOI 10.1111/j.1469-7793.1999.00705.x; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; Boehm T, 1998, BIOCHEM BIOPH RES CO, V252, P190, DOI 10.1006/bbrc.1998.9617; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Boye E, 2001, J CLIN INVEST, V107, P745, DOI 10.1172/JCI11432; BRAVO R, 1980, J CELL BIOL, V84, P795, DOI 10.1083/jcb.84.3.795; Bussolati B, 2001, AM J PATHOL, V159, P993, DOI 10.1016/S0002-9440(10)61775-0; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Christov C, 1998, NEUROPATH APPL NEURO, V24, P29; Chua CC, 1998, FREE RADICAL BIO MED, V25, P891, DOI 10.1016/S0891-5849(98)00115-4; Cooper CE, 1999, BBA-BIOENERGETICS, V1411, P290, DOI 10.1016/S0005-2728(99)00021-3; Denninger JW, 1999, BBA-BIOENERGETICS, V1411, P334, DOI 10.1016/S0005-2728(99)00024-9; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dimmeler S, 1999, CELL DEATH DIFFER, V6, P964, DOI 10.1038/sj.cdd.4400581; Dimmeler S, 1997, NITRIC OXIDE-BIOL CH, V1, P275, DOI 10.1006/niox.1997.0133; Ding YH, 1998, P NATL ACAD SCI USA, V95, P10443, DOI 10.1073/pnas.95.18.10443; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Feelisch M, 1998, N-S ARCH PHARMACOL, V358, P113, DOI 10.1007/PL00005231; Feldman AL, 2000, CANCER RES, V60, P1503; Iwata S, 1999, NEUROSURGERY, V45, P24, DOI 10.1097/00006123-199907000-00006; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; John H, 1999, BIOCHEMISTRY-US, V38, P10217, DOI 10.1021/bi990787+; Kane AJ, 2001, BRIT J PHARMACOL, V132, P1631, DOI 10.1038/sj.bjp.0703944; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; MacDonald NJ, 2001, J BIOL CHEM, V276, P25190, DOI 10.1074/jbc.M100743200; Mates JM, 2000, INT J BIOCHEM CELL B, V32, P157, DOI 10.1016/S1357-2725(99)00088-6; Miller MJS, 1996, INFLAMM RES, V45, P272, DOI 10.1007/BF02280990; Milligan SA, 1996, AM J PHYSIOL-LUNG C, V271, pL114, DOI 10.1152/ajplung.1996.271.1.L114; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; MIYACHI K, 1978, J IMMUNOL, V121, P2228; Moulton KS, 1999, CIRCULATION, V99, P1726, DOI 10.1161/01.CIR.99.13.1726; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Nilsson BO, 1999, INFLAMM RES, V48, P509, DOI 10.1007/s000110050495; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; Saarela J, 1998, MATRIX BIOL, V16, P319, DOI 10.1016/S0945-053X(98)90003-8; Schluesener HJ, 1997, GLIA, V20, P365, DOI 10.1002/(SICI)1098-1136(199708)20:4<365::AID-GLIA8>3.0.CO;2-4; Schuppan D, 1998, LANCET, V352, P879, DOI 10.1016/S0140-6736(05)60006-2; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Standker L, 1997, FEBS LETT, V420, P129, DOI 10.1016/S0014-5793(97)01503-2; Strik HM, 2001, CANCER, V91, P1013, DOI 10.1002/1097-0142(20010301)91:5<1013::AID-CNCR1092>3.0.CO;2-Q; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; TETSUKA T, 1995, AM J PHYSIOL-CELL PH, V269, pC55, DOI 10.1152/ajpcell.1995.269.1.C55; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Walter JW, 1999, AM J MED GENET, V82, P77, DOI 10.1002/(SICI)1096-8628(19990101)82:1<77::AID-AJMG15>3.0.CO;2-A; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Wen W, 1999, CANCER RES, V59, P6052; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414	50	26	36	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1267	1276		10.1096/fj.02-1118com	http://dx.doi.org/10.1096/fj.02-1118com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832291				2022-12-28	WOS:000184471600038
J	Portella, G; Laezza, C; Laccetti, P; De Petrocellis, L; Di Marzo, V; Bifulco, M				Portella, G; Laezza, C; Laccetti, P; De Petrocellis, L; Di Marzo, V; Bifulco, M			Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis	FASEB JOURNAL			English	Article						thyroid; cancer; endocannabinoid; p27; lung; VEGF	THYROID EPITHELIAL-CELLS; MURINE SARCOMA-VIRUS; IN-VIVO; UP-REGULATION; HUMAN BREAST; FRTL-5 CELLS; FACTOR VEGF; ANANDAMIDE; CANCER; PROLIFERATION	Stimulation of cannabinoid CB1 receptors by 2-methyl-arachidonyl-2'-fluoro-ethylamide (Met-F-AEA) inhibits the growth of a rat thyroid cancer cell-derived tumor in athymic mice by inhibiting the activity of the oncogene product p21(ras). Here we report that Met-F-AEA also blocks the growth of tumors previously induced in nude mice by the s.c. injection of the same rat thyroid carcinoma cells. Met-F-AEA significantly inhibited, in tumors as well as transformed cells, the expression of the vascular endothelial growth factor, an angiogenetic factor known to be up-regulated by p21ras, as well as of one of its receptors,flt-1/VEGFR-1. The levels of the cyclin-dependent kinase inhibitor p27(kip1),which is down-regulated by p21ras, were instead increased by Met-F-AEA. All these effects were antagonized by the selective CB1 receptor antagonist SR141716A. Met-F-AEA inhibited in vitro the growth of a metastasis-derived thyroid cancer cell line more potently than a primary cancer cell line. Therefore, the hypothesis that CB1 receptor stimulation interferes not only with angiogenesis but also with metastatic processes was tested in a widely used model of metastatic infiltration in vivo, the Lewis lung carcinoma(3LL) in C57Bl/6 mice. Three weeks from the paw injection of 3LL cells, Met-F-AEA reduced significantly the number of metastatic nodes, in away antagonized by SR141716A. Our findings indicate that CB1 receptor agonists might be used therapeutically to retard tumor growth in vivo by inhibiting at once tumor growth, angiogenesis, and metastasis.	Univ Naples Federico 2, Endocannabinoid Res Grp, Naples, Italy; Univ Naples Federico 2, Ist Endocrinol & Oncol Sperimentale, CNR, Naples, Italy; Univ Naples Federico 2, Dipartimento Biol & Patol Cellulare & Mol L Calif, Naples, Italy; CNR, Ist Cibernet, I-80078 Pozzuoli, NA, Italy; CNR, Ist Chim Biomol, I-80078 Pozzuoli, NA, Italy; Univ Salerno, Dipartimento Sci Farmaceut, I-84084 Fisciano, SA, Italy	University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); University of Naples Federico II; University of Naples Federico II; Consiglio Nazionale delle Ricerche (CNR); Istituto di Cibernetica "Eduardo Caianiello" (ICIB-CNR); Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica Biomolecolare (ICB-CNR); University of Salerno	Di Marzo, V (corresponding author), Univ Naples Federico 2, Endocannabinoid Res Grp, Naples, Italy.	maubiful@unina.it	laez, chi/AAW-4437-2020; Portella, Giuseppe/AFU-6826-2022; Di Marzo, Vincenzo/AAD-7742-2019	Di Marzo, Vincenzo/0000-0002-1490-3070; Bifulco, Maurizio/0000-0002-1771-4531; PORTELLA, Giuseppe/0000-0001-8276-9769				ADAMS IB, 1995, J PHARMACOL EXP THER, V273, P1172; AMBESIIMPIOMBATO FS, 1980, P NATL ACAD SCI-BIOL, V77, P3455, DOI 10.1073/pnas.77.6.3455; Belletti B, 1999, ONCOGENE, V18, P4860, DOI 10.1038/sj.onc.1202869; Bifulco M, 2002, NAT MED, V8, P547, DOI 10.1038/nm0602-547; Bifulco M, 2001, FASEB J, V15, P2745, DOI 10.1096/fj.01-0320fje; Bisogno T, 2000, BIOCHEM J, V351, P817, DOI 10.1042/0264-6021:3510817; Blazquez C, 2003, FASEB J, V17, P529, DOI 10.1096/fj.02-0795fje; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2000, PROSTAG OTH LIPID M, V61, P43, DOI 10.1016/S0090-6980(00)00054-X; DIMARZO V, 2002, BIOL MARIJUANA, P125; FUSCO A, 1981, INT J CANCER, V28, P655, DOI 10.1002/ijc.2910280519; FUSCO A, 1982, CANCER RES, V42, P618; Galve-Roperh I, 2000, NAT MED, V6, P313, DOI 10.1038/73171; Goukassian D, 2001, FASEB J, V15, P1877, DOI 10.1096/fj.01-0065com; Guzman M, 2001, J MOL MED-JMM, V78, P613, DOI 10.1007/s001090000177; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Howlett AC, 2000, CHEM PHYS LIPIDS, V108, P53, DOI 10.1016/S0009-3084(00)00187-0; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Jones CJ, 2000, MOL CELL BIOL, V20, P5690, DOI 10.1128/MCB.20.15.5690-5699.2000; Khoo MLC, 2002, J CLIN ENDOCR METAB, V87, P1814, DOI 10.1210/jcem.87.4.8353; LACCETTI P, 1994, CANCER RES, V54, P4253; Laezza C, 1998, P NATL ACAD SCI USA, V95, P13646, DOI 10.1073/pnas.95.23.13646; Larcher F, 1996, CANCER RES, V56, P5391; Lei HT, 2002, J BIOL CHEM, V277, P43137, DOI 10.1074/jbc.M203103200; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Melck D, 2000, ENDOCRINOLOGY, V141, P118, DOI 10.1210/en.141.1.118; Melck D, 1999, FEBS LETT, V463, P235, DOI 10.1016/S0014-5793(99)01639-7; Miyagi E, 2001, THYROID, V11, P539, DOI 10.1089/105072501750302831; Pertwee RG, 1997, PHARMACOL THERAPEUT, V74, P129, DOI 10.1016/S0163-7258(97)82001-3; PORTELLA G, 1989, ONCOGENE, V4, P181; RAK J, 1995, CANCER RES, V55, P4575; Rak J, 2000, CANCER RES, V60, P490; Rak J, 2001, METHOD ENZYMOL, V333, P267; Sanchez C, 2001, CANCER RES, V61, P5784; SUGIURA T, 1995, BIOCHEM BIOPH RES CO, V215, P89, DOI 10.1006/bbrc.1995.2437; VIGLIETTO G, 1995, ONCOGENE, V11, P1569; Viglietto G, 1997, ONCOGENE, V15, P2687, DOI 10.1038/sj.onc.1201456; Wang JF, 1998, J ENDOCRINOL, V157, P5, DOI 10.1677/joe.0.1570005	41	145	157	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1771	+		10.1096/fj.02-1129fje	http://dx.doi.org/10.1096/fj.02-1129fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958205				2022-12-28	WOS:000184471600021
J	Suzuki, H; Wu, JH; Hossain, K; Ohhata, T; Du, J; Akhand, AA; Hayakawa, A; Kimura, H; Hagiwara, M; Nakashima, I				Suzuki, H; Wu, JH; Hossain, K; Ohhata, T; Du, J; Akhand, AA; Hayakawa, A; Kimura, H; Hagiwara, M; Nakashima, I			Involvement of MKK6 in TCRa beta(int)CD69(lo): a target population for apoptotic cell death in thymocytes	FASEB JOURNAL			English	Article							KINASE SIGNALING PATHWAYS; NEGATIVE SELECTION; POSITIVE SELECTION; T-LYMPHOCYTES; STEM-CELLS; IN-VIVO; MAP; DIFFERENTIATION; RESPONSES; MICE	By analyzing real-time caspase activity and DNA fragmentation in live thymocytes, we found that apoptosis occurs predominantly in a TCRalphabeta(int/hi)CD69(lo) population. The number of caspase-active cells and DNA-fragmented cells in MKK6-deficient mice, which were originally generated in our laboratory by gene targeting, was decreased in the TCRalphabeta(int)CD69(lo) population but not in the TCRalphabeta(hi)CD69(lo) population. The percentage of caspase-active cells in the H-Y-specific TCRint population was more clearly decreased in male MKK6-deficient H-Y TCR-transgenic mice. Furthermore, the absolute number of TCR(hi)CD4(lo)CD8(lo) cells, which are developmentally next to TCR(int)CD4(hi)CD8(hi) cells, was increased in MKK6-deficient H-Y TCR-transgenic mice. Deletion of TCRalphabeta(int)CD4(hi)CD8(hi) cells by injecting antigenic lymphocytic chorio-meningitis virus (LCMV) peptide into LCMV-specific TCR-transgenic mice was incomplete in MKK6-deficient mice. Cellular death of TCRalphabeta(int) fetal thymocytes induced by adding an antigenic peptide into an in vitro fetal thymic organ culture system was also diminished in MKK6-deficient TCR-transgenic thymi. These results indicate that MKK6 plays a role in the developing thymocytes, especially in the population of TCRalphabeta(int)CD69(lo) cells, which possibly undergo negative selection.	Nagoya Univ, Grad Sch Med, Dept Immunol, Aichi 4668550, Japan; Nagoya Univ, Grad Sch Med, Ctr Res & Educ, Dept Equipment, Aichi, Japan; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Aichi, Japan; Tokyo Med & Dent Univ, Med Res Inst, Dept Funct Genom, Tokyo, Japan	Nagoya University; Nagoya University; Nagoya University; Tokyo Medical & Dental University (TMDU)	Suzuki, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Aichi 4668550, Japan.	k46200a@nucc.cc.nagoya-u.ac.jp		Hossain, Khaled/0000-0003-0878-915X; Ohhata, Tatsuya/0000-0003-1124-6164				Akashi K, 1998, IMMUNOL REV, V165, P13, DOI 10.1111/j.1600-065X.1998.tb01226.x; AlberolaIla J, 1996, J EXP MED, V184, P9, DOI 10.1084/jem.184.1.9; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; Allen M, 2000, J EXP MED, V191, P859, DOI 10.1084/jem.191.5.859; Dautigny N, 1999, J IMMUNOL, V162, P1294; Hare KJ, 2002, IMMUNOLOGY, V105, P163, DOI 10.1046/j.1365-2567.2002.01364.x; Jiang D, 1999, CELL DEATH DIFFER, V6, P402, DOI 10.1038/sj.cdd.4400513; Kishimoto H, 1998, J EXP MED, V187, P1427, DOI 10.1084/jem.187.9.1427; Lu HT, 1999, EMBO J, V18, P1845, DOI 10.1093/emboj/18.7.1845; Lucas B, 1996, IMMUNITY, V5, P461, DOI 10.1016/S1074-7613(00)80502-6; Nakayama T, 2002, J IMMUNOL, V168, P87, DOI 10.4049/jimmunol.168.1.87; OShea CC, 1996, EUR J IMMUNOL, V26, P2350, DOI 10.1002/eji.1830261012; Page DM, 1998, J IMMUNOL, V160, P120; Rincon M, 2001, ONCOGENE, V20, P2490, DOI 10.1038/sj.onc.1204382; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Sant'Angelo DB, 1998, IMMUNITY, V9, P179, DOI 10.1016/S1074-7613(00)80600-7; Sen J, 1996, J IMMUNOL, V156, P4535; Sugawara T, 1998, IMMUNITY, V9, P565, DOI 10.1016/S1074-7613(00)80639-1; SWAN KA, 1995, EMBO J, V14, P276, DOI 10.1002/j.1460-2075.1995.tb07001.x; Swat W, 1996, P NATL ACAD SCI USA, V93, P4683, DOI 10.1073/pnas.93.10.4683	21	5	8	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1538	+		10.1096/fj.02-0869fje	http://dx.doi.org/10.1096/fj.02-0869fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824301				2022-12-28	WOS:000183818000043
J	Thiagarajah, JR; Song, YL; Haggie, PM; Verkman, AS				Thiagarajah, JR; Song, YL; Haggie, PM; Verkman, AS			A small molecule CFTR inhibitor produces cystic fibrosis-like submucosal gland fluid secretions in normal airways	FASEB JOURNAL			English	Article						mucus; water transport; viscosity; bicarbonate	LIQUID SECRETION; CHLORIDE SECRETION; SURFACE LIQUID; LUNG; LOCALIZATION; BICARBONATE; TRANSPORT; PIG	Airway submucosal glands have been proposed as a primary site for initiating and sustaining airway disease in cystic fibrosis (CF). However, it has been difficult to define the role of CFTR in gland fluid secretion because of concerns in interpreting experiments on diseased CF human airways subjected to chronic infection and inflammation. Here, we test the role of CFTR in gland fluid secretion by using a selective CFTR inhibitor (CFTRinh-172) in pig and human airways. Measurements of single-gland fluid secretion rates showed inhibition of both cholinergic and cAMP-stimulated fluid secretion by CFTRinh-172. Secreted fluid [Na+] and [Cl-] measured by fluorescence ratio imaging were 101 and 116 mM, respectively, and not significantly altered by secretory agonists or CFTR inhibition. Gland fluid pH was 7.1 and reduced by 0.4 units after CFTR inhibition. Gland fluid viscosity, determined by photobleaching of FITC-dextran, was threefold increased in pilocarpine-stimulated gland fluid after CFTR inhibition, and protein concentration was increased from 12 to 20 mg/ml. Our data provide strong evidence that gland fluid secretion is CFTR-dependent. The relatively hyper-viscous and acidic fluid secretions produced by acute CFTR inhibition support a role for defective gland function in CF lung disease and provide a rational basis for pharmacological creation of a large animal model of CF.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu						Ballard ST, 1999, AM J PHYSIOL-LUNG C, V277, pL694, DOI 10.1152/ajplung.1999.277.4.L694; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; Cressman VL, 1998, AM J RESP CELL MOL, V19, P853, DOI 10.1165/ajrcmb.19.6.3194; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; ESTERLY JR, 1968, THORAX, V23, P670, DOI 10.1136/thx.23.6.670; Grubb Barbara R., 1999, Physiological Reviews, V79, pS193; JACQUOT J, 1993, EUR RESPIR J, V6, P169; Jayaraman S, 2001, J CLIN INVEST, V107, P317, DOI 10.1172/JCI11154; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; Joo NS, 2002, J BIOL CHEM, V277, P50710, DOI 10.1074/jbc.M208826200; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; KING M, 1989, BIORHEOLOGY, V26, P737; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; Ma TH, 2002, J CLIN INVEST, V110, P1651, DOI 10.1172/JCI200216112; MacVinish LJ, 2001, PFLUG ARCH EUR J PHY, V443, pS127; Nixon GM, 2002, ARCH DIS CHILD, V87, P306, DOI 10.1136/adc.87.4.306; ORNOY A, 1987, AM J MED GENET, V28, P935, DOI 10.1002/ajmg.1320280420; Sehgal A, 1996, AM J RESP CELL MOL, V15, P122, DOI 10.1165/ajrcmb.15.1.8679216; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; SOBONYA RE, 1986, AM REV RESPIR DIS, V134, P290; Sonawane ND, 2002, J BIOL CHEM, V277, P5506, DOI 10.1074/jbc.M110818200; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Thiagarajah JR, 2004, GASTROENTEROLOGY, V126, P511, DOI 10.1053/j.gastro.2003.11.005; TOMMOY M, 1983, CELL TISSUE RES, V228, P549; Trout L, 2003, J PHYSIOL-LONDON, V549, P845, DOI 10.1113/jphysiol.2002.035923; Trout L, 1998, AM J PHYSIOL-LUNG C, V275, pL1095, DOI 10.1152/ajplung.1998.275.6.L1095; Trout L, 1998, AM J PHYSIOL-LUNG C, V274, pL258, DOI 10.1152/ajplung.1998.274.2.L258; UEKI I, 1980, AM REV RESPIR DIS, V121, P351; Verkman AS, 2000, EXP PHYSIOL, V85, p233S, DOI 10.1111/j.1469-445X.2000.tb00028.x; Verkman AS, 2003, AM J PHYSIOL-CELL PH, V284, pC2, DOI 10.1152/ajpcell.00417.2002; Wine JJ, 1999, J CLIN INVEST, V103, P309, DOI 10.1172/JCI6222	34	95	98	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					875	+		10.1096/fj.03-1248fje	http://dx.doi.org/10.1096/fj.03-1248fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001557				2022-12-28	WOS:000220522800023
J	Delmas, P; Nauli, SM; Li, XG; Coste, B; Osorio, N; Crest, M; Brown, DA; Zhou, J				Delmas, P; Nauli, SM; Li, XG; Coste, B; Osorio, N; Crest, M; Brown, DA; Zhou, J			Gating of the polycystin ion channel signaling complex in neurons and kidney cells	FASEB JOURNAL			English	Article						polycystic kidney disease; polycystin-1; polycystin-2; G-protein; Ca2+-permeable channel	RAT SYMPATHETIC NEURONS; BETA-GAMMA-SUBUNITS; N-TERMINAL KINASE; CATION CHANNEL; CA2+ CHANNELS; GENE-PRODUCT; G-PROTEINS; DISEASE; PKD1; MODULATION	Mutations in either polycystin-2 (PC2) or polycystin-1 (PC1) proteins cause severe, potentially lethal, kidney disorders and multiple extrarenal (including brain) disease phenotypes. PC2, a member of the transient receptor potential channel superfamily, and PC1, an orphan membrane receptor of largely unknown function, are thought to be part of a common signaling pathway. Here, we show that in rat sympathetic neurons and kidney cells, coassembly of full-length PC1 with PC2 forms a plasmalemmal ion channel signaling complex in which PC1 stimulation simultaneously activates PC2 ion channels and G(i/o)-proteins. PC2 activation occurs through a structural rearrangement of PC1, independent of G-protein activation. Thus, PC1 acts as a prototypical membrane receptor that concordantly regulates PC2 channels and G-proteins, a bimodal mechanism that may account for the multifunctional roles of polycystin proteins in fundamental cellular processes of various cell types.	IFR Jean Roche, Fac Med, UMR 6150, F-13916 Marseille 20, France; Brigham & Womens Hosp, Dept Med, Div Renal, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; UCL, Dept Pharmacol, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England	UDICE-French Research Universities; Aix-Marseille Universite; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of London; University College London	Delmas, P (corresponding author), IFR Jean Roche, Fac Med, UMR 6150, Bd P Dramard, F-13916 Marseille 20, France.	delmas.p@jean-roche.univ-mrs.fr; zhou@rics.bwh.harvard.edu	Brown, David A/J-9019-2012					Arnould T, 1998, J BIOL CHEM, V273, P6013, DOI 10.1074/jbc.273.11.6013; Barr MM, 1999, NATURE, V401, P386, DOI 10.1038/43916; Barr MM, 2001, CURR BIOL, V11, P1341, DOI 10.1016/S0960-9822(01)00423-7; Calvet JP, 2001, SEMIN NEPHROL, V21, P107, DOI 10.1053/snep.2001.20929; Chen XZ, 2001, BIOCHEM BIOPH RES CO, V282, P1251, DOI 10.1006/bbrc.2001.4720; Delmas P, 2002, J BIOL CHEM, V277, P11276, DOI 10.1074/jbc.M110483200; Delmas P, 2002, NEURON, V36, P787, DOI 10.1016/S0896-6273(02)01097-8; Delmas P, 1999, J PHYSIOL-LONDON, V518, P23, DOI 10.1111/j.1469-7793.1999.0023r.x; Delmas P, 2002, NEURON, V34, P209, DOI 10.1016/S0896-6273(02)00641-4; Delmas P, 2000, NAT NEUROSCI, V3, P670, DOI 10.1038/76621; Delmas P, 1998, J PHYSIOL-LONDON, V506, P319, DOI 10.1111/j.1469-7793.1998.319bw.x; GABOW PA, 1990, AM J KIDNEY DIS, V16, P403, DOI 10.1016/S0272-6386(12)80051-5; Geng L, 1996, J CLIN INVEST, V98, P2674, DOI 10.1172/JCI119090; Gonzalez-Perrett S, 2002, J BIOL CHEM, V277, P24959, DOI 10.1074/jbc.M105084200; Gonzalez-Perrett S, 2001, P NATL ACAD SCI USA, V98, P1182, DOI 10.1073/pnas.021456598; Grimm DH, 2003, J BIOL CHEM, V278, P36786, DOI 10.1074/jbc.M306536200; Hanaoka K, 2000, NATURE, V408, P990, DOI 10.1038/35050128; Herlitze S, 1996, NATURE, V380, P258, DOI 10.1038/380258a0; HUGHES J, 1995, NAT GENET, V10, P151, DOI 10.1038/ng0695-151; Ikeda SR, 1996, NATURE, V380, P255, DOI 10.1038/380255a0; IKEDA SR, 1995, NEURON, V14, P1029, DOI 10.1016/0896-6273(95)90341-0; Koulen P, 2002, NAT CELL BIOL, V4, P191, DOI 10.1038/ncb754; Lu WN, 1997, NAT GENET, V17, P179, DOI 10.1038/ng1097-179; Lu WN, 2001, HUM MOL GENET, V10, P2385, DOI 10.1093/hmg/10.21.2385; Luo Y, 2003, MOL CELL BIOL, V23, P2600, DOI 10.1128/MCB.23.7.2600-2607.2003; Mengerink KJ, 2000, MOL BIOL CELL, V11, p406A; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Nauli SM, 2003, NAT GENET, V33, P129, DOI 10.1038/ng1076; Newby LJ, 2002, J BIOL CHEM, V277, P20763, DOI 10.1074/jbc.M107788200; Ong ACM, 2000, EXP NEPHROL, V8, P208; Parnell SC, 2002, J BIOL CHEM, V277, P19566, DOI 10.1074/jbc.M201875200; Qian F, 1997, NAT GENET, V16, P179, DOI 10.1038/ng0697-179; Sandford R, 1997, HUM MOL GENET, V6, P1483, DOI 10.1093/hmg/6.9.1483; Stayner C, 2001, TRENDS PHARMACOL SCI, V22, P543, DOI 10.1016/S0165-6147(00)01832-0; Tsiokas L, 1997, P NATL ACAD SCI USA, V94, P6965, DOI 10.1073/pnas.94.13.6965; Vacquier VD, 1997, DEV BIOL, V192, P125, DOI 10.1006/dbio.1997.8729; Vassilev PM, 2001, BIOCHEM BIOPH RES CO, V282, P341, DOI 10.1006/bbrc.2001.4554; Wu GQ, 2000, MOL GENET METAB, V69, P1, DOI 10.1006/mgme.1999.2943	38	129	137	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					740	+		10.1096/fj.03-0319fje	http://dx.doi.org/10.1096/fj.03-0319fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766803				2022-12-28	WOS:000220425000039
J	Jayanthi, S; Deng, XL; Noailles, PAH; Ladenheim, B; Cadet, JL				Jayanthi, S; Deng, XL; Noailles, PAH; Ladenheim, B; Cadet, JL			Methamphetamine induces neuronal apoptosis via cross-talks between endoplasmic reticulum and mitochondria-dependent death cascades	FASEB JOURNAL			English	Review						apoptosis-inducing factor; CHOP transcription factor; BiP/GRP78; DNA fragmentation	GAMMA-AMINOBUTYRIC-ACID; CYTOCHROME-C RELEASE; INDUCED NEUROTOXICITY; CELL-DEATH; DNA FRAGMENTATION; GENE-EXPRESSION; MOUSE-BRAIN; DOPAMINE TRANSPORTERS; CASPASE ACTIVATION; OXIDATIVE STRESS	Methamphetamine (METH) is an illicit drug that causes neurodegenerative effects in humans. In rodents, METH induces apoptosis of striatal glutamic acid decarboxylase (GAD) -containing neurons. This paper provides evidence that METH-induced cell death occurs consequent to interactions of ER stress and mitochondrial death pathways. Specifically, injections of METH are followed by an almost immediate activation of proteases calpain and caspase-12, events consistent with drug-induced ER stress. Involvement of ER stress was further supported by observations of increases in the expression of GRP78/BiP and CHOP. Participation of the mitochondrial pathway was demonstrated by the transition of AIF, smac/DIABLO, and cytochrome c from mitochondrial into cytoplasmic fractions. These changes occur before the apoptosome-associated pro-caspase-9 cleavage. Effector caspases-3 and -6, but not -7, were cleaved with the initial time of caspase-3 activation occurring before caspase 9 cleavage; this suggests possible earlier cleavage of caspase-3 by caspase-12. These events preceded proteolysis of the caspase substrates DFF-45, lamin A, and PARP in nuclear fractions. These findings indicate that METH causes neuronal apoptosis in part via cross-talks between ER- and mitochondria-generated processes, which cause activation of both caspase-dependent and -independent pathways.	NIDA, Mol Neuropsychiat Branch, Intramural Res Program, NIH,DHHS, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Cadet, JL (corresponding author), NIDA, Mol Neuropsychiat Branch, Intramural Res Program, NIH,DHHS, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.	jcadet@intra.nida.nih.gov	Jayanthi, Subramaniam/ABI-4023-2020	Jayanthi, Subramaniam/0000-0002-5209-303X	NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000153, Z01DA000174, ZIADA000174] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Asada H, 1996, BIOCHEM BIOPH RES CO, V229, P891, DOI 10.1006/bbrc.1996.1898; Asada H, 1997, P NATL ACAD SCI USA, V94, P6496, DOI 10.1073/pnas.94.12.6496; Barrett T, 2001, NEUROBIOL DIS, V8, P822, DOI 10.1006/nbdi.2001.0423; BROSTROM MA, 1995, J BIOL CHEM, V270, P4127, DOI 10.1074/jbc.270.8.4127; Budd SL, 2000, P NATL ACAD SCI USA, V97, P6161, DOI 10.1073/pnas.100121097; Burrows KB, 2000, EUR J PHARMACOL, V398, P11, DOI 10.1016/S0014-2999(00)00264-8; Burrows KB, 2003, GLUTAMATE ADDICTION, P211; Cadet JL, 1997, SYNAPSE, V25, P176; Cadet JL, 2003, FASEB J, V17, P1775, DOI 10.1096/fj.03-0073rev; Cadet JL, 2002, SYNAPSE, V44, P211, DOI 10.1002/syn.10074; CADET JL, 1994, J NEUROCHEM, V62, P380; Cadet JL, 2001, SYNAPSE, V41, P40, DOI 10.1002/syn.1058; Cadet JL, 1998, NEUROCHEM INT, V32, P117, DOI 10.1016/S0197-0186(97)00031-4; Cadet JL, 2003, GLUTAMATE ADDICTION, P201; CALDWELL J, 1972, BIOCHEM J, V129, P11, DOI 10.1042/bj1290011; Cappon GD, 2000, BRAIN RES, V863, P106, DOI 10.1016/S0006-8993(00)02107-7; Cho AK, 2001, SYNAPSE, V39, P161, DOI 10.1002/1098-2396(200102)39:2<161::AID-SYN7>3.0.CO;2-E; Choi HJ, 2002, MOL CELLS, V13, P221; CONNELL PH, 1968, P ROY SOC MED, V61, P178, DOI 10.1177/003591576806100228; Cregan SP, 2002, J CELL BIOL, V158, P507, DOI 10.1083/jcb.200202130; D'Amours D, 2001, J CELL SCI, V114, P3771; Daugas E, 2000, FASEB J, V14, P729, DOI 10.1096/fasebj.14.5.729; Davidson C, 2001, BRAIN RES REV, V36, P1, DOI 10.1016/S0165-0173(01)00054-6; Deng XL, 1999, J NEUROSCI, V19, P10107; Deng XL, 2000, MOL BRAIN RES, V83, P121, DOI 10.1016/S0169-328X(00)00169-8; Deng XL, 2002, MOL PHARMACOL, V62, P993, DOI 10.1124/mol.62.5.993; Deng XL, 2002, NEUROPHARMACOLOGY, V42, P837, DOI 10.1016/S0028-3908(02)00034-5; Deng XL, 2001, MOL BRAIN RES, V93, P64, DOI 10.1016/S0169-328X(01)00184-X; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Eisch AJ, 1998, SYNAPSE, V30, P329, DOI 10.1002/(SICI)1098-2396(199811)30:3<329::AID-SYN10>3.0.CO;2-V; Eisch AJ, 1998, SYNAPSE, V30, P433, DOI 10.1002/(SICI)1098-2396(199812)30:4<433::AID-SYN10>3.3.CO;2-F; ELLINWOOD E H JR, 1970, Biological Psychiatry, V2, P27; ELLISON G, 1993, NEUROREPORT, V5, P17, DOI 10.1097/00001756-199310000-00004; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ernst T, 2000, NEUROLOGY, V54, P1344, DOI 10.1212/WNL.54.6.1344; ESCALANTE OD, 1970, BRAIN RES, V21, P151; Farid P, 2001, NEOPLASMA, V48, P299; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fukumura M, 1998, BRAIN RES, V806, P1, DOI 10.1016/S0006-8993(98)00656-8; Genc K, 2003, BRAIN RES, V982, P125, DOI 10.1016/S0006-8993(03)02890-7; Gluck MR, 2001, J NEUROCHEM, V79, P152, DOI 10.1046/j.1471-4159.2001.00549.x; Gotz T, 1997, J NEUROSCI, V17, P204; Granville DJ, 2001, AM J PATHOL, V159, P305, DOI 10.1016/S0002-9440(10)61696-3; Graybiel A M, 1993, NIDA Res Monogr, V125, P72; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hacki J, 2000, ONCOGENE, V19, P2286, DOI 10.1038/sj.onc.1203592; Haughey HM, 2000, BRAIN RES, V863, P59, DOI 10.1016/S0006-8993(00)02094-1; HOTCHKISS AJ, 1979, LIFE SCI, V25, P1373, DOI 10.1016/0024-3205(79)90414-4; Jayanthi S, 1998, ANN NY ACAD SCI, V844, P92, DOI 10.1111/j.1749-6632.1998.tb08224.x; Jayanthi S, 2001, FASEB J, V15, P1745, DOI 10.1096/fj.01-0025com; Jayanthi S, 2002, MOL PHARMACOL, V61, P1124, DOI 10.1124/mol.61.5.1124; Kirkland RA, 2001, J NEUROSCI, V21, P1949, DOI 10.1523/JNEUROSCI.21-06-01949.2001; Kita T, 2003, J PHARMACOL SCI, V92, P178; KORSMEYER SJ, 1993, SEMIN CANCER BIOL, V4, P327; KRAMER JC, 1967, J AMER MED ASSOC, V201, P305, DOI 10.1001/jama.201.5.305; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Kwok KHH, 1997, BRAIN RES, V778, P43, DOI 10.1016/S0006-8993(97)00950-5; Lan KC, 1998, J FORMOS MED ASSOC, V97, P528; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; MARTIN DL, 1993, J NEUROCHEM, V60, P395, DOI 10.1111/j.1471-4159.1993.tb03165.x; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; McCann UD, 1998, J NEUROSCI, V18, P8417; McCullough KD, 2001, MOL CELL BIOL, V21, P1249, DOI 10.1128/MCB.21.4.1249-1259.2001; McIlroy D, 2000, GENE DEV, V14, P549; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; NASH JF, 1992, BRAIN RES, V581, P237, DOI 10.1016/0006-8993(92)90713-J; Nutt LK, 2002, J BIOL CHEM, V277, P9219, DOI 10.1074/jbc.M106817200; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; Perez JA, 1999, J EMERG MED, V17, P469, DOI 10.1016/S0736-4679(99)00009-8; Putcha GV, 2002, J CELL BIOL, V157, P441, DOI 10.1083/jcb.200110108; Ron D, 2002, J CLIN INVEST, V110, P1383, DOI 10.1172/JCI200216784; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; SAIDO TC, 1994, FASEB J, V8, P814, DOI 10.1096/fasebj.8.11.8070630; Schmued LC, 1997, BRAIN RES, V759, P135, DOI 10.1016/S0006-8993(97)00173-X; SCHOUSBOE A, 1992, PROG BRAIN RES, V94, P199; Seiden L S, 1996, NIDA Res Monogr, V163, P251; Sekine Y, 2001, AM J PSYCHIAT, V158, P1206, DOI 10.1176/appi.ajp.158.8.1206; Soghomonian JJ, 1998, TRENDS PHARMACOL SCI, V19, P500, DOI 10.1016/S0165-6147(98)01270-X; SONSALLA PK, 1988, PROG NEURO-PSYCHOPH, V12, P345, DOI 10.1016/0278-5846(88)90054-1; Stumm G, 1999, FASEB J, V13, P1065, DOI 10.1096/fasebj.13.9.1065; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thiriet N, 2002, FASEB J, V16, P1887, DOI 10.1096/fj.02-0502com; Thiriet N, 2001, BRAIN RES, V919, P31, DOI 10.1016/S0006-8993(01)02991-2; Uehara T, 1999, J NEUROCHEM, V72, P196, DOI 10.1046/j.1471-4159.1999.0720196.x; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Volkow ND, 2001, J NEUROSCI, V21, P9414, DOI 10.1523/JNEUROSCI.21-23-09414.2001; Volkow ND, 2001, AM J PSYCHIAT, V158, P2015, DOI 10.1176/appi.ajp.158.12.2015; Wang XC, 2002, SCIENCE, V298, P1587, DOI 10.1126/science.1076194; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Welihinda AA, 1999, GENE EXPRESSION, V7, P293; Wilson JM, 1996, NAT MED, V2, P699, DOI 10.1038/nm0696-699; Xie T, 2002, J NEUROSCI, V22, P274, DOI 10.1523/JNEUROSCI.22-01-00274.2002; Yakovlev AG, 2001, J NEUROSCI, V21, P7439, DOI 10.1523/JNEUROSCI.21-19-07439.2001; Yamamoto BK, 1998, J PHARMACOL EXP THER, V287, P107; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Yu ZF, 1999, EXP NEUROL, V155, P302, DOI 10.1006/exnr.1998.7002; ZALIS EG, 1967, J PHARMACOL EXP THER, V158, P115; Zhang XP, 2002, J NEUROCHEM, V82, P181, DOI 10.1046/j.1471-4159.2002.00975.x; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	109	223	227	2	20	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					238	251		10.1096/fj.03-0295com	http://dx.doi.org/10.1096/fj.03-0295com			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769818				2022-12-28	WOS:000220425000004
J	Axelrad, TW; Deo, DD; Ottino, P; Van Kirk, J; Bazan, NG; Bazan, HEP; Hunt, JD				Axelrad, TW; Deo, DD; Ottino, P; Van Kirk, J; Bazan, NG; Bazan, HEP; Hunt, JD			Platelet-activating factor (PAF) induces activation of matrix metalloproteinase 2 activity and vascular endothelial cell invasion and migration	FASEB JOURNAL			English	Article						HUVEC; MMP2; MT1-MMP; TIMP2; angiogenesis; PAF; PAF receptor; bFGF	TYPE-1 MATRIX-METALLOPROTEINASE; FIBROBLAST-GROWTH-FACTOR; NECROSIS-FACTOR-ALPHA; INDUCED IN-VIVO; GELATINASE-A; 1-MATRIX METALLOPROTEINASE; MOLECULAR-MECHANISMS; TISSUE INHIBITOR; FACTOR RECEPTOR; IV COLLAGENASE	Tumor-induced angiogenic responses lead to complex phenotypic changes in vascular endothelial cells, which must coordinate the expression of both proteases and protease inhibitors prior to the proliferation and invasion of surrounding stroma. Matrix metalloproteinase 2 (MMP2), which degrades Type IV collagen, is produced as proMMP2. proMMP2 is activated in part through its interactions with membrane Type 1 MMP (MT1-MMP) and tissue inhibitor of matrix metalloproteinase 2 (TIMP2). In this study, we demonstrate that platelet-activating factor (PAF) is a potent inducer of human umbilical vein endothelial cell (HUVEC) migration and invasion, which is attenuated by PAF receptor antagonists, and that PAF receptor antagonists inhibit the migration and invasion of HUVEC mediated by medium conditioned by a prostatic carcinoma cell line. We confirm that PAF receptor antagonists inhibit proliferation of HUVEC grown in rich growth medium. We show that PAF increases mRNA levels for MT1-MMP and TIMP2, followed by increased temporal conversion of latent proMMP2 to MMP2. Finally, we demonstrate that the ratio of MT1-MMP to TIMP2 in membrane preparations from PAF-stimulated HUVEC is 1.6:1, approximating the hypothesized ideal ratio of 2:1 necessary for the conversion of proMMP2 to MMP2. Our data support the involvement of PAF in vascular endothelial cell migration and invasion.	Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA; Louisiana State Univ, Hlth Sci Ctr, Ctr Neurosci, Dept Ophthalmol, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Hunt, JD (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Stanley S Scott Canc Ctr, 533 Bolivar St,CSB-4-18, New Orleans, LA 70112 USA.	jhunt@lsuhsc.edu	Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Hunt, Jay/0000-0002-8838-201X				ALI H, 1994, J BIOL CHEM, V269, P24557; BAZAN HEP, 1993, P NATL ACAD SCI USA, V90, P8678, DOI 10.1073/pnas.90.18.8678; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Bernatchez PN, 2002, J CELL BIOCHEM, V85, P629, DOI 10.1002/jcb.10155; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Brizzi MF, 1999, CIRC RES, V84, P785; Brower V, 1999, NAT BIOTECHNOL, V17, P963, DOI 10.1038/13654; Bussolati B, 2000, AM J PATHOL, V157, P1713, DOI 10.1016/S0002-9440(10)64808-0; BUSSOLINO F, 1995, J CLIN INVEST, V96, P940, DOI 10.1172/JCI118142; CAMUSSI G, 1995, J IMMUNOL, V154, P6492; Camussi G, 1997, J IMMUNOL, V158, P1302; Cao J, 1998, J BIOL CHEM, V273, P34745, DOI 10.1074/jbc.273.52.34745; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Colorado PC, 2000, CANCER RES, V60, P2520; Del Sorbo L, 2001, EUR J IMMUNOL, V31, P376, DOI 10.1002/1521-4141(200102)31:2<376::AID-IMMU376>3.0.CO;2-5; Deo DD, 2002, J BIOL CHEM, V277, P21237, DOI 10.1074/jbc.M110955200; DEO DD, 2003, J BIOL CHEM     1114; DVORAK HF, 1995, AM J PATHOL, V146, P1029; FARR RS, 1980, CLIN IMMUNOL IMMUNOP, V15, P318, DOI 10.1016/0090-1229(80)90044-6; Feldman L, 2002, MICROVASC RES, V63, P41, DOI 10.1006/mvre.2001.2364; Fillmore HL, 2001, J NEURO-ONCOL, V53, P187, DOI 10.1023/A:1012213604731; Flamme I, 1997, J CELL PHYSIOL, V173, P206, DOI 10.1002/(SICI)1097-4652(199711)173:2<206::AID-JCP22>3.0.CO;2-C; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; Gaumond F, 1997, J CARDIOVASC PHARM, V30, P169, DOI 10.1097/00005344-199708000-00004; Gerwins P, 2000, CRIT REV ONCOL HEMAT, V34, P185, DOI 10.1016/S1040-8428(00)00062-7; Gohlke U, 1996, FEBS LETT, V378, P126, DOI 10.1016/0014-5793(95)01435-7; Gourley M, 2000, CURR PHARM DESIGN, V6, P417, DOI 10.2174/1381612003400867; Ishii S, 2000, PROG LIPID RES, V39, P41, DOI 10.1016/S0163-7827(99)00016-8; Itoh T, 1998, CANCER RES, V58, P1048; Jackson JR, 1998, BBA-LIPID LIPID MET, V1392, P145, DOI 10.1016/S0005-2760(98)00012-5; KAIGHN ME, 1980, MODELS PROSTATE CANC, P85; Khoury J, 1996, AM J PHYSIOL-LUNG C, V270, pL298, DOI 10.1152/ajplung.1996.270.2.L298; Ko HM, 2002, CANCER RES, V62, P1809; Kume K, 1997, J BIOL CHEM, V272, P22898, DOI 10.1074/jbc.272.36.22898; LACASSE C, 1991, J LEUKOCYTE BIOL, V49, P245, DOI 10.1002/jlb.49.3.245; LaVallee TM, 1998, J CELL BIOL, V141, P1647, DOI 10.1083/jcb.141.7.1647; Li ZG, 2000, INT J ONCOL, V17, P453; Lupia E, 1996, EUR J IMMUNOL, V26, P1690, DOI 10.1002/eji.1830260804; Montrucchio G, 1997, AM J PATHOL, V151, P557; MONTRUCCHIO G, 1994, J EXP MED, V180, P377, DOI 10.1084/jem.180.1.377; Montrucchio G, 1998, AM J PATHOL, V153, P1589, DOI 10.1016/S0002-9440(10)65747-1; Morrison CJ, 2001, J BIOL CHEM, V276, P47402, DOI 10.1074/jbc.M108643200; Okumura Y, 1997, FEBS LETT, V402, P181, DOI 10.1016/S0014-5793(96)01523-2; Ottino P, 2002, EXP EYE RES, V74, P393, DOI 10.1006/exer.2001.1135; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SA G, 1994, J BIOL CHEM, V269, P3219; Sato T, 1999, ANN NY ACAD SCI, V878, P713, DOI 10.1111/j.1749-6632.1999.tb07770.x; Sato T, 1999, J BIOL CHEM, V274, P37280, DOI 10.1074/jbc.274.52.37280; SATO Y, 1988, J CELL BIOL, V107, P1199, DOI 10.1083/jcb.107.3.1199; Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25; Sirois MG, 1997, AM J PHYSIOL-HEART C, V272, pH2746, DOI 10.1152/ajpheart.1997.272.6.H2746; Southall MD, 2001, J BIOL CHEM, V276, P45548, DOI 10.1074/jbc.M105978200; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAO Y, 1995, INVEST OPHTH VIS SCI, V36, P345; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; Wang HM, 2003, ONCOGENE, V22, P2186, DOI 10.1038/sj.onc.1206348; Yoon SO, 2002, J BIOL CHEM, V277, P30271, DOI 10.1074/jbc.M202647200; Zhu ZP, 2002, CURR CANCER DRUG TAR, V2, P135, DOI 10.2174/1568009023333881; Zimmerman GA, 2002, CRIT CARE MED, V30, pS294, DOI 10.1097/00003246-200205001-00020; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A; Zucker S, 1998, J BIOL CHEM, V273, P1216, DOI 10.1074/jbc.273.2.1216	65	45	46	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					568	+		10.1096/fj.03-0479fje	http://dx.doi.org/10.1096/fj.03-0479fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715700				2022-12-28	WOS:000188829300025
J	Pinet, F; Poirier, F; Fuchs, S; Tharaux, PL; Caron, M; Corvol, P; Michel, JB; Joubert-Caron, R				Pinet, F; Poirier, F; Fuchs, S; Tharaux, PL; Caron, M; Corvol, P; Michel, JB; Joubert-Caron, R			Troponin T as a marker of differentiation revealed by proteomic analysis in renal arterioles	FASEB JOURNAL			English	Article						cell differentiation; hypertension; proteomics; renin angiotensin system; smooth muscle	SMOOTH-MUSCLE CELLS; JUXTAGLOMERULAR CELLS; MASS-SPECTROMETRY; GENE-EXPRESSION; ONE-CLIP; RENIN; KIDNEY; HYPERTENSION; PROTEINS; RAT	Renovascular hypertension is characterized by stenosis of the renal artery and high plasma renin levels. The renal phenotype is characterized by high levels of renin in the hypoperfused kidney due to the recruitment of renin-producing cells along the afferent arterioles. This increase in myoepithelioid cells is due mainly to the differentiation of existing smooth muscle cells with acquisition of a secretory phenotype. To understand the molecular mechanisms involved in this recruitment, we used the established rat model of renovascular hypertension known as the two-kidney, one-clip model in the Lewis rat. Renal arterioles were isolated using magnetized iron suspension. Differential proteomic analysis was performed using 2-D polyacrylamide gel electrophoresis followed by mass spectrometry. Comparative analysis of soluble proteins extracted from afferent arterioles of clipped and contralateral kidneys showed 14 proteins significantly differentially expressed by at least a factor of 2. These proteins were identified by mass spectrometry. The most striking protein revealed by proteomics is troponin T, which is down-regulated in the afferent arterioles of the clipped kidney. Confocal microscopy showed that troponin T is specific of the smooth muscle phenotype and absent in the myoepithelioid phenotype. Our data suggest that troponin T is only present in renal smooth muscle cells.	Inst Pasteur, INSERM, U508, F-59019 Lille, France; Univ Paris 13, Prot Biochem & Proteom Lab, UPRES EA 3408, F-93017 Bobigny, France; Coll France, INSERM, U36, F-75005 Paris, France; Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Bichat Claude Bernard, INSERM, U460, F-75870 Paris 18, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Pinet, F (corresponding author), Inst Pasteur, INSERM, U508, 1 Rue Professeur Calmette, F-59019 Lille, France.	florence.pinet@pasteur-lille.fr	Michel, Jean-Baptiste/AAH-9336-2020; Tharaux, Pierre-Louis/A-9155-2009; Pinet, Florence/F-2892-2013	Tharaux, Pierre-Louis/0000-0002-6062-5905; Pinet, Florence/0000-0002-5471-1487				Appel RD, 1997, ELECTROPHORESIS, V18, P2735, DOI 10.1002/elps.1150181507; Banks RE, 2000, LANCET, V356, P1749, DOI 10.1016/S0140-6736(00)03214-1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CANTIN M, 1977, AM J PATHOL, V87, P581; CHATZIANTONIOU C, 1993, AM J PHYSIOL, V265, pF853, DOI 10.1152/ajprenal.1993.265.6.F853; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corman B, 1995, MECH AGEING DEV, V84, P1, DOI 10.1016/0047-6374(95)01630-I; DESCHEPPER CF, 1986, P NATL ACAD SCI USA, V83, P7552, DOI 10.1073/pnas.83.19.7552; DUBEY RK, 1992, CIRC RES, V71, P1143, DOI 10.1161/01.RES.71.5.1143; GALEN FX, 1984, J CLIN INVEST, V74, P723, DOI 10.1172/JCI111488; Goldblatt H, 1934, J EXP MED, V59, P347, DOI 10.1084/jem.59.3.347; GOMEZ RA, 1990, AM J PHYSIOL, V259, pF660, DOI 10.1152/ajprenal.1990.259.4.F660; Joubert-Caron R, 2000, ELECTROPHORESIS, V21, P2566, DOI 10.1002/1522-2683(20000701)21:12<2566::AID-ELPS2566>3.0.CO;2-F; Joubert-Caron R, 1999, ELECTROPHORESIS, V20, P1017, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<1017::AID-ELPS1017>3.0.CO;2-K; KURTZ A, 1984, BIOCHEM BIOPH RES CO, V124, P359, DOI 10.1016/0006-291X(84)91561-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lopez MLSS, 2001, AM J PHYSIOL-RENAL, V281, pF345, DOI 10.1152/ajprenal.2001.281.2.F345; Mayer DCG, 1997, J CELL BIOL, V139, P1477, DOI 10.1083/jcb.139.6.1477; Medhora M, 2002, AM J PHYSIOL-HEART C, V282, pH414, DOI 10.1152/ajpheart.00292.2001; MENARD J, 1972, ENDOCRINOLOGY, V90, P422, DOI 10.1210/endo-90-2-422; MICHEL JB, 1986, KIDNEY INT, V29, P1011, DOI 10.1038/ki.1986.101; MIKSCHE L W, 1970, Circulation Research, V27, P973, DOI 10.1161/01.RES.27.6.973; Patterson SD, 2000, PHYSIOL GENOMICS, V2, P59, DOI 10.1152/physiolgenomics.2000.2.2.59; Pickering Thomas G., 1995, P2039; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Taugner R, 1989, JUXTAGLOMERULAR APPA; Thongboonkerd V, 2002, J BIOL CHEM, V277, P34708, DOI 10.1074/jbc.M203799200; Wiesel P, 1997, HYPERTENSION, V29, P1025, DOI 10.1161/01.HYP.29.4.1025; ZANELLATO AMC, 1991, CIRC RES, V68, P1349, DOI 10.1161/01.RES.68.5.1349	29	22	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					585	+		10.1096/fj.03-0939fje	http://dx.doi.org/10.1096/fj.03-0939fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715693				2022-12-28	WOS:000188829300030
J	Speidl, WS; Toller, WG; Kaun, C; Weiss, TW; Pfaffenberger, S; Kastl, SP; Furnkranz, A; Maurer, G; Huber, K; Metzler, H; Wojta, J				Speidl, WS; Toller, WG; Kaun, C; Weiss, TW; Pfaffenberger, S; Kastl, SP; Furnkranz, A; Maurer, G; Huber, K; Metzler, H; Wojta, J			Catecholamines potentiate LPS-induced expression of MMP-1 and MMP-9 in human monocytes and in the human monocytic cell line U937: possible implications for perioperative plaque instability	FASEB JOURNAL			English	Article						monocytes; lipopolysaccharide; epinephrine; norepinephrine; metalloproteinase	MATRIX-METALLOPROTEINASE EXPRESSION; NONCARDIAC SURGERY; CARDIAC RISK; ATHEROSCLEROTIC PLAQUES; ALVEOLAR MACROPHAGES; TISSUE INHIBITOR; ENDOTOXEMIA; INDUCTION; ASSOCIATION; MORBIDITY	Plaque destabilization leading to myocardial infarction is observed after surgery even if the intervention is of noncardiovascular nature. Mediators of peri- or postoperative stress responsible for such events could include catecholamines and lipopolysaccharide (LPS). Monocytes may be involved in destabilization of atherosclerotic plaques by production of matrix metalloproteinases (MMP). We examined whether catecholamines could affect the expression of MMPs in human monocytes/macrophages and whether catecholamines could modulate LPS-stimulated expression of particular MMPs in these cells. Epinephrine and norepinephrine up-regulated MMP-1 and potentiated LPS-induced expression of MMP-1 in peripheral blood monocytes and monocyte-derived macrophages. We further characterized this effect employing the monocytic cell line U937 and showed that catecholamines potentiate LPS-induced effects on MMP-1 and MMP-9 antigen and activity. mRNA levels of the respective MMPs also increased. These effects did not result from higher mRNA stability but rather from increased transcription possibly induced by enhanced DNA binding of AP-1 and were mediated by either beta(1)- or beta(2)-receptors. If this mechanism is also effective in vivo, our findings might, at least in part, help to explain the observation that cardiac events are important causes of morbidity and mortality after noncardiac surgery and support the findings that peri-operative beta-blockade has been shown to reduce postoperative mortality from cardiac events.	Univ Vienna, Dept Internal Med 2, A-1090 Vienna, Austria; Graz Univ, Dept Anaesthesiol & Intens Care Med, Graz, Austria; Univ Vienna, Dept Vasc Biol & Thrombosis Res, Vienna, Austria	University of Vienna; University of Graz; University of Vienna	Wojta, J (corresponding author), Univ Vienna, Dept Internal Med 2, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	johann.wojta@univie.ac.at	Wojta, Johann/AAC-8433-2020; Speidl, Walter S./AAU-8830-2020; Kastl, Stefan P/B-2695-2009; Kaun, Christoph/L-7543-2015	Wojta, Johann/0000-0002-1282-9276; Speidl, Walter S./0000-0002-7267-3138; Kastl, Stefan P/0000-0002-9682-0200; Kaun, Christoph/0000-0003-3873-7246; Maurer, Gerald/0000-0002-9043-7657				Bierhaus A, 2003, P NATL ACAD SCI USA, V100, P1920, DOI 10.1073/pnas.0438019100; Boelke E, 2000, ANGIOLOGY, V51, P743; Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; BROWN DL, 1995, CIRCULATION, V91, P2125, DOI 10.1161/01.CIR.91.8.2125; Burke AP, 1997, NEW ENGL J MED, V336, P1276, DOI 10.1056/NEJM199705013361802; Buttenschoen K, 2001, AM J SURG, V181, P36, DOI 10.1016/S0002-9610(00)00534-1; Death AK, 2002, J AM COLL CARDIOL, V39, P1943, DOI 10.1016/S0735-1097(02)01907-1; DOKTER WHA, 1993, BLOOD, V81, P337; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Fleisher LA, 2001, NEW ENGL J MED, V345, P1677, DOI 10.1056/NEJMcp002842; GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619; GALIS ZS, 1995, FASEB J, V9, P974, DOI 10.1096/fasebj.9.10.7615167; GOLDMAN L, 1995, ANESTH ANALG, V80, P810, DOI 10.1097/00000539-199504000-00028; Gornikiewicz A, 2000, FASEB J, V14, P1093, DOI 10.1096/fasebj.14.9.1093; Kai HK, 1998, J AM COLL CARDIOL, V32, P368, DOI 10.1016/S0735-1097(98)00250-2; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Lau LL, 2000, EUR J VASC ENDOVASC, V19, P619, DOI 10.1053/ejvs.2000.1063; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; Lim S, 2000, AM J RESP CRIT CARE, V162, P1355, DOI 10.1164/ajrccm.162.4.9910097; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Pierce RA, 1996, J CLIN INVEST, V97, P1890, DOI 10.1172/JCI118620; Rivera-Marrero CA, 2000, MICROB PATHOGENESIS, V29, P231, DOI 10.1006/mpat.2000.0383; Sametz W, 1999, EUR J CLIN INVEST, V29, P582; SHAH PK, 1995, CIRCULATION, V92, P1565; Shankavaram UT, 1998, J LEUKOCYTE BIOL, V64, P221, DOI 10.1002/jlb.64.2.221; SHAPIRO SD, 1991, J IMMUNOL, V146, P2724; Steiner S, 2003, ARTERIOSCL THROM VAS, V23, P1697, DOI 10.1161/01.ATV.0000087035.46547.89; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781	29	60	61	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					603	+		10.1096/fj.03-0454fje	http://dx.doi.org/10.1096/fj.03-0454fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715701				2022-12-28	WOS:000188829300027
J	Weber, AA; Neuhaus, T; Skach, RA; Hescheler, J; Ahn, HY; Schror, K; Ko, Y; Sachinidis, A				Weber, AA; Neuhaus, T; Skach, RA; Hescheler, J; Ahn, HY; Schror, K; Ko, Y; Sachinidis, A			Mechanisms of the inhibitory effects of epigallocatechin-3 gallate on platelet-derived growth factor-BB-induced cell signaling and mitogenesis	FASEB JOURNAL			English	Article						catechins; smooth muscle; endothelial cells; PDGF isoforms; receptor tyrosine kinases	SMOOTH-MUSCLE-CELLS; (-)-EPIGALLOCATECHIN GALLATE; TRANSDUCTION PATHWAY; GREEN TEA; TYROSINE-PHOSPHORYLATION; HUMAN GLIOBLASTOMA; FACTOR RECEPTORS; BETA-RECEPTOR; CANCER; RAT		Univ Clin Dusseldorf, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany; Univ Bonn, Med Policlin, Bonn, Germany; Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany; Chungbuk Natl Univ, Coll Med, Dept Pharmacol, Cheongju, South Korea	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf Hospital; University of Bonn; University of Cologne; Chungbuk National University	Sachinidis, A (corresponding author), Univ Cologne, Ctr Physiol & Pathophysiol, D-50931 Cologne, Germany.	A.Sachinidis@unikoeln.de	Sachinidis, Agapios/AAM-7988-2020; Weber, Artur-Aron/GOH-2864-2022; Sachinidis, Agapios/AAD-4178-2020		Deutsche Forschungsgemeinschaft [Sa 568/5-3, DFG KOR-113/157/0-1]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by a grant from the Deutsche Forschungsgemeinschaft (Sa 568/5-3) and DFG KOR-113/157/0-1. We thank Claudia Seul for excellent technical assistance.	Ahn HY, 1999, MOL BIOL CELL, V10, P1093, DOI 10.1091/mbc.10.4.1093; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; Chen QX, 1998, BIOCHEM MOL BIOL INT, V45, P465; George D, 2001, SEMIN ONCOL, V28, P27, DOI 10.1053/sonc.2001.29185; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; HOPPE J, 1989, BIOCHEMISTRY-US, V28, P2956, DOI 10.1021/bi00433a032; Kitano K, 1997, BIOPHYS CHEM, V65, P157, DOI 10.1016/S0301-4622(96)02254-5; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Naasani I, 1998, BIOCHEM BIOPH RES CO, V249, P391, DOI 10.1006/bbrc.1998.9075; Nam S, 2001, J BIOL CHEM, V276, P13322, DOI 10.1074/jbc.M004209200; Okabe S, 1999, JPN J CANCER RES, V90, P733, DOI 10.1111/j.1349-7006.1999.tb00808.x; Ostman A, 2001, ADV CANCER RES, V80, P1, DOI 10.1016/S0065-230X(01)80010-5; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rusnati M, 1999, MOL BIOL CELL, V10, P313, DOI 10.1091/mbc.10.2.313; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; Sachinidis A, 1996, EUR J CELL BIOL, V71, P79; Sachinidis A, 2002, FASEB J, V16, P893, DOI 10.1096/fj.01-0799fje; Sachinidis A, 1999, BRIT J PHARMACOL, V128, P1761, DOI 10.1038/sj.bjp.0702969; Sachinidis A, 1997, HYPERTENSION, V29, P326, DOI 10.1161/01.HYP.29.1.326; Sachinidis A, 2000, FEBS LETT, V471, P51, DOI 10.1016/S0014-5793(00)01360-0; Sazuka M, 1996, BIOSCI BIOTECH BIOCH, V60, P1317, DOI 10.1271/bbb.60.1317; Sazuka M, 1998, BIOSCI BIOTECH BIOCH, V62, P1031, DOI 10.1271/bbb.62.1031; Tosetti F, 2002, FASEB J, V16, P2, DOI 10.1096/fj.01-0300rev; WANG ZY, 1988, DRUG METAB DISPOS, V16, P98; Yang CS, 2000, J NUTR, V130, p472S, DOI 10.1093/jn/130.2.472S; Yu JH, 2003, J BIOCHEM MOL BIOL, V36, P49	27	70	72	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					128	130		10.1096/fj.03-0007fje	http://dx.doi.org/10.1096/fj.03-0007fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630705				2022-12-28	WOS:000188829300049
J	Wu, SF; Palese, T; Mishra, OM; Delivoria-Papadopoulos, M; De Luca, F				Wu, SF; Palese, T; Mishra, OM; Delivoria-Papadopoulos, M; De Luca, F			Effects of Ca2+ sensing receptor activation in the growth plate	FASEB JOURNAL			English	Article						bone growth; endochondral ossification; chondrocytes	LONGITUDINAL BONE-GROWTH; SKELETAL PHENOTYPE; CALCIUM; CHONDROCYTES; HOMEOSTASIS; PHOSPHATE; RICKETS; MICE; CELL	The Ca2+-sensing receptor (CaR) is a G protein-coupled receptor expressed in many mammalian tissues, including the long bone.s growth plate. CaR knockout mice exhibit growth retardation, suggesting that CaR may promote skeletal growth. However, the complex phenotype of these knockout mice, which includes hyperparathyroidism, hypercalcemia, and hypophosphatemia, may confound the effects of CaR activation. To determine whether CaR regulates growth plate chondrogenesis and longitudinal bone growth, we chose an organ culture model. Fetal rat metatarsal bones (dpc 20) were cultured in serum-free medium for 7 days in the presence or absence of NPS-R-568, a CaR agonist. The addition of 10 nM NPS-R-568 increased the cumulative longitudinal growth of the metatarsal explants. To explore the underlying mechanisms, we then assessed the effects of NPS-R-568 on growth plate chondrocyte hypertrophy/differentiation and chondrocyte proliferation. After 7 days in culture, NPS-R-568 increased the height of the growth plate hypertrophic zone and the expression of collagen X, a marker of growth plate chondrocyte differentiation (assessed by immunohistochemistry). NPSR-568 also induced a significant increase of the height of the growth plate proliferative zone and of the total thymidine incorporation in the metatarsal bone. In conclusion, our findings suggest that the activation of CaR in the growth plate accelerates longitudinal bone growth by stimulating growth plate chondrogenesis.	St Christophers Hosp Children, Philadelphia, PA 19134 USA; Drexel Univ, St Christophers Hosp Children, Coll Med, Dept Pediat,Sect Endocrinol & Diabet, Philadelphia, PA USA; Drexel Univ, St Christophers Hosp Children, Coll Med, Dept Pediat,Sect Neonatal Med, Philadelphia, PA USA; Univ Maryland, Sch Med, Dept Pediat, Div Pediat Endocrinol, Baltimore, MD USA	Drexel University; Drexel University; University System of Maryland; University of Maryland Baltimore	De Luca, F (corresponding author), St Christophers Hosp Children, Erie Ave & Front St, Philadelphia, PA 19134 USA.	francesco.deluca@drexel.edu						AHARINEJAD S, 1995, ANAT REC, V242, P111, DOI 10.1002/ar.1092420115; Amling M, 1999, ENDOCRINOLOGY, V140, P4982, DOI 10.1210/en.140.11.4982; BAGI C, 1989, CALCIFIED TISSUE INT, V45, P342, DOI 10.1007/BF02556004; BAGI CM, 1992, J BONE MINER RES, V7, P29; BONEN DK, 1991, J CELL BIOL, V115, P1171, DOI 10.1083/jcb.115.4.1171; BREUR GJ, 1991, J ORTHOPAED RES, V9, P348, DOI 10.1002/jor.1100090306; Brown EM, 2000, ANNU REV NUTR, V20, P507, DOI 10.1146/annurev.nutr.20.1.507; BRUCKNER P, 1989, J CELL BIOL, V109, P2537, DOI 10.1083/jcb.109.5.2537; Chang WH, 1999, ENDOCRINOLOGY, V140, P1911, DOI 10.1210/en.140.4.1911; Chang YH, 1999, ENDOCRINOLOGY, V140, P5883, DOI 10.1210/en.140.12.5883; De Luca F, 2001, ENDOCRINOLOGY, V142, P430, DOI 10.1210/en.142.1.430; FARNUM CE, 1987, MICROSCOP RES TECH, V28, P505; Garner SC, 2001, ENDOCRINOLOGY, V142, P3996, DOI 10.1210/en.142.9.3996; HUNZIKER EB, 1994, MICROSC RES TECHNIQ, V28, P505, DOI 10.1002/jemt.1070280606; IANNOTTI JP, 1990, ORTHOP CLIN N AM, V21, P1; KLEIN GL, 1993, ANN MED, V25, P379, DOI 10.3109/07853899309147300; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Noonan KJ, 1998, J ORTHOPAED RES, V16, P500, DOI 10.1002/jor.1100160416; Wang DS, 2001, J BIOL CHEM, V276, P33995, DOI 10.1074/jbc.M007757200; WUTHIER RE, 1993, J NUTR, V123, P301, DOI 10.1093/jn/123.suppl_2.301; Zuscik MJ, 2002, EXP CELL RES, V276, P310, DOI 10.1006/excr.2002.5527	22	42	45	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					143	145		10.1096/fj.03-0294fje	http://dx.doi.org/10.1096/fj.03-0294fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597561				2022-12-28	WOS:000188829300054
J	Yan, CH; Wang, H; Aggarwal, BB; Boyd, DD				Yan, CH; Wang, H; Aggarwal, BB; Boyd, DD			A novel homologous recombination system to study 92 kDa type IV collagenase transcription demonstrates that the NFKB motif drives the transition from a repressed to an activated state of gene expression	FASEB JOURNAL			English	Article						MMP-9; gene expression; chromatin; NF-kappa B	FACTOR-BINDING SITES; MATRIX-METALLOPROTEINASE; KAPPA-B; IN-VITRO; MATRIX-METALLOPROTEINASE-9; GELATINASE; PROMOTER; CANCER; ALPHA; MECHANISM	The 92-kDa type IV collagenase (MMP-9) contributes to tissue remodeling in both physiology and pathology. Previous studies on the transcriptional regulation of this gene have used transiently transfected promoter-reporter constructs. However, this approach suffers from several limitations including (a) multiple copies of the plasmid and (b) the plasmid is not genomically integrated and consequently poorly chromatinized. We developed a novel system for studying MMP-9 transcription in which a single copy of a MMP-9 promoter-luciferase construct(s) is integrated at an identical genomic locus in HT1080 cells by homologous recombination. We report that the activity of a genomic-integrated 2.2 kb MMP-9 promoter sequence mirrors expression of the endogenous MMP-9 gene in response to both physiological and pharmacological (curcumin) cues. Further, when constrained into chromatin, the integrated NF-kappaB-mutated NMP-9 promoter is repressed by PMA, a situation not apparent using nonintegrated plasmids. Thus, we have developed a novel method for studying NMP-9 expression that overcomes some of the limitations associated with transient transfection approaches and which may be of utility in screening for agents that repress the expression of this gene.	Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Boyd, DD (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Canc Biol, Box 173,1515 Holcombe Blvd, Houston, TX 77030 USA.	dboyd@mdanderson.org	Aggarwal, Bharat B/G-3388-2013	Yan, Chunhong/0000-0002-3974-7991				Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Baker KM, 2003, J BIOL CHEM, V278, P17876, DOI 10.1074/jbc.M209480200; BERGH PA, 1992, J ASSIST REPROD GEN, V9, P429, DOI 10.1007/BF01204048; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Cheutin T, 2003, SCIENCE, V299, P721, DOI 10.1126/science.1078572; COLLIER IE, 1991, GENOMICS, V9, P429, DOI 10.1016/0888-7543(91)90408-7; DAVIS GE, 1990, CANCER RES, V50, P1113; El Kharroubi A, 1998, MOL CELL BIOL, V18, P2535, DOI 10.1128/MCB.18.5.2535; Festenstein R, 2003, SCIENCE, V299, P719, DOI 10.1126/science.1078694; FINI ME, 1994, J BIOL CHEM, V269, P28620; FRIDMAN R, 1995, CANCER RES, V55, P2548; Gui CY, 2003, P NATL ACAD SCI USA, V100, P7009, DOI 10.1073/pnas.1236499100; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Haggerty TJ, 2003, P NATL ACAD SCI USA, V100, P5313, DOI 10.1073/pnas.0931346100; HIGASHINO F, 1995, ONCOGENE, V10, P1461; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hua J, 1996, CANCER RES, V56, P5279; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; Jiang Y, 2002, CANCER RES, V62, P1910; Jin SK, 1998, MOL CELL BIOL, V18, P4377, DOI 10.1128/MCB.18.7.4377; Kaya M, 1996, ONCOGENE, V12, P221; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; Lin LI, 1998, ONCOLOGY-BASEL, V55, P349, DOI 10.1159/000011876; LYONS JG, 1993, J BIOL CHEM, V268, P19143; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Moses MA, 1998, CANCER RES, V58, P1395; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; OKADA Y, 1992, J BIOL CHEM, V267, P21712; PUTNINS EE, 1995, J INVEST DERMATOL, V104, P989, DOI 10.1111/1523-1747.ep12606233; RAO JS, 1993, CANCER RES, V53, P2208; Rao SH, 2001, J IMMUNOL, V167, P4494, DOI 10.4049/jimmunol.167.8.4494; SATO H, 1993, J BIOL CHEM, V268, P23460; SATO H, 1993, ONCOGENE, V8, P395; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Sutter NB, 2003, P NATL ACAD SCI USA, V100, P1105, DOI 10.1073/pnas.242732999; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Weinmann AS, 2002, GENE DEV, V16, P235, DOI 10.1101/gad.943102; Yamamoto Y, 2003, NATURE, V423, P655, DOI 10.1038/nature01576; Yan CH, 2001, J BIOL CHEM, V276, P1164, DOI 10.1074/jbc.M008681200; Yan CH, 2003, J BIOL CHEM, V278, P2309, DOI 10.1074/jbc.M210369200; Yu Q, 2000, GENE DEV, V14, P163; ZUCKER S, 1993, CANCER RES, V53, P140	44	40	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					540	+		10.1096/fj.03-0960fje	http://dx.doi.org/10.1096/fj.03-0960fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715692				2022-12-28	WOS:000188829300023
J	de Lange, P; Ragni, M; Silvestri, E; Moreno, M; Schiavo, L; Lombardi, A; Farina, P; Feola, A; Goglia, F; Lanni, A				de Lange, P; Ragni, M; Silvestri, E; Moreno, M; Schiavo, L; Lombardi, A; Farina, P; Feola, A; Goglia, F; Lanni, A			Combined cDNA array/RT-PCR analysis of gene expression profile in rat gastrocnemius muscle: relation to its adaptive function in energy metabolism during fasting	FASEB JOURNAL			English	Article						differentiation; energy expenditure; protein degradation; muscle fibers; uncoupling protein 3	PROLIFERATOR-ACTIVATED RECEPTORS; UBIQUITIN-PROTEASOME PATHWAY; SKELETAL-MUSCLE; UNCOUPLING PROTEIN-3; MESSENGER-RNA; FATTY-ACIDS; SUBSTRATE METABOLISM; UP-REGULATION; UCP3; KINASE	We evaluated the effects of fasting on the gene expression profile in rat gastrocnemius muscle using a combined cDNA array and RT-PCR approach. Of the 1176 distinct rat genes analyzed on the cDNA array, 114 were up-regulated more than twofold in response to fasting, including all 17 genes related to lipid metabolism present on the membranes and all 10 analyzed components of the proteasome machinery. Only 7 genes were down-regulated more than twofold. On the basis of our analysis of genes on the cDNA array plus the data from our RT-PCR assays, the metabolic adaptations shown by rat gastrocnemius muscle during fasting are reflected by i) increased transcription both of myosin heavy chain (NMC) Ib (associated with type I fibers) and of at least three factors involved in the shift toward type I fibers [p27kip1, muscle LIM protein (MLP), cystein rich protein-2], of which one (MLP) has been shown to enhance the activity of MyoD, which would explain the known increase in the expression of skeletal muscle uncoupling protein-3 (UCP3); ii) increased lipoprotein lipase (LPL) expression, known to trigger UCP3 transcription, which tends, together with the first point, to underline the suggested role of UCP3 in mitochondrial lipid handling (the variations under the first point and this one have not been observed in mice, indicating a species-specific regulation of these mechanisms); iii) reduced expression of the muscle-specific coenzyme Q (CoQ)7 gene, which is necessary for mitochondrial CoQ synthesis, together with an increased expression of mitochondrial adenylate kinase 3, which inactivates the resident key enzyme for CoQ synthesis, 3-hydroxy-3-methylglutaryl CoA reductase (HMGR), the mRNA level for which fell during fasting; and iv) increased transcription of components of the proteasomal pathways involved in protein degradation/turnover.	Univ Naples 2, Dipartimento Sci Vita, I-81100 Caserta, Italy; Univ Sannio, Dipartimento Sci Biol & Ambientali, I-82100 Benevento, Italy; Univ Naples Federico II, Dipartimento Fisiol Gen & Ambientale, I-80134 Naples, Italy	Universita della Campania Vanvitelli; University of Sannio; University of Naples Federico II	Lanni, A (corresponding author), Univ Naples 2, Dipartimento Sci Vita, Via Vivaldi 43, I-81100 Caserta, Italy.	pieter.delange@unina2.it; antonia.lanni@unina2.it	de Lange, Pieter/GXA-3052-2022; Schiavo, Luigi/K-5202-2016; Ragni, Maurizio/AAB-1527-2020; Schiavo, Luigi/AAO-7168-2021	Schiavo, Luigi/0000-0003-3639-6847; Ragni, Maurizio/0000-0001-6548-741X; GOGLIA, Fernando/0000-0003-0468-9645; Silvestri, Elena/0000-0002-0592-9033; MORENO, Maria/0000-0002-6218-5501				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Allen DL, 2001, J BIOL CHEM, V276, P43524, DOI 10.1074/jbc.M108017200; Asaumi S, 1999, GENOMICS, V58, P293, DOI 10.1006/geno.1999.5838; Attaix D, 1998, ADV MOL CEL, V27, P235, DOI 10.1016/S1569-2558(08)60463-4; BARGOSSI AM, 1994, MOL ASPECTS MED, V15, P187, DOI 10.1016/0098-2997(94)90028-0; Boss O, 1998, J BIOL CHEM, V273, P5, DOI 10.1074/jbc.273.1.5; Bukovsky Antonin, 2001, BMC Clin Pathol, V1, P4, DOI 10.1186/1472-6890-1-4; Busquets S, 1998, FEBS LETT, V440, P348, DOI 10.1016/S0014-5793(98)01485-9; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Dulloo AG, 2001, BRIT J NUTR, V86, P123, DOI 10.1079/BJN2001412; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Escher P, 2001, ENDOCRINOLOGY, V142, P4195, DOI 10.1210/en.142.10.4195; Fang CH, 2000, ENDOCRINOLOGY, V141, P2743, DOI 10.1210/en.141.8.2743; Goglia F, 2003, FASEB J, V17, P1585, DOI 10.1096/fj.03-0159hyp; GROS G, 1988, ANNU REV PHYSIOL, V50, P669, DOI 10.1146/annurev.ph.50.030188.003321; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; HARTREE EF, 1972, ANAL BIOCHEM, V48, P422, DOI 10.1016/0003-2697(72)90094-2; Hildebrandt AL, 2000, AM J PHYSIOL-ENDOC M, V278, pE1078, DOI 10.1152/ajpendo.2000.278.6.E1078; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Hunt MC, 1999, J BIOL CHEM, V274, P34317, DOI 10.1074/jbc.274.48.34317; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Jaschinski F, 1998, AM J PHYSIOL-CELL PH, V274, pC365, DOI 10.1152/ajpcell.1998.274.2.C365; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031; KIRSCHKE H, 1987, LYSOSOMES THEIR ROLE, P193; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Korshunov SS, 1998, FEBS LETT, V435, P215, DOI 10.1016/S0014-5793(98)01073-4; Kratky D, 2001, BIOCHEM J, V355, P647, DOI 10.1042/bj3550647; LAEMMLI UK, 1970, NATURE, V193, P1058; Lanni A, 1999, FEBS LETT, V444, P250, DOI 10.1016/S0014-5793(99)00061-7; Lazennec G, 2000, MOL ENDOCRINOL, V14, P1962, DOI 10.1210/me.14.12.1962; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; Lloyd RV, 1999, AM J PATHOL, V154, P313, DOI 10.1016/S0002-9440(10)65277-7; Mascaro C, 1998, J BIOL CHEM, V273, P8560, DOI 10.1074/jbc.273.15.8560; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Moreno M, 2003, FASEB J, V17, P1112, DOI 10.1096/fj.02-0839fje; Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225; Pierrat B, 2000, EUR J BIOCHEM, V267, P2680, DOI 10.1046/j.1432-1327.2000.01285.x; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Richter E.A., 1996, COMPR PHYSIOL, P912, DOI [10.1002/cphy.cp120120, DOI 10.1002/CPHY.CP120120]; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; Samec S, 2002, PFLUG ARCH EUR J PHY, V445, P80, DOI 10.1007/s00424-002-0879-9; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Solanes G, 2000, FASEB J, V14, P2141; Son C, 2001, ENDOCRINOLOGY, V142, P4189, DOI 10.1210/en.142.10.4189; Tu N, 2000, LIFE SCI, V67, P2267, DOI 10.1016/S0024-3205(00)00802-X; Turunen M, 2002, FREE RADICAL RES, V36, P437, DOI 10.1080/10715760290021298; Van der Lee KAJM, 2001, J LIPID RES, V42, P1752; Wang L, 1998, SHOCK, V10, P298, DOI 10.1097/00024382-199810000-00011; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; WILLIS RA, 1990, P NATL ACAD SCI USA, V87, P8928, DOI 10.1073/pnas.87.22.8928; Willmann R, 2001, AM J PHYSIOL-CELL PH, V280, pC273, DOI 10.1152/ajpcell.2001.280.2.C273; Wing SS, 1996, BIOCHEM J, V319, P455, DOI 10.1042/bj3190455; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; Zhou M, 2000, AM J PHYSIOL-ENDOC M, V279, pE622, DOI 10.1152/ajpendo.2000.279.3.E622	60	50	52	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					350	+		10.1096/fj.03-0342fje	http://dx.doi.org/10.1096/fj.03-0342fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656997				2022-12-28	WOS:000188067500020
J	Namazi, MR				Namazi, MR			Pyridoxal 5 '-phosphateas a novel weapon against autoimmunity and transplant rejection	FASEB JOURNAL			English	Article						autoimmunity; HIV; pyridoxal 5 '-phosphate; transplant rejection; treatment; CD4	EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MONOCLONAL-ANTIBODY THERAPY; POSSIBLE INVOLVEMENT; CD4; ACTIVATION; RECEPTOR; PROLIFERATION; MOLECULE	Activation of CD4 T cells by antigen-presenting cells is required for the full expression of most autoimmune diseases and allogeneic transplant rejection. The extracellular part of CD4 molecule is composed of four domains, D1-D4. CD4 binds to MHC class II via its D1 and D2 domains. Pyridoxal 5'-phosphate (PLP) binds very tightly to the D1 domain of CD4 and therefore could interfere with proper CD4-MHC II interaction. Nonincorporation of CD4 into the activation complex can result in T cell apoptosis and anergy to autoantigen (s). Occupancy of D1 by PLP may prevent the proper protein-protein interactions of the CD4 molecule itself, which are important in T cell activation. PLP may also interfere with the dimerization of CD4 molecules, which occurs during T cell activation, or with the interaction of this dimer with other molecules on the T cell surface, such as CD45, thereby further rendering T cells anergic or driven to apoptosis. Therefore, PLP may have utility in the treatment of autoimmunity and transplant rejection. Furthermore, as the interaction of the HIV gp120 and CD4 occurs via D1, PLP is supposed to have anti-HIV effect as well. PLP may prove of special utility in the treatment of patients affected with both autoimmunity and HIV, for whom the routine immunosuppressives are contraindicated.	Shiraz Univ Med Sci, Dept Dermatol, Shiraz, Iran	Shiraz University of Medical Science	Namazi, MR (corresponding author), POB 71955-687, Shiraz, Iran.	namazi_mr@yahoo.com	namazi, mohammad reza/E-3197-2018	namazi, mohammad reza/0000-0002-7409-7437				BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; Breedveld FC, 1998, RHEUM DIS CLIN N AM, V24, P567, DOI 10.1016/S0889-857X(05)70026-0; Cobbold S P, 1990, Semin Immunol, V2, P377; CUSH JJ, 1991, CLIN ORTHOP RELAT R, V265, P9; DESILVA DR, 1991, J IMMUNOL, V147, P3261; KLEIN J, 1999, IMMUNOLOGY, P195; KORCHAK HM, 1990, P NATL ACAD SCI USA, V77, P2721; KOTZIN BL, 2001, CLIN IMMUNOLOGY PRIN, V1; Marini JC, 1996, J IMMUNOL, V157, P3706; MITTLER RS, 1991, J IMMUNOL, V147, P3434; PARNES JR, 1989, ADV IMMUNOL, V44, P265; RANGES GE, 1985, J EXP MED, V162, P1105, DOI 10.1084/jem.162.3.1105; SAKANE T, 1989, CLIN EXP IMMUNOL, V75, P269; SALHANY JM, 1993, J BIOL CHEM, V268, P7643; Schulze-Koops H, 2000, CURR DIRECT AUTOIMMU, V2, P24; WALDOR MK, 1985, SCIENCE, V227, P415, DOI 10.1126/science.3155574; ZERBIB AC, 1994, J EXP MED, V179, P1973, DOI 10.1084/jem.179.6.1973	18	4	5	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2184	2186		10.1096/fj.03-0465hyp	http://dx.doi.org/10.1096/fj.03-0465hyp			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656979				2022-12-28	WOS:000188067500038
J	Tomczak, KK; Marinescu, VD; Ramoni, MF; Sanoudou, D; Montanaro, F; Han, M; Kunkel, LM; Kohane, IS; Beggs, AH				Tomczak, KK; Marinescu, VD; Ramoni, MF; Sanoudou, D; Montanaro, F; Han, M; Kunkel, LM; Kohane, IS; Beggs, AH			Expression profiling and identification of novel genes involved in myogenic differentiation	FASEB JOURNAL			English	Article						C2C12 myoblasts; myogenesis; microarrays; cluster analysis; Expressed Sequence Tags	SKELETAL-MUSCLE REGENERATION; CELL-CYCLE WITHDRAWAL; TRANS-DIFFERENTIATION; MYOBLAST FUSION; MYOD; PROTEIN; PROSTAGLANDINS; TRANSCRIPTION; CAVEOLIN-3; INDUCTION	Skeletal muscle differentiation is a complex, highly coordinated process that relies on precise temporal gene expression patterns. To better understand this cascade of transcriptional events, we used expression profiling to analyze gene expression in a 12-day time course of differentiating C2C12 myoblasts. Cluster analysis specific for time-ordered microarray experiments classified 2895 genes and ESTs with variable expression levels between proliferating and differentiating cells into 22 clusters with distinct expression patterns during myogenesis. Expression patterns for several known and novel genes were independently confirmed by real-time quantitative RT-PCR and/or Western blotting and immunofluorescence. MyoD and MEF family members exhibited unique expression kinetics that were highly coordinated with cell-cycle withdrawal regulators. Among genes with peak expression levels during cell cycle withdrawal were Vcam1, Itgb3, Itga5, Vcl, as well as Ptger4, a gene not previously associated with the process of myogenesis. One interesting uncharacterized transcript that is highly induced during myogenesis encodes several immunoglobulin repeats with sequence similarity to titin, a large sarcomeric protein. These data sets identify many additional uncharacterized transcripts that may play important functions in muscle cell proliferation and differentiation and provide a baseline for comparison with C2C12 cells expressing various mutant genes involved in myopathic disorders.	Childrens Hosp Boston, Div Genet, Boston, MA 02115 USA; Childrens Hosp Boston, Genom Program, Boston, MA 02115 USA; Childrens Hosp, Informat Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Beggs, AH (corresponding author), Childrens Hosp Boston, Div Genet, 300 Longwood Ave, Boston, MA 02115 USA.	beggs@enders.tch.harvard.edu	Montanaro, Federica/GRJ-5139-2022; Sanoudou, Despina/AAD-8139-2019; Kohane, Isaac Kohane/K-3716-2012	Montanaro, Federica/0000-0002-3338-0498; Sanoudou, Despina/0000-0003-3704-1941; Kohane, Isaac Kohane/0000-0003-2192-5160; Beggs, Alan/0000-0001-8818-0568	NINDS NIH HHS [P01 NS040828] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS040828] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amthor H, 1996, DEV BIOL, V178, P343, DOI 10.1006/dbio.1996.0223; Anderson JE, 1998, BIOCHEM CELL BIOL, V76, P13, DOI 10.1139/bcb-76-1-13; Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BOBER E, 1991, J CELL BIOL, V6, P1255; Chambers R L, 1996, Can J Appl Physiol, V21, P155; Delgado I, 2003, GENOMICS, V82, P109, DOI 10.1016/S0888-7543(03)00104-6; ENTWISTLE A, 1986, J CELL BIOL, V103, P857, DOI 10.1083/jcb.103.3.857; Franklin DS, 1996, MOL BIOL CELL, V7, P1587, DOI 10.1091/mbc.7.10.1587; Friday BB, 2003, DIFFERENTIATION, V71, P217, DOI 10.1046/j.1432-0436.2003.710303.x; Galbiati F, 2001, TRENDS MOL MED, V7, P435, DOI 10.1016/S1471-4914(01)02105-0; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Granzier H, 2002, J PHYSIOL-LONDON, V541, P335, DOI 10.1113/jphysiol.2001.014381; Grimaldi PA, 1997, PROSTAG LEUKOTR ESS, V57, P71, DOI 10.1016/S0952-3278(97)90495-6; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Ikeda K, 2003, J BIOL CHEM, V278, P3514, DOI 10.1074/jbc.M204563200; Inoue C, 2001, GENES CELLS, V6, P977, DOI 10.1046/j.1365-2443.2001.00476.x; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Liu LA, 1999, J BIOL CHEM, V274, P38171, DOI 10.1074/jbc.274.53.38171; Machwate M, 2001, MOL PHARMACOL, V60, P36, DOI 10.1124/mol.60.1.36; Maeda T, 2001, J BIOL CHEM, V276, P3628, DOI 10.1074/jbc.M007898200; McKinsey TA, 2001, CURR OPIN GENET DEV, V11, P497, DOI 10.1016/S0959-437X(00)00224-0; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; Moran JL, 2002, PHYSIOL GENOMICS, V10, P103, DOI 10.1152/physiolgenomics.00011.2002; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, P438, DOI 10.1016/S0960-8966(01)00326-1; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Ohyama M, 2002, J PERIODONTOL, V73, P543, DOI 10.1902/jop.2002.73.5.543; PATAPOUTIAN A, 1995, DEVELOPMENT, V121, P3347; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Ramoni MF, 2002, P NATL ACAD SCI USA, V99, P9121, DOI 10.1073/pnas.132656399; ROSEN SD, 1992, TRENDS GLYCOSCI GLYC, V4, P1; ROSSI MJ, 1989, J CELL PHYSIOL, V141, P142, DOI 10.1002/jcp.1041410121; Rudiger M, 1998, BIOESSAYS, V20, P733; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Sanoudou D, 2003, P NATL ACAD SCI USA, V100, P4666, DOI 10.1073/pnas.0330960100; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Tamayo P, 1999, P NATL ACAD SCI USA, V96, P2907, DOI 10.1073/pnas.96.6.2907; Taverna D, 1998, J CELL BIOL, V143, P849, DOI 10.1083/jcb.143.3.849; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YAMAGUCHI A, 1995, SEMIN CELL BIOL, V6, P165, DOI 10.1006/scel.1995.0023; Yeow K, 2001, FEBS LETT, V506, P157, DOI 10.1016/S0014-5793(01)02900-3; Young P, 2001, J CELL BIOL, V154, P123, DOI 10.1083/jcb.200102110; Yun KS, 1996, CURR OPIN CELL BIOL, V8, P877, DOI 10.1016/S0955-0674(96)80091-3; ZALIN RJ, 1977, DEV BIOL, V59, P241, DOI 10.1016/0012-1606(77)90258-5; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	50	145	147	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					403	+		10.1096/f.03-0568fje	http://dx.doi.org/10.1096/f.03-0568fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688207				2022-12-28	WOS:000188067500013
J	Buckley, KA; Golding, SL; Rice, JM; Dillon, JP; Gallagher, JA				Buckley, KA; Golding, SL; Rice, JM; Dillon, JP; Gallagher, JA			Release and interconversion of P2 receptor agonists by human osteoblast-like cells	FASEB JOURNAL			English	Article						ATP; ADP; bone; ecto-nucleoside diphosphokinase; ecto-NDPK	NUCLEOSIDE DIPHOSPHATE KINASE; ATP RELEASE; ENDOTHELIAL-CELLS; BONE-CELLS; OSTEOCLASTS; ACTIVATION; NUCLEOTIDES; DIPHOSPHOKINASE; IDENTIFICATION; TRANSDUCTION	Nucleotides, acting as agonists at P2 receptors, are important extracellular signaling molecules in many tissues. In bone they affect both bone-forming osteoblast and bone-resorbing osteoclast cell activity. The presence of nucleotides in the extracellular microenvironment is largely determined by their release from cells and metabolism by ecto-enzymes, both of which have scarcely been studied in bone. We have investigated adenosine 5'-triphosphate (ATP) release from SaOS-2 osteoblastic cells and the activities of cell surface ecto-enzymes on ATP metabolism. ATP, but not LDH, was detected in SaOS-2 cell conditioned medium, suggesting these cells were actively releasing ATP. Introduction of ADP resulted in increased ATP concentrations in the medium, which was found not to be receptor mediated. Nucleotide inhibition and substrate specificity studies revealed an ecto-nucleoside diphosphokinase (ecto-NDPK) was responsible for the ADP-->ATP conversion; PCR and immunocytochemistry confirmed its presence. Analysis of ATP metabolism over time demonstrated overall ATP degradation was increased by inhibiting ecto-NDPK activity; confirming that the combined action of multiple osteoblast-expressed ecto-enzymes affected extracellular nucleotide concentration. The data establish the coexistence of ATP-consuming, and for the first time, ATP-generating activities on the osteoblast cell surface, the discovery of which has significant implications for studies involving P2 receptor subtypes in bone.	Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Clin Engn, Liverpool L69 3GA, Merseyside, England; UK Ctr Tissue Engn, Liverpool L69 3GA, Merseyside, England	University of Liverpool; University of Liverpool; University of Liverpool	Buckley, KA (corresponding author), Univ Liverpool, Dept Human Anat & Cell Biol, Human Bone Cell Res Grp, Sherrington Bldg,Ashton St, Liverpool L69 3GE, Merseyside, England.	buckleyk@liv.ac.uk		Buckley, Katherine/0000-0002-6585-8943				ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; BOWLER WB, 1995, J BONE MINER RES, V10, P1137; Bowler WB, 1998, BONE, V22, P195, DOI 10.1016/S8756-3282(97)00280-9; BOWLER WB, 1998, J BONE MINER RES, V13, P524; Brown J, 2000, LAB INVEST, V80, P37, DOI 10.1038/labinvest.3780006; Buckley KA, 2002, BONE, V31, P582, DOI 10.1016/S8756-3282(02)00877-3; Buckley KA, 2001, J BIOL CHEM, V276, P9565, DOI 10.1074/jbc.M005672200; Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x; Burnstock G., 1978, CELL MEMBRANE RECEPT, Vpp, P107; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; CASWELL AM, 1988, BIOCHIM BIOPHYS ACTA, V966, P310, DOI 10.1016/0304-4165(88)90080-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Feranchak AP, 1998, J BIOL CHEM, V273, P14906, DOI 10.1074/jbc.273.24.14906; FUKUCHI T, 1994, BBA-PROTEIN STRUCT M, V1205, P113, DOI 10.1016/0167-4838(94)90099-X; Gallagher James A., 1996, P233; Gartland A, 2001, J BONE MINER RES, V16, P846, DOI 10.1359/jbmr.2001.16.5.846; GARTLAND A, 2003, IN PRESS CALCIF TISS; Guidotti G, 1996, CHEM BIOL, V3, P703, DOI 10.1016/S1074-5521(96)90244-6; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; HILLARP NA, 1959, ACTA PHYSIOL SCAND, V45, P328, DOI 10.1111/j.1748-1716.1959.tb01705.x; Hoebertz A, 2001, FASEB J, V15, P1139, DOI 10.1096/fj.00-0395com; Hoebertz A, 2000, BONE, V27, P503, DOI 10.1016/S8756-3282(00)00351-3; Jorgensen NR, 2002, J BIOL CHEM, V277, P7574, DOI 10.1074/jbc.M104608200; Jorgensen NR, 2000, J BONE MINER RES, V15, P1024, DOI 10.1359/jbmr.2000.15.6.1024; KAPLAN N, 1995, COMPUTER MEDIATED CO, V2, P3; KIMURA N, 1990, J BIOL CHEM, V265, P15744; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Lazarowski ER, 1997, J BIOL CHEM, V272, P24348, DOI 10.1074/jbc.272.39.24348; LEW MJ, 1987, BRIT J PHARMACOL, V92, P349, DOI 10.1111/j.1476-5381.1987.tb11330.x; Maier R, 1997, BIOCHEM BIOPH RES CO, V237, P297, DOI 10.1006/bbrc.1997.7135; Mitchell CH, 1998, P NATL ACAD SCI USA, V95, P7174, DOI 10.1073/pnas.95.12.7174; Morrison MS, 1998, J PHYSIOL-LONDON, V511, P495, DOI 10.1111/j.1469-7793.1998.495bh.x; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; Postel EH, 1998, INT J BIOCHEM CELL B, V30, P1291, DOI 10.1016/S1357-2725(98)00087-9; REIMER WJ, 1992, AM J PHYSIOL, V263, pC1040, DOI 10.1152/ajpcell.1992.263.5.C1040; Romanello M, 2001, BIOCHEM BIOPH RES CO, V289, P1275, DOI 10.1006/bbrc.2001.6124; Schlosser SF, 1996, P NATL ACAD SCI USA, V93, P9948, DOI 10.1073/pnas.93.18.9948; Shimegi S, 1996, CALCIFIED TISSUE INT, V58, P109, DOI 10.1007/BF02529732; SONNEMANN J, 1995, BIOCHEM BIOPH RES CO, V209, P490, DOI 10.1006/bbrc.1995.1528; Todorov LD, 1996, J PHYSIOL-LONDON, V496, P731, DOI 10.1113/jphysiol.1996.sp021723; Watt WC, 1998, J BIOL CHEM, V273, P14053, DOI 10.1074/jbc.273.22.14053; Wiebe SH, 1999, CELL PHYSIOL BIOCHEM, V9, P323, DOI 10.1159/000016326; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; YU HH, 1993, FEBS LETT, V328, P209, DOI 10.1016/0014-5793(93)80994-6; YU HS, 1994, CELL SIGNAL, V6, P905, DOI 10.1016/0898-6568(94)90023-X; Zimmermann H, 1996, PROG NEUROBIOL, V49, P589, DOI 10.1016/0301-0082(96)00026-3	51	56	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1401	1410		10.1096/fj.02-0940com	http://dx.doi.org/10.1096/fj.02-0940com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890693				2022-12-28	WOS:000185345100032
J	Procino, G; Carmosino, M; Marin, O; Brunanti, AM; Contri, A; Pinna, LA; Mannucci, R; Nielsen, S; Kwon, TH; Svelto, M; Valenti, G				Procino, G; Carmosino, M; Marin, O; Brunanti, AM; Contri, A; Pinna, LA; Mannucci, R; Nielsen, S; Kwon, TH; Svelto, M; Valenti, G			Ser-256 phosphorylation dynamics of aquaporin 2 during maturation from the endoplasmic reticulum to the vesicular compartment in renal cells	FASEB JOURNAL			English	Article						Golgi casein kinase; PKA; NDI; phosphorylation	NEPHROGENIC DIABETES-INSIPIDUS; TRANS-GOLGI NETWORK; SUBSTRATE-SPECIFICITY DETERMINANTS; LACTATING MAMMARY-GLAND; KINASE-A ACTIVITY; WATER CHANNEL; CASEIN KINASE; BREFELDIN-A; PROTEIN-KINASES; AQP2 TRANSLOCATION	Aquaporin 2 (AQP2) phosphorylation at Ser-256 by protein kinase A (PKA) is a key signal for vasopressin-stimulated AQP2 insertion into the plasma membrane in renal cells. This study underscores the possible role of phosphorylation at Ser-256 in regulating AQP2 maturation. AQP2-transfected renal CD8 cells were incubated with brefeldin A (BFA) to accumulate newly synthesized AQP2 in the endoplasmic reticulum ( ER), and AQP2 flow from ER to the vesicular compartment was analyzed after BFA washout. We found that a) in the ER, AQP2 is weakly phosphorylated; b) the amount of phosphorylated AQP2 (p-AQP2) at Ser-256 increased significantly during transit in the Golgi, even in the presence of the PKA inhibitor H89; and c) AQP2 transport from the Golgi to the vasopressin-regulated vesicular compartment occurred with a concomitant decrease in p-AQP2 at Ser-256. These results support the hypothesis that AQP2 transition in the Golgi apparatus is associated with a PKA-independent increase in AQP2 phosphorylation at Ser-256. Conversely, impaired constitutive phosphorylation in a Golgi-associated compartment occurring in cells expressing mutated S256A-AQP2 or E258K-AQP2 causes phosphorylation-defective AQP2 routing to lysosomes. This result might explain the molecular basis of the dominant form of nephrogenic diabetes insipidus caused by the mutation E258K-AQP2, in which the phenotype is caused by an impaired routing of AQP2.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Padua, Dipartimento Chim Biol, I-35121 Padua, Italy; Univ Perugia, Dipartimento Med Clin & Sperimentale, I-06100 Perugia, Italy; Univ Aarhus, Dept Cell Biol, Inst Anat, DK-8000 Aarhus, Denmark; Dongguk Univ, Dept Physiol, Sch Med, Kyungju 780714, South Korea; Univ Bari, Ctr Eccellenza Genom Comparata, I-70121 Bari, Italy	Universita degli Studi di Bari Aldo Moro; University of Padua; University of Perugia; Aarhus University; Dongguk University; Universita degli Studi di Bari Aldo Moro	Valenti, G (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	g.valenti@biologia.uniba.it	Carmosino, Monica/O-2594-2014; Svelto, Maria/P-6186-2014; Kwon, Tae-Hwan/ABA-1981-2020	Carmosino, Monica/0000-0001-7600-8816; VALENTI, GIOVANNA/0000-0003-0233-0778; Svelto, Maria/0000-0002-5584-9541; Procino, Giuseppe/0000-0002-0043-7523				Brunati AM, 2000, FEBS LETT, V471, P151, DOI 10.1016/S0014-5793(00)01378-8; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; Christensen BM, 2000, AM J PHYSIOL-RENAL, V278, pF29, DOI 10.1152/ajprenal.2000.278.1.F29; DEMATTIA F, 2002, ASN 35 ANN M PENNS C; Donaldson JG, 2000, CELL, V101, P693, DOI 10.1016/S0092-8674(00)80881-8; Fiedler K, 1997, ELECTROPHORESIS, V18, P2613, DOI 10.1002/elps.1150181417; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Fushimi K, 1997, J BIOL CHEM, V272, P14800, DOI 10.1074/jbc.272.23.14800; Hirano K, 2002, HISTOCHEM CELL BIOL, V117, P41, DOI 10.1007/s00418-001-0370-2; Jones SM, 1998, J BIOL CHEM, V273, P10349, DOI 10.1074/jbc.273.17.10349; Kamsteeg EJ, 1999, EMBO J, V18, P2394, DOI 10.1093/emboj/18.9.2394; Kamsteeg EJ, 2000, J CELL BIOL, V151, P919, DOI 10.1083/jcb.151.4.919; Katsura T, 1997, Am J Physiol, V272, pF817; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Klussmann E, 1999, J BIOL CHEM, V274, P4934, DOI 10.1074/jbc.274.8.4934; Lande MB, 1996, J BIOL CHEM, V271, P5552, DOI 10.1074/jbc.271.10.5552; Lasa M, 1997, EUR J BIOCHEM, V243, P719, DOI 10.1111/j.1432-1033.1997.00719.x; LasaBenito M, 1996, FEBS LETT, V382, P149, DOI 10.1016/0014-5793(96)00136-6; LEFFERS H, 1993, J MOL BIOL, V231, P982, DOI 10.1006/jmbi.1993.1346; Martin ME, 2000, J BIOL CHEM, V275, P19050, DOI 10.1074/jbc.275.25.19050; MEGGIO F, 1995, EUR J BIOCHEM, V234, P317, DOI 10.1111/j.1432-1033.1995.317_c.x; MEGGIO F, 1988, EUR J BIOCHEM, V177, P281, DOI 10.1111/j.1432-1033.1988.tb14374.x; Molloy SS, 1998, J CELL BIOL, V142, P1399, DOI 10.1083/jcb.142.6.1399; Mulders SM, 1998, J CLIN INVEST, V102, P57, DOI 10.1172/JCI2605; Muniz M, 1997, P NATL ACAD SCI USA, V94, P14461, DOI 10.1073/pnas.94.26.14461; NABI IR, 1991, J CELL BIOL, V115, P1573, DOI 10.1083/jcb.115.6.1573; Nishimoto G, 1999, AM J PHYSIOL-RENAL, V276, pF254, DOI 10.1152/ajprenal.1999.276.2.F254; OKAMOTO CT, 1994, J BIOL CHEM, V269, P15676; Orzech E, 2000, J BIOL CHEM, V275, P15207, DOI 10.1074/jbc.275.20.15207; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PERKEL VS, 1989, P SOC EXP BIOL MED, V190, P286; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; PRICE PA, 1994, PROTEIN SCI, V3, P822; Sciaky N, 1997, J CELL BIOL, V139, P1137, DOI 10.1083/jcb.139.5.1137; Simon JP, 1996, J BIOL CHEM, V271, P16952, DOI 10.1074/jbc.271.28.16952; Tamarappoo BK, 1999, J BIOL CHEM, V274, P34825, DOI 10.1074/jbc.274.49.34825; Tamma G, 2003, J CELL SCI, V116, P1519, DOI 10.1242/jcs.00355; Valenti G, 2000, J CELL SCI, V113, P1985; Valenti G, 1996, J BIOL CHEM, V271, P24365, DOI 10.1074/jbc.271.40.24365; van Balkom BWM, 2002, J BIOL CHEM, V277, P41473, DOI 10.1074/jbc.M207525200; VANDEWALLE A, 1989, J CELL PHYSIOL, V141, P203, DOI 10.1002/jcp.1041410128	42	67	69	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1886	+		10.1096/fj.02-0870fje	http://dx.doi.org/10.1096/fj.02-0870fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897058				2022-12-28	WOS:000185345100016
J	Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW				Anakk, S; Kalsotra, A; Shen, Q; Vu, MT; Staudinger, JL; Davies, PJA; Strobel, HW			Genomic characterization and regulation of CYP3a13: role of xenobiotics and nuclear receptors	FASEB JOURNAL			English	Article						cytochrome P4503A; drug metabolism; sexual dimorphism; nuclear receptors	RETINOID-X-RECEPTOR; TATA-LESS; HUMAN HEPATOCYTES; CDNA CLONING; EXPRESSION; GENE; INDUCTION; LIVER; TRANSCRIPTION; DEXAMETHASONE	We report that CYP3a13 gene, located on mouse chromosome 5, spans 27.5 Kb and contains 13 exons. The transcription start site is 35 bp upstream of the coding region and results in a 109 bp 5' untranslated region. CYP3a13 promoter shows putative binding sites for retinoid X receptor, pregnane X receptor, and estrogen receptor. CYP3a13 shows a broad tissue distribution with predominant expression in liver. Although CYP3a13 shares 92% nucleotide identity with the female-specific rat CYP3A9, its expression does not exhibit sexual dimorphism. Ligand activation of peroxisomal proliferator-activated receptor-gamma and retinoid X receptor inhibit expression of CYP3a13 at the transcription level in a tissue-specific manner. Another novel finding is hepatic induction of CYP3a13 by dexamethasone occurring only in pregnane X receptor null mice. We also report that pregnane X receptor is essential to maintain robust in vivo basal levels of CYP3a13 in contrast to CYP3a11. CYP3a13 protein expressed in vitro can metabolize clinically active drugs ethylmorphine and erythromycin, as well as benzphetamine. We conclude that CYP3a13 is regulated differentially by various nuclear receptors. In humans this may lead to altered drug metabolism, as many of the newly synthesized ligands/drugs targeted toward these nuclear receptors could influence CYP3A gene expression.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA; Univ Texas, Sch Med, Dept Integrat Biol, Houston, TX 77225 USA; Univ Kansas, Med Ctr, Dept Pharmacol & Toxicol, Lawrence, KS 66045 USA	University of Texas System; University of Texas System; University of Kansas; University of Kansas Medical Center	Strobel, HW (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	henry.w.strobel@uth.tmc.edu		Kalsotra, Auinash/0000-0002-1011-0006				Balthazart J, 1998, TRENDS NEUROSCI, V21, P243, DOI 10.1016/S0166-2236(97)01221-6; Bernard P, 1999, MOL PHARMACOL, V56, P526, DOI 10.1124/mol.56.3.526; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; BURGER HJ, 1992, P NATL ACAD SCI USA, V89, P2145, DOI 10.1073/pnas.89.6.2145; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; Cui XM, 2002, GENE, V297, P179, DOI 10.1016/S0378-1119(02)00885-5; Dai D, 2001, J BIOCHEM MOL TOXIC, V15, P90, DOI 10.1002/jbt.4; Davies PJA, 2001, MOL PHARMACOL, V59, P170, DOI 10.1124/mol.59.2.170; Domanski TL, 2001, MOL PHARMACOL, V59, P386, DOI 10.1124/mol.59.2.386; El-Sankary W, 2002, DRUG METAB DISPOS, V30, P1029, DOI 10.1124/dmd.30.9.1029; Finta C, 2000, GENE, V260, P13, DOI 10.1016/S0378-1119(00)00470-4; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Howell SR, 1998, DRUG METAB DISPOS, V26, P234; Huber R, 1998, GENE, V214, P35, DOI 10.1016/S0378-1119(98)00233-9; ITOH S, 1994, EUR J BIOCHEM, V226, P877, DOI 10.1111/j.1432-1033.1994.t01-1-00877.x; JANIKAMJORN K, 2001, BIOCHEM PHARMACOL, V62, P161; JOUNAIDI Y, 1994, BIOCHEM BIOPH RES CO, V205, P1741, DOI 10.1006/bbrc.1994.2870; JUGEAUBRY CE, 1995, J BIOL CHEM, V270, P18117, DOI 10.1074/jbc.270.30.18117; KATO R, 1993, HORMONAL REGULATION; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; Lenhard JM, 1999, DIABETOLOGIA, V42, P545, DOI 10.1007/s001250051193; Mahnke Z, 1997, ARCH BIOCHEM BIOPHYS, V337, P62, DOI 10.1006/abbi.1996.9752; MOLOWA DT, 1986, P NATL ACAD SCI USA, V83, P5311, DOI 10.1073/pnas.83.14.5311; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Pascussi JM, 2000, MOL PHARMACOL, V58, P361, DOI 10.1124/mol.58.2.361; Pascussi JM, 2000, MOL PHARMACOL, V58, P1441, DOI 10.1124/mol.58.6.1441; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Robertson GR, 1998, BIOCHEM BIOPH RES CO, V242, P57, DOI 10.1006/bbrc.1997.7904; Rubin GL, 2002, ENDOCRINOLOGY, V143, P2863, DOI 10.1210/en.143.8.2863; Sakuma T, 2002, ARCH BIOCHEM BIOPHYS, V404, P234, DOI 10.1016/S0003-9861(02)00329-6; Sakuma T, 2000, ARCH BIOCHEM BIOPHYS, V377, P153, DOI 10.1006/abbi.2000.1747; Savas U, 1999, MOL PHARMACOL, V56, P851, DOI 10.1124/mol.56.5.851; Skak K, 1999, GENE, V236, P231, DOI 10.1016/S0378-1119(99)00286-3; Staudinger J, 2001, DRUG METAB DISPOS, V29, P1467; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Thummel KE, 2001, MOL PHARMACOL, V60, P1399, DOI 10.1124/mol.60.6.1399; Toide K, 1997, ARCH BIOCHEM BIOPHYS, V338, P43, DOI 10.1006/abbi.1996.9792; VandenBroek PJA, 1996, EXPERIENTIA, V52, P851; Wang HM, 2000, MOL CELL BIOCHEM, V213, P127, DOI 10.1023/A:1007124417566; Wang HM, 1997, ARCH BIOCHEM BIOPHYS, V344, P365, DOI 10.1006/abbi.1997.0230; Waxman DJ, 1999, ARCH BIOCHEM BIOPHYS, V369, P11, DOI 10.1006/abbi.1999.1351; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116; Yamada H, 2000, BIOCHEM BIOPH RES CO, V277, P66, DOI 10.1006/bbrc.2000.3620; YANAGIMOTO T, 1994, BBA-GEN SUBJECTS, V1201, P405, DOI 10.1016/0304-4165(94)90069-8; Yanagimoto T, 1997, ARCH BIOCHEM BIOPHYS, V340, P215, DOI 10.1006/abbi.1997.9900	53	27	27	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1736	+		10.1096/fj.02-1004fje	http://dx.doi.org/10.1096/fj.02-1004fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958193				2022-12-28	WOS:000184471600022
J	Rivat, C; Le Floch, N; Sabbah, M; Teyrol, I; Redeuilh, G; Bruyneel, E; Mareel, M; Matrisian, LM; Crawford, HC; Gespach, C; Attoub, S				Rivat, C; Le Floch, N; Sabbah, M; Teyrol, I; Redeuilh, G; Bruyneel, E; Mareel, M; Matrisian, LM; Crawford, HC; Gespach, C; Attoub, S			Synergistic cooperation between the AP-1 and LEF-1 transcription factors in the activation of the matrilysin promoter by the src oncogene: implications in cellular invasion	FASEB JOURNAL			English	Article						kidney and colonic cancer cells; HGF/Met; metastasis; PKC; MAPK	HUMAN COLORECTAL-CANCER; MATRIX-METALLOPROTEINASE MATRILYSIN; ADENOMATOUS POLYPOSIS-COLI; KIDNEY EPITHELIAL-CELLS; MIDDLE T-ONCOGENES; GROWTH-FACTOR-BETA; V-SRC; SIGNALING PATHWAYS; C-JUN; NEOPLASTIC PROGRESSION	The matrix metalloprotease matrilysin is expressed in premalignant polyps and plays a key role in local invasion during the progression of digestive tumors. In the present work, we investigated the possible relationships between the activity of the mouse and human matrilysin promoters (Mp), endogenous matrilysin protein expression, and two early oncogenetic defects frequently observed in human colonic cancers, namely activation of the src oncogene and impairment of the Wnt/APC/beta-catenin pathway. Using transient transfection assays, we report here that src signaling and the HMG-box transcription factor LEF-1 act synergistically with the proximal (-61 to -67) AP-1 binding site to transactivate the Mp in premalignant and tumorigenic kidney and colonic epithelial cells, through beta-catenin- and axin-independent signaling pathways. This synergism involves the -109 and -194 Tcf/LEF-1 binding sites in the Mp and a physical interaction between LEF-1 and c-Jun. Furthermore, src coordinates accumulation of the c-Jun factor and matrilysin transcripts. Conversely, the c-Jun dominant negative mutant TAM67 and the src tyrosine kinase inhibitor M475271 impaired src-induced Mp activation, matrilysin protein cellular invasion during the early-stage adenoma/adenocarcinoma conversion and the metastatic process of digestive tumors.	Hop St Antoine, INSERM, U482, F-75571 Paris 12, France; Univ Hosp, Expt Cancerol Lab, B-9000 Ghent, Belgium; Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Ghent University; Ghent University Hospital; Vanderbilt University	Attoub, S (corresponding author), Hop St Antoine, INSERM, U482, 184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	attoub@st-antoine.inserm.fr	Crawford, Howard/A-2874-2008; Attoub, Samir/N-6852-2018; LE FLOCH, Nathalie/I-3415-2015	LE FLOCH, Nathalie/0000-0002-6411-7975; SABBAH, Michele/0000-0001-5368-9022				Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Adachi Y, 2001, INT J CANCER, V95, P290, DOI 10.1002/1097-0215(20010920)95:5<290::AID-IJC1050>3.0.CO;2-I; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Barbier M, 2001, NATURE, V413, P796, DOI 10.1038/35101660; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; BISHOP JM, 1983, ANNU REV BIOCHEM, V52, P301, DOI 10.1146/annurev.bi.52.070183.001505; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; CHASTRE E, 1993, GASTROENTEROLOGY, V105, P1776, DOI 10.1016/0016-5085(93)91076-T; Cho-Chung YS, 1999, CURR OPIN MOL THER, V1, P386; Crawford HC, 1999, ONCOGENE, V18, P2883, DOI 10.1038/sj.onc.1202627; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; DECESARE D, 1995, ONCOGENE, V11, P365; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; DELAGE S, 1993, CANCER RES, V53, P2762; Dong ZG, 1996, J BIOL CHEM, V271, P9942, DOI 10.1074/jbc.271.17.9942; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; GAIRE M, 1994, J BIOL CHEM, V269, P2032; Gum R, 1996, J BIOL CHEM, V271, P10672, DOI 10.1074/jbc.271.18.10672; Gumbiner BM, 1997, CURR BIOL, V7, pR443, DOI 10.1016/S0960-9822(06)00214-4; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HAMAGUCHI M, 1995, ONCOGENE, V10, P1037; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Howe LR, 2001, J BIOL CHEM, V276, P20108, DOI 10.1074/jbc.M010692200; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Kadono Y, 1998, BIOCHEM BIOPH RES CO, V251, P681, DOI 10.1006/bbrc.1998.9531; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kataoka H, 2000, CANCER RES, V60, P6148; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Lengyel E, 1996, J BIOL CHEM, V271, P23176, DOI 10.1074/jbc.271.38.23176; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Masaki T, 1998, HEPATOLOGY, V27, P1257, DOI 10.1002/hep.510270511; Masaki T, 2001, BRIT J CANCER, V84, P1317, DOI 10.1054/bjoc.2001.1790; MELLSTROM K, 1987, MOL CELL BIOL, V7, P4178, DOI 10.1128/MCB.7.12.4178; MORI M, 1995, CANCER, V75, P1516, DOI 10.1002/1097-0142(19950315)75:6+<1516::AID-CNCR2820751522>3.0.CO;2-7; Munemitsu S, 1996, MOL CELL BIOL, V16, P4088; NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404; Noe V, 2001, J CELL SCI, V114, P111; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Pacheco MM, 2002, HEAD NECK-J SCI SPEC, V24, P24, DOI 10.1002/hed.10009; Pasche B, 2001, J CELL PHYSIOL, V186, P153, DOI 10.1002/1097-4652(200002)186:2<153::AID-JCP1016>3.0.CO;2-J; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Prunier C, 1999, J BIOL CHEM, V274, P22919, DOI 10.1074/jbc.274.33.22919; Riese J, 1997, CELL, V88, P777, DOI 10.1016/S0092-8674(00)81924-8; SATO H, 1993, J BIOL CHEM, V268, P23460; Shaw LM, 1997, CELL, V91, P949, DOI 10.1016/S0092-8674(00)80486-9; Silberman S, 1997, J BIOL CHEM, V272, P5927, DOI 10.1074/jbc.272.9.5927; Sparks AB, 1998, CANCER RES, V58, P1130; TERMUHLEN PM, 1993, J SURG RES, V54, P293, DOI 10.1006/jsre.1993.1046; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Uria JA, 1998, J BIOL CHEM, V273, P9769, DOI 10.1074/jbc.273.16.9769; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vider BZ, 1996, ONCOGENE, V12, P153; Visser CJT, 1996, LAB INVEST, V74, P2; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2; WILSON CL, 1995, MOL BIOL CELL, V6, P851, DOI 10.1091/mbc.6.7.851; Wilson CL, 1997, P NATL ACAD SCI USA, V94, P1402, DOI 10.1073/pnas.94.4.1402; YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504; ZANG Q, 1995, CELL GROWTH DIFFER, V6, P1367	73	66	67	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1721	+		10.1096/fj.03-0132fje	http://dx.doi.org/10.1096/fj.03-0132fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958188				2022-12-28	WOS:000184471600005
J	Yamada, M; Hirasawa, A; Shiojima, S; Tsujimoto, G				Yamada, M; Hirasawa, A; Shiojima, S; Tsujimoto, G			Granzyme A mediates glucocorticoid-induced apoptosis in leukemia cells	FASEB JOURNAL			English	Article						microarray; dexamethasone; caspase; Bcl-2	TOXIC LYMPHOCYTES-T; GENE-EXPRESSION; SERINE PROTEASES; OLIGONUCLEOTIDE ARRAYS; DNA FRAGMENTATION; MULTIPLE-MYELOMA; CARCINOMA-CELLS; DEATH; DEXAMETHASONE; PATHWAY	To identify the genes responsible for mediating apoptotic effects of glucocorticoid on leukemia cells, changes in gene expression were analyzed during dexamethasone-induced apoptosis of glucocorticoid-sensitive human acute lymphocytic leukemia 697 cells by using cDNA microarrays containing more than 4000 named genes. The microarray analysis showed that 26 genes had markedly differential expression after treatment with 100 nM dexamethasone; 17 genes were up-regulated, including granzyme A, glucocorticoid receptor, and suppressor of cytokine signaling-2; and nine genes were down-regulated, including early growth response 1 and acute myeloid leukemia 1. To circumvent the problem of recovering mRNA from dying cells, 697 cells that were stably transfected with the death inhibitor Bcl-2 were also used, and the expression of selected genes was examined by RT-PCR analysis, which confirmed the expression profile obtained by microarray analysis. The granzyme A protein accumulated in 697 cells and its enzymatic activity increased after dexamethasone treatment in a time-dependent manner, in accordance with the increase in caspase-3 activity. Furthermore, the granzyme inhibitor 3,4-dichloroisocoumarin inhibited the dexamethasone-induced apoptosis of 697 cells in a concentration-dependent manner. These results showed that granzyme A is critically involved in mediating the apoptotic effect of glucocorticoid on leukemia cells.	Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, Tokyo 1548567, Japan; Teikyo Univ, Biotech Ctr, Genox Res Inc, Kawasaki, Kanagawa 2160001, Japan	National Center for Child Health & Development - Japan; Teikyo University	Tsujimoto, G (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, 3-35-31 Taishido, Tokyo 1548567, Japan.	gtsujimoto@nch.go.jp						AEBISCHER F, 1992, IMMUNOPHARMACOLOGY, V23, P181, DOI 10.1016/0162-3109(92)90024-7; ALEXANIAN R, 1994, NEW ENGL J MED, V330, P484; BANSAL N, 1991, FASEB J, V5, P211, DOI 10.1096/fasebj.5.2.2004665; BARKER PE, 1987, CANCER GENET CYTOGEN, V25, P379, DOI 10.1016/0165-4608(87)90204-4; Beresford PJ, 1997, P NATL ACAD SCI USA, V94, P9285, DOI 10.1073/pnas.94.17.9285; BLEACKLEY RC, 1988, IMMUNOL REV, V103, P5, DOI 10.1111/j.1600-065X.1988.tb00746.x; CARONLESLIE LAM, 1994, FASEB J, V8, P639, DOI 10.1096/fasebj.8.9.8005391; Chauhan D, 2002, ONCOGENE, V21, P1346, DOI 10.1038/sj.onc.1205205; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Devireddy LR, 2001, SCIENCE, V293, P829, DOI 10.1126/science.1061075; Dong G, 2001, CANCER RES, V61, P4797; El-Naghy M, 2001, EXP CELL RES, V270, P166, DOI 10.1006/excr.2001.5350; Fraser A, 1996, CELL, V85, P781, DOI 10.1016/S0092-8674(00)81005-3; Galon J, 2002, FASEB J, V16, P61, DOI 10.1096/fj.01-0245com; Gaynon PS, 1999, ADV EXP MED BIOL, V457, P593; GERSHENFELD HK, 1988, P NATL ACAD SCI USA, V85, P1184, DOI 10.1073/pnas.85.4.1184; Greenstein S, 2002, CLIN CANCER RES, V8, P1681; Hameed A, 1996, HUM IMMUNOL, V49, P13, DOI 10.1016/0198-8859(96)00052-3; IRMLER M, 1995, J EXP MED, V181, P1917, DOI 10.1084/jem.181.5.1917; Ishibashi T, 2002, INVEST OPHTH VIS SCI, V43, P3691; JENNE DE, 1988, IMMUNOL REV, V103, P53, DOI 10.1111/j.1600-065X.1988.tb00749.x; Katsuma S, 2002, METHOD ENZYMOL, V345, P585; MIYASHITA T, 1993, BLOOD, V81, P151; Miyashita T, 1997, J BIOL CHEM, V272, P29238, DOI 10.1074/jbc.272.46.29238; Mohamadzadeh M, 1996, J INVEST DERMATOL, V107, P738, DOI 10.1111/1523-1747.ep12365634; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; NAKAJIMA H, 1995, J EXP MED, V181, P1037, DOI 10.1084/jem.181.3.1037; PASTERNACK MS, 1985, NATURE, V314, P743, DOI 10.1038/314743a0; Planey SL, 2003, CANCER RES, V63, P172; PODACK ER, 1985, P NATL ACAD SCI USA, V82, P8629, DOI 10.1073/pnas.82.24.8629; PODACK ER, 1991, ANNU REV IMMUNOL, V9, P129, DOI 10.1146/annurev.iy.09.040191.001021; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Riccardi C, 1999, CELL DEATH DIFFER, V6, P1182, DOI 10.1038/sj.cdd.4400609; SHI LF, 1992, J EXP MED, V176, P1521, DOI 10.1084/jem.176.6.1521; SHIVER JW, 1992, CELL, V71, P315, DOI 10.1016/0092-8674(92)90359-K; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Smets LA, 1996, LEUKEMIA LYMPHOMA, V20, P199, DOI 10.3109/10428199609051608; Smets LA, 1999, ADV EXP MED BIOL, V457, P607; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Sower LE, 1996, CELL IMMUNOL, V171, P159, DOI 10.1006/cimm.1996.0187; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; Tak PP, 1999, CLIN EXP IMMUNOL, V116, P366; TAKAYAMA H, 1987, J IMMUNOL, V138, P566; THOMPSON EB, 1994, MOL ENDOCRINOL, V8, P665, DOI 10.1210/me.8.6.665; Tonko M, 2001, FASEB J, V15, P693, DOI 10.1096/fj.00-0327com; TORIGOE T, 1994, CANCER RES, V54, P4851; VELOTTI F, 1989, EUR J IMMUNOL, V19, P575, DOI 10.1002/eji.1830190328; Vermijlen D, 1999, HEPATOLOGY, V29, P51, DOI 10.1002/hep.510290143; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yoshida NL, 2002, BIOCHEM BIOPH RES CO, V293, P1254; Zhang D, 2001, P NATL ACAD SCI USA, V98, P5746, DOI 10.1073/pnas.101329598; Zhou J, 1997, CELL IMMUNOL, V178, P108, DOI 10.1006/cimm.1997.1138	52	21	21	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1712	+		10.1096/fj.02-0116fje	http://dx.doi.org/10.1096/fj.02-0116fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958185				2022-12-28	WOS:000184471600026
J	Yet, SF; Layne, MD; Liu, XL; Chen, YH; Ith, B; Sibinga, NES; Perrella, MA				Yet, SF; Layne, MD; Liu, XL; Chen, YH; Ith, B; Sibinga, NES; Perrella, MA			Absence of heme oxygenase-1 exacerbates atherosclerotic lesion formation and vascular remodeling	FASEB JOURNAL			English	Article						atherosclerosis; vein graft; pressure overload; oxidative stress	SMOOTH-MUSCLE-CELLS; CORONARY-ARTERY DISEASE; APOE-DEFICIENT MICE; APOLIPOPROTEIN-E; CARBON-MONOXIDE; ACCELERATED ATHEROSCLEROSIS; MICROSATELLITE POLYMORPHISM; TRANSGENIC MICE; GRAFT FAILURE; VEIN GRAFTS	To examine the role of hemeoxygenase(HO)-1 in the pathophysiology of vascular diseases,we generated mice deficient in both HO-1 and apolipoprotein E( HO-1(-/-)apoE(-/-)). Despite similar total plasma cholesterol levels in response to hypercholesterolemia, HO-1-/-apoE-/-mice, in comparison with HO-1(+/+) apoE(-/-) mice, had an accelerated and more advanced atherosclerotic lesion formation. In addition to greater lipid accumulation, these advanced lesions from HO-1(-/-) apoE(-/-) mice contained macrophages and smooth muscle alpha-actin-positive cells. We further tested the role of HO-1 on neointimal formation in a mouse model of vein graft stenosis. Autologous vein grafts in HO-1(-/-) mice showed robust neointima consisting of alpha-actin-positive vascular smooth muscle cells(VSMC) 10 days after surgery in comparison to the smaller neointima formed in autologous vein grafts in HO-1(+/+) mice. However, at 14 days after surgery, the neointima from composite vessels of HO-1(-/-) mice was composed mainly of acellular material, indicative of substantial VSMC death. VSMC isolated from HO-1(-/-) mice were susceptible to oxidant stress, leading to cell death. Our data demonstrate that HO-1 plays an essential protective role in the pathophysiology of atherosclerosis and vein graft stenosis.	Brigham & Womens Hosp, Div Pulm & Crit Care, Dept Med, Boston, MA 02115 USA; Kaohsiung Med Univ, Dept Internal Med, Div Infect Dis, Kaohsiung, Taiwan; Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Div Cardiovasc, Bronx, NY 10467 USA	Harvard University; Brigham & Women's Hospital; Kaohsiung Medical University; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine	Yet, SF (corresponding author), Brigham & Womens Hosp, Div Pulm & Crit Care, Dept Med, 75 Francis St,Thorn 133, Boston, MA 02115 USA.	syet@rics.bwh.harvard.edu	Sibinga, Nicholas/GOJ-8544-2022; Liu, Xiaoli/HGE-7614-2022; Chen, Yen-Hsu/D-5484-2009; Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Sibinga, Nicholas/0000-0003-4838-910X; Yet, Shaw-Fang/0000-0001-9097-3962; Layne, Matthew/0000-0003-0007-4870; Chen, Yen-hsu/0000-0002-8667-4844; Liu, Xiaoli/0000-0003-2904-4413				Angelini GD, 2002, BIORHEOLOGY, V39, P491; Chen YH, 2002, HUM GENET, V111, P1, DOI 10.1007/s00439-002-0769-4; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; Dietrich H, 2000, AM J PATHOL, V157, P659, DOI 10.1016/S0002-9440(10)64576-2; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Exner M, 2001, J ENDOVASC THER, V8, P433, DOI 10.1583/1545-1550(2001)008<0433:HOGPMP>2.0.CO;2; Grundemar L, 1997, TRENDS PHARMACOL SCI, V18, P193, DOI 10.1016/S0165-6147(97)90622-2; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; Hishikawa K, 1997, CIRC RES, V81, P797; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Hunt SC, 2001, ATHEROSCLEROSIS, V154, P747, DOI 10.1016/S0021-9150(00)00420-2; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Johnson JL, 2001, ATHEROSCLEROSIS, V154, P399, DOI 10.1016/S0021-9150(00)00515-3; Juan SH, 2001, CIRCULATION, V104, P1519, DOI 10.1161/hc3801.095663; KEYSE SM, 1987, CARCINOGENESIS, V8, P1251, DOI 10.1093/carcin/8.9.1251; Kockx MM, 1996, CIRCULATION, V94, P1255, DOI 10.1161/01.CIR.94.6.1255; Lardenoye JHP, 2002, CIRC RES, V91, P577, DOI 10.1161/01.RES.0000036901.58329.D7; Layne MD, 1998, J BIOL CHEM, V273, P15654, DOI 10.1074/jbc.273.25.15654; Lee TS, 1999, CIRCULATION, V99, P1222, DOI 10.1161/01.CIR.99.9.1222; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Mehta D, 1997, INT J CARDIOL, V62, pS55, DOI 10.1016/S0167-5273(97)00214-3; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Morita T, 1995, J CLIN INVEST, V96, P2676, DOI 10.1172/JCI118334; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Nakayama M, 2001, ARTERIOSCL THROM VAS, V21, P1373, DOI 10.1161/hq0801.093592; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Patil CV, 2001, EUR HEART J, V22, P1183, DOI 10.1053/euhj.2000.2497; Perrella MA, 2001, FASEB J, V15, P1774, DOI 10.1096/fj.01-0017fje; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10919, DOI 10.1073/pnas.94.20.10919; ROSS R, 1995, ANNU REV PHYSIOL, V57, P791, DOI 10.1146/annurev.ph.57.030195.004043; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Serruys PW, 2001, NEW ENGL J MED, V344, P1117, DOI 10.1056/NEJM200104123441502; Shi CW, 1999, CIRC RES, V84, P883; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; STOCKER R, 1987, P NATL ACAD SCI USA, V84, P5918, DOI 10.1073/pnas.84.16.5918; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Wang A. Y., 1999, Journal of Submicroscopic Cytology and Pathology, V31, P423; Wang LJ, 1998, AM J PATHOL, V152, P711; Wiesel P, 2001, CIRC RES, V88, P1088, DOI 10.1161/hh1001.091521; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; Yet SF, 1997, J BIOL CHEM, V272, P4295, DOI 10.1074/jbc.272.7.4295; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543	51	249	259	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1759	+		10.1096/fj.03-0187fje	http://dx.doi.org/10.1096/fj.03-0187fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958201				2022-12-28	WOS:000184471600023
J	Koo, JW; Park, CH; Choi, SH; Kim, NJ; Kim, HS; Choe, JC; Suh, YH				Koo, JW; Park, CH; Choi, SH; Kim, NJ; Kim, HS; Choe, JC; Suh, YH			Postnatal environment can counteract prenatal effects on cognitive ability, cell proliferation, and synaptic protein expression	FASEB JOURNAL			English	Article						prenatal environment; enrichment; stress	ADULT-RAT HIPPOCAMPUS; SPONTANEOUS-ALTERNATION BEHAVIOR; DENTATE GYRUS; ANTIDEPRESSANT TREATMENT; ENRICHED ENVIRONMENT; NEUROTROPHIC FACTOR; ADHESION MOLECULES; INDUCED IMPAIRMENT; ALCOHOL EXPOSURE; SPATIAL MEMORY	Many environmental factors during the pre- or postnatal period can affect an individual's cognitive function and neural development throughout life. Little is known, however, about the combined effects of the pre- and postnatal environments on cognitive function of adult offspring and structural alterations in the adult brain. In this study, we confirmed that pre- or postnatal stress impaired learning and memory performance of rats. Conversely, pre- or postnatal enriched housing improved behavioral performance. These experience-dependent behavioral alterations were consistent with changes in 5-bromo-2'-deoxyuridine-labeled cell number in the granule cell layer of the hippocampus and in the expression level of synaptic markers such as neuronal cell adhesion molecule and synaptophysin, and expression of a neurotrophic factor, brain-derived neurotrophic factor. Postnatal stress appeared to have no influence on cell proliferation, however. We did find that postnatal environment could attenuate prenatal effects partly via a longitudinal cross-housing study, in which pups born to mothers housed under enriched conditions were reared under stressful conditions and vice versa. These results suggest that postnatal environmental manipulations can counteract the cognitive alterations in early adulthood and the structural changes in the young adult brain induced by prenatal experience.	Seoul Natl Univ, Coll Med, Dept Pharmacol, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Seoul Natl Univ, MRC, Neurosci Res Inst, Seoul 110799, South Korea	Seoul National University (SNU); Seoul National University (SNU)	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol, Natl Creat Res Initiat Ctr Alzheimers Dementia, 28 Youngon Dong, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					Benson DL, 2000, TRENDS CELL BIOL, V10, P473, DOI 10.1016/S0962-8924(00)01838-9; Berman RF, 1996, ALCOHOL, V13, P209, DOI 10.1016/0741-8329(95)02049-7; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Czeh B, 2001, P NATL ACAD SCI USA, V98, P12796, DOI 10.1073/pnas.211427898; de Quervain DJF, 1998, NATURE, V394, P787, DOI 10.1038/29542; Duman RS, 1999, BIOL PSYCHIAT, V46, P1181, DOI 10.1016/S0006-3223(99)00177-8; Eisch AJ, 2000, P NATL ACAD SCI USA, V97, P7579, DOI 10.1073/pnas.120552597; Fields RD, 1996, TRENDS NEUROSCI, V19, P473, DOI 10.1016/S0166-2236(96)30013-1; Figurov A, 1996, NATURE, V381, P706, DOI 10.1038/381706a0; Gould E, 2000, BIOL PSYCHIAT, V48, P715, DOI 10.1016/S0006-3223(00)01021-0; Gould E, 1997, J NEUROSCI, V17, P2492; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Graham KS, 1999, CURR OPIN NEUROBIOL, V9, P245, DOI 10.1016/S0959-4388(99)80035-X; HARRIS KM, 1994, ANNU REV NEUROSCI, V17, P341, DOI 10.1146/annurev.ne.17.030194.002013; Ickes BR, 2000, EXP NEUROL, V164, P45, DOI 10.1006/exnr.2000.7415; JORGENSEN OS, 1995, NEUROCHEM RES, V20, P533, DOI 10.1007/BF01694535; Kempermann G, 1998, J NEUROSCI, V18, P3206; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; KIYONO S, 1985, PHYSIOL BEHAV, V34, P431, DOI 10.1016/0031-9384(85)90207-0; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Lemaire V, 2000, P NATL ACAD SCI USA, V97, P11032, DOI 10.1073/pnas.97.20.11032; LEVINE ES, 1995, P NATL ACAD SCI USA, V92, P8074, DOI 10.1073/pnas.92.17.8074; Liu D, 2000, NAT NEUROSCI, V3, P799, DOI 10.1038/77702; Liu JL, 1998, J NEUROSCI, V18, P7768; Lordi B, 1997, PHYSIOL BEHAV, V62, P1087, DOI 10.1016/S0031-9384(97)00261-8; Magarinos AM, 1997, P NATL ACAD SCI USA, V94, P14002, DOI 10.1073/pnas.94.25.14002; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; Mizoguchi K, 2000, J NEUROSCI, V20, P1568; Mizuno M, 2000, J NEUROSCI, V20, P7116, DOI 10.1523/JNEUROSCI.20-18-07116.2000; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; Nakamura H, 1999, J NEUROSCI RES, V56, P307; NIBUYA M, 1995, J NEUROSCI, V15, P7539; Parent JM, 1997, J NEUROSCI, V17, P3727; Rampon C, 2000, NAT NEUROSCI, V3, P238, DOI 10.1038/72945; Rampon C, 2000, HIPPOCAMPUS, V10, P605, DOI 10.1002/1098-1063(2000)10:5<605::AID-HIPO11>3.0.CO;2-3; Rema V, 1999, J NEUROSCI, V19, P10993, DOI 10.1523/JNEUROSCI.19-24-10993.1999; Roy NS, 2000, NAT MED, V6, P271; Saffell JL, 1995, MOL CELL NEUROSCI, V6, P521, DOI 10.1006/mcne.1995.0004; SARTER M, 1988, PSYCHOPHARMACOLOGY, V94, P491, DOI 10.1007/BF00212843; Schinder AF, 2000, TRENDS NEUROSCI, V23, P639, DOI 10.1016/S0166-2236(00)01672-6; SHIOTA K, 1989, BIOL NEONATE, V56, P6; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Tanapat P, 1999, J NEUROSCI, V19, P5792, DOI 10.1523/JNEUROSCI.19-14-05792.1999; THOENEN H, 1995, SCIENCE, V270, P593, DOI 10.1126/science.270.5236.593; Vallee M, 1997, J NEUROSCI, V17, P2626; van Dellen A, 2000, NATURE, V404, P721, DOI 10.1038/35008142; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Vicario-Abejon C, 2000, EUR J NEUROSCI, V12, P677, DOI 10.1046/j.1460-9568.2000.00953.x; WALAAS SI, 1988, SYNAPSE, V2, P516, DOI 10.1002/syn.890020507; Weinstock M, 1997, NEUROSCI BIOBEHAV R, V21, P1, DOI 10.1016/S0149-7634(96)00014-0; WEST MJ, 1991, ANAT RECORD, V231, P482, DOI 10.1002/ar.1092310411; Yamada K, 1996, J PHARMACOL EXP THER, V276, P460	56	116	124	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1556	+		10.1096/fj.02-1032fje	http://dx.doi.org/10.1096/fj.02-1032fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824278				2022-12-28	WOS:000183818000040
J	Sengupta, S; Xiao, YJ; Xu, Y				Sengupta, S; Xiao, YJ; Xu, Y			A novel laminin-induced lysophosphatidic acid autocrine loop in the migration of ovarian	FASEB JOURNAL			English	Article						LPA; ovarian cancer; cell migration; beta(1) integrin	CELL-ADHESION MOLECULES; LYSOPHOSPHOLIPASE-D; EPITHELIAL TUMORS; PROTEIN-KINASE; CANCER; EXPRESSION; GROWTH; CARCINOMA; INTEGRIN; RECEPTORS	We have reported previously that levels of lysophosphatidic acid (LPA) are elevated in the blood and ascites from patients with ovarian cancer. LPA stimulates proliferation of ovarian cancer cells and has been proposed as an autocrine growth factor. Here, we show that a novel autocrine loop of LPA promotes the imigration of ovarian cancer cells, which is a critical step of tumor metastasis. We report that laminin, but not other extracellular matrix proteins, induces LPA production in ovarian cancer cells. A neutralizing antibody against beta(1) integrin and a calcium-independent phospholipase A(2)-specific inhibitor, HELSS, block both LPA production and the haptotactic activity of laminin. Exogenously added LPA restores the migratory ability of HEY ovarian cancer cells to laminin. These data suggest that laminin-induced cell migration is mediated by LPA. We further show that a specific receptor for LPA, LPA(3), is required for mediating the chemotactic activity of LPA. In addition, we show that cytosolic PLA(2) is required for cell migration and its activation is phosphatidylinositol-3 kinase-dependent. These findings have revealed a new mechanism of crosstalk between a beta(1) integrin receptor and a G protein-coupled receptor.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Obstet & Gynecol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org						Balboa MA, 1997, J BIOL CHEM, V272, P8576, DOI 10.1074/jbc.272.13.8576; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BARTOLAZZI A, 1993, ANTICANCER RES, V13, P1; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; BOTTINI C, 1993, INT J CANCER, V54, P261, DOI 10.1002/ijc.2910540217; Brindley DN, 2002, BBA-MOL CELL BIOL L, V1582, P33, DOI 10.1016/S1388-1981(02)00135-X; Buczek-Thomas JA, 1998, CELL SIGNAL, V10, P55, DOI 10.1016/S0898-6568(97)00074-0; BYERS LJ, 1995, CANCER LETT, V88, P67, DOI 10.1016/0304-3835(94)03625-S; CANNISTRA SA, 1995, GYNECOL ONCOL, V58, P216, DOI 10.1006/gyno.1995.1214; Capo-Chichi CD, 2002, CANCER-AM CANCER SOC, V95, P1802, DOI 10.1002/cncr.10870; Casey RC, 2001, AM J PATHOL, V159, P2071, DOI 10.1016/S0002-9440(10)63058-1; Casey RC, 2000, CLIN EXP METASTAS, V18, P67, DOI 10.1023/A:1026519016213; CATTERALL JB, 1994, CANCER LETT, V87, P199, DOI 10.1016/0304-3835(94)90223-2; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Erickson JR, 2001, PROSTAG OTH LIPID M, V64, P63, DOI 10.1016/S0090-6980(01)00100-9; Fang XJ, 2002, MOL CELL BIOL, V22, P2099, DOI 10.1128/MCB.22.7.2099-2110.2002; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; GARDNER MJ, 1995, CANCER LETT, V91, P229, DOI 10.1016/0304-3835(95)03743-G; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Ito H, 1997, DIAGN CYTOPATHOL, V16, P500, DOI 10.1002/(SICI)1097-0339(199706)16:6<500::AID-DC6>3.0.CO;2-D; Kuwashima Y., 1995, European Journal of Gynaecological Oncology, V16, P181; Locati M, 1996, J BIOL CHEM, V271, P6010, DOI 10.1074/jbc.271.11.6010; Lu J, 2002, J LIPID RES, V43, P463; Lynch KR, 1999, TRENDS PHARMACOL SCI, V20, P473, DOI 10.1016/S0165-6147(99)01401-7; Maatta M, 2001, J HISTOCHEM CYTOCHEM, V49, P711; Mills Gordon B, 2002, Cancer Treat Res, V107, P259; MIYASAKA M, 1995, CLIN ORTHOP RELAT R, V312, P10; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Moser TL, 1996, INT J CANCER, V67, P695, DOI 10.1002/(SICI)1097-0215(19960904)67:5<695::AID-IJC18>3.3.CO;2-2; Myou S, 2001, NAT IMMUNOL, V2, P145, DOI 10.1038/84244; Nelson PR, 1996, J VASC SURG, V24, P25, DOI 10.1016/S0741-5214(96)70141-6; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; PEREZ RP, 1991, SEMIN ONCOL, V18, P186; Plopper George E., 2000, Molecular Cell Biology Research Communications, V4, P129, DOI 10.1006/mcbr.2001.0267; Schwartz BM, 2001, GYNECOL ONCOL, V81, P291, DOI 10.1006/gyno.2001.6124; Sengupta S, 2001, J EXP CLIN CANC RES, V20, P585; Sengupta S, 2000, J EXP CLIN CANC RES, V19, P81; Shen ZZ, 2001, GYNECOL ONCOL, V83, P25, DOI 10.1006/gyno.2001.6357; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Silfani TN, 2002, ARCH BIOCHEM BIOPHYS, V402, P84, DOI 10.1016/S0003-9861(02)00066-8; TAKEICHI M, 1988, DEVELOPMENT, V102, P639; Tang J, 1997, J BIOL CHEM, V272, P8567, DOI 10.1074/jbc.272.13.8567; Tokumura A, 2002, BBA-MOL CELL BIOL L, V1582, P18, DOI 10.1016/S1388-1981(02)00133-6; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Xiao YJ, 2001, ANAL BIOCHEM, V290, P302, DOI 10.1006/abio.2001.5000; XU Y, 1995, J CELL PHYSIOL, V163, P441, DOI 10.1002/jcp.1041630303; Xu Y, 1998, JAMA-J AM MED ASSOC, V280, P719, DOI 10.1001/jama.280.8.719; Xu Y, 2001, J SOC GYNECOL INVEST, V8, P1, DOI 10.1016/S1071-5576(00)00092-7; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; XU Y, 1997, OVARIAN CANC, V5, P109; Yap AS, 1998, CANCER INVEST, V16, P252, DOI 10.3109/07357909809039774; Yoshida Y, 2001, INT J ONCOL, V18, P913	57	74	78	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1570	+		10.1096/fj.02-1145fje	http://dx.doi.org/10.1096/fj.02-1145fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824286				2022-12-28	WOS:000183818000036
J	Mack, JA; Abramson, SR; Ben, YX; Coffin, JC; Rothrock, JK; Maytin, EV; Hascall, VC; Largman, C; Stelnicki, EJ				Mack, JA; Abramson, SR; Ben, YX; Coffin, JC; Rothrock, JK; Maytin, EV; Hascall, VC; Largman, C; Stelnicki, EJ			Hoxb13 knockout adult skin exhibits high levels of hyaluronan and enhanced wound healing	FASEB JOURNAL			English	Article						transcription factor; fetal scarless wound healing; differentiation	HOMEODOMAIN PROTEIN; FETAL WOUNDS; DIFFERENTIATION; EXPRESSION; GENE; GROWTH; MOUSE; MICROANALYSIS; KERATINOCYTES; PROLIFERATION	In contrast to adult cutaneous wound repair, early gestational fetal cutaneous wounds heal by a process of regeneration, resulting in little or no scarring. Previous studies indicate that down-regulation of HoxB13, a member of the highly conserved family of Hox transcription factors, occurs during fetal scarless wound healing. No down-regulation was noted in adult wounds. Here, we evaluate healing of adult cutaneous wounds in Hoxb13 knockout (KO) mice, hypothesizing that loss of Hoxb13 in adult skin should result in enhanced wound healing. Tensiometry was used to measure the tensile strength of incisional wounds over a 60-day time course; overall, Hoxb13 KO wounds are significantly stronger than wild-type (WT). Histological evaluation of incisional wounds shows that 7-day-old Hoxb13 KO wounds are significantly smaller and that 60-day-old Hoxb13 KO wounds exhibit a more normal collagen architecture compared with WT wounds. We also find that excisional wounds close at a faster rate in Hoxb13 KO mice. Biochemical and histochemcial analyses show that Hoxb13 KO skin contains significantly elevated levels of hyaluronan. Because higher levels of hyaluronan and enhanced wound healing are characteristics of fetal skin, we conclude that loss of Hoxb13 produces a more "fetal-like" state in adult skin.	Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, Cleveland, OH 44195 USA; Cleveland Clin Florida, Dept Res, Weston, FL USA; Nova SE Univ, Coll Dent Med, Ft Lauderdale, FL 33314 USA; Cleveland Clin Fdn, Dept Dermatol, Cleveland, OH 44195 USA; Vet Affairs Med Ctr, Dept Dermatol, San Francisco, CA 94121 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Nova Southeastern University; Cleveland Clinic Foundation; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Mack, JA (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Biomed Engn ND20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	mackj@ccf.org						AN G, 1993, J BIOL CHEM, V268, P10977; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BONCINELLI E, 1991, TRENDS GENET, V7, P329, DOI 10.1016/0168-9525(91)90423-N; BRECHT M, 1986, BIOCHEM J, V239, P445, DOI 10.1042/bj2390445; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; Calabro A, 2000, GLYCOBIOLOGY, V10, P273, DOI 10.1093/glycob/10.3.273; Calabro A, 2000, GLYCOBIOLOGY, V10, P283, DOI 10.1093/glycob/10.3.283; Chang PY, 1998, BIOCHEM BIOPH RES CO, V248, P749, DOI 10.1006/bbrc.1998.9076; CHISAKA O, 1991, NATURE, V350, P458; Coleman PJ, 2002, BBA-GEN SUBJECTS, V1571, P173, DOI 10.1016/S0304-4165(02)00213-1; Cowherd RM, 1997, BIOCHEM BIOPH RES CO, V237, P470, DOI 10.1006/bbrc.1997.7160; DECRAEN MV, 1998, CELL DEATH DIFFER, V5, P838; Eckhart L, 2000, J INVEST DERMATOL, V115, P1148, DOI 10.1046/j.1523-1747.2000.00205.x; Economides KD, 2003, DEV BIOL, V256, P317, DOI 10.1016/S0012-1606(02)00137-9; ESTES JM, 1993, J PEDIATR SURG, V28, P1227, DOI 10.1016/S0022-3468(05)80303-3; Gardiner DM, 1998, AM ZOOL, V38, P659; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; HOPKINSONWOOLLEY J, 1994, J CELL SCI, V107, P1159; Itano N, 2002, P NATL ACAD SCI USA, V99, P3609, DOI 10.1073/pnas.052026799; Komuves LG, 2000, DEV DYNAM, V218, P636; Komuves LG, 2002, DEV DYNAM, V224, P58, DOI 10.1002/dvdy.10085; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; KUJAWA MJ, 1986, DEV BIOL, V113, P10, DOI 10.1016/0012-1606(86)90103-X; KUJAWA MJ, 1983, DEV BIOL, V99, P277, DOI 10.1016/0012-1606(83)90277-4; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; LEVENSON SM, 1965, ANN SURG, V161, P293, DOI 10.1097/00000658-196502000-00019; Lippens S, 2000, CELL DEATH DIFFER, V7, P1218, DOI 10.1038/sj.cdd.4400785; LONGAKER MT, 1990, J PEDIATR SURG, V25, P63, DOI 10.1016/S0022-3468(05)80165-4; MANAK JR, 1994, DEVELOPMENT, P61; Manley NR, 1998, DEV BIOL, V195, P1, DOI 10.1006/dbio.1997.8827; McCallion RL, 1996, MOL CELLULAR BIOL WO, P561; Packer AI, 2000, MECH DEVELOP, V99, P153, DOI 10.1016/S0925-4773(00)00471-8; Pienimaki JP, 2001, J BIOL CHEM, V276, P20428, DOI 10.1074/jbc.M007601200; SCOTT MP, 1992, CELL, V71, P551, DOI 10.1016/0092-8674(92)90588-4; Sonoda M, 1997, AM J SPORT MED, V25, P755, DOI 10.1177/036354659702500606; Sonoda M, 2000, AM J SPORT MED, V28, P90, DOI 10.1177/03635465000280012801; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; Stelnicki EJ, 1998, J INVEST DERMATOL, V111, P57, DOI 10.1046/j.1523-1747.1998.00238.x; Su DM, 2001, DEV BIOL, V236, P316, DOI 10.1006/dbio.2001.0342; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Weigel PH, 1997, J BIOL CHEM, V272, P13997, DOI 10.1074/jbc.272.22.13997; WHITBY DJ, 1991, DEV BIOL, V147, P207, DOI 10.1016/S0012-1606(05)80018-1	43	73	75	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1352	+		10.1096/fj.02-0959fje	http://dx.doi.org/10.1096/fj.02-0959fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759339				2022-12-28	WOS:000183165000018
J	Smit, AB; de Jong-Brink, M; Li, KW; Sassen, MMJ; Spijker, S; van Elk, R; Buijs, SP; van Minnen, J; van Kesteren, RE				Smit, AB; de Jong-Brink, M; Li, KW; Sassen, MMJ; Spijker, S; van Elk, R; Buijs, SP; van Minnen, J; van Kesteren, RE			Granularin, a novel molluscan opsonin comprising a single vWF type C domain is up-regulated during parasitation	FASEB JOURNAL			English	Article						Von Willebrand factor; parasite-host interaction; internal defense system; Lymnaea stagnalis; Trichobilharzia ocellata; schistosomiasis; bilharzia	SNAIL LYMNAEA-STAGNALIS; TRICHOBILHARZIA-OCELLATA; BIOMPHALARIA-GLABRATA; AVIAN SCHISTOSOME; FAMILY; GENES; CELLS; HOST; REQUIREMENTS; PARASITOSIS	Snails are intermediate hosts to schistosome parasites, some of which are the main cause of human schistosomiasis (bilharzia), and have been used as models for parasite-host interactions for a long time. Here, we have characterized a novel internal defense peptide of the snail Lymnaea stagnalis, of which the relative abundance in brain tissue increases upon infection with the avian schistosome Trichobilharzia ocellata. This protein, named granularin, is secreted by granular cells, which are numerous in the connective tissue surrounding the brain. The protein is unique because it comprises only a single Von Willebrand factor type C domain that is normally found in large transmembrane and secreted extracellular matrix proteins. The granularin gene is twice up-regulated during parasitation. Purified granularin stimulates phagocytosis of foreign particles by blood hemocytes. Together, our data indicate that granularin represents a novel protein that acts as an opsonin in the molluscan internal defense response.	Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Inst Neurosci, Grad Sch Neurosci Amsterdam, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Fac Earth & Life Sci, Dept Dev Neurobiol, NL-1081 HV Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	van Kesteren, RE (corresponding author), Vrije Univ Amsterdam, Dept Mol & Cellular Neurobiol, Inst Neurosci, Grad Sch Neurosci Amsterdam, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	revankes@bio.vu.nl	van Kesteren, Ronald E/E-2505-2014; Smit, August B/E-8410-2011; Spijker, Sabine/F-2300-2011	li, ka wan/0000-0001-6983-5055; Spijker, Sabine/0000-0002-6814-2019; van Kesteren, Ronald/0000-0002-9592-3777				Adema CM, 1997, P NATL ACAD SCI USA, V94, P8691, DOI 10.1073/pnas.94.16.8691; AMEN RI, 1992, PARASITOLOGY, V104, P33, DOI 10.1017/S0031182000060777; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DE JBM, 1995, ADV PARASIT, V35, P177; de Jong-Brink M, 2001, PARASITOLOGY, V123, pS129, DOI 10.1017/S0031182001008149; de Jong-Brink M, 2001, PEPTIDES, V22, P309, DOI 10.1016/S0196-9781(01)00332-1; DIKKEBOOM R, 1987, J INVERTEBR PATHOL, V49, P321, DOI 10.1016/0022-2011(87)90064-4; Hoek RM, 1996, EUR J IMMUNOL, V26, P939, DOI 10.1002/eji.1830260433; Hoek RM, 1997, P NATL ACAD SCI USA, V94, P14072, DOI 10.1073/pnas.94.25.14072; HOYER LW, 1981, BLOOD, V58, P1; HUNT LT, 1987, BIOCHEM BIOPH RES CO, V144, P876, DOI 10.1016/S0006-291X(87)80046-3; Jimenez CR, 1997, P NATL ACAD SCI USA, V94, P9481, DOI 10.1073/pnas.94.17.9481; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Leonard PM, 2001, GENE, V269, P155, DOI 10.1016/S0378-1119(01)00444-9; Li KW, 2004, J BIOL CHEM, V279, P987, DOI 10.1074/jbc.M303116200; NUNEZ PE, 1994, PARASITOLOGY, V109, P299, DOI 10.1017/S0031182000078331; Nunez PE, 1997, PARASITOLOGY, V115, P193, DOI 10.1017/S0031182097001169; PADAWER J, 1968, EXPERIENTIA, V24, P471, DOI 10.1007/BF02144399; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; SMINIA T, 1972, Z ZELLFORSCH MIK ANA, V130, P497, DOI 10.1007/BF00307004; SMINIA T, 1987, DEV COMP IMMUNOL, V11, P17, DOI 10.1016/0145-305X(87)90004-8; SMINIA T, 1979, CELL TISSUE RES, V196, P545, DOI 10.1007/BF00234748; SMINIA T, 1981, DEV COMP IMMUNOL, V5, P87; SMIT AB, 1988, NATURE, V331, P535, DOI 10.1038/331535a0; Van Der Steen W. J., 1969, NETH J ZOOL, V19, P131, DOI DOI 10.1163/002829669X00170; VANDERKNAAP WPW, 1987, Z PARASITENKD, V73, P57; VOORBERG J, 1991, J CELL BIOL, V113, P195, DOI 10.1083/jcb.113.1.195; VREUGDENHIL E, 1988, J NEUROSCI, V8, P4184; Wright AE, 1903, P R SOC LONDON, V72, P357, DOI 10.1098/rspl.1903.0062; Zhang SM, 2001, IMMUNOGENETICS, V53, P684, DOI 10.1007/s00251-001-0386-8	32	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					845	+		10.1096/fj.03-0590fje	http://dx.doi.org/10.1096/fj.03-0590fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033923				2022-12-28	WOS:000220522800007
J	Kam, Y; Exton, JH				Kam, Y; Exton, JH			Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid	FASEB JOURNAL			English	Article						platelet-derived growth factor; phosphoinositide 3-kinase	PROTEIN-KINASE B; 70-KDA S6 KINASE; MAMMALIAN TARGET; PHOSPHOINOSITIDE 3-KINASE; SIGNALING PATHWAY; CELL-GROWTH; RAPAMYCIN; TRANSLATION; PHOSPHORYLATION; ACTIVATION	Mitogens activate protein translation through phosphorylation of p7S6 kinase (p70(S6K)) and eIF4E binding protein 1 (4E-BP1) mediated by the mammalian target of rapamycin (mTOR) or phosphoinositide 3-kinase (PI3K). A recent report (Science 294, 1942, 2001) has implicated phospholipase D (PLD) in mTOR signaling. We studied the role of PLD in the phosphorylation of p70(S6K) and 4E-BP1 induced by lysophosphatidic acid (LPA) and platelet-derived growth factor (PDGF) using fibroblasts deficient in PLD activity and also 1-butanol, which inhibits phosphatidic acid production by PLD. The reduction in PLD activity in both situations impaired the effect of LPA on mTOR signaling but did not inhibit the effect of PDGF. PDGF induced marked phosphorylation of Akt (a PI3K target) but this was not affected by PLD deficiency. LPA caused much less phosphorylation of Akt and this was dependent on PLD activity. Toxin B, which inactivates Rho GTPases, markedly impaired PLD1 activation and phosphorylation of Akt, p70(S6K), and 4E-BP1 induced by LPA but had a minimal or no effect on the actions of PDGF. These results support the hypothesis that LPA activates protein translation through the action of PLD1-generated PA on mTOR and the PI3K/Akt pathway whereas PDGF acts through PI3K/Akt independent of PLD1.	Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University	Exton, JH (corresponding author), Vanderbilt Univ, Sch Med, Howard Hughes Med Inst, 221 Kirkland Hall, Nashville, TN 37232 USA.	john.exton@vanderbilt.edu		Kam, Yoonseok/0000-0003-4712-9058				Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Bannister P, 2001, TREE PHYSIOL SER, V1, P3; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Brunn GJ, 1996, EMBO J, V15, P5256, DOI 10.1002/j.1460-2075.1996.tb00911.x; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cantrell DA, 2001, J CELL SCI, V114, P1439; Chou MM, 1996, CELL, V85, P573, DOI 10.1016/S0092-8674(00)81257-X; Exton JH, 1999, BBA-MOL CELL BIOL L, V1439, P121, DOI 10.1016/S1388-1981(99)00089-X; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; JUST I, 1995, NATURE, V375, P500, DOI 10.1038/375500a0; Kam Y, 2001, MOL CELL BIOL, V21, P4055, DOI 10.1128/MCB.21.12.4055-4066.2001; Krugmann S, 2002, BIOCHEM J, V362, P725, DOI 10.1042/0264-6021:3620725; Lawrence JC, 1997, TRENDS BIOCHEM SCI, V22, P345, DOI 10.1016/S0968-0004(97)01101-8; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Thomas G, 1997, CURR OPIN CELL BIOL, V9, P782, DOI 10.1016/S0955-0674(97)80078-6; VanAelst L, 1997, GENE DEV, V11, P2295, DOI 10.1101/gad.11.18.2295; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Willard FS, 2001, BIOCHEM BIOPH RES CO, V287, P607, DOI 10.1006/bbrc.2001.5645; Xie Z, 2002, J BIOL CHEM, V277, P11979, DOI 10.1074/jbc.M109751200; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0	32	56	60	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2004	18	2					311	319		10.1096/fj.03-0731com	http://dx.doi.org/10.1096/fj.03-0731com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769825				2022-12-28	WOS:000220425000011
J	Li, QJ; Yao, M; Wong, W; Parpura, V; Martins-Green, M				Li, QJ; Yao, M; Wong, W; Parpura, V; Martins-Green, M			N- and C-terminal peptides of hIL-8/CXCL8 are ligands for hCXCR1 and hCXCR2	FASEB JOURNAL			English	Article						chemokine signaling; chemotaxis; Ca2+ imaging; MAPK; hMVEC	ACTIVATED PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; ANGIOGENIC FACTOR; TYROSINE KINASES; GENE-PRODUCT; AMINO-ACID; INTERLEUKIN-8; CHEMOKINE; RESIDUES; CASCADE	Chemokines are small cytokines that function in immune responses, wound healing, and pathological conditions such as chronic inflammation and tumorigenesis. This multifunctionality has been attributed primarily to ligand interaction with multiple or dimerized receptors. However, multifunctionality could also result from interactions of the receptors with small peptides produced by processing of the chemokines. Chemokine peptides are functional in vivo, but it is not yet known whether they can interact with and activate their receptors. The work presented here examines the interactions between the two forms of human interleukin 8 (hIL-8), and its N- and C-peptides, with the chemokine receptors hCXCR1 and hCXCR2. We used a Teton retroviral system to introduce CXCR1 into mouse NIH 3T3 cells (that lack endogenous CXCR1) and monitored activation of this receptor by the ligands by using quantitative Ca2+ imaging and mitogen-activated protein kinase (MAPK) activation. We found that the N and C termini of the chemokine can stimulate the respective CXCR1 to induce intracellular Ca2+ release and MAPK activation independent of the other regions of the molecules. Furthermore, we showed that these peptides can also stimulate chemotaxis of several cell types, including primary human microvascular endothelial cells, and that this function is specific and mediated by hCXCR1 and/or hCXCR2. These findings advance understanding of the multifunctionality exhibited by chemokines, reveal a new mode of functional regulation, and may serve as the basis for therapeutic targeting.	Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA	University of California System; University of California Riverside	Martins-Green, M (corresponding author), Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA.	mmgreen@ucrac1.ucr.edu	Parpura, Vladimir/A-1242-2010	Parpura, Vladimir/0000-0002-4643-2197				Atta-ur-Rahman, 1999, CURR PHARM DESIGN, V5, P241; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; Boisvert WA, 2000, IMMUNOL RES, V21, P129, DOI 10.1385/IR:21:2-3:129; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Feugate JE, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-13; Feugate JE, 2002, J CELL BIOL, V156, P161, DOI 10.1083/jcb.200103062; Fibbe WE, 1999, ANN NY ACAD SCI, V872, P71, DOI 10.1111/j.1749-6632.1999.tb08454.x; GUPTA SK, 1995, P NATL ACAD SCI USA, V92, P7799, DOI 10.1073/pnas.92.17.7799; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hemmerich S, 1999, BIOCHEMISTRY-US, V38, P13013, DOI 10.1021/bi991029m; Katancik JA, 2000, CYTOKINE, V12, P1480, DOI 10.1006/cyto.2000.0742; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; LEONG SR, 1994, J BIOL CHEM, V269, P19343; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Maghazachi AA, 1999, CELL SIGNAL, V11, P385, DOI 10.1016/S0898-6568(99)00008-X; Martins-Green M, 2001, INT J BIOCHEM CELL B, V33, P427, DOI 10.1016/S1357-2725(01)00029-2; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; Martins-Green M, 1998, CYTOKINE, V10, P819, DOI 10.1006/cyto.1998.0383; Mukaida N, 2000, INT J HEMATOL, V72, P391; NOURSHARGH S, 1992, J IMMUNOL, V148, P106; Parpura V, 2000, P NATL ACAD SCI USA, V97, P8629, DOI 10.1073/pnas.97.15.8629; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; ROBY P, 1995, BIOCHEM BIOPH RES CO, V206, P792, DOI 10.1006/bbrc.1995.1112; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rossi FMV, 1998, NAT GENET, V20, P389, DOI 10.1038/3871; Skelton NJ, 1999, STRUCTURE, V7, P157, DOI 10.1016/S0969-2126(99)80022-7; Terui Y, 1999, CANCER RES, V59, P5651; Thompson SK, 1996, INT J PEPT PROT RES, V47, P214; Vaingankar SM, 1998, J BIOL CHEM, V273, P5226, DOI 10.1074/jbc.273.9.5226; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; Wan Y, 1996, NATURE, V380, P541, DOI 10.1038/380541a0; Wan Y, 1997, J BIOL CHEM, V272, P17209, DOI 10.1074/jbc.272.27.17209	36	10	11	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					776	+		10.1096/fj.02-1175fje	http://dx.doi.org/10.1096/fj.02-1175fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766805				2022-12-28	WOS:000220425000038
J	Akunda, JK; Lao, HC; Lee, CA; Sessoms, AR; Slade, RM; Langenbach, R				Akunda, JK; Lao, HC; Lee, CA; Sessoms, AR; Slade, RM; Langenbach, R			Genetic deficiency or pharmacological inhibition of cyclooxygenase-1 or-2 induces mouse keratinocyte differentiation in vitro and in vivo	FASEB JOURNAL			English	Article						knockout; celecoxib; SC-560; terminal differentiation	NONSTEROIDAL ANTIINFLAMMATORY DRUGS; H SYNTHASE ISOENZYMES; COLON-CANCER CELLS; EPIDERMAL DIFFERENTIATION; GROWTH-INHIBITION; TUMOR-GROWTH; APOPTOSIS; SKIN; EXPRESSION; MICE	Previously we demonstrated that genetic deficiency of the cyclooxygenases (COX-1 or COX-2) altered keratinocyte differentiation in mouse skin [Tiano et. al. (2002) Cancer Res. 62, 3395-3401]. In this study, we show that topical application of SC-560 (a COX-1 selective inhibitor) or celecoxib (COX-2 selective) to TPA-treated wild-type skin caused fivefold increases in the number of basal keratinocytes expressing the early differentiation marker keratin 1 (K1). In contrast to skin, COX-2 not COX-1 was the major isoform expressed in cultured primary keratinocytes. COX-1 was predominantly expressed in detached, differentiated cells, whereas COX-2 was found in the attached, proliferating cells. High Ca++ medium induced K1 and COX-1 in wild-type keratinocytes but did not change COX-2 expression. As observed in skin, COX-1(-/-) and COX-2(-/-) primary keratinocytes expressed fivefold more K1 than wild-type cells. K1 levels in cultured wild-type keratinocytes were also increased by treatment with celecoxib and indomethacin. However, unlike its in vivo effect, SC-560, possibly due to low COX-1 expression in cultured mouse keratinocytes, did not increase K1 levels. Furthermore, no increases in apoptotic cell numbers were observed in COX-deficient keratinocytes or COX-inhibitor treated wild-type cells. Thus, a major effect of COX inhibitors and COX-deficiency is the induction of keratinocyte differentiation.	NIEHS, NIH, Mol Carcinogenesis Lab, Res Triangle Pk, NC 27709 USA; Myriad Pharmaceut Inc, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Myriad Genetics, Inc	Langenbach, R (corresponding author), NIEHS, MD C4-09,POB 12233, Res Triangle Pk, NC 27709 USA.	langenb1@niehs.nih.gov					The authors wish to thank Carl Bortner (NIEHS) for help with the FACS analysis, Kevin Trouba (NIEHS) for helping with human keratinocyte cultures, Robert Smart (North Carolina State University), Thomas Eling, Carol Trempus, and Thomas Gray (All at NIEHS) for the critical review of this manuscript.	Bol DK, 2002, CANCER RES, V62, P2516; Chulada PC, 2000, CANCER RES, V60, P4705; Dannenberg AJ, 2001, LANCET ONCOL, V2, P544, DOI 10.1016/S1470-2045(01)00488-0; DLUGOSZ AA, 1995, METHOD ENZYMOL, V254, P3; Elder DJE, 2000, INT J CANCER, V86, P553, DOI 10.1002/(SICI)1097-0215(20000515)86:4<553::AID-IJC18>3.3.CO;2-0; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Grosch S, 2001, FASEB J, V15, P2742, DOI 10.1096/fj.01-0299fje; Hanif R, 1996, BIOCHEM PHARMACOL, V52, P237, DOI 10.1016/0006-2952(96)00181-5; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; KARTASOVA T, 1992, MOL CARCINOGEN, V6, P18, DOI 10.1002/mc.2940060105; Kitamura T, 2002, CARCINOGENESIS, V23, P1463, DOI 10.1093/carcin/23.9.1463; Kundu N, 2002, CANCER RES, V62, P2343; LANGENBACH R, 1995, CELL, V83, P483, DOI 10.1016/0092-8674(95)90126-4; Leong J, 1996, EXP CELL RES, V224, P79, DOI 10.1006/excr.1996.0113; Loftin CD, 2001, P NATL ACAD SCI USA, V98, P1059, DOI 10.1073/pnas.031573498; Masferrer JL, 2000, CANCER RES, V60, P1306; MORHAM SG, 1995, CELL, V83, P473, DOI 10.1016/0092-8674(95)90125-6; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Muller-Decker K, 1999, INT J CANCER, V82, P648, DOI 10.1002/(SICI)1097-0215(19990827)82:5<648::AID-IJC6>3.0.CO;2-D; Muller-Decker K, 1998, EXP CELL RES, V242, P84, DOI 10.1006/excr.1998.4068; Muller-Decker K, 1998, MOL CARCINOGEN, V23, P36, DOI 10.1002/(SICI)1098-2744(199809)23:1<36::AID-MC5>3.0.CO;2-F; Neufang G, 2001, P NATL ACAD SCI USA, V98, P7629, DOI 10.1073/pnas.121574098; Nishimura G, 1999, JPN J CANCER RES, V90, P1152, DOI 10.1111/j.1349-7006.1999.tb00690.x; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; Pentland AP, 1999, CARCINOGENESIS, V20, P1939, DOI 10.1093/carcin/20.10.1939; Reddy BS, 1996, CANCER RES, V56, P4566; Richter M, 2001, CARCINOGENESIS, V22, P17, DOI 10.1093/carcin/22.1.17; SCHOLZ K, 1995, BIOCHEM J, V309, P263, DOI 10.1042/bj3090263; Shiff SJ, 1996, EXP CELL RES, V222, P179, DOI 10.1006/excr.1996.0023; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; Tiano HF, 2002, CANCER RES, V62, P3395; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Waskewich C, 2002, CANCER RES, V62, P2029; Williams CS, 2000, CANCER RES, V60, P6045; Yamazaki R, 2002, FEBS LETT, V531, P278, DOI 10.1016/S0014-5793(02)03535-4; YUSPA SH, 1989, J CELL BIOL, V109, P1207, DOI 10.1083/jcb.109.3.1207; Zhu SY, 1999, MOL CELL BIOL, V19, P7181	40	18	19	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					185	187		10.1096/fj.02-1192fje	http://dx.doi.org/10.1096/fj.02-1192fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630706				2022-12-28	WOS:000188829300068
J	Bergmann, M; Schutt, F; Holz, FG; Kopitz, J				Bergmann, M; Schutt, F; Holz, FG; Kopitz, J			Inhibition of the ATP-driven proton pump in RPE lysosomes by the major lipofuscin fluorophore A2-E may contribute to the pathogenesis of age-related macular degeneration	FASEB JOURNAL			English	Article						retinal disease; ATPase; proton transport; phagocytosis; autophagy	RETINAL-PIGMENT EPITHELIUM; DEGRADATIVE FUNCTIONS; MODEL MEMBRANES; OUTER SEGMENTS; CELL-SURFACE; A2E; COMPONENT; AUTOPHAGY; ACCUMULATION; APOPTOSIS	Lipofuscin accumulation in the retinal pigment epithelium (RPE) is associated with various blinding retinal diseases, including age-related macular degeneration (AMD). The major lipofuscin fluorophor A2-E is thought to play an important pathogenetic role. In previous studies A2-E was shown to severely impair lysosomal function of RPE cells. However, the underlying molecular mechanism remained obscure. Using purified lysosomes from RPE cells we now demonstrate that A2-E is a potent inhibitor of the ATP-driven proton pump located in the lysosomal membrane. Such inhibition of proton transport to the lysosomal lumen results in an increase of the lysosomal pH with subsequent inhibition of lysosomal hydrolases. An essential task of the lysosomal apparatus of postmitotic RPE for normal photoreceptor function is phagocytosis and degradation of membranous discs shed from photoreceptor outer segments (POS) and of biomolecules from autophagy. When the lysosomes of cultured RPE cells were experimentally loaded with A2-E, we observed intracellular accumulation of exogenously added POS with subsequent congestion of the phagocytic process. Moreover, the autophagic sequestration of cytoplasmic material was also markedly reduced after A2-E loading. These data support the hypothesis that A2-E-induced lysosomal dysfunction contributes to the pathogenesis of AMD and other retinal diseases associated with excessive lipofuscin accumulation.	Heidelberg Univ, Dept Mol Pathol, D-69120 Heidelberg, Germany; Heidelberg Univ, Dept Ophthalmol, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg; Ruprecht Karls University Heidelberg	Kopitz, J (corresponding author), Heidelberg Univ, Dept Mol Pathol, Neuenheimer Feld 220, D-69120 Heidelberg, Germany.	juergen-kopitz@med.uni-heidelberg.de						Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; Ben-Shabat S, 2002, J BIOL CHEM, V277, P7183, DOI 10.1074/jbc.M108981200; Bermann M, 2001, EXP EYE RES, V72, P191; Boulton M, 2001, EYE, V15, P384, DOI 10.1038/eye.2001.141; Brown D, 2002, INT J MED MICROBIOL, V291, P433; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Burke JM, 1998, INVEST OPHTH VIS SCI, V39, P1478; CARO LHP, 1988, EUR J BIOCHEM, V175, P325, DOI 10.1111/j.1432-1033.1988.tb14200.x; Davies S, 2001, FREE RADICAL BIO MED, V31, P256, DOI 10.1016/S0891-5849(01)00582-2; DAVIS AA, 1995, INVEST OPHTH VIS SCI, V36, P955; De S, 2002, J GEN PHYSIOL, V120, P147, DOI 10.1085/jgp.20028566; DEGUCHI J, 1994, INVEST OPHTH VIS SCI, V35, P568; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; ELDRED GE, 1988, EXP EYE RES, V47, P71, DOI 10.1016/0014-4835(88)90025-5; ELDRED GE, 1993, NATURE, V361, P724, DOI 10.1038/361724a0; FEENEYBURNS L, 1980, AM J OPHTHALMOL, V90, P783, DOI 10.1016/S0002-9394(14)75193-1; Finbow ME, 1997, BIOCHEM J, V324, P697, DOI 10.1042/bj3240697; Finnemann SC, 2002, P NATL ACAD SCI USA, V99, P3842, DOI 10.1073/pnas.052025899; GAILLARD ER, 1995, PHOTOCHEM PHOTOBIOL, V61, P448, DOI 10.1111/j.1751-1097.1995.tb02343.x; Glazer LC, 2002, OPHTHALMOL CLIN N AM, V15, pviii; Glazer Liane Clamen, 2002, Ophthalmol Clin North Am, V15, P93, DOI 10.1016/S0896-1549(01)00011-6; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; GORDON PB, 1986, BIOMED BIOCHIM ACTA, V45, P1635; Holz FG, 2001, INVEST OPHTH VIS SCI, V42, P1051; Holz FG, 1999, INVEST OPHTH VIS SCI, V40, P737; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; JONAS AJ, 1989, BIOCHIM BIOPHYS ACTA, V984, P257, DOI 10.1016/0005-2736(89)90290-3; Kennedy CJ, 1995, EYE, V9, P763, DOI 10.1038/eye.1995.192; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kopitz J, 1998, J BIOL CHEM, V273, P11205, DOI 10.1074/jbc.273.18.11205; KOPITZ J, 1994, CLIN CHIM ACTA, V227, P121, DOI 10.1016/0009-8981(94)90141-4; la Cour M, 2002, DRUG AGING, V19, P101, DOI 10.2165/00002512-200219020-00003; Lamb LE, 2001, ARCH BIOCHEM BIOPHYS, V393, P316, DOI 10.1006/abbi.2001.2492; Larsen KE, 2002, HISTOL HISTOPATHOL, V17, P897, DOI 10.14670/HH-17.897; Liu JH, 2000, J BIOL CHEM, V275, P29354, DOI 10.1074/jbc.M910191199; London E, 2002, CURR OPIN STRUC BIOL, V12, P480, DOI 10.1016/S0959-440X(02)00351-2; LULLMANNRAUCH R, 1981, A GRAEF ARCH KLIN EX, V215, P297, DOI 10.1007/BF00407668; MACKENZIE AH, 1983, AM J MED, V75, P5, DOI 10.1016/0002-9343(83)91264-0; Martens JR, 2001, J BIOL CHEM, V276, P8409, DOI 10.1074/jbc.M009948200; MARTINEZ CM, 1990, CELL BIOL INT REP, V14, P255, DOI 10.1016/S0309-1651(05)80008-6; Mata NL, 2000, P NATL ACAD SCI USA, V97, P7154, DOI 10.1073/pnas.130110497; Mousavi SA, 2001, BBA-BIOMEMBRANES, V1510, P243, DOI 10.1016/S0005-2736(00)00354-0; Mullins RF, 2000, FASEB J, V14, P835, DOI 10.1096/fasebj.14.7.835; O'Neill C, 2001, DRUG AGING, V18, P233, DOI 10.2165/00002512-200118040-00001; Owen CG, 2003, BRIT J OPHTHALMOL, V87, P312, DOI 10.1136/bjo.87.3.312; Parish CA, 1998, P NATL ACAD SCI USA, V95, P14609, DOI 10.1073/pnas.95.25.14609; Roberts JE, 2002, PHOTOCHEM PHOTOBIOL, V75, P184, DOI 10.1562/0031-8655(2002)075<0184:TROAIP>2.0.CO;2; Russell SR, 2000, AM J OPHTHALMOL, V129, P205, DOI 10.1016/S0002-9394(99)00345-1; SARKS JP, 1994, EYE, V8, P269, DOI 10.1038/eye.1994.57; SCHNEIDER DL, 2003, METHOD ENZYMOL, V157, P591; Schneider P, 1997, MICROSC RES TECHNIQ, V36, P253; Schraermeyer U, 1997, EXP EYE RES, V65, P277, DOI 10.1006/exer.1997.0339; Schraermeyer U, 1999, PIGM CELL RES, V12, P219, DOI 10.1111/j.1600-0749.1999.tb00755.x; Schutt F, 2002, GRAEF ARCH CLIN EXP, V240, P983, DOI 10.1007/s00417-002-0558-8; Schutt F, 2002, FEBS LETT, V528, P217, DOI 10.1016/S0014-5793(02)03312-4; Schutt F, 2000, INVEST OPHTH VIS SCI, V41, P2303; SCHUTT F, 2003, IN PRESS INVEST OPHT; SEGLEN PO, 1983, METHOD ENZYMOL, V96, P737; Shamsi FA, 2001, INVEST OPHTH VIS SCI, V42, P3041; Sparrow JR, 1999, INVEST OPHTH VIS SCI, V40, P2988; Sparrow JR, 2001, INVEST OPHTH VIS SCI, V42, P1356; Sparrow JR, 2000, INVEST OPHTH VIS SCI, V41, P1981; Stoka V, 2001, J BIOL CHEM, V276, P3149, DOI 10.1074/jbc.M008944200; Sundelin S, 1998, CURR EYE RES, V17, P851, DOI 10.1080/02713689808951268; Suter M, 2000, J BIOL CHEM, V275, P39625, DOI 10.1074/jbc.M007049200; Taute A, 2002, BIOCHEM BIOPH RES CO, V298, P5, DOI 10.1016/S0006-291X(02)02387-2; Uhlen P, 2003, ANN NY ACAD SCI, V986, P514, DOI 10.1111/j.1749-6632.2003.tb07237.x; Wan FY, 2002, ARCH BIOCHEM BIOPHYS, V404, P285, DOI 10.1016/S0003-9861(02)00280-1; Wassell J, 1999, J BIOL CHEM, V274, P23828, DOI 10.1074/jbc.274.34.23828; Winchester B G, 2001, Eur J Paediatr Neurol, V5 Suppl A, P11, DOI 10.1053/ejpn.2000.0428; YOUNG RW, 1987, SURV OPHTHALMOL, V31, P291, DOI 10.1145/1165387.275645; Zang Y, 2001, CELL DEATH DIFFER, V8, P477, DOI 10.1038/sj.cdd.4400843; Zarbin MA, 1998, EUR J OPHTHALMOL, V8, P199, DOI 10.1177/112067219800800401	74	166	180	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					562	+		10.1096/fj.03-0289fje	http://dx.doi.org/10.1096/fj.03-0289fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715704				2022-12-28	WOS:000188829300024
J	Barone, F; Aguanno, S; D'Alessio, A; D'Agostino, A				Barone, F; Aguanno, S; D'Alessio, A; D'Agostino, A			Sertoli cell modulates MAA-induced apoptosis of germ cells throughout voltage-operated calcium channels	FASEB JOURNAL			English	Article						apoptosis; Sertoli cells; calcium channels; seminiferous tubule	METHOXYACETIC-ACID; SEMINIFEROUS EPITHELIUM; SPERMATOCYTE TOXICITY; FLOW-CYTOMETRY; ADULT-RAT; CLUSTERIN; TESTIS; MICE; DEGENERATION; BLOCKERS	Spontaneous cell death by apoptosis-occurring during normal spermatogenesis in mammals-is a prominent event, which results in the loss of up to 75% of the potential number of mature spermatozoa. In the rat testis, the most conspicuous dying cells are pachytene spermatocytes, which are also the primary target of the apoptosis experimentally induced by methoxyacetic acid (MAA). In this paper, we have used clusterin expression as an indicator of germ cell apoptosis in rat seminiferous tubules treated with MAA in the presence or in the absence of voltage-operated calcium channels (VOCCs) inhibitors. We performed both a qualitative analysis of clusterin expression by immunofluorescence experiments and a quantitative analysis of apoptosis by in situ end labeling of apoptotic germ cells followed by flow cytometry. The results obtained demonstrate that Sertoli cells, the somatic component of the seminiferous epithelium, which control male germ cell differentiation, also modulate MAA-induced apoptosis of germ cells throughout voltage-operated calcium channels.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; ENEA, Casaccia Res Ctr, Biotechnol Unit, I-00060 Rome, Italy	Sapienza University Rome; Italian National Agency New Technical Energy & Sustainable Economics Development	D'Agostino, A (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via A Scarpa 14, I-00161 Rome, Italy.	angela.dagostino@uniroma1.it		Aguanno, Salvatore/0000-0002-0352-4948				Bailey RW, 2002, BIOL REPROD, V66, P1042, DOI 10.1095/biolreprod66.4.1042; BARTKE A, 1995, ENDOCRINOLOGY, V136, P3, DOI 10.1210/en.136.1.3; BlancoRodriguez J, 1996, CELL PROLIFERAT, V29, P13, DOI 10.1046/j.1365-2184.1996.d01-5.x; Cano-Abad MF, 2002, ANN NY ACAD SCI, V971, P171, DOI 10.1111/j.1749-6632.2002.tb04459.x; Clark AM, 1997, BIOL REPROD, V57, P837, DOI 10.1095/biolreprod57.4.837; DAGOSTINO A, 1992, BIOL REPROD, V46, P414, DOI 10.1095/biolreprod46.3.414; DEROOIJ DG, 1987, ANAT REC, V217, P124, DOI 10.1002/ar.1092170203; FLICKINGER C, 1967, ANAT RECORD, V158, P207, DOI 10.1002/ar.1091580210; Fragale A, 2000, MOL CELL ENDOCRINOL, V162, P25, DOI 10.1016/S0303-7207(00)00213-6; French LE, 1996, BIOL REPROD, V55, P1213, DOI 10.1095/biolreprod55.6.1213; Galdieri M, 1981, J ANDROL, V5, P249; GHANAYEM BI, 1990, EXP MOL PATHOL, V52, P279, DOI 10.1016/0014-4800(90)90069-P; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; HARDIN BD, 1983, TOXICOLOGY, V27, P91, DOI 10.1016/0300-483X(83)90014-8; Ho R, 2001, J ALZHEIMERS DIS, V3, P479, DOI 10.3233/JAD-2001-3507; HSDB, 2000, HSDB TOXNET HAZ SUBS; JEONGWU L, 1997, ENDOCRINOLOGY, V138, P2081; Krishnamurthy H, 1998, J ANDROL, V19, P710; KU WW, 1995, TOXICOL APPL PHARM, V134, P100, DOI 10.1006/taap.1995.1173; KU WW, 1994, TOXICOL IN VITRO, V8, P1191, DOI 10.1016/0887-2333(94)90109-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LH, 1997, TOXICOL APPL PHARM, V144, P105, DOI 10.1006/taap.1997.8129; LI LH, 1996, J ANDROL, V17, P153; Matsubara E, 1996, BIOCHEM J, V316, P671, DOI 10.1042/bj3160671; McHattie S, 1999, J COMP PATHOL, V121, P159, DOI 10.1053/jcpa.1999.0313; Otori Y, 2003, BRAIN RES, V961, P213, DOI 10.1016/S0006-8993(02)03951-3; Read DS, 2002, EXP EYE RES, V75, P415, DOI 10.1006/exer.2002.2034; Richburg JH, 2000, ENDOCRINOLOGY, V141, P787, DOI 10.1210/en.141.2.787; RUSSELL LD, 1978, ANAT REC, V190, P99, DOI 10.1002/ar.1091900109; SHERI AH, 2001, BIOL REPROD, V65, P1771; Taranta A, 2000, MATRIX BIOL, V19, P11, DOI 10.1016/S0945-053X(99)00054-2; Taranta A, 1997, MOL CELL ENDOCRINOL, V126, P117, DOI 10.1016/S0303-7207(96)03973-1; TELFORD WG, 1994, J IMMUNOL METHODS, V172, P1, DOI 10.1016/0022-1759(94)90373-5	33	10	11	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					353	+		10.1096/fj.03-0347fje	http://dx.doi.org/10.1096/fj.03-0347fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656996				2022-12-28	WOS:000188067500029
J	Cid, C; Alvarez-Cermeno, JC; Camafeita, E; Salinas, M; Alcazar, A				Cid, C; Alvarez-Cermeno, JC; Camafeita, E; Salinas, M; Alcazar, A			Antibodies reactive to heat shock protein 90 induce oligodendrocyte precursor cell death in culture. Implications for demyelination in multiple sclerosis	FASEB JOURNAL			English	Article						cell surface antigen expression; demyelinating diseases; O-2A progenitor cells; terminal complement complex; remyelination	HEAT-SHOCK PROTEINS; PROGENITOR CELLS; T-CELL; IDENTIFICATION; EXPRESSION; LESIONS; ASTROCYTE; DAMAGE; SERUM	Oligodendrocyte precursor cells (OPCs) are extremely efficient at remyelination. These cells persist in the adult human central nervous system and can proliferate. However, the failure to remyelinate is a pathological characteristic of the human demyelinating disease multiple sclerosis (MS), which suggests that these cells are ineffective in this disorder. This paper reports that IgG antibodies in the cerebrospinal fluid (CSF) of MS patients specifically recognize an antigen on OPCs in culture. Control patients were found not to possess these antibodies. The antigen was immunoprecipitated in cell extracts from cultures with purified IgG from MS CSF. Peptide mass fingerprinting identified it as the beta type of heat shock protein 90 (Hsp90). Two-dimensional electrophoresis and immunoblot showed that this antigen in fact corresponds to two specific isoforms of Hsp90beta. Several control assays using monoclonal and polyclonal anti-Hsp90 antibodies confirmed the specific expression of Hsp90 on OPCs. Labeling OPCs in vivo with MS CSF and anti-Hsp90 antibodies and subsequent immunofluorescence confocal microscopy located the antigen on the cell surface. The binding of CSF antibodies from MS patients to the OPC surface led to complement activation and significant extinction of the OPC population. These results suggest that OPCs may be a target of anti-Hsp90 antibodies in MS patients and that this could prevent remyelination.	Hosp Ramon & Cajal, Serv Bioquim Invest, E-28034 Madrid, Spain; Hosp Ramon & Cajal, Serv Neurol, E-28034 Madrid, Spain; Ctr Nacl Biotecnol, Madrid, Spain	Hospital Universitario Ramon y Cajal; Hospital Universitario Ramon y Cajal; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Alcazar, A (corresponding author), Hosp Ramon & Cajal, Serv Bioquim Invest, Ctra Colmenar Km 9-1, E-28034 Madrid, Spain.	alberto.alcazar@hrc.es	Messier, Claude/A-2322-2008; Alvarez-Cermeño, José/E-6432-2013	Messier, Claude/0000-0002-4791-1763; 				Alcazar A, 1996, MOL BRAIN RES, V38, P101, DOI 10.1016/0169-328X(95)00335-P; Alcazar A, 2000, J NEUROIMMUNOL, V104, P58, DOI 10.1016/S0165-5728(99)00225-8; Aquino DA, 1997, J NEUROPATH EXP NEUR, V56, P664; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; BARRES BA, 1993, NATURE, V361, P258, DOI 10.1038/361258a0; Blakemore WF, 1999, J NEUROIMMUNOL, V98, P69, DOI 10.1016/S0165-5728(99)00083-1; BOTTENSTEIN JE, 1979, P NATL ACAD SCI USA, V76, P514, DOI 10.1073/pnas.76.1.514; Brosnan CF, 1996, J NEUROPATH EXP NEUR, V55, P389, DOI 10.1097/00005072-199604000-00001; Chang A, 2002, NEW ENGL J MED, V346, P165, DOI 10.1056/NEJMoa010994; Conroy SE, 1996, BRIT J CANCER, V74, P717, DOI 10.1038/bjc.1996.427; EISENBARTH GS, 1979, P NATL ACAD SCI USA, V76, P4913, DOI 10.1073/pnas.76.10.4913; Fanarraga ML, 1999, EUR J NEUROSCI, V11, P517; FFRENCHCONSTANT C, 1986, NATURE, V319, P499, DOI 10.1038/319499a0; Franklin RJM, 2002, NAT REV NEUROSCI, V3, P705, DOI 10.1038/nrn917; FREEDMAN MS, 1992, J NEUROIMMUNOL, V41, P231, DOI 10.1016/0165-5728(92)90074-U; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Genain CP, 1999, NAT MED, V5, P170, DOI 10.1038/5532; Harlow E., 1999, USING ANTIBODIES LAB; Hayem G, 1999, ANN RHEUM DIS, V58, P291, DOI 10.1136/ard.58.5.291; HOVANESSIAN AG, 1987, EMBO J, V6, P1273, DOI 10.1002/j.1460-2075.1987.tb02364.x; Kakimura J, 2002, FASEB J, V16, P601, DOI 10.1096/fj.01-0530fje; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; LUBETZKI C, 1991, J NEUROCHEM, V56, P671, DOI 10.1111/j.1471-4159.1991.tb08202.x; Mycko MP, 2003, BRAIN, V126, P1048, DOI 10.1093/brain/awg107; Niehaus A, 1999, J NEUROSCI, V19, P4948; Niehaus A, 2000, ANN NEUROL, V48, P362, DOI 10.1002/1531-8249(200009)48:3<362::AID-ANA11>3.0.CO;2-6; Noseworthy JH, 2000, NEW ENGL J MED, V343, P938, DOI 10.1056/NEJM200009283431307; POSER CM, 1983, ANN NEUROL, V13, P227, DOI 10.1002/ana.410130302; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; RAFF MC, 1983, J NEUROSCI, V3, P1289; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Sadatipour BT, 1998, ANN NEUROL, V44, P980, DOI 10.1002/ana.410440621; Sapozhnikov AM, 1999, CELL PROLIFERAT, V32, P363, DOI 10.1111/j.1365-2184.1999.tb01354.x; Scolding NJ, 1999, NEUROSCIENCE, V89, P1, DOI 10.1016/S0306-4522(98)00548-X; SCOLDING NJ, 1995, NEUROREPORT, V6, P441, DOI 10.1097/00001756-199502000-00009; Shi JY, 1998, J NEUROSCI, V18, P4627; SOMMER I, 1981, DEV BIOL, V83, P311, DOI 10.1016/0012-1606(81)90477-2; SPIEGEL K, 1998, NEUROINFLAMMATION ME, P129; SUN JP, 1991, EUR J IMMUNOL, V21, P1461, DOI 10.1002/eji.1830210620; TAKENAKA IM, 1992, J CELL PHYSIOL, V152, P568, DOI 10.1002/jcp.1041520317; TEMPLE S, 1986, CELL, V44, P773, DOI 10.1016/0092-8674(86)90843-3; Wolswijk G, 2002, BRAIN, V125, P338, DOI 10.1093/brain/awf031; Wolswijk G, 1998, J NEUROSCI, V18, P601; WREN DR, 1989, P NATL ACAD SCI USA, V86, P9025, DOI 10.1073/pnas.86.22.9025; WUCHERPFENNIG KW, 1992, P NATL ACAD SCI USA, V89, P4588, DOI 10.1073/pnas.89.10.4588	46	40	42	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					409	+		10.1096/fj.03-0606fje	http://dx.doi.org/10.1096/fj.03-0606fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688203				2022-12-28	WOS:000188067500009
J	McArdle, A; Dillmann, WH; Mestril, R; Faulkner, JA; Jackson, MJ				McArdle, A; Dillmann, WH; Mestril, R; Faulkner, JA; Jackson, MJ			Overexpression of HSP70 in mouse skeletal muscle protects against muscle damage and age-related muscle dysfunction	FASEB JOURNAL			English	Article						lengthening contractions; regeneration; maximum tetanic force; transgenic	CONTRACTION-INDUCED INJURY; OXIDATIVE STRESS; HEAT-SHOCK; MICE; YOUNG; STRETCHES; INCREASES; PROTEINS; ANIMALS; RELEASE	Ageing is associated with skeletal muscle atrophy, a deficit in force generation, an increased susceptibility to contraction-induced injury, and a permanent force deficit following severe injury. Muscles of young mice adapt rapidly following exercise by an increase in the production of heat shock proteins (HSPs), whereas muscles of old mice show a severely diminished response. We hypothesized that overexpression of HSP70 in muscle throughout life would reduce age-related changes in function. The maximum tetanic force of extensor digitorum longus (EDL) muscles of adult and old wild-type (WT) and HSP70 overexpressor transgenic mice was determined. EDL muscles were subjected to damaging lengthening contractions and the ability to generate force was assessed for up to 28 days following the contractions. Overexpression of HSP70 in muscles of old transgenic mice prevented the specific force deficit observed in muscles of old WT mice. The complete recovery of muscles of old HSP70 transgenic mice by 14 days following the contraction protocol was in contrast to the 44% force deficit, which remained in muscles of old WT mice at 28 days following the protocol. These data indicate that a diminished production of HSP70 in muscles of old mammals has a major effect on age-related functional deficits.	Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Loyola Univ, Dept Physiol, Chicago, IL 60611 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Liverpool; University of California System; University of California San Diego; Loyola University Chicago; University of Michigan System; University of Michigan	McArdle, A (corresponding author), Univ Liverpool, Dept Med, Liverpool L69 3GA, Merseyside, England.	mdcr02@liv.ac.uk		Mestril, Ruben/0000-0003-3631-2236; Jackson, Malcolm/0000-0003-3683-8297				BALON TW, 1994, J APPL PHYSIOL, V77, P2519, DOI 10.1152/jappl.1994.77.6.2519; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BROOKS SV, 1990, AM J PHYSIOL, V258, pC436, DOI 10.1152/ajpcell.1990.258.3.C436; BROOKS SV, 1988, J PHYSIOL-LONDON, V404, P71, DOI 10.1113/jphysiol.1988.sp017279; Brooks SV, 2001, J APPL PHYSIOL, V91, P661, DOI 10.1152/jappl.2001.91.2.661; Brooks SV, 2001, J GERONTOL A-BIOL, V56, pB163, DOI 10.1093/gerona/56.4.B163; Brooks SV, 1996, J PHYSIOL-LONDON, V497, P573, DOI 10.1113/jphysiol.1996.sp021790; CARLSON BM, 1989, AM J PHYSIOL, V256, pC1262; Carlson BM, 2001, J GERONTOL A-BIOL, V56, pB224, DOI 10.1093/gerona/56.5.B224; CARLSON BM, 1988, EXP NEUROL, V102, P50, DOI 10.1016/0014-4886(88)90077-5; Cederna PS, 2001, J GERONTOL A-BIOL, V56, pB254, DOI 10.1093/gerona/56.6.B254; FLANAGAN SW, 1995, AM J PHYSIOL-REG I, V268, pR28, DOI 10.1152/ajpregu.1995.268.1.R28; GOLDSPINK G, 1994, STRENGTH POWER SPORT, P211; HADLEY EC, 1993, J GERONTOL, V48, pR7, DOI 10.1093/geronj/48.Special_Issue.vii; Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031; LEXELL J, 1988, J NEUROL SCI, V84, P275, DOI 10.1016/0022-510X(88)90132-3; LOPEZ ME, 2000, HDB OXIDANTS ANTIOXI; Manzerra P, 1997, J CELL PHYSIOL, V170, P130, DOI 10.1002/(SICI)1097-4652(199702)170:2<130::AID-JCP4>3.0.CO;2-P; MARBER MS, 1995, J CLIN INVEST, V95, P1446, DOI 10.1172/JCI117815; McArdle A, 2001, AM J PHYSIOL-CELL PH, V280, pC621, DOI 10.1152/ajpcell.2001.280.3.C621; MCCULLY KK, 1985, J APPL PHYSIOL, V59, P119, DOI 10.1152/jappl.1985.59.1.119; Moseley PL, 1998, ANN NY ACAD SCI, V856, P206, DOI 10.1111/j.1749-6632.1998.tb08327.x; Nosek TM, 2000, PHYSIOL GENOMICS, V4, P25, DOI 10.1152/physiolgenomics.2000.4.1.25; ONeill CA, 1996, J APPL PHYSIOL, V81, P1197, DOI 10.1152/jappl.1996.81.3.1197; PHILLIPS SK, 1991, J PHYSIOL-LONDON, V437, P63, DOI 10.1113/jphysiol.1991.sp018583; Porter M. M., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P129; REID MB, 1992, J APPL PHYSIOL, V73, P1805, DOI 10.1152/jappl.1992.73.5.1805; SALO DC, 1991, FREE RADICAL BIO MED, V11, P239, DOI 10.1016/0891-5849(91)90119-N; SKELDON P, 1994, MANUF CHEMIST, V65, P23; SOHAL RS, 1992, ANN NY ACAD SCI, V663, P74, DOI 10.1111/j.1749-6632.1992.tb38651.x; Vasilaki A, 2003, BIOCHEM SOC T, V31, P455, DOI 10.1042/BST0310455; Vasilaki A, 2002, MUSCLE NERVE, V25, P902, DOI 10.1002/mus.10094; WARNER HR, 1994, FREE RADICAL BIO MED, V17, P249, DOI 10.1016/0891-5849(94)90080-9; ZERBA E, 1990, AM J PHYSIOL, V258, pC429, DOI 10.1152/ajpcell.1990.258.3.C429	34	196	198	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					355	+		10.1096/fj.03-0395fje	http://dx.doi.org/10.1096/fj.03-0395fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688209	Green Submitted			2022-12-28	WOS:000188067500015
J	Pervaiz, S				Pervaiz, S			Resveratrol: from grapevines to mammalian biology	FASEB JOURNAL			English	Review							NF-KAPPA-B; RED WINE CONSTITUENT; CHEMOPREVENTIVE AGENT RESVERATROL; ARYL-HYDROCARBON RECEPTOR; LOW-DENSITY-LIPOPROTEIN; NITRIC-OXIDE SYNTHASE; TRANS-RESVERATROL; SUPEROXIDE ANION; GENE-EXPRESSION; CELL-CYCLE		Natl Univ Singapore, Natl Univ Med Inst, NUS Grad Sch Integrat Sci & Engn, Singapore 117597, Singapore; Natl Univ Singapore, Fac Med, Dept Physiol, Singapore 117597, Singapore	National University of Singapore; National University of Singapore	Pervaiz, S (corresponding author), Natl Univ Singapore, Natl Univ Med Inst, NUS Grad Sch Integrat Sci & Engn, MD9,03-06, Singapore 117597, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015					Ahmad N, 2001, CLIN CANCER RES, V7, P1466; ARNAOUT MA, 1990, BLOOD, V75, P1037; Ashby J, 1999, J APPL TOXICOL, V19, P39, DOI 10.1002/(SICI)1099-1263(199901/02)19:1&lt;39::AID-JAT534&gt;3.0.CO;2-M; Ashikawa K, 2002, J IMMUNOL, V169, P6490, DOI 10.4049/jimmunol.169.11.6490; Banerjee S, 2002, CANCER RES, V62, P4945; Basly JP, 2000, LIFE SCI, V66, P769, DOI 10.1016/S0024-3205(99)00650-5; Bernhard D, 2000, CELL DEATH DIFFER, V7, P834, DOI 10.1038/sj.cdd.4400719; Bhat KPL, 2002, ANN NY ACAD SCI, V957, P210, DOI 10.1111/j.1749-6632.2002.tb02918.x; Carbo N, 1999, BIOCHEM BIOPH RES CO, V254, P739, DOI 10.1006/bbrc.1998.9916; Casper RF, 1999, MOL PHARMACOL, V56, P784; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; Chan WK, 2000, LIFE SCI, V67, P3103, DOI 10.1016/S0024-3205(00)00888-2; Chang TKH, 2001, J PHARMACOL EXP THER, V299, P874; Ciolino HP, 1999, MOL PHARMACOL, V56, P760; Ciolino HP, 1998, CANCER RES, V58, P5707; Clement MV, 1996, EMBO J, V15, P216, DOI 10.1002/j.1460-2075.1996.tb00352.x; Clement MV, 1998, BLOOD, V92, P996; Clement MV, 1998, FEBS LETT, V440, P13, DOI 10.1016/S0014-5793(98)01410-0; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; Cuendet M, 2000, Drug Metabol Drug Interact, V17, P109; Culig Z, 2002, ENDOCR-RELAT CANCER, V9, P155, DOI 10.1677/erc.0.0090155; Della Ragione F, 1998, BIOCHEM BIOPH RES CO, V250, P53, DOI 10.1006/bbrc.1998.9263; DING Z, 2002, SLEEP, V25, P7; Dorrie J, 2001, CANCER RES, V61, P4731; Draczynska-Lusiak B, 1998, MOL CHEM NEUROPATHOL, V33, P139, DOI 10.1007/BF02870187; EBEL J, 1986, ANNU REV PHYTOPATHOL, V24, P235; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; Ferry-Dumazet H, 2002, CARCINOGENESIS, V23, P1327, DOI 10.1093/carcin/23.8.1327; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Fontecave M, 1998, FEBS LETT, V421, P277, DOI 10.1016/S0014-5793(97)01572-X; FRANKEL EN, 1993, LANCET, V341, P1103, DOI 10.1016/0140-6736(93)92472-6; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Freyberger A, 2001, ARCH TOXICOL, V74, P709, DOI 10.1007/s002040000186; FUHRMAN B, 1995, AM J CLIN NUTR, V61, P549, DOI 10.1093/ajcn/61.3.549; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gentilli M, 2001, LIFE SCI, V68, P1317, DOI 10.1016/S0024-3205(00)01018-3; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GOLDBERG DM, 1995, CLIN CHIM ACTA, V237, P155, DOI 10.1016/0009-8981(95)06069-P; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; GRUNEWALD R, 1992, J CLIN ONCOL, V10, P406, DOI 10.1200/JCO.1992.10.3.406; Gusman J, 2001, CARCINOGENESIS, V22, P1111, DOI 10.1093/carcin/22.8.1111; HAIN R, 1990, PLANT MOL BIOL, V15, P325, DOI 10.1007/BF00036918; HAIN R, 1993, NATURE, V361, P153, DOI 10.1038/361153a0; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HARLAN JM, 1987, ACTA MED SCAND, P123; Hattori R, 2002, AM J PHYSIOL-HEART C, V282, pH1988, DOI 10.1152/ajpheart.01012.2001; Haworth RS, 2001, BIOCHEM PHARMACOL, V62, P1647, DOI 10.1016/S0006-2952(01)00807-3; HAYASHI S, 1994, CARCINOGENESIS, V15, P801, DOI 10.1093/carcin/15.5.801; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HOOS G, 1988, VITIS, V27, P1; Hsieh TC, 2000, ANTICANCER RES, V20, P225; Hsieh TC, 1999, INT J ONCOL, V15, P245; Hsieh TC, 1999, EXP CELL RES, V249, P109, DOI 10.1006/excr.1999.4471; Hsieh TC, 1999, CANCER RES, V59, P2596; Huang CS, 1999, CARCINOGENESIS, V20, P237, DOI 10.1093/carcin/20.2.237; Hung LM, 2000, CARDIOVASC RES, V47, P549, DOI 10.1016/S0008-6363(00)00102-4; Hussain S P, 2000, Ann N Y Acad Sci, V919, P79; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Jeandet P, 2002, J AGR FOOD CHEM, V50, P2731, DOI 10.1021/jf011429s; JEANDET P, 1995, AM J ENOL VITICULT, V46, P1; JEANDET P, 1995, J PHYTOPATHOL, V143, P135, DOI 10.1111/j.1439-0434.1995.tb00246.x; Joe AK, 2002, CLIN CANCER RES, V8, P893; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 1998, P NATL ACAD SCI USA, V95, P9067, DOI 10.1073/pnas.95.16.9067; Kawada N, 1998, HEPATOLOGY, V27, P1265, DOI 10.1002/hep.510270512; KIMURA Y, 1985, BIOCHIM BIOPHYS ACTA, V834, P275; KIMURA Y, 1995, J ETHNOPHARMACOL, V45, P131, DOI 10.1016/0378-8741(94)01206-F; Kopp P, 1998, EUR J ENDOCRINOL, V138, P619, DOI 10.1530/eje.0.1380619; Korsmeyer SJ, 1999, CANCER RES, V59, p1693S; KUBO M, 1981, Shoyakugaku Zasshi, V35, P58; LAMUELARAVENTOS RM, 1995, J AGR FOOD CHEM, V43, P281, DOI 10.1021/jf00050a003; LANGCAKE P, 1976, PHYSIOL PLANT PATHOL, V9, P77, DOI 10.1016/0048-4059(76)90077-1; LANGCAKE P, 1977, PHYTOCHEMISTRY, V16, P1193, DOI 10.1016/S0031-9422(00)94358-9; LANGCAKE P, 1977, J CHEM SOC CHEM COMM, P208, DOI 10.1039/c39770000208; Lu RQ, 1999, J CELL PHYSIOL, V179, P297, DOI 10.1002/(SICI)1097-4652(199906)179:3<297::AID-JCP7>3.0.CO;2-P; Maccarrone M, 1999, EUR J BIOCHEM, V265, P27, DOI 10.1046/j.1432-1327.1999.00630.x; Mahyar-Roemer M, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-27; Mahyar-Roemer M, 2001, INT J CANCER, V94, P615, DOI 10.1002/ijc.1516; Manna SK, 2000, J IMMUNOL, V164, P6509, DOI 10.4049/jimmunol.164.12.6509; Martinez J, 2000, BIOCHEM PHARMACOL, V59, P865, DOI 10.1016/S0006-2952(99)00380-9; Mgbonyebi OP, 1998, INT J ONCOL, V12, P865; Miagkov AV, 1998, P NATL ACAD SCI USA, V95, P13859, DOI 10.1073/pnas.95.23.13859; Micheau O, 1997, J NATL CANCER I, V89, P783, DOI 10.1093/jnci/89.11.783; MILLER NJ, 1995, CLIN CHEM, V41, P1789; Mitchell SH, 1999, CANCER RES, V59, P5892; Mizutani K, 1998, BIOCHEM BIOPH RES CO, V253, P859, DOI 10.1006/bbrc.1998.9870; Morris GZ, 2002, PROSTATE, V52, P319, DOI 10.1002/pros.10122; Murray GI, 2000, J PATHOL, V192, P419; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; NONOMURA S, 1963, Yakugaku Zasshi, V83, P988; Olas B, 2001, MICROBIOS, V105, P7; Orsini F, 1997, J NAT PROD, V60, P1082, DOI 10.1021/np970069t; PACKER L, 1992, P SOC EXP BIOL MED, V200, P271; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pervaiz S, 2002, BIOCHEM BIOPH RES CO, V290, P1145, DOI 10.1006/bbrc.2001.6274; Pervaiz S, 1999, BLOOD, V93, P4096, DOI 10.1182/blood.V93.12.4096.412k44_4096_4108; Pervaiz S, 2001, LEUKEMIA LYMPHOMA, V40, P491, DOI 10.3109/10428190109097648; Pervaiz S, 1999, FEBS LETT, V459, P343, DOI 10.1016/S0014-5793(99)01258-2; Pozo-Guisado E, 2002, BIOCHEM PHARMACOL, V64, P1375, DOI 10.1016/S0006-2952(02)01296-0; Roman V, 2002, BRIT J HAEMATOL, V117, P842, DOI 10.1046/j.1365-2141.2002.03520.x; Rotondo S, 1998, BRIT J PHARMACOL, V123, P1691, DOI 10.1038/sj.bjp.0701784; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; SATO H, 1993, ONCOGENE, V8, P395; Sato M, 2002, ANN NY ACAD SCI, V957, P122, DOI 10.1111/j.1749-6632.2002.tb02911.x; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Schneider Y, 2000, CANCER LETT, V158, P85, DOI 10.1016/S0304-3835(00)00511-5; She QB, 2001, CANCER RES, V61, P1604; SIEMANN EH, 1992, AM J ENOL VITICULT, V43, P49; Soleas GJ, 1997, CLIN BIOCHEM, V30, P91, DOI 10.1016/S0009-9120(96)00155-5; Soleas GJ, 2001, ADV EXP MED BIOL, V492, P159; Soleas GJ, 2001, METHOD ENZYMOL, V335, P130; Stahl S, 1998, TOXICOL APPL PHARM, V152, P41, DOI 10.1006/taap.1998.8500; Steele RJC, 1998, BRIT J SURG, V85, P1460; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Subbaramaiah K, 1998, J BIOL CHEM, V273, P21875, DOI 10.1074/jbc.273.34.21875; Suganuma M, 1999, CANCER RES, V59, P4516; Sun AY, 1997, NEUROCHEM RES, V22, P1187, DOI 10.1023/A:1021968526696; Tessitore L, 2000, CARCINOGENESIS, V21, P1619, DOI 10.1093/carcin/21.8.1619; Thornberry NA, 1998, CHEM BIOL, V5, pR97, DOI 10.1016/S1074-5521(98)90615-9; Tinhofer I, 2001, FASEB J, V15, P1613, DOI 10.1096/fj.00-0675fje; TOTANI L, 1994, ARTERIOSCLER THROMB, V14, P125, DOI 10.1161/01.ATV.14.1.125; Tou JS, 2001, CELL SIGNAL, V13, P191, DOI 10.1016/S0898-6568(01)00137-1; Tsai SH, 1999, BRIT J PHARMACOL, V126, P673, DOI 10.1038/sj.bjp.0702357; Tsan MF, 2000, BRIT J HAEMATOL, V109, P405, DOI 10.1046/j.1365-2141.2000.01980.x; Tsan MF, 2002, LEUKEMIA LYMPHOMA, V43, P983, DOI 10.1080/10428190290021669; Turner RT, 1999, ENDOCRINOLOGY, V140, P50, DOI 10.1210/en.140.1.50; von Knethen A, 1999, J IMMUNOL, V163, P2858; Wadsworth TL, 1999, BIOCHEM PHARMACOL, V57, P941, DOI 10.1016/S0006-2952(99)00002-7; WHITEHEAD TP, 1995, CLIN CHEM, V41, P32; Wilson T, 1996, LIFE SCI, V59, pPL15, DOI 10.1016/0024-3205(96)00260-3	133	425	441	1	40	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					1975	1985		10.1096/fj.03-0168rev	http://dx.doi.org/10.1096/fj.03-0168rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597667				2022-12-28	WOS:000186961200034
J	Yoshioka, M; Tanaka, H; Shono, N; Snyder, EE; Shindo, M; St-Amand, J				Yoshioka, M; Tanaka, H; Shono, N; Snyder, EE; Shindo, M; St-Amand, J			Serial analysis of gene expression in the skeletal muscle of endurance athletes compared to sedentary men	FASEB JOURNAL			English	Article						athletes; endurance exercise; human mRNA; SAGE method and gene regulation	ALPHA-B-CRYSTALLIN; MESSENGER-RNAS; C-PROTEIN; MYOSIN; SAGE; ADAPTATION; EXERCISE; TRANSCRIPTOMES; DENERVATION; CHAPERONE	Physical exercise produces several adaptive changes in skeletal muscle. However, the molecular mechanisms of these effects are poorly understood. We performed serial analysis of gene expression (SAGE) to quantify the global gene expression profile in sedentary and endurance-trained muscle. A total of 10869 SAGE tags was sequenced and represented 4727 genes. The genes most expressed in muscle are mainly involved in contraction and energy metabolism. Thirty-three genes were differentially expressed between endurance athletes and sedentary individuals. Four genes such as myosin binding protein C fast-type, glycogen phosphorylase, and pyruvate kinase were expressed less in endurance athletes, whereas eight genes coding for expressed sequence tag similar to (EST) crystallin alpha B, EST myosin light chain 2, EST surfactant pulmonary-associated protein A1, EST thrombospondin, EST fructose-bisphosphate aldolase A, EST cytochrome oxidase 1, NADH dehydrogenase 3, and G8 protein were up-regulated. Most of the upregulated tags corresponded to novel genes. On the other hand, different isoforms of fructose-bisphosphate aldolase A were also differentially expressed. The current study underlying the most highly expressed genes allows a better understanding of global muscle characteristics in normal and endurance-trained individuals. Moreover, the current data suggest novel candidate genes that may be responsible for enhanced endurance performance.	Univ Laval, Med Ctr, Mol Endocrinol & Oncol Res Ctr, St Foy, PQ G1V 4G2, Canada; Fukuoka Univ, Fac Sport & Hlth Sci, Jonan Ku, Fukuoka 8140184, Japan; Saga Med Sch, Dept Prevent Med, Saga 8498501, Japan; Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA	Laval University; Fukuoka University; Saga University; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center	Yoshioka, M (corresponding author), Univ Laval, Med Ctr, Mol Endocrinol & Oncol Res Ctr, 2705 Boul Laurier, St Foy, PQ G1V 4G2, Canada.	Mayumi.Yoshioka@crchul.ulaval.ca		St-Amand, Jonny/0000-0002-2595-6127				ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; ATOMI Y, 1991, J BIOCHEM-TOKYO, V110, P812, DOI 10.1093/oxfordjournals.jbchem.a123665; ATOMI Y, 1990, P JPN ACAD B-PHYS, V66, P203, DOI 10.2183/pjab.66.203; ATOMI Y, 1991, BIOCHEM BIOPH RES CO, V181, P1323, DOI 10.1016/0006-291X(91)92083-V; BARANY K, 1979, J BIOL CHEM, V254, P3617; BERGH U, 1978, MED SCI SPORT EXER, V10, P151; BERGSTROM J, 1962, SCAND J CLIN LAB INV, V14, P1; BLAIR SN, 1989, JAMA-J AM MED ASSOC, V262, P2395, DOI 10.1001/jama.262.17.2395; Brady JP, 2001, INVEST OPHTH VIS SCI, V42, P2924; Buck SH, 1999, AM J PHYSIOL-HEART C, V276, pH1167, DOI 10.1152/ajpheart.1999.276.4.H1167; Goldman R., 1961, TECHNIQUES MEASURING, P78; Hamilton MT, 2000, J APPL PHYSIOL, V88, P327, DOI 10.1152/jappl.2000.88.1.327; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; HOLLOSZY JO, 1975, MED SCI SPORT EXER, V7, P155; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kannus P, 1998, HISTOCHEM J, V30, P799, DOI 10.1023/A:1003448106673; Kenzelmann M, 1999, NUCLEIC ACIDS RES, V27, P917, DOI 10.1093/nar/27.3.917; Koh TJ, 2002, EXERC SPORT SCI REV, V30, P117, DOI 10.1097/00003677-200207000-00005; LIANG P, 1995, METHOD ENZYMOL, V254, P304; LOCKE M, 1991, AM J PHYSIOL, V261, pC774, DOI 10.1152/ajpcell.1991.261.5.C774; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; Madden SL, 1997, ONCOGENE, V15, P1079, DOI 10.1038/sj.onc.1201091; McArdle WD., 2001, EXERCISE PHYSL ENERG; MEHLEN P, 1995, J IMMUNOL, V154, P363; MIYAHARA M, 1980, J BIOCHEM-TOKYO, V87, P1413, DOI 10.1093/oxfordjournals.jbchem.a132882; MOSS RL, 1982, J BIOL CHEM, V257, P8588; MURAKAMI T, 1994, AM J PHYSIOL, V267, pE388, DOI 10.1152/ajpendo.1994.267.3.E388; NICHOLL ID, 1994, EMBO J, V13, P945, DOI 10.1002/j.1460-2075.1994.tb06339.x; Novak JP, 2002, GENOMICS, V79, P104, DOI 10.1006/geno.2001.6675; NOWAK R, 1995, SCIENCE, V270, P368, DOI 10.1126/science.270.5235.368; OBINATA T, 1981, MUSCLE NERVE, V4, P456, DOI 10.1002/mus.880040604; Paffenbarger RS, 1999, EXERCISE FOR PREVENTING COMMON DISEASES, P121; PUNTSCHART A, 1995, AM J PHYSIOL-CELL PH, V269, pC619, DOI 10.1152/ajpcell.1995.269.3.C619; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Shindo M, 1999, EXERCISE FOR PREVENTING COMMON DISEASES, P131; SNYDER EE, 2000, SAGE 2000 FRONTIERS; St-Amand J, 2001, FASEB J, V15, P684, DOI 10.1096/fj.00-0150com; STAMAND J, 2000, SAGE 2000 FRONTIERS; TOKUYAMA K, 1993, AM J PHYSIOL, V265, pE298, DOI 10.1152/ajpendo.1993.265.2.E298; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; Velculescu VE, 1999, SCIENCE, V286, P1491, DOI 10.1126/science.286.5444.1491; Virlon B, 1999, P NATL ACAD SCI USA, V96, P15286, DOI 10.1073/pnas.96.26.15286; WATKINS SC, 1990, CELL TISSUE RES, V261, P73, DOI 10.1007/BF00329440; Welle S, 1999, GENOME RES, V9, P506; YAMAMOTO K, 1986, FEBS LETT, V208, P123, DOI 10.1016/0014-5793(86)81545-9; Yamamoto M, 2001, J IMMUNOL METHODS, V250, P45, DOI 10.1016/S0022-1759(01)00305-2; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	48	38	38	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1812	1819		10.1096/fj.02-1200com	http://dx.doi.org/10.1096/fj.02-1200com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519660				2022-12-28	WOS:000186343300035
J	Baar, K; Song, Z; Semenkovich, CF; Jones, TE; Han, DH; Nolte, LA; Ojuka, EO; Chen, M; Holloszy, JO				Baar, K; Song, Z; Semenkovich, CF; Jones, TE; Han, DH; Nolte, LA; Ojuka, EO; Chen, M; Holloszy, JO			Skeletal muscle overexpression of nuclear respiratory factor 1 increases glucose transport capacity	FASEB JOURNAL			English	Article						delta-aminolevulinate synthase; cytochrome c; mitochondria; pyruvate oxidation; respiratory enzymes	TRANSCRIPTIONAL COACTIVATOR PGC-1; GLUT4 GENE-EXPRESSION; MITOCHONDRIAL BIOGENESIS; CYTOCHROME-C; BIOCHEMICAL ADAPTATIONS; GAMMA COACTIVATOR-1; ENDURANCE EXERCISE; ACTIVATION; INSULIN; CELLS	Nuclear respiratory factor 1 (NRF-1) is a transcriptional activator of nuclear genes that encode a range of mitochondrial proteins including cytochrome c, various other respiratory chain subunits, and delta-aminolevulinate synthase. Activation of NRF-1 in fibroblasts has been shown to induce increases in cytochrome c expression and mitochondrial respiratory capacity. To further evaluate the role of NRF-1 in the regulation of mitochondrial biogenesis and respiratory capacity, we generated transgenic mice overexpressing NRF-1 in skeletal muscle. Cytochrome c expression was increased similar to twofold and delta-aminolevulinate synthase was increased similar to 50% in NRF-1 transgenic muscle. The levels of some mitochondrial proteins were increased 50 - 60%, while others were unchanged. Muscle respiratory capacity was not increased in the NRF-1 transgenic mice. A finding that provides new insight regarding the role of NRF-1 was that expression of MEF2A and GLUT4 was increased in NRF-1 transgenic muscle. The increase in GLUT4 was associated with a proportional increase in insulin-stimulated glucose transport. These results show that an isolated increase in NRF-1 is not sufficient to bring about a coordinated increase in expression of all of the proteins necessary for assembly of functional mitochondria. They also provide the new information that NRF-1 overexpression results in increased expression of GLUT4.	Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL)	Holloszy, JO (corresponding author), Washington Univ, Sch Med, Dept Med, Campus Box 8113,4566 Scott Ave, St Louis, MO 63110 USA.	jhollosz@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871; Baar, Keith/0000-0001-9337-6186	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018986, P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R56AG000425, R37AG000425, R01AG020091, R01AG000425] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58427] Funding Source: Medline; NIA NIH HHS [AG20091, AG00425] Funding Source: Medline; NIDDK NIH HHS [DK18986, DK56341] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com; Booth F, 1977, Ann N Y Acad Sci, V301, P431, DOI 10.1111/j.1749-6632.1977.tb38219.x; BOOTH FW, 1997, HDB PHYSL 12, P1075; BOUREY RE, 1990, J CLIN INVEST, V86, P542, DOI 10.1172/JCI114742; BRAIDOTTI G, 1993, J BIOL CHEM, V268, P1109; CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321; Connor MK, 2001, J BIOL CHEM, V276, P15898, DOI 10.1074/jbc.M100272200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUDLEY GA, 1987, J BIOL CHEM, V262, P9109; EVANS MJ, 1990, GENE DEV, V4, P1023, DOI 10.1101/gad.4.6.1023; FRIEDMAN JE, 1990, FEBS LETT, V268, P13, DOI 10.1016/0014-5793(90)80960-Q; GOODYEAR LJ, 1992, DIABETES, V41, P1091, DOI 10.2337/diabetes.41.9.1091; GOPALAKRISHNAN L, 1994, J BIOL CHEM, V269, P105; GOPALAKRISHNAN L, 1995, J BIOL CHEM, V270, P18019, DOI 10.1074/jbc.270.30.18019; HANSEN PA, 1994, J APPL PHYSIOL, V76, P979, DOI 10.1152/jappl.1994.76.2.979; Herzig RP, 2000, J BIOL CHEM, V275, P13134, DOI 10.1074/jbc.275.17.13134; HOLLOSZY JO, 1976, ANNU REV PHYSIOL, V38, P273, DOI 10.1146/annurev.ph.38.030176.001421; Holloszy JO, 1996, REV PHYSIOL BIOCH P, V128, P99; HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278; Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137; KLIP A, 1990, BIOCHEM BIOPH RES CO, V172, P728, DOI 10.1016/0006-291X(90)90735-6; Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268; Li B, 1999, J BIOL CHEM, V274, P17534, DOI 10.1074/jbc.274.25.17534; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; LIU ML, 1994, J BIOL CHEM, V269, P28514; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; MOLE PA, 1971, J CLIN INVEST, V50, P2323, DOI 10.1172/JCI106730; Mora S, 2000, J BIOL CHEM, V275, P16323, DOI 10.1074/jbc.M910259199; MURAKAMI S, 1998, J PLASMA FUSION RES, V1, P122; Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V283, pE1040, DOI 10.1152/ajpendo.00242.2002; Ojuka EO, 2002, AM J PHYSIOL-ENDOC M, V282, pE1008, DOI 10.1152/ajpendo.00512.2001; OSCAI LB, 1971, J BIOL CHEM, V246, P6968; Pilegaard H, 2003, J PHYSIOL-LONDON, V546, P851, DOI 10.1113/jphysiol.2002.034850; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REN JM, 1993, AM J PHYSIOL, V264, pC146, DOI 10.1152/ajpcell.1993.264.1.C146; REN JM, 1994, J BIOL CHEM, V269, P14396; Scarpulla RC, 2002, GENE, V286, P81, DOI 10.1016/S0378-1119(01)00809-5; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; VIRBASIUS CMA, 1993, GENE DEV, V7, P2431, DOI 10.1101/gad.7.12a.2431; VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309; WEINSTEIN SP, 1994, DIABETES, V43, P1185, DOI 10.2337/diabetes.43.10.1185; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; WINDER WW, 1975, AM J PHYSIOL, V228, P1341, DOI 10.1152/ajplegacy.1975.228.5.1341; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xia Y, 1997, P NATL ACAD SCI USA, V94, P11399, DOI 10.1073/pnas.94.21.11399; YOUNG DA, 1986, J BIOL CHEM, V261, P6049; Zheng DH, 2001, J APPL PHYSIOL, V91, P1073, DOI 10.1152/jappl.2001.91.3.1073	51	89	94	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1666	1673		10.1096/fj.03-0049com	http://dx.doi.org/10.1096/fj.03-0049com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958173				2022-12-28	WOS:000185925100041
J	Otaegui, PJ; Ferre, T; Riu, E; Bosch, F				Otaegui, PJ; Ferre, T; Riu, E; Bosch, F			Prevention of obesity and insulin resistance by glucokinase expression in skeletal muscle of transgenic mice	FASEB JOURNAL			English	Article						diabetes mellitus; glucose tolerance; UCP3	DEPENDENT DIABETES-MELLITUS; HUMAN UNCOUPLING PROTEIN-3; GLUCOSE-TRANSPORT; GLYCOGEN-SYNTHASE; HEXOKINASE II; GENE LOCUS; NIDDM; SENSITIVITY; GLUT4; LIVER	In type 2 diabetes, glucose phosphorylation, a regulatory step in glucose utilization by skeletal muscle, is impaired. Since glucokinase expression in skeletal muscle of transgenic mice increases glucose phosphorylation, we examined whether such mice conteract the obesity and insulin resistance induced by 12 wk of a high-fad diet. When fed this diet, control mice became obese, whereas transgenic mice remained lean. Further more, high-fat fed control mice developed hyperglycemia and hyperinsulinemia (a 3-fold increase) indicating that they were insulin resistant. In contrast, transgenic mice were normoglycemic and showed only a mild increase in insulinemia (1.5-fold). They also showed improved whole body glucose tolerance and insulin sensitivity and increased intramuscular concentrations of glucose 6-phosphate and glycogen. A parallel increase in uncoupling protein 3 mRNA levels in skeletal muscle of glucokinase-expressing transgenic mice was also observed. These results suggest that the rise in glucose phosphorylation by glucokinase expression in skeletal muscle leads to increased glucose utilization and energy expenditure that counteracts weight gain and maintains insulin sensitivity.	Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, E-08193 Bellaterra, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain.	fatima.bosch@uab.es		BOSCH, FATIMA/0000-0002-7705-5515; Riu, Efren/0000-0002-2574-3578; Ferre, Tura/0000-0001-9713-0829				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; BONADONNA RC, 1993, J CLIN INVEST, V92, P486, DOI 10.1172/JCI116592; Bonadonna RC, 1996, DIABETES, V45, P915, DOI 10.2337/diabetes.45.7.915; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; DELPRATO S, 1993, J CLIN INVEST, V91, P484, DOI 10.1172/JCI116226; DONOGHUE M, 1988, GENE DEV, V2, P1779, DOI 10.1101/gad.2.12b.1779; DONOGHUE MJ, 1991, P NATL ACAD SCI USA, V88, P5847, DOI 10.1073/pnas.88.13.5847; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; FINK RI, 1992, METABOLISM, V41, P897, DOI 10.1016/0026-0495(92)90174-9; GARVEY WT, 1988, J CLIN INVEST, V81, P1528, DOI 10.1172/JCI113485; Gutmann I, 1974, METHOD ENZYMAT AN, P1464; Hansen PA, 1998, J BIOL CHEM, V273, P26157, DOI 10.1074/jbc.273.40.26157; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; Harper ME, 2002, DIABETES, V51, P2459, DOI 10.2337/diabetes.51.8.2459; IKEMOTO S, 1995, P NATL ACAD SCI USA, V92, P3096, DOI 10.1073/pnas.92.8.3096; JETTON TL, 1992, P NATL ACAD SCI USA, V89, P2619, DOI 10.1073/pnas.89.7.2619; Jimenez-Chillaron JC, 1999, FASEB J, V13, P2153, DOI 10.1096/fasebj.13.15.2153; JIMENEZCHILLARO.JC, 2000, METABOLISM, V51, P121; Keppler D., 1984, METHOD ENZYMAT AN, V6, P11; Kim JK, 2001, J CLIN INVEST, V108, P153, DOI 10.1172/JCI10294; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Krook A, 1998, DIABETES, V47, P1528, DOI 10.2337/diabetes.47.9.1528; Kruszynska YT, 1998, DIABETES, V47, P1107, DOI 10.2337/diabetes.47.7.1107; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Marshall BA, 1999, AM J PHYSIOL-ENDOC M, V276, pE390, DOI 10.1152/ajpendo.1999.276.2.E390; Mathews ST, 2002, DIABETES, V51, P2450, DOI 10.2337/diabetes.51.8.2450; MICHAL G, 1981, METHOD ENZYMAT AN, V6, P185; Morral N, 2002, HUM GENE THER, V13, P1561, DOI 10.1089/10430340260201653; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; ORahilly S, 1997, NAT MED, V3, P1080, DOI 10.1038/nm1097-1080; Otabe S, 1999, DIABETES, V48, P206; Otaegui PJ, 2000, HUM GENE THER, V11, P1543, DOI 10.1089/10430340050083270; Pendergrass M, 1998, DIABETES, V47, P387, DOI 10.2337/diabetes.47.3.387; PICKUP JC, 1994, CHRONIC COMPLICATION; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Seoane J, 1999, J BIOL CHEM, V274, P31833, DOI 10.1074/jbc.274.45.31833; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; Shulman RG, 1996, DIABETES, V45, pS93, DOI 10.2337/diab.45.1.S93; Terauchi Y, 1999, NAT GENET, V21, P230, DOI 10.1038/6023; THORBURN AW, 1991, J CLIN INVEST, V87, P489, DOI 10.1172/JCI115022; Tsuboyama-Kasaoka N, 1999, BIOCHEM BIOPH RES CO, V258, P187, DOI 10.1006/bbrc.1999.0617; WRIGHT KS, 1988, DIABETES, V37, P436, DOI 10.2337/diabetes.37.4.436; YKIJARVINEN H, 1990, DIABETES, V39, P157, DOI 10.2337/diabetes.39.2.157; Zierath JB, 1997, DIABETES, V46, P215, DOI 10.2337/diabetes.46.2.215; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a; Zimmet PZ, 1997, LANCET, V350, pSI1	51	8	8	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2097	+		10.1096/fj.03-0081fje	http://dx.doi.org/10.1096/fj.03-0081fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500548				2022-12-28	WOS:000185925100002
J	Garcia, MC; Lopez, M; Gualillo, O; Seoane, LM; Dieguez, C; Senaris, RM				Garcia, MC; Lopez, M; Gualillo, O; Seoane, LM; Dieguez, C; Senaris, RM			Hypothalamic levels of NPY, MCH, and prepro-orexin mRNA during pregnancy and lactation in the rat: role of prolactin	FASEB JOURNAL			English	Article						hypothalamus; gestation; orexigenic peptides; lactogenic hormones	MELANIN-CONCENTRATING HORMONE; STIMULATES FOOD-INTAKE; AGOUTI-RELATED PEPTIDE; NEUROPEPTIDE-Y NPY; GENE-EXPRESSION; PARAVENTRICULAR NUCLEUS; SUCKLING STIMULUS; HYPOCRETIN OREXIN; LEPTIN REGULATION; RIBONUCLEIC-ACID	Pregnancy and lactation provide excellent models of physiological hyperphagia and hyper-prolactinemia. To identify possible factors associated with the increased feeding in these situations, we measured hypothalamic mRNA levels of three orexigenic neuropeptides - NPY, MCH, and orexins - in nonpregnant, pregnant, and lactating rats by in situ hybridization. NPY mRNA content in the arcuate nucleus was significantly increased during pregnancy and lactation. However, MCH and prepro-orexin expression was decreased in both states. 48 or 72 h of fasting in pregnant and lactating rats further elevated NPY mRNA levels and increased the low MCH mRNA content. Surprisingly, no effect was observed in preproorexin mRNA levels. Finally, we investigated the possible effect of high PRL levels on these orexigenic signals using a model of hyperprolactinemia induced by pituitary graft. NPY mRNA content was unchanged, but MCH and prepro-orexin mRNA levels were significantly decreased. Our results suggest that the increased NPY expression might be partly responsible for the hyperphagia observed during pregnancy and lactation. MCH and prepro-orexin may be involved in the adaptation of other homeostatic mechanisms and their decreased levels in these physiological settings could be mediated by the elevated circulating PRL levels.	Univ Santiago de Compostela, Fac Med, Dept Physiol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Senaris, RM (corresponding author), Univ Santiago de Compostela, Fac Med, Dept Physiol, R San Francisco S-N, Santiago De Compostela 15782, Spain.	fsrsr@usc.es	seoane, luisa M/E-6570-2013; García, María C/A-7565-2014; López, Miguel/ABF-4844-2021; Gualillo, Oreste/B-8223-2008	García, María C/0000-0001-5672-1366; López, Miguel/0000-0002-7823-1648; Gualillo, Oreste/0000-0002-7154-1328; dieguez, carlos/0000-0002-0919-4337; Senaris, Rosa/0000-0002-4536-2609				BAI FL, 1985, BRAIN RES, V331, P172, DOI 10.1016/0006-8993(85)90730-9; Beck B, 1999, BIOCHEM BIOPH RES CO, V258, P119, DOI 10.1006/bbrc.1999.0605; BLUETPAJOT MT, 1995, J NEUROENDOCRINOL, V7, P297, DOI 10.1111/j.1365-2826.1995.tb00761.x; Broberger C, 1999, BRAIN RES, V848, P101, DOI 10.1016/S0006-8993(99)01977-0; Brogan RS, 1999, ENDOCRINOLOGY, V140, P2621, DOI 10.1210/en.140.6.2621; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Coya R, 1999, J NEUROENDOCRINOL, V11, P351; CRIPPS AW, 1975, BRIT J NUTR, V33, P17, DOI 10.1079/BJN19750005; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Dhillon H, 2000, REGUL PEPTIDES, V92, P97, DOI 10.1016/S0167-0115(00)00155-5; Garcia MD, 2000, BIOL REPROD, V62, P698, DOI 10.1095/biolreprod62.3.698; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR276, DOI 10.1152/ajpregu.1989.256.1.R276; GERARDOGETTENS T, 1989, AM J PHYSIOL, V256, pR701, DOI 10.1152/ajpregu.1989.256.3.R701; Grattan D R, 2001, Prog Brain Res, V133, P153; Griffond B, 1997, J CHEM NEUROANAT, V12, P183, DOI 10.1016/S0891-0618(96)00200-1; Gualillo O, 1999, ENDOCRINOLOGY, V140, P5149, DOI 10.1210/en.140.11.5149; Gualillo O, 2002, OBES RES, V10, P682, DOI 10.1038/oby.2002.92; Jaszberenyi M, 2000, J NEUROENDOCRINOL, V12, P1174, DOI 10.1046/j.1365-2826.2000.00572.x; Kesterson RA, 1997, MOL ENDOCRINOL, V11, P630, DOI 10.1210/me.11.5.630; Kimura M, 1996, AM J PHYSIOL-REG I, V271, pR1063, DOI 10.1152/ajpregu.1996.271.4.R1063; Korner J, 2001, J NEUROENDOCRINOL, V13, P959, DOI 10.1046/j.1365-2826.2001.00716.x; LEWIS DE, 1993, AM J PHYSIOL, V264, pE279, DOI 10.1152/ajpendo.1993.264.2.E279; Li C, 1999, ENDOCRINOLOGY, V140, P118, DOI 10.1210/en.140.1.118; Li C, 1998, REGUL PEPTIDES, V75-6, P93, DOI 10.1016/S0167-0115(98)00057-3; Li C, 1998, ENDOCRINOLOGY, V139, P1645, DOI 10.1210/en.139.4.1645; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lopez M, 2000, BIOCHEM BIOPH RES CO, V269, P41, DOI 10.1006/bbrc.2000.2245; Lopez M, 2002, NEUROENDOCRINOLOGY, V75, P34, DOI 10.1159/000048219; MARKS JL, 1993, DIABETOLOGIA, V36, P497, DOI 10.1007/BF02743264; Mondal MS, 1999, BIOCHEM BIOPH RES CO, V256, P495, DOI 10.1006/bbrc.1999.0362; Murray JF, 2000, J NEUROENDOCRINOL, V12, P217; Nishino S, 2001, ANN NEUROL, V50, P381, DOI 10.1002/ana.1130; Pi XJ, 1999, J MOL ENDOCRINOL, V23, P13, DOI 10.1677/jme.0.0230013; Pinilla L, 1999, EUR J ENDOCRINOL, V140, P468, DOI 10.1530/eje.0.1400468; Presse F, 1996, NEUROSCIENCE, V71, P735, DOI 10.1016/0306-4522(95)00481-5; Pu S, 1998, REGUL PEPTIDES, V78, P133; RICHARD D, 1985, J NUTR, V115, P593, DOI 10.1093/jn/115.5.593; ROBERTS SB, 1984, J NUTR, V114, P2193, DOI 10.1093/jn/114.12.2193; Rossi M, 1997, ENDOCRINOLOGY, V138, P351, DOI 10.1210/en.138.1.351; SAHU A, 1988, PEPTIDES, V9, P83, DOI 10.1016/0196-9781(88)90013-7; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Santiago JR, 2001, ANN INTERN MED, V134, P396, DOI 10.7326/0003-4819-134-5-200103060-00012; Sauve D, 1996, BRAIN RES, V729, P75; SCHWARTZ MW, 1993, BRAIN RES BULL, V31, P361, DOI 10.1016/0361-9230(93)90228-4; Schwartz MW, 1996, DIABETES, V45, P531, DOI 10.2337/diabetes.45.4.531; Senaris RM, 1996, ENDOCRINOLOGY, V137, P5236, DOI 10.1210/en.137.12.5236; Seoane LM, 2003, ENDOCRINOLOGY, V144, P544, DOI 10.1210/en.2002-220795; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; SMITH MS, 1981, BIOL REPROD, V24, P967, DOI 10.1095/biolreprod24.5.967; STANLEY BG, 1986, PEPTIDES, V7, P1189; STEPHENS TW, 1995, NATURE, V377, P530, DOI 10.1038/377530a0; SUGIYAMA T, 1994, J ENDOCRINOL, V141, P325, DOI 10.1677/joe.0.1410325; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takekawa S, 2002, EUR J PHARMACOL, V438, P129, DOI 10.1016/S0014-2999(02)01314-6; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; TRAYHURN P, 1989, CAN J PHYSIOL PHARM, V67, P370, DOI 10.1139/y89-060; VOLOSCHIN LM, 1979, ENDOCRINOLOGY, V105, P1202, DOI 10.1210/endo-105-5-1202; Whitelegge T., 1890, REC AUST MUS, V1, P41, DOI DOI 10.3853/J.0067-1975.1.1890.1224; Wilding JPH, 1997, J ENDOCRINOL, V152, P365, DOI 10.1677/joe.0.1520365; Xu M, 2000, NEUROENDOCRINOLOGY, V72, P263, DOI 10.1159/000054595; Zhang SQ, 1999, PSYCHIAT CLIN NEUROS, V53, P101, DOI 10.1046/j.1440-1819.1999.00504.x	61	87	91	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1392	1400		10.1096/fj.02-0933com	http://dx.doi.org/10.1096/fj.02-0933com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890692				2022-12-28	WOS:000185345100031
J	Georget, M; Mateo, P; Vandecasteele, G; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Lugnier, C; Fischmeister, R				Georget, M; Mateo, P; Vandecasteele, G; Lipskaia, L; Defer, N; Hanoune, J; Hoerter, J; Lugnier, C; Fischmeister, R			Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8)	FASEB JOURNAL			English	Article						transgenic mouse; cAMP; isolated heart; L-type Ca2+ current; beta-adrenoceptors; muscarinic receptors; phosphodiesterase; compartmentation	PROTEIN-KINASE; NUCLEOTIDE PHOSPHODIESTERASES; MUSCARINIC RECEPTORS; CALCIUM CURRENT; PHOSPHORYLATION; CONTRACTILITY; ACTIVATION; SUBTYPES; CLONING; CANINE	Hearts from AC8TG mice develop a higher contractility (LVSP) and larger Ca2+ transients than NTG mice, with (surprisingly) no modification in L-type Ca2+ channel current (I-Ca,I-L) (1). In this study, we examined the cardiac response of AC8TG mice to beta-adrenergic and muscarinic agonists and IBMX, a cyclic nucleotide phosphodiesterase (PDE) inhibitor. Stimulation of LVSP and I-Ca,I-L by isoprenaline (ISO, 100 nM) was twofold smaller in AC8TG vs. NTG mice. In contrast, IBMX (100 muM) produced a twofold higher stimulation of ICa, L in AC8TG vs. NTG mice. IBMX (10 muM) increased LVSP by 40% in both types of mice, but contraction and relaxation were hastened in AC8TG mice only. Carbachol (10 muM) had no effect on basal contractility in NTG hearts but decreased LVSP by 50% in AC8TG mice. PDE assays demonstrated an increase in cAMP-PDE activity in AC8TG hearts, mainly due to an increase in the hydrolytic activity of PDE4 and PDE1 toward cAMP and a decrease in the activity of PDE1 and PDE2 toward cGMP. We conclude that cardiac expression of AC8 is accompanied by a rearrangement of PDE isoforms, leading to a strong compartmentation of the cAMP signal that shields L-type Ca2+ channels and protects the cardiomyocytes from Ca2+ overload.	Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, F-92296 Chatenay Malabry, France; Hop Henri Mondor, INSERM, U99, Lab Regulat Genes & Signalisat Cellulaire, F-94010 Creteil, France; Univ Strasbourg, CNRS, UMR 7034, Lab Pharmacol & Physicochim Interact Cellulaires, F-67401 Illkirch Graffenstaden, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Fischmeister, R (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446,Lab Cardiol Cellulaire & Mol, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	Fisch@vjf.inserm.fr	Lipskaia, Larissa/AAK-9322-2020; lugnier, claire/AAF-3911-2020; Fischmeister, Rodolphe/L-6061-2018; Vandecasteele, Gregoire/M-2922-2018	Fischmeister, Rodolphe/0000-0003-2086-9865; Vandecasteele, Gregoire/0000-0002-4046-4171				BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Bers DM, 2001, CIRC RES, V89, P373, DOI 10.1161/res.89.5.373; Boknik P, 1997, J CARDIOVASC PHARM, V30, P750, DOI 10.1097/00005344-199712000-00009; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRUNTON LL, 1979, NATURE, V280, P78, DOI 10.1038/280078a0; BUXTON ILO, 1983, J BIOL CHEM, V258, P233; CALI JJ, 1994, J BIOL CHEM, V269, P12190; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; Defer N, 2000, AM J PHYSIOL-RENAL, V279, pF400, DOI 10.1152/ajprenal.2000.279.3.F400; Dhein S, 2001, PHARMACOL RES, V44, P161, DOI 10.1006/phrs.2001.0835; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; EcklyMichel A, 1997, BRIT J PHARMACOL, V122, P158, DOI 10.1038/sj.bjp.0701339; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fisher DA, 1998, J BIOL CHEM, V273, P15559, DOI 10.1074/jbc.273.25.15559; GEORGET M, 2002, FASEB J, DOI DOI 10.1096/F4.02-0292F4E; HAYES JS, 1979, P NATL ACAD SCI USA, V76, P1570, DOI 10.1073/pnas.76.4.1570; HOHL CM, 1991, CIRC RES, V69, P1369, DOI 10.1161/01.RES.69.5.1369; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; Jiang Xin, 1998, Cell Biochemistry and Biophysics, V28, P135, DOI 10.1007/BF02737809; Jurevicius J, 1996, P NATL ACAD SCI USA, V93, P295, DOI 10.1073/pnas.93.1.295; KERAVIS TM, 1980, BIOCHIM BIOPHYS ACTA, V613, P116, DOI 10.1016/0005-2744(80)90198-9; Kuschel M, 1999, J BIOL CHEM, V274, P22048, DOI 10.1074/jbc.274.31.22048; Lipskaia L, 2000, CIRC RES, V86, P795, DOI 10.1161/01.RES.86.7.795; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Lugnier C, 1999, BBA-GEN SUBJECTS, V1472, P431, DOI 10.1016/S0304-4165(99)00145-2; LUGNIER C, 1993, J PHARMACOL EXP THER, V265, P1142; MERY PF, 1995, MOL PHARMACOL, V48, P121; Mery PF, 1997, LIFE SCI, V60, P1113, DOI 10.1016/S0024-3205(97)00055-6; Nielsen MD, 1996, J BIOL CHEM, V271, P33308, DOI 10.1074/jbc.271.52.33308; Okruhlicova L, 1996, HISTOCHEM J, V28, P165, DOI 10.1007/BF02331440; OKRUHLICOVA L, 1998, EXP CLIN CARDIOL, V3, P188; Petroff MGV, 2001, CIRC RES, V89, P445, DOI 10.1161/hh1701.095716; Rapundalo ST, 1998, CARDIOVASC RES, V38, P559, DOI 10.1016/S0008-6363(98)00063-7; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Shaul PW, 1998, AM J PHYSIOL-LUNG C, V275, pL843, DOI 10.1152/ajplung.1998.275.5.L843; Soderling SH, 1998, P NATL ACAD SCI USA, V95, P8991, DOI 10.1073/pnas.95.15.8991; Sonnenburg WK, 1998, METHODS, V14, P3, DOI 10.1006/meth.1997.0561; Steinberg SF, 1999, CIRC RES, V85, P1101; Steinberg SF, 2001, ANNU REV PHARMACOL, V41, P751, DOI 10.1146/annurev.pharmtox.41.1.751; Stoclet J.C., 1995, EXPERT OPIN INV DRUG, V4, P1081; Vandecasteele G, 1999, NAT MED, V5, P331, DOI 10.1038/6553; Verde I, 1999, BRIT J PHARMACOL, V127, P65, DOI 10.1038/sj.bjp.0702506; Verde I, 2001, J BIOL CHEM, V276, P11189, DOI 10.1074/jbc.M006546200; Wolska BM, 1996, AM J PHYSIOL-HEART C, V271, pH1250, DOI 10.1152/ajpheart.1996.271.3.H1250; Xiao RP, 1999, CIRC RES, V85, P1092; XIAO RP, 1994, J BIOL CHEM, V269, P19151	48	54	57	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1380	1391		10.1096/fj.02-0784com	http://dx.doi.org/10.1096/fj.02-0784com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890691	Green Submitted			2022-12-28	WOS:000185345100030
J	Murad, A; Nath, AK; Cha, ST; Demir, E; Flores-Riveros, J; Sierra-Honigmann, MR				Murad, A; Nath, AK; Cha, ST; Demir, E; Flores-Riveros, J; Sierra-Honigmann, MR			Leptin is an autocrine/paracrine regulator of wound healing	FASEB JOURNAL			English	Article						hypoxia; ischemia; tissue injury	ENDOTHELIAL GROWTH-FACTOR; TRANSCRIPTIONAL ACTIVATION; DIABETIC MICE; EXPRESSION; ANGIOGENESIS; PLACENTA; RECEPTOR; MOUSE; CELLS; GENE	Leptin, a 16 kDa pleiotropic cytokine primarily expressed in adipose tissue, has been shown to cause multiple systemic biological actions. Recently, leptin has also been documented as an important component of the wound healing process and its receptor appears to be expressed in wound tissue. We have previously demonstrated that leptin is a potent angiogenic factor exerting direct effects on endothelial cells and that transcription of its encoding gene is regulated by hypoxia. Here, we hypothesize that leptin expression is acutely up-regulated in the ischemic tissue of experimental wounds. Using a combination of in situ hybridization and quantitative RTPCR experiments, we show that leptin expression is rapidly and steadily up-regulated in skin tissue from incisional and excisional wounds. By immunohistochemistry, we demonstrate increased and sustained leptin protein levels in basal keratinocytes, blood vessel walls, and fibroblasts. To determine whether leptin is required for normal healing, excisional wounds were treated with neutralizing anti-leptin antibodies. This treatment markedly hampered healing progression and prevented wound closure and contraction. Finally, a transient rise in circulating blood leptin levels was detected within the first 24 h after inflicting the injury; we present evidence suggesting that this elevation is due to increased leptin production at the ischemic wound site. We conclude that leptin is acutely up-regulated in the injured skin and propose that this local production of leptin serves a critical functional role as an autocrine/paracrine regulator of normal wound healing.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Yale Univ, Sch Med, Dept Biol, New Haven, CT USA; Hollis Eden Pharmaceut, San Diego, CA USA	University of California System; University of California Los Angeles; Yale University	Sierra-Honigmann, MR (corresponding author), Cedars Sinai Res Inst, Dept Surg, Div Plast Surg, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	honigmannr@cshs.org						Akira S, 1997, INT J BIOCHEM CELL B, V29, P1401, DOI 10.1016/S1357-2725(97)00063-0; ALBERTSON S, 1993, SURGERY, V114, P368; Albertson S, 1993, SURGERY, V114, P72; Ambrosini G, 2002, J BIOL CHEM, V277, P34601, DOI 10.1074/jbc.M205172200; Antczak M, 1997, HUM REPROD, V12, P2226, DOI 10.1093/humrep/12.10.2226; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Cao RH, 2001, P NATL ACAD SCI USA, V98, P6390, DOI 10.1073/pnas.101564798; ChristofidouSolomidou M, 1997, AM J PATHOL, V151, P975; COLEMAN DL, 1973, DIABETOLOGIA, V9, P287, DOI 10.1007/BF01221856; DVONCH VM, 1992, SURGERY, V112, P18; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; GOODSON WH, 1986, DIABETES, V35, P491, DOI 10.2337/diab.35.4.491; GREENHALGH DG, 1990, AM J PATHOL, V136, P1235; GROSFELD A, 2002, J BIOL CHEM; Henson MC, 1999, J CLIN ENDOCR METAB, V84, P2543, DOI 10.1210/jc.84.7.2543; Hoggard N, 1997, P NATL ACAD SCI USA, V94, P11073, DOI 10.1073/pnas.94.20.11073; Howdieshell TR, 1998, ANN SURG, V228, P707, DOI 10.1097/00000658-199811000-00011; HUMMEL KP, 1972, BIOCHEM GENET, V7, P1, DOI 10.1007/BF00487005; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Masuzaki H, 1997, NAT MED, V3, P1029, DOI 10.1038/nm0997-1029; Nakata M, 1999, DIABETES, V48, P426, DOI 10.2337/diabetes.48.2.426; Nissen NN, 1998, AM J PATHOL, V152, P1445; Ring BD, 2000, ENDOCRINOLOGY, V141, P446, DOI 10.1210/en.141.1.446; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Senaris R, 1997, ENDOCRINOLOGY, V138, P4501, DOI 10.1210/en.138.10.4501; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Smith-Kirwin SM, 1998, J CLIN ENDOCR METAB, V83, P1810, DOI 10.1210/jc.83.5.1810; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Touw IP, 2000, MOL CELL ENDOCRINOL, V160, P1, DOI 10.1016/S0303-7207(99)00206-3; TSUBOI R, 1990, J EXP MED, V172, P245, DOI 10.1084/jem.172.1.245; Tsuboi Ryoji, 1992, Journal of Dermatology (Tokyo), V19, P673	36	110	130	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1895	+		10.1096/fj.03-0068fje	http://dx.doi.org/10.1096/fj.03-0068fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923067				2022-12-28	WOS:000185345100003
J	Walker, GA; Thompson, FJ; Brawley, A; Scanlon, T; Devaney, E				Walker, GA; Thompson, FJ; Brawley, A; Scanlon, T; Devaney, E			Heat shock factor functions at the convergence of the stress response and developmental pathways in Caenorhabditis elegans	FASEB JOURNAL			English	Article						dauer pathway; thermotolerance; life span	DAUER FORMATION; TRANSCRIPTION FACTORS; GENETIC-ANALYSIS; EXPRESSION; AGE; THERMOTOLERANCE; THERMOTAXIS; PARALLEL; RECEPTOR; MUTANT	Heat shock factor (HSF) is best characterized as the transcriptional regulator of heat shock protein genes, required by all cells to survive periods of stress. Recent evidence suggests that HSF also functions to regulate the expression of genes involved in growth and development under normal physiological conditions. In this study, we used RNA interference (RNAi) assays to investigate the role of HSF in Caenorhabditis elegans. Exposure of wild-type worms to hsf dsRNAi constructs caused a temperature-sensitive developmental arrest at the L2/L3 stage. At normal growth temperatures, hsf(RNAi) worms that developed to adults were small and scrawny, largely infertile, and showed a significant reduction in life span. These results demonstrate that HSF is required for normal postembryonic development under physiological conditions. Following heat shock, hsf(RNAi) worms were thermosensitive and displayed a significant reduction of hsp16 expression. When hsf(RNAi) was carried out in various dauer-constitutive mutant backgrounds, a dramatic reversal of dauer formation was observed, indicating that HSF is also required in the dauer pathway. In its natural habitat of the soil, where C. elegans is exposed to a constantly fluctuating environment; the ability to integrate the stress response with development may be an essential element of its ecology.	Univ Glasgow, Inst Comparat Med, Glasgow, Lanark, Scotland	University of Glasgow	Devaney, E (corresponding author), Univ Glasgow, Inst Comparat Med, Bearsden Rd, Glasgow, Lanark, Scotland.	e.devaney@vet.gla.ac.uk		Devaney, Eileen/0000-0002-1935-834X				Ailion M, 2000, GENETICS, V156, P1047; Antebi A, 2000, GENE DEV, V14, P1512; Antebi A, 1998, DEVELOPMENT, V125, P1191; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; Garigan D, 2002, GENETICS, V161, P1101; GOLDEN JW, 1984, P NATL ACAD SCI-BIOL, V81, P819, DOI 10.1073/pnas.81.3.819; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HEDGECOCK EM, 1975, P NATL ACAD SCI USA, V72, P4061, DOI 10.1073/pnas.72.10.4061; Hobert O, 1997, NEURON, V19, P345, DOI 10.1016/S0896-6273(00)80944-7; Holmberg CI, 2001, EMBO J, V20, P3800, DOI 10.1093/emboj/20.14.3800; Hsu AL, 2003, SCIENCE, V300, P1142, DOI 10.1126/science.1083701; Jedlicka P, 1997, EMBO J, V16, P2452, DOI 10.1093/emboj/16.9.2452; Koga M, 1999, DEVELOPMENT, V126, P5387; LARSEN PL, 1995, GENETICS, V139, P1567; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; LITHGOW GJ, 1994, J GERONTOL, V49, pB270, DOI 10.1093/geronj/49.6.B270; MORI I, 1995, NATURE, V376, P344, DOI 10.1038/376344a0; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Pirkkala L, 2001, FASEB J, V15, P1118, DOI 10.1096/fj00-0294rev; Riddle DL, 1997, C ELEGANS, P739; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schackwitz WS, 1996, NEURON, V17, P719, DOI 10.1016/S0896-6273(00)80203-2; Simmer F, 2002, CURR BIOL, V12, P1317, DOI 10.1016/S0960-9822(02)01041-2; Singh IS, 2002, J BIOL CHEM, V277, P4981, DOI 10.1074/jbc.M108154200; STRINGHAM EG, 1992, MOL BIOL CELL, V3, P221, DOI 10.1091/mbc.3.2.221; Sulston J., 1988, NEMATODE CAENORHABDI, P587; THOMAS JH, 1993, GENETICS, V134, P1105; Thompson FJ, 2001, EUR J BIOCHEM, V268, P5808, DOI 10.1046/j.0014-2956.2001.02525.x; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; VOWELS JJ, 1992, GENETICS, V130, P105; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Zhong M, 1998, MOL CELL, V2, P101, DOI 10.1016/S1097-2765(00)80118-5	35	54	64	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1960	+		10.1096/fj.03-0164fje	http://dx.doi.org/10.1096/fj.03-0164fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897069				2022-12-28	WOS:000185345100027
J	Wiendl, H; Mitsdoerffer, M; Schneider, D; Chen, LP; Lochmuller, H; Melms, A; Weller, M				Wiendl, H; Mitsdoerffer, M; Schneider, D; Chen, LP; Lochmuller, H; Melms, A; Weller, M			Human muscle cells express a B7-related molecule, B7-H1, with strong negative immune regulatory potential: a novel mechanism of counterbalancing the immune attack in idiopathic inflammatory myopathies	FASEB JOURNAL			English	Article						T cells; MHC class I/II; IFN-gamma; myopathy; immune regulation; costimulation	NATURAL-KILLER-CELLS; CD8(+) T-CELLS; B7 FAMILY; MYOBLAST TRANSPLANTATION; DIFFERENTIAL EXPRESSION; RECEPTOR REPERTOIRE; ENDOTHELIAL-CELLS; CLASS-I; HLA-G; POLYMYOSITIS	B7-H1 is a novel B7 family protein attributed to costimulatory and immune regulatory functions. Here we report that human myoblasts cultured from control subjects and patients with inflammatory myopathies as well as TE671 muscle rhabdomyosarcoma cells express high levels of B7-H1 after stimulation with the inflammatory cytokine IFN-gamma. Coculture experiments of MHC class I/II-positive myoblasts with CD4 and CD8 T cells in the presence of antigen demonstrated the functional consequences of muscle-related B7-H1 expression: production of inflammatory cytokines, IFN-gamma and IL-2, by CD4 as well CD8 T cells was markedly enhanced in the presence of a neutralizing anti-B7-H1 antibody. This observation was paralleled by an augmented expression of the T cell activation markers CD25, ICOS, and CD69, thus showing B7-H1-mediated inhibition of T cell activation. Further, we investigated 23 muscle biopsy specimens from patients with polymyositis ( PM), inclusion body myositis (IBM), dermatomyositis (DM), and nonmyopathic controls for B7-H1 expression by immunohistochemistry: B7-H1 was expressed in PM, IBM, and DM specimens but not in noninflammatory and nonmyopathic controls. Staining was predominantly localized to areas of strong inflammation and to muscle cells as well as mononuclear cells. These data highlight the immune regulatory properties of muscle cells and suggest that B7-H1 expression represents an inhibitory mechanism induced upon inflammatory stimuli and aimed at protecting muscle fibers from immune aggression.	Univ Tubingen, Dept Neurol, Sch Med, D-72076 Tubingen, Germany; Mayo Clin Rochester, Dept Immunol, Rochester, MN 55905 USA; Univ Munich, Dept Neurol, D-8000 Munich, Germany; Univ Munich, Genzentrum, Friedrich Baur Inst, Munich, Germany	Eberhard Karls University of Tubingen; Mayo Clinic; University of Munich; University of Munich	Wiendl, H (corresponding author), Univ Tubingen, Dept Neurol, Sch Med, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.	heinz.wiendl@uni-tuebingen.de	Wiendl, Heinz/AAX-6041-2021	Lochmuller, Hanns/0000-0003-2324-8001; Beier, Dagmar/0000-0002-3336-157X; Weller, Michael/0000-0002-1748-174X; Wiendl, Heinz/0000-0003-4310-3432				Behrens L, 1998, J IMMUNOL, V161, P5943; BENDER A, 1995, J EXP MED, V181, P1863, DOI 10.1084/jem.181.5.1863; Bernasconi P, 1998, J NEUROIMMUNOL, V85, P52, DOI 10.1016/S0165-5728(97)00254-3; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9; Coyle AJ, 2001, NAT IMMUNOL, V2, P203, DOI 10.1038/85251; Dalakas Marinos C, 2002, Adv Neurol, V88, P253; DALAKAS MC, 1995, ANN NEUROL, V37, P74; Dong HD, 1999, NAT MED, V5, P1365; Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730; EMSLIESMITH AM, 1989, HUM PATHOL, V20, P224, DOI 10.1016/0046-8177(89)90128-7; Eppihimer MJ, 2002, MICROCIRCULATION, V9, P133, DOI 10.1038/sj/mn/7800123; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; GOEBELS N, 1992, J IMMUNOL, V149, P661; Goebels N, 1996, J CLIN INVEST, V97, P2905, DOI 10.1172/JCI118749; HOHLFELD R, 1990, J CLIN INVEST, V86, P370, DOI 10.1172/JCI114711; HOHLFELD R, 1994, IMMUNOL TODAY, V15, P269, DOI 10.1016/0167-5699(94)90006-X; ILLA I, 1992, ANN NEUROL, V31, P46, DOI 10.1002/ana.410310109; Ishida M, 2002, IMMUNOL LETT, V84, P57, DOI 10.1016/S0165-2478(02)00142-6; KARPATI G, 1988, ANN NEUROL, V23, P64, DOI 10.1002/ana.410230111; Kobata T, 2000, Rev Immunogenet, V2, P74; Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330; Liang L, 2002, CURR OPIN IMMUNOL, V14, P384, DOI 10.1016/S0952-7915(02)00342-4; MANTEGAZZA R, 1993, J CLIN INVEST, V91, P2880, DOI 10.1172/JCI116533; Mazanet MM, 2002, J IMMUNOL, V169, P3581, DOI 10.4049/jimmunol.169.7.3581; MICHAELIS D, 1993, AM J PATHOL, V143, P1142; Murata K, 1999, AM J PATHOL, V155, P453, DOI 10.1016/S0002-9440(10)65141-3; Nagaraju K, 2000, P NATL ACAD SCI USA, V97, P9209, DOI 10.1073/pnas.97.16.9209; Nagaraju K, 2001, ACTA PHYSIOL SCAND, V171, P215, DOI 10.1046/j.1365-201x.2001.00823.x; Nagaraju K, 1999, CLIN IMMUNOL, V92, P161, DOI 10.1006/clim.1999.4743; Okazaki T, 2001, P NATL ACAD SCI USA, V98, P13866, DOI 10.1073/pnas.231486598; Petroff MG, 2002, PLACENTA, V23, pS95, DOI 10.1053/plac.2002.0813; Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727; Tseng SY, 2001, J EXP MED, V193, P839, DOI 10.1084/jem.193.7.839; Wang SD, 2003, J EXP MED, V197, P1083, DOI 10.1084/jem.20021752; Wiendl H, 2000, ANN NEUROL, V48, P679, DOI 10.1002/1531-8249(200010)48:4<679::AID-ANA19>3.3.CO;2-M; Wiendl H, 2003, BRAIN, V126, P176, DOI 10.1093/brain/awg017; Wiendl H, 2002, J IMMUNOL, V169, P515, DOI 10.4049/jimmunol.169.1.515	38	90	100	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1892	+		10.1096/fj.03-0039fje	http://dx.doi.org/10.1096/fj.03-0039fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923066				2022-12-28	WOS:000185345100002
J	Chen, CJ; Huang, HS; Chang, WC				Chen, CJ; Huang, HS; Chang, WC			Depletion of phospholipid hydroperoxide glutathione peroxidase up-regulates arachidonate metabolism by 12(S)-lipoxygenase and cyclooxygenase 1 in human epidermoid carcinoma A431 cells	FASEB JOURNAL			English	Article						PHGPx; peroxides; 12(S)-hydroxyeicosatetraenoic acid; prostaglandin E(2)	GROWTH-FACTOR; LIPOXYGENASE INHIBITOR; LIPID-PEROXIDATION; INDUCED APOPTOSIS; 12-LIPOXYGENASE; INVOLVEMENT; REDUCTION; PLATELETS; NECROSIS; SELENIUM	Phospholipid hydroperoxide glutathione peroxidase (PHGPx), a selenium-dependent glutathione peroxidase, can interact with lipophilic substrates, including the phospholipid hydroperoxides, fatty-acid hydroperoxides, and cholesteryl ester hydroperoxides, and reduce them to hydroxide compounds. We studied the functional role of endogenous PHGPx in regulation of 12(S)-lipoxygenase and cyclooxygenase 1 activities in human epidermoid carcinoma A431 cells by using a cell system overexpressing anti-PHGPx mRNA. A retroviral expression vector designated as L1-3, wherein cDNA of PHGPx was reversely inserted into pFB-ERV in antisense orientation, was constructed. A number of stable transfectants of A431 cells with PHGPx depletion were generated from virions containing plasmid L1-3. In an intact cell assay system, the metabolism of arachidonic acid to prostaglandin E(2) and 12(S)-hydroxyeicosatetraenoic acid was significantly enhanced in stable L1-3 transfectants compared with that in vector-control cells. Flow cytometric analysis revealed a significant elevated level of intracellular hydroperoxides in stable L1-3 transfectants. Treatment of stable L1-3 transfectants with 50 muM arsenite induced more significant formation of intracellular hydroperoxides than that of vector-control cells. Taken together, these results support the notion that the endogenous PHGPx plays a pivotal role in the regulation of 12(S)-lipoxygenase and cyclooxygenase 1 activities by reducing the level of intracellular lipid hydroperoxides in arachidonate metabolism in A431 cells.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 704, Taiwan	National Cheng Kung University; National Cheng Kung University	Chang, WC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 138 Sheng Li Rd, Tainan 704, Taiwan.	wcchang@mail.ncku.edu.tw	Huang, Huei-Sheng/F-9945-2011					BASS DA, 1983, J IMMUNOL, V130, P1910; CHANG WC, 1993, J BIOL CHEM, V268, P18734; CHANG WC, 1992, J BIOL CHEM, V267, P3657; CHANG WC, 1982, BIOCHEM J, V202, P771, DOI 10.1042/bj2020771; Chen CJ, 2002, J BIOMED SCI, V9, P453, DOI 10.1007/BF02256540; Chen CJ, 2000, PROSTAG LEUKOTR ESS, V62, P261, DOI 10.1103/PhysRevD.62.094026; Chen CJ, 1997, BIOCHEM J, V327, P193, DOI 10.1042/bj3270193; CHU FF, 1993, J BIOL CHEM, V268, P2571; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; Donato NJ, 1998, J BIOL CHEM, V273, P5067, DOI 10.1074/jbc.273.9.5067; GHYSELINCK NB, 1990, NUCLEIC ACIDS RES, V18, P7144, DOI 10.1093/nar/18.23.7144; Ho YS, 1997, J BIOL CHEM, V272, P16644, DOI 10.1074/jbc.272.26.16644; Huang HS, 2002, FREE RADICAL BIO MED, V33, P864, DOI 10.1016/S0891-5849(02)00983-8; Huang HS, 1999, PROSTAG OTH LIPID M, V58, P65, DOI 10.1016/S0090-6980(99)00017-9; Huang HS, 1998, FEBS LETT, V424, P22, DOI 10.1016/S0014-5793(98)00130-6; Imai H, 1998, J BIOL CHEM, V273, P1990, DOI 10.1074/jbc.273.4.1990; Jabs T, 1999, BIOCHEM PHARMACOL, V57, P231, DOI 10.1016/S0006-2952(98)00227-5; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDIPATI KR, 1987, ARCH BIOCHEM BIOPHYS, V254, P9, DOI 10.1016/0003-9861(87)90075-0; MAIORINO M, 1990, METHOD ENZYMOL, V186, P448; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; NELSON MJ, 1995, BIOCHEMISTRY-US, V34, P6159, DOI 10.1021/bi00018a019; Nomura K, 1999, J BIOL CHEM, V274, P29294, DOI 10.1074/jbc.274.41.29294; ROTRUCK JT, 1973, SCIENCE, V179, P588, DOI 10.1126/science.179.4073.588; Sakamoto H, 2000, J BIOL CHEM, V275, P40028, DOI 10.1074/jbc.M003191200; Sato T, 1997, PROSTAGLANDINS, V53, P355, DOI 10.1016/0090-6980(97)00036-1; Schnurr K, 1996, J BIOL CHEM, V271, P4653; SHORNICK LP, 1993, J BIOL CHEM, V268, P371; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Sutherland M, 2001, BIOCHEM J, V353, P91, DOI 10.1042/bj3530091; THOMAS JP, 1990, J BIOL CHEM, V265, P454; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; YAMAMOTO S, 1991, FREE RADICAL BIO MED, V10, P149, DOI 10.1016/0891-5849(91)90008-Q	34	28	29	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1694	+		10.1096/fj.02-0847fje	http://dx.doi.org/10.1096/fj.02-0847fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958179				2022-12-28	WOS:000184471600020
J	Wang, XR; Zhang, Z; Louboutin, JP; Moser, C; Weiner, DJ; Wilson, JM				Wang, XR; Zhang, Z; Louboutin, JP; Moser, C; Weiner, DJ; Wilson, JM			Airway epithelia regulate expression of human beta-defensin 2 through toll-like receptor 2	FASEB JOURNAL			English	Article						TLR; defensin; lung	TOLL-LIKE RECEPTORS; NF-KAPPA-B; MEDIATED TRANSCRIPTIONAL REGULATION; DERMAL ENDOTHELIAL-CELLS; INNATE IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDE; HUMAN BETA-DEFENSIN-2; ADAPTIVE IMMUNITY; ESCHERICHIA-COLI; DROSOPHILA TOLL	The goal of this study is to investigate whether TLR2 mediates hBD2 induction through NF-kappaB in response to bacterial components in the human airway epithelia. We showed that hTLR2 is expressed in the airway epithelial cells by immunohistochemical staining and RT-PCR. The biology of hTLR2 in this context was studied initially in 293 cells transfected with a plasmid expressing hTLR2 together with an hBD2 promoter-driven luciferase reporter(hBD2-promoter-LUC). Upon incubation with lipoteichoic acid(LTA), the major cell wall component of gram positive bacteria,luciferase activity was greatly increased compared with mock stimulation. Analysis of mutation constructs of the hBD2 promoter revealed that NF-kappaB sites are important for hTLR2-mediated hBD2 up-regulation upon LTA stimulation. When hBD2-promoter-LUC was transfected into primary human airway epithelial cells(EC), the luciferase activity was greatly increased upon LTA stimulation compared with mock stimulation. The hBD2 promoter mutation constructs were also tested in EC, which confirmed the studies in 293 cells. When a plasmid expressing a dominant-negative mutant of hTLR2 was co-transfected with hBD2 promoter-LUC into EC,LTA could not stimulate hBD2 expression. These data provide convincing evidence that up-regulation of hBD2 can be induced through hTLR2-mediated NFkappaB/IkappaB pathway in the human airway epithelial cells.	Univ Penn, Sch Med, Dept Med, Div Med Genet, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Wilson, JM (corresponding author), 204 Wistar Inst, 3601 Spruce St, Philadelphia, PA 19104 USA.	wilsonjm@mail.med.upenn.edu	Wilson, James M/F-9220-2011	Wilson, James M/0000-0002-9630-3131; Weiner, Daniel/0000-0001-8245-1961				Abreu MT, 2001, J IMMUNOL, V167, P1609, DOI 10.4049/jimmunol.167.3.1609; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; Bals R, 1999, INFECT IMMUN, V67, P3542, DOI 10.1128/IAI.67.7.3542-3547.1999; Bals R, 1998, J CLIN INVEST, V102, P874, DOI 10.1172/JCI2410; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Birchler T, 2001, EUR J IMMUNOL, V31, P3131, DOI 10.1002/1521-4141(200111)31:11<3131::AID-IMMU3131>3.0.CO;2-G; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; DIAMOND G, 1991, P NATL ACAD SCI USA, V88, P3952, DOI 10.1073/pnas.88.9.3952; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fusunyan RD, 2001, PEDIATR RES, V49, P589, DOI 10.1203/00006450-200104000-00023; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Huttner KM, 1997, FEBS LETT, V413, P45, DOI 10.1016/S0014-5793(97)00875-2; Janeway CA, 1998, SEMIN IMMUNOL, V10, P349, DOI 10.1006/smim.1998.0142; Jia HP, 2000, J BIOL CHEM, V275, P33314, DOI 10.1074/jbc.M006603200; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Ma XJ, 2000, J IMMUNOL, V164, P1722, DOI 10.4049/jimmunol.164.4.1722; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Morrison GM, 1999, FEBS LETT, V442, P112, DOI 10.1016/S0014-5793(98)01630-5; Naik S, 2001, J PEDIATR GASTR NUTR, V32, P449, DOI 10.1097/00005176-200104000-00011; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; SCHONWETTER BS, 1995, SCIENCE, V267, P1645, DOI 10.1126/science.7886453; Sebastiani G, 2000, GENOMICS, V64, P230, DOI 10.1006/geno.2000.6115; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Thoma-Uszynski S, 2000, J IMMUNOL, V165, P3804, DOI 10.4049/jimmunol.165.7.3804; Tsutsumi-Ishii Y, 2002, J LEUKOCYTE BIOL, V71, P154; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; Underhill DM, 1999, P NATL ACAD SCI USA, V96, P14459, DOI 10.1073/pnas.96.25.14459; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wada A, 2001, CELL MICROBIOL, V3, P115, DOI 10.1046/j.1462-5822.2001.00096.x; Wolfs TGAM, 2002, J IMMUNOL, V168, P1286, DOI 10.4049/jimmunol.168.3.1286; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	51	73	85	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1727	+		10.1096/fj.02-0616fje	http://dx.doi.org/10.1096/fj.02-0616fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958190				2022-12-28	WOS:000184471600024
J	Beebe, SJ; Fox, PM; Rec, LJ; Willis, LK; Schoenbach, KH				Beebe, SJ; Fox, PM; Rec, LJ; Willis, LK; Schoenbach, KH			Nanosecond, high-intensity pulsed electric fields induce apoptosis in human cells	FASEB JOURNAL			English	Article						electroporation; caspases; cytochrome c; annexin-V; flow cytometry	MAMMALIAN-CELLS; GENE-TRANSFER; DEATH; ELECTROCHEMOTHERAPY; FUNDAMENTALS; MECHANISM	Electroporation by using pulsed electric fields with long durations compared with the charging time of the plasma membrane can induce cell fusion or introduce xenomolecules into cells Nanosecond pulse power technology generates pulses with high-intensity electric fields, but with such short durations that the charging time of the plasma membrane is not reached, but intracellular membranes are affected. To determine more specifically their effects on cell structure and function, human cells were exposed to high intensity (up to 300 kV/cm) nanosecond (10-300 ns) pulsed electric fields (nsPEF) and were analyzed at the cellular and molecular levels. As the pulse duration decreased, plasma membrane electroporation decreased and appearances of apoptosis markers were delayed. NsPEF induced apoptosis within tens of minutes, depending on the pulses duration. Annexin-V binding, caspase activation, decreased forward light scatter, and cytochrome c release into the cytoplasm were coincident. Apoptosis was caspase- and mitochondria-dependent but independent of plasma membrane electroporation and thermal changes. The results suggest that with decreasing pulse duration, nsPEF modulate cell signaling from the plasma membrane to intracellular structures and functions. NsPEF technology provides a unique, high-power, energy-independent tool to recruit plasma membrane and/or intracellular signaling mechanisms that can delete aberrant cells by apoptosis.	Eastern Virginia Med Sch, Ctr Pediat Res, Norfolk, VA 23510 USA; Old Dominion Univ, Phys Electron Res Inst, Norfolk, VA USA	Eastern Virginia Medical School; Old Dominion University	Beebe, SJ (corresponding author), Eastern Virginia Med Sch, Ctr Pediat Res, 855 W Brambleton Ave, Norfolk, VA 23510 USA.	sbeebe@chkd.com						Amstad PA, 2001, BIOTECHNIQUES, V31, P608, DOI 10.2144/01313pf01; Beebe SJ, 2002, IEEE T PLASMA SCI, V30, P286, DOI 10.1109/TPS.2002.1003872; BELEHRADEK M, 1993, CANCER-AM CANCER SOC, V72, P3694, DOI 10.1002/1097-0142(19931215)72:12<3694::AID-CNCR2820721222>3.0.CO;2-2; Chang D.C., 1992, GUIDE ELECTROPORATIO; Cole KS, 1937, T FARADAY SOC, V33, P0966, DOI 10.1039/tf9373300966; Deng JD, 2000, CONFERENCE RECORD OF THE 2000 TWENTY-FOURTH INTERNATIONAL POWER MODULATOR SYMPOSIUM, 50TH ANNIVERSARY, P47, DOI 10.1109/MODSYM.2000.896161; DEV SB, 1994, CANCER TREAT REV, V20, P105, DOI 10.1016/0305-7372(94)90013-2; Dev SB, 2000, IEEE T PLASMA SCI, V28, P206, DOI 10.1109/27.842905; Ebert O, 1997, GENE THER, V4, P296, DOI 10.1038/sj.gt.3300394; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Foster KR, 2000, IEEE T PLASMA SCI, V28, P15, DOI 10.1109/27.842819; FOSTER KR, 1996, HDB BIOL EFFECTS ELE; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hofmann F, 1999, J MEMBRANE BIOL, V169, P103, DOI 10.1007/s002329900522; KARSTEN U, 1988, HYBRIDOMA, V7, P627, DOI 10.1089/hyb.1988.7.627; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Li LH, 2001, FASEB J, V15, P586, DOI 10.1096/fj.00-0447fje; Li LH, 1999, EXP CELL RES, V253, P541, DOI 10.1006/excr.1999.4666; LO MMS, 1984, NATURE, V310, P792, DOI 10.1038/310792a0; Muller KJ, 2001, J MEMBRANE BIOL, V184, P161, DOI 10.1007/s00232-001-0084-3; Neumann E, 1998, BIOPHYS J, V74, P98, DOI 10.1016/S0006-3495(98)77771-9; NEUMANN E, 1982, EMBO J, V1, P841, DOI 10.1002/j.1460-2075.1982.tb01257.x; Neumann E, 1999, BIOELECTROCH BIOENER, V48, P3, DOI 10.1016/S0302-4598(99)00008-2; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Schoenbach KH, 1997, IEEE T PLASMA SCI, V25, P284, DOI 10.1109/27.602501; Schoenbach KH, 2000, IEEE T DIELECT EL IN, V7, P637, DOI 10.1109/94.879359; Schoenbach KH, 2001, BIOELECTROMAGNETICS, V22, P440, DOI 10.1002/bem.71; Schoenbach KH, 1997, 11TH IEEE INTERNATIONAL PULSED POWER CONFERENCE - DIGEST OF TECHNICAL PAPERS, VOLS. 1 & 2, P73, DOI 10.1109/PPC.1997.679279; SCHOENBACH KH, 1998, P ERDEC SCI C CHEM B, P583; Shimokawa T, 2000, BIOCHEM BIOPH RES CO, V270, P94, DOI 10.1006/bbrc.2000.2388; Somiari S, 2000, MOL THER, V2, P178, DOI 10.1006/mthe.2000.0124; Tang DM, 1999, J BIOL CHEM, V274, P7245, DOI 10.1074/jbc.274.11.7245; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Weaver J.C., 1996, CRC HDB BIOL EFFECTS, P247; Weaver JC, 1999, ADV DRUG DELIVER REV, V35, P21, DOI 10.1016/S0169-409X(98)00061-1; WEAVER JC, 2000, BIOMEDICAL ENG HDB, P1431; WONG TK, 1982, BIOCHEM BIOPH RES CO, V107, P584, DOI 10.1016/0006-291X(82)91531-5; Zimmermann U, 2000, IEEE T PLASMA SCI, V28, P72, DOI 10.1109/27.842868	41	326	362	3	66	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1493	+		10.1096/fj.02-0859fje	http://dx.doi.org/10.1096/fj.02-0859fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824299				2022-12-28	WOS:000183818000022
J	Ha, KS; Kim, KM; Kwon, YG; Bai, SK; Nam, WD; Yoo, YM; Kim, PKM; Chung, HT; Billiar, TR; Kim, YM				Ha, KS; Kim, KM; Kwon, YG; Bai, SK; Nam, WD; Yoo, YM; Kim, PKM; Chung, HT; Billiar, TR; Kim, YM			Nitric oxide prevents 6-hydroxydopamine-induced apoptosis in PC12 cells through cGMP-dependent PI3 kinase/Akt activation	FASEB JOURNAL			English	Article						caspase; mitochondria; cytochrome c; Bad phosphorylation; protein kinase G	ALPHA-INDUCED APOPTOSIS; AKT PROTEIN-KINASE; MEDIATED APOPTOSIS; CYTOCHROME-C; SYMPATHETIC NEURONS; DISTINCT MECHANISMS; PARKINSONS-DISEASE; DEATH; NECROSIS; SURVIVAL	Nitric oxide (NO) functions not only as an important signaling molecule in the brain by producing cGMP, but also regulates neuronal cell apoptosis. The mechanism by which NO regulates apoptosis is unclear. In this study, we demonstrated that NO, produced either from the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) or by transfection of neuronal NO synthase, suppressed 6-hydroxydopamine (6-OHDA)-induced apoptosis in PC12 cells by inhibiting mitochondrial cytochrome c release, caspase-3 and -9 activation, and DNA fragmentation. This protection was significantly reversed by the soluble guanylyl cyclase inhibitor 1H-(1,2,4)-oxadiazole[4,3-a]quinoxalon-1-one, indicating that cGMP is a key mediator in NO-mediated anti-apoptosis. Moreover, the membrane-permeable cGMP analog 8-Br-cGMP inhibited 6-OHDA-induced apoptosis. These anti-apoptotic effects of SNAP and 8-Br-cGMP were suppressed by cGMP-dependent protein kinase G (PKG) inhibitor KT5823, indicating that PKG is a downstream signal mediator in the suppression of apoptosis by NO and cGMP. Both SNAP and 8-Br-cGMP induced endogenous Akt activation and Bad phosphorylation, resulting in the inhibition of Bad translocation to mitochondria; these effects were inhibited by KT5823 and the phosphatidylinositol 3-kinase (PI3K) inhibitors LY294002 and Wortmannin. Our data suggest that the NO/cGMP pathway suppresses 6-OHDA-induced PC12 cell apoptosis by suppressing the mitochondrial apoptosis signal via PKG/PI3K/Akt-dependent Bad phosphorylation.	Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Kangwon Do, South Korea; Kangwon Natl Univ, Sch Med, Vasc Syst Res Ctr, Chunchon, Kangwon Do, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA USA; Wonkwang Univ, Sch Med, Dept Microbiol & Immunol, Iksan, Chonbuk, South Korea	Kangwon National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Wonkwang University	Kim, YM (corresponding author), Kangwon Natl Univ, Sch Med, Dept Mol & Cellular Biochem, Chunchon, Kangwon Do, South Korea.	ymkim@kangwon.ac.kr	Ha, Kwon-Soo/AAU-4417-2020	Ha, Kwon-Soo/0000-0002-4219-1787				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARGER SW, 1995, J NEUROCHEM, V64, P2087; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Crowder RJ, 1998, J NEUROSCI, V18, P2933; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DAWSON VL, 1991, P NATL ACAD SCI USA, V88, P6368, DOI 10.1073/pnas.88.14.6368; DEL PL, 1997, SCIENCE, V278, P687; Deora AA, 1998, J BIOL CHEM, V273, P29923, DOI 10.1074/jbc.273.45.29923; Dodel RC, 1999, MOL BRAIN RES, V64, P141, DOI 10.1016/S0169-328X(98)00318-0; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Estevez AG, 1998, J NEUROSCI, V18, P923; ESTEVEZ AG, 1995, J NEUROCHEM, V65, P1543; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Hengartner MO, 2001, NATURE, V412, P27, DOI 10.1038/35083663; HILL IE, 1995, BRAIN RES, V676, P398, DOI 10.1016/0006-8993(95)00145-G; IGNARRO LJ, 1988, J PHARMACOL EXP THER, V244, P181; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; Kim YM, 1999, CIRC RES, V84, P253, DOI 10.1161/01.RES.84.3.253; KIM YM, 1995, J BIOL CHEM, V270, P5710, DOI 10.1074/jbc.270.11.5710; Kim YM, 1999, J NEUROSCI, V19, P6740, DOI 10.1523/JNEUROSCI.19-16-06740.1999; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Lotharius J, 1999, J NEUROSCI, V19, P1284; McDonald L J, 1995, Adv Pharmacol, V34, P263; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Narayanan V, 1997, PEDIATR NEUROL, V16, P9, DOI 10.1016/S0887-8994(96)00257-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ochu EE, 1998, J NEUROCHEM, V70, P2637; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Ozes ON, 1999, NATURE, V401, P82; Pettmann B, 1998, NEURON, V20, P633, DOI 10.1016/S0896-6273(00)81004-1; PRYOR WA, 1995, AM J PHYSIOL, V268, P699; RICHTERLANDSBERG C, 1994, J NEUROCHEM, V63, P2202; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Soto-Otero R, 2000, J NEUROCHEM, V74, P1605, DOI 10.1046/j.1471-4159.2000.0741605.x; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Tariq M, 2001, BRAIN RES BULL, V54, P77, DOI 10.1016/S0361-9230(00)00427-5; Viswanath V, 2001, J NEUROSCI, V21, P9519, DOI 10.1523/JNEUROSCI.21-24-09519.2001; ZHANG J, 1994, SCIENCE, V263, P687, DOI 10.1126/science.8080500	50	137	148	0	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1036	1047		10.1096/fj.02-0738com	http://dx.doi.org/10.1096/fj.02-0738com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773486				2022-12-28	WOS:000183818000007
J	Warrener, R; Beamish, H; Burgess, A; Waterhouse, NJ; Giles, N; Fairlie, DP; Gabrielli, B				Warrener, R; Beamish, H; Burgess, A; Waterhouse, NJ; Giles, N; Fairlie, DP; Gabrielli, B			Tumor cell-specific cytotoxicity by targeting cell cycle checkpoints	FASEB JOURNAL			English	Article						apoptosis; histone deacetylase inhibitors; mitotic spindle checkpoint	HISTONE-DEACETYLASE INHIBITORS; IN-VITRO; EXPRESSION; CENTROMERE; CANCER; HETEROCHROMATIN; MICROTUBULES; KINETOCHORES; TRANSDUCTION; DISRUPTION	Cell cycle checkpoints act to protect cells from external stresses and internal errors that would compromise the integrity of the cell. Checkpoints are often defective in cancer cells. Drugs that target checkpoint mechanisms should therefore be selective for tumor cells that are defective for the drug-sensitive checkpoint. Histone deacetylase inhibitors typify this class of agents. They trigger a G(2)-phase checkpoint response in normal cells but are cytotoxic in tumor cells in which this checkpoint is defective. In this study, we investigated that molecular basis of the tumor-selective cytotoxicity of these drugs and demonstrated that it is due to the disruption of two cell cycle checkpoints. The first is the histone deacetylase inhibitor-sensitive G(2)-phase checkpoint, which is defective in drug-sensitive cells and permits cells to enter an aberrant mitosis. The second is the drug-dependent bypass of the mitotic spindle checkpoint that normally detects aberrant mitosis and blocks mitotic exit until the defect is rectified. The disruption of both checkpoints results in the premature exit of cells from an abortive mitosis followed by apoptosis. This study of histone deacetylase inhibitors demonstrates that drugs targeting cell cycle checkpoints can provide the selectivity and cytotoxicity desired in effective chemotherapeutic agents.	Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia; Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4102, Australia; Peter MacCallum Canc Inst, Melbourne, Vic 3002, Australia	University of Queensland; University of Queensland; Peter Maccallum Cancer Center	Gabrielli, B (corresponding author), Univ Queensland, Ctr Immunol & Canc Res, Canc Biol Program, Brisbane, Qld 4102, Australia.	bgabrielli@cicr.uq.edu.au	Fairlie, David P/F-8865-2014; Waterhouse, Nigel/I-9813-2016; Burgess, Andrew/C-7952-2009; Gabrielli, Brian G/B-3655-2011; Burgess, Andrew/H-3339-2019; Waterhouse, Nigel/B-2498-2012	Fairlie, David P/0000-0002-7856-8566; Burgess, Andrew/0000-0003-4536-9226; Gabrielli, Brian G/0000-0003-3933-1651; Burgess, Andrew/0000-0003-4536-9226; 				Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Becker-Hapak M, 2001, METHODS, V24, P247, DOI 10.1006/meth.2001.1186; Burgess AJ, 2001, MOL PHARMACOL, V60, P828; Butler LM, 2000, CANCER RES, V60, P5165; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Eissenberg JC, 2000, CURR OPIN GENET DEV, V10, P204, DOI 10.1016/S0959-437X(00)00058-7; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Gibbs JB, 2000, SCIENCE, V287, P1969, DOI 10.1126/science.287.5460.1969; He LZ, 2001, J CLIN INVEST, V108, P1321, DOI 10.1172/JCI200111537; Howman EV, 2000, P NATL ACAD SCI USA, V97, P1148, DOI 10.1073/pnas.97.3.1148; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mello JA, 2001, CURR OPIN GENET DEV, V11, P136, DOI 10.1016/S0959-437X(00)00170-2; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Nabha SM, 2002, CLIN CANCER RES, V8, P2735; PIPERNO G, 1987, J CELL BIOL, V104, P289, DOI 10.1083/jcb.104.2.289; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Qiu L, 1999, BRIT J CANCER, V80, P1252, DOI 10.1038/sj.bjc.6690493; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Taddei A, 2001, NAT CELL BIOL, V3, P114, DOI 10.1038/35055010; Taddei A, 1999, J CELL BIOL, V147, P1153, DOI 10.1083/jcb.147.6.1153; Taylor SS, 1997, CELL, V89, P727, DOI 10.1016/S0092-8674(00)80255-X; Van Hooser AA, 1999, FASEB J, V13, pS216, DOI 10.1096/fasebj.13.9002.S216; Wang LG, 1999, CANCER CHEMOTH PHARM, V44, P355, DOI 10.1007/s002800050989; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Wood Kenneth W., 2001, Current Opinion in Pharmacology, V1, P370, DOI 10.1016/S1471-4892(01)00064-9; Wu JS, 2000, TRENDS BIOCHEM SCI, V25, P619, DOI 10.1016/S0968-0004(00)01718-7; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518	33	127	138	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1550	+		10.1096/fj.02-1003fje	http://dx.doi.org/10.1096/fj.02-1003fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824307				2022-12-28	WOS:000183818000041
J	Yegutkin, GG; Samburski, SS; Jalkanen, S				Yegutkin, GG; Samburski, SS; Jalkanen, S			Soluble purine-converting enzymes circulate in human blood and regulate extracellular ATP level via counteracting pyrophosphatase and phosphotransfer reactions	FASEB JOURNAL			English	Article						purine metabolism; human serum; soluble nucleotide kinases; adenosine	VASCULAR ENDOTHELIAL-CELLS; LIVER PLASMA-MEMBRANES; ADENOSINE-DEAMINASE; ECTO-ATPASE; NUCLEOTIDE PYROPHOSPHOHYDROLASE; NUCLEOSIDE DIPHOSPHOKINASE; INORGANIC PYROPHOSPHATE; HUMAN SERUM; METABOLISM; 5'-NUCLEOTIDASE	Extracellular ATP and other purines play a crucial role in the vasculature, and their turnover is selectively governed by a network of ectoenzymes expressed both on endothelial and hematopoietic cells. By studying the whole pattern of purine metabolism in human serum, we revealed the existence of soluble enzymes capable of both inactivating and transphosphorylating circulating purines. Evidence for this was obtained by using independent assays, including chromatographic analyses with H-3-labeled and unlabeled nucleotides and adenosine, direct transfer of gamma-terminal phosphate from [gamma-P-32]ATP to NDP/AMP, and bioluminescent measurement of ATP metabolism. Based on substrate-specificity and competitive studies, we identified three purine-inactivating enzymes in human serum, nucleotide pyrophosphatase (EC 3.6.1.9), 5'-nucleotidase (EC 3.1.3.5), and adenosine deaminase (EC 3.5.4.4), whereas an opposite ATP-generating pathway is represented by adenylate kinase (EC 2.7.4.3) and NDP kinase (EC 2.7.4.6). Comparative kinetic analysis revealed that the V-max values for soluble nucleotide kinases significantly exceed those of counteracting nucleotidases, whereas the apparent K-m values for serum enzymes were fairly comparable and varied within a range of 40-70 mumol/l. Identification of soluble enzymes contributing, along with membrane-bound ectoenzymes, to the active cycling between circulating ATP and other purines provides a novel insight into the regulatory mechanisms of purine homeostasis in the blood.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Univ Turku, Dept Med Microbiol, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, FIN-20520 Turku, Finland	University of Turku; University of Turku; Finland National Institute for Health & Welfare	Yegutkin, GG (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.	gennady.yegutkin@utu.fi	Yegutkin, Gennady G./K-3815-2014	Yegutkin, Gennady G./0000-0001-6684-7982				Airas L, 1997, J CELL BIOL, V136, P421, DOI 10.1083/jcb.136.2.421; Aldrich MB, 2000, BIOCHEM BIOPH RES CO, V272, P311, DOI 10.1006/bbrc.2000.2773; BEUKERS MW, 1993, BIOCHEM PHARMACOL, V46, P1959, DOI 10.1016/0006-2952(93)90637-C; Burnstock G, 2002, CLIN MED, V2, P45, DOI 10.7861/clinmedicine.2-1-45; Buxton ILO, 2001, AM J PHYSIOL-HEART C, V281, pH1657, DOI 10.1152/ajpheart.2001.281.4.H1657; Cardenal A, 1998, J RHEUMATOL, V25, P2175; Cardenal A, 1996, ARTHRITIS RHEUM, V39, P252, DOI 10.1002/art.1780390211; Chan ESL, 2002, ARTHRITIS RES, V4, P266, DOI 10.1186/ar419; COADE SB, 1989, CIRC RES, V65, P531, DOI 10.1161/01.RES.65.3.531; CRACK BE, 1994, BRIT J PHARMACOL, V113, P1432, DOI 10.1111/j.1476-5381.1994.tb17157.x; CRONSTEIN BN, 1994, J APPL PHYSIOL, V76, P5, DOI 10.1152/jappl.1994.76.1.5; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Donaldson SH, 2002, AM J RESP CELL MOL, V26, P209, DOI 10.1165/ajrcmb.26.2.4650; Franco R, 1998, IMMUNOL REV, V161, P27, DOI 10.1111/j.1600-065X.1998.tb01569.x; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Griffith DA, 1996, BBA-REV BIOMEMBRANES, V1286, P153, DOI 10.1016/S0304-4157(96)00008-1; Grobben B, 2000, BRIT J PHARMACOL, V130, P139, DOI 10.1038/sj.bjp.0703289; Kunapuli SP, 1998, BIOCHEM J, V336, P513, DOI 10.1042/bj3360513; Lazarowski ER, 1997, J BIOL CHEM, V272, P20402, DOI 10.1074/jbc.272.33.20402; Marcus AJ, 2001, ARTERIOSCL THROM VAS, V21, P178, DOI 10.1161/01.ATV.21.2.178; MEGHJI P, 1995, BIOCHEM J, V308, P725, DOI 10.1042/bj3080725; Park W, 1996, J RHEUMATOL, V23, P1233; Pinsky DJ, 2002, J CLIN INVEST, V109, P1031, DOI 10.1172/JCI200210649; Ralevic V, 1998, PHARMACOL REV, V50, P413; Resta R, 1998, IMMUNOL REV, V161, P95, DOI 10.1111/j.1600-065X.1998.tb01574.x; ROBSON S, 2000, EMERGING THER TARGET, V4, P155; Rutsch F, 2001, AM J PATHOL, V158, P543, DOI 10.1016/S0002-9440(10)63996-X; SIMMONDS RJ, 1981, J CHROMATOGR, V226, P369, DOI 10.1016/S0378-4347(00)86071-5; Spychala J, 2000, PHARMACOL THERAPEUT, V87, P161, DOI 10.1016/S0163-7258(00)00053-X; SUNDERMAN FW, 1990, ANN CLIN LAB SCI, V20, P123; Terkeltaub RA, 2001, AM J PHYSIOL-CELL PH, V281, pC1, DOI 10.1152/ajpcell.2001.281.1.C1; Todorov LD, 1997, NATURE, V387, P76, DOI 10.1038/387076a0; UNGERER JPJ, 1992, CLIN CHEM, V38, P1322; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Yegutkin GG, 2001, FASEB J, V15, P251, DOI 10.1096/fj.00-0268com; Yegutkin GG, 2002, BIOCHEM J, V367, P121, DOI 10.1042/BJ20020439; Yegutkin GG, 1997, BIOCHEMISTRY-MOSCOW+, V62, P619; Yegutkin GG, 2000, BBA-BIOMEMBRANES, V1466, P234, DOI 10.1016/S0005-2736(00)00165-6; Yegutkin GG, 1998, BBA-BIOMEMBRANES, V1373, P227, DOI 10.1016/S0005-2736(98)00108-4; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309; Zimmermann H, 1999, NAT MED, V5, P987, DOI 10.1038/12419; ZIMMERMANN H, 1992, BIOCHEM J, V285, P345, DOI 10.1042/bj2850345	42	78	79	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1328	+		10.1096/fj.02-1136fje	http://dx.doi.org/10.1096/fj.02-1136fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759341				2022-12-28	WOS:000183165000014
J	Ohtsuka, M; Takano, H; Zou, YZ; Toko, H; Akazawa, H; Qin, YJ; Suzuki, M; Hasegawa, H; Nakaya, H; Komuro, I				Ohtsuka, M; Takano, H; Zou, YZ; Toko, H; Akazawa, H; Qin, YJ; Suzuki, M; Hasegawa, H; Nakaya, H; Komuro, I			Cytokine therapy prevents left ventricular remodeling and dysfunction after myocardial infarction through neovascularization	FASEB JOURNAL			English	Article						apoptosis; bone marrow; G-CSF	STEM-CELLS; HEART; MICE; SURVIVAL; PROGENITOR; REPAIR	Pretreatment with a combination of granulocyte colony-stimulating factor (G-CSF) and stem cell factor (SCF) has been reported to attenuate left ventricular (LV) remodeling after acute myocardial infarction (MI). We here examined whether the cytokine treatment started after MI has also beneficial effects. Anterior MI was created in the recipient mice whose bone marrow had been replaced with that of transgenic mice expressing enhanced green fluorescent protein (GFP). We categorized mice into five groups according to the following treatment: 1) saline; 2) administration of G-CSF and SCF from 5 days before MI through 3 days after; 3) administration of G-CSF and SCF for 5 days after MI; 4) administration of G-CSF alone for 5 days after MI; 5) administration of SCF alone for 5 days after MI. All the three treatment groups with G-CSF showed less LV remodeling and improved cardiac function and survival rate after MI. The number of capillaries, which express GFP, was increased and the number of apoptotic cells was decreased in the border area of all the treatment groups with G-CSF. Even if the cytokine treatment is started after MI, it could prevent LV remodeling and dysfunction after MI-at least in part-through an increase in neovascularization and a decrease in apoptosis in the border area.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Pharmacol, Chuo Ku, Chiba 2608670, Japan	Chiba University; Chiba University	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.	komuro-tky@umin.ac.jp		Akazawa, Hiroshi/0000-0002-3574-9607				CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; Davani S, 2003, CIRCULATION, V108, P253, DOI 10.1161/01.cir.0000089186.09692.fa; Hadjantonakis AK, 2001, HISTOCHEM CELL BIOL, V115, P49, DOI 10.1007/s004180000233; Harada K, 1999, CIRCULATION, V100, P2093, DOI 10.1161/01.CIR.100.20.2093; Kamihata H, 2001, CIRCULATION, V104, P1046, DOI 10.1161/hc3501.093817; Koc ON, 2003, NAT MED, V9, P1109, DOI 10.1038/nm0903-1109; KRAUSE DS, 1994, BLOOD, V84, P691; Krijnen PAJ, 2002, J CLIN PATHOL, V55, P801, DOI 10.1136/jcp.55.11.801; Kupatt C, 2003, FASEB J, V17, P705, DOI 10.1096/fj.02-0673fje; Li YW, 2003, CIRCULATION, V107, P2499, DOI 10.1161/01.CIR.0000065579.19126.B8; Mangi AA, 2003, NAT MED, V9, P1195, DOI 10.1038/nm912; MOLINEUX G, 1991, BLOOD, V78, P961; Orlic D, 2001, P NATL ACAD SCI USA, V98, P10344, DOI 10.1073/pnas.181177898; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; PFEFFER MA, 1990, CIRCULATION, V81, P1161, DOI 10.1161/01.CIR.81.4.1161; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Takimoto E, 2002, FASEB J, V16, DOI 10.1096/fj.01-0735com; Tanaka J, 2002, INT J HEMATOL, V75, P489, DOI 10.1007/BF02982111; To LB, 1997, BLOOD, V89, P2233, DOI 10.1182/blood.V89.7.2233; Toko H, 2002, J BIOL CHEM, V277, P24735, DOI 10.1074/jbc.M107669200; Yoder MC, 1997, IMMUNITY, V7, P335, DOI 10.1016/S1074-7613(00)80355-6	21	157	176	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					851	+		10.1096/fj.03-0637fje	http://dx.doi.org/10.1096/fj.03-0637fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001565				2022-12-28	WOS:000220522800030
J	Riaz, AA; Wang, YS; Schramm, R; Sato, T; Menger, MD; Jeppsson, B; Thorlacius, H				Riaz, AA; Wang, YS; Schramm, R; Sato, T; Menger, MD; Jeppsson, B; Thorlacius, H			Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon	FASEB JOURNAL			English	Article						adhesion; inflammation; microcirculation; P-selectin	CONVERTING ENZYME-INHIBITION; ISCHEMIA-REPERFUSION; P-SELECTIN; ADHESION; RECEPTOR; EXPRESSION; PATHOPHYSIOLOGY; CHEMOATTRACTANT; CHEMOKINES; MESENTERY	The aims of the present study were to determine the effects and mechanisms of angiotensin II (Ang II) on leukocyte-endothelium interactions and the role of Ang II in a novel model of ischemia/reperfusion (I/R) in the mouse colon. Ang II dose-dependently increased leukocyte rolling and adhesion in colonic venules. Importantly, Ang II-induced leukocyte rolling was completely inhibited by immunoneutralization of P-selectin, and leukocyte adhesion was abolished in lymphocyte function antigen-1 (LFA-1)-deficient mice. The P-selectin-dependent rolling was found to be a precondition for the subsequent LFA-1-dependent leukocyte adhesion. Moreover, Ang II-induced leukocyte responses involved generation of reactive oxygen species and up-regulation of CXC chemokines. Notably, CXC chemokines, but not Ang II, stimulated leukocyte chemotaxis in vitro. I/R increased gene expression of angiotensin converting enzyme (ACE) in the colon and plasma concentrations of Ang II. Inhibition of ACE and the type 1 angiotensin (AT(1)) receptor significantly decreased the I/R-induced leukocyte adhesion. Taken together, these novel findings demonstrate that Ang II exerts potent pro-inflammatory effects in the colonic microcirculation and that inhibition of Ang II expression or function protects against I/R-induced leukocyte responses in the colon. Thus, it is suggested that Ang II is a major target to control pathological inflammation in the colon.	Lund Univ, Malmo Univ Hosp, Dept Surg, S-20502 Malmo, Sweden; Univ Saarland, Dept Thorac & Cardiovasc Surg, D-6650 Homburg, Germany; Univ Saarland, Inst Clin & Expt Surg, D-6650 Homburg, Germany	Lund University; Skane University Hospital; Saarland University; Saarland University	Thorlacius, H (corresponding author), Lund Univ, Malmo Univ Hosp, Dept Surg, S-20502 Malmo, Sweden.	henrik.thorlacius@kir.mas.lu.se						Alvarez A, 2001, J LEUKOCYTE BIOL, V70, P199; Anthuber M, 1997, HEPATOLOGY, V25, P648, DOI 10.1002/hep.510250326; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; CARLOS TM, 1994, BLOOD, V84, P2068; Collard CD, 2001, ANESTHESIOLOGY, V94, P1133, DOI 10.1097/00000542-200106000-00030; FARBER HW, 1990, EUR HEART J, V11, P100, DOI 10.1093/eurheartj/11.suppl_B.100; Grafe M, 1997, CIRC RES, V81, P804; GUNTHER S, 1980, CIRC RES, V47, P278, DOI 10.1161/01.RES.47.2.278; HARTMANN M, 1991, CRIT CARE MED, V19, P205, DOI 10.1097/00003246-199102000-00016; HernandezPresa M, 1997, CIRCULATION, V95, P1532; HOUSE SD, 1987, MICROVASC RES, V34, P363, DOI 10.1016/0026-2862(87)90068-9; Kim JA, 1996, BIOCHEM BIOPH RES CO, V226, P862, DOI 10.1006/bbrc.1996.1441; Muller MJ, 1996, FREE RADICAL BIO MED, V21, P189, DOI 10.1016/0891-5849(96)00028-7; OLOFSSON AM, 1994, BLOOD, V84, P2749, DOI 10.1182/blood.V84.8.2749.bloodjournal8482749; Padmanabhan N, 2000, J Renin Angiotensin Aldosterone Syst, V1, P316, DOI 10.3317/jraas.2000.060; Panes J, 1999, BRIT J PHARMACOL, V126, P537, DOI 10.1038/sj.bjp.0702328; Piqueras L, 2000, CIRCULATION, V102, P2118, DOI 10.1161/01.CIR.102.17.2118; Riaz AA, 2002, ANN SURG, V236, P777, DOI 10.1097/00000658-200212000-00010; Riaz AA, 2003, FREE RADICAL BIO MED, V35, P782, DOI 10.1016/S0891-5849(03)00405-2; Riaz AA, 2002, BRIT J SURG, V89, P1572, DOI 10.1046/j.1365-2168.2002.02279.x; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Touyz RM, 1999, HYPERTENSION, V34, P976, DOI 10.1161/01.HYP.34.4.976; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Wan MX, 2002, BRIT J PHARMACOL, V135, P1749, DOI 10.1038/sj.bjp.0704638; Wolf G, 2000, Curr Hypertens Rep, V2, P167, DOI 10.1007/s11906-000-0078-z; Xu Y, 2002, AM J PHYSIOL-HEART C, V282, pH1206, DOI 10.1152/ajpheart.00839.2000; Yilmaz EN, 1999, CARDIOVASC SURG, V7, P539, DOI 10.1016/S0967-2109(99)00009-5; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	29	40	43	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					881	+		10.1096/fj.03-0502fje	http://dx.doi.org/10.1096/fj.03-0502fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001561				2022-12-28	WOS:000220522800026
J	Peirce, SM; Van Gieson, EJ; Skalak, TC				Peirce, SM; Van Gieson, EJ; Skalak, TC			Multicellular simulation predicts microvascular patterning and in silico tissue assembly	FASEB JOURNAL			English	Article						microvascular networks; cellular automata; angiogenic growth factor; hemodynamic stresses	ENDOTHELIAL GROWTH-FACTOR; SMOOTH-MUSCLE-CELLS; TGF-BETA; CAPILLARY GROWTH; BLOOD-FLOW; FACTOR-BB; PROLIFERATION; MIGRATION; ANGIOGENESIS; EXPRESSION	Remodeling of microvascular networks in mammals is critical for physiological adaptations and therapeutic revascularization. Cellular behaviors such as proliferation, differentiation, and migration are coordinated in these remodeling events via combinations of biochemical and biomechanical signals. We developed a cellular automata (CA) computational simulation that integrates epigenetic stimuli, molecular signals, and cellular behaviors to predict microvascular network patterning events. Over 50 rules obtained from published experimental data govern independent behaviors (including proliferation, differentiation, and migration) of thousands of interacting cells and diffusible growth factors in their tissue environment. From initial network patterns of in vivo blood vessel networks, the model predicts emergent patterning responses to two stimuli: 1) network-wide changes in hemodynamic mechanical stresses, and 2) exogenous focal delivery of an angiogenic growth factor. The CA model predicts comparable increases in vascular density (370 +/- 29 mm/mm(3)) 14 days after treatment with exogenous growth factor to that in vivo (480 +/- 41 mm/mm(3)) and approximately a twofold increase in contractile vessel lengths 5-10 days after 10% increase in circumferential wall strain, consistent with in vivo results. The CA simulation was thus able to identify a functional patterning module capable of quantitatively predicting vessel network remodeling in response to two important epigenetic stimuli.	Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA	University of Virginia	Skalak, TC (corresponding author), Univ Virginia, Dept Biomed Engn, Box 800759 Hlth Syst, Charlottesville, VA 22908 USA.	tskalak@virginia.edu		Peirce, Shayn/0000-0001-5857-5606				Borrelli V, 2001, J SURG RES, V100, P154, DOI 10.1006/jsre.2001.6231; BUCHANAN RA, 1990, MICROCIRC ENDOTH LYM, V6, P159; Carmeliet P, 2001, NAT MED, V7, P575, DOI 10.1038/87904; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; Chaplain MAJ, 1996, INVAS METAST, V16, P222; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; Crank J., 1979, MATH DIFFUSION; Crosby JR, 1998, NAT GENET, V18, P385, DOI 10.1038/ng0498-385; Dowd CJ, 1999, J BIOL CHEM, V274, P5236, DOI 10.1074/jbc.274.8.5236; Ellis I, 1997, DEVELOPMENT, V124, P1593; ENGERMAN RL, 1967, LAB INVEST, V17, P738; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fritsch C, 1997, GASTROENTEROLOGY, V112, P826, DOI 10.1053/gast.1997.v112.pm9041244; Goligorsky MS, 1999, AM J PHYSIOL-CELL PH, V276, pC1271, DOI 10.1152/ajpcell.1999.276.6.C1271; Grainger DJ, 1998, J CELL SCI, V111, P2977; Haase HR, 1998, J CELL PHYSIOL, V174, P353, DOI 10.1002/(SICI)1097-4652(199803)174:3<353::AID-JCP9>3.0.CO;2-N; Hautmann MB, 1997, J BIOL CHEM, V272, P10948; Higuchi K, 2000, ARCH HISTOL CYTOL, V63, P115, DOI 10.1679/aohc.63.115; Hirschi KK, 1996, CARDIOVASC RES, V32, P687, DOI 10.1016/S0008-6363(96)00063-6; Hirschi KK, 1999, CIRC RES, V84, P298, DOI 10.1161/01.RES.84.3.298; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; HUDLICKA O, 1990, PFLUG ARCH EUR J PHY, V417, P67, DOI 10.1007/BF00370770; King-Briggs KE, 2000, DIFFERENTIATION, V66, P43, DOI 10.1046/j.1432-0436.2000.066001043.x; Koransky ML, 2002, TRENDS CARDIOVAS MED, V12, P108, DOI 10.1016/S1050-1738(01)00158-X; Krogh A, 1919, J PHYSIOL-LONDON, V52, P409, DOI 10.1113/jphysiol.1919.sp001839; Lemstrom KB, 1997, CIRCULATION, V96, P1240, DOI 10.1161/01.CIR.96.4.1240; Lindahl P, 1998, CURR OPIN LIPIDOL, V9, P407, DOI 10.1097/00041433-199810000-00004; Ma G, 2000, HYPERTENSION, V35, P948, DOI 10.1161/01.HYP.35.4.948; Maheshwari G, 1999, BIOPHYS J, V76, P2814, DOI 10.1016/S0006-3495(99)77435-7; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; MEINHARDT H, 1980, J THEOR BIOL, V85, P429, DOI 10.1016/0022-5193(80)90318-5; Melkonian G, 2000, TOXICOL APPL PHARM, V163, P26, DOI 10.1006/taap.1999.8789; MII S, 1993, SURGERY, V114, P464; Morishita R, 1998, BIOCHEM BIOPH RES CO, V243, P361, DOI 10.1006/bbrc.1997.8012; Nelson PR, 1997, J VASC SURG, V26, P104, DOI 10.1016/S0741-5214(97)70153-8; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319, DOI 10.1161/01.HYP.36.3.319; Peirce SM, 2004, AM J PHYSIOL-HEART C, V286, pH918, DOI 10.1152/ajpheart.00833.2003; Price RJ, 1998, MICROVASC RES, V55, P138, DOI 10.1006/mvre.1997.2062; PRICE RJ, 1994, MICROVASC RES, V47, P188, DOI 10.1006/mvre.1994.1015; Pries AR, 2001, AM J PHYSIOL-HEART C, V281, pH1015, DOI 10.1152/ajpheart.2001.281.3.H1015; RHODIN JAG, 1989, J SUBMICR CYTOL PATH, V21, P1; ROAT MI, 1993, AM J OPHTHALMOL, V116, P456, DOI 10.1016/S0002-9394(14)71404-7; Rubin C, 2001, NATURE, V412, P603, DOI 10.1038/35088122; SHOLLEY MM, 1977, AM J PATHOL, V89, P277; Skalak Thomas C., 1996, Microcirculation (Philadelphia), V3, P143, DOI 10.3109/10739689609148284; Smith JD, 2001, ENDOTHELIUM-J ENDOTH, V8, P41, DOI 10.3109/10623320109063156; Spalteholz W., 1888, ABH SACHS GES WISS M, V14, P509; STOKES CL, 1991, J CELL SCI, V99, P419; TANNENBAUM JE, 1995, PEDIATR RES, V37, P561, DOI 10.1203/00006450-199505000-00001; TANNOCK IF, 1972, CANCER RES, V32, P77; Unthank JL, 1996, CIRC RES, V79, P1015, DOI 10.1161/01.RES.79.5.1015; Van Gieson EJ, 2003, CIRC RES, V92, P929, DOI 10.1161/01.RES.0000068377.01063.79; von Dassow G, 2000, NATURE, V406, P188, DOI 10.1038/35018085; Yu PK, 1997, EXP EYE RES, V65, P379, DOI 10.1006/exer.1997.0340; Zeller PJ, 2001, AM J PHYSIOL-HEART C, V280, pH2116, DOI 10.1152/ajpheart.2001.280.5.H2116	59	109	111	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					731	+		10.1096/fj.03-0933fje	http://dx.doi.org/10.1096/fj.03-0933fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766791				2022-12-28	WOS:000220425000029
J	Seegers, HC; Avery, PS; McWilliams, DF; Haywood, L; Walsh, DA				Seegers, HC; Avery, PS; McWilliams, DF; Haywood, L; Walsh, DA			Combined effect of bradykinin B-2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis.	FASEB JOURNAL			English	Article						angiogenesis; neurogenic inflammation; bradykinin; substance P	GENE-RELATED PEPTIDE; RAT KNEE-JOINT; SUBSTANCE-P; NEUROGENIC INFLAMMATION; PLASMA EXTRAVASATION; RHEUMATOID-ARTHRITIS; UP-REGULATION; ANGIOGENESIS; INVOLVEMENT; MECHANISMS	During acute synovitis, early angiogenesis may enhance inflammation by facilitating edema formation and cellular infiltration. We have investigated the in vivo modulation by bradykinin of neurally enhanced early angiogenesis in rat models of knee synovitis. The increased endothelial cell proliferation that was observed 24 h after intra-articular injection of substance P (10 nmols) was completely blocked by either NK1 or B-2 receptor antagonists (SR140333 or FR172357, respectively). In mild synovitis induced by 0.03% Carrageenan, but not in naive animals, injection of bradykinin (100 nmols) increased endothelial cell proliferation. In moderate synovitis induced by 3% kaolin and 3% carrageenan, the combined blockade of both NK1 and B-2 receptors inhibited 64% of the synovitis-enhanced endothelial cell proliferation. Synovitis-enhanced endothelial cell proliferation was also inhibited by the B-2 receptor antagonist alone (27%) but not by the NK1 receptor antagonist alone. B-1 receptor agonist (des-Arg(9)-bradykinin) and antagonist (SR240612A) did not significantly modulate endothelial cell proliferation. B-2 receptor mRNA was constitutively expressed in both mild and moderate inflammation, whereas B-1 mRNA production was induced in the moderate inflammation model. These findings demonstrate that substance P and bradykinin can act on NK1 and B-2 receptors, respectively, to promote endothelial cell proliferation in acute synovitis.	Univ Nottingham, City Hosp, Nottingham NG5 1PB, England	Nottingham University Hospital NHS Trust; Nottingham City Hospital; University of Nottingham	Seegers, HC (corresponding author), Univ Nottingham, City Hosp, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.	helene.seegers@univ-angers.fr	McWilliams, Daniel F/E-4285-2010	McWilliams, Daniel F/0000-0002-0581-1895; Walsh, David/0000-0002-6316-5692				Baluk P, 1997, AM J PHYSIOL-LUNG C, V273, pL565, DOI 10.1152/ajplung.1997.273.3.L565; CAMBRIDGE H, 1995, BRIT J PHARMACOL, V115, P641, DOI 10.1111/j.1476-5381.1995.tb14980.x; CRUWYS SC, 1992, BRIT J PHARMACOL, V107, P116, DOI 10.1111/j.1476-5381.1992.tb14472.x; Davis AJ, 1996, BRIT J PHARMACOL, V118, P2206, DOI 10.1111/j.1476-5381.1996.tb15664.x; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Fedrowitz M, 2002, CANCER RES, V62, P1356; GARRETT NE, 1992, ANN RHEUM DIS, V51, P1014, DOI 10.1136/ard.51.8.1014; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; LAM FY, 1991, BRIT J PHARMACOL, V103, P1263, DOI 10.1111/j.1476-5381.1991.tb12334.x; MALE D, 1995, IMMUNOLOGY, V84, P453; MAPP PI, 1990, NEUROSCIENCE, V37, P143, DOI 10.1016/0306-4522(90)90199-E; Parenti A, 2001, FASEB J, V15, P1487, DOI 10.1096/fj.00-0503fje; Regoli D, 1998, EUR J PHARMACOL, V348, P1, DOI 10.1016/S0014-2999(98)00165-4; Richardson JD, 2002, J PHARMACOL EXP THER, V302, P839, DOI 10.1124/jpet.102.032797; SANNA PP, 1992, BIOTECH HISTOCHEM, V67, P346, DOI 10.3109/10520299209110047; Seegers HC, 2003, J PHARMACOL EXP THER, V306, P8, DOI 10.1124/jpet.103.050013; SLUKA KA, 1993, PAIN, V55, P367, DOI 10.1016/0304-3959(93)90013-F; Thuringer D, 2002, J BIOL CHEM, V277, P2028, DOI 10.1074/jbc.M109493200; Walsh D A, 2001, Curr Opin Investig Drugs, V2, P1054; Walsh DA, 1998, LAB INVEST, V78, P1513; WALSH DA, 1993, J PHARMACOL EXP THER, V267, P951; Walsh DA, 1998, AM J PATHOL, V152, P691; WALSH DA, 1992, INT J TISSUE REACT, V14, P101; WASEEM NH, 1990, J CELL SCI, V96, P121; Weber AJ, 2000, JOINT BONE SPINE, V67, P366; Yang CM, 2003, J BIOMED SCI, V10, P208, DOI 10.1159/000068713; Yang DL, 2002, ASIAN SURV, V42, P14, DOI 10.1525/as.2002.42.1.14; ZICHE M, 1991, LIFE SCI, V48, P7	28	25	29	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					762	+		10.1096/fj.03-0727fje	http://dx.doi.org/10.1096/fj.03-0727fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766794				2022-12-28	WOS:000220425000031
J	Schwab, JM; Beiter, T; Linder, JU; Laufer, S; Schulz, JE; Meyermann, R; Schluesener, HJ				Schwab, JM; Beiter, T; Linder, JU; Laufer, S; Schulz, JE; Meyermann, R; Schluesener, HJ			COX-3 - a virtual pain target in humans?	FASEB JOURNAL			English	Editorial Material									Univ Tubingen, Inst Brain Res, Sch Med, D-72076 Tubingen, Germany; Univ Tubingen, Inst Pharm, D-72064 Tubingen, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital	Schwab, JM (corresponding author), Univ Tubingen, Inst Brain Res, Sch Med, Calwer Str 3, D-72076 Tubingen, Germany.	jmschwab@med.uni-tuebingen.de		Schwab, Jan/0000-0001-6784-4919; Beiter, Thomas/0000-0001-7299-7303; Laufer, Stefan/0000-0001-6952-1486				Bazan NG, 2002, NATURE, V420, P135, DOI 10.1038/420135a; Botting RM, 2000, CLIN INFECT DIS, V31, pS202, DOI 10.1086/317520; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; Senior K, 2002, LANCET NEUROL, V1, P399, DOI 10.1016/S1474-4422(02)00207-7; Smith A, 2002, NAT REV DRUG DISCOV, V1, P839, DOI 10.1038/nrd951; Ulrich HD, 2002, EUKARYOT CELL, V1, P1, DOI 10.1128/EC.1.1.1-10.2002; Warner TD, 2002, P NATL ACAD SCI USA, V99, P13371, DOI 10.1073/pnas.222543099	7	39	40	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2174	2175		10.1096/fj.03-0595lte	http://dx.doi.org/10.1096/fj.03-0595lte			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656977				2022-12-28	WOS:000188067500036
J	Sung, S; Yao, YM; Uryu, K; Yang, HX; Lee, VMY; Trojanowski, JQ; Pratico, D				Sung, S; Yao, YM; Uryu, K; Yang, HX; Lee, VMY; Trojanowski, JQ; Pratico, D			Early Vitamin E supplementation in young but not aged mice reduces A beta levels and amyloid deposition in a transgenic model of Alzheimer's disease	FASEB JOURNAL			English	Article						oxidative stress; transgenic mouse models; amyloid beta; anti-oxidants	LIPID-PEROXIDATION; OXIDATIVE STRESS; IN-VIVO; INCREASED 8,12-ISO-IPF(2-ALPHA)-VI; COGNITIVE IMPAIRMENT; DOWNS-SYNDROME; MOUSE MODEL; DAMAGE	Increased brain oxidative stress is a key feature of Alzheimer's disease (AD) and manifests predominantly as lipid peroxidation. However, clinical evidence that antioxidants can affect the clinical course of the disease is limited. In the present study, we investigated the effect of the antioxidant Vitamin E on the AD-like phenotype when given to a transgenic mouse model (Tg2576) of the disease before or after the amyloid plaques are deposited. One group of Tg2576 received Vitamin E starting at 5 months of age until they were 13 months old, the second group started at 14 months of age until they were 20 months old. Brain levels of 8,12-iso-iPF(2alpha)-VI, a specific marker of lipid peroxidation, were significantly reduced in both groups of mice receiving Vitamin E compared with placebo. Tg2576 administered with Vitamin E at a younger age showed a significant reduction in Abeta levels and amyloid deposition. By contrast, mice receiving the diet supplemented with Vitamin E at a later age did not show any significant difference in either marker when compared with placebo. These results support the hypothesis that oxidative stress is an important early event in AD pathogenesis, and antioxidant therapy may be beneficial only if given at this stage of the disease process.	Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Inst Aging, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania	Pratico, D (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Ctr Expt Therapeut, BRB 2-3,Room 812,421 Curie Blvd, Philadelphia, PA 19104 USA.	domenico@spirit.gcrc.upenn.edu	Pratico, Domenico/ABA-9590-2020					Cyrus T, 2001, CIRCULATION, V104, P1940, DOI 10.1161/hc4101.097114; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Lim GP, 2001, J NEUROSCI, V21, P8370, DOI 10.1523/JNEUROSCI.21-21-08370.2001; Markesbery WR, 1999, ARCH NEUROL-CHICAGO, V56, P1449, DOI 10.1001/archneur.56.12.1449; Nunomura A, 2001, J NEUROPATH EXP NEUR, V60, P759, DOI 10.1093/jnen/60.8.759; Odetti P, 1998, BIOCHEM BIOPH RES CO, V243, P849, DOI 10.1006/bbrc.1998.8186; Pappolla MA, 1998, AM J PATHOL, V152, P871; Parks E, 2000, ANTIOXID REDOX SIGN, V2, P405, DOI 10.1089/15230860050192189; Pratico D, 2000, AM J MED, V109, P577, DOI 10.1016/S0002-9343(00)00547-7; Pratico D, 2000, ANN NEUROL, V48, P795, DOI 10.1002/1531-8249(200011)48:5<795::AID-ANA15>3.0.CO;2-#; Pratico D, 2001, Ital Heart J, V2, P878; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 2001, J NEUROSCI, V21, P4183, DOI 10.1523/JNEUROSCI.21-12-04183.2001; Pratico D, 2002, BIOCHEM PHARMACOL, V63, P563, DOI 10.1016/S0006-2952(01)00919-4; Pratico D, 2002, ARCH NEUROL-CHICAGO, V59, P972, DOI 10.1001/archneur.59.6.972; Pratico D, 1998, NAT MED, V4, P1189, DOI 10.1038/2685; Pratico D, 2000, ANN NEUROL, V48, P809, DOI 10.1002/1531-8249(200011)48:5<809::AID-ANA19>3.0.CO;2-9; PRATICO D, 2002, FASEB J, DOI DOI 10.1096/FJ02-0012FJE; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Smith MA, 1998, J NEUROCHEM, V70, P2212, DOI 10.1046/j.1471-4159.1998.70052212.x; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002	22	243	257	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					323	+		10.1096/fj.03-0961fje	http://dx.doi.org/10.1096/fj.03-0961fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656990				2022-12-28	WOS:000188067500021
J	Seeliger, S; Derian, CK; Vergnolle, N; Bunnett, NW; Nawroth, R; Schmelz, M; von der Weid, PY; Buddenkotte, J; Sunderkotter, C; Metze, D; Andrade-Gordon, P; Harms, E; Vestweber, D; Luger, TA; Steinhoff, M				Seeliger, S; Derian, CK; Vergnolle, N; Bunnett, NW; Nawroth, R; Schmelz, M; von der Weid, PY; Buddenkotte, J; Sunderkotter, C; Metze, D; Andrade-Gordon, P; Harms, E; Vestweber, D; Luger, TA; Steinhoff, M			Proinflammatory role of proteinase-activated receptor-2 in humans and mice during cutaneous inflammation in vivo	FASEB JOURNAL			English	Article						proteinase-activated receptors; G-protein-coupled receptors; immune response; knockout mouse; skin	MAST-CELL TRYPTASE; TUMOR-NECROSIS-FACTOR; P-SELECTIN; HUMAN-SKIN; NITRIC-OXIDE; SUBSTANCE-P; RECEPTOR-2-ACTIVATING PEPTIDES; VASCULAR-PERMEABILITY; CONTACT SENSITIVITY; ENDOTHELIAL-CELLS	Proteinase-activated receptor-2 belongs to a new subfamily of G-protein-coupled receptors. Its precise role during inflammation and the underlying mechanisms is still unclear. Our study establishes that PAR-2 plays a direct proinflammatory role during cutaneous inflammation in mice and humans in vivo. In a model of experimentally induced allergic (ACD) and toxic (ICD) contact dermatitis (CD) we show that ear swelling responses, plasma extravasation, and leucocyte adherence were significantly attenuated in PAR-2 null mutant (PAR-2(-/-)) mice compared with wild-type (PAR-2(+/+)) mice, especially at early stages. The proinflammatory effects by PAR-2 activation were significantly diminished using nitric oxide-synthase inhibitors, while NF-kappaB and neuropeptides appear to play a minor role in these mechanisms. PAR-2-mediated upregulation of E-selectin and cell adhesion molecule ICAM-1; enhanced plasma extravasation was observed in humans and mice and of interleukin-6 in mice in vivo. Thus, PAR-2 may be a beneficial therapeutic target for the treatment of inflammatory skin diseases.	Univ Munster, Dept Dermatol, D-48129 Munster, Germany; Univ Munster, Dept Pediat, D-48129 Munster, Germany; Univ Munster, Inst Expt Dermatol, D-48129 Munster, Germany; Johnson & Johnson Pharmaceut Res & Dev, Spring House, PA USA; Univ Calgary, Dept Pharmacol, Calgary, AB T2N 1N4, Canada; Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA USA; Univ Munster, ZMBE, Dept Cell Biol, D-4400 Munster, Germany; Univ Erlangen Nurnberg, Dept Physiol, Erlangen, Germany; Univ Calgary, Dept Physiol, Calgary, AB T2N 1N4, Canada	University of Munster; University of Munster; University of Munster; Johnson & Johnson; Johnson & Johnson USA; University of Calgary; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Munster; University of Erlangen Nuremberg; University of Calgary	Steinhoff, M (corresponding author), Univ Munster, Dept Dermatol, von Esmarch Str 58, D-48129 Munster, Germany.	msteinho@uni-muenster.de	Steinhoff, Martin/F-6312-2013; Vergnolle, Nathalie/C-7677-2018; Schmelz, Martin/A-9327-2013	Vergnolle, Nathalie/0000-0003-1825-6015; Schmelz, Martin/0000-0002-9736-7241; Bunnett, Nigel W./0000-0003-3367-0644; Vestweber, Dietmar/0000-0002-3517-732X; Sunderkotter, Cord/0000-0002-2929-145X; Steinhoff, Martin/0000-0002-7090-2187	NIDDK NIH HHS [DK43207] Funding Source: Medline; PHS HHS [57840] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043207, R56DK043207] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193, DOI 10.1152/ajplung.2000.278.1.L193; Alm AK, 2000, BIOCHEM BIOPH RES CO, V275, P77, DOI 10.1006/bbrc.2000.3267; BAATZ H, 1995, INT J MICROCIRC, V15, P85, DOI 10.1159/000178955; Benitez-Bribiesca L, 2001, J HISTOCHEM CYTOCHEM, V49, P1061, DOI 10.1177/002215540104900816; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; BOGGEMEYER E, 1994, CELL ADHES COMMUN, V2, P145, DOI 10.3109/15419069409004433; Brain SD, 2000, NAT MED, V6, P134, DOI 10.1038/72218; Brattsand M, 1999, J BIOL CHEM, V274, P30033, DOI 10.1074/jbc.274.42.30033; Cairns JA, 1996, J IMMUNOL, V156, P275; Camerer E, 2000, P NATL ACAD SCI USA, V97, P5255, DOI 10.1073/pnas.97.10.5255; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2002, CAN J PHYSIOL PHARM, V80, P987, DOI 10.1139/Y02-125; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Corvera CU, 1997, J CLIN INVEST, V100, P1383, DOI 10.1172/JCI119658; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coussens LM, 1999, GENE DEV, V13, P1382, DOI 10.1101/gad.13.11.1382; de Garavilla L, 2001, BRIT J PHARMACOL, V133, P975, DOI 10.1038/sj.bjp.0704152; DERY O, 1998, AM J PHYSIOL, V274, pG1429; Emilsson K, 1997, J VASC RES, V34, P267, DOI 10.1159/000159233; ENK AH, 1995, J INVEST DERMATOL, V105, pS80, DOI 10.1111/1523-1747.ep12316112; Ferrell WR, 2003, J CLIN INVEST, V111, P35, DOI 10.1172/JCI200316913; Fiorucci S, 2001, P NATL ACAD SCI USA, V98, P13936, DOI 10.1073/pnas.241377298; FRAKI JE, 1977, ACTA DERM-VENEREOL, V57, P393; Grabbe S, 1996, J IMMUNOL, V156, P473; Hamilton JR, 2001, J CARDIOVASC PHARM, V38, P108, DOI 10.1097/00005344-200107000-00012; Harari OA, 1999, J IMMUNOL, V163, P6860; He SH, 1997, EUR J PHARMACOL, V328, P89, DOI 10.1016/S0014-2999(97)83033-6; Hickey MJ, 1999, J IMMUNOL, V162, P1137; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Howells GL, 1997, J CELL SCI, V110, P881; Kanke T, 2001, J BIOL CHEM, V276, P31657, DOI 10.1074/jbc.M100377200; Kawabata A, 2002, LIFE SCI, V71, P2435, DOI 10.1016/S0024-3205(02)02044-1; Kawabata A, 2002, NEUROSCI LETT, V329, P349, DOI 10.1016/S0304-3940(02)00702-4; Kawabata A, 2001, J CLIN INVEST, V107, P1443, DOI 10.1172/JCI10806; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kawagoe J, 2002, JPN J PHARMACOL, V88, P77, DOI 10.1254/jjp.88.77; Klimuk SK, 2000, J PHARMACOL EXP THER, V292, P480; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797, DOI 10.1067/mai.2001.119025; Kong WY, 1997, P NATL ACAD SCI USA, V94, P8884, DOI 10.1073/pnas.94.16.8884; Koshikawa N, 1997, FEBS LETT, V409, P442, DOI 10.1016/S0014-5793(97)00565-6; Krishna MT, 2001, J ALLERGY CLIN IMMUN, V107, P1039, DOI 10.1067/mai.2001.115631; KRUEGER GG, 1989, J INVEST DERMATOL, V92, pS32; Langer F, 1999, BRIT J HAEMATOL, V105, P542; Lawrence T, 2001, NAT MED, V7, P1291, DOI 10.1038/nm1201-1291; Liden C, 2001, CONTACT DERMATITIS, V44, P65, DOI 10.1034/j.1600-0536.2001.440201.x; Lindner JR, 2000, J IMMUNOL, V165, P6504, DOI 10.4049/jimmunol.165.11.6504; Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Michel JB, 1996, J CARDIOVASC PHARM, V28, P142, DOI 10.1097/00005344-199607000-00021; Molino M, 1997, J BIOL CHEM, V272, P4043, DOI 10.1074/jbc.272.7.4043; NOLTE D, 1994, AM J PHYSIOL-HEART C, V267, pH1637, DOI 10.1152/ajpheart.1994.267.4.H1637; Nystedt S, 1996, J BIOL CHEM, V271, P14910, DOI 10.1074/jbc.271.25.14910; PETERSEN LJ, 1994, J ALLERGY CLIN IMMUN, V94, P773, DOI 10.1016/0091-6749(94)90186-4; Quinlan KL, 1998, AM J PHYSIOL-CELL PH, V275, pC1580, DOI 10.1152/ajpcell.1998.275.6.C1580; Ribatti D, 2000, INT J CANCER, V85, P171, DOI 10.1002/(SICI)1097-0215(20000115)85:2<171::AID-IJC4>3.0.CO;2-W; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672, DOI 10.1164/ajrccm.161.5.9907133; Sahin S, 2001, ARCH DERMATOL RES, V293, P214, DOI 10.1007/s004030100207; Saifeddine M, 1998, BRIT J PHARMACOL, V125, P1445, DOI 10.1038/sj.bjp.0702213; Sayers TJ, 1996, J LEUKOCYTE BIOL, V59, P763, DOI 10.1002/jlb.59.5.763; Schmelz M, 1999, CLIN EXP ALLERGY, V29, P695; Schmidlin F, 2001, AM J RESP CRIT CARE, V164, P1276, DOI 10.1164/ajrccm.164.7.2101157; Scholzen TE, 2001, J IMMUNOL, V166, P1285, DOI 10.4049/jimmunol.166.2.1285; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Steinhoff M, 1999, EXP DERMATOL, V8, P282; Steinhoff M, 2000, NAT MED, V6, P151, DOI 10.1038/72247; Sun G, 2001, J IMMUNOL, V167, P1014, DOI 10.4049/jimmunol.167.2.1014; Vergnolle N, 1999, J IMMUNOL, V163, P5064; Vergnolle N, 1999, BRIT J PHARMACOL, V126, P1262, DOI 10.1038/sj.bjp.0702408; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vila L, 2001, ALLERGY, V56, P568, DOI 10.1034/j.1398-9995.2001.056006568.x; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; von Stebut E, 2000, EUR J IMMUNOL, V30, P3498, DOI 10.1002/1521-4141(2000012)30:12&lt;3498::AID-IMMU3498&gt;3.0.CO;2-6; Wallengren J, 2001, ARCH DERMATOL RES, V293, P121, DOI 10.1007/s004030000198; Weidner C, 2000, J INVEST DERMATOL, V115, P1015, DOI 10.1046/j.1523-1747.2000.00142.x	82	105	117	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1871	1885		10.1096/fj.02-1112com	http://dx.doi.org/10.1096/fj.02-1112com			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519665				2022-12-28	WOS:000186343300040
J	Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH				Yogev-Falach, M; Amit, T; Bar-Am, O; Youdim, MBH			The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing	FASEB JOURNAL			English	Article						mitogen-activated protein kinase; Alzheimer's disease	CLOSED-HEAD INJURY; MAO-B INHIBITOR; ENDOGENOUS NEUROTOXIN; BETA-PROTEIN; ALZHEIMERS-DISEASE; CHOLINESTERASE; APOPTOSIS; N-METHYL(R)SALSOLINOL; RIVASTIGMINE; PEPTIDE	Rasagiline [N-propargyl-(1R)-aminoindan] a highly potent selective irreversible monoamine oxidase (MAO)-B inhibitor exerts neuroprotective and antiapoptotic effects against a variety of insults in cell cultures and in vivo and has finished its phase III clinical trials for Parkinson's disease. In the present study, we show that rasagiline (1 and 10 muM) significantly protected rat PC12 cells against beta-amyloid (Abeta(1-42)) toxicity. In addition, rasagiline significantly increased (approximately threefold) the secretion of the nonamyloidogenic soluble form of the amyloid precursor protein (sAPPalpha) from SH-SY5Y neuroblastoma and PC12 cells. The increase of sAPPa. was dose-dependent and was blocked by the hydroxamic acid-based metalloprotease inhibitor Ro31-9790 (100 muM), suggesting that the effect is mediated via alpha-secretase activity. Rasagiline-induced sAPPa. release was significantly reduced by the inhibitors of protein kinase C (PKC), GF109203X, and ERK mitogen-activated protein kinase (MAPK) PD98059. Moreover, rasagiline dose dependently (0.1-10 muM) increased the phosphorylation of p44 and p42 MAPK, which was abolished by PD98059 (30 muM) and GF109203X (2.5 muM). By comparing the actions of rasagiline with those of its S-isomer TVP1022, which is not an MAO inhibitor, we have been able to demonstrate that MAO-B inhibition is not a prerequisite for either sAPPalpha-induced release or ERK phosphorylation. In addition, structure-activity relationship among rasagiline-related compounds suggests the crucial role of the propargyl moiety in these molecules, because propargylamine itself significantly induced the secretion of sAPPa. and increased MAPK phosphorylation with similar potency to that of rasagiline and its derivatives.	Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Fac Med, Dept Pharmacol, NPF Ctr Neurodegenerat Dis, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Youdim, MBH (corresponding author), Technion Israel Inst Technol, Fac Med, Dept Pharmacol, Eve Topf Ctr Neurodegenerat Dis, POB 9697, IL-31096 Haifa, Israel.	Youdim@tx.technion.ac.il						Akao Y, 2002, J NEUROCHEM, V82, P913, DOI 10.1046/j.1471-4159.2002.01047.x; Akao Y, 2002, NEUROSCI LETT, V326, P105, DOI 10.1016/S0304-3940(02)00332-4; Akao Y, 1999, NEUROSCI LETT, V267, P153, DOI 10.1016/S0304-3940(99)00361-4; Bejar C, 1999, EUR J PHARMACOL, V383, P231, DOI 10.1016/S0014-2999(99)00643-3; Cardoso SM, 2002, BRAIN RES, V931, P117, DOI 10.1016/S0006-8993(02)02256-4; CHECLER F, 1995, J NEUROCHEM, V65, P1431; Chen Y, 1998, J NEUROTRAUM, V15, P231, DOI 10.1089/neu.1998.15.231; Desai A, 2001, Expert Opin Pharmacother, V2, P653, DOI 10.1517/14656566.2.4.653; Finberg J P, 1999, Adv Neurol, V80, P495; Grant SM, 1999, NEUROREPORT, V10, P41, DOI 10.1097/00001756-199901180-00008; Huang W, 1999, EUR J PHARMACOL, V366, P127, DOI 10.1016/S0014-2999(98)00929-7; HUNG AY, 1993, J BIOL CHEM, V268, P22959; Jang JH, 2003, FREE RADICAL BIO MED, V34, P1100, DOI 10.1016/S0891-5849(03)00062-5; KIEBURTZ K, 2001, PARK RELAT DISORD S, V60; Kim K., 1988, NEUROSCI RES COMMUN, V2, P121; Lamb HM, 2001, PHARMACOECONOMICS, V19, P303, DOI 10.2165/00019053-200119030-00008; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Maruyama W, 2002, J NEURAL TRANSM, V109, P467, DOI 10.1007/s007020200038; Maruyama W, 2001, ANN NY ACAD SCI, V939, P320; Maruyama W, 2000, ADV RES NEURODEGENER, V8, P171; Maruyama W, 2001, J NEURAL TRANSM, V108, P11, DOI 10.1007/s007020170093; Maruyama W, 2001, J NEUROCHEM, V78, P727, DOI 10.1046/j.1471-4159.2001.00448.x; MARUYAMA W, 2000, ANN NY ACAD SCI, V939, P320; MATTSON MP, 1993, NEURON, V10, P243, DOI 10.1016/0896-6273(93)90315-I; Mills J, 1999, J NEUROCHEM, V72, P443, DOI 10.1046/j.1471-4159.1999.0720443.x; Moreira PI, 2002, J NEUROSCI RES, V69, P257, DOI 10.1002/jnr.10282; Nunan J, 2000, FEBS LETT, V483, P6, DOI 10.1016/S0014-5793(00)02076-7; Pereira C, 1998, NEUROREPORT, V9, P1749, DOI 10.1097/00001756-199806010-00015; Rabey JM, 2000, CLIN NEUROPHARMACOL, V23, P324, DOI 10.1097/00002826-200011000-00005; Savage MJ, 1998, J NEUROSCI, V18, P1743; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Speiser Z, 1999, J NEURAL TRANSM, V106, P593, DOI 10.1007/s007020050182; Tatton WG, 2002, J PHARMACOL EXP THER, V301, P753, DOI 10.1124/jpet.301.2.753; Weinstock M, 1999, CNS DRUGS, V12, P307, DOI 10.2165/00023210-199912040-00005; Weinstock M, 2000, DRUG DEVELOP RES, V50, P216, DOI 10.1002/1098-2299(200007/08)50:3/4<216::AID-DDR4>3.3.CO;2-Q; WEINSTOCK M, 2000, J NEURAL TRANSM-SUPP, V60, pS157; Xu X, 1999, P NATL ACAD SCI USA, V96, P7547, DOI 10.1073/pnas.96.13.7547; Yogev-Falach M, 2002, FASEB J, V16, P1674, DOI 10.1096/fj.02-0198fje; Youdim M B, 1991, J Neural Transm Suppl, V34, P61; Youdim MBH, 2002, MECH AGEING DEV, V123, P1081, DOI 10.1016/S0047-6374(01)00391-8; Youdim MBH, 2001, CELL MOL NEUROBIOL, V21, P555, DOI 10.1023/A:1015131516649; Youdim MBH, 2001, BRIT J PHARMACOL, V132, P500, DOI 10.1038/sj.bjp.0703826; Youdim MBH, 2001, ANN NY ACAD SCI, V939, P450; YOUDIM MBH, 2003, IN PRESS BIOCH PHARM	44	107	122	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2325	+		10.1096/fj.03-0078fje	http://dx.doi.org/10.1096/fj.03-0078fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525944				2022-12-28	WOS:000186343300004
J	Zhang, WD; Mojsilovic-Petrovic, J; Andrade, MF; Zhang, H; Ball, M; Stanimirovic, DB				Zhang, WD; Mojsilovic-Petrovic, J; Andrade, MF; Zhang, H; Ball, M; Stanimirovic, DB			Expression and functional characterization of ABCG2 in brain endothelial cells and vessels	FASEB JOURNAL			English	Article						ABC transporters; brain endothelium; blood-brain barrier; drug resistance; glioblastoma	CANCER RESISTANCE PROTEIN; MULTIDRUG-RESISTANCE; BLOOD-BRAIN; P-GLYCOPROTEIN; DRUG-RESISTANCE; IN-VITRO; BARRIER; TRANSPORTER; GENE; OVEREXPRESSION	Delivery of drugs to the brain is impeded by the activity of efflux pumps expressed by endothelial cells of brain vasculature. The ATP binding cassette (ABC) transporters, among which ABCB1/MDR1 P-glycoprotein and ABCC1/multidrug resistance-associated protein 1 are expressed in brain endothelial cells, participate in drug efflux properties of the blood-brain barrier (BBB). Searches of the EST ( expressed sequence tags) database with the conserved ABC domain, conducted to identify other ABC transporters expressed in the BBB, recovered 15 ABC transporter sequences expressed in human brain cDNA libraries. One of these sequences, identical to ABCG2, was highly expressed in cultured human cerebromicrovascular endothelial cells and human brain tissue at both mRNA and protein levels. Overexpression of human ABCG2 in immortalized rat brain endothelial cells resulted in enhanced polarized abluminal to luminal transport of various substrates tested in the in vitro BBB model. Brain vessels extracted from tissue sections of nonmalignant human brain and glioblastoma tomors by laser capture microdissection microscopy and analyzed by real-time polymerase chain reaction showed higher expression of ABCG2 relative to ABCB1/MDR1 and ABCC1/MRP1. ABCG2 was up-regulated in both glioblastoma vessels and parenchymal tissue. These studies suggest a role for brain endothelial ABCG2 transporter in modulating drug delivery to the brain and in conferring drug resistance to glioblastomas.	Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, Ottawa, ON K1A 0R6, Canada	National Research Council Canada	Stanimirovic, DB (corresponding author), Natl Res Council Canada, Inst Biol Sci, Cerebrovasc Res Grp, NRC 1200,Montreal Rd Campus,Bldg M-54, Ottawa, ON K1A 0R6, Canada.	danica.stanimirovic@nrc-cnrc.gc.ca		Zhang, Wandong/0000-0001-6412-8124				Allen JD, 1999, CANCER RES, V59, P4237; Allikmets R, 1996, HUM MOL GENET, V5, P1649, DOI 10.1093/hmg/5.10.1649; Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055; CHOMCZYNSKI P, 1992, ANAL BIOCHEM, V201, P134, DOI 10.1016/0003-2697(92)90185-A; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Cooray HC, 2002, NEUROREPORT, V13, P2059, DOI 10.1097/00001756-200211150-00014; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Decleves X, 2002, INT J CANCER, V98, P173, DOI 10.1002/ijc.10135; Demeule M, 2002, VASC PHARMACOL, V38, P339, DOI 10.1016/S1537-1891(02)00201-X; Demeule M, 2001, INT J CANCER, V93, P62, DOI 10.1002/ijc.1306; Dombrowski SM, 2001, EPILEPSIA, V42, P1501, DOI 10.1046/j.1528-1157.2001.12301.x; Doolittle ND, 2000, CANCER, V88, P637, DOI 10.1002/(SICI)1097-0142(20000201)88:3<637::AID-CNCR22>3.0.CO;2-Y; Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665; Eisenblatter T, 2002, BIOCHEM BIOPH RES CO, V293, P1273, DOI 10.1016/S0006-291X(02)00376-5; Eisenblatter T, 2003, BRAIN RES, V971, P221, DOI 10.1016/S0006-8993(03)02401-6; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; Fromm MF, 2000, INT J CLIN PHARM TH, V38, P69; GERHART DZ, 1988, BRAIN RES BULL, V21, P785, DOI 10.1016/0361-9230(88)90047-0; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Han HY, 1998, BIOCHEM BIOPH RES CO, V243, P816, DOI 10.1006/bbrc.1997.8132; HEGMANN EJ, 1992, CANCER RES, V52, P6969; Honjo Y, 2001, CANCER RES, V61, P6635; Imai Y, 2002, MOL CANCER THER, V1, P611; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Lee G, 2001, PHARMACOL REV, V53, P569; Lee JS, 1997, J CELL BIOCHEM, V65, P513, DOI 10.1002/(SICI)1097-4644(19970615)65:4<513::AID-JCB7>3.3.CO;2-W; Lesniak M S, 2001, Curr Neurol Neurosci Rep, V1, P210, DOI 10.1007/s11910-001-0020-z; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mickley L, 2001, MAMM GENOME, V12, P86, DOI 10.1007/s003350010237; MITOMO H, 2003, IN PRESS BIOCH J; Miyake K, 1999, CANCER RES, V59, P8; Muruganandam A, 1997, FASEB J, V11, P1187, DOI 10.1096/fasebj.11.13.9367354; Muruganandam A, 2001, FASEB J, V15, P240, DOI 10.1096/fj.01-0343fje; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Plotkin SR, 2000, BRAIN RES, V881, P57, DOI 10.1016/S0006-8993(00)02772-4; Potschka H, 2001, NEUROREPORT, V12, P3557, DOI 10.1097/00001756-200111160-00037; Robey RW, 2001, BBA-BIOMEMBRANES, V1512, P171, DOI 10.1016/S0005-2736(01)00308-X; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Schinkel AH, 1996, J CLIN INVEST, V97, P2517, DOI 10.1172/JCI118699; Schinkel AH, 2001, ADV EXP MED BIOL, V500, P365; Seetharaman S, 1998, J NEUROCHEM, V70, P1151, DOI 10.1046/j.1471-4159.1998.70031151.x; Spiegl-Kreinecker S, 2002, J NEURO-ONCOL, V57, P27, DOI 10.1023/A:1015735815111; Stanimirovic D, 1996, J CELL PHYSIOL, V169, P455; Sun HY, 2003, ADV DRUG DELIVER REV, V55, P83, DOI 10.1016/S0169-409X(02)00172-2; Sun HY, 2001, BIOCHEM BIOPH RES CO, V284, P863, DOI 10.1006/bbrc.2001.5062; Tamai I, 2000, J PHARM SCI-US, V89, P1371, DOI 10.1002/1520-6017(200011)89:11<1371::AID-JPS1>3.0.CO;2-D; VANBREE JBMM, 1988, J PHARMACOL EXP THER, V247, P1233; VORBRODT AW, 1986, J HISTOCHEM CYTOCHEM, V34, P251, DOI 10.1177/34.2.3753715; YONG VW, 1992, GLIA, V6, P269, DOI 10.1002/glia.440060405; ZHANG W, 2000, HGM, V5, P67; ZHANG W, 2002, HGM, V7, P122; Zhang WD, 2000, J CEREBR BLOOD F MET, V20, P967, DOI 10.1097/00004647-200006000-00009	53	151	159	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2085	+		10.1096/fj.02-1131fje	http://dx.doi.org/10.1096/fj.02-1131fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958161				2022-12-28	WOS:000185925100026
J	Pettus, BJ; Bielawski, J; Porcelli, AM; Reames, DL; Johnson, KR; Morrow, J; Chalfant, CE; Obeid, LM; Hannun, YA				Pettus, BJ; Bielawski, J; Porcelli, AM; Reames, DL; Johnson, KR; Morrow, J; Chalfant, CE; Obeid, LM; Hannun, YA			The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE(2) production in response to TNF-alpha	FASEB JOURNAL			English	Article						prostaglandin E-2; inflammation; ceramide; sphingosine; RNA interference; tumor necrosis factor	TUMOR-NECROSIS-FACTOR; CYTOSOLIC PHOSPHOLIPASE A(2); PROGRAMMED CELL-DEATH; FC-GAMMA-RI; NF-KAPPA-B; EPITHELIAL-CELLS; SPHINGOLIPID METABOLISM; INTESTINAL POLYPOSIS; INHIBITS APOPTOSIS; TYROSINE KINASE	In this study we addressed the role of sphingolipid metabolism in the inflammatory response. In a L929 fibroblast model, tumor necrosis factor-alpha (TNF) induced prostaglandin E-2 (PGE(2)) production by 4 h and cyclooxygenase-2 (COX-2) induction as early as 2 h. This TNF-induced PGE(2) production was inhibited by NS398, a COX-2 selective inhibitor. GC-MS analysis revealed that only COX-2-generated prostanoids were produced in response to TNF, thus providing further evidence of COX-2 selectivity. As sphingolipids have been implicated in mediating several actions of TNF, their role in COX-2 induction and PGE(2) production was evaluated. Sphingosine-1-phosphate (S1P) induced both COX-2 and PGE(2) in a dose-responsive manner with an apparent ED50 of 100-300 nM. The related sphingolipid sphingosine also induced PGE(2), though with much less efficacy. TNF induced a 3.5-fold increase in sphingosine-1-phosphate levels at 10 min that rapidly returned to baseline by 40 min. Small interfering RNAs (siRNAs) directed against mouse SK1 decreased (typically by 80%) SK1 protein and inhibited TNF-induced SK activity. Treatment of cells with RNAi to SK1 but not SK2 almost completely abolished the ability of TNF to induce COX-2 or generate PGE(2). By contrast, cells treated with RNAi to S1P lyase or S1P phosphatase enhanced COX-2 induction leading to enhanced generation of PGE(2). Treatment with SK1 RNAi also abolished the effects of exogenous sphingosine and ceramide on PGE(2), revealing that the action of sphingosine and ceramide are due to intracellular metabolism into S1P. Collectively, these results provide novel evidence that SK1 and S1P are necessary for TNF to induce COX-2 and PGE(2) production. Based on these findings, this study indicates that SK1 and S1P could be implicated in pathological inflammatory disorders and cancer.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA; Med Univ S Carolina, Ralph H Johnson Vet Adm Med Ctr, Charleston, SC 29425 USA; Univ Bologna, Dept Biol, I-40126 Bologna, Italy; Vanderbilt Univ, Sch Med, Dept Med & Pharmacol, Nashville, TN 37212 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; US Department of Veterans Affairs; Veterans Health Administration (VHA); Ralph H Johnson VA Medical Center; University of Bologna; Vanderbilt University	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, Room 501,Basic Sci Bldg,173 Ashley Ave,POB 250509, Charleston, SC 29425 USA.	hannun@musc.edu		obeid, lina/0000-0002-0734-0847; Porcelli, Anna Maria/0000-0002-6209-0692	NATIONAL CANCER INSTITUTE [R01CA087584, P01CA077839] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM062887, P50GM015431, P01GM015431, R01GM043825] Funding Source: NIH RePORTER; NCI NIH HHS [CA77839, CA87584] Funding Source: Medline; NHLBI NIH HHS [HL 07260] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIGMS NIH HHS [GM08716, GM62887, GM43825, GM15431] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKARASEREENONT P, 1995, BRIT J PHARMACOL, V115, P401, DOI 10.1111/j.1476-5381.1995.tb16347.x; Altman D.G., 1991, PRACTICAL STAT MED R; Ammit AJ, 2001, FASEB J, V15, P1212, DOI 10.1096/fj.00-0742fje; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; BALLOU LR, 1992, J BIOL CHEM, V267, P20044; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; CANDELA M, 1991, J EXP MED, V174, P1363, DOI 10.1084/jem.174.6.1363; Chang HC, 2001, ONCOL REP, V8, P1321; Chen CC, 2000, J IMMUNOL, V165, P2719, DOI 10.4049/jimmunol.165.5.2719; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 1998, J BIOL CHEM, V273, P2910, DOI 10.1074/jbc.273.5.2910; Davaille J, 2000, J BIOL CHEM, V275, P34628, DOI 10.1074/jbc.M006393200; Dobrosotskaya IY, 2002, SCIENCE, V296, P879, DOI 10.1126/science.1071124; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fesik SW, 2000, CELL, V103, P273, DOI 10.1016/S0092-8674(00)00119-7; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Hayakawa M, 1996, BIOCHEM BIOPH RES CO, V220, P681, DOI 10.1006/bbrc.1996.0464; HEMPEL SL, 1994, J CLIN INVEST, V93, P391, DOI 10.1172/JCI116971; Jayadev S, 1997, J BIOL CHEM, V272, P17196, DOI 10.1074/jbc.272.27.17196; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; KARIM SMM, 1968, EUR J PHARMACOL, V4, P416, DOI 10.1016/0014-2999(68)90028-9; Kato M, 2001, J PHARM PHARMACOL, V53, P1679, DOI 10.1211/0022357011778070; Kawa S, 1997, FEBS LETT, V420, P196, DOI 10.1016/S0014-5793(97)01516-0; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; Mifflin RC, 2002, AM J PHYSIOL-CELL PH, V282, pC824, DOI 10.1152/ajpcell.00388.2001; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008, DOI 10.1111/j.1476-5381.1994.tb17093.x; Newton R, 2000, BIOCHEM BIOPH RES CO, V277, P675, DOI 10.1006/bbrc.2000.3722; Niwa M, 1999, LIFE SCI, V66, P245, DOI 10.1016/S0024-3205(99)00587-1; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Osawa Y, 2001, J IMMUNOL, V167, P173, DOI 10.4049/jimmunol.167.1.173; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Plo I, 1999, NEUROREPORT, V10, P2373, DOI 10.1097/00001756-199908020-00028; POLLARD JK, 1993, PROSTAGLANDINS, V46, P499, DOI 10.1016/0090-6980(93)90069-J; Prieschl EE, 1999, J EXP MED, V190, P1, DOI 10.1084/jem.190.1.1; RIEGELMAN RPH, 1992, STT 1 AID INTERPRETA; Siehler S, 2001, J BIOL CHEM, V276, P48733, DOI 10.1074/jbc.M011072200; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Spiegel S, 1996, FASEB J, V10, P1388, DOI 10.1096/fasebj.10.12.8903509; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; Takeshita A, 2000, J BIOL CHEM, V275, P32220, DOI 10.1074/jbc.M002569200; Vann LR, 2002, J BIOL CHEM, V277, P12649, DOI 10.1074/jbc.M109111200; von Knethen A, 1999, MOL BIOL CELL, V10, P361, DOI 10.1091/mbc.10.2.361; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4; Xia P, 2002, J BIOL CHEM, V277, P7996, DOI 10.1074/jbc.M111423200; Xia P, 1999, J BIOL CHEM, V274, P34499, DOI 10.1074/jbc.274.48.34499	58	274	304	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1411	1421		10.1096/fj.02-1038com	http://dx.doi.org/10.1096/fj.02-1038com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890694				2022-12-28	WOS:000185345100033
J	Alesci, S; De Martino, MU; Mirani, M; Benvenga, S; Trimarchi, F; Kino, T; Chrousos, GP				Alesci, S; De Martino, MU; Mirani, M; Benvenga, S; Trimarchi, F; Kino, T; Chrousos, GP			L-Carnitine: a nutritional modulator of glucocorticoid receptor functions	FASEB JOURNAL			English	Article						GR; immunity; cytokines	PHOSPHATIDYLCHOLINE SPECIES COMPOSITION; RAT; BETAMETHASONE; TRANSPORT; DETERMINANTS; COMBINATIONS; DEFICIENCY; ANTAGONIST; EXCRETION; MUSCLE	L-Carnitine is an essential nutrient with a major role in cellular energy production. There is evidence that, at high doses, L-carnitine might mimic some of the biological activities of glucocorticoids, especially immunomodulation. To explore the molecular basis of this effect, we tested the influence of L-carnitine on glucocorticoid receptor-alpha (GRalpha) functions. Millimolar concentrations of L-carnitine, which were not cytotoxic in vitro, significantly reduced the whole cell binding of [H-3]dexamethasone to GRalpha by decreasing the affinity of this receptor for its steroid ligand. At the same concentrations, L-carnitine was able to trigger nuclear translocation of green fluorescent protein (GFP)-fused human GRalpha and transactivate the glucocorticoid-responsive mouse mammary tumor virus (MMTV) and TAT3 promoters in a dose-dependent fashion. This effect was solely dependent on the presence of glucocorticoid-responsive elements on the promoter and on the expression of functional GRalpha by the cell. Finally, similarly to glucocorticoids, L-carnitine suppressed tumor necrosis factor-alpha (TNFalpha) and interleukin-12 release by human primary monocytes stimulated with lipopolysaccharide ex vivo. Both GRalpha transactivation and cytokine suppression by L-carnitine were abrogated by the GRalpha-antagonist RU 486. Taken together, our results suggest that pharmacological doses of L-carnitine can activate GRalpha and, through this mechanism, regulate glucocorticoid-responsive genes, potentially sharing some of the biological and therapeutic properties of glucocorticoids.	NICHD, PREB, NIH, Bethesda, MD 20892 USA; Univ Messina, Dipartimento Clin Sperimentale Med & Farmacol, Sez Endocrinol, I-98100 Messina, Italy	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Messina	Alesci, S (corresponding author), NICHD, PREB, NIH, 10 Ctr Dr,Bldg 10,Room 9D42, Bethesda, MD 20892 USA.	alescis@mail.nih.gov		Mirani, Marco/0000-0002-4187-5378	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000615, ZIAHD008732, ZIAHD000618] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000615, Z01HD008732, Z01HD000618] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH002659, Z01MH002659] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ANGELINI C, 1976, NEUROLOGY, V26, P633, DOI 10.1212/WNL.26.7.633; ARDUINI A, 1992, J BIOL CHEM, V267, P12673; Bamberger CM, 1997, MOL CELL ENDOCRINOL, V131, P233, DOI 10.1016/S0303-7207(97)00115-9; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; Benvenga S, 2001, J CLIN ENDOCR METAB, V86, P3579, DOI 10.1210/jc.86.8.3579; BOHLES H, 1984, EUR J PEDIATR, V143, P61, DOI 10.1007/BF00442751; BOURGEOIS S, 1984, EMBO J, V3, P751, DOI 10.1002/j.1460-2075.1984.tb01879.x; BRASS EP, 1997, L CARNITINE ITS ROLE, P21; Bremer J., 1997, CARNITINE TODAY, P1, DOI [10.1007/978-1-4615-6005-0_1, DOI 10.1007/978-1-4615-6005-0_1]; Chiu KM, 1999, CALCIFIED TISSUE INT, V64, P527, DOI 10.1007/s002239900644; CHRISTIANSEN RZ, 1976, BIOCHIM BIOPHYS ACTA, V448, P562, DOI 10.1016/0005-2736(76)90110-3; Chrousos GP, 2000, INT J OBESITY, V24, pS50, DOI 10.1038/sj.ijo.0801278; DaoPhan HP, 1997, MOL ENDOCRINOL, V11, P962, DOI 10.1210/me.11.7.962; DELOGU G, 1993, MEDIAT INFLAMM, V2, pS33, DOI 10.1155/S0962935193000730; DESIMONE C, 1993, IMMUNOPHARM IMMUNOT, V15, P1, DOI 10.3109/08923979309066930; Elenkov IJ, 1996, P ASSOC AM PHYSICIAN, V108, P374; FATTOROSSI A, 1993, MEDIAT INFLAMM, V2, pS37, DOI 10.1155/S0962935193000742; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; FOSTER SJ, 1993, AGENTS ACTIONS, V38, pC77, DOI 10.1007/BF01991143; Franchimont D, 2002, NEUROIMMUNOMODULAT, V10, P247, DOI 10.1159/000069969; FRITZ IB, 1965, P NATL ACAD SCI USA, V54, P1226, DOI 10.1073/pnas.54.4.1226; GUDJONSSON H, 1985, GASTROENTEROLOGY, V88, P1880, DOI 10.1016/0016-5085(85)90014-9; Guido EC, 1996, MOL ENDOCRINOL, V10, P1178, DOI 10.1210/me.10.10.1178; HUTH PJ, 1981, J NEUROCHEM, V36, P715, DOI 10.1111/j.1471-4159.1981.tb01647.x; KATAKAMI N, 1991, Kobe Journal of Medical Sciences, V37, P179; Kino T, 2001, J CLIN ENDOCR METAB, V86, P5600, DOI 10.1210/jc.86.11.5600; KURZ C, 1993, Z GEBURTSH PERINATOL, V197, P215; LEFEBVRE P, 1988, BIOCHEMISTRY-US, V27, P9186, DOI 10.1021/bi00426a017; LOBEMEIER M, 1999, P 27 GOTT NEUR C, V2, P761; Lohninger A, 1996, J PERINAT MED, V24, P591, DOI 10.1515/jpme.1996.24.6.591; LOHNINGER A, 1986, J CLIN CHEM CLIN BIO, V24, P361; LOHNINGER A, 1984, PEDIATR RES, V18, P1246, DOI 10.1203/00006450-198412000-00004; PANTER RA, 1969, FEBS LETT, V5, P169, DOI 10.1016/0014-5793(69)80322-4; Prasad PD, 1996, BBA-BIOMEMBRANES, V1284, P109, DOI 10.1016/0005-2736(96)00126-5; Pratt W B, 1996, EXS, V77, P79; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; Rani PJA, 2001, EXP GERONTOL, V36, P1713, DOI 10.1016/S0531-5565(01)00116-4; Ray A, 1995, ANN NY ACAD SCI, V762, P79; RAY A, 1995, ANN NY ACAD SCI, V762, P87; REBOUCHE CJ, 1992, FASEB J, V6, P3379, DOI 10.1096/fasebj.6.15.1464372; Rebouche CJ, 1998, ANNU REV NUTR, V18, P39, DOI 10.1146/annurev.nutr.18.1.39; REBOUCHE CJ, 1980, BIOCHIM BIOPHYS ACTA, V630, P22, DOI 10.1016/0304-4165(80)90133-6; ROE CR, 1984, J CLIN INVEST, V73, P1785, DOI 10.1172/JCI111387; RUGGIERO V, 1993, MEDIAT INFLAMM, V2, pS43, DOI 10.1155/S0962935193000754; SALZER H, 1983, WIEN KLIN WOCHENSCHR, V95, P724; TREEM WR, 1988, NEW ENGL J MED, V319, P1331, DOI 10.1056/NEJM198811173192006; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Walter P, 2000, ANN NUTR METAB, V44, P77, DOI 10.1159/000012825; WINTER BK, 1995, BRIT J CANCER, V72, P1173, DOI 10.1038/bjc.1995.482	49	36	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1553	+		10.1096/fj.02-1024fje	http://dx.doi.org/10.1096/fj.02-1024fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824292				2022-12-28	WOS:000183818000017
J	Kojima, E; Takeuchi, A; Haneda, M; Yagi, F; Hasegawa, T; Yamaki, K; Takeda, K; Akira, S; Shimokata, K; Isobe, K				Kojima, E; Takeuchi, A; Haneda, M; Yagi, F; Hasegawa, T; Yamaki, K; Takeda, K; Akira, S; Shimokata, K; Isobe, K			The function of GADD34 is a recovery from a shutoff of protein synthesis induced by ER stress - elucidation by GADD34-deficient mice	FASEB JOURNAL			English	Article						unfolded protein response; translational attenuation; eukaryotic initiation factor	HERPES-SIMPLEX VIRUS; PANCREATIC BETA-CELLS; ENDOPLASMIC-RETICULUM; DNA-DAMAGE; GROWTH ARREST; TRANSLATIONAL CONTROL; GAMMA(1)34.5 PROTEIN; ALPHA-SUBUNIT; KINASE; GENES	GADD34 is a protein that is induced by stresses such as DNA damage. The function of mammalian GADD34 has been proposed by in vitro transfection, but its function in vivo has not yet been elucidated. Here we generated and analyzed GADD34 knockout mice. Despite their embryonic stage- and tissue-specific expressions, GADD34 knockout mice showed no abnormalities at fetal development and in early adult life. However, in GADD34(-/-) mouse embryonic fibroblasts (MEFs), recovery from a shutoff of protein synthesis was delayed when MEFs were exposed to endoplasmic reticulum (ER) stress. The phosphorylation of eukaryotic translation initiator factor 2alpha (eIF2alpha) at Ser51 induced by thapsigargin or DTT was prolonged in GADD34(-/-) MEF, although following treatment with tunicamycin, the eIF2alpha phosphorylation level did not change in either GADD34(+/+) or GADD34(-/-) cells. ER stress stimuli induced expressions of Bip (binding Ig protein) and CHOP (C/EBP homologous protein) in MEF of wild-type mice. These expressions were strongly reduced in GADD34(-/-) MEF, which suggests that GADD34 up-regulates Bip and CHOP. These results indicate that GADD34 works as a sensor of ER stress stimuli and recovers cells from shutoff of protein synthesis.	Natl Inst Longev Sci, Dept Basic Gerontol, Aichi 4748522, Japan; Nagoya Univ, Grad Sch Med, Dept Internal Med, Showa Ku, Aichi 4668520, Japan; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 565, Japan	Nagoya University; Osaka University	Isobe, K (corresponding author), Natl Inst Longev Sci, Dept Basic Gerontol, 36-3 Gengo,Morioka Cho, Aichi 4748522, Japan.	kenisobe@nils.go.jp	Takeda, Kiyoshi/C-9331-2009; isobe, ken-ichi/A-6685-2011; Akira, Shizuo/C-3134-2009; Haneda, masataka/I-7266-2014; Takeuchi, Akihide/AAT-4675-2020	isobe, ken-ichi/0000-0002-8150-2496; Takeuchi, Akihide/0000-0002-2781-0180				Adler HT, 1999, MOL CELL BIOL, V19, P7050; Berlanga JJ, 1999, EUR J BIOCHEM, V265, P754, DOI 10.1046/j.1432-1327.1999.00780.x; Brown SM, 1997, J VIROL, V71, P9442, DOI 10.1128/JVI.71.12.9442-9449.1997; Chefalo PJ, 1998, EUR J BIOCHEM, V258, P820, DOI 10.1046/j.1432-1327.1998.2580820.x; Chin PL, 1997, ONCOGENE, V15, P87, DOI 10.1038/sj.onc.1201161; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; FORNACE AJ, 1988, P NATL ACAD SCI USA, V85, P8800, DOI 10.1073/pnas.85.23.8800; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gale M, 1998, PHARMACOL THERAPEUT, V78, P29, DOI 10.1016/S0163-7258(97)00165-4; Grishin AV, 2001, P NATL ACAD SCI USA, V98, P10172, DOI 10.1073/pnas.191130798; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hasegawa T, 1999, BIOCHEM BIOPH RES CO, V256, P249, DOI 10.1006/bbrc.1999.0275; He B, 1997, P NATL ACAD SCI USA, V94, P843, DOI 10.1073/pnas.94.3.843; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; He B, 1998, J BIOL CHEM, V273, P20737, DOI 10.1074/jbc.273.33.20737; Hollander MC, 1999, NAT GENET, V23, P176, DOI 10.1038/13802; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; Imai H, 2002, EUR J NEUROSCI, V15, P1929, DOI 10.1046/j.1460-9568.2002.02025.x; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Mengesdorf T, 2001, BIOCHEM J, V356, P805, DOI 10.1042/0264-6021:3560805; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oyadomari S, 2002, APOPTOSIS, V7, P335, DOI 10.1023/A:1016175429877; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Takeuchi A, 2003, NAT GENET, V33, P172, DOI 10.1038/ng1072; Takeuchi A, 1998, EUR J NEUROSCI, V10, P1613, DOI 10.1046/j.1460-9568.1998.00168.x; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu SY, 2002, J BIOL CHEM, V277, P18077, DOI 10.1074/jbc.M110164200; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	36	170	190	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1573	+		10.1096/fj.02-1184fje	http://dx.doi.org/10.1096/fj.02-1184fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824288				2022-12-28	WOS:000183818000039
J	Saunders, LR; Barber, GN				Saunders, LR; Barber, GN			The dsRNA binding protein family: critical roles, diverse cellular functions	FASEB JOURNAL			English	Review						mRNA; transcription; RNA editing; RNAi	DOUBLE-STRANDED-RNA; ZINC-FINGER PROTEIN; PRE-MESSENGER-RNA; NF-KAPPA-B; ADENOSINE-DEAMINASE ADAR1; SPLICE-SITE VARIANTS; IMMUNODEFICIENCY-VIRUS TYPE-1; ROUGH ENDOPLASMIC-RETICULUM; REOVIRUS SIGMA-3 PROTEIN; COLI RIBONUCLEASE-III	The dsRNA binding proteins (DRBPs) comprise a growing family of eukaryotic, prokaryotic, and viral-encoded products that share a common evolutionarily conserved motif specifically facilitating interaction with dsRNA. Proteins harboring dsRNA binding domains (DRBDs) have been reported to interact with as little as 11 bp of dsRNA, an event that is independent of nucleotide sequence arrangement. More than 20 DRBPs have been identified and reportedly function in a diverse range of critically important roles in the cell. Examples include the dsRNA-dependent protein kinase PKR that functions in dsRNA signaling and host defense against virus infection and DICER, which is implicated in RNA interference (RNAi)-mediated gene silencing. Other DRBPs such as Staufen, adenosine deaminase acting on RNA (ADAR), and spermatid perinuclear RNA binding protein (SPNR) are known to play essential roles in development, translation, RNA editing, and stability. In many cases, homozygous and even heterozygous disruption of DRBPs in animal models results in embryonic lethality. These results implicate the recognition of dsRNA as an evolutionarily conserved mechanism important in the regulation of gene expression and in host defense and underscore the diversity of essential biological tasks performed by dsRNA-related processes in the cell.	Univ Miami, Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA; Univ Miami, Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA	University of Miami; University of Miami	Barber, GN (corresponding author), Univ Miami, Sch Med, Dept Microbiol & Immunol, Room 511 Papanicolaou Bldg,1550 NW 10th Ave,M710, Miami, FL 33136 USA.	gbarber@med.miami.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008490] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32 GM008490] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham N, 1999, J BIOL CHEM, V274, P5953, DOI 10.1074/jbc.274.9.5953; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Aratani S, 2001, MOL CELL BIOL, V21, P4460, DOI 10.1128/MCB.21.14.4460-4469.2001; Attoui H, 1998, J GEN VIROL, V79, P2481, DOI 10.1099/0022-1317-79-10-2481; Balachandran S, 1998, EMBO J, V17, P6888, DOI 10.1093/emboj/17.23.6888; Balachandran S, 2000, IMMUNITY, V13, P129, DOI 10.1016/S1074-7613(00)00014-5; BARBER GN, 1993, P NATL ACAD SCI USA, V90, P4621, DOI 10.1073/pnas.90.10.4621; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1994, CURR BIOL, V4, P301, DOI 10.1016/S0960-9822(00)00069-5; Bass BL, 1997, RNA, V3, P947; BASS BL, 1989, CELL, V56, P331, DOI 10.1016/0092-8674(89)90234-1; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BEATTIE E, 1995, J VIROL, V69, P499, DOI 10.1128/JVI.69.1.499-505.1995; BEATTIE E, 1995, VIROLOGY, V210, P254, DOI 10.1006/viro.1995.1342; Benkirane M, 1997, EMBO J, V16, P611, DOI 10.1093/emboj/16.3.611; BERDICEVSKY FB, 1988, GENETIKA+, V24, P366; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Billy E, 2001, P NATL ACAD SCI USA, V98, P14428, DOI 10.1073/pnas.261562698; Bliskovskii V V, 1993, Mol Biol (Mosk), V27, P109; BRAUN RE, 1989, GENE DEV, V3, P793, DOI 10.1101/gad.3.6.793; Brooks R, 1998, FEBS LETT, V434, P121, DOI 10.1016/S0014-5793(98)00963-6; Brownawell AM, 2002, J CELL BIOL, V156, P53, DOI 10.1083/jcb.200110082; BRUSA R, 1995, SCIENCE, V270, P1677, DOI 10.1126/science.270.5242.1677; Brzostowski J, 2000, EMBO J, V19, P3683, DOI 10.1093/emboj/19.14.3683; Buaas FW, 1999, MAMM GENOME, V10, P451, DOI 10.1007/s003359901022; Burns CM, 1997, NATURE, V387, P303, DOI 10.1038/387303a0; CALNAN BJ, 1991, SCIENCE, V252, P1167, DOI 10.1126/science.252.5009.1167; CALNAN BJ, 1991, GENE DEV, V5, P201, DOI 10.1101/gad.5.2.201; CARROLL K, 1993, J BIOL CHEM, V268, P12837; CARTER WA, 1991, INT J IMMUNOPHARMACO, V13, P69, DOI 10.1016/0192-0561(91)90127-S; Casey JL, 2002, J VIROL, V76, P7385, DOI 10.1128/JVI.76.15.7385-7397.2002; CHANG HW, 1993, VIROLOGY, V194, P537, DOI 10.1006/viro.1993.1292; CHANG HW, 1992, P NATL ACAD SCI USA, V89, P4825, DOI 10.1073/pnas.89.11.4825; CHAPMAN D, 1983, MEMBRANE FLUIDITY BI, V2, P5; Chen CX, 2000, RNA, V6, P755, DOI 10.1017/S1355838200000170; Chen JH, 1998, J BIOL CHEM, V273, P1038, DOI 10.1074/jbc.273.2.1038; CHENG S, 1993, MAMM GENOME, V4, P338, DOI 10.1007/BF00357094; CHOI SY, 1992, J BIOL CHEM, V267, P286; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLEMENS MJ, 1975, P NATL ACAD SCI USA, V72, P1286, DOI 10.1073/pnas.72.4.1286; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; Conrad C, 2001, FEBS LETT, V509, P53, DOI 10.1016/S0014-5793(01)03142-8; Coolidge CJ, 2000, NUCLEIC ACIDS RES, V28, P1407, DOI 10.1093/nar/28.6.1407; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; COSENTINO GP, 1995, P NATL ACAD SCI USA, V92, P9445, DOI 10.1073/pnas.92.21.9445; Court DL, 1993, RNA PROCESSING DEGRA; Dar AC, 2002, MOL CELL, V10, P295, DOI 10.1016/S1097-2765(02)00590-7; DAS HK, 1981, J BIOL CHEM, V256, P6491; DAVIES MV, 1993, J VIROL, V67, P1688, DOI 10.1128/JVI.67.3.1688-1692.1993; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; DEHIO C, 1994, P NATL ACAD SCI USA, V91, P5538, DOI 10.1073/pnas.91.12.5538; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; DesGroseillers L, 1996, GENOMICS, V36, P527, DOI 10.1006/geno.1996.0499; Duarte M, 2000, J BIOMED SCI, V7, P494; Duchaine T, 2000, MOL CELL BIOL, V20, P5592, DOI 10.1128/MCB.20.15.5592-5601.2000; Duchange N, 2000, GENE, V261, P345, DOI 10.1016/S0378-1119(00)00495-9; DUNN JJ, 1976, J BIOL CHEM, V251, P3807; Eckmann CR, 1997, J CELL BIOL, V138, P239, DOI 10.1083/jcb.138.2.239; Eckmann CR, 1999, J CELL BIOL, V144, P603, DOI 10.1083/jcb.144.4.603; Eckmann CR, 2001, MOL BIOL CELL, V12, P1911, DOI 10.1091/mbc.12.7.1911; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FARRELL PJ, 1978, P NATL ACAD SCI USA, V75, P5893, DOI 10.1073/pnas.75.12.5893; Feldmeyer D, 1999, NAT NEUROSCI, V2, P57, DOI 10.1038/4561; FERRANDON D, 1994, CELL, V79, P1221, DOI 10.1016/0092-8674(94)90013-2; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; Filippov V, 2000, GENE, V245, P213, DOI 10.1016/S0378-1119(99)00571-5; Finerty PJ, 1997, J MOL BIOL, V271, P195, DOI 10.1006/jmbi.1997.1177; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fujii R, 2001, J BIOL CHEM, V276, P5445, DOI 10.1074/jbc.M006892200; FUKUNAGA A, 1975, GENETICS, V81, P135; GALABRU J, 1987, J BIOL CHEM, V262, P15538; GARIGLIO M, 1991, J IMMUNOTHER, V10, P20, DOI 10.1097/00002371-199102000-00004; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Geiss G, 2001, J BIOL CHEM, V276, P30178, DOI 10.1074/jbc.C100137200; George CX, 1999, P NATL ACAD SCI USA, V96, P4621, DOI 10.1073/pnas.96.8.4621; GIBSON TJ, 1994, NUCLEIC ACIDS RES, V22, P2552, DOI 10.1093/nar/22.13.2552; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; GITELMAN DR, 1980, BIOCHEM BIOPH RES CO, V96, P1063, DOI 10.1016/0006-291X(80)90060-1; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hartmuth K, 2002, P NATL ACAD SCI USA, V99, P16719, DOI 10.1073/pnas.262483899; Herb A, 1996, P NATL ACAD SCI USA, V93, P1875, DOI 10.1073/pnas.93.5.1875; Herbert A, 1997, P NATL ACAD SCI USA, V94, P8421, DOI 10.1073/pnas.94.16.8421; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; Hough RF, 1999, NUCLEIC ACIDS RES, V27, P3424, DOI 10.1093/nar/27.17.3424; Hough RF, 1997, RNA, V3, P356; Hubner S, 2002, BIOCHEM J, V361, P287, DOI 10.1042/0264-6021:3610287; HUNTER T, 1975, J BIOL CHEM, V250, P409; Hurst SR, 1995, RNA, V1, P1051; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; IINO Y, 1991, EMBO J, V10, P221, DOI 10.1002/j.1460-2075.1991.tb07939.x; IMANI F, 1988, P NATL ACAD SCI USA, V85, P7887, DOI 10.1073/pnas.85.21.7887; Iordanov MS, 2001, MOL CELL BIOL, V21, P61, DOI 10.1128/MCB.21.1.61-72.2001; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; Iwamura T, 2001, BIOCHEM BIOPH RES CO, V282, P515, DOI 10.1006/bbrc.2001.4606; Jacobs BL, 1998, CURR TOP MICROBIOL, V233, P185; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Johnson KN, 1998, J GEN VIROL, V79, P191, DOI 10.1099/0022-1317-79-1-191; KAO PN, 1994, J BIOL CHEM, V269, P20691; Katze Michael G., 1995, Trends in Microbiology, V3, P75, DOI 10.1016/S0966-842X(00)88880-0; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; Kibler KV, 1997, J VIROL, V71, P1992, DOI 10.1128/JVI.71.3.1992-2003.1997; Kiebler MA, 1999, J NEUROSCI, V19, P288, DOI 10.1523/JNEUROSCI.19-01-00288.1999; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KIMURATAKEUCHI M, 1992, J INFECT DIS, V166, P1266, DOI 10.1093/infdis/166.6.1266; Kleines M, 2001, GENE, V275, P157, DOI 10.1016/S0378-1119(01)00620-5; Knight S.W., 2001, SCIENCE, V2, P2; Kohrmann M, 1999, MOL BIOL CELL, V10, P2945, DOI 10.1091/mbc.10.9.2945; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; KOZAK CA, 1995, GENOMICS, V25, P66, DOI 10.1016/0888-7543(95)80110-8; Krovat BC, 1996, J BIOL CHEM, V271, P28112, DOI 10.1074/jbc.271.45.28112; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Kumar A, 1997, EMBO J, V16, P406, DOI 10.1093/emboj/16.2.406; Kumar M, 1997, P NATL ACAD SCI USA, V94, P3542, DOI 10.1073/pnas.94.8.3542; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; Kutish GF, 1996, VIROLOGY, V223, P303, DOI 10.1006/viro.1996.0482; Lai F, 1997, MOL CELL BIOL, V17, P2413, DOI 10.1128/MCB.17.5.2413; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LAMPSON GP, 1967, P NATL ACAD SCI USA, V58, P782, DOI 10.1073/pnas.58.2.782; Langland JO, 1999, BIOCHEMISTRY-US, V38, P6361, DOI 10.1021/bi982410u; LANGLAND JO, 1994, J VIROL, V68, P3821, DOI 10.1128/JVI.68.6.3821-3829.1994; Lee CG, 1998, GENOMICS, V47, P365, DOI 10.1006/geno.1997.5139; Lee CG, 1999, SOMAT CELL MOLEC GEN, V25, P33, DOI 10.1023/B:SCAM.0000007138.44216.3a; LEE CG, 1993, J BIOL CHEM, V268, P16822; Lee CG, 1998, P NATL ACAD SCI USA, V95, P13709, DOI 10.1073/pnas.95.23.13709; LEE CG, 1992, J BIOL CHEM, V267, P4398; Lee K, 1996, MOL CELL BIOL, V16, P3023; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LEE SB, 1993, VIROLOGY, V193, P1037, DOI 10.1006/viro.1993.1223; LEE SB, 1994, VIROLOGY, V199, P491, DOI 10.1006/viro.1994.1151; LEVIN D, 1978, P NATL ACAD SCI USA, V75, P1121, DOI 10.1073/pnas.75.3.1121; LEVY HB, 1969, P NATL ACAD SCI USA, V62, P357, DOI 10.1073/pnas.62.2.357; Li JZ, 1999, P NATL ACAD SCI USA, V96, P709, DOI 10.1073/pnas.96.2.709; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lipardi C, 2001, CELL, V107, P297, DOI 10.1016/S0092-8674(01)00537-2; Liu Y, 1999, J BIOL CHEM, V274, P5070, DOI 10.1074/jbc.274.8.5070; Liu Y, 1999, J BIOL CHEM, V274, P18351, DOI 10.1074/jbc.274.26.18351; Liu Y, 1997, J BIOL CHEM, V272, P4419, DOI 10.1074/jbc.272.7.4419; Lu C, 2000, PLANT CELL, V12, P2351, DOI 10.1105/tpc.12.12.2351; Maas S, 1996, J BIOL CHEM, V271, P12221, DOI 10.1074/jbc.271.21.12221; MANCHE L, 1992, MOL CELL BIOL, V12, P5238, DOI 10.1128/MCB.12.11.5238; MARAN A, 1994, SCIENCE, V265, P789, DOI 10.1126/science.7914032; Marion RM, 1999, MOL CELL BIOL, V19, P2212; Mattick JS, 2001, MOL BIOL EVOL, V18, P1611, DOI 10.1093/oxfordjournals.molbev.a003951; MATTIONI T, 1992, CHROMOSOMA, V101, P618, DOI 10.1007/BF00360539; Meagher MJ, 2001, MOL CELL BIOL, V21, P2880, DOI 10.1128/MCB.21.8.2880-2890.2001; Meagher MJ, 1999, GENE, V228, P197, DOI 10.1016/S0378-1119(98)00615-5; Melcher T, 1996, J BIOL CHEM, V271, P31795, DOI 10.1074/jbc.271.50.31795; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; Mendez-Vidal C, 2002, NUCLEIC ACIDS RES, V30, P1991, DOI 10.1093/nar/30.9.1991; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; Mian IS, 1998, J COMPUT BIOL, V5, P57, DOI 10.1089/cmb.1998.5.57; Micklem DR, 2000, EMBO J, V19, P1366, DOI 10.1093/emboj/19.6.1366; MILLER JE, 1992, J VIROL, V66, P5347, DOI 10.1128/JVI.66.9.5347-5356.1992; MINKS MA, 1979, J BIOL CHEM, V254, P180; Mittaz L, 1997, HUM GENET, V100, P398, DOI 10.1007/s004390050523; Mittaz L, 1997, GENOMICS, V41, P210, DOI 10.1006/geno.1997.4655; Morse DP, 2002, P NATL ACAD SCI USA, V99, P7906, DOI 10.1073/pnas.112704299; Moss EG, 2000, CURR BIOL, V10, pR436, DOI 10.1016/S0960-9822(00)00528-5; Mouland AJ, 2000, J VIROL, V74, P5441, DOI 10.1128/JVI.74.12.5441-5451.2000; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Nanduri S, 2000, EMBO J, V19, P5567, DOI 10.1093/emboj/19.20.5567; Nanduri S, 1998, EMBO J, V17, P5458, DOI 10.1093/emboj/17.18.5458; Nicholson AW, 1996, PROG NUCLEIC ACID RE, V52, P1, DOI 10.1016/S0079-6603(08)60963-0; Nicholson RH, 2002, MAMM GENOME, V13, P67, DOI 10.1007/s00335-001-2119-6; NORTH RJ, 1991, J INTERFERON RES, V11, P333, DOI 10.1089/jir.1991.11.333; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; OCONNELL MA, 1995, MOL CELL BIOL, V15, P1389; Ogilvie VC, 2003, NUCLEIC ACIDS RES, V31, P1470, DOI 10.1093/nar/gkg236; OHARA PJ, 1984, CELL, V36, P915, DOI 10.1016/0092-8674(84)90041-2; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Orford RL, 1998, MOL CELL BIOL, V18, P5557, DOI 10.1128/MCB.18.9.5557; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Palladino MJ, 2000, CELL, V102, P437, DOI 10.1016/S0092-8674(00)00049-0; Palladino MJ, 2000, RNA, V6, P1004, DOI 10.1017/S1355838200000248; PANET A, 1983, MOL CELL BIOCHEM, V52, P153; PARK HS, 1994, P NATL ACAD SCI USA, V91, P4713, DOI 10.1073/pnas.91.11.4713; Park Y, 2001, SCIENCE, V293, P1083, DOI 10.1126/science.1063073; Parrish S, 2000, MOL CELL, V6, P1077, DOI 10.1016/S1097-2765(00)00106-4; Pasquinelli AE, 2000, NATURE, V408, P86, DOI 10.1038/35040556; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PATTERSON JB, 1995, VIROLOGY, V210, P508, DOI 10.1006/viro.1995.1370; PATTERSON JB, 1995, MOL CELL BIOL, V15, P5376, DOI 10.1128/mcb.15.10.5376; Paupard MC, 2000, NEUROSCIENCE, V95, P869; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; Pires-daSilva A, 2001, DEV BIOL, V233, P319, DOI 10.1006/dbio.2001.0169; Polson AG, 1996, NATURE, V380, P454; Raitskin O, 2001, P NATL ACAD SCI USA, V98, P6571, DOI 10.1073/pnas.111153798; Ramos A, 2000, EMBO J, V19, P997, DOI 10.1093/emboj/19.5.997; RASTELLI L, 1995, MECH DEVELOP, V53, P223, DOI 10.1016/0925-4773(95)00438-7; Reinhart BJ, 2002, GENE DEV, V16, P1616, DOI 10.1101/gad.1004402; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICE AP, 1984, J VIROL, V50, P229, DOI 10.1128/JVI.50.1.229-236.1984; Richter L, 1996, GENES CELLS, V1, P325, DOI 10.1046/j.1365-2443.1996.26027.x; ROBERTSON HD, 1968, J BIOL CHEM, V243, P82; Roegiers F, 2000, TRENDS CELL BIOL, V10, P220, DOI 10.1016/S0962-8924(00)01767-0; ROMANO PR, 1995, MOL CELL BIOL, V15, P365, DOI 10.1128/MCB.15.1.365; Rotondo G, 1996, NUCLEIC ACIDS RES, V24, P2377, DOI 10.1093/nar/24.12.2377; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; SACCOMANNO L, 1994, MOL CELL BIOL, V14, P5425, DOI 10.1128/MCB.14.8.5425; Saunders LR, 2001, J BIOL CHEM, V276, P32300, DOI 10.1074/jbc.M104207200; Saunders LR, 2001, GENOMICS, V71, P256, DOI 10.1006/geno.2000.6423; Scadden ADJ, 2001, EMBO J, V20, P4243, DOI 10.1093/emboj/20.15.4243; SCHMEDT C, 1995, J MOL BIOL, V249, P29, DOI 10.1006/jmbi.1995.0278; Schumacher JM, 1998, BIOL REPROD, V59, P69, DOI 10.1095/biolreprod59.1.69; SCHUMACHER JM, 1995, BIOL REPROD, V52, P1274, DOI 10.1095/biolreprod52.6.1274; SCHUMACHER JM, 1995, J CELL BIOL, V129, P1023, DOI 10.1083/jcb.129.4.1023; Schwartz T, 2001, NAT STRUCT BIOL, V8, P761, DOI 10.1038/nsb0901-761; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; Sharp TV, 1998, VIROLOGY, V250, P302, DOI 10.1006/viro.1998.9365; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Siffroi JP, 2001, MOL HUM REPROD, V7, P219, DOI 10.1093/molehr/7.3.219; Silhavy D, 2002, EMBO J, V21, P3070, DOI 10.1093/emboj/cdf312; SILVERSTEIN SC, 1976, ANNU REV BIOCHEM, V45, P375, DOI 10.1146/annurev.bi.45.070176.002111; Slack FJ, 2000, MOL CELL, V5, P659, DOI 10.1016/S1097-2765(00)80245-2; STEWART WE, 1973, J GEN VIROL, V18, P237, DOI 10.1099/0022-1317-18-3-237; STEWART WE, 1972, P NATL ACAD SCI USA, V69, P1851, DOI 10.1073/pnas.69.7.1851; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1989, DEVELOPMENT, V107, P13; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Storz G, 2002, SCIENCE, V296, P1260, DOI 10.1126/science.1072249; Sun CT, 2001, J BIOL CHEM, V276, P24059, DOI 10.1074/jbc.M101330200; Sun WM, 2001, BIOCHEMISTRY-US, V40, P5102, DOI 10.1021/bi010022d; Sun WM, 2001, BIOCHEMISTRY-US, V40, P14976, DOI 10.1021/bi011570u; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; TAYLOR MW, 1971, P NATL ACAD SCI USA, V68, P836, DOI 10.1073/pnas.68.4.836; THOMIS DC, 1995, J VIROL, V69, P5195, DOI 10.1128/JVI.69.8.5195-5198.1995; Tulman ER, 2001, J VIROL, V75, P7122, DOI 10.1128/JVI.75.15.7122-7130.2001; TYTELL AA, 1967, P NATL ACAD SCI USA, V58, P1719, DOI 10.1073/pnas.58.4.1719; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; USHIJIMA H, 1993, J INTERFERON RES, V13, P161, DOI 10.1089/jir.1993.13.161; vandenHeuvel JFJM, 1997, J INVERTEBR PATHOL, V70, P169, DOI 10.1006/jipa.1997.4691; Vattem KM, 2001, EUR J BIOCHEM, V268, P1143, DOI 10.1046/j.1432-1327.2001.01979.x; VILCEK J, 1987, J CELL PHYSIOL, V130, P37, DOI 10.1002/jcp.1041300107; Villard L, 1997, SOMAT CELL MOLEC GEN, V23, P135, DOI 10.1007/BF02679972; Wang Q, 2000, SCIENCE, V290, P1765, DOI 10.1126/science.290.5497.1765; WANG Y, 1995, J MOL BIOL, V254, P184, DOI 10.1006/jmbi.1995.0610; Wargelius A, 1999, BIOCHEM BIOPH RES CO, V263, P156, DOI 10.1006/bbrc.1999.1343; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wianny F, 2000, NAT CELL BIOL, V2, P70, DOI 10.1038/35000016; Wickham L, 1999, MOL CELL BIOL, V19, P2220; Wilson SA, 1998, NUCLEIC ACIDS RES, V26, P3460, DOI 10.1093/nar/26.15.3460; Wong SK, 2001, RNA, V7, P846, DOI 10.1017/S135583820101007X; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; XU HP, 1990, NUCLEIC ACIDS RES, V18, P5304, DOI 10.1093/nar/18.17.5304; Yang ML, 1999, J BIOL CHEM, V274, P27399, DOI 10.1074/jbc.274.39.27399; Yang SC, 2001, MOL CELL BIOL, V21, P7807, DOI 10.1128/MCB.21.22.7807-7816.2001; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; YUWEN H, 1993, VIROLOGY, V195, P732, DOI 10.1006/viro.1993.1424; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0; Zamore PD, 1996, CURR BIOL, V6, P773, DOI 10.1016/S0960-9822(02)00591-2; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200; Zhang SS, 1999, J CELL SCI, V112, P1055; Zhang SS, 1997, J BIOL CHEM, V272, P11487; ZHANG SS, 1991, J BIOL CHEM, V266, P20483; Zhang SS, 1999, J CELL SCI, V112, P2693; Zhong J, 1999, NAT GENET, V22, P171, DOI 10.1038/9684; Zhong J, 1998, MAMM GENOME, V9, P413, DOI 10.1007/s003359900786; Zhou ZL, 2002, NATURE, V419, P182, DOI 10.1038/nature01031	276	285	303	1	46	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					961	983		10.1096/fj.02-0958rev	http://dx.doi.org/10.1096/fj.02-0958rev			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773480				2022-12-28	WOS:000183818000001
J	Ward, CW; Reiken, S; Marks, AR; Marty, I; Vassort, G; Lacampagne, A				Ward, CW; Reiken, S; Marks, AR; Marty, I; Vassort, G; Lacampagne, A			Defects in ryanodine receptor calcium release in skeletal muscle from postmyocardial infarcted rats	FASEB JOURNAL			English	Article						calcium sparks; heart failure; mammalian skeletal muscle; multiphoton microscopy; ryanodine receptor	CHRONIC HEART-FAILURE; INDIVIDUAL CA2+ SPARKS; PERFUSED MOUSE HEART; MYOCARDIAL-INFARCTION; EXERCISE CAPACITY; 2 MECHANISMS; FROG; FIBERS; EVENTS; RHOD-2	Defective calcium (Ca2+) signaling and impaired contractile function have been observed in skeletal muscle secondary to impaired mycocardial function. However, the molecular basis for these muscle defects have not been identified. In this study, we evaluated the alterations of the ryanodine-sensitive Ca2+ release channels (RyR1) by analyzing global and local <LF>Ca2+ signaling in a rat postmycocardial infarction (PMI) <LF>model of myocardial overload. Ca2+ transients, measured with multiphoton imaging in individual fibers within a whole extensor digitorum longus (EDL) muscle, exhibited significantly reduced amplitude and a prolonged time course in PMI. Spatio-temporal properties of spontaneous Ca2+ sparks in fibers isolated from PMI EDL muscles were also significantly altered. In addition, RyR1 from PMI skeletal muscles were PKA-hyperphosphorylated and depleted of the FK506 binding protein (FKBP12). These data show that PMI skeletal muscles exhibit altered local Ca2+ signaling, assocated with hyperphosphorylation of RyR1. The observed changes in Ca2+ signaling may contribute to defective excitation-contraction coupling in muscle that can attribute to the reduced exercise capacity in PMI, out of proportion to the degree of cardiac dysfunction.	CHU Arnaud de Villeneuve, INSERM, U390, IFR3, F-34295 Montpellier 05, France; Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Baltimore, MD 21201 USA; Columbia Univ, Coll Phys & Surg, Ctr Mol Cardiol, New York, NY USA; CEA Grenoble, DBMS, INSERM, E9931, Grenoble, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; University System of Maryland; University of Maryland Baltimore; Columbia University; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Lacampagne, A (corresponding author), CHU Arnaud de Villeneuve, INSERM, U390, IFR3, F-34295 Montpellier 05, France.	lacamp@montp.inserm.fr	Marty, Isabelle/N-7114-2017; Marty, Isabelle/ABF-5362-2020; Lacampagne, Alain/S-3719-2016	Marty, Isabelle/0000-0003-3625-913X; Lacampagne, Alain/0000-0003-0264-1787	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K01AR002177] Funding Source: NIH RePORTER; NIAMS NIH HHS [K01 AR002177] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aimond F, 1999, CARDIOVASC RES, V42, P402, DOI 10.1016/S0008-6363(99)00070-X; ARNOLDA L, 1991, AM J PHYSIOL, V261, pH434, DOI 10.1152/ajpheart.1991.261.2.H434; BRILLANTES AMB, 1994, CELL, V77, P513, DOI 10.1016/0092-8674(94)90214-3; Cheng H, 1999, BIOPHYS J, V76, P606, DOI 10.1016/S0006-3495(99)77229-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Cicoira M, 2001, CYTOKINE, V15, P80, DOI 10.1006/cyto.2001.0918; Clark AL, 1996, J AM COLL CARDIOL, V28, P1092, DOI 10.1016/S0735-1097(96)00323-3; Coats AJS, 1996, J MOL CELL CARDIOL, V28, P2255, DOI 10.1006/jmcc.1996.0218; DREXLER H, 1992, CIRCULATION, V85, P1751, DOI 10.1161/01.CIR.85.5.1751; Du CW, 2001, BIOPHYS J, V80, P549, DOI 10.1016/S0006-3495(01)76037-7; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Duscha BD, 2002, J AM COLL CARDIOL, V39, P1170, DOI 10.1016/S0735-1097(02)01740-0; FRANCIOSA JA, 1981, AM J CARDIOL, V47, P33, DOI 10.1016/0002-9149(81)90286-1; Gonzalez A, 2000, P NATL ACAD SCI USA, V97, P4380, DOI 10.1073/pnas.070056497; Hollingworth S, 2001, J GEN PHYSIOL, V118, P653, DOI 10.1085/jgp.118.6.653; Jiang YH, 1999, BIOPHYS J, V77, P2333, DOI 10.1016/S0006-3495(99)77072-4; Kirsch WG, 2001, J PHYSIOL-LONDON, V537, P379, DOI 10.1111/j.1469-7793.2001.00379.x; Klein MG, 1999, J PHYSIOL-LONDON, V515, P391, DOI 10.1111/j.1469-7793.1999.391ac.x; Klein MG, 1997, P NATL ACAD SCI USA, V94, P11061, DOI 10.1073/pnas.94.20.11061; Klein MG, 1996, NATURE, V379, P455, DOI 10.1038/379455a0; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; Lacampagne A, 2000, P NATL ACAD SCI USA, V97, P7823, DOI 10.1073/pnas.97.14.7823; Lacampagne A, 2003, J GEN PHYSIOL, V121, P179; Lacampagne A, 1998, J GEN PHYSIOL, V111, P207, DOI 10.1085/jgp.111.2.207; Lacampagne A, 1999, J GEN PHYSIOL, V113, P187, DOI 10.1085/jgp.113.2.187; Lannergren J, 2001, J MUSCLE RES CELL M, V22, P265, DOI 10.1023/A:1012227009544; Liu YW, 2001, J CELL BIOL, V155, P27, DOI 10.1083/jcb.200103020; LOPEZLOPEZ JR, 1995, SCIENCE, V268, P1042, DOI 10.1126/science.7754383; Lunde PK, 2002, J PHYSIOL-LONDON, V540, P571, DOI 10.1113/jphysiol.2001.013324; Lunde PK, 2001, ACTA PHYSIOL SCAND, V171, P277, DOI 10.1046/j.1365-201x.2001.00830.x; Lunde PK, 2001, CIRC RES, V88, P1299, DOI 10.1161/hh1201.092041; MacGowan GA, 2001, J BIOMED OPT, V6, P23, DOI 10.1117/1.1316091; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; MINOTTI JR, 1991, J CLIN INVEST, V88, P2077, DOI 10.1172/JCI115537; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; Pacher P, 2002, P NATL ACAD SCI USA, V99, P2380, DOI 10.1073/pnas.032423699; PERREAULT CL, 1993, CIRC RES, V73, P405, DOI 10.1161/01.RES.73.2.405; Peters DG, 1997, CIRC RES, V81, P703; Schneider MF, 2002, FRONT BIOSCI-LANDMRK, V7, pD1212, DOI 10.2741/schneide; Shtifman A, 2000, BIOPHYS J, V79, P814, DOI 10.1016/S0006-3495(00)76338-7; Simonini A, 1999, HEART, V81, P303, DOI 10.1136/hrt.81.3.303; VOLTERRANI M, 1994, EUR HEART J, V15, P801, DOI 10.1093/oxfordjournals.eurheartj.a060588; Williams JH, 1998, EXP PHYSIOL, V83, P85, DOI 10.1113/expphysiol.1998.sp004094; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	45	74	81	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1517	+		10.1096/fj.02-1083fje	http://dx.doi.org/10.1096/fj.02-1083fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824280				2022-12-28	WOS:000183818000031
J	Boulanger, A; McLemore, P; Copeland, NG; Gilbert, DJ; Jenkins, NA; Yu, SS; Gentleman, S; Redmond, TM				Boulanger, A; McLemore, P; Copeland, NG; Gilbert, DJ; Jenkins, NA; Yu, SS; Gentleman, S; Redmond, TM			Identification of beta-carotene 15,15 '-monooxygenase as a peroxisome proliferator-activated receptor target gene	FASEB JOURNAL			English	Article						carotenoids; retinoids; transcriptional regulation; promoter; RXR	RETINOL-BINDING PROTEIN; RAT SMALL-INTESTINE; RNA POLYMERASE-II; BETA,BETA-CAROTENE 15,15'-DIOXYGENASE; DIFFERENTIAL REGULATION; X-RECEPTOR; EXPRESSION; ENZYME; ALPHA; CLEAVAGE	beta-Carotene 15,15'-monooxygenase (BCM) catalyzes the first step of vitamin A biosynthesis from provitamin A carotenoids. We wished to determine the factors underlying the transcriptional regulation of this gene. After cloning of the 40 kilobase pair (kbp) mouse Bcm gene and determination of its genomic organization, analysis of the 2 kb 5'-flanking region showed several putative transcription factor binding sites including TATA box, a peroxisome proliferator response element (PPRE), AP2, and bHLH. The 2 kb fragment drove specific luciferase gene expression in vitro only in cell lines that express BCM (TC7, PF11, and monkey retinal pigment epithelium). Nucleotides -41 to +163, and -60 to +163 drove basal and specific Bcm transcriptional activity, respectively. Site-directed mutagenesis and gel shift experiments demonstrate that PPRE was essential for Bcm promoter specificity and that the peroxisome proliferator activated receptor (PPAR) gamma (PPARgamma) specifically binds to this element. Furthermore, cotransfection experiments and pharmacological treatments in vitro, using the specific PPARgamma agonists LY17883 and ciglitazone, demonstrate that the PPRE element confers peroxisome proliferator responsiveness via the PPARgamma and retinoid X receptor-alpha heterodimer. Treatment of mice with the PPARalpha/gamma agonist WY14643 increases BCM protein expression in liver. Thus PPAR is a key transcription factor for the transcriptional regulation of the Bcm gene, suggesting a broader function for PPARs in the regulation of carotenoid metabolism metabolism that is consistent with their established role in neutral lipid metabolism and transport.	NEI, Retinal Cell & Mol Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Mouse Canc Genet Program, Ft Detrick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Redmond, TM (corresponding author), NEI, Retinal Cell & Mol Biol Lab, NIH, Bldg 6,Rm 339,6 Ctr Dr,MSC 2740, Bethesda, MD 20892 USA.	redmond@helix.nih.gov		Redmond, T. Michael/0000-0002-1813-5291	NATIONAL EYE INSTITUTE [Z01EY000260, ZIAEY000260] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Bhatti RA, 2003, INVEST OPHTH VIS SCI, V44, P44, DOI 10.1167/iovs.02-0167; Bok D, 1999, NEURON, V23, P412, DOI 10.1016/S0896-6273(00)80791-6; Calvo S, 1996, DEV GENET, V19, P169, DOI 10.1002/(SICI)1520-6408(1996)19:2<169::AID-DVG9>3.3.CO;2-T; CASTELEIN H, 1994, J BIOL CHEM, V269, P26754; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dong D, 1998, BIOCHEMISTRY-US, V37, P10691, DOI 10.1021/bi980561r; During A, 1996, ANAL BIOCHEM, V241, P199, DOI 10.1006/abio.1996.0400; During A, 1998, BIOCHEM BIOPH RES CO, V249, P467, DOI 10.1006/bbrc.1998.9160; Duszka C, 1996, J NUTR, V126, P2550, DOI 10.1093/jn/126.10.2550; ERDMAN JW, 1993, ANN NY ACAD SCI, V691, P76, DOI 10.1111/j.1749-6632.1993.tb26159.x; GODA T, 1993, BIOCHIM BIOPHYS ACTA, V1168, P153; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; KAKKAD BP, 1988, J BIOL CHEM, V263, P12916; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lehmann JM, 1997, J BIOL CHEM, V272, P3406, DOI 10.1074/jbc.272.6.3406; Leuenberger MG, 2001, ANGEW CHEM INT EDIT, V40, P2614, DOI 10.1002/1521-3773(20010716)40:14<2613::AID-ANIE2613>3.0.CO;2-Z; MACDONALD PN, 1987, J BIOL CHEM, V262, P10550; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; Meier CA, 1997, J RECEPT SIGNAL TR R, V17, P319, DOI 10.3109/10799899709036612; Montano AM, 2000, BBA-MOL BASIS DIS, V1500, P323, DOI 10.1016/S0925-4439(99)00119-2; NAGAO A, 1994, FASEB J, V8, P968, DOI 10.1096/fasebj.8.12.8088462; Nagao A, 1996, ARCH BIOCHEM BIOPHYS, V328, P57, DOI 10.1006/abbi.1996.0142; Nakshatri H, 1998, NUCLEIC ACIDS RES, V26, P2491, DOI 10.1093/nar/26.10.2491; OLSON JA, 1965, P NATL ACAD SCI USA, V54, P1364, DOI 10.1073/pnas.54.5.1364; ONG DE, 1987, J BIOL CHEM, V262, P2729; Paik J, 2001, J BIOL CHEM, V276, P32160, DOI 10.1074/jbc.M010086200; PARKER CS, 1984, CELL, V37, P273, DOI 10.1016/0092-8674(84)90323-4; Peters JM, 1998, CARCINOGENESIS, V19, P1989, DOI 10.1093/carcin/19.11.1989; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; Redmond TM, 2001, J BIOL CHEM, V276, P6560, DOI 10.1074/jbc.M009030200; Suruga K, 1999, ARCH BIOCHEM BIOPHYS, V362, P159, DOI 10.1006/abbi.1998.1018; Tajima S, 2001, COMP BIOCHEM PHYS B, V128, P425, DOI 10.1016/S1096-4959(00)00347-X; Takase S, 2000, BRIT J NUTR, V84, pS217, DOI 10.1079/096582197388572; TUGWOOD JD, 1992, EMBO J, V11, P433, DOI 10.1002/j.1460-2075.1992.tb05072.x; vanVliet T, 1996, J NUTR, V126, P499, DOI 10.1093/jn/126.2.499; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; von Lintig J, 2001, P NATL ACAD SCI USA, V98, P1130, DOI 10.1073/pnas.031576398; Vu-Dac N, 1998, J CLIN INVEST, V102, P625, DOI 10.1172/JCI1581; Wyss A, 2000, BIOCHEM BIOPH RES CO, V271, P334, DOI 10.1006/bbrc.2000.2619; Wyss A, 2001, BIOCHEM J, V354, P521, DOI 10.1042/0264-6021:3540521; Yan WM, 2001, GENOMICS, V72, P193, DOI 10.1006/geno.2000.6476	49	80	86	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1304	+		10.1096/fj.02-0690fje	http://dx.doi.org/10.1096/fj.02-0690fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759335				2022-12-28	WOS:000183165000024
J	Grosch, S; Tegeder, I; Schilling, K; Maier, T; Niederberger, E; Geisslinger, G				Grosch, S; Tegeder, I; Schilling, K; Maier, T; Niederberger, E; Geisslinger, G			Activation of c-Jun-N-terminal-kinase is crucial for the induction of a cell cycle arrest in human colon carcinoma cells caused by flurbiprofen enantiomers	FASEB JOURNAL			English	Article						G(1)-phase block; apoptosis; colon cancer; flurbiprofen; enantiomer	R-FLURBIPROFEN; CYCLOOXYGENASE-2 INHIBITOR; PROSTAGLANDIN SYNTHESIS; RHEUMATOID-ARTHRITIS; D1 EXPRESSION; APOPTOSIS; PROLIFERATION; TRANSCRIPTION; SURVIVAL; CANCER	The unselective cyclooxygenase (COX) inhibitor S-flurbiprofen and its-in terms of COX-inhibition-"inactive" enantiomer R-flurbiprofen have been previously found to inhibit tumor development and growth in various animal models. The underlying mechanisms are unknown. Here, we show that both R- and S-flurbiprofen reduce survival of three colon cancer cell lines, which differ in the expression of COX-2 (HCT-15, no COX-2; Caco-2, inducible COX-2; and HT-29, constitutive COX-2). The IC50 for S- and R-flurbiprofen ranged from 250 to 450 muM. Both flurbiprofen enantiomers induced apoptosis in all three cell lines as indicated by DNA- and PARP-cleavage. In addition, R- and S-flurbiprofen caused a G(1)-cell cycle block. The latter was associated with an activation of c-Jun N-terminal kinase (JNK), an increase of the DNA binding activity of the transcription factor AP-1 and down-regulation of cyclin D1 expression. Western blot analysis, as well as supershift experiments, revealed that the AP-1 activation was associated with a change of AP-1 composition toward an increase of JunB. The JNK inhibitor SP600125 antagonized R- and S-flurbiprofen-induced AP-1 DNA binding, suppression of cyclin D1 expression, and the G(1)-cell cycle block. However, JNK inhibition had no effect on flurbiprofen-induced apoptosis. Hence, the cell cycle arrest is obviously mediated, at least in part, through JNK-activation, whereas R- and S-flurbiprofen-induced apoptosis is largely independent of JNK. Although in vitro effects of R- and S-flurbiprofen were indistinguishable, only R-flurbiprofen inhibited HCT-15 tumor growth in nude mice, suggesting the involvement of additional in vivo targets, which are differently affected by R- and S-flurbiprofen.	Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Grosch, S (corresponding author), Univ Frankfurt Klinikum, Inst Klin Pharmakol, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	groesch@em.uni-frankfurt.de	Groesch, Sabine/H-4251-2018; Tegeder, Irmgard/AAM-2266-2020; Tegeder, Irmgard/AAM-2246-2020	Groesch, Sabine/0000-0002-7262-6307; Tegeder, Irmgard/0000-0001-7524-8025; Tegeder, Irmgard/0000-0001-7524-8025				Andrecht S, 2002, J BIOL CHEM, V277, P35961, DOI 10.1074/jbc.M202847200; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BENNETT A, 1982, BRIT J CANCER, V45, P762, DOI 10.1038/bjc.1982.118; BENNETT A, 1979, PROSTAGLANDINS, V17, P179, DOI 10.1016/0090-6980(79)90037-6; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Damiens E, 2000, Prog Cell Cycle Res, V4, P219; DARZYNKIEWICZ Z, 1992, CYTOMETRY, V13, P795, DOI 10.1002/cyto.990130802; Dulic V, 1998, MOL CELL BIOL, V18, P546, DOI 10.1128/MCB.18.1.546; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Fajas L, 2001, MOL CELL BIOL, V21, P2956, DOI 10.1128/MCB.21.8.2956-2966.2001; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; GEISSLINGER G, 1992, J CHROMATOGR-BIOMED, V573, P163, DOI 10.1016/0378-4347(92)80492-9; Geisslinger G, 1996, J CLIN PHARMACOL, V36, P513, DOI 10.1002/j.1552-4604.1996.tb05041.x; Grosch S, 1999, BIOCHEM BIOPH RES CO, V261, P859, DOI 10.1006/bbrc.1999.1125; Leaper D J, 1980, Adv Prostaglandin Thromboxane Res, V6, P591; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Lin SK, 2001, MOL PHARMACOL, V60, P768; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; McCracken JD, 1996, J CLIN PHARMACOL, V36, P540, DOI 10.1002/j.1552-4604.1996.tb05043.x; Niculescu AB, 1998, MOL CELL BIOL, V18, P629, DOI 10.1128/MCB.18.1.629; Niculescu AB, 1998, MOL CELL BIOL, V18, P1763, DOI 10.1128/MCB.18.3.1763; RESNITZKY D, 1995, MOL CELL BIOL, V15, P4347; Rossat J, 1999, CLIN PHARMACOL THER, V66, P76, DOI 10.1016/S0009-9236(99)70056-1; Schmassmann A., 1998, AM J MED, V104, p[43S, 79S], DOI DOI 10.1016/S0002-9343(97)00211-8; Schmassmann Adrian, 1998, American Journal of Medicine, V104, p43S, DOI 10.1016/S0002-9343(97)00211-8; Schwenger P, 1999, J CELL PHYSIOL, V179, P109, DOI 10.1002/(SICI)1097-4652(199904)179:1<109::AID-JCP13>3.0.CO;2-W; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Simon LS, 1999, JAMA-J AM MED ASSOC, V282, P1921, DOI 10.1001/jama.282.20.1921; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sylvester AM, 1998, J CLIN INVEST, V101, P940, DOI 10.1172/JCI1630; Tegeder I, 2001, FASEB J, V15, P595, DOI 10.1096/fasebj.15.3.595; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; WADDELL WR, 1983, J SURG ONCOL, V24, P83, DOI 10.1002/jso.2930240119; Wechter WJ, 2000, CANCER RES, V60, P2203; Wechter WJ, 1997, CANCER RES, V57, P4316; Wechter WJ, 2000, LIFE SCI, V66, P745, DOI 10.1016/S0024-3205(99)00645-1; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326	43	44	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1316	+		10.1096/fj.02-0919fje	http://dx.doi.org/10.1096/fj.02-0919fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759338				2022-12-28	WOS:000183165000020
J	Liew, R; MacLeod, KT; Collins, P				Liew, R; MacLeod, KT; Collins, P			Novel stimulatory actions of the phytoestrogen genistein: effects on the gain of cardiac excitation-contraction coupling	FASEB JOURNAL			English	Article						cardiac myocyte; cell shortening; calcium transient; sarcoplasmic reticulum; myofilament calcium sensitivity	TYROSINE KINASE INHIBITOR; VASCULAR SMOOTH-MUSCLE; CA2+ SENSITIVITY; PHOSPHATASE INHIBITORS; REGIONAL DIFFERENCES; MEMBRANE CURRENTS; SOY ISOFLAVONES; CALCIUM CURRENT; RABBIT; RELAXATION	Genistein, a phytoestrogen found abundantly in soy products, is thought to be cardioprotective, partly through its ability to act as a natural Ca2+ channel antagonist. However, the precise nature and significance of such direct cardiac actions remain obscure. We investigated the hypothesis that genistein exerts important additional actions on cardiac excitation-contraction coupling (ECC). Genistein acutely increased cell shortening and the Ca2+ transient in field stimulated guinea-pig ventricular myocytes despite potently inhibiting the L-type Ca2+ current, I-Ca,I-L. The specific phosphotyrosine phosphatase inhibitor, bpV(phen), diminished the stimulatory effects of genistein on myocyte contractility, suggesting that the mechanism partly involved tyrosine kinase inhibition. Genistein increased sarcoplasmic reticulum (SR) Ca2+ load as measured with a caffeine pulse in Na+-free/Ca2+-free solution. Furthermore, in the continued presence of caffeine, genistein increased the time constant of decline of the caffeine-induced Ca2+ transient, implying impaired sarcolemmal Na+/Ca2+ exchanger function. Tetanization studies in intact myocytes revealed that 43% of cells exhibited increased myofilament Ca2+ sensitivity in the presence of genistein. These findings demonstrate novel cardiac actions of genistein on the SR Ca2+ load, Na+/Ca2+ exchanger, and myofilament Ca2+ sensitivity, which result in an overall increase in myocyte contractility and consequently the gain of ECC.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, London SW3 6LY, England	Imperial College London	Liew, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Cardiac Med, Dovehouse St, London SW3 6LY, England.	r.liew@imperial.ac.uk	MacLeod, Kenneth/GWU-8940-2022					ADLERCREUTZ H, 1990, SCAND J CLIN LAB INV, V50, P3, DOI 10.3109/00365519009085798; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ANDERSON JW, 1995, NEW ENGL J MED, V333, P276, DOI 10.1056/NEJM199508033330502; Anthony MS, 1998, AM J CLIN NUTR, V68, p1390S, DOI 10.1093/ajcn/68.6.1390S; ARTAUDWILD SM, 1993, CIRCULATION, V88, P2771, DOI 10.1161/01.CIR.88.6.2771; BASSANI JWM, 1994, J PHYSIOL-LONDON, V476, P279, DOI 10.1113/jphysiol.1994.sp020130; BERS DM, 1995, AM J PHYSIOL-CELL PH, V268, pC271, DOI 10.1152/ajpcell.1995.268.1.C271; BERS DM, 1989, CIRC RES, V65, P334, DOI 10.1161/01.RES.65.2.334; CHAMUNORWA JP, 1995, PFLUG ARCH EUR J PHY, V430, P195, DOI 10.1007/BF00374650; Chiang CE, 2002, J BIOMED SCI, V9, P321, DOI 10.1007/BF02256587; Chiang CE, 1996, BIOCHEM BIOPH RES CO, V223, P598, DOI 10.1006/bbrc.1996.0941; Chin-Dusting JPF, 2001, BRIT J PHARMACOL, V133, P595, DOI 10.1038/sj.bjp.0704088; Eisner DA, 2000, CIRC RES, V87, P1087, DOI 10.1161/01.RES.87.12.1087; Figtree GA, 2000, J AM COLL CARDIOL, V35, P1977, DOI 10.1016/S0735-1097(00)00645-8; HOLLENBERG MD, 1994, TRENDS PHARMACOL SCI, V15, P108, DOI 10.1016/0165-6147(94)90046-9; Hongo K, 1998, PFLUG ARCH EUR J PHY, V436, P639, DOI 10.1007/s004240050683; Hool LC, 1998, CIRC RES, V83, P33, DOI 10.1161/01.RES.83.1.33; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL666, DOI 10.1152/ajplung.2001.280.4.L666; JIANG C, 1992, BRIT J PHARMACOL, V106, P739, DOI 10.1111/j.1476-5381.1992.tb14403.x; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Keef KD, 2001, AM J PHYSIOL-CELL PH, V281, pC1743; Kurzer MS, 2002, J NUTR, V132, p570S, DOI 10.1093/jn/132.3.570S; LAB MJ, 1990, CIRC RES, V66, P585, DOI 10.1161/01.RES.66.3.585; LEWARTOWSKI B, 1993, J MOL CELL CARDIOL, V25, P23, DOI 10.1006/jmcc.1993.1004; Lewis JG, 2002, STEROIDS, V67, P25, DOI 10.1016/S0039-128X(01)00129-5; Liggins J, 2000, BRIT J NUTR, V84, P717; Liu HY, 1997, CAN J PHYSIOL PHARM, V75, P1058, DOI 10.1139/cjpp-75-9-1058; MACLEOD KT, 1991, J PHYSIOL-LONDON, V444, P481, DOI 10.1113/jphysiol.1991.sp018889; Main MC, 1998, EXP PHYSIOL, V83, P747, DOI 10.1113/expphysiol.1998.sp004156; Mazur W, 1998, BAILLIERE CLIN ENDOC, V12, P729, DOI 10.1016/S0950-351X(98)80013-X; Mishra Santosh K., 2000, Cardiovascular Research, V46, P539, DOI 10.1016/S0008-6363(00)00049-3; Murkies AL, 1998, J CLIN ENDOCR METAB, V83, P297, DOI 10.1210/jc.83.2.297; Obayashi K, 1999, PFLUG ARCH EUR J PHY, V438, P269, DOI 10.1007/s004240050909; Paillart C, 1997, J PHARMACOL EXP THER, V280, P521; POSNER BI, 1994, J BIOL CHEM, V269, P4596; Sato A, 2000, METHOD FIND EXP CLIN, V22, P25, DOI 10.1358/mf.2000.22.1.795816; Setchell KDR, 1998, AM J CLIN NUTR, V68, p1333S, DOI 10.1093/ajcn/68.6.1333S; Setchell KDR, 2001, J AM COLL NUTR, V20, p354S, DOI 10.1080/07315724.2001.10719168; SHAH AM, 1994, CIRC RES, V74, P970, DOI 10.1161/01.RES.74.5.970; Shuba LM, 1996, BRIT J PHARMACOL, V119, P335, DOI 10.1111/j.1476-5381.1996.tb15991.x; Sims C, 2000, MOL PHARMACOL, V58, P1213, DOI 10.1124/mol.58.6.1213; SMIRNOV SV, 1995, CIRC RES, V76, P310, DOI 10.1161/01.RES.76.2.310; SPURGEON HA, 1990, AM J PHYSIOL, V258, pH574, DOI 10.1152/ajpheart.1990.258.2.H574; STEUSLOFF A, 1995, ARCH BIOCHEM BIOPHYS, V320, P236, DOI 10.1016/0003-9861(95)90005-5; Tanabe S, 1999, AM J PHYSIOL-HEART C, V277, pH826, DOI 10.1152/ajpheart.1999.277.2.H826; Tham DM, 1998, J CLIN ENDOCR METAB, V83, P2223, DOI 10.1210/jc.83.7.2223; Walker HA, 2001, CIRCULATION, V103, P258, DOI 10.1161/01.CIR.103.2.258; Wang H, 2001, EUR J PHARMACOL, V424, P91, DOI 10.1016/S0014-2999(01)01125-6; Wang YG, 1998, AM J PHYSIOL-HEART C, V275, pH204, DOI 10.1152/ajpheart.1998.275.1.H204; Watts SW, 1996, J VASC RES, V33, P288, DOI 10.1159/000159156; Yokoshiki H, 1996, J MOL CELL CARDIOL, V28, P807, DOI 10.1006/jmcc.1996.0075	51	22	23	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1307	+		10.1096/fj.02-0760fje	http://dx.doi.org/10.1096/fj.02-0760fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759336				2022-12-28	WOS:000183165000017
J	Staykova, MA; Berven, LA; Cowden, WB; Willenborg, DO; Crouch, MF				Staykova, MA; Berven, LA; Cowden, WB; Willenborg, DO; Crouch, MF			Nitric oxide induces polarization of actin in encephalitogenic T cells and inhibits their in vitro transendothelial migration in a p70S6 kinase-independent manner	FASEB JOURNAL			English	Article						T lymphocyte migration; CNS microvascular endothelial cells; autoimmune encephalomyelitis; F-actin	BRAIN ENDOTHELIAL-CELLS; LYMPHOCYTE MIGRATION; IN-VITRO; HUMAN NEUTROPHILS; ADP-RIBOSYLATION; NADPH OXIDASE; EXPRESSION; ACTIVATION; SYNTHASE; SHAPE	Nitric oxide (NO) inhibits both actively induced and transferred autoimmune encephalomyelitis. To explore potential mechanisms, we examined the ability of NO to inhibit migration of T lymphoblasts through both collagen matrices and monolayers of rat brain endothelial cells. The NO donor 1-hydroxy-2-oxo-3, 3-bis (2-aminoethyl)-1-triazene (HOBAT) inhibited migration in a concentration-dependent manner. NO pretreatment of T cells inhibited migration through untreated endothelial cells, but NO pretreatment of endothelial cells had no inhibitory effect on untreated T cells. Therefore NO's migration inhibitory action was mediated through its effect on T cells and not endothelial cells. HOBAT did not inhibit migration by inducing T-cell death but rather by polarizing the T cells, resulting in a morphology suggestive of migrating cells. P70S6 kinase, shown to have a role in NO-induced migration inhibition in fibroblasts, had no role in the inhibitory effect of NO on T-cell migration. Thus, HOBAT did not alter p70S6K activity nor did rapamycin, a specific inhibitor of p70S6K, inhibit HOBAT-induced T-cell morphological changes or T-cell migration. We suggest that NO-induced morphological changes result in T cells with predefined migratory directionality, thus limiting the ability of these cells to respond to other migratory signals.	Canberra Hosp, Neurosci Res Unit, Canberra, ACT, Australia; Australian Natl Univ, Sch Med, Canberra, ACT, Australia; Australian Natl Univ, John Curtin Sch Med Res, Canberra, ACT 2601, Australia	Australian National University; Canberra Hospital; Australian National University; Australian National University; John Curtin School of Medical Research	Staykova, MA (corresponding author), Neurosci Res Unit, Bldg 10,Level 6,Yamba Dr, Garran, ACT 2606, Australia.	maria.staykova@anu.edu.au						Balyasnikova IV, 2000, J CEREBR BLOOD F MET, V20, P688, DOI 10.1097/00004647-200004000-00006; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Berven LA, 1999, BIOCHEM BIOPH RES CO, V266, P352, DOI 10.1006/bbrc.1999.1833; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; CLANCY R, 1995, J LEUKOCYTE BIOL, V58, P196, DOI 10.1002/jlb.58.2.196; COATES TD, 1992, J CELL BIOL, V117, P765, DOI 10.1083/jcb.117.4.765; Cowden WB, 1998, J NEUROIMMUNOL, V88, P1, DOI 10.1016/S0165-5728(98)00040-X; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Dustin ML, 2000, CELL, V103, P283, DOI 10.1016/S0092-8674(00)00120-3; FRIEDL P, 1995, J IMMUNOL, V154, P4973; Friedl P, 1998, EUR J IMMUNOL, V28, P2331, DOI 10.1002/(SICI)1521-4141(199808)28:08<2331::AID-IMMU2331>3.0.CO;2-C; Friedl P, 2001, J LEUKOCYTE BIOL, V70, P491; Hokari R, 1998, GASTROENTEROLOGY, V115, P618, DOI 10.1016/S0016-5085(98)70141-6; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; IGNARRO LJ, 1991, BLOOD VESSELS, V28, P67; Jun CD, 1996, CELL IMMUNOL, V174, P25, DOI 10.1006/cimm.1996.0290; Kim PKM, 2001, INT IMMUNOPHARMACOL, V1, P1421, DOI 10.1016/S1567-5769(01)00088-1; Kroncke KD, 2001, INT IMMUNOPHARMACOL, V1, P1407, DOI 10.1016/S1567-5769(01)00087-X; Li JM, 2002, CIRC RES, V90, P143, DOI 10.1161/hh0202.103615; Loitto VM, 2000, J CELL PHYSIOL, V182, P402, DOI 10.1002/(SICI)1097-4652(200003)182:3<402::AID-JCP11>3.0.CO;2-D; LUDOWYK PA, 1993, J NEUROIMMUNOL, V48, P121, DOI 10.1016/0165-5728(93)90184-Z; Magazine HI, 2000, J IMMUNOL, V165, P102, DOI 10.4049/jimmunol.165.1.102; Matheny HE, 2000, J IMMUNOL, V164, P6550, DOI 10.4049/jimmunol.164.12.6550; MONCADA S, 1995, FASEB J, V9, P1319, DOI 10.1096/fasebj.9.13.7557022; PABST R, 1988, IMMUNOL TODAY, V9, P43, DOI 10.1016/0167-5699(88)91258-3; RAINE CS, 1980, LAB INVEST, V43, P150; ROTZINGER S, 1995, LIFE SCI, V56, P1321, DOI 10.1016/0024-3205(94)00083-2; Sanchez-Madrid F, 1999, EMBO J, V18, P501, DOI 10.1093/emboj/18.3.501; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Serrador JM, 1999, TRENDS CELL BIOL, V9, P228, DOI 10.1016/S0962-8924(99)01553-6; Shoker AS, 1997, MOL CELL BIOCHEM, V171, P75, DOI 10.1023/A:1006815430622; Staykova M, 2000, J NEUROPATH EXP NEUR, V59, P120, DOI 10.1093/jnen/59.2.120; Sun J, 2001, CIRCULATION, V103, P2967, DOI 10.1161/01.CIR.103.24.2967; TERADA LS, 1991, J CELL PHYSIOL, V148, P191, DOI 10.1002/jcp.1041480202; Tudor KSRS, 2001, CYTOKINE, V15, P196, DOI 10.1006/cyto.2001.0922; van der Goes A, 2001, FASEB J, V15, P1852, DOI 10.1096/fj.00-0881fje; Zech JC, 1998, INVEST OPHTH VIS SCI, V39, P1600; Zettl UK, 1997, CELL IMMUNOL, V178, P1, DOI 10.1006/cimm.1997.1113	40	22	22	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1337	+		10.1096/fj.02-0577fje	http://dx.doi.org/10.1096/fj.02-0577fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759332				2022-12-28	WOS:000183165000023
J	Kim, J; Nam, KH; Kim, SO; Choi, JH; Kim, HC; Yang, SD; Kang, JH; Ryu, YH; Oh, GT; Yoo, SE				Kim, J; Nam, KH; Kim, SO; Choi, JH; Kim, HC; Yang, SD; Kang, JH; Ryu, YH; Oh, GT; Yoo, SE			KR-31378 ameliorates atherosclerosis by blocking monocyte recruitment in hypercholestrolemic mice	FASEB JOURNAL			English	Article						inflammation; nuclear factor-kappa B; adhesion molecules	NF-KAPPA-B; ADHESION MOLECULE EXPRESSION; ENDOTHELIAL-CELLS; GROWTH-FACTOR; RABBIT MODEL; INFLAMMATION; VCAM-1; GENES; MOBILIZATION; ACTIVATION	The recruitment of monocytes into the artery wall is a crucial early step in atherogenesis. A novel compound, KR-31378, has been shown to be a neuroprotective agent for ischemia-reperfusion damage in rat brain via its potent antioxidant and antiapoptotic actions. Here, we report the effects of this compound on atherogenesis and possible mechanisms of action. In Ldlr knockout mice fed with a high-fat, high-cholesterol diet, treatment with KR-31378 significantly inhibited fatty streak formation and macrophage accumulation. To address the possibility that KR-31378 may influence the initial stages of atherogenesis, we examined its effect on the adhesion and migration of monocytes to endothelial cells stimulated with tumor necrosis factor-alpha,. KR-31378 decreased the adhesion in a dose-dependent manner. The observed decreases in cell adhesion and migration correlated with KR-31378-mediated down-regulation of vascular cell adhesion molecule-1 (VCAM-1) and interleukin (IL)-8. Nuclear factor-kappaB (NF-kappaB) is known to regulate the expression of adhesive and chemotactic molecules including VCAM-1 and IL-8. Indeed, transient transfection experiments, electrophoretic mobility shift assay, and IkappaB degradation assay showed that KR-31378 decreased NF-kappaB activation. These results indicate that KR-31378 potently reduces fatty streak formation by inhibiting NF-kappaB-dependent cellular adhesion and chemotactic molecule expression, which are crucial to monocyte infiltration into the arterial wall during the early stages of atherogenesis.	Korea Res Inst Biosci & Biotechnol, Lab Dev & Differentiat, Taejon 305333, South Korea; Korea Res Inst Biosci & Biotechnol, Lab Expt Anim Resources, Taejon 305333, South Korea; Dongbu Hannong Chem Co Ltd, Agropharma Res Inst, Taejon 305708, South Korea; Korea Res Inst Chem Technol, 21st Century Frontier Program, Ctr Biol Modulators, Taejon 305343, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Bioscience & Biotechnology (KRIBB); Korea Research Institute of Chemical Technology (KRICT)	Oh, GT (corresponding author), Korea Res Inst Biosci & Biotechnol, Lab Dev & Differentiat, 52 Oun Dong, Taejon 305333, South Korea.	gootaeg@kribb.re.kr	Oh, Goo Taeg/AAQ-9995-2021					ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Blumenthal RS, 2000, AM HEART J, V139, P577, DOI 10.1016/S0002-8703(00)90033-4; Boyle EM, 1998, CIRCULATION, V98, pII282; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Carr AC, 2000, CIRC RES, V87, P349, DOI 10.1161/01.RES.87.5.349; Che WY, 2002, CIRC RES, V90, P1222, DOI 10.1161/01.RES.0000021127.83364.7D; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Cominacini I, 1999, CELL ADHES COMMUN, V7, P223, DOI 10.3109/15419069909010804; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; Cybulsky MI, 2001, J CLIN INVEST, V107, P1255, DOI 10.1172/JCI11871; Cyrus T, 2002, CIRCULATION, V106, P1282, DOI 10.1161/01.CIR.0000027816.54430.96; FARNIER M, 1998, AM J CARDIOL, V82, P3; FEARS R, 1987, BAILLIERE CLIN ENDOC, V1, P727, DOI 10.1016/S0950-351X(87)80030-7; FRIES JWU, 1993, AM J PATHOL, V143, P725; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; GERRITSEN ME, 1995, AM J PATHOL, V147, P278; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goossens V, 1999, BIOFACTORS, V10, P145, DOI 10.1002/biof.5520100210; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; HAKIM J, 1993, CR SOC BIOL, V187, P286; Hernandez-Presa MA, 2002, ATHEROSCLEROSIS, V160, P49, DOI 10.1016/S0021-9150(01)00547-0; Hong JJ, 2001, BIOCHEM BIOPH RES CO, V281, P1127, DOI 10.1006/bbrc.2001.4480; Ishibashi M, 2002, HYPERTENSION, V40, P687, DOI 10.1161/01.HYP.0000036396.64769.C2; ISHIBASHI S, 1994, J CLIN INVEST, V93, P1885, DOI 10.1172/JCI117179; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Kharbanda RK, 2002, CIRCULATION, V105, P2600, DOI 10.1161/01.CIR.0000017863.52347.6C; Kim HJ, 2000, BIOPHARM DRUG DISPOS, V21, P279, DOI 10.1002/bdd.240; Kim Ki Young, 2001, Korean Journal of Physiology and Pharmacology, V5, P381; Kim KY, 2002, J PHARMACOL EXP THER, V300, P535, DOI 10.1124/jpet.300.2.535; KORENAGA R, 1997, AM J PHYSIOL, V273, pC1506; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lockyer JM, 1998, CIRC RES, V82, P314, DOI 10.1161/01.RES.82.3.314; Mooney A, 1999, CURR MED RES OPIN, V15, P65, DOI 10.1185/03007999909113366; Murase T, 1999, ARTERIOSCL THROM VAS, V19, P1412, DOI 10.1161/01.ATV.19.6.1412; Napoli C, 2001, J CELL BIOCHEM, V82, P674, DOI 10.1002/jcb.1198; Ouaaz F, 1999, J EXP MED, V189, P999, DOI 10.1084/jem.189.6.999; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Reape TJ, 1999, ATHEROSCLEROSIS, V147, P213, DOI 10.1016/S0021-9150(99)00346-9; Robbesyn F, 2003, FASEB J, V17, P743, DOI 10.1096/fj.02-0240fje; ROSS R, 1976, SCIENCE, V193, P1094, DOI 10.1126/science.822515; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Wajant H, 2003, CELL DEATH DIFFER, V10, P45, DOI 10.1038/sj.cdd.4401189; WEBER C, 1994, ARTERIOSCLER THROMB, V14, P1665, DOI 10.1161/01.ATV.14.10.1665; WEBER C, 1995, CIRCULATION, V91, P1914, DOI 10.1161/01.CIR.91.7.1914; Yoo S, 2001, J MED CHEM, V44, P4207, DOI 10.1021/jm010183f; Zhang H, 2002, AM J PATHOL, V160, P2219, DOI 10.1016/S0002-9440(10)61169-8	53	17	17	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					714	+		10.1096/fj.03-0652fje	http://dx.doi.org/10.1096/fj.03-0652fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766797				2022-12-28	WOS:000220425000035
J	Kwan, JA; Schulze, CJ; Wang, WJ; Leon, H; Sariahmetoglu, M; Sung, M; Sawicka, J; Sims, DE; Sawicki, G; Schulz, R				Kwan, JA; Schulze, CJ; Wang, WJ; Leon, H; Sariahmetoglu, M; Sung, M; Sawicka, J; Sims, DE; Sawicki, G; Schulz, R			Matrix metalloproteinase-2 (MMP-2) is present in the nucleus of cardiac myocytes and is capable of cleaving poly (ADP-ribose) polymerase (PARP) in vitro	FASEB JOURNAL			English	Article						gelatinase; nucleoproteins; proteolysis	ISCHEMIA-REPERFUSION INJURY; POLY(ADP-RIBOSE) POLYMERASE; TISSUE INHIBITOR; GELATINASE-A; DEGRADATION; ACTIVATION; PEROXYNITRITE; CLEAVAGE; APOPTOSIS; INFLAMMATION	Matrix metalloproteinases (MMPs) are traditionally known for their role in extracellular matrix remodeling. Increasing evidence reveals several alternative substrates and novel biological roles for these proteases. Recent evidence showed the intracellular localization of MMP-2 within cardiac myocytes, colocalized with troponin I within myofilaments. Here we investigated the presence of MMP-2 in the nucleus of cardiac myocytes using both immunogold electron microscopy and biochemical assays with nuclear extracts. The gelatinase activity found in both human heart and rat liver nuclear extracts was blocked with MMP inhibitors. In addition, the ability of MMP-2 to cleave poly (ADP-ribose) polymerase (PARP) as a substrate was examined as a possible role for MMP-2 in the nucleus. PARP is a nuclear matrix enzyme involved in the repair of DNA strand breaks, which is known to be inactivated by proteolytic cleavage. PARP was susceptible to cleavage by MMP-2 in vitro in a concentration-dependent manner, yielding novel degradation products of similar to66 and <45 kDa. The cleavage of PARP by MMP-2 was also blocked by MMP inhibitors. This is the first characterization of MMP-2 within the nucleus and we hereby suggest its possible role in PARP degradation.	Univ Alberta, Dept Pharmacol, Heritage Med Res Ctr, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Pediat, Heritage Med Res Ctr, Cardiovasc Res Grp, Edmonton, AB T6G 2S2, Canada; Univ Prince Edward Isl, Atlantic Vet Coll, Dept Anat & Physiol, Charlottetown, PE C1A 4P3, Canada	University of Alberta; University of Alberta; University of Prince Edward Island	Schulz, R (corresponding author), Univ Alberta, Dept Pediat, Heritage Med Res Ctr 462, Edmonton, AB T6G 2S2, Canada.	richard.schulz@ualberta.ca	Schulz, Richard/A-8739-2012; Schulz, Richard/M-3518-2019	Schulz, Richard/0000-0002-5045-3193; Schulz, Richard/0000-0002-5045-3193				Alexandre S, 2000, BIOCHIMIE, V82, P1115, DOI 10.1016/S0300-9084(00)01194-9; CANNON RO, 1983, AM J CARDIOL, V52, P390, DOI 10.1016/0002-9149(83)90145-5; Chen EI, 2002, J BIOL CHEM, V277, P4485, DOI 10.1074/jbc.M109469200; Cheung PY, 2000, CIRCULATION, V101, P1833, DOI 10.1161/01.CIR.101.15.1833; Coker ML, 1999, AM J PHYSIOL-HEART C, V277, pH777, DOI 10.1152/ajpheart.1999.277.2.H777; Denis LJ, 1997, INVEST NEW DRUG, V15, P175, DOI 10.1023/A:1005855905442; DOLLERY CM, 1995, CIRC RES, V77, P863, DOI 10.1161/01.RES.77.5.863; Fernandez-Patron C, 2000, CIRC RES, V87, P670, DOI 10.1161/01.RES.87.8.670; Fernandez-Patron C, 1999, CIRC RES, V85, P906; Georgi AB, 2002, CURR BIOL, V12, P105, DOI 10.1016/S0960-9822(01)00662-5; GOLUB LM, 1991, CRIT REV ORAL BIOL M, V2, P297, DOI 10.1177/10454411910020030201; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Jackson DA, 1995, INT REV CYTOL, V162A, P125; KAUFMANN SH, 1993, CANCER RES, V53, P3976; LATT SA, 1969, BIOCHEM BIOPH RES CO, V37, P333, DOI 10.1016/0006-291X(69)90739-6; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Martelli AM, 1997, HISTOCHEM CELL BIOL, V108, P1, DOI 10.1007/s004180050140; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Nagase H, 1997, BIOL CHEM, V378, P151; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; Okamoto T, 2001, J BIOL CHEM, V276, P29596, DOI 10.1074/jbc.M102417200; Okamoto T, 1997, ARCH BIOCHEM BIOPHYS, V342, P261, DOI 10.1006/abbi.1997.0127; OWEN CA, 1995, SEMIN CELL BIOL, V6, P367, DOI 10.1016/S1043-4682(05)80007-8; POLLARD TD, 2002, CELL BIOL, P268; Ritter LM, 1999, BIOCHEM BIOPH RES CO, V257, P494, DOI 10.1006/bbrc.1999.0408; Rouet-Benzineb P, 1999, EUR J HEART FAIL, V1, P337, DOI 10.1016/S1388-9842(99)00048-3; Ruh MF, 1996, CRIT REV EUKAR GENE, V6, P271, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.80; SATO S, 1983, J MOL CELL CARDIOL, V15, P261, DOI 10.1016/0022-2828(83)90281-X; Sawicki G, 1998, THROMB HAEMOSTASIS, V80, P836; Sawicki G, 1997, NATURE, V386, P616, DOI 10.1038/386616a0; Si-Yayeb K, 2003, J HEPATOL, V38, P105, DOI 10.1016/S0168-8278(03)80622-0; Szabo C, 1998, TRENDS PHARMACOL SCI, V19, P287, DOI 10.1016/S0165-6147(98)01193-6; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; Thiemermann C, 1997, P NATL ACAD SCI USA, V94, P679, DOI 10.1073/pnas.94.2.679; Wang WJ, 2002, CIRCULATION, V106, P1543, DOI 10.1161/01.CIR.0000028818.33488.7B; Wang WJ, 2002, CARDIOVASC RES, V53, P165, DOI 10.1016/S0008-6363(01)00445-X; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yasmin W, 1997, CARDIOVASC RES, V33, P422, DOI 10.1016/S0008-6363(96)00254-4; Zhao WQ, 1998, J CELL SCI, V111, P1147	39	193	204	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					690	+		10.1096/fj.02-1202fje	http://dx.doi.org/10.1096/fj.02-1202fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766804				2022-12-28	WOS:000220425000042
J	Schwabe, RF; Uchinami, H; Qian, T; Bennett, BL; Lemasters, JJ; Brenner, DA				Schwabe, RF; Uchinami, H; Qian, T; Bennett, BL; Lemasters, JJ; Brenner, DA			Differential requirement for c-Jun NH2-terminal kinase in TNF-alpha- and Fas-mediated apoptosis in hepatocytes	FASEB JOURNAL			English	Article						signal transduction; mitochondrial permeability transition; caspase; cytochrome c	NECROSIS-FACTOR-ALPHA; N-TERMINAL KINASE; KAPPA-B; SIGNAL-TRANSDUCTION; JNK ACTIVATION; CELL-DEATH; LIVER; INHIBITION; PROLIFERATION; INDUCTION	The c-Jun NH2-terminal kinase (INK) is involved in the regulation of cell death, but its role in tumor necrosis factor (TNF)-alpha- and Fas-mediated apoptosis in primary cells is not well defined. In primary rat hepatocytes expressing an IkappaB superrepressor, the INK inhibitor SP600125 strongly decreased TNF-alpha-induced cell death, caspase 3 activation, and DNA laddering. In contrast, SP600125 did not rescue mouse hepatocytes from Fas-induced apoptosis. Apoptosis in mouse hepatocytes, induced by human TNF-alpha, was blocked by SP600125, indicating that TNF-receptor (TNF-R) 1-mediated JNK activation is important for TNF-alpha-induced death. However, mouse TNF-alpha was more efficient than human TNF-alpha in activating INK and killing mouse hepatocytes, suggesting that TNF-R1 and TNF-R2 cooperate in INK activation and apoptosis. SP600125 rescued actinomycin D-pretreated hepatocytes and hepatocytes expressing a dominant negative c-Jun from TNF-alpha, indicating that INK exerts its proapoptotic effect independently of transcription and c-Jun. SP600125 delayed the mitochondrial permeability transition, inhibited cytochrome c release and prevented bid degradation after TNF-alpha, suggesting that JNK-regulated proapoptotic factors act upstream of the mitochondria. Moreover, overexpression of JNK1 activated a mitochondrial death pathway in hepatocytes, albeit less efficiently than TNF-alpha. This study demonstrates that INK augments TNF-alpha-induced apoptosis in hepatocytes through a signaling pathway that is distinct from the pathway by which it regulates proliferation.	Univ N Carolina, Dept Med, Chapel Hill, NC USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC USA; Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC USA; Celgene Corp, Signal Res Div, San Diego, CA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Bristol-Myers Squibb; Celgene Corporation	Schwabe, RF (corresponding author), Univ N Carolina, Dept Med, Chapel Hill, NC USA.	rfs2102@columbia.edu	Schwabe, Robert/AAY-6506-2021	Brenner, David/0000-0003-2573-525X				Aoki H, 2002, J BIOL CHEM, V277, P10244, DOI 10.1074/jbc.M112355200; Behrens A, 2002, EMBO J, V21, P1782, DOI 10.1093/emboj/21.7.1782; Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bradham CA, 1998, MOL CELL BIOL, V18, P6353, DOI 10.1128/MCB.18.11.6353; Bradham CA, 2001, AM J PHYSIOL-GASTR L, V281, pG1279, DOI 10.1152/ajpgi.2001.281.5.G1279; Chen YR, 1996, J BIOL CHEM, V271, P631, DOI 10.1074/jbc.271.2.631; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; Crenesse D, 2001, HEPATOLOGY, V34, P972, DOI 10.1053/jhep.2001.28709; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fotin-Mleczek M, 2002, J CELL SCI, V115, P2757; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; HALDAR S, 1995, P NATL ACAD SCI USA, V92, P4507, DOI 10.1073/pnas.92.10.4507; HERMAN B, 1988, FASEB J, V2, P146, DOI 10.1096/fasebj.2.2.3342967; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Hochedlinger K, 2002, ONCOGENE, V21, P2441, DOI 10.1038/sj.onc.1205348; Iimuro Y, 1998, J CLIN INVEST, V101, P802, DOI 10.1172/JCI483; Kaneto H, 2002, J BIOL CHEM, V277, P30010, DOI 10.1074/jbc.M202066200; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Latta M, 2000, J EXP MED, V191, P1975, DOI 10.1084/jem.191.11.1975; Lehmann TG, 2000, HEPATOLOGY, V32, P1255, DOI 10.1053/jhep.2000.19814; Lei K, 2002, MOL CELL BIOL, V22, P4929, DOI 10.1128/MCB.22.13.4929-4942.2002; Lei K, 2003, P NATL ACAD SCI USA, V100, P2432, DOI 10.1073/pnas.0438011100; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; Liedtke C, 2002, HEPATOLOGY, V36, P315, DOI 10.1053/jhep.2002.34615; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Qiao L, 2003, MOL CELL BIOL, V23, P3052, DOI 10.1128/MCB.23.9.3052-3066.2003; Rudiger HA, 2002, GASTROENTEROLOGY, V122, P202, DOI 10.1053/gast.2002.30304; Sabapathy K, 1999, MECH DEVELOP, V89, P115, DOI 10.1016/S0925-4773(99)00213-0; Sanlioglu S, 2001, J BIOL CHEM, V276, P30188, DOI 10.1074/jbc.M102061200; Schlosser SF, 2000, HEPATOLOGY, V32, P779, DOI 10.1053/jhep.2000.18422; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; Schwabe RF, 2001, J IMMUNOL, V166, P6812, DOI 10.4049/jimmunol.166.11.6812; Schwabe RF, 2001, HEPATOLOGY, V33, P81, DOI 10.1053/jhep.2001.20799; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Streetz K, 2001, J IMMUNOL, V167, P514, DOI 10.4049/jimmunol.167.1.514; Tang FM, 2002, MOL CELL BIOL, V22, P8571, DOI 10.1128/MCB.22.24.8571-8579.2002; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Uehara T, 2001, HEPATOLOGY, V34, p348A; Villunger A, 2000, J IMMUNOL, V165, P1337, DOI 10.4049/jimmunol.165.3.1337; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	49	119	131	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					720	+		10.1096/fj.03-0771fje	http://dx.doi.org/10.1096/fj.03-0771fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766793				2022-12-28	WOS:000220425000044
J	Oshima, K; Shimamura, M; Mizuno, S; Tamai, K; Doi, K; Morishita, R; Nakamura, T; Kubo, T; Kaneda, Y				Oshima, K; Shimamura, M; Mizuno, S; Tamai, K; Doi, K; Morishita, R; Nakamura, T; Kubo, T; Kaneda, Y			Intrathecal injection of HVJ-E containing HGF gene to cerebrospinal fluid can prevent and ameliorate hearing impairment in rats	FASEB JOURNAL			English	Article						hair cell; spiral ganglion; cochlear implants; gene therapy	HEPATOCYTE GROWTH-FACTOR; ESSENTIAL TRANSCRIPTION FACTOR; CISPLATIN-INDUCED DAMAGE; SPIRAL GANGLION NEURONS; FACTOR-SCATTER FACTOR; AUDITORY NEURONS; TRANSGENE EXPRESSION; NEUROTROPHIC FACTOR; SUBARACHNOID SPACE; NUCLEAR-PROTEIN	Hearing impairment, which is the most prevalent sensory deficit of human beings, needs a breakthrough in therapeutic technologies. One technology is the usage of a vector system to reach the inner ear, and another is by a therapeutic molecule. Here we developed a novel gene therapy strategy by combining hepatocyte growth factor (HGF) with hemagglutinating virus of Japan envelope (HVJ-E) vector. When HVJ-E containing human HGF gene was injected intrathecally into the cerebrospinal fluid via cisterna magna of rats, the vector reached the inner ear region, and human HGF gene expression was detected in the spiral ganglion cells (SGCs) of the inner ear. Expression of endogenous rat HGF and its receptor, c-Met, was also induced in SGCs by human HGF. Kanamycin treatment results in hearing impairment by inducing degeneration of hair cells (HCs) and apoptosis of SGCs in rats. By HGF gene transfer before kanamycin treatment, both loss of HCs and apoptosis of SGCs were prevented. Furthermore, hearing function, evaluated by auditory brainstem response, was maintained at a normal level. When HGF gene transfer was performed 2 wk after kanamycin treatment, hearing impairment was significantly recovered. These results indicate a novel and effective therapeutic strategy against sensorineural hearing impairment.	Osaka Univ, Div Gene Therapy Sci, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Dept Otolaryngol & Sensory Organ Surg, Grad Sch Med, Suita, Osaka 5650871, Japan; Osaka Univ, Div Biochem, Grad Sch Med, Dept Oncol,Biomed Res Ctr B7, Suita, Osaka 5650871, Japan	Osaka University; Osaka University; Osaka University	Kaneda, Y (corresponding author), Osaka Univ, Div Gene Therapy Sci, Grad Sch Med, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	kaneday@gts.med.osaka-u.ac.jp			grants from the Ministry of Health, Labor and Welfare of Japan	grants from the Ministry of Health, Labor and Welfare of Japan	We thank Yoshinaga Saeki, Masayuki Endoh, Seiji Yamamoto, Yo C.Y., and members of our laboratory for helpful comments and discussions. This work was supported by grants from the Ministry of Health, Labor and Welfare of Japan.	Aoki M, 2000, GENE THER, V7, P417, DOI 10.1038/sj.gt.3301104; BICHLER E, 1983, ARCH OTO-RHINO-LARYN, V237, P201, DOI 10.1007/BF00453725; Bowers WJ, 2002, MOL THER, V6, P12, DOI 10.1006/mthe.2002.0627; Chen XW, 2001, MOL THER, V3, P958, DOI 10.1006/mthe.2001.0334; DOI K, 1999, OTOL JPN, V9, P85; Ernfors P, 1996, NAT MED, V2, P463, DOI 10.1038/nm0496-463; Forge A, 2000, AUDIOL NEURO-OTOL, V5, P3, DOI 10.1159/000013861; Gabaizadeh R, 1997, ACTA OTO-LARYNGOL, V117, P232, DOI 10.3109/00016489709117778; Gao WQ, 1998, MOL NEUROBIOL, V17, P17, DOI 10.1007/BF02802022; Hashimoto N, 2001, MOL BRAIN RES, V97, P83, DOI 10.1016/S0169-328X(01)00284-4; Hashimoto N, 2001, NEUROREPORT, V12, P1403, DOI 10.1097/00001756-200105250-00022; Hayashi K, 2001, GENE THER, V8, P1167, DOI 10.1038/sj.gt.3301498; HONDA S, 1995, MOL BRAIN RES, V32, P197, DOI 10.1016/0169-328X(95)00075-4; Incesulu A, 1998, ANN OTO RHINOL LARYN, V107, P906, DOI 10.1177/000348949810701102; Jero J, 2001, HUM GENE THER, V12, P539, DOI 10.1089/104303401300042465; JUNG W, 1994, J CELL BIOL, V126, P485, DOI 10.1083/jcb.126.2.485; KANEDA Y, 1989, SCIENCE, V243, P375, DOI 10.1126/science.2911748; Kaneda Y, 1999, MOL MED TODAY, V5, P298, DOI 10.1016/S1357-4310(99)01482-3; Kaneda Y, 2002, MOL THER, V6, P219, DOI 10.1006/mthe.2002.0647; KATO K, 1991, J BIOL CHEM, V266, P3361; Kawamoto K, 2001, MOL THER, V4, P575, DOI 10.1006/mthe.2001.0490; Kho ST, 2000, MOL THER, V2, P368, DOI 10.1006/mthe.2000.0129; Lalwani AK, 1997, HEARING RES, V114, P139, DOI 10.1016/S0378-5955(97)00151-2; Maina F, 1999, NAT NEUROSCI, V2, P213, DOI 10.1038/6310; Maina F, 1997, GENE DEV, V11, P3341, DOI 10.1101/gad.11.24.3341; MILLS JH, 1982, ENVIRON HEALTH PERSP, V44, P119, DOI 10.2307/3429484; Miyazawa T, 1998, J CEREBR BLOOD F MET, V18, P345, DOI 10.1097/00004647-199804000-00001; Morishita R, 2002, CIRC J, V66, P1077, DOI 10.1253/circj.66.1077; Nakagami H, 2002, DIABETES, V51, P2604, DOI 10.2337/diabetes.51.8.2604; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; Paumelle R, 2002, ONCOGENE, V21, P2309, DOI 10.1038/sj.onc.1205297; Shimamura M, 2003, BIOCHEM BIOPH RES CO, V300, P464, DOI 10.1016/S0006-291X(02)02807-3; SPOENDLIN H, 1975, ACTA OTO-LARYNGOL, V79, P266, DOI 10.3109/00016487509124683; Staecker H, 1996, NEUROREPORT, V7, P889, DOI 10.1097/00001756-199603220-00011; Stover T, 1999, HEARING RES, V136, P124, DOI 10.1016/S0378-5955(99)00115-X; Stover T, 2000, GENE THER, V7, P377, DOI 10.1038/sj.gt.3301108; Sun W, 2002, J NEUROSCI, V22, P6537; Sun W, 2002, MOL BRAIN RES, V103, P36, DOI 10.1016/S0169-328X(02)00168-7; Sun W, 1999, BRAIN RES, V851, P46, DOI 10.1016/S0006-8993(99)02097-1; Taniyama Y, 2002, HYPERTENSION, V40, P47, DOI 10.1161/01.HYP.0000020755.56955.BF; Tomita N, 1996, BIOCHEM BIOPH RES CO, V224, P43, DOI 10.1006/bbrc.1996.0982; Tomita N, 2003, CIRCULATION, V107, P1411, DOI 10.1161/01.CIR.0000055331.41937.AA; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tsujie M, 2001, J AM SOC NEPHROL, V12, P949, DOI 10.1681/ASN.V125949; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; Wu WJ, 2001, HEARING RES, V158, P165, DOI 10.1016/S0378-5955(01)00303-3; Yagi M, 2000, JARO-J ASSOC RES OTO, V1, P315, DOI 10.1007/s101620010011; Yamada K, 1996, AM J PHYSIOL-REG I, V271, pR1212, DOI 10.1152/ajpregu.1996.271.5.R1212; Yamasoba T, 1999, HUM GENE THER, V10, P769, DOI 10.1089/10430349950018526; Yang XM, 1998, J NEUROSCI, V18, P8369; Yoshimura S, 2002, HYPERTENSION, V39, P1028, DOI 10.1161/01.HYP.0000017553.67732.E1	52	41	46	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					212	214		10.1096/fj.03-0567fje	http://dx.doi.org/10.1096/fj.03-0567fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630698				2022-12-28	WOS:000188829300077
J	Shikata, Y; Birukov, KG; Birukova, AA; Verin, A; Garcia, JGN				Shikata, Y; Birukov, KG; Birukova, AA; Verin, A; Garcia, JGN			Involvement of site-specific FAK phosphorylation in sphingosine-1 phosphate- and thrombin-induced focal adhesion remodeling: role of Src and GIT	FASEB JOURNAL			English	Article						human pulmonary artery endothelium; barrier function; cytoskeleton	PROTEIN-KINASE-C; ENDOTHELIAL-CELLS; TYROSINE PHOSPHORYLATION; QUANTITATIVE MEASUREMENT; LYSOPHOSPHATIDIC ACID; BARRIER DYSFUNCTION; MOLECULAR-CLONING; BINDING-SITE; LIM DOMAINS; IN-VITRO	Sphingosine-1 phosphate (S1P) and thrombin are agents with profound but divergent effects on vascular endothelial cell (EC) barrier properties. We have previously reported that S1P-induced focal adhesion (FA) remodeling involves interactions between focal adhesion kinase (FAK), paxillin, and G-protein-coupled receptor kinase-interacting proteins GIT1 and GIT2 and suggested a critical involvement of focal adhesions in the EC barrier regulation. In this study, we examined redistribution of FA proteins (FAK, paxillin, GIT1, and GIT2) and site-specific FAK tyrosine phosphorylation in human pulmonary artery endothelial cells stimulated with thrombin. In contrast to S1P, which we have shown to induce peripheral translocation of FA proteins associated with cortical actin ring formation, thrombin caused the redistribution of FA proteins to the ends of the newly formed massive stress fibers. S1P and thrombin induced distinct patterns of FAK site-specific phosphorylation with the FAK Y-576 phosphorylation site targeted by SIP challenge and phosphorylation of three FAK sites (Y-397, Y-576, and Y-925) in response to thrombin stimulation. Pharmacological inhibition of Src with Src-specific inhibitor PP2 abolished S1P-induced translocation of FA proteins, cortical actin ring formation, and FAK [Y576] phosphorylation. However, PP2 failed to alter thrombin-induced morphological changes and exhibited only partial inhibition of FAK site-specific tyrosine phosphorylation. These observations highlight the differential mechanisms of focal adhesion protein complex remodeling and FAK activation by S1P and thrombin and link differential FA remodeling to EC barrier regulation.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21224 USA	Johns Hopkins University	Garcia, JGN (corresponding author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 5501 Hopkins Bayview Circle,JHAAC,4B-77, Baltimore, MD 21224 USA.	drgarcia@jhmi.edu	Garcia, Joe GN/E-8862-2010; Birukov, Konstantin/FJB-5755-2022		NHLBI NIH HHS [HL 69340, HL 58064, HL 50533] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050533, P01HL058064, R01HL069340] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; BELLIS SL, 1995, J BIOL CHEM, V270, P17437, DOI 10.1074/jbc.270.29.17437; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; Borbiev T, 2001, AM J PHYSIOL-LUNG C, V280, pL983, DOI 10.1152/ajplung.2001.280.5.L983; Brown MC, 1998, MOL BIOL CELL, V9, P1803, DOI 10.1091/mbc.9.7.1803; English D, 2001, CARDIOVASC RES, V49, P588, DOI 10.1016/S0008-6363(00)00230-3; FINCHAM VJ, 1995, ONCOGENE, V10, P2247; GARCIA JGN, 1992, BLOOD, V79, P2056; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; GARCIA JGN, 1992, AM J RESP CELL MOL, V6, P315, DOI 10.1165/ajrcmb/6.3.315; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garcia JGN, 1997, AM J RESP CELL MOL, V16, P489, DOI 10.1165/ajrcmb.16.5.9160829; GIMBRONE MA, 1969, NATURE, V221, P33; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hisano N, 1999, BLOOD, V93, P4293, DOI 10.1182/blood.V93.12.4293.412k26_4293_4299; Ilic Dusko, 1995, Nature (London), V377, P539, DOI 10.1038/377539a0; Lee MJ, 1998, SCIENCE, V279, P1552, DOI 10.1126/science.279.5356.1552; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; LO SK, 1988, AM J PHYSIOL, V254, pHMLO; Lum H, 1996, CAN J PHYSIOL PHARM, V74, P787, DOI 10.1139/cjpp-74-7-787; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Mazaki Y, 2001, MOL BIOL CELL, V12, P645, DOI 10.1091/mbc.12.3.645; MCDNAGH PF, 1986, AM J PHYSIOL, V251, pH581; Murata N, 2000, ANAL BIOCHEM, V282, P115, DOI 10.1006/abio.2000.4580; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 2003, J CELL SCI, V116, P1409, DOI 10.1242/jcs.00373; PATTERSON CE, 1994, MICROVASC RES, V48, P212, DOI 10.1006/mvre.1994.1050; Ren XD, 2000, J CELL SCI, V113, P3673; ROY AJ, 1972, P SOC EXP BIOL MED, V139, P137; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sastry SK, 2000, EXP CELL RES, V261, P25, DOI 10.1006/excr.2000.5043; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SCHALLER MD, 1995, MOL CELL BIOL, V15, P2635; SHEPRO D, 1984, THROMB RES, V35, P421, DOI 10.1016/0049-3848(84)90234-2; Shikata Y, 2003, J APPL PHYSIOL, V94, P1193, DOI 10.1152/japplphysiol.00690.2002; Shikata Y, 1999, BIOCHEM BIOPH RES CO, V257, P234, DOI 10.1006/bbrc.1999.0441; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; Turner CE, 1998, INT J BIOCHEM CELL B, V30, P955, DOI 10.1016/S1357-2725(98)00062-4; Vouret-Craviari V, 2002, J CELL SCI, V115, P2475; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Wang F, 1997, BIOCHEM J, V324, P481, DOI 10.1042/bj3240481; WENG ZG, 1993, J BIOL CHEM, V268, P14956; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; WOOD CK, 1994, J CELL SCI, V107, P709; YATOMI Y, 1995, ANAL BIOCHEM, V230, P315, DOI 10.1006/abio.1995.1480; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	49	107	109	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2240	2249		10.1096/fj.03-0198com	http://dx.doi.org/10.1096/fj.03-0198com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656986				2022-12-28	WOS:000188067500045
J	Bak, I; Szendrei, L; Turoczi, T; Papp, G; Joo, F; Das, DK; de Leiris, J; Der, P; Juhasz, B; Varga, E; Bacskay, I; Balla, J; Kovacs, P; Tosaki, A				Bak, I; Szendrei, L; Turoczi, T; Papp, G; Joo, F; Das, DK; de Leiris, J; Der, P; Juhasz, B; Varga, E; Bacskay, I; Balla, J; Kovacs, P; Tosaki, A			Heme oxygenase-1 related carbon monoxide production and ventricular fibrillation in isolated ischemic/reperfused mouse myocardium	FASEB JOURNAL			English	Article						heme oxygenase-1 expression ischemia/reperfusion; HO-1 knockout mouse hearts	ENDOGENOUS MODULATOR; REPERFUSION INJURY; NITRIC-OXIDE; GENE; INDUCTION; BILIRUBIN; PROTECTS; HEART; OVEREXPRESSION; DYSFUNCTION	Heme oxygenase-1 (HO-1)-dependent carbon monoxide (CO) production related to reperfusion-induced ventricular fibrillation (VF) was studied in HO-1 wild-type (+/+), heterozygous (+/-), and homozygous (-/-) isolated ischemic/reperfused mouse heart. In HO-1 homozygous myocardium, under aerobic conditions, HO-1 enzyme activity, HO-1 mRNA, and protein expression were not detected in comparison with aerobically perfused wild-type and heterozygous myocardium. In wild-type, HO-1 hetero- and homozygous hearts subjected to 20 min ischemia followed by 2 h of reperfusion, the expression of HO-1 mRNA, protein, and HO-1 enzyme activity was detected in various degrees. A reduction in the expression of HO-1 mRNA, protein, and enzyme activity in fibrillated wild-type and heterozygous myocardium was observed. In reperfused/nonfibrillated wild-type and heterozygous hearts, a reduction in HO-1 mRNA, protein expression, and HO-1 enzyme activity was not observed, indicating that changes in HO-1 mRNA, protein, and enzyme activity could be related to the development of VF. These changes were reflected in the HO-1-related endogenous CO production measured by gas chromatography. In HO-1 knockout ischemic/reperfused myocardium, all hearts showed VF, and no detection in HO-1 mRNA, protein, and enzyme activity was observed. Thus, interventions that are able to increase endogenous CO may prevent the development of VF.	Univ Debrecen, Hlth & Sci Ctr, Dept Pharmacol, H-4032 Debrecen, Hungary; Univ Debrecen, Hlth & Sci Ctr, Dept Internal Med 1, H-4032 Debrecen, Hungary; Univ Debrecen, Dept Phys Chem, H-4032 Debrecen, Hungary; Univ Debrecen, Hungarian Acad Sci, Res Grp Homogeneous Catalysis, H-4032 Debrecen, Hungary; Univ Connecticut, Ctr Hlth, Sch Med, Farmington, CT USA; Univ Grenoble 1, Dept Cardiovasc Pharmacol, Grenoble, France	University of Debrecen; University of Debrecen; University of Debrecen; Hungarian Academy of Sciences; University of Debrecen; University of Connecticut; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Tosaki, A (corresponding author), Univ Debrecen, Hlth & Sci Ctr, Dept Pharmacol, Nagyerdei Krt 98, H-4032 Debrecen, Hungary.	tosaki@king.pharmacol.dote.hu	Gábor, Papp/J-5534-2015; Ferenc, Joo/B-3753-2011	Balla, Jozsef/0000-0001-7923-2645				ALTO LE, 1979, AM J PHYSIOL, V237, pH713, DOI 10.1152/ajpheart.1979.237.6.H713; Birnbaum Y, 1997, J ELECTROCARDIOL, V30, P211, DOI 10.1016/S0022-0736(97)80006-4; Birnbaum Y, 1996, AM J CARDIOL, V78, P396, DOI 10.1016/S0002-9149(96)00326-8; Choi AMK, 2001, CIRC RES, V89, P105, DOI 10.1161/res.89.2.105; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTODOULIDES N, 1995, CIRCULATION, V91, P2306, DOI 10.1161/01.CIR.91.9.2306; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; COOK MN, 1995, CAN J PHYSIOL PHARM, V73, P515, DOI 10.1139/y95-065; CURTIS MJ, 1993, CARDIOVASC RES, V27, P703, DOI 10.1093/cvr/27.5.703; DEBIAS DA, 1976, ARCH ENVIRON HEALTH, V31, P42, DOI 10.1080/00039896.1976.10667188; Dickson EW, 2001, J MOL CELL CARDIOL, V33, P1751, DOI 10.1006/jmcc.2001.1436; DOROSHOW JH, 1980, J CLIN INVEST, V65, P128, DOI 10.1172/JCI109642; EWING JF, 1994, J PHARMACOL EXP THER, V271, P408; Gray RA, 1998, NATURE, V392, P75, DOI 10.1038/32164; HEWETT TE, 1994, CIRC RES, V74, P740, DOI 10.1161/01.RES.74.4.740; Hoenicka M, 1999, J MOL MED-JMM, V77, P14, DOI 10.1007/s001090050292; Hopkins PN, 1996, ARTERIOSCL THROM VAS, V16, P250, DOI 10.1161/01.ATV.16.2.250; Ingi T, 1996, NEURON, V16, P835, DOI 10.1016/S0896-6273(00)80103-8; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lakkisto P, 2002, J MOL CELL CARDIOL, V34, P1357, DOI 10.1006/jmcc.2002.2094; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; LI Y, 1995, MAT SCI ENG C-BIOMIM, V2, P221, DOI 10.1016/0928-4931(95)00075-5; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Melo LG, 2002, CIRCULATION, V105, P602, DOI 10.1161/hc0502.103363; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 1999, CHEST, V116, p61S, DOI 10.1378/chest.116.suppl_1.61S-a; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; Pataki T, 2001, ANTIOXID REDOX SIGN, V3, P125, DOI 10.1089/152308601750100623; Pellacani A, 1998, CIRC RES, V83, P396, DOI 10.1161/01.RES.83.4.396; PRIDJIAN AK, 1987, J THORAC CARDIOV SUR, V93, P428; Reeve VE, 1999, P NATL ACAD SCI USA, V96, P9317, DOI 10.1073/pnas.96.16.9317; ROSEN MR, 1995, CIRCULATION, V92, P3373, DOI 10.1161/01.CIR.92.12.3373; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Schultz JEJ, 1997, AM J PHYSIOL-HEART C, V272, pH2607, DOI 10.1152/ajpheart.1997.272.6.H2607; Sharma VS, 1999, METHODS, V19, P494, DOI 10.1006/meth.1999.0892; Simkhovich Boris Z, 2002, Heart Dis, V4, P63; SUEMATSU M, 1995, J CLIN INVEST, V96, P2431, DOI 10.1172/JCI118300; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tyrrell R, 1999, FREE RADICAL RES, V31, P335, DOI 10.1080/10715769900300901; TZIVONI D, 1983, AM HEART J, V105, P323, DOI 10.1016/0002-8703(83)90534-3; Vulapalli SR, 2002, AM J PHYSIOL-HEART C, V283, pH688, DOI 10.1152/ajpheart.00133.2002; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314	49	54	57	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2133	+		10.1096/fj.03-0032fje	http://dx.doi.org/10.1096/fj.03-0032fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958158				2022-12-28	WOS:000185925100021
J	Borlak, J; Thum, T				Borlak, J; Thum, T			Hallmarks of ion channel gene expression in end-stage heart failure	FASEB JOURNAL			English	Article						ion channels; gene expression; repressors; heart failure; assist device	HUMAN ATRIAL-FIBRILLATION; CURRENT DOWN-REGULATION; FAILING HUMAN HEART; CARDIAC TROPONIN-T; MESSENGER-RNA; DIFFERENTIAL REGULATION; DILATED CARDIOMYOPATHY; NATRIURETIC PEPTIDES; VENTRICULAR MYOCYTES; PRESSURE-OVERLOAD	Electrical conductance is greatly altered in end-stage heart failure, but little is known about the underlying events. We therefore investigated the expression of genes coding for major inward and outward ion channels, calcium binding proteins, ion receptors, ion exchangers, calcium ATPases, and calcium/calmodulin-dependent protein kinases in explanted hearts (n = 13) of patients diagnosed with end-stage heart failure. With the exception of Kv11.1 and Kir3.1 and when compared with healthy controls, major sodium, potassium, and calcium ion channels, ion transporters, and exchangers were significantly repressed, but expression of Kv7.1, HCN4, troponin C and I, SERCA1, and phospholamban was elevated. Hierarchical gene cluster analysis provided novel insight into regulated gene networks. Significant induction of the transcriptional repressor m-Bop and the translational repressor NAT1 coincided with repressed cardiac gene expression. The statistically significant negative correlation between repressors and ion channels points to a mechanism of disease. We observed coregulation of ion channels and the androgen receptor and propose a role for this receptor in ion channel regulation. Overall, the reversal of repressed ion channel gene expression in patients with implanted assist devices exemplifies the complex interactions between pressure load/stretch force and heart-specific gene expression.	Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, D-30625 Hannover, Germany	Fraunhofer Gesellschaft	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, Nicolai Fuchs Str 1, D-30659 Hannover, Germany.	Borlak@item.fraunhofer.de		Thum, Thomas/0000-0003-4360-1511				Akao M, 1997, J CLIN INVEST, V100, P3053, DOI 10.1172/JCI119860; Anger M, 1998, CIRCULATION, V98, P2477, DOI 10.1161/01.CIR.98.22.2477; Barrans JD, 2002, AM J PATHOL, V160, P2035, DOI 10.1016/S0002-9440(10)61153-4; Baumer AT, 2002, J APPL PHYSIOL, V92, P1058, DOI 10.1152/japplphysiol.00794.2001; BEUCKELMANN DJ, 1993, CIRC RES, V73, P379, DOI 10.1161/01.RES.73.2.379; Boixel C, 2001, CIRC RES, V89, P607, DOI 10.1161/hh1901.096702; Boknik P, 1999, CARDIOVASC RES, V43, P67, DOI 10.1016/S0008-6363(99)00053-X; Brown DW, 2000, AM HEART J, V140, P848, DOI 10.1067/mhj.2000.111112; BRUGADA P, 1992, J AM COLL CARDIOL, V20, P1391, DOI 10.1016/0735-1097(92)90253-J; Brundel BJJM, 2001, J AM COLL CARDIOL, V37, P926, DOI 10.1016/S0735-1097(00)01195-5; Caride AJ, 1996, BIOCHEM J, V316, P353, DOI 10.1042/bj3160353; CATTERALL WA, 2002, IUPHAR COMPENDIUM VO; de Boer RA, 2001, INT J CARDIOL, V78, P5, DOI 10.1016/S0167-5273(00)00440-X; Dobrev D, 2001, CIRCULATION, V104, P2551, DOI 10.1161/hc4601.099466; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; F'entzke RC, 1999, J PHYSIOL-LONDON, V517, P143, DOI 10.1111/j.1469-7793.1999.0143z.x; Fan QI, 2000, J MOL CELL CARDIOL, V32, P1841, DOI 10.1006/jmcc.2000.1217; Fraysse B, 2001, AM J PHYSIOL-CELL PH, V280, pC146, DOI 10.1152/ajpcell.2001.280.1.C146; GO LO, 1995, J CLIN INVEST, V95, P888, DOI 10.1172/JCI117739; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Hammes A, 1998, CIRC RES, V83, P877; Harding JD, 2001, CIRCULATION, V104, P1241, DOI 10.1161/hc3601.095718; Heerdt PM, 2000, CIRCULATION, V102, P2713, DOI 10.1161/01.CIR.102.22.2713; Hoch B, 1999, CIRC RES, V84, P713, DOI 10.1161/01.RES.84.6.713; Hoppe UC, 2000, J CLIN INVEST, V105, P1077, DOI 10.1172/JCI8757; Huang BY, 2000, CARDIOVASC RES, V46, P442, DOI 10.1016/S0008-6363(00)00017-1; Jiang MT, 2002, CIRC RES, V91, P1015, DOI 10.1161/01.RES.0000043663.08689.05; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; KAMITANI T, 1992, CIRC RES, V71, P1457, DOI 10.1161/01.RES.71.6.1457; Lai LP, 1999, J AM COLL CARDIOL, V33, P1231, DOI 10.1016/S0735-1097(99)00008-X; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Luss I, 1999, J MOL CELL CARDIOL, V31, P1299, DOI 10.1006/jmcc.1999.0962; Magnino Fabrice, 2000, Molecular Cell Biology Research Communications, V3, P374, DOI 10.1006/mcbr.2000.0242; Maier LS, 1998, AM J PHYSIOL-HEART C, V274, pH1361, DOI 10.1152/ajpheart.1998.274.4.H1361; Miki T, 2002, NAT MED, V8, P466, DOI 10.1038/nm0502-466; Miura H, 2003, CIRC RES, V92, P151, DOI 10.1161/01.RES.0000052671.53256.49; Munch G, 2001, CIRCULATION, V103, P2739; Nabauer M, 1998, CARDIOVASC RES, V37, P324, DOI 10.1016/S0008-6363(97)00274-5; Nakamura K, 2001, J CLIN INVEST, V107, P1245, DOI 10.1172/JCI12412; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; Pak BJ, 1999, J MOL CELL CARDIOL, V31, P1717, DOI 10.1006/jmcc.1999.1008; Periasamy M, 2001, J MOL CELL CARDIOL, V33, P1053, DOI 10.1006/jmcc.2001.1366; Prestle L, 1999, CARDIOVASC RES, V43, P323, DOI 10.1016/S0008-6363(99)00119-4; Qu JH, 2001, CIRC RES, V89, pE8, DOI 10.1161/hh1301.094395; Ranki HJ, 2002, J AM COLL CARDIOL, V40, P367, DOI 10.1016/S0735-1097(02)01947-2; Reinecke H, 1997, CARDIOVASC RES, V36, P216, DOI 10.1016/S0008-6363(97)00180-6; Reiter MJ, 1998, AM J CARDIOL, V82, p9I, DOI 10.1016/S0002-9149(98)00468-8; Ricchiuti V, 1999, CLIN CHEM, V45, P2129; Rieder CV, 2002, AM J PHYSIOL-HEART C, V283, pH273, DOI 10.1152/ajpheart.00042.2002; Rozanski GJ, 2002, CLIN EXP PHARMACOL P, V29, P132, DOI 10.1046/j.1440-1681.2002.03618.x; SASSE S, 1993, CIRC RES, V72, P932, DOI 10.1161/01.RES.72.5.932; Sato Y, 1998, J BIOL CHEM, V273, P28470, DOI 10.1074/jbc.273.43.28470; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Schwinger RHG, 1999, CIRCULATION, V99, P2105, DOI 10.1161/01.CIR.99.16.2105; SCHWORER CM, 1993, J BIOL CHEM, V268, P14443; Sehnert AJ, 2002, NAT GENET, V31, P106, DOI 10.1038/ng875; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; Takimoto E, 2002, FASEB J, V16, DOI 10.1096/fj.01-0735com; Tan FL, 2002, P NATL ACAD SCI USA, V99, P11387, DOI 10.1073/pnas.162370099; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Thum T, 2002, FASEB J, V16, P1537, DOI 10.1096/fj.02-0138com; Trepanier-Boulay W, 2001, CIRC RES, V89, P437, DOI 10.1161/hh1701.095644; Viswanathan PC, 2003, J CLIN INVEST, V111, P341, DOI 10.1172/JCI200316879; WANG Q, 1995, CELL, V80, P805, DOI 10.1016/0092-8674(95)90359-3; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; Wang ZG, 1998, CIRCULATION, V98, P2422, DOI 10.1161/01.CIR.98.22.2422; Wang ZY, 2001, J BIOL CHEM, V276, P17706, DOI 10.1074/jbc.M100544200; Wu AH, 1999, CLIN CARDIOL, V22, P267, DOI 10.1002/clc.4960220404; Yalcin Y, 1999, THYROID, V9, P53, DOI 10.1089/thy.1999.9.53; Yasui K, 2001, CIRC RES, V88, P536, DOI 10.1161/01.RES.88.5.536; Yue LX, 1999, CIRC RES, V84, P776; Zhu N, 1998, ENDOCRINOLOGY, V139, P4337, DOI 10.1210/en.139.10.4337; Zhu WD, 2000, J BIOL CHEM, V275, P15239, DOI 10.1074/jbc.275.20.15239	73	124	130	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1592	1608		10.1096/fj.02-0889com	http://dx.doi.org/10.1096/fj.02-0889com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958166				2022-12-28	WOS:000185925100034
J	Gardner, B; Zhu, LX; Sharma, S; Tashkin, DP; Dubinett, SM				Gardner, B; Zhu, LX; Sharma, S; Tashkin, DP; Dubinett, SM			Methanandamide increases COX-2 expression and tumor growth in murine lung cancer	FASEB JOURNAL			English	Article						cannabinoid; PGE(2); MAPK	MESSENGER-RNA EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; CANNABINOID RECEPTOR; ENDOGENOUS CANNABINOIDS; IN-VIVO; PROGNOSTIC-SIGNIFICANCE; SIGNALING PATHWAYS; ANTITUMOR IMMUNITY; EPITHELIAL-CELLS; GASTRIC-CANCER	Increased COX-2 expression and elevated PGE(2) have been associated with a poor prognosis in lung cancer. Cannabinoids have been known to exert some of their biological effects via modulation of prostaglandin production. We evaluated the impact of methanandamide on COX-2 expression, PGE(2) production, and tumor growth in murine lung cancer. Methanandamide administration (5 mg/kg, four times/wk i.p.) resulted in an increased rate of tumor growth (P<0.01 compared with diluent treated controls). The CB1 and CB2 receptor antagonists, SR141716 and SR144528, did not block the methanandamide-mediated increase in tumor growth. In vivo, methanandamide treatment increased the production of PGE(2) at the tumor site as well as in splenocytes. Consistent with these results, methanandamide increased PGE(2) and COX-2 levels in murine lung cancer cells in vitro via a cannabinoid receptor-independent mechanism. The COX-2-specific inhibitor, SC58236, abrogated methanandamide induction of PGE2 production in vitro and blocked methanandamide-enhanced tumor growth in vivo. Furthermore, the p38/MAPK inhibitor, SB203528, and the p42/44 inhibitor, PD98059, blocked methanandamide-mediated induction of PGE(2) and COX-2. These results suggest that methanandamide augments tumor growth by a cannabinoid receptor-independent pathway that is associated with the up-regulation of COX-2.	Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program,Ctr Hlth Sci 37 131, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Dubinett, SM (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Lung Canc Res Program,Ctr Hlth Sci 37 131, 10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu						ABADJI V, 1994, J MED CHEM, V37, P1889, DOI 10.1021/jm00038a020; Achiwa H, 1999, CLIN CANCER RES, V5, P1001; Akhmedkhanov A, 2002, BRIT J CANCER, V87, P49, DOI 10.1038/sj.bjc.6600370; Brabender J, 2002, ANN SURG, V235, P440, DOI 10.1097/00000658-200203000-00017; Calignano A, 2000, NATURE, V408, P96, DOI 10.1038/35040576; Casanova ML, 2003, J CLIN INVEST, V111, P43, DOI 10.1172/JCI200316116; Chan G, 1999, CANCER RES, V59, P991; De Petrocellis L, 1998, P NATL ACAD SCI USA, V95, P8375, DOI 10.1073/pnas.95.14.8375; DEROCQ JM, 1995, FEBS LETT, V369, P177, DOI 10.1016/0014-5793(95)00746-V; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; DIMARZO TBV, 2002, 2002 S CANN INT CANN; DOHADWALA M, 2002, J BIOL CHEM, V21, P21; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Fan XM, 2001, J GASTROEN HEPATOL, V16, P1098, DOI 10.1046/j.1440-1746.2001.02593.x; GALIEGUE S, 1995, EUR J BIOCHEM, V232, P54, DOI 10.1111/j.1432-1033.1995.tb20780.x; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Harris RE, 2002, ONCOL REP, V9, P693; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hida T, 1998, CANCER RES, V58, P3761; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Khuri FR, 2001, CLIN CANCER RES, V7, P861; LaPointe MC, 1999, HYPERTENSION, V33, P276, DOI 10.1161/01.HYP.33.1.276; Leahy KM, 2000, CURR MED CHEM, V7, P1163, DOI 10.2174/0929867003374336; Liu XH, 2000, J UROLOGY, V164, P820, DOI 10.1016/S0022-5347(05)67321-1; Liu XJ, 1998, CANCER RES, V58, P4752; Martin BR, 1999, LIFE SCI, V65, P573, DOI 10.1016/S0024-3205(99)00281-7; Masferrer JL, 2000, CANCER RES, V60, P1306; MECHOULAM R, 1995, BIOCHEM PHARMACOL, V50, P83, DOI 10.1016/0006-2952(95)00109-D; Miller PW, 2000, HUM GENE THER, V11, P53, DOI 10.1089/10430340050016157; Nong L, 2002, J NEUROIMMUNOL, V127, P169, DOI 10.1016/S0165-5728(02)00113-3; Pagotto U, 2001, J CLIN ENDOCR METAB, V86, P2687, DOI 10.1210/jc.86.6.2687; Parolaro D, 1999, LIFE SCI, V65, P637, DOI 10.1016/S0024-3205(99)00286-6; Ramer R, 2001, BIOCHEM BIOPH RES CO, V286, P1144, DOI 10.1006/bbrc.2001.5518; Recht LD, 2001, BIOCHEM PHARMACOL, V62, P755, DOI 10.1016/S0006-2952(01)00700-6; Salzet M, 2000, EUR J BIOCHEM, V267, P4917, DOI 10.1046/j.1432-1327.2000.01550.x; Sanchez C, 2001, CANCER RES, V61, P5784; Schmid PC, 2002, LIPIDS, V37, P907, DOI 10.1007/s11745-002-0978-z; SCHREINEMACHERS DM, 1994, EPIDEMIOLOGY, V5, P138, DOI 10.1097/00001648-199403000-00003; Shamma A, 2000, CLIN CANCER RES, V6, P1229; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Shivachar AC, 1996, BIOCHEM PHARMACOL, V51, P669, DOI 10.1016/S0006-2952(95)02248-1; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Someya A, 2002, EUR J PHARMACOL, V450, P131, DOI 10.1016/S0014-2999(02)02122-2; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Stolina M, 2000, J IMMUNOL, V164, P361, DOI 10.4049/jimmunol.164.1.361; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Uefuji K, 2000, CLIN CANCER RES, V6, P135; Valk P, 1997, BLOOD, V90, P1448, DOI 10.1182/blood.V90.4.1448.1448_1448_1457; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; Wolff H, 1998, CANCER RES, V58, P4997; Yip-Schneider MT, 2000, CARCINOGENESIS, V21, P139, DOI 10.1093/carcin/21.2.139; Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373	56	33	35	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2157	+		10.1096/fj.03-0254fje	http://dx.doi.org/10.1096/fj.03-0254fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958151				2022-12-28	WOS:000185925100017
J	Guo, RF; Riedemann, NC; Bernacki, KD; Sarma, VJ; Laudes, IJ; Reuben, JS; Younkin, EM; Neff, TA; Paulauskis, JD; Zetoune, FS; Ward, PA				Guo, RF; Riedemann, NC; Bernacki, KD; Sarma, VJ; Laudes, IJ; Reuben, JS; Younkin, EM; Neff, TA; Paulauskis, JD; Zetoune, FS; Ward, PA			Neutrophil C5a receptor and the outcome in a rat model of sepsis	FASEB JOURNAL			English	Article						innate immunity; polymorphonuclear cells; complement	HUMAN POLYMORPHONUCLEAR LEUKOCYTES; CHEMOATTRACTANT RECEPTOR; FORMYL PEPTIDE; IMMUNE-COMPLEX; ANAPHYLATOXIN; EXPRESSION; ACTIVATION; ANTI-C5A; INTERNALIZATION; BINDING	Complement fragment 5a (C5a)-C5a receptor (C5aR) signaling plays an essential role in neutrophil innate immunity. Blockade of either the ligand or the receptor improves survival rates in experimental sepsis. In the current study, sepsis was induced in rats by cecal ligation/puncture. Early in sepsis C5aR content on neutrophils significantly dropped, reached the nadir at 24 h after onset of sepsis, and progressively elevated thereafter. Western-blot, RT-PCR, and confocal microscopy analyses revealed that the loss and re-expression of C5aR during sepsis might be due, at least in part, to the receptor internalization and reconstitution. The reduction and reconstitution of C5aR correlate with the loss and restoration of innate immune functions of blood neutrophils (chemotaxis and reactive oxygen species production), respectively. Quantitative measurements of C5aR on blood neutrophils are highly predictive of survival or death during sepsis. These data suggest that neutrophil C5aR content represents an essential component of an efficient defense system in sepsis and may serve as a prognostic marker for the outcome.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Pfizer Global Res & Dev, Dept Drug Safety Evaluat, Ann Arbor, MI 48105 USA	University of Michigan System; University of Michigan; Pfizer	Ward, PA (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.	pward@umich.edu	Riedemann, Niels C/C-1633-2010; Reuben, Jayne/GWQ-6664-2022					AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BENGTSON A, 1988, ARCH SURG-CHICAGO, V123, P645; Bock D, 1997, EUR J IMMUNOL, V27, P1522, DOI 10.1002/eji.1830270631; Bone RC, 1996, CRIT CARE MED, V24, P1125, DOI 10.1097/00003246-199607000-00010; BOTHA AJ, 1995, SURGERY, V118, P358, DOI 10.1016/S0039-6060(05)80345-9; BOTHA AJ, 1995, SHOCK, V3, P157, DOI 10.1097/00024382-199503000-00001; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; CHENOWETH DE, 1978, P NATL ACAD SCI USA, V75, P3943, DOI 10.1073/pnas.75.8.3943; Cohen J, 2001, CRIT CARE MED, V29, P880, DOI 10.1097/00003246-200104000-00039; Czermak BJ, 1999, NAT MED, V5, P788, DOI 10.1038/10512; DARVILLE T, 1993, INFECTION, V21, P279, DOI 10.1007/BF01712446; DEBOER JP, 1993, INFECT IMMUN, V61, P4293, DOI 10.1128/IAI.61.10.4293-4301.1993; Faist E, 1996, WORLD J SURG, V20, P454, DOI 10.1007/s002689900071; GERARD NP, 1989, J BIOL CHEM, V264, P1760; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gilbert TL, 2001, BIOCHEMISTRY-US, V40, P3467, DOI 10.1021/bi001320y; GOLDMAN DW, 1986, J IMMUNOL, V137, P1971; GOYA T, 1994, SURGERY, V115, P145; Guo RF, 2000, J CLIN INVEST, V106, P1271, DOI 10.1172/JCI10793; Guo RF, 1999, GENOMICS, V58, P313, DOI 10.1006/geno.1999.5837; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; HU MH, 1999, BLOOD, V93, P3241; Huber-Lang M, 2001, J IMMUNOL, V166, P1193, DOI 10.4049/jimmunol.166.2.1193; Huber-Lang MS, 2001, FASEB J, V15, P568; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Koch T, 1997, SHOCK, V7, P42, DOI 10.1097/00024382-199701000-00005; KURIMOTO Y, 1989, J EXP MED, V170, P467, DOI 10.1084/jem.170.2.467; Laudes IJ, 2002, AM J PATHOL, V160, P1867, DOI 10.1016/S0002-9440(10)61133-9; Meddows-Taylor S, 2001, J INFECT DIS, V183, P662, DOI 10.1086/318532; Mollnes TE, 2002, BLOOD, V100, P1869; Naik N, 1997, J CELL SCI, V110, P2381; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; Ohno M, 2000, MOL IMMUNOL, V37, P407, DOI 10.1016/S0161-5890(00)00067-5; OPPERMANN M, 1994, IMMUNOLOGY, V82, P516; Riedemann NC, 2002, J CLIN INVEST, V110, P101, DOI 10.1172/JCI200215409; Schieferdecker HL, 2001, INT IMMUNOPHARMACOL, V1, P469, DOI 10.1016/S1567-5769(00)00038-2; Seely AJE, 2002, ANN SURG, V235, P550, DOI 10.1097/00000658-200204000-00014; SHIRATO M, 1988, FEBS LETT, V234, P231, DOI 10.1016/0014-5793(88)81341-3; SHUM JK, 1995, BIOCHEM BIOPH RES CO, V208, P223, DOI 10.1006/bbrc.1995.1327; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SMEDEGARD G, 1989, AM J PATHOL, V135, P489; SOLOMKIN JS, 1984, J SURG RES, V36, P407, DOI 10.1016/0022-4804(84)90119-7; STEVENS JH, 1986, J CLIN INVEST, V77, P1812, DOI 10.1172/JCI112506; Strachan AJ, 2000, J IMMUNOL, V164, P6560, DOI 10.4049/jimmunol.164.12.6560; Strachan AJ, 2001, BRIT J PHARMACOL, V134, P1778, DOI 10.1038/sj.bjp.0704417; TELLADO JM, 1993, CRIT CARE MED, V21, P1496, DOI 10.1097/00003246-199310000-00017; TENNENBERG SD, 1988, ARCH SURG-CHICAGO, V123, P171; VANEPPS DE, 1990, J LEUKOCYTE BIOL, V47, P519; VANEPPS DE, 1990, J IMMUNOL, V144, P1062; WERFEL T, 1992, BLOOD, V79, P152, DOI 10.1182/blood.V79.1.152.bloodjournal791152; ZIMMERMAN JJ, 1985, CRIT CARE MED, V13, P143, DOI 10.1097/00003246-198503000-00001	51	64	69	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1889	+		10.1096/fj.03-0009fje	http://dx.doi.org/10.1096/fj.03-0009fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897064	Green Submitted			2022-12-28	WOS:000185345100022
J	Kim, HS; Kim, EM; Lee, JP; Park, CH; Kim, S; Seo, JH; Chang, KA; Yu, E; Jeong, SJ; Chong, YH; Suh, YH				Kim, HS; Kim, EM; Lee, JP; Park, CH; Kim, S; Seo, JH; Chang, KA; Yu, E; Jeong, SJ; Chong, YH; Suh, YH			C-terminal fragments of amyloid precursor protein exert neurotoxicity by inducing glycogen synthase kinase-3 beta expression	FASEB JOURNAL			English	Article						Alzheimer's disease; Fe65; CP2/LSF/LBP1 transcription factor; AICD	ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; BETA-CATENIN; MOLECULAR-CLONING; KINASE 3-BETA; FE65; DEGENERATION; APOPTOSIS; APP; TAU	The AICD ( amyloid precursor protein [APP] intracellular domain) and C31, the caspase-cleaved C-terminal fragment of APP, have been found in the brains of patients with Alzheimer's disease (AD). Here, we demonstrate for the first time that the C-terminal fragments of APP (AICD [C57, C59] and C31) exert neurotoxicity on differentiated PC 12 cells and rat primary cortical neurons by inducing the expression of glycogen synthase kinase 3beta, forming a ternary complex with Fe65 and CP2/LSF/LBP1 in the nucleus, whereas deletion mutants and a point mutant with Y682G of the YENPTY domain, a Fe65 binding domain, do not. Moreover, expression of APP770 and Swedish mutant form of APP increased the levels of C-terminal fragments of APP (APP-CTs) in neuronal cells and also induced the up-regulation of glycogen synthase kinase-3beta at both the mRNA and the protein levels. In addition, we show that CP2/LSF/LBP1 binding site (nt + 0 to similar to+ 10) in human glycogen synthase kinase 3beta promoter region is essential for the induction of the gene transcription by APP-CTs. The neurotoxicities induced by APP-CTs ( AICD and C31) were accompanied by an increase in the active form of glycogen synthase knase-3beta, and by the induction of tau phosphorylation and a reduction in nuclear beta-catenin levels, and led to apoptosis.	Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea; Ewha Womans Univ, Coll Med, Div Neurosci, Med Res Ctr,Dep Microbiol, Seoul 158056, South Korea; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Seoul National University (SNU); Ewha Womans University; Harvard University; Harvard Medical School	Suh, YH (corresponding author), Seoul Natl Univ, Coll Med, Dept Pharmacol,MRC, Natl Creat Res Initiat Ctr Alzheimers Dementia, Seoul 110799, South Korea.	yhsuh@plaza.snu.ac.kr	Kim, Hye Sun/J-2752-2012; Suh, Yoo-Hun/J-2761-2012					AO Y, 2001, P NATL ACAD SCI USA, V98, P14979; Baek SH, 2002, CELL, V110, P55, DOI 10.1016/S0092-8674(02)00809-7; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; Biederer T, 2002, J NEUROSCI, V22, P7340; Bing ZY, 1999, J BIOL CHEM, V274, P24649, DOI 10.1074/jbc.274.35.24649; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Buxbaum JD, 1998, J NEUROSCI, V18, P9629; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; DeGiorgio LA, 2000, BRAIN RES, V874, P137, DOI 10.1016/S0006-8993(00)02545-2; Faure S, 1997, EMBO J, V16, P5550, DOI 10.1093/emboj/16.18.5550; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; GOEDERT M, 1989, NEURON, V3, P519, DOI 10.1016/0896-6273(89)90210-9; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Lau KF, 1999, GENOMICS, V60, P121, DOI 10.1006/geno.1999.5875; LIM LC, 1992, MOL CELL BIOL, V12, P828, DOI 10.1128/MCB.12.2.828; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Lucas JJ, 2001, EMBO J, V20, P27, DOI 10.1093/emboj/20.1.27; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; PASSER B, 2000, ALZ REPORTS, V2, P289; Pei JJ, 1999, J NEUROPATH EXP NEUR, V58, P1010, DOI 10.1097/00005072-199909000-00011; Roncarati R, 2002, P NATL ACAD SCI USA, V99, P7102, DOI 10.1073/pnas.102192599; Russo T, 1998, FEBS LETT, V434, P1, DOI 10.1016/S0014-5793(98)00941-7; SCHEINFELD MH, 2003, IN PRESS P NATL ACAD; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; SIMEONE A, 1994, DEV NEUROSCI-BASEL, V16, P53, DOI 10.1159/000112088; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Taylor AE, 2001, J MED GENET, V38, P232, DOI 10.1136/jmg.38.4.232; TROJANOWSKI JQ, 1993, CLIN NEUROSCI, V1, P184; Weihl CC, 1999, NEUROREPORT, V10, P2527, DOI 10.1097/00001756-199908200-00017; Wolfe MS, 2001, J BIOL CHEM, V276, P5413, DOI 10.1074/jbc.R000026200; YOON JB, 1994, MOL CELL BIOL, V14, P1776, DOI 10.1128/MCB.14.3.1776; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zhang JW, 2000, J NEUROCHEM, V75, P2346, DOI 10.1046/j.1471-4159.2000.0752346.x; Zhang ZH, 1998, NATURE, V395, P698, DOI 10.1038/27208; Zhu M, 2002, NEUROBIOL AGING, V23, pS205	42	193	204	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1951	+		10.1096/fj.03-0106fje	http://dx.doi.org/10.1096/fj.03-0106fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923068				2022-12-28	WOS:000185345100014
J	Hayashida, T; deCaestecker, M; Schnaper, HW				Hayashida, T; deCaestecker, M; Schnaper, HW			Cross-talk between ERK MAP kinase and Smad-signaling pathways enhances TGF-beta dependent responses in human mesangial cells	FASEB JOURNAL			English	Article						signal transduction; kidney cells; collagen; fibrogenesis	GROWTH-FACTOR-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; TRANSCRIPTIONAL ACTIVATION; FIBRONECTIN SYNTHESIS; EXTRACELLULAR-MATRIX; REGULATED KINASE; BINDING-PROTEIN; EXPRESSION; GENE; RAS	Transforming growth factor beta (TGF-beta) stimulates renal cell fibrogenesis by a poorly understood mechanism. Previously, we suggested a synergy between TGF-beta1 activated extracellular signal regulated kinase (ERK) and Smad signaling in collagen production by human glomerular mesangial cells. In a heterologous DNA binding transcription assay, biochemical or dominant-negative ERK blockade reduced TGF-beta1 induced Smad3 activity. Total serine phosphorylation of Smad2/3, but not phosphorylation of the C-terminal (SSXSP)-X-P motif, was de creased by pretreatment with the MEK/ERK inhibitors, PD98059 (10 muM) or U0126 (25 muM). This effect was not seen in the mouse mammary epithelial NMuMG cell line, indicating that ERK-dependent activation of Smad2/3 occurs only in certain cell types. TGF-beta stimulated phosphorylation of an expressed S m ad 3 A construct, wit h a mutated C-terminal (SSXSP)-X-P motif, was reduced by a MEK/ERK inhibitor. In contrast, MEK/ERK inhibition did not affect phosphorylation of a Smad3 construct mutated at consensus phosphorylation sites in the linker region (Smad3EPSM). Constitutively active MEK (caMEK) induced alpha2(I) collagen promoter activity, an effect blocked by co-transfected Smad3EPSM, but not Smad3A. The effects of caMEK and TGF-alpha1 on collagen promoter activity were additive. These results indicate that ERK-dependent R-Smad linker region phosphorylation enhances collagen I synthesis and imply positive cross talk between the ERK and Smad pathways in human mesangial cells.	Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; Vanderbilt Univ, Dept Med Hypertens & Nephrol, Nashville, TN USA	Northwestern University; Feinberg School of Medicine; Vanderbilt University	Hayashida, T (corresponding author), Northwestern Univ W140, Feinberg Sch Med, 303 E Chicago Ave,Ward 12-112, Chicago, IL 60611 USA.	hayashida@northwestern.edu		Hayashida, Tomoko/0000-0002-4160-7859	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049362] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK049362] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Atfi A, 1997, J BIOL CHEM, V272, P1429, DOI 10.1074/jbc.272.3.1429; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Bhowmick NA, 2001, J BIOL CHEM, V276, P46707, DOI 10.1074/jbc.M106176200; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; BRUIJN JA, 1994, J LAB CLIN MED, V123, P34; Calonge MJ, 1999, J BIOL CHEM, V274, P33637, DOI 10.1074/jbc.274.47.33637; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Frey RS, 1997, CANCER RES, V57, P628; Funaba M, 2002, J BIOL CHEM, V277, P41361, DOI 10.1074/jbc.M204597200; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Hartsough MT, 1996, J BIOL CHEM, V271, P22368, DOI 10.1074/jbc.271.37.22368; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Hayashida T, 1999, KIDNEY INT, V56, P1710, DOI 10.1046/j.1523-1755.1999.00733.x; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUWILER A, 1994, FEBS LETT, V354, P255, DOI 10.1016/0014-5793(94)01132-X; Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037; Janknecht R, 1998, GENE DEV, V12, P2114, DOI 10.1101/gad.12.14.2114; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kitamura M, 1997, NEPHROL DIAL TRANSPL, V12, P669, DOI 10.1093/ndt/12.4.669; Kretzschmar M, 1999, GENE DEV, V13, P804, DOI 10.1101/gad.13.7.804; Kretzschmar M, 1997, NATURE, V389, P618, DOI 10.1038/39348; Kretzschmar M, 1998, CURR OPIN GENET DEV, V8, P103, DOI 10.1016/S0959-437X(98)80069-5; Lehmann K, 2000, GENE DEV, V14, P2610, DOI 10.1101/gad.181700; Liu F, 1997, GENE DEV, V11, P3157, DOI 10.1101/gad.11.23.3157; Liu XD, 2000, ONCOGENE, V19, P5926, DOI 10.1038/sj.onc.1203991; Liu XD, 1997, P NATL ACAD SCI USA, V94, P10669, DOI 10.1073/pnas.94.20.10669; Massague J, 2000, GENE DEV, V14, P627; Massague J, 1996, CELL, V85, P947, DOI 10.1016/S0092-8674(00)81296-9; MCKAY NG, 1993, EXP MOL PATHOL, V59, P211, DOI 10.1006/exmp.1993.1040; Mucsi I, 1996, J BIOL CHEM, V271, P16567, DOI 10.1074/jbc.271.28.16567; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Peron P, 2001, J BIOL CHEM, V276, P10524, DOI 10.1074/jbc.M005919200; Poncelet AC, 1999, KIDNEY INT, V56, P1354, DOI 10.1046/j.1523-1755.1999.00680.x; Poncelet AC, 1998, AM J PHYSIOL-RENAL, V275, pF458; Poncelet AC, 2001, J BIOL CHEM, V276, P6983, DOI 10.1074/jbc.M006442200; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; Sowa H, 2002, J BIOL CHEM, V277, P36024, DOI 10.1074/jbc.M206030200; Stratton R, 2002, FASEB J, V16, P1949, DOI 10.1096/fj.02-0204fje; SUZUKI S, 1993, EXP NEPHROL, V1, P229; TOMOOKA S, 1992, KIDNEY INT, V42, P1462, DOI 10.1038/ki.1992.442; Topper JN, 1998, P NATL ACAD SCI USA, V95, P9506, DOI 10.1073/pnas.95.16.9506; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Wang WF, 1997, J BIOL CHEM, V272, P22771, DOI 10.1074/jbc.272.36.22771; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Yakmovych I, 2001, FASEB J, V15, P553; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN ZF, 1994, J BIOL CHEM, V269, P13231; Yang JW, 2002, J AM SOC NEPHROL, V13, P96, DOI 10.1681/ASN.V13196; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	69	318	336	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1576	+		10.1096/fj.03-0037fje	http://dx.doi.org/10.1096/fj.03-0037fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824291				2022-12-28	WOS:000183818000018
J	Minchenko, AG; Stevens, MJ; White, L; Abatan, OI; Komjati, K; Pacher, P; Szabo, C; Obrosova, IG				Minchenko, AG; Stevens, MJ; White, L; Abatan, OI; Komjati, K; Pacher, P; Szabo, C; Obrosova, IG			Diabetes-induced overexpression of endothelin-1 and endothelin receptors in the rat renal cortex is mediated via poly(adp-ribose) polymerase activation	FASEB JOURNAL			English	Article						3-aminobenzamide; diabetic nephropathy; 1,5-isoquinolinediol; poly(ADP-ribosyl)ation; streptozotocin-diabetic rat	ALPHA-LIPOIC ACID; NF-KAPPA-B; OXIDATIVE STRESS; TRANSCRIPTION FACTORS; GLOMERULAR-LESIONS; PERIPHERAL-NERVE; GENE-EXPRESSION; TRANSGENIC MICE; GROWTH-FACTOR; UP-REGULATION	We hypothesize the poly (ADP-ribosyl)ation, that is, poly (ADP-ribose) polymerase (PARP)-dependent transfer of ADP-ribose moieties from NAD to nuclear proteins, plays a role in diabetic nephropathy. We evaluated whether PARP activation is present and whether two unrelated PARP inhibitors, 3-aminobenzamide (ABA) and 1,5-isoquinolinediol (ISO), counteract overexpression of endothelin-1 (ET-1) and ET receptors in the renal cortex in short-term diabetes. The studies were performed in control rats and streptozotocin-diabetic rats treated with/without ABA or ISO (30 and 3 mg*kg-1*day(-1), intraperitoneally, <LF>for 2 weeks after 2 weeks of diabetes). Poly (ADP-ribose) immunoreactivity was increased in tubuli, but not glomeruli, of diabetic rats and this increase was corrected by ISO, whereas ABA had a weaker effect. ET-1 concentration (ELISA) was increased in diabetic rats, and this elevation was blunted by ISO. ET-1, ET(A), and ET(B) mRNA (ribonuclease protection assay), but not ET-3 mRNA (RT/PCR), abundance was increased in diabetic rats and three variable were at least partially corrected by ISO. ABA produced a trend towards normalization of ET-1 concentration and ET-1, ET(A), and ET(B) mRNA abundance, but the differences with untreated diabetic group were not significant. Poly(ADP-ribosyl)ation is involved in diabetes-induced renal overexpression of ET-1 and ET receptors. PARP inhibitors could provide a novel therapeutic approach for diabetic complications including nephropathy, and other diseases that involve the endothelin system.	Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, Ann Arbor, MI 48109 USA; Thomas Jefferson Univ, Dept Anesthesiol, Philadelphia, PA 19107 USA; Inotek Pharmaceut Corp, Beverly, MA USA	University of Michigan System; University of Michigan; Jefferson University; Inotek Pharmaceuticals	Obrosova, IG (corresponding author), Univ Michigan, Med Ctr, Dept Internal Med, Div Endocrinol & Metab, 1150 W Med Ctr Dr,MSRB 2,Room 5570, Ann Arbor, MI 48109 USA.	iobrosso@umich.edu	Pacher, Pal/B-6378-2008; Szabo, Csaba/D-1882-2013; Minchenko, Oleksandr/AAV-5742-2020; Szabo, Csaba/ABG-2644-2021	Pacher, Pal/0000-0001-7036-8108; Minchenko, Oleksandr/0000-0002-7093-5173				ANDREONE TL, IN PRESS J IMMUNOL; Arikawa E, 2001, J HYPERTENS, V19, P803, DOI 10.1097/00004872-200104000-00018; BANASIK M, 1992, J BIOL CHEM, V267, P1569; Beisswenger PJ, 2001, CLIN LAB MED, V21, P53; Benigni A, 1998, DIABETES, V47, P450, DOI 10.2337/diabetes.47.3.450; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Boffa JJ, 2001, HYPERTENSION, V37, P490, DOI 10.1161/01.HYP.37.2.490; Buchwald AB, 2002, J AM COLL CARDIOL, V39, P732, DOI 10.1016/S0735-1097(01)01797-1; Cameron NE, 1996, J PHARMACOL EXP THER, V278, P1262; Cattaruzza M, 2001, J BIOL CHEM, V276, P36999, DOI 10.1074/jbc.M105158200; Chang WJ, 2001, J BIOL CHEM, V276, P47664, DOI 10.1074/jbc.M104666200; Chen HC, 2000, J LAB CLIN MED, V135, P309, DOI 10.1067/mlc.2000.105616; Chen S, 2002, NEPHRON, V90, P86, DOI 10.1159/000046319; Cooper ME, 2001, DIABETOLOGIA, V44, P1957, DOI 10.1007/s001250100000; DOBASHI K, 1991, VIRCHOWS ARCH B, V60, P67, DOI 10.1007/BF02899529; Du X, 2002, DIABETES, V51, pA175; GomezGarre D, 1996, KIDNEY INT, V50, P962, DOI 10.1038/ki.1996.397; Gupta S, 2002, AM J PHYSIOL-CELL PH, V282, pC560, DOI 10.1152/ajpcell.00343.2001; Ha HC, 2002, P NATL ACAD SCI USA, V99, P3270, DOI 10.1073/pnas.052712399; Haneda M, 2001, AM J KIDNEY DIS, V38, pS178, DOI 10.1053/ajkd.2001.27438; Hassa PO, 2001, J BIOL CHEM, V276, P45588, DOI 10.1074/jbc.M106528200; Hocher B, 1998, J CARDIOVASC PHARM, V31, pS492, DOI 10.1097/00005344-199800001-00141; Horie K, 1997, J CLIN INVEST, V100, P2995, DOI 10.1172/JCI119853; Inoguchi T, 2000, DIABETES, V49, P1939, DOI 10.2337/diabetes.49.11.1939; Itoh Y, 2001, HORM RES, V56, P165, DOI 10.1159/000048113; Jagtap P, 2002, CRIT CARE MED, V30, P1071, DOI 10.1097/00003246-200205000-00019; Khan MA, 1999, NEPHRON, V83, P261, DOI 10.1159/000045519; Lal MA, 2000, DIABETES, V49, P1381, DOI 10.2337/diabetes.49.8.1381; Lariviere R, 1998, AM J HYPERTENS, V11, P989, DOI 10.1016/S0895-7061(98)00088-0; Lee AYW, 1999, FASEB J, V13, P23, DOI 10.1096/fasebj.13.1.23; Liaudet L, 2001, BRIT J PHARMACOL, V133, P1424, DOI 10.1038/sj.bjp.0704185; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Mabley JG, 2001, BRIT J PHARMACOL, V133, P909, DOI 10.1038/sj.bjp.0704156; Melhem MF, 2002, J AM SOC NEPHROL, V13, P108, DOI 10.1681/ASN.V131108; Melhem MF, 2001, J AM SOC NEPHROL, V12, P124, DOI 10.1681/ASN.V121124; MINCHENKO A, 1994, LAB INVEST, V71, P374; Minchenko AG, 1999, ENDOTHELIUM-NEW YORK, V6, P303, DOI 10.3109/10623329909078497; Nakamura T, 1996, NEPHROL DIAL TRANSPL, V11, P1528; Oates, 1999, Expert Opin Investig Drugs, V8, P2095, DOI 10.1517/13543784.8.12.2095; OBROSOVA I, 2002, OPHTHALM RES S1, V34, P128; Obrosova IG, 2003, FREE RADICAL BIO MED, V34, P186, DOI 10.1016/S0891-5849(02)01195-4; Obrosova IG, 2002, DIABETOLOGIA, V45, pA323; Obrosova IG, 2002, INT REV NEUROBIOL, V50, P3; Obrosova IG, 2001, DIABETOLOGIA, V44, P1102, DOI 10.1007/s001250100631; Oku H, 2001, RETINA-J RET VIT DIS, V21, P647, DOI 10.1097/00006982-200112000-00013; Ortiz A, 1997, J INVEST MED, V45, P50; Pacher P, 2002, DIABETES, V51, P514, DOI 10.2337/diabetes.51.2.514; Park JY, 2000, DIABETES, V49, P1239, DOI 10.2337/diabetes.49.7.1239; Quehenberger P, 2000, DIABETES, V49, P1561, DOI 10.2337/diabetes.49.9.1561; Reddi AS, 1997, BIOCHEM BIOPH RES CO, V235, P598, DOI 10.1006/bbrc.1997.6836; Schnackenberg CG, 2001, KIDNEY INT, V59, P1859, DOI 10.1046/j.1523-1755.2001.0590051859.x; Shindo T, 2002, J MOL MED, V80, P105, DOI 10.1007/s00109-001-0284-4; Simbulan-Rosenthal CM, 2000, P NATL ACAD SCI USA, V97, P11274, DOI 10.1073/pnas.200285797; Soldatenkov VA, 2002, J BIOL CHEM, V277, P665, DOI 10.1074/jbc.M108551200; Song Y, 1999, MOL BIOL CELL, V10, P1609, DOI 10.1091/mbc.10.5.1609; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; STEVENS EJ, 1995, BRIT J PHARMACOL, V115, P373, DOI 10.1111/j.1476-5381.1995.tb15888.x; Szabo C, 1998, EUR J PHARMACOL, V350, P1, DOI 10.1016/S0014-2999(98)00249-0; Szabo C, 2002, CIRCULATION, V106, P2680, DOI 10.1161/01.CIR.0000038365.78031.9C; Theuring F, 1998, J CARDIOVASC PHARM, V31, pS489, DOI 10.1097/00005344-199800001-00140; TRACHTMAN H, 1995, AM J PHYSIOL-RENAL, V269, pF429, DOI 10.1152/ajprenal.1995.269.3.F429; Ullrich O, 2001, NAT CELL BIOL, V3, P1035, DOI 10.1038/ncb1201-1035; VIOSSAT I, 1990, ARCH MAL COEUR VAISS, V83, P1263; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vogel V, 1999, CLIN SCI, V97, P91, DOI 10.1042/CS19980369; WONG M, 1995, BIOCHEM MOL BIOL INT, V35, P1359; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yorio T, 2002, J GLAUCOMA, V11, P259, DOI 10.1097/00061198-200206000-00016; Yu SW, 2002, SCIENCE, V297, P259, DOI 10.1126/science.1072221; Zhang WP, 1997, BIOCHEM MOL MED, V61, P58, DOI 10.1006/bmme.1997.2592	71	88	97	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1514	+		10.1096/fj.03-0013fje	http://dx.doi.org/10.1096/fj.03-0013fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824290	Green Submitted			2022-12-28	WOS:000183818000032
J	Paxian, M; Bauer, I; Rensing, H; Jaeschke, H; Mautes, AEM; Kolb, SA; Wolf, B; Stockhausen, A; Jeblick, S; Bauer, M				Paxian, M; Bauer, I; Rensing, H; Jaeschke, H; Mautes, AEM; Kolb, SA; Wolf, B; Stockhausen, A; Jeblick, S; Bauer, M			Recovery of hepatocellular ATP and "pericentral apoptosis" after hemorrhage and resuscitation	FASEB JOURNAL			English	Article						necrosis; apoptosis; necrapoptosis; liver; ATP; oxygen free radicals	MITOCHONDRIAL PERMEABILITY TRANSITION; HEPATIC ISCHEMIA-REPERFUSION; NECROSIS FACTOR-ALPHA; CASPASE INHIBITOR; CELL-DEATH; RADICAL SCAVENGER; ORGAN INJURY; SHOCK; RATS; LIVER	Progressive liver dysfunction contributes significantly to the development of multiple organ failure after trauma/hemorrhage. This study tested the relative impact of necrotic and apoptotic cell death in a graded model of hemorrhagic shock (mean arterial blood pressure = 35 +/- 5 mmHg for 1, 2, or 3 h, followed by 2 h, 1 h, or no resuscitation, respectively) in rats. Prolonged periods of hemorrhagic hypotension (3 h) were paralleled by a profound decrease of hepatic ATP levels and occurrence of pericentral necrosis. Resuscitation after shorter periods of hemorrhagic hypotension resulted in restoration of tissue ATP whereas hepatocellular function as assessed by indocyanine green clearance remained depressed (49.9 +/- 1.6 mL/(min . kg) at baseline, 28.8 +/- 1.2 mL/(min . kg) after 2 h of resuscitation; P<0.05). Under these conditions, induction of caspase activity and DNA fragmentation were observed in pericentral hepatocytes that could be prevented by the radical scavenger tempol. Pretreatment with z-Val-Ala-Asp(O-methyl)-flouromethylketone prevented de novo expression of caspase-generated cytokeratin 18, DNA fragmentation, and depression of hepatocellular indocyanine green clearance. These data suggest that prolonged low flow/hypoxia induces ATP depletion and pericentral necrosis and restoration of oxygen supply and ATP levels after shorter periods of low flow ischemia propagate programmed cell death or "pericentral apoptosis."	Univ Saarland, Dept Anesthesiol & Crit Care Med, D-66421 Homburg, Germany; Univ Saarland, Neurosurg Res Lab, D-66421 Homburg, Germany; Univ Arkansas Med Sci, Dept Pharmacol & Toxicol, Little Rock, AR 72205 USA; Univ Zurich Hosp, Dept Pathol, CH-8091 Zurich, Switzerland	Saarland University; Saarland University; University of Arkansas System; University of Arkansas Medical Sciences; University of Zurich; University Zurich Hospital	Bauer, M (corresponding author), Univ Saarland, Dept Anesthesiol & Crit Care Med, D-66421 Homburg, Germany.	aimbau@uniklinik-saarland.de	Jaeschke, Hartmut/J-6285-2013	Bauer, Michael/0000-0002-1521-3514				BAUER M, 1995, CRIT CARE MED, V23, P316, DOI 10.1097/00003246-199502000-00018; Bauer M, 1996, AM J PHYSIOL-GASTR L, V271, pG929, DOI 10.1152/ajpgi.1996.271.5.G929; BYNUM TE, 1979, DIGEST DIS SCI, V24, P129, DOI 10.1007/BF01324740; Cai JY, 1998, J BIOL CHEM, V273, P11401, DOI 10.1074/jbc.273.19.11401; Chandler JM, 1998, J BIOL CHEM, V273, P10815, DOI 10.1074/jbc.273.18.10815; COLLETTI LM, 1990, J CLIN INVEST, V85, P1936, DOI 10.1172/JCI114656; Cursio R, 1999, FASEB J, V13, P253, DOI 10.1096/fasebj.13.2.253; DEITCH EA, 1994, SHOCK, V1, P141, DOI 10.1097/00024382-199402000-00010; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Gardner AM, 1997, FREE RADICAL BIO MED, V22, P73, DOI 10.1016/S0891-5849(96)00235-3; GRASLKRAUPP B, 1995, HEPATOLOGY, V21, P1465, DOI 10.1016/0270-9139(95)90071-3; Green DR, 1998, CELL, V94, P695, DOI 10.1016/S0092-8674(00)81728-6; Gujral JS, 2001, HEPATOLOGY, V33, P397, DOI 10.1053/jhep.2001.22002; Jaeschke H, 2000, TOXICOL APPL PHARM, V169, P77, DOI 10.1006/taap.2000.9035; Leach M, 1998, BRIT J PHARMACOL, V125, P817, DOI 10.1038/sj.bjp.0702123; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; MARZI I, 1995, SHOCK, V3, P27, DOI 10.1097/00024382-199503010-00004; Mautes AEM, 2001, J MOL NEUROSCI, V16, P33, DOI 10.1385/JMN:16:1:33; McDonald MC, 1999, FREE RADICAL BIO MED, V27, P493, DOI 10.1016/S0891-5849(99)00100-8; McGuire GM, 1996, FREE RADICAL BIO MED, V20, P189, DOI 10.1016/0891-5849(95)02028-4; Mignotte B, 1998, EUR J BIOCHEM, V252, P1, DOI 10.1046/j.1432-1327.1998.2520001.x; Mota-Filipe H, 1999, SHOCK, V12, P255, DOI 10.1097/00024382-199910000-00002; Nieminen AL, 1997, AM J PHYSIOL-CELL PH, V272, pC1286; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; Paxian M, 2001, SHOCK, V15, P438, DOI 10.1097/00024382-200115060-00005; Regel G, 1996, WORLD J SURG, V20, P422, DOI 10.1007/s002689900067; Shimizu S, 1996, CANCER RES, V56, P2161; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	32	72	74	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					993	1002		10.1096/fj.02-0624com	http://dx.doi.org/10.1096/fj.02-0624com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773482				2022-12-28	WOS:000183818000003
J	Matsuyama, W; Kamohara, H; Galligan, C; Faure, M; Yoshimura, T				Matsuyama, W; Kamohara, H; Galligan, C; Faure, M; Yoshimura, T			RETRACTED: Interaction of discoidin domain receptor 1 isoform b (DDR1b) with collagen activates p38 mitogen-activated protein kinase and promotes differentiation of macrophages (Retracted article. See vol. 23, pg. 3251, 2009)	FASEB JOURNAL			English	Article; Retracted Publication						inflammation; receptor tyrosine kinase; dendritic cells; extracellular matrix	RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION PATHWAY; HUMAN DENDRITIC CELLS; CLASS-II GENES; COSTIMULATORY MOLECULES; EXPRESSION; MATURATION; LIPOPOLYSACCHARIDE; CYTOKINES; TRANSCRIPTION	Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase activated by collagen. DDR1 is constitutively expressed in a variety of normal and transformed epithelial cells and plays a role in cell migration and differentiation through as yet unidentified signaling pathways. We previously reported inducible expression of DDR1 in human leukocytes and suggested a role for the DDR1a isoform in leukocyte migration through extracellular matrix. Here, we evaluated the contribution of DDR1 in the differentiation of the human monocytic THP-1 cells overexpressing these isoforms and of primary macrophages. Interestingly, collagen activation of DDR1b, but not DDR1a, further promoted phorbol ester-induced differentiation of THP-1 cells as determined by reduced cell proliferation and up-regulated expression of HLA-DR, CD11c, CD14, and CD40. Collagen activation of DDR1b also induced the recruitment and phosphorylation of Shc and subsequent phosphorylation of p38 mitogen-activated protein (MAP) kinase and its substrate ATF2. A p38 MAP kinase inhibitor, SB203580, completely inhibited DDR1b-mediated HLA-DR expression. Activation of DDR1 endogenously expressed on macrophages also up-regulated their HLA-DR expression in a p38 MAP kinase-dependent manner. Thus, DDR1b in response to collagen transduces signals that promote maturation/differentiation of HLA-DR-positive antigen-presenting cells and contributes to the development of adaptive immunity in a tissue microenvironment.	NCI, Mol Immunoregulat Lab, Frederick, MD 21702 USA; SUGEN Inc, San Francisco, CA 94080 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Pfizer	Yoshimura, T (corresponding author), NCI, Mol Immunoregulat Lab, Bldg 559,Rm 9, Frederick, MD 21702 USA.	yoshimur@mail.ncifcrf.gov		Yoshimura, Teizo/0000-0002-3853-2075	DIVISION OF BASIC SCIENCES - NCI [Z01BC010258] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; ALVES F, 1995, ONCOGENE, V10, P609; Alves F, 2001, FASEB J, V15, P1321, DOI 10.1096/fj.00-0626fje; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; ASSEFFA A, 1993, ONCOL RES, V5, P11; Ayala JM, 2000, J LEUKOCYTE BIOL, V67, P869, DOI 10.1002/jlb.67.6.869; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BENOIST C, 1990, ANNU REV IMMUNOL, V8, P681, DOI 10.1146/annurev.immunol.8.1.681; Beresford GW, 2001, NAT IMMUNOL, V2, P652, DOI 10.1038/89810; Berton G, 1999, CELL SIGNAL, V11, P621, DOI 10.1016/S0898-6568(99)00003-0; Bhatt RS, 2000, GENE DEV, V14, P2216, DOI 10.1101/gad.821600; Boss JM, 1997, CURR OPIN IMMUNOL, V9, P107, DOI 10.1016/S0952-7915(97)80166-5; Brand U, 1998, EUR J IMMUNOL, V28, P1673, DOI 10.1002/(SICI)1521-4141(199805)28:05<1673::AID-IMMU1673>3.0.CO;2-J; Carter AB, 2001, J BIOL CHEM, V276, P33826, DOI 10.1074/jbc.M100209200; CAUX C, 1994, J EXP MED, V180, P1263, DOI 10.1084/jem.180.4.1263; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Foehr ED, 2000, FASEB J, V14, P973, DOI 10.1096/fasebj.14.7.973; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; GLIMCHER LH, 1992, ANNU REV IMMUNOL, V10, P13, DOI 10.1146/annurev.iy.10.040192.000305; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Jacob SS, 2001, BBA-MOL CELL RES, V1540, P50, DOI 10.1016/S0167-4889(01)00116-1; Jonuleit H, 1997, EUR J IMMUNOL, V27, P3135, DOI 10.1002/eji.1830271209; Kamohara H, 2001, FASEB J, V15, P2724, DOI 10.1096/fj.01-0359fje; L'hote CGML, 2001, FASEB J, V15, P234, DOI 10.1096/fj.01-0414fje; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; LU L, 1994, J EXP MED, V179, P1823, DOI 10.1084/jem.179.6.1823; Mahnke K, 1996, J LEUKOCYTE BIOL, V60, P465, DOI 10.1002/jlb.60.4.465; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Playford MP, 1996, GENOME RES, V6, P620, DOI 10.1101/gr.6.7.620; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Reith W, 2001, ANNU REV IMMUNOL, V19, P331, DOI 10.1146/annurev.immunol.19.1.331; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; SCHWARTZ RB, 1996, NEUROSURG FOCUS, V1, P1; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Suri RM, 1998, J IMMUNOL METHODS, V214, P149, DOI 10.1016/S0022-1759(98)00048-9; TING JPY, 1993, CURR OPIN IMMUNOL, V5, P8, DOI 10.1016/0952-7915(93)90074-3; TSUCHIYA S, 1982, CANCER RES, V42, P1530; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77; Vogel WF, 2001, MOL CELL BIOL, V21, P2906, DOI 10.1128/MCB.21.8.2906-2917.2001; XU LL, 1995, EUR J IMMUNOL, V25, P2612, DOI 10.1002/eji.1830250931; YOSHIMURA T, 1993, J IMMUNOL, V150, P5025	49	40	45	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1286	+		10.1096/fj.02-0320fje	http://dx.doi.org/10.1096/fj.02-0320fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12738814				2022-12-28	WOS:000183165000041
J	Kassed, CA; Butler, TL; Patton, GW; De Mesquita, DD; Navidomskis, MT; Memet, S; Israel, A; Pennypacker, KR				Kassed, CA; Butler, TL; Patton, GW; De Mesquita, DD; Navidomskis, MT; Memet, S; Israel, A; Pennypacker, KR			Injury-induced NF-kappa B activation in the hippocampus: implications for neuronal survival	FASEB JOURNAL			English	Review						signal transduction; Na+, K+-ATPase; neurodegeneration; NF-kappa B p50; transcription factors	AMYLOID PRECURSOR PROTEIN; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN INJURY; CENTRAL-NERVOUS-SYSTEM; HSP70 HOMOLOG GENE; K+-ATPASE ACTIVITY; GAMMA-SUBUNIT; RAT-BRAIN; TRANSCRIPTION FACTOR; IN-VIVO	Nuclear factor (NF)-kappaB p50 protein is involved in promoting survival in hippocampal neurons after trimethyltin (TMT)-injury. In the current study, hippocampal NF-kappaB activity was examined and quantitated from transgenic kappaB-lacZ reporter mice after chemical-induced injury. NF-kappaB activity was localized primarily to hippocampal neurons and significantly elevated over that in saline-treated mice between 4 and 21 days after TMT injection. Seven days after TMT injection, a timepoint of elevated NF-kappaB activity, gene expression in the hippocampus was studied by microarray analysis through comparison of expression profiles between treated nontransgenic and p50-null mice with their saline-injected controls. Seventeen genes increased in nontransgenic TMT-treated mice relative to saline-treated as well as showing no increase in p50-null mice, indicating a role for p50 in their regulation. One of these genes, the Na+, K+-ATPase-gamma subunit, was detected in brain for the first time. Several of the genes modulated by NF-kappaB are potentially related to neuroplasticity, providing additional evidence that this transcription factor is a neuroprotective signal in the hippocampus.	Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, Tampa, FL 33612 USA; Univ S Florida, Dept Med Microbiol, Tampa, FL 33612 USA; Inst Pasteur, Unite Biol Mol Express Gen, Paris, France	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Pennypacker, KR (corresponding author), Univ S Florida, Coll Med, Dept Pharmacol & Therapeut, 12901 Bruce B Downs Blvd,MDC 9, Tampa, FL 33612 USA.	kpennypa@hsc.usf.edu	Pennypacker, Keith/I-5092-2012; Ward, Tanya/J-4882-2015	Ward, Tanya/0000-0003-1576-521X; Memet, Sylvie/0000-0001-6571-4192				Albensi BC, 2000, SYNAPSE, V35, P151; ALDRIDGE WN, 1977, BIOCHEM J, V168, P353, DOI 10.1042/bj1680353; Anthony D C, 2001, Prog Brain Res, V132, P507; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Bagri A, 2002, DEVELOPMENT, V129, P4249; BALABAN CD, 1988, NEUROSCIENCE, V26, P337, DOI 10.1016/0306-4522(88)90150-9; Bayer KU, 1999, MOL BRAIN RES, V70, P147, DOI 10.1016/S0169-328X(99)00131-X; Bendiske J, 2003, J NEUROPATH EXP NEUR, V62, P451, DOI 10.1093/jnen/62.5.451; BESCHORNER R, 2002, BRAIN PATHOL, V12, P442; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLANCO G, 1990, J NEUROSCI RES, V27, P47, DOI 10.1002/jnr.490270108; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROCK TO, 1987, J NEUROSCI, V7, P931; Caran N, 2001, J BIOL CHEM, V276, P42514, DOI 10.1074/jbc.M103013200; Cechetto D F, 2001, Prog Brain Res, V132, P391; CHANG LW, 1983, NEUROBEH TOXICOL TER, V5, P673; CHANG LW, 1985, J TOXICOL ENV HEALTH, V16, P641, DOI 10.1080/15287398509530770; Chauhan BK, 2002, GENES CELLS, V7, P1267, DOI 10.1046/j.1365-2443.2002.00602.x; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Cruise L, 2000, NEUROREPORT, V11, P395, DOI 10.1097/00001756-200002070-00034; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; DEUSSING J, 2000, BIOCHIM BIOPHYS ACTA, V149, P93; Faison MO, 2002, INT J DEV NEUROSCI, V20, P585; Freudenthal R, 2000, BRAIN RES, V855, P274, DOI 10.1016/S0006-8993(99)02358-6; Gilmore TD, 1996, ONCOGENE, V13, P1367; Ginsberg SD, 2000, ANN NEUROL, V48, P77, DOI 10.1002/1531-8249(200007)48:1<77::AID-ANA12>3.3.CO;2-1; Grabellus F, 2002, CARDIOVASC RES, V53, P124, DOI 10.1016/S0008-6363(01)00433-3; Grewal RP, 1999, NEUROSCI LETT, V271, P65, DOI 10.1016/S0304-3940(99)00496-6; GRIMM S, 1993, BIOCHEM J, V290, P297, DOI 10.1042/bj2900297; Guerrini L, 1997, J NEUROSCI, V17, P6057; HARRY GJ, 1985, BRAIN RES, V326, P9, DOI 10.1016/0006-8993(85)91379-4; HERNANDEZ J, 1992, NEUROCHEM INT, V20, P1, DOI 10.1016/0197-0186(92)90119-C; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; HETMAN M, 1994, DNA CELL BIOL, V13, P419, DOI 10.1089/dna.1994.13.419; Hollmann TJ, 1998, MOL IMMUNOL, V35, P137, DOI 10.1016/S0161-5890(98)00021-2; Ito Y, 1998, J BIOCHEM, V124, P347, DOI 10.1093/oxfordjournals.jbchem.a022118; JOHNSON SA, 1994, DEV BRAIN RES, V80, P163, DOI 10.1016/0165-3806(94)90101-5; Jones DH, 1997, J CELL BIOL, V139, P1545, DOI 10.1083/jcb.139.6.1545; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KARPIAK SE, 1987, STROKE, V18, P184, DOI 10.1161/01.STR.18.1.184; Kassed CA, 2002, EXP NEUROL, V176, P277, DOI 10.1006/exnr.2002.7967; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; KRADY JK, 1990, MOL BRAIN RES, V7, P287, DOI 10.1016/0169-328X(90)90079-S; Kuster B, 2000, J BIOL CHEM, V275, P18441, DOI 10.1074/jbc.M001411200; LAHIRI DK, 1995, MOL BRAIN RES, V32, P233, DOI 10.1016/0169-328X(95)00078-7; LAI C, 1994, ONCOGENE, V9, P2567; Lee YW, 2001, BRAIN RES, V920, P125, DOI 10.1016/S0006-8993(01)03047-5; Li YH, 1999, J NEUROCHEM, V73, P1477; LITTLE A, 2001, SOC NEUR ABS; Little AR, 2002, NEUROSCIENCE, V115, P307, DOI 10.1016/S0306-4522(02)00359-7; Lu AG, 2003, J CEREBR BLOOD F MET, V23, P786, DOI 10.1097/01.WCB.0000062340.80057.06; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Makarov SS, 2000, MOL MED TODAY, V6, P441, DOI 10.1016/S1357-4310(00)01814-1; MARANGOS PJ, 1987, ANNU REV NEUROSCI, V10, P269, DOI 10.1146/annurev.ne.10.030187.001413; MATTIAZZI M, 2002, J BIOL CHEM, V5, P5; Mattson MP, 1997, J NEUROSCI RES, V49, P681, DOI 10.1002/(SICI)1097-4547(19970915)49:6<681::AID-JNR3>3.0.CO;2-3; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MATTSON MP, 1995, METHOD CELL BIOL, V46, P187; McCann MJ, 1996, NEUROSCIENCE, V72, P273, DOI 10.1016/0306-4522(95)00526-9; Meberg PJ, 1996, MOL BRAIN RES, V38, P179, DOI 10.1016/0169-328X(95)00229-L; MONNETTSCHUDI F, 1995, NEUROTOXICOLOGY, V16, P97; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nath A, 2000, J PSYCHOPHARMACOL, V14, P222, DOI 10.1177/026988110001400305; OKAZAKI MM, 1995, J COMP NEUROL, V352, P515, DOI 10.1002/cne.903520404; OMAR A, 2001, SOC NEUR ABS; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Pennypacker KR, 2001, EXP NEUROL, V172, P307, DOI 10.1006/exnr.2001.7817; PerezOtano I, 1996, GLIA, V16, P306, DOI 10.1002/(SICI)1098-1136(199604)16:4<306::AID-GLIA3>3.0.CO;2-Y; POWERS MF, 1991, J BIOL CHEM, V266, P17250; Prieto AL, 2000, J COMP NEUROL, V425, P295; Qin ZH, 1998, MOL PHARMACOL, V53, P33, DOI 10.1124/mol.53.1.33; Rothwarf D.M., 1999, SCI STKE, V1999, pRE1; ROZOVSKY I, 1994, NEUROSCIENCE, V62, P741, DOI 10.1016/0306-4522(94)90473-1; Sadik G, 1999, INT J BIOCHEM CELL B, V31, P1327, DOI 10.1016/S1357-2725(99)00053-9; Samuel SJ, 1997, HEPATOLOGY, V25, P1213, DOI 10.1002/hep.510250525; Sanz O, 2002, J NEUROSCI RES, V67, P772, DOI 10.1002/jnr.10140; SchmidtUllrich R, 1996, DEVELOPMENT, V122, P2117; SCHMIEDEKNECHT G, 1997, BIOCHEM BIOPH RES CO, V241, P58; Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Shingo T, 2001, J NEUROSCI, V21, P9733, DOI 10.1523/JNEUROSCI.21-24-09733.2001; SHIPLEY JM, 1991, GENOMICS, V10, P1009, DOI 10.1016/0888-7543(91)90192-H; SMITHSWINTOSKY VL, 1994, J NEUROCHEM, V63, P781, DOI 10.1046/j.1471-4159.1994.63020781.x; Song GQ, 2001, J NEUROCHEM, V79, P804, DOI 10.1046/j.1471-4159.2001.00626.x; Streck EL, 2001, NEUROCHEM RES, V26, P1195, DOI 10.1023/A:1013907104585; Streck EL, 2002, METAB BRAIN DIS, V17, P83, DOI 10.1023/A:1015594111778; Streck EL, 2002, INT J DEV NEUROSCI, V20, P77, DOI 10.1016/S0736-5748(02)00043-6; Sweadner KJ, 2000, BIOCHEM BIOPH RES CO, V279, P196, DOI 10.1006/bbrc.2000.3907; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Tam WF, 2000, MOL CELL BIOL, V20, P2269, DOI 10.1128/MCB.20.6.2269-2284.2000; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Timon M, 2001, IMMUNOLOGY, V102, P180, DOI 10.1046/j.1365-2567.2001.01177.x; TOGGAS SM, 1992, MOL PHARMACOL, V42, P44; Tone M, 1999, BBA-GENE STRUCT EXPR, V1446, P334, DOI 10.1016/S0167-4781(99)00103-7; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Truettner J, 2002, MOL BRAIN RES, V103, P106, DOI 10.1016/S0169-328X(02)00191-2; Tsunekawa N, 1999, MOL REPROD DEV, V52, P383, DOI 10.1002/(SICI)1098-2795(199904)52:4&lt;383::AID-MRD7&gt;3.0.CO;2-Z; UEBERLA K, 1993, J ACQ IMMUN DEF SYND, V6, P227; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; Vlahakis SR, 2002, J IMMUNOL, V169, P5546, DOI 10.4049/jimmunol.169.10.5546; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Walz W, 1999, J NEUROSCI RES, V56, P595, DOI 10.1002/(SICI)1097-4547(19990615)56:6<595::AID-JNR5>3.3.CO;2-X; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Warrington JA, 2000, PHYSIOL GENOMICS, V2, P143, DOI 10.1152/physiolgenomics.2000.2.3.143; Weber GF, 1999, NEUROSCI BIOBEHAV R, V23, P1079, DOI 10.1016/S0149-7634(99)00041-X; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yagita Y, 2001, STROKE, V32, P1890, DOI 10.1161/01.STR.32.8.1890; Yamashima T, 2000, PROG NEUROBIOL, V62, P273, DOI 10.1016/S0301-0082(00)00006-X; Yenari MA, 2002, ADV EXP MED BIOL, V513, P281; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999; Yu ZF, 2000, J MOL NEUROSCI, V15, P31, DOI 10.1385/JMN:15:1:31; Yunta M, 2003, ONCOGENE, V22, P1219, DOI 10.1038/sj.onc.1206183; ZABEL U, 1993, EMBO J, V12, P201, DOI 10.1002/j.1460-2075.1993.tb05646.x; Zhou DH, 2001, INT J RADIAT BIOL, V77, P763, DOI 10.1080/09553000110050047	118	44	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					723	+		10.1096/fj.03-0773fje	http://dx.doi.org/10.1096/fj.03-0773fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766792				2022-12-28	WOS:000220425000036
J	Ferrero, E; Scabini, S; Magni, E; Foglieni, C; Belloni, D; Colombo, B; Curnis, F; Villa, A; Ferrero, ME; Corti, A				Ferrero, E; Scabini, S; Magni, E; Foglieni, C; Belloni, D; Colombo, B; Curnis, F; Villa, A; Ferrero, ME; Corti, A			Chromogranin A protects vessels against tumor necrosis factor alpha-induced vascular leakage	FASEB JOURNAL			English	Article						Chromogranin A; tumor necrosis factor; endothelial cell; vascular permeability; heart failure	N-TERMINAL DOMAIN; CELL-ADHESION; HEART-FAILURE; RESISTANCE-ARTERIES; BARRIER FUNCTION; TNF; VASOSTATINS; ENDOCRINE; RECEPTORS; IDENTIFICATION	Elevated levels of circulating chromogranin A (CgA), a protein stored in the secretory granules of many neuroendocrine cells and neurons, have been detected in the blood of patients with neuroendocrine tumors or heart failure. The pathophysiological role of increased secretion of CgA is unknown. Using mice bearing subcutaneous tumors genetically engineered to secrete CgA in circulation, we have found that increased blood levels of this protein prevent vascular leakage induced by tumor necrosis factor-alpha. (TNF) in the liver venous system. Structure-activity studies, carried out with CgA fragments administered to normal mice, showed that an active site is located within residues 7-57 of CgA. Accordingly, an anti-CgA antibody directed to residues 53-57 inhibited the effect of circulating CgA, either endogenously produced or exogenously administered, on liver vessels. Studies of the mechanism of action showed that CgA inhibits TNF-induced VE-cadherin down-regulation and barrier alteration of cultured endothelial cells, in an indirect manner. Other effectors, such as thrombin and vascular endothelial growth factor were partially inhibited by CgA N-terminal fragments in in vitro permeability assays. These findings suggest that circulating CgA could help regulate the endothelial barrier function and to protect vessels against TNF-induced plasma leakage in pathological conditions characterized by increased production of TNF and CgA, such as cancer or heart failure.	Ist Sci San Raffaele, Dept Biol & Technol Res DIBIT, I-20132 Milan, Italy; CNR, Inst Gen Pathol, I-20131 Milan, Italy; CNR, Ctr Studies Cellular Pathol, I-20131 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Consiglio Nazionale delle Ricerche (CNR)	Corti, A (corresponding author), Ist Sci San Raffaele, Dept Biol & Technol Res DIBIT, Via Olgettina 60, I-20132 Milan, Italy.	elisabetta.ferrero@hsr.it	Curnis, Flavio/AAK-3542-2020; Corti, Angelo/F-7046-2012; Colombo, Barbara/AAN-5045-2020; Ferrero, Elisabetta/G-5690-2013; Villa, Antonello/B-4781-2012; Foglieni, Chiara/O-2339-2015; Belloni, Daniela/AAN-6718-2020	Curnis, Flavio/0000-0002-7231-9569; Corti, Angelo/0000-0002-0893-6191; Colombo, Barbara/0000-0002-5887-5868; Foglieni, Chiara/0000-0002-5155-6426; Belloni, Daniela/0000-0002-3487-4203; Ferrero, Elisabetta/0000-0003-2571-933X; Villa, Antonello/0000-0002-3820-8072; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; BALKWILL F, 1987, LANCET, V2, P1229; BRANSTER MV, 1957, NATURE, V180, P1283, DOI 10.1038/1801283a0; Brekke JF, 2002, REGUL PEPTIDES, V105, P93, DOI 10.1016/S0167-0115(02)00004-6; Brekke JF, 2000, ADV EXP MED BIOL, V482, P239; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Colombo B, 2002, CANCER RES, V62, P941; Colombo B, 2002, J BIOL CHEM, V277, P45911, DOI 10.1074/jbc.M202637200; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 2002, ANN NY ACAD SCI, V971, P362, DOI 10.1111/j.1749-6632.2002.tb04497.x; Corti A, 2000, ADV EXP MED BIOL, V482, P351; CORTI A, 1994, J IMMUNOL METHODS, V177, P191, DOI 10.1016/0022-1759(94)90156-2; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; EICHENHOLZ PW, 1992, AM J PHYSIOL, V263, pH668, DOI 10.1152/ajpheart.1992.263.3.H668; FERRARI R, 1995, CIRCULATION, V92, P1479, DOI 10.1161/01.CIR.92.6.1479; Ferrero E, 1996, CANCER RES, V56, P3211; Ferrero E, 2002, ANN NY ACAD SCI, V971, P355, DOI 10.1111/j.1749-6632.2002.tb04495.x; Ferrero E, 2001, AM J PHYSIOL-CELL PH, V281, pC1173, DOI 10.1152/ajpcell.2001.281.4.C1173; FERRERO E, 1995, FEBS LETT, V374, P323, DOI 10.1016/0014-5793(95)01110-Z; Friedl J, 2002, BLOOD, V100, P1334, DOI 10.1182/blood.V100.4.1334.h81602001334_1334_1339; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; GOLDBLUM SE, 1993, AM J PHYSIOL, V264, pC894, DOI 10.1152/ajpcell.1993.264.4.C894; HEGEWISCH S, 1990, LANCET, V335, P294, DOI 10.1016/0140-6736(90)90115-L; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; Kim T, 2001, CELL, V106, P499, DOI 10.1016/S0092-8674(01)00459-7; LAZURE C, 1990, PEPTIDES, V11, P79, DOI 10.1016/0196-9781(90)90114-K; LO SK, 1992, J CLIN INVEST, V89, P981, DOI 10.1172/JCI115681; Mandala M, 2000, ADV EXP MED BIOL, V482, P167; Mann D L, 1996, J Card Fail, V2, pS165, DOI 10.1016/S1071-9164(96)80073-X; Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Pelagi M, 2000, EUR CYTOKINE NETW, V11, P580; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; SIMON JP, 1989, BIOCHEM J, V262, P1; SOBOL RE, 1989, NEW ENGL J MED, V320, P444, DOI 10.1056/NEJM198902163200707; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WINKLER H, 1980, NEUROSCIENCE, V5, P1803, DOI 10.1016/0306-4522(80)90031-7; Wu TL, 1999, J CLIN LAB ANAL, V13, P312, DOI 10.1002/(SICI)1098-2825(1999)13:6<312::AID-JCLA11>3.0.CO;2-1; YOKOYAMA T, 1993, J CLIN INVEST, V92, P2303, DOI 10.1172/JCI116834; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122	45	91	98	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					554	+		10.1096/fj.03-0922fje	http://dx.doi.org/10.1096/fj.03-0922fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734634	Green Submitted			2022-12-28	WOS:000188829300018
J	Schoenfeld, N; Bauer, MKA; Grimm, S				Schoenfeld, N; Bauer, MKA; Grimm, S			The metastasis suppressor gene C33/CD82/KAI1 induces apoptosis through reactive oxygen intermediates	FASEB JOURNAL			English	Article						cell death; metastasis suppressor gene; reactive oxygen intermediates; glutathione; Cdc42		Here we describe the isolation of C33/CD82/KAI1 in a screen for apoptosis-inducing genes. C33 is a gene that is downregulated in many metastatic tumor cells and the expression of which can attenuate the process of metastases formation in a variety of tumors. In accordance, we observed cell death induction by C33 in many different cell types. C33 seems to promote cell death by the generation of reactive oxygen intermediates (ROIs). These ROIs, however, are not derived from the mitochondrial respiratory chain as in most other scenarios leading to apoptosis. We observed that C33 renders cells sensitive to ROIs by causing the specific release of the intracellular antioxidant glutathione (GSH) from cells. Moreover, C33 activates the GTPase Cdc42, which mediates GSH release and apoptosis induction and allows to detect the formation of ROIs.	Max Planck Inst Biochem, D-82152 Martinsried, Germany	Max Planck Society	Grimm, S (corresponding author), Max Planck Inst Biochem, D-82152 Martinsried, Germany.	sgrimm@biochem.mpg.de			Bavarian Government; Roche Diagnostics; Xantos Biomedicine AG	Bavarian Government; Roche Diagnostics; Xantos Biomedicine AG	We thank Drs. Riesenberg, Klinikum Groflhadern (Munich), for providing PC3 and LNCaP cells and T. Mak, Toronto, Canada, for the Apaf-1 negative cells. The expression constructs for PDGF-R, EGF-R, Cdc42 T17N, Rac1 T17N, and HER-2 were a gift of Dr. A. Ullrich, Martinsried. The vectors for catalase, glutathione peroxidase-1 and Cu/Zn superoxide dismutase were from Dr. S. Lenzen, Hannover. The monoclonal antibody C11 against CD82 was a kind gift of H. Conjeaud, Paris, France. Thanks also to A. Gewies and R. Gernert for helpful comments on the manuscript. This work was supported by the Bavarian Government, Roche Diagnostics, and Xantos Biomedicine AG.	Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Albayrak T, 2003, BIOCHEM BIOPH RES CO, V304, P772, DOI 10.1016/S0006-291X(03)00653-3; Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493; Bazenet CE, 1998, P NATL ACAD SCI USA, V95, P3984, DOI 10.1073/pnas.95.7.3984; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; Chandel NS, 1997, J BIOL CHEM, V272, P18808, DOI 10.1074/jbc.272.30.18808; CROSS AR, 1991, BIOCHIM BIOPHYS ACTA, V1057, P281, DOI 10.1016/S0005-2728(05)80140-9; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Deiss LP, 1996, EMBO J, V15, P3861, DOI 10.1002/j.1460-2075.1996.tb00760.x; Delaguillaumie A, 2002, J CELL SCI, V115, P433; DONG JT, 1995, SCIENCE, V268, P884, DOI 10.1126/science.7754374; Ellis LM, 1996, EUR J CANCER, V32A, P2451, DOI 10.1016/S0959-8049(96)00389-9; Gewies A, 2003, CANCER RES, V63, P682; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Glinsky GV, 1997, CANCER LETT, V115, P185, DOI 10.1016/S0304-3835(97)04738-1; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Grimm S, 1997, J EXP MED, V185, P1137, DOI 10.1084/jem.185.6.1137; Guo XZ, 1996, CANCER RES, V56, P4876; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Jia L, 1997, BRIT J HAEMATOL, V98, P686, DOI 10.1046/j.1365-2141.1997.2683085.x; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Lahiri S, 2000, J APPL PHYSIOL, V88, P1467, DOI 10.1152/jappl.2000.88.4.1467; LEBELBINAY S, 1995, J IMMUNOL, V155, P101; LEBELBINAY S, 1995, J LEUKOCYTE BIOL, V57, P956, DOI 10.1002/jlb.57.6.956; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Li PF, 1999, EMBO J, V18, P6027, DOI 10.1093/emboj/18.21.6027; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Malafa M, 2000, J SURG RES, V88, P130, DOI 10.1006/jsre.1999.5773; Mashimo T, 1998, P NATL ACAD SCI USA, V95, P11307, DOI 10.1073/pnas.95.19.11307; McConkey DJ, 1996, CANCER RES, V56, P5594; McGill Gael, 1997, Frontiers in Bioscience (online), V2, pD353; Mund T, 2003, FASEB J, V17, P696, DOI 10.1096/fj.02-0657fje; Neudecker F, 2000, BIOTECHNIQUES, V28, P107; NONAKA Y, 1993, INT J CANCER, V54, P983, DOI 10.1002/ijc.2910540620; Ono M, 1999, CANCER RES, V59, P2335; Pervaiz S, 2002, METHOD ENZYMOL, V352, P150; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Rokhlin OW, 1997, CANCER RES, V57, P1758; Rottenberg H, 1998, BBA-MOL CELL RES, V1404, P393, DOI 10.1016/S0167-4889(98)00088-3; ROUSSEL MF, 1984, MOL CELL BIOL, V4, P1999, DOI 10.1128/MCB.4.10.1999; Sidoti-de Fraisse C, 1998, ONCOGENE, V17, P1639, DOI 10.1038/sj.onc.1202094; Srinivasula SM, 1998, MOL CELL, V1, P949, DOI 10.1016/S1097-2765(00)80095-7; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; Subauste MC, 2000, J BIOL CHEM, V275, P9725, DOI 10.1074/jbc.275.13.9725; Sun IL, 1996, BIOCHEM MOL BIOL INT, V38, P175; Suzuki S, 1999, ONCOGENE, V18, P6380, DOI 10.1038/sj.onc.1203024; Takaoka A, 1998, ONCOGENE, V16, P1443, DOI 10.1038/sj.onc.1201648; Thomas A, 2000, ONCOGENE, V19, P5259, DOI 10.1038/sj.onc.1203895; vandenDobbelsteen DJ, 1996, J BIOL CHEM, V271, P15420, DOI 10.1074/jbc.271.26.15420; White A, 1998, ONCOGENE, V16, P3143, DOI 10.1038/sj.onc.1201852; Yoshida BA, 2000, JNCI-J NATL CANCER I, V92, P1717, DOI 10.1093/jnci/92.21.1717; Yu Y, 1997, CLIN CANCER RES, V3, P1045; Zamzami N, 1998, ONCOGENE, V16, P2265, DOI 10.1038/sj.onc.1201989	57	33	35	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					158	160		10.1096/fj.03-0420fje	http://dx.doi.org/10.1096/fj.03-0420fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597553				2022-12-28	WOS:000188829300060
J	Swamynathan, SK; Crawford, MA; Robison, WG; Kanungo, J; Piatigorsky, J				Swamynathan, SK; Crawford, MA; Robison, WG; Kanungo, J; Piatigorsky, J			Adaptive differences in the structure and macromolecular compositions of the air and water corneas of the "four-eyed" fish (Anableps anableps)	FASEB JOURNAL			English	Article							DROSOPHILA-MELANOGASTER; PRIMARY SPECTACLE; REFRACTIVE STATE; SEA LAMPREY; GELSOLIN; VISION; GLYCOGEN; EYE; EPITHELIUM; MECHANISMS	The water meniscus bisects the eyes of the "four-eyed" fish Anableps anableps, resulting in simultaneous vision in air and water. We compare the structure and macromolecular compositions of the Anableps dorsal (air) and ventral (water) corneas with the fully aquatic zebrafish cornea. The Anableps dorsal corneal epithelium is thicker (>20 cell layers), flatter (similar to 1. 94 nun radius of curvature), and contains similar to 15-fold more glycogen (0. 16 mug/mug water-soluble protein) than the ventral corneal epithelium (5-7 cell layers; similar to1.63 nun radius of curvature; 0.01 mug glycogen/mug watersoluble protein), which resembles the zebrafish corneal epithelium. Gelsolin is the major water-soluble protein in the zebrafish (similar to50%) and Anableps dorsal (similar to38%) and ventral (similar to21%) corneal epithelia, suggesting that gelsolin was recruited for high corneal expression before these two species diverged at least 100 million years ago and that abundant corneal gelsolin is not limited to aquatic vision. Anableps gelsolin, deduced from its cDNA, is 57% identical to zebrafish gelsolin. Paucity of Anableps corneal F-actin (consistent with high gelsolin) was confirmed by the absence of rhodamine-phalloidin staining. We suggest amphibious refraction and protection from UV irradiation and desiccation in air as selective constraints for the specializations of the Anableps dorsal cornea.	NEI, Mol & Dev Biol Lab, NIH, Bethesda, MD 20892 USA; NEI, Immunol Lab, NIH, Bethesda, MD 20892 USA; NEI, Lab Mech Ocular Dis, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI); National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)	Piatigorsky, J (corresponding author), NEI, Mol & Dev Biol Lab, NIH, 7 Mem Dr,Bldg 7,Room 100A, Bethesda, MD 20892 USA.	joramp@nei.nih.gov		Swamynathan, Shivalingappa/0000-0002-9158-1511	Intramural NIH HHS [Z01 EY000126-26, Z01 EY000259-18] Funding Source: Medline; NATIONAL EYE INSTITUTE [Z01EY000126, Z01EY000259] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Adamo KB, 1998, J APPL PHYSIOL, V84, P908, DOI 10.1152/jappl.1998.84.3.908; AMEMIYA T, 1978, ACTA HISTOCHEM, V62, P302, DOI 10.1016/S0065-1281(78)80096-8; [Anonymous], VERTEBRATE EYE ITS A, DOI 10.1097/00005053-194409000-00057; Folk DG, 2001, J EXP BIOL, V204, P3323; Gibbs AG, 1997, J EXP BIOL, V200, P1821; GRAHAM JB, 1970, SCIENCE, V168, P586, DOI 10.1126/science.168.3931.586; HOWLAND HC, 1984, VISION RES, V24, P1905, DOI 10.1016/0042-6989(84)90024-5; JERMANN T, 1992, EXPERIENTIA, V48, P217, DOI 10.1007/BF01930457; Kanungo J, 2003, P NATL ACAD SCI USA, V100, P3287, DOI 10.1073/pnas.0634473100; Knowles F., 1967, NATURE, V214, P307; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Land MF, 2002, ANIMAL EYES; LATTIMORE MR, 1989, PHOTOCHEM PHOTOBIOL, V49, P175, DOI 10.1111/j.1751-1097.1989.tb04093.x; Leonard DW, 1997, BIOPHYS J, V72, P1382, DOI 10.1016/S0006-3495(97)78784-8; LEVY B, 1980, J COMP PHYSIOL, V137, P267, DOI 10.1007/BF00657122; LO WK, 1993, EXP EYE RES, V56, P121, DOI 10.1006/exer.1993.1017; Muller F, 2002, BIOESSAYS, V24, P564, DOI 10.1002/bies.10096; MURPHY CJ, 1990, VISION RES, V30, P23, DOI 10.1016/0042-6989(90)90125-5; Nelson JS., 2016, FISHES WORLD, DOI DOI 10.1002/9781119174844.FMATTER; Passonneau JV, 1993, ENZYMATIC ANAL PRACT, P177; PATEL S, 1995, J REFRACT SURG, V11, P100; PATEL S, 1987, OPHTHAL PHYSL OPT, V7, P503, DOI 10.1016/0275-5408(87)90085-8; PEDERSON HJ, 1971, EXP EYE RES, V12, P147, DOI 10.1016/0014-4835(71)90139-4; Piatigorsky J, 1998, PROG RETIN EYE RES, V17, P145, DOI 10.1016/S1350-9462(97)00004-9; Piatigorsky J, 2001, CORNEA, V20, P853, DOI 10.1097/00003226-200111000-00015; Saidel WM, 1998, VISION RES, V38, P2001, DOI 10.1016/S0042-6989(97)00419-7; Schwab I R, 2001, Trans Am Ophthalmol Soc, V99, P145; Schwassmann H O, 1966, Vision Res, V5, P269; SIVAK J, 1987, PROC R SOC SER B-BIO, V229, P467, DOI 10.1098/rspb.1987.0005; SIVAK JG, 1976, VISION RES, V16, P531, DOI 10.1016/0042-6989(76)90035-3; SIVAK JG, 1989, J COMP PHYSIOL A, V165, P771, DOI 10.1007/BF00610875; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; VANHORN DL, 1969, J ULTRA MOL STRUCT R, V26, P454, DOI 10.1016/S0022-5320(69)90051-3; WALLMAN J, 1995, VISION RES, V35, P37, DOI 10.1016/0042-6989(94)E0049-Q; Xu YS, 2000, J BIOL CHEM, V275, P24645, DOI 10.1074/jbc.M001159200; Yu DY, 2001, PROG RETIN EYE RES, V20, P175, DOI 10.1016/S1350-9462(00)00027-6; ZIESKE JD, 1994, EXP CELL RES, V214, P621, DOI 10.1006/excr.1994.1300	37	29	31	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					1996	2005		10.1096/fj.03-0122com	http://dx.doi.org/10.1096/fj.03-0122com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597669	Green Accepted			2022-12-28	WOS:000186961200036
J	Goglia, F; Skulachev, VP				Goglia, F; Skulachev, VP			A function for novel uncoupling proteins: antioxidant defense of mitochondrial matrix by translocating fatty acid peroxides from the inner to the outer membrane leaflet	FASEB JOURNAL			English	Article						uncoupling protein; mitochondria; lipid peroxide; anion carrier	OXIDATIVE STRESS; SKELETAL-MUSCLE; SUPEROXIDE-DISMUTASE; CYTOCHROME-C; DIFFERENTIAL REGULATION; PROTON TRANSPORT; THYROID-HORMONE; MAMMALIAN-CELLS; ANION CARRIERS; COLD-EXPOSURE	It is hypothesized that mitochondrial uncoupling proteins operate as carriers of fatty acid peroxide anions. This is assumed to result in electrophoretic extrusion of such anions from the inner to the outer leaflet of the inner mitochondrial membrane, being driven by membrane potential ( mitochondrial interior negative). In this way, the inner leaflet is ridded of fatty acid peroxides that otherwise can form very aggressive oxidants damaging mitochondrial DNA, aconitase, and other mitochondrial matrix-localized components of vital importance. The steady-state concentration the fatty acid peroxides is known to be low. This explains why UCP2, 3, 4, and 5 are present in small amounts usually insufficient to make a large contribution to the H+ conductance of the mitochondrial membrane. -	Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Dept Bioenerget, Moscow 119992, Russia; Dipartimento Sci Biol & Ambientali, I-082100 Benevento, Italy	Lomonosov Moscow State University	Skulachev, VP (corresponding author), Moscow MV Lomonosov State Univ, AN Belozersky Inst Physicochem Biol, Dept Bioenerget, GSP-2, Moscow 119992, Russia.	skulach@belozersky.msu.ru	Skulachev, Vladimir P/J-4164-2012	Skulachev, Vladimir P/0000-0003-4886-2243; Skulachev, Vladimir/0000-0001-5141-7517; GOGLIA, Fernando/0000-0003-0468-9645				ANDREYEV AY, 1989, EUR J BIOCHEM, V182, P585, DOI 10.1111/j.1432-1033.1989.tb14867.x; Argiles JM, 2002, BIOCHEM BIOPH RES CO, V293, P1145, DOI 10.1016/S0006-291X(02)00355-8; Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Barja G, 2002, FREE RADICAL BIO MED, V33, P1167, DOI 10.1016/S0891-5849(02)00910-3; Bechmann I, 2002, BIOCHEM PHARMACOL, V64, P363, DOI 10.1016/S0006-2952(02)01166-8; Boss O, 1997, FEBS LETT, V412, P111, DOI 10.1016/S0014-5793(97)00755-2; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; CARLSSON LM, 1995, P NATL ACAD SCI USA, V92, P6264, DOI 10.1073/pnas.92.14.6264; Carmona MC, 1998, BIOCHEM BIOPH RES CO, V243, P224, DOI 10.1006/bbrc.1998.8088; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; Cortez-Pinto H, 1998, BIOCHEM BIOPH RES CO, V251, P313, DOI 10.1006/bbrc.1998.9473; de Lange P, 2001, ENDOCRINOLOGY, V142, P3414, DOI 10.1210/en.142.8.3414; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gardner PR, 1997, BIOSCIENCE REP, V17, P33, DOI 10.1023/A:1027383100936; Garlid KD, 1998, FEBS LETT, V438, P10, DOI 10.1016/S0014-5793(98)01246-0; Garlid KD, 2001, BIOCHEM SOC T, V29, P803, DOI 10.1042/BST0290803; Garlid KD, 1996, J BIOL CHEM, V271, P2615, DOI 10.1074/jbc.271.5.2615; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Graziewicz MA, 2002, NUCLEIC ACIDS RES, V30, P2817, DOI 10.1093/nar/gkf392; Harper ME, 2001, BBA-BIOENERGETICS, V1504, P159, DOI 10.1016/S0005-2728(00)00244-9; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Horvath B, 2002, BIOCHEM PHARMACOL, V64, P369, DOI 10.1016/S0006-2952(02)01167-X; Imai H, 2003, FREE RADICAL BIO MED, V34, P145, DOI 10.1016/S0891-5849(02)01197-8; Iwahashi H, 2002, BIOCHEM J, V361, P57, DOI 10.1042/0264-6021:3610057; Jarmuszkiewicz W, 2000, FEBS LETT, V467, P145, DOI 10.1016/S0014-5793(00)01138-8; Jezek P, 2003, FEBS LETT, V534, P15, DOI 10.1016/S0014-5793(02)03779-1; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jucker BM, 2000, P NATL ACAD SCI USA, V97, P6880, DOI 10.1073/pnas.120131997; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Laloi M, 1997, NATURE, V389, P135, DOI 10.1038/38156; Lanni A, 2002, FEBS LETT, V525, P7, DOI 10.1016/S0014-5793(02)02828-4; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Lin BZ, 1998, AM J PHYSIOL-ENDOC M, V275, pE386, DOI 10.1152/ajpendo.1998.275.3.E386; Liu SS, 1997, BIOSCIENCE REP, V17, P259, DOI 10.1023/A:1027328510931; Lombardi A, 2002, FEBS LETT, V532, P12, DOI 10.1016/S0014-5793(02)03690-6; Maia IG, 1998, FEBS LETT, V429, P403, DOI 10.1016/S0014-5793(98)00634-6; Mao WG, 1999, FEBS LETT, V443, P326, DOI 10.1016/S0014-5793(98)01713-X; Melov S, 1998, NAT GENET, V18, P159, DOI 10.1038/ng0298-159; Melov S, 2000, ANN NY ACAD SCI, V908, P219; Mizuno T, 2000, BIOCHEM BIOPH RES CO, V278, P691, DOI 10.1006/bbrc.2000.3859; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; NEUBERT D, 1962, P NATL ACAD SCI USA, V48, P1651, DOI 10.1073/pnas.48.9.1651; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Pecqueur C, 2001, J MOL MED, V79, P48, DOI 10.1007/s001090000150; Raimbault S, 2001, BIOCHEM J, V353, P441, DOI 10.1042/0264-6021:3530441; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200; Simonyan RA, 2001, BBA-BIOENERGETICS, V1505, P271, DOI 10.1016/S0005-2728(01)00168-2; SKULACHEV VP, 1991, FEBS LETT, V294, P158, DOI 10.1016/0014-5793(91)80658-P; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; Skulachev VP, 1997, BIOSCIENCE REP, V17, P347, DOI 10.1023/A:1027344914565; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; Skulachev VP, 1999, J BIOENERG BIOMEMBR, V31, P431, DOI 10.1023/A:1005492205984; Skulachev VP, 1996, Q REV BIOPHYS, V29, P169, DOI 10.1017/S0033583500005795; SKULACHEV VP, 1988, MEMBRANE BIOENERGETI, P234; Sluse FE, 2002, FEBS LETT, V510, P117, DOI 10.1016/S0014-5793(01)03229-X; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Tomas P, 2002, FEBS LETT, V526, P63, DOI 10.1016/S0014-5793(02)03116-2; Toyomizu M, 2002, FEBS LETT, V529, P313, DOI 10.1016/S0014-5793(02)03395-1; VERCESI AE, 1995, NATURE, V375, P24, DOI 10.1038/375024a0; Vianna CR, 2001, PHYSIOL GENOMICS, V5, P137, DOI 10.1152/physiolgenomics.2001.5.3.137; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; WINKLER E, 1994, J BIOL CHEM, V269, P2508; Wojtczak L, 1998, ARCH BIOCHEM BIOPHYS, V357, P76, DOI 10.1006/abbi.1998.0777; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; Yu XX, 2000, FASEB J, V14, P1611, DOI 10.1096/fj.14.11.1611; ZACKOVA M, 2003, J BIOL CHEM, V218, P20771; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	81	198	212	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1585	1591		10.1096/fj.03-0159hyp	http://dx.doi.org/10.1096/fj.03-0159hyp			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958165				2022-12-28	WOS:000185925100033
J	Lemieux, K; Konrad, D; Klip, A; Marette, A				Lemieux, K; Konrad, D; Klip, A; Marette, A			The AMP-activated protein kinase activator AICAR does not induce GLUT4 translocation to transverse tubules but stimulates glucose uptake and p38 mitogen-activated protein kinases alpha and beta in skeletal muscle	FASEB JOURNAL			English	Article						glucose transport; exercise; contraction; insulin; plasma membrane	ACETYL-COA CARBOXYLASE; N-TERMINAL KINASE; IN-VIVO; SIGNALING PATHWAYS; POTENTIAL ROLE; MALONYL-COA; T TUBULES; TRANSPORT; INSULIN; CONTRACTION	The AMP-activated protein kinase ( AMPK) pathway participates in the metabolic effects of contraction on muscle glucose uptake. We have shown that contraction increases both GLUT4 translocation to the cell surface and p38 mitogen-activated protein kinase ( p38 MAPK) activity. The latter pathway may be involved in the activation of GLUT4. Here we investigated whether the AMPK activator AICAR increases glucose uptake by inducing translocation of GLUT4 and/or by activating the p38 MAPK pathway. AICAR infusion into glucose-clamped rats increased muscle glucose uptake and GLUT4 translocation from an intracellular fraction to the plasma membrane but not to T-tubules. AICAR also caused recruitment of the transferrin receptor to the plasma membrane and increased [I-125]-transferrin uptake in isolated muscle. AICAR treatment in vivo or in vitro activated both p38 MAPKalpha and beta (1.6- to 2.8-fold) in EDL muscles with a time course identical to that of stimulation of AMPK and glucose transport. The p38 MAPK inhibitor SB203580 abrogated the stimulatory effect of AICAR on glucose uptake. These results suggest that AICAR increases muscle glucose uptake by two mechanisms: 1) inducing selective recruitment of GLUT4 to the plasma membrane, and 2) activating p38 MAPKalpha and beta, which may be involved in the activation of GLUT4.	Laval Univ Hosp, Res Ctr, Dept Anat & Physiol, Lipid Res Unit, St Foy, PQ G1V 4G2, Canada; Hosp Sick Children, Cell Biol Programme, Toronto, ON M5G 1X8, Canada	Laval University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Marette, A (corresponding author), Laval Univ Hosp, Res Ctr, Dept Physiol, 2705 Laurier Bld, St Foy, PQ G1V 4G2, Canada.	andre.marette@crchul.ulaval.ca	Marette, Andre/E-9342-2013	Konrad, Daniel/0000-0001-9067-4356				Abbud W, 2000, ARCH BIOCHEM BIOPHYS, V380, P347, DOI 10.1006/abbi.2000.1935; Bergeron R, 1999, AM J PHYSIOL-ENDOC M, V276, pE938, DOI 10.1152/ajpendo.1999.276.5.E938; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; CULLEN MJ, 1984, J ANAT, V138, P297; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DAVIES SP, 1989, EUR J BIOCHEM, V186, P123, DOI 10.1111/j.1432-1033.1989.tb15185.x; Dombrowski L, 1996, AM J PHYSIOL-ENDOC M, V270, pE667, DOI 10.1152/ajpendo.1996.270.4.E667; Eisenberg B. R., 2010, COMPREHENSIVE PHYSL, P73; Fryer LGD, 2002, FEBS LETT, V531, P189, DOI 10.1016/S0014-5793(02)03501-9; Goodyear LJ, 1996, AM J PHYSIOL-ENDOC M, V271, pE403, DOI 10.1152/ajpendo.1996.271.2.E403; Guo JH, 1998, J BIOL CHEM, V273, P16487, DOI 10.1074/jbc.273.26.16487; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hawley SA, 1996, J BIOL CHEM, V271, P27879, DOI 10.1074/jbc.271.44.27879; Hayashi T, 1998, DIABETES, V47, P1369, DOI 10.2337/diabetes.47.8.1369; Huang M, 2002, J BIOL CHEM, V277, P28364, DOI 10.1074/jbc.C200321200; Kemp BE, 1999, TRENDS BIOCHEM SCI, V24, P22, DOI 10.1016/S0968-0004(98)01340-1; Konrad D, 2001, DIABETES, V50, P1464, DOI 10.2337/diabetes.50.6.1464; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lemieux K, 2000, DIABETES, V49, P183, DOI 10.2337/diabetes.49.2.183; Merrill GF, 1997, AM J PHYSIOL-ENDOC M, V273, pE1107, DOI 10.1152/ajpendo.1997.273.6.E1107; Moxham CM, 1996, J BIOL CHEM, V271, P30765, DOI 10.1074/jbc.271.48.30765; Mu J, 2001, MOL CELL, V7, P1085, DOI 10.1016/S1097-2765(01)00251-9; Musi N, 2001, AM J PHYSIOL-ENDOC M, V280, pE677, DOI 10.1152/ajpendo.2001.280.5.E677; Park SH, 2002, J APPL PHYSIOL, V92, P2475, DOI 10.1152/japplphysiol.00071.2002; Ploug T, 1998, J CELL BIOL, V142, P1429, DOI 10.1083/jcb.142.6.1429; Rasmussen BB, 1998, J APPL PHYSIOL, V85, P1629, DOI 10.1152/jappl.1998.85.5.1629; Rasmussen BB, 1997, J APPL PHYSIOL, V83, P1104, DOI 10.1152/jappl.1997.83.4.1104; Roy D, 1997, AM J PHYSIOL-ENDOC M, V273, pE688, DOI 10.1152/ajpendo.1997.273.4.E688; Roy D, 1996, BIOCHEM BIOPH RES CO, V223, P147, DOI 10.1006/bbrc.1996.0860; Roy D, 1998, AM J PHYSIOL-ENDOC M, V274, pE692, DOI 10.1152/ajpendo.1998.274.4.E692; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Somwar R, 2000, DIABETES, V49, P1794, DOI 10.2337/diabetes.49.11.1794; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Vavvas D, 1997, J BIOL CHEM, V272, P13255, DOI 10.1074/jbc.272.20.13255; Widegren U, 1998, FASEB J, V12, P1379, DOI 10.1096/fasebj.12.13.1379; Winder WW, 1996, AM J PHYSIOL-ENDOC M, V270, pE299, DOI 10.1152/ajpendo.1996.270.2.E299; Xi X, 2001, J BIOL CHEM, V276, P41029, DOI 10.1074/jbc.M102824200	37	100	106	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1658	1665		10.1096/fj.02-1125com	http://dx.doi.org/10.1096/fj.02-1125com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958172				2022-12-28	WOS:000185925100040
J	Penkowa, M; Keller, C; Keller, P; Jauffred, S; Pedersen, BK				Penkowa, M; Keller, C; Keller, P; Jauffred, S; Pedersen, BK			RETRACTED: Immunohistochemical detection of interleukin-6 in human skeletal muscle fibers following exercise (Retracted article. See vol. 28, pg. 1526, 2014)	FASEB JOURNAL			English	Article; Retracted Publication						cytokine staining; physical training; health	IL-6; ACTIVATION; INCREASE; RELEASE; PATTERN; CELLS	Interleukin-6 (IL-6) is produced by many different cell types. Human skeletal muscles produce and release high amounts of IL-6 during exercise; however, the cell source of origin in the muscle is not known. Therefore, we studied the protein expression of IL-6 by immunohistochemistry in human muscle tissue from biopsies obtained at time points 0, 3, 4.5, 6, 9, and 24 h in relation to 3 h of bicycle exercise performed by healthy young males (n=12) and in resting controls (n=6). The IL-6 expression was clearly increased after exercise and remained high even by 24 h, relative to preexercise or resting individuals. The IL-6 immunostainings of skeletal muscle cells were homogeneous and without difference between muscle fiber types. The IL-6 mRNA peaked immediately after the exercise, and, in accordance, the IL-6 protein expression within muscle cells was most pronounced around 3 h post-exercise. However, the finding that plasma IL-6 concentration peaked in the end of exercise indicates a high turnover of muscle-derived IL-6. In conclusion, the finding of marked IL-6 protein expression exclusively within skeletal muscle fibers following exercise demonstrates that skeletal muscle fibers of all types are the dominant cell source of exercise-induced release of IL-6 from working muscle.	Univ Copenhagen, Rigshosp, Dept Infect Dis 7641, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark; Univ Copenhagen, Panum Inst, Dept Med Anat, DK-2100 Copenhagen, Denmark; Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen O, Denmark	Rigshospitalet; University of Copenhagen; University of Copenhagen; Rigshospitalet; University of Copenhagen	Pedersen, BK (corresponding author), Univ Copenhagen, Rigshosp, Dept Infect Dis 7641, Blegdamsvej 9, DK-2100 Copenhagen O, Denmark.			Pedersen, Bente Klarlund/0000-0001-6508-6288				Abbate F, 2002, AM J PHYSIOL-CELL PH, V283, pC42, DOI 10.1152/ajpcell.00416.2001; BARTOCCIONI E, 1994, IMMUNOL LETT, V42, P135, DOI 10.1016/0165-2478(94)90076-0; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Boppart MD, 2000, J PHYSIOL-LONDON, V526, P663, DOI 10.1111/j.1469-7793.2000.00663.x; BROOKE MH, 1970, J HISTOCHEM CYTOCHEM, V18, P670, DOI 10.1177/18.9.670; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLLNICK PD, 1974, J PHYSIOL-LONDON, V241, P45, DOI 10.1113/jphysiol.1974.sp010639; Helge JW, 2003, J PHYSIOL-LONDON, V546, P299, DOI 10.1113/jphysiol.2002.030437; Hostamisligil GS, 1999, EXP CLIN ENDOCR DIAB, V107, P119, DOI 10.1055/s-0029-1212086; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KELLER C, 2002, J PHYSL, pP539; Klouche M, 1999, J IMMUNOL, V163, P4583; Langberg H, 2002, J PHYSIOL-LONDON, V542, P985, DOI 10.1113/jphysiol.2002.019141; Nybo L, 2002, J PHYSIOL-LONDON, V542, P991, DOI 10.1113/jphysiol.2002.022285; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Ostrowski K, 1998, J PHYSIOL-LONDON, V508, P949, DOI 10.1111/j.1469-7793.1998.949bp.x; Pedersen BK, 2000, PHYSIOL REV, V80, P1055, DOI 10.1152/physrev.2000.80.3.1055; Pedersen BK, 2001, J PHYSIOL-LONDON, V536, P329, DOI 10.1111/j.1469-7793.2001.0329c.xd; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; RD L, 1965, HISTOPATHOLOGIC TECH; SOGAARD K, 1995, MUSCLE NERVE, V18, P292, DOI 10.1002/mus.880180305; Starkie R, 2003, FASEB J, V17, P884, DOI 10.1096/fj.02-0670fje; Starkie RL, 2001, J PHYSIOL-LONDON, V533, P585, DOI 10.1111/j.1469-7793.2001.0585a.x; Starkie RL, 2001, AM J PHYSIOL-CELL PH, V280, pC769, DOI 10.1152/ajpcell.2001.280.4.C769; Steensberg A, 2001, J PHYSIOL-LONDON, V537, P633, DOI 10.1111/j.1469-7793.2001.00633.x; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; van Hall G, 2003, J CLIN ENDOCR METAB, V88, P3005, DOI 10.1210/jc.2002-021687; YAN SF, 1995, J BIOL CHEM, V270, P11463, DOI 10.1074/jbc.270.19.11463	31	114	126	0	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12								10.1096/fj.03-0311fje	http://dx.doi.org/10.1096/fj.03-0311fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958150				2022-12-28	WOS:000185925100016
J	Torres, JM; Ortega, E				Torres, JM; Ortega, E			Differential regulation of steroid 5 alpha-reductase isozymes expression by androgens in the adult rat brain	FASEB JOURNAL			English	Article						transcriptional regulation; prefrontal cortex	GABA(A) RECEPTOR FUNCTION; CENTRAL-NERVOUS-SYSTEM; NEUROACTIVE STEROIDS; A RECEPTOR; SEX-DIFFERENCES; NEUROSTEROIDS; STRESS; PLASMA; ALLOPREGNANOLONE; AROMATASE	The enzyme 5alpha-reductase (5alpha-R) is present in many mammalian tissues, including the brain. The physiological importance of 5alpha-R in the brain derives from its capability to convert testosterone ( T) to a more potent androgen, dihydrotestosterone (DHT), and to convert progesterone and deoxycorticosterone (DOC) to their respective 5alpha-reduced derivatives, precursors of allopregnanolone and tetrahydroDOC, potent allosteric modulators of the gamma-aminobutyric acid receptor (GABA(A)-R). 5alpha-R occurs as two isoforms, 5alpha-R type 1 (5alpha-R1) and 5alpha-R type 2 (5alpha-R2). We studied the effects of T and DHT on the mRNA levels of both 5alpha-R isozymes in the prefrontal cortex of the adult rat, using an accurate and precise method that combines the high specificity of one-step quantitative RT-PCR with the sensitivity of capillary electrophoresis. Our results demonstrate that both isozymes of 5alpha-R are expressed in the cerebral cortex of adult rats. The gene expression of 5alpha-R type 2 is under the positive control of T and DHT. The gene that codes for 5alpha-R type 1 is not constitutive, because its expression is negatively regulated by T and DHT. These results open up a new research line that may lead to a better understanding of the role of 5alpha-R isozymes in the physiology of the central nervous system.	Univ Granada, Fac Med, Dept Biochem & Mol Biol, Granada 18012, Spain; Univ Granada, Inst Neurosci, Granada 18012, Spain	University of Granada; University of Granada	Ortega, E (corresponding author), Univ Granada, Fac Med, Dept Biochem & Mol Biol, Avda Madrid S-N, Granada 18012, Spain.	esortega@ugr.es	Torres, Jesus M/B-3634-2011					Barbaccia ML, 1997, BRIT J PHARMACOL, V120, P1582, DOI 10.1038/sj.bjp.0701046; Barbaccia ML, 1996, NEUROENDOCRINOLOGY, V63, P166, DOI 10.1159/000126953; Barbaccia ML, 2001, INT REV NEUROBIOL, V46, P243; BIGGIO G, 1999, GABA NERVOUS SYSTEM; CELOTTI F, 1992, FRONT NEUROENDOCRIN, V13, P163; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Compagnone NA, 2000, FRONT NEUROENDOCRIN, V21, P1, DOI 10.1006/frne.1999.0188; Concas A, 1998, P NATL ACAD SCI USA, V95, P13284, DOI 10.1073/pnas.95.22.13284; CORPECHOT C, 1993, ENDOCRINOLOGY, V133, P1003, DOI 10.1210/en.133.3.1003; EINARSSON K, 1973, J BIOL CHEM, V248, P4987; FINN DA, 1994, J PHARMACOL EXP THER, V271, P164; GEORGE FW, 1991, P NATL ACAD SCI USA, V88, P8044, DOI 10.1073/pnas.88.18.8044; LAMBERT JJ, 1995, TRENDS PHARMACOL SCI, V16, P295, DOI 10.1016/S0165-6147(00)89058-6; Lauber ME, 1996, ENDOCRINOLOGY, V137, P2718, DOI 10.1210/en.137.7.2718; Lephart ED, 1996, BRAIN RES REV, V22, P1; Li XD, 1997, J STEROID BIOCHEM, V60, P311, DOI 10.1016/S0960-0760(96)00195-1; Mahendroo MS, 1997, MOL ENDOCRINOL, V11, P917, DOI 10.1210/me.11.7.917; MAJEWSKA MD, 1992, PROG NEUROBIOL, V38, P379, DOI 10.1016/0301-0082(92)90025-A; Matsui D, 2002, NUCLEIC ACIDS RES, V30, P1387, DOI 10.1093/nar/30.6.1387; Melcangi RC, 1998, J STEROID BIOCHEM, V65, P295, DOI 10.1016/S0960-0760(98)00030-2; Mellon SH, 2002, TRENDS ENDOCRIN MET, V13, P35, DOI 10.1016/S1043-2760(01)00503-3; NegriCesi P, 1996, J STEROID BIOCHEM, V58, P455, DOI 10.1016/0960-0760(96)00083-0; NORMINGTON K, 1992, J BIOL CHEM, V267, P19548; PAUL SM, 1992, FASEB J, V6, P2311, DOI 10.1096/fasebj.6.6.1347506; Poletti A, 1998, STEROIDS, V63, P246, DOI 10.1016/S0039-128X(98)00018-X; Poletti A, 1998, ENDOCRINOLOGY, V139, P2171, DOI 10.1210/en.139.4.2171; Poletti A, 1997, MOL CELL ENDOCRINOL, V129, P181, DOI 10.1016/S0303-7207(97)04056-2; PURDY RH, 1991, P NATL ACAD SCI USA, V88, P4553, DOI 10.1073/pnas.88.10.4553; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Segovia S, 1999, BEHAV BRAIN RES, V105, P69, DOI 10.1016/S0166-4328(99)00083-2; Segovia S, 1996, NEUROREPORT, V7, P2553, DOI 10.1097/00001756-199611040-00030; Serra M, 2000, J NEUROCHEM, V75, P732, DOI 10.1046/j.1471-4159.2000.0750732.x; Torres JM, 2002, ANAL BIOCHEM, V307, P177, DOI 10.1016/S0003-2697(02)00023-4; Torres JM, 2001, NEUROCHEM RES, V26, P555, DOI 10.1023/A:1010925331768; TORRES JM, 2002, IN PRESS NEUROPSYCHO; TORRES JM, 2002, IN PRESS PROSTATE; VALENCIA A, 1992, DEV BRAIN RES, V8, P132	37	75	76	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1428	1433		10.1096/fj.02-1119com	http://dx.doi.org/10.1096/fj.02-1119com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890696				2022-12-28	WOS:000185345100035
J	Zhang, SXL; Gozal, D; Sachleben, LR; Rane, M; Klein, JB; Gozal, E				Zhang, SXL; Gozal, D; Sachleben, LR; Rane, M; Klein, JB; Gozal, E			Hypoxia induces an autocrine-paracrine survival pathway via platelet-derived growth factor (PDGF)-B/PDGF-beta receptor/phosphatidylinositol 3-kinase/Akt signaling in RN46A neuronal cells	FASEB JOURNAL			English	Article						signal transduction; protein kinase B; growth factors	INDUCIBLE FACTOR 1-ALPHA; FACTOR-B-CHAIN; BETA RECEPTOR EXPRESSION; DORSOCAUDAL BRAIN-STEM; FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; PROTEIN-KINASE; OXYGEN-TENSION; CANCER CELLS; RAT	In neurons, hypoxia activates intracellular death-related pathways, yet the antiapoptotic mechanisms triggered by hypoxiaremainunclear.InRN46Aneuronalcells,minimum media growth conditions induced cell death as early as 12 h after the cells were placed in these conditions(i.e.,after removal of B-27 supplement). However, apoptosis occurred in hypoxia(1% O-2) only after 48 h,and in fact hypoxia reduced the apoptosis associated with trophic factor withdrawal. Furthermore, hypoxia induced time-dependent increases in expression of platelet-derived growth factor(PDGF) B mRNA and protein, as well as PDGF-beta receptor phosphorylation. Although exogenous PDGF-BB-induced only transient Akt activation,hypoxia triggered persistent activation of Akt for up to 2 4 h. Inhibition of phosphatidylinositol 3-kinase(PI3K)or of PDGF-beta receptor phosphorylation abrogated both hypoxia-induced and exogenous PDGF-BB-induced Akt phosphorylation, and it completely abolished hypoxia-induced protection from media supplement deprivation, which suggests that the long-lasting activation of Akt during hypoxia and the prosurvival induction were due to endogenously generated PDGF-BB. Furthermore,these inhibitors decreased hypoxia-inducible factor 1alpha(HIF-1alpha) DNA binding, which suggests that the PDGF/PDGF-beta receptor/Akt pathway induces downstream HIF-1alpha gene transcription. We conclude that in RN46A neuronal cells, hypoxia activates an autocrine-paracrine antiapoptotic mechanism that involves up-regulation of PDGF-B and PDGF-beta receptor-dependent activation of the PI3K/Akt signaling pathway to induce downstream transcription of survival genes.	Univ Louisville, KCHRI, Dept Pediat, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA; Univ Louisville, Dept Med, Kidney Dis Program, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville	Gozal, E (corresponding author), Univ Louisville, KCHRI, Dept Pediat, 570 S Preston St, Louisville, KY 40202 USA.	Evelyne.gozal@louisville.edu	Gozal, David/ABH-3805-2020; Gozal, David/M-9492-2017; Klein, Jon/B-9833-2013					Alea OA, 2000, AM J PHYSIOL-REG I, V279, pR1625, DOI 10.1152/ajpregu.2000.279.5.R1625; ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; Blancher C, 2001, CANCER RES, V61, P7349; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CHENG B, 1995, J NEUROSCI, V15, P7095; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Faller DV, 1999, CLIN EXP PHARMACOL P, V26, P74, DOI 10.1046/j.1440-1681.1999.02992.x; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gozal D, 2000, J NEUROCHEM, V74, P310, DOI 10.1046/j.1471-4159.2000.0740310.x; Heldin CH, 1998, BBA-REV CANCER, V1378, pF79, DOI 10.1016/S0304-419X(98)00015-8; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; IIHARA K, 1994, J CEREBR BLOOD F MET, V14, P818, DOI 10.1038/jcbfm.1994.102; Iihara K, 1996, J CEREBR BLOOD F MET, V16, P941, DOI 10.1097/00004647-199609000-00018; Iihara K, 1997, J CEREBR BLOOD F MET, V17, P1097, DOI 10.1097/00004647-199710000-00012; Irving EA, 2000, MOL BRAIN RES, V77, P65, DOI 10.1016/S0169-328X(00)00043-7; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; KOUREMBANAS S, 1990, J CLIN INVEST, V86, P670, DOI 10.1172/JCI114759; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 2001, FREE RADICAL BIO MED, V31, P847, DOI 10.1016/S0891-5849(01)00657-8; NIKKHAH G, 1993, EXP BRAIN RES, V92, P516; Ohno M, 1999, NEUROSCIENCE, V90, P643, DOI 10.1016/S0306-4522(98)00593-4; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sharp FR, 2001, ADV EXP MED BIOL, V502, P273; Shimizu S, 1996, CANCER RES, V56, P2161; Simakajornboon N, 2001, BRAIN RES, V895, P111, DOI 10.1016/S0006-8993(01)02054-6; SMITS A, 1991, P NATL ACAD SCI USA, V88, P8159, DOI 10.1073/pnas.88.18.8159; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Suzuki H, 2001, ONCOGENE, V20, P5779, DOI 10.1038/sj.onc.1204742; Ulleras E, 2001, GROWTH FACTORS, V19, P233, DOI 10.3109/08977190109001089; Vlasic V, 2001, PEDIATR RES, V50, P236, DOI 10.1203/00006450-200108000-00012; WHITE LA, 1994, J NEUROSCI, V14, P6744; Zhong H, 2000, CANCER RES, V60, P1541; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	42	82	86	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1709	+		10.1096/fj.02-1111fje	http://dx.doi.org/10.1096/fj.02-1111fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958184				2022-12-28	WOS:000184471600030
J	McFeeters, RL; Oswald, RE				McFeeters, RL; Oswald, RE			Emerging structural explanations of ionotropic glutamate receptor function	FASEB JOURNAL			English	Review						crystal structure; NMR dynamics; molecular dynamics; channel gating; receptor desensitization	LIGAND-BINDING CORE; MOLECULAR-DYNAMICS SIMULATIONS; DEPENDENT K+ CHANNEL; N-TERMINAL DOMAINS; GATED ION-CHANNEL; CRYSTAL-STRUCTURES; NMDA RECEPTORS; 3-DIMENSIONAL MODELS; DIPOLAR COUPLINGS; AMPA RECEPTORS	High-resolution studies of ionotropic glutamate receptor (iGluR) extracellular domains are beginning to bridge the gap between structure and function. Crystal structures have defined the ligand binding pocket well beyond what was suggested by mutational analysis and homology models alone, providing initial suggestions about the mechanisms of channel gating and desensitization. NMR-derived backbone dynamics and molecular dynamics simulations have added further insights into the role of protein dynamics in receptor function. As a whole, the current knowledge of iGluR structure in conjunction with new advances in the understanding of K+ channels provides a vastly improved understanding of iGluR function. This review focuses on structural and dynamic studies of the extracellular ligand binding domain of iGluRs and the pore region of K+ channels that have contributed to mechanistic insights into the processes of iGluR gating and desensitization.	Cornell Univ, Dept Mol Med, Ithaca, NY 14850 USA	Cornell University	McFeeters, RL (corresponding author), Cornell Univ, Dept Mol Med, Ithaca, NY 14850 USA.	reol@cornell.edu						Abele R, 2000, J BIOL CHEM, V275, P21355, DOI 10.1074/jbc.M909883199; Abele R, 1999, BIOCHEMISTRY-US, V38, P10949, DOI 10.1021/bi982928y; Arinaminpathy Y, 2002, BIOPHYS J, V82, P676, DOI 10.1016/S0006-3495(02)75430-1; Armstrong N, 2003, P NATL ACAD SCI USA, V100, P5736, DOI 10.1073/pnas.1037393100; Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Arvola M, 1996, J BIOL CHEM, V271, P15527, DOI 10.1074/jbc.271.26.15527; AULT B, 1993, J PHARMACOL EXP THER, V265, P927; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; CAREAGA CL, 1995, BIOCHEMISTRY-US, V34, P3048, DOI 10.1021/bi00009a036; CARLTON SM, 1995, NEUROSCI LETT, V197, P25, DOI 10.1016/0304-3940(95)11889-5; Chen GQ, 1998, PROTEIN SCI, V7, P2623, DOI 10.1002/pro.5560071216; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Chen GQ, 1997, P NATL ACAD SCI USA, V94, P13431, DOI 10.1073/pnas.94.25.13431; Cheng Q, 2002, BIOCHEMISTRY-US, V41, P1602, DOI 10.1021/bi015729e; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Deming D, 2003, J BIOL CHEM, V278, P17589, DOI 10.1074/jbc.C300105200; Dingledine R, 1999, PHARMACOL REV, V51, P7; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; Gill SS, 1998, BRAIN RES BULL, V46, P429, DOI 10.1016/S0361-9230(98)00012-4; Goto NK, 2001, J MOL BIOL, V308, P745, DOI 10.1006/jmbi.2001.4614; Henley JM, 1997, BIOCHEM SOC T, V25, P838, DOI 10.1042/bst0250838; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Hogner A, 2003, J MED CHEM, V46, P214, DOI 10.1021/jm020989v; Hogner A, 2002, J MOL BIOL, V322, P93, DOI 10.1016/S0022-2836(02)00650-2; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Jayaraman V, 2000, BIOCHEMISTRY-US, V39, P8693, DOI 10.1021/bi000892f; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Jin RS, 2003, NAT NEUROSCI, V6, P803, DOI 10.1038/nn1091; Jin RS, 2003, BIOCHEMISTRY-US, V42, P5201, DOI 10.1021/bi020632t; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; Jones KS, 2002, J NEUROSCI, V22, P2044, DOI 10.1523/JNEUROSCI.22-06-02044.2002; JORGENSEN M, 1995, PHARMACOL TOXICOL, V76, P312, DOI 10.1111/j.1600-0773.1995.tb00153.x; Kasper C, 2002, FEBS LETT, V531, P173, DOI 10.1016/S0014-5793(02)03496-8; Keinanen K, 1998, BIOCHEM J, V330, P1461, DOI 10.1042/bj3301461; Keinanen K, 1997, BIOCHEM SOC T, V25, P835, DOI 10.1042/bst0250835; Kohda K, 2000, NAT NEUROSCI, V3, P315, DOI 10.1038/73877; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; KUUSINEN A, 1995, EUR J BIOCHEM, V233, P720, DOI 10.1111/j.1432-1033.1995.720_3.x; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; Lam HM, 1998, NATURE, V396, P125, DOI 10.1038/24066; Lampinen M, 2002, J BIOL CHEM, V277, P41940, DOI 10.1074/jbc.M205242200; Lampinen M, 1998, EMBO J, V17, P4704, DOI 10.1093/emboj/17.16.4704; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Laube B, 1998, J NEUROSCI, V18, P2954; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Lunn ML, 2003, J MED CHEM, V46, P872, DOI 10.1021/jm021020+; Madden DR, 2000, EUR J BIOCHEM, V267, P4281; Madden DR, 2001, J BIOL CHEM, V276, P37821; Mal TK, 2002, BIOCHEMISTRY-US, V41, P12899, DOI 10.1021/bi0264162; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; MARGOT KC, 1998, THESIS CORNELL U PUB; Mayer ML, 2001, J MOL BIOL, V311, P815, DOI 10.1006/jmbi.2001.4884; McFeeters RL, 2002, BIOCHEMISTRY-US, V41, P10472, DOI 10.1021/bi026010p; Mendieta J, 2001, PROTEINS, V44, P460, DOI 10.1002/prot.1111; Miyazawa A, 1999, J MOL BIOL, V288, P765, DOI 10.1006/jmbi.1999.2721; MOSBACHER J, 1994, SCIENCE, V266, P1059, DOI 10.1126/science.7973663; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; Nakanishi S, 1996, COLD SPRING HARB SYM, V61, P67; Niethammer M, 1996, J NEUROSCI, V16, P2157; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; Opella SJ, 1999, NAT STRUCT BIOL, V6, P374, DOI 10.1038/7610; Paas Y, 2000, TRENDS PHARMACOL SCI, V21, P87, DOI 10.1016/S0165-6147(99)01443-1; Paas Y, 1996, NEURON, V17, P979, DOI 10.1016/S0896-6273(00)80228-7; Panchenko VA, 2001, J GEN PHYSIOL, V117, P345, DOI 10.1085/jgp.117.4.345; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; RAYMOND LA, 1994, J PHYSIOLOGY-PARIS, V88, P181, DOI 10.1016/0928-4257(94)90004-3; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Roux B, 1999, SCIENCE, V285, P100, DOI 10.1126/science.285.5424.100; Safferling M, 2001, BIOCHEMISTRY-US, V40, P13948, DOI 10.1021/bi011143g; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Skrynnikov NR, 2000, J MOL BIOL, V295, P1265, DOI 10.1006/jmbi.1999.3430; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Sutcliffe MJ, 1998, FARADAY DISCUSS, V111, P259; Sutcliffe MJ, 1996, BIOPHYS J, V70, P1575, DOI 10.1016/S0006-3495(96)79724-2; Sutcliffe MJ, 1998, BIOCHEM SOC T, V26, P450, DOI 10.1042/bst0260450; Swanson GT, 1997, J NEUROSCI, V17, P58, DOI 10.1523/JNEUROSCI.17-01-00058.1997; Villarroel A, 1998, NEURON, V20, P329, DOI 10.1016/S0896-6273(00)80460-2; Weaver CD, 1996, J BIOL CHEM, V271, P12977, DOI 10.1074/jbc.271.22.12977; Wells GB, 2001, J BIOL CHEM, V276, P3031, DOI 10.1074/jbc.M006668200; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; WOLF A, 1994, J BIOL CHEM, V269, P23051; WOOD MW, 1995, P NATL ACAD SCI USA, V92, P4882, DOI 10.1073/pnas.92.11.4882; Xia HH, 2002, J BIOL CHEM, V277, P47765, DOI 10.1074/jbc.M207122200; Zhang S, 1998, NEURON, V21, P443, DOI 10.1016/S0896-6273(00)80553-X	100	42	45	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					428	438		10.1096/fj.03-0873rev	http://dx.doi.org/10.1096/fj.03-0873rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003989				2022-12-28	WOS:000220522800036
J	Rae, C; Mcquillan, JA; Parekh, SB; Bubb, WA; Weiser, S; Balcar, VJ; Hansen, AM; Ball, HJ; Hunt, NH				Rae, C; Mcquillan, JA; Parekh, SB; Bubb, WA; Weiser, S; Balcar, VJ; Hansen, AM; Ball, HJ; Hunt, NH			Brain gene expression, metabolism, and bioenergetics: interrelationships in murine models of cerebral and noncerebral malaria	FASEB JOURNAL			English	Article						Plasmodium berghei; cytokines; hypoxia; glycolysis; brain metabolism	TUMOR-NECROSIS-FACTOR; CEREBROSPINAL-FLUID LACTATE; FACTOR-ALPHA; GLUCOSE-UTILIZATION; ENERGY-METABOLISM; L-GLUTAMATE; IN-VIVO; C-13-NMR SPECTROSCOPY; FALCIPARUM-MALARIA; KYNURENINE PATHWAY	Malaria infection can cause cerebral symptoms without parasite invasion of brain tissue. We examined the relationships between brain biochemistry, bioenergetics, and gene expression in murine models of cerebral (Plasmodium berghei ANKA) and noncerebral (P. berghei K173) malaria using multinuclear NMR spectroscopy, neuropharmacological approaches, and real-time RT-PCR. In cerebral malaria caused by P. berghei ANKA infection, we found biochemical changes consistent with increased glutamatergic activity and decreased flux through the Krebs cycle, followed by increased production of the hypoxia markers lactate and alanine. This was accompanied by compromised brain bioenergetics. There were few significant changes in expression of mRNA for metabolic enzymes or transporters or in the rate of transport of glutamate or glucose. However, in keeping with a role for endogenous cytokines in malaria cerebral pathology, there was significant up-regulation of mRNAs for TNF-alpha, interferon-gamma, and lymphotoxin. These changes are consistent with a state of cytopathic hypoxia. By contrast, in P. berghei K173 infection the brain showed increased metabolic rate, with no deleterious effect on bioenergetics. This was accompanied by mild up-regulation of expression of metabolic enzymes. These changes are consistent with benign hypermetabolism whose cause remains a subject of speculation.	Univ Sydney, Sch Mol & Microbial Biosci, Discipline Biochem, Sydney, NSW 2006, Australia; Univ Sydney, Dept Pathol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Anat & Histol, Sydney, NSW 2006, Australia	University of Sydney; University of Sydney; University of Sydney	Rae, C (corresponding author), Univ Sydney, Sch Mol & Microbial Biosci, Discipline Biochem, Sydney, NSW 2006, Australia.	c.rae@mmb.usyd.edu.au	Ball, Helen J/A-4242-2010; Rae, Caroline/B-7537-2008; Hunt, Nick H/A-3636-2011	Ball, Helen J/0000-0003-3733-9748; Rae, Caroline/0000-0003-0673-8084; 				ALLEN K, 1992, NMR BIOMED, V5, P48, DOI 10.1002/nbm.1940050109; Amani V, 2000, EUR J IMMUNOL, V30, P1646, DOI 10.1002/1521-4141(200006)30:6&lt;1646::AID-IMMU1646&gt;3.0.CO;2-0; Arsenijevic D, 2000, EUR CYTOKINE NETW, V11, P662; BADARGOFFER RS, 1990, BIOCHEM J, V266, P133, DOI 10.1042/bj2660133; BALCAR VJ, 1992, LIFE SCI, V51, P1467, DOI 10.1016/0024-3205(92)90556-5; Balcar VJ, 2001, COLLECT CZECH CHEM C, V66, P1315, DOI 10.1135/cccc20011315; BARBIROLI B, 1993, J CEREBR BLOOD F MET, V13, P469, DOI 10.1038/jcbfm.1993.61; Bates TE, 1996, NEUROREPORT, V7, P1397, DOI 10.1097/00001756-199605310-00014; Ben-Joseph O, 1993, BIOCHEM J, V291, P915; BERENDT AR, 1994, PARASITOL TODAY, V10, P412, DOI 10.1016/0169-4758(94)90238-0; Berg S, 2003, CRIT CARE MED, V31, P1203, DOI 10.1097/01.CCM.0000059647.92390.92; Brown H, 1999, J INFECT DIS, V180, P1742, DOI 10.1086/315078; CHANLING T, 1992, AM J PATHOL, V140, P1121; CLARK IA, 1994, PARASITOL TODAY, V10, P410, DOI 10.1016/0169-4758(94)90237-2; Clark IA, 1999, PARASITOL TODAY, V15, P458, DOI 10.1016/S0169-4758(99)01535-5; Clavier N, 1999, CRIT CARE MED, V27, P628, DOI 10.1097/00003246-199903000-00047; COX DWG, 1983, BIOCHEM J, V212, P365, DOI 10.1042/bj2120365; CURFS JHAJ, 1989, CLIN EXP IMMUNOL, V75, P136; de Souza JB, 2002, MICROBES INFECT, V4, P291, DOI 10.1016/S1286-4579(02)01541-1; Demougeot C, 2001, J NEUROCHEM, V77, P408, DOI 10.1046/j.1471-4159.2001.00285.x; Dobbie M, 2000, AM J TROP MED HYG, V62, P284, DOI 10.4269/ajtmh.2000.62.284; Duelli R, 1999, BRAIN RES, V831, P254, DOI 10.1016/S0006-8993(99)01463-8; Engwerda CR, 2002, J EXP MED, V195, P1371, DOI 10.1084/jem.20020128; Feuerstein G, 1998, CELL MOL NEUROBIOL, V18, P695, DOI 10.1023/A:1020226020062; Fine SM, 1996, J BIOL CHEM, V271, P15303, DOI 10.1074/jbc.271.26.15303; Fink MP, 2002, CRIT CARE, V6, P491, DOI 10.1186/cc1824; GRAU GE, 1986, J IMMUNOL, V137, P2348; GRAU GE, 1989, IMMUNOL REV, V112, P49, DOI 10.1111/j.1600-065X.1989.tb00552.x; GRAU GE, 1989, P NATL ACAD SCI USA, V86, P5572, DOI 10.1073/pnas.86.14.5572; GRAU GE, 1987, SCIENCE, V237, P1210, DOI 10.1126/science.3306918; Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0; Hansen AM, 1999, REDOX REP, V4, P321, DOI 10.1179/135100099101535034; Hansen AM, 2000, REDOX REP, V5, P112, DOI 10.1179/135100000101535384; Hunt NH, 2003, TRENDS IMMUNOL, V24, P491, DOI 10.1016/S1471-4906(03)00229-1; Khan AU, 2002, AM J PHYSIOL-LUNG C, V282, pL1082, DOI 10.1152/ajplung.00358.2001; KRISHNA S, 1983, EXP PARASITOL, V56, P391, DOI 10.1016/0014-4894(83)90084-X; KUPCE E, 1995, J MAGN RESON SER A, V115, P273, DOI 10.1006/jmra.1995.1179; Lou J, 2001, CLIN MICROBIOL REV, V14, P810, DOI 10.1128/CMR.14.4.810-820.2001; MAITLAND AM, 1998, THESIS U SYDNEY SYDN; Marsh K, 1996, ANN TROP MED PARASIT, V90, P395, DOI 10.1080/00034983.1996.11813068; Mathur R, 1999, AM J RESP CRIT CARE, V160, P1994, DOI 10.1164/ajrccm.160.6.9810069; Medana IM, 2002, J INFECT DIS, V185, P650, DOI 10.1086/339009; Medana IM, 1997, AM J PATHOL, V150, P1473; Medana IM, 2001, NEUROPATH APPL NEURO, V27, P421, DOI 10.1046/j.0305-1846.2001.00360.x; MOLYNEUX ME, 1989, Q J MED, V71, P441; MOON RB, 1973, J BIOL CHEM, V248, P7276; Naressi A, 2001, MAGN RESON MATER PHY, V12, P141, DOI 10.1016/S1352-8661(01)00111-9; Nehar D, 1997, ENDOCRINOLOGY, V138, P1964, DOI 10.1210/en.138.5.1964; NEILL AL, 1992, PARASITOLOGY, V105, P165, DOI 10.1017/S0031182000074072; Piguet PF, 2000, INFECT IMMUN, V68, P3822, DOI 10.1128/IAI.68.7.3822-3829.2000; Pukrittayakamee S, 2002, TROP MED INT HEALTH, V7, P911, DOI 10.1046/j.1365-3156.2002.00955.x; Rae C, 2003, J NEUROCHEM, V85, P503, DOI 10.1046/j.1471-4159.2003.01713.x; Rae C, 2000, BRAIN RES BULL, V53, P373, DOI 10.1016/S0361-9230(00)00372-5; RAE C, 2003, IN PRESS DEV NEUROSC; REST JR, 1982, T ROY SOC TROP MED H, V76, P410, DOI 10.1016/0035-9203(82)90203-6; ROWE JG, 1995, J NEUROL NEUROSUR PS, V59, P451, DOI 10.1136/jnnp.59.4.451; Sanni LA, 1998, AM J PATHOL, V152, P611; Sanni LA, 2001, AM J PATHOL, V159, P1105, DOI 10.1016/S0002-9440(10)61786-5; SHANK RP, 1993, J NEUROCHEM, V61, P315, DOI 10.1111/j.1471-4159.1993.tb03570.x; Shin CY, 2001, BRAIN RES, V902, P198; Sibson NR, 1998, DEV NEUROSCI-BASEL, V20, P321, DOI 10.1159/000017327; Skinner TE, 1997, J MAGN RESON, V124, P474, DOI 10.1006/jmre.1996.1061; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; TUREEN J, 1995, J CLIN INVEST, V95, P1086, DOI 10.1172/JCI117755; Vanhamme L, 1997, J MAGN RESON, V129, P35, DOI 10.1006/jmre.1997.1244; Vannucci SJ, 1998, DEV NEUROSCI-BASEL, V20, P369, DOI 10.1159/000017333; WARRELL DA, 1988, LANCET, V2, P534; WHITE NJ, 1992, ADV PARASIT, V31, P83, DOI 10.1016/S0065-308X(08)60021-4; WHITE NJ, 1985, LANCET, V1, P776; YU NC, 1995, MOL PHARMACOL, V48, P550	70	52	55	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					499	510		10.1096/fj.03-0543com	http://dx.doi.org/10.1096/fj.03-0543com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003995				2022-12-28	WOS:000220522800042
J	Robenek, MJ; Severs, NJ; Schlattmann, K; Plenz, G; Zimmer, KP; Troyer, D; Robenek, H				Robenek, MJ; Severs, NJ; Schlattmann, K; Plenz, G; Zimmer, KP; Troyer, D; Robenek, H			Lipids partition caveolin-1 from ER membranes into lipid droplets: updating the model of lipid droplet biogenesis	FASEB JOURNAL			English	Article						lipid droplet formation; caveolin-1 targeting; membrane leaflet; neutral lipids	CHOLESTEROL TRAFFICKING; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; PROTEIN; COMPONENT; VESICLES; ISOFORMS; DOMAINS; COMPLEX; CELLS	Caveolin-1, a putative mediator of intracellular cholesterol transport, is generally assumed to be integrated into the cytoplasmic leaflets of all cellular membranes. Lipid droplets form by budding at the endoplasmic reticulum (ER), and caveolin-1 is thought to be transferred to the droplet surface along with the cytoplasmic leaflet of ER membranes and not to enter the droplet core. We explored how caveolin-1 accesses lipid droplets from the ER by localizing caveolin-1 in ER membranes and in lipid droplets in cultured smooth muscle cells using freeze-fracture immunocytochemistry. We detected caveolin-1 in endoplasmic leaflets of ER membranes but never in cytoplasmic leaflets. Caveolin-1 was also present in lipid droplet cores. These findings are incompatible with the current hypothesis of lipid droplet biogenesis. We suggest that the inherent high affinity of caveolin-1 for neutral lipids causes caveolin-1 molecules to be extracted from the endoplasmic leaflets of ER membranes and to be transferred into the droplet core by inundating lipids during droplet formation.	Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, D-48149 Munster, Germany; Univ Munster, Univ Childrens Hosp, D-4400 Munster, Germany; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; Univ Munster, Dept Cardiol & Angiol, D-4400 Munster, Germany; Univ Munster, Dept Thorac & Cardiovasc Surg, D-4400 Munster, Germany	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; Imperial College London; University of Munster; University of Munster	Robenek, H (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, Domagkstr 3, D-48149 Munster, Germany.	robenek@uni-muenster.de	Zimmer, Klaus-Peter/AAY-9351-2020; Zimmer, Klaus-Peter/AAY-9261-2020					BRANTON D, 1975, SCIENCE, V190, P54, DOI 10.1126/science.1166299; Brown DA, 2001, CURR BIOL, V11, pR446, DOI 10.1016/S0960-9822(01)00257-3; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Fujimoto T, 2001, J CELL BIOL, V152, P1079, DOI 10.1083/jcb.152.5.1079; Fujimoto T, 2000, J CELL SCI, V113, P3509; Keenan TW, 2001, J MAMMARY GLAND BIOL, V6, P365, DOI 10.1023/A:1011383826719; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Londos C, 1999, SEMIN CELL DEV BIOL, V10, P51, DOI 10.1006/scdb.1998.0275; Murphy DJ, 1999, TRENDS BIOCHEM SCI, V24, P109, DOI 10.1016/S0968-0004(98)01349-8; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Robenek MJ, 2003, FASEB J, V17, P1940, DOI 10.1096/fj.03-0008fje; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; SEVERS NJ, 1988, J CELL SCI, V90, P341; SHOTTON DM, 1995, RAPID FREEZING FREEZ, P1; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tauchi-Sato K, 2002, J BIOL CHEM, V277, P44507, DOI 10.1074/jbc.M207712200; Thyberg J, 2002, J HISTOCHEM CYTOCHEM, V50, P185, DOI 10.1177/002215540205000206; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29	26	88	89	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					866	+		10.1096/fj.03-0782fje	http://dx.doi.org/10.1096/fj.03-0782fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001554				2022-12-28	WOS:000220522800033
J	Fisher, JT; Vincent, SG; Gomeza, J; Yamada, M; Wess, J				Fisher, JT; Vincent, SG; Gomeza, J; Yamada, M; Wess, J			Loss of vagally mediated bradycardia and bronchoconstriction in mice lacking M-2 or M-3 muscarinic acetylcholine receptors	FASEB JOURNAL			English	Article						heart rate; airway smooth muscle; asthma; COPD; vagus nerve; parasympathetic nervous system	MULTIPLE SUBTYPES; MESSENGER-RNAS; KNOCKOUT MICE; RAT-HEART; GENE; ASTHMA; IDENTIFICATION; LOCALIZATION; STIMULATION; CONTRACTION	The presence of multiple muscarinic acetylcholine receptor (mAChR) subtypes in the heart and lung, combined with the lack of mAChR subtype-selective ligands, have complicated the task of identifying the mAChR subtypes mediating cardiac slowing (bradycardia) and airway narrowing (bronchoconstriction) due to vagal innervation. To determine which of the five mAChRs are responsible for the cholinergic control of heart rate and airway caliber in vivo, we performed experiments on mutant mice lacking the two prime candidates for such control, the M-2 or M-3 mAChR. Here, we report that in vivo, bradycardia caused by vagal stimulation or administration of the muscarinic agonist methacholine (MCh) was abolished in mice lacking functional M-2 mAChRs (M2(-/-) mice). In contrast, heart rate responses remained unchanged in M-3 receptor-deficient mice (M3(-/-) mice). The reduced hypotensive response of M3-/- mice to MCh suggests M-3 mAChRs contribute to peripheral vasodilation. The M2-/- mice showed significantly enhanced in vivo bronchoconstrictor responses to vagal stimulation or MCh administration. In contrast, bronchoconstrictor responses were totally abolished in M3-/- mice. Because altered cardiac or pulmonary vagal tone is involved in a number of pathophysiological conditions, including cardiac arrhythmias, chronic obstructive pulmonary disease and asthma, these results should be of considerable therapeutic relevance.	Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Med, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pediat, Kingston, ON K7L 3N6, Canada; NIDDKD, Bioorgan Chem Lab, Bethesda, MD 20892 USA	Queens University - Canada; Queens University - Canada; Queens University - Canada; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Fisher, JT (corresponding author), Queens Univ, Dept Physiol, Kingston, ON K7L 3N6, Canada.	fisherjt@post.queensu.ca	Fisher, John/E-2568-2012	Fisher, John/0000-0001-6185-5940	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARNES PJ, 1995, CHEST, V107, pS119, DOI 10.1378/chest.107.3_Supplement.119S; BARNES PJ, 1993, LIFE SCI, V52, P521, DOI 10.1016/0024-3205(93)90310-Y; Barnes PJ, 2000, CHEST, V117, P63; BLABER LC, 1985, BRIT J PHARMACOL, V86, P723, DOI 10.1111/j.1476-5381.1985.tb08951.x; Brodde OE, 1999, PHARMACOL REV, V51, P651; Brown JH, 2001, GOODMAN GILMANS PHAR, P155; BRUNING TA, 1994, CIRC RES, V74, P912, DOI 10.1161/01.RES.74.5.912; CABEZAS GA, 1971, J APPL PHYSIOL, V31, P651, DOI 10.1152/jappl.1971.31.5.651; CAULFIELD MP, 1993, PHARMACOL THERAPEUT, V58, P319, DOI 10.1016/0163-7258(93)90027-B; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Costello RW, 1998, THORAX, V53, P613, DOI 10.1136/thx.53.7.613; DEFERRARI GM, 1992, AM HEART J, V124, P883, DOI 10.1016/0002-8703(92)90968-2; Donahue JK, 2000, NAT MED, V6, P1395; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Eglen RM, 1996, PHARMACOL REV, V48, P531; EINTHOVEN W, 1975, TRANSLATIONS RESP PH, P319; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487, DOI 10.1165/ajrcmb.14.5.8624254; Fryer AD, 1998, AM J RESP CRIT CARE, V158, pS154, DOI 10.1164/ajrccm.158.supplement_2.13tac120; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; Hamilton SE, 1997, P NATL ACAD SCI USA, V94, P13311, DOI 10.1073/pnas.94.24.13311; Hardouin SN, 2002, J PHARMACOL EXP THER, V301, P129, DOI 10.1124/jpet.301.1.129; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; Hellgren I, 2000, CELL MOL LIFE SCI, V57, P175, DOI 10.1007/s000180050507; HOOVER DB, 1994, CIRC RES, V75, P813, DOI 10.1161/01.RES.75.5.813; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Jacoby DB, 2001, LIFE SCI, V68, P2565, DOI 10.1016/S0024-3205(01)01053-0; Krejci A, 2002, MOL PHARMACOL, V61, P1267, DOI 10.1124/mol.61.6.1267; LEVEY AI, 1993, LIFE SCI, V52, P441, DOI 10.1016/0024-3205(93)90300-R; LEVINE RR, 2001, LIFE SCI, V68, P2449; Levine RR, 1999, LIFE SCI, V64, P355; LOFFELHOLZ K, 1985, PHARMACOL REV, V37, P1; Matsui M, 2000, P NATL ACAD SCI USA, V97, P9579, DOI 10.1073/pnas.97.17.9579; MOLFINO NA, 1993, AM REV RESPIR DIS, V148, P1238, DOI 10.1164/ajrccm/148.5.1238; ROFFEL AF, 1987, N-S ARCH PHARMACOL, V335, P593, DOI 10.1007/BF00169130; Routledge HC, 2002, J CLIN PHARM THER, V27, P85, DOI 10.1046/j.1365-2710.2002.00404.x; Sawyer BD, 1999, GEN PHARMACOL, V32, P445, DOI 10.1016/S0306-3623(98)00215-8; SCHWARTZ PJ, 1992, CIRCULATION, V85, P77; Sharma VK, 1996, CIRC RES, V79, P86, DOI 10.1161/01.RES.79.1.86; Shi H, 1999, J MEMBRANE BIOL, V169, P55, DOI 10.1007/PL00005901; Shi H, 1999, MOL PHARMACOL, V55, P497; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Stengel PW, 2000, J PHARMACOL EXP THER, V292, P877; Wang HZ, 2001, MOL PHARMACOL, V59, P1029, DOI 10.1124/mol.59.5.1029; Wang HZ, 1999, BRIT J PHARMACOL, V126, P1725, DOI 10.1038/sj.bjp.0702486; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40; Wickman K, 1998, NEURON, V20, P103, DOI 10.1016/S0896-6273(00)80438-9; Yamada M, 2001, NATURE, V410, P207, DOI 10.1038/35065604; Yamada M, 2001, P NATL ACAD SCI USA, V98, P14096, DOI 10.1073/pnas.251542998; Zaagsma J, 1997, LIFE SCI, V60, P1061, DOI 10.1016/S0024-3205(97)00048-9	50	94	100	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					711	+		10.1096/fj.03-0648fje	http://dx.doi.org/10.1096/fj.03-0648fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977875				2022-12-28	WOS:000220425000015
J	Sitaraman, S; Liu, X; Charrier, L; Gu, LH; Ziegler, TR; Gewirtz, A; Merlin, D				Sitaraman, S; Liu, X; Charrier, L; Gu, LH; Ziegler, TR; Gewirtz, A; Merlin, D			Colonic leptin: source of a novel pro-inflammatory cytokine involved in inflammatory bowel disease	FASEB JOURNAL			English	Article						luminal leptin; IBD; colonic epithelial cells	POLARIZED INTESTINAL EPITHELIA; LUMINAL LEPTIN; HUMAN STOMACH; BRUSH-BORDER; SECRETION; TRANSPORT; CELLS; EXPRESSION; RECEPTOR; COLITIS	Leptin, a peptide encoded by the obese (ob) gene, is primarily secreted by adipocytes and is a critical hormone that controls body weight due to its central effects. Recently, additional roles for leptin in the gastrointestinal tract have been suggested because gastric lining cells also produce and release leptin in response to meal-related stimuli. While gastric epithelia might thus directly contribute to circulating leptin following a meal, here we show that inflamed colonic epithelial cells express and release leptin apically into the intestinal lumen. In addition, we demonstrate leptin expression and secretion in vitro in epithelial cells. In response to luminal leptin, model intestinal epithelia critically activate the NF-kappaB, a key signaling system to pro-inflammatory stimuli. The inflammatory effect of luminal leptin was characterized in vivo in mice administered intrarectal leptin. Leptin induced epithelial wall damage and neutrophil infiltration that represent characteristic histological findings in acute intestinal inflammation. These observations provide evidence for an intraluminal biological signaling of leptin and a new pathophysiological role for intraluminal leptin during states of intestinal inflammation such as inflammatory bowel disease.	Emory Univ, Sch Med, Dept Med, Div Digest Dis, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA	Emory University; Emory University	Merlin, D (corresponding author), Emory Univ, Sch Med, Dept Med, Div Digest Dis, 615 Michael St, Atlanta, GA 30322 USA.	dmerlin@emory.edu						Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Barbier M, 2001, LIFE SCI, V69, P567, DOI 10.1016/S0024-3205(01)01148-1; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barrenetxe J, 2002, GUT, V50, P797, DOI 10.1136/gut.50.6.797; Bouloumie A, 1999, FASEB J, V13, P1231, DOI 10.1096/fasebj.13.10.1231; Buyse M, 2003, AM J PATHOL, V163, P1969, DOI 10.1016/S0002-9440(10)63555-9; Buyse M, 2002, AM J PHYSIOL-CELL PH, V283, pC1795, DOI 10.1152/ajpcell.00186.2002; Buyse M, 2002, J BIOL CHEM, V277, P28182, DOI 10.1074/jbc.M203281200; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; Doi T, 2001, AM J PHYSIOL-REG I, V281, pR753, DOI 10.1152/ajpregu.2001.281.3.R753; ECKMANN L, 1993, GASTROENTEROLOGY, V105, P1689, DOI 10.1016/0016-5085(93)91064-O; Liu X, 2003, J BIOL CHEM, V278, P23672, DOI 10.1074/jbc.M302777200; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Mykoniatis A, 2003, GASTROENTEROLOGY, V124, P683, DOI 10.1053/gast.2003.50101; SADLACK B, 1993, CELL, V75, P253, DOI 10.1016/0092-8674(93)80067-O; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Sobhani I, 2000, GUT, V47, P178, DOI 10.1136/gut.47.2.178; Sobhani I, 2002, GASTROENTEROLOGY, V122, P259, DOI 10.1053/gast.2002.31385; Stan S, 2001, FEBS LETT, V508, P80, DOI 10.1016/S0014-5793(01)03032-0; Steinberg GR, 2002, J BIOL CHEM, V277, P8854, DOI 10.1074/jbc.M107683200; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	23	134	140	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					696	+		10.1096/fj.03-0422fje	http://dx.doi.org/10.1096/fj.03-0422fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977884				2022-12-28	WOS:000220425000024
J	Jacobs, EH; de Vries, TJ; Smit, AB; Schoffelmeer, ANM				Jacobs, EH; de Vries, TJ; Smit, AB; Schoffelmeer, ANM			Gene transcripts selectively down-regulated in the shell of the nucleus accumbens long after heroin self-administration are up-regulated in the core independent of response contingency	FASEB JOURNAL			English	Article						gene expression; instrumental learning; addiction; relapse	SEEKING BEHAVIOR; COCAINE-SEEKING; ADDICTION; DOPAMINE; RAT; REINFORCEMENT; AMPHETAMINE; SUBTERRITORIES; SENSITIZATION; LESIONS	Long-term drug-induced alterations in neurotransmission within the nucleus accumbens (NAc) shell and core may underlie relapse to drug-seeking behavior and drug-taking upon re-exposure to drugs and drug-associated stimuli (cues) during abstinence. Using an open screening strategy, we recently identified 25 gene transcripts, encoding for proteins involved in neuronal functioning and structure that are down-regulated in rat NAc shell after contingent (active), but not after noncontingent (passive), heroin administration. Studying the expression of the same transcripts in the NAc core by means of quantitative PCR, we now demonstrate that most of these transcripts are up-regulated in that NAc subregion long (3 weeks) after heroin self-administration in rats. A similar up-regulation in gene expression was also apparent in the NAc core of animals with a history of non-contingent heroin administration (yoked controls). These data indicate that heroin self-administration differentially regulates genes in the NAc core as compared with the shell. Moreover, whereas cognitive processes involved in active drug self-administration (e.g., instrumental learning) seems to direct gene expression in the NAc shell, neuroplasticity in the NAc core may be due to the pharmacological effects of heroin (including Pavlovian conditioning), as expressed in rats upon contingent as well as non-contingent administration of heroin.	Vrije Univ Amsterdam, VU Med Ctr, Neurosci Res Inst, Dept Med Pharmacol,Drug Abuse Program, NL-1081 BT Amsterdam, Netherlands; Vrije Univ Amsterdam, Neurosci Res Inst, Fac Earth & Life Sci, Drug Abuse Program,Dept Mol & Cellular Neurobiol, NL-1081 HV Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam	Schoffelmeer, ANM (corresponding author), Vrije Univ Amsterdam, VU Med Ctr, Neurosci Res Inst, Dept Med Pharmacol,Drug Abuse Program, Van der Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	anm.schoffelmeer@vumc.nl	Smit, August B/E-8410-2011; De Vries, Taco J/B-2831-2014	De Vries, Taco/0000-0002-0340-4946			We thank Rob Binnekade and Halfdan S. Raaso for their expert technical assistance	Alderson HL, 2001, PSYCHOPHARMACOLOGY, V153, P455, DOI 10.1007/s002130000634; ALHEID GF, 1988, NEUROSCIENCE, V27, P1, DOI 10.1016/0306-4522(88)90217-5; Bassareo V, 1999, NEUROSCIENCE, V89, P637, DOI 10.1016/S0306-4522(98)00583-1; BERENDSE HW, 1992, J NEUROSCI, V12, P2079; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Cadoni C, 2000, EUR J PHARMACOL, V387, pR23, DOI 10.1016/S0014-2999(99)00843-2; Cadoni C, 2000, EUR J PHARMACOL, V388, P69, DOI 10.1016/S0014-2999(99)00824-9; Cadoni C, 1999, NEUROSCIENCE, V90, P447, DOI 10.1016/S0306-4522(98)00466-7; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Corbit LH, 2001, J NEUROSCI, V21, P3251, DOI 10.1523/JNEUROSCI.21-09-03251.2001; De Vries TJ, 2002, J NEUROSCI, V22, P3321; De Vries TJ, 1998, EUR J NEUROSCI, V10, P3565, DOI 10.1046/j.1460-9568.1998.00368.x; Everitt BJ, 2001, BRAIN RES REV, V36, P129, DOI 10.1016/S0165-0173(01)00088-1; Groenewegen H. J., 1994, BASAL GANGLIA, P81; Haber SN, 2000, J NEUROSCI, V20, P2369; HEIMER L, 1991, PROG BRAIN RES, V87, P109; HEIMER L, 1991, NEUROSCIENCE, V41, P89, DOI 10.1016/0306-4522(91)90202-Y; Hutcheson DM, 2001, PSYCHOPHARMACOLOGY, V153, P464, DOI 10.1007/s002130000635; Hyman SE, 2001, NAT REV NEUROSCI, V2, P695, DOI 10.1038/35094560; Jacobs EH, 2002, FASEB J, V16, P1961, DOI 10.1096/fj.02-0272fje; JONGENRELO AL, 1994, EUR J NEUROSCI, V6, P1255, DOI 10.1111/j.1460-9568.1994.tb00315.x; Kelley AE, 1997, P NATL ACAD SCI USA, V94, P12174, DOI 10.1073/pnas.94.22.12174; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Parkinson JA, 1999, J NEUROSCI, V19, P2401; Pontieri FE, 1995, P NATL ACAD SCI USA, V92, P12304, DOI 10.1073/pnas.92.26.12304; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; Shalev U, 2002, PHARMACOL REV, V54, P1, DOI 10.1124/pr.54.1.1; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Weiner I, 1996, BEHAV BRAIN RES, V81, P123, DOI 10.1016/S0166-4328(96)00051-4; Wyvell CL, 2000, J NEUROSCI, V20, P8122; ZAHM DS, 1992, NEUROSCIENCE, V50, P751, DOI 10.1016/0306-4522(92)90202-D; Zahm DS, 1999, ANN NY ACAD SCI, V877, P113, DOI 10.1111/j.1749-6632.1999.tb09264.x; Zahm DS, 2000, NEUROSCI BIOBEHAV R, V24, P85, DOI 10.1016/S0149-7634(99)00065-2	33	27	28	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					200	202		10.1096/fj.03-0317fje	http://dx.doi.org/10.1096/fj.03-0317fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597559				2022-12-28	WOS:000188829300073
J	Moon, EJ; Jeong, CH; Jeong, JW; Kim, KR; Yu, DY; Murakami, S; Kim, CW; Kim, KW				Moon, EJ; Jeong, CH; Jeong, JW; Kim, KR; Yu, DY; Murakami, S; Kim, CW; Kim, KW			Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1 alpha	FASEB JOURNAL			English	Article						hepatocellular carcinoma; pVHL; HBx-transgenic mice; ubiquitination; hypoxia	UBIQUITIN-PROTEASOME PATHWAY; FACTOR 1-ALPHA; HEPATOCELLULAR-CARCINOMA; TRANSGENIC MICE; HBX PROTEIN; HIF-ALPHA; FACTOR-I; TRANSCRIPTION; GENE; TRANSACTIVATION	Hepatitis B virus X protein (HBx) is closely involved in the development of hepatocellular carcinoma, a highly vascularized solid tumor. Here we show that HBx increases the transcriptional activity and protein level of hypoxia-inducible factor-1alpha (HIF-1alpha) under both normoxic and hypoxic conditions, and it also stimulates angiogenesis. HBx directly interacted with the bHLH/PAS domain of HIF-1alpha but not with the von Hippel-Lindau protein (pVHL). HBx decreased the binding of pVHL to HIF-1alpha and prevented ubiquitin-dependent degradation of HIF-1alpha. In HBx-transgenic mice, HIF-1alpha and vascular endothelial growth factor were strongly detected in the dysplastic lesion, where HBx was also more highly expressed than in the non-neoplastic region of the liver. An immunohistochemical study showed that microvessels are more abundant in the dysplastic lesion than in the non-neoplastic region. Our data suggest that HBx stabilizes HIF-1alpha and leads to angiogenesis during hepatocarcinogenesis.	Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea; Pusan Natl Univ, Dept Mol Biol, Pusan 609735, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305333, South Korea; Kanazawa Univ, Canc Res Inst, Dept Mol Biol, Div Mol Oncol, Kanazawa, Ishikawa 920, Japan; Seoul Natl Univ, Coll Med, Dept Pathol, Ctr Canc Res, Seoul 110799, South Korea	Seoul National University (SNU); Pusan National University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Kanazawa University; Seoul National University (SNU)	Kim, KW (corresponding author), Seoul Natl Univ, Coll Pharm, Res Inst Pharmaceut Sci, Seoul 151742, South Korea.	qwonkim@plaza.snu.ac.kr	Kim, Kyu Won/AAJ-7213-2020; Kim, Chul-Woo/F-7008-2011					BREEDIS C, 1954, AM J PATHOL, V30, P969; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Choi BH, 1998, DNA CELL BIOL, V17, P951, DOI 10.1089/dna.1998.17.951; DORIA M, 1995, EMBO J, V14, P4747, DOI 10.1002/j.1460-2075.1995.tb00156.x; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Haviv I, 1998, MOL CELL BIOL, V18, P1562, DOI 10.1128/MCB.18.3.1562; Haviv I, 1996, EMBO J, V15, P3413, DOI 10.1002/j.1460-2075.1996.tb00707.x; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; LAU JYN, 1993, LANCET, V342, P1335; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; Lee YH, 1998, J BIOL CHEM, V273, P25510, DOI 10.1074/jbc.273.39.25510; Lin Y, 1997, J BIOL CHEM, V272, P7132, DOI 10.1074/jbc.272.11.7132; Liver Cancer Study Group of Japan, 1992, GEN RUL CLIN PATH ST; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; MURAKAMI S, 1994, J BIOL CHEM, V269, P15118; Murakami S, 2001, J GASTROENTEROL, V36, P651, DOI 10.1007/s005350170027; Nomura T, 1999, BBA-MOL BASIS DIS, V1453, P330, DOI 10.1016/S0925-4439(99)00004-6; Ohno H, 1997, J MED VIROL, V52, P413, DOI 10.1002/(SICI)1096-9071(199708)52:4<413::AID-JMV12>3.0.CO;2-H; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; SENGER DR, 1993, CANCER METAST REV, V12, P303, DOI 10.1007/BF00665960; Talks KL, 2000, AM J PATHOL, V157, P411, DOI 10.1016/S0002-9440(10)64554-3; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; UEDA K, 1992, HUM PATHOL, V23, P619, DOI 10.1016/0046-8177(92)90316-U; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANLESS IR, 1995, HEPATOLOGY, V22, P983, DOI 10.1002/hep.1840220341; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Zhong H, 1999, CANCER RES, V59, P5830	36	139	142	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					382	+		10.1096/fj.03-0153fje	http://dx.doi.org/10.1096/fj.03-0153fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688211				2022-12-28	WOS:000188067500017
J	Mozzicato, S; Joshi, BV; Jacobson, KA; Liang, BT				Mozzicato, S; Joshi, BV; Jacobson, KA; Liang, BT			Role of direct RhoA-phospholipase D interaction in mediating adenosine-induced protection from cardiac ischemia	FASEB JOURNAL			English	Article						receptor; monomeric G protein; heart cell; myocyte; A(3) agonist	A(3) RECEPTORS; SIMULATED ISCHEMIA; A(1); ACTIVATION; MYOCYTES; GENE; CARDIOMYOCYTES; INJURY; KINASE; HEART	Activation of adenosine A(1) or A(3) receptors protects heart cells from ischemia-induced injury. The A(3) receptor signals via RhoA and phospholipase D (PLD) to induce cardioprotection. The objective of the study was to investigate how RhoA activates PLD to achieve the anti-ischemic effect of adenosine A(3) receptors. In an established cardiac myocyte model of preconditioning using the cultured chick embryo heart cells, overexpression of the RhoA-noninteracting PLD1 mutant I870R selectively blocked the A(3) agonist (Cl-IBMECA, 10 nM)-induced cardioprotection. 1870R caused a significantly higher percentage of cardiac cells killed in A(3) agonist-treated than in A(1) agonist (CCPA, 10 nM)-treated myocytes (ANOVA and posttest comparison, P<0.01). Consistent with its inhibitory effect on the PLD activity, I870R attenuated the Cl-IBMECA-mediated PLD activation. Cl-IBMECA caused a 41 +/- 15% increase in PLD activity in mock-transfected myocytes (P<0.01, paired t test) while having only a slight stimulatory effect on the PLD activity in I870R-transfected cells. To further test the anti-ischemic role of a direct RhoA-PLD1 interaction, atrial cardiac myocytes were rendered null for native adenosine receptors by treatment with irreversible A(1) antagonist m-DITC-XAC and were selectively transfected with the human adenosine A(1) or A(3) receptor cDNA individually or they were cotransfected with cDNAs encoding either receptor plus I870R. 1870R preferentially inhibited the human A(3) receptor-mediated protection from ischemia. The RhoA-noninteracting PLD1 mutant caused a significantly higher percentage of cardiac cells killed in myocytes cotransfected with the human A(3) receptor than in those cells expressing the human A(1) receptor (ANOVA and posttest comparison, P<0.01). The present data provided the first demonstration of a novel physiological role for the direct RhoA-PLD1 interaction, that of potent protection from cardiac ischemia. The study further supported the concept that a divergent signaling mechanism mediates the anti-ischemic effect of adenosine A(1) and A(3) receptors.	Univ Connecticut, Ctr Hlth, Dept Cardiol, Farmington, CT 06030 USA; NIDDK, Mol Recognit Sect, NIH, Bethesda, MD 20892 USA	University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Liang, BT (corresponding author), Univ Connecticut, Ctr Hlth, Dept Cardiol, 263 Farmington Ave, Farmington, CT 06030 USA.	bliang@uchc.edu	Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031117] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbracchio MP, 1997, BIOCHEM BIOPH RES CO, V241, P297, DOI 10.1006/bbrc.1997.7705; ARMSTRONG S, 1994, CARDIOVASC RES, V28, P1049, DOI 10.1093/cvr/28.7.1049; Auchampach JA, 1997, CIRC RES, V80, P800; Bartlett RJ, 2000, NAT BIOTECHNOL, V18, P615, DOI 10.1038/76448; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Carr CS, 1997, CARDIOVASC RES, V36, P52, DOI 10.1016/S0008-6363(97)00160-0; Du GW, 2000, MOL BIOL CELL, V11, P4359, DOI 10.1091/mbc.11.12.4359; Exton JH, 1997, J BIOL CHEM, V272, P15579, DOI 10.1074/jbc.272.25.15579; GC, 1990, CIRCULATION, V82, P609; Goetzl EJ, 2000, J BIOL CHEM, V275, P14573, DOI 10.1074/jbc.275.19.14573; GROVER GJ, 1992, CIRCULATION, V86, P1310, DOI 10.1161/01.CIR.86.4.1310; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Jacobson KA, 2000, J BIOL CHEM, V275, P30272, DOI 10.1074/jbc.M001520200; Lee JE, 2001, FASEB J, V15, P1886, DOI 10.1096/fj.01-0212com; Liang BT, 1996, NUCLEIC ACIDS RES, V24, P1382, DOI 10.1093/nar/24.7.1382; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Parsons M, 2000, FASEB J, V14, P1423, DOI 10.1096/fj.14.10.1423; Safran N, 2001, MOL CELL BIOCHEM, V217, P143, DOI 10.1023/A:1007209321969; Shaikh N, 2001, INORG REACT MECH, V3, P117; Stambaugh K, 1997, AM J PHYSIOL-HEART C, V273, pH501; STILES GL, 1988, MOL PHARMACOL, V34, P724; Strickler J, 1996, J CLIN INVEST, V98, P1773, DOI 10.1172/JCI118976; Taylor JM, 2000, J BIOL CHEM, V275, P19250, DOI 10.1074/jbc.M909099199; Tracey WR, 1997, CARDIOVASC RES, V33, P410, DOI 10.1016/S0008-6363(96)00240-4; Wang JX, 1997, EUR J PHARMACOL, V320, P241, DOI 10.1016/S0014-2999(96)00901-6; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	29	41	42	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					406	+		10.1096/fj.03-0592fje	http://dx.doi.org/10.1096/fj.03-0592fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688204				2022-12-28	WOS:000188067500010
J	Nekhotiaeva, N; Elmquist, A; Rajarao, GK; Hallbrink, M; Langel, U; Good, L				Nekhotiaeva, N; Elmquist, A; Rajarao, GK; Hallbrink, M; Langel, U; Good, L			Cell entry and antimicrobial properties of eukaryotic cell-penetrating peptides	FASEB JOURNAL			English	Article						bacteria; fungi; cell-permeable peptide; drug delivery	MEMBRANES; PERMEABILITY; ANTIBIOTICS; MECHANISM; BUFORIN; ANALOGS	Antimicrobial drug action is limited by both microbial and host cell membranes. Microbes stringently exclude the entry of most drugs, and mammalian membranes limit drug distribution and access to intracellular pathogens. Recently, cell-penetrating peptides (CPPs) have been developed as carriers to improve mammalian cell uptake. Given that CPP's are cationic and often amphipathic, similar to membrane active antimicrobial peptides, it may be possible to use CPP activity to improve drug delivery to microbes. Here, two CPPs, TP10 and pVEC, were found to enter a range of bacteria and fungi. The uptake route involves rapid surface accumulation within minutes followed by cell entry. TP10 inhibited Candida albicans and Staphylococcus aureus growth, and pVEC inhibited Mycobacterium smegmatis growth at low micromolar doses, below the levels that harmed human HeLa cells. Therefore, although TP10 and pVEC entered all cell types tested, they preferentially damage microbes, and this effect was sufficient to clear HeLa cell cultures from noninvasive S. aureus infection. Also, conversion of the cytotoxicity indicator dye SYTOX Green showed that TP10 causes rapid and lethal permeabilization of S. aureus and pVEC permeabilizes M. smegmatis, but not HeLa cells. Therefore, TP10 and pVEC can enter both mammalian and microbial cells and preferentially permeabilize and kill microbes.	Karolinska Inst, Ctr Genom & Bioinformat, S-17177 Stockholm, Sweden; Stockholm Univ, Dept Neurochem & Neurotoxicol, SE-10691 Stockholm, Sweden	Karolinska Institutet; Stockholm University	Good, L (corresponding author), Karolinska Inst, Ctr Genom & Bioinformat, Berzelius Vag 35, S-17177 Stockholm, Sweden.	liam.good@cgb.ki.se		Good, Liam/0000-0002-2798-8640; Langel, Ulo/0000-0001-6107-0844				Dathe M, 1999, BBA-BIOMEMBRANES, V1462, P71, DOI 10.1016/S0005-2736(99)00201-1; Dathe M, 2002, BBA-BIOMEMBRANES, V1558, P171, DOI 10.1016/S0005-2736(01)00429-1; DAVIES J, 1994, SCIENCE, V264, P375, DOI 10.1126/science.8153624; Efron L, 2002, J BIOL CHEM, V277, P24067, DOI 10.1074/jbc.M202089200; Elmquist A, 2001, EXP CELL RES, V269, P237, DOI 10.1006/excr.2001.5316; Engelhardt H, 2002, J BIOL CHEM, V277, P37567, DOI 10.1074/jbc.M206983200; Good L, 2001, NAT BIOTECHNOL, V19, P360, DOI 10.1038/86753; Gratton JP, 2003, NAT MED, V9, P357, DOI 10.1038/nm835; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Levitt David G, 2003, BMC Clin Pharmacol, V3, P3, DOI 10.1186/1472-6904-3-3; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Lorian V., 2005, ANTIBIOTICS LAB MED; NIKAIDO H, 1994, SCIENCE, V264, P382, DOI 10.1126/science.8153625; Park CB, 1998, BIOCHEM BIOPH RES CO, V244, P253, DOI 10.1006/bbrc.1998.8159; Pokorny A, 2002, BIOCHEMISTRY-US, V41, P11044, DOI 10.1021/bi020244r; Pooga M, 2001, FASEB J, V15, P1451, DOI 10.1096/fj.00-0780fje; RICHARD JP, 2002, J BIOL CHEM, P585; Soomets U, 2000, BBA-BIOMEMBRANES, V1467, P165, DOI 10.1016/S0005-2736(00)00216-9; Takeshima K, 2003, J BIOL CHEM, V278, P1310, DOI 10.1074/jbc.M208762200; TRAVIS J, 1994, SCIENCE, V264, P360, DOI 10.1126/science.8153615; Xia HB, 2001, NAT BIOTECHNOL, V19, P640, DOI 10.1038/90242	21	109	114	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					394	+		10.1096/fj.03-0449fje	http://dx.doi.org/10.1096/fj.03-0449fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656995				2022-12-28	WOS:000188067500030
J	Wellman, TL; Jenkins, J; Penar, PL; Tranmer, B; Zahr, R; Lounsbury, KM				Wellman, TL; Jenkins, J; Penar, PL; Tranmer, B; Zahr, R; Lounsbury, KM			Nitric oxide and reactive oxygen species exert opposing effects on the stability of hypoxia inducible factor-1 alpha (HIF-1 alpha) in explants of human pial arteries	FASEB JOURNAL			English	Article						angiogenesis; oxidant stress; cerebral ischemia; VEGF transcription	ENDOTHELIAL GROWTH-FACTOR; MITOCHONDRIAL RESPIRATORY-CHAIN; SMOOTH-MUSCLE-CELLS; GENE-EXPRESSION; FACTOR-I; FACTOR 1-ALPHA; CARBON-MONOXIDE; PROTEIN-KINASE; RAT-BRAIN; ACTIVATION	Hypoxia induces angiogenesis, partly through stabilization of hypoxia-inducible factor-1alpha (HIF-1alpha), leading to transcription of pro-angiogenic factors. Here we examined the regulation of HIF-1alpha. by hypoxia and nitric oxide (NO) in explants of human cerebrovascular smooth muscle cells. Cells were treated with NO donors under normoxic or hypoxic (2% O-2) conditions, followed by analysis of HIF-1alpha. protein levels. Treatment with the NO donor sodium nitroprusside reduced levels of HIF-1alpha, whereas NO donors, NOC-18 and S-nitrosoglutathione, increased HIF-1alpha levels. SIN-1, which releases both NO and superoxide (O-2(.-)), reduced HIF-1alpha levels, suggesting that inhibitory NO donors may elicit effects through peroxynitrite (ONOO.-). O-2(.-) generation by xanthine/xanthine oxidase also reduced HIF-1alpha levels, confirming an inhibitory role for reactive oxygen species (ROS). Furthermore, superoxide dismutase increased HIF-1alpha levels, and the NO scavenger carboxy-PTIO reversed HIF-1alpha stabilization by NO donors. Effects on HIF-1alpha levels correlated with vascular endothelial growth factor transcription but did not affect HIF-1alpha transcription, as measured by RT-PCR and luciferase-reporter assays. The results indicate that HIF-1alpha is stabilized by agents that produce NO and reduce ROS but destabilized by agents that increase ROS, including O-2(.-) and ONOO.-. Thus we propose that the effect of NO on HIF-1alpha signaling is critically dependent on the form of NO and the physiological environment of the responding cell.	Univ Vermont, Dept Pharmacol, Burlington, VT 05405 USA; Univ Vermont, Dept Surg, Div Neurol Surg, Burlington, VT 05405 USA; Univ Vermont, Totman Ctr Cerebrovasc Res, Burlington, VT 05405 USA	University of Vermont; University of Vermont; University of Vermont	Lounsbury, KM (corresponding author), Univ Vermont, Dept Pharmacol, Given Bldg,89 Beaumont Ave, Burlington, VT 05405 USA.	Karen.Lounsbury@uvm.edu						Baldus S, 2002, FREE RADICAL BIO MED, V33, P1010, DOI 10.1016/S0891-5849(02)00993-0; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Christensen T, 1994, Neurobiol Dis, V1, P131, DOI 10.1006/nbdi.1994.0016; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; FEELISCH M, 1989, J CARDIOVASC PHARM, V14, pS13, DOI 10.1097/00005344-198906152-00004; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; GEBREMEDHIN D, 1994, PFLUG ARCH EUR J PHY, V428, P621, DOI 10.1007/BF00374586; Griendling KK, 2000, ARTERIOSCL THROM VAS, V20, P2175, DOI 10.1161/01.ATV.20.10.2175; Huang LE, 1996, J BIOL CHEM, V271, P32253, DOI 10.1074/jbc.271.50.32253; Huang LE, 1999, J BIOL CHEM, V274, P9038, DOI 10.1074/jbc.274.13.9038; IKEDA E, 1995, J BIOL CHEM, V270, P19761, DOI 10.1074/jbc.270.34.19761; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jin KL, 2000, NEUROSCIENCE, V99, P577, DOI 10.1016/S0306-4522(00)00207-4; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kimura H, 2002, BIOCHEM BIOPH RES CO, V296, P976, DOI 10.1016/S0006-291X(02)02029-6; Kimura H, 2000, BLOOD, V95, P189, DOI 10.1182/blood.V95.1.189.001k05_189_197; KITAZONO T, 1995, STROKE, V26, P1713, DOI 10.1161/01.STR.26.9.1713; Liu YX, 1998, J BIOL CHEM, V273, P15257, DOI 10.1074/jbc.273.24.15257; Lounsbury KM, 2000, FREE RADICAL BIO MED, V28, P1362, DOI 10.1016/S0891-5849(00)00222-7; LOUNSBURY KM, 1994, J BIOL CHEM, V269, P11285; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; Osipenko ON, 2000, CIRC RES, V86, P534, DOI 10.1161/01.RES.86.5.534; Palmer LA, 2000, MOL PHARMACOL, V58, P1197, DOI 10.1124/mol.58.6.1197; Palmer LA, 1998, AM J PHYSIOL-LUNG C, V274, pL212, DOI 10.1152/ajplung.1998.274.2.L212; PEARCE WJ, 1995, PHARMACOL THERAPEUT, V65, P75, DOI 10.1016/0163-7258(94)00058-B; PIPILISYNETOS E, 1994, BRIT J PHARMACOL, V111, P894, DOI 10.1111/j.1476-5381.1994.tb14822.x; Richard DE, 2000, J BIOL CHEM, V275, P26765; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Semenza GL, 1999, CELL, V98, P281, DOI 10.1016/S0092-8674(00)81957-1; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; Stevenson AS, 2001, EXP CELL RES, V263, P118, DOI 10.1006/excr.2000.5107; Sumbayev VV, 2003, FEBS LETT, V535, P106, DOI 10.1016/S0014-5793(02)03887-5; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Tsurumi Y, 1997, NAT MED, V3, P879, DOI 10.1038/nm0897-879; TUDER RM, 1995, J CLIN INVEST, V95, P1798, DOI 10.1172/JCI117858; Vaux EC, 2001, BLOOD, V98, P296, DOI 10.1182/blood.V98.2.296; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, BIOCHEM BIOPH RES CO, V216, P669, DOI 10.1006/bbrc.1995.2674; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wolff C B, 2000, High Alt Med Biol, V1, P33, DOI 10.1089/152702900320667; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zhang RL, 2003, CIRC RES, V92, P308, DOI 10.1161/01.RES.0000056757.93432.8C	50	67	71	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					379	+		10.1096/fj.03-0143fje	http://dx.doi.org/10.1096/fj.03-0143fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657004				2022-12-28	WOS:000188067500026
J	Takebe, K; Oka, Y; Radisky, D; Tsuda, H; Tochigui, K; Koshida, S; Kogo, K; Hirai, Y				Takebe, K; Oka, Y; Radisky, D; Tsuda, H; Tochigui, K; Koshida, S; Kogo, K; Hirai, Y			Epimorphin acts to induce hair follicle anagen in C57BL/6 mice	FASEB JOURNAL			English	Article						morphogenesis; hair cycle; organ culture assay; anagen induction; molecular dynamics	KERATINOCYTE GROWTH-FACTOR; IN-VITRO; EPITHELIAL MORPHOGENESIS; EXTRACELLULAR-MATRIX; VESICULAR TRANSPORT; ALOPECIA-AREATA; DERMAL PAPILLA; CYCLOSPORINE-A; MOUSE SKIN; EXPRESSION	Epimorphin is a mesenchymal morphogen that has been shown to mediate epithelial-mesenchymal signaling interactions in various organs. We now show that epimorphin functions in hair follicle morphogenesis; using a novel ex vivo organ culture assay, we define a mechanism for epimorphin signaling that may provide insight into general developmental processes. We found that epimorphin was produced by follicular mesenchymal cells and bound selectively to follicular epithelial cells, and that treatment with recombinant epimorphin could stimulate procession of hair follicles from telogen (resting stage) to anagen (growing stage). Based on analyses of epimorphin proteolytic digests that suggested a smaller peptide might be able to substitute for the full-length epimorphin molecule, we determined that pep7, a 10-amino acid peptide, was capable of inducing telogen-to-anagen transition both in the culture assay and in the mouse. That pep7 showed maximal activity only when modified with specific sulfhydryl-reactive reagents suggested that a particular structural conformation of the peptide was essential for activity; molecular dynamics studies were pursued to investigate the active peptide structure. These findings define a previously unknown morphogenic process in the hair follicle that may have applications to many other organs.	Sumitomo Elect Ind Ltd, Osaka R&D Labs, Sakae Ku, EPM Project Grp, Yokohama, Kanagawa 2448588, Japan; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA	Sumitomo Electric Industries; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Hirai, Y (corresponding author), Sumitomo Elect Ind Ltd, Osaka R&D Labs, Sakae Ku, EPM Project Grp, 1 Taya Cho, Yokohama, Kanagawa 2448588, Japan.	hirai-yohei@sei.co.jp	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784				Akiyama M, 1999, BRIT J DERMATOL, V141, P447; Andl T, 2002, DEV CELL, V2, P643, DOI 10.1016/S1534-5807(02)00167-3; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; BUFFEY JA, 1994, BRIT J DERMATOL, V131, P836, DOI 10.1111/j.1365-2133.1994.tb08586.x; Bull JJ, 2002, J INVEST DERMATOL, V118, P17, DOI 10.1046/j.0022-202x.2001.01629.x; Chanda S, 2000, AM J PHYSIOL-ENDOC M, V278, pE202, DOI 10.1152/ajpendo.2000.278.2.E202; CHASE HB, 1954, PHYSIOL REV, V34, P113, DOI 10.1152/physrev.1954.34.1.113; Commo S, 1997, BRIT J DERMATOL, V137, P31, DOI 10.1046/j.1365-2133.1997.17641854.x; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; COUCHMAN JR, 1993, J INVEST DERMATOL, V101, pS60, DOI 10.1111/1523-1747.ep12362642; DANILENKO DM, 1995, AM J PATHOL, V147, P145; Davey HW, 1999, AM J HUM GENET, V65, P959, DOI 10.1086/302599; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; Fang KC, 2000, AM J RESP CELL MOL, V23, P142, DOI 10.1165/ajrcmb.23.2.f195; Fernandez I, 1998, CELL, V94, P841, DOI 10.1016/S0092-8674(00)81742-0; Fritsch C, 2002, J CLIN INVEST, V110, P1629, DOI 10.1172/200213588; Galbraith H, 1998, P NUTR SOC, V57, P195, DOI 10.1079/PNS19980032; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hamada K, 1996, EXP ANIM TOKYO, V45, P251, DOI 10.1538/expanim.45.251; HARMON CS, 1993, LYMPHOKINE CYTOK RES, V12, P197; HIRAI Y, 1994, EUR J BIOCHEM, V225, P1133, DOI 10.1111/j.1432-1033.1994.1133b.x; HIRAI Y, 1989, DEVELOPMENT, V105, P271; HIRAI Y, 1992, CELL, V69, P471, DOI 10.1016/0092-8674(92)90448-L; Hirai Y, 2001, J CELL BIOL, V153, P785, DOI 10.1083/jcb.153.4.785; Hirai Y, 1998, J CELL BIOL, V140, P159, DOI 10.1083/jcb.140.1.159; Hirai Y, 2001, CELL BIOL INT, V25, P193, DOI 10.1006/cbir.2000.0618; Hirose M, 1996, BIOCHEM BIOPH RES CO, V225, P155, DOI 10.1006/bbrc.1996.1146; Hoffman R, 2001, EUR J DERMATOL, V11, P296; Jahoda CAB, 1996, DERMATOL CLIN, V14, P573, DOI 10.1016/S0733-8635(05)70385-5; Jahoda CAB, 2001, LANCET, V358, P1445, DOI 10.1016/S0140-6736(01)06532-1; Jarrousse F, 2001, INT J DERMATOL, V40, P385, DOI 10.1046/j.1365-4362.2001.01239.x; Jindo T, 1998, J INVEST DERMATOL, V110, P338, DOI 10.1046/j.1523-1747.1998.00144.x; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Jung HS, 1998, DEV BIOL, V196, P11, DOI 10.1006/dbio.1998.8850; KAO J, 1988, TOXICOL APPL PHARM, V94, P93, DOI 10.1016/0041-008X(88)90340-7; Kishimoto J, 1999, P NATL ACAD SCI USA, V96, P7336, DOI 10.1073/pnas.96.13.7336; Kishimoto J, 2000, GENE DEV, V14, P1181; Koshida S, 1997, BIOCHEM BIOPH RES CO, V234, P522, DOI 10.1006/bbrc.1997.6673; Kulessa H, 2000, EMBO J, V19, P6664, DOI 10.1093/emboj/19.24.6664; Lee SC, 1999, J INVEST DERMATOL, V112, P882, DOI 10.1046/j.1523-1747.1999.00602.x; Lehnert L, 2001, J CELL BIOL, V152, P911, DOI 10.1083/jcb.152.5.911; Lerman JC, 2000, BIOCHEMISTRY-US, V39, P8470, DOI 10.1021/bi0003994; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; Liu X, 2001, P NATL ACAD SCI USA, V98, P9139, DOI 10.1073/pnas.161016098; McElwee KJ, 1998, PATHOBIOLOGY, V66, P90, DOI 10.1159/000028002; Mori M, 2000, CELL TISSUE RES, V300, P331, DOI 10.1007/s004410000205; MORI O, 1990, Journal of Dermatology (Tokyo), V17, P276; NUCK BA, 1987, ARCH DERMATOL, V123, P59, DOI 10.1001/archderm.123.1.59; Oh HS, 1996, P NATL ACAD SCI USA, V93, P12525, DOI 10.1073/pnas.93.22.12525; Oka Y, 1996, EXP CELL RES, V222, P189, DOI 10.1006/excr.1996.0024; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, P65; Panteleyev AA, 2001, J CELL SCI, V114, P3419; PAUS R, 1989, LAB INVEST, V60, P365; PELHAM HRB, 1993, CELL, V73, P425, DOI 10.1016/0092-8674(93)90128-D; Peters EMJ, 1999, EXP DERMATOL, V8, P274; Peus D, 1996, DERMATOL CLIN, V14, P559, DOI 10.1016/S0733-8635(05)70384-3; PHILPOTT MP, 1994, J INVEST DERMATOL, V102, P857, DOI 10.1111/1523-1747.ep12382494; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Schmidt T, 2000, BBA-GENE STRUCT EXPR, V1493, P249, DOI 10.1016/S0167-4781(00)00163-9; SILVER AF, 1966, NATURE, V210, P1051, DOI 10.1038/2101051a0; Simian M, 2001, DEVELOPMENT, V128, P3117; SLOMINSKI A, 1993, J INVEST DERMATOL, V101, pS90, DOI 10.1111/1523-1747.ep12362991; STENN KS, 1994, J INVEST DERMATOL, V103, P107, DOI 10.1111/1523-1747.ep12391844; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Su H Y, 1999, Dermatol Online J, V5, P1; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; TAYLOR M, 1992, BRIT J DERMATOL, V126, P479, DOI 10.1111/j.1365-2133.1992.tb15120.x; THIVOLET J, 1991, PRESSE MED, V20, P2249; Tobin DJ, 1998, EXP DERMATOL, V7, P289; Watanabe S, 1998, BIOCHEM BIOPH RES CO, V250, P486, DOI 10.1006/bbrc.1998.9339; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zhang LY, 1999, J DERMATOL SCI, V20, P191, DOI 10.1016/S0923-1811(98)00081-4	74	21	25	1	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2003	17	14					2037	2047		10.1096/fj.03-0386com	http://dx.doi.org/10.1096/fj.03-0386com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597673				2022-12-28	WOS:000186961200040
J	Cao, WS; Baniecki, ML; McGrath, WJ; Bao, C; Deming, CB; Rade, JJ; Lowenstein, CJ; Mangel, WF				Cao, WS; Baniecki, ML; McGrath, WJ; Bao, C; Deming, CB; Rade, JJ; Lowenstein, CJ; Mangel, WF			Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo	FASEB JOURNAL			English	Article						S-nitrosylation; antiviral agent; proteinase inhibitor; cysteine proteinase; diethylamine NONOate	CYTOKERATIN NETWORK; SYNTHASE ACTIVITY; VIRUS-PARTICLES; REPLICATION; COFACTOR; PROTEASE; MECHANISM; PEPTIDE; BINDING; PAPAIN	Nitric oxide (NO) is an antiviral effector of the innate immune system, but few of the viral targets of NO have been identified. We now show that NO inhibits adenovirus replication by targeting the adenovirus proteinase (AVP). NO generated from diethylamine NONOate (DEA-NONOate) or spermine NONOate (Sp-NONOate) inhibited the AVP. Inhibition was reversible with dithiothreitol. The equilibrium dissociation constant for reversible binding to the AVP by Sp-NONOate, or K-i, was 0.47 mM, and the first-order rate constant for irreversible inhibition of the AVP by Sp-NONOate, or k(i), was 0.0036 s(-1). Two hallmarks of a successful adenovirus infection were abolished by the NO donors: the appearance of E1A protein and the cleavage of cytokeratin 18 by AVP. Treatment of infectious virus by DEA-NONOate dramatically decreased viral infectivity. These data suggest that NO may be a useful antiviral agent against viruses encoding a cysteine proteinase and in particular may be an antiadenovirus agent.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; Johns Hopkins Univ, Sch Med, Dept Med, Div Cardiol, Baltimore, MD 21205 USA; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; Johns Hopkins University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Mangel, WF (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.	Mangel@BNL.Gov		Lowenstein, Charles/0000-0003-0485-7514; McGrath, William/0000-0002-9375-624X				Akaike T, 1996, P NATL ACAD SCI USA, V93, P2448, DOI 10.1073/pnas.93.6.2448; Baniecki ML, 2001, BIOCHEMISTRY-US, V40, P12349, DOI 10.1021/bi0109008; BI ZB, 1995, J VIROL, V69, P2208, DOI 10.1128/JVI.69.4.2208-2213.1995; Brown MT, 2002, J BIOL CHEM, V277, P46298, DOI 10.1074/jbc.M202988200; BUKRINSKY MI, 1995, J EXP MED, V181, P735, DOI 10.1084/jem.181.2.735; CAO W, 2003, IN PRESS P NATL ACAD; CHEN PH, 1993, J VIROL, V67, P3507, DOI 10.1128/JVI.67.6.3507-3514.1993; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Ding JZ, 1996, EMBO J, V15, P1778, DOI 10.1002/j.1460-2075.1996.tb00526.x; DRENTH J, 1976, BIOCHEMISTRY-US, V15, P3731, DOI 10.1021/bi00662a014; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; HOOPER DC, 1995, P NATL ACAD SCI USA, V92, P5312, DOI 10.1073/pnas.92.12.5312; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Komatsu T, 1996, J NEUROIMMUNOL, V68, P101, DOI 10.1016/0165-5728(96)00083-5; LEYTUS SP, 1984, BIOCHIM BIOPHYS ACTA, V788, P74, DOI 10.1016/0167-4838(84)90299-1; MANGEL WF, 1993, NATURE, V361, P274, DOI 10.1038/361274a0; Mangel WF, 1996, J BIOL CHEM, V271, P536, DOI 10.1074/jbc.271.1.536; McGrath WJ, 1996, VIROLOGY, V217, P131, DOI 10.1006/viro.1996.0100; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P13237, DOI 10.1021/bi0111653; McGrath WJ, 2001, BIOCHEMISTRY-US, V40, P14468, DOI 10.1021/bi011562d; Pang YP, 2001, J COMPUT CHEM, V22, P1750, DOI 10.1002/jcc.1129; Pang YP, 2001, FEBS LETT, V502, P93, DOI 10.1016/S0014-5793(01)02672-2; POLGAR L, 1974, FEBS LETT, V47, P15, DOI 10.1016/0014-5793(74)80415-1; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; TUCKER PC, 1996, J VIROL, V770, P3971; WEBER J, 1976, J VIROL, V17, P462, DOI 10.1128/JVI.17.2.462-471.1976; WEBER JM, 1994, METHOD ENZYMOL, V244, P595; WEBSTER A, 1993, CELL, V72, P97, DOI 10.1016/0092-8674(93)90053-S; ZHANG Y, 1994, J VIROL, V68, P2544, DOI 10.1128/JVI.68.4.2544-2555.1994	34	19	21	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2345	+		10.1096/fj.03-0396fje	http://dx.doi.org/10.1096/fj.03-0396fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525937				2022-12-28	WOS:000186343300009
J	Tsugawa, K; Jones, MK; Akahoshi, T; Moon, WS; Maehara, Y; Hashizume, M; Sarfeh, IJ; Tarnawski, AS				Tsugawa, K; Jones, MK; Akahoshi, T; Moon, WS; Maehara, Y; Hashizume, M; Sarfeh, IJ; Tarnawski, AS			Abnormal PTEN expression in portal hypertensive gastric mucosa: A key to impaired PI 3-kinase/Akt activation and delayed injury healing?	FASEB JOURNAL			English	Article						gastropathy; tumor necrosis factor-alpha (TNF-alpha); early growth response factor-1 (Egr-1)	NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE SYNTHASE; PROTEIN-KINASE B; TUMOR-SUPPRESSOR; GROWTH-FACTOR; TNF-ALPHA; PHOSPHATIDYLINOSITOL 3-KINASE; INCREASED SUSCEPTIBILITY; CELL MIGRATION; EGR-1	Phosphatase and tensin homologue deleted on chromosome ten (PTEN) is a dual-specificity phosphatase that has activity toward both phosphorylated peptides and phospholipids. PTEN inhibits activation of Akt, the downstream effector of PI 3-kinase, which is integral to cell proliferation, migration, survival, and angiogenesis essential for tissue injury healing. PTEN expression and activation during injury healing remain unexplored. Portal hypertensive (PHT) gastric mucosa has impaired injury healing, but the underlying mechanisms remain unknown. We investigated whether impaired healing of injured PHT gastric mucosa is due to abnormal PTEN expression/activation that leads to decreased Akt activation. We also investigated the possible involvement of Egr-1, which regulates PTEN in some cells (e.g., fetal kidney epithelial cells), and TNF-alpha, which can induce Egr-1 expression. In PHT gastric mucosa 6 h after injury, PTEN protein levels were increased by 2.7-fold; unphosphorylated PTEN (reflecting activated PTEN) was increased by 2.4-fold; Akt phosphorylation (reflecting Akt activation) was reduced by 2-fold; and Egr-1 expression was increased by 3.3-fold vs. normal gastric mucosa. TNF-alpha neutralization reversed all of the above abnormalities in PHT gastric mucosa, reduced mucosal injury, and enhanced healing. We conclude that, in injured PHT gastric mucosa, overexpressed/activated PTEN leads to the reduced activation of the PI 3-kinase/Akt pathway that results in impaired injury healing.	Univ Calif Irvine, Irvine, CA 92717 USA; Dept Vet Affairs Med Ctr, Dept Med, Long Beach, CA USA; Dept Vet Affairs Med Ctr, Dept Surg, Long Beach, CA USA; Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Disaster & Emergency Med, Fukuoka 812, Japan	University of California System; University of California Irvine; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; Kyushu University; Kyushu University	Jones, MK (corresponding author), Univ Calif Irvine, Irvine, CA 92717 USA.	michael.jones4@med.va.gov	Akahoshi, Tomohiko/AAU-4886-2021; Maehara, Yoshihiko/A-4867-2010					Baatar D, 1999, EUR SURG RES, V31, P340, DOI 10.1159/000008711; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; DAMICO G, 1990, GASTROENTEROLOGY, V99, P1558, DOI 10.1016/0016-5085(90)90458-D; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ferraz JGP, 1997, AM J PHYSIOL-GASTR L, V272, pG809, DOI 10.1152/ajpgi.1997.272.4.G809; Fontaine V, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-07-j0001.2002; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Goetze S, 2001, ATHEROSCLEROSIS, V159, P93, DOI 10.1016/S0021-9150(01)00497-X; Grimbacher B, 1998, RHEUMATOL INT, V17, P185, DOI 10.1007/s002960050032; Gustin JA, 2001, J BIOL CHEM, V276, P27740, DOI 10.1074/jbc.M102559200; Holst LS, 1998, BIOCHEM BIOPH RES CO, V250, P181, DOI 10.1006/bbrc.1998.9166; ICHIKAWA Y, 1994, GASTROENTEROLOGY, V106, P702, DOI 10.1016/0016-5085(94)90705-6; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Kawanaka H, 2002, HEPATOLOGY, V35, P393, DOI 10.1053/jhep.2002.30958; Kawanaka H, 2001, FASEB J, V15, P574; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Liu LS, 1998, DIABETES, V47, P515, DOI 10.2337/diabetes.47.4.515; LOPEZTALAVERA JC, 1995, GASTROENTEROLOGY, V108, P761, DOI 10.1016/0016-5085(95)90449-2; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Ohta M, 1998, HEPATOLOGY, V27, P906, DOI 10.1002/hep.510270403; Ohta M, 1997, GASTROENTEROLOGY, V112, P1920, DOI 10.1053/gast.1997.v112.pm9178684; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Pai R, 1998, GASTROENTEROLOGY, V114, P706, DOI 10.1016/S0016-5085(98)70584-0; Pique JM, 1997, BAILLIERE CLIN GASTR, V11, P257, DOI 10.1016/S0950-3528(97)90039-7; Podolsky Daniel K., 2000, Journal of Gastroenterology, V35, P69; Polk DB, 1998, GASTROENTEROLOGY, V114, P493, DOI 10.1016/S0016-5085(98)70532-3; Rosenzweig T, 2002, DIABETES, V51, P1921, DOI 10.2337/diabetes.51.6.1921; SARFEH IJ, 1988, SURGERY, V104, P79; SARFEH IJ, 1989, DIGEST DIS SCI, V34, P225, DOI 10.1007/BF01536055; SARFEH IJ, 1983, GASTROENTEROLOGY, V84, P987; SARFEH IJ, 1982, SURG GYNECOL OBSTET, V155, P167; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; TARNAWSKI AS, 1988, HEPATOLOGY, V8, P1488, DOI 10.1002/hep.1840080604; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Tsugawa K, 2002, FRONT BIOSCI-LANDMRK, V7, pE245, DOI 10.2741/tsugawa; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Virolle T, 2001, NAT CELL BIOL, V3, P1124, DOI 10.1038/ncb1201-1124; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030	47	20	20	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2316	+		10.1096/fj.02-1107fje	http://dx.doi.org/10.1096/fj.02-1107fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525948				2022-12-28	WOS:000186343300006
J	Li, CH; Wernig, F; Leitges, M; Hu, YH; Xu, QB				Li, CH; Wernig, F; Leitges, M; Hu, YH; Xu, QB			Mechanical stress-activated PKC delta regulates smooth muscle cell migration	FASEB JOURNAL			English	Article						mechanical stress; smooth muscle cells; cell migration; cytoskeleton	PROTEIN-KINASE-C; MATRIX-METALLOPROTEINASE; ATHEROSCLEROSIS; EXPRESSION; APOPTOSIS; INTEGRINS; PATHWAYS; P53; PHOSPHORYLATION; TRANSLOCATION	Vascular smooth muscle cells (SMCs) are exposed to altered mechanical stress that may contribute to SMC migration in the development of atherosclerosis. Signal transduction pathways in SMCs activated by mechanical stress that instigate cell migration are undefined. Herein, we provide evidence that mechanical stress enhances SMC migration, which is mediated, at least in part, by protein kinase C (PKC) delta. When rat SMCs cultivated on a flexible membrane were subjected to cyclic strain stress (60 cycles/min, 5, 15, or 20% elongation), PKCdelta was translocated to the Triton-insoluble fraction, whereas PKCalpha was translocated to the membrane, which was confirmed by PKC kinase assays. Immunofluorescence and actin staining revealed a cytoskeleton translocation of PKCdelta in SMCs stimulated by cyclic strain. PKCdelta-deficient SMCs cultivated from PKCdelta-/- mice showed an abnormal cytoskeleton structure, which was related to a diminished phosphorylation of paxillin, focal adhesion kinase, and vinculin in response to mechanical stress. Mechanical stress enhanced SMC migration, which was diminished in PKCdelta-/- SMCs. Taken together, our data demonstrated that mechanical stress activates PKCdelta translocation to the cytoskeleton, which is related to decreased SMC migration and indicates that PKCdelta is a key signal transducer between mechanical stress and cell migration.	St George Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England; Austrian Acad Sci, Inst Biomed Aging Res, Innsbruck, Austria; Max Planck Inst Expt Endocrinol, Hannover, Germany	St Georges University London; Austrian Academy of Sciences; Max Planck Society	Xu, QB (corresponding author), St George Hosp, Sch Med, Dept Cardiol Sci, Granmer Terrance, London SW17 0RE, England.	q.xu@sghms.ac.uk	Leitges, Michael/AAN-1953-2021	Li, Chaohong/0000-0002-7979-1639				Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; BHAGYALAKSHMI A, 1989, BIOCHEM BIOPH RES CO, V158, P31, DOI 10.1016/S0006-291X(89)80172-X; Blobe GC, 1996, CANCER SURV, V27, P213; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Defilippi P, 1997, J BIOL CHEM, V272, P21726, DOI 10.1074/jbc.272.35.21726; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; Gschwendt M, 1999, EUR J BIOCHEM, V259, P555, DOI 10.1046/j.1432-1327.1999.00120.x; Hai CM, 2000, ARCH PHARM RES, V23, P535, DOI 10.1007/BF02975237; Hansen RS, 1996, ONCOGENE, V13, P995; Hu YH, 1999, CIRCULATION, V100, P861, DOI 10.1161/01.CIR.100.8.861; Hu YH, 1998, FASEB J, V12, P1135, DOI 10.1096/fasebj.12.12.1135; Hu YH, 1997, J BIOL CHEM, V272, P9113; Jockusch BM, 1995, ANNU REV CELL DEV BI, V11, P379, DOI 10.1146/annurev.cellbio.11.1.379; Lee RT, 1996, ARTERIOSCL THROM VAS, V16, P1070, DOI 10.1161/01.ATV.16.8.1070; Leitges M, 2001, J CLIN INVEST, V108, P1505; Li, 2000, Arterioscler Thromb Vasc Biol, V20, pE1; Li CH, 1999, J BIOL CHEM, V274, P25273, DOI 10.1074/jbc.274.36.25273; Li S, 2002, P NATL ACAD SCI USA, V99, P3546, DOI 10.1073/pnas.052018099; Liu S, 1999, NATURE, V402, P676, DOI 10.1038/45264; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Mayr M, 2002, FASEB J, V16, P1423, DOI 10.1096/fj.02-0042fje; Mayr U, 2002, CIRC RES, V90, P197, DOI 10.1161/hh0202.103715; Meininger GA, 1999, BIOPHYS J, V77, P973, DOI 10.1016/S0006-3495(99)76948-1; Metzler B, 1998, J BIOL CHEM, V273, P33320, DOI 10.1074/jbc.273.50.33320; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Okada Y, 1998, JPN J OPHTHALMOL, V42, P90, DOI 10.1016/S0021-5155(97)00129-9; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; Perez-Moreno M, 1998, J CELL SCI, V111, P3563; Pomerantz KB, 1997, BIOCHEMISTRY-US, V36, P9532, DOI 10.1021/bi963070k; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; RUBANYI GM, 1986, AM J PHYSIOL, V250, P1145, DOI 10.1152/ajpheart.1986.250.6.H1145; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Smith PG, 1997, EXP CELL RES, V232, P127, DOI 10.1006/excr.1997.3492; Suzuma I, 2002, J BIOL CHEM, V277, P1047, DOI 10.1074/jbc.M105336200; Takei T, 1997, J CELL BIOCHEM, V67, P327, DOI 10.1002/(SICI)1097-4644(19971201)67:3<327::AID-JCB5>3.0.CO;2-Y; Tanabe Y, 2000, MOL CELL BIOCHEM, V215, P103, DOI 10.1023/A:1026506801659; Traub O, 1997, J BIOL CHEM, V272, P31251, DOI 10.1074/jbc.272.50.31251; Tyagi SC, 1998, J CELL PHYSIOL, V176, P374, DOI 10.1002/(SICI)1097-4652(199808)176:2<374::AID-JCP16>3.0.CO;2-3; VINTERS HV, 1987, DIABETES METAB, V13, P294; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wernig F, 2003, HYPERTENSION, V41, P903, DOI 10.1161/01.HYP.0000062882.42265.88; Xu QB, 2000, TRENDS CARDIOVAS MED, V10, P35, DOI 10.1016/S1050-1738(00)00042-6; Xu QB, 1996, J CLIN INVEST, V97, P508, DOI 10.1172/JCI118442; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Ziegler WH, 2002, J BIOL CHEM, V277, P7396, DOI 10.1074/jbc.M110008200	51	98	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2106	+		10.1096/fj.03-0150fje	http://dx.doi.org/10.1096/fj.03-0150fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958154				2022-12-28	WOS:000185925100025
J	Castello, A; Alverez, M; Verdu, F				Castello, A; Alverez, M; Verdu, F			Just lip prints? No: there could be something else	FASEB JOURNAL			English	Editorial Material							DNA; FINGERPRINTS		Univ Valencia, Coll Med & Odontol, Dept Legal Med, 46010 Valencia, Spain	University of Valencia	Verdu, F (corresponding author), Fac Med Valencia, UD Med Legal,Av Blasco Ibanez 15, 46010 Valencia, Spain.	Fernando.Verdu@uv.es	Castello, Ana/AAA-4914-2019					Castello A, 2002, COLOR TECHNOL, V118, P316; CASTELLO A, 2002, FORENSIC SCI COMMUN, V4; LORENTE JA, 1994, FORENSIC SCI INT, V65, P169, DOI 10.1016/0379-0738(94)90272-0; Lorente M, 1998, J FORENSIC SCI, V43, P901; Schulz MM, 2002, FORENSIC SCI INT, V127, P128, DOI 10.1016/S0379-0738(02)00092-0; Segui MA, 2000, FORENSIC SCI INT, V112, P41, DOI 10.1016/S0379-0738(00)00173-0; vanOorschot RAH, 1997, NATURE, V387, P767, DOI 10.1038/42838; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018	8	10	10	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					615	616		10.1096/fj.03-0938lfe	http://dx.doi.org/10.1096/fj.03-0938lfe			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054083				2022-12-28	WOS:000221108800031
J	Laposa, RR; Henderson, JT; Xu, E; Wells, PG				Laposa, RR; Henderson, JT; Xu, E; Wells, PG			Atm-null mice exhibit enhanced radiation-induced birth defects and a hybrid form of embryonic cell death indicating a teratological suppressor function for ATM	FASEB JOURNAL			English	Article						genotoxicity; teratogenesis; DNA damage; ataxia-telangiectasia; DNA repair	ATAXIA-TELANGIECTASIA CELLS; CENTRAL-NERVOUS-SYSTEM; IONIZING-RADIATION; DNA-DAMAGE; GENE-PRODUCT; OXIDATIVE DAMAGE; P53; APOPTOSIS; PROTEIN; PHOSPHORYLATION	ATM (ataxia-telangiectasia mutated) is a genotoxic stress transducer. In this first report of Atm-dependent birth defects, Atm-null embryos were uniquely susceptible to low-dose (0.5 Gy) radiation, exhibiting severe runting, tail anomalies, and lethality, independent of cell cycle arrest or insulin-like growth factor 1. This treatment enhanced levels of p53 protein and central nervous system (CNS) apoptosis in wild-type mice, but not Atm-null mutants, at 6 h postirradiation. At 48 h, however, this pattern was reversed, with Atm-null mice exhibiting high levels of a hybrid form of programmed cell death within the CNS. Even heterozygous Atm-deficient embryos were radiosensitive to a higher radiation dose of 2 Gy. These results show that Atm is a novel teratologic suppressor gene protecting embryos from pathological cell death and teratogenesis initiated by even mild DNA damage.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON M5S 2S2, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca		Xu, Elaine/0000-0002-6180-6732				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BAR RS, 1978, NEW ENGL J MED, V298, P1164, DOI 10.1056/NEJM197805252982103; Barlow C, 2000, P NATL ACAD SCI USA, V97, P871, DOI 10.1073/pnas.97.2.871; Barlow C, 1999, P NATL ACAD SCI USA, V96, P9915, DOI 10.1073/pnas.96.17.9915; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; BAUM SJ, 1984, NUCL WEAPON EFFECT R, V10; Blevins LS, 1996, SOUTHERN MED J, V89, P619, DOI 10.1097/00007611-199606000-00013; Brown KD, 1999, AM J HUM GENET, V64, P46, DOI 10.1086/302223; Brown KD, 1997, P NATL ACAD SCI USA, V94, P1840, DOI 10.1073/pnas.94.5.1840; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; CEKAN E, 1985, ACTA RADIOL ONCOL, V24, P267, DOI 10.3109/02841868509134399; Chen G, 1996, J BIOL CHEM, V271, P33693, DOI 10.1074/jbc.271.52.33693; Chong MJ, 2000, P NATL ACAD SCI USA, V97, P889, DOI 10.1073/pnas.97.2.889; D'Sa-Eipper C, 2001, DEVELOPMENT, V128, P137; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELSON A, 1996, P NATL ACAD SCI USA, V93, P10384; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P243, DOI 10.1016/S0921-8777(00)00006-9; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Heyer BS, 2000, GENE DEV, V14, P2072; Johnson RT, 1999, BIOCHEM BIOPH RES CO, V261, P317, DOI 10.1006/bbrc.1999.1024; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KHANNA KK, 1993, ONCOGENE, V8, P3307; Kimler BF, 1998, INT J RADIAT BIOL, V73, P423, DOI 10.1080/095530098142266; Lakin ND, 1996, ONCOGENE, V13, P2707; Lomaga MA, 2000, J NEUROSCI, V20, P7384; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MEYN MS, 1995, CANCER RES, V55, P5991; MIDGLEY CA, 1995, J CELL SCI, V108, P1843; Moallem SA, 1998, DEVELOPMENT, V125, P3225; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Nomoto S, 1998, INT J RADIAT BIOL, V74, P419, DOI 10.1080/095530098141285; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; Peretz S, 2001, P NATL ACAD SCI USA, V98, P1676, DOI 10.1073/pnas.041416598; Rotman G, 1997, BIOESSAYS, V19, P911, DOI 10.1002/bies.950191011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Soares HD, 1998, NEUROSCIENCE, V86, P1045, DOI 10.1016/S0306-4522(98)00117-1; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Takagi M, 1998, CANCER RES, V58, P4923; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Watters D, 1997, ONCOGENE, V14, P1911, DOI 10.1038/sj.onc.1201037; Xu Y, 1996, GENE DEV, V10, P2401, DOI 10.1101/gad.10.19.2401; Yang J, 2000, J EARTHQUAKE ENG, V4, P1, DOI 10.1142/S1363246900000023; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	44	25	26	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					896	+		10.1096/fj.03-0903fje	http://dx.doi.org/10.1096/fj.03-0903fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033931				2022-12-28	WOS:000220522800016
J	Wei, L; Taffet, GE; Khoury, DS; Bo, J; Li, Y; Yatani, A; Delaughter, MC; Klevitsky, R; Hewett, TE; Robbins, J; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ				Wei, L; Taffet, GE; Khoury, DS; Bo, J; Li, Y; Yatani, A; Delaughter, MC; Klevitsky, R; Hewett, TE; Robbins, J; Michael, LH; Schneider, MD; Entman, ML; Schwartz, RJ			Disruption of Rho signaling results in progressive atrioventricular conduction defects while ventricular function remains preserved	FASEB JOURNAL			English	Article						Rho GDI alpha transgenic mouse; cardiac contractile function; atrial arrhythmias; connexin 40	CARDIAC MYOCYTE HYPERTROPHY; JUNCTION PROTEIN CONNEXIN40; GTP-BINDING PROTEINS; CONTRACTILE FAILURE; TRANSGENIC MICE; FAMILY GTPASES; BUNDLE-BRANCH; HEART-FAILURE; SYSTEM; MOUSE	Recent studies suggest that RhoA and Rac1 mediate hypertrophic signals in cardiac myocyte hypertrophy. However, effects on cardiac function caused by inhibition of their activity in the heart have yet to be evaluated. Cardiac-specific inhibition of Rho family protein activities was achieved by expressing Rho GDIalpha, an endogenous specific GDP dissociation inhibitor for Rho family proteins, using the alpha-myosin heavy-chain promoter. Increased expression of Rho GDIa led to atrial arrhythmias and mild ventricular hypertrophy in adult mice (4-7 months). However, left ventricular systolic and diastolic function was largely preserved before and after the development of cardiac hypertrophy, indicating that Rho GTPases are not required to maintain ventricular contractile function under basal physiological condition. Electrocardiography and intracardiac electrophysiological studies revealed first-degree atrioventricular (AV) block in the transgenic heart at 1 week of age, which further progressed into second-degree AV block at 4 weeks of age before the development of cardiac hypertrophy. Expression of connexin 40 dramatically decreased from 1 week to 4 weeks of age in the transgenic heart, which may contribute in part to the conduction defects in the transgenic mice. This study provides novel evidence for an important role of Rho GTPases in regulating AV conduction.	Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Ctr Cardiovasc Dev, Houston, TX 77030 USA; Baylor Coll Med, DeBakey Heart Ctr, Houston, TX 77030 USA; Baylor Coll Med, Cardiol Sect, Houston, TX 77030 USA; Methodist Hosp, Houston, TX 77030 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Cardiovasc Res Inst, Newark, NJ 07103 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Methodist DeBakey Heart & Vascular Center; Baylor College of Medicine; The Methodist Hospital System; The Methodist Hospital - Houston; Rutgers State University New Brunswick; Rutgers State University Medical Center; Cincinnati Children's Hospital Medical Center	Wei, L (corresponding author), Baylor Coll Med, Dept Med, Cardiovasc Sci Sect, 1 Baylor Plaza,Room 506D, Houston, TX 77030 USA.	lwei@bcm.tmc.edu	Hewett, Timothy/G-1023-2011; Hewett, Timothy E/E-3241-2011; Hewett, Timothy Edwin/GLT-1556-2022	Schneider, Michael/0000-0001-9645-1938	NHLBI NIH HHS [R01 HL072897-01, R01 HL072897] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072897] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1999, CIRC RES, V84, P458, DOI 10.1161/01.RES.84.4.458; Aoki H, 1998, CIRC RES, V82, P666, DOI 10.1161/01.RES.82.6.666; Aronow BJ, 2001, PHYSIOL GENOMICS, V6, P19, DOI 10.1152/physiolgenomics.2001.6.1.19; Berul CI, 1996, CIRCULATION, V94, P2641, DOI 10.1161/01.CIR.94.10.2641; Bevilacqua LM, 2000, J INTERV CARD ELECTR, V4, P459, DOI 10.1023/A:1009800328836; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; Clerk A, 2000, CIRC RES, V86, P1019, DOI 10.1161/01.RES.86.10.1019; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; GOURDIE RG, 1993, J CELL SCI, V105, P985; Guerrero PA, 1997, J CLIN INVEST, V99, P1991, DOI 10.1172/JCI119367; Gulick J, 1997, CIRC RES, V80, P655, DOI 10.1161/01.RES.80.5.655; Hagendorff A, 1999, CIRCULATION, V99, P1508, DOI 10.1161/01.CIR.99.11.1508; HALL A, 1994, ANNU REV CELL BIOL, V10, P31, DOI 10.1146/annurev.cb.10.110194.000335; Hein L, 1997, P NATL ACAD SCI USA, V94, P6391, DOI 10.1073/pnas.94.12.6391; Hoshijima M, 1998, J BIOL CHEM, V273, P7725, DOI 10.1074/jbc.273.13.7725; Jones WK, 1996, J CLIN INVEST, V98, P1906, DOI 10.1172/JCI118992; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; Kirchhoff S, 1998, CURR BIOL, V8, P299, DOI 10.1016/S0960-9822(98)70114-9; Laufs U, 2000, CIRCULATION, V102, P3104; Laufs U, 2002, CARDIOVASC RES, V53, P911, DOI 10.1016/S0008-6363(01)00540-5; Moorman AFM, 1998, CIRC RES, V82, P629, DOI 10.1161/01.RES.82.6.629; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Patel R, 2001, CIRCULATION, V104, P317, DOI 10.1161/hc2801.094031; Pracyk JB, 1998, J CLIN INVEST, V102, P929, DOI 10.1172/JCI2552; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Sah VP, 1999, J CLIN INVEST, V103, P1627, DOI 10.1172/JCI6842; Sasaki T, 1998, BIOCHEM BIOPH RES CO, V245, P641, DOI 10.1006/bbrc.1998.8253; Simon AM, 1998, CURR BIOL, V8, P295, DOI 10.1016/S0960-9822(98)70113-7; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Sussman MA, 2000, J CLIN INVEST, V105, P875, DOI 10.1172/JCI8497; Symons M, 2000, TRENDS CELL BIOL, V10, P415, DOI 10.1016/S0962-8924(00)01832-8; Taffet GE, 1996, AM J PHYSIOL-HEART C, V270, pH2204; Takemoto M, 2001, J CLIN INVEST, V108, P1429, DOI 10.1172/JCI200113350; Tamaddon HS, 2000, CIRC RES, V87, P929, DOI 10.1161/01.RES.87.10.929; Thomas SA, 1998, CIRCULATION, V97, P686, DOI 10.1161/01.CIR.97.7.686; UEDA T, 1990, J BIOL CHEM, V265, P9373; VAN AL, 1997, GENE DEV, V11, P2295; van Rijen HVM, 2001, CIRCULATION, V103, P1591; Verheule S, 1999, J CARDIOVASC ELECTR, V10, P1380, DOI 10.1111/j.1540-8167.1999.tb00194.x; Wei L, 2002, DEVELOPMENT, V129, P1705; Zhang D, 2000, NAT MED, V6, P556, DOI 10.1038/75037	41	39	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					857	+		10.1096/fj.03-0664fje	http://dx.doi.org/10.1096/fj.03-0664fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033930				2022-12-28	WOS:000220522800015
J	Rimbert, V; Boirie, Y; Bedu, M; Hocquette, JF; Ritz, P; Morio, B				Rimbert, V; Boirie, Y; Bedu, M; Hocquette, JF; Ritz, P; Morio, B			Muscle fat oxidative capacity is not impaired by age but by physical inactivity: association with insulin sensitivity	FASEB JOURNAL			English	Article; Proceedings Paper	25th ESPEN Congress	SEP 20-23, 2003	Cannes, FRANCE	ESPEN		insulin resistance; type 2 diabetes; fuel selection; endurance exercise; obesity	HUMAN SKELETAL-MUSCLE; GLUCOSE-TOLERANCE TEST; ELDERLY-PEOPLE; LIPID-CONTENT; RESISTANCE; METABOLISM; ACIDS; MITOCHONDRIA; RAT; MEN	The study aimed at determining whether aging and/or sedentariness impairs muscle fat oxidative capacity (OXFA) and whether this was associated with increased risk to develop insulin resistance. We first examined muscle mitochondrial functions, OXFA and insulin sensitivity (ISI; evaluated during an oral glucose tolerance test) in a cross-sectional study with 32 sedentary (S) and endurance-trained (T), young (Y) and elderly (E) men (24.2 +/- 2.6 vs. 66.6 +/- 3.2 yr). As for mitochondrial functions, OXFA was higher in T than in S but similar between age groups (SY 41.8 +/- 11.3, TY 68.0 +/- 17.7, SE 40.1 +/- 14.1, TE 73.1 +/- 20.1 palmitate.min(-1).g wet tissue(-1); activity P < 0.0001, age P = NS, activity x age P = NS). Similar results were obtained with ISI (SY 6.2 +/- 2.2, TY 11.4 +/- 4.4, SE 5.9 +/- 1.5, TE 11.0 +/- 3.5, activity P < 0.001, age P = NS, activity x age P = NS). Stepwise regression showed that, among body composition, VO2max and muscle biochemical characteristics, OXFA was the main predictor of ISI (r = 0.60, P < 0.001). We subsequently showed in eight sedentary elderly subjects (63.5 +/- 3.3 yr) that OXFA and insulin sensitivity (measured using insulin clamp) improved in parallel after 8 weeks of endurance training (r = 0.79, P < 0.01). We concluded that mitochondrial functions, OXFA and ISI, are not impaired by age but by physical inactivity and are closely correlated.	Auvergne Univ, Human Nutr Res Ctr Auvergne, Human Nutr Lab, Prot & Energy Metab Res Unit, F-63009 Clermont Ferrand 1, France; Auvergne Univ, Human Nutr Res Ctr Auvergne, Lab Physiol & Biol Sport, F-63009 Clermont Ferrand 1, France; INRA, Ruminant Res Unit, F-63122 St Genes Champanelle, France; Univ Hosp, Unit Clin Gerontol, Angers, France	Universite Clermont Auvergne (UCA); Universite Clermont Auvergne (UCA); INRAE; Universite d'Angers; Centre Hospitalier Universitaire d'Angers	Morio, B (corresponding author), Auvergne Univ, Human Nutr Res Ctr Auvergne, Human Nutr Lab, Prot & Energy Metab Res Unit, BP 321,58 Montalembert Str, F-63009 Clermont Ferrand 1, France.	morio@clermont.inra.fr	Hocquette, Jean-Francois/I-1034-2019; Morio, Béatrice/G-3571-2018	Hocquette, Jean-Francois/0000-0003-2409-3881; Morio, Béatrice/0000-0002-2418-1438				BAECKE JAH, 1982, AM J CLIN NUTR, V36, P936; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; Barrientos A, 1996, BIOCHEM BIOPH RES CO, V229, P536, DOI 10.1006/bbrc.1996.1839; Belfiore F, 2001, METABOLISM, V50, P573, DOI 10.1053/meta.2001.22518; Boden G, 2001, DIABETES, V50, P1612, DOI 10.2337/diabetes.50.7.1612; Boffoli D, 1996, BBA-MOL BASIS DIS, V1315, P66, DOI 10.1016/0925-4439(95)00107-7; Boirie Y, 2001, J CLIN ENDOCR METAB, V86, P638, DOI 10.1210/jc.86.2.638; Brierley EJ, 1997, MOL CELL BIOCHEM, V174, P325, DOI 10.1023/A:1006847319162; Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251; BROUGHTON DL, 1991, AGE AGEING, V20, P221, DOI 10.1093/ageing/20.3.221; CEDERHOLM J, 1990, DIABETES RES CLIN PR, V10, P167, DOI 10.1016/0168-8227(90)90040-Z; Chavez JA, 2003, J BIOL CHEM, V278, P10297, DOI 10.1074/jbc.M212307200; COGGAN AR, 1990, J APPL PHYSIOL, V68, P1896, DOI 10.1152/jappl.1990.68.5.1896; COGGAN AR, 1993, J APPL PHYSIOL, V75, P2125, DOI 10.1152/jappl.1993.75.5.2125; Conley KE, 2000, J PHYSIOL-LONDON, V526, P203, DOI 10.1111/j.1469-7793.2000.t01-1-00203.x; DEFRONZO RA, 1981, DIABETES CARE, V4, P493, DOI 10.2337/diacare.4.4.493; Dobrzyn A, 2002, AM J PHYSIOL-ENDOC M, V282, pE277, DOI 10.1152/ajpendo.00151.2001; Fannin SW, 1999, ARCH BIOCHEM BIOPHYS, V372, P399, DOI 10.1006/abbi.1999.1508; Ferrannini E, 1996, DIABETES, V45, P947, DOI 10.2337/diabetes.45.7.947; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Goodpaster BH, 2001, J CLIN ENDOCR METAB, V86, P5755, DOI 10.1210/jc.86.12.5755; He J, 2001, DIABETES, V50, P817, DOI 10.2337/diabetes.50.4.817; Jones Kenneth Lee, 2003, Curr Diab Rep, V3, P255, DOI 10.1007/s11892-003-0073-2; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; Kim JY, 2000, AM J PHYSIOL-ENDOC M, V279, pE1039, DOI 10.1152/ajpendo.2000.279.5.E1039; Matsuda M, 1999, DIABETES CARE, V22, P1462, DOI 10.2337/diacare.22.9.1462; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; Morio B, 2001, AM J PHYSIOL-ENDOC M, V280, pE143, DOI 10.1152/ajpendo.2001.280.1.E143; Morio B, 1999, INT J OBESITY, V23, P706, DOI 10.1038/sj.ijo.0800909; ORLANDER J, 1978, ACTA PHYSIOL SCAND, V104, P249, DOI 10.1111/j.1748-1716.1978.tb06277.x; PACINI G, 1988, J AM GERIATR SOC, V36, P317, DOI 10.1111/j.1532-5415.1988.tb02358.x; Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889; Petersen KF, 2002, AM J CARDIOL, V90, p11G; PROCTOR DN, 1995, J APPL PHYSIOL, V78, P2033, DOI 10.1152/jappl.1995.78.6.2033; Rasmussen UF, 2003, PFLUG ARCH EUR J PHY, V446, P270, DOI 10.1007/s00424-003-1022-2; Rooyackers OE, 1996, P NATL ACAD SCI USA, V93, P15364, DOI 10.1073/pnas.93.26.15364; ROWE JW, 1983, J CLIN INVEST, V71, P1581, DOI 10.1172/JCI110914; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Silverstein J H, 2001, Curr Diab Rep, V1, P19, DOI 10.1007/s11892-001-0006-x; Simoneau JA, 1999, FASEB J, V13, P2051, DOI 10.1096/fasebj.13.14.2051; Simoneau JA, 1997, J APPL PHYSIOL, V83, P166, DOI 10.1152/jappl.1997.83.1.166; Smith Steven R, 2002, Curr Diab Rep, V2, P223, DOI 10.1007/s11892-002-0087-1; Soonthornpun S, 2003, J CLIN ENDOCR METAB, V88, P1019, DOI 10.1210/jc.2002-021127; Thamer C, 2003, J CLIN ENDOCR METAB, V88, P1785, DOI 10.1210/jc.2002-021674; Tonkonogi M, 2003, PFLUG ARCH EUR J PHY, V446, P261, DOI 10.1007/s00424-003-1044-9; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; ZURLO F, 1994, METABOLISM, V43, P481, DOI 10.1016/0026-0495(94)90081-7	47	94	98	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					737	+		10.1096/fj.03-1104fje	http://dx.doi.org/10.1096/fj.03-1104fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977873				2022-12-28	WOS:000220425000013
J	Nubel, T; Dippold, W; Kleinert, H; Kaina, B; Fritz, G				Nubel, T; Dippold, W; Kleinert, H; Kaina, B; Fritz, G			Lovastatin inhibits Rho-regulated expression of E-selectin by TNF-alpha and attenuates tumor cell adhesion	FASEB JOURNAL			English	Article						statins; Rho GTPases; invasiveness	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INHIBITORS; HUMAN ENDOTHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; LEUKOCYTE ADHESION; P21RAS ISOPRENYLATION; CYTOKINE INDUCTION; ACTIN CYTOSKELETON; CYCLE PROGRESSION	E-selectin mediated cell-cell adhesion plays an important role in inflammatory processes and extravasation of tumor cells. Tumor necrosis factor-alpha (TNF-) induces E-selectin gene and protein expression in primary human endothelial cells (HUVEC) and in an endothelial cell line (EA.hy-926). As shown by ELISA and FACS analyses, HMG-CoA reductase inhibitors (e.g., lovastatin) impair the TNF-alpha stimulated increase in E-selectin protein expression. Similar results were obtained for E-selectin mRNA expression and promoter activity, indicating that the effect of lovastatin is based on inhibition of gene expression. The effective inhibitory concentration of lovastatin was in a physiologically relevant range (IC50<0.1 mu M). Lovastatin-mediated block of TNF-alpha induced E-selectin expression is due to inhibition of protein geranylgeranylation rather than farnesylation. Down-regulation of Rho signaling by coexpression of dominant-negative Rho mutants (i.e RhoA, RhoB and Rac) impaired TNF-alpha driven E-selectin gene expression, indicating Rho signaling to be essential for transcriptional activation of the E-selectin gene. Inhibition of E-selectin expression by lovastatin gives rise to a significant reduction in TNF-alpha stimulated adhesion of colon carcinoma cells to HUVEC. Furthermore, low concentration of lovastatin (i.e., <= 1 mu M) attenuated TNF-alpha induced tumor cell invasion in vitro. The data support the view that statins might be clinically useful in protection against E-selectin mediated metastasis.	Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany; St Vincenz & Elisabeth Hosp, D-55131 Mainz, Germany; Johannes Gutenberg Univ Mainz, Inst Pharmacol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz; Johannes Gutenberg University of Mainz	Fritz, G (corresponding author), Johannes Gutenberg Univ Mainz, Inst Toxicol, Div Appl Toxicol, D-55131 Mainz, Germany.	fritz@mail.uni-mainz.de	Kleinert, Hartmut/M-2988-2018	Kleinert, Hartmut/0000-0003-2202-3548	Deutsche Forschungsgemeinschaft [Fr 1241/3-1, SFB 519]; Wilhelm Sander-Stiftung [AZ: 1999.014.2]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Wilhelm Sander-Stiftung	This work was supported by the Deutsche Forschungsgemeinschaft (Fr 1241/3-1 and SFB 519) and the Wilhelm Sander-Stiftung (AZ: 1999.014.2). We would like to thank W. Roos for critical reading of the manuscript.	Barkalow FJ, 1996, BLOOD, V88, P4585, DOI 10.1182/blood.V88.12.4585.bloodjournal88124585; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; BEVILACQUA MP, 1993, J CLIN INVEST, V91, P379, DOI 10.1172/JCI116210; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Bresalier RS, 1996, GASTROENTEROLOGY, V110, P1354, DOI 10.1053/gast.1996.v110.pm8613039; Brodt P., 1996, Clinical and Experimental Metastasis, V14, P74; Chung HK, 2002, EXP MOL MED, V34, P451, DOI 10.1038/emm.2002.63; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DUNHAM AJ, 1995, ANAL CHEM, V67, P220, DOI 10.1021/ac00097a033; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; Forstermann U, 1998, FASEB J, V12, P773; Fritz G, 1997, J BIOL CHEM, V272, P30637, DOI 10.1074/jbc.272.49.30637; Fritz G, 2002, BRIT J CANCER, V87, P635, DOI 10.1038/sj.bjc.6600510; Geller DA, 1998, CANCER METAST REV, V17, P7, DOI 10.1023/A:1005940202801; Gnad R, 2001, EXP CELL RES, V264, P244, DOI 10.1006/excr.2001.5165; Gnad R, 2000, MOL PHARMACOL, V58, P1389, DOI 10.1124/mol.58.6.1389; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hallahan D, 1995, BIOCHEM BIOPH RES CO, V217, P784, DOI 10.1006/bbrc.1995.2841; Hallahan DE, 1998, CANCER RES, V58, P5484; Jaffe AB, 2002, ADV CANCER RES, V84, P57, DOI 10.1016/S0065-230X(02)84003-9; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Koch G, 1997, J PHARMACOL EXP THER, V283, P901; Kong LP, 1996, CLIN EXP METASTAS, V14, P335, DOI 10.1007/BF00123392; Krause T, 1999, CLIN EXP METASTAS, V17, P183, DOI 10.1023/A:1006626500852; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kusama T, 2001, CANCER RES, V61, P4885; Kusama T, 2002, GASTROENTEROLOGY, V122, P308, DOI 10.1053/gast.2002.31093; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Laufs U, 1998, J BIOL CHEM, V273, P24266, DOI 10.1074/jbc.273.37.24266; Matar P, 1999, CLIN EXP METASTAS, V17, P19; Meroni PL, 2001, ARTHRITIS RHEUM-US, V44, P2870, DOI 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y; MILLER AC, 1993, INT J CANCER, V53, P302, DOI 10.1002/ijc.2910530222; MILLER AC, 1995, INT J CANCER, V60, P249; Min W, 1997, J IMMUNOL, V159, P3508; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MONTGOMERY KF, 1991, P NATL ACAD SCI USA, V88, P6523, DOI 10.1073/pnas.88.15.6523; Mueck AO, 2001, EXP CLIN ENDOCR DIAB, V109, P181, DOI 10.1055/s-2001-14843; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Perona R, 1997, GENE DEV, V11, P463, DOI 10.1101/gad.11.4.463; Price LS, 2001, SEMIN CANCER BIOL, V11, P167, DOI 10.1006/scbi.2000.0367; Raab M, 2002, CLIN CHIM ACTA, V321, P11; Rasmussen LM, 2001, BIOCHEM J, V360, P363, DOI 10.1042/0264-6021:3600363; Sadeghi NM, 2000, J IMMUNOL, V165, P2712, DOI 10.4049/jimmunol.165.5.2712; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; Schmidt A, 2002, ATHEROSCLEROSIS, V164, P57, DOI 10.1016/S0021-9150(02)00053-9; Schmitz AAP, 2000, EXP CELL RES, V261, P1, DOI 10.1006/excr.2000.5049; Seeger H, 2001, Climacteric, V4, P209, DOI 10.1080/713605099; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Wang IK, 2000, ONCOLOGY-BASEL, V59, P245, DOI 10.1159/000012168; WELLER A, 1992, J BIOL CHEM, V267, P15176; Witcher M, 2003, BLOOD, V102, P237, DOI 10.1182/blood-2002-09-2725; Wittig BM, 1996, EUR J CANCER, V32A, P1215, DOI 10.1016/0959-8049(96)00086-X; WITTIG BM, 1995, GASTROENTEROLOGY SUP, V108; Wojciak-Stothard B, 1999, J CELL BIOL, V145, P1293, DOI 10.1083/jcb.145.6.1293; Yamada N, 1997, BRIT J CANCER, V76, P582, DOI 10.1038/bjc.1997.429; Yudoh K, 1997, CLIN EXP METASTAS, V15, P557, DOI 10.1023/A:1018487213157	61	106	108	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					140	142		10.1096/fj.03-0261fje	http://dx.doi.org/10.1096/fj.03-0261fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630701				2022-12-28	WOS:000188829300053
J	Suuronen, EJ; Nakamura, M; Watsky, MA; Stys, PK; Muller, LJ; Munger, RE; Shinozaki, N; Griffith, M				Suuronen, EJ; Nakamura, M; Watsky, MA; Stys, PK; Muller, LJ; Munger, RE; Shinozaki, N; Griffith, M			Innervated human corneal equivalents as in vitro models for nerve-target cell interactions	FASEB JOURNAL			English	Article						extracellular matrix; innervation; cornea; nerve function; tissue engineering	DORSAL-ROOT GANGLIA; GUINEA-PIG CORNEA; GROWTH-FACTOR-I; SUBSTANCE-P; SENSORY DENERVATION; RETINOIC ACID; NEURITE OUTGROWTH; EPITHELIAL-CELLS; RABBIT CORNEA; RAT	A sensory nerve supply is crucial for optimal tissue function. However, the mechanisms for successful innervation and the signaling pathways between nerves and their target tissue are not fully understood. Engineered tissue substitutes can provide controllable environments in which to study tissue innervation. We have therefore engineered human corneal substitutes that promote nerve in-growth in a pattern similar to in vivo re-innervation. We demonstrate that these nerves (a) are morphologically equivalent to natural corneal nerves; (b) make appropriate contact with target cells; (c) can generate action potentials; (d) respond to chemical and physical stimuli; and (e) play an important role in the overall functioning of the bioengineered tissue. This model can be used for studying the more general topics of nerve ingrowth or regeneration and the interaction between nerves and their target cells and, more specifically, the role of nerves in corneal function. This model could also be used as an in vitro alternative to animals for safety and efficacy testing of chemicals and drugs.	Univ Ottawa, Univ Ottawa Eye Inst, Ottawa Hlth Res Inst, Vis Ctr, Ottawa, ON K1H 8L6, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8L6, Canada; Santen Pharmaceut Co Ltd, Ikoma, Nara, Japan; Univ Tennessee, Ctr Hlth Sci, Dept Physiol, Memphis, TN 38163 USA; Univ Ottawa, Div Neurosci, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Netherlands Ophthalm Res Inst, Dept Morphol, NL-1100 AC Amsterdam, Netherlands; Tokyo Dent Coll Ichikawa Gen Hosp, Cornea Ctr, Chiba, Japan	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; Santen Pharmaceutical Co Ltd; University of Tennessee System; University of Tennessee Health Science Center; University of Ottawa; Ottawa Hospital Research Institute; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); Tokyo Dental College	Griffith, M (corresponding author), Univ Ottawa, Univ Ottawa Eye Inst, Ottawa Hlth Res Inst, Vis Ctr, 501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	mgriffith@ohri.ca		Griffith, May/0000-0003-1222-6720; Watsky, Mitchell/0000-0003-2079-9887	NSERC Canada; Santen Pharmaceutical Co;  [227212-1999];  [227951-01]	NSERC Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Santen Pharmaceutical Co; ; 	We thank E. Coderre for technical assistance; Dr. T. Nishida for in vivo confocal images; and Drs. R. Beuerman, D. Carlsson, and I. Spigelman for helpful insights. Supported by grants (227212-1999; 227951-01) and studentship from NSERC Canada and an extramural grant from Santen Pharmaceutical Co. E.J.S. is a Fellow of the International Foundation for Ethical Research.	ARAKI K, 1992, Nippon Ganka Gakkai Zasshi, V96, P710; ARAKI K, 1994, CURR EYE RES, V13, P203, DOI 10.3109/02713689408995778; Araki-Sasaki K, 2000, J CELL PHYSIOL, V182, P189, DOI 10.1002/(SICI)1097-4652(200002)182:2<189::AID-JCP7>3.0.CO;2-9; BAKER KS, 1993, INVEST OPHTH VIS SCI, V34, P137; BELMONTE C, 1991, J PHYSIOL-LONDON, V437, P709, DOI 10.1113/jphysiol.1991.sp018621; Belmonte C, 1997, PROG RETIN EYE RES, V16, P117, DOI 10.1016/S1350-9462(96)00027-4; BEUERMAN RW, 1980, EXP NEUROL, V69, P196, DOI 10.1016/0014-4886(80)90154-5; Bongenhielm U, 1995, REGUL PEPTIDES, V60, P91, DOI 10.1016/0167-0115(95)00115-8; Bowden JJ, 1996, AM J PHYSIOL-LUNG C, V270, pL393; Brock JA, 2001, J PHYSIOL-LONDON, V533, P493, DOI 10.1111/j.1469-7793.2001.0493a.x; Brock JA, 1998, J PHYSIOL-LONDON, V512, P211, DOI 10.1111/j.1469-7793.1998.211bf.x; BRUGGE JS, 1977, NATURE, V269, P346, DOI 10.1038/269346a0; CARR RW, 1993, NEUROREPORT, V4, P467, DOI 10.1097/00001756-199305000-00001; CHAN KY, 1987, EXP EYE RES, V45, P633, DOI 10.1016/S0014-4835(87)80112-4; CHAN KY, 1982, EXP EYE RES, V35, P137, DOI 10.1016/S0014-4835(82)80062-6; Corcoran J, 2000, J CELL SCI, V113, P2567; DASTON GP, 1991, DERMAL OCULAR TOXICO, P509; DELVALLE ME, 1993, CELL MOL BIOL, V39, P801; GALLAR J, 1990, INVEST OPHTH VIS SCI, V31, P1968; Gan L, 2001, ACTA OPHTHALMOL SCAN, V79, P488, DOI 10.1034/j.1600-0420.2001.790512.x; GARCIAHIRSCHFELD J, 1994, EXP EYE RES, V59, P597, DOI 10.1006/exer.1994.1145; Griffith M, 1999, SCIENCE, V286, P2169, DOI 10.1126/science.286.5447.2169; Head H, 1905, BRAIN, V28, P116, DOI 10.1093/brain/28.2.116; HOLZER P, 1988, NEUROSCIENCE, V24, P739, DOI 10.1016/0306-4522(88)90064-4; Jones MA, 1996, INVEST OPHTH VIS SCI, V37, P2535; JUMBLATT MM, 1983, INVEST OPHTH VIS SCI, V24, P1139; KEEN P, 1982, NEUROSCI LETT, V29, P231, DOI 10.1016/0304-3940(82)90322-6; Koopmans SJ, 1998, DIABETOLOGIA, V41, P813, DOI 10.1007/s001250050992; Krarup C, 2002, ANN NEUROL, V51, P69, DOI 10.1002/ana.10054; Li YB, 1997, EXP NEUROL, V147, P452, DOI 10.1006/exnr.1997.6624; LIM C H, 1976, British Journal of Physiological Optics, V31, P38; Liu MX, 1999, CELL TISSUE RES, V297, P423, DOI 10.1007/s004410051369; MACIVER MB, 1993, J NEUROPHYSIOL, V69, P1779, DOI 10.1152/jn.1993.69.5.1779; Maden M, 1996, CURR BIOL, V6, P417, DOI 10.1016/S0960-9822(02)00509-2; Maden M., 1999, HANDB EXP PHARM, P399; MAGGI CA, 1991, J AUTONOM NERV SYST, V33, P1, DOI 10.1016/0165-1838(91)90013-S; Maurer JK, 1999, TOXICOL APPL PHARM, V158, P61, DOI 10.1006/taap.1999.8686; Miller C, 2002, TISSUE ENG, V8, P367, DOI 10.1089/107632702760184646; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; Muller L, 1996, INVEST OPHTH VIS SCI, V37, P476; Muller LJ, 1997, INVEST OPHTH VIS SCI, V38, P985; Nakamura M, 1997, CURR EYE RES, V16, P275, DOI 10.1076/ceyr.16.3.275.15409; Neubert JK, 2000, BRAIN RES, V871, P181, DOI 10.1016/S0006-8993(00)02440-9; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Nishida T, 1996, J CELL PHYSIOL, V169, P159, DOI 10.1002/(SICI)1097-4652(199610)169:1<159::AID-JCP16>3.0.CO;2-8; Obedencio GP, 1999, J INVEST DERMATOL, V113, P851, DOI 10.1046/j.1523-1747.1999.00763.x; PALKAMA A, 1986, EXP EYE RES, V43, P1043, DOI 10.1016/0014-4835(86)90081-3; PAVLIDIS C, 1994, INT J DEV NEUROSCI, V12, P587, DOI 10.1016/0736-5748(94)90066-3; QUINN SDP, 1991, IN VITRO CELL DEV B, V27, P55; RIGGOTT MJ, 1987, J COMP NEUROL, V258, P580, DOI 10.1002/cne.902580408; ROSSINO P, 1991, CELL REGUL, V2, P1021, DOI 10.1091/mbc.2.12.1021; ROY ML, 1992, J NEUROSCI, V12, P2104; ROZSA AJ, 1982, PAIN, V14, P105, DOI 10.1016/0304-3959(82)90092-6; TENTUSSCHER MPM, 1989, BRAIN RES, V494, P95, DOI 10.1016/0006-8993(89)90147-9; Tuori A, 1996, CORNEA, V15, P286, DOI 10.1097/00003226-199605000-00010; UNGER WG, 1990, J OCUL PHARMACOL, V6, P337, DOI 10.1089/jop.1990.6.337; UNGER WG, 1988, CURR EYE RES, V7, P761, DOI 10.3109/02713688809033207; WATT FM, 1984, J CELL BIOL, V98, P16, DOI 10.1083/jcb.98.1.16; Yu XJ, 2003, TISSUE ENG, V9, P421, DOI 10.1089/107632703322066606; Yu XJ, 1999, TISSUE ENG, V5, P291, DOI 10.1089/ten.1999.5.291; ZICHE M, 1990, BRIT J PHARMACOL, V100, P11, DOI 10.1111/j.1476-5381.1990.tb12043.x	61	47	57	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					170	172		10.1096/fj.03-0043fje	http://dx.doi.org/10.1096/fj.03-0043fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597567				2022-12-28	WOS:000188829300064
J	Wang, YN; Burns, WR; Tang, PCY; Yi, T; Schechner, JS; Zerwes, HG; Sessa, WC; Lorber, MI; Pober, JS; Tellides, G				Wang, YN; Burns, WR; Tang, PCY; Yi, T; Schechner, JS; Zerwes, HG; Sessa, WC; Lorber, MI; Pober, JS; Tellides, G			Interferon-gamma plays a nonredundant role in mediating T-cell-dependent outward vascular remodeling of allogeneic human coronary arteries	FASEB JOURNAL			English	Article						arteriosclerosis; T cells; cytokines; vascular smooth muscle cells	CARDIAC ALLOGRAFT VASCULOPATHY; TRANSPLANTED MOUSE HEARTS; COMPENSATORY ENLARGEMENT; ATHEROSCLEROSIS; LYMPHOCYTES; REJECTION; DISEASE; ARTERIOSCLEROSIS; EXPRESSION; RESPONSES	Vascular remodeling (change in vessel diameter) rather than intimal hyperplasia is the most important predictor of luminal loss in immune-mediated arterial injury, yet little is known about its mechanisms. Here, we show that outward vascular remodeling and intimal thickening, two manifestations of arteriosclerosis with opposing effects on luminal size, result from immune effector mechanisms that are T-cell dependent and interferon (IFN)-gamma mediated. In our in vivo model of human coronary artery injury by allogeneic peripheral blood mononuclear cells, both processes occur concurrently and are characterized by T-cell infiltrates with a predominantly IFN-gamma-producing cytokine profile. Neutralization of IFN-gamma inhibits the arterial and intimal expansion, whereas administration of IFN-gamma enhances these effects. The nonredundant role of IFN-gamma in T-cell-dependent remodeling of human coronary arteries demonstrated here presents a new therapeutic target for preservation of vessel lumen in arteriosclerosis.	Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplantat, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Surg, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; Novartis Pharma AG, CH-4002 Basel, Switzerland	Yale University; Yale University; Yale University; Yale University; Yale University; Yale University; Novartis	Tellides, G (corresponding author), Boyer Ctr Mol Med, Room 454,295 Congress Ave, New Haven, CT 06510 USA.	george.tellides@yale.edu	Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Andriambeloson E, 2001, TRANSPLANTATION, V72, P1881, DOI 10.1097/00007890-200112270-00004; Benagiano M, 2003, P NATL ACAD SCI USA, V100, P6658, DOI 10.1073/pnas.1135726100; BIEBER CP, 1970, CIRCULATION, V41, P753, DOI 10.1161/01.CIR.41.5.753; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Dal Canto AJ, 2001, J CLIN INVEST, V107, pR15, DOI 10.1172/JCI11540; Dong CM, 1996, LAB INVEST, V74, P921; FISH RD, 1988, J CLIN INVEST, V81, P21, DOI 10.1172/JCI113297; Frostegard J, 1999, ATHEROSCLEROSIS, V145, P33, DOI 10.1016/S0021-9150(99)00011-8; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GLAGOV S, 1987, NEW ENGL J MED, V316, P1371, DOI 10.1056/NEJM198705283162204; Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465; HANSSON GK, 1989, AM J PATHOL, V135, P169; Lim TT, 1997, CIRCULATION, V95, P855; Lorber MI, 1999, TRANSPLANTATION, V67, P897, DOI 10.1097/00007890-199903270-00018; MASERI A, 1977, LANCET, V1, P713; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; MENNANDER A, 1991, ARTERIOSCLER THROMB, V11, P671, DOI 10.1161/01.ATV.11.3.671; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nagano H, 1997, J CLIN INVEST, V100, P550, DOI 10.1172/JCI119564; Oehen S, 1999, EUR J IMMUNOL, V29, P608, DOI 10.1002/(SICI)1521-4141(199902)29:02<608::AID-IMMU608>3.0.CO;2-A; PASTERKAMP G, 1995, CIRCULATION, V91, P1444, DOI 10.1161/01.CIR.91.5.1444; Pethig K, 1998, AM HEART J, V135, P628, DOI 10.1016/S0002-8703(98)70278-9; Pober JS, 1996, TRANSPLANTATION, V61, P343, DOI 10.1097/00007890-199602150-00001; Rentenaar RJ, 2000, J CLIN INVEST, V105, P541, DOI 10.1172/JCI8229; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; RUSSELL PS, 1994, TRANSPLANTATION, V57, P1367, DOI 10.1097/00007890-199405150-00014; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SALOMON RN, 1991, AM J PATHOL, V138, P791; Schonbeck U, 2002, AM J PATHOL, V161, P499, DOI 10.1016/S0002-9440(10)64206-X; Shimizu K, 2001, NAT MED, V7, P738, DOI 10.1038/89121; Tellides G, 2000, NATURE, V403, P207, DOI 10.1038/35003221; TELLIDES G, 1998, ORGAN TRANSPLANTATIO, P615; Thompson RW, 2002, CARDIOVASC SURG, V10, P389, DOI 10.1016/S0967-2109(02)00042-X; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; vanBesouw NM, 1997, TRANSPLANTATION, V63, P1313, DOI 10.1097/00007890-199705150-00020; Ward MR, 2000, CIRCULATION, V102, P1186, DOI 10.1161/01.CIR.102.10.1186; Whitman SC, 2000, AM J PATHOL, V157, P1819, DOI 10.1016/S0002-9440(10)64820-1; Zhao DXM, 2002, J IMMUNOL, V169, P1556, DOI 10.4049/jimmunol.169.3.1556	41	62	63	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					606	+		10.1096/fj.03-0840fje	http://dx.doi.org/10.1096/fj.03-0840fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734640				2022-12-28	WOS:000188829300008
J	Dupuis, L; di Scala, F; Rene, F; de Tapia, M; Oudart, H; Pradat, PF; Meininger, V; Loeffler, JP				Dupuis, L; di Scala, F; Rene, F; de Tapia, M; Oudart, H; Pradat, PF; Meininger, V; Loeffler, JP			Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis	FASEB JOURNAL			English	Article						mitochondria; neurodegeneration; motor neuron; metabolism	SUPEROXIDE-DISMUTASE GENE; MOTOR-NEURON DISEASE; OXIDATIVE DAMAGE; SKELETAL-MUSCLE; ENERGY-METABOLISM; SPINAL-CORDS; ANIMAL-MODEL; MICE; DEGENERATION; EXPRESSION	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting primarily motor neurons. Growing evidence suggests a mitochondrial defect in ALS. The precise molecular mechanisms underlying those defects are unknown. We studied the expression of mitochondrial uncoupling proteins (UCPs), key regulators of mitochondrial functions, in tissues from a mouse model of ALS (SOD1 G86R transgenic mice) and from muscular biopsies of human sporadic ALS. Surprisingly, in SOD1 G86R mice, UCPs, and particularly UCP3, were upregulated in skeletal muscle but not in spinal cord. Consistent with this pattern of expression, ATP levels were selectively depleted in muscle but not in neural tissues 1 month before disease onset and the respiratory control ratio of isolated mitochondria is decreased. UCP3 up-regulation was not observed in experimentally denervated muscles, suggesting that changes in muscular UCP3 expression are associated with the physiopathological processes of ALS. This is further supported by our observation of increased UCP3 levels in human ALS muscular biopsies. We propose that UCP3 up-regulation in skeletal muscle contributes to the characteristic mitochondrial damage of ALS and to the onset of the disease. Moreover, since skeletal muscle is a key metabolic tissue, our findings suggest that ALS may not solely arise from neuronal events but also from more generalized metabolic defects.	Univ Strasbourg, Fac Med, EA 3433, Lab Signalisat Mol & Neurodegenerescence, F-67085 Strasbourg, France; CNRS, CEPE, F-67087 Strasbourg, France; Hop La Pitie Salpetriere, Serv Neurol, F-75651 Paris 13, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Loeffler, JP (corresponding author), Univ Strasbourg, Fac Med, EA 3433, Lab Signalisat Mol & Neurodegenerescence, 11 Rue Humann, F-67085 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020; Dupuis, Luc/A-6981-2012					Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Bogdanov M, 2000, FREE RADICAL BIO MED, V29, P652, DOI 10.1016/S0891-5849(00)00349-X; Bonnefont-Rousselot D, 2000, J NEUROL SCI, V178, P57, DOI 10.1016/S0022-510X(00)00365-8; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; BROOKS BR, 1994, J NEUROL SCI, V124, P96, DOI 10.1016/0022-510X(94)90191-0; Brown RH, 1995, CURR OPIN NEUROBIOL, V5, P841, DOI 10.1016/0959-4388(95)80114-6; Brunetti O, 1997, MUSCLE NERVE, V20, P1404, DOI 10.1002/(SICI)1097-4598(199711)20:11<1404::AID-MUS8>3.0.CO;2-E; Cadenas S, 1999, FEBS LETT, V462, P257, DOI 10.1016/S0014-5793(99)01540-9; Carri MT, 1997, FEBS LETT, V414, P365, DOI 10.1016/S0014-5793(97)01051-X; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Couplan E, 2002, J BIOL CHEM, V277, P43079, DOI 10.1074/jbc.M206726200; Desport JC, 2001, AM J CLIN NUTR, V74, P328; Du G, 1998, FREE RADICAL BIO MED, V25, P1066, DOI 10.1016/S0891-5849(98)00148-8; DUCLERT A, 1990, P NATL ACAD SCI USA, V87, P1391, DOI 10.1073/pnas.87.4.1391; Dupuis L, 2002, ANN NY ACAD SCI, V973, P116, DOI 10.1111/j.1749-6632.2002.tb04618.x; Dupuis L, 2002, NEUROBIOL DIS, V10, P358, DOI 10.1006/nbdi.2002.0522; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Echtay KS, 2002, J BIOL CHEM, V277, P47129, DOI 10.1074/jbc.M208262200; EISEN A, 1995, MUSCLE NERVE, V18, P741, DOI 10.1002/mus.880180711; Ferrante RJ, 1997, ANN NEUROL, V42, P326, DOI 10.1002/ana.410420309; Fitzmaurice PS, 1996, MUSCLE NERVE, V19, P797; FRIDOVICH I, 1986, ADV ENZYMOL RAMB, V58, P61; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hand CK, 2002, MUSCLE NERVE, V25, P135; Higgins CMJ, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-06-j0001.2002; Huey KA, 1998, EUR J BIOCHEM, V256, P45, DOI 10.1046/j.1432-1327.1998.2560045.x; HUNTER DR, 1976, J BIOL CHEM, V251, P5069; Jaarsma D, 2001, ACTA NEUROPATHOL, V102, P293; Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568; Kong JM, 1998, J NEUROSCI, V18, P3241; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Li LX, 2001, BIOCHEM BIOPH RES CO, V282, P273, DOI 10.1006/bbrc.2001.4577; Mattiazzi M, 2002, J BIOL CHEM, V277, P29626, DOI 10.1074/jbc.M203065200; Mills EM, 2002, J BIOL CHEM, V277, P27385, DOI 10.1074/jbc.M111860200; MULDER DW, 1986, NEUROLOGY, V36, P511, DOI 10.1212/WNL.36.4.511; Pedersen WA, 1998, ANN NEUROL, V44, P819, DOI 10.1002/ana.410440518; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Swerdlow RH, 1998, EXP NEUROL, V153, P135, DOI 10.1006/exnr.1998.6866; Takeuchi H, 2002, J BIOL CHEM, V277, P50966, DOI 10.1074/jbc.M209356200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339; Wieckowski MR, 1998, FEBS LETT, V423, P339, DOI 10.1016/S0014-5793(98)00118-5; Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x; Windisch A, 1998, J PHYSIOL-LONDON, V510, P623, DOI 10.1111/j.1469-7793.1998.623bk.x; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Yang SQ, 2000, ARCH BIOCHEM BIOPHYS, V378, P259, DOI 10.1006/abbi.2000.1829; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	52	99	105	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2091	+		10.1096/fj.02-1182fje	http://dx.doi.org/10.1096/fj.02-1182fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500553				2022-12-28	WOS:000185925100011
J	Jacquel, A; Herrant, M; Legros, L; Belhacene, N; Luciano, F; Pages, G; Hofman, P; Auberger, P				Jacquel, A; Herrant, M; Legros, L; Belhacene, N; Luciano, F; Pages, G; Hofman, P; Auberger, P			Imatinib induces mitochondria-dependent apoptosis of the Bcr-Abl positive K562 cell line and its differentiation towards the erythroid lineage	FASEB JOURNAL			English	Article						apoptosis; signal transduction; erythroid differentiation; c-DNA array	CHRONIC MYELOGENOUS LEUKEMIA; ENDOTHELIAL GROWTH-FACTOR; CHRONIC MYELOID-LEUKEMIA; FAS-MEDIATED APOPTOSIS; MEGAKARYOCYTIC DIFFERENTIATION; TYROSINE KINASE; HEMATOPOIETIC-CELLS; SIGNALING PATHWAY; IN-VIVO; TRANSCRIPTION FACTORS	Imatinib has emerged as the lead compound for clinical development against chronic myeloid leukemia. Imatinib inhibits the kinase activity of Bcr-Abl, which functions by enhancing the proliferation of hematopoietic precursors and protecting them against apoptosis. Imatinib induces apoptosis of Bcr-Abl positive cells, but how the drug effectively kills these cells remains partially understood. We show here that in K562 cells imatinib i) abolished Bcr-Abl phosphorylation and activity and as a consequence Erk1/2, JNK, and AKT activation; ii) induced mitochondrial transmembrane permeability dissipation; iii) activated caspases 3, 9, and 8, demonstrating that the effect of imatinib is integrated at the mitochondrial level; and iv) triggered caspase-dependent cleavage of Bcr-Abl. Interestingly, imatinib-mediated apoptosis was accompanied by erythroid differentiation of K562 cells. Moreover, phorbol esters inhibited imatinib-induced cell death and promoted differentiation toward the megakaryocytic lineage. Finally, we determined by c-DNA array analysis that more than 20 genes were modulated by imatinib. These genes are involved in both cell death and differentiation programs, and some of them have never been reported before to be expressed or involved in erythroid differentiation. Our results demonstrate that imatinib is responsible for a major modification of the genetic program resulting in death and/or differentiation of K562 cells.	Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Canc, F-06107 Nice 2, France; Fac Med, EPI 0215, IFR50, F-06107 Nice 2, France; Ctr Antoine Lacassagne, UMR 6543, F-06107 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; UDICE-French Research Universities; Universite Cote d'Azur; UNICANCER; Centre Antoine Lacassagne	Auberger, P (corresponding author), Fac Med, INSERM, U526, Equipe Labellisee Ligue Natl Canc, Ave Valombrose, F-06107 Nice 2, France.	auberger@unice.fr	Hofman, Paul/P-7654-2018; Jacquel, Arnaud/O-1928-2017; Pages, Gilles/N-7135-2017; AUBERGER, Patrick/G-1491-2013; luciano, frederic/P-6264-2016	Hofman, Paul/0000-0003-0431-9353; Jacquel, Arnaud/0000-0001-5062-8048; AUBERGER, Patrick/0000-0002-2481-8275; luciano, frederic/0000-0001-9253-4998				Advani AS, 2002, LEUKEMIA RES, V26, P713, DOI 10.1016/S0145-2126(01)00197-7; Amarante-Mendes GP, 1998, BLOOD, V91, P1700, DOI 10.1182/blood.V91.5.1700.1700_1700_1705; Aro ALA, 2002, LEUKEMIA RES, V26, P831, DOI 10.1016/S0145-2126(02)00006-1; Athanasiou M, 2000, LEUKEMIA, V14, P439, DOI 10.1038/sj.leu.2401689; Bartel FO, 2000, ONCOGENE, V19, P6443, DOI 10.1038/sj.onc.1204038; Belhacene N, 1998, FASEB J, V12, P531; Bellamy WT, 1999, CANCER RES, V59, P728; Bellamy WT, 2001, SEMIN ONCOL, V28, P551, DOI 10.1053/sonc.2001.28606; Buchdunger E, 1996, CANCER RES, V56, P100; BURGER SR, 1992, EXP CELL RES, V202, P28, DOI 10.1016/0014-4827(92)90400-3; Burgess GS, 1998, BLOOD, V92, P2450, DOI 10.1182/blood.V92.7.2450.2450_2450_2460; Cortez D, 1996, ONCOGENE, V13, P2589; D'Arcangelo G, 1999, NEURON, V24, P471, DOI 10.1016/S0896-6273(00)80860-0; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; Deininger MWN, 1997, BLOOD, V90, P3691, DOI 10.1182/blood.V90.9.3691; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Donato NJ, 2001, BLOOD, V97, P2846, DOI 10.1182/blood.V97.9.2846; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Ebos JML, 2002, MOL CANCER RES, V1, P89; Fang GF, 2000, BLOOD, V96, P2246, DOI 10.1182/blood.V96.6.2246.h8002246_2246_2253; Gillet R, 2002, BIOL CELL, V94, P267, DOI 10.1016/S0248-4900(02)01201-7; Gomez-Angelats M, 2001, J BIOL CHEM, V276, P44944, DOI 10.1074/jbc.M104919200; Herrant M, 2002, ONCOGENE, V21, P4957, DOI 10.1038/sj.onc.1205689; Hong Y, 1996, BLOOD, V87, P123, DOI 10.1182/blood.V87.1.123.bloodjournal871123; Ikonomi P, 2000, EXP HEMATOL, V28, P1423, DOI 10.1016/S0301-472X(00)00553-1; Jain SK, 1996, BLOOD, V88, P1542; Kawabata H, 2001, BLOOD, V98, P2714, DOI 10.1182/blood.V98.9.2714; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Lam LT, 2000, J BIOL CHEM, V275, P19676, DOI 10.1074/jbc.M002866200; le Coutre P, 1999, J NATL CANCER I, V91, P163, DOI 10.1093/jnci/91.2.163; Le'Negrate G, 2000, J CELL BIOL, V150, P1479, DOI 10.1083/jcb.150.6.1479; Lecoq-Lafon C, 1999, BLOOD, V93, P2578, DOI 10.1182/blood.V93.8.2578.408k24_2578_2585; Luciano F, 2001, ONCOGENE, V20, P4935, DOI 10.1038/sj.onc.1204661; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Maulon L, 1998, BLOOD, V91, P4232, DOI 10.1182/blood.V91.11.4232.411k32_4232_4241; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; NOWELL PC, 1960, SCIENCE, V132, P1497; O'Dwyer ME, 2002, ANNU REV MED, V53, P369, DOI 10.1146/annurev.med.53.082901.103853; Osawa M, 2002, BLOOD, V100, P2769, DOI 10.1182/blood-2002-01-0182; Pane F, 2002, ONCOGENE, V21, P8652, DOI 10.1038/sj.onc.1206094; Park JI, 2001, CELL GROWTH DIFFER, V12, P481; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RAKIC P, 1995, NEURON, V14, P1101, DOI 10.1016/0896-6273(95)90258-9; Ricci JE, 1999, ONCOGENE, V18, P3963, DOI 10.1038/sj.onc.1202782; Ricci JE, 2001, FASEB J, V15, P1777, DOI 10.1096/fj.00-0665fje; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Saleque S, 2002, GENE DEV, V16, P301, DOI 10.1101/gad.959102; SAWYERS CL, 1993, LEUKEMIA LYMPHOMA, V11, P101, DOI 10.3109/10428199309064268; Shet AS, 2002, LEUKEMIA, V16, P1402, DOI 10.1038/sj.leu.2402577; Shivdasani RA, 2001, STEM CELLS, V19, P397, DOI 10.1634/stemcells.19-5-397; Sordet O, 1999, CELL DEATH DIFFER, V6, P351, DOI 10.1038/sj.cdd.4400499; Talpaz M, 2002, BLOOD, V99, P1928, DOI 10.1182/blood.V99.6.1928; Whalen AM, 1997, MOL CELL BIOL, V17, P1947, DOI 10.1128/MCB.17.4.1947; Yu CR, 2002, CANCER RES, V62, P188; Yuksel S, 2002, LEUKEMIA RES, V26, P391, DOI 10.1016/S0145-2126(01)00147-3; ZAMZAMI N, 1995, J EXP MED, V181, P1661, DOI 10.1084/jem.181.5.1661; Zhu J, 2002, ONCOGENE, V21, P3295, DOI 10.1038/sj.onc.1205318; ZUTTER MM, 1992, J BIOL CHEM, V267, P20233	61	102	107	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2160	+		10.1096/fj.03-0322fje	http://dx.doi.org/10.1096/fj.03-0322fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14597677				2022-12-28	WOS:000185925100024
J	Jungling, K; Nagler, K; Pfrieger, FW; Gottmann, K				Jungling, K; Nagler, K; Pfrieger, FW; Gottmann, K			Purification of embryonic stem cell-derived neurons by immunoisolation	FASEB JOURNAL			English	Article						L1 antibodies; action potentials; glutamatergic synapses; GABAergic synapses; cell replacement	RETINAL GANGLION-CELLS; IN-VITRO; NEURAL PRECURSORS; LINEAGE SELECTION; MOUSE EMBRYOS; CULTURE; DIFFERENTIATION; TRANSPLANTATION; SURVIVAL	The pluripotency and high proliferative capacity of embryonic stem (ES) cells (1-3) makes them an attractive source of different cell types for biomedical research and cell replacement therapies. A major prerequisite for these applications is the availability of a homogeneous population of the desired cell type. However, ES cell-derived material contains, for example, undifferentiated cells, which can cause tumor formation after transplantation into the brain (4). To avoid such unwanted side effects, effective purification of distinct types of cells needs to be developed. Here, we describe an immunoisolation procedure to purify neurons from in vitro differentiated mouse ES cells using an antibody against the neuronal cell adhesion molecule L1 (5, 6). Our procedure yields a pure population of differentiated neurons, which are electrically excitable and form excitatory, glutamatergic, and inhibitory GABAergic synapses. The ability to highly purify ES cell-derived neurons will boost their molecular characterization and the further exploration of their therapeutic potential.	Ruhr Univ Bochum, Dept Cell Physiol, D-44780 Bochum, Germany; Ctr Neurochim, Max Planck CNRS Grp, CNRS, UPR 2356, F-67084 Strasbourg, France	Ruhr University Bochum; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Gottmann, K (corresponding author), Ruhr Univ Bochum, Dept Cell Physiol, Univ Str 150, D-44780 Bochum, Germany.	kurt.gottmann@ruhr-uni-bochum.de	Pfrieger, Frank/AAX-3208-2020	Pfrieger, Frank/0000-0001-7085-1431				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; BARRES BA, 1988, NEURON, V1, P791, DOI 10.1016/0896-6273(88)90127-4; BEKKERS JM, 1991, P NATL ACAD SCI USA, V88, P7834, DOI 10.1073/pnas.88.17.7834; Bjorklund LM, 2002, P NATL ACAD SCI USA, V99, P2344, DOI 10.1073/pnas.022438099; BLOCHGALLEGO E, 1991, DEVELOPMENT, V111, P221; Brummendorf T, 1998, CURR OPIN NEUROBIOL, V8, P87, DOI 10.1016/S0959-4388(98)80012-3; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Gomperts SN, 1998, NEURON, V21, P1443, DOI 10.1016/S0896-6273(00)80662-5; HOGAN B, 1994, MANIPULATING MOUSE E, P254; Li M, 1998, CURR BIOL, V8, P971, DOI 10.1016/S0960-9822(98)70399-9; Malatesta P, 2000, DEVELOPMENT, V127, P5253; MARTIN GR, 1981, P NATL ACAD SCI-BIOL, V78, P7634, DOI 10.1073/pnas.78.12.7634; MEYERFRANKE A, 1995, NEURON, V15, P805, DOI 10.1016/0896-6273(95)90172-8; Mohrmann R, 1999, J NEUROSCI, V19, P10004; Nagler K, 2001, J PHYSIOL-LONDON, V533, P665, DOI 10.1111/j.1469-7793.2001.00665.x; RATHJEN FG, 1984, EMBO J, V3, P1; Smith AG, 2001, ANNU REV CELL DEV BI, V17, P435, DOI 10.1146/annurev.cellbio.17.1.435; STRUBING C, 1995, MECH DEVELOP, V53, P275, DOI 10.1016/0925-4773(95)00446-8; Wernig M, 2002, J NEUROSCI RES, V69, P918, DOI 10.1002/jnr.10395; ZHANG SC, NAT BIOTECHNOL, V19, P1129	21	33	35	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2100	+		10.1096/fj.03-0118fje	http://dx.doi.org/10.1096/fj.03-0118fje			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500547	Green Submitted			2022-12-28	WOS:000185925100005
J	Ramsay, PL; Luo, ZQ; Major, A; Park, MS; Finegold, M; Welty, SE; Kwak, I; Darlington, G; DeMayo, FJ				Ramsay, PL; Luo, ZQ; Major, A; Park, MS; Finegold, M; Welty, SE; Kwak, I; Darlington, G; DeMayo, FJ			Multiple mechanisms for oxygen-induced regulation of the Clara cell secretory protein gene	FASEB JOURNAL			English	Article						CCSP; Nkx2.1; AP-1; C/EBP; hyperoxia exposure	HEPATOCYTE NUCLEAR FACTOR-3; TRANSCRIPTION FACTOR-I; CIS-ACTING ELEMENTS; B GENE; BRONCHIOLAR EPITHELIUM; FAMILY-MEMBERS; 10-KD PROTEIN; C/EBP-ALPHA; MOUSE LUNG; CC10 GENE	The Clara cell secretory protein (CCSP) imparts a protective effect to the lung during oxidant injury. However, exposure to supplemental oxygen, a common therapeutic modality for lung disease, represses the expression of CCSP in the adult mouse lung. We investigated the mechanisms of hyperoxia-induced repression of the mouse CCSP promoter. Deletion experiments in vivo and in vitro indicated that the hyperoxia-responsive elements are localized to the proximal -166 by of the CCSP promoter. Electrophoretic mobility shift and supershift analyses demonstrated increased binding of c-Jun at the activator protein-1 site, increased binding of CCAAT/enhancer binding protein (C/EBP) (3 at the C/EBP sites, and decreased binding at the Nkx2.1 sites. Western analyses revealed that hyperoxia exposure induced an increase in the expression of the C/EBP(3 isoform liver-inhibiting protein (LIP) and an increase in cytoplasmic Nkx2.1. Cotransfection of LIP or c-Jun expression plasmids decreased the transcriptional activity of the proximal -166-by CCSP promoter. These observations suggest that hyperoxia-induced repression of the CCSP gene is mediated, at least in part, at the level of transcription and that multiple mechanisms mediate this repression. Moreover, these novel observations may provide insights for generation of therapeutic interventions for the amelioration of oxidant-induced lung injury.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Ajou Univ, Dept Pediat, Suwon 441749, South Korea; Childrens Res Inst, Columbus, OH 43205 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine; Ajou University; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital	DeMayo, FJ (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	fdemayo@bcm.tmc.edu	Welty, Stephen/AAZ-4307-2021; Welty, Stephen/AGS-7454-2022; DeMayo, Francesco/C-6255-2019	Welty, Stephen/0000-0002-6321-8440; DeMayo, Francesco/0000-0002-9480-7336				BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671, DOI 10.1128/MCB.14.9.5671; Cassel TN, 2002, J BIOL CHEM, V277, P36970, DOI 10.1074/jbc.M201293200; Cassel TN, 2000, AM J RESP CELL MOL, V22, P469, DOI 10.1165/ajrcmb.22.4.3916; Daly HE, 1997, TOXICOL APPL PHARM, V142, P303, DOI 10.1006/taap.1996.8056; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; EVANS MJ, 1978, LAB INVEST, V38, P648; FACCHIANO A, 1991, LIFE SCI, V48, P453, DOI 10.1016/0024-3205(91)90501-2; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; Ikeda K, 1996, MOL CELL BIOL, V16, P3626; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147, DOI 10.1165/ajrcmb.17.2.2676; Kadoya Hirokazu, 2001, Osaka City Medical Journal, V47, P23; Kumar AS, 1997, J BIOL CHEM, V272, P20764, DOI 10.1074/jbc.272.33.20764; LAZZARO D, 1991, DEVELOPMENT, V113, P1093; Lee PJ, 2000, AM J PHYSIOL-LUNG C, V279, pL175, DOI 10.1152/ajplung.2000.279.1.L175; LUM H, 1978, AM REV RESPIR DIS, V118, P335; Magdaleno SM, 1997, AM J PHYSIOL-LUNG C, V272, pL1142, DOI 10.1152/ajplung.1997.272.6.L1142; Mango GW, 1998, AM J PHYSIOL-LUNG C, V275, pL348, DOI 10.1152/ajplung.1998.275.2.L348; Nord M, 2000, ANN NY ACAD SCI, V923, P154; Ramsay PL, 2003, AM J PHYSIOL-LUNG C, V284, pL108, DOI 10.1152/ajplung.00186.2002; Ray MK, 1996, J HISTOCHEM CYTOCHEM, V44, P919, DOI 10.1177/44.8.8756763; RAY MK, 1995, J BIOL CHEM, V270, P2689, DOI 10.1074/jbc.270.6.2689; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Reynolds SD, 2000, AM J PHYSIOL-LUNG C, V278, pL1256, DOI 10.1152/ajplung.2000.278.6.L1256; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAWAYA PL, 1993, MOL CELL BIOL, V13, P3860, DOI 10.1128/MCB.13.7.3860; Sever-Chroneos Z, 1999, AM J PHYSIOL-LUNG C, V277, pL79, DOI 10.1152/ajplung.1999.277.1.L79; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73, DOI 10.1177/36.1.3275712; STRIPP BR, 1994, GENOMICS, V20, P27, DOI 10.1006/geno.1994.1123; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; TIMBLIN CR, 1995, CANCER RES, V55, P2723; VENKATESH VC, 1995, AM J PHYSIOL-LUNG C, V268, pL674, DOI 10.1152/ajplung.1995.268.4.L674; Welm AL, 1999, MOL CELL BIOL, V19, P1695; Zhao BH, 2000, ANN NY ACAD SCI, V923, P346	33	9	12	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2142	+		10.1096/fj.03-0048fje	http://dx.doi.org/10.1096/fj.03-0048fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500549				2022-12-28	WOS:000185925100009
J	Marko, NF; Dieffenbach, PB; Yan, G; Ceryak, S; Howell, RW; Mccaffrey, TA; Hu, VW				Marko, NF; Dieffenbach, PB; Yan, G; Ceryak, S; Howell, RW; Mccaffrey, TA; Hu, VW			Does metabolic radiolabeling stimulate the stress response? Gene expression profiling reveals differential cellular responses to internal beta vs. external gamma radiation	FASEB JOURNAL			English	Article						DNA microarray; DNA damage; ionizing radiation; radioisotopes; sulfur-35 methionine	DNA-DAMAGE; IONIZING-RADIATION; SIGNAL-TRANSDUCTION; GROWTH ARREST; CELLS; REPAIR; FRAGMENTATION; IRRADIATION; INDUCTION; DOSIMETRY	DNA microarray analyses were used to investigate the effect of cell-incorporated S-35-methionine on human colorectal carcinoma cells. This beta-radiation-induced gene expression profile was compared with that induced by external gamma-radiation. The extent of DNA fragmentation was used as a biomarker to determine the external gamma dose that was bioequivalent to that received by cells incubated in medium containing S-35-methionine. Studies showed that S-35-methionine at 100 muCi/mL induced a much more robust transcriptional response than gamma-radiation (2000 cGy) when evaluated 2 h after the labeling or irradiation period. The cellular response to internal beta-radiation was greater not only with respect to the number of genes induced, but also with respect to the level of gene induction. Not surprisingly, the induced genes overlapped with the set of gamma-responsive genes. However, a distinct beta-gene induction profile that included a large number of cell adhesion proteins was also observed. Taken together, these studies demonstrate that metabolic incorporation of a low energy beta-emitter, such as S-35-methionine, can globally influence a diverse set of cellular activities that can, in turn, affect the outcome of many experiments by altering the cell cycle, metabolic, signaling, or redox status (set point) of the cell. Additional studies of the mechanism of beta-induced proliferation arrest and cell death and of the significance of its differential gene induction/repression profile in comparison to pulsed gamma-irradiation may lead to new insights into the ways in which ionizing radiation can interact with cells.	George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, Washington, DC 20037 USA; George Washington Univ, Med Ctr, Dept Pharmacol, Washington, DC 20037 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Radiol, Newark, NJ 07103 USA	George Washington University; George Washington University; Rutgers State University New Brunswick; Rutgers State University Medical Center	Hu, VW (corresponding author), George Washington Univ, Med Ctr, Dept Biochem & Mol Biol, 2300 Eye St NW, Washington, DC 20037 USA.	bcmvwh@gwumc.edu	Howell, Roger W/AAO-2086-2020; Howell, Roger/GXZ-5412-2022	Howell, Roger W/0000-0002-7057-8110; Hu, Valerie/0000-0002-3357-0777	NATIONAL CANCER INSTITUTE [R01CA083838] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG012712, R01AG012712] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA083838, R01 CA083838-02, R01 CA83838] Funding Source: Medline; NIA NIH HHS [AG12712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADELSTEIN SJ, 2002, J ICRU, V2, P11; Alahari SK, 2002, INT REV CYTOL, V220, P145; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 1999, ONCOGENE, V18, P3666, DOI 10.1038/sj.onc.1202676; Azzam EI, 1997, CELL GROWTH DIFFER, V8, P1161; Bond JA, 1999, ONCOGENE, V18, P3788, DOI 10.1038/sj.onc.1202733; BOND VP, 1966, HEALTH PHYS, V12, P1007, DOI 10.1097/00004032-196608000-00002; Chen XB, 1996, GENE DEV, V10, P2438, DOI 10.1101/gad.10.19.2438; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DOVER R, 1994, J CELL SCI, V107, P1181; Durante M, 1999, RADIAT RES, V151, P670, DOI 10.2307/3580205; Fareh J, 1999, CIRCULATION, V99, P1477, DOI 10.1161/01.CIR.99.11.1477; Gichner T, 2000, MUTAT RES-GEN TOX EN, V470, P1, DOI 10.1016/S1383-5718(00)00081-4; Goddu SM, 1998, J NUCL MED, V39, P547; GODDU SM, 1994, J NUCL MED, V35, P521; Goddu SM, 1997, MIRD CELLULAR S VALU; Haimovitz-Friedman A, 1998, RADIAT RES, V150, pS102, DOI 10.2307/3579812; HALPERN A, 1977, RADIAT ENVIRON BIOPH, V14, P257, DOI 10.1007/BF01325241; Howell RW, 1998, RADIAT RES, V150, P391, DOI 10.2307/3579657; Howell RW, 1997, J NUCL MED, V38, P727; Hu VW, 2002, FASEB J, V16, P1456, DOI 10.1096/fj.02-0142fje; Hu VW, 2001, FASEB J, V15, P1562, DOI 10.1096/fj.01-0102com; Hu VW, 2000, FASEB J, V14, P448, DOI 10.1096/fasebj.14.3.448; KASSIS AI, 1980, RADIAT RES, V84, P407, DOI 10.2307/3575480; Linke SP, 1997, CANCER RES, V57, P1171; Loevinger R, 1991, MIRD PRIMER ABSORBED; Mustonen R, 1999, MUTAT RES-FUND MOL M, V429, P169, DOI 10.1016/S0027-5107(99)00123-2; *NAT COUNC RAD PRO, 1979, 63 NCRP NAT COUNC RA; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; OSTLING O, 1984, BIOCHEM BIOPH RES CO, V123, P291, DOI 10.1016/0006-291X(84)90411-X; POLLARD JW, 1996, PROTEIN PROTOCOLS HD; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Schneiderman MH, 2001, RADIAT RES, V155, P529, DOI 10.1667/0033-7587(2001)155[0529:TFRICD]2.0.CO;2; SOLARY E, 1992, EXP CELL RES, V203, P495, DOI 10.1016/0014-4827(92)90027-6; STRAUME T, 1993, HEALTH PHYS, V65, P657, DOI 10.1097/00004032-199312000-00005; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Weber D. A., 1989, MIRD RADIONUCLIDE DA; Wenz F, 1998, RADIAT RES, V149, P32, DOI 10.2307/3579679; WHALEY JM, 1990, RADIAT RES, V123, P68, DOI 10.2307/3577659; Yanokura M, 2000, INT J RADIAT BIOL, V76, P295, DOI 10.1080/095530000138637; YEARGIN J, 1995, CURR BIOL, V5, P423, DOI 10.1016/S0960-9822(95)00083-2; YonishRouach E, 1996, EXPERIENTIA, V52, P1001, DOI 10.1007/BF01920109	43	26	27	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1470	1486		10.1096/fj.02-1194com	http://dx.doi.org/10.1096/fj.02-1194com			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890701				2022-12-28	WOS:000185345100040
J	Zehntner, SP; Brisebois, M; Tran, E; Owens, T; Fournier, S				Zehntner, SP; Brisebois, M; Tran, E; Owens, T; Fournier, S			Constitutive expression of a costimulatory ligand on antigen-presenting cells in the nervous system drives demyelinating disease	FASEB JOURNAL			English	Article						autoimmunity; CD28-B7; microglia; CD8+T cells	CD8(+) T-CELLS; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; B7 COSTIMULATION; MICE; BLOCKADE; TH1; MOLECULES; CTLA4IG; BRAIN; BLOOD	It has been proposed that the activation status of antigen-presenting cells (APCs) plays a significant role in the development of autoimmune disease. Whether expression of costimulatory ligands on tissue-resident APCs controls organ-specific autoimmune responses has not been tested. We here report that transgenic mice constitutively expressing the costimulatory ligand B7.2/CD86 on microglia in the central nervous system (CNS) and on related cells in the proximal peripheral nervous tissue spontaneously develop autoimmune demyelinating disease. Disease-affected nervous tissue in transgenic mice showed infiltration characterized by a predominance of CD8+ memory-effector T cells, as well as CD4+ T cells. Transgenic animals lacking alphabeta TCR+ T cells were completely resistant to disease development. Transgenic T cells induced disease when adoptively transferred into T cell-deficient B7.2 transgenic recipients but not into non-transgenic recipients. These data provide evidence that B7/CD28 interactions within the nervous tissue are critical determinants of disease development. Our findings have important implications for understanding the etiology of nervous system autoimmune diseases such as multiple sclerosis (MS) and Guillain-Barre syndrome (GBS).	McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3A 2B4, Canada; McGill Univ, Montreal Neurol Inst, Neuroimmunol Unit, Montreal, PQ H3A 2B4, Canada	McGill University; McGill University	Fournier, S (corresponding author), McGill Univ, Dept Microbiol & Immunol, 3775 Univ St, Montreal, PQ H3A 2B4, Canada.	sylvie.fournier@mcgill.ca		Owens, Trevor/0000-0001-9315-6036				Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Arima T, 1996, J IMMUNOL, V156, P4916; Babbe H, 2000, J EXP MED, V192, P393, DOI 10.1084/jem.192.3.393; Brabb T, 1997, J IMMUNOL, V159, P497; Brabb T, 2000, J EXP MED, V192, P871, DOI 10.1084/jem.192.6.871; Chambers CA, 2001, TRENDS IMMUNOL, V22, P217, DOI 10.1016/S1471-4906(01)01868-3; Chang TT, 1999, J EXP MED, V190, P733, DOI 10.1084/jem.190.5.733; Christensen JE, 2001, INT IMMUNOL, V13, P593, DOI 10.1093/intimm/13.4.593; Croxford JL, 1998, EUR J IMMUNOL, V28, P3904, DOI 10.1002/(SICI)1521-4141(199812)28:12<3904::AID-IMMU3904>3.0.CO;2-5; FINCK BK, 1994, SCIENCE, V265, P1225, DOI 10.1126/science.7520604; Fournier S, 1997, IMMUNITY, V6, P327, DOI 10.1016/S1074-7613(00)80335-0; Hickey WF, 2001, GLIA, V36, P118, DOI 10.1002/glia.1101; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Issazadeh S, 1998, J IMMUNOL, V161, P1104; Katz-Levy Y, 1999, J CLIN INVEST, V104, P599, DOI 10.1172/JCI7292; KHOURY SJ, 1995, J IMMUNOL, V155, P4521; Kiefer R, 2000, J NEUROL NEUROSUR PS, V69, P362, DOI 10.1136/jnnp.69.3.362; Laflamme N, 2003, EUR J IMMUNOL, V33, P1127, DOI 10.1002/eji.200323821; Laflamme N, 2001, J NEUROCHEM, V79, P648, DOI 10.1046/j.1471-4159.2001.00603.x; LENSCHOW DJ, 1995, J EXP MED, V181, P1145, DOI 10.1084/jem.181.3.1145; Lyons JA, 1999, J NEUROIMMUNOL, V93, P26, DOI 10.1016/S0165-5728(98)00185-4; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; Oliveira-dos-Santos AJ, 1999, J IMMUNOL, V162, P4490; Perrin PJ, 1999, J IMMUNOL, V163, P1704; RENNO T, 1995, J IMMUNOL, V154, P944; Rivest S, 2000, P SOC EXP BIOL MED, V223, P22, DOI 10.1046/j.1525-1373.2000.22304.x; Sindern E, 1997, J NEUROL SCI, V151, P29, DOI 10.1016/S0022-510X(97)00082-8; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Tada Y, 1999, J IMMUNOL, V162, P203; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; VANDENBERG LH, 1995, J NEUROIMMUNOL, V58, P37, DOI 10.1016/0165-5728(94)00185-Q; WINDHAGEN A, 1995, J EXP MED, V182, P1985, DOI 10.1084/jem.182.6.1985; Yu X, 2000, J IMMUNOL, V164, P3543, DOI 10.4049/jimmunol.164.7.3543; Zhu Y, 2001, J NEUROIMMUNOL, V114, P114, DOI 10.1016/S0165-5728(01)00241-7	34	41	43	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1910	+		10.1096/fj.03-0199fje	http://dx.doi.org/10.1096/fj.03-0199fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923072				2022-12-28	WOS:000185345100009
J	Goldschmidt, O; Zcharia, E; Cohen, M; Aingorn, H; Cohen, I; Nadav, L; Katz, BZ; Geiger, B; Vlodavsky, I				Goldschmidt, O; Zcharia, E; Cohen, M; Aingorn, H; Cohen, I; Nadav, L; Katz, BZ; Geiger, B; Vlodavsky, I			Heparanase mediates cell adhesion independent of its enzymatic activity	FASEB JOURNAL			English	Article						extracellular matrix; heparan sulfate; invasion	EXTRACELLULAR-MATRIX; SULFATE PROTEOGLYCANS; MAMMALIAN HEPARANASE; TUMOR-METASTASIS; EXPRESSION; CLONING; ANGIOGENESIS; INVASION; BINDING; IDENTIFICATION	Heparanase is an endo-beta-D-glucuronidase that cleaves heparan sulfate and is implicated in diverse physiological and pathological processes. In this study we report on a novel direct involvement of heparanase in cell adhesion. We demonstrate that expression of heparanase in nonadherent lymphoma cells induces early stages of cell adhesion, provided that the enzyme is expressed on the cell surface. Heparanase-mediated cell adhesion to extracellular matrix (ECM) results in integrin-dependent cell spreading, tyrosine phosphorylation of paxillin, and reorganization of the actin cytoskeleton. The surface-bound enzyme also augments cell invasion through a reconstituted basement membrane. Cell adhesion was augmented by cell surface heparanase regardless of whether the cells were transfected with active or point mutated inactive enzyme, indicating that heparanase functions as an adhesion molecule independent of its endoglycosidase activity. The combined feature of heparanase as an ECM-degrading enzyme and a cell adhesion molecule emphasizes its significance in processes involving cell adhesion, migration, and invasion, including embryonic development, neovascularization, and cancer metastasis.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Weizmann Inst Sci, Dept Cellular & Mol Biol, IL-76100 Rehovot, Israel; Tel Aviv Sourasky Med Ctr, Inst Hematol, IL-64239 Tel Aviv, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hadassah University Medical Center; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il	Cohen, Miriam/E-8143-2011		NCI NIH HHS [R21 CA87085] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087085] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bitan M, 2002, EXP HEMATOL, V30, P34, DOI 10.1016/S0301-472X(01)00766-4; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; Cukierman E, 2001, SCIENCE, V294, P1708, DOI 10.1126/science.1064829; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; Dempsey LA, 2000, GLYCOBIOLOGY, V10, P467, DOI 10.1093/glycob/10.5.467; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; Dwir O, 2001, J CELL BIOL, V155, P145, DOI 10.1083/jcb.200103042; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; FOLKMAN J, 1988, AM J PATHOL, V130, P393; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; Gohji K, 2001, INT J CANCER, V95, P295, DOI 10.1002/1097-0215(20010920)95:5<295::AID-IJC1051>3.0.CO;2-A; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Hood JD, 2002, NAT REV CANCER, V2, P91, DOI 10.1038/nrc727; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; HUMPHRIES MJ, 1986, SCIENCE, V233, P467, DOI 10.1126/science.3726541; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; KOHN EC, 1995, CANCER RES, V55, P1856; Koliopanos A, 2001, CANCER RES, V61, P4655; Kussie PH, 1999, BIOCHEM BIOPH RES CO, V261, P183, DOI 10.1006/bbrc.1999.0962; Miao HQ, 1999, INT J CANCER, V83, P424, DOI 10.1002/(SICI)1097-0215(19991029)83:3<424::AID-IJC20>3.3.CO;2-C; Miranti CK, 2002, NAT CELL BIOL, V4, pE83, DOI 10.1038/ncb0402-e83; Nadav L, 2002, J CELL SCI, V115, P2179; NAKAJIMA M, 1988, J CELL BIOCHEM, V36, P157, DOI 10.1002/jcb.240360207; Parish CR, 1999, CANCER RES, V59, P3433; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Preissner KT, 2000, CURR OPIN CELL BIOL, V12, P621, DOI 10.1016/S0955-0674(00)00141-1; Rochefort H, 1996, ENZYME PROTEIN, V49, P106, DOI 10.1159/000468620; SIVARAM P, 1995, J BIOL CHEM, V270, P29760; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Turner CE, 2000, NAT CELL BIOL, V2, pE231, DOI 10.1038/35046659; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1994, INVAS METAST, V14, P290; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; West KA, 2001, J CELL BIOL, V154, P161, DOI 10.1083/jcb.200101039; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yamada KM, 1997, CURR OPIN CELL BIOL, V9, P76, DOI 10.1016/S0955-0674(97)80155-X; Zamir E, 2001, J CELL SCI, V114, P3583; Zimmerman E, 2002, BIOPHYS J, V82, P1848, DOI 10.1016/S0006-3495(02)75535-5	54	155	167	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1015	1025		10.1096/fj.02-0773com	http://dx.doi.org/10.1096/fj.02-0773com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773484				2022-12-28	WOS:000183818000005
J	Jurk, K; Clemetson, KJ; de Groot, PG; Brodde, MF; Steiner, M; Savion, N; Varon, D; Sixma, JJ; Van Aken, H; Kehrel, BE				Jurk, K; Clemetson, KJ; de Groot, PG; Brodde, MF; Steiner, M; Savion, N; Varon, D; Sixma, JJ; Van Aken, H; Kehrel, BE			Thrombospondin-1 mediates platelet adhesion at high shear via glycoprotein Ib (GPIb): an alternative/backup mechanism to von Willebrand factor	FASEB JOURNAL			English	Article						adhesion molecules; extracellular matrix; thrombosis; arteriosclerosis; inflammation	INTEGRIN-ASSOCIATED PROTEIN; MEMBRANE-GLYCOPROTEINS; EXTRACELLULAR-MATRIX; THROMBUS FORMATION; FLOW CONDITIONS; WHOLE-BLOOD; RECEPTOR; BINDS; FIBRONECTIN; SPECIFICITY	Acute thrombotic arterial occlusion is the leading cause of morbidity and mortality in the Western world. Von Willebrand factor is thought to be the only indispensable adhesive substrate to promote thrombus formation in high shear environments. We found that thrombospondin-1, a glycoprotein enriched in arteriosclerotic plaques, might function as an alternative substrate for thrombus formation. Platelets adhered to thrombospondin-1 in a shear dependent manner with an optimum shear as found in stenosed arteries. Adhesion is extremely firm, with no detachment of platelets up to a shear rate of 4000 s(-1). Experiments using platelets from a patient completely lacking von Willebrand factor showed that von Willebrand factor is not involved in platelet binding to thrombospondin-1. Platelet adhesion to thrombospondin-1 is not mediated via beta(3)-integrins or GPIa. CD36 partially mediates the adhesion of pre-activated platelets. We identified GPIb as high shear adhesion-receptor for thrombospondin-1. Soluble GPIb, as well as antibodies against the GPIb, blocked platelet adhesion almost completely. The new discovered thrombospondin-1-GPIb adhesion axis under arterial shear conditions might be important, not only during thrombus formation but also for pathological processes where other cells bind to the endothelium or subendothelium, including arteriosclerosis, inflammation and tumor metastasis, and a promising therapeutic target.	Univ Hosp Munster, Dept Anaesthesiol & Intens Care, D-48149 Munster, Germany; Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland; Univ Med Ctr Utrecht, Dept Haematol, Utrecht, Netherlands; Univ Rostock, Inst Clin Chem, D-2500 Rostock, Germany; Tel Aviv Univ, Sackler Fac Med, Goldschleger Eye Res Inst, IL-69978 Tel Aviv, Israel; Hadassah Hebrew Univ Med Ctr, Dept Hematol, Coagulat Unit, Jerusalem, Israel	University of Munster; University of Bern; Utrecht University; Utrecht University Medical Center; University of Rostock; Tel Aviv University; Sackler Faculty of Medicine; Hebrew University of Jerusalem	Kehrel, BE (corresponding author), Univ Hosp Munster, Dept Anaesthesiol & Intens Care, Mendelstr 11, D-48149 Munster, Germany.	kehrel@uni-muenster.de	Savion, Naphtali/K-1013-2019; Jurk, Kerstin/AAT-7768-2020	Savion, Naphtali/0000-0001-8899-0624				Adams JC, 1997, INT J BIOCHEM CELL B, V29, P861, DOI 10.1016/S1357-2725(96)00171-9; AGBANYO FR, 1993, J CLIN INVEST, V92, P288, DOI 10.1172/JCI116563; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; Beacham DA, 1999, J CELL BIOCHEM, V73, P508, DOI 10.1002/(SICI)1097-4644(19990615)73:4<508::AID-JCB9>3.0.CO;2-O; BEUMER S, 1994, BLOOD, V84, P3724, DOI 10.1182/blood.V84.11.3724.bloodjournal84113724; Bonnefoy A, 2001, THROMB HAEMOSTASIS, V85, P552, DOI 10.1055/s-0037-1615620; Bornstein P, 2001, J CLIN INVEST, V107, P929, DOI 10.1172/JCI12749; Brittain JE, 2001, BLOOD, V97, P2159, DOI 10.1182/blood.V97.7.2159; Clemetson KJ, 1997, THROMB HAEMOSTASIS, V78, P266; Dardik R, 1999, EXP CELL RES, V248, P407, DOI 10.1006/excr.1999.4415; DETWILER TC, 1987, SEMIN THROMB HEMOST, V13, P276, DOI 10.1055/s-2007-1003502; DiPietro LA, 1996, AM J PATHOL, V148, P1851; Gao AG, 1996, J BIOL CHEM, V271, P21, DOI 10.1074/jbc.271.1.21; Herrmann M, 1997, J INFECT DIS, V176, P984, DOI 10.1086/516502; JANDROTPERRUS M, 1992, BLOOD, V80, P2781; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Kasirer-Friede A, 2001, THROMB HAEMOSTASIS, V86, P653, DOI 10.1055/s-0037-1616101; Kehrel B, 1996, BLOOD COAGUL FIBRIN, V7, P202, DOI 10.1097/00001721-199603000-00023; KEHREL B, 1991, BIOCHEM BIOPH RES CO, V179, P985, DOI 10.1016/0006-291X(91)91915-Y; KEHREL B, 1993, BLOOD, V82, P3364; KLEIN H, 1996, LEUCOCYTE TYPING, V6, P643; Kronenberg A, 1998, THROMB HAEMOSTASIS, V79, P1021; LAHAV J, 1993, BIOCHIM BIOPHYS ACTA, V1182, P1, DOI 10.1016/0925-4439(93)90146-R; Lawler J, 2000, CURR OPIN CELL BIOL, V12, P634, DOI 10.1016/S0955-0674(00)00143-5; LAWLER J, 1989, BLOOD, V74, P2022; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Ni HY, 2000, J CLIN INVEST, V106, P385, DOI 10.1172/JCI9896; NIEUWENHUIS HK, 1986, BLOOD, V68, P692; NIEVELSTEIN PFEM, 1988, BLOOD, V72, P82; ROBERTS DD, 1985, J BIOL CHEM, V260, P9405; Roest M, 2000, BLOOD, V96, P1433, DOI 10.1182/blood.V96.4.1433.h8001433_1433_1437; Ruggeri ZM, 1999, BLOOD, V94, P172, DOI 10.1182/blood.V94.1.172.413k17_172_178; Ruggeri ZM, 1997, J CLIN INVEST, V100, pS41; SAKARIASSEN KS, 1983, J LAB CLIN MED, V102, P522; Shrimpton CN, 2002, J EXP MED, V196, P1057, DOI 10.1084/jem.20020143; SILVERSTEIN RL, 1992, J BIOL CHEM, V267, P16607; TUSZYNSKI GP, 1985, J BIOL CHEM, V260, P2240; VANZANTEN GH, 1994, J CLIN INVEST, V93, P615, DOI 10.1172/JCI117014; Varon D, 1997, THROMB RES, V85, P283, DOI 10.1016/S0049-3848(97)00014-5; WIGHT TN, 1985, J HISTOCHEM CYTOCHEM, V33, P295, DOI 10.1177/33.4.3884704; Wu YP, 1997, ARTERIOSCL THROM VAS, V17, P3202, DOI 10.1161/01.ATV.17.11.3202; Yamamoto K, 1998, BLOOD, V92, P2791, DOI 10.1182/blood.V92.8.2791.420k24_2791_2801; YURCHENCO PD, 1990, FASEB J, V4, P1577, DOI 10.1096/fasebj.4.6.2180767	43	109	118	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1490	+		10.1096/fj.02-0830fje	http://dx.doi.org/10.1096/fj.02-0830fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824298				2022-12-28	WOS:000183818000025
J	Li, YP; Lecker, SH; Chen, YL; Waddell, ID; Goldberg, AL; Reid, MB				Li, YP; Lecker, SH; Chen, YL; Waddell, ID; Goldberg, AL; Reid, MB			TNF-alpha increases ubiquitin-conjugating activity in skeletal muscle by up-regulating UbcH2/E2(20k)	FASEB JOURNAL			English	Article						cachexia; catabolism; atrophy; cytokines; nuclear factor kappa B	TUMOR-NECROSIS-FACTOR; END RULE PATHWAY; KAPPA-B ACTIVATION; GENE-EXPRESSION; PROTEASOME PATHWAY; HEART-FAILURE; BEARING RATS; PROTEIN LOSS; CACHEXIA; ENZYME	In some inflammatory diseases, TNF-alpha is thought to stimulate muscle catabolism via an NF-kappaB-dependent process that increases ubiquitin conjugation to muscle proteins. The transcriptional mechanism of this response has not been determined. Here we studied the potential role of UbcH2, a ubiquitin carrier protein and homologue of murine E2(20k). We find that UbcH2 is constitutively expressed by human skeletal and cardiac muscles, murine limb muscle, and cultured myotubes. TNF-alpha stimulates UbcH2 expression in mouse limb muscles in vivo and in cultured myotubes. The UbcH2 promoter region contains a functional NF-kappaB binding site; NF-kappaB binding to this sequence is increased by TNF-alpha stimulation. A dominant negative inhibitor of NF-kappaB activation blocks both UbcH2 up-regulation and the increase in ubiquitin-conjugating activity stimulated by TNF-alpha. In extracts from TNF-alpha-treated myotubes, ubiquitin-conjugating activity is limited by UbcH2 availability; activity is inhibited by an antiserum to UbcH2 or a dominant negative mutant of UbcH2 and is enhanced by wild-type UbcH2. Thus, UbcH2 upregulation is a novel response to TNF-alpha/NF-kappaB signaling in skeletal muscle that appears to be essential for the increased ubiquitin conjugation induced by this cytokine.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; AstraZeneca, Alderley Pk SK10 4TG, Cheshire, England; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	Baylor College of Medicine; Harvard University; Beth Israel Deaconess Medical Center; AstraZeneca; Harvard University; Harvard Medical School	Reid, MB (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	reid@bcm.tmc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59878] Funding Source: Medline; NIDDK NIH HHS [DK02707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Anker SD, 1999, CURR OPIN CARDIOL, V14, P211, DOI 10.1097/00001573-199905000-00004; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; FAGEN JM, 1987, BIOCHEM J, V243, P335; Farber MO, 2000, NEUROL CLIN, V18, P245, DOI 10.1016/S0733-8619(05)70188-2; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; GarciaMartinez C, 1995, BIOCHEM BIOPH RES CO, V217, P839, DOI 10.1006/bbrc.1995.2848; GARCIAMARTINEZ C, 1994, BIOCHEM BIOPH RES CO, V201, P682, DOI 10.1006/bbrc.1994.1754; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; Hasselgren PO, 2001, ANN SURG, V233, P9, DOI 10.1097/00000658-200101000-00003; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; KAISER P, 1994, J BIOL CHEM, V269, P8797; Kaiser P, 1995, FEBS LETT, V377, P193, DOI 10.1016/0014-5793(95)01323-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Li YP, 2000, AM J PHYSIOL-REG I, V279, pR1165, DOI 10.1152/ajpregu.2000.279.4.R1165; Li YP, 1998, FASEB J, V12, P871, DOI 10.1096/fasebj.12.10.871; Li YP, 2001, FASEB J, V15, P1413, DOI 10.1096/fj.00-0632fje; Lin YQ, 2002, J BIOL CHEM, V277, P21913, DOI 10.1074/jbc.M109398200; LIU YC, 1990, BIOTECHNIQUES, V9, P558; Llovera M, 1998, CANCER LETT, V133, P83, DOI 10.1016/S0304-3835(98)00216-X; Llovera M, 1996, BIOCHEM BIOPH RES CO, V221, P653, DOI 10.1006/bbrc.1996.0651; Llovera M, 1997, BIOCHEM BIOPH RES CO, V230, P238, DOI 10.1006/bbrc.1996.5827; Moldawer LL, 1998, SEMIN ONCOL, V25, P73; Moynihan TP, 1998, GENOMICS, V51, P124, DOI 10.1006/geno.1998.5257; NAKASHIMA J, 1995, CANCER RES, V55, P4881; Reid MB, 2001, RESP RES, V2, P269, DOI 10.1186/rr67; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SOCHER SH, 1988, J EXP MED, V167, P1957, DOI 10.1084/jem.167.6.1957; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Solomon V, 1998, J BIOL CHEM, V273, P25216, DOI 10.1074/jbc.273.39.25216; TESSITORE L, 1993, BRIT J CANCER, V67, P15, DOI 10.1038/bjc.1993.4; Tisdale MJ, 1999, J NUTR, V129, p243S, DOI 10.1093/jn/129.1.243S; Townsley FM, 1997, P NATL ACAD SCI USA, V94, P2362, DOI 10.1073/pnas.94.6.2362; Vary T C, 1998, Curr Opin Clin Nutr Metab Care, V1, P217, DOI 10.1097/00075197-199803000-00013; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; VREUGDENHIL G, 1992, EUR J CLIN INVEST, V22, P488, DOI 10.1111/j.1365-2362.1992.tb01495.x; WEFES I, 1995, GENE, V163, P321, DOI 10.1016/0378-1119(95)00374-F; WEFES I, 1995, P NATL ACAD SCI USA, V92, P4982, DOI 10.1073/pnas.92.11.4982; Zar JH, 1974, BIOSTATISTICAL ANAL	47	153	160	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1048	1057		10.1096/fj.02-0759com	http://dx.doi.org/10.1096/fj.02-0759com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773487				2022-12-28	WOS:000183818000008
J	Solito, E; Kamal, A; Russo-Marie, F; Buckingham, JC; Marullo, S; Perretti, M				Solito, E; Kamal, A; Russo-Marie, F; Buckingham, JC; Marullo, S; Perretti, M			A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils	FASEB JOURNAL			English	Article						inflammation; calcium channel; fMLP; chemotaxis; L-selectin	L-SELECTIN; MOLECULAR-STRUCTURE; HUMAN-LEUKOCYTES; MONOCYTIC CELLS; LIPOCORTIN 1; APOPTOSIS; ADHESION; DEXAMETHASONE; EXPRESSION; MEMBRANE	The glucocorticoid-inducible protein annexin (ANXA) 1 is an anti-inflammatory mediator that down-regulates the host response. Endogenously, ANXA1 is released in large amounts from adherent polymorphonuclear neutrophils (PMN) and binds to their cell surface to inhibit their extravasation into inflamed tissues. The present study determined the effects of exogenous ANXA1 on several functions of human PMN in vitro. Addition of 0.1-1 mu human recombinant ANXA1 to the PMN provoked rapid and transient changes in intracellular Ca2+ concentrations that were blocked by the Ca2+ channel inhibitor SKF-96365. Although ANXA1 did not affect oxidant production and only minimally affected PMN chemotactic properties, the ANXA1-promoted Ca2+ influx was associated with two important functional effects: shedding of L-selectin and acceleration of PMN apoptosis. The latter effect was confirmed using three distinct technical procedures, namely, cell cycle, Hoechst staining, and ANXA5 binding assay. ANXA1-induced PMN apoptosis was insensitive to inhibitors of L-selectin shedding, whereas it appeared to be associated with dephosphorylation of the proapoptotic intracellular mediator BAD. In conclusion, exogenous ANXA1 displayed selective actions on human PMN. We propose that the new proapoptotic effect reported here may be part of the spectrum of ANXA1-mediated events involved in the resolution of acute inflammation.	Univ London Imperial Coll Sci Technol & Med, Dept Neuroendocrinol, London W12 0NN, England; Queen Mary SMD, Barts London, William Harvey Res Inst, London EC1M 6BQ, England; Inst Cochin Genet Mol, Dept Cell Biol, F-75014 Paris, France	Imperial College London; University of London; Queen Mary University London; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Solito, E (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Neuroendocrinol, Hammersmith Campus,Commonwealth Bldg,Du Cane Rd, London W12 0NN, England.	e.solito@ic.ac.uk	Marullo, Stefano/C-6142-2008	Marullo, Stefano/0000-0001-9604-9973; Solito, Egle/0000-0001-5279-0049				Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; ANDERSSON T, 1986, MOL PHARMACOL, V30, P437; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P51; CHRISTMAS P, 1991, J BIOL CHEM, V266, P2499; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224, DOI 10.1002/jlb.61.2.224; Dalpiaz A, 1999, BBA-PROTEIN STRUCT M, V1432, P27, DOI 10.1016/S0167-4838(99)00081-3; Dalpiaz A, 2002, EUR J PHARMACOL, V436, P187, DOI 10.1016/S0014-2999(01)01627-2; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Donnelly SR, 1997, CELL MOL LIFE SCI, V53, P533, DOI 10.1007/s000180050068; DRANSFIELD I, 1995, BLOOD, V85, P3264, DOI 10.1182/blood.V85.11.3264.bloodjournal85113264; ELSTEIN KH, 1994, EXP CELL RES, V211, P322, DOI 10.1006/excr.1994.1094; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; FLOWER RJ, 1988, BRIT J PHARMACOL, V94, P987, DOI 10.1111/j.1476-5381.1988.tb11614.x; FRANCIS JW, 1992, J CLIN INVEST, V90, P537, DOI 10.1172/JCI115892; Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001; GOULDING NJ, 1990, LANCET, V335, P1416, DOI 10.1016/0140-6736(90)91445-G; GOULDING NJ, 1990, BIOCHEM SOC T, V18, P1237, DOI 10.1042/bst0181237; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUBER R, 1992, J MOL BIOL, V223, P683, DOI 10.1016/0022-2836(92)90984-R; HUBER R, 1990, EMBO J, V9, P3867, DOI 10.1002/j.1460-2075.1990.tb07605.x; JOHNSTON RB, 1975, J CLIN INVEST, V55, P1357, DOI 10.1172/JCI108055; KELLER HU, 1976, AGENTS ACTIONS, V6, P326, DOI 10.1007/BF01972250; Kern PM, 2000, INT J RADIAT BIOL, V76, P1265, DOI 10.1080/09553000050134492; Kettritz R, 1997, J AM SOC NEPHROL, V8, P1091; Kubista H, 1999, CURR BIOL, V9, P1403, DOI 10.1016/S0960-9822(00)80085-8; Le YY, 2001, CYTOKINE GROWTH F R, V12, P91, DOI 10.1016/S1359-6101(01)00003-X; LEW DP, 1989, EUR J CLIN INVEST, V19, P338, DOI 10.1111/j.1365-2362.1989.tb00240.x; Lim LHK, 1998, P NATL ACAD SCI USA, V95, P14535, DOI 10.1073/pnas.95.24.14535; LUECKE H, 1995, NATURE, V378, P512, DOI 10.1038/378512a0; Maianski NA, 2003, BLOOD, V101, P1987, DOI 10.1182/blood-2002-02-0522; MANCUSO F, 1995, J IMMUNOL, V155, P377; Matsuda R, 1997, BIOCHEM BIOPH RES CO, V237, P499, DOI 10.1006/bbrc.1997.7177; Meagher LC, 1996, J IMMUNOL, V156, P4422; Oliani SM, 2001, AM J PATHOL, V158, P603, DOI 10.1016/S0002-9440(10)64002-3; PEERS SH, 1991, EUR J PHARMACOL, V196, P37, DOI 10.1016/0014-2999(91)90406-G; Perretti M, 2002, J IMMUNOL, V169, P2085, DOI 10.4049/jimmunol.169.4.2085; Perretti M, 2002, NAT MED, V8, P1296, DOI 10.1038/nm786; PERRETTI M, 1995, BIOCHEM PHARMACOL, V50, P1037, DOI 10.1016/0006-2952(95)00238-U; PERRETTI M, 1993, J IMMUNOL, V151, P4306; Perretti M, 1997, TRENDS PHARMACOL SCI, V18, P418; PERRETTI M, 1993, J IMMUNOL, V150, P992; Perretti M, 1996, NAT MED, V2, P1259, DOI 10.1038/nm1196-1259; Perretti M, 1996, BRIT J PHARMACOL, V117, P1145, DOI 10.1111/j.1476-5381.1996.tb16709.x; Perretti M, 2000, CELL BIOL INT, V24, P163, DOI 10.1006/cbir.1999.0468; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; POLLARD H, 1992, SYNEXIN ANNEXIN 7; Porter AG, 1999, TRENDS CELL BIOL, V9, P394, DOI 10.1016/S0962-8924(99)01624-4; POZZAN T, 1983, SCIENCE, V221, P1413, DOI 10.1126/science.6310757; Preece G, 1996, J BIOL CHEM, V271, P11634, DOI 10.1074/jbc.271.20.11634; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RUSSOMARIE F, 1992, ANNEXINS; SOLITO E, 1991, FEBS LETT, V291, P238, DOI 10.1016/0014-5793(91)81293-H; Solito E, 2000, J IMMUNOL, V165, P1573, DOI 10.4049/jimmunol.165.3.1573; Solito E, 2001, BRIT J PHARMACOL, V133, P217, DOI 10.1038/sj.bjp.0704054; Strausbaugh HJ, 2001, J IMMUNOL, V166, P6294, DOI 10.4049/jimmunol.166.10.6294; TISSOT M, 1991, J LEUKOCYTE BIOL, V50, P607, DOI 10.1002/jlb.50.6.607; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120, DOI 10.1165/ajrcmb.18.1.2808; Vergnolle N, 1997, AM J PHYSIOL-REG I, V273, pR623, DOI 10.1152/ajpregu.1997.273.2.R623; VERGNOLLE N, 1995, EUR J BIOCHEM, V232, P603, DOI 10.1111/j.1432-1033.1995.603zz.x; Walther A, 2000, MOL CELL, V5, P831, DOI 10.1016/S1097-2765(00)80323-8; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Ward C, 1999, TRENDS PHARMACOL SCI, V20, P503, DOI 10.1016/S0165-6147(99)01391-7; Watson RWG, 1997, J IMMUNOL, V158, P945; WHYTE MKB, 1993, J CLIN INVEST, V92, P446, DOI 10.1172/JCI116587; ZIGMOND SH, 1973, J EXP MED, V137, P387, DOI 10.1084/jem.137.2.387; Zouki C, 2000, FASEB J, V14, P572, DOI 10.1096/fasebj.14.3.572	68	154	163	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1544	+		10.1096/fj.02-0941fje	http://dx.doi.org/10.1096/fj.02-0941fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824302				2022-12-28	WOS:000183818000023
J	Karakashian, AA; Giltiay, NV; Smith, GM; Nikolova-Karakashian, MN				Karakashian, AA; Giltiay, NV; Smith, GM; Nikolova-Karakashian, MN			Expression of neutral sphingomyelinase-2 (NSMase-2) in primary rat hepatocytes modulates IL-beta-induced JNK activation	FASEB JOURNAL			English	Article						ceramide; PP2A; plasma membrane; IRAK	RECEPTOR-ASSOCIATED KINASE; TUMOR-NECROSIS-FACTOR; CYTOCHROME-P450 2C11 CYP2C11; N-TERMINAL KINASE; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; SUBCELLULAR-LOCALIZATION; ACID SPHINGOMYELINASE; CELL-DIFFERENTIATION; FREE SPHINGOSINE	Neutral sphingomyelinase (NSMase) has been proposed to mediate interleukin (IL)-1beta signaling in liver. In this paper, we used adenovirus-mediated gene transfer to inducibly express FLAG-tagged mouse NSMase-2 in primary rat hepatocytes in order to further elucidate the molecular nature of the NSMase involved. Initial studies confirmed that the EST clone used in these experiments encoded a Mg2+-dependent NSMase. The in vitro activity of the heterologously expressed enzyme was inhibited in the presence of 0.5% Triton or 50 mM EDTA. In addition, the expression of this NSMase-2 clone in primary hepatocytes led to increased cellular levels of ceramide, indicating that the enzyme is active in situ. Immunofluorescence studies in Hep G2 cells infected with NSMase-2 expressing adenoviruses showed that the FLAG-tagged NSMase-2 was localized to the plasma membrane. Cell viability remained unchanged 72 h following infection and induction. The effect of NSMase-2 expression on IL-1beta-induced activation of c-Jun N-terminal kinase (JNK) was tested. Expression of NSMase-2 increased JNK phosphorylation between 1.5- and 2-fold over the basal level. Furthermore, NSMase-2 was found to strongly increase the ability of IL-1beta to phosphorylate JNK. This potentiation was mediated by a phosphatase from the PP2A family, possibly by modulating the phosphorylation pattern of IL-1beta receptor-associated kinase (IRAK). In conclusion, the data presented suggest that NSMase-2 could be involved in IL-1beta-induced JNK activation in hepatocytes.	Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky	Nikolova-Karakashian, MN (corresponding author), Univ Kentucky, Albert B Chandler Med Ctr, Dept Physiol, MS 508,800 Rose St, Lexington, KY 40536 USA.	mnikolo@uky.edu	Giltiay, Natalia V./H-8655-2019; Giltiay, Natalia/AAH-2130-2019	Giltiay, Natalia/0000-0001-7284-514X	NIA NIH HHS [R03 AG19435, R01 AG019223-01A2, R01 AG019223] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R03AG019435, R01AG019223] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BALLOU LR, 1992, IMMUNOL TODAY, V13, P339, DOI 10.1016/0167-5699(92)90167-6; BOUCHER LM, 1995, J EXP MED, V181, P2059, DOI 10.1084/jem.181.6.2059; Brann AB, 2002, J BIOL CHEM, V277, P9812, DOI 10.1074/jbc.M109862200; CHEN JQ, 1995, J BIOL CHEM, V270, P25233, DOI 10.1074/jbc.270.42.25233; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Hannun YA, 2002, J BIOL CHEM, V277, P25847, DOI 10.1074/jbc.R200008200; Hayashi Y, 1997, J BIOL CHEM, V272, P18082, DOI 10.1074/jbc.272.29.18082; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hernandez OM, 2000, CIRC RES, V86, P198, DOI 10.1161/01.RES.86.2.198; Hofmann K, 2000, P NATL ACAD SCI USA, V97, P5895, DOI 10.1073/pnas.97.11.5895; HOSTETLER KY, 1979, J LIPID RES, V20, P456; Janssens S, 2003, MOL CELL, V11, P293, DOI 10.1016/S1097-2765(03)00053-4; Jiang ZF, 2002, MOL CELL BIOL, V22, P7158, DOI 10.1128/MCB.22.20.7158-7167.2002; Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200; Jones BE, 1999, HEPATOLOGY, V30, P215, DOI 10.1002/hep.510300146; KOK JW, 1995, BIOCHEM J, V309, P905, DOI 10.1042/bj3090905; LEVADE T, 1991, J BIOL CHEM, V266, P13519; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; Mansat-De Mas V, 1999, MOL PHARMACOL, V56, P867, DOI 10.1124/mol.56.5.867; Marchesini N, 2003, J BIOL CHEM, V278, P13775, DOI 10.1074/jbc.M212262200; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NikolovaKarakashian M, 1997, J BIOL CHEM, V272, P18718, DOI 10.1074/jbc.272.30.18718; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; OKAZAKI T, 1994, J BIOL CHEM, V269, P4070; QUINTERN LE, 1987, BIOCHIM BIOPHYS ACTA, V922, P323, DOI 10.1016/0005-2760(87)90055-5; Sawai H, 1999, J BIOL CHEM, V274, P38131, DOI 10.1074/jbc.274.53.38131; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; Shirakabe K, 1997, J BIOL CHEM, V272, P8141, DOI 10.1074/jbc.272.13.8141; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; Tomiuk S, 2000, J BIOL CHEM, V275, P5710, DOI 10.1074/jbc.275.8.5710; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Venkataraman K, 2000, TRENDS CELL BIOL, V10, P408, DOI 10.1016/S0962-8924(00)01830-4; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WILLIAMS RD, 1984, ARCH BIOCHEM BIOPHYS, V228, P282, DOI 10.1016/0003-9861(84)90069-9; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; Xia P, 1998, P NATL ACAD SCI USA, V95, P14196, DOI 10.1073/pnas.95.24.14196; Zumbansen M, 2002, MOL CELL BIOL, V22, P3633, DOI 10.1128/MCB.22.11.3633-3638.2002	42	68	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					968	+		10.1096/fj.03-0875fje	http://dx.doi.org/10.1096/fj.03-0875fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059969				2022-12-28	WOS:000221108800020
J	Ko, J; Jang, SW; Kim, YS; Kim, IS; Sung, HJ; Kim, HH; Park, JY; Lee, YH; Kim, J; Na, DS				Ko, J; Jang, SW; Kim, YS; Kim, IS; Sung, HJ; Kim, HH; Park, JY; Lee, YH; Kim, J; Na, DS			Human LZIP binds to CCR1 and differentially affects the chemotactic activities of CCR1-dependent chemokines	FASEB JOURNAL			English	Article						Lkn-1; signal transduction; chemotaxis; monocyte; chemokine receptor	CELL-DERIVED FACTOR-1-ALPHA; SIGNALING PATHWAYS; BETA-CHEMOKINE; PROTEIN; GENE; RECEPTORS; VP16; LUMAN; INFLAMMATION; LYMPHOCYTES	Signaling molecules that bind to chemokine receptors should play key roles in regulation of cell migration induced by chemokines. To characterize the CCR1-mediated cellular signal transduction mechanism, we used the yeast two-hybrid system to identify a cellular ligand for CCR1. LZIP, which has been known as a transcription factor in various cell types, was identified as a CCR1 binding protein. Although the ability of LZIP to bind DNA is possibly what allows it to function as a transcription factor, its detailed function and participation in chemotaxis have not been established. We found that LZIP binds to CCR1 based on results of a mammalian two-hybrid assay and immunoprecipitation experiments. The 21-260 residues of LZIP were essential for interaction with CCR1. Results from a chemotaxis assay using LZIP transfected cells showed that LZIP enhanced Lkn-1-induced chemotaxis, whereas the chemotactic activities induced by other CC chemokines that bind to CCR1, including MIP-lalpha, RANTES, or HCC-4, were not affected by LZIP overexpression. These data indicate that LZIP binds to CCR1 and that the interaction between CCR1 and LZIP participates in regulation of Lkn-1-dependent cell migration without affecting the chemotactic activities of other CC chemokines that bind to CCR1.	Univ Ulsan, Coll Med, Asan Inst Life Sci, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Internal Med, Seoul 138736, South Korea; Univ Ulsan, Coll Med, Dept Biochem & Mol Biol, Seoul 138736, South Korea; Seoul Natl Univ, Coll Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea; Yeungnam Univ, Coll Med, Dept Biochem & Mol Biol, Taegu 705717, South Korea; Kyung Hee Univ, Grad Sch Biotechnol, Yongin 449701, South Korea	University of Ulsan; University of Ulsan; University of Ulsan; Seoul National University (SNU); Yeungnam University; Kyung Hee University	Ko, J (corresponding author), Univ Ulsan, Coll Med, Asan Inst Life Sci, 388-1 Poongnap Dong, Seoul 138736, South Korea.	jesangko@amc.seoul.kr						ABEL T, 1989, NATURE, V341, P24, DOI 10.1038/341024a0; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Burbelo PD, 1998, GENOMICS, V54, P357, DOI 10.1006/geno.1998.5574; BURBELO PD, 1994, GENE, V139, P241, DOI 10.1016/0378-1119(94)90763-3; Burns JM, 1997, BIOTECHNIQUES, V23, P1022, DOI 10.2144/97236bm11; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Dutt P, 1998, J IMMUNOL, V161, P3652; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Jin DY, 2000, EMBO J, V19, P729, DOI 10.1093/emboj/19.4.729; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Ko JS, 2002, FEBS LETT, V515, P159, DOI 10.1016/S0014-5793(02)02465-1; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, J VIROL, V74, P934, DOI 10.1128/JVI.74.2.934-943.2000; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Mellado M, 1999, NATURE, V400, P723, DOI 10.1038/23382; Mellado M, 2001, ANNU REV IMMUNOL, V19, P397, DOI 10.1146/annurev.immunol.19.1.397; Murdoch C, 2000, BLOOD, V95, P3032; Murphy Philip M., 1996, Cytokine and Growth Factor Reviews, V7, P47, DOI 10.1016/1359-6101(96)00009-3; Pukac L, 1998, EXP CELL RES, V242, P548, DOI 10.1006/excr.1998.4138; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; STEHLE JH, 1993, NATURE, V365, P314, DOI 10.1038/365314a0; Tapia JA, 1999, BBA-MOL CELL RES, V1448, P486, DOI 10.1016/S0167-4889(98)00157-8; THEODORSEN L, 1995, CLIN LAB HAEMATOL, V17, P225; TURNER L, 1995, J IMMUNOL, V155, P2437; Wang JM, 1998, J IMMUNOL METHODS, V220, P1, DOI 10.1016/S0022-1759(98)00128-8; WANG JM, 1993, CYTOKINE, V5, P264, DOI 10.1016/1043-4666(93)90014-V; YEBRA M, 1995, MOL BIOL CELL, V6, P841, DOI 10.1091/mbc.6.7.841; Youn BS, 1997, J IMMUNOL, V159, P5201	35	34	37	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					890	+		10.1096/fj.03-0867fje	http://dx.doi.org/10.1096/fj.03-0867fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001559				2022-12-28	WOS:000220522800024
J	Sarady, JK; Zuckerbraun, BS; Bilban, M; Wagner, O; Usheva, A; Liu, F; Ifedigbo, E; Zamora, R; Choi, AMK; Otterbein, LE				Sarady, JK; Zuckerbraun, BS; Bilban, M; Wagner, O; Usheva, A; Liu, F; Ifedigbo, E; Zamora, R; Choi, AMK; Otterbein, LE			Carbon monoxide protection against endotoxic shock involves reciprocal effects on iNOS in the lung and liver	FASEB JOURNAL			English	Article						nitric oxide; iNOS/NOS2; heme oxygenase; oxidative stress; inflammation	NITRIC-OXIDE SYNTHASE; ALPHA-INDUCED APOPTOSIS; HEME OXYGENASE-1; PROVIDES PROTECTION; GENE-EXPRESSION; INJURY; INDUCTION; INHIBITION; ANIMALS; SEPSIS	Carbon monoxide (CO) has recently emerged as having potent cytoprotective properties; the mechanisms underlying these effects, however, are just beginning to be elucidated. In a rat model of lipopolysaccharide (LPS)-induced multiorgan failure, we demonstrate that exposure to a low concentration of CO for only 1 h imparts a potent defense against lethal endotoxemia and effectively abrogates the inflammatory response. Exposure to CO leads to long-term survival of >80% of animals vs. 20% in controls. In the lung, CO suppressed LPS-induced lung alveolitis and associated edema formation, while in the liver, it reduced expression of serum alanine aminotransferase, a marker of liver injury. This protection appears to be based in part on different mechanisms in the lung and liver in that CO had reciprocal effects on LPS-induced expression of iNOS and NO production, important mediators in the response to LPS. CO prevented the up-regulation of iNOS and NO in the lung while augmenting expression of iNOS and NO in the liver. Studies of primary lung macrophages and hepatocytes in vitro revealed a similar effect; CO inhibited LPS-induced cytokine production in lung macrophages while reducing LPS-induced iNOS expression and nitrite accumulation and protected hepatocytes from apoptosis while augmenting iNOS expression. Although it is unclear to which extent these changes in iNOS contribute to the cytoprotection conferred by CO, it is fascinating that in each organ CO influences iNOS in a manner known to be protective in that organ: NO is therapeutic in the liver while it is damaging in the lung.	Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15213 USA; Med Univ Vienna, Dept Med & Chem Lab Diagnost, Vienna, Austria; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Medical University of Vienna; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Otterbein, LE (corresponding author), Univ Pittsburgh, Sch Med, Montefiore Univ Hosp, Rm 628 NW, Pittsburgh, PA 15213 USA.	otterbeinl@upmc.edu		Bilban, Martin/0000-0001-7043-7142				Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Arkovitz MS, 1996, J PEDIATR SURG, V31, P1009, DOI 10.1016/S0022-3468(96)90075-5; Balk RA, 2000, CRIT CARE CLIN, V16, P179, DOI 10.1016/S0749-0704(05)70106-8; BILLIAR TR, 1990, J LEUKOCYTE BIOL, V48, P565, DOI 10.1002/jlb.48.6.565; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387, DOI 10.1165/ajrcmb.13.4.7546768; Carraway MS, 1998, AM J PHYSIOL-LUNG C, V275, pL583, DOI 10.1152/ajplung.1998.275.3.L583; Choi S, 2001, ELECTRON LETT, V37, P823, DOI 10.1049/el:20010563; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Duckers HJ, 2001, NAT MED, V7, P693, DOI 10.1038/89068; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; Gunther L, 2002, DIABETES, V51, P994, DOI 10.2337/diabetes.51.4.994; HADDAD IY, 1994, J CLIN INVEST, V94, P2407, DOI 10.1172/JCI117607; HARBRECHT BG, 1995, SHOCK, V3, P79, DOI 10.1097/00024382-199503020-00001; Hierholzer C, 1998, J EXP MED, V187, P917, DOI 10.1084/jem.187.6.917; Hinder F, 1999, AM J RESP CRIT CARE, V159, P252, DOI 10.1164/ajrccm.159.1.9806024; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; KOOY NW, 1995, AM J RESP CRIT CARE, V151, P1250; LEWANG F, 2002, AM J RESP CRIT CARE, V12, P1634; Mikawa K, 1998, CRIT CARE MED, V26, P905, DOI 10.1097/00003246-199805000-00026; Mojena M, 2001, FASEB J, V15, P583; MORITA T, 1995, P NATL ACAD SCI USA, V92, P1475, DOI 10.1073/pnas.92.5.1475; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nathan C, 1997, J CLIN INVEST, V100, P2417, DOI 10.1172/JCI119782; Numata M, 1998, J IMMUNOL, V160, P3031; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595, DOI 10.1165/ajrcmb.13.5.7576696; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; Paxian M, 2001, SHOCK, V15, P438, DOI 10.1097/00024382-200115060-00005; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Richards MJ, 1999, CRIT CARE MED, V27, P887, DOI 10.1097/00003246-199905000-00020; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Scumpia PO, 2002, AM J PHYSIOL-LUNG C, V283, pL1231, DOI 10.1152/ajplung.00102.2002; Shanley TP, 2002, CRIT CARE MED, V30, P1960, DOI 10.1097/00003246-200209000-00003; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Tetreau C, 1999, BIOCHEMISTRY-US, V38, P7210, DOI 10.1021/bi9901026; TRIILIEFF A, 2000, J IMMUNOL, V165, P1526; Vallance P, 1993, New Horiz, V1, P77; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Worrall NK, 1997, AM J PHYSIOL-HEART C, V273, pH2565, DOI 10.1152/ajpheart.1997.273.6.H2565; Zhang XC, 2003, J BIOL CHEM, V278, P1248, DOI 10.1074/jbc.M208419200; Zuckerbraun BS, 2003, J EXP MED, V198, P1707, DOI 10.1084/jem.20031003; [No title captured]	49	156	178	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					854	+		10.1096/fj.03-0643fje	http://dx.doi.org/10.1096/fj.03-0643fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001560				2022-12-28	WOS:000220522800025
J	Thakur, AK; Yang, W; Wetzel, R				Thakur, AK; Yang, W; Wetzel, R			Inhibition of polyglutamine aggregate cytotoxicity by a structure-based elongation inhibitor	FASEB JOURNAL			English	Article						Huntington's disease; polyGIn peptide sequences; CAG repeat sequence	NEURONAL INTRANUCLEAR INCLUSIONS; HUNTINGTONS-DISEASE; IN-VITRO; NEURODEGENERATIVE DISEASE; MUTANT HUNTINGTIN; PROTEIN; RECRUITMENT; PEPTIDES; LOCALIZATION; SUPPRESSION	Huntington's disease and other expanded CAG repeat diseases are associated with the expression of proteins containing polyglutamine (polyGln) tracts expanded beyond a pathological repeat length threshold of similar to38. Aggregation of these expanded polyGln proteins may trigger disease by recruiting and sequestering other polyGln-containing proteins in the cell, depriving the cellular environment of critical protein activities. We describe here proline-containing polyGln peptide sequences that are effective inhibitors of the ability of polyGln aggregates to be elongated by recruiting additional polyGln monomers. These peptides are also effective inhibitors of polyGln aggregate toxicity in a cell culture model based on delivery of preassembled polyGln aggregates into the cell nucleus. These results are not only consistent with a role for polyGln aggregates in the disease mechanisms of expanded CAG repeat disorders, but also directly implicate the elongation phase of aggregate growth in the toxicity mechanism, supporting the recruitment-sequestration model for polyGln toxicity. These results may be related to the ability of the glutamine/proline-rich protein PQE-1 to protect C. elegans against polyglutamine toxicity. Inhibition of aggregate elongation is a therapeutic strategy that, based on our results, may be effective even in neurons already compromised by polyGln aggregates.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Albany Med Coll, Ctr Immunol & Microbial Dis, Albany, NY 12208 USA	Max Planck Society; Albany Medical College	Wetzel, R (corresponding author), Univ Tennessee, Med Ctr, Grad Sch Med, R221,1924 Alcoa Highway, Knoxville, TN 37920 USA.	rwetzel@mc.utmck.edu	Wetzel, Ronald/G-7453-2011; Thakur, Ashwani Kumar/AAL-5784-2021					Bates G, 2003, LANCET, V361, P1642, DOI 10.1016/S0140-6736(03)13304-1; Bates G. P., 2002, HUNTINGTONS DIS, P429; Bennett MJ, 2002, P NATL ACAD SCI USA, V99, P11634, DOI 10.1073/pnas.182393899; Berthelier V, 2001, ANAL BIOCHEM, V295, P227, DOI 10.1006/abio.2001.5217; Chai YH, 1999, HUM MOL GENET, V8, P673, DOI 10.1093/hmg/8.4.673; Chen S, 2001, J MOL BIOL, V311, P173, DOI 10.1006/jmbi.2001.4850; Chen SM, 2002, P NATL ACAD SCI USA, V99, P11884, DOI 10.1073/pnas.182276099; Chen SM, 2002, BIOCHEMISTRY-US, V41, P7391, DOI 10.1021/bi011772q; Chen SM, 2001, PROTEIN SCI, V10, P887, DOI 10.1110/ps.42301; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; Cummings CJ, 2000, HUM MOL GENET, V9, P909, DOI 10.1093/hmg/9.6.909; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Faber PW, 2002, P NATL ACAD SCI USA, V99, P17131, DOI 10.1073/pnas.262544899; Forman MS, 2003, TRENDS NEUROSCI, V26, P407, DOI 10.1016/S0166-2236(03)00197-8; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; Jenkins J, 2001, PROG BIOPHYS MOL BIO, V77, P111, DOI 10.1016/S0079-6107(01)00013-X; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; KAZANTSEV A., 2002, NAT GENET, V25, P25; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Li SH, 1999, J NEUROSCI, V19, P5159; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; Morimoto A, 2002, BIOCHEM BIOPH RES CO, V295, P306, DOI 10.1016/S0006-291X(02)00670-8; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; O'Nuallain B, 2002, P NATL ACAD SCI USA, V99, P1485, DOI 10.1073/pnas.022662599; ONUALLAIN B, 2001, IN PRESS J BIOL CHEM, V279; OSMAND AP, 2002, IDENTIFICATION AGGRE; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Perutz MF, 2002, P NATL ACAD SCI USA, V99, P5591, DOI 10.1073/pnas.042681399; Pickersgill RW, 2003, STRUCTURE, V11, P137, DOI 10.1016/S0969-2126(03)00009-1; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Preisinger E, 1999, PHILOS T ROY SOC B, V354, P1029, DOI 10.1098/rstb.1999.0455; Richardson JS, 2002, P NATL ACAD SCI USA, V99, P2754, DOI 10.1073/pnas.052706099; Ross CA, 2003, P NATL ACAD SCI USA, V100, P1, DOI 10.1073/pnas.0237018100; Scherzinger E, 1999, P NATL ACAD SCI USA, V96, P4604, DOI 10.1073/pnas.96.8.4604; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Soto C, 1996, BIOCHEM BIOPH RES CO, V226, P672, DOI 10.1006/bbrc.1996.1413; Taylor JP, 2002, SCIENCE, V296, P1991, DOI 10.1126/science.1067122; Thakur AK, 2002, P NATL ACAD SCI USA, V99, P17014, DOI 10.1073/pnas.252523899; Wetzel R, 2002, STRUCTURE, V10, P1031, DOI 10.1016/S0969-2126(02)00809-2; WETZEL R, 2004, IN PRESS PROTEIN FOL; Williams AD, 2004, J MOL BIOL, V335, P833, DOI 10.1016/j.jmb.2003.11.008; Wilmot GR, 1998, GENETIC INSTABILITIES AND HEREDITARY NEUROLOGICAL DISEASES, P3; WOOD SJ, 1995, BIOCHEMISTRY-US, V34, P724, DOI 10.1021/bi00003a003; Yang W, 2002, HUM MOL GENET, V11, P2905, DOI 10.1093/hmg/11.23.2905; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	52	32	32	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					923	+		10.1096/fj.03-1238fje	http://dx.doi.org/10.1096/fj.03-1238fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001566				2022-12-28	WOS:000220522800019
J	Radak, Z; Chung, HY; Naito, H; Takahashi, R; Jung, KJ; Kim, HJ; Goto, S				Radak, Z; Chung, HY; Naito, H; Takahashi, R; Jung, KJ; Kim, HJ; Goto, S			Age-associated increases in oxidative stress and nuclear transcription factor kappa B activation are attenuated in rat liver by regular exercise	FASEB JOURNAL			English	Article						aging; redox signaling; NF-kappa B; adaptation; oxidative stress; free radicals	INFLAMMATION HYPOTHESIS; FREE-RADICALS; PROTEINS; DAMAGE; MUSCLE; ANTIOXIDANT; EXPRESSION; RADIATION; DNA	The combined effects of aging and regular physical exercise was investigated on the production of reactive oxygen species (ROS), lipid peroxidation, glutathione status, and the activity of nuclear factor-kappaB (NF-kappaB) in rat liver. A group of 24 male F344 rats was divided into the following categories: adult control (18 months), adult exercised (18 months), and aged control (28 months) and aged exercised (28 months). The ROS formation increased as a function of age and exercise training decreased the rate of ROS formation in the two age groups. Significant positive correlation was found between ROS production and lipid peroxidation (LIPOX). The reduced glutathione (GSH) level was higher and the oxidized glutathione (GSSG) level lower in exercised groups compared with the sedentary controls (P<0.05). An age-associated increase in NF-kappa B activity was attenuated by the regular exercise. The content of p50 and p65 subunits of NF-kappa B increased with age and decreased with exercise training. The content of inhibitory factor-kappa B was inversely related to NF-kappa B activation. Regular exercise-induced adaptive responses, including attenuation of an increase in ROS production, LIPOX level, NF-kappa B activation, and reduced GSH/GSSG ratio, appear to be capable, even in old age, of reducing increases in inflammatory and other detrimental consequences that are often associated with advancing age.	Semmelweis Univ, Sch Sport Sci, Exercise Physiol Lab, Budapest, Hungary; Pusan Natl Univ, Dept Pharm, Pusan, South Korea; Toho Univ, Fac Pharmaceut Sci, Dept Biochem, Funabashi, Chiba 274, Japan	Semmelweis University; Pusan National University; Toho University	Radak, Z (corresponding author), Semmelweis Univ, Sch Sport Sci, Exercise Physiol Lab, Budapest, Hungary.	radak@mail.hupe.hu; hjung@pusan.ac.kr	Naito, Hisashi/F-5655-2011	Naito, Hisashi/0000-0002-0522-9512; Radak, Zsolt/0000-0003-1297-6804				ABERG F, 1992, ARCH BIOCHEM BIOPHYS, V295, P230, DOI 10.1016/0003-9861(92)90511-T; Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Atalay M, 1999, ANN NY ACAD SCI, V874, P169, DOI 10.1111/j.1749-6632.1999.tb09234.x; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Bruunsgaard H, 2001, CURR OPIN HEMATOL, V8, P131, DOI 10.1097/00062752-200105000-00001; CADENAS E, 1995, BIOCHEM PHARMACOL, V49, P127, DOI 10.1016/S0006-2952(94)00333-5; Canty TG, 1999, CIRCULATION, V100, P361; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; DAVIES KJA, 1982, BIOCHEM BIOPH RES CO, V107, P1198, DOI 10.1016/S0006-291X(82)80124-1; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Goto S, 1999, MECH AGEING DEV, V107, P245, DOI 10.1016/S0047-6374(98)00133-X; Goto S, 2001, ANN NY ACAD SCI, V928, P54; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; Helenius M, 1996, BIOCHEM J, V318, P603, DOI 10.1042/bj3180603; Helenius M, 2001, ANTIOXID REDOX SIGN, V3, P147, DOI 10.1089/152308601750100669; Holloszy John O., 1995, P633; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Kim HJ, 2002, FREE RADICAL BIO MED, V32, P991, DOI 10.1016/S0891-5849(02)00798-0; Kim HJ, 2000, FREE RADICAL BIO MED, V28, P683, DOI 10.1016/S0891-5849(99)00274-9; Kotler DP, 2000, ANN INTERN MED, V133, P622, DOI 10.7326/0003-4819-133-8-200010170-00015; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Miller RA, 1996, SCIENCE, V273, P70, DOI 10.1126/science.273.5271.70; Naito H, 2001, MED SCI SPORT EXER, V33, P729; Pedersen BK, 2003, SCAND J MED SCI SPOR, V13, P56, DOI 10.1034/j.1600-0838.2003.20218.x; Powers SK, 2001, MED SCI SPORT EXER, V33, P386, DOI 10.1097/00005768-200103000-00009; Pugh KG, 2001, DRUG AGING, V18, P263, DOI 10.2165/00002512-200118040-00004; Radak Z, 2002, PFLUG ARCH EUR J PHY, V445, P273, DOI 10.1007/s00424-002-0918-6; Radak Z, 2001, EXERC IMMUNOL REV, V7, P90; Radak Z, 1999, FREE RADICAL BIO MED, V27, P69, DOI 10.1016/S0891-5849(99)00038-6; Radak Z, 2000, ARCH BIOCHEM BIOPHYS, V376, P248, DOI 10.1006/abbi.2000.1719; RADAK Z, 2000, FREE RADICALS EXERCI, P177; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Venditti P, 1999, ARCH BIOCHEM BIOPHYS, V368, P112, DOI 10.1006/abbi.1999.1269; Xiao ZQ, 2000, AM J PHYSIOL-GASTR L, V278, pG855, DOI 10.1152/ajpgi.2000.278.6.G855; Yan ZQ, 1999, ARTERIOSCL THROM VAS, V19, P2854, DOI 10.1161/01.ATV.19.12.2854	42	132	137	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					749	+		10.1096/fj.03-0509fje	http://dx.doi.org/10.1096/fj.03-0509fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766800				2022-12-28	WOS:000220425000033
J	Raymond, MA; Desormeaux, A; Laplante, P; Vigneault, N; Filep, JG; Landry, K; Pshezhetsky, AV; Hebert, MJ				Raymond, MA; Desormeaux, A; Laplante, P; Vigneault, N; Filep, JG; Landry, K; Pshezhetsky, AV; Hebert, MJ			Apoptosis of endothelial cells triggers a caspase-dependent anti-apoptotic paracrine loop active on vascular smooth muscle cells	FASEB JOURNAL			English	Article						endothelium; p53; Bcl-xl; extracellular signal-regulated kinase; perlecan	LIPOPROTEIN INDUCES APOPTOSIS; INHIBITS NEOINTIMA FORMATION; ADHESION MOLECULES; ANGIOTENSIN-II; GENE-TRANSFER; NITRIC-OXIDE; VESSEL WALL; PROLIFERATION; ANGIOGENESIS; ATHEROSCLEROSIS	Increased endothelial apoptosis and decreased apoptosis of vascular smooth muscle cells (VSMC) are central to initiation of myo-intimal thickening. We hypothesized that apoptosis of endothelial cells (EC) induces the release of anti-apoptotic mediator(s) active on VSMC. We found that serum-free medium conditioned by apoptotic EC decreases apoptosis of VSMC compared with fresh serum-free medium. Inhibition of endothelial apoptosis during conditioning with a pan-caspase inhibitor ZVAD-FMK blocked the release of the anti-apoptotic factor(s) active on VSMC. VSMC exposed to serum-free medium conditioned by apoptotic EC showed increased ERK 1/2 phosphorylation, enhanced Bcl-xl expression, and inhibition of p53 expression. Fractionation of the conditioned medium followed by mass spectral analysis identified one bioactive component as a C-terminal fragment of the domain V of perlecan. Serum-free medium supplemented with either a synthetic peptide containing the EGF motif of the domain V of perlecan or chondroitin 4-sulfate, a glycosaminoglycan anchored on the domain V of perlecan, increased ERK 1/2 phosphorylation and Bcl-xl protein levels while inhibiting apoptosis of VSMC. These results suggest that a proteolytic activity developing downstream of activated caspases in apoptotic EC initiates degradation of pericellular proteoglycans and liberation of bioactive fragments with a robust impact on inhibition of VSMC apoptosis.	Univ Montreal, CRCHUM, Montreal, PQ H2L 4M1, Canada; Univ Montreal, Hop St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada; Guy Bernier Res Ctr, Montreal, PQ H1T 2M4, Canada	Universite de Montreal; Universite de Montreal	Hebert, MJ (corresponding author), Univ Montreal, CRCHUM, 1560 Sherbrooke E, Montreal, PQ H2L 4M1, Canada.	marie-josee.hebert.chum@ssss.gouv.qc.ca		A, Pshezhetsky/0000-0002-6612-1062				BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; CASTELLOT JJ, 1981, J CELL BIOL, V90, P372, DOI 10.1083/jcb.90.2.372; COHEN IR, 1993, P NATL ACAD SCI USA, V90, P10404, DOI 10.1073/pnas.90.21.10404; Diez J, 1998, EUR HEART J, V19, pG29; Dimmeler S, 1997, CIRCULATION, V95, P1760; Du XL, 1998, DIABETOLOGIA, V41, P249, DOI 10.1007/s001250050900; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; George SJ, 2001, GENE THER, V8, P668, DOI 10.1038/sj.gt.3301431; Gluckman PD, 1998, MOL CELL ENDOCRINOL, V140, P95, DOI 10.1016/S0303-7207(98)00035-5; Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585; Hamet P, 1995, Curr Opin Nephrol Hypertens, V4, P1, DOI 10.1097/00041552-199501000-00001; Hamet P, 2001, CAN J CARDIOL, V17, p26A; Harada-Shiba M, 1998, J BIOL CHEM, V273, P9681, DOI 10.1074/jbc.273.16.9681; Hebert MJ, 1998, AM J PATHOL, V152, P523; Hu YH, 2000, ARTERIOSCL THROM VAS, V20, P18, DOI 10.1161/01.ATV.20.1.18; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; KALLUNKI P, 1992, J CELL BIOL, V116, P559, DOI 10.1083/jcb.116.2.559; Kalluri R, 2003, NAT REV CANCER, V3, P422, DOI 10.1038/nrc1094; KARNOVSKY MJ, 1981, AM J PATHOL, V105, P200; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Lopez-Farre A, 1998, INT J BIOCHEM CELL B, V30, P1095, DOI 10.1016/S1357-2725(98)00071-5; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Malik N, 1998, CIRCULATION, V98, P1657, DOI 10.1161/01.CIR.98.16.1657; Mongiat M, 2003, J BIOL CHEM, V278, P4238, DOI 10.1074/jbc.M210445200; Mooney A, 1997, J IMMUNOL, V159, P3949; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Pollman MJ, 1999, CIRC RES, V84, P113; Raymond MA, 2003, FASEB J, V17, P515, DOI 10.1096/fj.02-0500fje; Raymond MA, 2002, BIOCHEM BIOPH RES CO, V291, P261, DOI 10.1006/bbrc.2002.6449; Reddy S. M., 1999, Journal of the American Society of Nephrology, V10, p519A; Rodriguez-Campos A, 2001, ARTERIOSCL THROM VAS, V21, P214, DOI 10.1161/01.ATV.21.2.214; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Santos BC, 1998, AM J PHYSIOL-RENAL, V274, pF1167, DOI 10.1152/ajprenal.1998.274.6.F1167; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Sata M, 1998, P NATL ACAD SCI USA, V95, P1213, DOI 10.1073/pnas.95.3.1213; Shichiri M, 2000, ARTERIOSCL THROM VAS, V20, P989, DOI 10.1161/01.ATV.20.4.989; Shimizu A, 2002, LAB INVEST, V82, P673, DOI 10.1097/01.LAB.0000017370.74529.89; Suzuki J, 2000, CARDIOVASC RES, V45, P783, DOI 10.1016/S0008-6363(99)00356-9; Suzuki J, 2002, CIRCULATION, V106, P847, DOI 10.1161/01.CIR.0000024103.04821.86; Tithof PK, 2002, FASEB J, V16, P1463, DOI 10.1096/fj.02-0092fje; Vogt CJ, 2001, MICROCIRCULATION, V8, P129, DOI 10.1080/713774024; Walsh K, 2000, CIRC RES, V87, P184, DOI 10.1161/01.RES.87.3.184; Walsh K, 2000, CARDIOVASC RES, V45, P756, DOI 10.1016/S0008-6363(99)00270-9; Wang J, 2001, MOL GENET METAB, V72, P82, DOI 10.1006/mgme.2000.3115	44	65	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					705	+		10.1096/fj.03-0573fje	http://dx.doi.org/10.1096/fj.03-0573fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977881				2022-12-28	WOS:000220425000021
J	Poliakov, E; Brennan, ML; Macpherson, J; Zhang, RL; Sha, W; Narine, IA; Salomon, RG; Hazen, SL				Poliakov, E; Brennan, ML; Macpherson, J; Zhang, RL; Sha, W; Narine, IA; Salomon, RG; Hazen, SL			Isolevuglandins, a novel class of isoprostenoid derivatives, function as integrated sensors of oxidant stress and are generated by myeloperoxidase in vivo	FASEB JOURNAL			English	Article						isoprostane; myeloperoxidase; isolevuglandin; oxidant stress	LOW-DENSITY-LIPOPROTEIN; HUMAN ATHEROSCLEROTIC LESIONS; GAMMA-KETOALDEHYDES ISOLEVUGLANDINS; SCAVENGER RECEPTOR CD36; LIPID-PEROXIDATION; PROTEIN ADDUCTS; OXIDIZED PHOSPHOLIPIDS; 8-EPI-PROSTAGLANDIN F2-ALPHA; STRUCTURAL IDENTIFICATION; CARDIOVASCULAR-DISEASE	Isolevuglandins (isoLGs) are a family of reactive gamma-ketoaldehydes generated by free radical oxidation of arachidonate-containing lipids through the isoprostane pathway. Elevated plasma levels of isoLG protein adducts are observed in subjects with atherosclerosis compared with age/gender-matched controls. However, mechanisms for the generation of isoLGs in vivo are not established. Here we show that free radical-induced peroxidation promoted by the myeloperoxidase (MPO)/H2O2 system of leukocytes serves as one mechanism for the generation of isoLGs in vivo. Using a Candida sepsis model of inflammation, we demonstrate 3.5- and 2.7-fold increases in iso[4]LGE(2) and isoLGE(2) adducts of plasma proteins after pathogen exposure in wild-type mice. Plasma levels of F-2 isoprostanes were not significantly increased after pathogen challenge in this model. MPO knockout mice demonstrated significant reductions (34%, P=0.003) in plasma levels of iso[4]LGE(2) protein adducts after pathogen challenge compared with wild-type mice. Mass spectrometry and immunochemical methods demonstrate MPO-dependent formation of iso[4]LGE(2) and isoLGE(2) phospholipids and their corresponding isoLG protein adducts in model systems. The present studies thus identify MPO as one pathway for generation of isoLGs in vivo. They also suggest that long-lived protein isoLG adducts may serve as an alternative integrated sensor of oxidant stress in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Salomon, Robert G/C-3463-2008; Hazen, Stanley L/ABD-5845-2021	Salomon, Robert/0000-0001-9456-3557	NCRR NIH HHS [M01 RR018390] Funding Source: Medline; NHLBI NIH HHS [HL61878, HL70621, HL62526] Funding Source: Medline; NIGMS NIH HHS [GM21249] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR018390] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061878, R01HL070621, R01HL062526] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021249] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aratani Y, 1999, INFECT IMMUN, V67, P1828; AWAD JA, 1993, J BIOL CHEM, V268, P4161; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; Boutaud O, 1999, BIOCHEMISTRY-US, V38, P9389, DOI 10.1021/bi990470+; Brame CJ, 1999, J BIOL CHEM, V274, P13139, DOI 10.1074/jbc.274.19.13139; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Carr AC, 2000, ARTERIOSCL THROM VAS, V20, P1716, DOI 10.1161/01.ATV.20.7.1716; Chiabrando C, 1999, J BIOL CHEM, V274, P1313, DOI 10.1074/jbc.274.3.1313; Chisolm GM, 2000, FREE RADICAL BIO MED, V28, P1815, DOI 10.1016/S0891-5849(00)00344-0; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; DIFRANCO E, 1995, CHEM RES TOXICOL, V8, P61, DOI 10.1021/tx00043a008; FARRELL AJ, 1992, ANN RHEUM DIS, V51, P1219, DOI 10.1136/ard.51.11.1219; Gniwotta C, 1997, ARTERIOSCL THROM VAS, V17, P3236, DOI 10.1161/01.ATV.17.11.3236; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazell LJ, 1996, J CLIN INVEST, V97, P1535, DOI 10.1172/JCI118576; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Hoppe G, 1997, BBA-LIPID LIPID MET, V1344, P1, DOI 10.1016/S0005-2760(96)00160-9; IYER RS, 1989, PROSTAGLANDINS, V37, P471, DOI 10.1016/0090-6980(89)90096-8; JIROUSEK MR, 1990, PROSTAGLANDINS, V40, P187, DOI 10.1016/0090-6980(90)90083-8; KLEBANOFF SJ, 1978, NEUTROPHIL FUNCTION, P447; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Lawson JA, 1999, J BIOL CHEM, V274, P24441, DOI 10.1074/jbc.274.35.24441; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V200, P951, DOI 10.1006/bbrc.1994.1542; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Marathe GK, 1999, J BIOL CHEM, V274, P28395, DOI 10.1074/jbc.274.40.28395; Meagher EA, 2000, FREE RADICAL BIO MED, V28, P1745, DOI 10.1016/S0891-5849(00)00232-X; Mezzetti A, 2000, CARDIOVASC RES, V47, P475, DOI 10.1016/S0008-6363(00)00118-8; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MURTHI KK, 1990, PROSTAGLANDINS, V39, P611, DOI 10.1016/0090-6980(90)90022-N; MURTHI KK, 1993, BIOCHEMISTRY-US, V32, P4090, DOI 10.1021/bi00066a034; Noguchi N, 2000, J BIOCHEM-TOKYO, V127, P971, DOI 10.1093/oxfordjournals.jbchem.a022713; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratico D, 1999, ATHEROSCLEROSIS, V147, P1, DOI 10.1016/S0021-9150(99)00257-9; Roberts LJ, 1999, FASEB J, V13, P1157, DOI 10.1096/fasebj.13.10.1157; Roberts LJ, 1996, J BIOL CHEM, V271, P20617, DOI 10.1074/jbc.271.34.20617; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; Salomon RG, 1997, CHEM RES TOXICOL, V10, P536, DOI 10.1021/tx960157y; Salomon RG, 2000, BBA-MOL CELL BIOL L, V1485, P225, DOI 10.1016/S1388-1981(00)00038-X; Salomon RG, 1999, J BIOL CHEM, V274, P20271, DOI 10.1074/jbc.274.29.20271; Salomon RG, 2000, TRENDS CARDIOVAS MED, V10, P53, DOI 10.1016/S1050-1738(00)00040-2; SALOMON RG, 1987, PROSTAGLANDINS, V34, P643, DOI 10.1016/0090-6980(87)90289-9; Salomon RG, 2000, CHEM RES TOXICOL, V13, P557, DOI 10.1021/tx000007u; Salomon RG, 1997, CHEM RES TOXICOL, V10, P750, DOI 10.1021/tx970016b; Sayre LM, 1996, CHEM RES TOXICOL, V9, P1194, DOI 10.1021/tx960094j; SCHMIDLEY JW, 1992, PROSTAG LEUKOTR ESS, V47, P105, DOI 10.1016/0952-3278(92)90145-9; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; Shishehbor MH, 2003, CIRCULATION, V108, P426, DOI 10.1161/01.CIR.0000080895.05158.8B; Shishehbor MH, 2003, JAMA-J AM MED ASSOC, V289, P1675, DOI 10.1001/jama.289.13.1675; SPECTOR IM, 1974, NATURE, V249, P66, DOI 10.1038/249066a0; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBRECHER UP, 1990, FREE RADICAL BIO MED, V9, P155, DOI 10.1016/0891-5849(90)90119-4; Subbanagounder G, 1997, J ORG CHEM, V62, P7658, DOI 10.1021/jo970858f; Torre D, 1996, J CLIN PATHOL, V49, P574, DOI 10.1136/jcp.49.7.574; UEDA T, 1995, ELECTROPHORESIS, V16, P1002, DOI 10.1002/elps.11501601167; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; Wassmann S, 2002, ARTERIOSCL THROM VAS, V22, P300, DOI 10.1161/hq0202.104081; Watson AD, 1999, J BIOL CHEM, V274, P24787, DOI 10.1074/jbc.274.35.24787; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Zhang RL, 2002, J BIOL CHEM, V277, P46116, DOI 10.1074/jbc.M209124200; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	70	41	44	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2209	2220		10.1096/fj.03-0086com	http://dx.doi.org/10.1096/fj.03-0086com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656983				2022-12-28	WOS:000188067500042
J	Gilroy, DW; Colville-Nash, PR; McMaster, S; Sawatzky, DA; Willoughby, DA; Lawrence, T				Gilroy, DW; Colville-Nash, PR; McMaster, S; Sawatzky, DA; Willoughby, DA; Lawrence, T			Inducible cyclooxygenase-derived 15deoxy Delta(12-14)PGJ(2) brings about acute inflammatory resolution in rat pleurisy by inducing neutrophil and macrophage apoptosis	FASEB JOURNAL			English	Article						inflammation; PMN; cyclopentenone prostaglandins	CARRAGEENAN-INDUCED PLEURISY; DRAINING LYMPH-NODES; CELL-DEATH; IN-VITRO; CYCLOPENTENONE PROSTAGLANDINS; NONPHLOGISTIC PHAGOCYTOSIS; GASTROINTESTINAL TOXICITY; GROWTH-FACTOR; CUTTING EDGE; RECOGNITION	Failure of acute inflammation to resolve leads to persistence of the inflammatory response and may contribute to the development of chronic inflammation. Thus, an understanding of inflammatory resolution will provide insight into the etiology of chronic inflammation. In an acute pleurisy, polymorphonuclear leukocytes (PMNs) were found to predominate at the onset of the lesion but decreased in number by undergoing apoptosis, the principal mechanism by which PMNs died in this model. PMNs were progressively replaced by monocytes, which differentiated into macrophages. As with PMNs, macrophages also underwent programmed cell death leading to an abatement of the inflammatory response and eventual resolution. It was found that apoptosis of both these inflammatory cell types was mediated by pro-resolving cyclooxygenase 2-derived 15deoxyDelta(12-14)PGJ(2), which is uniquely expressed during active resolution. Although PMN programmed cell death is well understood, the observation that macrophages apoptose during resolution of acute inflammation is less well described. These results provide insight into the mechanisms that switch off acute inflammation and prevent complications of wound healing and potentially the development of immune-mediated chronic inflammation.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England	University of London; Queen Mary University London	Gilroy, DW (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England.	d.w.gilroy@qmul.ac.uk	Lawrence, Toby/GLU-3895-2022; Gilroy, Derek/AAP-7227-2020; Gilroy, Derek W/C-2588-2009	Lawrence, Toby/0000-0003-0967-6122; Gilroy, Derek/0000-0003-3476-0844; 				Adams DO., 1992, INFLAMMATION BASIC P, P637; Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; Bandeira-Melo C, 2000, J IMMUNOL, V164, P2267, DOI 10.4049/jimmunol.164.5.2267; BARRES BA, 1992, CELL, V70, P31, DOI 10.1016/0092-8674(92)90531-G; Bellingan GJ, 2002, J EXP MED, V196, P1515, DOI 10.1084/jem.20011794; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; BURSCH W, 1990, CARCINOGENESIS, V11, P847, DOI 10.1093/carcin/11.5.847; CAPASSO F, 1975, J PATHOL, V116, P117, DOI 10.1002/path.1711160208; CAPASSO F, 1975, AGENTS ACTIONS, V5, P528, DOI 10.1007/BF01972690; Castrillo A, 2003, MOL CELL BIOL, V23, P1196, DOI 10.1128/MCB.23.4.1196-1208.2003; COLES HSR, 1993, DEVELOPMENT, V118, P777; DUMONDE DC, 1965, J PATHOL BACTERIOL, V90, P649, DOI 10.1002/path.1700900235; DUMONDE DC, 1962, BRIT J EXP PATHOL, V43, P373; EBERT RH, 1974, INFLAMMATORY PROCESS; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074, DOI 10.1164/ajrccm.161.6.9906085; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Florey HW, 1970, GEN PATHOLOGY; FUTAKI N, 1994, PROSTAGLANDINS, V47, P55, DOI 10.1016/0090-6980(94)90074-4; Giles KM, 2001, J IMMUNOL, V167, P976, DOI 10.4049/jimmunol.167.2.976; Gilroy DW, 1998, EUR J PHARMACOL, V355, P211, DOI 10.1016/S0014-2999(98)00508-1; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; Hortelano S, 2000, J IMMUNOL, V165, P6525, DOI 10.4049/jimmunol.165.11.6525; Hughes J, 1997, AM J PATHOL, V150, P223; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Lan HY, 1997, AM J PATHOL, V151, P531; LAN HY, 1993, CLIN EXP IMMUNOL, V92, P336; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Liu YQ, 1999, J IMMUNOL, V162, P3639; Meagher LC, 1996, J IMMUNOL, V156, P4422; MEAGHER LC, 1992, J LEUKOCYTE BIOL, V52, P269, DOI 10.1002/jlb.52.3.269; MIYAKE A, 1993, BRIT J PHARMACOL, V110, P447, DOI 10.1111/j.1476-5381.1993.tb13831.x; Morse D., 1976, MED HIST, V20, P461; Moulding DA, 2001, J LEUKOCYTE BIOL, V70, P783; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; Pasquale CP, 1999, EUR J PHARMACOL, V368, P67, DOI 10.1016/S0014-2999(99)00010-2; Persson CGA, 2001, TRENDS PHARMACOL SCI, V22, P538, DOI 10.1016/S0165-6147(00)01839-3; RAMZI S, 1999, ROBBINS PATHOLOGIC B, V6, P50; Riches DW, 1988, MOL CELLULAR BIOL WO, P213; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1996, MOL CELLULAR BIOL WO, P275; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SAVILL J, 1992, KIDNEY INT, V42, P924, DOI 10.1038/ki.1992.369; SAVILL J, 1992, CLIN SCI, V83, P649, DOI 10.1042/cs0830649; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; Smith CJ, 1998, P NATL ACAD SCI USA, V95, P13313, DOI 10.1073/pnas.95.22.13313; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006; TOMLINSON A, 1994, BRIT J PHARMACOL, V113, P693, DOI 10.1111/j.1476-5381.1994.tb17048.x; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; Urade Y, 2000, VITAM HORM, V58, P89, DOI 10.1016/S0083-6729(00)58022-4; van Lent PLEM, 2001, J LEUKOCYTE BIOL, V70, P708; VANFURTH R, 1992, INFLAMMATION BASIC P, P325; von Knethen A, 2000, MOL CELL BIOCHEM, V212, P35, DOI 10.1023/A:1007124203607; Wallace JL, 1998, GASTROENTEROLOGY, V115, P101, DOI 10.1016/S0016-5085(98)70370-1; Warner TD, 1999, P NATL ACAD SCI USA, V96, P7563, DOI 10.1073/pnas.96.13.7563; WEISSMANN G, 1965, AM J PATHOL, V46, P129; WILLOUGHBY DA, 1962, J PATHOL BACTERIOL, V83, P389, DOI 10.1002/path.1700830208; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237, DOI 10.1164/ajrccm.154.1.8680686; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZYCHLINSKY A, 1992, NATURE, V358, P167, DOI 10.1038/358167a0	68	120	122	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2269	+		10.1096/fj.02-1162fje	http://dx.doi.org/10.1096/fj.02-1162fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563690				2022-12-28	WOS:000186343300022
J	Rhen, T; Grissom, S; Afshari, C; Cidlowski, JA				Rhen, T; Grissom, S; Afshari, C; Cidlowski, JA			Dexamethasone blocks the rapid biological effects of 17 beta-estradiol in the rat uterus without antagonizing its global genomic actions	FASEB JOURNAL			English	Article						17 beta-estradiol; dexamethasone; uterus; microarray	RETINOIC ACID SYNTHESIS; UTERINE GROWTH; MESSENGER-RNA; ESTROUS-CYCLE; MOUSE UTERUS; GLUCOCORTICOID RECEPTOR; ALCOHOL-DEHYDROGENASE; GENE-EXPRESSION; STRESS; PROGESTERONE	Estrogens and glucocorticoids have opposing effects on the female reproductive tract, but the molecular basis for this antagonism is poorly understood. We therefore examined the biological and transcriptional programs induced by estrogens and glucocorticoids in the uterus of immature female rats. Estradiol 17beta (E2) rapidly induced morphological changes reminiscent of an acute inflammatory response, including infiltration of eosinophils, edema in the stroma and myometrium, and a decrease in the height of luminal epithelial cells, whereas dexamethasone (Dex) only altered stromal cell morphology. When coadministered with E2, Dex completely blocked the proinflammatory effects of E2. Surprisingly, examination of E2 and Dex effects on gene expression using cDNA microarrays and real-time PCR revealed that these hormones had similar effects on the expression of many genes and that very few genes displayed antagonistic regulation. Together, these results indicate strong discord between the early biologic and genomic actions of estrogens and glucocorticoids and highlight a complex regulatory role for glucocorticoids and GR in the mammalian uterus.	NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Cidlowski, JA (corresponding author), NIEHS, Lab Signal Transduct, NIH, 111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cidlows1@niehs.nih.gov	Cidlowski, John A/G-2548-2019	Cidlowski, John A/0000-0003-1420-0516	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES023026, Z01ES023026] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ang HL, 1996, ALCOHOL CLIN EXP RES, V20, P1050, DOI 10.1111/j.1530-0277.1996.tb01946.x; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BITMAN J, 1967, ENDOCRINOLOGY, V80, P423, DOI 10.1210/endo-80-3-423; Boehm N, 1997, MOL CELL ENDOCRINOL, V132, P101, DOI 10.1016/S0303-7207(97)00126-3; Chandran UR, 1999, BEHAV BRAIN RES, V105, P29, DOI 10.1016/S0166-4328(99)00080-7; Chen Y, 1997, J Biomed Opt, V2, P364, DOI 10.1117/12.281504; Chrousos George P., 1998, Annals of Internal Medicine, V129, P229; Cidlowski JA, 1996, RECENT PROG HORM RES, V51, P457; DALLMAN MF, 1993, FRONT NEUROENDOCRIN, V14, P303, DOI 10.1006/frne.1993.1010; DELBENDE C, 1992, BRIT J PSYCHIAT, V160, P24, DOI 10.1192/S0007125000296657; Dodson RE, 1997, J BIOL CHEM, V272, P12249, DOI 10.1074/jbc.272.19.12249; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Galton VA, 1999, J CLIN INVEST, V103, P979, DOI 10.1172/JCI6073; Gibbs RB, 1996, J NEUROSCI, V16, P1049; Gunin AG, 2001, J ENDOCRINOL, V169, P23, DOI 10.1677/joe.0.1690023; Hamadeh HK, 2002, TOXICOL SCI, V67, P219, DOI 10.1093/toxsci/67.2.219; Hilgendorf I, 2001, PANCREATOLOGY, V1, P24, DOI 10.1159/000055788; Huang TJ, 2001, BIOL REPROD, V64, P163, DOI 10.1095/biolreprod64.1.163; Ikeda M, 2001, GENE, V273, P207, DOI 10.1016/S0378-1119(01)00589-3; IZAWA M, 1984, ENDOCRINOL JAPON, V31, P491; Jetten AM, 1996, MOL CELL ENDOCRINOL, V123, P7, DOI 10.1016/0303-7207(96)03871-3; JOHNSON DC, 1980, BIOL REPROD, V22, P1136, DOI 10.1093/biolreprod/22.5.1136; Jonsson P, 1996, PANCREAS, V12, P303; KINYAMU HK, IN PRESS MOL CELL BI; Kuno N, 1998, FEBS LETT, V425, P191, DOI 10.1016/S0014-5793(98)00213-0; Leal-Cerro A, 2001, Pituitary, V4, P111, DOI 10.1023/A:1012903330944; Lobenhofer EK, 2002, MOL ENDOCRINOL, V16, P1215, DOI 10.1210/me.16.6.1215; MARKAVERICH BM, 1981, J STEROID BIOCHEM, V14, P125, DOI 10.1016/0022-4731(81)90164-3; MCGIMSEY WC, 1991, ENDOCRINOLOGY, V129, P3064, DOI 10.1210/endo-129-6-3064; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; MCKAY LI, 2000, CANC MED, P730; MEDLOCK KL, 1991, J RECEPTOR RES, V11, P743, DOI 10.3109/10799899109064677; Miller DB, 2002, METABOLISM, V51, P5, DOI 10.1053/meta.2002.33184; Mitch W E, 2000, Trans Am Clin Climatol Assoc, V111, P258; Mizoguchi K, 2001, PSYCHONEUROENDOCRINO, V26, P443, DOI 10.1016/S0306-4530(01)00004-X; PANKO WB, 1981, J RECEPTOR RES, V2, P29, DOI 10.3109/10799898109038796; PFAFF DW, 1994, J STEROID BIOCHEM, V49, P373, DOI 10.1016/0960-0760(94)90282-8; RAMBO CO, 1983, J CELL BIOL, V97, P679, DOI 10.1083/jcb.97.3.679; Reibiger I, 2000, J REPROD FERTIL, V118, P243, DOI 10.1530/reprod/118.2.243; RESNIK R, 1981, AM J OBSTET GYNECOL, V140, P151, DOI 10.1016/0002-9378(81)90102-2; Rumpel E, 1996, ANN ANAT, V178, P337, DOI 10.1016/S0940-9602(96)80089-6; SAPOLSKY RM, 1993, BEHAV BRAIN RES, V57, P175, DOI 10.1016/0166-4328(93)90133-B; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; Sarrel PM, 1999, HUM REPROD UPDATE, V5, P205, DOI 10.1093/humupd/5.3.205; SZEGO CM, 1988, AM J PHYSIOL, V254, P775; Tibbetts TA, 1998, BIOL REPROD, V59, P1143, DOI 10.1095/biolreprod59.5.1143; Tibbetts TA, 1999, BIOL REPROD, V60, P1158, DOI 10.1095/biolreprod60.5.1158; Tilbrook AJ, 2000, REV REPROD, V5, P105, DOI 10.1530/ror.0.0050105; Twigger S, 2002, NUCLEIC ACIDS RES, V30, P125, DOI 10.1093/nar/30.1.125; Ujioka T, 2000, BIOL REPROD, V63, P1513, DOI 10.1095/biolreprod63.5.1513; VELARDO JT, 1956, ENDOCRINOLOGY, V59, P165, DOI 10.1210/endo-59-2-165; Viau V, 2002, J NEUROENDOCRINOL, V14, P506, DOI 10.1046/j.1365-2826.2002.00798.x; VIAU V, 1991, ENDOCRINOLOGY, V129, P2503, DOI 10.1210/endo-129-5-2503; Wan YH, 2002, MOL ENDOCRINOL, V16, P1204, DOI 10.1210/me.16.6.1204; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Welberg LAM, 2001, J NEUROENDOCRINOL, V13, P113, DOI 10.1046/j.1365-2826.2001.00601.x; Whitworth JA, 2001, CLIN EXP PHARMACOL P, V28, P993, DOI 10.1046/j.1440-1681.2001.03584.x; Xiao LJ, 2002, MOL REPROD DEV, V63, P47, DOI 10.1002/mrd.10128; YOSHIKAWA K, 1986, BIOCHEM BIOPH RES CO, V139, P1, DOI 10.1016/S0006-291X(86)80071-7	62	50	57	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1849	1870		10.1096/fj.02-1099com	http://dx.doi.org/10.1096/fj.02-1099com			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519664				2022-12-28	WOS:000186343300039
J	Jung, YJ; Isaacs, JS; Lee, SM; Trepel, J; Neckers, L				Jung, YJ; Isaacs, JS; Lee, SM; Trepel, J; Neckers, L			IL-1 beta mediated up-regulation of HIF-1 alpha via an NFkB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis	FASEB JOURNAL			English	Article						hypoxia-inducible factor-1 alpha; inflammation-induced cancer	NF-KAPPA-B; ENDOTHELIAL GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; DNA-BINDING; PHOSPHATIDYLINOSITOL 3-KINASE; STABILIZE HIF-1-ALPHA; PROLYL HYDROXYLATION; SYNOVIAL FIBROBLASTS; SIGNAL-TRANSDUCTION	Growing evidence indicates that inflammation is a contributing factor leading to cancer development. However, pathways involved in this progression are not well understood. To examine whether HIF-1alpha is a factor linking inflammation and tumorigenesis, we investigated whether the HIF-1 signaling pathway was stimulated by the pro-inflammatory cytokine interleukin-1beta (IL- 1beta) in A549 cells. We find that IL-1beta up-regulated HIF-1alpha protein under normoxia and activated the HIF-1-responsive gene vascular endothelial growth factor ( VEGF) via a pathway dependent on nuclear factor kappaB (NFkB). Interestingly, although this pathway is stimulated by upstream signaling via AKT and mTOR and requires new transcription, IL- 1 mediated HIF-1alpha induction also utilizes a post-transcriptional mechanism that involves antagonism of VHL-dependent HIF-1alpha degradation, which results in increased HIF-1alpha protein stability. IL-1 mediated NFkB-dependent cyclooxygenases-2 (COX-2) expression served as a positive effector for HIF-1alpha induction. Although COX-2 inhibitors attenuated IL-1 mediated HIF-1alpha induction, prostaglandin E-2 (PGE(2)), a physiological product of COX-2, induced HIF-1alpha protein in a dose-dependent manner. Our data, therefore, demonstrate that IL-1beta up-regulates functional HIF-1alpha protein through a classical inflammatory signaling pathway involving NFkB and COX-2, culminating in up-regulation of VEGF, a potent angiogenic factor required for tumor growth and metastasis. Thus, HIF- 1 is identified as a pivotal transcription factor linking the inflammatory and oncogenic pathways.	NCI, Cell & Canc Biol Branch, CCR, Rockville, MD 20850 USA; NCI, Med Oncol Clin Res Unit, CCR, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Neckers, L (corresponding author), NCI, Cell & Canc Biol Branch, CCR, 9610 Med Ctr Dr,Suite 300, Rockville, MD 20850 USA.	len@helix.nih.gov			NATIONAL CANCER INSTITUTE [Z01SC010074, Z01SC006743, ZICSC006743, ZIASC010074] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albina JE, 2001, AM J PHYSIOL-CELL PH, V281, pC1971, DOI 10.1152/ajpcell.2001.281.6.C1971; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Apte RN, 2000, ADV EXP MED BIOL, V479, P277; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Cao Y, 2002, J CELL PHYSIOL, V190, P279, DOI 10.1002/jcp.10068; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dempke W, 2001, J CANCER RES CLIN, V127, P411, DOI 10.1007/s004320000225; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; Ding Min, 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P129; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Fang HY, 2003, EUR J SURG ONCOL, V29, P171, DOI 10.1053/ejso.2002.1316; Farrow B, 2002, SURG ONCOL, V10, P153, DOI 10.1016/S0960-7404(02)00015-4; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Gately S, 2000, CANCER METAST REV, V19, P19, DOI 10.1023/A:1026575610124; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Haefner B, 2002, DRUG DISCOV TODAY, V7, P653, DOI 10.1016/S1359-6446(02)02309-7; Hanada T, 2002, CYTOKINE GROWTH F R, V13, P413, DOI 10.1016/S1359-6101(02)00026-6; Hellwig-Burgel T, 1999, BLOOD, V94, P1561, DOI 10.1182/blood.V94.5.1561.417a06_1561_1567; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson JR, 1997, J RHEUMATOL, V24, P1253; Jain RK, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.37265; Jung YJ, 2003, J BIOL CHEM, V278, P7445, DOI 10.1074/jbc.M209804200; Jung YJ, 2003, BIOCHEM J, V370, P1011, DOI 10.1042/BJ20021279; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Koyama S, 2002, EUR RESPIR J, V20, P1449, DOI 10.1183/09031936.02.00089802; Kudryavtsev IA, 2002, BIOCHEMISTRY-MOSCOW+, V67, P1021, DOI 10.1023/A:1020526119866; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Lukashev D, 2001, J BIOL CHEM, V276, P48754, DOI 10.1074/jbc.M104782200; Malkinson AM, 2002, CARCINOGENESIS, V23, P411, DOI 10.1093/carcin/23.3.411; Maxwell PH, 2001, CURR OPIN GENET DEV, V11, P293, DOI 10.1016/S0959-437X(00)00193-3; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mecklenburgh KI, 2002, BLOOD, V100, P3008, DOI 10.1182/blood-2002-02-0454; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Mitchell JA, 1998, INFLAMM RES, V47, pS88; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; O'Neill L A, 2000, Sci STKE, V2000, pre1; PRESCOTT SM, 2000, BIOCHIM BIOPHYS ACTA, V1470, P69, DOI [10.1016/s0304-419x(00)00006-8), DOI 10.1016/S0304-419X(00)00006-8]; Rapisarda A, 2002, CANCER RES, V62, P4316; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Sandau KB, 2001, BLOOD, V97, P1009, DOI 10.1182/blood.V97.4.1009; Semenza GL, 1998, CURR OPIN GENET DEV, V8, P588, DOI 10.1016/S0959-437X(98)80016-6; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Spencer W, 1999, ONCOGENE, V18, P495, DOI 10.1038/sj.onc.1202335; Stiehl DP, 2002, FEBS LETT, V512, P157, DOI 10.1016/S0014-5793(02)02247-0; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xu XC, 2002, ANTI-CANCER DRUG, V13, P127, DOI 10.1097/00001813-200202000-00003; Zhong H, 2000, CANCER RES, V60, P1541; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhou J, 2003, AM J PHYSIOL-CELL PH, V284, pC439, DOI 10.1152/ajpcell.00294.2002	76	548	584	4	52	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2115	+		10.1096/fj.03-0329fje	http://dx.doi.org/10.1096/fj.03-0329fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958148				2022-12-28	WOS:000185925100023
J	Riu, E; Ferre, T; Hidalgo, A; Mas, A; Franckhauser, S; Otaegui, P; Bosch, F				Riu, E; Ferre, T; Hidalgo, A; Mas, A; Franckhauser, S; Otaegui, P; Bosch, F			Overexpression of c-myc in the liver prevents obesity and insulin resistance	FASEB JOURNAL			English	Article						transgenic mice; type 2 diabetes; glucose metabolism	PHOSPHOENOLPYRUVATE CARBOXYKINASE GTP; PROLIFERATOR-ACTIVATED RECEPTORS; ELEMENT-BINDING PROTEIN-1C; TRANSGENIC MICE; GENE-EXPRESSION; UNCOUPLING PROTEIN-2; DIABETIC ALTERATIONS; RIBONUCLEIC-ACID; PPAR-ALPHA; GLUCOKINASE	Alterations in hepatic glucose metabolism play a key role in the development of the hyperglycemia observed in type 2 diabetes. Because the transcription factor c-Myc induces hepatic glucose uptake and utilization and blocks gluconeogenesis, we examined whether hepatic overexpression of c-myc counteracts the insulin resistance induced by a high-fat diet. After 3 months on this diet, control mice became obese, hyperglycemic, and hyperinsulinemic, indicating that they had developed insulin resistance. In contrast, transgenic mice remained lean and showed improved glucose disposal and normal levels of blood glucose and insulin, indicating that they had developed neither obesity nor insulin resistance. These findings were concomitant with normalization of hepatic glucokinase and pyruvate kinase gene expression and enzyme activity, which led to normalization of intrahepatic glucose-6-phosphate and glycogen content. In the liver of control mice fed a high-fat diet, the expression of genes encoding proteins that control energy metabolism, such as sterol receptor element binding protein 1-c, peroxisome proliferator activated receptor a, and uncoupling protein-2, was altered. In contrast, in the liver of transgenic mice fed a high-fat diet, the expression of these genes was normal. These results suggest that c-myc overexpression counteracted the obesity and insulin resistance induced by a high-fat diet by modulating the expression of genes that regulate hepatic metabolism.	Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain; Univ Autonoma Barcelona, Ctr Anim Biotechnol & Gene Therapy, E-08193 Bellaterra, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Bosch, F (corresponding author), Univ Autonoma Barcelona, Sch Vet Med, Dept Biochem & Mol Biol, E-08193 Bellaterra, Spain.	fatima.bosch@uab.es		BOSCH, FATIMA/0000-0002-7705-5515; Ferre, Tura/0000-0001-9713-0829; Riu, Efren/0000-0002-2574-3578; Franckhauser, Sylvie/0000-0001-5255-1224				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Boss O, 1998, EUR J ENDOCRINOL, V139, P1, DOI 10.1530/eje.0.1390001; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Chakravarty K, 2001, J BIOL CHEM, V276, P34816, DOI 10.1074/jbc.M103310200; Chavin KD, 1999, J BIOL CHEM, V274, P5692, DOI 10.1074/jbc.274.9.5692; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DAVIS SN, 1994, DIABETES ANN, V8, P119; DeFronzo RA, 1997, DIABETES REV, V5, P177; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Duckworth WC, 1998, ENDOCR REV, V19, P608, DOI 10.1210/er.19.5.608; Ferre T, 1996, FASEB J, V10, P1213, DOI 10.1096/fasebj.10.10.8751724; Ferre T, 1996, P NATL ACAD SCI USA, V93, P7225, DOI 10.1073/pnas.93.14.7225; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Foretz M, 1999, P NATL ACAD SCI USA, V96, P12737, DOI 10.1073/pnas.96.22.12737; Foretz M, 1999, MOL CELL BIOL, V19, P3760; GIRARD J, 1994, FASEB J, V8, P36, DOI 10.1096/fasebj.8.1.7905448; Guerre-Millo M, 2001, DIABETES, V50, P2809, DOI 10.2337/diabetes.50.12.2809; Hanson RW, 1997, ANNU REV BIOCHEM, V66, P581, DOI 10.1146/annurev.biochem.66.1.581; Hariharan N, 1997, DIABETES, V46, P11, DOI 10.2337/diabetes.46.1.11; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Iynedjian PB, 1998, BIOCHEM J, V333, P705, DOI 10.1042/bj3330705; IYNEDJIAN PB, 1987, J BIOL CHEM, V262, P6032; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KATO GJ, 1992, FASEB J, V6, P3065, DOI 10.1096/fasebj.6.12.1521738; Kelly LJ, 1998, ENDOCRINOLOGY, V139, P4920, DOI 10.1210/en.139.12.4920; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; Kim H, 2000, DIABETES, V49, P1517, DOI 10.2337/diabetes.49.9.1517; Koyama K, 1997, AM J PHYSIOL-ENDOC M, V273, pE708, DOI 10.1152/ajpendo.1997.273.4.E708; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; Memon RA, 2000, ENDOCRINOLOGY, V141, P4021, DOI 10.1210/en.141.11.4021; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MITRAKOU A, 1990, DIABETES, V39, P1381, DOI 10.2337/diabetes.39.11.1381; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; Niswender KD, 1997, J BIOL CHEM, V272, P22570, DOI 10.1074/jbc.272.36.22570; O'Doherty RM, 1999, DIABETES, V48, P2022, DOI 10.2337/diabetes.48.10.2022; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Okamoto Y, 2002, HEPATOL RES, V23, P138, DOI 10.1016/S1386-6346(01)00172-3; Pagliassotti M, 1994, ROLE LIVER MAINTAINI, P45; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Riu E, 2002, BIOCHEM J, V368, P931, DOI 10.1042/BJ20020605; Riu E, 1996, P NATL ACAD SCI USA, V93, P2198, DOI 10.1073/pnas.93.5.2198; ROSELLA G, 1995, MOL ENDOCRINOL, V9, P1396, DOI 10.1210/me.9.10.1396; Scott DK, 1998, J BIOL CHEM, V273, P24145, DOI 10.1074/jbc.273.37.24145; Scott DK, 1996, J BIOL CHEM, V271, P31909, DOI 10.1074/jbc.271.50.31909; Shiota M, 2001, DIABETES, V50, P622, DOI 10.2337/diabetes.50.3.622; STANTON LW, 1984, NATURE, V310, P423, DOI 10.1038/310423a0; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; VALERA A, 1995, FASEB J, V9, P1067, DOI 10.1096/fasebj.9.11.7649406; VALERA A, 1994, P NATL ACAD SCI USA, V91, P9151, DOI 10.1073/pnas.91.19.9151; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; VAULONT S, 1989, J MOL BIOL, V209, P205, DOI 10.1016/0022-2836(89)90273-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; YAMAMOTO T, 1991, BIOCHEM BIOPH RES CO, V175, P995, DOI 10.1016/0006-291X(91)91663-W; YOOWARREN H, 1983, P NATL ACAD SCI-BIOL, V80, P3656, DOI 10.1073/pnas.80.12.3656	58	30	31	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1715	+		10.1096/fj.02-1163fje	http://dx.doi.org/10.1096/fj.02-1163fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958186				2022-12-28	WOS:000184471600008
J	Kunzmann, S; Mantel, PY; Wohlfahrt, JG; Akdis, M; Blaser, K; Schmidt-Weber, CB				Kunzmann, S; Mantel, PY; Wohlfahrt, JG; Akdis, M; Blaser, K; Schmidt-Weber, CB			Histamine enhances TGF-beta 1-mediated suppression of Th2 responses	FASEB JOURNAL			English	Article						transforming growth factor beta 1; CD4(+) T cells; cAMP/PKA pathway; nucleofection	GROWTH-FACTOR-BETA; T-CELL; PROTEIN-KINASE; ALLERGIC DISEASES; HUMAN LYMPHOCYTES; FUNCTIONAL-CHARACTERIZATION; 2 PARTS; RECEPTOR; EXPRESSION; IDENTIFICATION	Susceptibility of T cells to TGF-beta1 produced by regulatory T cells has an important impact on the induction and maintenance of peripheral tolerance and therefore on the development of autoimmunity, cancer, and allergy. Histamine not only mediates the deleterious effects of allergic reactions, it can also modulate the Th1/Th2 cell balance. We demonstrate that histamine dose-dependently enhanced TGF-beta1-mediated suppression and TGF-beta1 responsiveness of CD4(+) T cells. This effect was mediated by the histamine 2 receptor (H2R), as demonstrated by receptor-specific agonists and antagonists. Furthermore, the histamine effect on TGF-beta1 responsiveness was cAMP/PKA dependent. This pathway is activated by the H2R, which is preferentially expressed on Th2 cells. Thus a higher additive effect of histamine on TGF-beta1 responsiveness was found in Th2 cells compared with Th1 cells. In fact, findings are confirmed by analysis of cytokine regulation, since activation of the H2R/cAMP pathway promoted TGF-beta1-mediated IL-4 inhibition but was ineffective in suppressing IFN-gamma. These results demonstrate that histamine supports TGF-beta1 susceptibility of T cells. Moreover, Th2 cells are more affected by histamine-enhanced TGF-beta1 suppression, which is particularly important for the regulation of allergen-specific T cells in allergic immune responses.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research	Schmidt-Weber, CB (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	csweber@siaf.unizh.ch	Schmidt-Weber, Carsten B./AAU-1621-2021; Mantel, Pierre-Yves/N-3065-2015; Akdis, Cezmi/AAV-4844-2020	Schmidt-Weber, Carsten B./0000-0002-3203-8084; Mantel, Pierre-Yves/0000-0001-9526-9309; Akdis, Cezmi/0000-0001-8020-019X				ADAMS GK, 1979, J IMMUNOL, V122, P555; Akdis CA, 1999, FASEB J, V13, P603, DOI 10.1096/fasebj.13.6.603; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Bachert C, 2002, ALLERGY, V57, P287, DOI 10.1034/j.1398-9995.2002.1r3542.x; Bitzer M, 2000, GENE DEV, V14, P187; BOURNE HR, 1974, SCIENCE, V184, P19, DOI 10.1126/science.184.4132.19; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987, DOI 10.1152/ajpgi.1997.273.5.G987; Diepgen TL, 2002, PEDIAT ALLERG IMM-UK, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Drutel G, 2001, MOL PHARMACOL, V59, P1; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770a; HAAKSMA EEJ, 1990, PHARMACOL THERAPEUT, V47, P73, DOI 10.1016/0163-7258(90)90046-5; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; HILL SJ, 1990, PHARMACOL REV, V42, P45; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106; Kay AB, 2001, NEW ENGL J MED, V344, P109, DOI 10.1056/NEJM200101113440206; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; KEMP BE, 1975, BIOCHEM J, V145, P241, DOI 10.1042/bj1450241; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; MURRAY AW, 1972, BIOCHEM J, V129, P995, DOI 10.1042/bj1290995a; Oda T, 2000, J BIOL CHEM, V275, P36781, DOI 10.1074/jbc.M006480200; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; Schmidt-Weber Carsten B, 2002, Curr Allergy Asthma Rep, V2, P259, DOI 10.1007/s11882-002-0028-8; Schmidt-Weber CB, 2002, ALLERGY, V57, P762, DOI 10.1034/j.1398-9995.2002.02158.x; Schneider E, 2002, TRENDS IMMUNOL, V23, P255, DOI 10.1016/S1471-4906(02)02215-9; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Smit MJ, 1999, CLIN EXP ALLERGY, V29, P19, DOI 10.1046/j.1365-2222.1999.00008.x; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Vang T, 2001, J EXP MED, V193, P497, DOI 10.1084/jem.193.4.497; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; ZHENG T, 1994, J IMMUNOL, V153, P4742; Zhu Y, 2001, MOL PHARMACOL, V59, P434, DOI 10.1124/mol.59.3.434	39	77	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1089	1095		10.1096/fj.02-1008com	http://dx.doi.org/10.1096/fj.02-1008com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773491				2022-12-28	WOS:000183818000012
J	Ling, TY; Huang, YH; Lai, MC; Huang, SS; Huang, JS				Ling, TY; Huang, YH; Lai, MC; Huang, SS; Huang, JS			Fatty acids modulate transforming growth factor-beta activity and plasma clearance	FASEB JOURNAL			English	Article						arachidonic acid; myristic acid; TGF-beta; activated alpha(2-)macroglobulin; TGF-beta-alpha M-2 complexes	TGF-BETA; BINDING-PROTEIN; TISSUE-INJURY; RECEPTOR; ALPHA(2)-MACROGLOBULIN; GROWTH-FACTOR-BETA-1; COMPLEX; ALPHA-2-MACROGLOBULIN; INHIBITION; CYTOKINES	The activity and plasma clearance of transforming growth factor (TGF)-beta are known to be regulated by activated alpha(2)-macroglobulin (alpha(2)M*). This has been implicated in pathophysiological processes, but no small molecule compounds have been reported to modulate TGF-beta activity by affecting the interaction of TGF-beta and alpha(2)M*. Here, we demonstrate that fatty acids are capable of inhibiting complex formation of TGF-beta isoforms and alpha(2)M* as demonstrated by nondenaturing and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. This is dependent on carbon chain length (C20, C18, C16, C14 > C12 > C10), degree of unsaturation (polyunsaturated > saturated), and TGF-beta isoforms (TGF-beta1 > TGF-beta2 > TGF-beta3). Arachidonic acid, which is one of the most potent inhibitors, is also capable of dissociating TGF-beta-alpha(2)M* complexes, but higher concentrations are required. Arachidonic acid appears to inhibit TGF-beta-alpha(2)M* complex formation by binding specifically to alpha(2)M* on TGF-beta binding, TGF-beta-induced growth inhibition, and TGF-beta-induced transcriptional activation in mink lung epithelial cells and affects plasma clearance of TGF-beta-alpha(2)M* complexes in mice. These results show that fatty acids are effective modulators of TGF-beta activity and plasma clearance and my be useful in treating human diseases through their effects on the interaction of TGF-beta and alpha(2)M*.	St Louis Univ, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; Taipei Med Univ, Grad Inst Med Sci, Dept Biochem, Taipei, Taiwan	Saint Louis University; Academia Sinica - Taiwan; Taipei Medical University	Huang, JS (corresponding author), St Louis Univ, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	huangjs@slu.edu		Ling, Thai-Yen/0000-0002-3992-883X				BORDER WA, 1992, NATURE, V360, P361, DOI 10.1038/360361a0; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BRUNING PF, 1986, CANCER RES, V46, P2606; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; CHEN CA, 1988, BIOTECHNIQUES, V6, P632; CROOKSTON KP, 1994, J BIOL CHEM, V269, P1533; DANIELPOUR D, 1990, J BIOL CHEM, V265, P6973; Demetriou M, 1996, J BIOL CHEM, V271, P12755, DOI 10.1074/jbc.271.22.12755; Feige JJ, 1996, HORM RES, V45, P227, DOI 10.1159/000184793; FLAUMENHAFT R, 1993, J CELL BIOL, V120, P995, DOI 10.1083/jcb.120.4.995; Gaedeke J, 2001, CONTRIB NEPHROL, V135, P153; HALL SW, 1991, J BIOL CHEM, V266, P12329; Huang SS, 1999, J BIOL CHEM, V274, P27754, DOI 10.1074/jbc.274.39.27754; HUANG SS, 1988, J BIOL CHEM, V263, P1535; JAMES K, 1990, IMMUNOL TODAY, V11, P163, DOI 10.1016/0167-5699(90)90067-J; JENNINGS JC, 1988, J CELL PHYSIOL, V137, P167, DOI 10.1002/jcp.1041370120; KURECKI T, 1909, ANAL BIOCHEM, V99, P415; Liu QJ, 2001, J BIOL CHEM, V276, P46212, DOI 10.1074/jbc.M105177200; Lyon M, 1997, J BIOL CHEM, V272, P18000, DOI 10.1074/jbc.272.29.18000; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MENDEL CM, 1986, J CLIN ENDOCR METAB, V63, P1394, DOI 10.1210/jcem-63-6-1394; MERWIN JR, 1991, AM J PATHOL, V138, P37; MURPHYULLRICH JE, 1992, MOL BIOL CELL, V3, P181, DOI 10.1091/mbc.3.2.181; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OKane S, 1997, INT J BIOCHEM CELL B, V29, P63, DOI 10.1016/S1357-2725(96)00120-3; PHILIP A, 1991, J BIOL CHEM, V266, P22290; PIPER HM, 1986, BASIC RES CARDIOL, V81, P373, DOI 10.1007/BF01907458; QIAN SW, 1994, BIOCHEMISTRY-US, V33, P12298, DOI 10.1021/bi00206a037; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; Rotzer D, 2001, EMBO J, V20, P480, DOI 10.1093/emboj/20.3.480; SALVESEN G, 1993, METHOD ENZYMOL, V223, P121; SHAH M, 1995, J CELL SCI, V108, P985; STARNES HF, 1988, J CLIN INVEST, V82, P1321, DOI 10.1172/JCI113733; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; Webb DJ, 2000, PROTEIN SCI, V9, P1986, DOI 10.1110/ps.9.10.1986; Wilson DM, 1997, AM J PATHOL, V150, P2181; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	39	11	13	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1559	+		10.1096/fj.02-1063fje	http://dx.doi.org/10.1096/fj.02-1063fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824279				2022-12-28	WOS:000183818000033
J	Hiscock, N; Chan, MHS; Bisucci, T; Darby, IA; Febbraio, MA				Hiscock, N; Chan, MHS; Bisucci, T; Darby, IA; Febbraio, MA			Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity	FASEB JOURNAL			English	Article						cytokine; glycogen; type 2	MUSCLE FIBERS; EXERCISE; IL-6; ACTIVATION; MECHANISMS; CELLS; GENE	In this study, we aimed to determine whether skeletal muscle cells per se are a source of interleukin (IL)-6 during contraction and whether IL-6 production is fiber type specific. Muscle biopsy samples were collected from seven males before (PRE) and after (POST) completing 120 min of continuous bicycle ergometry. Biopsies were sectioned and analyzed for the following: IL-6 protein detected by immunohistochemistry (IHC), IL-6 mRNA content detected by in situ hybridization, fiber type measured by either IHC or myofibrillar ATPase activity stain, and glycogen content measured by periodic acid schiff ( PAS) assay. Fibers were qualitatively categorized according to glycogen content to one of five groups (1-5), with 1 being very low (LOW) and 5 being very high ( HIGH) glycogen. Total fluorescence (PRE vs. POST) and glycogen-dependent fluorescence (LOW vs. HIGH) of IL-6 protein were quantitated using Metamorph software. Total IL-6 protein was elevated from PRE to POST exercise (P<0.05). At PRE, IL-6 protein was evenly distributed across all fibers at low levels, consistent with glycogen distribution. At POST, IL-6 protein was greater (P<0.05) in HIGH compared with LOW glycogen fibers, which coincided with type 2 fibers. IL-6 mRNA was distributed peripherally in all fibers at PRE. At POST, however, IL-6 mRNA appeared predominantly in type 2 fibers, which also had higher glycogen content (P<0.05). These data demonstrate that myocytes per se are a source of IL-6 produced during contraction. Our data also suggest that type 2 fibers predominantly produce IL-6 during muscle contractile activity.	RMIT Univ, Ctr Endocrinol Metab & Nutr, Skeletal Muscle Res Lab, Bundoora, Vic 3083, Australia; RMIT Univ, Sch Med Sci, Microvasc Res Grp, Melbourne, Vic, Australia	Royal Melbourne Institute of Technology (RMIT); Royal Melbourne Institute of Technology (RMIT)	Hiscock, N (corresponding author), RMIT Univ, Ctr Endocrinol Metab & Nutr, Skeletal Muscle Res Lab, POB 71, Bundoora, Vic 3083, Australia.	natalie.hiscock@rmit.edu.au	Febbraio, Mark/AAE-9632-2019	Febbraio, Mark/0000-0002-9296-4418; Chan, Stanley/0000-0002-4103-9441; Darby, Ian/0000-0002-0990-1986				Baylor SM, 2003, J PHYSIOL-LONDON, V551, P125, DOI 10.1113/jphysiol.2003.041608; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CICCO NA, 1990, BLOOD, V75, P2049; De Rossi M, 2000, INT IMMUNOL, V12, P1329, DOI 10.1093/intimm/12.9.1329; FEBBRAIO MA, 1994, J APPL PHYSIOL, V76, P589, DOI 10.1152/jappl.1994.76.2.589; Febbraio MA, 2002, FASEB J, V16, P1335, DOI 10.1096/fj.01-0876rev; Febbraio MA, 2002, BIOCHEM BIOPH RES CO, V296, P1264, DOI 10.1016/S0006-291X(02)02079-X; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GOLLNICK PD, 1973, PFLUG ARCH EUR J PHY, V344, P1, DOI 10.1007/BF00587437; HOLMES AG, 2004, IN PRESS METABOLISM; Keller C, 2001, FASEB J, V15, P2748, DOI 10.1096/fj.01-0507fje; KELLER C, 2002, J PHYSL P, V539; Klouche M, 1999, J IMMUNOL, V163, P4583; MABUCHI K, 1980, MUSCLE NERVE, V3, P233, DOI 10.1002/mus.880030308; Malm C, 2000, J PHYSIOL-LONDON, V529, P243, DOI 10.1111/j.1469-7793.2000.00243.x; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Penkowa M, 2003, FASEB J, V17, DOI 10.1096/fj.03-0311fje; PODOR TJ, 1989, ANN NY ACAD SCI, V557, P374; STARKIE RL, 2001, J PHYSL, V533, P285; Steensberg A, 2000, J PHYSIOL-LONDON, V529, P237, DOI 10.1111/j.1469-7793.2000.00237.x; STEENSBERG A, J PHYSL, V537, P633	21	186	203	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					992	+		10.1096/fj.03-1259fje	http://dx.doi.org/10.1096/fj.03-1259fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059966				2022-12-28	WOS:000221108800017
J	Karbat, I; Cohen, L; Gilles, N; Gordon, D; Gurevitz, M				Karbat, I; Cohen, L; Gilles, N; Gordon, D; Gurevitz, M			Conversion of a scorpion toxin agonist into an antagonist highlights an acidic residue involved in voltage sensor trapping during activation of neuronal Na+ channels	FASEB JOURNAL			English	Article						scorpion beta-toxin; sodium channel; voltage sensor; competitive antagonist	INSECT SODIUM-CHANNELS; DEPENDENT K+ CHANNEL; DOMAIN-II; DIVERSIFICATION; NEUROTOXINS	Gating modifiers constitute a large group of polypeptide toxins that interact with the voltage-sensing module of ion channels. Among them, scorpion beta-toxins induce a negative shift in the voltage dependence of sodium channel activation. To explain their effect, a "voltage sensor trapping" model has been proposed in which the voltage sensor of domain-II (DIIS4) is trapped in an outward, activated position by a prebound beta-toxin upon membrane depolarization. Whereas toxin effect on channel activation was enhanced upon neutralization of the two outermost arginines in DIIS4, toxin residues involved in sensor trapping have not been identified. Using the scorpion excitatory beta-toxin, Bj-xtrIT, we found two conserved acidic residues, Glu15 and Glu30, mandatory for toxin action. Whereas mutagenesis of Glu30 affected both toxicity and binding affinity, substitutions E15A/F abolished activity but had minor effects on binding. Complete uncoupling of activity from binding was obtained with mutant E15R, acting as an efficient antagonist of Bj-xtrIT. On the basis of the voltage sensor trapping model and our results, we propose that Glu15 interacts with the emerging gating charges of DIIS4 upon membrane depolarization. Conserved acidic residues found in a variety of gating modifiers from scorpions and spiders may interact similarly with the voltage sensor.	Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Ramat Aviv, Tel Aviv, Israel; CEA Saclay, Dept Ingn Etud Prot, F-91191 Gif Sur Yvette, France	Tel Aviv University; CEA; UDICE-French Research Universities; Universite Paris Saclay	Gordon, D (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Plant Sci, IL-69978 Ramat Aviv, Tel Aviv, Israel.	dgordon@post.tau.ac.il						Catterall WA, 2000, NEURON, V26, P13, DOI 10.1016/S0896-6273(00)81133-2; CATTERALL WA, 1992, PHYSIOL REV, V72, pS15, DOI 10.1152/physrev.1992.72.suppl_4.S15; Cestele S, 1998, NEURON, V21, P919, DOI 10.1016/S0896-6273(00)80606-6; Cestele S, 2001, J GEN PHYSIOL, V118, P291, DOI 10.1085/jgp.118.3.291; Froy O, 1999, J BIOL CHEM, V274, P5769, DOI 10.1074/jbc.274.9.5769; Gilles N, 2003, FEBS LETT, V540, P81, DOI 10.1016/S0014-5793(03)00226-6; Gilles N, 2000, J NEUROCHEM, V75, P1735, DOI 10.1046/j.1471-4159.2000.0751735.x; Gordon D, 2003, EUR J BIOCHEM, V270, P2663, DOI 10.1046/j.1432-1033.2003.03643.x; Gordon Dalia, 1997, Invertebrate Neuroscience, V3, P103, DOI 10.1007/BF02480365; Gurevitz M, 2001, FASEB J, V15, P1201, DOI 10.1096/fj.00-0571hyp; Hille B., 1992, IONIC CHANNELS EXCIT; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Krimm I, 1999, J MOL BIOL, V285, P1749, DOI 10.1006/jmbi.1998.2418; Lee D, 2000, J INSECT PHYSIOL, V46, P499, DOI 10.1016/S0022-1910(99)00136-5; Mitrovic N, 1998, J GEN PHYSIOL, V111, P451, DOI 10.1085/jgp.111.3.451; Oren DA, 1998, STRUCTURE, V6, P1095, DOI 10.1016/S0969-2126(98)00111-7; Pintar A, 1999, J MOL BIOL, V287, P359, DOI 10.1006/jmbi.1999.2611; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Rash LD, 2002, TOXICON, V40, P225, DOI 10.1016/S0041-0101(01)00199-4; REED L. J., 1938, AMER JOUR HYG, V27, P493; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; SCHILD HO, 1957, PHARMACOL REV, V9, P242; Shichor I, 2002, J NEUROSCI, V22, P4364, DOI 10.1523/JNEUROSCI.22-11-04364.2002; Xiong YM, 1999, TOXICON, V37, P1165, DOI 10.1016/S0041-0101(98)00253-0	24	41	43	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					683	689		10.1096/fj.03-0733com	http://dx.doi.org/10.1096/fj.03-0733com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054090				2022-12-28	WOS:000221108800038
J	Andrabi, SA; Sayeed, I; Siemen, D; Wolf, G; Horn, TFW				Andrabi, SA; Sayeed, I; Siemen, D; Wolf, G; Horn, TFW			Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for antiapoptotic effects of melatonin	FASEB JOURNAL			English	Article						patch clamp; intracellular calcium; TMRM; NMDA; apoptosis; fluo-4	CEREBRAL-ARTERY OCCLUSION; TRANSIENT FOREBRAIN ISCHEMIA; NITRIC-OXIDE SYNTHASE; NF-KAPPA-B; CYCLOSPORINE-A; CYTOCHROME-C; CELL-DEATH; OXIDATIVE STRESS; STRIATAL NEURONS; BRAIN-DAMAGE	Melatonin, the secretory product of the pineal gland, is known to be neuroprotective in cerebral ischemia, which is so far mostly attributed to its antioxidant properties. Here we show that melatonin directly inhibits the mitochondrial permeability transition pore (mtPTP). mtPTP contributes to the pathology of ischemia by releasing calcium and cytochrome c (cyt c) from mitochondria. Consistently, NMDA-induced calcium rises were diminished by melatonin in cultured mouse striatal neurons, similar to the pattern seen with cyclosporine A (CsA). When the mouse striatal neurons were subjected to oxygen-glucose deprivation (OGD), melatonin strongly prevented the OGD-induced loss of the mitochondrial membrane potential. To assess the direct effect of melatonin on the mtPTP activity at the single channel level, recordings from the inner mitochondrial membrane were obtained by a patch-clamp approach using rat liver mitoplasts. Melatonin strongly inhibited mtPTP currents in a dose-dependent manner with an IC50 of 0.8 muM. If melatonin is an inhibitor of the mtPTP, it should prevent mitochondrial cyt c release as seen in stroke models. Rats underwent middle cerebral artery occlusion (MCAO) for 2 h followed by reperfusion. Melatonin (10 mg/kg ip) or vehicle was given at the time of occlusion and at the time of reperfusion. Indeed, infarct area in the brain sections of melatonin-treated animals displayed a considerably decreased cyt c release along with less activation of caspase-3 and apoptotic DNA fragmentation. Melatonin treatment diminished the loss of neurons and decreased the infarct volume as compared with untreated MCAO rats. Our findings suggest that the direct inhibition of the mtPTP by melatonin may essentially contribute to its anti-apoptotic effects in transient brain ischemia.	Otto Von Guericke Univ, Inst Med Neurobiol, D-39120 Magdeburg, Germany; Otto Von Guericke Univ, Dept Neurol, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Horn, TFW (corresponding author), Otto Von Guericke Univ, Inst Med Neurobiol, Leipziger Str 44, D-39120 Magdeburg, Germany.	thomas.horn@medizin.uni-magdeburg.de	Andrabi, Shaida/I-6167-2012	Andrabi, Shaida/0000-0002-3305-2638				ACUNACASTROVIEJ.D, 1997, LIFE SCI, V60, P23; Alano CC, 2002, J NEUROCHEM, V80, P531, DOI 10.1046/j.0022-3042.2001.00738.x; Andreyev A, 1999, CELL DEATH DIFFER, V6, P825, DOI 10.1038/sj.cdd.4400565; Antolin I, 1996, FASEB J, V10, P882, DOI 10.1096/fasebj.10.8.8666165; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; BARLOWWALDEN LR, 1995, NEUROCHEM INT, V26, P497, DOI 10.1016/0197-0186(94)00154-M; Belayev L, 1996, STROKE, V27, P1616, DOI 10.1161/01.STR.27.9.1616; Bernardi P, 2001, TRENDS BIOCHEM SCI, V26, P112, DOI 10.1016/S0968-0004(00)01745-X; Cassarino DS, 1999, BBA-MOL BASIS DIS, V1453, P49, DOI 10.1016/S0925-4439(98)00083-0; Cho S, 1997, BRAIN RES, V755, P335, DOI 10.1016/S0006-8993(97)00188-1; Chung SY, 2003, J PINEAL RES, V34, P95, DOI 10.1034/j.1600-079X.2003.00010.x; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Crompton M, 2000, J PHYSIOL-LONDON, V529, P11, DOI 10.1111/j.1469-7793.2000.00011.x; CROMPTON M, 1988, BIOCHEM J, V255, P357; Cuzzocrea S, 2000, J PINEAL RES, V29, P217, DOI 10.1034/j.1600-0633.2002.290404.x; Ferrand-Drake M, 2003, J NEUROCHEM, V85, P1431, DOI 10.1046/j.1471-4159.2003.01794.x; Fiskum G, 1999, J CEREBR BLOOD F MET, V19, P351, DOI 10.1097/00004647-199904000-00001; FOURNIER N, 1987, J BIOENERG BIOMEMBR, V19, P297, DOI 10.1007/BF00762419; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; GOLDBERG MP, 1987, J PHARMACOL EXP THER, V243, P784; GOLDBERG MP, 1993, J NEUROSCI, V13, P3510; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Halestrap AP, 2002, BIOCHIMIE, V84, P153, DOI 10.1016/S0300-9084(02)01375-5; Halestrap AP, 1999, BIOCHEM SOC SYMP, V66, P181, DOI 10.1042/bss0660181; HANSEN AJ, 1981, ACTA PHYSIOL SCAND, V113, P437, DOI 10.1111/j.1748-1716.1981.tb06920.x; Harms C, 2000, FASEB J, V14, P1814, DOI 10.1096/fj.99-0899com; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; HORTNAGL H, 1991, N-S ARCH PHARMACOL, V344, P213, DOI 10.1007/BF00167221; HUERTODELGADILLO L, 1994, J PINEAL RES, V17, P55, DOI 10.1111/j.1600-079X.1994.tb00114.x; Ichas F, 1998, BBA-BIOENERGETICS, V1366, P33, DOI 10.1016/S0005-2728(98)00119-4; Jiang DM, 2001, J BIOL CHEM, V276, P47524, DOI 10.1074/jbc.M108834200; Joo WS, 1998, NEUROREPORT, V9, P4123, DOI 10.1097/00001756-199812210-00022; Khaspekov L, 1999, EUR J NEUROSCI, V11, P3194, DOI 10.1046/j.1460-9568.1999.00743.x; Kilic E, 1999, J CEREBR BLOOD F MET, V19, P511, DOI 10.1097/00004647-199905000-00005; Kowaltowski AJ, 2001, FEBS LETT, V495, P12, DOI 10.1016/S0014-5793(01)02316-X; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Krohn AJ, 1999, J NEUROSCI, V19, P7394, DOI 10.1523/JNEUROSCI.19-17-07394.1999; Kunduzova OR, 2003, FASEB J, V17, P872, DOI 10.1096/fj.02-0504fje; Lapin IP, 1998, J PINEAL RES, V24, P215; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu W, 2001, BRAIN RES, V916, P239, DOI 10.1016/S0006-8993(01)03006-2; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; LONGA EZ, 1989, STROKE, V20, P84, DOI 10.1161/01.STR.20.1.84; Lorenz P, 2003, NITRIC OXIDE-BIOL CH, V9, P64, DOI 10.1016/j.niox.2003.09.005; Loupatatzis C, 2002, CELL PHYSIOL BIOCHEM, V12, P269, DOI 10.1159/000067897; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsumoto S, 2002, LIFE SCI, V72, P591, DOI 10.1016/S0024-3205(02)02267-1; Matsumoto S, 1999, J CEREBR BLOOD F MET, V19, P736, DOI 10.1097/00004647-199907000-00002; Mohan N, 1995, BIOCHEM MOL BIOL INT, V37, P1063; Nakatsuka H, 1999, BRAIN RES, V849, P216, DOI 10.1016/S0006-8993(99)01971-X; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Pei Z, 2002, J PINEAL RES, V32, P168, DOI 10.1034/j.1600-079x.2002.1o847.x; Pei Z, 2003, STROKE, V34, P770, DOI 10.1161/01.STR.0000057460.14810.3E; Peng TI, 1998, EXP NEUROL, V149, P1, DOI 10.1006/exnr.1997.6599; Pennartz CMA, 2002, NATURE, V416, P286, DOI 10.1038/nature728; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; Qian T, 1999, TOXICOL APPL PHARM, V154, P117, DOI 10.1006/taap.1998.8580; Reichert SA, 2001, J NEUROSCI, V21, P6608, DOI 10.1523/JNEUROSCI.21-17-06608.2001; REITER RJ, 1992, BIOESSAYS, V14, P169, DOI 10.1002/bies.950140307; Shen YX, 2002, J PINEAL RES, V32, P163, DOI 10.1034/j.1600-079x.2002.1o839.x; SIEMEN, 2002, REST NEURO NEUROSCI, V20, P275; SIESJO BK, 1985, PROG BRAIN RES, V63, P121; SIESJO BK, 1992, J NEUROSURG, V77, P169, DOI 10.3171/jns.1992.77.2.0169; SIMON RP, 1984, J CEREBR BLOOD F MET, V4, P350, DOI 10.1038/jcbfm.1984.52; Smaili SS, 1999, CELL CALCIUM, V26, P121, DOI 10.1054/ceca.1999.0061; Szewczyk A, 2002, PHARMACOL REV, V54, P101, DOI 10.1124/pr.54.1.101; Tan DX, 2000, BIOL SIGNAL RECEPT, V9, P137; Uchino H, 2002, NEUROBIOL DIS, V10, P219, DOI 10.1006/nbdi.2002.0514; Uchino H, 1998, BRAIN RES, V812, P216, DOI 10.1016/S0006-8993(98)00902-0; Wang XD, 2001, GENE DEV, V15, P2922; Yoo YM, 2002, J PINEAL RES, V33, P146, DOI 10.1034/j.1600-079X.2002.02899.x; Yoshimoto T, 1999, BRAIN RES, V839, P283, DOI 10.1016/S0006-8993(99)01733-3; Zamzami N, 1996, FEBS LETT, V384, P53, DOI 10.1016/0014-5793(96)00280-3; ZORATTI M, 1994, J BIOENERG BIOMEMBR, V26, P543, DOI 10.1007/BF00762739	75	258	278	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					869	+		10.1096/fj.03-1031fje	http://dx.doi.org/10.1096/fj.03-1031fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033929				2022-12-28	WOS:000220522800013
J	O'Connell-Rodwell, CE; Shriver, D; Simanovskii, DM; Mcclure, C; Cao, YA; Zhang, WS; Bachmann, MH; Beckham, JT; Jansen, ED; Palanker, D; Schwettman, HA; Contag, CH				O'Connell-Rodwell, CE; Shriver, D; Simanovskii, DM; Mcclure, C; Cao, YA; Zhang, WS; Bachmann, MH; Beckham, JT; Jansen, ED; Palanker, D; Schwettman, HA; Contag, CH			A genetic reporter of thermal stress defines physiologic zones over a defined temperature range	FASEB JOURNAL			English	Article						laser-tissue interactions; luciferase; Hsp70; thermal stress	LIVING MAMMALS; EXPRESSION; DAMAGE; HYPERTHERMIA	We define five unique cellular responses to thermal stress using a reporter construct generated using the stress-inducible promoter from the gene encoding a murine 70 kDa heat shock protein (Hsp70A.1) to express luciferase (luc). Thermal stress was delivered over a range of temperatures (42-68degreesC) for 5 s to 20 min and luciferase activity was measured in live cells using a cooled CCD camera as a measure of reporter gene transcription. Reporter gene expression was assessed every 2 h for 10 h, and at 24 h post-stress. Expression patterns were validated for selected temperatures. A transition zone where cells lose the ability to produce light and beyond which > 50% of cells die was observed to occur within a narrow (2.5degreesC) temperature window. Although luc and hsp70 mRNA levels in this transition zone were high, there were reduced levels of Luc and Hsp70 protein and ATP levels. Cells treated at these temperatures recovered the ability to produce light in response to a secondary stress at 30 h. This Hsp70-luc reporter gene construct may be useful for defining zones of physiologic responses and assessing collateral thermal damage generated during treatment of biological tissue with lasers and other sources of heat.	Stanford Univ, Sch Med, Dept Pediat Microbiol & Immunol & Radiol, Stanford, CA 94305 USA; Stanford Univ, WW Hansen Expt Phys Lab, Picosecond Free Electron Laser Ctr, Stanford, CA 94305 USA; Xenogen Corp, Alameda, CA USA; Vanderbilt Univ, Dept Biomed Engn, Nashville, TN 37235 USA	Stanford University; Stanford University; Vanderbilt University	Contag, CH (corresponding author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94035 USA.	ccontag@cmgm.stanford.edu	Palanker, Daniel V/G-5447-2013; Bachmann, Michael Hubertus/N-9339-2016; Jansen, E. Duco/B-1894-2013	Bachmann, Michael Hubertus/0000-0002-0204-3720; Contag, Christopher/0000-0002-1011-8278; Palanker, Daniel/0000-0002-0480-3025				BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; Beckham JT, 2001, PROC SPIE, V4257, P377, DOI 10.1117/12.434723; Contag CH, 1997, PHOTOCHEM PHOTOBIOL, V66, P523, DOI 10.1111/j.1751-1097.1997.tb03184.x; Contag PR, 1998, NAT MED, V4, P245, DOI 10.1038/nm0298-245; Edelman Linda S., 1997, Journal of Burn Care and Rehabilitation, V18, P483, DOI 10.1097/00004630-199711000-00003; Fujitomi Y, 1999, LASER SURG MED, V24, P14, DOI 10.1002/(SICI)1096-9101(1999)24:1<14::AID-LSM4>3.0.CO;2-2; GERWECK LE, 1985, CANCER RES, V45, P3408; GULLINO PM, 1982, J NATL CANCER I, V68, P519; HOOPER CE, 1994, J BIOLUM CHEMILUM, V9, P113, DOI 10.1002/bio.1170090303; KAMAT BR, 1985, J INVEST DERMATOL, V85, P274, DOI 10.1111/1523-1747.ep12276758; Kiang JG, 1998, PHARMACOL THERAPEUT, V80, P183, DOI 10.1016/S0163-7258(98)00028-X; LASZLO A, 1992, CELL PROLIFERAT, V25, P59, DOI 10.1111/j.1365-2184.1992.tb01482.x; London RA, 1997, APPL OPTICS, V36, P9068, DOI 10.1364/AO.36.009068; MORITZ AR, 1947, AM J PATHOL, V23, P695; Smith RC, 2002, HUM GENE THER, V13, P697, DOI 10.1089/104303402317322267; Yang M, 2000, P NATL ACAD SCI USA, V97, P12278, DOI 10.1073/pnas.97.22.12278; ZWEIG AD, 1990, LASER SURG MED, V10, P262, DOI 10.1002/lsm.1900100306	17	49	54	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2004	18	2					264	271		10.1096/fj.03-0585com	http://dx.doi.org/10.1096/fj.03-0585com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769820				2022-12-28	WOS:000220425000006
J	Anders, HJ; Vielhauer, V; Eis, V; Linde, Y; Kretzler, M; de Lema, GP; Strutz, F; Bauer, S; Rutz, M; Wagner, H; Grone, HJ; Schlbndorff, D				Anders, HJ; Vielhauer, V; Eis, V; Linde, Y; Kretzler, M; de Lema, GP; Strutz, F; Bauer, S; Rutz, M; Wagner, H; Grone, HJ; Schlbndorff, D			Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice	FASEB JOURNAL			English	Article						chemokines; autoimmune diseases; kidney; lupus; immunity	SYSTEMIC-LUPUS-ERYTHEMATOSUS; BACTERIAL CPG-DNA; IMMUNE-COMPLEX GLOMERULONEPHRITIS; CHEMOKINE RECEPTOR; NZB/NZW MICE; EXPRESSION; CELLS; IMMUNIZATION; AUTOIMMUNITY; ANTIBODIES	How bacterial or viral infections trigger flares of autoimmunity is poorly understood. As toll-like receptor (TLR)-9 activation by exogenous or endogenous CpG-DNA may contribute to disease activity of systemic lupus erythematosus, we examined the effects of CpG-oligodeoxynucleotides (ODN) or DNA derived from Escherichia coli (E. coli) on the course of nephritis in MRL1pr/1pr mice. In kidneys of these mice, TLR9 localized to glomerular, tubulointerstitial, and perivascular infiltrates. After intraperitoneal injection labeled CpG-ODN localized to glomerular and interstitial macrophages and dendritic cells in nephritic kidneys of MRL1pr/1pr mice but not in healthy MRL controls. Furthermore, murine J774 macrophages and splenocytes from MRL1pr/1pr mice, but not tubular epithelial cells, renal fibroblasts, or mesangial cells, expressed TLR9 and up-regulated CCL5/RANTES mRNA upon stimulation with CpG-ODN in vitro. In vivo both E. coli DNA and CpG-ODN increased serum DNA autoantibodies of the IgG(2a) isotype in MRL1pr/1pr mice. This was associated with progression of mild to crescentic glomerulonephritis, interstitial fibrosis, and heavy proteinuria. CpG-ODN increased renal CCL2/MCP-1 and CCL5/RANTES expression associated with increased glomerular and interstitial leukocyte recruitment. In contrast control GpC-ODN had no effect. We conclude that TLR9 activation triggers disease activity of systemic autoimmunity, for example, lupus nephritis, and that adaptive and innate immune mechanisms contribute to the CpG-DNA-induced progression of lupus nephritis.	Univ Munich, Med Poliklin, Nephrol Ctr, D-80336 Munich, Germany; Univ Med Ctr, Dept Nephrol & Rheumatol, Gottingen, Germany; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-8000 Munich, Germany; German Canc Res Ctr, Div Mol & Cellular Pathol, D-6900 Heidelberg, Germany	University of Munich; University of Gottingen; Technical University of Munich; Helmholtz Association; German Cancer Research Center (DKFZ)	Anders, HJ (corresponding author), Univ Munich, Med Poliklin, Nephrol Ctr, Pettenkoferstr 8A, D-80336 Munich, Germany.	hjanders@med.uni-muenchen.de	Fernandez-Nebro, Antonio/K-7628-2012; Anders, Hans-Joachim/ABD-6247-2021	Fernandez-Nebro, Antonio/0000-0002-2962-9844; Perez de Lema, Guillermo/0000-0002-6244-1480; Bauer, Stefan/0000-0002-8462-1845; Anders, Hans-Joachim/0000-0003-2434-2956				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Anders HJ, 2003, KIDNEY INT, V63, P401, DOI 10.1046/j.1523-1755.2003.00750.x; Anders HJ, 2003, J AM SOC NEPHROL, V14, P317, DOI 10.1097/01.ASN.0000042169.23931.73; Anders HJ, 2002, J CLIN INVEST, V109, P251, DOI 10.1172/JCI14040; Anders HJ, 2001, J AM SOC NEPHROL, V12, P919, DOI 10.1681/ASN.V125919; AUSTIN HA, 1984, KIDNEY INT, V25, P689, DOI 10.1038/ki.1984.75; Butler M, 1997, LAB INVEST, V77, P379; Carroll M, 2001, NAT IMMUNOL, V2, P1089, DOI 10.1038/ni1201-1089; De Lema GP, 2001, J AM SOC NEPHROL, V12, P1369, DOI 10.1681/ASN.V1271369; Gao JJ, 2002, J LEUKOCYTE BIOL, V72, P1234; GILKESON GS, 1995, J CLIN INVEST, V95, P1398, DOI 10.1172/JCI117793; Gilkeson GS, 1998, J IMMUNOL, V161, P3890; Gilkeson GS, 1996, J EXP MED, V183, P1389, DOI 10.1084/jem.183.4.1389; GILKESON GS, 1989, J IMMUNOL, V142, P1482; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; HAVERTY TP, 1988, J CELL BIOL, V107, P1359, DOI 10.1083/jcb.107.4.1359; Heeg K, 2000, INT ARCH ALLERGY IMM, V121, P87, DOI 10.1159/000024303; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Holdsworth SR, 1999, KIDNEY INT, V55, P1198, DOI 10.1046/j.1523-1755.1999.00369.x; KRIEG AM, 1995, J CLIN IMMUNOL, V15, P284, DOI 10.1007/BF01541318; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krieg AM, 2002, NAT IMMUNOL, V3, P423, DOI 10.1038/ni0502-423; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Miyata M, 2000, ARTHRITIS RHEUM-US, V43, P2578, DOI 10.1002/1529-0131(200011)43:11<2578::AID-ANR27>3.0.CO;2-V; Older SA, 1999, SEMIN ARTHRITIS RHEU, V29, P131, DOI 10.1016/S0049-0172(99)80024-9; Pisetsky DS, 2001, CLIN IMMUNOL, V100, P157, DOI 10.1006/clim.2001.5064; Qu WM, 2000, EUR J IMMUNOL, V30, P2027, DOI 10.1002/1521-4141(200007)30:7<2027::AID-IMMU2027>3.0.CO;2-S; RICHARDSON B, 1990, ARTHRITIS RHEUM, V33, P1665, DOI 10.1002/art.1780331109; SANO H, 1982, J IMMUNOL, V128, P1341; Satriano JA, 1997, J AM SOC NEPHROL, V8, P596; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Tesch GH, 1999, J EXP MED, V190, P1813, DOI 10.1084/jem.190.12.1813; Tsuboi N, 2002, J IMMUNOL, V169, P2026, DOI 10.4049/jimmunol.169.4.2026; Vinuesa CG, 2002, NATURE, V416, P595, DOI 10.1038/416595a; Wagner H, 2002, CURR OPIN MICROBIOL, V5, P62, DOI 10.1016/S1369-5274(02)00287-4; WOLF G, 1990, J AM SOC NEPHROL, V1, P918; YUNG RL, 1994, LUPUS, V3, P487, DOI 10.1177/096120339400300611	42	162	180	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					534	+		10.1096/fj.03-0646fje	http://dx.doi.org/10.1096/fj.03-0646fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734643				2022-12-28	WOS:000188829300017
J	Webb, LMC; Smith, VP; Alcami, A				Webb, LMC; Smith, VP; Alcami, A			The gammaherpesvirus chemokine binding protein can inhibit the interaction of chemokines with glycosaminoglycans	FASEB JOURNAL			English	Article						GAG; N-loop; vCKBP-3; heparin-coated surface	MONOCYTE CHEMOATTRACTANT PROTEIN-1; HEPARAN-SULFATE; MYXOMA VIRUS; MURINE GAMMAHERPESVIRUS-68; GAMMA RECEPTOR; IN-VIVO; RANTES; SURFACE; HERPESVIRUS; HOMOLOG	Chemokines are small glycosaminoglycan (GAG) binding proteins that direct the migration of leukocytes by signaling through G protein coupled receptors (GPCR). Many viruses encode proteins that disrupt chemokine responses. The murine gammaherpesvirus-68 gene M3 encodes a chemokine binding protein (vCKBP-3), which has no sequence similarity to chemokine receptors. Initial characterization of vCKBP-3 showed that it inhibits receptor binding and chemokine-induced calcium influx. The structural requirements for the chemokines CXCL8 and CCL2 to bind to vCKBP-3 have been determined. Both chemokines bind to vCKBP-3 via their N-loop, a site that can participate in GAG binding for some chemokines. We have investigated the effect of vCKBP-3 on the interaction of chemokines with GAGs. We found that vCKBP-3 can prevent a range of chemokines from binding to GAGs. Moreover, we also found that vCKBP-3 can displace chemokines from a heparin-coated surface. Together, these data imply that vCKBP-3 can inhibit chemokine activity at two distinct levels. First, it inhibits chemokines from binding to their GPCR Second, it inhibits their GAG binding and disrupts pre-formed chemokine gradients. This dual ability of vCKBP-3 makes it a more effective inhibitor of chemokine activity.	Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Pathol, Div Virol, Cambridge CB2 1QP, England	University of Cambridge; University of Cambridge	Alcami, A (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Level 5,Box 157,Hills Rd, Cambridge CB2 2QQ, England.	aa258@mole.bio.cam.ac.uk	Alcami, Antonio/F-8512-2015; Webb, Louise/V-3121-2019	Alcami, Antonio/0000-0002-3333-6016; Webb, Louise/0000-0003-3417-1484	Medical Research Council [G9800943] Funding Source: Medline; MRC [G9800943] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alcami A, 1998, J IMMUNOL, V160, P624; Alexander JM, 2002, CELL, V111, P343, DOI 10.1016/S0092-8674(02)01007-3; Ali S, 2000, J BIOL CHEM, V275, P11721, DOI 10.1074/jbc.275.16.11721; Ali S, 2002, GLYCOBIOLOGY, V12, P535, DOI 10.1093/glycob/cwf069; Ali S, 2001, BIOCHEM J, V358, P737, DOI 10.1042/0264-6021:3580737; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Beck CG, 2001, J BIOL CHEM, V276, P43270, DOI 10.1074/jbc.M106305200; Bridgeman A, 2001, J EXP MED, V194, P301, DOI 10.1084/jem.194.3.301; Bryant NA, 2003, EMBO J, V22, P833, DOI 10.1093/emboj/cdg092; Burns JM, 1999, P NATL ACAD SCI USA, V96, P14499, DOI 10.1073/pnas.96.25.14499; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Fairbrother WJ, 1997, METHOD ENZYMOL, V287, P45; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Jensen KK, 2003, J VIROL, V77, P624, DOI 10.1128/JVI.77.1.624-630.2003; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lortat-Jacob H, 2002, P NATL ACAD SCI USA, V99, P1229, DOI 10.1073/pnas.032497699; Martin L, 2001, BIOCHEMISTRY-US, V40, P6303, DOI 10.1021/bi002670n; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Mossman K, 1996, VIROLOGY, V215, P17, DOI 10.1006/viro.1996.0003; Parry CM, 2000, J EXP MED, V191, P573, DOI 10.1084/jem.191.3.573; Proudfoot AEI, 2003, P NATL ACAD SCI USA, V100, P1885, DOI 10.1073/pnas.0334864100; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Seet BT, 2003, ANNU REV IMMUNOL, V21, P377, DOI 10.1146/annurev.immunol.21.120601.141049; Seet BT, 2001, P NATL ACAD SCI USA, V98, P9008, DOI 10.1073/pnas.171069398; Seet BT, 2001, J BIOL CHEM, V276, P30504, DOI 10.1074/jbc.M011401200; Smith CA, 1997, VIROLOGY, V236, P316, DOI 10.1006/viro.1997.8730; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; Van Berkel V, 2000, J VIROL, V74, P6741, DOI 10.1128/JVI.74.15.6741-6747.2000; van Berkel V, 2002, J CLIN INVEST, V109, P905, DOI 10.1172/JCI14358; Wang DZ, 2003, BIOCHEMISTRY-US, V42, P1071, DOI 10.1021/bi026425a; WEBB LM, 2003, IN PRESS J VIROL; Yoshie O, 2001, ADV IMMUNOL, V78, P57, DOI 10.1016/S0065-2776(01)78002-9	35	32	33	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					571	+		10.1096/fj.03-0485fje	http://dx.doi.org/10.1096/fj.03-0485fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734646				2022-12-28	WOS:000188829300004
J	Petrosillo, G; Ruggiero, FM; Paradies, G				Petrosillo, G; Ruggiero, FM; Paradies, G			Role of reactive oxygen species and cardiolipin in the release of cytochrome c from mitochondria	FASEB JOURNAL			English	Article						ROS; cytochrome c release; mitochondrial dysfunction	ELECTRON-TRANSPORT CHAIN; LIVER-MITOCHONDRIA; RESPIRATORY-CHAIN; PEROXIDATION; APOPTOSIS; MEMBRANE; PERMEABILIZATION; DISSOCIATION; METABOLISM; BINDING	Several lines of evidence indicate that mitochondria-mediated reactive oxygen species (ROS) generation is a major source of oxidative stress in the cell. Release of cytochrome c from mitochondria is a central event in apoptosis induction and appears to be mediated by ROS. Dissociation of cytochrome c from the IMM, where it is bound to cardiolipin, represents a necessary first step for cytochrome c release. In the present study, the role of ROS and cardiolipin in the release of cytochrome c from rat liver mitochondria was investigated. ROS were produced by mitochondria oxidizing succinate in the nonphosphorylating state. Cytochrome c was quantitated by a new, very sensitive and rapid reverse-phase HPLC method. We found that succinate-supported ROS production resulted in a release of cytochrome c from mitochondria and a parallel loss of cardiolipin content. These effects were directly and significantly correlated and also abolished by ADP, which prevents succinate-mediated ROS production. The ROS-induced cytochrome c release was independent from MPT and appears to involve VDAC. It is suggested that mitochondrial-induced ROS production promotes cytochrome c release from mitochondria by a two-steps process, consisting of the dissociation of this protein from cardiolipin, followed by permeabilization of the outer membrane, probably by interaction with VDAC. The data may help clarify the molecular mechanism underlying the release of cytochrome c from the mitochondria to the cytosol and the role of ROS and cardiolipin in this release.	Univ Bari, Dept Biochem & Mol Biol, Bari, Italy; Univ Bari, CNR, Inst Biomembranes & Bioenerget, Bari, Italy	Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Universita degli Studi di Bari Aldo Moro	Paradies, G (corresponding author), Univ Bari, Dept Biochem & Mol Biol, Bari, Italy.	g.paradies@biologia.uniba.it		PETROSILLO, GIUSEPPE/0000-0001-8035-8368				Asumendi A, 2002, BRIT J CANCER, V86, P1951, DOI 10.1038/sj.bjc.6600356; BLACK MJ, 1974, ANAL BIOCHEM, V58, P246, DOI 10.1016/0003-2697(74)90464-3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; BROWN LR, 1977, BIOCHIM BIOPHYS ACTA, V468, P389, DOI 10.1016/0005-2736(77)90290-5; Buege J A, 1978, Methods Enzymol, V52, P302; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; Crompton M, 1999, BIOCHEM J, V341, P233, DOI 10.1042/0264-6021:3410233; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; Doran E, 2000, BIOCHEM J, V348, P343, DOI 10.1042/0264-6021:3480343; Duchen MR, 2000, CELL CALCIUM, V28, P339, DOI 10.1054/ceca.2000.0170; DUTTON PL, 1975, BIOCHIM BIOPHYS ACTA, V387, P536, DOI 10.1016/0005-2728(75)90092-4; Fernandez MG, 2002, CELL GROWTH DIFFER, V13, P449; Gottlieb RA, 2000, FEBS LETT, V482, P6, DOI 10.1016/S0014-5793(00)02010-X; HOCH FL, 1992, BIOCHIM BIOPHYS ACTA, V1113, P71, DOI 10.1016/0304-4157(92)90035-9; Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Kuwana T, 2002, CELL, V111, P331, DOI 10.1016/S0092-8674(02)01036-X; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lutter M, 2000, NAT CELL BIOL, V2, P754, DOI 10.1038/35036395; Madesh M, 2001, J CELL BIOL, V155, P1003, DOI 10.1083/jcb.200105057; McMillin JB, 2002, BBA-MOL CELL BIOL L, V1585, P97, DOI 10.1016/S1388-1981(02)00329-3; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Nomura K, 2000, BIOCHEM J, V351, P183, DOI 10.1042/0264-6021:3510183; Ostrander DB, 2001, J BIOL CHEM, V276, P38061; Ott M, 2002, P NATL ACAD SCI USA, V99, P1259, DOI 10.1073/pnas.241655498; Paradies G, 2002, GENE, V286, P135, DOI 10.1016/S0378-1119(01)00814-9; Paradies G, 2001, MITOCHONDRION, V1, P151, DOI 10.1016/S1567-7249(01)00011-3; PARADIES G, 1991, ARCH BIOCHEM BIOPHYS, V284, P332, DOI 10.1016/0003-9861(91)90304-2; Paradies G, 1999, FREE RADICAL BIO MED, V27, P42, DOI 10.1016/S0891-5849(99)00032-5; Paradies G, 2000, FEBS LETT, V466, P323, DOI 10.1016/S0014-5793(00)01082-6; PETIT JM, 1994, EUR J BIOCHEM, V220, P871, DOI 10.1111/j.1432-1033.1994.tb18690.x; Petrosillo G, 2001, FEBS LETT, V509, P435, DOI 10.1016/S0014-5793(01)03206-9; Picklo MJ, 1999, ANAL BIOCHEM, V276, P166, DOI 10.1006/abio.1999.4349; ROBINSON NC, 1993, J BIOENERG BIOMEMBR, V25, P153, DOI 10.1007/BF00762857; RUGGIERO FM, 1984, LIPIDS, V19, P171, DOI 10.1007/BF02534794; Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Shidoji Y, 1999, BIOCHEM BIOPH RES CO, V264, P343, DOI 10.1006/bbrc.1999.1410; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; SOUSSI B, 1990, BIOCHEM J, V265, P227, DOI 10.1042/bj2650227; Subramanian M, 1998, BIOCHEMISTRY-US, V37, P1394, DOI 10.1021/bi9716581; Tuominen EKJ, 2002, J BIOL CHEM, V277, P8822, DOI 10.1074/jbc.M200056200; Zamzami N, 2003, CURR BIOL, V13, pR71, DOI 10.1016/S0960-9822(02)01433-1	45	491	516	1	23	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2202	2208		10.1096/fj.03-0012com	http://dx.doi.org/10.1096/fj.03-0012com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656982				2022-12-28	WOS:000188067500041
J	Mei, N; Lee, J; Sun, XJ; Xing, JZ; Hanson, J; Le, XC; Weinfeld, M				Mei, N; Lee, J; Sun, XJ; Xing, JZ; Hanson, J; Le, XC; Weinfeld, M			Genetic predisposition to the cytotoxicity of arsenic: the role of DNA damage and ATM	FASEB JOURNAL			English	Article						DNA double-strand breaks; p53; cell cycle	STRAND BREAK REPAIR; NUCLEOTIDE EXCISION-REPAIR; PROTEIN CROSS-LINKS; ATAXIA-TELANGIECTASIA; FANCONI-ANEMIA; IONIZING-RADIATION; DEFECTIVE REPAIR; P53; PHOSPHORYLATION; SENSITIVITY	Arsenic is a pervasive cytotoxin and carcinogen in the environment. Although its mode of action has yet to be fully elucidated, oxidative DNA damage has been suggested. A series of DNA repair-defective human and hamster cell lines associated with sensitivity to oxidative agents were examined for their response to arsenic-induced cytotoxicity. Only the Ataxia telangiectasia (AT) cells displayed a marked hypersensitive response (greater than twofold). The protective role of the ATM protein was confirmed by the normal response to arsenic displayed by AT cells expressing wild-type ATM. Although the ATM protein plays a pivotal role in response to DNA double-strand breakage, none of the other cell lines with defects in double-strand break repair displayed a similar hypersensitivity. Further examination indicated that concentrations of sodium arsenite as high as 1 mg/l do not generate significant levels of double-strand breaks. Our data suggest that the ATM protein functions in an important but different capacity in the cellular response to arsenic toxicity than it does in response to agents that generate double-strand breaks, such as ionizing radiation. Furthermore, the lack of hypersensitivity to arsenic displayed by the other cell lines calls into question the hypothesis that DNA damage is a significant factor in arsenic cytotoxicity.	Cross Canc Inst, Dept Expt Oncol, Edmonton, AB T6G 1Z2, Canada; Univ Alberta, Fac Med & Dent, Dept Publ Hlth Sci, Edmonton, AB T6G 2G3, Canada; Cross Canc Inst, Div Epidemiol, Edmonton, AB T6G 1Z2, Canada	University of Alberta; University of Alberta; University of Alberta	Le, XC (corresponding author), US FDA, Natl Ctr Toxicol Res, Div genet & Reprod Toxicol, 3900 NCTR Rd, Jefferson, AR 72079 USA.	xc.le@ualberta.ca; michaelw@cancerboard.ab.ca	Mei, Nan/E-8915-2011; Le, X. Chris/O-4947-2015	Mei, Nan/0000-0002-3501-9014; Le, X. Chris/0000-0002-7690-6701				Abernathy CO, 1999, ENVIRON HEALTH PERSP, V107, P593, DOI 10.2307/3434403; ALLALUNISTURNER MJ, 1995, RADIAT RES, V144, P288, DOI 10.2307/3578948; Bagla P, 1996, SCIENCE, V274, P174, DOI 10.1126/science.274.5285.174; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bogliolo M, 2002, MUTAGENESIS, V17, P529, DOI 10.1093/mutage/17.6.529; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Cartwright R, 1998, NUCLEIC ACIDS RES, V26, P3084, DOI 10.1093/nar/26.13.3084; CHEN CJ, 1992, BRIT J CANCER, V66, P888, DOI 10.1038/bjc.1992.380; Chen GQ, 1997, BLOOD, V89, P3345; Dawson B, 2001, BASIC CLIN BIOSTATIS, V3rd; DEBENHAM PG, 1988, MUTAT RES, V199, P1; DONG JT, 1993, MUTAT RES, V302, P97, DOI 10.1016/0165-7992(93)90010-S; Driggers WJ, 1996, CANCER RES, V56, P1262; FUJIWARA Y, 1982, BIOCHIM BIOPHYS ACTA, V699, P217, DOI 10.1016/0167-4781(82)90110-5; FULLER LF, 1988, MUTAT RES, V193, P109, DOI 10.1016/0167-8817(88)90041-7; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatti RA, 1999, MOL GENET METAB, V68, P419, DOI 10.1006/mgme.1999.2942; Gebel T, 1998, ANTICANCER RES, V18, P4253; Hartwig A, 1997, CARCINOGENESIS, V18, P399, DOI 10.1093/carcin/18.2.399; Hei TK, 1998, P NATL ACAD SCI USA, V95, P8103, DOI 10.1073/pnas.95.14.8103; Jimenez GS, 1999, ONCOGENE, V18, P7656, DOI 10.1038/sj.onc.1203013; Johnson RD, 1999, NATURE, V401, P397, DOI 10.1038/43935; JONES NJ, 1987, MUTAT RES, V183, P279, DOI 10.1016/0167-8817(87)90011-3; JORGENSEN TJ, 1995, RADIAT RES, V143, P219, DOI 10.2307/3579160; Kanzawa T, 2003, CANCER RES, V63, P2103; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; Le Page F, 2000, CELL, V101, P159, DOI 10.1016/S0092-8674(00)80827-2; Le XC, 1998, ANAL CHEM, V70, P1926, DOI 10.1021/ac971247q; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li DS, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454712; Lieber MR, 1999, GENES CELLS, V4, P77, DOI 10.1046/j.1365-2443.1999.00245.x; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Liu SX, 2001, P NATL ACAD SCI USA, V98, P1643, DOI 10.1073/pnas.031482998; Lynn S, 2000, CIRC RES, V86, P514, DOI 10.1161/01.RES.86.5.514; Mass MJ, 2001, CHEM RES TOXICOL, V14, P355, DOI 10.1021/tx000251l; Matsui M, 1999, J INVEST DERMATOL, V113, P26, DOI 10.1046/j.1523-1747.1999.00630.x; Mei N, 2002, BIOCHEM BIOPH RES CO, V297, P924, DOI 10.1016/S0006-291X(02)02309-4; Menendez D, 2001, MUTAGENESIS, V16, P443, DOI 10.1093/mutage/16.5.443; Murray D, 1996, MUTAT RES-DNA REPAIR, V364, P217, DOI 10.1016/S0921-8777(96)00036-5; Nakagawa K, 1999, MOL CELL BIOL, V19, P2828; National Research Council, 1999, ARS DRINK WAT; Nickson R, 1998, NATURE, V395, P338, DOI 10.1038/26387; NICOTERA TM, 1991, CANCER GENET CYTOGEN, V53, P1, DOI 10.1016/0165-4608(91)90109-8; Ochi T, 1998, ARCH TOXICOL, V72, P566, DOI 10.1007/s002040050544; OKUI T, 1986, MUTAT RES, V172, P69, DOI 10.1016/0165-1218(86)90108-4; Pagano G, 2003, BIOESSAYS, V25, P589, DOI 10.1002/bies.10283; PAINTER RB, 1981, MUTAT RES, V84, P183, DOI 10.1016/0027-5107(81)90061-0; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Smith AH, 1998, AM J EPIDEMIOL, V147, P660, DOI 10.1093/oxfordjournals.aje.a009507; Su Y, 2000, ANN INTERN MED, V133, P770, DOI 10.7326/0003-4819-133-10-200011210-00009; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; Vogt BL, 2001, MUTAT RES-FUND MOL M, V478, P159, DOI 10.1016/S0027-5107(01)00137-3; Wang TS, 2001, FREE RADICAL BIO MED, V31, P321, DOI 10.1016/S0891-5849(01)00581-0; Weinfeld M, 1997, MUTAT RES-FUND MOL M, V378, P127, DOI 10.1016/S0027-5107(97)00103-6; Yih LH, 2000, CANCER RES, V60, P6346; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Ziv Y, 1997, ONCOGENE, V15, P159, DOI 10.1038/sj.onc.1201319	63	23	24	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2310	+		10.1096/fj.02-0093fje	http://dx.doi.org/10.1096/fj.02-0093fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563695				2022-12-28	WOS:000186343300020
J	Arnould, T; Mercy, L; Houbion, A; Vankoningsloo, S; Renard, P; Pascal, T; Ninane, N; Demazy, C; Raes, M				Arnould, T; Mercy, L; Houbion, A; Vankoningsloo, S; Renard, P; Pascal, T; Ninane, N; Demazy, C; Raes, M			MtCLIC is up-regulated and maintains a mitochondrial membrane potential in mtDNA-depleted L929 cells	FASEB JOURNAL			English	Article						mitochondrial dysfunction; chloride flux; CREB; p53; differential gene expression	CHLORIDE CHANNEL PROTEIN; RHO-DEGREES CELLS; OXIDATIVE-PHOSPHORYLATION; DIFFERENTIAL EXPRESSION; SIGNALING PATHWAY; MOLECULAR-CLONING; GENE-EXPRESSION; DNA; MUTATION; P64H1	To explain why mitochondrial DNA ( mtDNA)-depleted or rho0 cells still keep a mitochondrial membrane potential (Deltapsim) in the absence of respiration, several hypotheses have been proposed. The principal and well accepted one involves a reverse of action for ANT combined to F1-ATPase activity. However, the existence of other putative electrogenic channels has been speculated. Here, using mRNA differential display reverse transcriptase-polymerase chain reaction on L929 mtDNA-depleted cells, we identified mtCLIC as a differentially expressed gene in cells deprived from mitochondrial ATP production. Mitochondrial chloride intracellular channel ( mtCLIC), a member of a recently discovered and expanding family of chloride intracellular channels, is up-regulated in mtDNA-depleted and rho0 cells. We showed that its expression is dependent on CREB and p53 and is sensitive to calcium and tumor necrosis factor alpha. Interestingly, up- or down-regulation of mtCLIC protein expression changes Deltapsim whereas the chloride channel inhibitor NPPB reduces the Deltapsim in mtDNA-depleted L929 cells, measured with the fluorescent probe rhodamine 123. Finally, we demonstrated that purified mitochondria from mtDNA-depleted cells incorporate, in a NPPB-sensitive manner, more (36)chloride than parental mitochondria. These findings suggest that mtCLIC could be involved in mitochondrial membrane potential generation in mtDNA-depleted cells, a feature required to prevent apoptosis and to drive continous protein import into mitochondria.	Univ Namur, FUNDP, Lab Biochim & Biol Cellulaire, B-5000 Namur, Belgium	University of Namur	Arnould, T (corresponding author), Univ Namur, FUNDP, Lab Biochim & Biol Cellulaire, 61 Rue Bruxelles, B-5000 Namur, Belgium.	thierry.arnould@fundp.ac.be						Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53; Berryman M, 2000, MOL BIOL CELL, V11, P1509, DOI 10.1091/mbc.11.5.1509; Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983; CHEN LB, 1989, METHOD CELL BIOL, V29, P103; Chuang JZ, 1999, J NEUROSCI, V19, P2919; DUAN JM, 1989, CAN J PHYSIOL PHARM, V67, P704, DOI 10.1139/y89-114; DUEE ED, 1969, J BIOL CHEM, V244, P3920; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Epstein CB, 2001, MOL BIOL CELL, V12, P297, DOI 10.1091/mbc.12.2.297; Fernandez-Salas E, 2002, MOL CELL BIOL, V22, P3610, DOI 10.1128/MCB.22.11.3610-3620.2002; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Geissler A, 2001, MOL CELL BIOL, V21, P7097, DOI 10.1128/MCB.21.20.7097-7104.2001; Giebler HA, 2000, MOL CELL BIOL, V20, P4849, DOI 10.1128/MCB.20.13.4849-4858.2000; GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0; Heiss NS, 1997, GENOMICS, V45, P224, DOI 10.1006/geno.1997.4922; HERZBERG NH, 1993, EUR J CELL BIOL, V61, P400; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jiang SN, 1999, J BIOL CHEM, V274, P29905, DOI 10.1074/jbc.274.42.29905; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; Kitamura A, 2001, BIOCHEM BIOPH RES CO, V287, P435, DOI 10.1006/bbrc.2001.5577; LANDRY DW, 1989, SCIENCE, V244, P1469, DOI 10.1126/science.2472007; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509; Morin C, 2000, FUND CLIN PHARMACOL, V14, P493, DOI 10.1111/j.1472-8206.2000.tb00432.x; Naviaux RK, 2000, EUR J PEDIATR, V159, pS219, DOI 10.1007/PL00014407; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; Park KS, 2001, AM J PHYSIOL-ENDOC M, V280, pE1007, DOI 10.1152/ajpendo.2001.280.6.E1007; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; REMACLE JA, 1980, BIOCHIM BIOPHYS ACTA, V630, P57, DOI 10.1016/0304-4165(80)90137-3; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sherer TB, 2000, BBA-MOL CELL RES, V1496, P341, DOI 10.1016/S0167-4889(00)00027-6; SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N; Suginta W, 2001, BIOCHEM J, V359, P55, DOI 10.1042/0264-6021:3590055; Thomas AW, 1999, CLIN SCI, V97, P207, DOI 10.1042/CS19980400; Tulk BM, 2000, J BIOL CHEM, V275, P26986; Valenzuela SM, 1997, J BIOL CHEM, V272, P12575, DOI 10.1074/jbc.272.19.12575; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; Wang H, 1997, BBA-GENE STRUCT EXPR, V1352, P325, DOI 10.1016/S0167-4781(97)00035-3; Zhang H, 1996, NUCLEIC ACIDS RES, V24, P2454, DOI 10.1093/nar/24.12.2454	46	35	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2145	+		10.1096/fj.03-0075fje	http://dx.doi.org/10.1096/fj.03-0075fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958156				2022-12-28	WOS:000185925100027
J	Walia, B; Wang, LX; Merlin, D; Sitaraman, SV				Walia, B; Wang, LX; Merlin, D; Sitaraman, SV			TGF-beta down-regulates IL-6 signaling in intestinal epithelial cells: Critical role of SMAD-2	FASEB JOURNAL			English	Article						inflammatory bowel disease; intercellular adhesion molecule-1 (ICAM-1); STAT, Smad	INFLAMMATORY-BOWEL-DISEASE; CYTOKINE MESSENGER-RNA; CROHNS-DISEASE; TRANSFORMING GROWTH-FACTOR-BETA-1; MUCOSAL INFLAMMATION; ADHESION MOLECULE-1; COLONIC-MUCOSA; INTERLEUKIN-6; EXPRESSION; GROWTH	Interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays an important role in the pathogenesis of inflammatory bowel disease. TGF-beta, a multifunctional cytokine, is a potent negative regulator of mucosal inflammation in the intestine. The aim of the present study is to determine possible cross-talk between IL-6 and TGF-beta signaling pathways. Model intestinal epithelial cell lines, Caco2-BBE were used. We show that TGF-beta receptor Type II is predominantly present in the basolateral membrane of intestinal epithelial cells. TGF-beta1 induces a time-dependent phosphorylation of Smad2 and co-immunoprecipitation of SMAD-2 with Smad-4 and its subsequently translocation to the nucleus. We show that pretreatment of cells with TGF-beta1 is associated with a down-regulation of IL-6 induced tyrosine phosphorylation of STAT1 and STAT3 and suppression of ICAM-1 expression. Furthermore, TGF-beta1 pretreatment resulted in a significant inhibition of IL-6 induced ICAM-1 promoter activity. TGF-beta mediated inhibition of IL-6 induced ICAM-1 expression was reversed by transfection with dominant negative Smad2 constructs. In conclusion, we show that: 1) TGF-beta receptor Type II is predominantly located on basolateral membrane and receptor stimulation activates Smad pathway; 2) TGF-beta1 down-regulates IL-6-induced tyrosine phoshorylation of STAT 1 and STAT3 and ICAM-1 expression; and 3) Smad2 is required for the down-regulation of IL-6 signaling by TGF-beta. Collectively, our data demonstrate a cross-talk between TGF-beta and IL-6, and TGF-beta may play a role in the negative regulation of IL-6 signaling in intestinal epithelial cells.	Emory Univ, Div Digest Dis, Atlanta, GA 30322 USA	Emory University	Sitaraman, SV (corresponding author), Emory Univ, Div Digest Dis, Room 201-F,615 Michael St,Whitehead Res Bldg, Atlanta, GA 30322 USA.	ssitar2@emory.edu						Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P975, DOI 10.1053/gast.1996.v110.pm8613031; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; Bowen-Yacyshyn MB, 2002, J PHARMACOL EXP THER, V302, P908, DOI 10.1124/jpet.102.036053; Burns RC, 2001, GASTROENTEROLOGY, V121, P1428, DOI 10.1053/gast.2001.29568; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; Derynck R, 1998, CELL, V95, P737, DOI 10.1016/S0092-8674(00)81696-7; Derynck R, 1997, BBA-REV CANCER, V1333, pF105, DOI 10.1016/S0304-419X(97)00017-6; Gonnella PA, 1998, J IMMUNOL, V160, P4708; GROSS V, 1992, GASTROENTEROLOGY, V102, P514, DOI 10.1016/0016-5085(92)90098-J; Hahm KB, 2002, ALIMENT PHARM THERAP, V16, P115, DOI 10.1046/j.1365-2036.16.s2.3.x; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; HEINRICH PC, 2003, BIOCH J         0529; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hosokawa T, 1999, J GASTROEN HEPATOL, V14, P987, DOI 10.1046/j.1440-1746.1999.01989.x; KISHIMOTO T, 1989, BLOOD, V74, P1, DOI 10.1182/blood.V74.1.1.1; KVALE D, 1992, SCAND J IMMUNOL, V35, P669, DOI 10.1111/j.1365-3083.1992.tb02973.x; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MAHIDA YR, 1991, GUT, V32, P1531, DOI 10.1136/gut.32.12.1531; MCCABE RP, 1993, CLIN IMMUNOL IMMUNOP, V66, P52, DOI 10.1006/clin.1993.1007; Merlin D, 2001, GASTROENTEROLOGY, V120, P1666, DOI 10.1053/gast.2001.24845; MITSUYAMA K, 1991, DIGESTION, V50, P104, DOI 10.1159/000200747; Monteleone G, 2001, J CLIN INVEST, V108, P601, DOI 10.1172/JCI200112821; MOOSEKER MS, 1985, ANNU REV CELL BIOL, V1, P209, DOI 10.1146/annurev.cellbio.1.1.209; Nakabayashi T, 1997, J IMMUNOL, V158, P5527; PELTON RW, 1991, J CELL BIOL, V115, P1091, DOI 10.1083/jcb.115.4.1091; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.3.CO;2-D; Reinisch W, 1999, AM J GASTROENTEROL, V94, P2156; Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501; Sitaraman SV, 2001, J CLIN INVEST, V107, P861, DOI 10.1172/JCI11783; Starr R, 1999, BIOESSAYS, V21, P47, DOI 10.1002/(SICI)1521-1878(199901)21:1<47::AID-BIES6>3.0.CO;2-N; Strober W, 1997, IMMUNOL TODAY, V18, P61, DOI 10.1016/S0167-5699(97)01000-1; Strober W, 2001, ACTA ODONTOL SCAND, V59, P244, DOI 10.1080/00016350152509274; Sun ZW, 1999, J SURG RES, V87, P90, DOI 10.1006/jsre.1999.5746; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Takenoshita S, 2002, J GASTROENTEROL, V37, P991, DOI 10.1007/s005350200168; THOMPSON NL, 1989, J CELL BIOL, V108, P661, DOI 10.1083/jcb.108.2.661; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Whiting CV, 2001, J HISTOCHEM CYTOCHEM, V49, P727, DOI 10.1177/002215540104900606; Wierenga ATJ, 2002, LEUKEMIA, V16, P675, DOI 10.1038/sj.leu.2402425; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang X, 1999, EMBO J, V18, P1280, DOI 10.1093/emboj/18.5.1280	45	60	70	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2130	+		10.1096/fj.02-1211fje	http://dx.doi.org/10.1096/fj.02-1211fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500551				2022-12-28	WOS:000185925100008
J	Hong, GZ; Lockhart, A; Davis, B; Rahmoune, H; Baker, S; Ye, L; Thompson, P; Shou, YP; O'Shaughnessy, K; Ronco, P; Brown, J				Hong, GZ; Lockhart, A; Davis, B; Rahmoune, H; Baker, S; Ye, L; Thompson, P; Shou, YP; O'Shaughnessy, K; Ronco, P; Brown, J			PPAR gamma activation enhances cell surface ENaC alpha via up-regulation of SGK1 in human collecting duct cells	FASEB JOURNAL			English	Article						nuclear receptor; PPAR gamma agonists; sodium retention	EPITHELIAL SODIUM-CHANNEL; RECEPTORS PPARS; ALDOSTERONE; KINASE; EXPRESSION; AGONISTS; CONSEQUENCES; CONVERGENCE; TRANSPORT; DISCOVERY	Peroxisome proliferator-activated receptor gamma (PPARgamma) is a ligand-dependent transcription factor that belongs to the nuclear receptor family that plays a critical role in adipocyte differentiation and lipid metabolism. Here we report for the first time that PPAR. is expressed in human renal cortical collecting ducts (CCD), segments of the nephor involved in regulation of sodium and water homeostasis via action of the epithelial sodium channel (ENaC). ENaC activity is regulated by the hormones aldosterone and insulin, primarily through co-ordinate actions on serum and glucocorticoid regulated kinase 1 (SGK1). We show that SGK1 activity is stimulated by treatment of a human CCD cell line with PPARgamma agonists, paralleled by an increase in SGK1 mRNA that is abolished by pretreatment with a specific PPARgamma antagonist, and that this leads to increased levels of cell surface ENaCalpha. Electrophoretic mobility shift assays suggest that these effects are caused by binding of PPARgamma to a specific response element in the SGK1 promoter. Our results identify SGK1 as a target for PPARgamma and suggest a novel role for PPARgamma in regulation of sodium re-absorption in the CCD via stimulation of ENaC activity. This pathway may play a role in sodium retention caused by activation of PPARgamma in man.	Addenbrookes Hosp, ACCI, Translat Med & Technol, GlaxoSmithKline, Cambridge, England; GlaxoSmithKline, Translat Med & Technol, Res Triangle Pk, NC USA; Addenbrookes Hosp, Clin Pharmacol Unit, Cambridge CB2 2QQ, England; Univ Paris 06, Hop Tenon, Paris, France; INSERM, U489, Paris, France	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; GlaxoSmithKline; University of Cambridge; GlaxoSmithKline; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Hong, GZ (corresponding author), Addenbrookes Hosp, ACCI, Translat Med & Technol, GlaxoSmithKline, Hills Rd, Cambridge, England.	Guizhu_2_Hong@gsk.com	Ronco, Pierre/AAC-8390-2022					Blazer-Yost BL, 1999, AM J PHYSIOL-CELL PH, V277, pC531, DOI 10.1152/ajpcell.1999.277.3.C531; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Debonneville C, 2001, EMBO J, V20, P7052, DOI 10.1093/emboj/20.24.7052; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Gorson DM, 1999, ARCH INTERN MED, V159, P99, DOI 10.1001/archinte.159.1.99; Guan YF, 2001, KIDNEY INT, V60, P14, DOI 10.1046/j.1523-1755.2001.00766.x; Guan YF, 1997, AM J PHYSIOL-RENAL, V273, pF1013, DOI 10.1152/ajprenal.1997.273.6.F1013; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Henke BR, 1998, J MED CHEM, V41, P5020, DOI 10.1021/jm9804127; JACKSON KE, 1996, PHARMACOL BASIS THER, P685; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kassam A, 1998, MOL CELL ENDOCRINOL, V141, P153, DOI 10.1016/S0303-7207(98)00085-9; Kersten S, 2000, NATURE, V405, P421, DOI 10.1038/35013000; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Leesnitzer LM, 2002, BIOCHEMISTRY-US, V41, P6640, DOI 10.1021/bi0159581; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Loffing J, 2001, AM J PHYSIOL-RENAL, V280, pF675, DOI 10.1152/ajprenal.2001.280.4.F675; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; Mukherjee R, 1997, J BIOL CHEM, V272, P8071, DOI 10.1074/jbc.272.12.8071; Murphy GJ, 2000, TRENDS PHARMACOL SCI, V21, P469, DOI 10.1016/S0165-6147(00)01559-5; Naray-Fejes-Toth A, 1999, J BIOL CHEM, V274, P16973, DOI 10.1074/jbc.274.24.16973; PALMER CNA, 1995, J BIOL CHEM, V270, P16114, DOI 10.1074/jbc.270.27.16114; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Pearce D, 2001, TRENDS ENDOCRIN MET, V12, P341, DOI 10.1016/S1043-2760(01)00439-8; PRIE D, 1995, KIDNEY INT, V47, P1310, DOI 10.1038/ki.1995.186; Rieusset J, 2001, FEBS LETT, V502, P98, DOI 10.1016/S0014-5793(01)02674-6; Takeda K, 2001, J BIOL CHEM, V276, P48950, DOI 10.1074/jbc.M108722200; Verrey F, 1999, AM J PHYSIOL-RENAL, V277, pF319, DOI 10.1152/ajprenal.1999.277.3.F319; Wang J, 2001, AM J PHYSIOL-RENAL, V280, pF303, DOI 10.1152/ajprenal.2001.280.2.F303; Wang T, 1999, ANAL BIOCHEM, V269, P198, DOI 10.1006/abio.1999.4022; WEBSTER MK, 1993, MOL CELL BIOL, V13, P2031, DOI 10.1128/MCB.13.4.2031; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Yang TX, 1999, AM J PHYSIOL-RENAL, V277, pF966, DOI 10.1152/ajprenal.1999.277.6.F966; Yoshimoto T, 1997, AM J PHYSIOL-ENDOC M, V272, pE989, DOI 10.1152/ajpendo.1997.272.6.E989	39	93	95	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1966	+		10.1096/fj.03-0181fje	http://dx.doi.org/10.1096/fj.03-0181fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923071				2022-12-28	WOS:000185345100011
J	Monsinjon, T; Gasque, P; Chan, P; Ischenko, A; Brady, JJ; Fontaine, M				Monsinjon, T; Gasque, P; Chan, P; Ischenko, A; Brady, JJ; Fontaine, M			Regulation by complement C3a and C5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells	FASEB JOURNAL			English	Article						C3aR; C5aR; MAP kinases	ALTERNATIVE PATHWAY PROTEINS; RECEPTOR MESSENGER-RNA; MOLECULAR-CLONING; CELLULAR EXPRESSION; NONMYELOID CELLS; EFFECTOR PHASE; FACTOR-H; INTERLEUKIN-8; NEUTROPHILS; IDENTIFICATION	C3a and C5a anaphylatoxins are cytokine-like polypeptides generated during complement (C) system activation and released at the inflammatory site. They exert several biological activities through binding to the G-protein-coupled receptors C3aR and C5aR, respectively. Cloning and Northern blot experiments have indicated that both receptors are expressed by myeloid as well as nonmyeloid cells (e.g., endothelial and epithelial cells). To better understand the roles of C anaphylatoxins during inflammation, we investigated their effects on the expression of cytokine and chemokine genes by cultured human umbilical cord endothelial cells (HUVEC). HUVEC constitutively expressed both anaphylatoxin receptors, and addition of physiological concentrations of C3a or C5a (nM range) caused a strong up-regulation of IL-8, IL-1beta, and RANTES mRNA in a time- and dose-dependent manner. Conversely, a decrease in IL-6 mRNA was observed, but only with C5a stimulation. These variations in mRNA levels were inhibited by pretreatment with anti-C5aR and anti-C3aR antibodies as well as pertussis toxin, indicating that G-proteins are involved in anaphylatoxin-activated signal transduction pathways. Finally, we showed that C3a and C5a both strongly activate downstream MAP kinase signaling pathways (p44 and p42 Erk kinases).	Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Cardiff CF14 4XN, S Glam, Wales; Univ Rouen, INSERM, U519, Immunol Lab, F-76821 Mont St Aignan, France; Res Inst Highly Pure Biopreparat, St Petersburg, Russia	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Gasque, P (corresponding author), Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Tenovus Bldg, Cardiff CF14 4XN, S Glam, Wales.	Tiphaine_Monsinj@hotmail.com; gasque@cardiff.ac.uk		monsinjon, Tiphaine/0000-0001-6959-5522				Abe K, 2001, KIDNEY INT, V60, P137, DOI 10.1046/j.1523-1755.2001.00780.x; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; BROOIMANS RA, 1989, J IMMUNOL, V142, P2024; Cain SA, 2002, J BIOL CHEM, V277, P7165, DOI 10.1074/jbc.C100714200; COULPIER M, 1995, CLIN EXP IMMUNOL, V101, P142; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; DAUCHEL H, 1990, EUR J IMMUNOL, V20, P1669, DOI 10.1002/eji.1830200808; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Ember JA, 1997, IMMUNOPHARMACOLOGY, V38, P3, DOI 10.1016/S0162-3109(97)00088-X; Erdei A, 1997, EXP CLIN IMMUNOGENET, V14, P16; Fayyazi A, 2000, IMMUNOLOGY, V99, P38, DOI 10.1046/j.1365-2567.2000.00911.x; Foreman KE, 1996, INFLAMMATION, V20, P1, DOI 10.1007/BF01487740; FOREMAN KE, 1994, J CLIN INVEST, V94, P1147, DOI 10.1172/JCI117430; FRANK MM, 1991, IMMUNOL TODAY, V12, P322, DOI 10.1016/0167-5699(91)90009-I; Fukuoka Y, 1998, J IMMUNOL, V161, P2977; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; Fukuoka Y, 2001, CURR EYE RES, V23, P320, DOI 10.1076/ceyr.23.5.320.5437; Gasque P, 1998, J IMMUNOL, V160, P3543; GASQUE P, 1995, J IMMUNOL, V155, P4882; Gasque P, 1997, AM J PATHOL, V150, P31; Grant EP, 2002, J EXP MED, V196, P1461, DOI 10.1084/jem.20020205; HAEFFNERCAVAILLON N, 1987, J IMMUNOL, V139, P794; HAVILAND DL, 1995, J IMMUNOL, V154, P1861; Hollmann TJ, 1998, MOL IMMUNOL, V35, P137, DOI 10.1016/S0161-5890(98)00021-2; HORUK R, 1994, IMMUNOL TODAY, V15, P169, DOI 10.1016/0167-5699(94)90314-X; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Ikeda K, 1997, THROMB HAEMOSTASIS, V77, P394; Ischenko A, 1998, J NEUROCHEM, V71, P2487; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Kalant D, 2003, J BIOL CHEM, V278, P11123, DOI 10.1074/jbc.M206169200; Kaplanski G, 2003, TRENDS IMMUNOL, V24, P25, DOI 10.1016/S1471-4906(02)00013-3; LACY M, 1995, J NEUROIMMUNOL, V61, P71, DOI 10.1016/0165-5728(95)00075-D; Langeggen H, 2001, INFLAMMATION, V25, P83, DOI 10.1023/A:1007162320882; Laudes IJ, 2002, J IMMUNOL, V169, P5962, DOI 10.4049/jimmunol.169.10.5962; MARKS RM, 1989, NATURE, V339, P314, DOI 10.1038/339314a0; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Monsinjon T, 2001, FEBS LETT, V487, P339, DOI 10.1016/S0014-5793(00)02320-6; Nabil K, 1997, BIOCHEM J, V326, P377, DOI 10.1042/bj3260377; Nilsson G, 1996, J IMMUNOL, V157, P1693; NORGAUER J, 1993, EUR J BIOCHEM, V217, P289, DOI 10.1111/j.1432-1033.1993.tb18245.x; Riedemann NC, 2002, J IMMUNOL, V168, P1919, DOI 10.4049/jimmunol.168.4.1919; RIPOCHE J, 1988, J EXP MED, V168, P1917, DOI 10.1084/jem.168.5.1917; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Schieferdecker HL, 1997, FEBS LETT, V406, P305, DOI 10.1016/S0014-5793(97)00292-5; Schlaf G, 2003, HISTOL HISTOPATHOL, V18, P299, DOI 10.14670/HH-18.299; Schraufstatter IU, 2002, J IMMUNOL, V169, P2102, DOI 10.4049/jimmunol.169.4.2102; Shushakova N, 2002, J CLIN INVEST, V110, P1823, DOI 10.1172/JCI200216577; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stahel PF, 1997, J IMMUNOL, V159, P861; Takayama A, 1996, PHYS PLASMAS, V3, P3, DOI 10.1063/1.871832; Tornetta MA, 1997, J IMMUNOL, V158, P5277; Utgaard JO, 1998, J EXP MED, V188, P1751, DOI 10.1084/jem.188.9.1751; Van Beek J, 2000, EXP NEUROL, V161, P373, DOI 10.1006/exnr.1999.7273; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X; Wolff B, 1998, J EXP MED, V188, P1757, DOI 10.1084/jem.188.9.1757	58	182	188	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1003	1014		10.1096/fj.02-0737com	http://dx.doi.org/10.1096/fj.02-0737com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773483				2022-12-28	WOS:000183818000004
J	Murakami, S; Salmon, A; Miller, RA				Murakami, S; Salmon, A; Miller, RA			Multiplex stress resistance in cells from long-lived dwarf mice	FASEB JOURNAL			English	Article						aging; cellular stress resistance; fibroblasts; dwarf mouse	CAENORHABDITIS-ELEGANS; LIFE-SPAN; OXIDATIVE STRESS; EXTENSION; LONGEVITY; DAF-2	Mutations that extend nematode longevity by interference with IGF-I/insulin sensing pathways also lead to resistance to multiple forms of stress. Here, we report that skin-derived fibroblasts from Shell dwarf mice, already known to show increased longevity and delayed aspects of aging, are resistant to multiple forms of cellular stress, including UV light, heat, paraquat, H(2)O(2), and the toxic metal cadmium. The findings suggest that increases in cellular resistance to stress may mediate extended longevity in mammals.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; Univ Michigan, Sch Med, Geriatr Ctr, Ann Arbor, MI USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI USA; Ann Arbor VA Med Ctr, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Miller, RA (corresponding author), 5410 CCGCB,Box 0940,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	millerr@umich.edu	Murakami, Shin/AAQ-3454-2021	Murakami, Shin/0000-0001-8806-0611				Barsyte D, 2001, FASEB J, V15, P627, DOI 10.1096/fj.99-0966com; Brown-Borg HM, 1999, ENDOCRINE, V11, P41, DOI 10.1385/ENDO:11:1:41; Flurkey K, 2001, P NATL ACAD SCI USA, V98, P6736, DOI 10.1073/pnas.111158898; Honda Y, 1999, FASEB J, V13, P1385, DOI 10.1096/fasebj.13.11.1385; Johnson TE, 1996, J GERONTOL A-BIOL, V51, pB392, DOI 10.1093/gerona/51A.6.B392; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; Melov S, 2000, SCIENCE, V289, P1567, DOI 10.1126/science.289.5484.1567; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; MILLER RA, 2001, HDB BIOL AGING, P369; Murakami S, 1996, GENETICS, V143, P1207; VANFLETEREN JR, 1993, BIOCHEM J, V292, P605, DOI 10.1042/bj2920605	12	166	168	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1565	+		10.1096/fj.02-1092fje	http://dx.doi.org/10.1096/fj.02-1092fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824282	Green Submitted			2022-12-28	WOS:000183818000029
J	Akhtar, M; Watson, JL; Nazli, A; McKay, DM				Akhtar, M; Watson, JL; Nazli, A; McKay, DM			Bacterial DNA evokes epithelial IL-8 production by a MAPK-dependent, NF kappa B-independent pathway	FASEB JOURNAL			English	Article						TLR-9; AP-1; signal; permeability; COX-2	ACTIVATED PROTEIN-KINASES; TOLL-LIKE RECEPTOR-9; CPG-DNA; CYCLOOXYGENASE-2 EXPRESSION; CUTTING EDGE; IMMUNE CELLS; MOTIFS; AP-1; INTERLEUKIN-12; INFLAMMATION	Recognition of bacterial products by the innate immune system is dependent on pattern-recognition receptors: toll-like receptor 9 (TLR-9) in the case of bacterial DNA. We hypothesized that bacterial DNA can directly affect enteric epithelial cells. RT-PCR revealed constitutive TLR-9 mRNA expression in three human colonic epithelial cell lines (T84, HT-29, Caco-2) and THP-1 monocytes. Epithelial cells, in six-well culture plates or on filter supports, were exposed to E. coli DNA (1-50 mug/ml), synthetic CpG-rich oligonucleotides, or calf thymus DNA for 6-48 h. Exposure to E. coli DNA resulted in an increase in IL-8 mRNA, and a time- and dose-dependent increase in IL-8 secretion. Also, CpG oligonucleotides induced epithelial IL-8 production, whereas calf thymus DNA did not. Exposure to E. coli DNA resulted in phosphorylation of ERK 1/2 MAPK and inhibitors of ERK activity (PD98059, UO126) significantly reduced the evoked IL-8 production. In contrast, inhibitors of NFkappaB activity (PDTC, SN50) did not block E. coli DNA-induced IL-8 production. Electrophoretic mobility shift assays revealed that E. coli DNA stimulated epithelial AP-1 but not NFkappaB activation. The barrier (i.e., transepithelial resistance) and ion transport parameters of epithelial monolayers (assessed in Ussing chambers) were unaltered following E. coli DNA exposure. Thus model gut epithelia express TLR-9 mRNA and, while maintaining their barrier function, can respond to E. coli DNA by increased IL-8 production.	McMaster Univ, Intestinal Dis Res Programme, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada	McMaster University	McKay, DM (corresponding author), McMaster Univ, Intestinal Dis Res Programme, Dept Pathol & Mol Med, HSC-3N5C,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	mckayd@mcmaster.ca	McKay, Derek/HCH-3240-2022	Nazli, Aisha/0000-0001-7410-9963				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akhtar M, 2001, CANCER RES, V61, P2399; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Bae MA, 2003, MOL PHARMACOL, V63, P401, DOI 10.1124/mol.63.2.401; Ballas ZK, 1996, J IMMUNOL, V157, P1840; BARRETT KE, 1993, AM J PHYSIOL, V265, pC859; Bauer M, 2001, J IMMUNOL, V166, P5000, DOI 10.4049/jimmunol.166.8.5000; Botelho FM, 1998, J BIOL CHEM, V273, P5211, DOI 10.1074/jbc.273.9.5211; Cario E, 2000, J IMMUNOL, V164, P966, DOI 10.4049/jimmunol.164.2.966; Chang YH, 2002, EXP CELL RES, V278, P166, DOI 10.1006/excr.2002.5573; Chen HC, 2002, J BIOL CHEM, V277, P23554, DOI 10.1074/jbc.M201152200; Chen YJ, 2001, INT IMMUNOL, V13, P1013, DOI 10.1093/intimm/13.8.1013; Chuang TH, 2002, J LEUKOCYTE BIOL, V71, P538; CRAVEN PA, 1983, J CLIN INVEST, V72, P1365, DOI 10.1172/JCI111093; Deng GM, 1999, NAT MED, V5, P702, DOI 10.1038/9554; Deng GM, 2001, J IMMUNOL, V167, P4616, DOI 10.4049/jimmunol.167.8.4616; Gewirtz AT, 2003, CURR PHARM DESIGN, V9, P1, DOI 10.2174/1381612033392422; Grandjean-Laquerriere A, 2002, CYTOKINE, V18, P168, DOI 10.1006/cyto.2002.0888; Hacker H, 1999, EMBO J, V18, P6973, DOI 10.1093/emboj/18.24.6973; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Halpern MD, 1996, CELL IMMUNOL, V167, P72, DOI 10.1006/cimm.1996.0009; Hayashi R, 2000, EUR RESPIR J, V16, P452, DOI 10.1034/j.1399-3003.2000.016003452.x; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Jijon HB, 2002, AM J PHYSIOL-CELL PH, V283, pC31, DOI 10.1152/ajpcell.00113.2001; JORDANA M, 1992, ANN NY ACAD SCI, V664, P180, DOI 10.1111/j.1749-6632.1992.tb39759.x; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2000, CURR OPIN IMMUNOL, V12, P35, DOI 10.1016/S0952-7915(99)00048-5; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Maaser C, 2002, Z GASTROENTEROL, V40, P525, DOI 10.1055/s-2002-32808; Maeda S, 2001, J BIOL CHEM, V276, P44856, DOI 10.1074/jbc.M105381200; McKay DM, 1996, AM J PHYSIOL-CELL PH, V270, pC418, DOI 10.1152/ajpcell.1996.270.2.C418; McKay DM, 2001, TRENDS IMMUNOL, V22, P497, DOI 10.1016/S1471-4906(01)02000-2; McKay DM, 1997, J IMMUNOL, V159, P2382; McKay DM, 1999, CAN J GASTROENTEROL, V13, P509, DOI 10.1155/1999/680206; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Miyata M, 2001, ANN RHEUM DIS, V60, P685, DOI 10.1136/ard.60.7.685; PERDUE MH, 1994, AM J PHYSIOL, V267, pG151, DOI 10.1152/ajpgi.1994.267.2.G151; Pisetsky DS, 1996, IMMUNITY, V5, P303, DOI 10.1016/S1074-7613(00)80256-3; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Singer II, 1998, GASTROENTEROLOGY, V115, P297, DOI 10.1016/S0016-5085(98)70196-9; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Utaisincharoen P, 2002, CLIN EXP IMMUNOL, V128, P467, DOI 10.1046/j.1365-2249.2002.01866.x; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wallace JL, 2001, GASTROENTEROL CLIN N, V30, P971, DOI 10.1016/S0889-8553(05)70223-5; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	51	141	144	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1319	+		10.1096/fj.02-0950fje	http://dx.doi.org/10.1096/fj.02-0950fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12832293				2022-12-28	WOS:000183165000037
J	Grounds, MD; Torrisi, J				Grounds, MD; Torrisi, J			Anti-TNF alpha (Remicade (R)) therapy protects dystrophic skeletal muscle from necrosis	FASEB JOURNAL			English	Article						mdx mice; dystropathology; DMD	JUVENILE IDIOPATHIC ARTHRITIS; DUCHENNE MUSCULAR-DYSTROPHY; MDX MICE; RHEUMATOID-ARTHRITIS; MEMBRANE REPAIR; MYOGENIC CELLS; CROHNS-DISEASE; ANIMAL-MODELS; EXPRESSION; INFLIXIMAB	Necrosis of skeletal muscle fibers in the lethal childhood myopathy Duchenne muscular dystrophy (DMD) results from defects in the cell membrane-associated protein, dystrophin. This study tests the novel hypothesis that the initial sarcolemmal breakdown resulting from dystrophin deficiency is exacerbated by inflammatory cells and that cytokines, specifically tumor necrosis factor- (TNF), contribute to muscle necrosis. To block in vivo TNF bioactivity, young dystrophic mdx mice (a model for DMD) were injected weekly from 7 days of age with the anti-TNF antibody Remicade(R) before the onset of muscle necrosis and dystropathology that normally occurs at 21 days postnatally. The extent of inflammation, muscle necrosis, and myotube formation was measured by histological analysis from 18 to 28 days and muscle damage was also visualized by penetration of Evans blue dye into myofibers. Data from Remicade(R)-treated and control mdx mice were compared with mdx/TNF(-/-) mice that lack TNF. Pharmacological blockade of TNF activity with Remicade(R) clearly delayed and greatly reduced the breakdown of dystrophic muscle, in marked contrast to the situation in mdx and mdx/TNF(-/-) mice. Remicade(R) had no adverse effect on new muscle formation. Remicade(R) is a highly specific anti-inflammatory intervention, and clinical application to muscular dystrophies is suggested by this marked protective effect against skeletal muscle breakdown.	Univ Western Australia, Sch Anat & Human Biol, Crawley, WA 6009 USA	University of Western Australia		mgrounds@anhb.uwa.edu		Grounds, Miranda/0000-0002-4530-9402				AREND WP, 2002, J RHEUMATOL S, V65, P16; Bansal D, 2003, NATURE, V423, P168, DOI 10.1038/nature01573; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; BEILHARZ MW, 1992, MOL CELL NEUROSCI, V3, P326, DOI 10.1016/1044-7431(92)90029-2; Billiau AD, 2002, J RHEUMATOL, V29, P1111; Bogdanovich S, 2002, NATURE, V420, P418, DOI 10.1038/nature01154; Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Cheung EV, 2003, INFLAMM RES, V52, P170, DOI 10.1007/s000110300068; Collins RA, 2001, J HISTOCHEM CYTOCHEM, V49, P989, DOI 10.1177/002215540104900807; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Cozzi F, 2001, ACTA NEUROPATHOL, V101, P469; Doherty KR, 2003, TRENDS MOL MED, V9, P327, DOI 10.1016/S1471-4914(03)00136-9; Economides AN, 2003, NAT MED, V9, P47, DOI 10.1038/nm811; ELLIOTT MJ, 1994, LANCET, V344, P1105, DOI 10.1016/S0140-6736(94)90628-9; Emery AEH, 2002, LANCET, V359, P687, DOI 10.1016/S0140-6736(02)07815-7; Engvall E, 2003, FASEB J, V17, P1579, DOI 10.1096/fj.02-1215rev; Gabay C, 2002, EXPERT OPIN BIOL TH, V2, P135, DOI 10.1517/14712598.2.2.135; GOSSELIN LE, 2003, IN PRESS MUSCLE NERV; Hamer PW, 2002, J ANAT, V200, P69, DOI 10.1046/j.0021-8782.2001.00008.x; Hodge-Dufour J, 1998, P NATL ACAD SCI USA, V95, P13806, DOI 10.1073/pnas.95.23.13806; Hoffman EP, 2002, RHEUM DIS CLIN N AM, V28, P743, DOI 10.1016/S0889-857X(02)00031-5; Hyams JS, 2000, J PEDIATR-US, V137, P192, DOI 10.1067/mpd.2000.107161; Khurana TS, 2003, NAT REV DRUG DISCOV, V2, P379, DOI 10.1038/nrd1085; Kuru S, 2003, ACTA NEUROPATHOL, V105, P217, DOI 10.1007/s00401-002-0632-4; Lahdenne P, 2003, ANN RHEUM DIS, V62, P245, DOI 10.1136/ard.62.3.245; LEFAUCHEUR JP, 1995, ANAT REC, V242, P70, DOI 10.1002/ar.1092420109; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Lundberg I E, 2000, Curr Rheumatol Rep, V2, P216, DOI 10.1007/s11926-000-0082-y; MCGEACHIE JK, 1993, J NEUROL SCI, V119, P169, DOI 10.1016/0022-510X(93)90130-Q; McGeachie JK, 1999, J ANAT, V194, P287, DOI 10.1046/j.1469-7580.1999.19420287.x; MCLOUGHLIN TJ, 2003, IN PRESS CELL TISSUE; MITCHELL CA, 1992, CELL TISSUE RES, V269, P159, DOI 10.1007/BF00384736; Moghadaszadeh B, 2003, HUM MOL GENET, V12, P2467, DOI 10.1093/hmg/ddg264; Muntoni F, 2002, NEUROMUSCULAR DISORD, V12, pS162, DOI 10.1016/S0960-8966(02)00101-3; Nguyen HH, 2002, P NATL ACAD SCI USA, V99, P5616, DOI 10.1073/pnas.082613599; Nguyen HX, 2003, J PHYSIOL-LONDON, V550, P347, DOI 10.1113/jphysiol.2003.040907; Nguyen HX, 2003, J PHYSIOL-LONDON, V547, P125, DOI 10.1113/jphysiol.2002.031450; Pizza FX, 2001, AM J PHYSIOL-CELL PH, V281, pC335, DOI 10.1152/ajpcell.2001.281.1.C335; Porter JD, 2002, HUM MOL GENET, V11, P263, DOI 10.1093/hmg/11.3.263; Schatzberg SJ, 1999, NEUROMUSCULAR DISORD, V9, P289, DOI 10.1016/S0960-8966(99)00011-5; Serrano MS, 2001, ANN PHARMACOTHER, V35, P823; Skuk D, 2003, J MUSCLE RES CELL M, V24, P285; Spencer MJ, 2000, NEUROMUSCULAR DISORD, V10, P612, DOI 10.1016/S0960-8966(00)00160-7; Spencer MJ, 2002, HUM MOL GENET, V11, P2645, DOI 10.1093/hmg/11.21.2645; Spencer MJ, 2001, NEUROMUSCULAR DISORD, V11, P556, DOI 10.1016/S0960-8966(01)00198-5; Straub V, 2000, MAGNET RESON MED, V44, P655, DOI 10.1002/1522-2594(200010)44:4<655::AID-MRM22>3.0.CO;2-T; Straub V, 1997, J CELL BIOL, V139, P375, DOI 10.1083/jcb.139.2.375; Tews DS, 1998, CLIN IMMUNOL IMMUNOP, V87, P240, DOI 10.1006/clin.1998.4527; Torrente Y, 2003, CELL TRANSPLANT, V12, P91, DOI 10.3727/000000003783985115; Tseng BS, 2002, J APPL PHYSIOL, V93, P537, DOI 10.1152/japplphysiol.00202.2002; van Deventer SJH, 1999, ALIMENT PHARM THER, V13, P3, DOI 10.1046/j.1365-2036.1999.00024.x; Wagner KR, 2002, ANN NEUROL, V52, P832, DOI 10.1002/ana.10385; Warren GL, 2002, FASEB J, V16, P1630, DOI 10.1096/fj.02-0187fje; Wells Dominic J, 2002, Expert Rev Mol Med, V4, P1, DOI 10.1017/S146239940200515X; Wong BLY, 2002, J CHILD NEUROL, V17, P183, DOI 10.1177/088307380201700306; Xing J, 2002, NEUROBIOL DIS, V10, P234, DOI 10.1006/nbdi.2002.0504	56	189	196	0	13	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					676	682		10.1096/fj.03-1024com	http://dx.doi.org/10.1096/fj.03-1024com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054089				2022-12-28	WOS:000221108800037
J	Biasi, F; Leonarduzzi, G; Vizio, B; Zanetti, D; Sevanian, A; Sottero, B; Verde, V; Zingaro, B; Chiarpotto, E; Poli, G				Biasi, F; Leonarduzzi, G; Vizio, B; Zanetti, D; Sevanian, A; Sottero, B; Verde, V; Zingaro, B; Chiarpotto, E; Poli, G			Oxysterol mixtures prevent proapoptotic effects of 7-ketocholesterol in macrophages: implications for proatherogenic gene modulation	FASEB JOURNAL			English	Article						apoptosis; oxidized low-density lipoproteins; reactive oxygen species; cholesterol oxidized products; caspase activity	LOW-DENSITY-LIPOPROTEIN; CHOLESTEROL OXIDATION-PRODUCTS; CELL-MEDIATED OXIDATION; HUMAN ENDOTHELIAL-CELLS; INDUCED APOPTOSIS; MASS-SPECTROMETRY; HUMAN ATHEROMA; OXIDIZED LDL; IN-VIVO; ATHEROSCLEROSIS	Oxysterols are common components of oxidized low-density lipoprotein and accumulate in the core of fibrotic plaques as a mixture of cholesterol and cholesteryl ester oxidation products. The proapoptotic effects of a biologically representative mixture of oxysterols was compared with equimolar amounts of 7-ketocholesterol and unoxidized cholesterol. The oxysterol mixture in a concentration range actually detectable in hypercholesterolemic patients did not stimulate programmed cell death in cultivated murine macrophages. Unoxidized cholesterol also produced no effect. By contrast, when given alone, 7-ketocholesterol strongly stimulated the mitochondrial pathway of apoptosis with cytochrome c release, caspase-9 activation, and eventually caspase-3 activation. Subsequent experiments showed that when 7-ketocholesterol was administered to cells together with another oxysterol, namely 7betaOH-cholesterol, the strong proapoptotic effect of 7-ketocholesterol was markedly attenuated. As regards the mechanism underlying this quenching, we found that the combined oxysterol treatment counteracted the ability of 7-ketocholesterol, when administered alone, to strongly up-regulate the steady-state levels of reactive oxygen species (ROS) without interfering with sterol uptake. Furthermore, this increase in intracellular ROS appeared to be responsible for the up-regulation of proapoptotic factor, p21, after treatment with 7-ketocholesterol but not in cells challenged with the oxysterol mixture. Competition among oxysterols, apparently at the level of NADPH oxidase, diminishes the ROS induction and direct toxicity that is evoked by specific oxysterols. As a consequence, a more subtle gene modulation by oxysterols becomes facilitated in vascular cells.	Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	University of Turin; University of Southern California	Poli, G (corresponding author), Univ Turin, S Luigi Gonzaga Hosp, Dept Clin & Biol Sci, I-10043 Turin, Italy.	giuseppe.poli@unito.it	VIZIO, Barbara/AAB-8854-2019; Leonarduzzi, Gabriella/AAA-6575-2019	VIZIO, Barbara/0000-0003-2389-8581; LEONARDUZZI, Gabriella Marisa/0000-0002-3422-821X				ADDIS PB, 1989, FREE RADICAL BIO MED, V7, P179, DOI 10.1016/0891-5849(89)90011-7; Agrawal S, 2002, MOL CELL BIOL, V22, P1981, DOI 10.1128/MCB.22.7.1981-1992.2002; AUPEIX K, 1995, IMMUNOBIOLOGY, V194, P415, DOI 10.1016/S0171-2985(11)80108-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; Chang YH, 1997, FREE RADICAL BIO MED, V23, P202, DOI 10.1016/S0891-5849(96)00626-0; Colles SM, 1996, J LIPID RES, V37, P2018; Dimmeler S, 1997, CIRCULATION, V95, P1760; DZELETOVIC S, 1995, ANAL BIOCHEM, V225, P73, DOI 10.1006/abio.1995.1110; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; GENG YJ, 1995, AM J PATHOL, V147, P251; Han JH, 1997, J BIOL CHEM, V272, P21654, DOI 10.1074/jbc.272.34.21654; Hansson G K, 1999, Curr Atheroscler Rep, V1, P150, DOI 10.1007/s11883-999-0011-0; Hayden JM, 2002, J LIPID RES, V43, P26; Heinloth A, 2002, ATHEROSCLEROSIS, V162, P93, DOI 10.1016/S0021-9150(01)00687-6; HODIS HN, 1991, ATHEROSCLEROSIS, V89, P117, DOI 10.1016/0021-9150(91)90051-4; HODIS HN, 1994, J LIPID RES, V35, P669; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; KOCHX MM, 2000, CARDIOVASC RES, V45, P736; Kolodgie FD, 2000, AM J PATHOL, V157, P1259, DOI 10.1016/S0002-9440(10)64641-X; Leitinger N, 1999, P NATL ACAD SCI USA, V96, P12010, DOI 10.1073/pnas.96.21.12010; Lemaire S, 1998, FEBS LETT, V440, P434, DOI 10.1016/S0014-5793(98)01496-3; Leonarduzzi G, 2002, J NUTR BIOCHEM, V13, P700, DOI 10.1016/S0955-2863(02)00222-X; Leonarduzzi G, 2001, FASEB J, V15, P1619, DOI 10.1096/fj.00-0668fje; Li W, 2001, ARTERIOSCL THROM VAS, V21, P1124, DOI 10.1161/hq0701.092145; Lizard G, 1999, ARTERIOSCL THROM VAS, V19, P1190, DOI 10.1161/01.ATV.19.5.1190; Maziere C, 2002, BIOCHEM BIOPH RES CO, V293, P1327, DOI 10.1016/S0006-291X(02)00389-3; Miguet C, 2001, CELL DEATH DIFFER, V8, P83, DOI 10.1038/sj.cdd.4400792; Muller K, 2001, ATHEROSCLEROSIS, V156, P133, DOI 10.1016/S0021-9150(00)00641-9; Okura Y, 2000, CIRCULATION, V102, P2680, DOI 10.1161/01.CIR.102.22.2680; Panini SR, 2001, CURR OPIN LIPIDOL, V12, P529, DOI 10.1097/00041433-200110000-00008; PARKER CS, 1984, CELL, V36, P357, DOI 10.1016/0092-8674(84)90229-0; Rosenblat M, 1999, J BIOL CHEM, V274, P13790, DOI 10.1074/jbc.274.20.13790; Rosenblat M, 2002, ATHEROSCLEROSIS, V160, P69, DOI 10.1016/S0021-9150(01)00563-9; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Salvayre R, 2002, BBA-MOL CELL BIOL L, V1585, P213, DOI 10.1016/S1388-1981(02)00343-8; Sevanian A, 1997, J LIPID RES, V38, P419; SEVANIAN A, 1995, J LIPID RES, V36, P1971; SEVANIAN A, 1994, FREE RADICAL BIO MED, V17, P397, DOI 10.1016/0891-5849(94)90166-X; Steinberg D, 2002, NAT MED, V8, P1211, DOI 10.1038/nm1102-1211; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stiko A, 1996, ARTERIOSCL THROM VAS, V16, P194, DOI 10.1161/01.ATV.16.2.194; Ueda S, 2002, ANTIOXID REDOX SIGN, V4, P405, DOI 10.1089/15230860260196209; Watanabe T, 2001, ATHEROSCLEROSIS, V155, P37, DOI 10.1016/S0021-9150(00)00526-8; Watson AD, 1997, J BIOL CHEM, V272, P13597, DOI 10.1074/jbc.272.21.13597; Yao PM, 2001, J BIOL CHEM, V276, P42468, DOI 10.1074/jbc.M101419200; Zhang Z, 2003, FREE RADICAL BIO MED, V34, P1333, DOI 10.1016/S0891-5849(03)00145-X	48	86	89	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					693	+		10.1096/fj.03-0401fje	http://dx.doi.org/10.1096/fj.03-0401fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977888				2022-12-28	WOS:000220425000028
J	Payne, GW; Madri, TA; Sessa, WC; Segal, S				Payne, GW; Madri, TA; Sessa, WC; Segal, S			Histamine inhibits conducted vasodilation through endothelium-derived NO production in arterioles of mouse skeletal muscle	FASEB JOURNAL			English	Article						microcirculation; nitric oxide; gap junctions; cell adhesion	NITRIC-OXIDE SYNTHASE; HAMSTER-CHEEK POUCH; CELL-CELL CONTACTS; VENULAR PERMEABILITY; PHOSPHORYLATION; PECAM-1; MICE; INFLAMMATION; MEDIATORS; INCREASES	Conducted vasodilation along arterioles manifests the spread of hyperpolarization through gap junction channels along endothelium. Whereas histamine increases the permeability of capillary and venular endothelium, its effect on the integrity of arteriolar endothelium is unknown. We tested whether histamine could inhibit conducted vasodilation. In second-order arterioles (2A) supplying the cremaster muscle of C57BL6, PECAM-1(-/-), and eNOS(-/-) mice (8-12 wk), neither resting (16+/-2 mum) nor maximal (38+/-2 mum) diameters were different. Acetylcholine (ACh) micro-iontophoresis (1 muA, 500 ms pulse) triggered vasodilation that was conducted > 1400 mum along arterioles. Neither local (14+/-2 mum) nor conducted vasodilation (10+/-2 mum) was different among mice. Histamine (5 muM) had no effect on resting diameter or local vasodilation to ACh yet inhibited conduction by > 50% in C57BL6 and PECAM-1(-/-) mice (P<0.05); this effect was abolished after blockade of NO synthase or of soluble guanylate cyclase. Washout of histamine restored conduction, though recovery was longer (P<0.05) in PECAM-1(-/-) mice vs. C57BL6 mice. Remarkably, conducted vasodilation in eNOS(-/-) mice was insensitive to histamine. These findings indicate that histamine inhibits cell-to-cell coupling through an NO-dependent mechanism and suggests a dynamic interaction among intercellular adhesion molecules and gap junction channels along arteriolar endothelium.	Yale Univ, Sch Med, John B Pierce Lab, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Cellular & Mol Physiol, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06519 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06519 USA	Yale University; The John B Pierce Laboratory, Inc; Yale University; Yale University; Yale University	Segal, S (corresponding author), Yale Univ, Sch Med, John B Pierce Lab, 290 Congress Ave, New Haven, CT 06519 USA.	steven.segal@yale.edu	Payne, Geoffrey/AAG-8282-2019; Sessa, William C/B-6844-2011	Sessa, William C/0000-0001-5759-1938; Segal, Steven/0000-0001-5667-2154	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057665, R01HL041026, R37HL028373] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R21AG019347] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL41026, R37-HL28373, R01-HL57665] Funding Source: Medline; NIA NIH HHS [R21-AG19347] Funding Source: Medline; NIDDK NIH HHS [P01-DK38979] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1990, J CELL BIOL, V110, P1227, DOI 10.1083/jcb.110.4.1227; Alexander JS, 2002, J ANAT, V200, P561, DOI 10.1046/j.1469-7580.2002.00057.x; Alexander JS, 2000, INFLAMMATION, V24, P99, DOI 10.1023/A:1007025325451; Andriopoulou P, 1999, ARTERIOSCL THROM VAS, V19, P2286, DOI 10.1161/01.ATV.19.10.2286; BALDWIN AL, 1995, AM J PHYSIOL-HEART C, V269, pH1528, DOI 10.1152/ajpheart.1995.269.5.H1528; Bartlett IS, 2000, AM J PHYSIOL-HEART C, V278, pH604, DOI 10.1152/ajpheart.2000.278.2.H604; Biswas P, 2003, BIOCHEM BIOPH RES CO, V303, P212, DOI 10.1016/S0006-291X(03)00313-9; Duncan GS, 1999, J IMMUNOL, V162, P3022; Emerson GG, 2000, CIRC RES, V86, P94, DOI 10.1161/01.RES.86.1.94; Fischer S, 1999, AM J PHYSIOL-CELL PH, V276, pC812; FOLKOW B, 1971, ACTA PHYSIOL SCAND, V81, P459, DOI 10.1111/j.1748-1716.1971.tb04924.x; FOX J, 1980, MICROVASC RES, V19, P108, DOI 10.1016/0026-2862(80)90087-4; Gardner TW, 1996, BIOCHEM J, V320, P717, DOI 10.1042/bj3200717; Govers R, 2002, BIOCHEM J, V361, P193, DOI 10.1042/0264-6021:3610193; Graesser D, 2002, J CLIN INVEST, V109, P383, DOI 10.1172/JCI13595; Gratzinger D, 2003, BIOCHEM BIOPH RES CO, V301, P243, DOI 10.1016/S0006-291X(02)02982-0; Haas TL, 1997, MICROVASC RES, V53, P113, DOI 10.1006/mvre.1996.1999; Hungerford JE, 2000, FASEB J, V14, P197, DOI 10.1096/fasebj.14.1.197; IALENTI A, 1992, EUR J PHARMACOL, V211, P177, DOI 10.1016/0014-2999(92)90526-A; KUBES P, 1992, AM J PHYSIOL, V262, P611; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAMPUGNANI MG, 1992, J CELL BIOL, V118, P1511, DOI 10.1083/jcb.118.6.1511; MAJNO G, 1967, CIRC RES, V21, P833, DOI 10.1161/01.RES.21.6.833; MAYHAN WG, 1992, INFLAMMATION, V16, P295, DOI 10.1007/BF00917622; MAYHAN WG, 1994, AM J PHYSIOL, V266, pH2369, DOI 10.1152/ajpheart.1994.266.6.H2369; McDonald DM, 1999, MICROCIRCULATION, V6, P7; Moy AB, 2000, AM J PHYSIOL-LUNG C, V278, pL888, DOI 10.1152/ajplung.2000.278.5.L888; Newman PJ, 1997, J CLIN INVEST, V99, P3, DOI 10.1172/JCI119129; PAYNE GW, 2003, AM J PHYSIOL, V285, pH487; SEGAL SS, 1989, AM J PHYSIOL, V256, pH838, DOI 10.1152/ajpheart.1989.256.3.H838; Segal SS, 2001, J PHYSIOL-LONDON, V536, P937, DOI 10.1111/j.1469-7793.2001.00937.x; Shasby DM, 2002, AM J PHYSIOL-LUNG C, V282, pL1330, DOI 10.1152/ajplung.00329.2001; SHELDON R, 1993, AM J PHYSIOL, V265, pL606, DOI 10.1152/ajplung.1993.265.6.L606; Shesely EG, 1996, P NATL ACAD SCI USA, V93, P13176, DOI 10.1073/pnas.93.23.13176; Welsh DG, 1998, AM J PHYSIOL-HEART C, V274, pH178, DOI 10.1152/ajpheart.1998.274.1.H178; WU NZ, 1992, AM J PHYSIOL, V262, pH1238; YUAN YA, 1993, AM J PHYSIOL, V264, pH1734, DOI 10.1152/ajpheart.1993.264.5.H1734	37	25	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2004	18	2					280	286		10.1096/fj.03-0752com	http://dx.doi.org/10.1096/fj.03-0752com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769822				2022-12-28	WOS:000220425000008
J	Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E				Beni, SM; Kohen, R; Reiter, RJ; Tan, DX; Shohami, E			Melatonin-induced neuroprotection after closed head injury is associated with increased brain antioxidants and attenuated late-phase activation of NF-kappa B and AP-1	FASEB JOURNAL			English	Article						ascorbic acid; cyclic voltammetry; reactive oxygen species; traumatic brain injury	TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITIES; REACTIVE OXYGEN; HYDROGEN-PEROXIDE; TRANSCRIPTION FACTORS; OXIDATIVE STRESS; REDOX REGULATION; GENE-EXPRESSION; FACTOR-ALPHA; DAMAGE	Traumatic brain injury (TBI) is followed by massive production of reactive oxygen species (ROS), which mediate secondary cellular damage. Low molecular weight antioxidants (LMWA)constitute one of the defense mechanisms of the brain, and their levels correlate with post-TBI outcome. Melatonin, the main pineal hormone, possesses antioxidant properties. We investigated the effects of melatonin on neurobehavioral recovery, brain LMWA, and activation of the redoxsensitive transcription factors nuclear factor-kappaB (NF-kappa B) and AP-1 in mice subjected to closed head injury (CHI). Given 1 h after CHI, melatonin facilitated recovery during at least 1 wk (P<0.05) and decreased lesion size by similar to twofold (P<0.01). The dose response displayed a bell-shape, i.e., neuroprotection was achieved with 5 but not 1 or 10 mg/kg. At the neuroprotective dose, melatonin treatment was associated with sustained (4 days) elevation of brain LMWA, including ascorbic acid (P<0.05). In contrast, LMWA were unaffected by the administration of the neuroprotective endocannabinoid 2-arachidonoyl glycerol. Furthermore, melatonin did not alter early phase (24 h) CHI-induced activation of NF-kappa B and AP-1; however, it blocked the robust late-phase (8 days) activation of NF-kappa B and decreased that of AP-1 to below basal levels. Our results demonstrate that melatonin induces neuroprotection, presumably via potentiation of brain antioxidants and attenuation of NF-kappa B and AP-1 activation.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Univ Texas, Dept Cellular & Struct Biol, San Antonio, TX USA	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of Texas System	Shohami, E (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.	esty@cc.huji.ac.il	Kohen, Ron/ABC-2281-2021; tan, dun-xian/E-3610-2010; Tan, David/HIR-2214-2022	Kohen, Ron/0000-0001-7268-9845; 	US-Israeli Bi-National Science Foundation [97-00259-2]; Israel Science Foundation [117/00]	US-Israeli Bi-National Science Foundation(US-Israel Binational Science Foundation); Israel Science Foundation(Israel Science Foundation)	This study was supported by the US-Israeli Bi-National Science Foundation (#97-00259-2) and the Israel Science Foundation (117/00). E. Shohami and R. Kohen are affiliated with the David R. Bloom Center for Pharmacy, The Hebrew University School of Pharmacy, Jerusalem.	ALKALAY I, 1995, MOL CELL BIOL, V15, P1294; ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Antunes F, 1999, FREE RADICAL BIO MED, V26, P117, DOI 10.1016/S0891-5849(98)00168-3; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Borlongan CV, 2000, FASEB J, V14, P1307, DOI 10.1096/fj.14.10.1307; Cabrera J, 2000, NEUROPHARMACOLOGY, V39, P507, DOI 10.1016/S0028-3908(99)00128-8; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; Chen ST, 1999, EXP BRAIN RES, V124, P241, DOI 10.1007/s002210050619; Cirak B, 1999, PEDIATR NEUROSURG, V31, P298, DOI 10.1159/000028879; Clapp-Lilly KL, 2001, NEUROREPORT, V12, P1277, DOI 10.1097/00001756-200105080-00044; Clemens JA, 1998, STROKE, V29, P677, DOI 10.1161/01.STR.29.3.677; Dabbeni-Sala F, 2001, FASEB J, V15, P164, DOI 10.1096/fj.00-0129com; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; DUGAN LL, 1994, ANN NEUROL, V35, pS17, DOI 10.1002/ana.410350707; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fowler G, 2003, FREE RADICAL BIO MED, V34, P77, DOI 10.1016/S0891-5849(02)01186-3; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; GARFINKEL D, 1995, LANCET, V346, P541, DOI 10.1016/S0140-6736(95)91382-3; Gilad E, 1997, LIFE SCI, V60, pPL169, DOI 10.1016/S0024-3205(97)00008-8; Gilad E, 1998, FASEB J, V12, P685, DOI 10.1096/fasebj.12.9.685; Ginis I, 2000, MOL MED, V6, P1028, DOI 10.1007/BF03402054; Giusti P, 1996, FASEB J, V10, P891, DOI 10.1096/fasebj.10.8.8666166; HAYES RL, 1995, J NEUROTRAUM, V12, P779, DOI 10.1089/neu.1995.12.779; Huang CY, 2001, J CEREBR BLOOD F MET, V21, P163, DOI 10.1097/00004647-200102000-00008; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Kamata H, 2002, ANN NY ACAD SCI, V973, P419, DOI 10.1111/j.1749-6632.2002.tb04675.x; Kamata H, 1999, CELL SIGNAL, V11, P1, DOI 10.1016/S0898-6568(98)00037-0; Kaptanoglu E, 2000, J NEUROSURG, V93, P77, DOI 10.3171/spi.2000.93.1.0077; Kohen R, 1999, METHOD ENZYMOL, V300, P428; Kotler M, 1998, J PINEAL RES, V24, P83, DOI 10.1111/j.1600-079X.1998.tb00371.x; Letechipia-Vallejo G, 2001, ARCH MED RES, V32, P186, DOI 10.1016/S0188-4409(01)00268-5; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Livrea MA, 1997, FREE RADICAL BIO MED, V23, P706, DOI 10.1016/S0891-5849(97)00018-X; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Martin M, 2000, FASEB J, V14, P1677; Martin V, 2002, J PINEAL RES, V33, P204, DOI 10.1034/j.1600-079X.2002.02113.x; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Mathews KS, 2000, J NEUROSCI METH, V102, P43, DOI 10.1016/S0165-0270(00)00277-6; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; Mesenge C, 1998, J PINEAL RES, V25, P41, DOI 10.1111/j.1600-079X.1998.tb00384.x; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nonaka M, 1999, J NEUROTRAUM, V16, P1023, DOI 10.1089/neu.1999.16.1023; OGITA K, 1994, J NEUROCHEM, V63, P525; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; Osseni RA, 2000, LIFE SCI, V68, P387, DOI 10.1016/S0024-3205(00)00955-3; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; PIERI C, 1994, LIFE SCI, V55, pPL271, DOI 10.1016/0024-3205(94)00666-0; POEGGELER B, 1993, J PINEAL RES, V14, P151, DOI 10.1111/j.1600-079X.1993.tb00498.x; Polidori MC, 2001, STROKE, V32, P898, DOI 10.1161/01.STR.32.4.898; POVLISHOCK JT, 1992, HUM CELL, V4, P345; POZO D, 1994, LIFE SCI, V55, pPL455, DOI 10.1016/0024-3205(94)00532-X; Reiter RJ, 2001, CELL BIOCHEM BIOPHYS, V34, P237, DOI 10.1385/CBB:34:2:237; Sasaki M, 2003, BMC GASTROENTEROL, V3, DOI 10.1186/1471-230X-3-3; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Siushansian R, 1997, J NEUROCHEM, V68, P2378; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Tan DX, 2001, FASEB J, V15, P2294, DOI 10.1096/fj.01-0309fje; Tan DX, 2000, FREE RADICAL BIO MED, V29, P1177, DOI 10.1016/S0891-5849(00)00435-4; Tehranian R, 2002, J NEUROTRAUM, V19, P939, DOI 10.1089/089771502320317096; Trembovler V, 1999, J INTERF CYTOK RES, V19, P791, DOI 10.1089/107999099313640; Vollgraf U, 1999, J NEUROCHEM, V73, P2501, DOI 10.1046/j.1471-4159.1999.0732501.x; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Xiong Y, 2001, NEUROL RES, V23, P129, DOI 10.1179/016164101101198460; YONEDA Y, 1994, BRAIN RES, V667, P54, DOI 10.1016/0006-8993(94)91713-2	73	145	153	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					149	151		10.1096/fj.03-0323fje	http://dx.doi.org/10.1096/fj.03-0323fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597558				2022-12-28	WOS:000188829300057
J	Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY				Zou, Y; Jung, KJ; Kim, JW; Yu, BP; Chung, HY			Alteration of soluble adhesion molecules during aging and their modulation by calorie restriction	FASEB JOURNAL			English	Article						vascular aging; inflammation; oxidative stress; endothelial cells; reactive oxygen/nitrogen species	OXIDATIVE STRESS; DIETARY RESTRICTION; INFLAMMATION HYPOTHESIS; XANTHINE-OXIDASE; HEART-DISEASE; LUNG-CELLS; AGE; PLASMA; INHALATION; ENDOTOXIN	To investigate the status of soluble adhesion molecules (sAMs) during aging, the present study determined protein levels of several major sAMs in serum samples obtained from rats at different ages. These sAMs include E-selection, P-selection, vascular cell adhesion molecule 1 (VCAM-1), and intercellular adhesion molecule 1 (ICAM-1) Fischer 344 rats, ages 6, 12, 18, and 24 months, fed ad libitum (AL) and calorie restricted (CR) diets were used in this study. Analysis by Western blotting showed that the levels of all sAMs studied increased during aging in AL rats, but were effectively blunted in the CR rats. Total reactive oxygen species/reactive nitrogen species (ROS/RNS) levels were measured by fluorescent probe 2',7'-dichlorofluorescin diacetate. Increased ROS/RNS levels were found to coincide with increase levels of superoxide-generating xanthine oxidase in serum during aging, but were found suppressed by CR. Increases in sAMs levels were duplicated in another experiment in which young (13-month-old) and old (31-month-old) rats were injected with proinflammatory lipopolysaccharide. These findings suggest that the altered expressions of sAMs may be due to increased oxidative stress with advanced age and that these increases were prevented by CR through its antioxidative action.	Pusan Natl Univ, Coll Pharm, Dept Pharm, Pusan 609735, South Korea; Univ Texas, Hlth Sci Ctr, Dept Physiol, San Antonio, TX 78229 USA	Pusan National University; University of Texas System; University of Texas Health San Antonio	Chung, HY (corresponding author), Pusan Natl Univ, Coll Pharm, Dept Pharm, 30 Jangjeon Dong, Pusan 609735, South Korea.	hyjung@pusan.ac.kr	zou, yani/F-6361-2011					BERTRAND HA, 1999, METHODS AGING RES, P271; Brown AA, 2001, AM J CLIN NUTR, V73, P673; Calingasan NY, 2000, BRAIN RES, V885, P62, DOI 10.1016/S0006-8993(00)02933-4; CATHCART R, 1984, METHOD ENZYMOL, V105, P352; Chung H Y, 1999, J Nutr Health Aging, V3, P19; Chung HY, 1997, AGE, V20, P127, DOI 10.1007/s11357-997-0012-2; Chung HY, 2002, MICROSC RES TECHNIQ, V59, P264, DOI 10.1002/jemt.10203; Chung HY, 2001, ANN NY ACAD SCI, V928, P327; DEROCHEMONTEIXGALVE B, 1991, INFECT IMMUN, V59, P3646, DOI 10.1128/IAI.59.10.3646-3650.1991; Droge W, 2002, EXP GERONTOL, V37, P1333, DOI 10.1016/S0531-5565(02)00175-4; Espinosa-Heidmann DG, 2002, INVEST OPHTH VIS SCI, V43, P1567; Galis ZS, 2002, CIRC RES, V90, P251, DOI 10.1161/res.90.3.251; Guo ZM, 2002, MECH AGEING DEV, V123, P1121, DOI 10.1016/S0047-6374(02)00008-8; HABIB A, 1993, J BIOL CHEM, V268, P32448; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Hawes E M, 1993, Am J Cardiovasc Pathol, V4, P326; Heinz A, 2003, PSYCHOPHARMACOLOGY, V165, P111, DOI 10.1007/s00213-002-1244-6; HSIEH V, 1994, INT ARCH ALLERGY IMM, V104, P42, DOI 10.1159/000236707; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARTIGUEMATTEI C, 1990, J CHROMATOGR-BIOMED, V529, P93, DOI 10.1016/S0378-4347(00)83810-4; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lowe JB, 1997, J CLIN INVEST, V100, pS47; Lyons PD, 1998, GLIA, V22, P103, DOI 10.1002/(SICI)1098-1136(199802)22:2<103::AID-GLIA1>3.0.CO;2-8; Marin J, 1999, EXP GERONTOL, V34, P503, DOI 10.1016/S0531-5565(99)00029-7; Miles EA, 2001, CLIN SCI, V100, P91, DOI 10.1042/CS20000198; Morisaki N, 1997, ATHEROSCLEROSIS, V131, P43, DOI 10.1016/S0021-9150(97)06083-8; Mukherjee P, 2002, BRIT J CANCER, V86, P1615, DOI 10.1038/sj.bjc.6600298; Nash MC, 1996, CLIN EXP IMMUNOL, V103, P167, DOI 10.1046/j.1365-2249.1996.925616.x; Nielsen VG, 1996, AM J RESP CRIT CARE, V154, P1364, DOI 10.1164/ajrccm.154.5.8912749; Pu FR, 2002, BIOMATERIALS, V23, P4705, DOI 10.1016/S0142-9612(02)00219-3; Purschwitz K, 2001, Z GERONTOL GERIATR, V34, P476, DOI 10.1007/s003910170022; Radi ZA, 2001, J VET INTERN MED, V15, P516, DOI 10.1892/0891-6640(2001)015&lt;0516:CAMLTA&gt;2.3.CO;2; Ridker PM, 1998, LANCET, V351, P88, DOI 10.1016/S0140-6736(97)09032-6; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; Yu BP, 2001, DIABETES RES CLIN PR, V54, pS73, DOI 10.1016/S0168-8227(01)00338-2; Yu BP, 1996, FREE RADICAL BIO MED, V21, P651, DOI 10.1016/0891-5849(96)00162-1; YU BP, 1985, J GERONTOL, V40, P657, DOI 10.1093/geronj/40.6.657; Zaremba Jaroslaw, 2002, Folia Morphol (Warsz), V61, P1	38	88	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					320	+		10.1096/fj.03-0849fje	http://dx.doi.org/10.1096/fj.03-0849fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688195				2022-12-28	WOS:000188067500001
J	Xu, XZ; Stern, DF				Xu, XZ; Stern, DF			NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors	FASEB JOURNAL			English	Article						53BP1; gamma-H2AX; MRE11 complex; ATM/ATR substrates; assembly of ionizing radiation-induced foci	BUDDING YEAST RAD9; DAMAGE CHECKPOINT; HISTONE H2AX; EARLY PARTICIPANT; 53BP1; PROTEIN; PHOSPHORYLATION; MEDIATOR; MDC1; CHK2	NFBD1/MDC1 (mediator of DNA damage checkpoint 1) is a nuclear factor with an amino-terminal FHA (forkhead-associated) domain and a tandem repeat of BRCT (breast cancer susceptibility gene-1 carboxyl terminus) domains. We have previously shown that NFBD1 is an early participant in DNA damage signaling pathways and that ionizing radiation-induced nuclear foci (IRIF) of NFBD1 colocalize with several DNA checkpoint signaling and repair factors. We report here that NFBD1 physically associates with ATM, p53, components of the MRE11-RAD50-NBS1 (MRN) complex, and gamma-H2AX. An overexpressed FHA domain-containing fragment of NFBD1 binds to endogenous NFBD1 and components of the MRN complex, but not to gamma-H2AX. This fragment interferes with IRIF formation by endogenous NFBD1, MRE11, or NBS1. A BRCT domain-containing fragment of NFBD1 binds to gamma-H2AX and 53BP1, but not to components of the MRN complex, and abolishes IRIF formation by NFBD1, MRE11, NBS1, 53BP1, CHK2 phospho-T68, gamma-H2AX, and possible ATM/ATR substrates recognized by anti-phospho-SQ/TQ antibody. These results suggest that NFBD1 is an ATM/ATR dependent organizer that recruits DNA checkpoint signaling and repair proteins to the sites of DNA damage.	Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA	Yale University	Stern, DF (corresponding author), Yale Univ, Sch Med, Dept Pathol, 310 Cedar St,BML342, New Haven, CT 06510 USA.	df.stern@yale.edu	xu, xingzhi/E-8158-2012	xu, xingzhi/0000-0002-4459-2082	NCI NIH HHS [R01CA82257] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082257] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Abraham RT, 2002, NAT CELL BIOL, V4, pE277, DOI 10.1038/ncb1202-e277; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bradbury JM, 2003, BIOCHEM SOC T, V31, P40, DOI 10.1042/bst0310040; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; D'Amours D, 2002, NAT REV MOL CELL BIO, V3, P317, DOI 10.1038/nrm805; DiTullio RA, 2002, NAT CELL BIOL, V4, P998, DOI 10.1038/ncb892; Fernandez-Capetillo O, 2002, NAT CELL BIOL, V4, P993, DOI 10.1038/ncb884; Gilbert CS, 2001, MOL CELL, V8, P129, DOI 10.1016/S1097-2765(01)00267-2; Goldberg M, 2003, NATURE, V421, P952, DOI 10.1038/nature01445; IWABUCHI K, 1994, P NATL ACAD SCI USA, V91, P6098, DOI 10.1073/pnas.91.13.6098; Jullien D, 2002, J CELL SCI, V115, P71; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Ozaki T, 2000, DNA CELL BIOL, V19, P475, DOI 10.1089/10445490050128403; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Peng AM, 2003, J BIOL CHEM, V278, P8873, DOI 10.1074/jbc.C300001200; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schwartz MF, 2002, MOL CELL, V9, P1055, DOI 10.1016/S1097-2765(02)00532-4; Shang YL, 2003, J BIOL CHEM, V278, P6323, DOI 10.1074/jbc.M210749200; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Sun ZX, 1998, SCIENCE, V281, P272, DOI 10.1126/science.281.5374.272; Vialard JE, 1998, EMBO J, V17, P5679, DOI 10.1093/emboj/17.19.5679; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Ward IM, 2003, MOL CELL BIOL, V23, P2556, DOI 10.1128/MCB.23.7.2556-2563.2003; Xu XZ, 1999, ONCOGENE, V18, P5554, DOI 10.1038/sj.onc.1203091; Xu XZ, 2003, J BIOL CHEM, V278, P8795, DOI 10.1074/jbc.M211392200; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932	32	82	90	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1842	1848		10.1096/fj.03-0310com	http://dx.doi.org/10.1096/fj.03-0310com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519663				2022-12-28	WOS:000186343300038
J	Xing, KY; Lou, MF				Xing, KY; Lou, MF			Possible physiological function of thioltransferase in cells	FASEB JOURNAL			English	Article; Proceedings Paper	United States-Japan Cooperative Research Conference	NOV 03-07, 2001	KONA, HI			over-expression; cadmium; repair function; oxidative stress; dethiolation	THIOL MIXED DISULFIDES; LENS EPITHELIAL-CELLS; HIGH-LEVEL EXPRESSION; EARLY EMBRYONIC LETHALITY; ACTIVATED PROTEIN-KINASE; ESCHERICHIA-COLI; OXIDATIVE STRESS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; INDUCED CATARACT; IN-VITRO	We sought to study the possible physiological function of thioltransferase (TTase) in combating oxidative damage in the lens epithelial cells. The cells transfected with either TTase-containing plasmid or vector only were compared for their resistance to oxidative stress in the presence of a bolus of H2O2 (0.1 mM) for 3 h. Cells depleted of TTase activity upon cadmium treatment were also examined for the resistance to oxidative stress under the same conditions. TTase activity assay, Western blot, and Northern blot analyses confirmed that hTTase gene was successfully transfected into the HLE B3 cells and was overexpressed. The TTase-transfected cells detoxified H2O2 as efficiently as the control cells but displayed a faster and more complete recovery of oxidatively inactivated glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and glutathione peroxidase (GPx) activities and suppressed protein thiolation (PSSG formation). With TTase activity being inhibited by cadmium, the spontaneous reactivation of GAPDH under bolus H2O2 treatment was not accomplished in cadmium-pretreated cells. These data indicate a new physiological function of TTase, which involves in the reactivation of the oxidatively inactivated enzymes through dethiolation; thus this redox-regulating enzyme can protect the human lens epithelial cells and maybe other cell types by preventing them from permanent oxidative damage.	Univ Nebraska, Dept Vet & Biomed Sci, VBS 134, Lincoln, NE 68583 USA; Univ Nebraska, Dept Biochem, Lincoln, NE 68583 USA; Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Medical Center	Lou, MF (corresponding author), Univ Nebraska, Dept Vet & Biomed Sci, VBS 134, Lincoln, NE 68583 USA.	mlou1@unl.edu						Adams James D. Jr., 2001, Current Topics in Medicinal Chemistry, V1, P473, DOI 10.2174/1568026013394778; ANDLEY U, 2000, PRINCIPLE PRACTICES; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bergmeyer HU, 1974, METHOD ENZYMAT AN, P466; Bhuyan DK, 1996, BBA-BIOMEMBRANES, V1285, P21, DOI 10.1016/S0005-2736(96)00142-3; BRODIE AE, 1987, BIOCHEM BIOPH RES CO, V148, P120, DOI 10.1016/0006-291X(87)91084-9; Cai JY, 2000, PROG RETIN EYE RES, V19, P205, DOI 10.1016/S1350-9462(99)00009-9; Cho YW, 2000, BBA-GENE STRUCT EXPR, V1517, P171, DOI 10.1016/S0167-4781(00)00242-6; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CU XL, 1993, EXP EYE RES, V57, P157, DOI 10.1006/exer.1993.1111; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Davis A, 1997, HEALTH TECHNOL ASSES, V1, P1; Draculic T, 2000, MOL MICROBIOL, V36, P1167, DOI 10.1046/j.1365-2958.2000.01948.x; FERNANDO MR, 2003, ANN M ABSTR PROGR PL; Galan A, 2000, J BIOL CHEM, V275, P11418, DOI 10.1074/jbc.275.15.11418; GIBLIN FJ, 1995, EXP EYE RES, V60, P219, DOI 10.1016/S0014-4835(05)80105-8; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Harrison J., 1976, P1; Hildebrandt A G, 1978, Methods Enzymol, V52, P342; HIRATO K, 2000, BIOCHEM BIOPH RES CO, V274, P177; Hirose S, 2000, DEVELOPMENT, V127, P3263; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOU MF, 1995, CURR EYE RES, V14, P951, DOI 10.3109/02713689508995135; Lou MF, 1997, ADVANCES IN OCULAR TOXICOLOGY, P27; Lou MF, 1998, EXP EYE RES, V66, P477, DOI 10.1006/exer.1997.0464; LOU MF, 1990, EXP EYE RES, V50, P819, DOI 10.1016/0014-4835(90)90133-F; LOU MF, 1992, EXP EYE RES, V55, P889, DOI 10.1016/0014-4835(92)90015-K; Lou MF, 2000, J OCUL PHARMACOL TH, V16, P137, DOI 10.1089/jop.2000.16.137; LOU MF, 2002, ANN M ABSTR PROGR PL; Matsui M, 1996, DEV BIOL, V178, P179, DOI 10.1006/dbio.1996.0208; Meyer EB, 1999, FREE RADICAL BIO MED, V26, P770, DOI 10.1016/S0891-5849(98)00247-0; MIEYAL JJ, 1995, GLUTATHIONYL SPECIFI, P305; Nakamura T, 1999, FREE RADICAL RES, V31, P357, DOI 10.1080/10715769900300931; Nonn L, 2003, MOL CELL BIOL, V23, P916, DOI 10.1128/MCB.23.3.916-922.2003; Padilla CA, 1996, FEBS LETT, V378, P69; Park SU, 2002, PLANT PHYSIOL, V128, P696, DOI 10.1104/pp.010741; Patzel V, 2000, NUCLEIC ACIDS RES, V28, P2462, DOI 10.1093/nar/28.13.2462; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Qiao FY, 2000, EXP EYE RES, V70, P745, DOI 10.1006/exer.2000.0836; Qiao FY, 2001, INVEST OPHTH VIS SCI, V42, P743; Raghavachari N, 2001, INVEST OPHTH VIS SCI, V42, P1002; Raghavachari N, 1996, EXP EYE RES, V63, P433, DOI 10.1006/exer.1996.0133; RAVICHANDRAN V, 1994, J BIOL CHEM, V269, P25010; SCHUPPEKOISTINEN I, 1994, EUR J BIOCHEM, V221, P1033, DOI 10.1111/j.1432-1033.1994.tb18821.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; SPECTOR A, 1985, OCULAR LENS STRUCTUR, P405; STEFFENSEN IL, 1994, GEN PHARMACOL-VASC S, V25, P1621, DOI 10.1016/0306-3623(94)90364-6; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsangaris GT, 1998, TOXICOLOGY, V128, P143, DOI 10.1016/S0300-483X(98)00032-8; Wang GM, 1997, EXP EYE RES, V64, P693, DOI 10.1006/exer.1996.0251; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; WELLS WW, 1994, J BIOENERG BIOMEMBR, V26, P369, DOI 10.1007/BF00762777; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Xing KY, 2002, EXP EYE RES, V74, P113, DOI 10.1006/exer.2001.1103; XU GT, 1992, EXP EYE RES, V54, P63, DOI 10.1016/0014-4835(92)90070-9; YANG Y, 1990, J BIOL CHEM, V265, P589; YEGOROVA S, 2003, ANN M ABSTR PROGR PL; YEGOROVA S, 2003, IN PRESS INVEST OPHT; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500; Zatechka DS, 2002, EXP EYE RES, V74, P703, DOI 10.1006/exer.2002.1168; ZIGMAN S, 1991, INVEST OPHTH VIS SCI, V32, P1723	65	25	26	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2088	+		10.1096/fj.02-1164fje	http://dx.doi.org/10.1096/fj.02-1164fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958160				2022-12-28	WOS:000185925100020
J	Perl, O; Ilani, T; Strous, RD; Lapidus, R; Fuchs, S				Perl, O; Ilani, T; Strous, RD; Lapidus, R; Fuchs, S			The alpha 7 nicotinic acetylcholine receptor in schizophrenia: decreased mRNA levels in peripheral blood lymphocytes	FASEB JOURNAL			English	Article						human blood lymphocytes; RT-PCR; smoking	CIGARETTE-SMOKING; EXPRESSION; DONEPEZIL; PATHOLOGY; SUBUNIT; GENE	Recent studies have suggested that the alpha7 nicotinic acetylcholine receptor (alpha AChR) may play a role in the pathogenesis of schizophrenia. In search for peripheral biological markers for schizophrenia we have investigated alpha7 mRNA levels in peripheral blood lymphocytes (PBLs) of schizophrenic patients and healthy controls. Peripheral blood samples were collected from medicated and non-medicated (drug naive) schizophrenic patients as well as from healthy (non-mentally ill) smokers and non-smokers. RNA was prepared from isolated lymphocytes. Polymerase chain reaction products specific for human alpha7 AChR were quantified by densitometry using Scion image-analysis (shared NIH software). We observed a significant decrease of alpha7 mRNA levels on PBLs of schizophrenic patients compared with controls. The decrease in alpha7 mRNA levels was not a result of medication management, because non-medicated schizophrenic patients displayed the same level of reduction in alpha7 mRNA as did patients receiving medication. In addition, we exclude the possibility that the observed decrease in alpha7 mRNA levels resulted from nicotine consumption in smoking, because healthy smokers exhibited the same levels of alpha7 mRNA as non-smokers. We propose that alpha7 AChR may be involved in the pathophysiology of the disease and may serve as a reliable peripheral biological marker in schizophrenia.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Tel Aviv Univ, Beer Yaakov Mental Hlth Ctr, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel	Weizmann Institute of Science; Tel Aviv University; Tel Aviv University; Sackler Faculty of Medicine	Fuchs, S (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	sara.fuchs@weizmann.ac.il		Ilani, Tal/0000-0003-2806-4455				Albuquerque EX, 1997, J PHARMACOL EXP THER, V280, P1117; American Psychiatric Association, 1994, DSM 4 DIAGNOSTIC STA; Baron M, 2001, AM J HUM GENET, V68, P299, DOI 10.1086/318212; Court J, 1999, J NEUROCHEM, V73, P1590, DOI 10.1046/j.1471-4159.1999.0731590.x; Dalack GW, 1998, AM J PSYCHIAT, V155, P1490, DOI 10.1176/ajp.155.11.1490; Freedman R, 2000, J CHEM NEUROANAT, V20, P299, DOI 10.1016/S0891-0618(00)00109-5; Friedman JI, 2002, BIOL PSYCHIAT, V51, P349, DOI 10.1016/S0006-3223(01)01342-7; Gault J, 1998, GENOMICS, V52, P173, DOI 10.1006/geno.1998.5363; Guan ZZ, 1999, NEUROREPORT, V10, P1779, DOI 10.1097/00001756-199906030-00028; Hellstrom-Lindahl E, 1999, MOL BRAIN RES, V66, P94, DOI 10.1016/S0169-328X(99)00030-3; Hyde TM, 2001, J CHEM NEUROANAT, V22, P53, DOI 10.1016/S0891-0618(01)00101-6; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Leonard S, 2000, EUR J PHARMACOL, V393, P237, DOI 10.1016/S0014-2999(00)00035-2; Leonard S, 2002, ARCH GEN PSYCHIAT, V59, P1085, DOI 10.1001/archpsyc.59.12.1085; LEONARD S, 2000, PHARM BIOCH BEHAV, V70, P561; Lieberman JA, 1999, J CLIN PSYCHIAT, V60, P9; Lindstrom J, 1997, MOL NEUROBIOL, V15, P193, DOI 10.1007/BF02740634; Olincy A, 1998, NEUROPSYCHOPHARMACOL, V18, P175, DOI 10.1016/S0893-133X(97)00095-X; Olincy A, 1997, BIOL PSYCHIAT, V42, P1, DOI 10.1016/S0006-3223(96)00302-2; Olincy A, 1999, NEUROPSYCHOPHARMACOL, V20, P52, DOI 10.1016/S0893-133X(98)00053-0; Risch SC, 2001, NEUROCASE, V7, P105, DOI 10.1076/neur.7.2.105.16262; Sato KZ, 1999, NEUROSCI LETT, V266, P17, DOI 10.1016/S0304-3940(99)00259-1; Stassen HH, 2000, AM J MED GENET, V96, P173, DOI 10.1002/(SICI)1096-8628(20000403)96:2<173::AID-AJMG10>3.0.CO;2-U; TRINA BA, 2002, AM J PSYCHIAT, V159, P1244	24	50	54	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1948	+		10.1096/fj.03-0104fje	http://dx.doi.org/10.1096/fj.03-0104fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897067				2022-12-28	WOS:000185345100025
J	Werner, T; Fessele, S; Maier, H; Nelson, PJ				Werner, T; Fessele, S; Maier, H; Nelson, PJ			Computer modeling of promoter organization as a tool to study transcriptional coregulation	FASEB JOURNAL			English	Review						promoter; modeling; bioinformatics; module; functional context	OXIDE SYNTHASE EXPRESSION; LARGE GENOMIC SEQUENCES; CHEMOKINE RECEPTORS; FUNCTIONAL PROMOTER; RANTES CHEMOKINE; GENE-EXPRESSION; ANGIOTENSIN-II; DNA-SEQUENCES; BINDING SITES; RENAL-DISEASE	Understanding how the regulation of gene networks is orchestrated is an important challenge for characterizing complex biological processes. Gene transcription is regulated in part by nuclear factors that recognize short DNA sequence motifs, called transcription factor binding sites, in most cases located upstream of the gene coding sequence in promoter and enhancer regions. Genes expressed in the same tissue under similar conditions often share a common organization of at least some of these regulatory binding elements. In this way the organization of promoter motifs represents a "footprint" of the transcriptional regulatory mechanisms at work in a specific biologic context and thus provides information about signal and tissue specific control of expression. Analysis of promoters for organizational features as demonstrated here provides a crucial link between the static nucleotide sequence of the genome and the dynamic aspects of gene regulation and expression.	Univ Munich, Med Poliklin, D-80336 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany; Genomatix Software GmbH, D-80339 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Nelson, PJ (corresponding author), Univ Munich, Med Poliklin, Schillerstr 42, D-80336 Munich, Germany.	nelson@medpoli.med.uni-muenchen.de		Fessele, Sabine/0000-0002-5399-3574				Agerberth B, 2000, BLOOD, V96, P3086, DOI 10.1182/blood.V96.9.3086.h8003086_3086_3093; Bajetto A, 2002, J NEUROCHEM, V82, P1311, DOI 10.1046/j.1471-4159.2002.01091.x; Beck KF, 1998, FEBS LETT, V435, P35, DOI 10.1016/S0014-5793(98)01035-7; Boehlk S, 2000, EUR J IMMUNOL, V30, P1102, DOI 10.1002/(SICI)1521-4141(200004)30:4<1102::AID-IMMU1102>3.0.CO;2-X; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Brazma A, 1998, J COMPUT BIOL, V5, P279, DOI 10.1089/cmb.1998.5.279; CHEN QK, 1995, COMPUT APPL BIOSCI, V11, P563; D'haeseleer P, 2000, BIOINFORMATICS, V16, P707, DOI 10.1093/bioinformatics/16.8.707; Egwuagu CE, 2002, J IMMUNOL, V168, P3181, DOI 10.4049/jimmunol.168.7.3181; Fessele S, 2002, TRENDS GENET, V18, P60, DOI 10.1016/S0168-9525(02)02591-X; Fessele S, 2001, FASEB J, V15, P577; Finley SK, 1999, J NEUROBIOL, V40, P446; Firulli AB, 1997, TRENDS GENET, V13, P364, DOI 10.1016/S0168-9525(97)01171-2; Frech K, 1997, TRENDS BIOCHEM SCI, V22, P103; Frech K, 1997, COMPUT APPL BIOSCI, V13, P89; Frech K, 1997, J MOL BIOL, V270, P674, DOI 10.1006/jmbi.1997.1140; Frech K, 1997, Pac Symp Biocomput, P151; Freeman GJ, 2000, J EXP MED, V192, P1027, DOI 10.1084/jem.192.7.1027; Frisch M, 2002, GENOME RES, V12, P349, DOI 10.1101/gr.206602.ArticlepublishedonlinebeforeprintinJanuary2002; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Gyetko MR, 1999, J LAB CLIN MED, V133, P274, DOI 10.1016/S0022-2143(99)90084-7; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; Iwata S, 1999, INT IMMUNOL, V11, P417, DOI 10.1093/intimm/11.3.417; Kel A E, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P197; Kitchens RL, 1999, J BIOL CHEM, V274, P34116, DOI 10.1074/jbc.274.48.34116; Klingenhoff A, 1999, BIOINFORMATICS, V15, P180, DOI 10.1093/bioinformatics/15.3.180; Klingenhoff A., 2002, In Silico Biology, V2, pS17; Koning GA, 2002, ENDOTHELIUM-J ENDOTH, V9, P161, DOI 10.1080/10623320213631; Kopydlowski KM, 1999, J IMMUNOL, V163, P1537; Miyamoto NG, 2000, J NEUROIMMUNOL, V105, P78, DOI 10.1016/S0165-5728(00)00195-8; Moriuchi H, 1997, J IMMUNOL, V158, P3483; Murphy PM, 2000, PHARMACOL REV, V52, P145; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; Nelson PJ, 1997, METHOD ENZYMOL, V287, P148; Nelson PJ, 1996, J IMMUNOL, V157, P1139; Nelson PJ, 2001, IMMUNITY, V14, P377, DOI 10.1016/S1074-7613(01)00118-2; Ortiz BD, 1996, MOL CELL BIOL, V16, P202; Ortiz BD, 1997, IMMUNOL TODAY, V18, P468, DOI 10.1016/S0167-5699(97)01128-6; Perier RC, 2000, NUCLEIC ACIDS RES, V28, P302, DOI 10.1093/nar/28.1.302; Pilpel Y, 2001, NAT GENET, V29, P153, DOI 10.1038/ng724; Prestridge D S, 2000, Methods Mol Biol, V130, P265; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Robertson KD, 2002, ONCOGENE, V21, P5361, DOI 10.1038/sj.onc.1205609; Sabbioni S, 1999, CYTOGENET CELL GENET, V86, P214, DOI 10.1159/000015341; Scherf M, 2001, GENOME RES, V11, P333, DOI 10.1101/gr.154601; Scherf M, 2000, J MOL BIOL, V297, P599, DOI 10.1006/jmbi.2000.3589; Segerer S, 2000, J AM SOC NEPHROL, V11, P152, DOI 10.1681/ASN.V111152; Shinosaki T, 2002, LAB INVEST, V82, P505, DOI 10.1038/labinvest.3780443; Song A, 1999, IMMUNITY, V10, P93, DOI 10.1016/S1074-7613(00)80010-2; Stormo GD, 2000, BIOINFORMATICS, V16, P16, DOI 10.1093/bioinformatics/16.1.16; Taniuchi M, 1999, KIDNEY INT, V56, pS156, DOI 10.1046/j.1523-1755.1999.07140.x; Wang Q, 2000, CIRC RES, V86, P478, DOI 10.1161/01.RES.86.4.478; Werner T, 1999, MAMM GENOME, V10, P168, DOI 10.1007/s003359900963; Werner T, 2001, BIOMOL ENG, V17, P87, DOI 10.1016/S1389-0344(00)00071-X; Werner T, 2001, NAT GENET, V29, P105, DOI 10.1038/ng1001-105; Werner T, 2001, PHARMACOGENOMICS, V2, P25, DOI 10.1517/14622416.2.1.25; Wolf G, 1998, NEPHROLOGIE, V19, P451; Wong HR, 1996, AM J PHYSIOL-LUNG C, V271, pL166, DOI 10.1152/ajplung.1996.271.1.L166; Yahata T, 1999, EUR J IMMUNOL, V29, P727, DOI 10.1002/(SICI)1521-4141(199903)29:03<727::AID-IMMU727>3.0.CO;2-0; Yamada T, 1999, CLIN CHEM LAB MED, V37, P381, DOI 10.1515/CCLM.1999.063	61	69	76	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1228	1237		10.1096/fj.02-0955rev	http://dx.doi.org/10.1096/fj.02-0955rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832287				2022-12-28	WOS:000184471600034
J	Zhu, SY; Darbon, H; Dyason, K; Verdonck, F; Tytgat, J				Zhu, SY; Darbon, H; Dyason, K; Verdonck, F; Tytgat, J			Evolutionary origin of inhibitor cystine knot peptides	FASEB JOURNAL			English	Article						gene structure; evolution; exon shuffling; viruses	PATHOGEN CLADOSPORIUM-FULVUM; CONVERGENT EVOLUTION; POTASSIUM CHANNEL; SCORPION TOXINS; DRUG DESIGN; VENOM PEPTIDES; ANIMAL TOXINS; CDNA SEQUENCE; PROTEIN; FAMILY	The inhibitor cystine knot (ICK) fold is an evolutionarily conserved structural motif shared by a large group of polypeptides with diverse sequences and bioactivities. Although found in different phyla (animal, plant, and fungus), ICK peptides appear to be most prominent in venoms of cone snail and spider. Recently, two scorpion toxins activating a calcium release channel have been found to adopt an ICK fold. We have isolated and identified both cDNA and genomic clones for this family of ICK peptides from the scorpion Opistophthalmus carinatus. The gene characterized by three well-delineated exons respectively coding for three structural and functional domains in the toxin precursors illustrates the correlation between exon and module as suggested by the "exon theory of genes." Based on the analysis of precursor organization and gene structure combined with the 3-D fold and functional data, our results highlight a common evolutionary origin for ICK peptides from animals. In contrast, ICK peptides from plant and fungus might be independently evolved from another ancestor.	Univ Leuven, Toxicol Lab, B-3000 Louvain, Belgium; Univ Aix Marseille 1, AFMB, CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 2, AFMB, CNRS, UMR 6098, F-13402 Marseille 20, France; Univ Potchefstroom, Dept Physiol, ZA-2520 Potchefstroom, South Africa; Univ Leuven, Interdisciplinary Res Ctr, B-8500 Kortrijk, Belgium	KU Leuven; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; North West University - South Africa; KU Leuven	Tytgat, J (corresponding author), Univ Leuven, Toxicol Lab, E Van Evenstr 4, B-3000 Louvain, Belgium.	Jan.Tytgat@pharm.kuleuven.ac.be	Tytgat, Jan/F-1560-2010	Tytgat, Jan/0000-0003-1778-6022				Anderluh G, 1999, TOXICON, V37, P1391, DOI 10.1016/S0041-0101(99)00082-3; Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BERGET SM, 1995, J BIOL CHEM, V270, P2411, DOI 10.1074/jbc.270.6.2411; Bernard C, 2000, PROTEIN SCI, V9, P2059; BONTEMS F, 1991, SCIENCE, V254, P1521, DOI 10.1126/science.1720574; Craik DJ, 2001, TOXICON, V39, P43, DOI 10.1016/S0041-0101(00)00160-4; Dauplais M, 1997, J BIOL CHEM, V272, P4302, DOI 10.1074/jbc.272.7.4302; DOOLITTLE RF, 1994, TRENDS BIOCHEM SCI, V19, P15, DOI 10.1016/0968-0004(94)90167-8; Duda TF, 1999, P NATL ACAD SCI USA, V96, P6820, DOI 10.1073/pnas.96.12.6820; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Froy O, 1998, FASEB J, V12, P1793, DOI 10.1096/fasebj.12.15.1793; Froy O, 1999, J MOL EVOL, V48, P187, DOI 10.1007/PL00006457; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert W, 1997, P NATL ACAD SCI USA, V94, P7698, DOI 10.1073/pnas.94.15.7698; Gilquin B, 2002, J BIOL CHEM, V277, P37406, DOI 10.1074/jbc.M206205200; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; Holm L, 1997, TRENDS BIOCHEM SCI, V22, P116, DOI 10.1016/S0968-0004(97)01021-9; Hu ZH, 1998, VIRUS RES, V55, P71, DOI 10.1016/S0168-1702(98)00029-X; Kalapothakis E, 1998, TOXICON, V36, P1971, DOI 10.1016/S0041-0101(98)00127-5; Kuzio J, 1999, VIROLOGY, V253, P17, DOI 10.1006/viro.1998.9469; LEWIN B, 1997, GENES, V6, P243; Li LL, 2002, VIROLOGY, V297, P226, DOI 10.1006/viro.2002.1411; LING MH, 1993, J BIOL CHEM, V268, P810; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Long MY, 1996, P NATL ACAD SCI USA, V93, P7727, DOI 10.1073/pnas.93.15.7727; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; Murzin AG, 1998, NAT STRUCT BIOL, V5, P101, DOI 10.1038/nsb0298-101; NARASIMHAN L, 1994, NAT STRUCT BIOL, V1, P850, DOI 10.1038/nsb1294-850; Norton RS, 2002, PERSPECTIVES IN MOLECULAR TOXINOLOGY, P159; Ohno M, 1998, PROG NUCLEIC ACID RE, V59, P307; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; Olivera BM, 1999, ANN NY ACAD SCI, V870, P223, DOI 10.1111/j.1749-6632.1999.tb08883.x; OLIVERA BM, 1990, SCIENCE, V249, P257, DOI 10.1126/science.2165278; Olivera BM, 1997, MOL BIOL CELL, V8, P2101, DOI 10.1091/mbc.8.11.2101; PALLAGHY PK, 1994, PROTEIN SCI, V3, P1833, DOI 10.1002/pro.5560031022; PEAR JR, 1989, PLANT MOL BIOL, V13, P639, DOI 10.1007/BF00016019; Ponting CP, 2002, ANNU REV BIOPH BIOM, V31, P45, DOI 10.1146/annurev.biophys.31.082901.134314; Possani LD, 1999, EUR J BIOCHEM, V264, P287, DOI 10.1046/j.1432-1327.1999.00625.x; Srinivasan KN, 2002, J BIOL CHEM, V277, P30040, DOI 10.1074/jbc.M111258200; Valcarcel J, 1996, SCIENCE, V273, P1706, DOI 10.1126/science.273.5282.1706; VANDENACKERVEKEN GFJM, 1992, PLANT J, V2, P359, DOI 10.1111/j.1365-313X.1992.00359.x; Vervoort J, 1997, FEBS LETT, V404, P153, DOI 10.1016/S0014-5793(97)00117-8; Villanueva J, 1998, FEBS LETT, V440, P175, DOI 10.1016/S0014-5793(98)01447-1; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Zhu SY, 2001, TOXICON, V39, P1291, DOI 10.1016/S0041-0101(01)00078-2	46	126	137	1	18	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1765	+		10.1096/fj.02-1044fje	http://dx.doi.org/10.1096/fj.02-1044fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958203				2022-12-28	WOS:000184471600019
J	Inui, A; Asakawa, A; Bowers, CY; Mantovani, G; Laviano, A; Meguid, MM; Fujimiya, M				Inui, A; Asakawa, A; Bowers, CY; Mantovani, G; Laviano, A; Meguid, MM; Fujimiya, M			Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ	FASEB JOURNAL			English	Review						GHS; orexigenic signal; enteric nutrition; ATP/AgRP neurons	GROWTH-HORMONE SECRETAGOGUE; CENTRAL-NERVOUS-SYSTEM; HELICOBACTER-PYLORI INFECTION; GLUCAGON-LIKE PEPTIDE-1; INCREASES FOOD-INTAKE; ANOREXIA-CACHEXIA SYNDROME; VAGAL AFFERENT NEURONS; DIET-INDUCED OBESE; DES-ACYL GHRELIN; NEUROPEPTIDE-Y	Recent progress in the field of energy homeostasis was triggered by the discovery of adipocyte hormone leptin and revealed a complex regulatory neuroendocrine network. A late addition is the novel stomach hormone ghrelin, which is an endogenous agonist at the growth hormone secretagogne receptor and is the motilin-related family of regulatory peptides. In addition to its ability to stimulate GH secretion and gastric motility, ghrelin stimulates appetite and induces a positive energy balance leading to body weight gain. Leptin and ghrelin are complementary, yet antagonistic, signals reflecting acute and chronic changes in energy balance, the effects of which are mediated by hypothalamic neuropeptides such as neuropeptide Y and agouti-related peptide. Endocrine and vagal afferent pathways are involved in these actions of ghrelin and leptin. Ghrelin is a novel neuroendocrine signal possessing a wide spectrum of biological activities that illustrates the importance of the stomach in providing input into the brain. Defective ghrelin signaling from the stomach could contribute to abnormalities in energy balance, growth, and associated gastrointestinal and neuroendocrine functions.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA; Univ Cagliari, Dept Med Oncol, Cagliari, Italy; Univ Roma La Sapienza, Dept Clin Med, Rome, Italy; Upstate Med Univ, Univ Hosp, Dept Surg, Neurosci Program,Surg Metab & Nutr Lab, Syracuse, NY USA; Shiga Univ Med Sci, Dept Anat, Otsu, Shiga 52021, Japan	Kobe University; Tulane University; University of Cagliari; Sapienza University Rome; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; Shiga University of Medical Science	Inui, A (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	inui@med.kobe-u.ac.jp						Ahlman H, 2001, ANN ONCOL, V12, pS63, DOI 10.1093/annonc/12.suppl_2.S63; ANDERSON AE, 1980, J PEDIATR SURG, V15, P876, DOI 10.1016/S0022-3468(80)80297-1; Andrews PLR, 2002, CURR OPIN PHARMACOL, V2, P650, DOI 10.1016/S1471-4892(02)00227-8; Ariyasu H, 2001, J CLIN ENDOCR METAB, V86, P4753, DOI 10.1210/jc.86.10.4753; Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Asakawa A, 1999, GASTROENTEROLOGY, V116, P1287, DOI 10.1016/S0016-5085(99)70491-9; Asakawa A, 2003, GUT, V52, P947, DOI 10.1136/gut.52.7.947; Asakawa A, 2001, NEUROENDOCRINOLOGY, V74, P143, DOI 10.1159/000054680; Asakawa A, 1998, PEPTIDES, V19, P987, DOI 10.1016/S0196-9781(97)00477-4; Asakawa A, 2003, GASTROENTEROLOGY, V124, P1325, DOI 10.1016/S0016-5085(03)00216-6; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Baldanzi G, 2002, J CELL BIOL, V159, P1029, DOI 10.1083/jcb.200207165; Banks WA, 2002, J PHARMACOL EXP THER, V302, P822, DOI 10.1124/jpet.102.034827; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Barrachina MD, 1997, P NATL ACAD SCI USA, V94, P10455, DOI 10.1073/pnas.94.19.10455; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; BAURA GD, 1993, J CLIN INVEST, V92, P1824, DOI 10.1172/JCI116773; Beck B, 2002, BIOCHEM BIOPH RES CO, V292, P1031, DOI 10.1006/bbrc.2002.6737; Bednarek MA, 2000, J MED CHEM, V43, P4370, DOI 10.1021/jm0001727; BLOCH B, 1984, NATURE, V307, P272, DOI 10.1038/307272a0; BONACINI M, 1993, AM J GASTROENTEROL, V88, P208; BOWERS CY, 1984, ENDOCRINOLOGY, V114, P1537, DOI 10.1210/endo-114-5-1537; BOWERS CY, 1980, ENDOCRINOLOGY, V106, P663, DOI 10.1210/endo-106-3-663; Bowers CY, 2001, J CLIN ENDOCR METAB, V86, P1464, DOI 10.1210/jc.86.4.1464; Bray GA, 2000, P NUTR SOC, V59, P373, DOI 10.1017/S0029665100000422; Bray GA, 1998, RECENT PROG HORM RES, V53, P95; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Broglio F, 2001, J CLIN ENDOCR METAB, V86, P5083, DOI 10.1210/jc.86.10.5083; BUENO L, 1993, J PHYSIOLOGY-PARIS, V87, P301, DOI 10.1016/0928-4257(93)90036-S; Burdyga G, 2003, GASTROENTEROLOGY, V124, P129, DOI 10.1053/gast.2003.50020; Burdyga G, 2002, NEUROSCIENCE, V109, P339, DOI 10.1016/S0306-4522(01)00474-2; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; Buyse M, 2001, EUR J NEUROSCI, V14, P64, DOI 10.1046/j.0953-816x.2001.01628.x; Buyukgebiz A, 2001, J PEDIATR ENDOCR MET, V14, P549; Campfield LA, 1998, SCIENCE, V280, P1383, DOI 10.1126/science.280.5368.1383; Carlini VP, 2002, BIOCHEM BIOPH RES CO, V299, P739, DOI 10.1016/S0006-291X(02)02740-7; Casanueva Felipe F, 2002, Rev Endocr Metab Disord, V3, P325, DOI 10.1023/A:1020901624103; Casanueva FF, 1999, TRENDS ENDOCRIN MET, V10, P30, DOI 10.1016/S1043-2760(98)00116-7; Cassoni P, 2001, J CLIN ENDOCR METAB, V86, P1738, DOI 10.1210/jc.86.4.1738; Cassoni P, 2000, J ENDOCRINOL, V165, P139, DOI 10.1677/joe.0.1650139; Chance W. T., 2003, Current Medicinal Chemistry - Central Nervous System Agents, V3, P127, DOI 10.2174/1568015033477857; CHANCE WT, 1995, ANN SURG, V221, P579, DOI 10.1097/00000658-199505000-00016; Chapman IM, 1996, J CLIN ENDOCR METAB, V81, P4249, DOI 10.1210/jc.81.12.4249; Chen CH, 1997, NEUROGASTROENT MOTIL, V9, P109, DOI 10.1046/j.1365-2982.1997.d01-26.x; Choi KC, 2003, ENDOCRINOLOGY, V144, P754, DOI 10.1210/en.2002-220783; Cone RD, 2001, INT J OBESITY, V25, pS63, DOI 10.1038/sj.ijo.0801913; Copinschi G, 1997, NEUROENDOCRINOLOGY, V66, P278, DOI 10.1159/000127249; Cowley MA, 2003, NEURON, V37, P649, DOI 10.1016/S0896-6273(03)00063-1; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Cummings DE, 2002, NAT MED, V8, P643, DOI 10.1038/nm0702-643; Cummings DE, 2002, NEW ENGL J MED, V346, P1623, DOI 10.1056/NEJMoa012908; CUNEO RC, 1992, CLIN ENDOCRINOL, V37, P387, DOI 10.1111/j.1365-2265.1992.tb02347.x; Cuntz Ulrich, 2002, Am Clin Lab, V21, P22; Date Y, 2002, GASTROENTEROLOGY, V123, P1120, DOI 10.1053/gast.2002.35954; Date Y, 2000, ENDOCRINOLOGY, V141, P4255, DOI 10.1210/en.141.11.4255; Date Y, 2002, DIABETES, V51, P124, DOI 10.2337/diabetes.51.1.124; Date Y, 2001, BIOCHEM BIOPH RES CO, V280, P904, DOI 10.1006/bbrc.2000.4212; DelPparigi A, 2002, J CLIN ENDOCR METAB, V87, P5461, DOI 10.1210/jc.2002-020871; Demir H, 2001, ARCH DIS CHILD, V84, P89; Dickson SL, 1997, ENDOCRINOLOGY, V138, P771, DOI 10.1210/en.138.2.771; Dieguez C, 2000, EUR J ENDOCRINOL, V142, P413, DOI 10.1530/eje.0.1420413; DIEGUEZ C, 1995, TRENDS ENDOCRIN MET, V6, P55, DOI 10.1016/1043-2760(94)00206-J; Dube MG, 2002, DIABETES, V51, P1729, DOI 10.2337/diabetes.51.6.1729; DUGGAN JP, 1986, SCIENCE, V231, P609, DOI 10.1126/science.3511527; Elmquist JK, 1998, NAT NEUROSCI, V1, P445, DOI 10.1038/2164; English PJ, 2002, J CLIN ENDOCR METAB, V87, P2984, DOI 10.1210/jc.87.6.2984; Flier JS, 1998, CELL, V92, P437, DOI 10.1016/S0092-8674(00)80937-X; FORSTER ER, 1990, AM J PHYSIOL, V258, pG552, DOI 10.1152/ajpgi.1990.258.4.G552; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FROHMAN LA, 1992, FRONT NEUROENDOCRIN, V13, P344; Fujimiya M, 2000, PEPTIDES, V21, P1565, DOI 10.1016/S0196-9781(00)00313-2; Fujimiya M, 2000, AM J PHYSIOL-GASTR L, V278, pG32, DOI 10.1152/ajpgi.2000.278.1.G32; Fujino K, 2003, J PHYSIOL-LONDON, V550, P227, DOI 10.1113/jphysiol.2003.040600; Furness JB, 2001, AUTON NEUROSCI-BASIC, V92, P28, DOI 10.1016/S1566-0702(01)00311-3; Gaige S, 2002, J PHYSIOL-LONDON, V543, P679, DOI 10.1113/jphysiol.2002.021857; Garcia A, 2001, MOL ENDOCRINOL, V15, P1484, DOI 10.1210/me.15.9.1484; GARTHWAITE TL, 1985, PEPTIDES, V6, P41, DOI 10.1016/0196-9781(85)90074-9; Gayle D, 1997, BRAIN RES BULL, V44, P311, DOI 10.1016/S0361-9230(97)00159-7; Ghe C, 2002, ENDOCRINOLOGY, V143, P484, DOI 10.1210/en.143.2.484; Ghigo E, 2001, ENDOCRINE, V14, P87, DOI 10.1385/ENDO:14:1:087; Ghigo E, 1999, HORM RES, V51, P9, DOI 10.1159/000053156; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Goiot H, 2001, GASTROENTEROLOGY, V121, P1417, DOI 10.1053/gast.2001.29581; Gualillo O, 2001, ENDOCRINOLOGY, V142, P788, DOI 10.1210/en.142.2.788; Guan XM, 1997, MOL BRAIN RES, V48, P23, DOI 10.1016/S0169-328X(97)00071-5; GUILLEMIN R, 1982, SCIENCE, V218, P585, DOI 10.1126/science.6812220; Hansen TK, 2002, CLIN ENDOCRINOL, V56, P203, DOI 10.1046/j.0300-0664.2001.01456.x; Hashmonai M, 1998, AM J PHYSIOL-GASTR L, V274, pG677, DOI 10.1152/ajpgi.1998.274.4.G677; Hasler William L, 2003, Gastroenterology, V124, P575, DOI 10.1053/gast.2003.1240575; Hattori N, 2001, J CLIN ENDOCR METAB, V86, P4284, DOI 10.1210/jc.86.9.4284; Hayashida T, 2002, J ENDOCRINOL, V173, P239, DOI 10.1677/joe.0.1730239; Hewson AK, 2002, DIABETES, V51, P3412, DOI 10.2337/diabetes.51.12.3412; Hewson AK, 2000, J NEUROENDOCRINOL, V12, P1047, DOI 10.1046/j.1365-2826.2000.00584.x; HIROSUE Y, 1993, AM J PHYSIOL, V265, pR481, DOI 10.1152/ajpregu.1993.265.3.R481; Horvath TL, 2001, ENDOCRINOLOGY, V142, P4163, DOI 10.1210/en.142.10.4163; Hosoda H, 2000, J BIOL CHEM, V275, P21995, DOI 10.1074/jbc.M002784200; Hosoda H, 2003, J BIOL CHEM, V278, P64, DOI 10.1074/jbc.M205366200; Hosoda H, 2000, BIOCHEM BIOPH RES CO, V279, P909, DOI 10.1006/bbrc.2000.4039; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Ikezaki A, 2002, DIABETES, V51, P3408, DOI 10.2337/diabetes.51.12.3408; Iniguez G, 2002, J CLIN ENDOCR METAB, V87, P5830, DOI 10.1210/jc.2002-021206; Inui A, 2000, PHARMACOL REV, V52, P35; Inui A, 2002, CA-CANCER J CLIN, V52, P72, DOI 10.3322/canjclin.52.2.72; Inui A, 1999, MOL MED TODAY, V5, P79, DOI 10.1016/S1357-4310(98)01395-1; Inui A, 2001, NAT REV NEUROSCI, V2, P551, DOI 10.1038/35086018; Inui A, 1999, CANCER RES, V59, P4493; Inui A, 2001, MOL PSYCHIATR, V6, P620, DOI 10.1038/sj.mp.4000944; Inui A, 1999, TRENDS PHARMACOL SCI, V20, P43, DOI 10.1016/S0165-6147(99)01303-6; Inui A, 1999, TRENDS NEUROSCI, V22, P62, DOI 10.1016/S0166-2236(98)01292-2; Inui A, 2000, FASEB J, V14, P2158, DOI 10.1096/fj.00-0291rev; INUI Y, 2003, CURR MED CHEM, pR1; Ishiguchi T, 2001, J PHYSIOL-LONDON, V533, P801, DOI 10.1111/j.1469-7793.2001.t01-1-00801.x; Ishiguchi T, 2001, AM J PHYSIOL-REG I, V281, pR1522, DOI 10.1152/ajpregu.2001.281.5.R1522; Ishii S, 2002, ENDOCRINOLOGY, V143, P4934, DOI 10.1210/en.2002-220612; Itoh Z, 1997, PEPTIDES, V18, P593, DOI 10.1016/S0196-9781(96)00333-6; ITOH Z, 1983, SCAND J GASTROENTERO, V18, P121; Janssen JAMJL, 2001, EUR J ENDOCRINOL, V145, P711, DOI 10.1530/eje.0.1450711; JANSSENS J, 1990, NEW ENGL J MED, V322, P1028, DOI 10.1056/NEJM199004123221502; Jeanrenaud B, 2001, ANNU REV MED, V52, P339, DOI 10.1146/annurev.med.52.1.339; Jeffery PL, 2002, J ENDOCRINOL, V172, pR7, DOI 10.1677/joe.0.172R007; JOLOBE O, 2000, ARCH DIS CHILD, V82, P136; JORGENSEN JOL, 1989, LANCET, V1, P1221; Kaga T, 2001, DIABETES, V50, P1206, DOI 10.2337/diabetes.50.5.1206; Kalra SP, 1999, ENDOCR REV, V20, P68, DOI 10.1210/er.20.1.68; Kamegai J, 2000, ENDOCRINOLOGY, V141, P4797, DOI 10.1210/en.141.12.4797; KAYE WH, 1990, ARCH GEN PSYCHIAT, V47, P548; KELLOW JE, 1987, AM J PHYSIOL, V252, pG345, DOI 10.1152/ajpgi.1987.252.3.G345; KELLOW JE, 1986, GASTROENTEROLOGY, V91, P386, DOI 10.1016/0016-5085(86)90573-1; Kihara N, 2001, AM J PHYSIOL-GASTR L, V280, pG406, DOI 10.1152/ajpgi.2001.280.3.G406; Kirchgessner AL, 1999, NEURON, V24, P941, DOI 10.1016/S0896-6273(00)81041-7; Kohno D, 2003, DIABETES, V52, P948, DOI 10.2337/diabetes.52.4.948; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Korbonits M, 2001, J CLIN ENDOCR METAB, V86, P881, DOI 10.1210/jc.86.2.881; Korbonits M, 2002, J CLIN ENDOCR METAB, V87, P4005, DOI 10.1210/jc.87.8.4005; Krsek M, 2002, ENDOCR RES, V28, P27, DOI 10.1081/ERC-120004535; LARON Z, 1995, CLIN ENDOCRINOL, V43, P631, DOI 10.1111/j.1365-2265.1995.tb02929.x; Lawrence CB, 2002, ENDOCRINOLOGY, V143, P155, DOI 10.1210/en.143.1.155; Lee HM, 2002, ENDOCRINOLOGY, V143, P185, DOI 10.1210/en.143.1.185; Levin BE, 1998, AM J PHYSIOL-REG I, V274, pR412, DOI 10.1152/ajpregu.1998.274.2.R412; Levin BE, 1999, AM J PHYSIOL-REG I, V276, pR382, DOI 10.1152/ajpregu.1999.276.2.R382; Lin L, 1997, BRAIN RES, V745, P205, DOI 10.1016/S0006-8993(96)01152-3; LIN L, 1993, PHYSIOL BEHAV, V53, P789, DOI 10.1016/0031-9384(93)90190-Q; Lindqvist Andreas, 2003, Current Medicinal Chemistry - Central Nervous System Agents, V3, P157, DOI 10.2174/1568015033477712; LOCKE W, 1995, LIFE SCI, V56, P1347, DOI 10.1016/0024-3205(95)00087-9; Lovshin Julie A., 2003, Current Medicinal Chemistry - Central Nervous System Agents, V3, P73, DOI 10.2174/1568015033477866; Lowell BB, 2000, NATURE, V404, P652, DOI 10.1038/35007527; Lu S, 2002, NEUROSCI LETT, V321, P157, DOI 10.1016/S0304-3940(01)02544-7; Mantovani G, 2001, DRUGS, V61, P499, DOI 10.2165/00003495-200161040-00004; Martinez V, 1998, AM J PHYSIOL-GASTR L, V274, pG965, DOI 10.1152/ajpgi.1998.274.5.G965; Masuda Y, 2000, BIOCHEM BIOPH RES CO, V276, P905, DOI 10.1006/bbrc.2000.3568; MATSUDA M, 1993, DIGEST DIS SCI, V38, P845, DOI 10.1007/BF01295910; MCCARTHY HD, 1993, AM J PHYSIOL, V264, pE638, DOI 10.1152/ajpendo.1993.264.4.E638; Meguid MM, 2000, NUTRITION, V16, P843, DOI 10.1016/S0899-9007(00)00449-4; MORAN TH, 1992, AM J PHYSIOL, V262, pR46, DOI 10.1152/ajpregu.1992.262.1.R46; Moran TH, 2000, NUTRITION, V16, P858, DOI 10.1016/S0899-9007(00)00419-6; MORAN TH, 1982, AM J PHYSIOL, V242, pR491, DOI 10.1152/ajpregu.1982.242.5.R491; Mori K, 2000, FEBS LETT, V486, P213, DOI 10.1016/S0014-5793(00)02308-5; Morris MJ, 1998, REGUL PEPTIDES, V75-6, P441, DOI 10.1016/S0167-0115(98)00100-1; Morton GJ, 2001, INT J OBESITY, V25, pS56, DOI 10.1038/sj.ijo.0801915; Muccioli G, 2002, EUR J PHARMACOL, V440, P235, DOI 10.1016/S0014-2999(02)01432-2; Murata M, 2002, J BIOL CHEM, V277, P5667, DOI 10.1074/jbc.M103898200; Murphy MG, 1998, J CLIN ENDOCR METAB, V83, P320, DOI 10.1210/jc.83.2.320; Nagaya N, 2001, CIRCULATION, V104, P2034, DOI 10.1161/hc4201.097836; Nagaya N, 2001, AM J PHYSIOL-REG I, V280, pR1483, DOI 10.1152/ajpregu.2001.280.5.R1483; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Nauck MA, 1997, AM J PHYSIOL-ENDOC M, V273, pE981, DOI 10.1152/ajpendo.1997.273.5.E981; Nedvidkova J, 2003, J CLIN ENDOCR METAB, V88, P1678, DOI 10.1210/jc.2002-021669; NEELY J, 1971, BRIT J SURG, V58, P21, DOI 10.1002/bjs.1800580104; Nicholls RD, 2001, ANNU REV GENOM HUM G, V2, P153, DOI 10.1146/annurev.genom.2.1.153; Nozu T, 1999, AM J PHYSIOL-GASTR L, V276, pG867, DOI 10.1152/ajpgi.1999.276.4.G867; Nwokolo CU, 2003, GUT, V52, P637, DOI 10.1136/gut.52.5.637; Ogura K, 2000, J EXP MED, V192, P1601, DOI 10.1084/jem.192.11.1601; Okada K, 1996, ENDOCRINOLOGY, V137, P5155, DOI 10.1210/en.137.11.5155; Okano H, 1996, PEPTIDES, V17, P895; Otto B, 2001, Eur J Endocrinol, V145, P669; Papotti M, 2001, J CLIN ENDOCR METAB, V86, P5052, DOI 10.1210/jc.86.10.5052; Papotti M, 2000, J CLIN ENDOCR METAB, V85, P3803, DOI 10.1210/jc.85.10.3803; PEETERS TL, 1992, GASTROENTEROLOGY, V102, P97, DOI 10.1016/0016-5085(92)91788-6; PEETERS TL, 1993, GASTROENTEROLOGY, V105, P1886, DOI 10.1016/0016-5085(93)91089-Z; Petersenn S, 2002, HORM RES, V58, P56, DOI 10.1159/000066487; Pinkney J, 2002, LANCET, V359, P1360, DOI 10.1016/S0140-6736(02)08387-3; Plata-Salaman CR, 2000, NUTRITION, V16, P1009, DOI 10.1016/S0899-9007(00)00413-5; PlataSalaman CR, 1996, NUTRITION, V12, P69, DOI 10.1016/S0899-9007(96)90702-9; PLOURDE V, 1993, PEPTIDES, V14, P1225, DOI 10.1016/0196-9781(93)90180-O; Poitras P, 1997, AM J PHYSIOL-GASTR L, V272, pG4, DOI 10.1152/ajpgi.1997.272.1.G4; Poitras P, 1994, GUT PEPTIDES BIOCH P, P261; PRAGER D, 1993, ANN NY ACAD SCI, V692, P102; Ravussin E, 2001, J CLIN ENDOCR METAB, V86, P4547, DOI 10.1210/jc.86.9.4547; RAYBOULD HE, 1988, J NEUROSCI, V8, P3018; Rehfeld JF, 1998, PHYSIOL REV, V78, P1087, DOI 10.1152/physrev.1998.78.4.1087; Richter T, 2001, J PEDIATR GASTR NUTR, V33, P472, DOI 10.1097/00005176-200110000-00010; Rigamonti AE, 2002, J ENDOCRINOL, V175, pR1, DOI 10.1677/joe.0.175R001; Rindi G, 2002, HISTOCHEM CELL BIOL, V117, P511, DOI 10.1007/s00418-002-0415-1; RITTMASTER RS, 1987, NEUROENDOCRINOLOGY, V45, P118, DOI 10.1159/000124713; ROSENFELD DJ, 1987, PHYSIOL BEHAV, V39, P753, DOI 10.1016/0031-9384(87)90261-7; RUPPIN H, 1976, SCAND J GASTROENTERO, V11, P89; Sakata I, 2002, PEPTIDES, V23, P531, DOI 10.1016/S0196-9781(01)00633-7; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; SAMSON WK, 1984, BRAIN RES BULL, V12, P57, DOI 10.1016/0361-9230(84)90215-6; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; Sauve-Martin H, 1999, J PEDIATR GASTR NUTR, V28, P354, DOI 10.1097/00005176-199903000-00035; Schaller G, 2003, DIABETES, V52, P16, DOI 10.2337/diabetes.52.1.16; Schwartz GJ, 2000, NUTRITION, V16, P866, DOI 10.1016/S0899-9007(00)00464-0; SCHWARTZ GJ, 1994, ANN NY ACAD SCI, V713, P121, DOI 10.1111/j.1749-6632.1994.tb44058.x; Schwartz GJ, 1996, NEUROSCI BIOBEHAV R, V20, P47, DOI 10.1016/0149-7634(95)00039-H; SCHWARTZ MW, 1995, AM J PHYSIOL-REG I, V269, pR949, DOI 10.1152/ajpregu.1995.269.5.R949; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Shiiya T, 2002, J CLIN ENDOCR METAB, V87, P240, DOI 10.1210/jc.87.1.240; Shimada M, 1998, NATURE, V396, P670, DOI 10.1038/25341; Shimizu Y, 2003, CLIN CANCER RES, V9, P774; Shintani M, 2001, DIABETES, V50, P227, DOI 10.2337/diabetes.50.2.227; Shuto Y, 2002, J CLIN INVEST, V109, P1429, DOI 10.1172/JCI0213300; Shuto YJ, 2001, LIFE SCI, V68, P991, DOI 10.1016/S0024-3205(00)01001-8; Sibilia V, 2002, NEUROENDOCRINOLOGY, V75, P92, DOI 10.1159/000048225; Sibilia V, 2003, ENDOCRINOLOGY, V144, P353, DOI 10.1210/en.2002-220756; Sindelar DK, 2002, DIABETES, V51, P778, DOI 10.2337/diabetes.51.3.778; SMITH GP, 1994, ANN NY ACAD SCI, V713, P236, DOI 10.1111/j.1749-6632.1994.tb44071.x; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Sobhani I, 2000, GUT, V47, P178, DOI 10.1136/gut.47.2.178; Sobhani I, 2002, GASTROENTEROLOGY, V122, P259, DOI 10.1053/gast.2002.31385; SOPER RT, 1975, J PEDIATR SURG, V10, P51, DOI 10.1016/S0022-3468(75)80008-X; Sorhede M, 1996, PEPTIDES, V17, P609, DOI 10.1016/0196-9781(96)00017-4; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; SUTO G, 1994, GASTROENTEROLOGY, V106, P1568; TACHE Y, 1990, GASTROENTEROLOGY, V98, P517, DOI 10.1016/0016-5085(90)90849-V; TACHE Y, 1995, PEPTIDES, V16, P431, DOI 10.1016/0196-9781(94)00212-O; TACK J, 1992, GASTROENTEROLOGY, V103, P72, DOI 10.1016/0016-5085(92)91097-N; Takaya K, 2000, J CLIN ENDOCR METAB, V85, P4908, DOI 10.1210/jc.85.12.4908; Tamura H, 2002, ENDOCRINOLOGY, V143, P3268, DOI 10.1210/en.2002-220268; Tanaka M, 2002, EUR J ENDOCRINOL, V146, pR1, DOI 10.1530/eje.0.146R001; Tena-Sempere M, 2002, ENDOCRINOLOGY, V143, P717, DOI 10.1210/en.143.2.717; Tomasetto C, 2000, GASTROENTEROLOGY, V119, P395, DOI 10.1053/gast.2000.9371; Tomasetto C, 2001, PEPTIDES, V22, P2055, DOI 10.1016/S0196-9781(01)00557-5; Torsello A, 1998, EUR J PHARMACOL, V360, P123, DOI 10.1016/S0014-2999(98)00677-3; Torsello A, 2000, NEUROENDOCRINOLOGY, V72, P327, DOI 10.1159/000054601; Toshinai K, 2003, ENDOCRINOLOGY, V144, P1506, DOI 10.1210/en.2002-220788; Toshinai K, 2001, BIOCHEM BIOPH RES CO, V281, P1220, DOI 10.1006/bbrc.2001.4518; Traebert M, 2002, J NEUROENDOCRINOL, V14, P580, DOI 10.1046/j.1365-2826.2002.00810.x; Trudel L, 2002, AM J PHYSIOL-GASTR L, V282, pG948, DOI 10.1152/ajpgi.00339.2001; Tschop M, 2001, DIABETES, V50, P707, DOI 10.2337/diabetes.50.4.707; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; Tschop M, 2002, OBES RES, V10, P991, DOI 10.1038/oby.2002.135; Tschop M, 2002, ENDOCRINOLOGY, V143, P558, DOI 10.1210/en.143.2.558; Tschop M, 2001, J ENDOCRINOL INVEST, V24, pRC19, DOI 10.1007/BF03351037; Ukkola A, 2002, ANN MED, V34, P102, DOI 10.1080/07853890252953491; Ukkola O, 2002, OBES RES, V10, P782, DOI 10.1038/oby.2002.106; Ukkola O, 2001, J CLIN ENDOCR METAB, V86, P3996, DOI 10.1210/jc.86.8.3996; Van den Berghe G, 2000, EUR J ENDOCRINOL, V143, P1, DOI 10.1530/eje.0.1430001; Van den Berghe G, 1998, J CLIN ENDOCR METAB, V83, P309, DOI 10.1210/jc.83.2.309; van der Toorn FM, 2002, EUR J ENDOCRINOL, V147, P195, DOI 10.1530/eje.0.1470195; Verkijk M, 1998, AM J PHYSIOL-GASTR L, V275, pG1209, DOI 10.1152/ajpgi.1998.275.5.G1209; Volante M, 2002, J HISTOCHEM CYTOCHEM, V50, P1013, DOI 10.1177/002215540205000803; Volante M, 2002, J CLIN ENDOCR METAB, V87, P1300, DOI 10.1210/jc.87.3.1300; Wang GY, 2002, REGUL PEPTIDES, V105, P75, DOI 10.1016/S0167-0115(02)00012-5; Wang LX, 2002, NEUROSCI LETT, V325, P47; Wang LX, 2000, REGUL PEPTIDES, V92, P79, DOI 10.1016/S0167-0115(00)00153-1; Weikel JC, 2003, AM J PHYSIOL-ENDOC M, V284, pE407, DOI 10.1152/ajpendo.00184.2002; Welle S, 1998, Curr Opin Clin Nutr Metab Care, V1, P257, DOI 10.1097/00075197-199805000-00004; Wierup N, 2002, REGUL PEPTIDES, V107, P63, DOI 10.1016/S0167-0115(02)00067-8; Willesen MG, 1999, NEUROENDOCRINOLOGY, V70, P306, DOI 10.1159/000054491; WINGATE DL, 1981, DIGEST DIS SCI, V26, P641, DOI 10.1007/BF01367678; Wisse BE, 2001, ENDOCRINOLOGY, V142, P3292, DOI 10.1210/en.142.8.3292; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Wren AM, 2000, ENDOCRINOLOGY, V141, P4325, DOI 10.1210/en.141.11.4325; Wren AM, 2001, J CLIN ENDOCR METAB, V86, P5992, DOI 10.1210/jc.86.12.5992; WRIGHT RA, 1983, GASTROENTEROLOGY, V84, P747; XU Y, 2002, 26 M ASS VA SURG HOU, P28; Yamamoto H, 2002, J CLIN INVEST, V110, P43, DOI 10.1172/JCI200215595; Zander M, 2002, LANCET, V359, P824, DOI 10.1016/S0140-6736(02)07952-7; Zhang WH, 2001, J PHYSIOL-LONDON, V537, P231, DOI 10.1111/j.1469-7793.2001.0231k.x	271	311	334	1	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					439	456		10.1096/fj.03-0641rev	http://dx.doi.org/10.1096/fj.03-0641rev			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003990				2022-12-28	WOS:000220522800037
J	Akamatsu, Y; Haga, M; Tyagi, S; Yamashita, K; Graca-Souza, AV; Ollinger, R; Czismadia, E; May, GA; Ifedigbo, E; Otterbein, LE; Bach, FH; Soares, MP				Akamatsu, Y; Haga, M; Tyagi, S; Yamashita, K; Graca-Souza, AV; Ollinger, R; Czismadia, E; May, GA; Ifedigbo, E; Otterbein, LE; Bach, FH; Soares, MP			Heme oxygenase-1-derived carbon monoxide protects hearts from transplant-associated ischemia reperfusion injury	FASEB JOURNAL			English	Article						apoptosis; transplantation; inflammation; protective genes; endothelial cells	ISCHEMIA/REPERFUSION INJURY; MYOCARDIAL-ISCHEMIA; OXIDATIVE STRESS; FREE-RADICALS; EXPRESSION; OXYGENASE; ANTIOXIDANT; SUPPRESSES; ACTIVATION; REJECTION	Heme oxygenase-1 (HO-1) degrades heme into iron, biliverdin, and carbon monoxide (CO). HO-1 expression can be used therapeutically to ameliorate undesirable consequences of ischemia reperfusion injury (IRI), but the mechanism by which this occurs, remains to be established. Rat hearts, exposed to a prolonged period (24 h) of cold (4 C) ischemia, failed to function upon transplantation into syngeneic recipients. Induction of HO-1 expression by administration of cobalt protoporphyrin IX (CoPPIX) to the graft donor restored graft function. Inhibition of HO-1 enzymatic activity, by administration of zinc protoporphyrin (ZnPPIX) at the time of transplantation, reversed the protective effect of HO-1. Exposure of the graft donor as well as the graft (during ischemia) to exogenous CO mimicked the protective effect of HO-1. This was associated with a significant reduction in the number of cells undergoing apoptosis in the graft with no apparent decrease of intravascular fibrin polymerization, platelet aggregation, or P-selectin expression. In conclusion, HO-1-derived CO prevents IRI associated with cardiac transplantation based on its antiapoptotic action. The observation that exposure of the donor and the graft to CO is sufficient to afford this protective effect should have important clinical implications in terms of preventing IRI associated with heart transplantation in humans.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, Boston, MA 02215 USA; Univ Pittsburgh, Sch Med, Pittsburgh, PA USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Inst Gulbenkian Ciencias, Inflammat Lab, Rua Quinta Grande 6, P-2780156 Oeiras, Portugal.	mpsoares@igc.gulbenkian.pt	Öllinger, Robert/D-1538-2009; Soares, Miguel P/G-4188-2011	Soares, Miguel/0000-0002-9314-4833; Ollinger, Robert/0000-0002-4499-1673				Amersi F, 2002, HEPATOLOGY, V35, P815, DOI 10.1053/jhep.2002.32467; Baldwin WM, 1999, TRANSPLANTATION, V68, P894, DOI 10.1097/00007890-199909270-00024; BALLA G, 1992, J BIOL CHEM, V267, P18148; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Baxter GF, 2002, BASIC RES CARDIOL, V97, P268, DOI 10.1007/s00395-002-0366-7; Berberat PO, 2003, FASEB J, V17, P1724, DOI 10.1096/fj.03-0229fje; Brocheriou V, 2000, J GENE MED, V2, P326, DOI 10.1002/1521-2254(200009/10)2:5<326::AID-JGM133>3.0.CO;2-1; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; BRUNE B, 1987, MOL PHARMACOL, V32, P497; Burne MJ, 2001, J CLIN INVEST, V108, P1283, DOI 10.1172/JCI200112080; Clark JE, 2000, AM J PHYSIOL-HEART C, V278, pH643, DOI 10.1152/ajpheart.2000.278.2.H643; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; GOTTLIEB RA, 1994, J CLIN INVEST, V94, P1621, DOI 10.1172/JCI117504; Haramaki N, 1998, FREE RADICAL BIO MED, V25, P329, DOI 10.1016/S0891-5849(98)00066-5; Harrison GJ, 1998, CARDIOVASC RES, V40, P74, DOI 10.1016/S0008-6363(98)00123-0; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; Jones SP, 2003, AM J PHYSIOL-HEART C, V284, pH277, DOI 10.1152/ajpheart.00236.2002; Kaminski KA, 2002, INT J CARDIOL, V86, P41, DOI 10.1016/S0167-5273(02)00189-4; Kang PM, 2000, CIRC RES, V87, P118, DOI 10.1161/01.RES.87.2.118; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Katori M, 2002, TRANSPLANTATION, V74, P905, DOI 10.1097/00007890-200210150-00001; KLONER RA, 1989, CIRCULATION, V80, P1115, DOI 10.1161/01.CIR.80.5.1115; Lee P, 2003, AM J PHYSIOL-HEART C, V284, pH456, DOI 10.1152/ajpheart.00777.2002; MASSAELI H, 1995, CARDIOVASC RES, V29, P597; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Maulik N, 1998, FREE RADICAL BIO MED, V24, P869, DOI 10.1016/S0891-5849(97)00388-2; NOLL T, 1992, AM J PHYSIOL, V262, pC1297, DOI 10.1152/ajpcell.1992.262.5.C1297; ONO K, 1969, J THORAC CARDIOV SUR, V57, P225, DOI 10.1016/S0022-5223(19)42744-X; Otterbein LE, 2003, TRENDS IMMUNOL, V24, P449, DOI 10.1016/S1471-4906(03)00181-9; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Otterbein LE, 2003, NAT MED, V9, P183, DOI 10.1038/nm817; PRZYKLENK K, 1989, CIRC RES, V64, P86, DOI 10.1161/01.RES.64.1.86; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Sharma HS, 1999, MOL CELL BIOCHEM, V196, P133, DOI 10.1023/A:1006984027403; Soares MP, 2002, ANTIOXID REDOX SIGN, V4, P321, DOI 10.1089/152308602753666370; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Soares MP, 2000, EMERGING THERAPEUTIC, V4, P11; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Takada M, 1997, TRANSPLANTATION, V64, P1520, DOI 10.1097/00007890-199712150-00003; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Wagener FADTG, 1997, P SOC EXP BIOL MED, V216, P456; Wagener FADTG, 2003, PHARMACOL REV, V55, P551, DOI 10.1124/pr.55.3.5; Wagener FADTG, 2001, BLOOD, V98, P1802, DOI 10.1182/blood.V98.6.1802; Wagner CT, 1997, J CLIN INVEST, V100, P589, DOI 10.1172/JCI119569; Weiser MR, 1996, J EXP MED, V183, P2343, DOI 10.1084/jem.183.5.2343; Yaoita H, 1998, CIRCULATION, V97, P276, DOI 10.1161/01.CIR.97.3.276; Yet SF, 2001, CIRC RES, V89, P168, DOI 10.1161/hh1401.093314; ZHANG J, 2003, MOL THER, V278, P1248	52	169	196	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					771	+		10.1096/fj.03-0921fje	http://dx.doi.org/10.1096/fj.03-0921fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977880				2022-12-28	WOS:000220425000020
J	Li, Z; Chan, C				Li, Z; Chan, C			Inferring pathways and networks with a Bayesian framework	FASEB JOURNAL			English	Article						reverse engineering; metabolic network; Bayesian network analysis; hepatocytes	METABOLIC FLUX ANALYSIS; CULTURED-HEPATOCYTES; PLASMA	Numerous mathematical methods have been adapted and developed to quantitatively reverse engineer biological networks, for example, signal transduction pathways, from experimental micro-array data. Compared with stochastic methods, such as Boolean networks, and deterministic methods, such as thermodynamic or differential equation-based models, Bayesian network analysis has the ability to assess, with scoring metrics, causal relations based on conditional probabilities and thus permit hypothesis testing. The goal of this paper is to illustrate the integration of several Bayesian based techniques into a unified Bayesian framework that can infer hepatocellular networks from metabolic data. Reverse engineering of pathways and networks provides a framework for predictive modeling and hypotheses testing to gain deeper insight into living organisms, disease mechanisms, and targeted therapeutics. Evaluating this methodology initially against the known biochemical network provides confidence in the networks that are uncovered from the experimental data using this framework. From the metabolic data we inferred the known sub-networks, such as the tricarboxylic acid (TCA) and urea cycles. In addition, we combined the relationships learned from the data and our current knowledge of the biological system to postulate several alternative metabolic sub-network models that can predict a particular cellular function, such as intracellular triglyceride accumulation.	Michigan State Univ, Dept Chem Engn & Mat Sci, E Lansing, MI 48824 USA	Michigan State University	Chan, C (corresponding author), Michigan State Univ, Dept Chem Engn & Mat Sci, 1257 EB, E Lansing, MI 48824 USA.	krischan@egr.msu.edu						Akutsu T, 1999, Pac Symp Biocomput, P17; Castillo E, 1997, IEEE T SYST MAN CY A, V27, P412, DOI 10.1109/3468.594909; Chan C, 2003, BIOTECHNOL BIOENG, V81, P33, DOI 10.1002/bit.10453; Chan C, 2003, METAB ENG, V5, P1, DOI 10.1016/S1096-7176(02)00011-3; Chan C, 2003, BIOTECHNOL PROGR, V19, P580, DOI 10.1021/bp025660h; Chan C, 2002, BIOTECHNOL BIOENG, V78, P753, DOI 10.1002/bit.10275; CHEN T, 1999, P PAC S BIOC, V4, P29; Cheng J, 2002, ARTIF INTELL, V137, P43, DOI 10.1016/S0004-3702(02)00191-1; COOPER GF, 1992, MACH LEARN, V9, P309, DOI 10.1007/BF00994110; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Friedman N, 2000, J COMPUT BIOL, V7, P601, DOI 10.1089/106652700750050961; Friedman N, 1996, PROCEEDINGS OF THE THIRTEENTH NATIONAL CONFERENCE ON ARTIFICIAL INTELLIGENCE AND THE EIGHTH INNOVATIVE APPLICATIONS OF ARTIFICIAL INTELLIGENCE CONFERENCE, VOLS 1 AND 2, P1277; HAKAMADA K, 2001, GENOME INFOR, V12, P272; HARTEMINK AJ, 2001, PAC S BIOCOMPUT, V6, P422; HECKERMAN D, 1995, MACH LEARN, V20, P197, DOI 10.1007/BF00994016; HWANG DH, 2003, IN PRESS BIOINFORMAT; Liang S, 1998, Pac Symp Biocomput, P18; Maki Y, 2001, Pac Symp Biocomput, P446; MURPHY KP, 2001, COMPUTING SCI STAT, V33; Pe'er D, 2001, Bioinformatics, V17 Suppl 1, pS215; Schilling CH, 1999, BIOTECHNOL PROGR, V15, P288, DOI 10.1021/bp9900357; Spirtes P., 2000, CAUSATION PREDICTION, Vsecond; Suzuki J., 1996, P INT C MACH LEARN B; WANG H, 2002, 2002 AAAI SPRING S P	25	29	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					746	+		10.1096/fj.03-0475fje	http://dx.doi.org/10.1096/fj.03-0475fje			31	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766801				2022-12-28	WOS:000220425000037
J	Martinez-Lemus, LA; Hill, MA; Bolz, SS; Pohl, U; Meininger, GA				Martinez-Lemus, LA; Hill, MA; Bolz, SS; Pohl, U; Meininger, GA			Acute mechanoadaptation of vascular smooth muscle cells in response to continuous arteriolar vasoconstriction: implications for functional remodeling	FASEB JOURNAL			English	Article						vascular structure; cell morphology; hypertension; arterioles	FLUID SHEAR-STRESS; RESISTANCE ARTERIES; HYPERTENSIVE-RATS; ENDOTHELIAL-CELLS; INTEGRINS; MIGRATION; EXPRESSION; ALIGNMENT; KINASE; PROLIFERATION	Arterioles exposed to norepinephrine (NE) for 4 h exhibit incomplete relaxation on removal of the agonist. We hypothesized that this is due to a mechanoadaptation process associated with active repositioning of vascular smooth muscle cells (VSMCs) within the vascular wall. Isolated arterioles were exposed to NE (10(-5.5) M) for either 5 min (n = 7) or 4 h (n = 13). During the 5-min exposure, vessel diameter was reduced to 61 +/- 2.6%, and cells shortened to 76.3 +/- 3.8% of control. After NE removal, vessel diameter and cell length returned to control values, which indicated that during acute vasoconstriction cells shorten and relengthen in a reversible fashion. In contrast, when NE exposure lasted 4 h, vessels did not return to control diameter, but VSMCs returned to control length after NE removal. During the 4-h constriction, 56% of the VSMCs began returning to control length, and the overlap between VSMCs increased, which indicated that cellular repositioning had occurred in the presence of the maintained constriction. Thus, in response to prolonged constriction, VSMCs undergo a mechanoadaptation process involving "length autoregulation" that would be energetically favorable for maintenance of a reduced diameter and may provide a mechanism for the development of eutrophic remodeling of the vascular wall.	Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Cardiovasc Res Inst,Div Vasc Biol, College Stn, TX 77843 USA; RMIT Univ, Sch Med Sci, Microvasc Biol Grp, Bundoora, Vic 3083, Australia; Univ Munich, Inst Physiol, D-8000 Munich, Germany	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Royal Melbourne Institute of Technology (RMIT); University of Munich	Meininger, GA (corresponding author), Texas A&M Univ Syst, Hlth Sci Ctr, Dept Med Physiol, Cardiovasc Res Inst,Div Vasc Biol, Reynolds Med Bldg,Room 349, College Stn, TX 77843 USA.	gam@tamu.edu	Hill, Michael/AAV-5350-2020	Hill, Michael/0000-0002-4455-2072				Arribas SM, 1996, STROKE, V27, P1118, DOI 10.1161/01.STR.27.6.1118; Bakker ENTP, 2002, J VASC RES, V39, P12, DOI 10.1159/000048989; Blindt R, 2002, J MOL CELL CARDIOL, V34, P1633, DOI 10.1006/jmcc.2002.2113; BochatonPiallat ML, 1996, ARTERIOSCL THROM VAS, V16, P815, DOI 10.1161/01.ATV.16.6.815; Briest W, 2003, CARDIOVASC RES, V57, P379, DOI 10.1016/S0008-6363(02)00700-9; Dao HH, 2001, J HYPERTENS, V19, P1801, DOI 10.1097/00004872-200110000-00014; DAVIES PF, 1994, J CLIN INVEST, V93, P2031, DOI 10.1172/JCI117197; DENG LY, 1992, AM J HYPERTENS, V5, P817, DOI 10.1093/ajh/5.11.817; Dickhout JG, 2000, AM J PHYSIOL-HEART C, V279, pH2085, DOI 10.1152/ajpheart.2000.279.5.H2085; Hao H, 2002, ARTERIOSCL THROM VAS, V22, P1093, DOI 10.1161/01.ATV.0000022407.91111.E4; HEAGERTY AM, 1993, HYPERTENSION, V21, P391, DOI 10.1161/01.HYP.21.4.391; Helmke BP, 2000, CIRC RES, V86, P745, DOI 10.1161/01.RES.86.7.745; Hill MA, 2003, AM J PHYSIOL-HEART C, V285, pH849, DOI 10.1152/ajpheart.00986.2002; Hou GP, 2002, CIRC RES, V90, P1147, DOI 10.1161/01.RES.0000022166.74073.F8; Hrometz SL, 1999, J PHARMACOL EXP THER, V290, P452; Intengan HD, 1999, HYPERTENSION, V33, P569, DOI 10.1161/01.HYP.33.1.569; Intengan HD, 2001, HYPERTENSION, V38, P581, DOI 10.1161/hy09t1.096249; Intengan HD, 2000, HYPERTENSION, V36, P312, DOI 10.1161/01.HYP.36.3.312; KORSGAARD N, 1993, HYPERTENSION, V22, P523, DOI 10.1161/01.HYP.22.4.523; Langille BL, 2001, MICROCIRCULATION, V8, P195, DOI 10.1038/sj.mn.7800085; Li JS, 1996, AM J PHYSIOL-HEART C, V271, pH88, DOI 10.1152/ajpheart.1996.271.1.H88; Li SH, 2001, CIRC RES, V89, P517, DOI 10.1161/hh1801.097165; Malek AM, 1996, J CELL SCI, V109, P713; Martinez-Lemus LA, 2003, J VASC RES, V40, P211, DOI 10.1159/000071886; Mauban JRH, 2001, AM J PHYSIOL-HEART C, V280, pH2399, DOI 10.1152/ajpheart.2001.280.5.H2399; MEININGER GA, 1984, HYPERTENSION, V6, P27, DOI 10.1161/01.HYP.6.1.27; MILLER BG, 1986, ANAT REC, V216, P95, DOI 10.1002/ar.1092160116; Mills I, 1997, J CELL PHYSIOL, V170, P228, DOI 10.1002/(SICI)1097-4652(199703)170:3<228::AID-JCP2>3.0.CO;2-Q; Mulvany MJ, 1996, HYPERTENSION, V28, P505; Nishio E, 1997, BRIT J PHARMACOL, V121, P665, DOI 10.1038/sj.bjp.0701171; O'Callaghan CJ, 2002, J HYPERTENS, V20, P287, DOI 10.1097/00004872-200202000-00019; Paulhe F, 2001, J BIOL CHEM, V276, P41832, DOI 10.1074/jbc.M105459200; Peng HL, 2001, CIRC RES, V88, P810, DOI 10.1161/hh0801.089603; Platts SH, 2002, J VASC RES, V39, P173, DOI 10.1159/000057765; Rizzoni D, 1996, HYPERTENSION, V28, P785, DOI 10.1161/01.HYP.28.5.785; Standley PR, 2002, AM J PHYSIOL-HEART C, V283, pH1907, DOI 10.1152/ajpheart.01043.2001; THYBO NK, 1992, J HYPERTENS, V10, P1191, DOI 10.1097/00004872-199210000-00012; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Yamboliev IA, 2001, AM J PHYSIOL-CELL PH, V281, pC709, DOI 10.1152/ajpcell.2001.281.2.C709; Yasunari K, 2000, CIRCULATION, V101, P2302, DOI 10.1161/01.CIR.101.19.2302	40	110	112	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					708	+		10.1096/fj.03-0634fje	http://dx.doi.org/10.1096/fj.03-0634fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977879				2022-12-28	WOS:000220425000019
J	Zcharia, E; Metzger, S; Chajek-Shaul, T; Aingorn, H; Elkin, M; Friedmann, Y; Weinstein, T; Li, JP; Lindahl, U; Vlodavsky, I				Zcharia, E; Metzger, S; Chajek-Shaul, T; Aingorn, H; Elkin, M; Friedmann, Y; Weinstein, T; Li, JP; Lindahl, U; Vlodavsky, I			Transgenic expression of mammalian heparanase uncovers physiological functions of heparan sulfate in tissue morphogenesis, vascularization, and feeding behavior	FASEB JOURNAL			English	Article						transgenic mice; mammary glands; hair growth; implantation; heparan sulfate; angiogenesis; body weight	FIBROBLAST-GROWTH-FACTOR; EXTRACELLULAR-MATRIX; PROTEOGLYCANS; METASTASIS; ANGIOGENESIS; MICE; INVOLVEMENT; SEQUENCE; CLONING; BINDING	We have generated homozygous transgenic mice (hpa-tg) overexpressing human heparanase (endo-beta-D-glucuronidase) in all tissues and characterized the involvement of the enzyme in tissue morphogenesis, vascularization, and energy metabolism. Biochemical analysis of heparan sulfate (HS) isolated from newborn mice and adult tissues revealed a profound decrease in the size of HS chains derived from hpa-tg vs. control mice. Despite this, the mice appeared normal, were fertile, and exhibited a normal life span. A significant increase in the number of implanted embryos was noted in the hpa-tg vs. control mice. Overexpression of heparanase resulted in increased levels of urinary protein and creatinine, suggesting an effect on kidney function, reflected also by electron microscopy examination of the kidney tissue. The hpa-tg mice exhibited a reduced food consumption and body weight compared with control mice. The effect of heparanase on tissue remodeling and morphogenesis was best demonstrated by the phenotype of the hpa-tg mammary glands, showing excess branching and widening of ducts associated with enhanced neovascularization and disruption of the epithelial basement membrane. The hpa-tg mice exhibited an accelerated rate of hair growth, correlated with high expression of heparanase in hair follicle keratinocytes and increased vascularization. Altogether, characterization of the hpa-tg mice emphasizes the involvement of heparanase and HS in processes such as embryonic implantation, food consumption, tissue remodeling, and vascularization.	Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel; Hadassah Hebrew Univ Med Ctr, Dept Oncol, Jerusalem, Israel; Hadassah Hebrew Univ Med Ctr, Dept Med, Jerusalem, Israel; Rabin Med Ctr, Dept Nephrol, Petah Tiqwa, Israel; Uppsala Univ, Ctr Biomed, Dept Med Biochem, S-75123 Uppsala, Sweden	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Hebrew University of Jerusalem; Hebrew University of Jerusalem; Rabin Medical Center; Uppsala University	Vlodavsky, I (corresponding author), Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, POB 9649, IL-31096 Haifa, Israel.	vlodavsk@cc.huji.ac.il			NATIONAL CANCER INSTITUTE [R21CA087085] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA87085] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bissell MJ, 1998, ANN NY ACAD SCI, V842, P1, DOI 10.1111/j.1749-6632.1998.tb09625.x; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Chang Z, 2000, FASEB J, V14, P137, DOI 10.1096/fasebj.14.1.137; DANIEL CW, 1995, DEV BIOL, V169, P511, DOI 10.1006/dbio.1995.1165; David G, 1998, MATRIX BIOL, V17, P461, DOI 10.1016/S0945-053X(98)90092-0; Dempsey LA, 2000, TRENDS BIOCHEM SCI, V25, P349, DOI 10.1016/S0968-0004(00)01619-4; EISENBERG S, 1992, J CLIN INVEST, V90, P2013, DOI 10.1172/JCI116081; Elkin M, 2001, FASEB J, V15, P1661, DOI 10.1096/fj.00-0895fje; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fairbanks MB, 1999, J BIOL CHEM, V274, P29587, DOI 10.1074/jbc.274.42.29587; Forsberg E, 2001, J CLIN INVEST, V108, P175, DOI 10.1172/JCI13561; Friedmann Y, 2000, AM J PATHOL, V157, P1167, DOI 10.1016/S0002-9440(10)64632-9; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Goshen R, 1996, MOL HUM REPROD, V2, P679, DOI 10.1093/molehr/2.9.679; Hofstetter JR, 1997, BIOCHEM MOL MED, V62, P197, DOI 10.1006/bmme.1997.2637; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Iozzo RV, 2001, J CLIN INVEST, V108, P349, DOI 10.1172/JCI13738; Iozzo RV, 2001, J CLIN INVEST, V108, P165, DOI 10.1172/JCI13560; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Katz A, 2002, ISRAEL MED ASSOC J, V4, P996; KJELLEN L, 1991, ANNU REV BIOCHEM, V60, P443, DOI 10.1146/annurev.bi.60.070191.002303; Levidiotis V, 2001, KIDNEY INT, V60, P1287, DOI 10.1046/j.1523-1755.2001.00934.x; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Maccarana M, 1996, J BIOL CHEM, V271, P17804, DOI 10.1074/jbc.271.30.17804; McParland BJ, 1998, BRIT J RADIOL, V71, P950, DOI 10.1259/bjr.71.849.10195010; Merry CLR, 2002, BBA-GEN SUBJECTS, V1573, P319, DOI 10.1016/S0304-4165(02)00399-9; Miao HQ, 1997, J CLIN INVEST, V99, P1565, DOI 10.1172/JCI119319; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Numasaki M, 2003, BLOOD, V101, P2620, DOI 10.1182/blood-2002-05-1461; Okada Y, 2002, J BIOL CHEM, V277, P42488, DOI 10.1074/jbc.M206510200; Parish CR, 2001, BBA-REV CANCER, V1471, pM99, DOI 10.1016/S0304-419X(01)00017-8; Pikas DS, 1998, J BIOL CHEM, V273, P18770, DOI 10.1074/jbc.273.30.18770; Reizes O, 2001, CELL, V106, P105, DOI 10.1016/S0092-8674(01)00415-9; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2001, J CLIN INVEST, V108, P341, DOI 10.1172/JCI200113662; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1992, INVAS METAST, V12, P112; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1993, BASEMENT MEMBRANES C, P327; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; WEINSTEIN T, 1992, J AM SOC NEPHROL, V3, P1279; Weinstein T, 1997, J AM SOC NEPHROL, V8, P586; Wight Thomas N., 1992, Current Opinion in Cell Biology, V4, P793, DOI 10.1016/0955-0674(92)90102-I; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Zimanyi IA, 2003, CURR PHARM DESIGN, V9, P627, DOI 10.2174/1381612033391234	55	200	207	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					252	263		10.1096/fj.03-0572com	http://dx.doi.org/10.1096/fj.03-0572com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769819				2022-12-28	WOS:000220425000005
J	Bartholome, B; Spies, CM; Gaber, T; Schuchmann, S; Berki, T; Kunkel, D; Bienert, M; Radbruch, A; Burmester, GR; Lauster, R; Scheffold, A; Buttgereit, F				Bartholome, B; Spies, CM; Gaber, T; Schuchmann, S; Berki, T; Kunkel, D; Bienert, M; Radbruch, A; Burmester, GR; Lauster, R; Scheffold, A; Buttgereit, F			Membrane glucocorticoid receptors (mGCR) are expressed in normal human peripheral blood mononuclear cells and up-regulated after in vitro stimulation and in patients with rheumatoid arthritis	FASEB JOURNAL			English	Article						nongenomic glucocorticoid effects; high-sensitivity immunofluorescent staining; mGCR-positive monocytes; human glucocorticoid receptor alpha	NONGENOMIC ACTIONS; SURFACE; ACTIVATION; LYMPHOMA; CLASSIFICATION; TESTOSTERONE; ASSOCIATION; MECHANISM; NUCLEAR; ALPHA	Glucocorticoids mediate their therapeutic actions mostly by genomic effects via cytosolic receptors, but some effects are too rapid to be mediated by changes at the genomic level. The detailed mechanisms of these nongenomic actions are still unclear. Membrane-bound glucocorticoid receptors (mGCR) have been suggested to be involved, although their physiological existence in humans so far is hypothetical. For the first time we demonstrate the existence of mGCR on monocytes and B cells obtained from healthy blood donors using high-sensitivity immunofluorescent staining. Immunostimulation with lipopolysaccharide increases the percentage of mGCR-positive monocytes, which can be prevented by inhibiting the secretory pathway. Overexpression of the human glucocorticoid receptor alpha alone is not sufficient to enhance mGCR expression. These in vitro findings are consistent with our clinical observation that in patients with rheumatoid arthritis the frequency of mGCR positive monocytes is increased and positively correlated with disease activity. We conclude that mGCR are 1) indeed physiologically present in healthy blood donors, but remained unidentified by conventional techniques due to their small number per cell and 2) actively up-regulated and transported through the cell after immunostimulation. These receptors may reflect a feedback mechanism of the organism upon immunostimulation and/or play a role in pathogenesis.	Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, D-10117 Berlin, Germany; Deutsch Rheuma Forschungszentrum Berlin, D-10117 Berlin, Germany; Univ Pecs, Fac Med, Dept Immunol & Biotechnol, H-7643 Pecs, Hungary	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Deutsches Rheuma-Forschungszentrum (DRFZ); University of Pecs	Buttgereit, F (corresponding author), Humboldt Univ, Dept Rheumatol & Clin Immunol, Charite Univ Hosp, Schumannstr 20-21, D-10117 Berlin, Germany.	frank.buttgereit@charite.de	Scheffold, Alexander/S-2090-2016; Burmester, Gerd R./AAY-7514-2020	Scheffold, Alexander/0000-0002-0626-343X; Buttgereit, Frank/0000-0003-2534-550X; Radbruch, Andreas/0000-0001-5753-0000; Berki, Timea/0000-0002-0134-8127				Almawi WY, 2002, J MOL ENDOCRINOL, V28, P69, DOI 10.1677/jme.0.0280069; Alzamora R, 2003, ENDOCRINOLOGY, V144, P1266, DOI 10.1210/en.2002-220950; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Benten WPM, 2002, STEROIDS, V67, P647, DOI 10.1016/S0039-128X(02)00013-2; Benten WPM, 2001, ENDOCRINOLOGY, V142, P1669, DOI 10.1210/en.142.4.1669; Berki T, 1998, J IMMUNOL METHODS, V214, P19, DOI 10.1016/S0022-1759(98)00037-4; Borski RJ, 2000, TRENDS ENDOCRIN MET, V11, P427, DOI 10.1016/S1043-2760(00)00325-8; Broutman G, 2001, J NEUROSCI, V21, P27, DOI 10.1523/JNEUROSCI.21-01-00027.2001; Bruno L, 1999, CURR BIOL, V9, P559, DOI 10.1016/S0960-9822(99)80259-0; Buttgereit F, 2000, IMMUNOL TODAY, V21, P192; Buttgereit F, 2002, STEROIDS, V67, P529, DOI 10.1016/S0039-128X(01)00171-4; Buttgereit F, 1998, ARTHRITIS RHEUM, V41, P761, DOI 10.1002/1529-0131(199805)41:5<761::AID-ART2>3.0.CO;2-M; Cato A.C., 2002, SCI STKE, V2002, pre9, DOI [10.1126/stke.2002.138.re9, DOI 10.1126/STKE.2002.138.RE9]; Chen FH, 1999, J CELL BIOCHEM, V74, P430, DOI 10.1002/(SICI)1097-4644(19990901)74:3<430::AID-JCB11>3.0.CO;2-5; Chen HC, 1999, CURR BIOL, V9, pR478, DOI 10.1016/S0960-9822(99)80300-5; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Davis PJ, 2002, THYROID, V12, P459, DOI 10.1089/105072502760143827; Diba F, 2001, J CELL BIOCHEM, V81, P149, DOI 10.1002/1097-4644(20010401)81:1<149::AID-JCB1031>3.3.CO;2-N; Erben RG, 2002, MOL ENDOCRINOL, V16, P1524, DOI 10.1210/me.16.7.1524; Falkenstein E, 2000, PHARMACOL REV, V52, P513; Falkenstein E, 2000, J CLIN ENDOCR METAB, V85, P2072, DOI 10.1210/jc.85.5.2072; Gametchu B, 1999, STEROIDS, V64, P107, DOI 10.1016/S0039-128X(98)00097-X; GAMETCHU B, 1993, FASEB J, V7, P1283, DOI 10.1096/fasebj.7.13.8405814; Guo ZY, 2002, J BIOL CHEM, V277, P29600, DOI 10.1074/jbc.M202997200; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Heinlein CA, 2002, MOL ENDOCRINOL, V16, P2181, DOI 10.1210/me.2002-0070; Kang TB, 2002, J BIOL CHEM, V277, P25583, DOI 10.1074/jbc.M203532200; Karin M, 2001, J ENDOCRINOL, V169, P447, DOI 10.1677/joe.0.1690447; LASSOUED K, 1993, CELL, V73, P73, DOI 10.1016/0092-8674(93)90161-I; Losel R, 2003, NAT REV MOL CELL BIO, V4, P46, DOI 10.1038/nrm1009; Nadal A, 2001, TRENDS PHARMACOL SCI, V22, P597, DOI 10.1016/S0165-6147(00)01846-0; ORCHINIK M, 1991, SCIENCE, V252, P1848, DOI 10.1126/science.2063198; Powell CE, 1999, ENDOCRINE, V10, P271, DOI 10.1007/BF02738626; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Sackey FNA, 1997, AM J PHYSIOL-ENDOC M, V273, pE571, DOI 10.1152/ajpendo.1997.273.3.E571; SALKOWSKI CA, 1992, J IMMUNOL, V149, P4041; Scheffold A, 2000, NAT MED, V6, P107, DOI 10.1038/71441; Solito E, 2003, ENDOCRINOLOGY, V144, P1164, DOI 10.1210/en.2002-220592; Verheggen MM, 1996, EUR RESPIR J, V9, P2036, DOI 10.1183/09031936.96.09102036; Villaverde V, 2000, J RHEUMATOL, V27, P2576; Wang ZY, 2001, NATURE, V410, P380, DOI 10.1038/35066597; Zola H, 1994, IMMUNOLOGIST, V2, P47	44	157	165	0	12	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					70	80		10.1096/fj.03-0328com	http://dx.doi.org/10.1096/fj.03-0328com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718388				2022-12-28	WOS:000188829300041
J	BLANCO, JG; EDICK, MJ; Relling, MV				BLANCO, JG; EDICK, MJ; Relling, MV			Etoposide induces chimeric Mll gene fusions	FASEB JOURNAL			English	Article						translocations; secondary leukemia; topoisomerase II inhibitors; DNA	ACUTE MYELOID-LEUKEMIA; BREAKPOINT CLUSTER REGION; DNA TOPOISOMERASE-II; ACUTE LYMPHOBLASTIC-LEUKEMIA; HOMOLOGOUS RECOMBINATION; INFANT LEUKEMIA; CHROMOSOME-ABERRATIONS; TANDEM DUPLICATION; NORMAL KARYOTYPE; LEUCINE-ZIPPER	MLL gene fusions are the hallmark of more than 70% of therapy-related leukemias (t-ML) associated with topoisomerase II inhibitors (e.g., etoposide) and cause leukemia in murine transgenic models. To determine whether Mll genomic fusions can occur after exposure to topoisomerase II inhibitors, we developed a long-distance inverse PCR DNA-based assay for chimeric MY fusions in mouse embryonic stem cells. We detected Mll fusions at a higher frequency following 100 muM etoposide for 8 h (16x 10(-6) cell(-1))) than in no-drug controls (1.0 x 10(-6) cell (-1), P=0.0002) or after treatment with a comparably cytotoxic exposure to the antimicrotubule drug vincristine (1.0 x 10(-6) cell(-1), P=0.0047). The fusion points in Mll chimeric products induced by etoposide were localized to a 1.5 kb region between exons 9 and 11, analogous to the MLL breakpoint cluster region in human leukemia. All 49 Mll fusion partners analyzed matched known genomic murine sequences, with 40 (82%) matching annotated genes covering eighteen murine autosomes. One partner was Runx1, the murine homologue of the transcription factor AML-1, a target of human translocations in therapy-related leukemia. These findings indicate that etoposide triggers the formation of MY gene fusions, a critical step for the development of treatment-induced leukemic transformation.	St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA; Univ Tennessee, Knoxville, TN 37996 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Knoxville	Relling, MV (corresponding author), St Jude Childrens Res Hosp, 332 N Lauderdale, Memphis, TN 38105 USA.	mary.relling@stjude.org			National Institutes of Health [CA51001, CA36401, CA21765]; Center of Excellence grant from the State of Tennessee; American Lebanese Syrian Associated Charities (ALSAC)	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center of Excellence grant from the State of Tennessee; American Lebanese Syrian Associated Charities (ALSAC)(American Lebanese Syrian Associated Charities (ALSAC))	We acknowledge the assistance of Ozden Artinaz, Jean Cai, Perdeep Mehta, Miriam Tamano, Mark Wilkinson, and Wenjian Yang. This work was supported by grants CA51001, CA36401, and CA21765 from the National Institutes of Health; by a Center of Excellence grant from the State of Tennessee; and by American Lebanese Syrian Associated Charities (ALSAC).	Biondi A, 2000, BLOOD, V96, P24, DOI 10.1182/blood.V96.1.24; Blanco JG, 2001, P NATL ACAD SCI USA, V98, P10338, DOI 10.1073/pnas.181199898; Broeker PLS, 1996, BLOOD, V87, P1912, DOI 10.1182/blood.V87.5.1912.bloodjournal8751912; Christiansen DH, 2001, LEUKEMIA, V15, P1848, DOI 10.1038/sj.leu.2402246; COLLINS FS, 1984, P NATL ACAD SCI-BIOL, V81, P6812, DOI 10.1073/pnas.81.21.6812; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; DiMartino JF, 2002, BLOOD, V99, P3780, DOI 10.1182/blood.V99.10.3780; Dobson CL, 1999, EMBO J, V18, P3564, DOI 10.1093/emboj/18.13.3564; DOMER PH, 1995, LEUKEMIA, V9, P1305; Downing J R, 1996, Cancer Treat Res, V84, P73; Downing JR, 2001, LEUKEMIA, V15, P664, DOI 10.1038/sj.leu.2402035; Echlin-Bell DR, 2003, HUM GENET, V113, P80, DOI 10.1007/s00439-003-0936-2; Ernst P, 2002, CURR OPIN HEMATOL, V9, P282, DOI 10.1097/00062752-200207000-00004; FISHER JP, 1989, EXP CELL RES, V182, P403, DOI 10.1016/0014-4827(89)90245-0; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; GU Y, 1994, CANCER RES, V54, P2327; Huret JL, 2001, LEUKEMIA, V15, P987, DOI 10.1038/sj.leu.2402135; Lambert S, 1999, MUTAT RES-DNA REPAIR, V433, P159, DOI 10.1016/S0921-8777(99)00004-X; Lorsbach RB, 2001, INT J HEMATOL, V74, P258, DOI 10.1007/BF02982058; Lovett BD, 2001, P NATL ACAD SCI USA, V98, P9802, DOI 10.1073/pnas.171309898; Megonigal MD, 2000, P NATL ACAD SCI USA, V97, P2814, DOI 10.1073/pnas.050397097; PEDERSENBJERGAARD J, 1994, BLOOD, V83, P2780, DOI 10.1182/blood.V83.10.2780.2780; PRASAD R, 1994, P NATL ACAD SCI USA, V91, P8107, DOI 10.1073/pnas.91.17.8107; Pui CH, 2000, BRIT J HAEMATOL, V109, P13, DOI 10.1046/j.1365-2141.2000.01843.x; Rabbitts TH, 2001, ONCOGENE, V20, P5763, DOI 10.1038/sj.onc.1204597; RATAIN MJ, 1992, ANN ONCOL, V3, P107, DOI 10.1093/oxfordjournals.annonc.a058121; RATAIN MJ, 1987, BLOOD, V70, P1412; Relling MV, 1998, LEUKEMIA, V12, P346, DOI 10.1038/sj.leu.2400928; Relling MV, 2003, BLOOD, V101, P3862, DOI 10.1182/blood-2002-08-2405; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Rowley JD, 2002, GENE CHROMOSOME CANC, V33, P331, DOI 10.1002/gcc.10040; Rudin CM, 2001, GENE CHROMOSOME CANC, V30, P64, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1066>3.0.CO;2-F; SCHICHMAN SA, 1994, CANCER RES, V54, P4277; Severson Richard K., 1999, Current Opinion in Oncology, V11, P20, DOI 10.1097/00001622-199901000-00005; So CW, 2003, CANCER CELL, V3, P161, DOI 10.1016/S1535-6108(03)00019-9; SPITZNER JR, 1988, NUCLEIC ACIDS RES, V16, P5533, DOI 10.1093/nar/16.12.5533; Stanulla M, 1997, LEUKEMIA, V11, P490, DOI 10.1038/sj.leu.2400632; Stine KC, 1997, J CLIN ONCOL, V15, P1583, DOI 10.1200/JCO.1997.15.4.1583; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Strissel PL, 1998, GENOMICS, V47, P217, DOI 10.1006/geno.1997.5103; Strissel PL, 1998, BLOOD, V92, P3793, DOI 10.1182/blood.V92.10.3793.422a24_3793_3803; Strout MP, 1998, P NATL ACAD SCI USA, V95, P2390, DOI 10.1073/pnas.95.5.2390; THIRMAN MJ, 1993, NEW ENGL J MED, V329, P909, DOI 10.1056/NEJM199309233291302; Thomsen JB, 1999, CANCER-AM CANCER SOC, V86, P1080, DOI 10.1002/(SICI)1097-0142(19990915)86:6<1080::AID-CNCR26>3.0.CO;2-5; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Webb JC, 1999, BLOOD, V94, P283, DOI 10.1182/blood.V94.1.283.413k23_283_290; Zhang YM, 2002, P NATL ACAD SCI USA, V99, P3070, DOI 10.1073/pnas.042702899	47	33	33	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					173	175		10.1096/fj.03-0638fje	http://dx.doi.org/10.1096/fj.03-0638fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630694				2022-12-28	WOS:000188829300065
J	Zhang, W; Wang, TG; Qin, LY; Gao, HM; Wilson, B; Ali, SF; Zhang, WQ; Hong, JS; Liu, B				Zhang, W; Wang, TG; Qin, LY; Gao, HM; Wilson, B; Ali, SF; Zhang, WQ; Hong, JS; Liu, B			Neuroprotective effect of dextromethorphan in the MPTP Parkinson's disease model: role of NADPH oxidase	FASEB JOURNAL			English	Article						reactive oxygen species; microglia; dopamine; substantia nigra; morphinan	INJURY FOLLOWING TRANSIENT; DOPAMINERGIC-NEURONS; FOCAL ISCHEMIA; NITRIC-OXIDE; MICROGLIAL ACTIVATION; SUPEROXIDE PRODUCTION; GLUTAMATE TOXICITY; TETRAZOLIUM SALT; MOUSE MODEL; PROTECTS	Parkinson's disease (PD) is a neurodegenerative movement disorder characterized by a progressive loss of dopaminergic neurons in the substantia nigra and depletion of the neurotransmitter dopamine in the striatum. Progress in the search for effective therapeutic strategies that can halt this degenerative process remains limited. Mechanistic studies using animal systems such as the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) rodent PD model have revealed the involvement of the brain's immune cells and free radical-generating processes. We recently reported that dextromethorphan (DM), a widely used anti-tussive agent, attenuated endotoxin-induced dopaminergic neurodegeneration in vitro. In the current study, we investigated the potential neuroprotective effect of DM and the underlying mechanism of action in the MPTP rodent PD model. Mice (C57BL/6J) that received daily MPTP injections (15 mg free base/kg body weight, s.c.) for 6 consecutive days exhibited significant degeneration of the nigrostriatal dopaminergic pathway. However, the MPTP-induced loss of nigral dopaminergic neurons was significantly attenuated in those mice receiving DM (10 mg/kg body weight, s.c.). In mesencephalic neuron-glia cultures, DM significantly reduced the MPTP-induced production of both extracellular superoxide free radicals and intracellular reactive oxygen species (ROS). Because NADPH oxidase is the primary source of extracellular superoxide and intracellular ROS, we investigated the involvement of NADPH oxidase in the neuroprotective effect of DM. Indeed, the neuroprotective effect of DM was only observed in the wild-type but not in the NADPH oxidase-deficient mice, indicating that NADPH oxidase is a critical mediator of the neuroprotective activity of DM. More importantly, due to its proven safety record of long-term clinical use in humans, DM may be a promising agent for the treatment of degenerative neurological disorders such as PD.	Univ Florida, Coll Pharm, Dept Pharmacodynam, Gainesville, FL 32610 USA; NIEHS, Lab Pharmacol & Chem, Res Triangle Pk, NC 27709 USA; First Clin Hosp, Dept Neurol, Dalian, Peoples R China; Dalian Med Univ, Dept Physiol, Dalian, Peoples R China; US FDA, Neurochem Lab, Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Dalian Medical University; US Food & Drug Administration (FDA)	Liu, B (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, Box 100487 HSC, Gainesville, FL 32610 USA.	liu@cop.ufl.edu	gao, huiming/C-8454-2012; liu, Bin/A-7695-2009; Hong, Jau-Shyong/F-1920-2019	Hong, Jau-Shyong/0000-0002-3056-8401				ALI SF, 1994, BRAIN RES, V658, P33, DOI 10.1016/S0006-8993(09)90007-5; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Bianca V D, 1999, J Biol Chem, V274, P15493; Britton P, 1997, LIFE SCI, V60, P1729, DOI 10.1016/S0024-3205(97)00132-X; Chao CC, 1996, J NEUROVIROL, V2, P234, DOI 10.3109/13550289609146886; CHOI DW, 1987, BRAIN RES, V403, P333, DOI 10.1016/0006-8993(87)90070-9; DECOSTER MA, 1995, BRAIN RES, V671, P45, DOI 10.1016/0006-8993(94)01294-R; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Gao HM, 2003, FASEB J, V17, DOI 10.1096/fj.03-0109fje; Gao HM, 2003, J NEUROSCI, V23, P6181; Gao HM, 2003, J NEUROSCI, V23, P1228, DOI 10.1523/JNEUROSCI.23-04-01228.2003; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; GEORGE CP, 1988, BRAIN RES, V440, P375, DOI 10.1016/0006-8993(88)91011-6; Green SP, 2001, J CEREBR BLOOD F MET, V21, P374, DOI 10.1097/00004647-200104000-00006; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Haberecht MF, 1997, J NEUROSCI RES, V47, P416; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LESAGE AS, 1995, SYNAPSE, V20, P156, DOI 10.1002/syn.890200210; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2000, J PHARMACOL EXP THER, V293, P607; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu YX, 2003, J PHARMACOL EXP THER, V305, P212, DOI 10.1124/jpet.102.043166; Liu YX, 2002, J PHARMACOL EXP THER, V302, P1212, DOI 10.1124/jpet.102.035956; McGeer PL, 2001, ADV NEUROL, V86, P83; MIYAKE H, 1989, EUR J PHARMACOL, V166, P49, DOI 10.1016/0014-2999(89)90682-1; MONYER H, 1988, BRAIN RES, V446, P144, DOI 10.1016/0006-8993(88)91304-2; Olanow CW, 1999, ANNU REV NEUROSCI, V22, P123, DOI 10.1002/mds.23732; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Peskin AV, 2000, CLIN CHIM ACTA, V293, P157, DOI 10.1016/S0009-8981(99)00246-6; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; PRINCE DA, 1988, NEUROSCI LETT, V85, P291, DOI 10.1016/0304-3940(88)90581-2; ROSENKRANZ AR, 1992, J IMMUNOL METHODS, V156, P39, DOI 10.1016/0022-1759(92)90008-H; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; STEINBERG GK, 1988, STROKE, V19, P1112, DOI 10.1161/01.STR.19.9.1112; Tan AS, 2000, J IMMUNOL METHODS, V238, P59, DOI 10.1016/S0022-1759(00)00156-3; Tortella FC, 1999, J PHARMACOL EXP THER, V291, P399; TORTELLA FC, 1989, TRENDS PHARMACOL SCI, V10, P501, DOI 10.1016/0165-6147(89)90050-3; UHL GR, 1985, LANCET, V1, P956; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Wu DC, 2003, P NATL ACAD SCI USA, V100, P6145, DOI 10.1073/pnas.0937239100; [No title captured]	47	158	163	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					589	+		10.1096/fj.03-0983fje	http://dx.doi.org/10.1096/fj.03-0983fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734632				2022-12-28	WOS:000188829300001
J	Straub, RH; Besedovsky, HO				Straub, RH; Besedovsky, HO			Integrated evolutionary, immunological, and neuroendocrine framework for the pathogenesis of chronic disabling inflammatory diseases	FASEB JOURNAL			English	Article						chronic inflammatory disease; immune system; endocrine system; nervous system; reproductive system	TUMOR-NECROSIS-FACTOR; NONSTEROIDAL ANTIESTROGENS INHIBIT; RHEUMATOID-ARTHRITIS; DENDRITIC CELLS; IMMUNE-SYSTEM; SUBSTANCE-P; SYNOVIAL MACROPHAGES; BETA(1) INTEGRINS; HUMAN ENDOMETRIUM; HUMAN-MONOCYTES	The pathogenesis of chronic disabling inflammatory diseases (CDIDs) is poorly understood. Current concepts that focus on abnormalities of the immune system are, in our view, incomplete. Here we propose that chronic disruption of homeostasis through abnormal neuronal and endocrine host responses to transient inflammatory reactions contributes to the appearance of CDIDs. Coordinated reactions of the supersystems (immune, nervous, endocrine, and reproductive) that maintain homeostasis have been evolutionarily conserved to respond to and eliminate foreign agents over a period of days to a few weeks. If the responses of these supersystems fail to return to normal after elimination of the pathogen, a continuous aggressive immune response is created; this situation can trigger development of CDIDs. Maladaptation of the supersystems during CDIDs has not been evolutionarily conserved but is nevertheless still prevalent because a large proportion of these diseases tend to appear after the reproductive phase. We propose that this integrated systems hypothesis may permit better identification of a patient at risk or in the early stages of developing a CDID such as rheumatoid arthritis and enable more coordinated intervention than is presently attempted.	Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany; Univ Marburg, Inst Normal & Pathol Physiol, D-35033 Marburg, Germany	University of Regensburg; Philipps University Marburg	Straub, RH (corresponding author), Univ Hosp Regensburg, Dept Internal Med 1, D-93042 Regensburg, Germany.	rainer.straub@klinik.uni-regensburg.de		Straub, Rainer H/0000-0003-1165-4555				Abbas A K, 2003, CELL MOL IMMUNOL, P115; ADASHI EY, 1989, J BIOL CHEM, V264, P11591; AGRAWAL B, 1991, J IMMUNOL, V147, P383; BAUR M, 2001, ODYSSE MENSCHEN ESBE; BELL DA, 1984, J RHEUMATOL, V11, P475; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Blass S, 1999, ARTHRITIS RHEUM, V42, P2499, DOI 10.1002/1529-0131(199912)42:12<2499::AID-ANR1>3.0.CO;2-R; BLUTHE RM, 1994, PSYCHONEUROENDOCRINO, V19, P197, DOI 10.1016/0306-4530(94)90009-4; Braun J, 2002, CLIN EXP RHEUMATOL, V20, pS1; Burkhardt H, 2002, ARTHRITIS RHEUM, V46, P2339, DOI 10.1002/art.10472; Burnett F. M., 1959, CONAL SELECTION THEO; CASTAGNETTA L, 2003, IN PRESS J RHEUMATOL; CHRISTEFF N, 1987, J STEROID BIOCHEM, V26, P67, DOI 10.1016/0022-4731(87)90032-X; CID MC, 1994, J CLIN INVEST, V93, P17, DOI 10.1172/JCI116941; Crofford LJ, 1997, J CLIN ENDOCR METAB, V82, P1279, DOI 10.1210/jc.82.4.1279; CROKER BP, 1983, LAB INVEST, V48, P19; Cutolo M, 2000, RHEUM DIS CLIN N AM, V26, P825, DOI 10.1016/S0889-857X(05)70171-X; CUTOLO M, 1988, ARTHRITIS RHEUM, V31, P1314, DOI 10.1002/art.1780311015; de Jong EC, 1999, J LEUKOCYTE BIOL, V66, P201, DOI 10.1002/jlb.66.2.201; del Rey A, 2002, J NEUROIMMUNOL, V127, P44, DOI 10.1016/S0165-5728(02)00096-6; Delneste Y, 1999, J IMMUNOL, V163, P3071; DHABHAR FS, 1995, J IMMUNOL, V154, P5511; FAN PT, 1993, TXB RHEUMATOLOGY, P961; FELDMAN C, 1989, S AFR MED J, V76, P593; Galasso F, 1996, J DERMATOL SCI, V13, P76, DOI 10.1016/0923-1811(95)00501-3; Herrmann M, 2000, RHEUM DIS CLIN N AM, V26, P737, DOI 10.1016/S0889-857X(05)70167-8; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JONES SB, 1984, CIRC SHOCK, V14, P189; JORGENSEN C, 1995, J RHEUMATOL, V22, P1829; Kirkwood TBL, 2000, NATURE, V408, P233, DOI 10.1038/35041682; Kohm AP, 2000, IMMUNOL TODAY, V21, P539, DOI 10.1016/S0167-5699(00)01747-3; Komi J, 2001, RHEUMATOLOGY, V40, P185, DOI 10.1093/rheumatology/40.2.185; Komi J, 2000, BLOOD, V95, P2875, DOI 10.1182/blood.V95.9.2875.009k12_2875_2882; KURTZKE JF, 1992, NEUROEPIDEMIOLOGY, V11, P226, DOI 10.1159/000110935; Lambrecht BN, 1999, EUR J IMMUNOL, V29, P3815, DOI 10.1002/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#; LOTZ M, 1988, SCIENCE, V241, P1218, DOI 10.1126/science.2457950; Lutz MB, 2002, TRENDS IMMUNOL, V23, P445, DOI 10.1016/S1471-4906(02)02281-0; MADDEN K S, 1989, Brain Behavior and Immunity, V3, P72, DOI 10.1016/0889-1591(89)90007-X; Marchalonis JJ, 2002, FASEB J, V16, DOI 10.1096/fj.01-0953hyp; MASI AT, 1984, SEMIN ARTHRITIS RHEU, V14, P1, DOI 10.1016/0049-0172(84)90005-2; MATERA L, 1992, BRAIN BEHAV IMMUN, V6, P409, DOI 10.1016/0889-1591(92)90039-Q; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Miller LE, 2000, FASEB J, V14, P2097, DOI 10.1096/fj.99-1082com; MONEKOSSO GL, 1966, LANCET, V1, P1347; Murray JS, 1998, IMMUNOL TODAY, V19, P157, DOI 10.1016/S0167-5699(97)01237-1; NILSSON J, 1985, NATURE, V315, P61, DOI 10.1038/315061a0; Ostensen M, 2000, J RHEUMATOL, V27, P1783; PEREIRA DSJ, 1990, J RHEUMATOL, V17, P1592; PEREZ E, 1987, INVEST OPHTH VIS SCI, V28, P221; Reichenberg A, 2001, ARCH GEN PSYCHIAT, V58, P445, DOI 10.1001/archpsyc.58.5.445; REYNOLDS ML, 1995, J COMP NEUROL, V358, P487, DOI 10.1002/cne.903580403; ROCHARVEILLER M, 1986, PHARMACOLOGY, V33, P266, DOI 10.1159/000138225; RUFF MR, 1985, PEPTIDES, V6, P107, DOI 10.1016/0196-9781(85)90142-1; SCHAIBLE HG, 1993, PAIN, V55, P5, DOI 10.1016/0304-3959(93)90183-P; Seiffert K, 2002, J IMMUNOL, V168, P6128, DOI 10.4049/jimmunol.168.12.6128; Shifren JL, 1996, J CLIN ENDOCR METAB, V81, P3112, DOI 10.1210/jc.81.8.3112; Shiokawa S, 1996, J CLIN ENDOCR METAB, V81, P1533, DOI 10.1210/jc.81.4.1533; SIMMONS D, 1990, DIABETIC MED, V7, P238, DOI 10.1111/j.1464-5491.1990.tb01377.x; SKLAR CA, 1986, AM J DIS CHILD, V140, P877, DOI 10.1001/archpedi.1986.02140230047026; SMITH JB, 1992, ARCH DERMATOL, V128, P1608, DOI 10.1001/archderm.128.12.1608; SPANGELO BL, 1987, IMMUNOPHARMACOLOGY, V14, P11, DOI 10.1016/0162-3109(87)90004-X; Straub RH, 2002, FASEB J, V16, P993, DOI 10.1096/fj.02-0085com; Straub RH, 2002, J ENDOCRINOL, V175, P467, DOI 10.1677/joe.0.1750467; Straub RH, 2002, ARTHRITIS RHEUM, V46, P654, DOI 10.1002/art.10177; SUZUKI S, 1986, AM J PHYSIOL, V250, pE470, DOI 10.1152/ajpendo.1986.250.4.E470; Thomas L., 1998, CLIN LAB DIAGNOSTICS, V1; TOFT P, 1994, ACTA ANAESTH SCAND, V38, P254, DOI 10.1111/j.1399-6576.1994.tb03884.x; Tonnesen MG, 2000, J INVEST DERM SYMP P, V5, P40, DOI 10.1046/j.1087-0024.2000.00014.x; Torii H, 1999, J DERMATOL SCI, V20, P21, DOI 10.1016/S0923-1811(99)00004-3; Westerman R A, 1993, Clin Exp Neurol, V30, P39; WUCHERPFENNIG AL, 1990, ARCH ORAL BIOL, V35, P443, DOI 10.1016/0003-9969(90)90207-Q; Yoshimura Y, 1998, HORM RES, V50, P46, DOI 10.1159/000053123	73	67	72	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2176	2183		10.1096/fj.03-0433hyp	http://dx.doi.org/10.1096/fj.03-0433hyp			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656978				2022-12-28	WOS:000188067500037
J	Fischer, DF; De Vos, RAI; Van Dijk, R; De Vrij, FMS; Proper, EA; Sonnemans, MAF; Verhage, MC; Sluijs, JA; Hobo, B; Zouambia, M; Steur, ENHJ; Kamphorst, W; Hol, EM; Van Leeuwen, FW				Fischer, DF; De Vos, RAI; Van Dijk, R; De Vrij, FMS; Proper, EA; Sonnemans, MAF; Verhage, MC; Sluijs, JA; Hobo, B; Zouambia, M; Steur, ENHJ; Kamphorst, W; Hol, EM; Van Leeuwen, FW			Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain	FASEB JOURNAL			English	Article						tauopathies; synucleinopathies; molecular misreading; UBB+1; lentivirus	ALPHA-SYNUCLEIN INCLUSIONS; TAU GENE-MUTATIONS; ALZHEIMERS-DISEASE; PARKINSONS-DISEASE; FRAMESHIFT MUTATIONS; DEGRADATION; FREQUENCY; PROTEIN; SYSTEM; PATHOGENESIS	Molecular misreading of the ubiquitin-B (UBB) gene results in a dinucleotide deletion in UBB mRNA. The resulting mutant protein, UBB+1, accumulates in the neuropathological hallmarks of Alzheimer disease. In vitro, UBB+1 inhibits proteasomal proteolysis, although it is also an ubiquitin fusion degradation substrate for the proteasome. Using the ligase chain reaction to detect dinucleotide deletions, we report here that UBB+1 transcripts are present in each neurodegenerative disease studied (tauo- and synucleinopathies) and even in control brain samples. In contrast to UBB+1 transcripts, UBB+1 protein accumulation in the ubiquitin-containing neuropathological hallmarks is restricted to the tauopathies such as Pick disease, frontotemporal dementia, progressive supranuclear palsy, and argyrophilic grain disease. Remarkably, UBB+1 protein is not detected in the major forms of synucleinopathies (Lewy body disease and multiple system atrophy). The neurologically intact brain can cope with UBB+1 as lentivirally delivered UBB+1 protein is rapidly degraded in rat hippocampus, whereas the K29,48R mutant of UBB+1, which is not ubiquitinated, is abundantly expressed. The finding that UBB+1 protein only accumulates in tauopathies thus implies that the ubiquitin-proteasome system is impaired specifically in this group of neurodegenerative diseases and not in synucleinopathies and that the presence of UBB+1 protein reports proteasomal dysfunction in the brain.	Netherlands Inst Brain Res, NL-1105 AZ Amsterdam, Netherlands; Grad Sch Neurosci Amsterdam, Amsterdam, Netherlands; Pathol Lab Oost Nederland & Med Spectrum Twente, Enschede, Netherlands; Utrecht Med Ctr, Rudolf Magnus Inst Neurosci, Utrecht, Netherlands; Univ Hosp Free Univ, Dept Neuropathol, Amsterdam, Netherlands	Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW); University of Amsterdam; Medical Spectrum Twente; Utrecht University; Utrecht University Medical Center	Van Leeuwen, FW (corresponding author), Netherlands Inst Brain Res, Meibergdreef 33, NL-1105 AZ Amsterdam, Netherlands.	f.van.leeuwen@nih.knaw.nl	Hol, Elly M/F-1891-2013; de Vrij, Femke M.S./O-9706-2019; Hol, Elly/J-2025-2019	Hol, Elly M/0000-0001-5604-2603; de Vrij, Femke M.S./0000-0003-0825-3806; Hol, Elly/0000-0001-5604-2603; Fischer, David/0000-0002-6690-0197				Alves-Rodrigues A, 1998, TRENDS NEUROSCI, V21, P516, DOI 10.1016/S0166-2236(98)01276-4; BARANY F, 1991, P NATL ACAD SCI USA, V88, P189, DOI 10.1073/pnas.88.1.189; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Braak H, 1998, J NEURAL TRANSM, V105, P801, DOI 10.1007/s007020050096; Braak H, 2000, ANN NY ACAD SCI, V911, P221; CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; De Vrij FMS, 2001, FASEB J, V15, P2680, DOI 10.1096/fj.01-0438com; EVANS DAP, 1994, P NATL ACAD SCI USA, V91, P6059, DOI 10.1073/pnas.91.13.6059; Fergusson J, 2000, NEUROSCI LETT, V279, P69, DOI 10.1016/S0304-3940(99)00917-9; Furukawa Y, 2002, ANN NEUROL, V51, P779, DOI 10.1002/ana.10207; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; Hasegawa M, 2002, J BIOL CHEM, V277, P49071, DOI 10.1074/jbc.M208046200; Huitinga I, 2001, J NEUROPATH EXP NEUR, V60, P1208, DOI 10.1093/jnen/60.12.1208; Hutton M, 1998, NATURE, V393, P702, DOI 10.1038/31508; Ingram EM, 2002, TRENDS MOL MED, V8, P555, DOI 10.1016/S1471-4914(02)02440-1; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Keck S, 2003, J NEUROCHEM, V85, P115, DOI 10.1046/j.1471-4159.2003.01642.x; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; Lee VMY, 2001, ANNU REV NEUROSCI, V24, P1121, DOI 10.1146/annurev.neuro.24.1.1121; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lindsten K, 2002, J CELL BIOL, V157, P417, DOI 10.1083/jcb.200111034; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; McNaught KSP, 2002, NEUROSCI LETT, V326, P155, DOI 10.1016/S0304-3940(02)00296-3; McPhaul LW, 2002, GASTROENTEROLOGY, V122, P1878, DOI 10.1053/gast.2002.33629; Naldini L, 1996, SCIENCE, V272, P263, DOI 10.1126/science.272.5259.263; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Poorkaj P, 2001, ARCH NEUROL-CHICAGO, V58, P383, DOI 10.1001/archneur.58.3.383; Schwartz AL, 1999, ANNU REV MED, V50, P57; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Spillantini MG, 1998, TRENDS NEUROSCI, V21, P428, DOI 10.1016/S0166-2236(98)01337-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Swaab DF, 1998, PROG BRAIN RES, V117, P343; Tofaris GK, 2001, FEBS LETT, V509, P22, DOI 10.1016/S0014-5793(01)03115-5; Van Broeckhoven C, 1998, PROG BRAIN RES, V117, P315; van den Hurk WH, 2001, J BIOL CHEM, V276, P11496, DOI 10.1074/jbc.M011040200; van Leeuwen FW, 2000, NEUROBIOL AGING, V21, P879, DOI 10.1016/S0197-4580(00)00151-2; van Leeuwen FW, 1998, SCIENCE, V279, P242, DOI 10.1126/science.279.5348.242; van Leeuwen FW, 1998, TRENDS NEUROSCI, V21, P331, DOI 10.1016/S0166-2236(98)01280-6; WIEDMANN M, 1994, PCR METH APPL, V3, pS51	46	99	103	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2014	2024		10.1096/fj.03-0205com	http://dx.doi.org/10.1096/fj.03-0205com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597671				2022-12-28	WOS:000186961200038
J	Da Silva, CA; Heilbock, C; Kassel, O; Frossard, N				Da Silva, CA; Heilbock, C; Kassel, O; Frossard, N			Transcription of stem cell factor (SCF) is potentiated by glucocorticoids and interleukin-1 beta through concerted regulation of a GRE-like and an NF-kappa B response element	FASEB JOURNAL			English	Article						glucocorticoids; GRE; transactivation; inflammation; NF-KB	TUMOR-NECROSIS-FACTOR; C-KIT LIGAND; FACTOR-ALPHA; CROSS-TALK; MAST-CELL; ANTIINFLAMMATORY ACTION; AIRWAY INFLAMMATION; PROTEIN-KINASE; SI-LOCUS; RECEPTOR	Expression of stem cell factor SCF, a major mast cell growth factor, is potentiated shortly after co-treatment with interleukin (IL)-1beta and glucocorticoids. SCF promoter contains a GRE-like sequence and a putative kappaB site. We assessed the mechanisms of the regulation of SCF transcription in human lung fibroblasts in culture. Chromatin immunoprecipitation showed that co-treatment with IL-1beta and the glucocorticoid budesonide increased the SCF promoter occupancy by NF-kappaB and GR, as compared with IL-1beta and budesonide alone. In reporter gene assays, IL-1beta time-dependently increased the promoter activity, which was abolished by either pre-treatment with the MAP kinase inhibitors PD98059 (MEK) and SB203580 (p38), pretreatment with the NF-kappaB inhibitor PDTC, or deletion of the kappaB site. Budesonide time-dependently decreased the promoter activity, an effect requiring the GRE-like element. Cotreatment with IL-1beta and budesonide potentiated the promoter activity at 30 min, an effect blocked by PD98059 and SB203580, PDTC, or deletion of the kappaB or GRE-like element. In conclusion, the GRE-like sequence mediating the repression of SCF expression, thus acting as a negative-responsive element, is turned into a positive element in an NF-kappaB site-dependent manner, indicating a concerted action of these two regulatory elements in the potentiation of SCF gene expression.	Univ Strasbourg 1, INSERM, U425, Fac Pharm, F-67401 Illkirch Graffenstaden, France; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Helmholtz Association; Karlsruhe Institute of Technology	Da Silva, CA (corresponding author), Univ Strasbourg 1, INSERM, U425, Fac Pharm, 74 Route Rhin,BP 24, F-67401 Illkirch Graffenstaden, France.	carla.dasilva@pharma.u-strasbg.fr	Frossard, Nelly/F-8301-2013; Kassel, Olivier/H-2117-2013	Kassel, Olivier/0000-0002-8616-3091				Adcock IM, 2001, PULM PHARMACOL THER, V14, P211, DOI 10.1006/pupt.2001.0283; Ballard PL, 1996, AM J RESP CELL MOL, V14, P599, DOI 10.1165/ajrcmb.14.6.8652188; BISCHOFF SC, 1992, J EXP MED, V175, P237, DOI 10.1084/jem.175.1.237; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; CALDENHOVEN E, 1995, MOL ENDOCRINOL, V9, P401, DOI 10.1210/me.9.4.401; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Chen CC, 1999, J BIOL CHEM, V274, P31559, DOI 10.1074/jbc.274.44.31559; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; Da Silva CA, 2002, BRIT J PHARMACOL, V135, P1634, DOI 10.1038/sj.bjp.0704617; Dumont A, 1998, TRENDS BIOCHEM SCI, V23, P233, DOI 10.1016/S0968-0004(98)01212-2; Eder J, 1997, TRENDS PHARMACOL SCI, V18, P319, DOI 10.1016/S0165-6147(97)01097-3; Herrlich P, 2001, ONCOGENE, V20, P2465, DOI 10.1038/sj.onc.1204388; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; IEMURA A, 1994, AM J PATHOL, V144, P321; Israel A, 1997, NATURE, V388, P519, DOI 10.1038/41433; Janssen-Heininger YMW, 1999, AM J RESP CELL MOL, V20, P942, DOI 10.1165/ajrcmb.20.5.3452; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890, DOI 10.1164/ajrccm/145.4_Pt_1.890; Jung YD, 2002, CYTOKINE, V18, P206, DOI 10.1006/cyto.2002.1034; Kassel O, 1998, MOL PHARMACOL, V54, P1073, DOI 10.1124/mol.54.6.1073; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; KIRSHENBAUM AS, 1992, J IMMUNOL, V148, P772; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lebovic DI, 2001, J CLIN ENDOCR METAB, V86, P4759, DOI 10.1210/jc.86.10.4759; Lian JP, 1999, J IMMUNOL, V163, P4527; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; MARTIN FH, 1990, CELL, V63, P203, DOI 10.1016/0092-8674(90)90301-T; McKay LI, 1998, MOL ENDOCRINOL, V12, P45, DOI 10.1210/mend.12.1.0044; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Pelaia G, 2001, BIOCHEM PHARMACOL, V62, P1719, DOI 10.1016/S0006-2952(01)00791-2; Pryhuber GS, 1996, AM J PHYSIOL-LUNG C, V270, pL714, DOI 10.1152/ajplung.1996.270.5.L714; ROTTEM M, 1994, BLOOD, V84, P2489; Schjerven H, 2001, J IMMUNOL, V167, P6412, DOI 10.4049/jimmunol.167.11.6412; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; Taylor WE, 1996, ENDOCRINOLOGY, V137, P5407, DOI 10.1210/en.137.12.5407; Vermeulen L, 2002, BIOCHEM PHARMACOL, V64, P963, DOI 10.1016/S0006-2952(02)01161-9; Webster JC, 2002, ENDOCRINOLOGY, V143, P3866, DOI 10.1210/en.2002-220188; Xu Y, 1999, DNA CELL BIOL, V18, P709, DOI 10.1089/104454999314999; ZSEBO KM, 1990, CELL, V63, P213, DOI 10.1016/0092-8674(90)90302-U	39	41	41	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2334	+		10.1096/fj.03-0136fje	http://dx.doi.org/10.1096/fj.03-0136fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563684				2022-12-28	WOS:000186343300018
J	Garrison, HH; Gerbi, SA; Kincade, PW				Garrison, HH; Gerbi, SA; Kincade, PW			In an era of scientific opportunity, are there opportunities for biomedical scientists?	FASEB JOURNAL			English	Article						NIH; training; postdoctoral; employment	EDUCATION	Has the dramatic growth in the NIH budget affected the training and production of biomedical Ph.D.s? Examination of new survey data reveals surprising findings. Despite the need for an increased workforce to carry out the expansion in biomedical research, there has not been an increase in new U.S. doctorates awarded, and time-to-degree in the biomedical sciences is no longer increasing. Furthermore, both the frequency and length of postdoctoral appointments are decreasing for U.S. biomedical science recipients. There has been, however, continued growth in the number of foreign postdoctorals. Industrial employment of biomedical scientists continues to increase, but there has been only modest growth in tenured or tenure-track academic jobs.	Federat Amer Soc Expt Biol, Bethesda, MD 20814 USA; Brown Univ, Div Biol & Med, Providence, RI 02912 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Brown University; Oklahoma Medical Research Foundation	Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, 9650 Rockville Pike, Bethesda, MD 20814 USA.	hgarrison@opa.faseb.org		Garrison, Howard/0000-0001-9455-3527				*FED AM SOC EXP BI, 1997, GRAD ED CONS C REP; Freeman R, 2001, SCIENCE, V294, P2293, DOI 10.1126/science.1067477; Garrison HH, 1998, FASEB J, V12, P139, DOI 10.1096/fasebj.12.2.139; Gerbi SA, 2001, SCIENCE, V292, P1489, DOI 10.1126/science.1059268; GOLDMAN CA, 2001, THESIS BOSTON MA; Hecker DE, 2001, MON LABOR REV, V124, P57; Kennedy D, 2002, SCIENCE, V298, P323, DOI 10.1126/science.298.5592.323; Marincola E, 1998, SCIENCE, V281, P645, DOI 10.1126/science.281.5377.645; *NAT POSTD ASS, 2003, POL REC NAT I HLTH; *NAT RES COUNC, 1994, FUND YOUNG INV BIOL; *NAT SCI FDN, 2003, GRAD STUD POSTD SCI; National Research Council, 1998, TRENDS EARL CAR LIF; *PHARM RES MAN ASS, 2002, IND PROF; Zumeta W, 2002, ISSUES SCI TECHNOL, V19, P36	14	14	14	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2169	+		10.1096/fj.03-0836life	http://dx.doi.org/10.1096/fj.03-0836life			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525935				2022-12-28	WOS:000186343300016
J	Hwang, YYC; Bakr, S; Ellery, CA; Oates, PJ; Ramasamy, R				Hwang, YYC; Bakr, S; Ellery, CA; Oates, PJ; Ramasamy, R			Sorbitol dehydrogenase: a novel target for adjunctive protection of ischemic myocardium	FASEB JOURNAL			English	Article						SDH; ischemia; reperfusion	ALDOSE REDUCTASE INHIBITION; POLYOL DEHYDROGENASES; RAT HEARTS; GLUCOSE; STIMULATION; METABOLISM; CARNITINE; LIVER; OXIDOREDUCTASES; ALCOHOL	Sorbitol dehydrogenase (SDH) is a polyol pathway enzyme that catalyzes conversion of sorbitol to fructose. Recent studies have demonstrated that activation of aldose reductase, the first enzyme of the polyol pathway, is a key response to ischemia and that inhibition of aldose reductase reduces myocardial ischemic injury. In our efforts to understand the role of pathway in affecting metabolism under normoxic and ischemic conditions, as well as in ischemic injury in myocardium, we investigated the importance of SDH by use of a specific inhibitor (SDI), CP-470,711. SDH inhibition increased glucose oxidation, whereas palmitate oxidation remained unaffected. Global ischemia increased myocardial SDH activity by similar to1.5 fold. The tissue lactate/pyruvate ratio, a measure of cytosolic NADH/NAD(+), was reduced by SDH inhibition under both normoxic and ischemic conditions. ATP was higher in SDI hearts during ischemia and reperfusion. Creatine kinase release during reperfusion, a marker of myocardial ischemic injury, was markedly attenuated in SDH-inhibited hearts. These data indicate that myocardial SDH activation is a component of ischemic response and that interventions that inhibit SDH protect ischemic myocardium. Furthermore, these data identify SDH as a novel target for adjunctive cardioprotective interventions.	Columbia Univ, Coll Phys & Surg, Dept Surg, Div Surg Sci, New York, NY 10032 USA; Pfizer Inc, Global Res & Dev, Groton, CT 06340 USA	Columbia University; Pfizer	Ramasamy, R (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Surg, Div Surg Sci, 630 W 168th St, New York, NY 10032 USA.	rr260@columbia.edu		Ramasamy, Ravichandran/0000-0002-3666-3346				ALVAREZ A, 1993, J INHERIT METAB DIS, V16, P67, DOI 10.1007/BF00711317; Amano S, 2002, BIOCHEM BIOPH RES CO, V299, P183, DOI 10.1016/S0006-291X(02)02584-6; Banfield MJ, 2001, J MOL BIOL, V306, P239, DOI 10.1006/jmbi.2000.4381; BERGMEYER HU, 1995, CARBOHYDRATES, P570; BLAKLEY RL, 1951, BIOCHEM J, V49, P257, DOI 10.1042/bj0490257; Broderick TL, 1995, CARDIOVASC RES, V30, P815, DOI 10.1016/S0008-6363(95)00111-5; BRODERICK TL, 1992, J BIOL CHEM, V267, P3758; BRODERICK TL, 1993, CIRCULATION, V87, P972, DOI 10.1161/01.CIR.87.3.972; CHIDA K, 1975, ACTA HISTOCHEM CYTOC, V8, P234, DOI 10.1267/ahc.8.234; Chu-Moyer MY, 2002, J MED CHEM, V45, P511, DOI 10.1021/jm010440g; COHEN RB, 1961, LAB INVEST, V10, P459; ELKUND H, 1985, BIOCHEMISTRY-US, V24, P8005; HOLLMANN S, 1957, J BIOL CHEM, V225, P87; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; Johansson K, 2001, CHEM-BIOL INTERACT, V130, P351, DOI 10.1016/S0009-2797(00)00260-X; JOHANSSON K, 2001, CHEM-BIOL INTERACT, P130; KARLSSON C, 1993, EUR J BIOCHEM, V216, P103, DOI 10.1111/j.1432-1033.1993.tb18121.x; Lindstad RI, 1998, BIOCHEM J, V330, P479; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; MARET W, 1991, ADV EXP MED BIOL, V284, P327; MCCORKINDALE J, 1954, BIOCHEM J, V57, P518, DOI 10.1042/bj0570518; Oates PJ, 1997, NEUROSCI RES COMMUN, V21, P33; Park JW, 1998, INT J CARDIOL, V65, P139, DOI 10.1016/S0167-5273(98)00117-X; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH290, DOI 10.1152/ajpheart.2001.281.1.H290; Ramasamy R, 2001, CARDIOVASC RES, V51, P275, DOI 10.1016/S0008-6363(01)00301-7; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; Ramasamy R, 1999, CARDIOVASC RES, V42, P130, DOI 10.1016/S0008-6363(98)00303-4; Ramasamy R, 1998, AM J PHYSIOL-HEART C, V275, pH195, DOI 10.1152/ajpheart.1998.275.1.H195; Siegel TW, 2000, ANAL BIOCHEM, V280, P329, DOI 10.1006/abio.2000.4531; SMITH MG, 1962, BIOCHEM J, V83, P135, DOI 10.1042/bj0830135; Stanley WC, 1997, CARDIOVASC RES, V33, P243, DOI 10.1016/S0008-6363(96)00245-3; Tracey WR, 2000, AM J PHYSIOL-HEART C, V279, pH1447, DOI 10.1152/ajpheart.2000.279.4.H1447; TRUBLOOD NA, 2000, AM J PHYSIOL, V279, pH764; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; WALSALL EP, 1978, COMP BIOCHEM PHYS B, V59, P213; WILLIAMSON JR, 1993, DIABETES, V42, P801, DOI 10.2337/diabetes.42.6.801	37	38	39	4	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2331	+		10.1096/fj.03-0128fje	http://dx.doi.org/10.1096/fj.03-0128fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525943				2022-12-28	WOS:000186343300014
J	Kumar, A; Lnu, S; Malya, R; Barron, D; Moore, J; Corry, DB; Boriek, AM				Kumar, A; Lnu, S; Malya, R; Barron, D; Moore, J; Corry, DB; Boriek, AM			Mechanical stretch activates nuclear factor-kappaB, activator protein-1, and mitogen-activated protein kinases in lung parenchyma: implications in asthma	FASEB JOURNAL			English	Article						mechanotransduction; lung mechanics; nuclear factor-kappaB; activator protein-1; free radicals; stretch-activated channels; asthma; MAP kinases; cyclooxygenase-2	UNIAXIAL CYCLIC STRETCH; TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; SMOOTH-MUSCLE; B ACTIVATION; TISSUE RESISTANCE; OXIDATIVE STRESS; REDOX REGULATION	We investigated the effects of mechanical stretch and induced stimulation of lung parenchyma on the activation of proinflammatory transcription factors in normal mice and in a mouse model of asthma. Mechanical stretching of lung parenchyma led to increased activation of NF-kappaB and AP-1 transcription factors. Incubation of lung parenchyma with methacholine increased the activation of NF-kappaB, which was further augmented by stretch. Activation of NF-kappaB in response to mechanical stretch was associated with the phosphorylation and degradation of IkappaBalpha and the activation of IkappaB kinase. Stretch-induced activation of NF-kappaB involves activation of stretch-activated (SA) channels and the production of free radicals. Mechanical stretch and/or treatment with methacholine resulted in an increased activation of ERK1/2 and p38 MAP kinase, and the inhibition of the activity of these kinases partially blocked the stretch-induced NF-kappaB and AP-1 activation. A greater level of NF-kappaB and ERK1/2 activity was observed in the asthmatic mice, which was further increased by mechanical stretching. The level of cyclooxygenase-2, an NF-kappaB-regulated enzyme, was also higher in lung parenchyma from asthmatic mice than in normal mice. Our data suggest that mechanical stretching of lung parenchyma activates NF-kappaB and AP-1, at least in part, through the activation of MAP kinase signaling pathways.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, 1 Baylor Plaza, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0002-2444-9529; Kumar, Ashok/0000-0001-8571-2848	PHS HHS [63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; Aggarwal BB, 2003, ANTICANCER RES, V23, P363; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; BARNES PJ, 1995, NEW ENGL J MED, V332, P868, DOI 10.1056/NEJM199503303321307; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bennett A, 2000, THORAX, V55, pS54, DOI 10.1136/thorax.55.suppl_2.S54; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Bureau F, 2000, J IMMUNOL, V165, P5822, DOI 10.4049/jimmunol.165.10.5822; Bureau F, 2000, AM J RESP CRIT CARE, V161, P1314, DOI 10.1164/ajrccm.161.4.9907010; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405, DOI 10.1164/ajrccm/147.2.405; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaqour B, 1999, J MOL CELL CARDIOL, V31, P1345, DOI 10.1006/jmcc.1999.0967; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Correa-Meyer E, 2002, AM J PHYSIOL-LUNG C, V282, pL883, DOI 10.1152/ajplung.00203.2001; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; DAVIES PF, 1993, CIRC RES, V72, P239, DOI 10.1161/01.RES.72.2.239; Donovan CE, 1999, J IMMUNOL, V163, P6827; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752, DOI 10.1164/ajrccm.156.6.9611016; FREDBERG JJ, 1993, J APPL PHYSIOL, V74, P1387, DOI 10.1152/jappl.1993.74.3.1387; GLOGAUER M, 1995, AM J PHYSIOL-CELL PH, V269, pC1093, DOI 10.1152/ajpcell.1995.269.5.C1093; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585, DOI 10.1164/ajrccm.158.5.9706116; Henderson WR, 2002, J IMMUNOL, V169, P5294, DOI 10.4049/jimmunol.169.9.5294; INGENITO EP, 1993, J APPL PHYSIOL, V75, P2541, DOI 10.1152/jappl.1993.75.6.2541; INGRAM RH, 1990, LUNG, V168, P237, DOI 10.1007/BF02719700; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; Kaltschmidt B, 1999, ANTIOXID REDOX SIGN, V1, P129, DOI 10.1089/ars.1999.1.2-129; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2001, BIOFACTORS, V15, P87, DOI 10.1002/biof.5520150207; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kato T, 1998, BIOCHEM BIOPH RES CO, V244, P615, DOI 10.1006/bbrc.1998.8335; Kheradmand F, 2002, J IMMUNOL, V169, P5904, DOI 10.4049/jimmunol.169.10.5904; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; Kumar A, 1998, BIOCHEM PHARMACOL, V55, P775, DOI 10.1016/S0006-2952(97)00557-1; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, ONCOGENE, V17, P913, DOI 10.1038/sj.onc.1201998; Liu MY, 2000, J APPL PHYSIOL, V89, P2078, DOI 10.1152/jappl.2000.89.5.2078; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; Muller JM, 1997, METHODS, V11, P301, DOI 10.1006/meth.1996.0424; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; Nelson PJ, 1996, J IMMUNOL, V157, P1139; Oldenhof AD, 2002, AM J PHYSIOL-CELL PH, V283, pC1530, DOI 10.1152/ajpcell.00607.2001; Parente L, 2003, BIOCHEM PHARMACOL, V65, P153, DOI 10.1016/S0006-2952(02)01422-3; Scichilone N, 2001, INT ARCH ALLERGY IMM, V124, P262, DOI 10.1159/000053728; Senftleben U, 2002, CRIT CARE MED, V30, pS18, DOI 10.1097/00003246-200201001-00003; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Shukla A, 2000, AM J RESP CELL MOL, V23, P182, DOI 10.1165/ajrcmb.23.2.4035; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Tamura M, 2002, J BIOL CHEM, V277, P26208, DOI 10.1074/jbc.M201347200; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447, DOI 10.1164/ajrccm.157.2.9611043; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584, DOI 10.1164/ajrccm/141.3.584; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; WIDMER U, 1993, J IMMUNOL, V150, P4996; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251, DOI 10.1164/ajrccm/145.6.1251; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yamazaki T, 1998, CIRC RES, V82, P430, DOI 10.1161/01.RES.82.4.430; YANAI M, 1992, J APPL PHYSIOL, V72, P1016, DOI 10.1152/jappl.1992.72.3.1016; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	69	76	82	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1800	1811		10.1096/fj.02-1148com	http://dx.doi.org/10.1096/fj.02-1148com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519659				2022-12-28	WOS:000186343300034
J	Reinecke, K; Lucius, R; Reinecke, A; Rickert, U; Herdegen, T; Unger, T				Reinecke, K; Lucius, R; Reinecke, A; Rickert, U; Herdegen, T; Unger, T			Angiotensin II accelerates functional recovery in the rat sciatic nerve in vivo: role of the AT(2) receptor and the transcription factor NF-kappa B	FASEB JOURNAL			English	Article						axonal regeneration; angiotensin receptors; PD 123319; losartan	MICROTUBULE-ASSOCIATED PROTEINS; DORSAL-ROOT GANGLIA; C-JUN; AXONAL REGENERATION; NEURONAL DEATH; GROWTH-FACTOR; CELL-DEATH; EXPRESSION; INJURY; AT(1)	The AT(2) receptor regulates several functions of nerve cells, e.g., ionic fluxes, cell differentiation, and axonal regeneration, but also modulates programmed cell death. We tested the hypothesis that angiotensin II (ANG II) via its AT(2) receptor not only promotes regeneration but also functional recovery after sciatic nerve crush in adult rats. ANG II (10(-7), 10(-9), 10(-11) M) applied locally via osmotic minipumps promoted functional recovery with maximal effects after the lowest concentration. The toe spread distance as a parameter for re-innervation after 20 days was significantly (P<0.01) greater (10.2 +/- 10.27 mm) compared with the control group (8.73 +/- 0.16 mm). The response to local electrical stimulation (return of sensorimotor function) was reduced to 14.6 days vs. 17.9 days in the control group (P<0.01). The AT(2) receptor antagonist PD 123319 administered alone or in combination with ANG II completely prevented the ANG II-induced recovery, whereas the AT(1) receptor antagonist losartan had no effect. Furthermore, ANG II induces, via the AT(2) receptor, activation of the transcription factor NF-kappaB in Schwann cells. Histological criteria, morphometric analyses, and electron microscopy confirmed the functional data. These results are the first to present direct evidence for an involvement of the AT(2) receptor and NF-kappaB in peripheral nerve regeneration.	Humboldt Univ, Charite Hosp, Inst Pharmacol & Toxicol, D-10117 Berlin, Germany; Univ Kiel, Inst Pharmacol, D-24105 Kiel, Germany; Univ Kiel, Inst Anat, D-24098 Kiel, Germany; German Inst High Blood Pressure Res, Heidelberg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Kiel; University of Kiel	Unger, T (corresponding author), Humboldt Univ, Charite Hosp, Inst Pharmacol & Toxicol, Dorotheenstr 94, D-10117 Berlin, Germany.	thomas.unger@charite.de	herdegen, thomas/E-5135-2010; Lucius, Ralph/B-1614-2010					Averill DB, 2000, BRAIN RES BULL, V51, P119, DOI 10.1016/S0361-9230(99)00237-3; BAIN JR, 1989, PLAST RECONSTR SURG, V83, P129, DOI 10.1097/00006534-198901000-00024; BLEUEL A, 1995, J NEUROSCI, V15, P750; Book AA, 1996, EXP NEUROL, V138, P214, DOI 10.1006/exnr.1996.0060; BUISSON B, 1995, J BIOL CHEM, V270, P1670, DOI 10.1074/jbc.270.4.1670; CHEN YS, 1989, EXP NEUROL, V103, P52, DOI 10.1016/0014-4886(89)90184-2; CULMAN J, 1995, CLIN EXP HYPERTENS, V17, P281, DOI 10.3109/10641969509087071; de Gasparo M, 2000, PHARMACOL REV, V52, P415; DELLON AL, 1989, ANN PLAS SURG, V23, P197, DOI 10.1097/00000637-198909000-00002; DEMEDINACELI L, 1982, EXP NEUROL, V77, P634, DOI 10.1016/0014-4886(82)90234-5; Dol F, 2001, J CARDIOVASC PHARM, V38, P395, DOI 10.1097/00005344-200109000-00008; DRAGUNOW M, 1993, MOL BRAIN RES, V18, P347, DOI 10.1016/0169-328X(93)90101-T; ESTABLEPUIG JF, 1965, J NEUROPATH EXP NEUR, V24, P531, DOI 10.1097/00005072-196507000-00012; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Gallinat S, 2000, AM J PHYSIOL-ENDOC M, V278, pE357, DOI 10.1152/ajpendo.2000.278.3.E357; Gallinat S, 1997, NEUROSCI LETT, V227, P29, DOI 10.1016/S0304-3940(97)00291-7; Gallinat S, 1998, MOL BRAIN RES, V57, P111, DOI 10.1016/S0169-328X(98)00079-5; Grothe C, 2001, ANAT EMBRYOL, V204, P171, DOI 10.1007/s004290100205; HARE GMT, 1992, PLAST RECONSTR SURG, V89, P251, DOI 10.1097/00006534-199202000-00009; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 1998, J NEUROSCI, V18, P5124, DOI 10.1523/JNEUROSCI.18-14-05124.1998; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Kenney AM, 1998, J NEUROSCI, V18, P1318; Laflamme L, 1996, J BIOL CHEM, V271, P22729, DOI 10.1074/jbc.271.37.22729; LEAH JD, 1993, NEUROSCIENCE, V57, P53, DOI 10.1016/0306-4522(93)90111-R; Lucius R, 1998, J EXP MED, V188, P661, DOI 10.1084/jem.188.4.661; Lucius R, 1999, CELL MOL LIFE SCI, V56, P1008, DOI 10.1007/s000180050490; McKinley MJ, 1996, CLIN EXP PHARMACOL P, V23, pS99, DOI 10.1111/j.1440-1681.1996.tb02821.x; Meffert S, 1996, MOL CELL ENDOCRINOL, V122, P59, DOI 10.1016/0303-7207(96)03873-7; Nickols JC, 2003, NAT NEUROSCI, V6, P161, DOI 10.1038/nn995; OMER GE, 1981, SURG CLIN N AM, V61, P303; RICH KM, 1987, J NEUROCYTOL, V16, P261, DOI 10.1007/BF01795309; RICHARDSON PM, 1994, J NEUROL, V242, pS57, DOI 10.1007/BF00939244; Rosenstiel P, 2002, CNS DRUGS, V16, P145, DOI 10.2165/00023210-200216030-00001; Ruiz-Ortega M, 2000, CIRC RES, V86, P1266, DOI 10.1161/01.RES.86.12.1266; Stroth U, 1998, MOL BRAIN RES, V53, P187, DOI 10.1016/S0169-328X(97)00298-2; STROTH U, 1997, J HYPERTENS, V15, P64; SVENSSON M, 1992, J NEUROCYTOL, V21, P222, DOI 10.1007/BF01194980; TANAKA M, 1995, BIOCHEM BIOPH RES CO, V207, P593, DOI 10.1006/bbrc.1995.1229; TONGE DA, 1993, SEMIN NEUROSCI, V5, P385; Vaudano E, 2001, EUR J NEUROSCI, V13, P1, DOI 10.1046/j.1460-9568.2001.01356.x; von Bohlen und Halbach O, 2001, REGUL PEPTIDES, V99, P209, DOI 10.1016/S0167-0115(01)00258-0; WALKER JL, 1994, RESTOR NEUROL NEUROS, V6, P189, DOI 10.3233/RNN-1994-6303; Walther T, 2002, FASEB J, V16, P169, DOI 10.1096/fj.01-0601com; Wang MS, 1997, J PHARMACOL EXP THER, V282, P1084; WOODHAMS PL, 1989, NEUROSCIENCE, V28, P49, DOI 10.1016/0306-4522(89)90231-5; Yamauchi F, 1996, NEPHROLOGY, V2, P93, DOI 10.1111/j.1440-1797.1996.tb00071.x	47	104	107	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2094	+		10.1096/fj.02-1193fje	http://dx.doi.org/10.1096/fj.02-1193fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500552				2022-12-28	WOS:000185925100007
J	Lee, H; Kim, YO; Kim, H; Kim, SY; Noh, HS; Kang, SS; Cho, GJ; Choi, WS; Suk, K				Lee, H; Kim, YO; Kim, H; Kim, SY; Noh, HS; Kang, SS; Cho, GJ; Choi, WS; Suk, K			Flavonoid wogonin from medicinal herb is neuroprotective by inhibiting inflammatory activation of microglia	FASEB JOURNAL			English	Article						nitric oxide; Scutellaria baicalensis; inflammation; neurodegenerative diseases	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; SCUTELLARIA-BAICALENSIS-GEORGI; NITRIC-OXIDE PRODUCTION; REGULATORY FACTOR-I; PROSTAGLANDIN E-2; OXIDATIVE STRESS; INTERFERON-GAMMA; PLANT FLAVONOIDS; ALPHA SYNERGISM	Wogonin (5,7-dihydroxy-8-methoxyflavone), a flavonoid originated from the root of a medicinal herb Scutellaria baicalensis Georgi, has been previously shown to have anti-inflammatory activities in various cell types including macrophages. In this work, we have found that wogonin is a potent neuroprotector from natural source. Wogonin inhibited inflammatory activation of cultured brain microglia by diminishing lipopolysaccharide-induced tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta, and nitric oxide ( NO) production. Wogonin inhibited NO production by suppressing inducible NO synthase (iNOS) induction and NF-kappaB activation in microglia. Inhibition of inflammatory activation of microglia by wogonin led to the reduction in microglial cytotoxicity toward cocultured PC12 cells, supporting a neuroprotective role for wogonin in vitro. The neuroprotective effect of wogonin was further demonstrated in vivo using two experimental brain injury models; transient global ischemia by four-vessel occlusion and excitotoxic injury by systemic kainate injection. In both animal models, wogonin conferred neuroprotection by attenuating the death of hippocampal neurons, and the neuroprotective effect was associated with inhibition of the inflammatory activation of microglia. Hippocampal induction of inflammatory mediators such as iNOS and TNF-alpha was reduced by wogonin in the global ischemia model, and microglial activation was markedly down-regulated by wogonin in the kainate injection model as judged by microglia-specific isolectin B4 staining. Taken together, our results indicate that wogonin exerts its neuroprotective effect by inhibiting microglial activation, which is a critical component of pathogenic inflammatory responses in neurodegenerative diseases. The current study emphasizes the importance of medicinal herbs and their constituents as an invaluable source for the development of novel neuroprotective drugs.	Gyeongsang Natl Univ, Coll Med, Dept Anat & Neurobiol, Res Inst Nat Sci, Jinju 660751, Kyungnam, South Korea; Gyeongsang Natl Univ, Coll Med, Inst Hlth Sci, Jinju 660751, South Korea; Kyung Hee Univ, Grad Sch EW Med Sci, Dept Herbal Pharmacol, Seoul 130701, South Korea	Gyeongsang National University; Gyeongsang National University; Kyung Hee University	Suk, K (corresponding author), Gyeongsang Natl Univ, Coll Med, Dept Anat & Neurobiol, Res Inst Nat Sci, 92 Chilam Dong, Jinju 660751, Kyungnam, South Korea.	ksuk@nongae.gsnu.ac.kr						Aloisi F, 1999, J NEUROSCI RES, V56, P571; Aschner M, 1998, NEUROTOXICOLOGY, V19, P269; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; Chang YL, 2001, MOL PHARMACOL, V60, P507; Chen XY, 2002, J CHROMATOGR B, V775, P169, DOI 10.1016/S1570-0232(02)00288-X; Delhase M, 2000, NATURE, V406, P367, DOI 10.1038/35019154; Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761; Gao ZH, 1999, BBA-GEN SUBJECTS, V1472, P643, DOI 10.1016/S0304-4165(99)00152-X; GEHRMANN J, 1995, BRAIN RES REV, V20, P269, DOI 10.1016/0165-0173(94)00015-H; Gong XD, 1999, TRENDS PHARMACOL SCI, V20, P191, DOI 10.1016/S0165-6147(98)01276-0; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HAMADA H, 1993, ARCH BIOCHEM BIOPHYS, V306, P261, DOI 10.1006/abbi.1993.1509; KANDASWAMI C, 1994, ADV EXP MED BIOL, V366, P351; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim H, 2001, NEUROSCI LETT, V309, P67, DOI 10.1016/S0304-3940(01)02028-6; Kim HK, 1999, BIOCHEM PHARMACOL, V58, P759, DOI 10.1016/S0006-2952(99)00160-4; Kim YO, 2001, J ETHNOPHARMACOL, V77, P183, DOI 10.1016/S0378-8741(01)00283-5; KOH JY, 1987, J NEUROSCI METH, V20, P83, DOI 10.1016/0165-0270(87)90041-0; Lee J, 2001, J BIOL CHEM, V276, P32956, DOI 10.1074/jbc.M104700200; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lee P, 2001, BRAIN RES, V892, P380, DOI 10.1016/S0006-8993(00)03257-1; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; Li YK, 2001, J NEUROSCI RES, V66, P163, DOI 10.1002/jnr.1208; Liu HT, 1999, P NATL ACAD SCI USA, V96, P12096, DOI 10.1073/pnas.96.21.12096; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; Middleton E, 2000, PHARMACOL REV, V52, P673; MIDDLETON E, 1992, BIOCHEM PHARMACOL, V43, P1167, DOI 10.1016/0006-2952(92)90489-6; MIYAZAWA T, 1992, J CEREBR BLOOD F MET, V12, P817, DOI 10.1038/jcbfm.1992.113; Noh HS, 2003, EPILEPSY RES, V53, P119, DOI 10.1016/S0920-1211(02)00262-0; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Park BK, 2001, EUR J PHARMACOL, V425, P153, DOI 10.1016/S0014-2999(01)01187-6; PULSINELLI WA, 1979, STROKE, V10, P267, DOI 10.1161/01.STR.10.3.267; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shieh DE, 2000, ANTICANCER RES, V20, P2861; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; SUK K, 1993, IMMUNOLOGY, V80, P617; Suk K, 2002, LIFE SCI, V70, P2467, DOI 10.1016/S0024-3205(02)01534-5; Suk K, 2001, J BIOL CHEM, V276, P13153, DOI 10.1074/jbc.M007646200; Suk K, 2001, J IMMUNOL, V166, P4481, DOI 10.4049/jimmunol.166.7.4481; SUK KH, 1995, P NATL ACAD SCI USA, V92, P4269, DOI 10.1073/pnas.92.10.4269; Wakabayashi I, 1999, PHARMACOL TOXICOL, V84, P288, DOI 10.1111/j.1600-0773.1999.tb01496.x; Wakabayashi I, 2000, EUR J PHARMACOL, V406, P477, DOI 10.1016/S0014-2999(00)00695-6; WOOLLEY DE, 1962, AM J PHYSIOL, V202, P379, DOI 10.1152/ajplegacy.1962.202.2.379; Zhang YY, 1998, BIOMED CHROMATOGR, V12, P31, DOI 10.1002/(SICI)1099-0801(199801/02)12:1<31::AID-BMC716>3.3.CO;2-J	47	234	245	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1943	+		10.1096/fj.03-0057fje	http://dx.doi.org/10.1096/fj.03-0057fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897065				2022-12-28	WOS:000185345100023
J	Bajari, TM; Strasser, V; Nimpf, J; Schneider, WJ				Bajari, TM; Strasser, V; Nimpf, J; Schneider, WJ			A model for modulation of leptin activity by association with clusterin	FASEB JOURNAL			English	Article						apolipoprotein; LDL receptor; obesity; signaling; uptake	DENSITY-LIPOPROTEIN RECEPTOR; APOLIPOPROTEIN-J/CLUSTERIN; BINDING DOMAIN; HUMAN BLOOD; GENE; EXPRESSION; PROTEIN; COMPLEMENT; PLASMA; SP-40,40	Transport, biological actions, and clearance of leptin are subject to modulation by plasma components responsible for the formation of the so-called "bound" fraction of serum leptin. Candidates for modulators have been identified previously, but mechanisms for their action, and thus their physiological roles, have remained unclear. Here we have obtained evidence for a role of serum-borne clusterin in leptin biology and have delineated a possible mechanism for its action. We demonstrate complex formation between clusterin and leptin by several approaches and show that the binary complex retains the ability to transduce the leptin signal via binding to the leptin receptor and activation of the Janus kinase/signal transducer and activator of transcription pathway. The interaction of leptin with clusterin does not require additional serum components. Furthermore, and importantly for modulation of the bioactivity of leptin, uptake of leptin present in the complex can be mediated by members of the low density lipoprotein (LDL) receptor family, i.e., apolipoprotein receptor type-2 and the very LDL receptor, which here are shown to efficiently endocytose both free and leptin-associated clusterin. Thus, bioavailability of leptin at a given tissue site may be determined by the levels of clusterin and/or by the relative distribution of certain relatives of the LDL receptor vis-a-vis active leptin receptors.	Inst Med Biochem, Dept Mol Genet, Bioctr, A-1030 Vienna, Austria; Univ Vienna, A-1030 Vienna, Austria	University of Vienna	Schneider, WJ (corresponding author), Inst Med Biochem, Dept Mol Genet, Bioctr, Dr Bohr Gasse 9-2, A-1030 Vienna, Austria.	wjs@mol.univie.ac.at		Nimpf, Johannes/0000-0002-9273-3492				Bajari TM, 1998, BIOL CHEM, V379, P1053, DOI 10.1515/bchm.1998.379.8-9.1053; Barth S, 2000, APPL ENVIRON MICROB, V66, P1572, DOI 10.1128/AEM.66.4.1572-1579.2000; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; Birkenmeier G, 1998, EUR J ENDOCRINOL, V139, P224, DOI 10.1530/eje.0.1390224; Brabant G, 2000, DIABETOLOGIA, V43, P438, DOI 10.1007/s001250051326; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Chapman IM, 1997, CLIN ENDOCRINOL, V46, P175, DOI 10.1046/j.1365-2265.1997.1200936.x; CHOIMIURA NH, 1992, ACTA NEUROPATHOL, V83, P260, DOI 10.1007/BF00296787; CHOIMIURA NH, 1993, CLIN EXP IMMUNOL, V93, P242; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cohen P, 2001, J CLIN INVEST, V108, P1113, DOI 10.1172/JCI200113914; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Diamond FB, 1997, BIOCHEM BIOPH RES CO, V233, P818, DOI 10.1006/bbrc.1997.6538; Faggioni R, 1998, AM J PHYSIOL-REG I, V274, pR204, DOI 10.1152/ajpregu.1998.274.1.R204; Flier JS, 1998, J CLIN ENDOCR METAB, V83, P1407, DOI 10.1210/jc.83.5.1407; Forte TM, 1999, J LIPID RES, V40, P1276; FREDERICH RC, 1995, NAT MED, V1, P1311, DOI 10.1038/nm1295-1311; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Hatters DM, 2002, EUR J BIOCHEM, V269, P2789, DOI 10.1046/j.1432-1033.2002.02957.x; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; Holub M, 1999, INT J OBESITY, V23, P60, DOI 10.1038/sj.ijo.0800759; Houseknecht KL, 1996, DIABETES, V45, P1638, DOI 10.2337/diabetes.45.11.1638; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Hynes GR, 2001, CURR OPIN LIPIDOL, V12, P321, DOI 10.1097/00041433-200106000-00012; JAMES RW, 1991, ARTERIOSCLER THROMB, V11, P645, DOI 10.1161/01.ATV.11.3.645; JENNE DE, 1991, J BIOL CHEM, V266, P11030; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; KIPRIYANOV SM, 1994, MOL IMMUNOL, V31, P1047, DOI 10.1016/0161-5890(94)90100-7; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; Klimaschewski L, 2001, CELL TISSUE RES, V306, P209, DOI 10.1007/s004410100431; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P13070, DOI 10.1074/jbc.270.22.13070; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Mahon MG, 1999, J BIOL CHEM, V274, P4036, DOI 10.1074/jbc.274.7.4036; Maione D, 1998, EMBO J, V17, P5588, DOI 10.1093/emboj/17.19.5588; Ronacher B, 2000, VIROLOGY, V278, P541, DOI 10.1006/viro.2000.0636; SAKAI J, 1994, J BIOL CHEM, V269, P2173; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Silkensen JR, 1998, J LAB CLIN MED, V131, P28, DOI 10.1016/S0022-2143(98)90074-9; SINHA MK, 1996, J CLIN INVEST, V98, P127; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Swertfeger DK, 1996, AM J PATHOL, V148, P1971; TARGAGLIA LA, 1995, CELL, V83, P1263; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Waelput W, 2000, BIOCHEM J, V348, P55, DOI 10.1042/0264-6021:3480055; Wang YP, 1997, J BIOL CHEM, V272, P16216, DOI 10.1074/jbc.272.26.16216; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	56	39	43	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1505	+		10.1096/fj.02-1106fje	http://dx.doi.org/10.1096/fj.02-1106fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824284				2022-12-28	WOS:000183818000038
J	Franklin, CC; Rosenfeld-Franklin, ME; White, C; Kavanagh, TJ; Fausto, N				Franklin, CC; Rosenfeld-Franklin, ME; White, C; Kavanagh, TJ; Fausto, N			TGF beta 1-induced suppression of glutathione antioxidant defenses in hepatocytes: caspase-dependent posttranslational and caspase-independent transcriptional regulatory mechanisms	FASEB JOURNAL			English	Article						glutamate cysteine ligase; apoptosis; Bcl-X-L	GROWTH-FACTOR-BETA; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; CYTOCHROME-C RELEASE; FACTOR-BETA(1) INDUCES APOPTOSIS; TRANSFORMING GROWTH-FACTOR-BETA-1; CELL-DEATH; CATALYTIC SUBUNIT; FETAL HEPATOCYTES; ACTIVATION; EXPRESSION	TGFbeta1-induced hepatocyte apoptosis involves the production of reactive oxygen species. An effective cellular defense mechanism against oxidative stress is the tripeptide glutathione (GSH), and the rate-limiting step in GSH biosynthesis is catalyzed by the heterodimeric holoenzyme glutamate cysteine ligase (GCL). Here, we demonstrate the TGFbeta1-induced apoptosis in the TAMH murine hepatocyte cell line is accompanied by both the cleavage and loss of the catalytic subunit of GCL (GCLC) and the down-regulation of GCLC gene expression resulting in a reduction in GCL activity and depletion of intracellular GSH. TGFbeta1-induced apoptosis is also accompanied by a reduction in Bcl-X-L, an effect that may facilitate TGFbeta1-induced apoptosis as Bcl-X-L overexpression inhibits TGFbeta1-induced caspase activation and cell death. Interestingly, Bcl-X-L overexpression prevents TGFbeta1-induced cleavage of GCLC protein but not down-regulation of GCLC mRNA. Furthermore, TGFbeta1-induced down-regulation of GCLC mRNA is prevented by inhibition of histone deacetylase activity, suggesting that this is an active repression of GCLF gene transcription. These findings suggest that the suppression of GSH antioxidant defenses associated with the caspase-dependent cleavage of GCLC protein, caspase-independent suppression of GCLC gene expression, and depletion of intracellular GSH may play a role enhancing TGFbeta1-induced oxidative stress and potentiating apoptotic cell death.	Univ Washington, Dept Pathol, Seattle, WA 98195 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Franklin, CC (corresponding author), Univ Washington, Dept Pathol, Box 357705,1959 NE Pacific St,HSB K-088, Seattle, WA 98195 USA.	cfrankli@u.washington.edu			NATIONAL CANCER INSTITUTE [R29CA075316, R01CA090473, R37CA023226, R01CA023226, R01CA074131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES007033, P42ES004696] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001751] Funding Source: NIH RePORTER; NCI NIH HHS [CA75316, CA23226, CA90473, CA74131] Funding Source: Medline; NIA NIH HHS [AG01751] Funding Source: Medline; NIDDK NIH HHS [F32-DK09920] Funding Source: Medline; NIEHS NIH HHS [ES07033, ES04696] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Arsalane K, 1997, AM J RESP CELL MOL, V17, P599, DOI 10.1165/ajrcmb.17.5.2833; Arsura M, 1997, CELL GROWTH DIFFER, V8, P1049; Bellas RE, 1997, AM J PATHOL, V151, P891; BRAUN L, 1988, P NATL ACAD SCI USA, V85, P1539, DOI 10.1073/pnas.85.5.1539; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Christensen JG, 1998, CELL GROWTH DIFFER, V9, P815; Cook T, 1999, J BIOL CHEM, V274, P29500, DOI 10.1074/jbc.274.41.29500; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; Demasi M, 2001, ARCH BIOCHEM BIOPHYS, V389, P254, DOI 10.1006/abbi.2001.2332; Fabregat I, 2000, HEPATOLOGY, V32, P528, DOI 10.1053/jhep.2000.9774; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; Franklin CC, 2002, AM J PATHOL, V160, P1887, DOI 10.1016/S0002-9440(10)61135-2; Franklin CC, 1998, P NATL ACAD SCI USA, V95, P3014, DOI 10.1073/pnas.95.6.3014; Freathy C, 2000, HEPATOLOGY, V32, P750, DOI 10.1053/jhep.2000.18329; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Gross A, 1999, J BIOL CHEM, V274, P1156, DOI 10.1074/jbc.274.2.1156; Herrera B, 2001, FASEB J, V15, P741, DOI 10.1096/fj.00-0267com; InayatHussain SH, 1997, HEPATOLOGY, V25, P1516, DOI 10.1002/hep.510250634; Islam KN, 1997, FREE RADICAL BIO MED, V22, P1007, DOI 10.1016/S0891-5849(96)00493-5; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Lo RS, 1999, NAT CELL BIOL, V1, P472, DOI 10.1038/70258; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Lu SC, 1998, SEMIN LIVER DIS, V18, P331, DOI 10.1055/s-2007-1007168; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Medema JP, 1998, J BIOL CHEM, V273, P3388, DOI 10.1074/jbc.273.6.3388; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; OBERHAMMER F, 1992, TOXICOL LETT, V64-5, P701, DOI 10.1016/0378-4274(92)90250-N; Patel T, 1998, SEMIN LIVER DIS, V18, P105, DOI 10.1055/s-2007-1007147; Perlman R, 2001, NAT CELL BIOL, V3, P708, DOI 10.1038/35087019; Pierce RH, 2000, AM J PATHOL, V157, P221, DOI 10.1016/S0002-9440(10)64533-6; Ribeiro A, 1999, HEPATOLOGY, V30, P1490, DOI 10.1002/hep.510300620; RUSSELL WE, 1988, P NATL ACAD SCI USA, V85, P5126, DOI 10.1073/pnas.85.14.5126; Sanchez A, 1996, J BIOL CHEM, V271, P7416, DOI 10.1074/jbc.271.13.7416; SANCHEZ A, 1995, J CELL PHYSIOL, V165, P398, DOI 10.1002/jcp.1041650221; Sanchez A, 1997, HEPATOLOGY, V26, P935, DOI 10.1002/hep.510260420; SANDERSON N, 1995, P NATL ACAD SCI USA, V92, P2572, DOI 10.1073/pnas.92.7.2572; Schrum LW, 2001, AM J PHYSIOL-GASTR L, V280, pG139, DOI 10.1152/ajpgi.2001.280.1.G139; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Shima Y, 1999, HEPATOLOGY, V30, P1215, DOI 10.1002/hep.510300503; Siitonen T, 1999, ANN ONCOL, V10, P1361, DOI 10.1023/A:1008382912096; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Thompson SA, 1999, TOXICOL LETT, V110, P1, DOI 10.1016/S0378-4274(99)00133-2; Thorgeirsson SS, 1998, SEMIN LIVER DIS, V18, P115, DOI 10.1055/s-2007-1007148; Tzung SP, 2001, NAT CELL BIOL, V3, P183, DOI 10.1038/35055095; Urano T, 1999, J BIOL CHEM, V274, P12197, DOI 10.1074/jbc.274.18.12197; WU JC, 1994, CANCER RES, V54, P5964; WU JC, 1994, P NATL ACAD SCI USA, V91, P674, DOI 10.1073/pnas.91.2.674; Zhang JS, 2001, MOL CELL BIOL, V21, P5041, DOI 10.1128/MCB.21.15.5041-5049.2001; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974	56	79	79	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1535	+		10.1096/fj.02-0867fje	http://dx.doi.org/10.1096/fj.02-0867fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824300				2022-12-28	WOS:000183818000021
J	Brezniceanu, ML; Volp, K; Bosse, S; Solbach, C; Lichter, P; Joos, S; Zornig, M				Brezniceanu, ML; Volp, K; Bosse, S; Solbach, C; Lichter, P; Joos, S; Zornig, M			HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma	FASEB JOURNAL			English	Article						high-mobility group box protein; apoptosis; Bak	DNA-BINDING DOMAIN; CYTOCHROME-C; CASPASE ACTIVATION; CHROMATIN PROTEIN; APOPTOTIC CHANGES; ENHANCES BINDING; BAX; GENE; MITOCHONDRIA; RELEASE	Apoptosis is a fundamental biological process used to eliminate unwanted cells in a multicellular organism. An increasing number of regulatory proteins have been identified that either promote or inhibit apoptosis. For tumors to arise, apoptosis must be blocked in the transformed cells, for example by mutational overexpression of anti-apoptotic proteins, which represent attractive target proteins for molecular therapy strategies. In a functional yeast survival screen designed to select new anti-apoptotic mammalian genes, we have identified the chromosomal high-mobility group box-1 protein (HMGB1) as an inhibitor of yeast cell death induced by the pro-apoptotic Bcl-2 family member Bak. The C-terminal 33 amino acids of HMGB1 are dispensable for this inhibitory function. HMGB1 is also able to protect mammalian cells against different death stimuli including ultraviolet radiation, CD95-, TRAIL-, Casp-8-, and Bax-induced apoptosis. We found high HMGB1 protein levels in human primary breast carcinoma. Hmgb1 RNA levels are changing during different stages of mouse mammary gland development and are particularly low during lactation and involution. These data suggest that HMGB1 may participate in the regulation of mammary gland apoptosis and that its high expression level promotes tumor growth because of its anti-apoptotic properties.	Chemotherapeut Forschungsinst, D-60596 Frankfurt, Germany; Goethe Univ Frankfurt, Klin Gynakol & Geburtshilfe, D-60590 Frankfurt, Germany; Deutsch Krebsforschungszentrum, D-69120 Heidelberg, Germany	Goethe University Frankfurt; Helmholtz Association; German Cancer Research Center (DKFZ)	Zornig, M (corresponding author), Chemotherapeut Forschungsinst, Georg Speyer Haus,Paul Ehrlich St 42-44, D-60596 Frankfurt, Germany.	zoernig@em.uni-frankfurt.de	li, tao/B-2402-2008					Ameisen JC, 2002, CELL DEATH DIFFER, V9, P367, DOI 10.1038/sj.cdd.4400950; Bianchi ME, 2000, EMBO REP, V1, P109, DOI 10.1093/embo-reports/kvd030; Bianchi ME, 1998, AM J HUM GENET, V63, P1573, DOI 10.1086/302170; Boonyaratanakornkit V, 1998, MOL CELL BIOL, V18, P4471, DOI 10.1128/MCB.18.8.4471; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; Chiappetta G, 1996, ONCOGENE, V13, P2439; Conradt B, 2002, NAT CELL BIOL, V4, pE139, DOI 10.1038/ncb0602-e139; Damiano JS, 2002, CURR CANCER DRUG TAR, V2, P37, DOI 10.2174/1568009023334033; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Fedele M, 2002, ONCOGENE, V21, P3190, DOI 10.1038/sj.onc.1205428; Flohr AM, 2001, ANTICANCER RES, V21, P3881; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Greenhalf W, 1999, YEAST, V15, P1307, DOI 10.1002/(SICI)1097-0061(19990930)15:13<1307::AID-YEA455>3.3.CO;2-V; Gross A, 2000, MOL CELL BIOL, V20, P3125, DOI 10.1128/MCB.20.9.3125-3136.2000; GROSSCHEDL R, 1994, TRENDS GENET, V10, P94, DOI 10.1016/0168-9525(94)90232-1; Gutierrez-Puente Y, 2002, SEMIN ONCOL, V29, P71, DOI 10.1053/sonc.2002.34058; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hawkins CJ, 2001, APOPTOSIS, V6, P331, DOI 10.1023/A:1011329917895; Imamura T, 2001, J BIOL CHEM, V276, P7534, DOI 10.1074/jbc.M008143200; Ink B, 1997, MOL CELL BIOL, V17, P2468, DOI 10.1128/MCB.17.5.2468; Jamieson ER, 1999, CHEM REV, V99, P2467, DOI 10.1021/cr980421n; Jayaraman L, 1998, GENE DEV, V12, P462, DOI 10.1101/gad.12.4.462; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Kang JJ, 1999, J BIOL CHEM, V274, P3189, DOI 10.1074/jbc.274.5.3189; Kawahara N, 1996, CANCER RES, V56, P5330; Kwon J, 1998, MOL CELL, V2, P829, DOI 10.1016/S1097-2765(00)80297-X; Ligr M, 1998, FEBS LETT, V438, P61, DOI 10.1016/S0014-5793(98)01227-7; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Madeo F, 1997, J CELL BIOL, V139, P729, DOI 10.1083/jcb.139.3.729; Manon S, 1997, FEBS LETT, V415, P29, DOI 10.1016/S0014-5793(97)01087-9; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; Mitsouras K, 2002, MOL CELL BIOL, V22, P4390, DOI 10.1128/MCB.22.12.4390-4401.2002; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muller S, 2001, EMBO J, V20, P4337, DOI 10.1093/emboj/20.16.4337; Nechushtan A, 2001, J CELL BIOL, V153, P1265, DOI 10.1083/jcb.153.6.1265; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Pasheva EA, 2002, INT J BIOCHEM CELL B, V34, P87, DOI 10.1016/S1357-2725(01)00096-6; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; Priault M, 1999, EUR J BIOCHEM, V260, P684, DOI 10.1046/j.1432-1327.1999.00198.x; READ CM, 1993, NUCLEIC ACIDS RES, V21, P3427, DOI 10.1093/nar/21.15.3427; Romine LE, 1998, MOL ENDOCRINOL, V12, P664, DOI 10.1210/me.12.5.664; Roucou X, 2000, FEBS LETT, V471, P235, DOI 10.1016/S0014-5793(00)01404-6; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Shaham S, 1998, CELL, V92, P425, DOI 10.1016/S0092-8674(00)80934-4; Shi YG, 2002, MOL CELL, V9, P459, DOI 10.1016/S1097-2765(02)00482-3; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Stros M, 2002, J BIOL CHEM, V277, P7157, DOI 10.1074/jbc.M110233200; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Thatte U, 1997, DRUGS, V54, P511, DOI 10.2165/00003495-199754040-00002; Thomas JO, 2001, TRENDS BIOCHEM SCI, V26, P167, DOI 10.1016/S0968-0004(01)01801-1; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Travers A, 2000, CURR OPIN STRUC BIOL, V10, P102, DOI 10.1016/S0959-440X(99)00056-1; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; WEIR HM, 1993, EMBO J, V12, P1311, DOI 10.1002/j.1460-2075.1993.tb05776.x; Xiang YY, 1997, INT J CANCER, V74, P1; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Yaffe MP, 1996, P NATL ACAD SCI USA, V93, P11664, DOI 10.1073/pnas.93.21.11664; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	64	174	207	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1295	+		10.1096/fj.02-0621fje	http://dx.doi.org/10.1096/fj.02-0621fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759333				2022-12-28	WOS:000183165000022
J	Skerrett, IM; Di, WL; Kasperek, EM; Kelsell, DP; Nicholson, BJ				Skerrett, IM; Di, WL; Kasperek, EM; Kelsell, DP; Nicholson, BJ			Aberrant gating, but a normal expression pattern, underlies the recessive phenotype of the deafness mutant Connexin26M34T	FASEB JOURNAL			English	Article						Connexin26; gap junction; channel gating	MUTATIONS; CONNEXIN-26	Mutations in the gene GJB2, encoding the gap junction protein Connexin26 (Cx26), are the most prevalent cause of inherited hearing loss, and Cx26M34T was one of the first mutations linked to deafness (Kelsell et al., 1997; Nature 387, 80-83). We report the first characterization of the gating properties of M34T, which had previously been reported to be nonfunctional. Although homotypic mutant channels did not produce detectable currents, heterotypic pairings with wtCx26 confirmed that M34T formed intercellular channels, although the gating properties were altered. Cx26M34T displayed an inverted response to transjunctional voltage (Vj), mediating currents that activate in a time- and Vj-dependent manner. These characteristics suggest that the channel population is only partially open at rest, consistent with previous reports that dye transfer in M34T-expressing cells is reduced or abolished ( e. g., Thonnissen et al., Human Genet. 111, 190-197). To investigate the controversial recessive/dominant behavior of this mutant, we coexpressed M34T with wtCx26 RNA at equimolar levels, mimicking the situation in heterozygotic individuals. Under these conditions, M34T did not significantly reduce Cx26/Cx26 coupling, or alter the electrophysiological properties of the wt channels, consistent with the recessive nature of the allele. Overexpression of the mutant did have some inhibitory effects on conductance, possibly explaining some of the previous reports in exogenous expression systems and some patients. Consistent with its electrophysiological behavior, we also show that M34T localizes to cell junctions in both transfected HeLa cells and patient-derived tissue.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA; Barts & London Queen Marys Sch Med & Dent, Ctr Cutaneous Res, London E1 2AT, England	University of Texas System; University of Texas Health San Antonio; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of London; Queen Mary University London	Nicholson, BJ (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	nicholsonb@uthscsa.edu	Kelsell, David P/F-8767-2011	Nicholson, Bruce/0000-0003-1649-7173; Kelsell, David/0000-0002-9910-7144				BARRIO LC, 1991, P NATL ACAD SCI USA, V88, P8410, DOI 10.1073/pnas.88.19.8410; Cohen-Salmon M, 2002, CURR BIOL, V12, P1106, DOI 10.1016/S0960-9822(02)00904-1; Cucci RA, 2000, GENET TEST, V4, P335, DOI 10.1089/109065700750065063; Di WL, 2001, J INVEST DERMATOL, V117, P958, DOI 10.1046/j.0022-202x.2001.01468.x; Griffith AJ, 2000, AM J HUM GENET, V67, P745, DOI 10.1086/303045; Houseman MJ, 2001, J MED GENET, V38, P20, DOI 10.1136/jmg.38.1.20; Kelsell DP, 1997, NATURE, V387, P80, DOI 10.1038/387080a0; Kelsell DP, 2001, AM J HUM GENET, V68, P559, DOI 10.1086/318803; Kikuchi Toshihiko, 2000, Medical Electron Microscopy, V33, P51, DOI 10.1007/s007950070001; Kudo T, 2003, HUM MOL GENET, V12, P995, DOI 10.1093/hmg/ddg116; Martin PEM, 1999, HUM MOL GENET, V8, P2369, DOI 10.1093/hmg/8.13.2369; NICHOLSON BJ, 1993, PROG CELL R, V3, P3; Oh S, 1997, NEURON, V19, P927, DOI 10.1016/S0896-6273(00)80973-3; Oshima A, 2003, J BIOL CHEM, V278, P1807, DOI 10.1074/jbc.M207713200; Scott DA, 1998, NATURE, V391, P32, DOI 10.1038/34079; Skerrett IM, 2001, CELL COMMUN ADHES, V8, P179, DOI 10.3109/15419060109080720; Skerrett IM, 2001, METH MOL B, V154, P225; Skerrett IM, 2000, CURR TOP MEMBR, V49, P249; Smith RJH, 2001, ARCH OTOLARYNGOL, V127, P941, DOI 10.1001/archotol.127.8.941; Thonnissen E, 2002, HUM GENET, V111, P190, DOI 10.1007/s00439-002-0750-2; White TW, 1998, NATURE, V394, P630, DOI 10.1038/29202	21	35	39	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					860	+		10.1096/fj.03-0763fje	http://dx.doi.org/10.1096/fj.03-0763fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033936				2022-12-28	WOS:000220522800004
J	Liu, XM; Reyna, SV; Ensenat, D; Peyton, KJ; Wang, H; Schafer, AI; Durante, W				Liu, XM; Reyna, SV; Ensenat, D; Peyton, KJ; Wang, H; Schafer, AI; Durante, W			Platelet-derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth	FASEB JOURNAL			English	Article						amino acid transport; apoptosis	AMINO-ACID TRANSPORTER; HEAVY-CHAIN; SYSTEM-L; FUNCTIONAL-CHARACTERIZATION; PROTEIN; CLONING; IDENTIFICATION; PERMEASE; TARGET	Platelet-derived growth factor (PDGF) contributes to vascular disease by stimulating the growth of vascular smooth muscle cells (SMCs). Since amino acids are required for cell growth, the present study examined the effect of PDGF on system L amino acid transport, which is the predominant cellular pathway for the uptake of essential amino acids. System L amino acid transport was monitored by measuring the uptake of L-leucine. Treatment of SMCs with PDGF stimulated L-leucine transport in a concentration- and time-dependent manner, and this was associated with a selective increase in LAT1 mRNA and protein. PDGF failed to induce the expression of the other system L transport proteins, LAT2 and the heavy chain of the 4172 cell surface antigen. The induction of LAT1 by PDGF was dependent on de novo RNA and protein synthesis and on mTOR activity. Serum, thrombin, and angiotensin II likewise stimulated L-leucine transport by inducing LAT1 expression. Inhibition of system L amino acid transport by the model substrate 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid blocked growth factor-mediated SMC proliferation and induced SMC apoptosis, whereas it had no effect on quiescent cells. These results demonstrate that growth factors stimulate system L amino acid transport by inducing LAT1 gene expression and that system L amino acid transport is essential for SMC proliferation and survival. The capacity of vascular mitogens to induce LAT1 expression may represent a basic mechanism by which these agents promote cell growth and provide a novel therapeutic target for treatment of vasculoproliferative disorders.	Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Durante, W (corresponding author), Michael E DeBakey VA Med Ctr, Bldg 109,Room 130,2002 Holcombe Blvd, Houston, TX 77030 USA.	wdurante@bcm.tmc.edu						BERK BC, 1986, SCIENCE, V232, P87, DOI 10.1126/science.3485309; Campbell WA, 2000, J BIOL CHEM, V275, P5347, DOI 10.1074/jbc.275.8.5347; Campbell WA, 2001, J BIOL CHEM, V276, P16877, DOI 10.1074/jbc.M008248200; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; DURANTE W, 1993, AM J PHYSIOL, V264, pH617, DOI 10.1152/ajpheart.1993.264.2.H617; Durante W, 1996, J BIOL CHEM, V271, P11838, DOI 10.1074/jbc.271.20.11838; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Liu XM, 2002, CARDIOVASC RES, V55, P396, DOI 10.1016/S0008-6363(02)00410-8; LOW BC, 1993, J CELL PHYSIOL, V156, P626, DOI 10.1002/jcp.1041560323; MAJESKY MW, 1990, J CELL BIOL, V111, P2149, DOI 10.1083/jcb.111.5.2149; Mastroberardino L, 1998, NATURE, V395, P288, DOI 10.1038/26246; Nakamura E, 1999, J BIOL CHEM, V274, P3009, DOI 10.1074/jbc.274.5.3009; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; Nii T, 2001, BIOCHEM J, V358, P693, DOI 10.1042/0264-6021:3580693; OKAMOTO Y, 2000, AM J PHYSIOL-CELL PH, V282, pC196; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; Prasad PD, 1999, BIOCHEM BIOPH RES CO, V255, P283, DOI 10.1006/bbrc.1999.0206; Rajan DP, 2000, BBA-BIOMEMBRANES, V1463, P6, DOI 10.1016/S0005-2736(99)00224-2; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rossier G, 1999, J BIOL CHEM, V274, P34948, DOI 10.1074/jbc.274.49.34948; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Tamai S, 2001, CANCER DETECT PREV, V25, P439; Wolf DA, 1996, CANCER RES, V56, P5012; Yao SYM, 1998, BIOCHEM J, V330, P745	28	62	62	1	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					768	+		10.1096/fj.03-0886fje	http://dx.doi.org/10.1096/fj.03-0886fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977877				2022-12-28	WOS:000220425000017
J	Stangl, V; Lorenz, M; Meiners, S; Ludwig, A; Bartsch, C; Moobed, M; Vietzke, A; Kinkel, HT; Baumann, G; Stangl, K				Stangl, V; Lorenz, M; Meiners, S; Ludwig, A; Bartsch, C; Moobed, M; Vietzke, A; Kinkel, HT; Baumann, G; Stangl, K			Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway	FASEB JOURNAL			English	Article						endothelium; nitric oxide synthase; inhibitors; vasodilation; proteasome	NITRIC-OXIDE SYNTHASE; CELLS; ATHEROSCLEROSIS; EXPRESSION; PHOSPHORYLATION; HYPERTENSION; GROWTH; NO	The ubiquitin-proteasome system is the major pathway for intracellular protein degradation in eukaryotic cells. Endothelial nitric oxide synthase (eNOS) is the key enzyme of vascular homeostasis involved in the pathophysiology of several cardiovascular diseases. The aim of our study was to investigate whether eNOS expression and activity are regulated by the proteasome. Bovine pulmonary artery endothelial cells (CPAE cells) were treated with the proteasome inhibitor MG132. MG132 (50-250 nmol/L) dose-dependently increased mRNA and protein levels of eNOS. Comparable results were obtained with other specific proteasome inhibitors, whereas the nonproteasomal calpain and cathepsin inhibitor ALLM had no effect. Efficacy of proteasome inhibition was evidenced by accumulation of poly-ubiquitinylated proteins and by measuring proteasomal activity in cell extracts. Cycloheximide prevented up-regulation of eNOS protein, indicating that post-translational stabilization of eNOS is not involved. eNOS activity was increased up to 2.8-fold (MG132 100 nmol/L, 48 h). Incubation of rat aortic rings with MG132 significantly enhanced endothelial-dependent vasorelaxation. Single MG132 treatment (100 nmol/L) induced long-term effects in CPAE cells, with increases of eNOS protein and activity for up to 10 days. Our results indicate that low-dose proteasome inhibition enhances eNOS expression and activity, and improves endothelial function.	Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, D-10117 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Stangl, V (corresponding author), Humboldt Univ, Charite, Med Klin Schwerpunkt Kardiol Angiol Pneumol, Campus Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	verena.stang1@charite.de	, Antje Ludwig/ABF-6556-2021; Meiners, S/M-9822-2014	Meiners, S/0000-0003-3678-7995; Lorenz, Mario/0000-0001-5267-4101; Ludwig, Antje/0000-0002-8369-7020				Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Dimmeler S, 2000, FEBS LETT, V477, P258, DOI 10.1016/S0014-5793(00)01657-4; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Dschietzig T, 2001, INTENS CARE MED, V27, P751, DOI 10.1007/s001340100882; HERSHKO A, 2002, NAT MED, V10, P1073; Kojda G, 1999, CARDIOVASC RES, V43, P562, DOI 10.1016/S0008-6363(99)00169-8; Kumeda SI, 1999, ANTICANCER RES, V19, P3961; Laufs U, 1998, CIRCULATION, V97, P1129, DOI 10.1161/01.CIR.97.12.1129; Li HG, 2002, NITRIC OXIDE-BIOL CH, V7, P132, DOI 10.1016/S1089-8603(02)00127-1; Oemar BS, 1998, CIRCULATION, V97, P2494, DOI 10.1161/01.CIR.97.25.2494; Ramet ME, 2003, J AM COLL CARDIOL, V41, P2288, DOI 10.1016/S0735-1097(03)00481-9; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Salhab WA, 2000, AM J PHYSIOL-HEART C, V278, pH2134, DOI 10.1152/ajpheart.2000.278.6.H2134; Searles CD, 1999, CIRC RES, V85, P588, DOI 10.1161/01.RES.85.7.588; TREASURE CB, 1990, CIRCULATION, V81, P772, DOI 10.1161/01.CIR.81.3.772; Wu KK, 2002, ANN NY ACAD SCI, V962, P122, DOI 10.1111/j.1749-6632.2002.tb04062.x; ZEIHER AM, 1993, J CLIN INVEST, V92, P652, DOI 10.1172/JCI116634; ZHANG R, 1995, J BIOL CHEM, V270, P15320, DOI 10.1074/jbc.270.25.15320; Ziegler T, 1998, HYPERTENSION, V32, P351, DOI 10.1161/01.HYP.32.2.351	20	99	101	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2004	18	2					272	279		10.1096/fj.03-0054com	http://dx.doi.org/10.1096/fj.03-0054com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769821				2022-12-28	WOS:000220425000007
J	Andersen, JN; Jansen, PG; Echwald, SM; Mortensen, OH; Fukada, T; Del Vecchio, R; Tonks, NK; Moller, NPH				Andersen, JN; Jansen, PG; Echwald, SM; Mortensen, OH; Fukada, T; Del Vecchio, R; Tonks, NK; Moller, NPH			A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes, and genetic disease linkage	FASEB JOURNAL			English	Review						genome analysis; protein classification; PTP exon structure; PTP gene family; processed pseudogenes; PTPs and cancer; alternative splicing	GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR GENE; MULTIPLE-SCLEROSIS; SIGNAL-TRANSDUCTION; NOONAN-SYNDROME; HUMAN BREAST; PHOSPHATIDYLINOSITOL PHOSPHATASE; CHROMOSOMAL LOCALIZATION; TRANSLATIONAL REGULATION; INSULIN SENSITIVITY	The protein tyrosine phosphatases (PTPs) are now recognized as critical regulators of signal transduction under normal and pathophysiological conditions. In this analysis we have explored the sequence of the human genome to define the composition of the PTP family. Using public and proprietary sequence databases, we discovered one novel human PTP gene and defined chromosomal loci and exon structure of the additional 37 genes encoding known PTP transcripts. Direct orthologs were present in the mouse genome for all 38 human PTP genes. In addition, we identified 12 PTP pseudogenes unique to humans that have probably contaminated previous bioinformatics analysis of this gene family. PCR amplification and transcript sequencing indicate that some PTP pseudogenes are expressed, but their function (if any) is unknown. Furthermore, we analyzed the enhanced diversity generated by alternative splicing and provide predicted amino acid sequences for four human PTPs that are currently defined by fragments only. Finally, we correlated each PTP locus with genetic disease markers and identified 4 PTPs that map to known susceptibility loci for type 2 diabetes and 19 PTPs that map to regions frequently deleted in human cancers. We have made our analysis available at http://ptp.cshl.edu or http://science.novonordisk.com/ptp and we hope this resource will facilitate the functional characterization of these key enzymes.	Cold Spring Harbor Lab, New York, NY USA; Novo Nordisk AS, Sci Comp, DK-2760 Malov, Denmark; Exiqon, DK-2950 Vedbaek, Denmark; Novo Nordisk AS, NPHM, Signal Transduct, DK-2880 Bagsvaerd, Denmark	Cold Spring Harbor Laboratory; Novo Nordisk; Novo Nordisk	Moller, NPH (corresponding author), Novo Nordisk AS, NPHM, Signal Transduct, Bldg 6A1-086, DK-2880 Bagsvaerd, Denmark.	tonks@csh1.edu; nphm@novonordisk.com	Mortensen, Ole Hartvig/AAA-8835-2019	Mortensen, Ole Hartvig/0000-0003-1118-6317	NATIONAL CANCER INSTITUTE [R37CA053840] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 1996, CELL, V85, P15; Andersen JN, 2001, MOL CELL BIOL, V21, P7117, DOI 10.1128/MCB.21.21.7117-7136.2001; [Anonymous], 1999, NAT GENET, V22, P1; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Ballerini C, 2002, NEUROSCI LETT, V328, P325, DOI 10.1016/S0304-3940(02)00565-7; Barcellos LF, 2001, NAT GENET, V29, P23, DOI 10.1038/ng722; Baust C, 2000, GENOMICS, V66, P98, DOI 10.1006/geno.2000.6175; Benatar T, 1996, J EXP MED, V183, P329, DOI 10.1084/jem.183.1.329; Besco Julie A., 2001, BMC Genomics, V2, P1, DOI 10.1186/1471-2164-2-1; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Boutanaev AM, 2002, NATURE, V420, P666, DOI 10.1038/nature01216; Bowden DW, 1997, DIABETES, V46, P882, DOI 10.2337/diabetes.46.5.882; BRADYKALNAY SM, 1995, CURR OPIN CELL BIOL, V7, P650, DOI 10.1016/0955-0674(95)80106-5; BROWNSHIMER S, 1992, CANCER RES, V52, P478; Byth KF, 1996, J EXP MED, V183, P1707, DOI 10.1084/jem.183.4.1707; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Caron H, 2001, SCIENCE, V291, P1289, DOI 10.1126/science.1056794; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Cox NJ, 2001, HUM MOL GENET, V10, P2301, DOI 10.1093/hmg/10.20.2301; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; Dadke SS, 2000, BIOCHEM BIOPH RES CO, V274, P583, DOI 10.1006/bbrc.2000.3188; Daigo Y, 1999, CANCER RES, V59, P1966; DECHERT U, 1995, HUM GENET, V96, P609; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; Dickson D, 1999, NATURE, V401, P311, DOI 10.1038/43722; Echwald SM, 2002, DIABETES, V51, P1; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Elson A, 1995, P NATL ACAD SCI USA, V92, P12235, DOI 10.1073/pnas.92.26.12235; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; Fedorov A, 2001, P NATL ACAD SCI USA, V98, P13177, DOI 10.1073/pnas.231491498; Forsell PKAL, 2000, GENE, V260, P145, DOI 10.1016/S0378-1119(00)00464-9; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Ghosh S, 1999, P NATL ACAD SCI USA, V96, P2198, DOI 10.1073/pnas.96.5.2198; GILBERT W, 1986, CELL, V46, P151, DOI 10.1016/0092-8674(86)90730-0; Goncalves I, 2000, GENOME RES, V10, P672, DOI 10.1101/gr.10.5.672; Hao LN, 1997, J BIOL CHEM, V272, P29322, DOI 10.1074/jbc.272.46.29322; HARRIS C, 1996, NAT GENET, V13, P161; Harrison PM, 2002, J MOL BIOL, V318, P1155, DOI 10.1016/S0022-2836(02)00109-2; Harrison PM, 2002, GENOME RES, V12, P272, DOI 10.1101/gr.207102; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; ISOBE M, 1994, ONCOGENE, V9, P1751; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jacobsen M, 2000, NAT GENET, V26, P495, DOI 10.1038/82659; JAMIESON CR, 1994, NAT GENET, V8, P357, DOI 10.1038/ng1294-357; Jansen RP, 2001, NAT REV MOL CELL BIO, V2, P247, DOI 10.1038/35067016; JOHNSON CV, 1993, GENOMICS, V16, P619, DOI 10.1006/geno.1993.1239; Klaman LD, 2000, MOL CELL BIOL, V20, P5479, DOI 10.1128/MCB.20.15.5479-5489.2000; Koshi JM, 1999, PROTEINS, V34, P333, DOI 10.1002/(SICI)1097-0134(19990215)34:3<333::AID-PROT6>3.0.CO;2-2; Kraut J, 2002, EXP CELL RES, V281, P182, DOI 10.1006/excr.2002.5661; Kung C, 2000, NAT MED, V6, P343; LAFORGIA S, 1991, P NATL ACAD SCI USA, V88, P5036, DOI 10.1073/pnas.88.11.5036; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lathrop W, 1999, MAMM GENOME, V10, P366, DOI 10.1007/s003359901003; Lee JH, 1999, AM J HUM GENET, V64, P196, DOI 10.1086/302195; Legius E, 1998, EUR J HUM GENET, V6, P32, DOI 10.1038/sj.ejhg.5200150; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; Lim LP, 2001, P NATL ACAD SCI USA, V98, P11193, DOI 10.1073/pnas.201407298; Lynch KW, 2001, J BIOL CHEM, V276, P24341, DOI 10.1074/jbc.M102175200; Macdonald P, 2001, CURR OPIN CELL BIOL, V13, P326, DOI 10.1016/S0955-0674(00)00215-5; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Maulik G, 2002, CYTOKINE GROWTH F R, V13, P41, DOI 10.1016/S1359-6101(01)00029-6; Mauro LJ, 1996, ENDOCRINOLOGY, V137, P925, DOI 10.1210/en.137.3.925; Mighell AJ, 2000, FEBS LETT, V468, P109, DOI 10.1016/S0014-5793(00)01199-6; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; Mok A, 2002, J CLIN ENDOCR METAB, V87, P724, DOI 10.1210/jc.87.2.724; Moller N P, 2000, Curr Opin Drug Discov Devel, V3, P527; MOLLER NP, 2002, HDB CELL SIGNALING, P659; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; Morrison DF, 2000, GENE, V257, P195, DOI 10.1016/S0378-1119(00)00397-8; Nakamura M, 2003, CANCER RES, V63, P737; Oganesian A, 2003, P NATL ACAD SCI USA, V100, P7563, DOI 10.1073/pnas.1336511100; Palka HL, 2003, J BIOL CHEM, V278, P5728, DOI 10.1074/jbc.M210656200; Partanen S, 1996, ANTICANCER RES, V16, P943; Penninger JM, 2001, NAT IMMUNOL, V2, P389, DOI 10.1038/87687; Pennisi E, 2003, SCIENCE, V300, P1484, DOI 10.1126/science.300.5625.1484b; Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957; Roy SW, 1999, GENE, V238, P85, DOI 10.1016/S0378-1119(99)00292-9; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Seifert RA, 2003, EXP CELL RES, V287, P374, DOI 10.1016/S0014-4827(03)00121-6; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tanuma N, 1999, EUR J BIOCHEM, V259, P46, DOI 10.1046/j.1432-1327.1999.00004.x; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; Tchilian EZ, 2001, J IMMUNOL, V166, P1308, DOI 10.4049/jimmunol.166.2.1308; Tiganis T, 1998, MOL CELL BIOL, V18, P1622, DOI 10.1128/MCB.18.3.1622; Tonks NK, 2001, CURR OPIN CELL BIOL, V13, P182, DOI 10.1016/S0955-0674(00)00196-4; TROWBRIDGE IS, 1994, ANNU REV IMMUNOL, V12, P85, DOI 10.1146/annurev.iy.12.040194.000505; Ureta-Vidal A, 2003, NAT REV GENET, V4, P251, DOI 10.1038/nrg1043; van Huijsduijnen RH, 1998, GENE, V225, P1; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Wain HM, 2002, GENOMICS, V79, P464, DOI 10.1006/geno.2002.6748; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Wheeler MA, 2002, J CELL BIOCHEM, V87, P363, DOI 10.1002/jcb.10297; Willett CG, 1997, J CLIN INVEST, V99, P2979, DOI 10.1172/JCI119493; Wright MB, 1998, J BIOL CHEM, V273, P23929, DOI 10.1074/jbc.273.37.23929; Xu Z, 2002, NAT IMMUNOL, V3, P764, DOI 10.1038/ni822; Zabolotny JM, 2002, DEV CELL, V2, P489, DOI 10.1016/S1534-5807(02)00148-X; ZANDER NF, 1993, ONCOGENE, V8, P1175; ZHAI YF, 1993, CANCER RES, V53, P2272; Zhang ZY, 2001, CURR OPIN CHEM BIOL, V5, P416, DOI 10.1016/S1367-5931(00)00223-4; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	107	263	279	1	29	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					8	30		10.1096/fj.02-1212rev	http://dx.doi.org/10.1096/fj.02-1212rev			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718383				2022-12-28	WOS:000188829300036
J	Higami, Y; Pugh, TD; Page, GP; Allison, DB; Prolla, TA; Weindruch, R				Higami, Y; Pugh, TD; Page, GP; Allison, DB; Prolla, TA; Weindruch, R			Adipose tissue energy metabolism: altered gene expression profile of mice subjected to long-term caloric restriction	FASEB JOURNAL			English	Article						white adipose tissue; oligonucleotide microarrays; aging	INSULIN-RECEPTOR SUBSTRATE-1; VISCERAL FAT; ADIPOCYTE DIFFERENTIATION; TRANSCRIPTIONAL PROFILES; 3T3-L1 PREADIPOCYTES; DIETARY RESTRICTION; UNCOUPLING PROTEINS; LEPTIN RESISTANCE; BROWN ADIPOCYTES; ANTIAGING ACTION	We investigated the influences of short-term and lifespan-prolonging long-term caloric restriction (LCR) on gene expression in white adipose tissue (WAT). Over 11,000 genes were examined using high-density oligonucleotide microarrays in four groups of 10- to 11-month-old male C57B16 mice that were either fasted for 18 h before death (F), subjected to short-term caloric restriction for 23 days (SCR), or LCR for 9 months and compared with nonfasted control (CO) mice. Only a few transcripts of F and SCR were differentially expressed compared with CO mice. In contrast, 345 transcripts of 6,266 genes found to be expressed in WAT were altered significantly by LCR. The expression of several genes encoding proteins involved in energy metabolism was increased by LCR. Further, many of the shifts in gene expression after LCR are known to occur during adipocyte differentiation. Selected LCR-associated alterations of gene expression were supported by quantitative reverse transcriptase-polymerase chain reaction, histology, and histochemical examinations. Our data provide new insights on the metabolic state associated with aging retardation by LCR.	Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin Reg Primate Res Ctr, Madison, WI 53715 USA; Univ Alabama, Dept Biostat, Sect Stat Genet, Birmingham, AL 35249 USA; Univ Alabama, Clin Nutr Res Ctr, Birmingham, AL 35249 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Univ Wisconsin, Dept Med Genet, Madison, WI 53706 USA	Geriatric Research Education & Clinical Center; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Weindruch, R (corresponding author), Vet Adm Hosp, Ctr Geriatr Res Educ & Clin, 2500 Overlook Terrace, Madison, WI 53705 USA.	rhweindr@wisc.edu		Allison, David/0000-0003-3566-9399; Higami, Yoshikazu/0000-0003-1381-0777; Page, Grier/0000-0003-2582-3786				Ahima RS, 2000, ANNU REV PHYSIOL, V62, P413, DOI 10.1146/annurev.physiol.62.1.413; Ailhaud G, 2002, CURR OPIN CLIN NUTR, V5, P385, DOI 10.1097/00075197-200207000-00006; Barzilai N, 1998, J CLIN INVEST, V101, P1353, DOI 10.1172/JCI485; Barzilai N, 1999, DIABETES, V48, P94, DOI 10.2337/diabetes.48.1.94; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Berwick DC, 2002, J BIOL CHEM, V277, P33895, DOI 10.1074/jbc.M204681200; Bodnar JS, 2002, NAT GENET, V30, P110, DOI 10.1038/ng811; Cao SX, 2001, P NATL ACAD SCI USA, V98, P10630, DOI 10.1073/pnas.191313598; Chendrasekhar A, 1996, J TRAUMA, V40, P963, DOI 10.1097/00005373-199606000-00016; Clouthier DE, 1997, J CLIN INVEST, V100, P2697, DOI 10.1172/JCI119815; Collins S, 2001, EXP BIOL MED, V226, P982, DOI 10.1177/153537020122601104; COUSIN B, 1992, J CELL SCI, V103, P931; Davidson RT, 2002, AM J PHYSIOL-ENDOC M, V282, pE270, DOI 10.1152/ajpendo.00232.2001; Dean DJ, 2000, ACTA PHYSIOL SCAND, V169, P133, DOI 10.1046/j.1365-201x.2000.00723.x; Du H, 2001, J LIPID RES, V42, P489; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; ENZI G, 1986, AM J CLIN NUTR, V44, P739, DOI 10.1093/ajcn/44.6.739; Fernandez-Galaz C, 2002, DIABETOLOGIA, V45, P997, DOI 10.1007/s00125-002-0851-4; FRAZE E, 1987, J AM GERIATR SOC, V35, P224, DOI 10.1111/j.1532-5415.1987.tb02313.x; Gabriely I, 2002, DIABETES, V51, P2951, DOI 10.2337/diabetes.51.10.2951; Himms-Hagen J, 2000, AM J PHYSIOL-CELL PH, V279, pC670, DOI 10.1152/ajpcell.2000.279.3.C670; HOLLIDAY R, 1989, BIOESSAYS, V10, P125, DOI 10.1002/bies.950100408; Jessen BA, 2002, GENE, V299, P95, DOI 10.1016/S0378-1119(02)01017-X; Jimenez M, 2003, EUR J BIOCHEM, V270, P699, DOI 10.1046/j.1432-1033.2003.03422.x; Kerner J, 2000, BBA-MOL CELL BIOL L, V1486, P1, DOI 10.1016/S1388-1981(00)00044-5; Kirschner LS, 1999, THYROID, V9, P143, DOI 10.1089/thy.1999.9.143; Kratchmarova I, 2002, MOL CELL PROTEOMICS, V1, P213, DOI 10.1074/mcp.M200006-MCP200; Le Roith D, 2001, DIABETES CARE, V24, P588, DOI 10.2337/diacare.24.3.588; Lee CK, 2002, P NATL ACAD SCI USA, V99, P14988, DOI 10.1073/pnas.232308999; Londos C, 1999, ANN NY ACAD SCI, V892, P155, DOI 10.1111/j.1749-6632.1999.tb07794.x; Ma XH, 2002, J GERONTOL A-BIOL, V57, pB225, DOI 10.1093/gerona/57.6.B225; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Masoro EJ, 1996, J GERONTOL A-BIOL, V51, pB387, DOI 10.1093/gerona/51A.6.B387; Matsuzaka T, 2002, J LIPID RES, V43, P911; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Mori M, 1999, FEBS LETT, V458, P17, DOI 10.1016/S0014-5793(99)01111-4; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Nam S Y, 2000, Obes Rev, V1, P73, DOI 10.1046/j.1467-789x.2000.00015.x; Nonogaki K, 2000, DIABETOLOGIA, V43, P533, DOI 10.1007/s001250051341; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; OLSEN SR, 1991, MOL ENDOCRINOL, V5, P1246, DOI 10.1210/mend-5-9-1246; Pugh TD, 1999, NEUROBIOL AGING, V20, P157, DOI 10.1016/S0197-4580(99)00043-3; Ramsay RR, 2000, BIOCHEM SOC T, V28, P182, DOI 10.1042/bst0280182; Rashid Mitchell N, 2003, Prev Cardiol, V6, P42, DOI 10.1111/j.1520-037X.2003.01358.x; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Salway J.G., 2017, METABOLISM GLANCE; SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1; Shimokawa I, 1999, AGING-CLIN EXP RES, V11, P380, DOI 10.1007/BF03339816; Shimokawa I, 2001, MECH AGEING DEV, V122, P1511, DOI 10.1016/S0047-6374(01)00284-6; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Soukas A, 2000, GENE DEV, V14, P963; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; SPINDLER SR, 1991, J GERONTOL, V46, pB233, DOI 10.1093/geronj/46.6.B233; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Strosberg AD, 1996, TRENDS PHARMACOL SCI, V17, P373, DOI 10.1016/S0165-6147(96)80011-3; Sykiotis GP, 2001, MOL ENDOCRINOL, V15, P1864, DOI 10.1210/me.15.11.1864; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; THAJCHAYAPONG P, 1976, HORM METAB RES, V8, P190, DOI 10.1055/s-0028-1093658; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; Wang ZQ, 1997, EXP GERONTOL, V32, P671, DOI 10.1016/S0531-5565(97)00054-5; Wang ZW, 2001, FASEB J, V15, P108, DOI 10.1096/fj.00-0310com; Weindruch R., 1988, RETARDATION AGING DI; Wonsey DR, 2002, P NATL ACAD SCI USA, V99, P6649, DOI 10.1073/pnas.102523299; YU BP, 1994, MODULATION AGING PRO; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	69	131	138	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					415	+		10.1096/fj.03-0678fje	http://dx.doi.org/10.1096/fj.03-0678fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688200				2022-12-28	WOS:000188067500006
J	Schild, L; Reinheckel, T; Reiser, M; Horn, TFW; Wolf, G; Augustin, W				Schild, L; Reinheckel, T; Reiser, M; Horn, TFW; Wolf, G; Augustin, W			Nitric oxide produced in rat liver mitochondria causes oxidative stress and impairment of respiration after transient hypoxia	FASEB JOURNAL			English	Article						oxidative phosphorylation; protein carbonyls; glutathione	CYTOCHROME-C RELEASE; SYNTHASE; OXYGEN; PROTEIN; PEROXYNITRITE; SUPEROXIDE; ISCHEMIA; INJURY; HYPOXIA/REOXYGENATION; REOXYGENATION	Nitric oxide (NO) is produced in mammals by different isoforms of NO synthase (NOS), including the constitutive mitochondrial enzyme (mtNOS). Here we demonstrate that the concentration of NO resulting from a mitochondrial NOS activity increases under hypoxic conditions in isolated rat liver mitochondria. We show that mitochondrially derived NO mediates the impairment of active (state 3) respiration as measured in the presence of the substrates glutamate and malate after reoxygenation. Simultaneously, NO induces oxidative stress in mitochondria, characterized by an increase in the amount of protein carbonyls and a decrease in glutathione (GSH). Both the accumulation of oxidative stress markers during and the impaired respiration after reoxygenation were prevented by blocking NO production with the NOS inhibitor L-NAME. These observations suggest that mitochondria are exposed to high amounts of NO generated by a mitochondrial NOS upon hypoxia/reoxygenation. Such increased NO levels, in turn, inhibit mitochondrial respiration and may cause oxidative stress that leads to irreversible impairment of mitochondria.	Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, D-39120 Magdeburg, Germany; Univ Magdeburg, Inst Med Neurobiol, Fac Med, D-39120 Magdeburg, Germany	Otto von Guericke University; Otto von Guericke University	Schild, L (corresponding author), Univ Magdeburg, Inst Clin Chem & Pathol Biochem, Dept Pathol Biochem, Leipziger Str 44, D-39120 Magdeburg, Germany.	lorenz.schild@medizin.uni-magdeburg.de	Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105				AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Alonso D, 2002, NEUROSCIENCE, V111, P47, DOI 10.1016/S0306-4522(01)00571-1; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Barker JE, 2001, J PATHOL, V194, P109, DOI 10.1002/path.845; Bates TE, 1996, BIOCHEM BIOPH RES CO, V218, P40, DOI 10.1006/bbrc.1996.0008; BATES TE, 1995, BIOCHEM BIOPH RES CO, V213, P896, DOI 10.1006/bbrc.1995.2213; Bauer G, 2000, ANTICANCER RES, V20, P4115; Becker LB, 1999, AM J PHYSIOL-HEART C, V277, pH2240, DOI 10.1152/ajpheart.1999.277.6.H2240; Bernardi P, 1999, EUR J BIOCHEM, V264, P687, DOI 10.1046/j.1432-1327.1999.00725.x; BERNARDI P, 1992, J BIOL CHEM, V267, P8834; Bolanos JP, 1998, BRAIN RES, V787, P117, DOI 10.1016/S0006-8993(97)01530-8; Boveris A, 1999, METHOD ENZYMOL, V301, P188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Brown GC, 2001, BBA-BIOENERGETICS, V1504, P46, DOI 10.1016/S0005-2728(00)00238-3; Cassina A, 1996, ARCH BIOCHEM BIOPHYS, V328, P309, DOI 10.1006/abbi.1996.0178; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Fridovich I, 1999, ANN NY ACAD SCI, V893, P13, DOI 10.1111/j.1749-6632.1999.tb07814.x; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giulivi C, 1998, BIOCHEM J, V332, P673, DOI 10.1042/bj3320673; Giulivi C, 1998, J BIOL CHEM, V273, P11038, DOI 10.1074/jbc.273.18.11038; Grattagliano I, 1999, J SURG RES, V86, P2, DOI 10.1006/jsre.1999.5620; Henrich M, 2002, MOL CELL NEUROSCI, V20, P307, DOI 10.1006/mcne.2002.1111; Horn TFW, 2002, FASEB J, V16, P1611, DOI 10.1096/fj.02-0126com; Ikemoto H, 2000, CELL DEATH DIFFER, V7, P511, DOI 10.1038/sj.cdd.4400682; Jaeschke Hartmut, 2002, Hepatology, V36, P243; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Madesh M, 2000, BBA-MOL BASIS DIS, V1500, P204, DOI 10.1016/S0925-4439(99)00107-6; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; MCCORMACK JG, 1989, METHOD ENZYMOL, V174, P95; Ockaili R, 1999, AM J PHYSIOL-HEART C, V277, pH2425, DOI 10.1152/ajpheart.1999.277.6.H2425; Poderoso JJ, 1996, ARCH BIOCHEM BIOPHYS, V328, P85, DOI 10.1006/abbi.1996.0146; POU S, 1995, BBA-GEN SUBJECTS, V1244, P62, DOI 10.1016/0304-4165(94)00197-6; Rakhit RD, 2001, CIRCULATION, V103, P2617; Reinheckel T, 2000, ARCH BIOCHEM BIOPHYS, V376, P59, DOI 10.1006/abbi.1999.1680; Rengasamy A, 1996, J PHARMACOL EXP THER, V276, P30; REYNAFARJE B, 1985, ANAL BIOCHEM, V145, P406, DOI 10.1016/0003-2697(85)90381-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schild L, 1997, BIOCHEM J, V328, P205, DOI 10.1042/bj3280205; Schild L, 1997, BIOCHEM MOL BIOL INT, V43, P35; Sims NR, 2002, NEUROCHEM INT, V40, P511, DOI 10.1016/S0197-0186(01)00122-X; TOVEY ER, 1987, J BIOCHEM BIOPH METH, V14, P1, DOI 10.1016/0165-022X(87)90002-9; Vidugiriene J, 1999, J BIOL CHEM, V274, P15203, DOI 10.1074/jbc.274.21.15203; Wu B, 2002, FREE RADICAL BIO MED, V33, P649, DOI 10.1016/S0891-5849(02)00917-6; Xie YW, 1996, CIRCULATION, V94, P2580, DOI 10.1161/01.CIR.94.10.2580; Zhivotovsky B, 1998, NATURE, V391, P449, DOI 10.1038/35060	50	61	63	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2194	2201		10.1096/fj.02-1170com	http://dx.doi.org/10.1096/fj.02-1170com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656981				2022-12-28	WOS:000188067500040
J	Suschek, CV; Schroeder, P; Aust, O; Sies, H; Mahotka, C; Horstjann, M; Ganser, H; Murtz, M; Hering, P; Schnorr, O; Kroncke, KD; Kolb-Bachofen, V				Suschek, CV; Schroeder, P; Aust, O; Sies, H; Mahotka, C; Horstjann, M; Ganser, H; Murtz, M; Hering, P; Schnorr, O; Kroncke, KD; Kolb-Bachofen, V			The presence of nitrite during UVA irradiation protects from apoptosis	FASEB JOURNAL			English	Article						apoptosis; DNA fragmentation; endothelial cells; lipid peroxidation; nitrite	ENDOTHELIAL-CELLS; OXIDE SYNTHASE; HUMAN SKIN; SODIUM-NITRITE; RELAXATION; EXPRESSION; PHOTOLYSIS; TOXICITY; WATER	Nitrite occurs ubiquitously in biological fluids such as blood and sweat, representing an oxidation product of nitric oxide. Nitrite has been associated with a variety of adverse effects such as mutagenicity, carcinogenesis, and toxicity. In contrast, here we demonstrate that the presence of nitrite, but not nitrate, during irradiation of endothelial cells in culture exerts a potent and concentration-dependent protection against UVA-induced apoptotic cell death. Protection is half-maximal at a concentration of 3 mM, and complete rescue is observed at 10 mM. Nitrite-mediated protection is mediated via inhibition of lipid peroxidation in a similar manner as seen with butylated hydroxytoluene, a known inhibitor of lipid peroxidation. Interestingly, nitrite-mediated protection is completely abolished by coincubation with the NO scavenger cPTIO. Using electron paramagnetic resonance (EPR) spectroscopy or Faraday modulation spectroscopy, we directly prove UVA-induced NO formation in solutions containing nitrite. In conclusion, evidence is presented that nitrite represents a protective agent against UVA-induced apoptosis due to photodecomposition of nitrite and subsequent formation of NO.	Univ Dusseldorf, Dept Immunobiol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Pathol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Inst Laser Med, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf	Suschek, CV (corresponding author), Univ Dusseldorf, Dept Immunobiol, Bldg 23-12-02,POB 10 10 07, D-40001 Dusseldorf, Germany.	suschek@uni-duesseldorf.de	Sies, Helmut/ABE-7355-2020; Sies, Helmut/B-7266-2008	Sies, Helmut/0000-0002-1000-3198				Bruch-Gerharz D, 1998, ARCH DERMATOL RES, V290, P643, DOI 10.1007/s004030050367; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; Bruch-Gerharz D, 1998, J INVEST DERMATOL, V110, P1, DOI 10.1046/j.1523-1747.1998.00084.x; BruchGerharz D, 1996, J EXP MED, V184, P2007, DOI 10.1084/jem.184.5.2007; Capasso F, 1999, OPT PHOTONICS NEWS, V10, P31, DOI 10.1364/OPN.10.10.000031; DANPURE HJ, 1976, PHOTOCHEM PHOTOBIOL, V23, P171, DOI 10.1111/j.1751-1097.1976.tb07238.x; Darley-Usmar VM, 2000, NITRIC OXIDE BIOL PA, P265; EHRREICH SJ, 1968, NATURE, V218, P682, DOI 10.1038/218682a0; Fan AM, 1996, REGUL TOXICOL PHARM, V23, P35, DOI 10.1006/rtph.1996.0006; FEHSEL K, 1994, J HISTOCHEM CYTOCHEM, V42, P613, DOI 10.1177/42.5.8157933; Fischer M, 1996, J PHYS CHEM-US, V100, P18749, DOI 10.1021/jp961692+; Fukuhara K, 2001, J AM CHEM SOC, V123, P8662, DOI 10.1021/ja0109038; Fukuto JM, 2000, NITRIC OXIDE BIOL PA, P23, DOI DOI 10.1016/B978-012370420-7/50003-4; FURCHGOTT RF, 1991, SEMIN PERINATOL, V15, P11; GRANT D, 1989, FOOD CHEM TOXICOL, V27, P565, DOI 10.1016/0278-6915(89)90015-X; Horstmann A, 2002, NITRIC OXIDE-BIOL CH, V6, P135, DOI 10.1006/niox.2001.0398; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; Ishii M, 1999, J CARDIOVASC PHARM, V33, P295, DOI 10.1097/00005344-199902000-00018; Janssen YMW, 1998, AM J PHYSIOL-LUNG C, V275, pL1100, DOI 10.1152/ajplung.1998.275.6.L1100; Kroncke KD, 1996, METHOD ENZYMOL, V269, P279; KULL FC, 1983, APPL BIOCHEM BIOTECH, V8, P97, DOI 10.1007/BF02778090; MIRANDA KM, 2000, NITRIC OXIDE BIOL PA, P41; Noda Y, 1997, RES COMMUN MOL PATH, V96, P115; *NTP, 2001, NATL TOXICOL PROGRAM, V495, P1; ROCHE MG, 1983, NAHRUNG, V27, P837; STREHLOW H, 1982, Z PHYS CHEM NEUE FOL, V132, P151, DOI 10.1524/zpch.1982.132.2.151; SUSCHEK C, 1993, J IMMUNOL, V151, P3283; SUSCHEK C, 1994, AM J PATHOL, V145, P685; Suschek CV, 2001, CELL DEATH DIFFER, V8, P515, DOI 10.1038/sj.cdd.4400839; Suschek CV, 2001, J INVEST DERMATOL, V117, P1200, DOI 10.1046/j.0022-202x.2001.01502.x; Suschek CV, 1999, J BIOL CHEM, V274, P6130, DOI 10.1074/jbc.274.10.6130; TREININ A, 1970, J AM CHEM SOC, V92, P5821, DOI 10.1021/ja00723a001; Tsuchiya K, 1999, FREE RADICAL BIO MED, V27, P347, DOI 10.1016/S0891-5849(99)00062-3; Weller R, 1996, J INVEST DERMATOL, V107, P327, DOI 10.1111/1523-1747.ep12363167; WIGILIUS IM, 1990, BIOCHEM BIOPH RES CO, V169, P129, DOI 10.1016/0006-291X(90)91443-V; ZAFIRIOU OC, 1987, PHOTOCHEM PHOTOBIOL, V45, P723, DOI 10.1111/j.1751-1097.1987.tb07873.x	36	40	41	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2342	+		10.1096/fj.03-0359fje	http://dx.doi.org/10.1096/fj.03-0359fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525939				2022-12-28	WOS:000186343300008
J	Kim, HH; Shin, HS; Kwak, HJ; Ahn, KY; Kim, JH; Lee, HJ; Lee, MS; Lee, ZH; Koh, GY				Kim, HH; Shin, HS; Kwak, HJ; Ahn, KY; Kim, JH; Lee, HJ; Lee, MS; Lee, ZH; Koh, GY			RANKL regulates endothelial cell survival through the phosphatidylinositol 3 '-kinase/Akt signal transduction pathway	FASEB JOURNAL			English	Article						RANK; RANKL; endothelial cells; apoptosis	NF-KAPPA-B; OSTEOPROTEGERIN-LIGAND; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; EXPRESSION; APOPTOSIS; AKT; ANGIOGENESIS; CYTOKINE	The maintenance of endothelial integrity is important for prevention of vascular diseases. Several growth factors, such as bFGF and angiopoietin-1, have been shown to suppress endothelial cell apoptosis and thus help to maintain endothelial integrity. Several studies suggested that receptor activator of NF-kappaB (RANK) and its ligand (RANKL) could be involved in endothelial physiology. Using immunofluorescence and reverse transcriptase-polymerse chain reaction, we found that RANK was expressed by endothelial cells, and RANKL was expressed by arterial smooth muscle cells. Furthermore, RANKL suppressed apoptosis of primary cultured endothelial cells. The RANKL-induced survival appeared to be dependent on PI 3'-kinase activity, because wortmannin and LY294002, PI 3'-kinase-specific inhibitors, blocked the RANKL-induced survival effect. RANKL elicited the phosphorylation of the serine-threonine kinase Akt at Ser473 in a PI 3'-kinase-dependent manner. The expression of a dominant-negative form of Akt or pretreatment of Akt-specific inhibitor in endothelial cells reversed the RANKL-induced survival effect. Tumor necrosis factor-alpha, which causes endothelial cell apoptosis, induced endothelial cells to express osteoprotegerin, a decoy receptor that inhibits RANK-RANKL signaling. These findings indicate that RANK, in response to the paracrine stimulus of RANKL, may play an important role in maintaining endothelial cell integrity through the PI 3'-kinase/Akt signal transduction pathway.	Chosun Univ, Natl Res Lab Bone Metab, Kwangju 501759, South Korea; Seoul Natl Univ, Sch Dent, Dept Cell & Dev Biol, Seoul 110749, South Korea; Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Endothelial Cells, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Chonnam Natl Univ, Res Inst Med Sci, Kwangju 501190, South Korea; Chosun Univ, Sch Dent, Kwangju 501759, South Korea	Chosun University; Seoul National University (SNU); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Chonnam National University; Chosun University	Lee, ZH (corresponding author), Chosun Univ, Natl Res Lab Bone Metab, Kwangju 501759, South Korea.	jhblee@mail.chosun.ac.kr; gykoh@postech.ac.kr	Kim, Juhyun/AAD-6817-2019; Koh, Gou Young/C-1615-2011	Kim, Juhyun/0000-0002-3098-5010; 				BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bucay N, 1998, GENE DEV, V12, P1260, DOI 10.1101/gad.12.9.1260; Cines DB, 1998, BLOOD, V91, P3527; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; DOWNWARD J, 1995, NATURE, V376, P553, DOI 10.1038/376553a0; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; Gerber HP, 1998, J BIOL CHEM, V273, P13313, DOI 10.1074/jbc.273.21.13313; GIACHELLI CM, 1993, J CLIN INVEST, V92, P1686, DOI 10.1172/JCI116755; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kim I, 2001, FASEB J, V15, P126, DOI 10.1096/fj.01-0556fje; Kim I, 2001, CARDIOVASC RES, V49, P872, DOI 10.1016/S0008-6363(00)00295-9; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; Kwak HJ, 2000, CIRCULATION, V101, P2317, DOI 10.1161/01.CIR.101.19.2317; Lacey DL, 2000, AM J PATHOL, V157, P435, DOI 10.1016/S0002-9440(10)64556-7; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; Paris F, 2001, SCIENCE, V293, P293, DOI 10.1126/science.1060191; Rodan GA, 2000, SCIENCE, V289, P1508, DOI 10.1126/science.289.5484.1508; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Stefanec T, 2000, CHEST, V117, P841, DOI 10.1378/chest.117.3.841; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; Theill LE, 2002, ANNU REV IMMUNOL, V20, P795, DOI 10.1146/annurev.immunol.20.100301.064753; Veikkola T, 1999, SEMIN CANCER BIOL, V9, P211, DOI 10.1006/scbi.1998.0091; Warren JB, 1990, ENDOTHELIUM INTRO CU; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567	29	63	68	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2163	+		10.1096/fj.03-0215fje	http://dx.doi.org/10.1096/fj.03-0215fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500543				2022-12-28	WOS:000185925100006
J	Zhang, HJ; Xu, LJ; Drake, VJ; Xie, LT; Oberley, LW; Kregel, KC				Zhang, HJ; Xu, LJ; Drake, VJ; Xie, LT; Oberley, LW; Kregel, KC			Heat-induced liver injury in old rats is associated with exaggerated oxidative stress and altered transcription factor activation	FASEB JOURNAL			English	Article						free radicals; ROS; aging; hyperthermia; signal transduction	NF-KAPPA-B; FREE-RADICAL GENERATION; SUPEROXIDE-DISMUTASE; LIPID-PEROXIDATION; REDOX REGULATION; GLUTATHIONE; CELLS; AP-1; DIFFERENTIATION; OVEREXPRESSION	A decline in stress tolerance is a hallmark of aging. For instance, older organisms showed extensive hepatic damage, along with increased morbidity and mortality, after environmental heating. We hypothesized that hyperthermic challenge would produce exaggerated oxidative stress in old animals, leading to increased hepatic injury. After a heat-stress protocol, time-course changes in reactive oxygen species (ROS) levels, oxidative damage markers, glutathione (GSH)/glutathione disulfide (GSSG) ratios, and activation of stress-response transcription factors (AP-1 and NF-kappaB) were measured in young and old rats. A small, transient increase in hepatic oxidative damage, with minimal injury, was observed in young rats. However, old rats showed widespread hepatic injury that was manifested over a 24 h period after heating. This pathology was preceded by elevated steady-state levels of ROS, along with large increases in lipid peroxidation products, prolonged hepatic DNA oxidation damage, aberrant GSH/GSSG profiles, and altered activation patterns for AP-1. These data indicate that young animals have an effective oxidation-reduction buffering system in the liver that provides protection from oxidative damage to intracellular macromolecules under stress conditions. In sharp contrast, an environmental challenge in older animals produces exaggerated oxidative stress and alterations in signal transduction pathways, which can contribute to cellular dysfunction and age-related reductions in stress tolerance.	Univ Iowa, Dept Exercise Sci, Integrat Physiol Lab, FH 532, Iowa City, IA 52242 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Kregel, KC (corresponding author), Univ Iowa, Dept Exercise Sci, Integrat Physiol Lab, FH 532, Iowa City, IA 52242 USA.	kevin-kregel@uiowa.edu						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bejma J, 2000, ACTA PHYSIOL SCAND, V169, P343; Bejma J, 1999, J APPL PHYSIOL, V87, P465, DOI 10.1152/jappl.1999.87.1.465; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Camandola S, 1997, BIOFACTORS, V6, P173, DOI 10.1002/biof.5520060211; Cheng JZ, 2001, ARCH BIOCHEM BIOPHYS, V392, P197, DOI 10.1006/abbi.2001.2452; Cortopassi GA, 1999, BBA-BIOENERGETICS, V1410, P183, DOI 10.1016/S0005-2728(98)00166-2; GRANGER DN, 1986, ACTA PHYSIOL SCAND, V126, P47; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hall DM, 2000, FASEB J, V14, P78, DOI 10.1096/fasebj.14.1.78; HALL DM, 1994, J APPL PHYSIOL, V77, P548, DOI 10.1152/jappl.1994.77.2.548; Hall DM, 2000, J APPL PHYSIOL, V89, P749, DOI 10.1152/jappl.2000.89.2.749; Harris AG, 1998, AM J PHYSIOL-HEART C, V274, pH1009, DOI 10.1152/ajpheart.1998.274.3.H1009; HATTORI M, 1990, DNA CELL BIOL, V9, P777, DOI 10.1089/dna.1990.9.777; Headrick JP, 1998, J MOL CELL CARDIOL, V30, P1415, DOI 10.1006/jmcc.1998.0710; HENSCHEL A, 1969, AM J PUBLIC HEALTH N, V59, P2232, DOI 10.2105/AJPH.59.12.2232; Johnson FB, 1999, CELL, V96, P291, DOI 10.1016/S0092-8674(00)80567-X; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KEW M, 1971, T ROY SOC TROP MED H, V65, P325, DOI 10.1016/0035-9203(71)90007-1; Kirlin WG, 1999, FREE RADICAL BIO MED, V27, P1208, DOI 10.1016/S0891-5849(99)00145-8; Kregel K. C., 1996, J APPL PHYSIOL, V80, P262; Kregel KC, 2002, J APPL PHYSIOL, V92, P2177, DOI 10.1152/japplphysiol.01267.2001; KREGEL KC, 1995, J APPL PHYSIOL, V79, P1673, DOI 10.1152/jappl.1995.79.5.1673; Kregel KC, 1996, J APPL PHYSIOL, V80, P540, DOI 10.1152/jappl.1996.80.2.540; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonarduzzi G, 2000, FREE RADICAL BIO MED, V28, P1370, DOI 10.1016/S0891-5849(00)00216-1; Li N, 2002, AM J PHYSIOL-RENAL, V282, pF1111, DOI 10.1152/ajprenal.00218.2001; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Miller FJ, 2002, ARTERIOSCL THROM VAS, V22, P560, DOI 10.1161/01.ATV.0000013778.72404.30; Morrison RJ, 1998, TOXICOL APPL PHARM, V148, P229, DOI 10.1006/taap.1997.8339; Nkabyo YS, 2002, AM J PHYSIOL-GASTR L, V283, pG1352, DOI 10.1152/ajpgi.00183.2002; PAPACONSTANTINOU J, 1994, ANN NY ACAD SCI, V719, P195, DOI 10.1111/j.1749-6632.1994.tb56829.x; Parola M, 1998, J CLIN INVEST, V102, P1942, DOI 10.1172/JCI1413; Parola M, 1999, INT J MOL MED, V4, P425; Piette J, 1997, BIOL CHEM, V378, P1237; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Rikans LE, 1999, MECH AGEING DEV, V108, P173, DOI 10.1016/S0047-6374(99)00012-3; RYAN AJ, 1995, J APPL PHYSIOL, V78, P38, DOI 10.1152/jappl.1995.78.1.38; Schafer FQ, 2000, FREE RADICAL BIO MED, V28, P1175, DOI 10.1016/S0891-5849(00)00319-1; Semenza JC, 1996, NEW ENGL J MED, V335, P84, DOI 10.1056/NEJM199607113350203; SLATER TF, 1982, BIOCHEM J, V22, P1; Tani M, 1997, J MOL CELL CARDIOL, V29, P3081, DOI 10.1006/jmcc.1997.0533; Tjalkens RB, 1999, ARCH BIOCHEM BIOPHYS, V361, P113, DOI 10.1006/abbi.1998.0946; Toyokuni S, 1999, PATHOL INT, V49, P91, DOI 10.1046/j.1440-1827.1999.00829.x; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; YEN TC, 1994, FREE RADICAL BIO MED, V16, P207, DOI 10.1016/0891-5849(94)90145-7; Zhang HJ, 2002, J BIOL CHEM, V277, P20919, DOI 10.1074/jbc.M109801200; Zhang HJ, 2002, J VIROL, V76, P355, DOI 10.1128/JVI.76.1.355-363.2002; Zwacka RM, 1998, NAT MED, V4, P698, DOI 10.1038/nm0698-698	50	84	91	1	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2293	+		10.1096/fj.03-0139fje	http://dx.doi.org/10.1096/fj.03-0139fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500545				2022-12-28	WOS:000185925100013
J	Eisenhofer, G; Tian, H; Holmes, C; Matsunaga, J; Roffler-Tarlov, S; Hearing, VJ				Eisenhofer, G; Tian, H; Holmes, C; Matsunaga, J; Roffler-Tarlov, S; Hearing, VJ			Tyrosinase: a developmentally specific major determinant of peripheral dopamine	FASEB JOURNAL			English	Article						L-dopa; tyrosine hydroxylase; sympathetic nervous system; melanocyte; melanin	TARGETED DISRUPTION; MONOAMINE-OXIDASE; SUBSTANTIA-NIGRA; CATECHOLAMINES; HYDROXYLASE; BRAIN; GENE; POPULATIONS; EXPRESSION; METABOLISM	L-3,4-dihydroxyphenylalanine, the immediate precursor of dopamine, can be formed by two enzymes: tyrosine hydroxylase (TH) in catecholamine-producing neurons and chromaffin cells and tyrosinase in melanocytes. In this study we examined whether tyrosinase contributes to production of dopamine. Deficiency of TH caused marked reductions in norepinephrine in albino and pigmented 15-day-old mice. In contrast, peripheral levels of dopamine were reduced only in albino TH-deficient mice and were higher in pigmented than in albino mice, regardless of the presence or absence of TH. We next examined age-related changes in dopamine and cutaneous expression of tyrosinase and melanin in albino and pigmented TH wild-type mice. We found that the differences in peripheral dopamine between pigmented and albino mice disappeared with advancing age following changes in expression and function of tyrosinase. In young animals, tyrosinase was present in epidermis but did not produce detectable melanin. With advancing age, tyrosinase was localized only around hair follicles, melanin synthesis became more pronounced, and dopamine synthesis decreased. The data reveal a previously unrecognized TH-independent major pathway of peripheral dopamine synthesis in young, but not adult, mice. The transient nature of this source of dopamine reflects a developmental switch in tyrosinase-dependent production of dopamine to production of melanin.	NINDS, Sect Clin Neurocardiol, NIH, Bethesda, MD 20892 USA; NINDS, Sect Neural Dev, NIH, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Anat, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Cell Biol, Boston, MA 02111 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Tufts University; Tufts University; Tufts University	Eisenhofer, G (corresponding author), NINDS, Sect Clin Neurocardiol, NIH, Bldg 10,Room 6N252,10 Ctr Dr,MSC 1620, Bethesda, MD 20892 USA.	ge@box-g.nih.gov	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035639] Funding Source: NIH RePORTER; NINDS NIH HHS [NS35639] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amicarelli F, 1999, CELL MOL BIOL, V45, P1093; BATTYANI Z, 1993, PIGM CELL RES, V6, P400; Biswas S, 1999, ARCH DIS CHILD, V80, P565, DOI 10.1136/adc.80.6.565; BRADBURY AJ, 1986, NEUROPHARMACOLOGY, V25, P897, DOI 10.1016/0028-3908(86)90016-X; CICCARONE V, 1989, CANCER RES, V49, P219; Cransac H, 1997, COMP BIOCHEM PHYS A, V116, P341, DOI 10.1016/S0300-9629(96)00231-9; DAVID JC, 1974, ARCH BIOCHEM BIOPHYS, V160, P561, DOI 10.1016/0003-9861(74)90432-9; EISENHOFER G, 1995, AM J PHYSIOL-GASTR L, V268, pG641, DOI 10.1152/ajpgi.1995.268.4.G641; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; Eisenhofer G, 1998, Adv Pharmacol, V42, P374; Fenoll LG, 2002, INT J BIOCHEM CELL B, V34, P1594, DOI 10.1016/S1357-2725(02)00076-6; GilLoyzaga P, 1997, BRAIN RES, V746, P265, DOI 10.1016/S0006-8993(96)01258-9; Goldstein D S, 1995, Hypertens Res, V18 Suppl 1, pS93, DOI 10.1291/hypres.18.SupplementI_S93; GREEN E, 1973, MOUSE NEWS LETT, V49, P31; HEARING VJ, 1991, FASEB J, V5, P2902, DOI 10.1096/fasebj.5.14.1752358; Hofele K, 2001, EXP NEUROL, V168, P116, DOI 10.1006/exnr.2000.7588; Ilia M, 1999, J COMP NEUROL, V405, P394, DOI 10.1002/(SICI)1096-9861(19990315)405:3<394::AID-CNE9>3.0.CO;2-Y; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KOBAYASHI K, 1995, J BIOL CHEM, V270, P27235, DOI 10.1074/jbc.270.45.27235; KURTZKE JF, 1990, NEUROLOGY, V40, P42, DOI 10.1212/WNL.40.1.42; LAMBERT GW, 1991, LIFE SCI, V49, P1061, DOI 10.1016/0024-3205(91)90593-Z; LeFur N, 1996, GENOMICS, V37, P245; LUPP A, 1993, N-S ARCH PHARMACOL, V347, P141; NAGATSU T, 1964, J BIOL CHEM, V239, P2910; Rachel RA, 2002, J NEUROSCI, V22, P4249, DOI 10.1523/JNEUROSCI.22-11-04249.2002; Raper HS, 1926, BIOCHEM J, V20, P735, DOI 10.1042/bj0200735; Richards M, 1996, NEUROEPIDEMIOLOGY, V15, P214, DOI 10.1159/000109910; Riley PA, 1999, CELL MOL BIOL, V45, P951; Rios M, 1999, J NEUROSCI, V19, P3519; ROSATI G, 1980, NEUROLOGY, V30, P250, DOI 10.1212/WNL.30.3.250; ROSS RA, 1985, CANCER RES, V45, P1628; SLACK R, 1992, EXP CELL RES, V202, P17, DOI 10.1016/0014-4827(92)90399-S; Tian H, 2000, J NEUROSCI, V20, P7362; Tief K, 1996, EUR J BIOCHEM, V241, P12, DOI 10.1111/j.1432-1033.1996.0012t.x; Tief K, 1996, DEV DYNAM, V205, P445, DOI 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; Xu YM, 1997, MOL BRAIN RES, V45, P159, DOI 10.1016/S0169-328X(96)00308-7; ZHOU QY, 1995, NATURE, V374, P640, DOI 10.1038/374640a0	38	63	80	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1248	1255		10.1096/fj.02-0736com	http://dx.doi.org/10.1096/fj.02-0736com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832289				2022-12-28	WOS:000184471600036
J	Ishii, H; Zanesi, N; Vecchione, A; Trapasso, F; Yendamuri, S; Sarti, M; Baffa, R; During, MJ; Huebner, K; Fong, LYY; Croce, CM				Ishii, H; Zanesi, N; Vecchione, A; Trapasso, F; Yendamuri, S; Sarti, M; Baffa, R; During, MJ; Huebner, K; Fong, LYY; Croce, CM			Regression of upper gastric cancer in mice by FHIT gene delivery	FASEB JOURNAL			English	Article						NMBA; FHIT viruses; forestomach; tumor reversal; Bcl2-Bax	TUMOR-DEVELOPMENT; LUNG-CANCER; APOPTOSIS; EXPRESSION; THERAPY	Fhit expression is reduced in most cancers, and Fhit replacement by FHIT expression viruses in lung, esophageal, pancreatic, and cervical cancers induces apoptosis in the cancer cells. Mice carrying one or two inactivated Fhit alleles are hypersensitive to development of N-nitrosomethylbenzylamine (NMBA)-induced forestomach tumors. In the present study, we investigated the kinetics and mechanism of tumor reversal and intervention by oral delivery of FHIT expression viruses. Tumor analysis showed that: a) by 37 days post-NMBA, control mice showed similar to7 tumors and by 84 days similar to10 tumors/forestomach; b) mice receiving FHIT virus at 2 or 42 days post-NMBA showed significantly reduced tumor burdens; c) Fhit was still expressed at 82 days postinfection; d) control viral infection had no effect on tumor development; and e) reduced Bcl2, increased Bax expression, and increased TUNEL-positive apoptotic nuclei characterized the restored epithelia of FHIT transduced forestomachs. Thus, FHIT viral gene delivery prevents or retards development of carcinogen-induced forestomach tumors and reverses development of established tumors by 60 - 70% through an apoptotic pathway. This dramatic reduction in tumor burden emphasizes the efficacy of targeting the FHIT apoptotic pathway for tumor eradication.	Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, CNS, Gene Therapy Ctr, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Croce, CM (corresponding author), BLSB, Room 1050,233 S 10th St, Philadelphia, PA 19107 USA.	C_Croce@lacjci.tju.edu	Young, Richard A/F-6495-2012; During, Matthew/AAC-1388-2020	Young, Richard A/0000-0001-8855-8647; Vecchione, Andrea/0000-0002-5497-6856; Yendamuri, Sai/0000-0001-6654-3487; Fong, Louise/0000-0001-7654-7035				Dumon KR, 2001, P NATL ACAD SCI USA, V98, P3346, DOI 10.1073/pnas.061020098; Dumon KR, 2001, CANCER RES, V61, P4827; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; During MJ, 1998, NAT MED, V4, P1131, DOI 10.1038/2625; Fong LYY, 2000, P NATL ACAD SCI USA, V97, P4742, DOI 10.1073/pnas.080063497; Grimm D, 1998, HUM GENE THER, V9, P2745, DOI 10.1089/hum.1998.9.18-2745; Huebner K, 2001, NAT REV CANCER, V1, P214, DOI 10.1038/35106058; Ishii H, 2001, CANCER RES, V61, P1578; Ji L, 1999, CANCER RES, V59, P3333; Mori M, 2000, CANCER RES, V60, P1177; Ramesh R, 2001, MOL THER, V3, P337, DOI 10.1006/mthe.2001.0266; Sard L, 1999, P NATL ACAD SCI USA, V96, P8489, DOI 10.1073/pnas.96.15.8489; Siprashvili Z, 1997, P NATL ACAD SCI USA, V94, P13771, DOI 10.1073/pnas.94.25.13771; Sozzi G, 1998, CANCER RES, V58, P5032; Tseng JE, 1999, CANCER RES, V59, P4798; Zanesi N, 2001, P NATL ACAD SCI USA, V98, P10250, DOI 10.1073/pnas.191345898	16	47	55	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1768	+		10.1096/fj.03-0241fje	http://dx.doi.org/10.1096/fj.03-0241fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958204				2022-12-28	WOS:000184471600031
J	Boilard, E; Bourgoin, SG; Bernatchez, C; Poubelle, PE; Surette, ME				Boilard, E; Bourgoin, SG; Bernatchez, C; Poubelle, PE; Surette, ME			Interaction of low molecular weight group IIA phospholipase A(2) with apoptotic human T cells: role of heparan sulfate proteoglycans	FASEB JOURNAL			English	Article						lymphocytes; apoptosis; IIA phospholipase A(2); heparan sulfate proteoglycan; arachidonic acid; arthritis	ARACHIDONIC-ACID RELEASE; REGULATORY FUNCTIONS; HUMAN NEUTROPHILS; GROUP IB; BINDING; MEMBRANE; RECEPTOR; IDENTIFICATION; DIVERSITY; PROTEIN	Human group IIA phospholipase A(2) (hIIA PLA(2)) is a 14 kDa secreted enzyme associated with inflammatory diseases. A newly discovered property of hIIA PLA(2) is the binding affinity for the heparan sulfate proteoglycan (HSPG) glypican-1. In this study, the binding of hIIA PLA(2) to apoptotic human T cells was investigated. Little or no exogenous hIIA PLA(2) bound to CD3-activated T cells but significant binding was measured on activated T cells induced to undergo apoptosis by anti-CD95. Binding to early apoptotic T cells was greater than to late apoptotic cells. The addition of heparin and the hydrolysis of HSPG by heparinase III only partially inhibited hIIA PLA(2) binding to apoptotic cells, suggesting an interaction with both HSPG and other binding protein(s). Two low molecular weight HSPG were coimmunoprecipitated with hIIA PLA(2) from apoptotic T cells, but not from living cells. Treatment of CD95-stimulated T cells with hIIA PLA(2) resulted in the release of arachidonic acid but not oleic acid from cells and this release was blocked by heparin and heparinase III. Altogether, these results suggest a role for hIIA PLA(2) in the release of arachidonic acid from apoptotic cells through interactions with HSPG and its potential implication in the progression of inflammatory diseases.	Pilot Therapeut Inc, Charleston, SC 29492 USA; Univ Laval, Fac Med, Quebec City, PQ G1V 4G2, Canada; Ctr Hosp Univ Quebec, Ctr Rech Rhumatol & Immunol, Ctr Rech, Quebec City, PQ G1V 4G2, Canada	Laval University; Laval University	Surette, ME (corresponding author), Pilot Therapeut Inc, 2000 Daniel Isl Dr,Suite 440, Charleston, SC 29492 USA.	MarcS@pilott.com	Surette, Marc/AAW-1078-2021	Bourgoin, Sylvain/0000-0001-9779-0368				ANCIAN P, 1995, J BIOL CHEM, V270, P8963, DOI 10.1074/jbc.270.15.8963; Atsumi G, 1997, BBA-LIPID LIPID MET, V1349, P43, DOI 10.1016/S0005-2760(97)00082-9; Bezzine S, 2002, J BIOL CHEM, V277, P48523, DOI 10.1074/jbc.M203137200; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fonteh AN, 2000, J IMMUNOL, V165, P2773, DOI 10.4049/jimmunol.165.5.2773; Fonteh AN, 1998, BBA-LIPID LIPID MET, V1393, P253, DOI 10.1016/S0005-2760(98)00079-4; Gensler TJ, 2001, J AUTOIMMUN, V16, P59, DOI 10.1006/jaut.2000.0464; Gilbert C, 2002, J IMMUNOL METHODS, V261, P85, DOI 10.1016/S0022-1759(01)00553-1; GREEN JA, 1991, INFLAMMATION, V15, P355, DOI 10.1007/BF00917352; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; HART DA, 1975, J IMMUNOL, V115, P871; Hernandez M, 1998, J BIOL CHEM, V273, P606, DOI 10.1074/jbc.273.1.606; Huwiler A, 1997, BBA-LIPID LIPID MET, V1348, P257, DOI 10.1016/S0005-2760(97)00073-8; Janssen MJW, 1999, BBA-MOL CELL BIOL L, V1440, P59, DOI 10.1016/S1388-1981(99)00122-5; Jiang JZ, 2002, AM J PATHOL, V160, P667, DOI 10.1016/S0002-9440(10)64886-9; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kretz-Rommel A, 2001, CELL IMMUNOL, V208, P125, DOI 10.1006/cimm.2001.1774; Kudo I, 2002, PROSTAG OTH LIPID M, V68-9, P3, DOI 10.1016/S0090-6980(02)00020-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; Lernmark A, 2001, J CLIN INVEST, V108, P1091, DOI 10.1172/JCI200114234; Lilja I, 2000, CLIN CHEM LAB MED, V38, P1231, DOI 10.1515/CCLM.2000.194; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nevalainen TJ, 2000, BBA-MOL CELL BIOL L, V1488, P83, DOI 10.1016/S1388-1981(00)00112-8; Nielson KH, 2000, BBA-MOL CELL BIOL L, V1484, P163, DOI 10.1016/S1388-1981(00)00004-4; Ozgen U, 2000, CYTOMETRY, V42, P74, DOI 10.1002/(SICI)1097-0320(20000215)42:1<74::AID-CYTO11>3.0.CO;2-6; Sartipy P, 1996, J BIOL CHEM, V271, P26307, DOI 10.1074/jbc.271.42.26307; Singer AG, 2002, J BIOL CHEM, V277, P48535, DOI 10.1074/jbc.M205855200; Surette ME, 1999, MOL PHARMACOL, V56, P1055, DOI 10.1124/mol.56.5.1055; Tischfield JA, 1997, J BIOL CHEM, V272, P17247, DOI 10.1074/jbc.272.28.17247; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Vincent A, 1999, PATHOL RES PRACT, V195, P535, DOI 10.1016/S0344-0338(99)80002-8; WALL JR, 1993, J ENDOCRINOL INVEST, V16, P863, DOI 10.1007/BF03348946; Wilson HA, 1999, J BIOL CHEM, V274, P11494, DOI 10.1074/jbc.274.17.11494; Yokota Y, 2000, FEBS LETT, V478, P187, DOI 10.1016/S0014-5793(00)01848-2; ZAMAI L, 1993, CYTOMETRY, V14, P891, DOI 10.1002/cyto.990140807; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	54	42	46	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1068	1080		10.1096/fj.02-0938com	http://dx.doi.org/10.1096/fj.02-0938com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773489				2022-12-28	WOS:000183818000010
J	Harfouche, R; Gratton, JP; Yancopoulos, GD; Noseda, M; Karsan, A; Hussain, SNA				Harfouche, R; Gratton, JP; Yancopoulos, GD; Noseda, M; Karsan, A; Hussain, SNA			Angiopoietin-1 activates both anti- and proapoptotic mitogen-activated protein kinases	FASEB JOURNAL			English	Article						angiogenesis; caspases; programmed cell death; JNK/SAPK kinases; apopotosis	ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASE; CELL-SURVIVAL; PHOSPHATIDYLINOSITOL 3-KINASE; TIE2 RECEPTOR; APOPTOSIS; PATHWAYS; DEATH; AKT; PHOSPHORYLATION	In this study, we identified whether mitogen-activated protein kinases (MAPKs) mediate the effects of angiopoietin-1 (Ang-1) on endothelial cell apoptosis. Exposure of human umbilical vein endothelial cells to Ang-1 (300 ng/ml) evoked within 15-30 min a 15-fold and a 5-fold increase in phosphorylation of ERK1/2 and p38 MAPKs, respectively. Inhibitors of the PI-3 kinase pathway attenuated Ang-1-induced ERK1/2 phosphorylation at a level up-stream from Raf and MEK1/2, but these inhibitors augmented Ang-1-induced p38 phosphorylation. When serum and growth supplements were withdrawn, the percentage of endothelial apoptosis tripled over 24 h compared with control cells. The presence of Ang-1 (300 ng/ml) significantly attenuated endothelial cell apoptosis and inhibited caspase-9, -7, and -3 activation. These antiapoptotic effects were augmented when a p38 inhibitor was combined with Ang-1, whereas inhibition of ERK1/2 eliminated the antiapoptotic properties of Ang-1. We conclude that both anti- (ERK1/2) and pro- (p38) apoptotic members of MAPKs are simultaneously activated by Ang-1 in endothelial cells and that activation of ERK1/2 by Ang-1 is mediated through the PI-3 kinase pathway. The strong antiapoptotic effects of the ERK and the PI-3 kinase pathways mask the proapoptotic function of p38 MAPKs resulting in net attenuation of apoptosis by Ang-1.	Royal Victoria Hosp, Crit Care Div, Montreal, PQ H3A 1A1, Canada; Royal Victoria Hosp, Div Resp, Montreal, PQ H3A 1A1, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; McGill Univ, Inst Rech Clin Montreal, Montreal, PQ, Canada; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; British Columbia Canc Agcy, Dept Med Biophys, Vancouver, BC V5Z 4E6, Canada; British Columbia Canc Agcy, Dept Pathol & Lab Med, Vancouver, BC V5Z 4E6, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Institut de Recherche Clinique de Montreal (IRCM); McGill University; Universite de Montreal; Regeneron; University of British Columbia; British Columbia Cancer Agency; British Columbia Cancer Agency	Hussain, SNA (corresponding author), Royal Victoria Hosp, Crit Care Div, Room L3-05,687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	sabah.hussain@muhc.mcgill.ca	Karsan, Aly/K-2067-2015; Hussain, Sabah/ABC-5315-2021	Gratton, Jean-Philippe/0000-0001-9877-8520				Buckley S, 1999, AM J PHYSIOL-LUNG C, V277, pL159, DOI 10.1152/ajplung.1999.277.1.L159; Cardier JE, 2002, MICROVASC RES, V63, P10, DOI 10.1006/mvre.2001.2360; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chaudhary LR, 2001, J CELL BIOCHEM, V81, P304, DOI 10.1002/1097-4644(20010501)81:2<304::AID-JCB1045>3.3.CO;2-L; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dragovich T, 1998, ONCOGENE, V17, P3207, DOI 10.1038/sj.onc.1202587; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Fujikawa K, 1999, EXP CELL RES, V253, P663, DOI 10.1006/excr.1999.4693; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Gratton JP, 2001, J BIOL CHEM, V276, P30359, DOI 10.1074/jbc.M009698200; Gupta K, 1999, EXP CELL RES, V247, P495, DOI 10.1006/excr.1998.4359; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Harfouche R, 2002, MICROVASC RES, V64, P135, DOI 10.1006/mvre.2002.2421; Hayes AJ, 1999, MICROVASC RES, V58, P224, DOI 10.1006/mvre.1999.2179; HUANG LW, 1995, ONCOGENE, V11, P2097; Jan MS, 1999, BIOCHEM BIOPH RES CO, V264, P724, DOI 10.1006/bbrc.1999.1475; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Karsan A, 1996, J BIOL CHEM, V271, P27201, DOI 10.1074/jbc.271.44.27201; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIM I, 2002, FASEB J, V16, pU63; KOLIZEK TI, 1998, CURR BIOL, V8, P529; Kontos CD, 1998, MOL CELL BIOL, V18, P4131, DOI 10.1128/MCB.18.7.4131; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lee SH, 2002, J BIOCHEM, V131, P161, DOI 10.1093/oxfordjournals.jbchem.a003071; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Matsumoto T, 2002, J CELL BIOL, V156, P149, DOI 10.1083/jcb.200103096; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Papadakis CM, 2000, EUR PHYS J E, V1, P275, DOI 10.1007/s101890050029; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Witzenbichler B, 1998, J BIOL CHEM, V273, P18514, DOI 10.1074/jbc.273.29.18514; Yu Y, 1999, J CELL PHYSIOL, V178, P235, DOI 10.1002/(SICI)1097-4652(199902)178:2<235::AID-JCP13>3.3.CO;2-J; Zachary I, 2001, AM J PHYSIOL-CELL PH, V280, pC1375, DOI 10.1152/ajpcell.2001.280.6.C1375; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhou JH, 2001, J IMMUNOL, V167, P4436, DOI 10.4049/jimmunol.167.8.4436	42	90	91	4	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1523	+		10.1096/fj.02-0698fje	http://dx.doi.org/10.1096/fj.02-0698fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824293				2022-12-28	WOS:000183818000026
J	Zwaka, TP; Torzewski, J; Hoeflich, A; Dejosez, M; Kaiser, S; Hombach, V; Jehle, PM				Zwaka, TP; Torzewski, J; Hoeflich, A; Dejosez, M; Kaiser, S; Hombach, V; Jehle, PM			The terminal complement complex inhibits apoptosis in vascular smooth muscle cells by activating an autocrine IGF-1 loop	FASEB JOURNAL			English	Article						arteriosclerosis; cell death; inflammation; C5b-9; growth factors	C-REACTIVE PROTEIN; HUMAN ATHEROSCLEROTIC PLAQUES; HUMAN CORONARY-ARTERIES; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-I; UNSENSITIZED CELLS; MEDIATED LYSIS; SUBLYTIC C5B-9; PROLIFERATION; RESTENOSIS	Two counteracting processes determine accumulation of human vascular smooth muscle cells (SMCs) in atherosclerotic lesions: cell proliferation and apoptosis. SMCs synthesize insulin-like growth factor-1 (IGF-1), which potently inhibits apoptosis. The terminal complement complex C5b-9 interacts with SMCs in early human atherogenesis. In this study, we investigated whether C5b-9 may activate the IGF-1 system in SMCs, resulting in the inhibition of SMC apoptosis. C5b-9 generation on SMCs in vitro markedly reduced CD95-mediated apoptosis as assessed by flowcytometric analysis of annexin V binding and in caspase 3 assays. C5b-9 induced both significant IGF-1 release and up-regulation of IGF-1 binding sites in SMCs. Immunoneutralization of IGF-1 with a monoclonal IGF-1 antibody abolished the antiapoptotic effects of C5b-9. We conclude that C5b-9 inhibits apoptosis in SMCs by inducing an autocrine IGF-1 loop. This mechanism may contribute to the accumulation of SMCs in early human atherosclerotic lesions.	Univ Ulm, Dept Internal Med 2, D-89069 Ulm, Germany; Univ Munich, Gene Ctr, Inst Mol Anim Breeding, D-80539 Munich, Germany; Creatogen AG, Augsburg, Germany	Ulm University; University of Munich	Torzewski, J (corresponding author), Univ Ulm, Dept Internal Med Cardiol 2, Robert Koch Str 8, D-89081 Ulm, Germany.	jan.torzewski@medizin.uni-ulm.de		Hoeflich, Andreas/0000-0003-2018-2836; Torzewski, Jan/0000-0003-4959-7293				Bayes-Genis A, 2000, CIRC RES, V86, P125, DOI 10.1161/01.RES.86.2.125; BENZAQUEN LR, 1994, J EXP MED, V179, P985, DOI 10.1084/jem.179.3.985; Buono C, 2002, CIRCULATION, V105, P3025, DOI 10.1161/01.CIR.0000019584.04929.83; Dashiell SM, 2000, GLIA, V30, P187, DOI 10.1002/(SICI)1098-1136(200004)30:2<187::AID-GLIA8>3.0.CO;2-7; Dejosez M, 2000, CELL DEATH DIFFER, V7, P1127, DOI 10.1038/sj.cdd.4400746; Flossmann-Kast BBM, 1998, CANCER RES, V58, P3551; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200, DOI 10.1161/01.ATV.17.10.2200; GORDON D, 1990, P NATL ACAD SCI USA, V87, P4600, DOI 10.1073/pnas.87.12.4600; Haverkate F, 1997, LANCET, V349, P462, DOI 10.1016/S0140-6736(96)07591-5; Hila S, 2001, GLIA, V36, P58, DOI 10.1002/glia.1095; ISNER JM, 1995, CIRCULATION, V91, P2703, DOI 10.1161/01.CIR.91.11.2703; Jehle PM, 1999, HORM METAB RES, V31, P97, DOI 10.1055/s-2007-978705; Kockx MM, 2000, J PATHOL, V190, P267, DOI 10.1002/(SICI)1096-9896(200002)190:3<267::AID-PATH523>3.0.CO;2-A; Kockx MM, 2000, CARDIOVASC RES, V45, P736, DOI 10.1016/S0008-6363(99)00235-7; Kockx MM, 1998, CIRCULATION, V97, P2307, DOI 10.1161/01.CIR.97.23.2307; LACHMANN PJ, 1970, J EXP MED, V131, P643, DOI 10.1084/jem.131.4.643; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Niculescu F, 1999, MOL IMMUNOL, V36, P949, DOI 10.1016/S0161-5890(99)00117-0; Niculescu F, 1999, ATHEROSCLEROSIS, V142, P47, DOI 10.1016/S0021-9150(98)00185-3; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1993, AM J PATHOL, V143, P987; Rus HG, 2001, IMMUNOL REV, V180, P49, DOI 10.1034/j.1600-065X.2001.1800104.x; Schmiedt W, 1998, ARTERIOSCL THROM VAS, V18, P1790, DOI 10.1161/01.ATV.18.11.1790; SEIFERT PS, 1988, ATHEROSCLEROSIS, V73, P91, DOI 10.1016/0021-9150(88)90030-5; Soane L, 1999, J IMMUNOL, V163, P6132; THOMPSON RA, 1970, J EXP MED, V131, P629, DOI 10.1084/jem.131.4.629; Torzewski J, 1996, ARTERIOSCL THROM VAS, V16, P673, DOI 10.1161/01.ATV.16.5.673; Torzewski J, 1998, ARTERIOSCL THROM VAS, V18, P1386, DOI 10.1161/01.ATV.18.9.1386; Torzewski J, 1997, ATHEROSCLEROSIS, V132, P131, DOI 10.1016/S0021-9150(97)00100-7; Torzewski M, 1997, ARTERIOSCL THROM VAS, V17, P2448, DOI 10.1161/01.ATV.17.11.2448; Viedt C, 2000, FASEB J, V14, P2370; von Wichert G, 2000, CANCER RES, V60, P4573; Yasojima K, 2001, AM J PATHOL, V158, P1039, DOI 10.1016/S0002-9440(10)64051-5; Zhang YX, 1999, ATHEROSCLEROSIS, V145, P375, DOI 10.1016/S0021-9150(99)00105-7; Zwaka TP, 2001, CIRCULATION, V103, P1194; Zwaka TP, 2002, AM J PATHOL, V161, P449, DOI 10.1016/S0002-9440(10)64201-0	37	27	27	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1346	+		10.1096/fj.02-0814fje	http://dx.doi.org/10.1096/fj.02-0814fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759337				2022-12-28	WOS:000183165000016
J	Sidhu, A; Wersinger, C; Vernier, P				Sidhu, A; Wersinger, C; Vernier, P			Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?	FASEB JOURNAL			English	Review						dopamine transporter; Parkinson's disease; synucleopathies; neurodegeneration; MPTP; Lewy bodies	MULTIPLE-SYSTEM ATROPHY; CENTRAL-NERVOUS-SYSTEM; A-BETA COMPONENT; CORTICAL LEWY BODIES; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; WILD-TYPE; HUMAN BRAIN; NEUROTRANSMITTER TRANSPORTERS; NEURODEGENERATIVE DISORDERS	Alpha-Synuclein is a key component of the pathological process of neurodegeneration in Parkinson's disease. Although its contributions to normal physiological conditions remain elusive, converging observations suggest that a primary function of this protein in dopaminergic neurons may be the regulation of dopamine content and synaptic tone at the synapse. We review here cumulative evidence that demonstrates the participation of alpha-synuclein in the life cycle of dopamine from its synthesis, storage, release, and reuptake. The regulatory role of alpha-synuclein on dopamine metabolism is assessed by discussing the experimental evidence supporting each of these observations in the healthy physiological maintenance of dopaminergic neurons, as well as showing how disruption of these events can initiate the observed neurotoxicity of alpha-synuclein and the genesis of the degenerative processes associated with Parkinson's disease.	Georgetown Univ, Dept Pediat, Washington, DC USA; CNRS, Inst Neurobiol Alfred FESSARD, F-91198 Gif Sur Yvette, France	Georgetown University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Sidhu, A (corresponding author), Lab Molec Neurochem, Res Bldg,Room W222,3970 Reservoir Rd,NW, Washington, DC 20007 USA.	sidhua@georgetown.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045326, R01NS034914] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-45326, NS-34914] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Ahn BH, 2002, J BIOL CHEM, V277, P12334, DOI 10.1074/jbc.M110414200; Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Baba M, 1998, AM J PATHOL, V152, P879; Bodles AM, 2001, J NEUROCHEM, V78, P384, DOI 10.1046/j.1471-4159.2001.00408.x; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chan P, 1998, NEUROLOGY, V50, P1136, DOI 10.1212/WNL.50.4.1136; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; D'Andrea MR, 2001, NEUROSCI LETT, V306, P137, DOI 10.1016/S0304-3940(01)01811-0; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; Dai JG, 2003, J NEUROCHEM, V84, P23, DOI 10.1046/j.1471-4159.2003.01254.x; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Dauer W, 2002, P NATL ACAD SCI USA, V99, P14524, DOI 10.1073/pnas.172514599; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dhillon AS, 2003, MOL CELL BIOL, V23, P1983, DOI 10.1128/MCB.23.6.1983-1993.2003; Du HN, 2003, BIOCHEMISTRY-US, V42, P8870, DOI 10.1021/bi034028+; Eells JB, 2003, CURR MED CHEM, V10, P857, DOI 10.2174/0929867033457700; Eiden LE, 2000, FASEB J, V14, P2396, DOI 10.1096/fj.00-0817rev; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Gainetdinov RR, 1997, J NEUROCHEM, V69, P1322; Gainetdinov RR, 1998, J NEUROCHEM, V70, P1973; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Galvin JE, 2001, EXP NEUROL, V168, P347, DOI 10.1006/exnr.2000.7615; George JM, 2002, GENOME BIOL, V3; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; GRAHAM DG, 1978, MOL PHARMACOL, V14, P633; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; HEUSER JE, 1973, J CELL BIOL, V57, P315, DOI 10.1083/jcb.57.2.315; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; ICHIMURA T, 1987, FEBS LETT, V219, P79, DOI 10.1016/0014-5793(87)81194-8; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakowec MW, 2001, DEV NEUROSCI-BASEL, V23, P91, DOI 10.1159/000048700; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Jensen PJ, 2003, J NEUROCHEM, V86, P196, DOI 10.1046/j.1471-4159.2003.01835.x; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kakimura J, 2001, EUR J PHARMACOL, V417, P59, DOI 10.1016/S0014-2999(01)00902-5; Kanda S, 2000, NEUROSCIENCE, V97, P279, DOI 10.1016/S0306-4522(00)00077-4; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kim TD, 2000, PROTEIN SCI, V9, P2489, DOI 10.1110/ps.9.12.2489; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kumer SC, 1996, J NEUROCHEM, V67, P443; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee CS, 2000, ANN NEUROL, V47, P493, DOI 10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4; Lee D, 2002, J NEUROCHEM, V82, P1007, DOI 10.1046/j.1471-4159.2002.01024.x; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li JY, 2002, NEUROSCIENCE, V113, P463, DOI 10.1016/S0306-4522(02)00143-4; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; MAKER HS, 1981, J NEUROCHEM, V36, P589, DOI 10.1111/j.1471-4159.1981.tb01631.x; Manning-Bog AB, 2003, J NEUROSCI, V23, P3095; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; Martinez J, 2003, J BIOL CHEM, V278, P17379, DOI 10.1074/jbc.M209020200; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mori F, 2002, BRAIN RES, V941, P118, DOI 10.1016/S0006-8993(02)02643-4; Mori F, 2002, EXP NEUROL, V176, P98, DOI 10.1006/exnr.2002.7929; Moron JA, 2003, J NEUROSCI, V23, P8480; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Nakamura T, 2002, FEBS LETT, V521, P190, DOI 10.1016/S0014-5793(02)02861-2; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nelson N, 1998, J NEUROCHEM, V71, P1785; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Parsons SM, 2000, FASEB J, V14, P2423, DOI 10.1096/fj.00-0203rev; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Petersen K, 1999, NEUROSCIENCE, V91, P651, DOI 10.1016/S0306-4522(98)00596-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Quilty MC, 2003, EXP NEUROL, V182, P195, DOI 10.1016/S0014-4886(03)00108-0; Richfield EK, 2002, EXP NEUROL, V175, P35, DOI 10.1006/exnr.2002.7882; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Scott WK, 1999, NEUROGENETICS, V2, P191, DOI 10.1007/s100480050083; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stephan A, 2002, HIPPOCAMPUS, V12, P55, DOI 10.1002/hipo.10006; Takahashi N, 1997, P NATL ACAD SCI USA, V94, P9938, DOI 10.1073/pnas.94.18.9938; Takeda A, 1998, AM J PATHOL, V152, P367; Torres GE, 2003, NAT REV NEUROSCI, V4, P13, DOI 10.1038/nrn1008; Toska K, 2002, J NEUROCHEM, V83, P775, DOI 10.1046/j.1471-4159.2002.01172.x; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uhl GR, 2000, FASEB J, V14, P2459, DOI 10.1096/fj.00-0205rev; Uversky VN, 2003, J BIOMOL STRUCT DYN, V21, P211, DOI 10.1080/07391102.2003.10506918; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Weihe E, 2000, FASEB J, V14, P2435, DOI 10.1096/fj.00-0202rev; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2003, FASEB J, V17, P2151, DOI 10.1096/fj.03-0152fje; Wersinger C, 2003, MOL CELL NEUROSCI, V24, P91, DOI 10.1016/S1044-7431(03)00124-6; WERSINGER C, 2004, IN PRESS BIOCHEMISTR; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Youdim MBH, 2003, J NEURAL TRANSM-SUPP, P73; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zhu M, 2003, J BIOL CHEM, V278, P40186, DOI 10.1074/jbc.M305326200	142	131	143	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					637	647		10.1096/fj.03-1112rev	http://dx.doi.org/10.1096/fj.03-1112rev			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054086				2022-12-28	WOS:000221108800034
J	Stolzing, A; Grune, T				Stolzing, A; Grune, T			Neuronal apoptotic bodies: phagocytosis and degradation by primary microglial cells	FASEB JOURNAL			English	Article						proteasome; lysosome; scavenger receptor; microglia; protein oxidation	CENTRAL-NERVOUS-SYSTEM; SCAVENGER RECEPTOR; OXIDATIVE-STRESS; PHOSPHATIDYLSERINE EXPOSURE; RECOGNITION MECHANISM; DYING CELLS; IN-VITRO; CLEARANCE; CD36; MACROPHAGES	Neuronal loss via apoptosis is a key element in numerous neurodegenerative diseases. To avoid accumulation of apoptotic material, the remains of apoptotic cells should be degraded. It was suggested that microglial cells are phagocytosing and degrading apoptotic material. There is only limited information available concerning the fate of the remains of apoptotic neurons. In this study, we investigated the ability of microglial cells to take up and degrade neuronal apoptotic material. We isolated primary microglial cells and used apoptotic bodies of apoptotic neuron-like PC12 cells as a substrate. The apoptotic material was taken up and degraded within the microglial cells. The uptake is clearly activation dependent. We were able to demonstrate that the CD36 scavenger receptor is involved in the uptake of the apoptotic material via competition studies, antibody blockage, and use of a CD36 mutant rat strain. Blockage of other uptake mechanisms was also able to inhibit the uptake to some extent. Furthermore, we were able to demonstrate the role of the microglial lysosomal and proteasomal pathways in the degradation of proteins originating from apoptotic bodies.	Univ Dusseldorf, Environm Med Res Inst, D-40225 Dusseldorf, Germany; Humboldt Univ, Fac Med Charite, Neurosci Res Ctr, Berlin, Germany	Heinrich Heine University Dusseldorf; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Grune, T (corresponding author), Univ Dusseldorf, Environm Med Res Inst, Hennekamp 50, D-40225 Dusseldorf, Germany.	Tilman.Grune@uni-duesseldorf.de	Stolzing, Alexandra/O-7815-2016; Stolzing, Alexandra/S-4208-2019	Stolzing, Alexandra/0000-0002-2975-5736; Stolzing, Alexandra/0000-0002-2975-5736; Grune, Tilman/0000-0003-4775-9973				Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aloisi F, 2000, J IMMUNOL, V164, P1705, DOI 10.4049/jimmunol.164.4.1705; Andersen JK, 2001, BIOESSAYS, V23, P640, DOI 10.1002/bies.1089; Azuma Y, 2002, BIOL PHARM BULL, V25, P1277, DOI 10.1248/bpb.25.1277; Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002; Bedner E, 1999, CYTOMETRY, V35, P181, DOI 10.1002/(SICI)1097-0320(19990301)35:3<181::AID-CYTO1>3.0.CO;2-5; Boullier A, 2000, J BIOL CHEM, V275, P9163, DOI 10.1074/jbc.275.13.9163; Buss H, 1997, FREE RADICAL BIO MED, V23, P361, DOI 10.1016/S0891-5849(97)00104-4; Chan A, 2003, GLIA, V43, P231, DOI 10.1002/glia.10258; Chang MK, 1999, P NATL ACAD SCI USA, V96, P6353, DOI 10.1073/pnas.96.11.6353; COMPTON MM, 1992, CANCER METAST REV, V11, P105, DOI 10.1007/BF00048058; Darzynkiewicz Z, 1997, CYTOMETRY, V27, P1; Erwig LP, 1999, BLOOD, V93, P1406, DOI 10.1182/blood.V93.4.1406.404k10_1406_1412; Fadok VA, 1998, J IMMUNOL, V161, P6250; Fadok VA, 1998, CURR BIOL, V8, pR693, DOI 10.1016/S0960-9822(98)70438-5; Fadok VA, 2001, SEMIN IMMUNOL, V13, P365, DOI 10.1006/smim.2001.0333; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Floyd RA, 2002, NEUROBIOL AGING, V23, P795, DOI 10.1016/S0197-4580(02)00019-2; Girotti AW, 1998, J LIPID RES, V39, P1529; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Gu ZZ, 2000, ANTIOXID REDOX SIGN, V2, P437, DOI 10.1089/15230860050192215; Hanayama R, 2002, NATURE, V417, P182, DOI 10.1038/417182a; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Hughes J, 1997, J IMMUNOL, V158, P4389; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; Husemann J, 2002, GLIA, V40, P195, DOI 10.1002/glia.10148; Ihara T, 1998, VIRCHOWS ARCH, V433, P443, DOI 10.1007/s004280050272; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Kaufmann JA, 2001, J NEUROCHEM, V76, P1099, DOI 10.1046/j.1471-4159.2001.00118.x; Kuhlmann T, 2002, J NEUROSCI RES, V67, P185, DOI 10.1002/jnr.10104; Lasch P, 2001, J BIOL CHEM, V276, P9492, DOI 10.1074/jbc.M008528200; Magnus T, 2002, J NEUROIMMUNOL, V130, P1, DOI 10.1016/S0165-5728(02)00212-6; Magnus T, 2001, J IMMUNOL, V167, P5004, DOI 10.4049/jimmunol.167.9.5004; Manfredi AA, 2002, APOPTOSIS, V7, P153, DOI 10.1023/A:1014366531885; Mehlhase J, 2000, IUBMB LIFE, V50, P331, DOI 10.1080/15216540051081137; Messmer UK, 2000, BIOESSAYS, V22, P878, DOI 10.1002/1521-1878(200010)22:10<878::AID-BIES2>3.3.CO;2-A; Miyazaki A, 2002, TRENDS CARDIOVAS MED, V12, P258, DOI 10.1016/S1050-1738(02)00171-8; Panousis CG, 2000, J LIPID RES, V41, P75; Parnaik R, 2000, CURR BIOL, V10, P857, DOI 10.1016/S0960-9822(00)00598-4; PARTHASERATHY S, 1990, P NATL ACAD SCI USA, V84, P537; Platt N, 2000, J IMMUNOL, V164, P4861, DOI 10.4049/jimmunol.164.9.4861; Platt N, 1996, P NATL ACAD SCI USA, V93, P12456, DOI 10.1073/pnas.93.22.12456; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Rudeck M, 2000, IUBMB LIFE, V49, P451; Savill J, 1997, BRIT MED BULL, V53, P491; SAVILL J, 1993, IMMUNOL TODAY, V14, P131, DOI 10.1016/0167-5699(93)90215-7; Shiratsuchi A, 1999, J BIOL CHEM, V274, P5901, DOI 10.1074/jbc.274.9.5901; Sitte N, 1998, FEBS LETT, V440, P399, DOI 10.1016/S0014-5793(98)01495-1; Skulachev VP, 2001, EXP GERONTOL, V36, P995, DOI 10.1016/S0531-5565(01)00109-7; SOMMERBURG O, 1993, MEDIAT INFLAMM, V2, P27, DOI 10.1155/S0962935193000031; Stern M, 1996, AM J PATHOL, V149, P911; Stohwasser R, 2000, GLIA, V29, P355, DOI 10.1002/(SICI)1098-1136(20000215)29:4<355::AID-GLIA6>3.0.CO;2-4; Stolzing A, 2003, J NEUROSCI RES, V71, P264, DOI 10.1002/jnr.10478; Stolzing A, 2002, ARCH BIOCHEM BIOPHYS, V400, P171, DOI 10.1016/S0003-9861(02)00003-6; Tonevitsky AG, 2003, BIOCHEMISTRY-MOSCOW+, V68, P275, DOI 10.1023/A:1023050132342; Ullrich O, 1999, FREE RADICAL BIO MED, V27, P487, DOI 10.1016/S0891-5849(99)00060-X; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; WHITEHOUSE PJ, 1982, SCIENCE, V215, P1237, DOI 10.1126/science.7058341; Wiegand UK, 2001, CELL DEATH DIFFER, V8, P734, DOI 10.1038/sj.cdd.4400867; Williamson P, 2001, METHOD CELL BIOL, V66, P339; Witting A, 2000, J NEUROCHEM, V75, P1060, DOI 10.1046/j.1471-4159.2000.0751060.x; WONG SHY, 1987, CLIN CHEM, V33, P214; Wu Q, 2000, NEUROBIOL AGING, V21, P797, DOI 10.1016/S0197-4580(00)00219-0; Zingg JM, 2000, IUBMB LIFE, V49, P397	65	73	75	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					743	+		10.1096/fj.03-0374fje	http://dx.doi.org/10.1096/fj.03-0374fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766802				2022-12-28	WOS:000220425000034
J	Zheng, PS; Wen, JP; Ang, LC; Sheng, W; Viloria-Petit, A; Wang, YL; Wu, YJ; Kerbel, RS; Yang, BB				Zheng, PS; Wen, JP; Ang, LC; Sheng, W; Viloria-Petit, A; Wang, YL; Wu, YJ; Kerbel, RS; Yang, BB			Versican/PG-M G3 domain promotes tumor growth and angiogenesis	FASEB JOURNAL			English	Article						fibronectin; endothelial cell; vascular endothelial growth factor; astrocytoma	CHONDROITIN SULFATE PROTEOGLYCAN; FACTOR-LIKE MOTIFS; LARGE AGGREGATING PROTEOGLYCAN; SMOOTH-MUSCLE-CELLS; PG-M/VERSICAN; G1 DOMAIN; HYALURONIC-ACID; HUMAN TISSUES; LINK PROTEIN; L-SELECTIN	Versican/PG-M is an extracellular matrix proteoglycan, expression of which is elevated in a variety of human tumors. The significance of this change is unclear. Here we show that versican G3-containing fragments are present at high levels in human astrocytoma. Expression of a versican G3 construct in U87 astrocytoma cells enhances colony growth in soft agarose gel and tumor growth and blood vessel formation in nude mice. The G3-containing medium enhances endothelial cell adhesion, proliferation, and migration. G3-expressing cells and tumors formed by these cells express increased levels of fibronectin and vascular endothelial growth factor (VEGF). Furthermore, the G3 domain directly binds to fibronectin and forms a complex together with VEGF. In the presence of these three molecules, endothelial cell adhesion, proliferation, and migration were found to be significantly enhanced. Removal of the complex containing these molecules reverses these processes. Taken together, these findings implicate G3 as a modifier of tumor growth and angiogenesis and suggest a new avenue for development of anticancer and anti-angiogenic therapies based on targeting versican G3 fragments.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Western Ontario, Div Neuropathol, London, ON N6A 3K7, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Western University (University of Western Ontario); University of Toronto; University of Toronto	Yang, BB (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Burton.Yang@sw.ca						Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; Aspberg A, 1999, J BIOL CHEM, V274, P20444, DOI 10.1074/jbc.274.29.20444; ASPBERG A, 1995, P NATL ACAD SCI USA, V92, P10590, DOI 10.1073/pnas.92.23.10590; BINETTE F, 1994, J BIOL CHEM, V269, P19116; BodeLesniewska B, 1996, J HISTOCHEM CYTOCHEM, V44, P303, DOI 10.1177/44.4.8601689; BRAUNEWELL KH, 1995, EUR J NEUROSCI, V7, P805, DOI 10.1111/j.1460-9568.1995.tb00683.x; Brown LF, 1999, CLIN CANCER RES, V5, P1041; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; DOURSZIMMERMANN MT, 1994, J BIOL CHEM, V269, P32992; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; GROVER J, 1993, BIOCHEM J, V291, P361, DOI 10.1042/bj2910361; Halpert I, 1996, P NATL ACAD SCI USA, V93, P9748, DOI 10.1073/pnas.93.18.9748; Isogai C, 2001, CANCER RES, V61, P5587; Isogai Z, 2002, J BIOL CHEM, V277, P4565, DOI 10.1074/jbc.M110583200; Isogai Z, 1996, CANCER RES, V56, P3902; ITO K, 1995, J BIOL CHEM, V270, P958, DOI 10.1074/jbc.270.2.958; Kawashima H, 1999, INT IMMUNOL, V11, P393, DOI 10.1093/intimm/11.3.393; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; LEBARON RG, 1992, J BIOL CHEM, V267, P10003; Lebaron RG, 1996, PERSPECT DEV NEUROBI, V3, P261; Lemire JM, 1999, ARTERIOSCL THROM VAS, V19, P1630, DOI 10.1161/01.ATV.19.7.1630; Matsumoto K, 2003, J BIOL CHEM, V278, P41205, DOI 10.1074/jbc.M305060200; Nara Y, 1997, HISTOCHEM J, V29, P21, DOI 10.1023/A:1026460700592; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; PAULUS W, 1994, J NEUROSURG, V80, P515, DOI 10.3171/jns.1994.80.3.0515; PERIDES G, 1993, ANAT EMBRYOL, V188, P467; PERIDES G, 1992, J BIOL CHEM, V267, P23883; Pettersson A, 2000, LAB INVEST, V80, P99, DOI 10.1038/labinvest.3780013; PLATE KH, 1992, NATURE, V359, P845, DOI 10.1038/359845a0; Ricciardelli C, 2002, CLIN CANCER RES, V8, P1054; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; UJITA M, 1994, J BIOL CHEM, V269, P27603; Wang F, 2002, JNCI-J NATL CANCER I, V94, P1494, DOI 10.1093/jnci/94.19.1494; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wijelath ES, 2002, CIRC RES, V91, P25, DOI 10.1161/01.RES.0000026420.22406.79; WU CY, 1995, CELL, V83, P715, DOI 10.1016/0092-8674(95)90184-1; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; WU YJ, 2004, IN PRESS J CELL SCI; YAMAGATA M, 1986, J BIOL CHEM, V261, P3526; Yamazaki Kosuke, 1995, In Vivo (Attiki), V9, P421; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; Yi M, 2001, P NATL ACAD SCI USA, V98, P620, DOI 10.1073/pnas.98.2.620; Zhang Y, 1999, J CELL BIOCHEM, V73, P445, DOI 10.1002/(SICI)1097-4644(19990615)73:4<445::AID-JCB3>3.0.CO;2-D; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x; ZIMMERMANN DR, 1994, J CELL BIOL, V124, P817, DOI 10.1083/jcb.124.5.817	52	135	140	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					754	+		10.1096/fj.03-0545fje	http://dx.doi.org/10.1096/fj.03-0545fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766798				2022-12-28	WOS:000220425000040
J	Kumar, A; Khandelwal, N; Malya, R; Reid, MB; Boriek, AM				Kumar, A; Khandelwal, N; Malya, R; Reid, MB; Boriek, AM			Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers	FASEB JOURNAL			English	Article						dystrophin; skeletal muscle; MAP kinases; AP-1; mechanotransduction	DUCHENNE MUSCULAR-DYSTROPHY; SIGNAL-TRANSDUCTION PATHWAYS; PROTEIN-KINASES; GLYCOPROTEIN COMPLEX; ACTIVATOR PROTEIN-1; MAPK ACTIVATION; MDX-MYOTUBES; IN-VIVO; CELLS; STRETCH	Dystrophin is a cytoskeletal protein found at the inner surface of skeletal and cardiac muscle fibers. We hypothesize that deficiency of dystrophin increases muscle compliance and causes an aberrant mechanotransduction in muscle fibers. To test this hypothesis, we measured the length-tension relationships and determined intracellular signaling leading to the activation of mitogen-activated protein (MAP) kinases in diaphragm muscle fibers from dystrophin-deficient mdx mice. Compared with controls, length-tension curves of the mdx mice were shifted to the right. A higher level of activation of extracellular signal-reffulated kinase 1/2 (ERK1/2) but not c-Jun N-terminal kinase-1 or p38 MAP kinase was observed in the mdx muscle compared with the normal muscle in response to mechanical stretch. Removal of Ca2+ from the medium inhibited stretch-induced ERK1/2 activation only in mdx muscle fibers but not in the normal fibers. Conversely, pretreatment with TMB-8 (an antagonist of intracellular Ca2+) blocked the mechanical stretch-induced ERK1/2 activation in normal but not in mdx muscle fibers. pretreatment of muscle with nifedipine (L-type calcium channel antagonist) marginally decreased the activation of ERK1/2 in normal or mdx muscle whereas pretreatment with gadolinium (III) chloride (an inhibitor of stretch-activated channels) only blocked the activation of ERK1/2 in mdx muscle, with no significant effect on normal muscle. A higher basal level of activation of activator protein-1 (AP-1) transcription factor was observed in dystrophin-deficient diaphragm, which was further augmented by mechanical stretch. Mechanical stretch-induced activation of AP-1 was decreased by pretreatment of muscle fibers with PD98059 (ERK1/2 inhibitor) and removal of Ca2+ ions from incubation medium. Our results show that dystrophin is a load-bearing element and its deficiency leads to loss of muscle stiffness and aberrant mechanotransduction in skeletal muscle fibers.	Baylor Coll Med, Dept Med, Pulm Sect, Houston, TX 77030 USA	Baylor College of Medicine	Boriek, AM (corresponding author), Baylor Coll Med, Dept Med, Pulm Sect, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	boriek@bcm.tmc.edu		Kumar, Ashok/0000-0001-8571-2848; Kumar, Ashok/0000-0002-2444-9529	PHS HHS [R01-46230, R01-63134] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Agell N, 2002, CELL SIGNAL, V14, P649, DOI 10.1016/S0898-6568(02)00007-4; Alderton JM, 2000, J BIOL CHEM, V275, P9452, DOI 10.1074/jbc.275.13.9452; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Boriek AM, 2001, AM J PHYSIOL-CELL PH, V280, pC46, DOI 10.1152/ajpcell.2001.280.1.C46; BORIEK AM, 1994, AM J RESP CRIT CARE, V149, pA226; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Danialou G, 2001, FASEB J, V15, P1655, DOI 10.1096/fj.01-0030fje; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Durbeej M, 2002, CURR OPIN GENET DEV, V12, P349, DOI 10.1016/S0959-437X(02)00309-X; Ehmsen J, 2002, J CELL SCI, V115, P2801; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; FRANCO A, 1991, BIOPHYS J, V59, P1164, DOI 10.1016/S0006-3495(91)82332-3; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Gailly P, 2002, BBA-PROTEINS PROTEOM, V1600, P38, DOI 10.1016/S1570-9639(02)00442-9; Gillespie PG, 2001, NATURE, V413, P194, DOI 10.1038/35093011; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Henry MD, 1996, CURR OPIN CELL BIOL, V8, P625, DOI 10.1016/S0955-0674(96)80103-7; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1987, SCIENCE, V238, P347, DOI 10.1126/science.3659917; Ingber DE, 1998, BIOL BULL-US, V194, P323, DOI 10.2307/1543102; Inoh H, 2002, FASEB J, V16, P405, DOI 10.1096/fj.01-0354fje; JUNG D, 1995, J BIOL CHEM, V270, P27305, DOI 10.1074/jbc.270.45.27305; Kamogawa Y, 2001, CARDIOVASC RES, V50, P509, DOI 10.1016/S0008-6363(01)00205-X; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kato T, 1998, BIOCHEM BIOPH RES CO, V244, P615, DOI 10.1006/bbrc.1998.8335; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; Kumar A, 1999, METHOD ENZYMOL, V300, P339; Kumar A, 2003, FASEB J, V17, P386, DOI 10.1096/fj.02-0542com; Kumar A, 2003, J BIOL CHEM, V278, P18868, DOI 10.1074/jbc.M212777200; Kumar A, 2002, J BIOL CHEM, V277, P46493, DOI 10.1074/jbc.M203654200; Kumar A, 1998, J IMMUNOL, V161, P776; LAW DJ, 1994, J CELL SCI, V107, P1477; Li W, 2001, AM J PHYSIOL-GASTR L, V280, pG75, DOI 10.1152/ajpgi.2001.280.1.G75; Liu MY, 1999, AM J PHYSIOL-LUNG C, V277, pL667, DOI 10.1152/ajplung.1999.277.4.L667; Martineau LC, 2001, J APPL PHYSIOL, V91, P693, DOI 10.1152/jappl.2001.91.2.693; MASSA R, 1994, ACTA NEUROPATHOL, V87, P377; O'Brien KF, 2001, MOL GENET METAB, V74, P75, DOI 10.1006/mgme.2001.3220; PASTERNAK C, 1995, J CELL BIOL, V128, P355, DOI 10.1083/jcb.128.3.355; Pelham RJ, 1997, P NATL ACAD SCI USA, V94, P13661, DOI 10.1073/pnas.94.25.13661; PETROF BJ, 1993, P NATL ACAD SCI USA, V90, P3710, DOI 10.1073/pnas.90.8.3710; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Rando TA, 2001, MUSCLE NERVE, V24, P1575, DOI 10.1002/mus.1192; Ruwhof C, 2000, CARDIOVASC RES, V47, P23, DOI 10.1016/S0008-6363(00)00076-6; Rybakova IN, 1996, J CELL BIOL, V135, P661, DOI 10.1083/jcb.135.3.661; Ryder JW, 2000, J BIOL CHEM, V275, P1457, DOI 10.1074/jbc.275.2.1457; Soderling TR, 2001, CHEM REV, V101, P2341, DOI 10.1021/cr0002386; Spencer MJ, 1997, J CLIN INVEST, V99, P2745, DOI 10.1172/JCI119464; SPENCER MJ, 1995, J BIOL CHEM, V270, P10909, DOI 10.1074/jbc.270.18.10909; STEDMAN HH, 1991, NATURE, V352, P536, DOI 10.1038/352536a0; Stull JT, 2001, J BIOL CHEM, V276, P2311, DOI 10.1074/jbc.R000030200; TIDBALL JG, 1995, J CELL SCI, V108, P2197; Wang HB, 2001, P NATL ACAD SCI USA, V98, P11295, DOI 10.1073/pnas.201201198; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Winder SJ, 1997, J MUSCLE RES CELL M, V18, P617, DOI 10.1023/A:1018627705273; Wisdom R, 1999, EXP CELL RES, V253, P180, DOI 10.1006/excr.1999.4685	59	121	126	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					102	113		10.1096/fj.03-0453com	http://dx.doi.org/10.1096/fj.03-0453com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718391				2022-12-28	WOS:000188829300044
J	Lecker, SH; Jagoe, RT; Gilbert, A; Gomes, M; Baracos, V; Bailey, J; Price, SR; Mitch, WE; Goldberg, AL				Lecker, SH; Jagoe, RT; Gilbert, A; Gomes, M; Baracos, V; Bailey, J; Price, SR; Mitch, WE; Goldberg, AL			Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression	FASEB JOURNAL			English	Article						ubiquitin-proteasome pathway; transcription	PROTEASOME PROTEOLYTIC PATHWAY; MESSENGER-RNAS; MATRIX METALLOPROTEINASES; UBIQUITIN CONJUGATION; TRANSCRIPTION FACTOR; OXIDATIVE STRESS; INSULIN ACTION; CATHEPSIN-L; PROTEIN; IDENTIFICATION	Skeletal muscle atrophy is a debilitating response to starvation and many systemic diseases including diabetes, cancer, and renal failure. We had proposed that a common set of transcriptional adaptations underlie the loss of muscle mass in these different states. To test this hypothesis, we used cDNA microarrays to compare the changes in content of specific mRNAs in muscles atrophying from different causes. We compared muscles from fasted mice, from rats with cancer cachexia, streptozotocin-induced diabetes mellitus, uremia induced by subtotal nephrectomy, and from pair-fed control rats. Although the content of >90% of mRNAs did not change, including those for the myofibrillar apparatus, we found a common set of genes (termed atrogins) that were induced or suppressed in muscles in these four catabolic states. Among the strongly induced genes were many involved in protein degradation, including polyubiquitins, Ub fusion proteins, the Ub ligases atrogin-1/MAFbx and MuRF-1, multiple but not all subunits of the 20S proteasome and its 19S regulator, and cathepsin L. Many genes required for ATP production and late steps in glycolysis were down-regulated, as were many transcripts for extracellular matrix proteins. Some genes not previously implicated in muscle atrophy were dramatically up-regulated (lipin, metallothionein, AMP deaminase, RNA helicase-related protein, TG interacting factor) and several growth-related mRNAs were down-regulated (P311, JUN, IGF-1-BP5). Thus, different types of muscle atrophy share a common transcriptional program that is activated in many systemic diseases.	Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA 02215 USA; Aintree Univ Hosp NHS Fdn Trust, Dept Med, Pulm & Rehabil Res Grp, Liverpool L9 7AL, Merseyside, England; Univ Alberta, Dept Agr Food & Nutr Sci, Edmonton, AB T6G 2M7, Canada; Emory Univ, Sch Med, Dept Med, Div Renal, Atlanta, GA USA; Univ Texas, Med Branch, Dept Med, Galveston, TX 77550 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Aintree University Hospitals NHS Foundation Trust; University of Liverpool; University of Alberta; Emory University; University of Texas System; University of Texas Medical Branch Galveston; Harvard University; Harvard Medical School	Goldberg, AL (corresponding author), Harvard Univ, Sch Med, Dept Biol, Boston, MA 02115 USA.	Alfred_goldberg@hms.harvard.edu	Gomes, Marcelo/AAC-6041-2021	Baracos, Vickie/0000-0002-9609-1001	NIDDK NIH HHS [DK50740, DK63658, DK37175, R37 DK037175, DK02727] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002727, R37DK037175, R01DK050740, R01DK063658, R01DK037175] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adegoke OAJ, 2002, AM J PHYSIOL-ENDOC M, V283, pE482, DOI 10.1152/ajpendo.00097.2002; ARACOS VE, 1995, AM J PHYSIOL, V268, pE996; Attaix D, 1997, MOL BIOL REP, V24, P95, DOI 10.1023/A:1006806103675; Auclair D, 1997, AM J PHYSIOL-CELL PH, V272, pC1007; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; Balcerzak D, 2001, J ANIM SCI, V79, P94; Baracos VE, 2002, CURR OPIN CLIN NUTR, V5, P237, DOI 10.1097/00075197-200205000-00001; Bayol S, 2000, BIOCHEM BIOPH RES CO, V273, P282, DOI 10.1006/bbrc.2000.2667; Bertolino E, 1995, J BIOL CHEM, V270, P31178, DOI 10.1074/jbc.270.52.31178; Bode BP, 2001, J NUTR, V131, p2475S, DOI 10.1093/jn/131.9.2475S; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; Borodovsky A, 2001, EMBO J, V20, P5187, DOI 10.1093/emboj/20.18.5187; BOYD, 1994, CELL, V79, P1121; Chan KM, 2001, P NATL ACAD SCI USA, V98, P4611, DOI 10.1073/pnas.081082098; Chandrasekhar S, 1999, AM J PHYSIOL-LUNG C, V276, pL319, DOI 10.1152/ajplung.1999.276.2.L319; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; Chrysis D, 1999, ENDOCRINOLOGY, V140, P5635, DOI 10.1210/en.140.12.5635; Cros N, 2001, J CELL BIOCHEM, V83, P508, DOI 10.1002/jcb.1248; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deval C, 2001, BIOCHEM J, V360, P143, DOI 10.1042/0264-6021:3600143; Fagan JM, 1999, ANN SURG, V229, P106, DOI 10.1097/00000658-199901000-00014; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; Fischer D, 2000, BIOCHEM BIOPH RES CO, V267, P504, DOI 10.1006/bbrc.1999.1987; Glass DJ, 2003, NAT CELL BIOL, V5, P87, DOI 10.1038/ncb0203-87; Goldring K, 2002, J CELL SCI, V115, P355; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; GUARDAVACCARO D, 1995, CELL GROWTH DIFFER, V6, P159; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hasselgren P O, 1999, Curr Opin Clin Nutr Metab Care, V2, P201, DOI 10.1097/00075197-199905000-00002; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Huffman TA, 2002, P NATL ACAD SCI USA, V99, P1047, DOI 10.1073/pnas.022634399; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Jagoe RT, 2001, CURR OPIN CLIN NUTR, V4, P183, DOI 10.1097/00075197-200105000-00003; Karinch AM, 2001, J NUTR, V131, p2535S, DOI 10.1093/jn/131.9.2535S; KAYALI AG, 1987, AM J PHYSIOL, V252, pE621, DOI 10.1152/ajpendo.1987.252.5.E621; Kelly EJ, 1997, P NATL ACAD SCI USA, V94, P10045, DOI 10.1073/pnas.94.19.10045; Kubasiak LA, 2002, P NATL ACAD SCI USA, V99, P12825, DOI 10.1073/pnas.202474099; Kwon YT, 2001, MOL CELL BIOL, V21, P8007, DOI 10.1128/MCB.21.23.8007-8021.2001; Lecker SH, 1999, J NUTR, V129, p227S, DOI 10.1093/jn/129.1.227S; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; Lee KK, 1998, J BIOL CHEM, V273, P19160, DOI 10.1074/jbc.273.30.19160; Lester D, 2000, BIOCHEM BIOPH RES CO, V269, P474, DOI 10.1006/bbrc.2000.2302; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; LLOVERA M, 1994, FEBS LETT, V338, P311, DOI 10.1016/0014-5793(94)80290-4; LOWENSTEIN JM, 1978, FED PROC, V37, P2308; Mannhaupt G, 1999, FEBS LETT, V450, P27, DOI 10.1016/S0014-5793(99)00467-6; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; Mariani L, 2001, CANCER RES, V61, P4190; Marinovic AC, 2002, J BIOL CHEM, V277, P16673, DOI 10.1074/jbc.M200501200; Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; MITCH WE, 1994, J CLIN INVEST, V93, P2127, DOI 10.1172/JCI117208; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Nath R, 2000, TOXICOLOGY, V155, P17, DOI 10.1016/S0300-483X(00)00273-0; Nishimoto S, 2002, BBA-GENE STRUCT EXPR, V1576, P225, DOI 10.1016/S0167-4781(02)00345-7; OLIVE M, 1994, NEUROPATH APPL NEURO, V20, P495, DOI 10.1111/j.1365-2990.1994.tb01001.x; Pan DS, 2002, J CLIN INVEST, V110, P1349, DOI 10.1172/JCI200215614; Penner G, 2002, AM J PHYSIOL-REG I, V282, pR439, DOI 10.1152/ajpregu.00512.2001; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Pineda M, 1999, J BIOL CHEM, V274, P19738, DOI 10.1074/jbc.274.28.19738; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Reid MB, 2001, ACTA PHYSIOL SCAND, V171, P225, DOI 10.1046/j.1365-201x.2001.00824.x; Reznick AZ, 2003, MUSCLE NERVE, V27, P51, DOI 10.1002/mus.10277; Rommel C, 2001, NAT CELL BIOL, V3, P1009, DOI 10.1038/ncb1101-1009; Schneider MR, 2002, J ENDOCRINOL, V172, P423, DOI 10.1677/joe.0.1720423; Schoser BG, 1999, NEUROREPORT, V10, P2795, DOI 10.1097/00001756-199909090-00018; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; TAKAHASHI H, 1993, AM REV RESPIR DIS, V147, P1562, DOI 10.1164/ajrccm/147.6_Pt_1.1562; TEMPARIS S, 1994, CANCER RES, V54, P5568; Tiao G, 1997, J CLIN INVEST, V99, P163, DOI 10.1172/JCI119143; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Tkatchenko AV, 2001, NEUROMUSCULAR DISORD, V11, P269, DOI 10.1016/S0960-8966(00)00198-X; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; Voisin L, 1996, J CLIN INVEST, V97, P1610, DOI 10.1172/JCI118586; WING SS, 1994, AM J PHYSIOL, V267, pE39, DOI 10.1152/ajpendo.1994.267.1.E39; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; Wray CJ, 2003, INT J BIOCHEM CELL B, V35, P698, DOI 10.1016/S1357-2725(02)00341-2; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Zhou Q, 1999, J BIOL CHEM, V274, P19807, DOI 10.1074/jbc.274.28.19807; Zierath JR, 2000, DIABETOLOGIA, V43, P821, DOI 10.1007/s001250051457	88	1141	1201	2	98	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					39	51		10.1096/fj.03-0610com	http://dx.doi.org/10.1096/fj.03-0610com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718385				2022-12-28	WOS:000188829300038
J	Mellott, TJ; Williams, CL; Meck, WH; Blusztajn, JK				Mellott, TJ; Williams, CL; Meck, WH; Blusztajn, JK			Prenatal choline supplementation advances hippocampal development and enhances MAPK and CREB activation	FASEB JOURNAL			English	Article						behavior; nutrition; pregnancy; learning; memory	ELEMENT-BINDING PROTEIN; LONG-TERM-MEMORY; CAMP-RESPONSIVE ELEMENT; SPATIAL MEMORY; ADULT RATS; DIETARY SUPPLEMENTATION; REARING ENVIRONMENT; KINASE CASCADE; PROXIMAL-CUE; DISTAL-CUE	Choline is an essential nutrient for animals and humans. Previous studies showed that supplementing the maternal diet with choline during the second half of gestation in rats permanently enhances memory performance of the adult offspring. Here we show that prenatal choline supplementation causes a 3-day advancement in the ability of juvenile rats to use relational cues in a water maze task, indicating that the treatment accelerates hippocampal maturation. Moreover, phosphorylation and therefore activation of hippocampal mitogen-ctivated protein kinase (MAPK) and cAMP-response element binding protein (CREB) in response to stimulation by glutamate, N-methyl-D-aspartate, or depolarizing concentrations of K+ were increased by prenatal choline supplementation and reduced by prenatal choline deficiency. These data provide the first evidence that developmental plasticity of the hippocampal MAPK and CREB signaling pathways is controlled by the supply of a single essential nutrient, choline, during fetal development and point to these pathways as candidate mechanisms for the developmental and long-term cognitive enhancement induced by prenatal choline supplementation.	Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA; Duke Univ, Dept Psychol & Brain Sci, Durham, NC 27708 USA	Boston University; Duke University	Blusztajn, JK (corresponding author), Boston Univ, Sch Med, Dept Pathol & Lab Med, 715 Albany St,L804, Boston, MA 02118 USA.	jbluszta@bu.edu		/0000-0001-8438-3122; Meck, Warren/0000-0002-6120-4790; Mellott, Tiffany/0000-0003-3287-9374				Albright CD, 1999, DEV BRAIN RES, V115, P123, DOI 10.1016/S0165-3806(99)00057-7; Albright CD, 1999, DEV BRAIN RES, V113, P13, DOI 10.1016/S0165-3806(98)00183-7; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Berman DE, 1998, J NEUROSCI, V18, P10037; Bernabeu R, 1997, P NATL ACAD SCI USA, V94, P7041, DOI 10.1073/pnas.94.13.7041; Blum S, 1999, J NEUROSCI, V19, P3535; Blusztajn JK, 1998, SCIENCE, V281, P794, DOI 10.1126/science.281.5378.794; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Brandner C, 2002, BRAIN RES, V928, P85, DOI 10.1016/S0006-8993(01)03363-7; Cammarota M, 2000, MOL BRAIN RES, V76, P36, DOI 10.1016/S0169-328X(99)00329-0; CASTRO CA, 1987, DEV PSYCHOBIOL, V20, P521, DOI 10.1002/dev.420200506; Cermak JM, 1998, FASEB J, V12, P349, DOI 10.1096/fasebj.12.3.349; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; *FOOD NUTR BOARD I, 1998, DIET REF INT THIAM R; Ginty DD, 1997, NEURON, V18, P183, DOI 10.1016/S0896-6273(00)80258-5; Guzowski JF, 1997, P NATL ACAD SCI USA, V94, P2693, DOI 10.1073/pnas.94.6.2693; Holmes GL, 2002, EPILEPSY RES, V48, P3, DOI 10.1016/S0920-1211(01)00321-7; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; Izquierdo I, 1997, NEUROBIOL LEARN MEM, V68, P285, DOI 10.1006/nlme.1997.3799; Jones JP, 1999, DEV BRAIN RES, V118, P159, DOI 10.1016/S0165-3806(99)00103-0; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kogan JH, 1997, CURR BIOL, V7, P1, DOI 10.1016/S0960-9822(06)00022-4; Lamprecht R, 1997, J NEUROSCI, V17, P8443; Lucas A, 1998, J NUTR, V128, p401S, DOI 10.1093/jn/128.2.401S; Martinez JL, 1996, ANNU REV PSYCHOL, V47, P173, DOI 10.1146/annurev.psych.47.1.173; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; Meck WH, 1997, NEUROREPORT, V8, P3053, DOI 10.1097/00001756-199709290-00010; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; Meck WH, 1997, NEUROREPORT, V8, P3045, DOI 10.1097/00001756-199709290-00009; Meck WH, 1999, DEV BRAIN RES, V118, P51, DOI 10.1016/S0165-3806(99)00105-4; Meck WH, 2003, NEUROSCI BIOBEHAV R, V27, P385, DOI 10.1016/S0149-7634(03)00069-1; Montoya D, 2000, NEUROSCI LETT, V296, P85, DOI 10.1016/S0304-3940(00)01660-8; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Pyapali GK, 1998, J NEUROPHYSIOL, V79, P1790, DOI 10.1152/jn.1998.79.4.1790; Ricceri L, 1998, BEHAV NEUROSCI, V112, P1387, DOI 10.1037/0735-7044.112.6.1387; RUDY JW, 1987, BEHAV NEUROSCI, V101, P62, DOI 10.1037/0735-7044.101.1.62; Schenk F, 1995, PSYCHOBIOLOGY, V23, P302; Selcher JC, 1999, LEARN MEMORY, V6, P478, DOI 10.1101/lm.6.5.478; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; Soderling TR, 2000, TRENDS NEUROSCI, V23, P75, DOI 10.1016/S0166-2236(99)01490-3; Sweatt JD, 2001, J NEUROCHEM, V76, P1, DOI 10.1046/j.1471-4159.2001.00054.x; Taubenfeld SM, 1999, NAT NEUROSCI, V2, P309, DOI 10.1038/7217; Tees RC, 1999, DEV PSYCHOBIOL, V35, P328, DOI 10.1002/(SICI)1098-2302(199912)35:4&lt;328::AID-DEV7&gt;3.0.CO;2-4; Tees RC, 1999, DEV PSYCHOBIOL, V35, P226, DOI 10.1002/(SICI)1098-2302(199911)35:3&lt;226::AID-DEV7&gt;3.0.CO;2-H; Tees RC, 1999, BEHAV BRAIN RES, V105, P173, DOI 10.1016/S0166-4328(99)00074-1; Viola HE, 2000, J NEUROSCI, V20; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yang YL, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0006.2000; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	55	90	92	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					545	+		10.1096/fj.03-0877fje	http://dx.doi.org/10.1096/fj.03-0877fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715695				2022-12-28	WOS:000188829300022
J	Nagai, Y; Tsugane, M; Oka, JI; Kimura, H				Nagai, Y; Tsugane, M; Oka, JI; Kimura, H			Hydrogen sulfide induces calcium waves in astrocytes	FASEB JOURNAL			English	Article						calcium influx; H2S; neuromodulator; brain	CENTRAL NERVOUS-SYSTEM; MECHANICAL STIMULATION; CULTURED ASTROCYTES; HIPPOCAMPAL SLICE; NEURONAL-ACTIVITY; MAMMALIAN BRAIN; NITRIC-OXIDE; GLIAL-CELLS; IN-SITU; GLUTAMATE	Hydrogen sulfide (H2S) modifies hippocampal long-term potentiation (LTP) and functions as a neuromodulator. Here, we show that H2S increases intracellular Ca2+ and induces Ca2+ waves in primary cultures of astrocytes as well as hippocampal slices. H2S increases the influx of Ca2+ and to a lesser extent causes the release from intracellular Ca2+ stores. Ca2+ waves induced by neuronal excitation as well as responses to exogenously applied H2S are potently blocked by La3+ and Gd3+, inhibitors of Ca2+ channels. These observations suggest that H2S induces Ca2+ waves that propagate to neighboring astrocytes.	Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Tokyo 1878502, Japan; Tokyo Univ Sci, Fac Pharmaceut Sci, Chiba 2788510, Japan	National Center for Neurology & Psychiatry - Japan; Tokyo University of Science	Kimura, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.	kimura@ncnp.go.jp	Kimura, Hideo/AGK-0606-2022; Kimura, Hideo/J-6811-2016	Kimura, Hideo/0000-0002-6069-0475; 				Abe K, 1996, J NEUROSCI, V16, P1066; Araque A, 1999, TRENDS NEUROSCI, V22, P208, DOI 10.1016/S0166-2236(98)01349-6; Baranano DE, 2001, TRENDS NEUROSCI, V24, P99, DOI 10.1016/S0166-2236(00)01716-1; BEAUCHAMP RO, 1984, CRC CR REV TOXICOL, V13, P25, DOI 10.3109/10408448409029321; Beedle AM, 2002, J MEMBRANE BIOL, V187, P225, DOI 10.1007/s00232-001-0166-2; CHARLES AC, 1991, NEURON, V6, P983, DOI 10.1016/0896-6273(91)90238-U; CHARLES AC, 1994, DEV NEUROSCI-BASEL, V16, P196, DOI 10.1159/000112107; Churchill GC, 1996, J CELL SCI, V109, P355; Cibulsky SM, 1999, J PHARMACOL EXP THER, V289, P1447; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Dallwig R, 2002, J NEUROSCI METH, V116, P77, DOI 10.1016/S0165-0270(02)00030-4; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DUFFY S, 1995, J NEUROSCI, V15, P5535; EBERHARD M, 1991, BIOCHEM BIOPH RES CO, V180, P209, DOI 10.1016/S0006-291X(05)81278-1; Fam SR, 2000, J NEUROSCI, V20, P2800; FINKBEINER S, 1992, NEURON, V8, P1101, DOI 10.1016/0896-6273(92)90131-V; GOODWIN LR, 1989, J ANAL TOXICOL, V13, P105, DOI 10.1093/jat/13.2.105; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P366; Guthrie PB, 1999, J NEUROSCI, V19, P520, DOI 10.1523/jneurosci.19-02-00520.1999; Harris-White ME, 1998, J NEUROPHYSIOL, V79, P1045, DOI 10.1152/jn.1998.79.2.1045; HASSINGER TD, 1995, J NEUROBIOL, V28, P159, DOI 10.1002/neu.480280204; Haydon PG, 2001, NAT REV NEUROSCI, V2, P185, DOI 10.1038/35058528; Hosoki R, 1997, BIOCHEM BIOPH RES CO, V237, P527, DOI 10.1006/bbrc.1997.6878; Kang J, 1998, NAT NEUROSCI, V1, P683, DOI 10.1038/3684; KIM WT, 1994, GLIA, V11, P173, DOI 10.1002/glia.440110211; KOMBIAN SB, 1993, J NEUROPHYSIOL, V70, P81, DOI 10.1152/jn.1993.70.1.81; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; Newman EA, 1998, J NEUROSCI, V18, P4022; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Parri HR, 2001, NAT NEUROSCI, V4, P803, DOI 10.1038/90507; REIFFENSTEIN RJ, 1992, ANNU REV PHARMACOL, V32, P109, DOI 10.1146/annurev.pa.32.040192.000545; SAVAGE JC, 1990, J CHROMATOGR-BIOMED, V526, P540, DOI 10.1016/S0378-4347(00)82537-2; Shelton MK, 2000, J NEUROCHEM, V74, P555, DOI 10.1046/j.1471-4159.2000.740555.x; STIPANUK MH, 1982, BIOCHEM J, V206, P267, DOI 10.1042/bj2060267; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; SWAROOP M, 1992, J BIOL CHEM, V267, P11455; TARDY M, 1989, J NEUROCHEM, V52, P162, DOI 10.1111/j.1471-4159.1989.tb10911.x; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; WARENYCIA MW, 1989, NEUROTOXICOLOGY, V10, P191; WARENYCIA MW, 1989, BIOCHEM PHARMACOL, V38, P973, DOI 10.1016/0006-2952(89)90288-8; Willmott NJ, 2000, J NEUROSCI, V20, P1767; Zhao WM, 2001, EMBO J, V20, P6008, DOI 10.1093/emboj/20.21.6008	44	259	285	1	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					557	+		10.1096/fj.03-1052fje	http://dx.doi.org/10.1096/fj.03-1052fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734631				2022-12-28	WOS:000188829300010
J	Huc, L; Sparfel, L; Rissel, M; Dimanche-Boitrel, MT; Guillouzo, A; Fardel, O; Lagadic-Gossmann, D				Huc, L; Sparfel, L; Rissel, M; Dimanche-Boitrel, MT; Guillouzo, A; Fardel, O; Lagadic-Gossmann, D			Identification of Na+/H+ exchange as a new target for toxic polycyclic aromatic hydrocarbons in liver cells	FASEB JOURNAL			English	Article						intracellular pH; benzo(a)pyrene; apoptosis; metabolism	INTRACELLULAR PH; DEPENDENT APOPTOSIS; HYDROGEN-PEROXIDE; DENDRITIC CELLS; IN-VIVO; ACTIVATION; EXPRESSION; INDUCTION; PATHWAY; PHOSPHORYLATION	The ubiquitous environmental pollutants polycyclic aromatic hydrocarbons are responsible for important carcinogenic and apoptotic effects, whose mechanisms are still poorly understood, owing to the multiplicity of possible cellular targets. Among these mechanisms, alterations of ionic homeostasis have been suggested. In this work, the effects of benzo(a)pyrene [B(a)P] on pH(i) were tested in the rat liver F258 epithelial cell line, using the fluoroprobe carboxy-SNARF-1. After a 48-h treatment, B(a)P (50 nM) induced an alkalinization, followed by an acidification after 72 h and the development of apoptosis. Determinations of pHi recovery following an acid load showed an increased acid efflux at 48 h. Cariporide inhibited both the early alkalinization and the increased acid efflux, thus suggesting the involvement of Na+/H+ exchanger 1 (NHE1). Besides, alpha-naphtoflavone (alpha-NF), an inhibitor of CYP1A1-mediated B(a)P metabolism, prevented all pH(i) changes, and NBE1 activation was blocked by the antioxidant thiourea, which inhibited CYP1A1 metabolism-dependent H2O2 production. Regarding B(a)P-induced apoptosis, this was prevented by alpha-NF and bongkrekic acid, an inhibitor of mitochondria-dependent apoptosis. Interestingly, apoptosis was significantly reduced by cariporide. Taken together, our results indicate that B(a)P, via H2O2 produced by CYP1A1-dependent metabolism, induces an early activation of NBE1, resulting in alkalinization; this appears to play a significant role in mitochondria-dependent B(a)P-induced apoptosis.	Univ Rennes 1, Fac Pharm, INSERM, U456, F-35043 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes	Lagadic-Gossmann, D (corresponding author), Univ Rennes 1, Fac Pharm, INSERM, U456, 2 Ave Professeur Leon Bernard, F-35043 Rennes, France.	Dominique.Lagadic@rennes.inserm.fr	LAGADIC-GOSSMANN, Dominique/I-5079-2015; Dimanche-Boitrel, Marie-Therese M/I-4642-2015; GUILLOUZO, Andre/Z-2373-2019; Fardel, Olivier/J-8560-2015; Huc, Laurence/J-1888-2014; SPARFEL, Lydie/K-1319-2015	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Huc, Laurence/0000-0002-0336-7559; SPARFEL, Lydie/0000-0002-4877-7017; Dimanche-Boitrel, Marie-Therese/0000-0002-8038-7780				Barriere H, 2001, AM J PHYSIOL-CELL PH, V281, pC810, DOI 10.1152/ajpcell.2001.281.3.C810; Benedetti A, 2001, GASTROENTEROLOGY, V120, P545, DOI 10.1053/gast.2001.21203; BLACK KA, 1989, TOXICOL APPL PHARM, V97, P463, DOI 10.1016/0041-008X(89)90251-2; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BUCKLER KJ, 1990, PFLUG ARCH EUR J PHY, V417, P234, DOI 10.1007/BF00370705; Burchiel SW, 1999, CLIN IMMUNOL, V90, P285, DOI 10.1006/clim.1998.4692; Chin BY, 1998, AM J PHYSIOL-LUNG C, V275, pL942, DOI 10.1152/ajplung.1998.275.5.L942; Delescluse C, 2000, TOXICOLOGY, V153, P73, DOI 10.1016/S0300-483X(00)00305-X; Dertinger SD, 2000, BIOCHEM PHARMACOL, V60, P189, DOI 10.1016/S0006-2952(00)00314-2; Dertinger SD, 2001, CARCINOGENESIS, V22, P171, DOI 10.1093/carcin/22.1.171; ETHIER SP, 1982, J NATL CANCER I, V69, P1199; Flowers L, 1996, BIOCHEMISTRY-US, V35, P13664, DOI 10.1021/bi961077w; Gilot D, 2002, J BIOL CHEM, V277, P49220, DOI 10.1074/jbc.M207325200; GRINSTEIN S, 1988, J BIOL CHEM, V263, P8658; HENDERSON PJ, 1970, J BIOL CHEM, V245, P1319; Hirpara JL, 2001, J BIOL CHEM, V276, P514, DOI 10.1074/jbc.M004687200; Khaled AR, 2001, MOL CELL BIOL, V21, P7545, DOI 10.1128/MCB.21.22.7545-7557.2001; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; Kwon YW, 2002, J BIOL CHEM, V277, P1837, DOI 10.1074/jbc.M105033200; Lagadic-Gossmann D, 1999, BRIT J PHARMACOL, V128, P1673, DOI 10.1038/sj.bjp.0702972; LAGADICGOSSMANN D, 1992, J PHYSIOL-LONDON, V458, P361, DOI 10.1113/jphysiol.1992.sp019422; Laupeze W, 2002, J IMMUNOL, V168, P2652, DOI 10.4049/jimmunol.168.6.2652; Lei W, 1998, CANCER RES, V58, P2102; LEWIS DFV, 1995, MUTAT RES-FUND MOL M, V328, P207, DOI 10.1016/0027-5107(95)00009-8; LI JF, 1995, J BIOL CHEM, V270, P3203, DOI 10.1074/jbc.270.7.3203; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Matikainen TM, 2002, ENDOCRINOLOGY, V143, P615, DOI 10.1210/en.143.2.615; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Matsuyama S, 2000, NAT CELL BIOL, V2, P318, DOI 10.1038/35014006; MENNEAR JH, 1993, REGUL TOXICOL PHARM, V17, P77, DOI 10.1006/rtph.1993.1008; Mounho BJ, 1998, TOXICOL APPL PHARM, V149, P80, DOI 10.1006/taap.1997.8345; Page TJ, 2002, MOL PHARMACOL, V62, P313, DOI 10.1124/mol.62.2.313; Payen L, 2001, TOXICOLOGY, V156, P109, DOI 10.1016/S0300-483X(00)00348-6; PELKONEN O, 1982, PHARMACOL REV, V34, P189; Pessah IN, 2001, MOL PHARMACOL, V59, P506, DOI 10.1124/mol.59.3.506; Putney LK, 2002, ANNU REV PHARMACOL, V42, P527, DOI 10.1146/annurev.pharmtox.42.092001.143801; Reshkin SJ, 2000, FASEB J, V14, P2185, DOI 10.1096/fj.00-0029com; Revel A, 2001, REPROD TOXICOL, V15, P479, DOI 10.1016/S0890-6238(01)00149-6; Rich IN, 2000, BLOOD, V95, P1427, DOI 10.1182/blood.V95.4.1427.004k48_1427_1434; Rieder CV, 2002, AM J PHYSIOL-HEART C, V283, pH273, DOI 10.1152/ajpheart.00042.2002; Robertson JD, 2000, CRIT REV TOXICOL, V30, P609, DOI 10.1080/10408440008951122; Rothstein EC, 2002, AM J PHYSIOL-HEART C, V283, pH598, DOI 10.1152/ajpheart.00198.2002; Santodonato J, 1997, CHEMOSPHERE, V34, P835, DOI 10.1016/S0045-6535(97)00012-X; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; SCHOLZ W, 1993, BRIT J PHARMACOL, V109, P562, DOI 10.1111/j.1476-5381.1993.tb13607.x; Snabaitis AK, 2002, CARDIOVASC RES, V53, P470, DOI 10.1016/S0008-6363(01)00464-3; Sparfel L, 2002, TOXICOL LETT, V129, P245, DOI 10.1016/S0378-4274(02)00015-2; Tannheimer SL, 1999, MOL CARCINOGEN, V25, P48, DOI 10.1002/(SICI)1098-2744(199905)25:1<48::AID-MC6>3.0.CO;2-6; van Grevenynghe J, 2003, J IMMUNOL, V170, P2374, DOI 10.4049/jimmunol.170.5.2374; VAUGHANJONES RD, 1990, J PHYSIOL-LONDON, V428, P441, DOI 10.1113/jphysiol.1990.sp018221; VAUGHANJONES RD, 1983, NATURE, V301, P522, DOI 10.1038/301522a0; Wei S, 2001, AM J PHYSIOL-CELL PH, V281, pC1542, DOI 10.1152/ajpcell.2001.281.5.C1542; Wilson CL, 1998, TOXICOL PATHOL, V26, P657, DOI 10.1177/019262339802600510; Woods GM, 2000, IMMUNOLOGY, V99, P16, DOI 10.1046/j.1365-2567.2000.00928.x; Wu JX, 1999, MOL CELL BIOL, V19, P8292; Yoshii S, 2001, MOL CELL BIOL, V21, P6796, DOI 10.1128/MCB.21.20.6796-6807.2001; ZEDECK MS, 1980, J ENVIRON PATHOL TOX, V3, P537	57	42	45	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					344	+		10.1096/fj.03-0316fje	http://dx.doi.org/10.1096/fj.03-0316fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656999	Green Submitted			2022-12-28	WOS:000188067500025
J	Iivanainen, E; Nelimarkka, L; Elenius, V; Heikkinen, SM; Junttila, TT; Sihombing, L; Sundvall, M; Maatta, JA; Jukka, V; Laine, O; Yla-Herttuala, S; Higashiyama, S; Alitalo, K; Elenius, K				Iivanainen, E; Nelimarkka, L; Elenius, V; Heikkinen, SM; Junttila, TT; Sihombing, L; Sundvall, M; Maatta, JA; Jukka, V; Laine, O; Yla-Herttuala, S; Higashiyama, S; Alitalo, K; Elenius, K			Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor	FASEB JOURNAL			English	Article						angiogenesis; cancer; ErbB; HB-EGF; Herceptin	DIPHTHERIA-TOXIN RECEPTOR; BLOOD-VESSEL FORMATION; DIFFERENTIAL EXPRESSION; TYROSINE KINASE; TIE2 RECEPTOR; PDGF-B; NEUREGULIN; MEMBER; GENE; ANGIOGENESIS	Recruitment of vascular smooth muscle cells (SMC) by endothelial cells (EC) is essential for angiogenesis. Endothelial-derived heparin binding EGF-like growth factor (HB- EGF) was shown to mediate this process by signaling via ErbB1 and ErbB2 receptors in SMCs. 1) Analysis of ErbB-ligands demonstrated that primary ECs expressed only HB- EGF and neuregulin-1. 2) Primary SMCs expressed ErbB1 and ErbB2, but not ErbB3 or ErbB4. 3) Consistent with their known receptor specificities, recombinant HBEGF, but not neuregulin-1, stimulated tyrosine phosphorylation of ErbB1 and ErbB2 and migration in SMCs. 4) Neutralization of HB- EGF or inhibition of ErbB1 or ErbB2 blocked 70 - 90% of the potential of ECs to stimulate SMC migration. Moreover, 5) angiopoietin-1, an EC effector with a role in recruitment of SMC-like cells to vascular structures in vivo, enhanced EC-stimulated SMC migration by a mechanism involving up-regulation of endothelial HB- EGF. Finally, 6) immunohistochemical analysis of developing human tissues demonstrated that HB- EGF was expressed in vivo in ECs associated with SMCs or pericytes but not in ECs of the hyaloid vessels not associated with SMCs. These results suggest an important role for HB- EGF and ErbB receptors in the recruitment of SMCs by ECs and elaborate on the mechanism by which angiopoietins exert their vascular effects.	Univ Turku, Med Res Labs, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem & Mol Biol, FIN-20520 Turku, Finland; Univ Turku, Turku Grad Sch Biomed Sci, FIN-20520 Turku, Finland; Univ Turku, Dept Pathol, FIN-20520 Turku, Finland; Turku Univ, Cent Hosp, Dept Med, FIN-20520 Turku, Finland; Univ Kuopio, AI Virtanen Inst, Dept Mol Med, FIN-70210 Kuopio, Finland; Ehime Univ, Sch Med, Dept Biochem Med, Shigenobu, Ehime 7910295, Japan; Univ Helsinki, Haartman Inst, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Turku Univ, Cent Hosp, Dept Oncol, FIN-20520 Turku, Finland	University of Turku; University of Turku; University of Turku; University of Turku; University of Turku; Finland National Institute for Health & Welfare; University of Eastern Finland; Ehime University; University of Helsinki; University of Helsinki; University of Turku	Elenius, K (corresponding author), Univ Turku, Med Res Labs, Tykistokatu 6 A, FIN-20520 Turku, Finland.	klaus.elenius@utu.fi	Elenius, Klaus/AAI-7594-2021; Alitalo, Kari K/J-5013-2014	Elenius, Klaus/0000-0001-5700-0827; Alitalo, Kari K/0000-0002-7331-0902; Sundvall, Maria H/0000-0002-0494-2965; Yla-Herttuala, Seppo/0000-0001-7593-2708				Abramovitch R, 1998, FEBS LETT, V425, P441, DOI 10.1016/S0014-5793(98)00283-X; Arkonac BM, 1998, J BIOL CHEM, V273, P4400, DOI 10.1074/jbc.273.8.4400; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BOYDEN S, 1962, J EXP MED, V115, P453, DOI 10.1084/jem.115.3.453; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Ciardiello F, 2001, CLIN CANCER RES, V7, P1459; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; HIGASHIYAMA S, 1994, HORM RES, V42, P9, DOI 10.1159/000184137; Higashiyama S, 1997, J BIOCHEM-TOKYO, V122, P675; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; HIGASHIYAMA S, 1993, J CELL BIOL, V122, P933, DOI 10.1083/jcb.122.4.933; IRUELAARISPE ML, 1991, LAB INVEST, V64, P174; Iwamoto R, 2003, P NATL ACAD SCI USA, V100, P3221, DOI 10.1073/pnas.0537588100; Izumi Y, 2002, NATURE, V416, P279, DOI 10.1038/416279b; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; Jones N, 1999, J BIOL CHEM, V274, P30896, DOI 10.1074/jbc.274.43.30896; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2; Kainulainen V, 2000, J BIOL CHEM, V275, P8641, DOI 10.1074/jbc.275.12.8641; KRAUS MH, 1989, P NATL ACAD SCI USA, V86, P9193, DOI 10.1073/pnas.86.23.9193; Laitinen M, 1998, HUM GENE THER, V9, P1481, DOI 10.1089/hum.1998.9.10-1481; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; NAGLICH JG, 1992, CELL, V69, P1051, DOI 10.1016/0092-8674(92)90623-K; Nykanen AI, 2003, CIRCULATION, V107, P1308, DOI 10.1161/01.CIR.0000054623.35669.3F; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PIERCE JH, 1988, SCIENCE, V239, P628, DOI 10.1126/science.3257584; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Riese DJ, 1996, J BIOL CHEM, V271, P20047, DOI 10.1074/jbc.271.33.20047; Russell KS, 1999, AM J PHYSIOL-HEART C, V277, pH2205, DOI 10.1152/ajpheart.1999.277.6.H2205; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; YOSHIZUMI M, 1992, J BIOL CHEM, V267, P9467; Zhang K, 1996, J BIOL CHEM, V271, P3884; Zhu MD, 2000, EXP EYE RES, V70, P767, DOI 10.1006/exer.2000.0844	50	94	101	1	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1609	1621		10.1096/fj.02-0939com	http://dx.doi.org/10.1096/fj.02-0939com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958167				2022-12-28	WOS:000185925100035
J	Joseph, TW; Zaika, A; Moll, UM				Joseph, TW; Zaika, A; Moll, UM			Nuclear and cytoplasmic degradation of endogenous p53 and HDM2 occurs during down-regulation of the p53 response after multiple types of DNA damage	FASEB JOURNAL			English	Article						p53/HDM2; ubiquitination; proteasomes; degradation; cytoplasm; nucleus	RING-FINGER DOMAIN; SUBCELLULAR-LOCALIZATION; EXPORT SIGNAL; MDM2; UBIQUITINATION; PROTEASOME; CELLS; INHIBITOR; PROTEIN; LIGASE	The principal regulator of p53 stability is HDM2, an E3 ligase mediating p53 degradation via the ubiquitin - 26S proteasome pathway. Until recently, the accepted model held that p53 degradation occurs exclusively on cytoplasmic proteasomes, with an absolute requirement for nuclear export of p53 via the CRM1 pathway. However, 26S proteasomes are abundant in cytosol and nucleus. Using forced overexpression of HDM2 in mutant p53 tumor cells, we previously found that p53 degradation occurs in both the nucleus and the cytoplasm. p53 null cells coexpressing export-defective p53 and HDM2 retained partial competence for p53 degradation, challenging the obligatory export model. Because the ability of local nuclear destruction might add important control in switching off the p53 pathway, we now test this notion for physiological situations in untransfected cells and determine the significance of this regulation. Despite nuclear export blockade by leptomycin B and HTLV1-Rex protein, two potent CRM1 inhibitors, nuclear degradation of endogenous wild-type p53 and HDM2 occurs during down-regulation of the p53 response. This was seen in RKO and U2OS cells recovering from all major forms of DNA damage, including UV, gamma-IR, camptothecin, or cisplatinum. Moreover, significant nuclear degradation of endogenous p53 and HDM2 occurs in isolated nuclear fractions prepared from these recovering cells. Furthermore, nuclear proteasomes efficiently degrade ubiquitinated p53 in vitro. Our data indicate that in nonlethal outcomes of cellular stress, when DNA damage has been successfully repaired and the active p53 response needs to be down-regulated quickly to resume normal homeostasis, both nuclear and cytoplasmic proteasomes are recruited to efficiently degrade the elevated p53 and HDM2 protein levels. The physiological significance of local nuclear destruction lies in the fact that it adds tighter control and speed to switching the p53 pathway off.	SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Moll, UM (corresponding author), SUNY Stony Brook, Dept Pathol, Stony Brook, NY 11794 USA.	umoll@notes.cc.sunysb.edu			NCI NIH HHS [T32 CA09176-24] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009176] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Brooks P, 2000, BIOCHEM J, V346, P155, DOI 10.1042/0264-6021:3460155; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Geyer RK, 2000, NAT CELL BIOL, V2, P569, DOI 10.1038/35023507; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Henderson BR, 2000, EXP CELL RES, V256, P213, DOI 10.1006/excr.2000.4825; Hirsch C, 2000, TRENDS CELL BIOL, V10, P268, DOI 10.1016/S0962-8924(00)01768-2; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; KATAHIRA J, 1995, J VIROL, V69, P3125, DOI 10.1128/JVI.69.5.3125-3133.1995; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kumar KS, 2000, WIND STRUCT, V3, P1; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; Lain S, 1999, EXP CELL RES, V248, P457, DOI 10.1006/excr.1999.4433; Lohrum MAE, 2001, MOL CELL BIOL, V21, P8521, DOI 10.1128/MCB.21.24.8521-8532.2001; Maki CG, 1996, CANCER RES, V56, P2649; PALMER A, 1994, EUR J CELL BIOL, V64, P163; Palmer A, 1996, BIOCHEM J, V316, P401, DOI 10.1042/bj3160401; Reits EAJ, 1997, EMBO J, V16, P6087, DOI 10.1093/emboj/16.20.6087; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Shirangi TR, 2002, FASEB J, V16, P420, DOI 10.1096/fj.01-0617fje; Smart P, 1999, ONCOGENE, V18, P7378, DOI 10.1038/sj.onc.1203260; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; Xirodimas DP, 2001, EXP CELL RES, V270, P66, DOI 10.1006/excr.2001.5314; Yu ZK, 2000, ONCOGENE, V19, P5892, DOI 10.1038/sj.onc.1203980; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	28	40	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1622	1630		10.1096/fj.02-0931com	http://dx.doi.org/10.1096/fj.02-0931com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958168				2022-12-28	WOS:000185925100036
J	Gilham, D; Ho, S; Rasouli, M; Martres, P; Vance, DE; Lehner, R				Gilham, D; Ho, S; Rasouli, M; Martres, P; Vance, DE; Lehner, R			Inhibitors of hepatic microsomal triacylglycerol hydrolase decrease very low density lipoprotein secretion	FASEB JOURNAL			English	Article						VLDL; apoB; hepatocytes; atherosclerosis; lipase	HORMONE-SENSITIVE LIPASE; TRIGLYCERIDE TRANSFER PROTEIN; B-CONTAINING LIPOPROTEINS; APOLIPOPROTEIN-B; RAT HEPATOCYTES; DIACYLGLYCEROL ACYLTRANSFERASE; ENDOPLASMIC-RETICULUM; FATTY-ACIDS; ARYLACETAMIDE DEACETYLASE; ATHEROGENIC DYSLIPIDEMIA	The presence of elevated circulating triacylglycerol (TG)-rich very low density lipoprotein (VLDL) and apolipoprotein B-100 (apoB-100) levels represents an independent risk factor for coronary artery disease. Triacylglycerol hydrolase catalyzes the mobilization of cytoplasmic TG stores. To test the hypothesis that the enzyme plays a role in the provision of core lipids for the assembly of VLDL, we inhibited the lipase activity in primary rat hepatocytes and analyzed lipid and apoB synthesis and secretion. Inhibition of lipolysis resulted in a dramatic decrease in secretion of TGs. In addition, secretion of cholesteryl ester and phosphatidylcholine was substantially decreased. Analysis of secreted apolipoproteins indicated that apoB-100 secretion was much more sensitive to lipase inhibition than was apoB-48 secretion, perhaps because of the ability of apoB-48 to be secreted as a relatively lipid-poor particle. The results agreed with those obtained with hepatoma cells transfected with triacylglycerol hydrolase cDNA, in which preferential lipidation of apoB-100 was observed. Together, our findings provide evidence that inhibition of intracellular TG hydrolysis significantly decreases apoB-100 secretion and suggest that triacylglycerol hydrolase may be a suitable pharmacological target in efforts to lower plasma lipid levels.	Univ Alberta, Dept Cell Biol, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Dept Biochem, CIHR Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; GlaxoSmithKline Inc, F-91951 Les Ulis, France	University of Alberta; University of Alberta; GlaxoSmithKline	Lehner, R (corresponding author), Univ Alberta, Dept Pediat, Heritage Med Res Ctr 328, Edmonton, AB T6G 2S2, Canada.	richard.lehner@ualberta.ca	rasouli, mehdi/F-6374-2017	rasouli, mehdi/0000-0002-1842-7198; Lehner, Richard/0000-0002-6008-1805				Aarsland A, 1998, J LIPID RES, V39, P1280; Abo-Hashema KAH, 1999, J BIOL CHEM, V274, P35577, DOI 10.1074/jbc.274.50.35577; BORCHARDT RA, 1987, J BIOL CHEM, V262, P16394; BOREN J, 1993, ARTERIOSCLER THROMB, V13, P1743, DOI 10.1161/01.ATV.13.12.1743; Cases S, 1998, P NATL ACAD SCI USA, V95, P13018, DOI 10.1073/pnas.95.22.13018; Cases S, 2001, J BIOL CHEM, V276, P38870, DOI 10.1074/jbc.M106219200; Diczfalusy MA, 1996, ARTERIOSCL THROM VAS, V16, P606, DOI 10.1161/01.ATV.16.4.606; DIXON JL, 1993, J LIPID RES, V34, P167; Fisher EA, 2002, J BIOL CHEM, V277, P17377, DOI 10.1074/jbc.R100068200; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; GIBBONS GF, 1994, J LIPID RES, V35, P1801; GIBBONS GF, 1992, BIOCHEM J, V287, P749, DOI 10.1042/bj2870749; Gibbons GF, 2000, BBA-MOL CELL BIOL L, V1483, P37, DOI 10.1016/S1388-1981(99)00182-1; Grundy SM, 1998, AM J CARDIOL, V81, p18B, DOI 10.1016/S0002-9149(98)00033-2; Grundy SM, 1997, CIRCULATION, V95, P1, DOI 10.1161/01.CIR.95.1.1; Haemmerle G, 2002, J BIOL CHEM, V277, P12946, DOI 10.1074/jbc.M108640200; Haidara K, 2002, BBA-MOL CELL RES, V1542, P173, DOI 10.1016/S0167-4889(01)00178-1; HODIS HN, 1995, CURR OPIN LIPIDOL, V6, P209, DOI 10.1097/00041433-199508000-00004; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Kulinski A, 2002, J BIOL CHEM, V277, P31516, DOI 10.1074/jbc.M202015200; Lankester DL, 1998, J LIPID RES, V39, P1889; Lehner R, 1999, BIOCHEM J, V343, P1, DOI 10.1042/0264-6021:3430001; Lehner R, 1999, BIOCHEM J, V338, P761, DOI 10.1042/0264-6021:3380761; Lehner R, 1997, BIOCHEMISTRY-US, V36, P1861, DOI 10.1021/bi962186d; Liao W, 1998, J BIOL CHEM, V273, P27225, DOI 10.1074/jbc.273.42.27225; Moldeus P, 1978, Methods Enzymol, V52, P60; MOREAU H, 1991, BIOCHEMISTRY-US, V30, P1037, DOI 10.1021/bi00218a022; NIKAWA J, 1979, FEBS LETT, V102, P223, DOI 10.1016/0014-5793(79)80005-8; Owen MR, 1997, BIOCHEM J, V323, P17, DOI 10.1042/bj3230017; Pease RJ, 1999, BIOCHEM J, V341, P453, DOI 10.1042/0264-6021:3410453; PROBST MR, 1994, J BIOL CHEM, V269, P21650; Raabe M, 1999, J CLIN INVEST, V103, P1287, DOI 10.1172/JCI6576; Shelness GS, 2001, CURR OPIN LIPIDOL, V12, P151, DOI 10.1097/00041433-200104000-00008; STRALFORS P, 1987, ENZYMES B, V18, P147; Trickett JI, 2001, J BIOL CHEM, V276, P39522, DOI 10.1074/jbc.M101764200; VANCE DE, 1984, BIOCHIM BIOPHYS ACTA, V792, P39, DOI 10.1016/0005-2760(84)90280-7; Wang YW, 1999, J BIOL CHEM, V274, P27793, DOI 10.1074/jbc.274.39.27793; WIGGINS D, 1992, BIOCHEM J, V284, P457, DOI 10.1042/bj2840457; Wu XJ, 1996, J LIPID RES, V37, P1198; Yang LY, 1996, J LIPID RES, V37, P262; YAO ZM, 1988, J BIOL CHEM, V263, P2998; Yao ZM, 1997, J LIPID RES, V38, P1937	43	101	105	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1685	+		10.1096/fj.02-0728fje	http://dx.doi.org/10.1096/fj.02-0728fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958176				2022-12-28	WOS:000184471600015
J	Funke-Kaiser, H; Lemmer, J; Langsdorff, CV; Thomas, A; Kovacevic, SD; Strasdat, M; Behrouzi, T; Zollmann, FS; Paul, M; Orzechowski, HD				Funke-Kaiser, H; Lemmer, J; Langsdorff, CV; Thomas, A; Kovacevic, SD; Strasdat, M; Behrouzi, T; Zollmann, FS; Paul, M; Orzechowski, HD			Endothelin-converting enzyme-1 is a downstream target of the homeobox transcription factor Nkx2-5	FASEB JOURNAL			English	Article						Nkx2-5; ECE-1; heart development; alternative promoters; gene regulation	ISOFORM-SPECIFIC EXPRESSION; HEART-FAILURE; ALTERNATIVE PROMOTERS; GENE-EXPRESSION; B RECEPTOR; SUBCELLULAR LOCALIZATIONS; MOLECULAR-CLONING; UP-REGULATION; ECE-1; CELLS	The homeobox transcription factor Nkx2-5 and the zinc metalloprotease endothelin-converting enzyme-1 (ECE-1) are essential for cardiac development. Here, we demonstrate for the first time a functional link between Nkx2-5 and ECE-1. In transiently transfected rat H9c2 cardiomyoblasts, the alternative promoters specific for ECE-1a, ECE-1b, and ECE-1c are activated by Nkx2-5 coexpression. Lack of a consensus sequence for Nkx2-5 binding within the ECE-1c promoter and mutational analyses of Nkx2-5 consensus sequences identified in the ECE-1a and ECE-1b promoters, respectively, reveal an indirect mechanism of activation that is supported by gel shift assays. Furthermore, we have evidence of an additional direct activation mechanism of the ECE-1b promoter by Nkx2-5. With the use of RNase protection assay, Northern blot, and real-time PCR, the activating effect of Nkx2-5 on mRNA expression of ECE-1 isoforms was confirmed in the chromatin context of H9c2 and endothelial EA. hy926 cells, respectively, by stable Nkx2-5 overexpression. The interaction presented in this work provides a possible explanation for distinct phenotypic aspects of patients carrying mutations in the Nkx2-5 gene and may also be of significance for the pathophysiology of heart failure.	Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Clin Pharmacol, Inst Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Orzechowski, HD (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Clin Pharmacol, Inst Clin Pharmacol & Toxicol, Hindenburgdamm 30, D-12200 Berlin, Germany.	hans-dieter.orzechowski@medizin.fu-berlin.de	Paul, Martin/K-5425-2015; Funke-Kaiser, Heiko/E-2519-2012					Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 2000, CIRC RES, V87, P888, DOI 10.1161/01.RES.87.10.888; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; Cattaruzza M, 2000, FASEB J, V14, P991, DOI 10.1096/fasebj.14.7.991; Chen CY, 1996, DEV GENET, V19, P119, DOI 10.1002/(SICI)1520-6408(1996)19:2<119::AID-DVG3>3.0.CO;2-C; Clouthier DE, 1998, DEVELOPMENT, V125, P813; Ehrman LA, 1999, DEV BIOL, V207, P163, DOI 10.1006/dbio.1998.9167; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Ergul A, 2000, AM J PHYSIOL-HEART C, V278, pH2050, DOI 10.1152/ajpheart.2000.278.6.H2050; Evans SM, 1999, SEMIN CELL DEV BIOL, V10, P73, DOI 10.1006/scdb.1999.0282; Funke-Kaiser H, 2000, FEBS LETT, V466, P310, DOI 10.1016/S0014-5793(00)01086-3; Giannessi D, 2001, PHARMACOL RES, V43, P111, DOI 10.1006/phrs.2000.0758; Goldmuntz E, 2001, CIRCULATION, V104, P2565, DOI 10.1161/hc4601.098427; Goto K, 2001, BIOL PHARM BULL, V24, P1219, DOI 10.1248/bpb.24.1219; Hasegawa H, 1998, FEBS LETT, V428, P304, DOI 10.1016/S0014-5793(98)00554-7; Heinemeyer T, 1999, NUCLEIC ACIDS RES, V27, P318, DOI 10.1093/nar/27.1.318; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hofstra RMW, 1999, AM J HUM GENET, V64, P304, DOI 10.1086/302184; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Kasahara H, 2001, J CLIN INVEST, V108, P189, DOI 10.1172/JCI200112694; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; Korth P, 1999, J HISTOCHEM CYTOCHEM, V47, P447, DOI 10.1177/002215549904700403; KURIHARA Y, 1994, NATURE, V368, P703, DOI 10.1038/368703a0; Lee Y, 1998, MOL CELL BIOL, V18, P3120, DOI 10.1128/MCB.18.6.3120; LINTS TJ, 1993, DEVELOPMENT, V119, P419; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Molkentin JD, 2000, DEV BIOL, V217, P301, DOI 10.1006/dbio.1999.9544; Muller L, 2003, J BIOL CHEM, V278, P545, DOI 10.1074/jbc.M208949200; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; Parnot C, 1997, HYPERTENSION, V30, P837, DOI 10.1161/01.HYP.30.4.837; RUBANYI GM, 1994, PHARMACOL REV, V46, P325; Sakai S, 1996, NATURE, V384, P353, DOI 10.1038/384353a0; SCHIBLER U, 1987, ANNU REV GENET, V21, P237, DOI 10.1146/annurev.ge.21.120187.001321; Schiffrin EL, 2001, AM J HYPERTENS, V14, p83S, DOI 10.1016/S0895-7061(01)02074-X; SCHMIDT M, 1994, FEBS LETT, V356, P238, DOI 10.1016/0014-5793(94)01277-6; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwartz RJ, 1999, DEVELOPMENT, V126, P4187; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; Serneri GGN, 2000, CIRC RES, V86, P377, DOI 10.1161/01.RES.86.4.377; SHIMADA K, 1995, BIOCHEM BIOPH RES CO, V207, P807, DOI 10.1006/bbrc.1995.1258; Shiojima I, 1996, CIRC RES, V79, P920, DOI 10.1161/01.RES.79.5.920; TAKAHASHI M, 1995, BIOCHEM J, V311, P657, DOI 10.1042/bj3110657; Takebayashi-Suzuki K, 2000, DEVELOPMENT, V127, P3523; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thompson JT, 1998, AM J PHYSIOL-HEART C, V274, pH1569, DOI 10.1152/ajpheart.1998.274.5.H1569; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1; Yanagisawa H, 1998, DEVELOPMENT, V125, P825; Zolk O, 1999, CIRCULATION, V99, P2118, DOI 10.1161/01.CIR.99.16.2118	56	13	13	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1487	+		10.1096/fj.02-0700fje	http://dx.doi.org/10.1096/fj.02-0700fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824294				2022-12-28	WOS:000183818000028
J	Grotendorst, GR; Rahmanie, H; Duncan, MR				Grotendorst, GR; Rahmanie, H; Duncan, MR			Combinatorial signaling pathways determine fibroblast proliferation and myofibroblast differentiation	FASEB JOURNAL			English	Article						myofibroblasts; TGF-beta; CTGF; fibrotic tissue	TRANSFORMING-GROWTH-FACTOR; ANCHORAGE-INDEPENDENT GROWTH; SMOOTH MUSCLE ACTIN; BETA TGF-BETA; FIBRONECTIN MESSENGER-RNAS; HUMAN DERMAL FIBROBLASTS; HUMAN SKIN FIBROBLASTS; GENE-EXPRESSION; ALPHA-5-BETA-1 INTEGRIN; COLLAGEN-SYNTHESIS	Fibroblast proliferation, differentiation into myofibroblasts, and increased collagen synthesis are key events during both normal wound repair and fibrotic lesion formation. Here we report that these biological responses to TGF-beta by fibroblasts are regulated via a CTGF-dependent pathway in concert with either EGF or IGF-2. Our studies indicate these responses to TGF-beta are mutually exclusive, and cells that are proliferating do not express alpha-SMA or elevated levels of collagen synthesis. Cells expressing alpha-SMA do not exhibit DNA synthesis but do coexpress higher levels of types I and III collagen mRNA. Thus, fibroblast proliferation and differentiation are controlled by combinatorial signaling pathways involving not only components of the TGF-beta/CTGF pathway, but also signaling events induced by EGF and IGF-2-activated receptors. Collectively, our studies indicate TGF-beta functions as a classic embryonic inducer, initiating a cascade that is controlled by other factors in the cellular environment. We propose a model for this process with regard to wound repair and fibrotic lesion formation that is likely applicable to other instances of CTGF action during embryogenesis.	Univ Miami, Sch Med, Dept Cell Biol & Anat, RMSB 2030 A, Miami, FL 33136 USA	University of Miami	Grotendorst, GR (corresponding author), Univ Miami, Sch Med, Dept Cell Biol & Anat, RMSB 2030 A, 1600 NW 10th Ave, Miami, FL 33136 USA.	ggrotend@miami.edu			NIGMS NIH HHS [GM 65603, GM 37223] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065603, R01GM037223] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANZANO MA, 1983, P NATL ACAD SCI-BIOL, V80, P6264, DOI 10.1073/pnas.80.20.6264; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; ASSOIAN RK, 1984, CELL, V36, P35, DOI 10.1016/0092-8674(84)90071-0; Badid C, 2000, HISTOL HISTOPATHOL, V15, P269, DOI 10.14670/HH-15.269; BARNES D, 1980, CELL, V22, P649, DOI 10.1016/0092-8674(80)90540-1; Border WA, 1998, KIDNEY INT, V54, P1390, DOI 10.1046/j.1523-1755.1998.00127.x; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; BRANDES ME, 1991, J CLIN INVEST, V87, P1108, DOI 10.1172/JCI115073; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Clark DA, 1998, INT J BIOCHEM CELL B, V30, P293, DOI 10.1016/S1357-2725(97)00128-3; Crean John KG, 2001, Expert Opin Ther Targets, V5, P519; Dalton SL, 1999, J BIOL CHEM, V274, P30139, DOI 10.1074/jbc.274.42.30139; DELARCO JE, 1978, J CELL PHYSIOL, V94, P335, DOI 10.1002/jcp.1040940311; DELARCO JE, 1978, P NATL ACAD SCI USA, V75, P4001; Derynck R, 1997, BIOCHIM BIOPHYS ACTA, V1333, P105; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; DESMOULIERE A, 1995, EXP NEPHROL, V3, P134; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; DUNCAN MR, 1989, J INVEST DERMATOL, V92, P699, DOI 10.1111/1523-1747.ep12696891; Folger PA, 2001, INVEST OPHTH VIS SCI, V42, P2534; Frazier K, 1996, J INVEST DERMATOL, V107, P404, DOI 10.1111/1523-1747.ep12363389; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Gabbiani G, 1998, CARDIOVASC RES, V38, P545, DOI 10.1016/S0008-6363(98)00065-0; GABBIANI G, 1992, KIDNEY INT, V41, P530, DOI 10.1038/ki.1992.75; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Grotendorst Gary R., 1997, Cytokine and Growth Factor Reviews, V8, P171, DOI 10.1016/S1359-6101(97)00010-5; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Gupta S, 2000, KIDNEY INT, V58, P1389, DOI 10.1046/j.1523-1755.2000.00301.x; HALES AM, 1994, CURR EYE RES, V13, P885, DOI 10.3109/02713689409015091; HEIMARK RL, 1986, SCIENCE, V233, P1078, DOI 10.1126/science.3461562; Hogan BLM, 1999, CELL, V96, P225, DOI 10.1016/S0092-8674(00)80562-0; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; IGARASHI A, 1993, MOL BIOL CELL, V4, P637, DOI 10.1091/mbc.4.6.637; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Jester JV, 1996, CORNEA, V15, P505; JOYCE ME, 1990, J CELL BIOL, V110, P2195, DOI 10.1083/jcb.110.6.2195; Kim HS, 1997, P NATL ACAD SCI USA, V94, P12981, DOI 10.1073/pnas.94.24.12981; Kothapalli D, 1998, FASEB J, V12, P1151, DOI 10.1096/fasebj.12.12.1151; Kothapalli D, 1997, CELL GROWTH DIFFER, V8, P61; Lee JW, 2002, BBA-MOL CELL RES, V1542, P23, DOI 10.1016/S0167-4889(01)00161-6; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mo FE, 2002, MOL CELL BIOL, V22, P8709, DOI 10.1128/MCB.22.24.8709-8720.2002; Moses HL, 1996, CURR OPIN GENET DEV, V6, P581, DOI 10.1016/S0959-437X(96)80087-6; MOSES HL, 1994, MOLECULAR AND CELLULAR BASIS FOR CELL TO CELL INTERACTION: ITS SIGNIFICANCE IN CANCER, P250; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; O'Dell SD, 1998, INT J BIOCHEM CELL B, V30, P767, DOI 10.1016/S1357-2725(98)00048-X; OKAZAKI R, 1995, BIOCHEM BIOPH RES CO, V207, P963, DOI 10.1006/bbrc.1995.1279; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; ROBERTS AB, 1986, P NATL ACAD SCI USA, V83, P4167, DOI 10.1073/pnas.83.12.4167; ROBERTS AB, 1980, P NATL ACAD SCI-BIOL, V77, P3494, DOI 10.1073/pnas.77.6.3494; ROBERTS AB, 1993, GROWTH FACTORS, V8, P1; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Robertson G, 2001, UASGCP REP, V2001, P43; ROSA F, 1988, SCIENCE, V239, P783, DOI 10.1126/science.3422517; Schurch W, 1998, AM J SURG PATHOL, V22, P141, DOI 10.1097/00000478-199802000-00001; Shinozaki M, 1997, BIOCHEM BIOPH RES CO, V237, P292, DOI 10.1006/bbrc.1997.7134; SOMA Y, 1989, J CELL PHYSIOL, V140, P246, DOI 10.1002/jcp.1041400209; STJOHNSTON D, 1992, CELL, V68, P201; TAKEHARA K, 1987, CELL, V49, P415, DOI 10.1016/0092-8674(87)90294-7; Takigawa M, 2003, J CELL PHYSIOL, V194, P256, DOI 10.1002/jcp.10206; TUCKER RF, 1984, SCIENCE, V226, P705, DOI 10.1126/science.6093254; VARGA J, 1987, BIOCHEM J, V247, P597, DOI 10.1042/bj2470597; Voci A, 1999, EUR J ENDOCRINOL, V140, P577, DOI 10.1530/eje.0.1400577; Wahab NA, 2002, J AM SOC NEPHROL, V13, P2437, DOI 10.1097/01.ASN.0000031828.58276.02; Wahl SM, 2000, CYTOKINE GROWTH F R, V11, P71, DOI 10.1016/S1359-6101(99)00030-1; WEBSTER DF, 1979, ANAL BIOCHEM, V96, P220, DOI 10.1016/0003-2697(79)90576-1; Weston BS, 2003, J AM SOC NEPHROL, V14, P601, DOI 10.1097/01.ASN.0000051600.53134.B9; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yamamoto Y, 2002, SPINE, V27, P1852, DOI 10.1097/00007632-200209010-00009	73	225	238	1	19	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					469	479		10.1096/fj.03-0699com	http://dx.doi.org/10.1096/fj.03-0699com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003992				2022-12-28	WOS:000220522800039
J	Sainz, IM; Uknis, AB; Isordia-Salas, I; DeLa Cadena, RA; Pixley, RA; Colman, RW				Sainz, IM; Uknis, AB; Isordia-Salas, I; DeLa Cadena, RA; Pixley, RA; Colman, RW			Interactions between bradykinin (BK) and cell adhesion molecule (CAM) expression in peptidoglycan-polysaccharide (PG-PS)-induced arthritis	FASEB JOURNAL			English	Article						inflammation; B1 receptor; B2 receptor; leukocyte cascade	B-2 RECEPTOR ANTAGONIST; L-SELECTIN; RHEUMATOID-ARTHRITIS; KININ RECEPTOR; MECHANISMS; DEFICIENCY; ANGIOGENESIS; MODULATION; ACTIVATION; INSIGHTS	Bradykinin (BK), a vasoactive, proinflammatory nonapeptide, promotes cell adhesion molecule (CAM) expression, leukocyte sequestration, inter-endothelial gap formation, and protein extravasation in postcapillary venules. These effects are mediated by bradykinin-1 (B1R) and- 2 (B2R) receptors. We delineated some of the mechanisms by which BK could influence chronic inflammation by altering CAM expression on leukocytes, endothelium, and synovium in joint sections of peptidoglycan-polysaccharide- injected Lewis rats. Blocking B1R results in significantly increased joint inflammation. Immunohistochemistry of the B1R antagonist group revealed increased leukocyte and synovial CD11b and CD54 expression and increased CD11b and CD44 endothelial expression. B2R antagonism decreased leukocyte and synovial CD44 and CD54 and endothelial CD11b expression. Although these findings implicate B2R involvement in the acute phase of inflammation by facilitating leukocyte activation (CD11b), homing (CD44), and transmigration (CD54). Treatment with a B2R antagonist did not affect the disease evolution in this model. In contrast, when both BK receptors are blocked, the aggravation of inflammation by B1R blockade is neutralized and there is no difference from the disease-untreated model. Our findings suggest that B1R and B2R signaling show physiologic antagonism. B1R signaling suggests involvement in down-regulation of leukocyte activation, transmigration, and homing. Further studies are needed to evaluate the B1 receptor agonist's role in this model.	Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, OMS, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Colman, RW (corresponding author), Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, OMS, 3400 N Broad St,Room 300, Philadelphia, PA 19140 USA.	colmanr@temple.edu						Abbott NJ, 2000, CELL MOL NEUROBIOL, V20, P131, DOI 10.1023/A:1007074420772; Asano M, 1997, BRIT J PHARMACOL, V122, P1436, DOI 10.1038/sj.bjp.0701534; Bandeira-Melo C, 1999, BRIT J PHARMACOL, V127, P315, DOI 10.1038/sj.bjp.0702536; Blais C, 1997, ARTHRITIS RHEUM, V40, P1327, DOI 10.1002/1529-0131(199707)40:7<1327::AID-ART18>3.0.CO;2-B; Bockmann S, 2000, J LEUKOCYTE BIOL, V68, P587; BOSARI S, 1992, HUM PATHOL, V23, P755, DOI 10.1016/0046-8177(92)90344-3; Bullard DC, 2002, IMMUNOL RES, V26, P27, DOI 10.1385/IR:26:1-3:027; BURCH RM, 1990, MED RES REV, V10, P237, DOI 10.1002/med.2610100204; Cao T, 2002, INFLAMM RES, V51, P295, DOI 10.1007/PL00000307; CARLOS TM, 1994, BLOOD, V84, P2068; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; COLMAN RW, 1975, J CLIN INVEST, V56, P1650, DOI 10.1172/JCI108247; deBlois D, 2001, BRIT J PHARMACOL, V132, P327, DOI 10.1038/sj.bjp.0703748; DELACADENA RA, 1987, J LAB CLIN MED, V109, P601; Dray A, 1997, CAN J PHYSIOL PHARM, V75, P704, DOI 10.1139/cjpp-75-6-704; DRAY A, 1993, TRENDS NEUROSCI, V16, P99, DOI 10.1016/0166-2236(93)90133-7; EichRathfelder S, 1997, IMMUNOPHARMACOLOGY, V36, P173, DOI 10.1016/S0162-3109(97)00018-0; Emanueli C, 1997, PHARMACOL RES, V35, P523, DOI 10.1006/phrs.1997.0180; FARMER SG, 1991, AGENTS ACTIONS, V34, P191, DOI 10.1007/BF01993275; Gabra BH, 2003, NEUROPEPTIDES, V37, P36, DOI 10.1016/S0143-4179(02)00148-8; Gera L, 1996, IMMUNOPHARMACOLOGY, V33, P183, DOI 10.1016/0162-3109(96)00100-2; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HARLAN JM, 1993, CLIN IMMUNOL IMMUNOP, V67, pS16, DOI 10.1006/clin.1993.1079; Koller M, 1999, ANN RHEUM DIS, V58, P709, DOI 10.1136/ard.58.11.709; Kourtis AP, 2003, CLIN IMMUNOL, V109, P224, DOI 10.1016/S1521-6616(03)00209-2; Ley K, 1996, CARDIOVASC RES, V32, P733, DOI 10.1016/0008-6363(96)00066-1; Littler AJ, 1997, BRIT J RHEUMATOL, V36, P164; Marceau F, 1998, CLIN REV ALLERG IMMU, V16, P385, DOI 10.1007/BF02737658; Middleton J, 2002, BLOOD, V100, P3853, DOI 10.1182/blood.V100.12.3853; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Palacios FAS, 1999, MEDIAT INFLAMM, V8, P245, DOI 10.1080/09629359990414; Paleolog EM, 1998, SPRINGER SEMIN IMMUN, V20, P73, DOI 10.1007/BF00832000; Paleolog EM, 1998, ARTHRITIS RHEUM, V41, P1258, DOI 10.1002/1529-0131(199807)41:7<1258::AID-ART17>3.0.CO;2-1; Paleolog EM, 2002, ARTHRITIS RES THER, V4, pS81, DOI 10.1186/ar575; Pinheiro RM, 2001, INFLAMM RES, V50, P570, DOI 10.1007/PL00000235; Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175; PROCTOR RR, 1961, AM J CLIN PATHOL, V36, P212; RAPAPORT SI, 1961, BLOOD, V18, P149, DOI 10.1182/blood.V18.2.149.149; RIDGE SC, 1988, METHOD ENZYMOL, V162, P373; SARTOR RB, 1989, INFECT IMMUN, V57, P1177, DOI 10.1128/IAI.57.4.1177-1185.1989; SCOTT CF, 1988, J LAB CLIN MED, V111, P708; Sfikakis PP, 1999, CLIN RHEUMATOL, V18, P28, DOI 10.1007/s100670050047; Shimizu Y, 1999, ADV IMMUNOL, V72, P325, DOI 10.1016/S0065-2776(08)60024-3; Siebeck M, 1996, IMMUNOPHARMACOLOGY, V33, P81, DOI 10.1016/0162-3109(96)00060-4; Szekanecz Z, 1996, J INVEST MED, V44, P124; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Uknis AB, 2001, INFLAMM RES, V50, P149, DOI 10.1007/s000110050739; Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6; Vianna RMJ, 1998, BRIT J PHARMACOL, V123, P281, DOI 10.1038/sj.bjp.0701590; WILDER RL, 1999, CURR RHEUMATOL REP, V1, P139; Yekebas E, 2000, CRIT CARE MED, V28, P1119, DOI 10.1097/00003246-200004000-00035	52	25	27	1	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					887	+		10.1096/fj.03-0835fje	http://dx.doi.org/10.1096/fj.03-0835fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001555				2022-12-28	WOS:000220522800020
J	Sodhi, A; Montaner, S; Gutkind, JS				Sodhi, A; Montaner, S; Gutkind, JS			Does dysregulated expression of a deregulated viral GPCR trigger Kaposi's sarcomagenesis?	FASEB JOURNAL			English	Article						Kaposi's sarcoma-associated herpesvirus; human herpesvirus-8; G-protein-coupled receptor; HIV	PROTEIN-COUPLED RECEPTOR; NF-KAPPA-B; CONSTITUTIVE ACTIVITY; ENDOTHELIAL-CELLS; HERPESVIRUS; ACTIVATION; INFECTION; KINASE; INTERLEUKIN-8; ANGIOGENESIS	In 1994, the Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) was identified as the etiologic agent of Kaposi's sarcoma (KS). KSHV has since been associated with two additional AIDS-related malignancies: primary effusion lymphomas (PEL) and multicentric Castleman's disease (MCD). Although molecular characterization of the KSHV genome has revealed several candidate oncogenes, infection with KSHV alone is not sufficient to cause KS, suggestive of an accomplice in KS initiation. Recent experimental evidence supports a key role for a particular KSHV gene, a constitutively-active G-protein-coupled receptor (vGPCR), in the development of KS. However, it is unclear how a lytic gene expressed in cells destined to die can cause cancer. Here we propose that dysregulation of the viral gene program may lead to nonlytic vGPCR expression. Several candidate cofactors (e.g., HIV-1 Tat, inflammation, aborted lytic cycle progression) are identified that may trigger vGPCR dysregulation, enabling oncogenic signaling pathways up-regulated by vGPCR, combined with the paracrine secretions from vGPCR-expressing cells, to promote the initiation of KS. If KS is indeed dependent on vGPCR dysregulation, then the development of new therapeutic modalities specifically targeting this viral protein or its downstream targets may ultimately prove to be the most effective treatment strategy for this enigmatic disease.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sodhi, A (corresponding author), NIDR, Cell Growth Regulat Sect, Oral & Pharyngeal Canc Branch, NIH, 30 Convent Dr,Bldg 30,Room 211, Bethesda, MD 20892 USA.	asodhi@nidcr.nih.gov; sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Antman K, 2000, NEW ENGL J MED, V342, P1027, DOI 10.1056/NEJM200004063421407; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bais C, 2003, CANCER CELL, V3, P131, DOI 10.1016/S1535-6108(03)00024-2; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; Cesarman E, 1996, J VIROL, V70, P8218, DOI 10.1128/JVI.70.11.8218-8223.1996; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Geras-Raaka E, 1998, J EXP MED, V188, P405, DOI 10.1084/jem.188.2.405; Geras-Raaka E, 1998, BIOCHEM BIOPH RES CO, V253, P725, DOI 10.1006/bbrc.1998.9557; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; Guo HG, 2003, J VIROL, V77, P2631, DOI 10.1128/JVI.77.4.2631-2639.2003; Hengge UR, 2002, LANCET INFECT DIS, V2, P281, DOI 10.1016/S1473-3099(02)00263-3; Ho HH, 2001, J BIOL CHEM, V276, P1376, DOI 10.1074/jbc.M007885200; Holst PJ, 2001, J CLIN INVEST, V108, P1789, DOI 10.1172/JCI13622; Lane BR, 2002, J VIROL, V76, P11570, DOI 10.1128/JVI.76.22.11570-11583.2002; Lee BJ, 2003, J IMMUNOL, V170, P243, DOI 10.4049/jimmunol.170.1.243; Manji KP, 2000, TROP MED INT HEALTH, V5, P85, DOI 10.1046/j.1365-3156.2000.00523.x; Martin JN, 1998, NEW ENGL J MED, V338, P948, DOI 10.1056/NEJM199804023381403; Masood R, 2002, AM J PATHOL, V160, P23, DOI 10.1016/S0002-9440(10)64344-1; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Montaner S, 2001, CANCER RES, V61, P2641; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Munshi N, 1999, J BIOL CHEM, V274, P31863, DOI 10.1074/jbc.274.45.31863; Nador RG, 2001, VIROLOGY, V287, P62, DOI 10.1006/viro.2001.1016; Polson AG, 2002, CANCER RES, V62, P4525; Pozniak A, 2001, ANN NY ACAD SCI, V953, P192, DOI 10.1111/j.1749-6632.2001.tb11377.x; Schwarz M, 2001, J IMMUNOL, V167, P505, DOI 10.4049/jimmunol.167.1.505; Shepard LW, 2001, J BIOL CHEM, V276, P45979, DOI 10.1074/jbc.M104783200; Sodhi A, 2000, CANCER RES, V60, P4873; Talbot SJ, 1999, VIROLOGY, V257, P84, DOI 10.1006/viro.1999.9672; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webster-Cyriaque J, 2002, NEW ENGL J MED, V346, P1207, DOI 10.1056/NEJMoa012125; Yang TY, 2000, J EXP MED, V191, P445, DOI 10.1084/jem.191.3.445; Yen-Moore A, 2000, VIROLOGY, V267, P247, DOI 10.1006/viro.1999.0125	33	53	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					422	427		10.1096/fj.03-1035hyp	http://dx.doi.org/10.1096/fj.03-1035hyp			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003988				2022-12-28	WOS:000220522800035
J	Danilova, N; Krupnik, VE; Sugden, D; Zhdanova, IV				Danilova, N; Krupnik, VE; Sugden, D; Zhdanova, IV			Melatonin stimulates cell proliferation in zebrafish embryo and accelerates its development	FASEB JOURNAL			English	Article						melatonin receptors; MT1; MT2	RECEPTOR SUBTYPES; BINDING; BRAIN; ANTAGONISTS; EXPRESSION; RETINA; MATTER; MEL1A; LIFE	All vertebrates show a dramatic circadian rhythm in circulating melatonin with high levels at night and very low levels during daytime. In adults, melatonin is thought to synchronize other circadian rhythms and regulate seasonal rhythms in photoperiodic animals by acting on specific G-protein coupled receptors. The role of melatonin in development is unknown, even though melatonin receptors appear to be more highly expressed in developing embryos and neonates than in adults. In this study on zebrafish embryos, we describe a role for melatonin in increasing cell proliferation and accelerating development. We propose that melatonin has a role in extending the safe limit of proliferation rate at night to allow more rapid development when potentially damaging ultraviolet light is absent.	MIT, Dept Biol, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Ctr, Dept Mol Biol, Boston, MA 02215 USA; Kings Coll London, Sch Biomed Sci, Ctr Reprod Endocrinol & Diabet, London SE1 1UL, England; Boston Univ, Sch Med, Dept Anat & Neurobiol, Boston, MA 02118 USA	Massachusetts Institute of Technology (MIT); Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of London; King's College London; Boston University	Danilova, N (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	ndanilov@mit.edu		Zhdanova, Irina/0000-0002-8401-9571				Arendt J., 1995, MELATONIN MAMMALIAN; Blask David E., 2002, Current Topics in Medicinal Chemistry, V2, P113, DOI 10.2174/1568026023394407; Browning C, 2000, BRIT J PHARMACOL, V129, P877, DOI 10.1038/sj.bjp.0703130; Drazen DL, 2001, NEUROENDOCRINOLOGY, V74, P178, DOI 10.1159/000054684; Drew JE, 1997, BRAIN RES, V761, P87, DOI 10.1016/S0006-8993(97)00335-1; Drew JE, 1998, J ENDOCRINOL, V156, P261, DOI 10.1677/joe.0.1560261; Dubocovich ML, 1997, N-S ARCH PHARMACOL, V355, P365, DOI 10.1007/PL00004956; DUBOCOVICH ML, 1988, J PHARMACOL EXP THER, V246, P902; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Frisch SM, 2000, NAT CELL BIOL, V2, pE167, DOI 10.1038/35023650; Fujieda H, 2003, NEUROSCIENCE, V120, P301, DOI 10.1016/S0306-4522(03)00298-7; Gothilf Y, 1999, ENDOCRINOLOGY, V140, P4895, DOI 10.1210/en.140.10.4895; Griffiths HR, 1998, CRIT REV CL LAB SCI, V35, P189, DOI 10.1080/10408369891234192; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Herzog W, 2003, DEV BIOL, V254, P36, DOI 10.1016/S0012-1606(02)00124-0; Husson I, 2002, ANN NEUROL, V51, P82, DOI 10.1002/ana.10072; Kazimi N, 1999, DEV BRAIN RES, V117, P47, DOI 10.1016/S0165-3806(99)00096-6; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Nonno R, 1999, BRIT J PHARMACOL, V127, P1288, DOI 10.1038/sj.bjp.0702658; Nonno R, 1999, BIOL SIGNAL RECEPT, V8, P32; REPPERT SM, 1995, NEURON, V15, P1003, DOI 10.1016/0896-6273(95)90090-X; REPPERT SM, 1995, P NATL ACAD SCI USA, V92, P8734, DOI 10.1073/pnas.92.19.8734; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; RIVKEES SA, 1991, BRAIN RES, V568, P345, DOI 10.1016/0006-8993(91)91424-Y; Shiu SYW, 2000, BIOL SIGNAL RECEPT, V9, P172; Sugden D, 1995, EUR J PHARMACOL, V287, P239, DOI 10.1016/0014-2999(95)00489-0; Sugden D, 1999, REPROD NUTR DEV, V39, P335, DOI 10.1051/rnd:19990306; Vanecek J, 1998, PHYSIOL REV, V78, P687, DOI 10.1152/physrev.1998.78.3.687; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE; Wullimann MF, 2000, ANAT EMBRYOL, V202, P385, DOI 10.1007/s004290000115; Yuan L, 2002, MOL CELL ENDOCRINOL, V192, P147, DOI 10.1016/S0303-7207(02)00029-1	31	65	69	1	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					751	+		10.1096/fj.03-0544fje	http://dx.doi.org/10.1096/fj.03-0544fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766799				2022-12-28	WOS:000220425000030
J	Fuller, W; Eaton, P; Bell, JR; Shattock, MJ				Fuller, W; Eaton, P; Bell, JR; Shattock, MJ			Ischemia-induced phosphorylation of phospholemman directly activates rat cardiac Na/K ATPase	FASEB JOURNAL			English	Article						ischemia; phospholemman; protein kinase; isolated heart	PROTEIN-KINASE-C; NA+-K+-ATPASE; PIG VENTRICULAR MYOCYTES; GAMMA-SUBUNIT; ALPHA-SUBUNITS; SODIUM-PUMP; NA,K-ATPASE; MEMBRANE; BINDING; HEARTS	Regulation of the Na/K ATPase by protein kinases is model-specific. We have observed a profound activation of the sarcolemmal Na/K ATPase during cardiac ischemia, which is masked by an inhibitor of the enzyme in the cytosol. The aim of these studies was to characterize the pathways involved in this activation in the Langendorff-perfused rat heart. Na/K ATPase activity was determined by measuring ouabain-sensitive phosphate generation by cardiac homogenates at 37degreesC. In isolated sarcolemma, ischemia (30 min) caused a substantial activation of the Na/K ATPase compared with aerobic controls, which was abolished by perfusing the heart with staurosporine or H89. However, the alpha1 subunit of the Na/K ATPase was not phosphorylated during ischemia. The sarcolemmal protein phospholemman (PLM) was found associated with the Na/K ATPase alpha1 and beta1 but not alpha2 subunits, and PLM increased its association with the catalytic subunit of PKA following ischemia. In vitro 14-3-3 binding assays indicated that PLM was phosphorylated following ischemia. These results indicate that the ischemia-induced activation of the Na/K ATPase is indirect, through phosphorylation of PLM, which is an integral part of the Na/K ATPase enzyme complex in the heart. The role of PLM is analogous to phospholamban in regulating the sarcoplasmic reticulum calcium ATPase.	Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Shattock, MJ (corresponding author), Kings Coll London, St Thomas Hosp, Rayne Inst, Ctr Cardiovasc Biol & Med, London SE1 7EH, England.	shattock@kcl.ac.uk	Eaton, Philip/I-5444-2015	Eaton, Philip/0000-0003-0748-2367; Shattock, Michael/0000-0001-6242-7585; Fuller, William/0000-0002-5883-4433	British Heart Foundation; the Wellcome Trust	British Heart Foundation(British Heart Foundation); the Wellcome Trust(Wellcome TrustEuropean Commission)	This work was supported by grants from the British Heart Foundation and the Wellcome Trust. All authors have no conflicts of interest to disclose. The technical assistance of Semjidmaa Dashnyam is gratefully acknowledged	Albert CJ, 1999, AM J PHYSIOL-HEART C, V276, pH642, DOI 10.1152/ajpheart.1999.276.2.H642; Arystarkhova E, 1996, J BIOL CHEM, V271, P23407, DOI 10.1074/jbc.271.38.23407; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Chen ZH, 1998, CIRC RES, V82, P367, DOI 10.1161/01.RES.82.3.367; Cheng SXJ, 1999, J PHYSIOL-LONDON, V518, P37, DOI 10.1111/j.1469-7793.1999.0037r.x; Cheng XJ, 1997, AM J PHYSIOL-CELL PH, V273, pC893, DOI 10.1152/ajpcell.1997.273.3.C893; Cornelius F, 2001, J BIOENERG BIOMEMBR, V33, P415, DOI 10.1023/A:1010671607911; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; Feschenko MS, 2000, J BIOL CHEM, V275, P34693, DOI 10.1074/jbc.M005869200; Feschenko MS, 2003, J NEUROSCI, V23, P2161; Feschenko MS, 1997, J BIOL CHEM, V272, P17726, DOI 10.1074/jbc.272.28.17726; Fotis H, 1999, EUR J BIOCHEM, V260, P904, DOI 10.1046/j.1432-1327.1999.00237.x; Fuller W, 2003, CARDIOVASC RES, V57, P1044, DOI 10.1016/S0008-6363(02)00810-6; Fuller W, 2001, ANAL BIOCHEM, V293, P216, DOI 10.1006/abio.2001.5127; GAO J, 1994, J PHYSIOL-LONDON, V477, P373, DOI 10.1113/jphysiol.1994.sp020199; James AF, 2001, BIOCHEM BIOPH RES CO, V284, P1048, DOI 10.1006/bbrc.2001.5083; KAKAR SS, 1987, J BIOL CHEM, V262, P42; KIHARA Y, 1989, CIRC RES, V65, P1029, DOI 10.1161/01.RES.65.4.1029; Kockskamper J, 2000, J PHYSIOL-LONDON, V523, P561, DOI 10.1111/j.1469-7793.2000.t01-2-00561.x; Kurihara K, 2000, AM J PHYSIOL-CELL PH, V279, pC1516, DOI 10.1152/ajpcell.2000.279.5.C1516; LEFER AM, 1974, ARCH INT PHARMACOD T, V211, P225; Lehoux S, 2001, J BIOL CHEM, V276, P15794, DOI 10.1074/jbc.M100410200; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; MERCER RW, 1993, J CELL BIOL, V121, P579, DOI 10.1083/jcb.121.3.579; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Netticadan T, 1997, BIOCHEM BIOPH RES CO, V238, P544, DOI 10.1006/bbrc.1997.7305; OWENS K, 1982, AM J PHYSIOL, V242, pH456, DOI 10.1152/ajpheart.1982.242.3.H456; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PITTS BJR, 1984, AM J PHYSIOL, V247, pH840, DOI 10.1152/ajpheart.1984.247.5.H840; PRESTI CF, 1985, J BIOL CHEM, V260, P3879; PRESTI CF, 1985, J BIOL CHEM, V260, P3860; Rice WJ, 2001, BIOPHYS J, V80, P2187, DOI 10.1016/S0006-3495(01)76191-7; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; SILVERMAN BDZ, 2002, BIOPHYS J, V82; Simmerman HKB, 1998, PHYSIOL REV, V78, P921, DOI 10.1152/physrev.1998.78.4.921; Song JL, 2002, AM J PHYSIOL-HEART C, V283, pH576, DOI 10.1152/ajpheart.00197.2002; STEENBERGEN C, 1977, CIRC RES, V41, P849, DOI 10.1161/01.RES.41.6.849; Sweadner KJ, 2001, AM J PHYSIOL-CELL PH, V280, pC1017, DOI 10.1152/ajpcell.2001.280.4.C1017; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Therien AG, 2000, AM J PHYSIOL-CELL PH, V279, pC541, DOI 10.1152/ajpcell.2000.279.3.C541; Van Emous JG, 1998, J MOL CELL CARDIOL, V30, P337, DOI 10.1006/jmcc.1997.0597; VANECHTELD CJA, 1991, J MOL CELL CARDIOL, V23, P297, DOI 10.1016/0022-2828(91)90066-U; Vittone L, 2002, J MOL CELL CARDIOL, V34, P39, DOI 10.1006/jmcc.2001.1488; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; YAMAGUCHI M, 1983, J BIOL CHEM, V258, P5260	46	95	95	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					197	199		10.1096/fj.03-0213fje	http://dx.doi.org/10.1096/fj.03-0213fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597563				2022-12-28	WOS:000188829300072
J	Johnson, NA; Sengupta, S; Saidi, SA; Lessan, K; Charnock-Jones, SD; Scott, L; Stephens, R; Freeman, TC; Tom, BDM; Harris, M; Denyer, G; Sundaram, M; Sasisekharan, R; Smith, SK; Print, CG				Johnson, NA; Sengupta, S; Saidi, SA; Lessan, K; Charnock-Jones, SD; Scott, L; Stephens, R; Freeman, TC; Tom, BDM; Harris, M; Denyer, G; Sundaram, M; Sasisekharan, R; Smith, SK; Print, CG			Endothelial cells preparing to die by apoptosis initiate a program of transcriptome and glycome regulation	FASEB JOURNAL			English	Article						gene array; survival factor deprivation; cell surface glycosaminoglycans; independent component analysis; cluster analysis	CASPASE-MEDIATED CLEAVAGE; GROWTH-FACTOR VEGF; GENE-EXPRESSION; KAPPA-B; ANGIOGENESIS; ACTIVATION; REGRESSION; SURVIVAL; HEPARIN; PROTEIN	The protein-based changes that underlie the cell biology of apoptosis have been extensively studied. In contrast, mRNA- and polysaccharide-based changes have received relatively little attention. We have combined transcriptome and glycome analyses to show that apoptotic endothelial cell cultures undergo programmed changes to RNA transcript abundance and cell surface polysaccharide profiles. Although a few of the transcriptome changes were protective, most appeared to prepare cells for apoptosis by decreasing the reception and transduction of prosurvival signals, increasing pro-death signals, increasing abundance of apoptotic machinery, inhibiting cellular proliferation, recruiting phagocytes to regions of cell death, and promoting phagocytosis. Additional transcriptornal changes appeared to alter the synthesis and modification of cell surface glycosaminoglycans. The resultant reduced abundance of sulphated cell surface glycosaminoglycans may further promote cell death by inhibiting the presentation of extracellular matrix-tethered survival factors to their receptors on dying cells. We propose that the transcriptome and glycome regulation presented here synergize with previously described protein-based changes to guide the apoptotic program.	Univ Cambridge, Dept Pathol, Cambridge CB2 1QP, England; MIT, Biol Engn Div, Cambridge, MA 02139 USA; UK MRC HGMP Resource Ctr, Cambridge, England; MRC, Biostat Unit, Cambridge CB2 2BW, England; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia	University of Cambridge; Massachusetts Institute of Technology (MIT); MRC Biostatistics Unit; University of Sydney	Print, CG (corresponding author), Univ Cambridge, Dept Pathol, Tennis Court Rd, Cambridge CB2 1QP, England.	cgp22@cam.ac.uk	denyer, gareth/E-3437-2010; Denyer, Gareth/M-5417-2016; Charnock-Jones, D. Stephen/B-3743-2009; Charnock-Jones, D. Stephen/AAE-3391-2020	Denyer, Gareth/0000-0003-1551-3936; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Charnock-Jones, D. Stephen/0000-0002-2936-4890; Smith, Stephen/0000-0003-1912-3935; Saidi, Samir/0000-0001-5165-2461; Tom, Brian/0000-0002-3335-9322; Freeman, Thomas/0000-0001-5235-8483; Print, Cristin/0000-0001-8345-7812	Pfizer/BBSRC studentship; Wellcome Trust Fellowship	Pfizer/BBSRC studentship; Wellcome Trust Fellowship(Wellcome Trust)	We wish to thank Andrew Sharkey, Amanda Evans, and Reija Valtola for assistance with gene array analysis; Richard Clarkson and Jeremy Skepper for assistance with time-lapse fluorescent microscopy, and Andrew Wyllie for advice on the manuscript. N. J. was funded by a Pfizer/BBSRC studentship, and C. P. was funded by a Wellcome Trust Fellowship.	Aitkenhead M, 2002, MICROVASC RES, V63, P159, DOI 10.1006/mvre.2001.2380; Allen RL., 2001, GENOME BIOL, V2; AMPOFO SA, 1991, ANAL BIOCHEM, V199, P249, DOI 10.1016/0003-2697(91)90098-E; AZMI TI, 1984, LAB INVEST, V51, P206; Bach FH, 1997, IMMUNOL TODAY, V18, P483, DOI 10.1016/S0167-5699(97)01129-8; Bach UC, 2001, EXP CELL RES, V265, P11, DOI 10.1006/excr.2001.5159; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Chavakis E, 2002, ARTERIOSCL THROM VAS, V22, P887, DOI 10.1161/01.ATV.0000017728.55907.A9; Chiang LW, 2001, P NATL ACAD SCI USA, V98, P2814, DOI 10.1073/pnas.051630598; Choy JC, 2001, J MOL CELL CARDIOL, V33, P1673, DOI 10.1006/jmcc.2001.1419; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Djonov V, 2001, MICROSC RES TECHNIQ, V52, P182, DOI 10.1002/1097-0029(20010115)52:2<182::AID-JEMT1004>3.3.CO;2-D; Harada N, 2002, BIOCHEM BIOPH RES CO, V299, P488, DOI 10.1016/S0006-291X(02)02670-0; Herren B, 1998, MOL BIOL CELL, V9, P1589, DOI 10.1091/mbc.9.6.1589; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jain RK, 1998, P NATL ACAD SCI USA, V95, P10820, DOI 10.1073/pnas.95.18.10820; Kabir J, 2002, BIOCHEM J, V367, P145, DOI 10.1042/BJ20020665; Karsan A, 1996, J Atheroscler Thromb, V3, P75; Levkau B, 1998, J EXP MED, V187, P579, DOI 10.1084/jem.187.4.579; Levkau B, 2001, CIRC RES, V88, P282, DOI 10.1161/01.RES.88.3.282; Levkau B, 1999, NAT CELL BIOL, V1, P227, DOI 10.1038/12050; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Li XW, 2002, J BIOL CHEM, V277, P15309, DOI 10.1074/jbc.M201253200; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; Martoglio AM, 2002, BIOINFORMATICS, V18, P1617, DOI 10.1093/bioinformatics/18.12.1617; Mason JC, 2002, AM J PHYSIOL-CELL PH, V282, pC578, DOI 10.1152/ajpcell.00339.2001; Meier P, 2000, NATURE, V407, P796, DOI 10.1038/35037734; Nakai A, 1997, MOL CELL BIOL, V17, P469, DOI 10.1128/MCB.17.1.469; OBERHAMMER FA, 1994, J CELL BIOL, V126, P827, DOI 10.1083/jcb.126.4.827; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Plendl J, 2000, ANAT HISTOL EMBRYOL, V29, P257, DOI 10.1046/j.1439-0264.2000.00265.x; Pober JS, 1998, PATHOL BIOL, V46, P159; Rich T, 1999, NAT CELL BIOL, V1, pE69, DOI 10.1038/11038; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; Schick BP, 2001, BLOOD, V97, P449, DOI 10.1182/blood.V97.2.449; Shriver Z, 2002, TRENDS CARDIOVAS MED, V12, P71, DOI 10.1016/S1050-1738(01)00150-5; Shriver Z, 2000, P NATL ACAD SCI USA, V97, P10359, DOI 10.1073/pnas.97.19.10359; Spataro V, 1997, J BIOL CHEM, V272, P30470, DOI 10.1074/jbc.272.48.30470; Venkataraman G, 1999, P NATL ACAD SCI USA, V96, P1892, DOI 10.1073/pnas.96.5.1892; Venkataraman G, 1999, SCIENCE, V286, P537, DOI 10.1126/science.286.5439.537; Wajant H, 2001, INT J BIOCHEM CELL B, V33, P19, DOI 10.1016/S1357-2725(00)00064-9; Wang NP, 2001, CIRC RES, V88, P1223, DOI 10.1161/hh1201.093162; Wang YQ, 2002, NAT CELL BIOL, V4, P888, DOI 10.1038/ncb872; Zoellner H, 1996, J CELL SCI, V109, P2571	46	29	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					188	190		10.1096/fj.03-0097fje	http://dx.doi.org/10.1096/fj.03-0097fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630703				2022-12-28	WOS:000188829300069
J	Baumann, R; Casaulta, C; Simon, D; Conus, S; Yousefi, S; Simon, HU				Baumann, R; Casaulta, C; Simon, D; Conus, S; Yousefi, S; Simon, HU			Macrophage migration inhibitory factor delays apoptosis in neutrophils by inhibiting the mitochondria-dependent death pathway	FASEB JOURNAL			English	Article						inflammation; MIF; mitochondria	CYTOCHROME-C RELEASE; COLONY-STIMULATING FACTOR; PERMEABILITY TRANSITION PORE; REGULATORY ROLE; FAS RECEPTOR; TYROSINE PHOSPHORYLATION; CELL-DEATH; CYTOKINE; ACTIVATION; PROTEIN	Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine known to activate macrophages and T cells. In this study, we demonstrate that recombinant MIF delays apoptosis of neutrophils in vitro. MIF action is dose and time dependent as well as specific since it was abolished with a neutralizing anti-MIF antibody. MIF, like G-CSF, delayed cleavage of the proapoptotic members of the Bcl-2 family Bid and Bax in neutrophils, suggesting that MIF inhibits apoptosis pathways proximal to mitochondria activation. Indeed, MIF also prevented release of cytochrome c and Smac from the mitochondria and subsequent activation of the critical effector caspase-3 in these cells. Moreover, we observed increased MIF plasma levels in patients with cystic fibrosis, a heterogeneous recessive genetic disorder associated with bacterial infections and delayed neutrophil apoptosis. In conclusion, MIF is a survival cytokine for human neutrophils, a finding with potential pathologic relevance in infectious diseases.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland; Univ Bern, Dept Pediat, CH-3010 Bern, Switzerland; Univ Bern, Dept Dermatol, CH-3010 Bern, Switzerland	University of Bern; University of Bern; University of Bern	Simon, HU (corresponding author), Univ Bern, Dept Pharmacol, Friedbuhlstr 49, CH-3010 Bern, Switzerland.	hus@pki.unibe.ch	Yousefi, Shida/AAU-7986-2020; Simon, Hans-Uwe/AAU-5079-2020; Yousefi, Shida/L-9689-2016; Simon, Hans-Uwe/AAU-7410-2020	Yousefi, Shida/0000-0002-9855-4305; Yousefi, Shida/0000-0002-9855-4305; Simon, Hans-Uwe/0000-0002-9404-7736				Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Baugh JA, 2002, CRIT CARE MED, V30, pS27, DOI 10.1097/00003246-200201001-00004; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; BLOOM BR, 1966, SCIENCE, V153, P80, DOI 10.1126/science.153.3731.80; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; BRACH MA, 1992, BLOOD, V80, P2920; Breitschopf K, 2000, J BIOL CHEM, V275, P21648, DOI 10.1074/jbc.M001083200; CALANDRA T, 1994, J EXP MED, V179, P1895, DOI 10.1084/jem.179.6.1895; Calandra T, 2000, NAT MED, V6, P164, DOI 10.1038/72262; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; CLARK JM, 1980, J CELL BIOL, V84, P102, DOI 10.1083/jcb.84.1.102; COLOTTA F, 1992, BLOOD, V80, P2012; Daigle I, 2002, NAT MED, V8, P61, DOI 10.1038/nm0102-61; Daigle I, 2001, INT ARCH ALLERGY IMM, V126, P147, DOI 10.1159/000049506; DAVID JR, 1966, P NATL ACAD SCI USA, V56, P72, DOI 10.1073/pnas.56.1.72; de Jong YP, 2001, NAT IMMUNOL, V2, P1061, DOI 10.1038/ni720; Desagher S, 1999, J CELL BIOL, V144, P891, DOI 10.1083/jcb.144.5.891; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Dibbert B, 1999, P NATL ACAD SCI USA, V96, P13330, DOI 10.1073/pnas.96.23.13330; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Gao G, 2000, J CELL BIOCHEM, V80, P53; GRIGG JM, 1991, LANCET, V338, P720, DOI 10.1016/0140-6736(91)91443-X; Hebestreit H, 1998, J EXP MED, V187, P415, DOI 10.1084/jem.187.3.415; Hebestreit H, 1996, EUR J IMMUNOL, V26, P1775, DOI 10.1002/eji.1830260817; Heinisch IVWM, 2000, EUR J IMMUNOL, V30, P3441, DOI 10.1002/1521-4141(2000012)30:12<3441::AID-IMMU3441>3.0.CO;2-L; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; IWAI K, 1994, BLOOD, V84, P1201; Khwaja A, 1999, BLOOD, V94, P291, DOI 10.1182/blood.V94.1.291.413k10_291_301; Kim TH, 2000, J BIOL CHEM, V275, P39474, DOI 10.1074/jbc.M003370200; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Maianski NA, 2002, BLOOD, V99, P672, DOI 10.1182/blood.V99.2.672; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Nufer O, 1999, BIOCHEMISTRY-US, V38, P636, DOI 10.1021/bi981294s; Pongracz J, 1999, J BIOL CHEM, V274, P37329, DOI 10.1074/jbc.274.52.37329; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Simon D, 2002, ALLERGY, V57, P431, DOI 10.1034/j.1398-9995.2002.13506.x; Simon HU, 2003, IMMUNOL REV, V193, P101, DOI 10.1034/j.1600-065X.2003.00038.x; Simon HU, 1998, BLOOD, V92, P547, DOI 10.1182/blood.V92.2.547.414k02_547_557; Simon HU, 1997, J IMMUNOL, V158, P3902; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Watson RWG, 1999, FEBS LETT, V453, P67, DOI 10.1016/S0014-5793(99)00688-2; WEISER WY, 1989, P NATL ACAD SCI USA, V86, P7522, DOI 10.1073/pnas.86.19.7522; Wood DE, 1998, ONCOGENE, V17, P1069, DOI 10.1038/sj.onc.1202034; Yousefi S, 2002, CELL DEATH DIFFER, V9, P595, DOI 10.1038/sj.cdd.4401037; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YOUSEFI S, 1994, P NATL ACAD SCI USA, V91, P10868, DOI 10.1073/pnas.91.23.10868	53	106	108	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2221	2230		10.1096/fj.03-0110com	http://dx.doi.org/10.1096/fj.03-0110com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656984				2022-12-28	WOS:000188067500043
J	Mehats, C; Jin, SLC; Wahlstrom, J; Law, E; Umetsu, DT; Conti, M				Mehats, C; Jin, SLC; Wahlstrom, J; Law, E; Umetsu, DT; Conti, M			PDE4D plays a critical role in the control of airway smooth muscle contraction	FASEB JOURNAL			English	Article						cyclic AMP; metabolism; second messengers; trachea	PROTEIN-KINASE-A; PHOSPHODIESTERASE ISOZYMES; CYCLIC-AMP; AUTORADIOGRAPHIC LOCALIZATION; RYANODINE RECEPTOR; MICE; IDENTIFICATION; ROLIPRAM; INVOLVEMENT; RELAXATION	The airways of mice deficient in the cAMP phosphodiesterase PDE4D gene are refractory to muscarinic cholinergic stimulation. This study was undertaken to determine whether altered smooth muscle contractility causes the PDE4D(-/-) phenotype. A major disruption in contractility was observed in isolated PDE4D(-/-) tracheas, with a 60% reduction in maximal tension and a fivefold decrease in sensitivity to muscarinic cholinergic agonists. Conversely, responses to KCl or arginine vasopressin were unaffected. PDE4D is the predominant PDE4 form in tracheal extracts and PDE4D mRNA is expressed in smooth muscle where muscarinic binding sites are most abundant. Cyclic AMP accumulation in response to acute Gsalpha-coupled receptor stimulation was increased up to fourfold in the airway of PDE4D(-/-) mice when compared with wild-type. This increase in cAMP was associated with an increased sensitivity to PGE(2)-induced relaxation of the PDE4D(-/-) tracheas. Furthermore, a blockade of prostanoid accumulation in PDE4D(-/-) tracheas restored the response to muscarinic cholinergic stimulation in vitro and in vivo. These results demonstrate that PDE4D plays a key role in balancing relaxant and contracting cues in airway smooth muscle, suggesting that natural mutations in the PDE4D gene have profound effects on airway tone.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA	Stanford University; Stanford University	Conti, M (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, 300 Pasteur Dr,Room A344, Stanford, CA 94305 USA.	marco.conti@stanford.edu	Mehats, Celine/D-8650-2017; Law, Evelyn C/AAM-4083-2020	Law, Evelyn C/0000-0003-4683-7220; Mehats, Celine/0000-0002-3677-2024	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020788] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL067674, P50HL067674] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67674] Funding Source: Medline; NICHD NIH HHS [R01 HD20788] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Abdel-Latif AA, 2001, EXP BIOL MED, V226, P153, DOI 10.1177/153537020122600302; BARNES PJ, 1992, BRIT MED BULL, V48, P149, DOI 10.1093/oxfordjournals.bmb.a072531; BARNES PJ, 1982, EUR J PHARMACOL, V86, P103, DOI 10.1016/0014-2999(82)90405-8; Birnbaumer M, 2000, TRENDS ENDOCRIN MET, V11, P406, DOI 10.1016/S1043-2760(00)00304-0; Bymaster FP, 2001, LIFE SCI, V68, P2473, DOI 10.1016/S0024-3205(01)01041-4; Catalli A, 2002, AM J PHYSIOL-LUNG C, V283, pL1151, DOI 10.1152/ajplung.00038.2002; Cheng JB, 1997, J PHARMACOL EXP THER, V280, P621; Conti M, 2000, PROG NUCLEIC ACID RE, V63, P1; deSouza N, 2002, J BIOL CHEM, V277, P39397, DOI 10.1074/jbc.M207059200; Dodge KL, 2001, EMBO J, V20, P1921, DOI 10.1093/emboj/20.8.1921; Fortner CN, 2001, AM J PHYSIOL-LUNG C, V281, pL469, DOI 10.1152/ajplung.2001.281.2.L469; GARSSEN J, 1990, J PHARMACOL METHOD, V24, P209, DOI 10.1016/0160-5402(90)90031-F; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; Iona S, 1998, MOL PHARMACOL, V53, P23, DOI 10.1124/mol.53.1.23; Janssen LJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1161, DOI 10.1152/ajplung.00452.2001; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Kapiloff MS, 2001, J CELL SCI, V114, P3167; KARIM SMM, 1967, BRIT J PHARM CHEMOTH, V31, P340, DOI 10.1111/j.1476-5381.1967.tb02003.x; Kohyama T, 2002, AM J RESP CELL MOL, V26, P694, DOI 10.1165/ajrcmb.26.6.4743; Kung TT, 2000, BRIT J PHARMACOL, V130, P457, DOI 10.1038/sj.bjp.0703308; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li L, 1998, BRIT J PHARMACOL, V123, P1337, DOI 10.1038/sj.bjp.0701741; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Marx SO, 2001, J CELL BIOL, V153, P699, DOI 10.1083/jcb.153.4.699; Matsui M, 2003, J PHARMACOL EXP THER, V305, P106, DOI 10.1124/jpet.102.044701; RABE KF, 1993, AM J PHYSIOL, V264, pL458, DOI 10.1152/ajplung.1993.264.5.L458; Richter M, 2000, EUR J PHARMACOL, V389, P225, DOI 10.1016/S0014-2999(99)00878-X; Rousseau E, 1995, CAN J PHYSIOL PHARM, V73, P1784, DOI 10.1139/y95-243; Stengel PW, 2002, AM J PHYSIOL-REG I, V282, pR1443, DOI 10.1152/ajpregu.00486.2001; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Tsafriri A, 1996, DEV BIOL, V178, P393, DOI 10.1006/dbio.1996.0226; Underwood DC, 1997, J PHARMACOL EXP THER, V280, P210; WAMSLEY JK, 1981, J NEUROSCI, V1, P176	39	110	111	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1831	1841		10.1096/fj.03-0274com	http://dx.doi.org/10.1096/fj.03-0274com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519662				2022-12-28	WOS:000186343300037
J	Malgrange, B; Knockaert, M; Belachew, S; Nguyen, L; Moonen, G; Meijer, L; Lefebvre, PP				Malgrange, B; Knockaert, M; Belachew, S; Nguyen, L; Moonen, G; Meijer, L; Lefebvre, PP			Inhibition of cyclin-dependent kinases induces differentiation of supernumerary hair cells and Deiters' cells in the developing organ of Corti	FASEB JOURNAL			English	Article						cochlea; MAP kinase; 2,6,9-trisubstituted purines; kinase inhibitor; roscovitine	PHEOCHROMOCYTOMA PC12 CELLS; MAMMALIAN INNER-EAR; NEURONAL DIFFERENTIATION; CDK INHIBITORS; AFFINITY-CHROMATOGRAPHY; INTRACELLULAR TARGETS; SUPPORTING CELLS; ACOUSTIC TRAUMA; NERVOUS-SYSTEM; ADULT ORGAN	In the embryonic day 19 organs of Corti, we showed that roscovitine, a chemical inhibitor of cyclin-dependent kinases (CDKs), significantly increased the number of hair cells (HCs) and corresponding supporting cells (SCs) by triggering differentiation of precursor cells without interacting with cell proliferation. The effect of roscovitine was mimicked by other CDK1, 2, 5, and 7 inhibitors but not by CDK4/6 and mitogen-activated protein kinase pathway antagonists. Immunohistochemical analysis indicated that roscovitine-specific intracellular targets, CDK1, 2, 5, and 7, were expressed in the organ of Corti and especially in Hensen's cells. Affinity chromatography studies showed a tight correlation between the protein levels of CDK1/2 and 5 and the rate of roscovitine-induced supernumerary cells in the organ of Corti. In addition, we demonstrated that basal CDK activity was higher and more roscovitine-sensitive at developmental stages that are selectively permissive for the emergence of supernumerary cells. These results suggest that CDKs are involved in the normal development of the organ of Corti and that, at least in E19 embryos, inhibition of CDKs is sufficient to trigger the differentiation of HCs and corresponding SCs, presumably from the Hensen's cell progenitors and/or from progenitors located in the greater epithelial ridge area.	Univ Liege, Ctr Cellular & Mol Neurobiol, B-4000 Liege, Belgium; Univ Liege, Dept Neurol, B-4000 Liege, Belgium; CNRS, Biol Stn, Roscoff, Bretagne, France	University of Liege; University of Liege; Centre National de la Recherche Scientifique (CNRS)	Malgrange, B (corresponding author), Univ Liege, Ctr Cellular & Mol Neurobiol, 17 Pl Delcour, B-4020 Liege, Belgium.	bmalgrange@ulg.ac.be	Belachew, Shibeshih/V-9185-2019; Nguyen, Laurent/E-9882-2016; Malgrange, Brigitte/F-8384-2010; Malgrange, Brigitte/A-4887-2019	Belachew, Shibeshih/0000-0003-3976-1950; Nguyen, Laurent/0000-0002-8560-3008; Malgrange, Brigitte/0000-0002-8957-2528; , laurent/0000-0003-3511-4916				ABDOUH A, 1993, NEUROREPORT, V5, P33, DOI 10.1097/00001756-199310000-00008; Alessi F, 1998, EXP CELL RES, V245, P8, DOI 10.1006/excr.1998.4216; Bermingham NA, 1999, SCIENCE, V284, P1837, DOI 10.1126/science.284.5421.1837; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Buolamwini JK, 2000, CURR PHARM DESIGN, V6, P379, DOI 10.2174/1381612003400948; Chang YT, 1999, CHEM BIOL, V6, P361, DOI 10.1016/S1074-5521(99)80048-9; Chen P, 2003, NAT CELL BIOL, V5, P422, DOI 10.1038/ncb976; Chen P, 1999, DEVELOPMENT, V126, P1581; CORWIN JT, 1988, SCIENCE, V240, P1772, DOI 10.1126/science.3381100; CORWIN JT, 1985, P NATL ACAD SCI USA, V82, P3911, DOI 10.1073/pnas.82.11.3911; Dobashi Y, 1996, BIOCHEM BIOPH RES CO, V221, P351, DOI 10.1006/bbrc.1996.0599; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; Dobashi Y, 2000, J BIOL CHEM, V275, P12572, DOI 10.1074/jbc.275.17.12572; Durand B, 1997, EMBO J, V16, P306, DOI 10.1093/emboj/16.2.306; Edamatsu H, 2000, ONCOGENE, V19, P3059, DOI 10.1038/sj.onc.1203625; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fekete DM, 1998, J NEUROSCI, V18, P7811; Flink IL, 1998, J MOL CELL CARDIOL, V30, P563, DOI 10.1006/jmcc.1997.0620; Gao CY, 1999, EXP EYE RES, V69, P695, DOI 10.1006/exer.1999.0749; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; JORGENSEN JM, 1988, NATURWISSENSCHAFTEN, V75, P319, DOI 10.1007/BF00367330; Kawamoto K, 2003, J NEUROSCI, V23, P4395; Keezer SM, 2002, EXP CELL RES, V273, P54, DOI 10.1006/excr.2001.5421; KELLEY MW, 1995, J NEUROSCI, V15, P3013; Kelley MW, 2001, HANDBOOK OF MOUSE AUDITORY RESEARCH: FROM BEHAVIOR TO MOLECULAR BIOLOGY, P137; KELLEY MW, 1993, DEVELOPMENT, V119, P1041; Knockaert M, 2002, BIOCHEM PHARMACOL, V64, P819, DOI 10.1016/S0006-2952(02)01144-9; Knockaert M, 2000, CHEM BIOL, V7, P411, DOI 10.1016/S1074-5521(00)00124-1; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Knockaert M, 2002, ONCOGENE, V21, P6413, DOI 10.1038/sj.onc.1205908; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Lang HN, 2001, DEV BIOL, V234, P120, DOI 10.1006/dbio.2001.0248; Lee HR, 1999, INT J ONCOL, V15, P161; Lefebvre PP, 2000, ACTA OTO-LARYNGOL, V120, P142; Ljungman M, 2001, MOL PHARMACOL, V60, P785; Lowenheim H, 1999, P NATL ACAD SCI USA, V96, P4084, DOI 10.1073/pnas.96.7.4084; Maas JW, 1998, J NEUROCHEM, V70, P1401; Malgrange B, 2002, CELL MOL LIFE SCI, V59, P1744, DOI 10.1007/PL00012502; Malgrange B, 2002, MECH DEVELOP, V112, P79, DOI 10.1016/S0925-4773(01)00642-6; Malgrange B, 2002, HEARING RES, V170, P48, DOI 10.1016/S0378-5955(02)00451-3; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Mgbonyebi OP, 1999, CANCER RES, V59, P1903; Nikolic M, 1996, GENE DEV, V10, P816, DOI 10.1101/gad.10.7.816; Ohnuma S, 2001, CURR OPIN NEUROBIOL, V11, P66, DOI 10.1016/S0959-4388(00)00175-6; Park DS, 1996, J BIOL CHEM, V271, P8161, DOI 10.1074/jbc.271.14.8161; PUJO, 1998, DEV AUDITORY SYSTEM, V1436, P146; ROBERSON DF, 1992, HEARING RES, V57, P166, DOI 10.1016/0378-5955(92)90149-H; Rosania GR, 1999, P NATL ACAD SCI USA, V96, P4797, DOI 10.1073/pnas.96.9.4797; Ruben R.J., 1967, ACTA OTO-LARYNGOL, DOI DOI 10.3109/00016486709127790; RYALS BM, 1988, SCIENCE, V240, P1774, DOI 10.1126/science.3381101; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shou JY, 2003, MOL CELL NEUROSCI, V23, P169, DOI 10.1016/S1044-7431(03)00066-6; Soni R, 2000, BIOCHEM BIOPH RES CO, V275, P877, DOI 10.1006/bbrc.2000.3349; Tang XM, 1998, J CELL BIOCHEM, V68, P128, DOI 10.1002/(SICI)1097-4644(19980101)68:1<128::AID-JCB13>3.0.CO;2-D; TSAI LH, 1993, DEVELOPMENT, V119, P1029; Urashima M, 1997, BLOOD, V90, P4106, DOI 10.1182/blood.V90.10.4106; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; Xiong W, 1997, MOL CELL BIOL, V17, P6585, DOI 10.1128/MCB.17.11.6585; Zheng JL, 2000, NAT NEUROSCI, V3, P580, DOI 10.1038/75753; Zheng JL, 2000, DEVELOPMENT, V127, P4551; Zine A, 2000, DEVELOPMENT, V127, P3373; Zine A, 2001, J NEUROSCI, V21, P4712, DOI 10.1523/JNEUROSCI.21-13-04712.2001	65	18	18	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2136	+		10.1096/fj.03-0035fje	http://dx.doi.org/10.1096/fj.03-0035fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958157				2022-12-28	WOS:000185925100030
J	Forbes, JM; Thallas, V; Thomas, MC; Founds, HW; Burns, WC; Jerums, G; Cooper, ME				Forbes, JM; Thallas, V; Thomas, MC; Founds, HW; Burns, WC; Jerums, G; Cooper, ME			The breakdown of pre-existing advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes	FASEB JOURNAL			English	Article						diabetic nephropathy; advanced glycation; cross-link breaker; extracellular matrix; ALT-711	TISSUE GROWTH-FACTOR; MAILLARD REACTION-PRODUCTS; NONENZYMATIC GLYCATION; EXTRACELLULAR-MATRIX; BASEMENT-MEMBRANE; CROSS-LINKING; IN-VITRO; COLLAGEN; AMINOGUANIDINE; EXPRESSION	Renal accumulation of advanced glycation end products (AGEs) has been linked to the progression of diabetic nephropathy. Cleavage of pre-formed AGEs within the kidney by a cross-link breaker, such as ALT-711, may confer renoprotection in diabetes. STZ diabetic rats were randomized into a) no treatment (D); b) treatment with the AGE cross-link breaker, ALT-711, weeks 16-32 (DALT early); and c) ALT-711, weeks 24-32 (DALT late). Treatment with ALT-711 resulted in a significant reduction in diabetes-induced serum and renal AGE peptide fluorescence, associated with decreases in renal carboxymethyllsine and RAGE immunostaining. Cross-linking of tail tendon collagen seen in diabetic groups was attenuated only by 16 weeks of ALT-711 treatment. ALT-711, independent of treatment duration, retarded albumin excretion rate (AER), reduced blood pressure, and renal hypertrophy. It also reduced diabetes-induced increases in gene expression of transforming growth factor beta1 (TGF-beta1), connective tissue growth factor (CTGF), and collagen IV. However, glomerulosclerotic index, tubulointerstitial area, total renal collagen, nitrotryrosine, protein expression of collagen IV, and TGF-beta1 only showed improvement with early ALT treatment alone. This study demonstrates the utility of a cross-link breaker as a treatment for diabetic nephropathy and describes effects not only on renal AGEs but on putative mediators of renal injury, such as prosclerotic cytokines and oxidative stress.	Baker Med Res Inst, Div Diabet Complicat, Melbourne, Vic, Australia; Alteon Inc, Ramsey, NJ 07446 USA; Austin & Repatriat Med Ctr, Dept Endocrinol, Heidelberg, Germany	Baker Heart and Diabetes Institute	Forbes, JM (corresponding author), Baker Heart Res Inst, Div Diabet Complicat, POB 6492,St Kilda Rd, Cent Melbourne, Vic 8008, Australia.	Josephine.forbes@baker.edu.au	Cooper, Mark E/E-8680-2010; Forbes, Josephine M/A-4569-2012; Cooper, Mark/AAC-5326-2020	Cooper, Mark E/0000-0002-5953-642X; Forbes, Josephine M/0000-0002-5595-8174; Thomas, Merlin/0000-0003-0694-8743				Adler AI, 2000, BMJ-BRIT MED J, V321, P412, DOI 10.1136/bmj.321.7258.412; ALLEN TJ, 1990, DIABETES, V39, P1182, DOI 10.2337/diabetes.39.10.1182; BEISSWENGER PJ, 1995, DIABETES, V44, P824, DOI 10.2337/diabetes.44.7.824; BEISSWENGER PJ, 1993, J CLIN INVEST, V92, P212, DOI 10.1172/JCI116552; BILOUS RW, 1989, DIABETES, V38, P1142, DOI 10.2337/diabetes.38.9.1142; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; BUNAG RD, 1973, J APPL PHYSIOL, V34, P279, DOI 10.1152/jappl.1973.34.2.279; CEFALU WT, 1994, CLIN CHEM, V40, P1317; CHARONIS AS, 1990, DIABETES, V39, P807, DOI 10.2337/diabetes.39.7.807; COOPER ME, 1988, J HYPERTENS, V6, P1009, DOI 10.1097/00004872-198812000-00009; Cooper ME, 2000, DIABETOLOGIA, V43, P660, DOI 10.1007/s001250051355; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; EDMONDSON SR, 1995, ENDOCRINOLOGY, V136, P4602, DOI 10.1210/en.136.10.4602; Forbes JM, 1999, KIDNEY INT, V55, P198, DOI 10.1046/j.1523-1755.1999.00253.x; Forbes JM, 2000, KIDNEY INT, V57, P2375, DOI 10.1046/j.1523-1755.2000.00097.x; Forbes JM, 2002, DIABETES, V51, P3274, DOI 10.2337/diabetes.51.11.3274; Forbes JM, 2001, DIABETOLOGIA, V44, P108, DOI 10.1007/s001250051587; GERBER G, 1960, J BIOL CHEM, V235, P2653; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; Ito Y, 1998, KIDNEY INT, V53, P853, DOI 10.1046/j.1523-1755.1998.00820.x; Jandeleit-Dahm K, 2002, CURR OPIN NEPHROL HY, V11, P221, DOI 10.1097/00041552-200203000-00014; Kass DA, 2001, CIRCULATION, V104, P1464, DOI 10.1161/hc3801.097806; Kelly DJ, 2001, J AM SOC NEPHROL, V12, P2098, DOI 10.1681/ASN.V12102098; KILO C, 1972, DIABETES, V21, P881, DOI 10.2337/diab.21.8.881; Kochakian M, 1996, DIABETES, V45, P1694, DOI 10.2337/diabetes.45.12.1694; MAKINO H, 1995, KIDNEY INT, V48, P517, DOI 10.1038/ki.1995.322; MAKITA Z, 1992, J BIOL CHEM, V267, P5133; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; MCCANCE DR, 1993, J CLIN INVEST, V91, P2470, DOI 10.1172/JCI116482; McLennan SV, 2002, DIABETES, V51, P2612, DOI 10.2337/diabetes.51.8.2612; Mentink CJAL, 2002, CLIN CHIM ACTA, V321, P69, DOI 10.1016/S0009-8981(02)00097-9; MINAKER KL, 1987, AM J MED, V82, P47, DOI 10.1016/0002-9343(87)90271-3; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; Mott JD, 1997, KIDNEY INT, V52, P1302, DOI 10.1038/ki.1997.455; Murphy M, 1999, J BIOL CHEM, V274, P5830, DOI 10.1074/jbc.274.9.5830; Oldfield MD, 2001, J CLIN INVEST, V108, P1853; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; PILLSBUR.HC, 1974, AM HEART J, V87, P783, DOI 10.1016/0002-8703(74)90427-X; PRICE RG, 1977, J BIOL CHEM, V252, P8597; REISER KM, 1991, P SOC EXP BIOL MED, V196, P17; Riser BL, 2000, J AM SOC NEPHROL, V11, P25, DOI 10.1681/ASN.V11125; Schwedler SB, 2001, DIABETES OBES METAB, V3, P230, DOI 10.1046/j.1463-1326.2001.00096.x; Soulis T, 1996, KIDNEY INT, V50, P627, DOI 10.1038/ki.1996.358; SOULISLIPAROTA T, 1991, DIABETES, V40, P1328, DOI 10.2337/diabetes.40.10.1328; STEGEMAN.H, 1967, CLIN CHIM ACTA, V18, P267, DOI 10.1016/0009-8981(67)90167-2; Sun ZL, 2001, CLIN CHIM ACTA, V313, P69, DOI 10.1016/S0009-8981(01)00651-9; TSILIBARY EC, 1988, J BIOL CHEM, V263, P4302; Twigg SM, 2002, ENDOCRINOLOGY, V143, P4907, DOI 10.1210/en.2002-220619; Twigg SM, 2001, ENDOCRINOLOGY, V142, P1760, DOI 10.1210/endo.142.5.8141; van der Pijl JW, 1998, DIABETOLOGIA, V41, P791, DOI 10.1007/s001250050989; Vasan S, 1996, NATURE, V382, P275, DOI 10.1038/382275a0; Wolffenbuttel BHR, 1998, P NATL ACAD SCI USA, V95, P4630, DOI 10.1073/pnas.95.8.4630; Wrobel K, 1997, CLIN CHEM, V43, P1563; YAGIHASHI S, 1992, DIABETES, V41, P47, DOI 10.2337/diabetes.41.1.47; YAMAMOTO T, 1993, P NATL ACAD SCI USA, V90, P1814, DOI 10.1073/pnas.90.5.1814; Youssef S, 1999, KIDNEY INT, V55, P907, DOI 10.1046/j.1523-1755.1999.055003907.x; ZIYADEH FN, 1991, KIDNEY INT, V39, P464, DOI 10.1038/ki.1991.57	58	211	219	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1762	+		10.1096/fj.02-1102fje	http://dx.doi.org/10.1096/fj.02-1102fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958202				2022-12-28	WOS:000184471600013
J	Foster, PA; Costa, SKP; Poston, R; Hoult, JRS; Brain, SD				Foster, PA; Costa, SKP; Poston, R; Hoult, JRS; Brain, SD			Endothelial cells play an essential role in the thermal hyperalgesia induced by nerve growth factor	FASEB JOURNAL			English	Article						neutrophils; endothelial cells; ICAM-1	RAT HIND PAW; NEUTROPHIL ACCUMULATION; NONNEURONAL CELLS; CUTANEOUS MICROVASCULATURE; MURINE NEUTROPHILS; ADULT-RAT; EXPRESSION; NOCICEPTORS; INVIVO; 5-LIPOXYGENASE	Nerve growth factor (NGF) is a potent mediator of inflammatory hyperalgesia, in addition to roles in the development and maintenance of neurons, We provide evidence for the novel concept that microvascular endothelial cells play a critical primary role in NGF-mediated events that lead to inflammatory hyperalgesia in rat skin. We show that, surprisingly, neutrophils are not directly activated by NGF, although local administration of NGF mediates thermal hyperalgesia via mechanisms involving concomitant neutrophil accumulation. The co-administration of actinomycin D with NGF negated both neutrophil accumulation and thermal hyperalgesia, indicating the dependence of NGF on local de novo protein synthesis. More significantly, an antibody against the endothelial-derived adhesion molecule ICAM-1 also blocked neutrophil accumulation and thermal hyperalgesia. Finally the ability of NGF to stimulate ICAM-1 in human cultured umbilical vein endothelial cells is shown. We propose that NGF acts primarily to activate endothelial cells and that this response is essential for the ensuing neutrophil accumulation and hyperalgesia. The findings reveal a central role of the endothelial cell in initiating NGF-dependent inflammatory hyperalgesia and emphasize the importance of further investigations aimed at examining the feasibility of new therapeutic strategies that target NGF.	Kings Coll London, Ctr Cardiovasc Biol & Med, Sch Biomed Sci, London SE1 1UL, England	University of London; King's College London	Brain, SD (corresponding author), Kings Coll London, Ctr Cardiovasc Biol & Med, Sch Biomed Sci, New Hunts House,Guys Campus, London SE1 1UL, England.	sue.brain@kcl.ac.uk	COSTA, SORAIA K P/X-6388-2019; Costa, Soraia KP/K-7227-2012; Foster, Paul/D-1615-2011; Brain, Susan/L-3681-2013	COSTA, SORAIA K P/0000-0002-2574-4490; Costa, Soraia KP/0000-0002-2574-4490; Foster, Paul/0000-0001-7190-1592; Brain, Susan/0000-0002-9684-8342				ALOE L, 1992, ARTHRITIS RHEUM, V35, P351, DOI 10.1002/art.1780350315; Amann R, 1996, PAIN, V64, P323, DOI 10.1016/0304-3959(95)00120-4; Amann R, 1996, EUR J PHARMACOL, V306, P89, DOI 10.1016/0014-2999(96)00255-5; ANDREEV NY, 1995, PAIN, V63, P109, DOI 10.1016/0304-3959(95)00024-M; Bennett DLH, 2001, NEUROSCIENTIST, V7, P13, DOI 10.1177/107385840100700105; Bennett G, 1998, PAIN, V77, P315, DOI 10.1016/S0304-3959(98)00114-6; BEVILACQUA MP, 1993, ANNU REV IMMUNOL, V11, P767, DOI 10.1146/annurev.iy.11.040193.004003; BOYLE MDP, 1985, J IMMUNOL, V134, P564; Cantarella G, 2002, FASEB J, V16, P1307, DOI 10.1096/fj.01-1000fje; Cao T, 2000, J IMMUNOL, V164, P5424, DOI 10.4049/jimmunol.164.10.5424; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541, DOI 10.1164/ajrccm.159.5.9808058; di Mola FF, 2000, GUT, V46, P670, DOI 10.1136/gut.46.5.670; DONNERER J, 1992, NEUROSCIENCE, V49, P693, DOI 10.1016/0306-4522(92)90237-V; Foster PA, 2002, J PATHOL, V197, P245, DOI 10.1002/path.1111; Friedman WJ, 1999, EXP CELL RES, V253, P131, DOI 10.1006/excr.1999.4705; GEE AP, 1983, P NATL ACAD SCI-BIOL, V80, P7215, DOI 10.1073/pnas.80.23.7215; GRUBER DF, 1990, AM J VET RES, V51, P921; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; HATTORI A, 1993, J BIOL CHEM, V268, P2577; Hoglund CO, 2002, PULM PHARMACOL THER, V15, P51, DOI 10.1006/pupt.2001.0314; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Issekutz AC, 1999, J LEUKOCYTE BIOL, V65, P117, DOI 10.1002/jlb.65.1.117; KANNAN Y, 1992, BIOCHEM BIOPH RES CO, V186, P1050, DOI 10.1016/0006-291X(92)90853-D; KANNAN Y, 1991, BLOOD, V77, P1320; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LEWIN GR, 1993, J NEUROSCI, V13, P2136; LEWIN GR, 1994, EUR J NEUROSCI, V6, P1903, DOI 10.1111/j.1460-9568.1994.tb00581.x; LI AKC, 1980, P NATL ACAD SCI-BIOL, V77, P4379, DOI 10.1073/pnas.77.7.4379; LINDHOLM D, 1987, NATURE, V330, P658, DOI 10.1038/330658a0; Malcangio M, 1997, EUR J NEUROSCI, V9, P1101, DOI 10.1111/j.1460-9568.1997.tb01462.x; MARTIN HA, 1988, J NEUROPHYSIOL, V60, P438, DOI 10.1152/jn.1988.60.2.438; Mendell LM, 1999, MICROSC RES TECHNIQ, V45, P252, DOI 10.1002/(SICI)1097-0029(19990515/01)45:4/5<252::AID-JEMT9>3.0.CO;2-N; MORONEY MA, 1990, BRIT J PHARMACOL, V101, P128, DOI 10.1111/j.1476-5381.1990.tb12101.x; MOVAT HZ, 1987, CAN J PHYSIOL PHARM, V65, P451, DOI 10.1139/y87-077; Pinter E, 1999, EUR J PHARMACOL, V369, P91, DOI 10.1016/S0014-2999(99)00054-0; RAMPART M, 1988, BRIT J PHARMACOL, V94, P1143, DOI 10.1111/j.1476-5381.1988.tb11632.x; Raychaudhuri SK, 2001, ARCH DERMATOL RES, V293, P291, DOI 10.1007/s004030100224; Raychaudhuri SP, 1998, ACTA DERM-VENEREOL, V78, P84; Rueff A, 1996, J NEUROPHYSIOL, V76, P3593, DOI 10.1152/jn.1996.76.5.3593; Rueff A, 1996, PAIN, V66, P359, DOI 10.1016/0304-3959(96)03060-6; SCHIERWAGEN C, 1990, J PHARMACOL METHOD, V23, P179, DOI 10.1016/0160-5402(90)90061-O; Skaper SD, 2001, MOL NEUROBIOL, V24, P183, DOI 10.1385/MN:24:1-3:183; Wagner JG, 2000, PHARMACOL REV, V52, P349; Woodnutt DA, 2000, CELL TISSUE RES, V299, P225, DOI 10.1007/s004419900129; WOOLF CJ, 1994, NEUROSCIENCE, V62, P327, DOI 10.1016/0306-4522(94)90366-2; YOUNG M, 1985, MOL CELL BIOCHEM, V66, P65	47	12	12	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1703	+		10.1096/fj.02-1000fje	http://dx.doi.org/10.1096/fj.02-1000fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958182				2022-12-28	WOS:000184471600006
J	Kong, WM; Stanley, S; Gardiner, J; Abbott, C; Murphy, K; Seth, A; Connoley, I; Ghatei, M; Stephens, D; Bloom, S				Kong, WM; Stanley, S; Gardiner, J; Abbott, C; Murphy, K; Seth, A; Connoley, I; Ghatei, M; Stephens, D; Bloom, S			A role for arcuate cocaine and amphetamine regulated transcript in hyperphagia, thermogenesis, and cold adaptation	FASEB JOURNAL			English	Article						CART; appetite; brown adipose tissue; hypothalamus; gene transfer; cold adaptation	HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; THYROTROPIN-RELEASING-HORMONE; GLUCAGON-LIKE PEPTIDE-1; AGOUTI-RELATED PROTEIN; NEUROPEPTIDE-Y; IN-VIVO; MESSENGER-RNA; CART NEURONS; ENERGY-EXPENDITURE; GENE-EXPRESSION	We have recently shown that injection of the hypothalamic peptide cocaine and amphetamine regulated transcript (CART) into discrete hypothalamic nuclei stimulates food intake. This stimulation was particularly marked in the arcuate nucleus. Here we show that twice daily intra-arcuate injection of 0.2 nmole CART peptide for 7 days was associated with a 60% higher daytime food intake, an 85% higher thermogenic response to the beta3 agonist BRL 35135, and a 60% increase in brown adipose tissue UCP-1 mRNA. In a separate study, using stereotactically targeted gene transfer, a CART transgene was delivered by using polyethylenimine to the arcuate nucleus of adult rats. Food intake was increased significantly during ad libitum feeding and following periods of food withdrawal and food restriction in CART over-expressing animals. CART over-expressing animals lost 12% more weight than controls following a 24-h fast. Brown adipose tissue uncoupling protein-1 (UCP-1) mRNA levels (collected Day 25) were 80% higher in CART over-expressing animals. Finally, by using quantitative in situ hybridization, we found that chronic cold exposure (20 days at 4degreesC) increased arcuate nucleus CART mRNA by 124%. Together with the orexigenic and thermogenic effects of CART, this finding suggests a role for arcuate nucleus CART in cold adaptation.	Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Investigat Sci, Fac Med, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Dept Math, Fac Phys Sci, London W12 0NN, England; Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England	Imperial College London; Imperial College London; St Georges University London	Bloom, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Metab Med, Div Investigat Sci, Fac Med, Hammersmith Campus, London W12 0NN, England.	s.bloom@imperial.ac.uk		Gardiner, James/0000-0001-9357-1387; Murphy, Kevin/0000-0002-3417-0310				Abbott CR, 2001, ENDOCRINOLOGY, V142, P3457, DOI 10.1210/en.142.8.3457; Abdallah B, 1996, HUM GENE THER, V7, P1947, DOI 10.1089/hum.1996.7.16-1947; Aja S, 2001, AM J PHYSIOL-REG I, V281, pR1862, DOI 10.1152/ajpregu.2001.281.6.R1862; Arancibia S, 1996, NEUROENDOCRINOLOGY, V64, P257, DOI 10.1159/000127126; Asnicar MA, 2001, ENDOCRINOLOGY, V142, P4394, DOI 10.1210/en.142.10.4394; Beak SA, 1996, ENDOCRINOLOGY, V137, P4130, DOI 10.1210/en.137.10.4130; BILLINGTON CJ, 1991, AM J PHYSIOL, V260, P321; Bing C, 1998, AM J PHYSIOL-REG I, V274, pR62, DOI 10.1152/ajpregu.1998.274.1.R62; Bing C, 1997, NEUROSCIENCE, V80, P277, DOI 10.1016/S0306-4522(97)00121-8; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Broberger C, 1999, BRAIN RES, V848, P101, DOI 10.1016/S0006-8993(99)01977-0; CATZEFLIS C, 1993, ENDOCRINOLOGY, V132, P224, DOI 10.1210/en.132.1.224; Challis BG, 2000, DIABETES, V49, P872, DOI 10.2337/diabetes.49.5.872; Charnay Y, 1999, J CHEM NEUROANAT, V17, P123, DOI 10.1016/S0891-0618(99)00028-9; Crowder M.J., 1990, ANAL REPEATED MEASUR; del Giudice EM, 2001, DIABETES, V50, P2157, DOI 10.2337/diabetes.50.9.2157; DOUGLASS J, 1995, J NEUROSCI, V15, P2471; Edwards CMB, 2000, BRAIN RES, V866, P128, DOI 10.1016/S0006-8993(00)02257-5; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Elias CF, 2001, J COMP NEUROL, V432, P1, DOI 10.1002/cne.1085; Fekete C, 2000, J NEUROSCI, V20, P9224; Gautvik KM, 1996, P NATL ACAD SCI USA, V93, P8733, DOI 10.1073/pnas.93.16.8733; Guissouma H, 1998, FASEB J, V12, P1755, DOI 10.1096/fasebj.12.15.1755; Haynes WG, 1999, HYPERTENSION, V33, P542, DOI 10.1161/01.HYP.33.1.542; Kim MS, 2000, DIABETES, V49, P177, DOI 10.2337/diabetes.49.2.177; Kristensen P, 1998, NATURE, V393, P72, DOI 10.1038/29993; Lambert PD, 1998, SYNAPSE, V29, P293, DOI 10.1002/(SICI)1098-2396(199808)29:4<293::AID-SYN1>3.0.CO;2-0; Larsen PJ, 2000, OBES RES, V8, P590, DOI 10.1038/oby.2000.76; LIU YL, 1995, BRIT J PHARMACOL, V114, P888, DOI 10.1111/j.1476-5381.1995.tb13287.x; Martres MP, 1998, EUR J NEUROSCI, V10, P3607, DOI 10.1046/j.1460-9568.1998.00366.x; Murphy KG, 2000, J ENDOCRINOL, V166, P659, DOI 10.1677/joe.0.1660659; PAXINOS G, RAT BRAIN; SCHEIDEGGER K, 1984, J CLIN ENDOCR METAB, V58, P895, DOI 10.1210/jcem-58-5-895; Small CJ, 2001, DIABETES, V50, P248, DOI 10.2337/diabetes.50.2.248; Stanley SA, 2001, BRAIN RES, V893, P186, DOI 10.1016/S0006-8993(00)03312-6; STEEL JH, 1988, HISTOCHEMISTRY, V89, P75, DOI 10.1007/BF00496588; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Wang CF, 2000, NEUROREPORT, V11, P3251, DOI 10.1097/00001756-200009280-00040; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Zhao J, 1998, AM J PHYSIOL-REG I, V275, pR2002, DOI 10.1152/ajpregu.1998.275.6.R2002	41	91	92	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1688	+		10.1096/fj.02-0805fje	http://dx.doi.org/10.1096/fj.02-0805fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958177				2022-12-28	WOS:000184471600014
J	Salnikov, AV; Iversen, VV; Koisti, M; Sundberg, C; Johansson, L; Stuhr, LB; Sjoquist, M; Ahlstrom, H; Reed, RK; Rubin, K				Salnikov, AV; Iversen, VV; Koisti, M; Sundberg, C; Johansson, L; Stuhr, LB; Sjoquist, M; Ahlstrom, H; Reed, RK; Rubin, K			Lowering of tumor interstitial fluid pressure specifically augments efficacy of chemotherapy	FASEB JOURNAL			English	Article						5-fluorouracil; prostaglandin E; histopathology; apoptosis; vasculature	IRON-OXIDE NANOPARTICLES; BRADYKININ MODULATION; IN-VITRO; INHIBITION; ANGIOGENESIS; TRANSPORT; DELIVERY; CANCER; AGENTS; MICROENVIRONMENT	Chemotherapy of solid tumors is presently largely ineffective at dosage levels that are compatible with survival of the patient. Here, it is argued that a condition of raised interstitial fluid pressure (IFP) that can be observed in many tumors is a major factor in preventing optimal access of systemically administered chemotherapeutic agents. Using prostaglandin E-1-methyl ester (PGE(1)), which is known transiently to reduce IFP, it was shown that 5-fluorouracil (5-FU) caused significant growth inhibition on two experimental tumors in rats but only after administration of PGE(1). Furthermore, timing experiments showed that only in the period in which IFP is reduced did 5-FU have an antitumor effect. These experiments uniquely demonstrate a clear and, according to the starting hypothesis, logical, synergistic effect of PGE(1) and 5-FU that offers hope for better treatment of many tumors in which raised IFP is likely to be inhibiting optimal results with water-soluble cancer chemotherapeutic agents.	Uppsala Univ, Dept Med Biochem & Microbiol, BMC, SE-75123 Uppsala, Sweden; Univ Bergen, Dept Physiol, N-5009 Bergen, Norway; Univ Hosp, Dept Radiol, SE-75185 Uppsala, Sweden; Uppsala Univ, Dept Med Cell Biol, Physiol Sect, BMC, SE-75123 Uppsala, Sweden	Uppsala University; University of Bergen; Uppsala University; Uppsala University Hospital; Uppsala University	Rubin, K (corresponding author), Uppsala Univ, Dept Med Biochem & Microbiol, BMC, Box 582, SE-75123 Uppsala, Sweden.	Kristofer.Rubin@imbim.uu.se	Rubin, Kristofer/AAC-1810-2020; Reed, Rolf K./B-9422-2017	Rubin, Kristofer/0000-0003-2789-6276; Reed, Rolf K./0000-0002-2633-6595				AUKLAND K, 1993, PHYSIOL REV, V73, P1, DOI 10.1152/physrev.1993.73.1.1; Bagnato A, 2002, CANCER RES, V62, P6381; Berg A, 1998, AM J PHYSIOL-HEART C, V274, pH663, DOI 10.1152/ajpheart.1998.274.2.H663; Bjornerud A, 2002, MAGNET RESON MED, V47, P461, DOI 10.1002/mrm.10066; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Emerich DF, 2001, J PHARMACOL EXP THER, V296, P632; Emerich DF, 2001, J PHARMACOL EXP THER, V296, P623; Fisher GA, 2002, EUR J CANCER, V38, pS63; Griffon-Etienne G, 1999, CANCER RES, V59, P3776; GULLINO PM, 1995, ACTA ONCOL, V34, P439, DOI 10.3109/02841869509094005; GULLINO PM, 1964, CANCER RES, V24, P780; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; Jain RK, 1998, NAT MED, V4, P655, DOI 10.1038/nm0698-655; JAIN RK, 1987, CANCER RES, V47, P3039; Kellar KE, 2000, JMRI-J MAGN RESON IM, V11, P488; Lau C, 2001, TOXICOL SCI, V59, P37, DOI 10.1093/toxsci/59.1.37; Leu AJ, 2000, CANCER RES, V60, P4324; Martin M, 1996, INT J CANCER, V65, P796, DOI 10.1002/(SICI)1097-0215(19960315)65:6<796::AID-IJC16>3.0.CO;2-2; NELSON MJ, 1993, EXP MOL PATHOL, V58, P105, DOI 10.1006/exmp.1993.1009; Netti PA, 2000, CANCER RES, V60, P2497; PHILLIPS RM, 1990, JNCI-J NATL CANCER I, V82, P1457, DOI 10.1093/jnci/82.18.1457; Pietras K, 2002, CANCER RES, V62, P5476; Pietras K, 2001, CANCER RES, V61, P2929; Rubin K, 2000, INT J CANCER, V86, P636, DOI 10.1002/(SICI)1097-0215(20000601)86:5<636::AID-IJC6>3.0.CO;2-R; Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885; Sundberg C, 1996, LAB INVEST, V74, P452; Tannock IF, 1996, J CLIN ONCOL, V14, P3156, DOI 10.1200/JCO.1996.14.12.3156; Tannock IF, 2001, CANCER METAST REV, V20, P123, DOI 10.1023/A:1013125027697; Trifan OC, 2002, CANCER RES, V62, P5778; Turetschek K, 2001, RADIOLOGY, V218, P562, DOI 10.1148/radiology.218.2.r01fe37562; VAUPEL P, 1989, CANCER RES, V49, P6449; Wassberg E, 1999, AM J PATHOL, V154, P395, DOI 10.1016/S0002-9440(10)65286-8; WIIG H, 1982, SCAND J CLIN LAB INV, V42, P159; YAUN I, 1998, SEMIN RADIAT ONCOL, V8, P164	34	91	95	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1756	+		10.1096/fj.02-1201fje	http://dx.doi.org/10.1096/fj.02-1201fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958200				2022-12-28	WOS:000184471600004
J	Stalker, TJ; Skvarka, CB; Scalia, R				Stalker, TJ; Skvarka, CB; Scalia, R			A novel role for calpains in the endothelial dysfunction of hyperglycemia	FASEB JOURNAL			English	Article						diabetes mellitus; endothelium; NO; superoxide; cell adhesion	NITRIC-OXIDE SYNTHASE; ADHESION MOLECULE EXPRESSION; C-REACTIVE PROTEIN; FACTOR-KAPPA-B; INHIBITOR-I; ACTIVATION; PROTEOLYSIS; REPERFUSION; HSP90; MICROVASCULATURE	Recent studies have reported that the activity of the calcium-dependent protease calpain is increased in acute inflammatory processes of the cardiovascular system. Because diabetes is associated with vascular inflammation, we hypothesized that increased calpain activity in response to hyperglycemia may play a role in diabetic cardiovascular disease. The effects of calpain inhibition on leukocyte-endothelium interactions induced by hyperglycemia were examined by intravital microscopy. Intraperitoneal administration of the selective calpain inhibitor benzyloxycarbonyl-leucyl-leucinal (5 mumol/L) prevented the up-regulation of leukocyte-endothelium interactions in response to 25 mmol/L D-glucose via a nitric oxide-dependent mechanism. Furthermore, treatment of rats with D-glucose significantly decreased basal endothelial NO release in mesenteric post-capillary venules, a phenomenon prevented by inhibition of calpain activity. Immunoprecipitation studies revealed that glucose induces loss of NO via a calpain-dependent decrease in the association of hsp90 with endothelial nitric oxide synthase. In addition, inhibition of calpain activity decreased endothelial cell surface expression of the pro-inflammatory adhesion molecules ICAM-1 and VCAM-1 during hyperglycemia. These data demonstrate that calpains contribute to important inflammatory events during hyperglycemia and that pharmacological inhibition of calpain activity attenuates leuckocyte-endothelium interactions and preserves eNOS function.	Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, Philadelphia, PA 19107 USA	Jefferson University	Scalia, R (corresponding author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Physiol, 1020 Locust St, Philadelphia, PA 19107 USA.	Rosario.Scalia@mail.tju.edu		Stalker, Timothy/0000-0002-0017-4268; Scalia, Rosario/0000-0002-1829-943X				Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Bellocq A, 1999, J BIOL CHEM, V274, P36891, DOI 10.1074/jbc.274.52.36891; Bierhaus A, 2001, DIABETES, V50, P2792, DOI 10.2337/diabetes.50.12.2792; Booth G, 2002, DIABETES, V51, P1556, DOI 10.2337/diabetes.51.5.1556; Booth G, 2001, AM J PHYSIOL-ENDOC M, V280, pE848, DOI 10.1152/ajpendo.2001.280.6.E848; BORDERS JL, 1984, MICROVASC RES, V27, P117, DOI 10.1016/0026-2862(84)90047-5; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; De Vriese AS, 2000, BRIT J PHARMACOL, V130, P963, DOI 10.1038/sj.bjp.0703393; DECATERINA R, 1995, J CLIN INVEST, V96, P60, DOI 10.1172/JCI118074; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Garcia-Cardena G, 1998, NATURE, V392, P821, DOI 10.1038/33934; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Hink U, 2001, CIRC RES, V88, pE14; Ho FM, 2000, CIRCULATION, V101, P2618, DOI 10.1161/01.CIR.101.22.2618; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Ikeda Y, 2002, AM J PHYSIOL-HEART C, V282, pH1421, DOI 10.1152/ajpheart.00626.2001; KOBAYASHI S, 1989, ENDOCRINOL JAPON, V36, P833; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUBES P, 1992, AM J PHYSIOL, V262, pH611, DOI 10.1152/ajpheart.1992.262.2.H611; Libby P, 2001, CIRCULATION, V104, P365, DOI 10.1161/01.CIR.104.3.365; McDonald MC, 2001, FASEB J, V15, P171, DOI 10.1096/fj.99-0645com; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Miyamoto K, 1998, INVEST OPHTH VIS SCI, V39, P2190; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Newcomb JK, 2000, METH MOL B, V144, P219; Panes J, 1996, CIRCULATION, V93, P161, DOI 10.1161/01.CIR.93.1.161; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; Ruetten H, 1997, BRIT J PHARMACOL, V121, P695, DOI 10.1038/sj.bjp.0701180; Scalia R, 2000, FASEB J, V14, P2357, DOI 10.1096/fj.00-0183com; Scalia R, 1997, P NATL ACAD SCI USA, V94, P9967, DOI 10.1073/pnas.94.18.9967; Shah V, 1999, AM J PHYSIOL-GASTR L, V277, pG463, DOI 10.1152/ajpgi.1999.277.2.G463; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; Spiecker M, 1998, J LEUKOCYTE BIOL, V63, P732, DOI 10.1002/jlb.63.6.732; Srivastava K, 2002, CLIN CHIM ACTA, V317, P213, DOI 10.1016/S0009-8981(01)00794-X; Stehouwer CDA, 1997, CARDIOVASC RES, V34, P55, DOI 10.1016/S0008-6363(96)00272-6; Su YC, 2000, AM J PHYSIOL-LUNG C, V278, pL1204, DOI 10.1152/ajplung.2000.278.6.L1204; Takahashi S, 2003, J BIOL CHEM, V278, P9339, DOI 10.1074/jbc.M212651200; Tsubuki S, 1996, J BIOCHEM-TOKYO, V119, P572, DOI 10.1093/oxfordjournals.jbchem.a021280; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WEYRICH AS, 1995, J LEUKOCYTE BIOL, V57, P45, DOI 10.1002/jlb.57.1.45; Williams SB, 1998, CIRCULATION, V97, P1695, DOI 10.1161/01.CIR.97.17.1695; YOSHIDA K, 1995, CIRC RES, V77, P603, DOI 10.1161/01.RES.77.3.603	47	67	71	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1511	+		10.1096/fj.02-1213fje	http://dx.doi.org/10.1096/fj.02-1213fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824289				2022-12-28	WOS:000183818000037
J	Moro, C; Crampes, F; Sengenes, C; De Glisezinski, I; Galitzky, J; Thalamas, C; Lafontan, M; Berlan, M				Moro, C; Crampes, F; Sengenes, C; De Glisezinski, I; Galitzky, J; Thalamas, C; Lafontan, M; Berlan, M			Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans	FASEB JOURNAL			English	Article						microdialysis; lipolysis; adrenergic receptors; nonesterified fatty acids; adipose tissue	DEPENDENT PROTEIN-KINASE; GROWTH-HORMONE PULSE; TISSUE BLOOD-FLOW; ADIPOSE-TISSUE; ADRENERGIC REGULATION; EXERCISE METABOLISM; LIPOLYTIC PATHWAY; RAT ADIPOCYTES; FAT-CELLS; BLOCKADE	In humans, lipid mobilization is considered to depend mainly on sympathetic nervous system activation and catecholamine action. A contribution of ANP was hypothesized because we have previously shown that atrial natriuretic peptide (ANP) is a lipolytic agent on isolated human fat cells. Control of lipid-mobilizing mechanisms was investigated using in situ microdialysis in subcutaneous adipose tissue (SCAT) in healthy young men during two successive exercise bouts performed at 35% and 60% peak oxygen consumption (VO(2)max) after placebo or acute oral tertatolol (nonselective beta-antagonist) treatment. In placebo-treated subjects, infusion of propranolol in the probe (100 mumol/l) only partially reduced (40%) the increment in extracellular glycerol concentration (EGC) promoted by exercise. Moreover, oral beta-adrenergic receptor blockade did not prevent exercise-induced lipid mobilization in SCAT while exerting fat cell beta-adrenergic receptor blockade. Exercise-induced increase in plasma ANP was potently amplified by oral tertatolol. A positive correlation was found between EGC and plasma ANP levels but also between extracellular cGMP (i.e., index of ANP-mediated lipolysis) and EGC. Thus, we demonstrate that exercise-induced lipid mobilization resistant to local propranolol and lipid-mobilizing action observed under oral beta-blockade is related to the action of ANP. Oral beta-adrenergic receptor blockade, which potentiates exercise-induced ANP release by the heart, may contribute to lipid mobilization in SCAT. The potential relevance of an ANP-related lipid-mobilizing pathway is discussed.	Univ Toulouse 3, CHU Rangueil, Inst Louis Bugnard, INSERM,U586,Unite Rech Obes, F-31062 Toulouse, France; Toulouse Hosp, Ctr Clin Invest, Toulouse, France; Dept Clin & Med Pharmacol, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse	Berlan, M (corresponding author), Fac Med, INSERM, U586, Lab Pharmacol Med & Clin, 37 Allees Jules Guesde, F-31073 Toulouse, France.	max.lafontan@toulouse.inserm.fr; berlan@cict.fr	Galitzky, Jean/R-6599-2017; Moro, Cedric/N-5754-2017; Sengenes, Coralie/GSN-0709-2022	Moro, Cedric/0000-0003-4294-0597; de Glisezinski, Isabelle/0000-0002-3166-549X; Sengenes, Coralie/0000-0002-4820-6660				ALLEN DO, 1988, J PHARMACOL EXP THER, V244, P852; ARNER P, 1990, J CLIN INVEST, V85, P893, DOI 10.1172/JCI114516; Balati B, 2002, FUND CLIN PHARMACOL, V16, P361, DOI 10.1046/j.1472-8206.2002.00072.x; BERLIN I, 1993, EUR J CLIN PHARMACOL, V44, P127, DOI 10.1007/BF00315469; BERNT E, 1974, METHOD ENZYMAT AN, P1499; BOUSQUETMELOU A, 1995, J LIPID RES, V36, P451; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; BULOW J, 1981, SCAND J CLIN LAB INV, V41, P415, DOI 10.3109/00365518109092065; ENOKSSON S, 1995, INT J OBESITY, V19, P350; Fellander G, 1996, INT J OBESITY, V20, P220; Galitzky J, 2001, J LIPID RES, V42, P536; Hansen TK, 2002, GROWTH HORM IGF RES, V12, P342, DOI 10.1016/S1096-6374(02)00061-8; Head A, 1997, BRIT J SPORT MED, V31, P120, DOI 10.1136/bjsm.31.2.120; Head A, 1999, SPORTS MED, V27, P81, DOI 10.2165/00007256-199927020-00002; Hellstrom L, 1996, INT J SPORTS MED, V17, P439, DOI 10.1055/s-2007-972875; HENDERSON SA, 1989, INT ORTHOP, V13, P69; HONNOR RC, 1985, J BIOL CHEM, V260, P5122; HONNOR RC, 1985, J BIOL CHEM, V260, P5130; Huang WS, 2002, METABOLISM, V51, P1423, DOI 10.1053/meta.2002.35194; JANSSON PA, 1990, AM J PHYSIOL, V258, pE918, DOI 10.1152/ajpendo.1990.258.6.E918; Lafontan M, 2003, TRENDS PHARMACOL SCI, V24, P276, DOI 10.1016/S0165-6147(03)00132-9; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Luchner A, 1998, J AM COLL CARDIOL, V32, P1839, DOI 10.1016/S0735-1097(98)00478-1; LUNDVALL J, 1981, VASODILATATION, P107; MOLLER N, 1990, AM J PHYSIOL, V258, pE86, DOI 10.1152/ajpendo.1990.258.1.E86; MOLLER N, 1992, METABOLISM, V41, P172, DOI 10.1016/0026-0495(92)90147-3; Moro C, 2004, J PHARMACOL EXP THER, V308, P984, DOI 10.1124/jpet.103.060913; Sengenes C, 2002, INT J OBESITY, V26, P24, DOI 10.1038/sj.ijo.0801845; Sengenes C, 2000, FASEB J, V14, P1345, DOI 10.1096/fj.14.10.1345; Steele IC, 1997, EUR J CLIN INVEST, V27, P270, DOI 10.1046/j.1365-2362.1997.1070653.x; Stich V, 2000, J APPL PHYSIOL, V88, P1277, DOI 10.1152/jappl.2000.88.4.1277; Stich V, 2000, AM J PHYSIOL-REG I, V279, pR499, DOI 10.1152/ajpregu.2000.279.2.R499; TANIGUCHI A, 1987, J LIPID RES, V28, P490; Tsai KS, 1997, INT J SPORTS MED, V18, P583, DOI 10.1055/s-2007-972685; VALET P, 1990, J CLIN INVEST, V85, P291, DOI 10.1172/JCI114425; WIJNEN JAG, 1993, EUR J CLIN PHARMACOL, V45, P101, DOI 10.1007/BF00315488	36	130	140	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					908	+		10.1096/fj.03-1086fje	http://dx.doi.org/10.1096/fj.03-1086fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033935				2022-12-28	WOS:000220522800003
J	Kannemeier, C; Al-Fakhri, N; Preissner, KT; Kanse, SM				Kannemeier, C; Al-Fakhri, N; Preissner, KT; Kanse, SM			Factor VII activating protease (FSAP) inhibits growth factor-mediated cell proliferation and migration of vascular smooth muscle cells.	FASEB JOURNAL			English	Article						PHBSP; PHBP; serine-protease; PDGF-BB	HYALURONAN-BINDING PROTEIN; MARBURG-I POLYMORPHISM; FACTOR-XA; EXTRACELLULAR-MATRIX; SERINE-PROTEASE; HEPARIN; RECEPTOR; PLASMA; ATHEROSCLEROSIS; HEMOSTASIS	The factor VII activating protease (FSAP) is a serine-protease present in human plasma that serves to activate single-chain plasminogen activators, as well as coagulation factor VII. FSAP was localized within atherosclerotic lesions, and a genetic polymorphism in FSAP is associated with carotid stenosis. Hence, this study was conducted to gain broader insights into the cellular effects of FSAP on vascular smooth muscle cells (VSMC). DNA synthesis and cell proliferation assays revealed an inhibitory action of FSAP on platelet-derived growth factor BB (PDGF-BB)mediated proliferation of VSMC. FSAP also inhibited PDGF-BB-induced migration of VSMC. These cellular effects of FSAP could be neutralized by an anti-FSAP mAb as well as by protease inhibitors such as aprotinin or a chloromethylketone inhibitor. Moreover, unfractionated heparin promoted the antiproliferative effect of FSAP on VSMC and was essential for the inhibition of VSMC migration. FSAP inhibited PDGF-BB binding to human VSMC and concomitantly blocked PDGF-BB-dependent phosphorylation of mitogen activated protein kinase p42/p44 and tyrosine phosphorylation of other proteins. These results unravel a new function of FSAP as an inhibitor of the proatherogenic phenotype of vascular smooth muscle.	Univ Giessen, Inst Biochem, D-35392 Giessen, Germany; Univ Giessen, Inst Clin Chem, Giessen, Germany	Justus Liebig University Giessen; Justus Liebig University Giessen	Kanse, SM (corresponding author), Univ Giessen, Inst Biochem, Friedrichstr 24, D-35392 Giessen, Germany.	sandip.kanse@biochemie.med.uni-giessen.de		Kanse, Sandip/0000-0003-0782-9957				BARSHAVIT R, 1990, CELL REGUL, V1, P453, DOI 10.1091/mbc.1.6.453; Bretschneider E, 2000, THROMB HAEMOSTASIS, V84, P499; Choi-Miura NH, 2001, BIOL PHARM BULL, V24, P140, DOI 10.1248/bpb.24.140; ChoiMiura NH, 1996, J BIOCHEM, V119, P1157; CLOWES AW, 1977, NATURE, V265, P625, DOI 10.1038/265625a0; Cuff CA, 2001, J CLIN INVEST, V108, P1031, DOI 10.1172/JCI12455; Dumler I, 1999, CURR BIOL, V9, P1468, DOI 10.1016/S0960-9822(00)80116-5; Etscheid M, 2000, BIOL CHEM, V381, P1223, DOI 10.1515/BC.2000.150; GAILIT J, 1994, CURR OPIN CELL BIOL, V6, P717, DOI 10.1016/0955-0674(94)90099-X; Garg HG, 2000, AM J PHYSIOL-LUNG C, V279, pL779, DOI 10.1152/ajplung.2000.279.5.L779; GASIC GP, 1992, P NATL ACAD SCI USA, V89, P2317, DOI 10.1073/pnas.89.6.2317; GUYTON JR, 1980, CIRC RES, V46, P625, DOI 10.1161/01.RES.46.5.625; HERBERT JM, 1992, FEBS LETT, V301, P155, DOI 10.1016/0014-5793(92)81237-G; HOOVER RL, 1980, CIRC RES, V47, P578, DOI 10.1161/01.RES.47.4.578; Kannemeier C, 2001, EUR J BIOCHEM, V268, P3789, DOI 10.1046/j.1432-1327.2001.02285.x; Kanse SM, 1997, ARTERIOSCL THROM VAS, V17, P2848, DOI 10.1161/01.ATV.17.11.2848; Kazi M, 2002, J CELL PHYSIOL, V193, P365, DOI 10.1002/jcp.10184; Kisker O, 2001, CANCER RES, V61, P7298; Patel MK, 2002, THROMB HAEMOSTASIS, V87, P149; Preissner KT, 2000, J PATHOL, V190, P360; Rauch BH, 2002, CIRC RES, V90, P1122, DOI 10.1161/01.RES.0000019240.72809.76; Riewald M, 2003, CRIT CARE, V7, P123, DOI 10.1186/cc1825; Roemisch J, 2002, BLOOD COAGUL FIBRIN, V13, P433, DOI 10.1097/00001721-200207000-00008; Romisch J, 2002, BIOL CHEM, V383, P1119, DOI 10.1515/BC.2002.121; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Stepanova V, 1999, MOL CELL BIOCHEM, V195, P199, DOI 10.1023/A:1006936623106; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Willeit J, 2003, CIRCULATION, V107, P667, DOI 10.1161/01.CIR.0000055189.18831.B1	28	50	53	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					728	+		10.1096/fj.03-0898fje	http://dx.doi.org/10.1096/fj.03-0898fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977886				2022-12-28	WOS:000220425000026
J	Poch, E; Carbonell, P; Franco, S; Diez-Juan, A; Blasco, MA; Andres, V				Poch, Enric; Carbonell, Paz; Franco, Sonia; Diez-Juan, Antonio; Blasco, Maria A.; Andres, Vicente			Short telomeres protect from diet-induced atherosclerosis in apolipoprotein E-null mice	FASEB JOURNAL			English	Article									[Poch, Enric; Carbonell, Paz; Diez-Juan, Antonio; Andres, Vicente] CSIC, Inst Biomed Valencia, Dept Mol & Cellular Pathol & Therapy, Lab Vasc Biol, Valencia 46010, Spain; [Franco, Sonia; Blasco, Maria A.] CSIC, Ctr Nacl Biotecnol, Dept Oncol & Immunol, E-28049 Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biomedicina de Valencia (IBV); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB)	Andres, V (corresponding author), CSIC, Inst Biomed Valencia, Dept Mol & Cellular Pathol & Therapy, Lab Vasc Biol, Valencia 46010, Spain.	vandres@ibv.csic.es	Diez Juan, Antonio/D-3695-2018; Blasco, Maria A./M-1694-2014; Andres, Vicente/I-6440-2014; Diez-Juan, Antonio/H-5464-2015	Blasco, Maria A./0000-0002-4211-233X; Andres, Vicente/0000-0002-0125-7209; Diez-Juan, Antonio/0000-0002-0166-1869					0	66	68	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					418	420		10.1096/fj.03-0710fje	http://dx.doi.org/10.1096/fj.03-0710fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	V38YG	14688198	Green Submitted			2022-12-28	WOS:000209378100001
J	Tricarico, D; Barbieri, M; Mele, A; Carbonara, G; Camerino, DC				Tricarico, D; Barbieri, M; Mele, A; Carbonara, G; Camerino, DC			Carbonic anhydrase inhibitors are specific openers of skeletal muscle BK channel of K+-deficient rats	FASEB JOURNAL			English	Article						hypokalaemic periodic paralysis; carbonic anhydrase inhibitors; modeling studies; patch clamp	HYPOKALEMIC PERIODIC PARALYSIS; ACTIVATED POTASSIUM CHANNELS; LARGE-CONDUCTANCE; CALCIUM; INACTIVATION; MODULATORS; MECHANISM; FIBERS; MODEL; PH	Carbonic-anhydrase (CA) inhibitors are used in the treatment of hypokalaemic periodic paralysis (hypoPP) and related channelopathies but their mechanism of action is unknown. Patch-clamp experiments and molecular modeling investigations were performed to evaluate the mechanism of actions of CA inhibitors on skeletal muscle Ca2+-activated-K+ (BK) channel of K+-deficient rats used as animal model of hypoPP. CA inhibitors showing different degree of CA inhibition such as acetazolamide (ACTZ), dichlorphenamide (DCP), hydrochlorthiazide (HCT), etoxzolamide (ETX), methazolamide (MTZ), and bendroflumethiazide (BFT), which lacks inhibitory effects on CA enzymes, were tested in vitro on BK channels. The application of ACTZ, BFT, ETX, and DCP to excised patches activated the BK channel with potency: ACTZ(DE50=7.3x10(-6)M)>BFT(DE50=5.93x10(-5)M)>ETX(DE50=1.17x10(-4)M)>>DCP. In contrast, MTZ and HCT failed to activate the BK channel. Molecular modeling studies showed that the capability of CA inhibitors to open the BK channel was related to the presence in their structures of an intramolecular hydrogen bond with calculated inter-atomic distances ranging between 1.82 Angstrom and 3.01 Angstrom and of an aromatic ring poor of electrons. ACTZ, BFT, ETX, and DCP showed these pharmacofores, while MTZ and HCT did not. Our data indicate that the activation of BK channel is a property of CA inhibitors that interact with the channel subunit/s and that this effect is not related to their capability to inhibit the CA enzymes.	Univ Bari, Fac Pharm, Dept Pharmacobiol, Pharmacol Unit, I-70125 Bari, Italy; Univ Bari, Fac Pharm, Dept Med Chem, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Camerino, DC (corresponding author), Univ Bari, Fac Pharm, Dept Pharmacobiol, Pharmacol Unit, Via Orabona 4, I-70125 Bari, Italy.	conte@farmbiol.uniba.it		Mele, Antonietta/0000-0002-9278-7183; Conte, Diana/0000-0003-0162-9698	Telethon [1208] Funding Source: Medline	Telethon(Fondazione Telethon)		Bendahhou S, 2001, ANN NEUROL, V50, P417, DOI 10.1002/ana.1144; Bian S, 2001, P NATL ACAD SCI USA, V98, P4776, DOI 10.1073/pnas.081072398; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Cannon SC, 2002, NEUROMUSCULAR DISORD, V12, P533, DOI 10.1016/S0960-8966(02)00007-X; Chambers CC, 1996, J PHYS CHEM-US, V100, P16385, DOI 10.1021/jp9610776; Coghlan MJ, 2001, J MED CHEM, V44, P1627, DOI 10.1021/jm000484+; COPPELLO J, 1995, J PHYSL, V434, P577; Greenberg A., 2000, AMIDE LINKAGE STRUCT; Hewawasam P, 2002, J MED CHEM, V45, P1487, DOI 10.1021/jm0101850; Hewawasam P, 2002, BIOORG MED CHEM LETT, V12, P1779, DOI 10.1016/S0960-894X(02)00240-8; Kuzmenkin A, 2002, BRAIN, V125, P835, DOI 10.1093/brain/awf071; LATORRE R, 1989, ANNU REV PHYSIOL, V51, P385, DOI 10.1146/annurev.ph.51.030189.002125; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Lindskog S, 1997, PHARMACOL THERAPEUT, V74, P1, DOI 10.1016/S0163-7258(96)00198-2; MCMANUS OB, 1991, J BIOENERG BIOMEMBR, V23, P537, DOI 10.1007/BF00785810; MEYERSON LR, 1991, BIOCHEM PHARMACOL, V41, P995, DOI 10.1016/0006-2952(91)90206-K; ROBITAILLE R, 1992, J NEUROSCI, V12, P297; Romine JL, 2002, J MED CHEM, V45, P2942, DOI 10.1021/jm010569q; RUFF RL, 2003, P 47 ANN M BIOPH SOC; Starrett JE, 1996, CURR PHARM DESIGN, V2, P413; TABEI K, 1995, AM J PHYSIOL-RENAL, V268, pF490, DOI 10.1152/ajprenal.1995.268.3.F490; Tawil R, 2000, ANN NEUROL, V47, P46, DOI 10.1002/1531-8249(200001)47:1<46::AID-ANA9>3.3.CO;2-8; Tricarico D, 2002, NEUROMUSCULAR DISORD, V12, P258, DOI 10.1016/S0960-8966(01)00270-X; Tricarico D, 1997, PFLUG ARCH EUR J PHY, V434, P822, DOI 10.1007/s004240050471; Tricarico D, 2001, J PHARMACOL EXP THER, V298, P1167; Tricarico D, 1999, J CLIN INVEST, V103, P675, DOI 10.1172/JCI4552; Tricarico D, 1998, MOL PHARMACOL, V54, P197, DOI 10.1124/mol.54.1.197; Tricarico D, 2000, ANN NEUROL, V48, P304, DOI 10.1002/1531-8249(200009)48:3<304::AID-ANA4>3.0.CO;2-A; VOLKL H, 1994, NEPHRON, V68, P234, DOI 10.1159/000188263; Wetzel P, 1998, ARCH BIOCHEM BIOPHYS, V356, P151, DOI 10.1006/abbi.1998.0762; WETZEL P, 2000, CARBONIC ANHYDRASES	31	64	64	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					760	+		10.1096/fj.03-0722fje	http://dx.doi.org/10.1096/fj.03-0722fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766795				2022-12-28	WOS:000220425000032
J	Ali, M; Hicks, AER; Hellewell, PG; Thoma, G; Norman, KE				Ali, M; Hicks, AER; Hellewell, PG; Thoma, G; Norman, KE			Polymers carrying sLe(x)-mimetics are superior inhibitors of E-selectin-dependent leukocyte rolling in vivo	FASEB JOURNAL			English	Article						multivalency; microcirculation; neutrophil; inflammation; intravital microscopy	P-SELECTIN; DEFICIENT MICE; ADHESION; LIGANDS; SLE(X); PATHOGENESIS; VENULES	Selectins mediate leukocyte rolling and may represent good anti-inflammatory drug targets. Detailed knowledge regarding the structure of selectin ligands has permitted development of selectin antagonists with varying specificities and activity. Efficacy of monovalent selectin antagonists may be increased by presenting them on a polymer backbone. We have synthesized a range of multivalent selectin antagonists and characterized their activity by using intravital microscopy of the mouse cremaster muscle. The monovalent inhibitor CGP77175A inhibited E-selectin-dependent leukocyte rolling at a dose of 3 mg/kg. Multivalent presentation of CGP77175A on a modified polylysine backbone (degree of polymerization = 1200; 50% of the polylysines carry the inhibitor) greatly enhanced in vivo activity giving an inhibitor that produced an equivalent effect at 0.1 mg/kg. The polylysine conjugate was also longer acting than the monovalent antagonist. In spite of greatly enhanced activity against E-selectin compared with monovalent inhibitor, the multivalent inhibitor had no measurable effect on P- or L-selectin-dependent leukocyte rolling.	Univ Sheffield, Div Clin Sci N, Cardiovasc Res Grp, Sheffield, S Yorkshire, England; Novartis Pharma AG, CH-4002 Basel, Switzerland	University of Sheffield; Novartis	Norman, KE (corresponding author), No Gen Hosp, Clin Sci Ctr, Cardiovasc Res Grp, Sheffield S5 7AU, S Yorkshire, England.	k.norman@shef.ac.uk			Medical Research Council of the United Kingdom; British Heart Foundation [FS/98051]	Medical Research Council of the United Kingdom(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); British Heart Foundation(British Heart Foundation)	K.E.N. is the recipient of a Career Establishment Grant from the Medical Research Council of the United Kingdom, which supported this study. A.E.R.H. was supported by a studentship (FS/98051) from the British Heart Foundation.	ALTAVILLA D, 1994, EUR J PHARM-ENVIRON, V270, P45, DOI 10.1016/0926-6917(94)90079-5; ALTAVILLA D, 1995, EUR J PHARMACOL, V272, P223, DOI 10.1016/0014-2999(94)00658-T; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Damiano ER, 1996, CIRC RES, V79, P1122, DOI 10.1161/01.RES.79.6.1122; Dunne JL, 2002, BLOOD, V99, P336, DOI 10.1182/blood.V99.1.336; Ernst B, 2001, CHIMIA, V55, P268; ETZIONI A, 1992, NEW ENGL J MED, V327, P1789, DOI 10.1056/NEJM199212173272505; Hicks AER, 2003, BLOOD, V101, P3249, DOI 10.1182/blood-2002-07-2329; HICKS AER, 2002, FASEB J; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Katopodis AG, 2002, J CLIN INVEST, V110, P1869, DOI 10.1172/JCI200216526; Kunkel EJ, 1996, CIRC RES, V79, P1196, DOI 10.1161/01.RES.79.6.1196; Kunkel EJ, 1996, J EXP MED, V183, P57, DOI 10.1084/jem.183.1.57; LABOW MA, 1994, IMMUNITY, V1, P709, DOI 10.1016/1074-7613(94)90041-8; LEES WJ, 1994, J MED CHEM, V37, P3419, DOI 10.1021/jm00046a027; Lefer DJ, 2000, ANNU REV PHARMACOL, V40, P283, DOI 10.1146/annurev.pharmtox.40.1.283; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marquardt T, 1999, BLOOD, V94, P3976, DOI 10.1182/blood.V94.12.3976.424k06_3976_3985; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; Mocco J, 2002, CIRC RES, V91, P907, DOI 10.1161/01.RES.0000042063.15901.20; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; Norman KE, 1998, BLOOD, V91, P475, DOI 10.1182/blood.V91.2.475.475_475_483; Owen RM, 2002, ORG LETT, V4, P2293, DOI 10.1021/ol0259239; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PICKER LJ, 1991, CELL, V66, P921, DOI 10.1016/0092-8674(91)90438-5; Ridger VC, 2002, FASEB J, V16, pA1213; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Setiadi H, 1998, J CELL BIOL, V142, P859, DOI 10.1083/jcb.142.3.859; Singbartl K, 2000, CRIT CARE MED, V28, P2507, DOI 10.1097/00003246-200007000-00053; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Sperandio M, 2001, BLOOD, V97, P3812, DOI 10.1182/blood.V97.12.3812; Stahn R, 1998, GLYCOBIOLOGY, V8, P311, DOI 10.1093/glycob/8.4.311; Thoma G, 2001, J AM CHEM SOC, V123, P10113, DOI 10.1021/ja0164430; Thoma G, 1999, J MED CHEM, V42, P4909, DOI 10.1021/jm990422n; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; WELPLY JK, 1994, GLYCOBIOLOGY, V4, P259, DOI 10.1093/glycob/4.3.259; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4	41	19	31	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					152	154		10.1096/fj.03-0346fje	http://dx.doi.org/10.1096/fj.03-0346fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597557				2022-12-28	WOS:000188829300058
J	Alzghoul, MB; Gerrard, D; Watkins, BA; Hannon, K				Alzghoul, MB; Gerrard, D; Watkins, BA; Hannon, K			Ectopic expression of IGF-1 and Shh by skeletal muscle inhibits disuse-mediated skeletal muscle atrophy and bone osteopenia in vivo	FASEB JOURNAL			English	Article						spaceflight; insulin growth factor-1; growth hormone	GROWTH-FACTOR; SOLEUS MUSCLE; SONIC HEDGEHOG; INSULIN; MICE; RAT; DENSITY; SPACE; MODEL	The loss of normal weight-bearing activity, which occurs during bed rest, limb immobilization, and spaceflight, stimulates a catabolic response within the musculoskeletal system, which results in a loss of skeletal muscle mass and bone mineral. The mechanism by which loading of muscle and bone is sensed and translated into signals controlling tissue formation remains a major question in the field of musculoskeletal research. In this investigation, we have examined the ability of two potentially anti-atrophic proteins, IGF-I and Shh, to inhibit disuse atrophy within muscle and bone, when electroporated into skeletal muscle. We have found that electroporation and ectopic expression of IGF-I and/or Shh within the gastrocnemius/soleus muscle significantly stimulated muscle fiber hypertrophy and increases in muscle size. In addition, we report that electroporation and ectopic expression of IGF-I and/or Shh within the gastrocnemius/soleus muscle attenuated the lost of muscle fiber area, muscle mass, and muscle mass density that normally occurs during disuse muscle atrophy. Finally, we found that ectopic expression of IGF-I and Shh within the gastrocnemius/soleus muscle inhibits parameters of osteopenia within the tibia and fibula associated with hindlimb unloading. These results support the theory that skeletal muscle can regulate bone maintenance and could offer potentially novel and efficient therapeutic options for attenuating muscle and bone atrophy during aging, illness and spaceflight.	Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; Purdue Univ, Dept Food Sci, Lipid Chem & Mol Biol Lab, W Lafayette, IN 47907 USA; Sch Vet Med, Irbid, Jordan	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Hannon, K (corresponding author), Purdue Univ, Sch Vet Med, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	kmh@vet.purdue.edu	Alzghoul, Mohammad/ABE-8281-2021; gerrard, david/AAG-7507-2019	Watkins, Bruce/0000-0002-2793-4538; gerrard, david/0000-0002-3482-1400				Allen DL, 1997, J APPL PHYSIOL, V83, P1857, DOI 10.1152/jappl.1997.83.6.1857; Barton-Davis ER, 1998, P NATL ACAD SCI USA, V95, P15603, DOI 10.1073/pnas.95.26.15603; Bikle DD, 1999, J BONE MINER METAB, V17, P233, DOI 10.1007/s007740050090; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Borrelli J, 2002, J ORTHOP TRAUMA, V16, P691, DOI 10.1097/00005131-200211000-00002; Borycki AG, 1998, DEVELOPMENT, V125, P777; Carmeliet G, 2001, CRIT REV EUKAR GENE, V11, P131; Conover CA, 2002, GROWTH HORM IGF RES, V12, P178, DOI 10.1016/S1096-6374(02)00044-8; Criswell DS, 1998, AM J PHYSIOL-ENDOC M, V275, pE373; Day CS, 2001, J RECONSTR MICROSURG, V17, P51, DOI 10.1055/s-2001-12689; Draghia-Akli R, 2003, FASEB J, V17, P526, DOI 10.1096/fj.02-0671fje; Duprez D, 1998, DEVELOPMENT, V125, P495; HANNON K, 1992, DEV BIOL, V151, P137, DOI 10.1016/0012-1606(92)90221-2; Hannon K, 1996, J CELL BIOL, V132, P1151, DOI 10.1083/jcb.132.6.1151; Hikida RS, 1997, ANAT REC, V247, P350, DOI 10.1002/(SICI)1097-0185(199703)247:3<350::AID-AR6>3.0.CO;2-Y; Kraemer WJ, 2000, HISTOCHEM CELL BIOL, V114, P349; KU Z, 1994, AM J PHYSIOL, V267, pC115, DOI 10.1152/ajpcell.1994.267.1.C115; LeBlanc A, 1998, BONE, V22, p113S, DOI 10.1016/S8756-3282(98)00013-1; Lee SJ, 1999, CURR OPIN GENET DEV, V9, P604, DOI 10.1016/S0959-437X(99)00004-0; Marchetti M E, 1996, J Shoulder Elbow Surg, V5, P471, DOI 10.1016/S1058-2746(96)80020-6; Mir LM, 1999, P NATL ACAD SCI USA, V96, P4262, DOI 10.1073/pnas.96.8.4262; Morey E.R., 1979, PHYSIOLOGIST, V22, P23; PARK E, 1993, AVIAT SPACE ENVIR MD, V64, P401; Pirskanen A, 2000, DEV BIOL, V224, P189, DOI 10.1006/dbio.2000.9784; Rabinovsky ED, 2002, FASEB J, V16, P53, DOI 10.1096/fj.02-0183fje; Rantakokko J, 1999, J BONE MINER RES, V14, P1934, DOI 10.1359/jbmr.1999.14.11.1934; Reichel CL, 2000, DOMEST ANIM ENDOCRIN, V18, P337, DOI 10.1016/S0739-7240(00)00054-0; RILEY DA, 1990, J APPL PHYSIOL, V69, P58, DOI 10.1152/jappl.1990.69.1.58; Rubin C, 2001, FASEB J, V15, P2225, DOI 10.1096/fj.01-0166com; Sjogren K, 2001, J NUTR, V131, P2963, DOI 10.1093/jn/131.11.2963; Stabnov L, 2002, BONE, V30, P909, DOI 10.1016/S8756-3282(02)00738-X; THOMASON DB, 1990, J APPL PHYSIOL, V68, P1, DOI 10.1152/jappl.1990.68.1.1; Young BH, 2002, CLIN ORTHOP RELAT R, pS243, DOI 10.1097/01.blo.0000031984.92980.5d	33	80	84	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					221	223		10.1096/fj.03-0293fje	http://dx.doi.org/10.1096/fj.03-0293fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597562				2022-12-28	WOS:000188829300079
J	Bar, D; Apte, RN; Voronov, E; Dinarello, CA; Cohen, S				Bar, D; Apte, RN; Voronov, E; Dinarello, CA; Cohen, S			A continuous delivery system of IL-1 receptor antagonist reduces angiogenesis and inhibits tumor development	FASEB JOURNAL			English	Article						tumor inhibition; controlled delivery; proinflammatory cytokine; genetically engineered cells; microencapsulated cells	IN-VIVO; INTERLEUKIN-1; MELANOMA; GROWTH; INVASIVENESS; METASTASIS; IL-1-BETA; CARCINOMA; ARTHRITIS; GENE	The involvement of interleukin-1 (IL-1) in inflammation, tumor growth, and metastasis makes it an attractive target for therapeutic intervention. Here, we show that a continuous delivery of a low, but steady-state level of the naturally occurring IL-I receptor antagonist (IL-IRa) reduced inflammatory responses and inhibited tumor development in mice, phenomena that are induced by IL-1, mainly secretable IL-1 beta. The IL-IRa was delivered from microencapsulated genetically engineered cells, which overexpress and secrete this mediator. For a tumor model, we used fibrosarcoma cell line, which secretes high levels of IL-1 beta; when injected s.c. into mice, the cells developed into large tumors characterized by very active angiogenic patterns. The proangiogenic features of IL-1 beta were manifested at low levels of the cytokine, and release of 25 ng per day of the IL-IRa was needed to oppose its effects and inhibit tumor development. The continuous delivery of the IL-IRa contributed to improved biocompatibility of the microencapsulated cell systems; the fibrotic sac surrounding the systems was much thinner with significantly less blood capillaries and inflammatory cells. Not only do our findings point to the antiangiogenic properties of IL-1Ra in inflammation and tumor growth, but they also provide a more efficient and convenient way for treating diseases involving IL- 1.	Ben Gurion Univ Negev, Dept Biotechnol Engn, Fac Engn Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Inst Appl Biosci, Fac Engn Sci, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Ctr Canc, IL-84105 Beer Sheva, Israel; Ben Gurion Univ Negev, Fac Hlth Sci, Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; Univ Colorado, Hlth Sci Ctr, Denver, CO 80262 USA	Ben Gurion University; Ben Gurion University; Ben Gurion University; Ben Gurion University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Cohen, S (corresponding author), Ben Gurion Univ Negev, Dept Biotechnol Engn, Fac Engn Sci, Bldg 39,Room 222, IL-84105 Beer Sheva, Israel.	scohen@bgumail.bgu.ac.il	Dinarello, Charles/C-8524-2013		Israel Science Foundation; Israel Science Foundation and the Association for International Cancer Research; Kamea Program of the Israel Ministry of Immigrant Absorption; Israel Cancer Association; NIH [AI-15614]	Israel Science Foundation(Israel Science Foundation); Israel Science Foundation and the Association for International Cancer Research; Kamea Program of the Israel Ministry of Immigrant Absorption; Israel Cancer Association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	We thank Ms. Parvin Zerin for excellent assistance in tissue embedding and processing and Prof. Daniel Benharroch for his advice and assistance in histology assessment. S.C. is supported by The Israel Science Foundation; R.N.A. is supported by The Israel Science Foundation and the Association for International Cancer Research; E.V. is supported by the Kamea Program of the Israel Ministry of Immigrant Absorption, The Israel Science Foundation, and the Israel Cancer Association; and C.A.D. is supported by NIH grant AI-15614	Apte RN, 2000, ADV EXP MED BIOL, V479, P277; Apte RN, 2002, SEMIN CANCER BIOL, V12, P277, DOI 10.1016/S1044-579X(02)00014-7; Bar D, 2001, J CONTROL RELEASE, V72, P228; BAR D, THESIS BEN GURION U; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; Bresnihan B, 1998, ARTHRITIS RHEUM, V41, P2196, DOI 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.3.CO;2-U; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; Douvdevani A, 1991, Eur Cytokine Netw, V2, P257; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; GIAVAZZI R, 1990, CANCER RES, V50, P4771; GRANOWTIZ EV, 1992, CYTOKINE, V4, P353, DOI 10.1016/1043-4666(92)90078-6; Horai R, 2000, J EXP MED, V191, P313, DOI 10.1084/jem.191.2.313; LIM F, 1980, SCIENCE, V210, P908, DOI 10.1126/science.6776628; Machluf M, 1997, J CONTROL RELEASE, V43, P35, DOI 10.1016/S0168-3659(96)01466-6; Nicklin MJH, 2000, J EXP MED, V191, P303, DOI 10.1084/jem.191.2.303; Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469; ULUDAG H, 1990, BIOMATERIALS, V11, P708, DOI 10.1016/0142-9612(90)90032-L; VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667; VidalVanaclocha F, 1996, JNCI-J NATL CANCER I, V88, P198, DOI 10.1093/jnci/88.3-4.198; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; Wingren AG, 1996, CELL IMMUNOL, V169, P226, DOI 10.1006/cimm.1996.0113	22	83	85	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					161	163		10.1096/fj.03-0483fje	http://dx.doi.org/10.1096/fj.03-0483fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597552				2022-12-28	WOS:000188829300061
J	Fowler, AM; Solodin, N; Preisler-Mashey, MT; Zhang, P; Lee, AV; Alarid, ET				Fowler, AM; Solodin, N; Preisler-Mashey, MT; Zhang, P; Lee, AV; Alarid, ET			Increases in estrogen receptor-alpha concentration in breast cancer cells promote serine 118/104/106-independent AF-1 transactivation and growth in the absence of estrogen	FASEB JOURNAL			English	Article						nuclear receptor; steroid hormone; transcription; proliferation; ligand-independent	ACTIVATED PROTEIN-KINASE; PROTEASOME-MEDIATED PROTEOLYSIS; TRANSCRIPTIONAL ACTIVATION; NUCLEAR-LOCALIZATION; SIGNAL-TRANSDUCTION; C-FOS; BINDING; GENE; PATHWAY; COACTIVATOR	A common phenotype in breast cancer is the expansion of the estrogen receptor-alpha (ER+) cell population and an inappropriate elevation of ERalpha protein, the latter predisposing patients for a poorer prognosis than those with lower levels of the receptor. A tetracycline-inducible ERalpha overexpression model was developed in the MCF-7 cell line to assess induction of endogenous gene activation and growth in response to elevations in ERalpha protein. Heightened levels of ERalpha resulted in aberrant promoter occupancy and gene activation in the absence of hormone, which was independent of ligand and AF-2 function. This increased receptor activity required the amino-terminal A/B domain and was not inhibited by tamoxifen, which supports an enhancement of AF-1 function, yet was independent of serine-104, 106, and 118 phosphorylation. Ligand-independent transcription was accompanied by an increase in growth in the absence of hormonal stimulation. The results suggest that elevated levels of ERalpha in breast cancer cells can result in activation of receptor transcriptional function in a manner distinct from classical mechanisms that involve ligand binding or growth factor-induced phosphorylation. Further, they describe a potential mechanism whereby increases in ERalpha concentration may provide a proliferative advantage by augmenting ERalpha function regardless of ligand status.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	University of Wisconsin System; University of Wisconsin Madison; Baylor College of Medicine; Baylor College of Medicine	Alarid, ET (corresponding author), Univ Wisconsin, Dept Physiol, 120 Serv Mem Inst,1300 Univ Ave, Madison, WI 53706 USA.	alarid@physiology.wisc.edu			NATIONAL CANCER INSTITUTE [K01CA079090] Funding Source: NIH RePORTER; NCI NIH HHS [K01 CA-79090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; BERRY M, 1989, P NATL ACAD SCI USA, V86, P1218, DOI 10.1073/pnas.86.4.1218; BERRY M, 1990, EMBO J, V9, P2811, DOI 10.1002/j.1460-2075.1990.tb07469.x; BLACK R, 1983, CLIN ONCOL, V9, P311; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Castoria G, 1999, EMBO J, V18, P2500, DOI 10.1093/emboj/18.9.2500; Chan CMW, 2002, J STEROID BIOCHEM, V81, P333, DOI 10.1016/S0960-0760(02)00074-2; Chun TY, 1998, P NATL ACAD SCI USA, V95, P2325, DOI 10.1073/pnas.95.5.2325; CLARKE R, 1989, P NATL ACAD SCI USA, V86, P3649, DOI 10.1073/pnas.86.10.3649; Coleman KM, 2001, FRONT BIOSCI, V6, pD1379, DOI 10.2741/Coleman; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DUBIK D, 1988, J BIOL CHEM, V263, P12705; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FABRIS G, 1987, J STEROID BIOCHEM, V27, P171, DOI 10.1016/0022-4731(87)90307-4; FAWELL SE, 1990, P NATL ACAD SCI USA, V87, P6883, DOI 10.1073/pnas.87.17.6883; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hupperets PS, 1997, AM J CLIN ONCOL-CANC, V20, P546, DOI 10.1097/00000421-199712000-00002; JOU WM, 1980, CELL, V19, P683, DOI 10.1016/S0092-8674(80)80045-6; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KATZENELLENBOGEN BS, 1987, CANCER RES, V47, P4355; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Maniatis T., 1982, MOL CLONING; Marquez DC, 2001, ONCOGENE, V20, P5420, DOI 10.1038/sj.onc.1204729; MASAMURA S, 1995, J CLIN ENDOCR METAB, V80, P2918, DOI 10.1210/jc.80.10.2918; MASTERS JRW, 1978, EUR J CANCER, V14, P303, DOI 10.1016/0014-2964(78)90194-9; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Miyamoto S, 1998, MOL CELL BIOL, V18, P19, DOI 10.1128/MCB.18.1.19; Monje P, 2001, MOL CELL ENDOCRINOL, V181, P117, DOI 10.1016/S0303-7207(01)00526-3; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; Prall OWJ, 1997, J BIOL CHEM, V272, P10882; Preisler-Mashek MT, 2002, AM J PHYSIOL-ENDOC M, V282, pE891, DOI 10.1152/ajpendo.00353.2001; Razandi M, 2003, J BIOL CHEM, V278, P2701, DOI 10.1074/jbc.M205692200; REDDEL RR, 1984, CANCER RES, V44, P2398; ROBERSON MS, 1995, MOL CELL BIOL, V15, P3531; ROMAIN S, 1994, INT J CANCER, V59, P17, DOI 10.1002/ijc.2910590105; SANCHOGARNIER H, 1995, EUR J CANCER, V31A, P1851, DOI 10.1016/0959-8049(95)00387-X; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Song RXD, 2002, MOL ENDOCRINOL, V16, P116, DOI 10.1210/me.16.1.116; Stenoien DL, 2001, NAT CELL BIOL, V3, P15, DOI 10.1038/35050515; THORPE SM, 1993, EUR J CANCER, V29A, P971, DOI 10.1016/S0959-8049(05)80204-7; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TZUKERMAN MT, 1994, MOL ENDOCRINOL, V8, P21, DOI 10.1210/me.8.1.21; VANDERBILT JN, 1987, MOL ENDOCRINOL, V1, P68, DOI 10.1210/mend-1-1-68; VANDERBURG B, 1989, MOL CELL ENDOCRINOL, V64, P223, DOI 10.1016/0303-7207(89)90149-4; Watanabe M, 2001, EMBO J, V20, P1341, DOI 10.1093/emboj/20.6.1341; Watson CS, 1999, STEROIDS, V64, P5, DOI 10.1016/S0039-128X(98)00107-X; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; WEBB P, 1992, MOL ENDOCRINOL, V6, P157, DOI 10.1210/me.6.2.157; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; Weigel NL, 1998, J MOL MED, V76, P469, DOI 10.1007/s001090050241; Weinmann AS, 2002, METHODS, V26, P37, DOI 10.1016/S1046-2023(02)00006-3; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WELSHONS WV, 1987, EUR J CANCER CLIN ON, V23, P1935, DOI 10.1016/0277-5379(87)90062-9; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Wu XY, 2001, J BIOL CHEM, V276, P23962, DOI 10.1074/jbc.M101041200; YLIKOMI T, 1992, EMBO J, V11, P3681, DOI 10.1002/j.1460-2075.1992.tb05453.x; ZAJCHOWSKI DA, 1993, CANCER RES, V53, P5004; ZHANG HJ, 1984, BREAST CANCER RES TR, V4, P221, DOI 10.1007/BF01806488	67	63	64	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					81	93		10.1096/fj.03-0038com	http://dx.doi.org/10.1096/fj.03-0038com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718389				2022-12-28	WOS:000188829300042
J	Gelfi, C; De Palma, S; Ripamonti, M; Wait, R; Eberini, I; Bajracharya, A; Marconi, C; Schneider, A; Hoppeler, H; Cerretelli, P				Gelfi, C; De Palma, S; Ripamonti, M; Wait, R; Eberini, I; Bajracharya, A; Marconi, C; Schneider, A; Hoppeler, H; Cerretelli, P			New aspects of altitude adaptation in Tibetans: a proteomic approach	FASEB JOURNAL			English	Article						muscle; two-dimensional gel electrophoresis; hypoxia; glutathione-S-transferase; myoglobin	VASTUS-LATERALIS MUSCLE; NITRIC-OXIDE; POLYACRYLAMIDE-GELS; MASS-SPECTROMETRY; PERSISTENT INHIBITION; CHRONIC HYPOXIA; GROWTH-FACTOR; MYOGLOBIN; PROTEINS; OXYGEN	A prolonged sojourn above 5500 m induces muscle deterioration and accumulation of lipofuscin in Caucasians, probably because of overproduction of reactive oxygen species (ROS). Because Sherpas, who live at high altitude, have very limited muscle damage, it was hypothesized that Himalayan natives possess intrinsic mechanisms protecting them from oxidative damage. This possibility was investigated by comparing the muscle proteomes of native Tibetans permanently residing at high altitude, second-generation Tibetans born and living at low altitude, and Nepali control subjects permanently residing at low altitude, using 2D gel electrophoresis and mass spectrometry. Seven differentially regulated proteins were identified: glutathione-S-transferase PI-1, which was 380% and 50% overexpressed in Tibetans born and living at high and low altitude, respectively; Delta(2)-enoyl-CoA-hydratase, which was up-regulated in both Tibetan groups; glyceraldehyde-3-phosphate dehydrogenase and lactate dehydrogenase, which were both slightly down-regulated in Tibetans born and living at high altitude; phosphoglycerate mutase, which was 50% up-regulated in the native Tibetans; NADH-ubiquinone oxidoreductase, slightly overexpressed in Tibetans born and living at high altitude; and myoglobin, which was overexpressed in both Tibetan groups. We concluded that Tibetans at high altitude, and to some extent, those born and living at low altitude, are protected from ROS-induced tissue damage and possess specific metabolic adaptations.	CNR, Inst Mol Bioimaging & Physiol, I-20090 Milan, Italy; Univ London Imperial Coll Sci Technol & Med, Kennedy Inst Rheumatol, London, England; Univ Milan, Dept Pharmacol Sci, I-20122 Milan, Italy; Royal Nepal Acad Sci & Technol, Kathmandu, Nepal; Fac Med, Inst Anat, Bern, Switzerland; Univ Milan, Fac Med, Dept Biomed Sci & Technol, I-20122 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Bioimmagini e Fisiologia Molecolare (IBFM-CNR); Imperial College London; University of Oxford; University of Milan; Nepal Academy of Science & Technology (NAST); University of Geneva; University of Milan	Gelfi, C (corresponding author), CNR, Inst Mol Bioimaging & Physiol, Via Fratelli Cervi 93, I-20090 Milan, Italy.	cecilia.gelfi@ibfm.cnr.it	Ripamonti, Marilena/AAY-4013-2020	RIPAMONTI, MARILENA/0000-0001-9403-9915; De Palma, Sara/0000-0002-6795-4138				Agani FH, 2002, AM J PHYSIOL-CELL PH, V283, pC178, DOI 10.1152/ajpcell.00381.2001; Alderton AL, 2003, BIOCHEMISTRY-US, V42, P4398, DOI 10.1021/bi0271695; Allaire J, 2002, MUSCLE NERVE, V25, P383, DOI 10.1002/mus.10039; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andriambeloson E, 2002, REDOX REP, V7, P131, DOI 10.1179/135100002125000361; Beall CM, 2001, NATURE, V414, P411, DOI 10.1038/35106641; BERHANE K, 1994, P NATL ACAD SCI USA, V91, P1480, DOI 10.1073/pnas.91.4.1480; BOULTON FE, 1971, BIOCHIM BIOPHYS ACTA, V229, P716, DOI 10.1016/0005-2795(71)90288-1; Brown GC, 2003, SCIENCE, V299, P838, DOI 10.1126/science.1082028; Brunk UT, 2002, FREE RADICAL BIO MED, V33, P611, DOI 10.1016/S0891-5849(02)00959-0; Carmeli E, 2002, EXP GERONTOL, V37, P477, DOI 10.1016/S0531-5565(01)00220-0; CERRETELLI P, 1976, J APPL PHYSIOL, V40, P658, DOI 10.1152/jappl.1976.40.5.658; Cerretelli P, 1996, HDB PHYSL 4, V4, P1155; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Cotgreave IA, 2002, FASEB J, V16, P435, DOI 10.1096/fj.01-0685fje; Desplanches D, 1996, J APPL PHYSIOL, V81, P1946, DOI 10.1152/jappl.1996.81.5.1946; Dhakshinamoorthy S, 2002, ONCOGENE, V21, P5301, DOI 10.1038/sj.onc.1205642; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Futcher B, 1999, MOL CELL BIOL, V19, P7357; GELFI C, 1995, ELECTROPHORESIS, V16, P780, DOI 10.1002/elps.11501601127; Gelfi C, 2003, ELECTROPHORESIS, V24, P286, DOI 10.1002/elps.200390025; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P53, DOI 10.1002/elps.1150060113; Gnaiger E, 2000, P NATL ACAD SCI USA, V97, P11080, DOI 10.1073/pnas.97.20.11080; Grassi B, 1996, J APPL PHYSIOL, V80, P685, DOI 10.1152/jappl.1996.80.2.685; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hochachka PW., 1988, ANN SPORTS MED, V4, P184; HOPPELER H, 1990, INT J SPORTS MED, V11, pS3, DOI 10.1055/s-2007-1024846; HOPPELER H, 1981, RESP PHYSIOL, V44, P87, DOI 10.1016/0034-5687(81)90078-5; HOWALD H, 1990, INT J SPORTS MED, V11, pS10, DOI 10.1055/s-2007-1024847; Jurgens KD, 2000, NEWS PHYSIOL SCI, V15, P269; KAYSER B, 1991, J APPL PHYSIOL, V70, P1938, DOI 10.1152/jappl.1991.70.5.1938; Kayser B, 1996, J APPL PHYSIOL, V81, P419, DOI 10.1152/jappl.1996.81.1.419; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; MARTINELLI M, 1990, EXPERIENTIA, V46, P672, DOI 10.1007/BF01939930; Molloy MP, 2000, EUR J BIOCHEM, V267, P2871, DOI 10.1046/j.1432-1327.2000.01296.x; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Moore DH, 2002, AMYOTROPH LATERAL SC, V3, P3; Orsi A, 2000, BIOCHEM J, V346, P407, DOI 10.1042/0264-6021:3460407; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pollak ES, 2002, BLOOD, V100, P359, DOI 10.1182/blood-2002-02-0412; RABILLOUD T, 1994, CELL MOL BIOL, V40, P57; REYNAFARJE B, 1962, J APPL PHYSIOL, V17, P301, DOI 10.1152/jappl.1962.17.2.301; SAMAJA M, 1977, ACTA PHYSL SCAND, V159, P249; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; VANHALL G, 2001, J PHYSL, V563, P963; Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142; WEIBEL ER, 1979, STEREOLOGICAL METHOD, pCH4; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0; Wittenberg JB, 2003, J EXP BIOL, V206, P2011, DOI 10.1242/jeb.00243; Yan JX, 2000, ELECTROPHORESIS, V21, P3666, DOI 10.1002/1522-2683(200011)21:17<3666::AID-ELPS3666>3.0.CO;2-6	54	113	123	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					612	+		10.1096/fj.03-1077fje	http://dx.doi.org/10.1096/fj.03-1077fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734630				2022-12-28	WOS:000188829300015
J	Krysan, K; Merchant, FH; Zhu, L; Dohadwala, M; Luo, J; Lin, Y; Heuze-Vourc'h, N; Pold, M; Seligson, D; Chia, D; Goodglick, L; Wang, HJ; Strieter, R; Sharma, S; Dubinett, S				Krysan, K; Merchant, FH; Zhu, L; Dohadwala, M; Luo, J; Lin, Y; Heuze-Vourc'h, N; Pold, M; Seligson, D; Chia, D; Goodglick, L; Wang, HJ; Strieter, R; Sharma, S; Dubinett, S			COX-2-dependent stabilization of survivin in non-small cell lung cancer	FASEB JOURNAL			English	Article						cyclooxygenase 2; prostaglandin; NSCLC cells	CASPASE ACTIVATION; PROSTAGLANDIN E-2; CYTOCHROME-C; CYCLOOXYGENASE-2; APOPTOSIS; PROTEIN; EXPRESSION; INHIBITOR; INVOLVEMENT; DEATH	Elevated tumor cyclooxygenase 2 (COX-2) expression is associated with increased angiogenesis, tumor invasion and promotion of tumor cell resistance to apoptosis. The mechanism(s) by which COX-2 exerts its cytoprotective effects are not completely understood but may be due to an imbalance of pro- and anti-apoptotic gene expression. To analyze COX-2-dependent gene expression and apoptosis, we created cell lines constitutively expressing COX-2 cDNA in sense and antisense orientations. Whereas COX-2 sense cells have significantly heightened resistance to radiation and drug-induced apoptosis, COX-2 antisense cells are highly sensitive to apoptosis induction. We found that the expression of the anti-apoptotic protein survivin correlated positively with COX-2 expression. A COX-2-dependent modulation of survivin ubiquitination led to its stabilization in COX-2 overexpressing cells, and this effect was replicated by exogenous PGE2 treatment of parental tumor cells. In contrast to previous studies in other cell types, in nonsmall cell lung cancer cells survivin was expressed in a cell cycle-independent manner. When established in SCID mice in vivo, COX-2 antisense-derived tumors had significantly decreased survivin levels while COX-2 sense-derived tumors demonstrated elevated levels compared with controls. In accord with these findings, survivin and COX-2 were frequently upregulated and co-expressed in human lung cancers in situ.	Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Lung Canc Res Program, Los Angeles, CA 90024 USA; Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA; Univ Calif Los Angeles, Defined Tumor Marker Evaluat Ctr, Los Angeles, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles	Dubinett, S (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, 37-131 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.	sdubinett@mednet.ucla.edu	HEUZE-VOURC'H, Nathalie/P-8081-2016	Heuze-Vourc'h, Nathalie/0000-0003-4929-5068	UCLA SPORE In Lung Cancer NIH [P50 CA90388]; TRDRP grant [12FT-0061]; Early Detection Research Network [NCI CA-99-008]; NATIONAL CANCER INSTITUTE [U24CA086366] Funding Source: NIH RePORTER	UCLA SPORE In Lung Cancer NIH; TRDRP grant; Early Detection Research Network; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by the UCLA SPORE In Lung Cancer NIH P50 CA90388, TRDRP grant #12FT-0061 (K. Krysan) and the Early Detection Research Network (NCI CA-99-008; L. Goodglick, D. Chia, D. Seligson, and F. Merchant).	ALTORKI N, 2002, ASCO, V21, P101; Ambrosini G, 1998, J BIOL CHEM, V273, P11177, DOI 10.1074/jbc.273.18.11177; CARBONE D, 2002, ASCO, V21, P1270; Chang HC, 2001, ONCOL REP, V8, P1321; Chang YWE, 2000, MOL CELL BIOL, V20, P8571, DOI 10.1128/MCB.20.22.8571-8579.2000; CSIKI I, 2002, ASCO, V21, P1187; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Dohadwala M, 2001, J BIOL CHEM, V276, P20809, DOI 10.1074/jbc.C100140200; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Fujita T, 1998, CANCER RES, V58, P4823; Herschman HR, 1996, BBA-LIPID LIPID MET, V1299, P125, DOI 10.1016/0005-2760(95)00194-8; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hida T, 2000, CLIN CANCER RES, V6, P2006; Hosomi Y, 2000, LUNG CANCER, V30, P73, DOI 10.1016/S0169-5002(00)00132-X; Hsu AL, 2000, J BIOL CHEM, V275, P11397, DOI 10.1074/jbc.275.15.11397; Huang M, 1998, CANCER RES, V58, P1208; Kirschenbaum A, 2001, UROLOGY, V58, P127, DOI 10.1016/S0090-4295(01)01255-9; Kobayashi K, 1999, P NATL ACAD SCI USA, V96, P1457, DOI 10.1073/pnas.96.4.1457; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Li FZ, 1998, NATURE, V396, P580, DOI 10.1038/25141; Lin MT, 2001, J BIOL CHEM, V276, P48997, DOI 10.1074/jbc.M107829200; Milas L, 1999, J NATL CANCER I, V91, P1501, DOI 10.1093/jnci/91.17.1501; O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697; Piazza GA, 1997, CANCER RES, V57, P2452; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Subbaramaiah K, 2000, J BIOL CHEM, V275, P14838, DOI 10.1074/jbc.275.20.14838; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Wolff H, 1998, CANCER RES, V58, P4997; Yu J, 2002, BRIT J CANCER, V87, P91, DOI 10.1038/sj.bjc.6600421; Zhao J, 2000, J CELL SCI, V113, P4363	45	111	138	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					205	206		10.1096/fj.03-0369fje	http://dx.doi.org/10.1096/fj.03-0369fje			2	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597555				2022-12-28	WOS:000188829300075
J	Paulsson, KM; Wang, P				Paulsson, KM; Wang, P			Quality control of MHC class I maturation	FASEB JOURNAL			English	Review						loading complex; tapasin; TAP; peptide; COPI; transport; optimization	THIOL-DEPENDENT REDUCTASE; MAJOR HISTOCOMPATIBILITY HEAVY; ENDOPLASMIC-RETICULUM; PEPTIDE-BINDING; INTERMEDIATE COMPARTMENT; ANTIGEN PRESENTATION; GOLGI-COMPLEX; TAPASIN; MOLECULES; TAP	Assembly of MHC class I molecules in the ER is regulated by the so-called loading complex (LC). This multiprotein complex is of definite importance for class I maturation, but its exact organization and order of assembly are not known. Evidence implies that the quality of peptides loaded onto class I molecules is controlled at multiple stages during MHC class I assembly. We recently found that tapasin, an important component of the LC, interacts with COPI-coated vesicles. Biochemical studies suggested that the tapasin-COPI interaction regulates the retrograde transport of immature MHC class I molecules from the Golgi network back to the ER. Also other findings now propose that in addition to the peptide-loading control, the quality control of MHC class I antigen presentation includes the restriction of export of suboptimally loaded MHC class I molecules to the cell surface. In this review, we use recent studies of tapasin to examine the efficiency of TAP, the LC constitution, ER quality control of class I assembly, and peptide optimization. The concepts of MHC class I recycling and ER retention are also discussed.	UCL, Ctr Mol Med, Dept Med, Rayne Inst, London WC1E 6JJ, England; Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, Immunol Grp, London EC1A 7ED, England	University of London; King's College London; University College London; University of London; Queen Mary University London	Paulsson, KM (corresponding author), UCL, Ctr Mol Med, Dept Med, Rayne Inst, 5 Univ St, London WC1E 6JJ, England.	k.paulsson@ucl.ac.uk			Biotechnology and Biological Sciences Research Council [C17891] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		ANDROLEWICZ MJ, 1994, P NATL ACAD SCI USA, V91, P12716, DOI 10.1073/pnas.91.26.12716; Antoniou AN, 2002, IMMUNOLOGY, V106, P182, DOI 10.1046/j.1365-2567.2002.01415.x; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Bouvier M, 1998, NAT STRUCT BIOL, V5, P377, DOI 10.1038/nsb0598-377; Bresnahan PA, 1997, HUM IMMUNOL, V53, P129, DOI 10.1016/S0198-8859(97)00001-3; Cascio P, 2001, EMBO J, V20, P2357, DOI 10.1093/emboj/20.10.2357; Chun T, 2001, J IMMUNOL, V167, P1507, DOI 10.4049/jimmunol.167.3.1507; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; Dick TP, 2002, IMMUNITY, V16, P87, DOI 10.1016/S1074-7613(02)00263-7; FALK K, 1990, NATURE, V348, P248, DOI 10.1038/348248a0; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEEMELS MT, 1995, ANNU REV BIOCHEM, V64, P463, DOI 10.1146/annurev.bi.64.070195.002335; HIRANO N, 1995, EUR J BIOCHEM, V234, P336, DOI 10.1111/j.1432-1033.1995.336_c.x; HSU VW, 1991, NATURE, V352, P441, DOI 10.1038/352441a0; Hughes EA, 1998, CURR BIOL, V8, P709, DOI 10.1016/S0960-9822(98)70278-7; Khan Muhammad Asim, 1995, Current Opinion in Rheumatology, V7, P263, DOI 10.1097/00002281-199507000-00001; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; Klein J., 1975, BIOL MOUSE HISTOCOMP; Knittler MR, 1999, CURR BIOL, V9, P999, DOI 10.1016/S0960-9822(99)80448-5; Lankat-Buttgereit B, 1999, FEBS LETT, V464, P108, DOI 10.1016/S0014-5793(99)01676-2; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; LETOURNEUR F, 1994, CELL, V79, P1199, DOI 10.1016/0092-8674(94)90011-6; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Lewis JW, 1998, CURR BIOL, V8, P717, DOI 10.1016/S0960-9822(98)70280-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 1999, J BIOL CHEM, V274, P8649, DOI 10.1074/jbc.274.13.8649; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; Lindquist JA, 1998, EMBO J, V17, P2186, DOI 10.1093/emboj/17.8.2186; Lybarger L, 2001, J IMMUNOL, V167, P2097, DOI 10.4049/jimmunol.167.4.2097; Mancino L, 2002, P NATL ACAD SCI USA, V99, P5931, DOI 10.1073/pnas.092031799; Margel S., 1999, MICROSPHERES MICROCA, V2, P11; Morrice NA, 1998, CURR BIOL, V8, P713, DOI 10.1016/S0960-9822(98)70279-9; Myers NB, 2000, J IMMUNOL, V165, P5656, DOI 10.4049/jimmunol.165.10.5656; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; NEEFJES JJ, 1993, J EXP MED, V178, P1971, DOI 10.1084/jem.178.6.1971; NOSSNER E, 1995, J EXP MED, V181, P327, DOI 10.1084/jem.181.1.327; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Park B, 2003, J BIOL CHEM, V278, P14337, DOI 10.1074/jbc.M212882200; Park B, 2003, J IMMUNOL, V170, P961, DOI 10.4049/jimmunol.170.2.961; Park B, 2001, IMMUNITY, V15, P213, DOI 10.1016/S1074-7613(01)00179-0; Paulk M. C., 2000, Cutter IT Journal, V13, P23; Paulsson K, 2003, BBA-MOL CELL RES, V1641, P1, DOI 10.1016/S0167-4889(03)00048-X; Paulsson KM, 2002, J BIOL CHEM, V277, P18266, DOI 10.1074/jbc.M201388200; Paulsson KM, 2001, INT IMMUNOL, V13, P1063, DOI 10.1093/intimm/13.8.1063; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Pentcheva T, 2002, J IMMUNOL, V168, P1538, DOI 10.4049/jimmunol.168.4.1538; Pentcheva T, 2001, J IMMUNOL, V166, P6625, DOI 10.4049/jimmunol.166.11.6625; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; Raghuraman G, 2002, J BIOL CHEM, V277, P41786, DOI 10.1074/jbc.M207128200; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; Serwold T, 2002, NATURE, V419, P480, DOI 10.1038/nature01074; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SUGITA M, 1994, J EXP MED, V180, P2163, DOI 10.1084/jem.180.6.2163; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, CELL, V44, P959, DOI 10.1016/0092-8674(86)90019-X; Turnquist HR, 2002, TISSUE ANTIGENS, V59, P18, DOI 10.1034/j.1399-0039.2002.590104.x; URADE R, 1992, J BIOL CHEM, V267, P15152; Williams AP, 2002, IMMUNITY, V16, P509, DOI 10.1016/S1074-7613(02)00304-7; Yamamoto K, 2001, EMBO J, V20, P3082, DOI 10.1093/emboj/20.12.3082	73	29	30	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					31	38		10.1096/fj.03-0846rev	http://dx.doi.org/10.1096/fj.03-0846rev			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718384				2022-12-28	WOS:000188829300037
J	Pauws, E; Veenboer, GJM; Smit, JWA; de Vijlder, JJM; Morreau, H; Ris-Stalpers, C				Pauws, E; Veenboer, GJM; Smit, JWA; de Vijlder, JJM; Morreau, H; Ris-Stalpers, C			Genes differentially expressed in thyroid carcinoma identified by comparison of SAGE expression profiles	FASEB JOURNAL			English	Article						tissue preferential expression; serial analysis of gene expression; extracellular matrix protein 1	ENDOTHELIAL GROWTH-FACTOR; SERIAL ANALYSIS; NODULAR DISEASE; CANCER; PAPILLARY; GALECTIN-3; TUMORS; CARCINOGENESIS; MUTATIONS; HETEROZYGOSITY	To identify transcripts that distinguish malignant from benign thyroid disease serial analysis of gene expression (SAGE) profiles of papillary thyroid carcinoma and of normal thyroid are compared. Of the 21,000 tags analyzed, 204 tags are differentially expressed with statistical significance in the tumor. Thyroid tumor specificity of these transcripts is determined in silico using the tissue preferential expression (TPE) algorithm. TPE values demonstrate that 42 tags of the 204 are thyroid tumor specific. BC013035, a cDNA encoding a novel protein, is up-regulated from 0 to 24 tags in the thyroid tumor SAGE library. In a tissue panel of 30 thyroid tumors and 12 controls, it has an expression pattern similar to thyroid peroxidase, indicating possible involvement of BC013035 in thyroid differentiation. A tag coding for extracellular matrix protein 1 (ECM1) is absent in the normal thyroid SAGE library and present 55 times in the tumor. ECM1, a protein recently associated with angiogenesis and expressed in metastatic breast carcinoma, is up-regulated in 50% of all thyroid carcinoma and absent in normal controls and follicular adenoma. In conclusion, SAGE analysis and subsequent determination of TPE values facilitates the rapid distinction of genes specifically expressed in cancer tissues.	Univ Amsterdam, Acad Med Ctr, Lab Pediat Endocrinol, NL-1100 DE Amsterdam, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Endocrinol, Leiden, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Ris-Stalpers, C (corresponding author), Univ Amsterdam, Acad Med Ctr, Lab Pediat Endocrinol, Room G2-136,POB 22700, NL-1100 DE Amsterdam, Netherlands.	c.ris@amc.uva.nl	Smit, J.W.A./H-8091-2014; Pauws, Erwin/J-4848-2019; Pauws, Erwin/C-1665-2008	Smit, J.W.A./0000-0003-1052-9314; Pauws, Erwin/0000-0003-1751-0317; 				Akslen LA, 2000, HUM PATHOL, V31, P439, DOI 10.1053/1-ip.2000.6548; CORREA P, 1995, CANCER, V75, P338, DOI 10.1002/1097-0142(19950101)75:1+<338::AID-CNCR2820751316>3.0.CO;2-F; Dean D S, 2000, Cancer Control, V7, P229; Deckers MML, 2001, BONE, V28, P14, DOI 10.1016/S8756-3282(00)00428-2; ELISEI R, 1994, J CLIN ENDOCR METAB, V78, P867, DOI 10.1210/jc.78.4.867; Gerard CJ, 2000, MOL DIAGN, V5, P39, DOI 10.1016/S1084-8592(00)00009-6; Gimm O, 2001, CANCER LETT, V163, P143, DOI 10.1016/S0304-3835(00)00697-2; Han ZQ, 2001, FASEB J, V15, P988, DOI 10.1096/fj.99-0934com; Herrmann ME, 2002, ARCH PATHOL LAB MED, V126, P710; Hibi K, 1998, CANCER RES, V58, P5690; Huang Y, 2001, P NATL ACAD SCI USA, V98, P15044, DOI 10.1073/pnas.251547398; Jhiang SM, 2000, ONCOGENE, V19, P5590, DOI 10.1038/sj.onc.1203857; Kal AJ, 1999, MOL BIOL CELL, V10, P1859, DOI 10.1091/mbc.10.6.1859; Katoh R, 1999, HUM PATHOL, V30, P891, DOI 10.1016/S0046-8177(99)90241-1; Klein M, 2001, J CLIN ENDOCR METAB, V86, P656, DOI 10.1210/jc.86.2.656; Krohn K, 2002, MOL GENET METAB, V75, P202, DOI 10.1006/mgme.2001.3290; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Lash AE, 2000, GENOME RES, V10, P1051, DOI 10.1101/gr.10.7.1051; Lennard CM, 2001, SURGERY, V129, P552, DOI 10.1067/msy.2001.112592; Madden SL, 2000, DRUG DISCOV TODAY, V5, P415, DOI 10.1016/S1359-6446(00)01544-0; Martins L, 2002, J CLIN ENDOCR METAB, V87, P4806, DOI 10.1210/jc.2002-020094; MATHIEU E, 1994, J BONE MINER RES, V9, P903; Moreno JC, 2001, GENOMICS, V75, P70, DOI 10.1006/geno.2001.6586; Nascimento MCPA, 2001, ENDOCR PATHOL, V12, P275, DOI 10.1385/EP:12:3:275; Niedziela M, 2002, J CLIN ENDOCR METAB, V87, P4411, DOI 10.1210/jc.2002-020387; Pauws E, 2000, J CLIN ENDOCR METAB, V85, P1923, DOI 10.1210/jc.85.5.1923; Pauws E, 2001, NUCLEIC ACIDS RES, V29, P1690, DOI 10.1093/nar/29.8.1690; Pierotti MA, 2001, CANCER LETT, V166, P1, DOI 10.1016/S0304-3835(01)00439-6; Rabes HM, 2001, MED PEDIATR ONCOL, V36, P574, DOI 10.1002/mpo.1133; Ros P, 1999, BIOCHIMIE, V81, P389, DOI 10.1016/S0300-9084(99)80086-8; RUSSO D, 1995, ONCOGENE, V11, P1907; Scheurle D, 2000, CANCER RES, V60, P4037; Schlumberger MJ, 1998, NEW ENGL J MED, V338, P297, DOI 10.1056/NEJM199801293380506; Smit JWA, 2001, CLIN ENDOCRINOL, V55, P543, DOI 10.1046/j.1365-2265.2001.01311.x; Smits P, 1997, GENOMICS, V45, P487, DOI 10.1006/geno.1997.4918; Smits P, 2000, J INVEST DERMATOL, V114, P718, DOI 10.1046/j.1523-1747.2000.00916.x; Suarez HG, 1998, CLIN ENDOCRINOL, V48, P531, DOI 10.1046/j.1365-2265.1998.00443.x; Takano T, 2000, BRIT J CANCER, V83, P1495, DOI 10.1054/bjoc.2000.1483; Takano T, 2002, ENDOCR J, V49, P97, DOI 10.1507/endocrj.49.97; Trovato M, 1999, J CLIN ENDOCR METAB, V84, P3235, DOI 10.1210/jcem.84.9.5986; van Kampen AHC, 2000, BIOINFORMATICS, V16, P899, DOI 10.1093/bioinformatics/16.10.899; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; Wilkens L, 2000, VIRCHOWS ARCH, V436, P312, DOI 10.1007/s004280050452; Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537; ZEDENIUS J, 1995, HUM GENET, V96, P27, DOI 10.1007/BF00214182; Zhang L, 1997, SCIENCE, V276, P1268, DOI 10.1126/science.276.5316.1268	46	19	22	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					560	+		10.1096/fj.03-0101fje	http://dx.doi.org/10.1096/fj.03-0101fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715705				2022-12-28	WOS:000188829300028
J	Pirko, I; Johnson, A; Ciric, B; Gamez, J; Macura, SI; Pease, LR; Rodriguez, M				Pirko, I; Johnson, A; Ciric, B; Gamez, J; Macura, SI; Pease, LR; Rodriguez, M			In vivo magnetic resonance imaging of immune cells in the central nervous system with superparamagnetic antibodies	FASEB JOURNAL			English	Article						cell-specific MRI; targeted contrast materials; experimental MRI imaging	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IRON-OXIDE PARTICLES; CONTRAST AGENTS; T-CELLS; MONOCLONAL-ANTIBODY; RAT; BRAIN; INFLAMMATION; ENHANCEMENT; MENINGITIS	We developed a novel MRI technique to image immune cell location and homing in vivo to the central nervous system (CNS). Superparamagnetic antibodies specific for cell surface markers allowed imaging of CD4+ T cells, CD8+ T cells, and Mac1+ cells in the CNS of mice infected with Theiler's murine encephalomyelitis virus (TMEV) and in mice with experimental autoimmune encephalomyelitis (EAE). Superparamagnetic antibodies have excellent T2, T2*, and good T1 relaxation properties, which makes them ideal MRI contrast materials. Immunohistochemistry of corresponding sections confirmed the specificity of the technique to detect immune cell types in the CNS. This powerful technique has potential to image any cell with unique surface antigens. Because superparamagnetic antibodies similar to those used in the study are approved for human use, the in vivo MRI technique we have described could be developed for human use.	Mayo Clin & Mayo Fdn, Dept Neurol, Rochester, MI 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MI 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MI 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Rodriguez, M (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 200 1st St SW, Rochester, MI 55905 USA.	Rodriguez@mayo.edu		Rodriguez, Moses/0000-0001-6328-6497	NIH [NS32129, NS24180, NS38468]; National Multiple Sclerosis Society	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Multiple Sclerosis Society(National Multiple Sclerosis Society)	This work was supported by NIH grants NS32129, NS24180 and NS38468. We would also like to thank the National Multiple Sclerosis Society for additional funding.	Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Akiyama H, 2000, ALZ DIS ASSOC DIS, V14, pS47, DOI 10.1097/00002093-200000001-00008; Allkemper T, 2002, RADIOLOGY, V223, P432, DOI 10.1148/radiol.2232010241; ANDERSONBERG WT, 1986, J NUCL MED, V27, P829; Bjornerud A, 2002, MAGNET RESON MED, V47, P461, DOI 10.1002/mrm.10066; Brugger W, 2002, SEMIN ONCOL, V29, P23, DOI 10.1053/sonc.2002.32751; CERDAN S, 1989, MAGN RESON MED, V12, P151, DOI 10.1002/mrm.1910120202; Costa GL, 2001, J IMMUNOL, V167, P2379, DOI 10.4049/jimmunol.167.4.2379; Dardzinski BJ, 2001, MAGN RESON IMAGING, V19, P1209, DOI 10.1016/S0730-725X(01)00448-9; DEWYNTER EA, 1995, STEM CELLS, V13, P524, DOI 10.1002/stem.5530130510; Dousset V, 1999, MAGNET RESON MED, V41, P329, DOI 10.1002/(SICI)1522-2594(199902)41:2<329::AID-MRM17>3.0.CO;2-Z; Dousset V, 1999, MAGN RESON MATER PHY, V8, P185; Enochs WS, 1999, JMRI-J MAGN RESON IM, V9, P228, DOI 10.1002/(SICI)1522-2586(199902)9:2<228::AID-JMRI12>3.3.CO;2-B; Fleige G, 2001, NEOPLASIA, V3, P489, DOI 10.1038/sj.neo.7900176; Franklin RJM, 1999, NEUROREPORT, V10, P3961, DOI 10.1097/00001756-199912160-00043; GOHRROSENTHAL S, 1993, INVEST RADIOL, V28, P789; Huber JD, 2001, TRENDS NEUROSCI, V24, P719, DOI 10.1016/S0166-2236(00)02004-X; Hudgins PA, 2002, AM J NEURORADIOL, V23, P649; Johansson LO, 2001, J MAGN RESON IMAGING, V13, P615, DOI 10.1002/jmri.1086; Johnson AJ, 1999, J VIROL, V73, P3702, DOI 10.1128/JVI.73.5.3702-3708.1999; Johnson AJ, 2001, FASEB J, V15, P2760, DOI 10.1096/fj.01-0373fje; Kerr DA, 2002, CURR OPIN NEUROL, V15, P339, DOI 10.1097/00019052-200206000-00019; LAUFFER RB, 1987, CHEM REV, V87, P901, DOI 10.1021/cr00081a003; Meli DN, 2002, CURR OPIN INFECT DIS, V15, P253, DOI 10.1097/00001432-200206000-00007; Miller DJ, 1997, J NEUROIMMUNOL, V75, P204, DOI 10.1016/S0165-5728(97)00027-1; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Owens T, 2001, NAT MED, V7, P161, DOI 10.1038/84603; Piehl F, 2001, IMMUNOL REV, V184, P212, DOI 10.1034/j.1600-065x.2001.1840119.x; RENSHAW PF, 1986, MAGNET RESON MED, V3, P217, DOI 10.1002/mrm.1910030205; Stohlman SA, 2001, BRAIN PATHOL, V11, P92; SU XM, 1991, J NEUROIMMUNOL, V34, P181; Suwa T, 1998, INT J CANCER, V75, P626, DOI 10.1002/(SICI)1097-0215(19980209)75:4<626::AID-IJC22>3.0.CO;2-5; Sweeney TJ, 1999, P NATL ACAD SCI USA, V96, P12044, DOI 10.1073/pnas.96.21.12044; UNGER EC, 1985, INVEST RADIOL, V20, P693, DOI 10.1097/00004424-198510000-00008; Weissleder R, 1997, J MAGN RESON IMAGING, V7, P258, DOI 10.1002/jmri.1880070140; Wingerchuk DM, 2001, LAB INVEST, V81, P263, DOI 10.1038/labinvest.3780235; Ye Q, 2002, KIDNEY INT, V61, P1124, DOI 10.1046/j.1523-1755.2002.00195.x; YEH TC, 1993, MAGN RESON MED, V30, P617, DOI 10.1002/mrm.1910300513; YEH TC, 1995, MAGN RESON MED, V33, P200, DOI 10.1002/mrm.1910330209; Zhang YQ, 2000, KIDNEY INT, V58, P1300, DOI 10.1046/j.1523-1755.2000.00286.x	40	66	66	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					179	182		10.1096/fj.02-1124fje	http://dx.doi.org/10.1096/fj.02-1124fje			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630708				2022-12-28	WOS:000188829300066
J	Walther, T; Menrad, A; Orzechowski, HD; Siemeister, G; Paul, M; Schirner, M				Walther, T; Menrad, A; Orzechowski, HD; Siemeister, G; Paul, M; Schirner, M			Differential regulation of in vivo angiogenesis by angiotensin II receptors	FASEB JOURNAL			English	Article						alginate implant angiogenesis; angiotensin receptor AT1; angiotensin receptor AT2	CONVERTING ENZYME-INHIBITION; TYPE-2 RECEPTOR; BLOOD-PRESSURE; TUMOR-CELLS; GROWTH; EXPRESSION; MICE; GENE; ALGINATE; MODEL	Angiotensin II (ANG II), a key regulator of blood pressure and body fluid homeostasis, exerts mitogenic effects on endothelial cells. We therefore hypothesized that ANG 11 could be a mediator between homeostatic changes within the vascular perfusion bed and growth factor-driven angiogenesis. In the present study, we applied the alginate implant angiogenesis model in mice with normal ANG 11 levels, elevated ANG 11 levels by transgenic overexpression of angiotensinogen (AOGEN), or in AT2 receptor-deficient mice. We demonstrate that a decrease in the amount of circulating ANG 11 by the angiotensin-converting enzyme (ACE) inhibitor enalapril or the AT1 receptor antagonist losartan induced a stimulation of in vivo angiogenesis implying an inhibitory function of ANG 11 through the AT1 receptor. However, the strong increase of angiogenesis in AOGEN-transgenic mice compared with mice with normal ANG 11 levels suggests additional stimulatory activity. We showed that the ANG 11-induced stimulation of angiogenesis is linked to the AT2 receptor as an impaired induction of angiogenesis was obtained in AT2 receptor knockout mice. These findings provide the first evidence that the AT2 receptor mediates a stimulation of in vivo angiogenesis and indicate that ANG 11 is a humoral regulator of peripheral angiogenesis involving two receptor subtypes with opposing actions.	Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pneumol, D-12200 Berlin, Germany; Schering AG, Res Labs, Expt Oncol, D-13342 Berlin, Germany; Free Univ Berlin, Benjamin Franklin Med Ctr, Inst Clin Pharmacol & Toxicol, D-12200 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Schering AG; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Walther, T (corresponding author), Free Univ Berlin, Benjamin Franklin Med Ctr, Dept Cardiol & Pneumol, Hindenburgdamm 30, D-12200 Berlin, Germany.	thomas.walther@ukbf.fu-berlin.de	Paul, Martin/K-5425-2015	, Gerhard/0000-0002-4712-0531				AHMED A, 1995, J CLIN INVEST, V96, P848, DOI 10.1172/JCI118131; CURNOW KM, 1995, MOL ENDOCRINOL, V9, P1250, DOI 10.1210/me.9.9.1250; Fabre JE, 1999, CIRCULATION, V99, P3043, DOI 10.1161/01.CIR.99.23.3043; FERNANDEZ LA, 1985, J LAB INVEST CLIN, V105, pR141; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; Hoffmann J, 1997, CANCER RES, V57, P3847; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; KIMURA S, 1992, EMBO J, V11, P821, DOI 10.1002/j.1460-2075.1992.tb05119.x; LENOBLE FAC, 1993, AM J PHYSIOL, V264, pR460, DOI 10.1152/ajpregu.1993.264.2.R460; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MINCHENKO A, 1994, LAB INVEST, V71, P374; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; Ozawa Y, 1996, BIOCHEM BIOPH RES CO, V228, P328, DOI 10.1006/bbrc.1996.1661; PLUNKETT ML, 1990, LAB INVEST, V62, P510; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Schirner M, 1998, CLIN CANCER RES, V4, P1331; Silvestre JS, 2002, CIRC RES, V90, P1072, DOI 10.1161/01.RES.0000019892.41157.24; Silvestre JS, 2001, CIRC RES, V89, P678, DOI 10.1161/hh2001.097691; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; UNGER T, 1992, HYPERTENSION, V20, P478, DOI 10.1161/01.HYP.20.4.478; VISWANATHAN M, 1992, PEPTIDES, V13, P783, DOI 10.1016/0196-9781(92)90187-8; Walsh DA, 1997, BRIT J PHARMACOL, V120, P1302, DOI 10.1038/sj.bjp.0701062	25	97	106	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2003	17	14					2061	2067		10.1096/fj.03-0129com	http://dx.doi.org/10.1096/fj.03-0129com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597675				2022-12-28	WOS:000186961200042
J	Fraysse, B; Desaphy, JF; Pierno, S; De Luca, A; Liantonio, A; Mitolo, CI; Camerino, DC				Fraysse, B; Desaphy, JF; Pierno, S; De Luca, A; Liantonio, A; Mitolo, CI; Camerino, DC			Decrease in resting calcium and calcium entry associated with slow-to-fast transition in unloaded rat soleus muscle	FASEB JOURNAL			English	Article						resting cytosolic calcium; sarcolemmal permeability to cations; slow-twitch and fast-twitch skeletal muscles hindlimb unloading-induced slow-to-fast transition; fura-2	MYOSIN HEAVY-CHAIN; SKELETAL-MUSCLE; SARCOPLASMIC-RETICULUM; GENE-EXPRESSION; RYANODINE RECEPTOR; METABOLIC ENZYMES; SARCOMERE-LENGTH; CA2+ TRANSIENTS; MESSENGER-RNA; SINGLE FIBERS	Using fura-2 and the manganese quenching technique, we show here that sarcolemmal permeability to cations (SP-Ca) of slow-twitch muscles is greater than that of fast-twitch ones. This appears to be related to a higher expression and/or activity of stretch-activated channels, whereas leak channel activities are similar. During hindlimb suspension (HU), we found highly correlated decreases in SPCa and resting calcium of soleus muscle toward values of extensor digitorum longus (EDL) muscle. This was significant as soon as 3 days of suspension, contrary to soleus muscle caffeine sensitivity and responsiveness that were not modified after this HU period. After 14 days of HU, SP-Ca, resting calcium, and caffeine response of soleus muscle became similar to that normally observed in EDL muscle. These results demonstrate that the correlated decreases in SP-Ca and resting calcium precede most functional changes due to HU. Given the known shortening of HU soleus muscle, we proposed that this could induce a decrease of SP-Ca and a consequent reduction of resting calcium. According to the crucial role of resting cytosolic free calcium in the maintenance and the adaptation of muscle phenotype, our results suggest that slow-to-fast transition of HU soleus muscle is calcium dependent.	Univ Bari, Dipartimento Farmacobiol, Sez Farmacol, I-70125 Bari, Italy	Universita degli Studi di Bari Aldo Moro	Camerino, DC (corresponding author), Univ Bari, Dipartimento Farmacobiol, Sez Farmacol, Via Orabona 4 Campus, I-70125 Bari, Italy.	conte@farmbiol.uniba.it	Desaphy, Jean-Francois/T-6191-2019; Fraysse, Bodvaël/ABH-3589-2020	Desaphy, Jean-Francois/0000-0001-8816-9369; De Luca, Annamaria/0000-0002-5652-7341; Liantonio, Antonella/0000-0002-4103-7577; FRAYSSE, Bodvael/0000-0002-3782-931X; Pierno, Sabata/0000-0003-3121-2666; Conte, Diana/0000-0003-0162-9698				Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Bastide B, 2000, BIOCHEM BIOPH RES CO, V270, P442, DOI 10.1006/bbrc.2000.2446; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Booth FW, 1997, INT J SPORTS MED, V18, pS265, DOI 10.1055/s-2007-972723; BRYANT SH, 1991, PFLUG ARCH EUR J PHY, V417, P605, DOI 10.1007/BF00372958; Burkholder TJ, 2001, J EXP BIOL, V204, P1529; Carroll S, 1999, AM J PHYSIOL-CELL PH, V277, pC1122, DOI 10.1152/ajpcell.1999.277.6.C1122; Carroll SL, 1997, J PHYSIOL-LONDON, V501, P573, DOI 10.1111/j.1469-7793.1997.573bm.x; CHAPMAN RA, 1976, J PHYSIOL-LONDON, V258, pP1; Cros N, 2001, J CELL BIOCHEM, V83, P508, DOI 10.1002/jcb.1248; Desaphy JF, 2001, BRAIN, V124, P1100, DOI 10.1093/brain/124.6.1100; DULHUNTY AF, 1983, J PHYSIOL-LONDON, V341, P213, DOI 10.1113/jphysiol.1983.sp014802; Endo M, 2000, HANDB EXP PHARM, V147, P583; Fitts RH, 2000, J APPL PHYSIOL, V89, P823, DOI 10.1152/jappl.2000.89.2.823; Franco-Obregon A, 2002, J PHYSIOL-LONDON, V539, P391, DOI 10.1113/jphysiol.2001.013043; Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; GAILLY P, 1993, CELL CALCIUM, V14, P473, DOI 10.1016/0143-4160(93)90006-R; Gajdosik RL, 2001, CLIN BIOMECH, V16, P87, DOI 10.1016/S0268-0033(00)00061-9; Gillis JM, 1996, ACTA PHYSIOL SCAND, V156, P397, DOI 10.1046/j.1365-201X.1996.201000.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAWS CM, 1991, P ROY SOC B-BIOL SCI, V245, P173, DOI 10.1098/rspb.1991.0105; Hopf FW, 1996, AM J PHYSIOL-CELL PH, V271, pC1325, DOI 10.1152/ajpcell.1996.271.4.C1325; Hu H, 1997, J MOL CELL CARDIOL, V29, P1511, DOI 10.1006/jmcc.1997.0392; HuchetCadiou C, 1996, J APPL PHYSIOL, V80, P1100, DOI 10.1152/jappl.1996.80.4.1100; Ikemoto M, 2001, FASEB J, V15, P1279, DOI 10.1096/fj.00-0629fje; Ingalls CP, 2001, AVIAT SPACE ENVIR MD, V72, P471; Ingalls CP, 1999, J APPL PHYSIOL, V87, P386, DOI 10.1152/jappl.1999.87.1.386; ISAACSON A, 1970, AM J PHYSIOL, V218, P33, DOI 10.1152/ajplegacy.1970.218.1.33; KANDARIAN S, 1992, J APPL PHYSIOL, V72, P2510, DOI 10.1152/jappl.1992.72.6.2510; Kandarian SC, 1996, AM J PHYSIOL-CELL PH, V270, pC1588, DOI 10.1152/ajpcell.1996.270.6.C1588; Kubis HP, 1997, P NATL ACAD SCI USA, V94, P4205, DOI 10.1073/pnas.94.8.4205; LEDVINA MA, 1995, J APPL PHYSIOL, V78, P2047, DOI 10.1152/jappl.1995.78.6.2047; Makabe M, 1996, PFLUG ARCH EUR J PHY, V432, P717, DOI 10.1007/s004240050190; MANCHESTER JK, 1990, FASEB J, V4, P55, DOI 10.1096/fasebj.4.1.1967237; Meissner JD, 2001, J PHYSIOL-LONDON, V533, P215, DOI 10.1111/j.1469-7793.2001.0215b.x; Meissner JD, 2000, J PHYSIOL-LONDON, V523, P19, DOI 10.1111/j.1469-7793.2000.t01-1-00019.x; Morey-Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001; Morgan AJ, 1999, METH MOL B, V114, P93; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; PAGALA MK, 1998, AM J PHYSIOL, V274, pC923; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Pierno S, 2002, BRAIN, V125, P1510, DOI 10.1093/brain/awf162; Pierno S, 1999, FEBS LETT, V449, P12, DOI 10.1016/S0014-5793(99)00202-1; RILEY DA, 1990, J APPL PHYSIOL, V69, P58, DOI 10.1152/jappl.1990.69.1.58; Rossi R, 2001, AM J PHYSIOL-CELL PH, V281, pC585, DOI 10.1152/ajpcell.2001.281.2.C585; SCHULTE LM, 1993, AM J PHYSIOL, V264, pC1308, DOI 10.1152/ajpcell.1993.264.5.C1308; Stevens L, 1999, FEBS LETT, V463, P15, DOI 10.1016/S0014-5793(99)01596-3; STEVENS L, 1992, J APPL PHYSIOL, V72, P1735, DOI 10.1152/jappl.1992.72.5.1735; Suzuki M, 1999, J BIOL CHEM, V274, P6330, DOI 10.1074/jbc.274.10.6330; Taillandier D, 1996, BIOCHEM J, V316, P65, DOI 10.1042/bj3160065; Talmadge RJ, 2000, MUSCLE NERVE, V23, P661, DOI 10.1002/(SICI)1097-4598(200005)23:5<661::AID-MUS3>3.0.CO;2-J; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435; TURNER PR, 1991, J CELL BIOL, V115, P1701, DOI 10.1083/jcb.115.6.1701; Tutdibi O, 1999, J PHYSIOL-LONDON, V515, P859, DOI 10.1111/j.1469-7793.1999.859ab.x; Vandebrouck C, 2002, J CELL BIOL, V158, P1089, DOI 10.1083/jcb.200203091; WU KD, 1993, AM J PHYSIOL, V264, pC333, DOI 10.1152/ajpcell.1993.264.2.C333; ZARAINHERZBERG A, 1990, J BIOL CHEM, V265, P4670	59	60	63	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1916	+		10.1096/fj.02-1012fje	http://dx.doi.org/10.1096/fj.02-1012fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923063				2022-12-28	WOS:000185345100010
J	Wolf, R; Mirmohammadsadegh, A; Walz, M; Lysa, B; Tartler, U; Remus, R; Hengge, U; Michel, G; Ruzicka, T				Wolf, R; Mirmohammadsadegh, A; Walz, M; Lysa, B; Tartler, U; Remus, R; Hengge, U; Michel, G; Ruzicka, T			Molecular cloning and characterization of alternatively spliced mRNA isoforms from psoriatic skin encoding a novel member of the S100 family	FASEB JOURNAL			English	Article						differential display RT-PCR analysis; EF-hand Ca2+-binding motifs; chromosome 1q21; epidermal differentiation	CALCIUM-BINDING PROTEINS; EPIDERMAL DIFFERENTIATION COMPLEX; POLYMERASE-CHAIN-REACTION; SQUAMOUS-CELL CARCINOMAS; HUMAN KERATINOCYTES; GENE-EXPRESSION; T-LYMPHOCYTES; GROWTH-FACTOR; DISPLAY; SUSCEPTIBILITY	In an effort to identify psoriasis-associated genes, we compared gene expression in normal and psoriatic skin, using differential display RT-PCR technique. Sequence analysis of a 650-bp cDNA fragment ( clone 110) that was highly up-regulated in lesional skin revealed homology to a noncoding cDNA (NICE-2). By subsequent cDNA cloning, using RNA from psoriatic skin, we have identified two alternatively spliced mRNA-isoforms (0.5 and 4.4 kb), which differ in composition of their untranslated regions. By sequence comparison, we have mapped the novel gene, named S100A15, to the S100 gene cluster within the epidermal differentiation complex ( chromosome 1q21). Analysis of the deduced amino acid sequence revealed a protein of 101 amino acids containing two potential EF-hand motifs with high homology to the S100A7. Northern blot hybridization and semiquantitative RT-PCR analysis confirmed the S100A15 overexpression in psoriasis, showing different levels of expression of the S100A15 mRNA isoforms. In situ hybridization of the S100A15 revealed a markedly increased staining of basal and suprabasal epidermal layers of psoriatic skin compared with healthy tissue. Our data suggest an involvement of the novel S100A15 in epidermal differentiation and inflammation and might therefore be important for the pathogenesis of psoriasis and other diseases.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Charles Univ Prague, Dept Dermatol, Prague, Czech Republic; Univ Dusseldorf, Inst Human Genet, D-4000 Dusseldorf, Germany	Heinrich Heine University Dusseldorf; Charles University Prague; Heinrich Heine University Dusseldorf	Wolf, R (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Ronald.Wolf@med.uni-duesseldorf.de						Abts HF, 2000, METH MOL B, V99, P347; Albertazzi E, 1998, DNA CELL BIOL, V17, P1003, DOI 10.1089/dna.1998.17.1003; Algermissen B, 1996, ARCH DERMATOL RES, V288, P426, DOI 10.1007/BF02505229; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; AMBARTSUMIAN N, 1995, GENE, V159, P125, DOI 10.1016/0378-1119(94)00778-Q; Ayoubi TAY, 1996, FASEB J, V10, P453, DOI 10.1096/fasebj.10.4.8647344; BAKER BS, 1991, J INVEST DERMATOL, V97, P606, DOI 10.1111/1523-1747.ep12481954; BATACSORGO Z, 1995, J CLIN INVEST, V95, P317, DOI 10.1172/JCI117659; Bhalerao J, 1998, HUM MOL GENET, V7, P1537, DOI 10.1093/hmg/7.10.1537; Bockelmann R, 2001, AM J PATHOL, V158, P367, DOI 10.1016/S0002-9440(10)63978-8; Bonifati C, 1999, INT J DERMATOL, V38, P241, DOI 10.1046/j.1365-4362.1999.00622.x; Brodersen DE, 1998, STRUCTURE, V6, P477, DOI 10.1016/S0969-2126(98)00049-5; Capon F, 1999, J INVEST DERMATOL, V112, P32, DOI 10.1046/j.1523-1747.1999.00471.x; Celis JE, 1996, J UROLOGY, V155, P2105, DOI 10.1016/S0022-5347(01)66118-4; Christophers E, 1996, INT ARCH ALLERGY IMM, V110, P199, DOI 10.1159/000237288; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; El-Rifai W, 2002, CANCER RES, V62, P6823; ELDER JT, 1994, J INVEST DERMATOL, V102, pS24, DOI 10.1111/1523-1747.ep12386091; ELDER JT, 1990, J INVEST DERMATOL, V95, pS7, DOI 10.1111/1523-1747.ep12505653; Enerback C, 2002, CANCER RES, V62, P43; FAIRLEY JA, 1985, J INVEST DERMATOL, V84, P195, DOI 10.1111/1523-1747.ep12264823; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; FIETZ MJ, 1992, J INVEST DERMATOL, V99, P542, DOI 10.1111/1523-1747.ep12667301; Forstermann U, 1998, FASEB J, V12, P773; GOTTLIEB AB, 1986, J EXP MED, V164, P1013, DOI 10.1084/jem.164.4.1013; Gottsch J D, 1997, Trans Am Ophthalmol Soc, V95, P111; Gottsch J. D., 1997, T AM OPHTHAL SOC, V95, P126; Gudmundsdottir AS, 1999, CLIN EXP IMMUNOL, V117, P580; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; Heizmann CW, 1998, BIOMETALS, V11, P383, DOI 10.1023/A:1009212521172; HOFFMANN HJ, 1994, J INVEST DERMATOL, V103, P370, DOI 10.1111/1523-1747.ep12395202; Kapp Alexander, 1993, Journal of Dermatological Science, V5, P133, DOI 10.1016/0923-1811(93)90760-M; KIIL J, 1985, LANCET, V2, P16; KLIGMAN D, 1988, TRENDS BIOCHEM SCI, V13, P437, DOI 10.1016/0968-0004(88)90218-6; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; KRETSINGER RH, 1976, ANNU REV BIOCHEM, V45, P239, DOI 10.1146/annurev.bi.45.070176.001323; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; KRETSINGER RH, 1987, COLD SPRING HARB SYM, V52, P499, DOI 10.1101/SQB.1987.052.01.057; KRETSINGER RH, 1972, NATURE-NEW BIOL, V240, P85, DOI 10.1038/newbio240085a0; Kuroda K, 2001, J INVEST DERMATOL, V116, P713, DOI 10.1046/j.1523-1747.2001.01316.x; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1995, CURR OPIN IMMUNOL, V7, P274, DOI 10.1016/0952-7915(95)80015-8; Lin SC, 2000, J ORAL PATHOL MED, V29, P159, DOI 10.1034/j.1600-0714.2000.290403.x; MADSEN P, 1991, J INVEST DERMATOL, V97, P701, DOI 10.1111/1523-1747.ep12484041; Marenholz I, 2001, GENOME RES, V11, P341, DOI 10.1101/gr.114801; Matthews D, 1996, NAT GENET, V14, P231, DOI 10.1038/ng1096-231; MCKAY IA, 1995, CLIN DERMATOL, V13, P105, DOI 10.1016/0738-081X(95)93817-8; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Mirmohammadsadegh A, 2000, J INVEST DERMATOL, V114, P1207, DOI 10.1046/j.1523-1747.2000.00005-2.x; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nevitt GJ, 1996, BRIT J DERMATOL, V135, P533, DOI 10.1046/j.1365-2133.1996.d01-1035.x; Nickoloff BJ, 2001, J CUTAN PATHOL, V28, P57, DOI 10.1034/j.1600-0560.2001.280201.x; Nickoloff BJ, 1998, J INVEST DERMATOL, V110, P459, DOI 10.1046/j.1523-1747.1998.00158.x; PARENT D, 1990, J INVEST DERMATOL, V95, P333, DOI 10.1111/1523-1747.ep12485084; Pietas A, 2002, GENOMICS, V79, P513, DOI 10.1006/geno.2002.6744; Prinz JC, 2001, CLIN EXP DERMATOL, V26, P326, DOI 10.1046/j.1365-2230.2001.00831.x; Rivas MV, 1997, J INVEST DERMATOL, V108, P188, DOI 10.1111/1523-1747.ep12334217; SAINTIGNY G, 1992, J INVEST DERMATOL, V99, P639, DOI 10.1111/1523-1747.ep12668098; Sambrook J., 2002, MOL CLONING LAB MANU; Schafer BW, 1996, TRENDS BIOCHEM SCI, V21, P134, DOI 10.1016/S0968-0004(96)80167-8; SCHAFER BW, 1995, GENOMICS, V25, P638, DOI 10.1016/0888-7543(95)80005-7; Semprini S, 2002, HUM GENET, V111, P310, DOI 10.1007/s00439-002-0812-5; Semprini S, 1999, HUM GENET, V104, P130, DOI 10.1007/s004390050925; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813; TURBITT ML, 1990, J INVEST DERMATOL, V95, P229, DOI 10.1111/1523-1747.ep12478077; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; WATT FM, 1984, J CELL BIOL, V99, P2211, DOI 10.1083/jcb.99.6.2211; Wicki R, 1996, BIOCHEM BIOPH RES CO, V227, P594, DOI 10.1006/bbrc.1996.1551; WroneSmith T, 1997, AM J PATHOL, V151, P1321	71	58	60	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1969	+		10.1096/fj.03-0148fje	http://dx.doi.org/10.1096/fj.03-0148fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923069				2022-12-28	WOS:000185345100005
J	Van der Meer-Van Kraaij, C; Van Lieshout, EMM; Kramer, E; Van der Meer, R; Keijer, J				Van der Meer-Van Kraaij, C; Van Lieshout, EMM; Kramer, E; Van der Meer, R; Keijer, J			Mucosal pentraxin (Mptx), a novel rat gene 10-fold down-regulated in colon by dietary heme	FASEB JOURNAL			English	Article						red meat; microarray; colon cancer	AMYLOID-P COMPONENT; C-REACTIVE PROTEIN; RED MEAT; COLORECTAL-CANCER; EXPRESSION; MICROARRAY; BINDING; RISK; FAT; PCR	Consumption of red meat is associated with increased colon cancer risk. Our previous work indicated that this association might be due to the heme content of red meat. In rat studies, dietary heme increased colonic cytotoxicity and epithelial cell turnover, carcinogenesis biomarkers. Here we apply DNA microarray technology to examine effects of heme on colonic gene expression. A rat colon-specific microarray was constructed and hybridized in duplicate to RNA extracts from colon scrapings of rats fed diets with or without heme (n = 6 - 7). We were able to reproducibly identify changes in colonic mRNA abundance in response to heme. Most striking was a > 10-fold downregulation of a single rat gene, an unprecedented gene-modulating effect of a dietary component. Based on homology, the novel gene encodes a pentraxin, the first identified in colon. Pentraxins are postulated to be involved in dealing with dying cells. Quantitative PCR confirmed the strong heme-induced down-regulation of this gene, which we named mucosal pentraxin (Mptx). Overall, our data support the efficacy of cDNA array expression profiling to investigate effects of specific nutrients in an in vivo system and may provide an approach to establishing markers for diet-induced stress of mammalian colonic mucosa.	WCFS, NL-6700 AE Wageningen, Netherlands; RIKILT, Inst Food Safety, NL-6700 AE Wageningen, Netherlands; NIZO Food Res, NL-6710 BA Ede, Netherlands	Wageningen University & Research; NIZO Food Research	Keijer, J (corresponding author), WCFS, Bornsesteeg 45,POB 230, NL-6700 AE Wageningen, Netherlands.	jaap.keijer@wur.nl	Keijer, Jaap/J-8089-2013	Keijer, Jaap/0000-0002-9720-7491				Bharadwaj D, 2001, J IMMUNOL, V166, P6735, DOI 10.4049/jimmunol.166.11.6735; Blanchard RK, 2001, P NATL ACAD SCI USA, V98, P13507, DOI 10.1073/pnas.251532498; Boeuf S, 2001, PHYSIOL GENOMICS, V7, P15, DOI 10.1152/physiolgenomics.00048.2001; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Bustin SA, 2002, J MOL ENDOCRINOL, V29, DOI 10.1677/jme.0.0290023; Crescenzi M, 2001, FEBS LETT, V507, P114, DOI 10.1016/S0014-5793(01)02973-8; de Haas CJC, 1999, FEMS IMMUNOL MED MIC, V26, P197, DOI 10.1016/S0928-8244(99)00148-0; Du Clos TW, 2000, ANN MED, V32, P274, DOI 10.3109/07853890009011772; DuClos TW, 1996, MOL BIOL REP, V23, P253, DOI 10.1007/BF00351177; Eastwood GL, 1995, J CLIN GASTROENTEROL, V21, pS1; Familian A, 2001, J IMMUNOL, V167, P647, DOI 10.4049/jimmunol.167.2.647; Franssen-val Hal NLW, 2002, ANAL BIOCHEM, V308, P5, DOI 10.1016/S0003-2697(02)00203-8; GRUBBS FE, 1972, TECHNOMETRICS, V14, P847, DOI 10.2307/1267134; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McGeer EG, 2001, NEUROBIOL AGING, V22, P843, DOI 10.1016/S0197-4580(01)00288-3; Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126; Reeves PG, 1993, AIN 93 PURIFIED DIET; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sesink ALA, 2001, CARCINOGENESIS, V22, P1653, DOI 10.1093/carcin/22.10.1653; Sesink ALA, 1999, CANCER RES, V59, P5704; Sesink ALA, 2000, CARCINOGENESIS, V21, P1909, DOI 10.1093/carcin/21.10.1909; SESINK LA, 2001, THESIS U GRONINGEN N; van Hal NLW, 2000, J BIOTECHNOL, V78, P271, DOI 10.1016/S0168-1656(00)00204-2; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404	26	22	23	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1277	1285		10.1096/fj.02-1036com	http://dx.doi.org/10.1096/fj.02-1036com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832292				2022-12-28	WOS:000184471600039
J	Nicchia, GP; Frigeri, A; Liuzzi, GM; Svelto, M				Nicchia, GP; Frigeri, A; Liuzzi, GM; Svelto, M			Inhibition of AQP4 expression in astrocytes by RNAi determines alterations in cell morphology, growth, and water transport and induces changes in ischemia related genes	FASEB JOURNAL			English	Article						aquaporin 4; astrocyte primary cultures; GLUT1	FIBRILLARY ACIDIC PROTEIN; CULTURED-MAMMALIAN-CELLS; FOCAL CEREBRAL-ISCHEMIA; HSP70 MESSENGER-RNA; RAT-BRAIN; MEMBRANE DOMAINS; TRANSGENIC MICE; SKELETAL-MUSCLE; RECEPTOR GENE; MULLER CELLS	Recent studies indicate a key role of aquaporin (AQP) 4 in astrocyte swelling and brain edema and suggest that AQP4 inhibition may be a new therapeutic way for reducing cerebral water accumulation. To understand the physiological role of AQP4-mediated astroglial swelling, we used 21-nucleotide small interfering RNA duplexes (siRNA) to specifically suppress AQP4 expression in astrocyte primary cultures. Semiquantitative RT-PCR experiments and Western blot analysis showed that AQP4 silencing determined a progressive and parallel reduction in AQP4 mRNA and protein. AQP4 gene suppression determined the appearance of a new morphological cell phenotype associated with a strong reduction in cell growth. Water transport measurements showed that the rate of shrinkage of AQP4 knockdown astrocytes was one-half of that of controls. Finally, cDNA microarray analysis revealed that the gene expression pattern perturbed by AQP4 gene silencing concerned ischemia-related genes, such as GLUT1 and hexokinase. Taken together, these results indicate that 1) AQP4 seems to be the major factor responsible for the fast water transport of cultured astrocytes; 2) as in skeletal muscle, AQP4 is a protein involved in cell plasticity; 3) AQP4 alteration may be a primary factor in ischemia-induced cerebral edema; and 4) RNA interference could be a new potent tool for studying AQP pathophysiology in those organs and tissues where they are expressed.	Univ Bari, Dept Gen & Environm Physiol, I-70126 Bari, Italy; Univ Bari, Ctr Excellence Comparat Genom, I-70126 Bari, Italy; Univ Bari, Dept Biochem & Mol Biol, I-70126 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	Liuzzi, Grazia Maria/GVR-7164-2022; frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014	Latronico, Tiziana/0000-0001-6971-5416; Liuzzi, Grazia Maria/0000-0001-5692-9335; Svelto, Maria/0000-0002-5584-9541; Frigeri, Antonio/0000-0002-5284-2934				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BIGNAMI A, 1972, BRAIN RES, V43, P429, DOI 10.1016/0006-8993(72)90398-8; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; Campagne MV, 1999, P NATL ACAD SCI USA, V96, P12870; CAZIN M, 1990, EUR RESPIR J, V3, P1015; Cogoni C, 2001, ANNU REV MICROBIOL, V55, P381, DOI 10.1146/annurev.micro.55.1.381; Crepel V, 1998, J NEUROSCI, V18, P1196; EBADI M, 1995, NEUROCHEM INT, V27, P1, DOI 10.1016/0197-0186(94)00164-P; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; GARCIASEGURA LM, 1994, GLIA, V10, P59, DOI 10.1002/glia.440100108; GOLDMAN JE, 1990, BRAIN RES, V528, P189, DOI 10.1016/0006-8993(90)91657-3; Harborth J, 2001, J CELL SCI, V114, P4557; HASEGAWA H, 1994, J BIOL CHEM, V269, P5497; Hawrylak N, 1998, GLIA, V22, P260, DOI 10.1002/(SICI)1098-1136(199803)22:3<260::AID-GLIA5>3.0.CO;2-9; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUGOWISSEMANN D, 1991, HEPATOLOGY, V13, P297, DOI 10.1016/0270-9139(91)92443-C; JUNG JS, 1994, P NATL ACAD SCI USA, V91, P13052, DOI 10.1073/pnas.91.26.13052; Kimelberg H.K., 1986, ASTROCYTES CELL BIOL, P77; KIMELBERG HK, 1992, J NEUROTRAUM, V9, pS71; KINOUCHI H, 1994, J CEREBR BLOOD F MET, V14, P808, DOI 10.1038/jcbfm.1994.101; Lavialle M, 2001, GLIA, V34, P88, DOI 10.1002/glia.1044; LINDVALL O, 1992, P NATL ACAD SCI USA, V89, P648, DOI 10.1073/pnas.89.2.648; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; LOIKE JD, 1992, AM J PHYSIOL, V263, pC326, DOI 10.1152/ajpcell.1992.263.2.C326; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matzke MA, 2001, CURR OPIN GENET DEV, V11, P221, DOI 10.1016/S0959-437X(00)00183-0; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MIKAWA S, 1995, MOL BRAIN RES, V33, P288, DOI 10.1016/0169-328X(95)00146-J; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MONTGOMERY DL, 1994, VET PATHOL, V31, P145, DOI 10.1177/030098589403100201; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; Nico B, 2001, J CELL SCI, V114, P1297; Nielsen S, 1997, J NEUROSCI, V17, P171; Niitsu Y, 1999, MOL BRAIN RES, V74, P26, DOI 10.1016/S0169-328X(99)00245-4; OGAWA S, 1990, J CLIN INVEST, V85, P1090, DOI 10.1172/JCI114540; Papadopoulos MC, 2002, MT SINAI J MED, V69, P242; Pekny M, 2001, Prog Brain Res, V132, P23; SAGAR SM, 1995, BRAIN RES BULL, V36, P381, DOI 10.1016/0361-9230(94)00217-O; SALM AK, 1982, BRAIN RES, V236, P471, DOI 10.1016/0006-8993(82)90729-6; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; SHAO YP, 1994, GLIA, V11, P1, DOI 10.1002/glia.440110103; SHARP FR, 1994, NEUROTOXICOLOGY, V15, P51; SIREVAAG AM, 1991, BRAIN RES, V540, P273, DOI 10.1016/0006-8993(91)90517-Y; Tabara H, 1998, SCIENCE, V282, P430, DOI 10.1126/science.282.5388.430; Taniguchi M, 2000, MOL BRAIN RES, V78, P131, DOI 10.1016/S0169-328X(00)00084-X; Vajda Z, 2000, BIOCHEM BIOPH RES CO, V270, P495, DOI 10.1006/bbrc.2000.2472; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Vizuete ML, 1999, NEUROBIOL DIS, V6, P245, DOI 10.1006/nbdi.1999.0246; Wasterlain CG, 1997, EPILEPSIA, V38, P728, DOI 10.1111/j.1528-1157.1997.tb01244.x; WASTERLAIN CG, 1968, ARCH NEUROL-CHICAGO, V19, P71, DOI 10.1001/archneur.1968.00480010089007; WATSON MA, 1989, MOL CELL BIOL, V9, P4213, DOI 10.1128/MCB.9.10.4213; Wells T, 1998, MOL CELL ENDOCRINOL, V136, P103, DOI 10.1016/S0303-7207(97)00219-0; Won CK, 2000, BRAIN RES, V887, P250, DOI 10.1016/S0006-8993(00)02922-X; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0	65	122	143	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1508	+		10.1096/fj.02-1183fje	http://dx.doi.org/10.1096/fj.02-1183fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824287				2022-12-28	WOS:000183818000019
J	Nikitenko, LL; Smith, DM; Bicknell, R; Rees, MCP				Nikitenko, LL; Smith, DM; Bicknell, R; Rees, MCP			Transcriptional regulation of the CRLR gene in human microvascular endothelial cells by hypoxia	FASEB JOURNAL			English	Article						G-protein coupled receptor; CRLR; 5 '-flanking region; promoter; HRE; hypoxia; adrenomedullin; RAMP; microvascular endothelial cells	RECEPTOR-LIKE RECEPTOR; ACTIVITY-MODIFYING PROTEINS; POSSIBLE PROMOTION MECHANISM; RAT ADRENOMEDULLIN RECEPTOR; SMOOTH-MUSCLE CELLS; GENOMIC ORGANIZATION; INDUCIBLE FACTOR-1; UP-REGULATION; CANCER-CELLS; TUMOR-GROWTH	Adrenomedullin is a 52 amino acid peptide that shows a remarkable range of effects on the vasculature that include inter alia, vasodilatation, regulation of permeability, inhibition of endothelial cell apoptosis, and promotion of angiogenesis. Recently the G-protein coupled receptor (GPCR) calcitonin receptor-like receptor (CRLR), and receptor activity modifying proteins (RAMPs) have become recognized as integral components of the adrenomedullin signaling system. However, mechanisms of regulation of CRLR expression are still largely unknown. This is in part due to lack of information on the gene promoter. In this study we have determined the transcriptional start of human CRLR cDNA by 5'-RACE and cloned the proximal 5'-flanking region of the gene by PCR. The 2318 bp genomic fragment contains the basal promoter of human CRLR, including potential TATA-boxes and several GC boxes. Regulatory elements binding known transcription factors, such as Sp-1, Pit-1, glucocorticoid receptor, and hypoxia-inducible factor-1alpha (HIF-1alpha) were also identified. When cloned into reporter gene vectors, the genomic fragment showed significant promoter activity, indicating that the 5'-flanking region isolated by PCR contains the gene promoter of human CRLR. Of significance is that the cloned promoter fragments were activated by hypoxia when transfected in primary microvascular endothelial cells. Site-directed mutagenesis of the consensus hypoxia-response element (HRE) in the 5'-flanking region abolished such a response. We also demonstrated by semi-quantitative RT-PCR that transcription of the gene is activated by hypoxia in microvascular endothelial cells. In contrast, expression of RAMPs 1, 2, and 3 was unaffected by low oxygen tension. We conclude that simultaneous transcriptional up-regulation of CRLR and its ligand adrenomedullin in endothelial cells could lead to a potent survival loop and therefore might play a significant role in vascular responses to hypoxia and ischemia.	Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England; AstraZeneca, CVGI, Macclesfield SK10 4TG, Cheshire, England; Canc Res UK, Weatherall Inst Mol Med, Nuffield Dept Obstet & Gynaecol, Macclesfield SK10 4TG, Cheshire, England; Canc Res UK, Weatherall Inst Mol Med, Mol Angiogenesis Lab, Macclesfield SK10 4TG, Cheshire, England	University of Oxford; AstraZeneca; Cancer Research UK; Cancer Research UK	Nikitenko, LL (corresponding author), Univ Oxford, John Radcliffe Hosp, Oxford OX3 9DU, England.	leonid.nikitenko@obs-gyn.ox.ac.uk	Nikitenko, Leonid L/I-3215-2013	Nikitenko, Leonid L/0000-0003-3801-729X; Smith, David/0000-0001-6831-280X; Bicknell, Roy/0000-0002-0941-8919				Aiyar N, 1996, J BIOL CHEM, V271, P11325, DOI 10.1074/jbc.271.19.11325; Ameri K, 2002, BRIT J CANCER, V87, P1173, DOI 10.1038/sj.bjc.6600576; Anagnou N P, 1985, Prog Clin Biol Res, V191, P163; Brakhage AA, 1998, MICROBIOL MOL BIOL R, V62, P547, DOI 10.1128/MMBR.62.3.547-585.1998; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; Chakravarty P, 2000, BRIT J PHARMACOL, V130, P189, DOI 10.1038/sj.bjp.0702975; Champion HC, 2000, CIRCULATION, V101, P923, DOI 10.1161/01.CIR.101.8.923; Chenchik A, 1996, BIOTECHNIQUES, V21, P526; Conner AC, 2001, TRENDS PHARMACOL SCI, V22, P272, DOI 10.1016/S0165-6147(00)01721-1; FLUHMANN B, 1995, BIOCHEM BIOPH RES CO, V206, P341, DOI 10.1006/bbrc.1995.1047; Frayon S, 2000, BIOCHEM BIOPH RES CO, V270, P1063, DOI 10.1006/bbrc.2000.2552; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Hafezi-Moghadam A, 2002, NAT MED, V8, P473, DOI 10.1038/nm0502-473; Hagner S, 2002, CELL TISSUE RES, V310, P41, DOI 10.1007/s00441-002-0616-x; Hanze J, 2002, BIOCHEM BIOPH RES CO, V291, P1160, DOI 10.1006/bbrc.2002.6595; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; He B, 2002, J MOL ENDOCRINOL, V29, P193, DOI 10.1677/jme.0.0290193; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; Hippenstiel S, 2002, CIRC RES, V91, P618, DOI 10.1161/01.RES.0000036603.61868.F9; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; KAPAS S, 1995, J BIOL CHEM, V270, P25344, DOI 10.1074/jbc.270.43.25344; Kennedy SP, 1998, BIOCHEM BIOPH RES CO, V244, P832, DOI 10.1006/bbrc.1998.8349; Ladoux A, 2000, J BIOL CHEM, V275, P39914, DOI 10.1074/jbc.M006512200; LYUBCHENKO YL, 1993, BIOCHEMISTRY-US, V32, P4121, DOI 10.1021/bi00066a038; Mandriota SJ, 2000, AM J PATHOL, V156, P2077, DOI 10.1016/S0002-9440(10)65079-1; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Minamino N, 2000, CLIN HEMORHEOL MICRO, V23, P95; Nagata D, 1999, KIDNEY INT, V55, P1259, DOI 10.1046/j.1523-1755.1999.00361.x; Nakayama M, 1999, PEPTIDES, V20, P769, DOI 10.1016/S0196-9781(99)00061-3; Nakazawa I, 2001, J HUM GENET, V46, P132, DOI 10.1007/s100380170100; Nikitenko LL, 2002, TRENDS PHARMACOL SCI, V23, P101, DOI 10.1016/S0165-6147(00)01983-0; Nikitenko LL, 2001, MOL HUM REPROD, V7, P655, DOI 10.1093/molehr/7.7.655; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; Nishiyama J, 2001, BIOCHEM J, V360, P49, DOI 10.1042/0264-6021:3600049; NJUKI F, 1993, CLIN SCI, V85, P385, DOI 10.1042/cs0850385; Oehler MK, 2001, ONCOGENE, V20, P2937, DOI 10.1038/sj.onc.1204422; Ogbourne S, 1998, BIOCHEM J, V331, P1; Ogita T, 2001, J HYPERTENS, V19, P603, DOI 10.1097/00004872-200103001-00013; Oliver KR, 2002, J CEREBR BLOOD F MET, V22, P620, DOI 10.1097/00004647-200205000-00014; Poyner DR, 2002, PHARMACOL REV, V54, P233, DOI 10.1124/pr.54.2.233; Prestridge D S, 2000, Methods Mol Biol, V130, P265; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; Rabadan-Diehl C, 2000, J NEUROENDOCRINOL, V12, P437; Robert-Nicoud M, 2001, P NATL ACAD SCI USA, V98, P2712, DOI 10.1073/pnas.051603198; ROZEN F, 1995, P NATL ACAD SCI USA, V92, P200, DOI 10.1073/pnas.92.1.200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; Sexton PM, 2001, CELL SIGNAL, V13, P73, DOI 10.1016/S0898-6568(00)00143-1; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; Whitworth JA, 2001, CLIN EXP PHARMACOL P, V28, P993, DOI 10.1046/j.1440-1681.2001.03584.x	55	61	64	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1499	+		10.1096/fj.02-0993fje	http://dx.doi.org/10.1096/fj.02-0993fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824306				2022-12-28	WOS:000183818000020
J	Cattaruzza, S; Schiappacassi, M; Kimata, K; Colombatti, A; Perris, R				Cattaruzza, S; Schiappacassi, M; Kimata, K; Colombatti, A; Perris, R			The globular domains of PGM/versican modulate the proliferation-apoptosis equilibrium and invasive capabilities of tumor cells	FASEB JOURNAL			English	Article						tissue sarcoma; hyaluronan; G1; G3	CHONDROITIN SULFATE PROTEOGLYCAN; HYALURONIC-ACID; G3 DOMAIN; EXTRACELLULAR-MATRIX; PG-M/VERSICAN; G1 DOMAIN; VERSICAN; BINDING; GROWTH; EXPRESSION	To dissect the role of the globular domains of PGM/versican - a large hyaluronan binding proteoglycan (PG) enriched in tumor lesions-we have stably transduced a human leiomyosarcoma cell line with either the G1 or G3 domain of the PG and subsequently assayed the effect of this manipulation on several cellular processes in vitro and in vivo. G1- and G3-overexpressing cells were found to exhibit an enhanced growth that was more accentuated in the absence of serum components and was seen both when cells were cultured on ECM substrates and in the absence of ECM anchorage. Accordingly, if inoculated subcutaneously into nude mice, G1 transfectants formed larger tumor masses than control cells at the site of implantation, albeit after a certain latency period. Upon binding to cell surface CD44, proliferation of G1-, but not G3-, overexpressing cells were dose dependently inhibited by exogenous hyaluronan (HA) or HA fragments. G1- and G3-transduced cells did not differ in their intrinsic ability to adhere and migrate on various purified ECM components, whereas G1-overproducing sarcoma cells were more invasive than the corresponding G3 mutants, and their locomotion was perturbed by exogenous HA. The augmented anchorage-independent growth exhibited solely by G1-transduced was largely ascribable to a reduced apoptotic rate, thereby indicating a shift in the proliferation-apoptosis equilibrium of the cells toward the former. In fact, G1-overexpressing cells appeared resistant to both cytotoxic drug-induced and Fas-dependent programmed cell death, and this resistance implicated mitochondrial apoptotic genes. The results indicate that the terminal domains of versican may differentially control propagation of tumor cells and diversely modulate their responses to environmental HA.	IRCCS, CRO, Natl Canc Inst, Div Expt Oncol 2, I-33081 Aviano, PN, Italy; Univ Parma, Dept Evolutionary & Funct Biol, I-43100 Parma, Italy; Aichi Med Univ, Inst Mol Sci Med, Aichi 48011, Japan; Univ Udine, Dept Tech & Biomed Sci & Micrograv, Aging Training & Immobil Ctr Excellence, I-33100 Udine, UD, Italy	IRCCS Aviano (CRO); University of Parma; Aichi Medical University; University of Udine	Perris, R (corresponding author), IRCCS, CRO, Natl Canc Inst, Div Expt Oncol 2, Via Pedemontana Occidentale 12, I-33081 Aviano, PN, Italy.	rperris@cro.it	Schiappacassi, Monica/AAX-5505-2020	Schiappacassi, Monica/0000-0003-4804-4291; colombatti, alfonso/0000-0002-3676-2379				Aguiar DJ, 1999, EXP CELL RES, V252, P292, DOI 10.1006/excr.1999.4641; Ahrens T, 2001, ONCOGENE, V20, P3399, DOI 10.1038/sj.onc.1204435; Ahrens T, 2001, J INVEST DERMATOL, V116, P93, DOI 10.1046/j.1523-1747.2001.00236.x; Ang LC, 1999, J NEUROPATH EXP NEUR, V58, P597, DOI 10.1097/00005072-199906000-00004; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Cao L, 1999, EXP CELL RES, V246, P527, DOI 10.1006/excr.1998.4335; Cattaruzza S, 2002, J BIOL CHEM, V277, P47626, DOI 10.1074/jbc.M206521200; Evanko SP, 1999, ARTERIOSCL THROM VAS, V19, P1004, DOI 10.1161/01.ATV.19.4.1004; Fedtsova N, 2003, DEV BIOL, V261, P456, DOI 10.1016/S0012-1606(03)00316-6; Gal I, 2003, J BIOL CHEM, V278, P11150, DOI 10.1074/jbc.M210661200; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Isogai Z, 1996, CANCER RES, V56, P3902; Kawasaki K, 1999, J CELL PHYSIOL, V179, P142, DOI 10.1002/(SICI)1097-4652(199905)179:2<142::AID-JCP4>3.0.CO;2-Q; Lesley J, 2002, J BIOL CHEM, V277, P26600, DOI 10.1074/jbc.M201068200; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Mazzucato M, 2002, FASEB J, V16, P1903, DOI 10.1096/fj.02-0382com; Nakagawa T, 1996, ANTICANCER RES, V16, P2917; Nara Y, 1997, HISTOCHEM J, V29, P21, DOI 10.1023/A:1026460700592; NASO MF, 1994, J BIOL CHEM, V269, P32999; Paulus W, 1996, J NEUROPATH EXP NEUR, V55, P528, DOI 10.1097/00005072-199605000-00005; Perissinotto D, 2000, DEVELOPMENT, V127, P2823; PERRIS R, 1990, DEV BIOL, V137, P1, DOI 10.1016/0012-1606(90)90002-Z; Perris R, 1996, FASEB J, V10, P293, DOI 10.1096/fasebj.10.2.8641562; Perris R, 2000, MECH DEVELOP, V95, P3, DOI 10.1016/S0925-4773(00)00365-8; Ricciardelli C, 1998, CLIN CANCER RES, V4, P963; Sakko AJ, 2001, CANCER RES, V61, P926; Sandy JD, 2001, J BIOL CHEM, V276, P13372, DOI 10.1074/jbc.M009737200; SHINOMURA T, 1993, J BIOL CHEM, V268, P14461; Spessotto P, 2000, METH MOL B, V139, P321; Spessotto P, 2001, CANCER RES, V61, P339; Touab M, 2003, AM J CLIN PATHOL, V119, P587, DOI 10.1309/ME25J1G5E57LM3; Touab M, 2002, AM J PATHOL, V160, P549, DOI 10.1016/S0002-9440(10)64874-2; Vincent T, 2001, J BIOL CHEM, V276, P14728, DOI 10.1074/jbc.M003965200; Voutilainen K, 2003, INT J CANCER, V107, P359, DOI 10.1002/ijc.11423; Wight TN, 2002, CURR OPIN CELL BIOL, V14, P617, DOI 10.1016/S0955-0674(02)00375-7; Wu YJ, 2001, J BIOL CHEM, V276, P14178, DOI 10.1074/jbc.M100618200; YAMAGATA M, 1994, J CELL SCI, V107, P2581; Yang BL, 2000, J BIOL CHEM, V275, P21255, DOI 10.1074/jbc.M001443200; Yang BL, 1999, J CELL BIOCHEM, V72, P210, DOI 10.1002/(SICI)1097-4644(19990201)72:2<210::AID-JCB5>3.0.CO;2-E; Zhang Y, 1998, J BIOL CHEM, V273, P33054, DOI 10.1074/jbc.273.49.33054; Zhang Y, 1998, J BIOL CHEM, V273, P21342, DOI 10.1074/jbc.273.33.21342; Zhang Y, 2001, EXP CELL RES, V263, P33, DOI 10.1006/excr.2000.5095; Zhao M, 1999, J ORAL PATHOL MED, V28, P37; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	44	55	55	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					779	+		10.1096/fj.03-0660fje	http://dx.doi.org/10.1096/fj.03-0660fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977887				2022-12-28	WOS:000220425000027
J	Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C				Benazzouz, A; Tai, CH; Meissner, W; Bioulac, B; Bezard, E; Gross, C			High-frequency stimulation of both zona incerta and subthalamic nucleus induces a normalization of basal ganglia metabolic activity in experimental parkinsonism	FASEB JOURNAL			English	Article						cytochrome oxidase; globus pallidus; deep brain stimulation; Parkinson's Disease; substantia nigra	NIGRA PARS RETICULATA; DECARBOXYLASE MESSENGER-RNA; CONVERGENT SYNAPTIC INPUTS; GLOBUS-PALLIDUS NEURONS; DEEP BRAIN-STIMULATION; MPTP-TREATED MONKEYS; NIGROSTRIATAL DENERVATION; FIRING PATTERN; ENTOPEDUNCULAR NUCLEUS; CYTOCHROME-OXIDASE	High-frequency stimulation (HFS) of the subthalamic nucleus (STN) alleviates dramatically motor symptoms in Parkinson's disease, and recently it has been suggested that zona incerta (ZI) stimulation might be as beneficial to patients. We used in situ cytochrome oxidase (Col) mRNA hybridization to investigate and compare the effects of HFS of the STN and the ZI on metabolic activity of the STN, globus pallidus (GP), and substantia nigra reticulata (SNr) in normal rats as well as in rats with 6-hydroxydopamine (6-OHDA) lesion, an animal model of Parkinson's disease. In normal rats, HFS of the STN, as well as of the ZI, induced a significant decrease in Col mRNA expression within the STN and SNr but an increase within the GP. In 6-OHDA rats, HFS of the STN reversed dopamine denervation-induced changes in the expression of Col mRNA in the STN, SNr, and GP. Similar results were obtained with HFS of the ZI except for the STN, which showed only a trend toward nomlization. These data suggest that the ZI, as well as the STN, are implicated in the functional mechanism of HFS supporting the involvement of GABA transmission for the reduction of neuronal activity in the basal ganglia output structures.	Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, F-33076 Bordeaux, France; Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei, Taiwan; Humboldt Univ, Charite Campus Virchow, Dept Neurol, Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; National Taiwan University; National Taiwan University Hospital; National Taiwan University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Benazzouz, A (corresponding author), Univ Victor Segalen, CNRS, UMR 5543, Lab Physiol & Physiopathol Signalisat Cellulaire, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Abdelhamid.Benazzouz@umr5543.u-bordeaux2.fr	Benazzouz, Abdelhamid/E-5050-2016; Bezard, Erwan/ABD-5153-2021; Meissner, Wassilios/C-7817-2015; Bezard, Erwan/A-8173-2008	Meissner, Wassilios/0000-0003-2172-7527; Tai, Chun-Hwei/0000-0002-3493-8879; Bezard, Erwan/0000-0002-0410-4638				AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; Benazzouz A, 2002, MOVEMENT DISORD, V17, pS145, DOI 10.1002/mds.10156; Benazzouz A, 1996, MOVEMENT DISORD, V11, P627, DOI 10.1002/mds.870110606; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; BEVAN MD, 1994, BRAIN RES, V659, P99, DOI 10.1016/0006-8993(94)90868-0; BEVAN MD, 1994, EUR J NEUROSCI, V6, P320, DOI 10.1111/j.1460-9568.1994.tb00275.x; Bezard E, 1999, EUR J NEUROSCI, V11, P2167, DOI 10.1046/j.1460-9568.1999.00627.x; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; BEZARD E, 2001, FASEB J, V10, P1096; BOLAM JP, 1992, J COMP NEUROL, V321, P456, DOI 10.1002/cne.903210312; Boraud T, 2001, BRAIN, V124, P546, DOI 10.1093/brain/124.3.546; Boraud T, 1998, BRAIN RES, V787, P157, DOI 10.1016/S0006-8993(97)01563-1; BURBAUD P, 1995, EXP BRAIN RES, V105, P48; DELFS JM, 1995, EXP NEUROL, V133, P175, DOI 10.1006/exnr.1995.1020; DELFS JM, 1995, J NEUROSCI, V15, P6562; DeLong M. R., 1987, BASAL GANGLIA, P415, DOI 10.1007/978-1-4684-5347-8_29; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; Gross CE, 2003, J NEUROCHEM, V84, P1246, DOI 10.1046/j.1471-4159.2003.01600.x; Gross CE, 1999, PROG NEUROBIOL, V59, P509, DOI 10.1016/S0301-0082(99)00015-5; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HASSLER R, 1965, CONFIN NEUROL, V26, P282; HEVNER RF, 1992, NEUROSCI LETT, V138, P188, DOI 10.1016/0304-3940(92)90502-X; Hirsch EC, 2000, TRENDS NEUROSCI, V23, pS78, DOI 10.1016/S1471-1931(00)00021-5; HOLLERMAN JR, 1992, BRAIN RES, V590, P291, DOI 10.1016/0006-8993(92)91108-Q; Hutchison WD, 1998, ANN NEUROL, V44, P622, DOI 10.1002/ana.410440407; KINCAID AE, 1992, NEUROSCIENCE, V51, P705, DOI 10.1016/0306-4522(92)90309-P; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; MARGINOSASCONE C, 2002, NEUROSCIENCE, V115, P1109; Miller Rupert G., 1981, SIMULTANEOUS STAT IN, V2nd, DOI [DOI 10.1007/978-1-4613-8122-8, 10.1007/978-1-4613-8122-8_1]; MILNER KL, 1988, BRAIN RES, V452, P273, DOI 10.1016/0006-8993(88)90031-5; Murer MG, 1997, SYNAPSE, V27, P278, DOI 10.1002/(SICI)1098-2396(199712)27:4<278::AID-SYN2>3.3.CO;2-S; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Ni ZG, 2001, SYNAPSE, V40, P145, DOI 10.1002/syn.1036.abs; Ni ZG, 2000, EUR J NEUROSCI, V12, P4338, DOI 10.1111/j.1460-9568.2000.01346.x; NI ZG, 2000, IN PRESS NEUROSCIENC; PAN HS, 1988, SYNAPSE, V2, P650, DOI 10.1002/syn.890020612; Paxinos G., 1996, RAT BRAIN STEREOTAXI; Perier C, 2000, NEUROREPORT, V11, P3275, DOI 10.1097/00001756-200009280-00045; Perier C, 2000, EXP NEUROL, V162, P215, DOI 10.1006/exnr.1999.7331; Perier C, 2002, J NEUROSCI, V22, P8711; Raz A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-03-j0006.2001; Saint-Cyr JA, 2002, J NEUROSURG, V97, P1152, DOI 10.3171/jns.2002.97.5.1152; Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002; SOGHOMONIAN JJ, 1992, SYNAPSE, V11, P124, DOI 10.1002/syn.890110205; SUPKO DE, 1991, BRAIN RES, V564, P159, DOI 10.1016/0006-8993(91)91367-A; Tai CH, 2003, FASEB J, V17, P1820, DOI 10.1096/fj.03-0163com; Vila M, 2000, EUR J NEUROSCI, V12, P337, DOI 10.1046/j.1460-9568.2000.00901.x; Vila M, 1997, J NEUROSCI, V17, P765; Vila M, 1996, NEUROLOGY, V46, P802, DOI 10.1212/WNL.46.3.802; Voges J, 2002, J NEUROSURG, V96, P269, DOI 10.3171/jns.2002.96.2.0269; Wichmann T, 1999, EXP BRAIN RES, V125, P397, DOI 10.1007/s002210050696; WINDELS F, 2002, INVOLVEMENT GABA MEC; WONGRILEY MTT, 1989, TRENDS NEUROSCI, V12, P94, DOI 10.1016/0166-2236(89)90165-3	63	45	47	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					528	+		10.1096/fj.03-0576fje	http://dx.doi.org/10.1096/fj.03-0576fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715698				2022-12-28	WOS:000188829300020
J	Morrow, G; Samson, M; Michaud, S; Tanguay, RM				Morrow, G; Samson, M; Michaud, S; Tanguay, RM			Overexpression of the small mitochondrial Hsp22 extends Drosophila life span and increases resistance to oxidative stress	FASEB JOURNAL			English	Article						mitochondria; Hsp22; Drosophila melanogaster; oxidants; motorneurons	HEAT-SHOCK-PROTEIN; METHIONINE SULFOXIDE REDUCTASE; CAENORHABDITIS-ELEGANS; GENETIC-ANALYSIS; RODENT CELLS; C-ELEGANS; MELANOGASTER; EXTENSION; EXPRESSION; LONGEVITY	Heat shock proteins (Hsp) are involved in protein folding, transport and stress resistance. Studies reporting an increased mRNA level of hsp genes in aged Drosophila suggest that expression of Hsp might be beneficial in preventing damages induced by aging. Because oxidative damage is often observed in aged organisms and mitochondria are sensitive to reactive oxygen species, we tested the hypothesis that increased levels of a small Hsp localized in mitochondria, Hsp22 of Drosophila melanogaster, could protect mitochondrial proteins and influence the aging process. We demonstrate that a ubiquitous or a targeted expression of Hsp22 within motorneurons increases the mean life span by more than 30%. Hsp22 shows beneficial effects on early-aging events since the premortality phase displays the same increase as the mean lifespan. Moreover, flies expressing Hsp22 in their motorneurons maintain their locomotor activity longer as assessed by a negative geotaxis assay. The motorneurons-targeted expression of Hsp22 also significantly increases flies' resistance to oxidative injuries induced by paraquat (up to 35%) and thermal stress (39% at 30degreesC and 23% at 37degrees). These observations establish Hsp22 as a key player in cell-protection mechanisms against oxidative injuries and aging in Drosophila and corroborate the pivotal role of mitochondria in the process of aging.	Univ Laval, Lab Cell & Dev Genet, CREFSIP, Ste Foy, PQ G1K 7P4, Canada; Univ Laval, Dept Med, Ste Foy, PQ G1K 7P4, Canada	Laval University; Laval University	Tanguay, RM (corresponding author), Univ Laval, Lab Cell & Dev Genet, CREFSIP, Pav Marchand, Ste Foy, PQ G1K 7P4, Canada.	robert.tanguay@rsvs.ulaval.ca						Anisimov VN, 1998, MECH AGEING DEV, V103, P123, DOI 10.1016/S0047-6374(98)00034-7; Bonilla E, 2002, EXP GERONTOL, V37, P629, DOI 10.1016/S0531-5565(01)00229-7; Boulianne GL, 2001, MECH AGEING DEV, V122, P883, DOI 10.1016/S0047-6374(01)00245-7; Brack C, 1997, CELL MOL LIFE SCI, V53, P960, DOI 10.1007/PL00013199; BRAND AH, 1993, DEVELOPMENT, V118, P401; Bruey JM, 2000, NAT CELL BIOL, V2, P645, DOI 10.1038/35023595; Butov A, 2001, EXP GERONTOL, V37, P57, DOI 10.1016/S0531-5565(01)00161-9; Chavous DA, 2001, P NATL ACAD SCI USA, V98, P14814, DOI 10.1073/pnas.251446498; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; Ekengren S, 2001, CURR BIOL, V11, P714, DOI 10.1016/S0960-9822(01)00203-2; Garigan D, 2002, GENETICS, V161, P1101; Humphreys JM, 1996, GENOME, V39, P749, DOI 10.1139/g96-094; Kang HL, 2002, P NATL ACAD SCI USA, V99, P838, DOI 10.1073/pnas.022631999; Khavinson VK, 2000, MECH AGEING DEV, V120, P141, DOI 10.1016/S0047-6374(00)00217-7; Khazaeli AA, 1997, J GERONTOL A-BIOL, V52, pB48, DOI 10.1093/gerona/52A.1.B48; King V, 1999, DEV BIOL, V207, P107, DOI 10.1006/dbio.1998.9147; Kurapati R, 2000, J GERONTOL A-BIOL, V55, pB552, DOI 10.1093/gerona/55.11.B552; LANDRY J, 1989, J CELL BIOL, V109, P7, DOI 10.1083/jcb.109.1.7; Le Bourg E, 2001, BIOGERONTOLOGY, V2, P155, DOI 10.1023/A:1011561107055; Leal SM, 2002, J NEUROBIOL, V50, P245, DOI 10.1002/neu.10030; Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172; Lee SS, 2003, SCIENCE, V300, P644, DOI 10.1126/science.1083614; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; LITHGOW GJ, 1995, P NATL ACAD SCI USA, V92, P7540, DOI 10.1073/pnas.92.16.7540; MEHLEN P, 1993, EUR J BIOCHEM, V215, P277, DOI 10.1111/j.1432-1033.1993.tb18032.x; Minois N, 2001, EXP GERONTOL, V36, P1137, DOI 10.1016/S0531-5565(00)00263-1; Morrow G, 2000, J BIOL CHEM, V275, P31204, DOI 10.1074/jbc.M002960200; Moskovitz J, 2001, P NATL ACAD SCI USA, V98, P12920, DOI 10.1073/pnas.231472998; Munoz MJ, 2003, MECH AGEING DEV, V124, P43, DOI 10.1016/S0047-6374(02)00168-9; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Rattan SIS, 1998, BIOCHEM MOL BIOL INT, V45, P753; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; ROLLET E, 1992, BIOCHEM BIOPH RES CO, V185, P116, DOI 10.1016/S0006-291X(05)80963-5; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Ruan H, 2002, P NATL ACAD SCI USA, V99, P2748, DOI 10.1073/pnas.032671199; Seong KH, 2001, BIOGERONTOLOGY, V2, P209, DOI 10.1023/A:1011517325711; Sohal RS, 2002, FREE RADICAL BIO MED, V33, P37, DOI 10.1016/S0891-5849(02)00856-0; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Verbeke P, 2001, CELL BIOL INT, V25, P845, DOI 10.1006/cbir.2001.0789; Vettraino J, 2001, J GERONTOL A-BIOL, V56, pB415, DOI 10.1093/gerona/56.10.B415; Walker GA, 2003, AGING CELL, V2, P131, DOI 10.1046/j.1474-9728.2003.00045.x; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; WHEELER JC, 1995, P NATL ACAD SCI USA, V92, P10408, DOI 10.1073/pnas.92.22.10408; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036	44	233	264	0	30	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					598	+		10.1096/fj.03-0860fje	http://dx.doi.org/10.1096/fj.03-0860fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734639				2022-12-28	WOS:000188829300007
J	Quintana, E; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Barrachina, MD				Quintana, E; Hernandez, C; Alvarez-Barrientos, A; Esplugues, JV; Barrachina, MD			Synthesis of nitric oxide in post-ganglionic myenteric neurons during endotoxemia: implications for gastric motor function	FASEB JOURNAL			English	Article						myenteric plexus; motility; confocal microscopy; DAF; neuronal NOS	VASOACTIVE INTESTINAL POLYPEPTIDE; NONADRENERGIC NONCHOLINERGIC RELAXATION; RAT HIPPOCAMPAL SLICES; SMOOTH-MUSCLE-CELLS; SYNTHASE EXPRESSION; CIRCULAR MUSCLE; NERVOUS-SYSTEM; FUNDUS; INVOLVEMENT; PATHWAY	We have investigated the mechanisms underlying acute changes in gastric motor function triggered by endotoxemia. In fundal strips from rats pre-treated with endotoxin (40 mug/kg, i.p. 30 min), mechanical activity was analyzed and the source of nitric oxide (NO) was visualized by confocal microscopy of tissue loaded with the fluorescent dye DAF-FM. NOS expression was determined by quantitative RT-PCR and Western blot, and enzyme activity by the citrulline assay. Strips from endotoxin-treated rats were hypo-contractile. This was prevented by preincubation with the neurotoxin tetrodotoxin, the gangliar blocker hexamethonium, or nonselective and neuronal-specific NOS inhibitors (L-NOARG and TRIM, respectively). The Ca2+ soluble guanylyl cyclase (sGC) inhibitor ODQ and the inhibitor of small conductance Ca2+-activated K+ channels apamin prevented relaxation induced by endotoxin, nicotine, exogenous NO (DETA-NONOate), and the NO-independent sGC activator BAY 41-2272. NO synthesis was observed in neuronal soma, axons, and nerve endings of the myenteric plexus in the fundus of endotoxin-treated rats and was prevented by L-NAME, tetrodotoxin, and hexamethonium. nNOS and iNOS mRNA and protein contents were unchanged. Our findings demonstrate synthesis of NO in post-ganglionic myenteric neurons during early endotoxemia that mediates Ca2+-gastric hypo-contractility. The effect of NO is mediated via sGC and small conductance Ca2+-activated K+ channels.	Univ Valencia, Fac Med, Dept Pharmacol, Valencia 46010, Spain; Univ Valencia, Fac Med, CNIC UVEG, Unidad Mixta, Valencia 46010, Spain; Fdn Ctr Nacl Invest Cardiovasc, Cytometry Unit, Madrid 28029, Spain	University of Valencia; University of Valencia; Centro Nacional de Investigaciones Cardiovasculares (CNIC)	Esplugues, JV (corresponding author), Univ Valencia, Fac Med, Dept Pharmacol, Avd Blasco Ibanez 15, Valencia 46010, Spain.	Juan.V.Esplugues@uv.es	SAEZ, CARLOS HERNANDEZ/M-3029-2014; Alvarez-Barrientos, Alberto/L-9299-2014; Esplugues, Juan/ABC-1488-2021; Barrachina, Maria/ABB-9683-2021	SAEZ, CARLOS HERNANDEZ/0000-0001-8536-429X; Alvarez-Barrientos, Alberto/0000-0003-4761-0212; Esplugues Mota, Juan Vicente/0000-0001-8205-021X; Barrachina, Maria Dolores/0000-0002-4332-2929				BARRETT HC, 2001, MIND SOC, V3, P1; BERTHOUD HR, 1995, J COMP NEUROL, V358, P428, DOI 10.1002/cne.903580309; BOLOTINA VM, 1994, NATURE, V368, P850, DOI 10.1038/368850a0; Brown LA, 2000, NEUROSCI LETT, V294, P9, DOI 10.1016/S0304-3940(00)01521-4; Calatayud S, 2003, BRIT J PHARMACOL, V139, P263, DOI 10.1038/sj.bjp.0705239; Calatayud S, 2003, N-S ARCH PHARMACOL, V367, P51, DOI 10.1007/s00210-002-0646-7; Calatayud S, 2002, AM J PHYSIOL-GASTR L, V283, pG1360, DOI 10.1152/ajpgi.00168.2002; Calatayud S, 2001, N-S ARCH PHARMACOL, V363, P276, DOI 10.1007/s002100000359; Chang HY, 2003, AM J PHYSIOL-GASTR L, V284, pG357, DOI 10.1152/ajpgi.00478.2002; DAMATO M, 1992, J AUTONOM NERV SYST, V37, P175, DOI 10.1016/0165-1838(92)90039-J; DESAI KM, 1991, NATURE, V351, P477, DOI 10.1038/351477a0; DESAI KM, 1991, P NATL ACAD SCI USA, V88, P11490, DOI 10.1073/pnas.88.24.11490; Dick JMC, 2000, EUR J PHARMACOL, V397, P389, DOI 10.1016/S0014-2999(00)00299-5; Elmquist JK, 1996, J COMP NEUROL, V371, P85, DOI 10.1002/(SICI)1096-9861(19960715)371:1<85::AID-CNE5>3.0.CO;2-H; Ergun Y, 2001, PHARMACOL RES, V44, P221, DOI 10.1006/phrs.2001.0844; Eskandari MK, 1999, AM J PHYSIOL-GASTR L, V277, pG478, DOI 10.1152/ajpgi.1999.277.2.G478; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Fossier P, 1999, TRENDS NEUROSCI, V22, P161, DOI 10.1016/S0166-2236(98)01307-1; Furness JB, 2000, J AUTONOM NERV SYST, V81, P87, DOI 10.1016/S0165-1838(00)00127-2; GRIDER JR, 1990, J PHARMACOL EXP THER, V253, P738; Guilmard C, 1998, NITRIC OXIDE-BIOL CH, V2, P147, DOI 10.1006/niox.1998.0170; Haugland R.P., 2002, HDB FLUORESCENT PROB; Helmer KS, 2002, J SURG RES, V104, P46, DOI 10.1006/jsre.2002.6404; Helmer KS, 2002, GASTROENTEROLOGY, V123, P173, DOI 10.1053/gast.2002.34178; HOM GJ, 1995, J PHARMACOL EXP THER, V272, P452; Ishiguchi T, 2000, AM J PHYSIOL-GASTR L, V279, pG740, DOI 10.1152/ajpgi.2000.279.4.G740; Jenkinson KM, 2000, BRIT J PHARMACOL, V130, P1627, DOI 10.1038/sj.bjp.0703481; Kalsi JS, 2003, J UROLOGY, V169, P761, DOI 10.1016/S0022-5347(05)64009-8; KAMATA K, 1993, GEN PHARMACOL, V24, P1403, DOI 10.1016/0306-3623(93)90426-X; KITAMURA K, 1993, BRIT J PHARMACOL, V109, P415, DOI 10.1111/j.1476-5381.1993.tb13585.x; KNOWLES RG, 1990, BIOCHEM J, V270, P833, DOI 10.1042/bj2700833; Kojima H, 2001, J NEUROCHEM, V76, P1404, DOI 10.1046/j.1471-4159.2001.00161.x; LEFEBVRE RA, 1995, BRIT J PHARMACOL, V116, P2017, DOI 10.1111/j.1476-5381.1995.tb16406.x; Lefebvre RA, 1998, BRIT J PHARMACOL, V124, P1439, DOI 10.1038/sj.bjp.0701992; LI CG, 1990, EUR J PHARMACOL, V191, P303; MartinezCuesta MA, 1996, BRIT J PHARMACOL, V118, P1335, DOI 10.1111/j.1476-5381.1996.tb15542.x; Mashimo H, 2000, GASTROENTEROLOGY, V119, P766, DOI 10.1053/gast.2000.16509; MATHARU MS, 1992, BRIT J PHARMACOL, V106, P395, DOI 10.1111/j.1476-5381.1992.tb14346.x; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; Nakamura K, 1998, J CLIN INVEST, V101, P1479, DOI 10.1172/JCI627; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; Quintana E, 2001, BRIT J PHARMACOL, V134, P325, DOI 10.1038/sj.bjp.0704258; ROBERTSON BE, 1993, AM J PHYSIOL, V265, pC299; SANDERS KM, 1992, AM J PHYSIOL, V262, pG379, DOI 10.1152/ajpgi.1992.262.3.G379; Saur D, 2002, AM J PHYSIOL-GASTR L, V282, pG349, DOI 10.1152/ajpgi.00226.2001; Shuttleworth CWR, 1996, P SOC EXP BIOL MED, V211, P16, DOI 10.3181/00379727-211-43950C; Takakura K, 1997, ANESTHESIOLOGY, V87, P652, DOI 10.1097/00000542-199709000-00027; Teng BQ, 1998, AM J PHYSIOL-GASTR L, V275, pG342, DOI 10.1152/ajpgi.1998.275.2.G342; van Miert A S, 1970, Arch Int Pharmacodyn Ther, V184, P27; VOOGD TE, 1993, PHARMACOL REV, V45, P177; Wiklund NP, 1997, J NEUROSCI RES, V47, P224, DOI 10.1002/(SICI)1097-4547(19970115)47:2<224::AID-JNR11>3.0.CO;2-2; Willmott NJ, 2000, J NEUROSCI, V20, P1767	54	16	20	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					531	+		10.1096/fj.03-0596fje	http://dx.doi.org/10.1096/fj.03-0596fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715697				2022-12-28	WOS:000188829300029
J	Chen, Y; Ke, QG; Yang, YK; Rana, JMS; Tang, J; Morgan, JP; Xiao, YF				Chen, Y; Ke, QG; Yang, YK; Rana, JMS; Tang, J; Morgan, JP; Xiao, YF			Cardiomyocytes overexpressing TNF-alpha attract migration of embryonic stem cells via activation of p38 and c-Jun amino-terminal kinase	FASEB JOURNAL			English	Article						myocardial infarction; transfection; Transwell assay	NECROSIS-FACTOR-ALPHA; ACUTE MYOCARDIAL-INFARCTION; IMPROVES CARDIAC-FUNCTION; NF-KAPPA-B; GROWTH-FACTOR; FETAL CARDIOMYOCYTES; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; ACTIN REORGANIZATION; VIRAL MYOCARDITIS	Tumor necrosis factor-alpha (TNF-alpha) plays an important role in the pathogenesis of myocardial infarction. Stem cells are able to regenerate infarcted myocardium. This study investigated whether TNF-alpha was able to induce migration of embryonic stem cells (ESCs) in vitro. We used a Transwell assay in which neonatal rat cardiomyocytes, with or without transfection of TNF-alpha cDNA, were plated in the lower compartments and mouse ESCs tagged with green fluorescent protein were added to the upper compartments. TNF-alpha level was significantly increased in the medium of the lower compartments seeded with TNF-alpha-transfected cardiomyocytes. Compared with the controls, overexpression of TNF-alpha significantly enhanced migration of ESCs to the lower compartments. This enhancement was attenuated by preincubation of ESCs with the antibody against the type II TNF-alpha receptor (TNF-RII), but not by the antibody against the type I TNF-alpha receptor (TNF-RI). Western blot analysis showed that the phosphorylated protein levels of p38 and c-Jun amino-terminal kinase (JNK) were significantly increased in TNF-alpha-treated ESCs. Inhibition of the activity of p38 or JNK significantlyattenuated TNF-alpha-induced ESC migration. Our data demonstrate that excessive TNF-alpha stimulates TNF-RII and enhances migration of ESCs in vitro. Activation of p38 and JNK is required for TNF-alpha-enhanced ESC migration.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med,Harvard Thorndike Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Charles A Dana Res Inst,Stem Cells Rees Lab, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Xiao, YF (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Cardiovasc,Dept Med,Harvard Thorndike Lab, 330 Brookline Ave, Boston, MA 02215 USA.	yxiao@caregroup.harvard.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA012774, R01DA011762] Funding Source: NIH RePORTER; NIDA NIH HHS [DA12774, DA11762] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		AnandApte B, 1997, STEM CELLS, V15, P259, DOI 10.1002/stem.150259; Bahra P, 1998, CELL ADHES COMMUN, V6, P491, DOI 10.3109/15419069809010797; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Carpentier I, 1998, FEBS LETT, V425, P195, DOI 10.1016/S0014-5793(98)00226-9; CHIU RCJ, 1995, ANN THORAC SURG, V60, P12; Condorelli G, 2002, FASEB J, V16, P1732, DOI 10.1096/fj.02-0419com; Cumberbatch M, 1999, BRIT J DERMATOL, V141, P192; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Dekaris I, 1999, J IMMUNOL, V162, P4235; Ebert EC, 1998, GUT, V42, P650, DOI 10.1136/gut.42.5.650; Fiers W, 1996, J INFLAMM, V47, P67; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; Goetze S, 1999, HYPERTENSION, V33, P183, DOI 10.1161/01.HYP.33.1.183; Halawa B, 1999, Pol Arch Med Wewn, V101, P197; Irwin MW, 1999, CIRCULATION, V99, P1492, DOI 10.1161/01.CIR.99.11.1492; Jacobs M, 1999, J MOL CELL CARDIOL, V31, P1949, DOI 10.1006/jmcc.1999.1007; Jovinge S, 1997, ARTERIOSCL THROM VAS, V17, P490, DOI 10.1161/01.ATV.17.3.490; KIMBER I, 1992, J INVEST DERMATOL, V99, pS48, DOI 10.1111/1523-1747.ep12668986; Klug MG, 1996, J CLIN INVEST, V98, P216, DOI 10.1172/JCI118769; Kocher AA, 2001, NAT MED, V7, P430, DOI 10.1038/86498; Kondo S, 1997, EUR J IMMUNOL, V27, P1713, DOI 10.1002/eji.1830270718; Laflamme MA, 2002, CIRC RES, V90, P634, DOI 10.1161/01.RES.0000014822.62629.EB; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li DY, 1999, AM HEART J, V137, P1145, DOI 10.1016/S0002-8703(99)70375-3; Li RK, 1996, CIRC RES, V78, P283, DOI 10.1161/01.RES.78.2.283; Matsumoto T, 1999, J BIOL CHEM, V274, P13954, DOI 10.1074/jbc.274.20.13954; MAURY CPJ, 1989, J INTERN MED, V225, P333, DOI 10.1111/j.1365-2796.1989.tb00090.x; Min JY, 2002, ANN THORAC SURG, V74, P1568, DOI 10.1016/S0003-4975(02)03952-8; Min JY, 2002, J APPL PHYSIOL, V92, P288, DOI 10.1152/jappl.2002.92.1.288; Min JY, 2002, CIRCULATION, V106, P419; Muller P, 2002, CIRCULATION, V106, P31, DOI 10.1161/01.CIR.0000022405.68464.CA; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Peschon JJ, 1998, J IMMUNOL, V160, P943; Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399, DOI 10.1038/74447; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Satoh M, 2000, J AM COLL CARDIOL, V36, P1288, DOI 10.1016/S0735-1097(00)00827-5; Seko Y, 2002, CARDIOVASC PATHOL, V11, P166, DOI 10.1016/S1054-8807(02)00101-1; SMART SJ, 1994, AM J PHYSIOL, V266, pL238, DOI 10.1152/ajplung.1994.266.3.L238; Smith AG., 1991, J TISSUE CULT METHOD, V13, P89, DOI [10.1007/BF01666137, DOI 10.1007/BF01666137, 10.1007/bf01666137]; SOONPAA MH, 1994, SCIENCE, V264, P98, DOI 10.1126/science.8140423; Strauer BE, 2002, CIRCULATION, V106, P1913, DOI 10.1161/01.CIR.0000034046.87607.1C; Sundstrom M, 2001, EXP CELL RES, V267, P144, DOI 10.1006/excr.2001.5239; Thomson JA, 1998, SCIENCE, V282, P1145, DOI 10.1126/science.282.5391.1145; Wada H, 2001, CIRCULATION, V103, P743; Wang BH, 1997, J IMMUNOL, V159, P6148; Wang JF, 2002, CELL TRANSPLANT, V11, P753; Wang ZB, 2001, FEBS LETT, V508, P360, DOI 10.1016/S0014-5793(01)03109-X; Wong CK, 2002, CLIN EXP IMMUNOL, V128, P483, DOI 10.1046/j.1365-2249.2002.01880.x; Wuu YD, 1998, BIOL REPROD, V58, P1416, DOI 10.1095/biolreprod58.6.1416; Yang YK, 2002, J APPL PHYSIOL, V93, P1140, DOI 10.1152/japplphysiol.00307.2002	50	33	37	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2231	2239		10.1096/fj.03-0030com	http://dx.doi.org/10.1096/fj.03-0030com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656985				2022-12-28	WOS:000188067500044
J	Choi, SI; Vidal, R; Frangione, B; Levy, E				Choi, SI; Vidal, R; Frangione, B; Levy, E			Axonal transport of British and Danish amyloid peptides via secretory vesicles	FASEB JOURNAL			English	Article						amyloid; axonal transport; familial British and Danish dementia; BRI2 processing; neurite outgrowth	DISULFIDE-BONDED LOOP; CEREBELLAR-ATAXIA; CHROMOGRANIN-B; DEMENTIA; FURIN; EXPRESSION; ACTIVATION; PROTEINS; CELLS; GOLGI	The ABri and ADan amyloid peptides deposited in familial British and Danish neurodegenerative disorders are generated by processing mutant forms of the precursor protein BRI2. Although the pathogenic process that leads to deposition of amyloid in the brains of patients has been studied extensively, the cellular processes and normal function of the precursor protein did not receive much attention. We observed in a variety of transfected cell lines the presence of two independent proteolytic processing events. In addition to the previously described cleavage, which results in the production of carb oxyl-terminal similar to3 kDa wild-type peptide or similar to4 kDa ABri or ADan peptides, we describe a novel amino-terminal cleavage site within BRI2. Both cleavages occur within the cis- or medial-Golgi. Following cleavage, the BRI2-derived carb oxyl-terminal peptides are transported via a regulated secretory pathway into secretory vesicles in neuronal cells. Worth noting is that expression of wild-type British or Danish mutants of BRI2, in mouse neuroblastoma N2a cells that do not express endogenous BRI2, induces elongation of neurites, which suggests a role for this protein in differentiation of neuronal cells.	NYU, Sch Med, Dept Pathol, New York, NY USA; NYU, Sch Med, Dept Psychiat, New York, NY USA; NYU, Sch Med, Dept Pharmacol, New York, NY USA; Indiana Univ, Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA; NYU, Sch Med, Nathan S Kline Inst Psychiat Res, Orangeburg, NY 10962 USA	New York University; New York University; New York University; Indiana University System; Indiana University-Purdue University Indianapolis; Nathan Kline Institute for Psychiatric Research; New York University	Levy, E (corresponding author), NYU, Sch Med, Nathan S Kline Inst Psychiat Res, 140 Old Orangeburg Rd, Orangeburg, NY 10962 USA.	elevy@nki.rfmh.org		choi, seung-il/0000-0001-7168-8795				BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cool DR, 1997, CELL, V88, P73, DOI 10.1016/S0092-8674(00)81860-7; De Strooper B, 2000, J CELL SCI, V113, P1857; Dickson DW, 1997, ANN NEUROL, V42, P541, DOI 10.1002/ana.410420403; El-Agnaf OMA, 2001, BIOCHEMISTRY-US, V40, P3449, DOI 10.1021/bi002287i; Ghiso JA, 2001, J BIOL CHEM, V276, P43909, DOI 10.1074/jbc.M105956200; Glombik MM, 1999, EMBO J, V18, P1059, DOI 10.1093/emboj/18.4.1059; GRIFFITHS G, 1983, J CELL BIOL, V96, P835, DOI 10.1083/jcb.96.3.835; GRIFFITHS RA, 1982, J NEUROL NEUROSUR PS, V45, P396, DOI 10.1136/jnnp.45.5.396; Holton JL, 2001, AM J PATHOL, V158, P515, DOI 10.1016/S0002-9440(10)63993-4; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Kim SH, 2002, J BIOL CHEM, V277, P1872, DOI 10.1074/jbc.M108739200; Kim SH, 2000, ANN NY ACAD SCI, V920, P93; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Kromer A, 1998, J CELL BIOL, V140, P1331, DOI 10.1083/jcb.140.6.1331; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Logeat F, 1998, P NATL ACAD SCI USA, V95, P8108, DOI 10.1073/pnas.95.14.8108; LOVE S, 1982, J NEUROL NEUROSUR PS, V45, P271, DOI 10.1136/jnnp.45.3.271; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Pittois K, 1998, GENE, V217, P141, DOI 10.1016/S0378-1119(98)00354-0; PLANT GT, 1990, BRAIN, V113, P721, DOI 10.1093/brain/113.3.721; Rostagno A, 2002, J BIOL CHEM, V277, P49782, DOI 10.1074/jbc.M206448200; STROMGREN E, 1970, ACTA NEUROL SCAND, V46, P261; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; Vidal R, 2000, P NATL ACAD SCI USA, V97, P4920, DOI 10.1073/pnas.080076097; Vidal R, 1999, NATURE, V399, P776; Vidal R, 2001, GENE, V266, P95, DOI 10.1016/S0378-1119(01)00374-2; Worster-Drought C, 1933, J NEUROL PSYCHOPATHO, V14, P27	32	45	47	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					373	+		10.1096/fj.03-0730fje	http://dx.doi.org/10.1096/fj.03-0730fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656991				2022-12-28	WOS:000188067500032
J	Francis, K; Lewis, BM; Akatsu, H; Monk, PN; Cain, SA; Scanlon, MF; Morgan, BP; Ham, J; Gasque, P				Francis, K; Lewis, BM; Akatsu, H; Monk, PN; Cain, SA; Scanlon, MF; Morgan, BP; Ham, J; Gasque, P			Complement C3a receptors in the pituitary gland: a novel pathway by which an innate immune molecule releases hormones involved in the control of inflammation	FASEB JOURNAL			English	Article						anaphylatoxin; sepsis; endocrine; hypothalamo-pituitary-adrenal axis	GROWTH-FACTOR-I; ANAPHYLATOXIN C3A; HUMAN-LEUKOCYTES; C5A RECEPTORS; TNF-ALPHA; EXPRESSION; C3A(DESARG); CLONING; NEUTROPHILS; PROLACTIN	Two-way communication exists between the endocrine and immune systems using molecules such as hormones and cytokines. Here we describe a new pathway by which C3a, a complement-derived cytokine, stimulates anterior pituitary hormone release and activates the hypothalamic-pituitary-adrenal axis, a reflex central to the stress response and to the control of inflammation. We show that C3a receptors are expressed in pituitary hormone secreting and non-hormone secreting (folliculostellate) cells and that both C3a and C3adesArg (a non-inflammatory metabolite) stimulate pituitary cell cultures to release prolactin, growth hormone, and adrenocorticotropin. Serum levels of these hormones, together with adrenal corticosterone, increase dose dependently with recombinant C3a and C3adesArg administration in vivo. Pertussis toxin blocks the response to C3a but not C3adesArg, which indicates the presence of two receptors, only one of which is coupled to G(alphai)-proteins. We propose that the complement innate immune molecules (cytokines) modulate tissue-specific and systemic inflammatory responses through communication with the endocrine pituitary gland.	Cardiff Univ, Dept Med Biochem & Immunol, Brain Inflammat & Immun Grp, Cardiff CF4 4XN, S Glam, Wales; Cardiff Univ, Dept Med Biochem & Immunol, Complement Biol Grp, Cardiff CF4 4XN, S Glam, Wales; Cardiff Univ, Dept Med, Sect Endocrinol Diabet & Metab, Cardiff CF4 4XN, S Glam, Wales; Fukushimura Hosp, Choju Med Inst, Toyohashi, Aichi, Japan; Univ Sheffield, Sch Med, Div Genom Med, Neurol Sect, Sheffield, S Yorkshire, England	Cardiff University; Cardiff University; Cardiff University; University of Sheffield	Gasque, P (corresponding author), Cardiff Univ, Dept Med Biochem, Brain Inflammat & Immun Grp, Tenovus Bldg,Heath Pk, Cardiff CF14 4XN, S Glam, Wales.	Gasque@cardiff.ac.uk	Monk, Peter/C-6155-2008; Cain, Stuart A/G-2836-2017	Monk, Peter/0000-0003-4637-3059; Cain, Stuart/0000-0001-8417-1058; Morgan, Paul/0000-0003-4075-7676				Akatsu H, 1997, MICROBIOL IMMUNOL, V41, P575, DOI 10.1111/j.1348-0421.1997.tb01894.x; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; Beutler B, 2001, BIOCHEM SOC T, V29, P853, DOI 10.1042/0300-5127:0290853; BOKISCH VA, 1970, J CLIN INVEST, V49, P2427, DOI 10.1172/JCI106462; Bole-Feysot C, 1998, ENDOCR REV, V19, P225, DOI 10.1210/edrv.19.3.0334; CHARRIAUT C, 1982, P NATL ACAD SCI-BIOL, V79, P6003, DOI 10.1073/pnas.79.19.6003; CIANFLONE KM, 1989, J BIOL CHEM, V264, P426; Clark R, 1997, ENDOCR REV, V18, P157, DOI 10.1210/er.18.2.157; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; Davoust N, 1999, GLIA, V26, P201, DOI 10.1002/(SICI)1098-1136(199905)26:3<201::AID-GLIA2>3.0.CO;2-M; Dorshkind K, 2000, ENDOCR REV, V21, P292, DOI 10.1210/er.21.3.292; Drouin SM, 2001, J IMMUNOL, V166, P2025, DOI 10.4049/jimmunol.166.3.2025; Fischer WH, 1997, J IMMUNOL, V159, P4279; Fukuoka Y, 1998, BIOCHEM BIOPH RES CO, V242, P663, DOI 10.1006/bbrc.1997.8034; Gasque P, 1998, J IMMUNOL, V160, P3543; Gasque P, 2000, IMMUNOPHARMACOLOGY, V49, P171, DOI 10.1016/S0162-3109(00)80302-1; GLOVSKY MM, 1979, J CLIN INVEST, V64, P804, DOI 10.1172/JCI109527; HACK CE, 1989, AM J MED, V86, P20, DOI 10.1016/0002-9343(89)90224-6; HAM J, 1997, CELL TISSUE CULTURE; Hollmann TJ, 1998, MOL IMMUNOL, V35, P137, DOI 10.1016/S0161-5890(98)00021-2; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; Ischenko A, 1998, J NEUROCHEM, V71, P2487; Kildsgaard J, 2000, J IMMUNOL, V165, P5406, DOI 10.4049/jimmunol.165.10.5406; Martin U, 1997, J EXP MED, V186, P199, DOI 10.1084/jem.186.2.199; Murray I, 1999, BIOCHEM J, V342, P41, DOI 10.1042/0264-6021:3420041; NAKAE H, 1994, RES COMMUN CHEM PATH, V84, P189; NORGAUER J, 1993, EUR J BIOCHEM, V217, P289, DOI 10.1111/j.1432-1033.1993.tb18245.x; Paczkowski NJ, 1999, BRIT J PHARMACOL, V128, P1461, DOI 10.1038/sj.bjp.0702938; SAVINO W, 1995, IMMUNOL TODAY, V16, P318, DOI 10.1016/0167-5699(95)80144-8; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; Schwartz J, 2000, ENDOCR REV, V21, P488, DOI 10.1210/er.21.5.488; Takabayashi T, 1998, J INFECT DIS, V177, P1622, DOI 10.1086/515316; Takabayashi T, 1996, J IMMUNOL, V156, P3455; Tseng YH, 1997, MOL CELL ENDOCRINOL, V128, P117, DOI 10.1016/S0303-7207(97)04028-8; Tsigos C, 1997, NEUROENDOCRINOLOGY, V66, P54, DOI 10.1159/000127219; Turnbull AV, 1999, PHYSIOL REV, V79, P1, DOI 10.1152/physrev.1999.79.1.1; Turrin NP, 2000, BRAIN RES BULL, V51, P3, DOI 10.1016/S0361-9230(99)00203-8; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Wilken HC, 1999, IMMUNOL LETT, V67, P141, DOI 10.1016/S0165-2478(99)00002-4; Zwirner J, 1997, EUR J IMMUNOL, V27, P2317, DOI 10.1002/eji.1830270928; Zwirner J, 1998, SCAND J IMMUNOL, V47, P19; Zwirner J, 1999, IMMUNOLOGY, V97, P166; Zwirner J, 1998, EUR J IMMUNOL, V28, P1570, DOI 10.1002/(SICI)1521-4141(199805)28:05<1570::AID-IMMU1570>3.3.CO;2-Y	45	44	52	1	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2266	+		10.1096/fj.02-1103fje	http://dx.doi.org/10.1096/fj.02-1103fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563692				2022-12-28	WOS:000186343300025
J	Delgado, M; Ganea, D				Delgado, M; Ganea, D			Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma	FASEB JOURNAL			English	Article						VIP; inflammation; endotoxin; cytokines; neuropeptides	TUMOR-NECROSIS-FACTOR; SPINAL-CORD-INJURY; MESSENGER-RNA; FACTOR-ALPHA; RAT-BRAIN; CHEMOKINE PRODUCTION; TNF-ALPHA; IN-VITRO; KAPPA-B; PITUITARY	In most neurodegenerative disorders, including multiple sclerosis, Parkinson's disease, and Alzheimer's disease, a massive neuronal cell death occurs as a consequence of an uncontrolled inflammatory response, where activated microglia and its cytotoxic agents play a crucial pathologic role. Because current treatments for these diseases are not effective, several regulatory molecules termed "microglia-deactivating factors" recently have been the focus of considerable research. Vasoactive intestinal peptide ( VIP) is a neuropeptide with a potent antiinflammatory effect, which has been found to protect from other inflammatory disorders, such as endotoxic shock and rheumatoid arthritis. In the present study, we investigate the effect of VIP on inflammation-mediated neurodegeneration in vitro and in vivo as well as on the putative neuroprotective effect of VIP on experimental pathological conditions in which central nervous system (CNS) inflammation is involved, such as brain trauma. The involvement of activated microglia and their derived cytotoxic products is also studied. VIP has a clear neuroprotective effect on inflammatory conditions by inhibiting the production of microglia-derived proinflammatory factors (tumor necrosis factor alpha, interleukin-1beta, nitric oxide). In this sense, VIP prevents neuronal cell death following brain trauma by reducing the inflammatory response of neighboring microglia. Therefore, VIP emerges as a valuable neuroprotective agent for the treatment of pathologic conditions of the CNS where inflammation-induced neurodegeneration occurs.	CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain; Rutgers State Univ, Dept Biol Sci, Newark, NJ 07102 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Rutgers State University Newark; Rutgers State University New Brunswick	Delgado, M (corresponding author), CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18001, Spain.	mdelgado@ipb.csic.es	Delgado, Mario/P-1524-2016	Delgado, Mario/0000-0003-1893-5982				Bartholdi D, 1997, EUR J NEUROSCI, V9, P1422, DOI 10.1111/j.1460-9568.1997.tb01497.x; Carlson SL, 1998, EXP NEUROL, V151, P77, DOI 10.1006/exnr.1998.6785; CHAO CC, 1992, J IMMUNOL, V149, P2736; DAVID S, 1990, NEURON, V5, P463, DOI 10.1016/0896-6273(90)90085-T; de Yebenes EG, 1999, J NEUROCHEM, V73, P812, DOI 10.1046/j.1471-4159.1999.0730812.x; Delgado M, 1998, J BIOL CHEM, V273, P31427, DOI 10.1074/jbc.273.47.31427; Delgado M, 1999, J IMMUNOL, V162, P4685; Delgado M, 1999, J IMMUNOL, V162, P2358; Delgado M, 1999, J NEUROIMMUNOL, V96, P167, DOI 10.1016/S0165-5728(99)00023-5; Delgado M, 2003, FASEB J, V17, P944, DOI 10.1096/fj.02-0799fje; Delgado M, 2003, J LEUKOCYTE BIOL, V73, P155, DOI 10.1189/jlb.0702372; Delgado M, 1999, J IMMUNOL, V162, P1200; Delgado M, 2002, GLIA, V39, P148, DOI 10.1002/glia.10098; Delgado M, 2001, J IMMUNOL, V167, P966, DOI 10.4049/jimmunol.167.2.966; FRANK M, 1996, GLIA, V7, P146; Ganea D, 2001, MICROBES INFECT, V3, P141, DOI 10.1016/S1286-4579(00)01361-7; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Gomariz RP, 2001, CURR PHARM DESIGN, V7, P89, DOI 10.2174/1381612013398374; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gourlet P, 1997, PEPTIDES, V18, P1539, DOI 10.1016/S0196-9781(97)00228-3; Gressens P, 1997, J CLIN INVEST, V100, P390, DOI 10.1172/JCI119545; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HIRSCHBERG DL, 1994, J NEUROIMMUNOL, V50, P9, DOI 10.1016/0165-5728(94)90209-7; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; KNO JY, 1987, J NEUROSCI, V20, P83; Lawrence CB, 1998, EUR J NEUROSCI, V10, P1188, DOI 10.1046/j.1460-9568.1998.00136.x; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; LIPTON JM, 1993, NEUROBIOLOGY CYTOK B, P61; MORENOFLORES MT, 1993, GLIA, V7, P146, DOI 10.1002/glia.440070204; Moro O, 1997, J BIOL CHEM, V272, P966, DOI 10.1074/jbc.272.2.966; Nadeau S, 2000, J NEUROSCI, V20, P3456, DOI 10.1523/JNEUROSCI.20-09-03456.2000; Offen D, 2000, BRAIN RES, V854, P257, DOI 10.1016/S0006-8993(99)02375-6; Pozo D, 2000, IMMUNOL TODAY, V21, P7, DOI 10.1016/S0167-5699(99)01525-X; Quan N, 1998, NEUROSCIENCE, V83, P281, DOI 10.1016/S0306-4522(97)00350-3; Rajora N, 1997, J NEUROSCI, V17, P2181; SAID SI, 1991, AM REV RESPIR DIS, V143, pS22, DOI 10.1164/ajrccm/143.3_Pt_2.S22; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; SAWADA M, 1989, BRAIN RES, V491, P394, DOI 10.1016/0006-8993(89)90078-4; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; SHER PK, 1990, GLIA, V3, P350, DOI 10.1002/glia.440030506; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; TAUPIN V, 1993, J NEUROIMMUNOL, V42, P177, DOI 10.1016/0165-5728(93)90008-M; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; Xia MG, 1997, J PHARMACOL EXP THER, V281, P629; [No title captured]	46	96	101	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1922	+		10.1096/fj.02-1029fje	http://dx.doi.org/10.1096/fj.02-1029fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923064				2022-12-28	WOS:000185345100006
J	Gao, HM; Liu, B; Zhang, WQ; Hong, JS				Gao, HM; Liu, B; Zhang, WQ; Hong, JS			Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease	FASEB JOURNAL			English	Article						microglia; microgliosis; neurodegeneration; reactive oxygen species; astroglia	LIPOPOLYSACCHARIDE-INDUCED NEUROTOXICITY; NIGRAL DOPAMINERGIC-NEURONS; NECROSIS-FACTOR-ALPHA; NITRIC-OXIDE; NEURODEGENERATIVE DISEASES; ACTIVATED MICROGLIA; INTRANIGRAL INJECTION; GLIAL-CELLS; BRAIN; 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) damages dopaminergic neurons as seen in Parkinson's disease. Although increasing evidence suggests an involvement of glia in MPTP neurotoxicity, the nature of this involvement remains unclear. Exploiting the advantage of cell culture systems, we demonstrated that microglia, but not astroglia, significantly enhanced the progression of MPTP-induced dopaminergic neurodegeneration. Characterization of the temporal relationship between neurodegeneration and microglial activation demonstrates that reactive microgliosis resulting from MPTP-initiated neuronal injury, but not direct activation, underlies the microglia-enhanced MPTP neurotoxicity. Mechanistically, through the release of NADPH oxidase-derived reactive oxygen species, microglia contribute to the progressive neuronal damage. Among the factors measured, the production of extracellular superoxide was the most prominent. NADPH oxidase inhibitor, apocynin, attenuated MPTP-induced dopaminergic neurodegeneration only in the presence of glia. More importantly, dopaminergic neurons from mice lacking NADPH oxidase, a key enzyme for superoxide production in immune cells, are significantly more resistant to MPTP neurotoxicity than those from wild-type controls, and microglia dictate the resistance. This study demonstrates that reactive microgliosis triggered by MPTP-induced neuronal injury and NADPH oxidase-mediated superoxide production in microglia constitute an integral component of MPTP neurotoxicity. This study also suggests that NADPH oxidase may be a promising target for therapeutic interventions in Parkinson's disease.	NIEHS, Neuropharmacol Sect, Lab Pharmacol & Chem, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Liu, B (corresponding author), Univ Florida, Coll Pharm, Dept Pharmacodynam, POB 100487 HSC, Gainesville, FL 32610 USA.	liu@cop.ufl.edu	gao, huiming/C-8454-2012; Hong, Jau-shyong/F-1920-2019; liu, Bin/A-7695-2009	Hong, Jau-shyong/0000-0002-3056-8401; 				Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; BANATI RB, 1993, GLIA, V9, P199, DOI 10.1002/glia.440090305; BECKMAN JS, 1993, NATURE, V364, P584, DOI 10.1038/364584a0; Castano A, 1998, J NEUROCHEM, V70, P1584; CHAN P, 1991, J NEUROCHEM, V57, P348, DOI 10.1111/j.1471-4159.1991.tb02134.x; CHAO CC, 1992, J IMMUNOL, V149, P2736; DAWSON TM, 1994, J NEUROSCI, V14, P5147; de Yebenes J G, 1988, J Neural Transm Suppl, V27, P141; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Feng ZH, 2002, NEUROSCI LETT, V329, P354, DOI 10.1016/S0304-3940(02)00704-8; Fleckenstein AE, 1997, EUR J PHARMACOL, V334, P111, DOI 10.1016/S0014-2999(97)01175-8; FUKUI T, 1995, BBA-BIOENERGETICS, V1231, P215, DOI 10.1016/0005-2728(95)00098-4; Gao HM, 2002, J NEUROSCI, V22, P782, DOI 10.1523/JNEUROSCI.22-03-00782.2002; Gao HM, 2002, J NEUROCHEM, V81, P1285, DOI 10.1046/j.1471-4159.2002.00928.x; Gayle DA, 2002, DEV BRAIN RES, V133, P27, DOI 10.1016/S0165-3806(01)00315-7; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Hanson GR, 1998, ANN NY ACAD SCI, V844, P103, DOI 10.1111/j.1749-6632.1998.tb08225.x; Hao AJ, 2002, NEUROSCIENCE, V112, P889, DOI 10.1016/S0306-4522(02)00144-6; HASEGAWA E, 1990, BIOCHEM BIOPH RES CO, V170, P1049, DOI 10.1016/0006-291X(90)90498-C; Hunot S, 1999, J NEUROSCI, V19, P3440; Hunot S, 1996, NEUROSCIENCE, V72, P355, DOI 10.1016/0306-4522(95)00578-1; JACKSONLEWIS V, 1995, NEURODEGENERATION, V4, P257, DOI 10.1016/1055-8330(95)90015-2; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kay JN, 2000, DEV NEUROSCI-BASEL, V22, P56, DOI 10.1159/000017427; Kim WG, 2000, J NEUROSCI, V20, P6309, DOI 10.1523/JNEUROSCI.20-16-06309.2000; Klegeris A, 2002, NEUROBIOL AGING, V23, P787, DOI 10.1016/S0197-4580(02)00021-0; KOSTIC V, 1991, NEUROLOGY, V41, P202, DOI 10.1212/WNL.41.2_Part_1.202; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Liberatore GT, 1999, NAT MED, V5, P1403; Liu B, 2000, J PHARMACOL EXP THER, V295, P125; Liu B, 2000, NEUROSCIENCE, V97, P749, DOI 10.1016/S0306-4522(00)00057-9; Liu B, 2003, J PHARMACOL EXP THER, V304, P1, DOI 10.1124/jpet.102.035048; Liu B, 2002, ANN NY ACAD SCI, V962, P318, DOI 10.1111/j.1749-6632.2002.tb04077.x; Liu B, 2001, J NEUROCHEM, V77, P182, DOI 10.1046/j.1471-4159.2001.t01-1-00216.x; McGeer PL, 1995, BRAIN RES REV, V21, P195, DOI 10.1016/0165-0173(95)00011-9; MYTILINEOU C, 1984, SCIENCE, V225, P529, DOI 10.1126/science.6610939; NAGATSU T, 2000, J NEURAL TRANSM-SUPP, P77290; Noh KM, 2000, J NEUROSCI, V20; PARESHERBUTE N, 1988, DEV BRAIN RES, V40, P89, DOI 10.1016/0165-3806(88)90011-9; Park SU, 2002, J NEUROSCI, V22, P4399, DOI 10.1523/JNEUROSCI.22-11-04399.2002; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Quinn NP, 1998, NEUROLOGY, V51, pS25, DOI 10.1212/WNL.51.2_Suppl_2.S25; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sriram K, 2002, FASEB J, V16, P1474, DOI 10.1096/fj.02-0216fje; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Tammariello SP, 2000, J NEUROSCI, V20; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Vila M, 2001, CURR OPIN NEUROL, V14, P483, DOI 10.1097/00019052-200108000-00009; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002	54	241	252	0	16	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11								10.1096/fj.03-0109fje	http://dx.doi.org/10.1096/fj.03-0109fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897068				2022-12-28	WOS:000185345100026
J	Valente, RC; Capella, LS; Monteiro, RQ; Rumjanek, VM; Lopes, AG; Capella, MAM				Valente, RC; Capella, LS; Monteiro, RQ; Rumjanek, VM; Lopes, AG; Capella, MAM			Mechanisms of ouabain toxicity	FASEB JOURNAL			English	Article						hypertension; glutathione; reactive oxygen species; apoptosis; necrosis	GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; PLASMA-MEMBRANE DEPOLARIZATION; ACTIVATED PROTEIN-KINASES; RATIO BLOCKS APOPTOSIS; SIGNAL-TRANSDUCTION; NA+/K+-ATPASE; ALZHEIMERS-DISEASE; ENDOTHELIAL-CELLS; CARDIAC MYOCYTES	The suggested involvement of ouabain in hypertension raised the need for a better understanding of its cellular action, but the mechanisms of ouabain toxicity are only now being uncovered. In the present study, we show that reduced glutathione (GSH) protected ouabain-sensitive (OS) cells from ouabain-induced toxicity and that the inhibition of GSH synthesis by D, L-buthionine-(S, R)-sulfoximine (BSO) sensitized ouabain-resistant (OR) cells. We could not observe formation of (OH)-O-. or H2O2, but there was an increase in O-2(.-) only in OS cells. Unexpectedly, an increased number of OR cells depolarized after treatment with ouabain, and BSO blocked this depolarization. Moreover, GSH increased ouabain-induced depolarization in OS cells. A sustained increase in tyrosine phosphorylation (P-Tyr) and Ras expression was observed after treatment of OS cells, and GSH prevented it. Conversely, BSO induced P-Tyr and Ras expression in ouabain-treated OR cells. The results obtained have three major implications: There is no direct correlation between membrane depolarization and ouabain-induced cell death; ouabain toxicity is not directly related to its classical action as a Na+, K+-ATPase inhibitor but seems to be associated to signal transduction, and GSH plays a major role in preventing ouabain-induced cell death.	Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Bioquim Med, Inst Ciencias Biomed, BR-21949900 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Dept Clin Med, BR-21949900 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Capella, MAM (corresponding author), Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, CCS, Bloco G, BR-21949900 Rio De Janeiro, Brazil.	capella@bioqmed.ufrj.br	Capella, Marcia/F-1097-2013; Lopes, Anibal/C-4880-2013; Monteiro, Robson/GRX-0672-2022; FISIOLOGIA, PG/C-5362-2013; Valente, Raphael/ABH-7796-2020; Rumjanek, Vivian Mary/V-8741-2019; DE QUEIROZ MONTEIRO, ROBSON/B-8007-2014; de Queiroz Monteiro, Robson/M-7097-2019	Capella, Marcia/0000-0001-8407-9235; Monteiro, Robson/0000-0002-5260-2332; Valente, Raphael/0000-0001-5041-2343; 				Balestrino M, 1999, BRAIN RES, V838, P37, DOI 10.1016/S0006-8993(99)01674-1; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; BOLIVAR JJ, 1987, AM J PHYSIOL, V253, pC151, DOI 10.1152/ajpcell.1987.253.1.C151; Bortner CD, 2001, J BIOL CHEM, V276, P4304, DOI 10.1074/jbc.M005171200; Botella JA, 2003, MOL BIOL CELL, V14, P241, DOI 10.1091/mbc.E02-05-0297; Capella LS, 2002, ARCH BIOCHEM BIOPHYS, V406, P65, DOI 10.1016/S0003-9861(02)00408-3; Capella LS, 2001, BBA-GEN SUBJECTS, V1526, P293, DOI 10.1016/S0304-4165(01)00144-1; Chen CY, 2003, ARCH TOXICOL, V77, P123, DOI 10.1007/s00204-002-0427-6; Chueh SC, 2001, J UROLOGY, V166, P347, DOI 10.1016/S0022-5347(05)66157-5; CLARK S, 1993, BIOCHEM J, V292, P217, DOI 10.1042/bj2920217; Contreras RG, 1999, J CELL SCI, V112, P4223; CONTRERAS RG, 1995, J MEMBRANE BIOL, V145, P305; CONTRERAS RG, 1995, J MEMBRANE BIOL, V145, P295; Emerit I, 1996, P NATL ACAD SCI USA, V93, P12799, DOI 10.1073/pnas.93.23.12799; Filipe P, 1999, MOL MED, V5, P517, DOI 10.1007/BF03401979; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; Haas A, 2002, J BIOL CHEM, V277, P18694, DOI 10.1074/jbc.M111357200; Haas M, 2000, J BIOL CHEM, V275, P27832; HAGEN TM, 1988, KIDNEY INT, V34, P74, DOI 10.1038/ki.1988.147; Hamlyn JM, 1996, J HYPERTENS, V14, P151, DOI 10.1097/00004872-199602000-00002; Ho CK, 2000, EUR J CELL BIOL, V79, P765, DOI 10.1078/0171-9335-00091; Janaky R, 1999, J NEUROCHEM, V73, P889, DOI 10.1046/j.1471-4159.1999.0730889.x; Kajikawa M, 2002, DIABETES, V51, P2522, DOI 10.2337/diabetes.51.8.2522; Kannan R, 1999, J NEUROCHEM, V73, P390, DOI 10.1046/j.1471-4159.1999.0730390.x; Kannan R, 1996, J BIOL CHEM, V271, P9754, DOI 10.1074/jbc.271.16.9754; KELLY RA, 1993, J AM COLL CARDIOL, V22, pA107, DOI 10.1016/0735-1097(93)90472-D; Kitanaka C, 2002, J NATL CANCER I, V94, P358; Kometiani P, 1998, J BIOL CHEM, V273, P15249, DOI 10.1074/jbc.273.24.15249; Kurashina T, 1996, CLIN SCI, V91, P497, DOI 10.1042/cs0910497; Liu J, 2000, J BIOL CHEM, V275, P27838; Luth HJ, 2000, BRAIN RES, V852, P45, DOI 10.1016/S0006-8993(99)02178-2; Mann CL, 2001, ENDOCRINOLOGY, V142, P5059, DOI 10.1210/en.142.12.5059; Manunta P, 1999, HYPERTENSION, V34, P450, DOI 10.1161/01.HYP.34.3.450; Manunta P, 2001, HYPERTENSION, V37, P472, DOI 10.1161/01.HYP.37.2.472; Manunta P, 2000, HYPERTENS RES, V23, pS77, DOI 10.1291/hypres.23.Supplement_S77; Nemeth I, 2001, FREE RADICAL BIO MED, V30, P715, DOI 10.1016/S0891-5849(00)00516-5; Olej B, 1998, BIOSCIENCE REP, V18, P1, DOI 10.1023/A:1022259832207; Orlov SN, 1999, J BIOL CHEM, V274, P16545, DOI 10.1074/jbc.274.23.16545; Orlov SN, 2000, HYPERTENSION, V35, P1062, DOI 10.1161/01.HYP.35.5.1062; Pchejetski D, 2003, BIOCHEM BIOPH RES CO, V301, P735, DOI 10.1016/S0006-291X(02)03002-4; POTAPOVA TV, 1990, FEBS LETT, V262, P69, DOI 10.1016/0014-5793(90)80156-D; POU S, 1993, ANAL BIOCHEM, V212, P85, DOI 10.1006/abio.1993.1295; Rigacci S, 1997, BIOCHEM J, V324, P791, DOI 10.1042/bj3240791; Seres T, 2000, J IMMUNOL, V165, P3333, DOI 10.4049/jimmunol.165.6.3333; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Soler RM, 1998, J NEUROSCI, V18, P1230; Thamilselvan S, 2003, UROL RES, V31, P3, DOI 10.1007/s00240-002-0286-x; Vaziri ND, 2000, HYPERTENSION, V36, P142, DOI 10.1161/01.HYP.36.1.142; Ward SC, 2002, HYPERTENSION, V39, P536, DOI 10.1161/hy0202.103048; Wilhelm D, 1997, MOL CELL BIOL, V17, P4792, DOI 10.1128/MCB.17.8.4792; Xiao AY, 2002, J NEUROSCI, V22, P1350, DOI 10.1523/JNEUROSCI.22-04-01350.2002; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323; Yang JQ, 2002, MOL CARCINOGEN, V33, P206, DOI 10.1002/mc.10037; Yang JQ, 2001, FREE RADICAL BIO MED, V31, P520, DOI 10.1016/S0891-5849(01)00613-X; Zhang Z, 2001, ARCH BIOCHEM BIOPHYS, V392, P311, DOI 10.1006/abbi.2001.2464; Zwick E, 1999, J BIOL CHEM, V274, P20989, DOI 10.1074/jbc.274.30.20989	58	32	40	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1700	+		10.1096/fj.02-0937fje	http://dx.doi.org/10.1096/fj.02-0937fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958181				2022-12-28	WOS:000184471600010
J	Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA				Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA			T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells	FASEB JOURNAL			English	Article						activation-induced cell death; atopic dermatitis; cytokines; T cells; Th1/Th2	ACTIVATION-INDUCED APOPTOSIS; LYMPHOCYTE-ASSOCIATED ANTIGEN; HECA-452 EPITOPE; IN-SITU; DEATH; EXPRESSION; FAS; DERMATITIS; INDUCTION; RECEPTOR	T cells constitute a large population of cellular infiltrate in atopic/allergic inflammation and a dysregulated, Th2-biased peripheral immune response appears to be an important pathogenetic factor. In atopic dermatitis, circulating cutaneous lymphocyte-associated antigen-bearing (CLA(+)) CD45RO(+) T cells with skin-specific homing property represent an activated memory/effector T cell subset. They express high levels of Fas and Fas ligand and undergo activation-induced apoptosis. The freshly purified (CLA(+)) CD45RO(+) T cells of atopic individuals display distinct features of in vivo-triggered apoptosis such as procaspase degradation and active caspase-8 formation. In particular, the Th1 compartment of activated memory/effector T cells selectively undergoes activation-induced cell death, skewing the immune response toward surviving Th2 cells in atopic dermatitis patients. The apoptosis of circulating memory/effector T cells was confined to atopic individuals whereas non-atopic patients such as psoriasis, intrinsic-type asthma, contact dermatitis, intrinsic type of atopic dermatitis, bee venom allergic patients, and healthy controls showed no evidence for enhanced T cell apoptosis in vivo. These results define a novel mechanism for peripheral Th2 response in atopic diseases.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Istanbul Univ, Expt Med Res Inst, TR-34280 Istanbul, Turkey; Clin Dermatol & Allergy, CH-7270 Davos, Switzerland	Swiss Institute of Allergy & Asthma Research; Istanbul University	Akdis, CA (corresponding author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.unizh.ch	Akdis, Cezmi/AAV-4844-2020; kucuksezer, umut/AAD-5168-2020	Akdis, Cezmi/0000-0001-8020-019X; 				ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; HANIFIN JM, 1980, ACTA DERM-VENEREOL S, V92, P44, DOI [10.2340/00015555924447, DOI 10.2340/00015555924447]; Hunger RE, 1999, BRIT J DERMATOL, V141, P565; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Ledru E, 1998, J IMMUNOL, V160, P3194; Li XC, 2000, J IMMUNOL, V164, P1193, DOI 10.4049/jimmunol.164.3.1193; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MULLER G, 1994, J CLIN INVEST, V94, P1799, DOI 10.1172/JCI117528; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ng TTC, 1997, J IMMUNOL, V158, P2984; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; PICKER LJ, 1990, AM J PATHOL, V136, P1053; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; SHYRTE J, 1995, NATURE, V373, P444; Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WALKER C, 1992, AM REV RESPIR DIS, V146, P109, DOI 10.1164/ajrccm/146.1.109; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Yawalkar N, 2000, EUR J IMMUNOL, V30, P491, DOI 10.1002/1521-4141(200002)30:2<491::AID-IMMU491>3.3.CO;2-8; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	55	134	147	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1026	1035		10.1096/fj.02-1070com	http://dx.doi.org/10.1096/fj.02-1070com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773485				2022-12-28	WOS:000183818000006
J	Pakneshan, P; Xing, RHM; Rabbani, SA				Pakneshan, P; Xing, RHM; Rabbani, SA			Methylation status of uPA promoter as a molecular mechanism regulating prostate cancer invasion and growth in vitro and in vivo	FASEB JOURNAL			English	Article						urokinase plasminogen activator; CpG dinucleotides; MSP	UROKINASE PLASMINOGEN-ACTIVATOR; TUMOR-SUPPRESSOR GENE; DNA METHYLATION; BREAST-CANCER; EXPRESSION; RECEPTOR; HYPOMETHYLATION; CELLS; METASTASIS; CARCINOMAS	Urokinase plasminogen activator (uPA) promotes tumor invasion and metastasis in several malignancies including prostate cancer, one of the most commonly detected male cancers that result in a high incidence of mortality. In the present study we have examined the differential regulation of uPA gene expression in different stages of prostate cancer by DNA methylation. We determined levels of uPA expression in normal prostate epithelial cells (PrEC) and in hormone-responsive (LNCaP) and -insensitive (PC-3) prostate cancer cell lines. We found that uPA is expressed only in the highly invasive PC-3 cells where the uPA promoter is unmethylated. The lack of uPA expression in PrEC and LNCaP cells, where uPA promoter is highly methylated, is due to suppression of uPA gene transcription by DNA methylation. Treatment of LNCaP cells with 5'-azacytidine, a potent demethylating agent, resulted in induction of uPA mRNA expression, uPA activity, and higher invasive capacity in vitro. Additionally, a marked increase in tumor volume was observed after inoculation of these cells into the flank of male BALB/c (nu/nu) mice. Collectively these studies have demonstrated that DNA methylation is the underlying molecular mechanism responsible for uPA gene silencing in normal and early stages of prostate cancer, which has a direct effect on tumor cell invasion and growth in vitro and in vivo.	McGill Univ, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Ctr Hlth, Dept Oncol, Montreal, PQ H3A 1A1, Canada	McGill University; McGill University	Rabbani, SA (corresponding author), McGill Univ, Ctr Hlth, Dept Med, 687 Pine Ave W,Room H4-67, Montreal, PQ H3A 1A1, Canada.	shafaat.rabbani@mcgill.ca		rabbani, shafaat/0000-0001-5594-3899				Ahuja N, 1997, CANCER RES, V57, P3370; Altschmied J, 1997, BIOL CHEM, V378, P1457, DOI 10.1515/bchm.1997.378.12.1457; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; Denmeade SR, 2002, NAT REV CANCER, V2, P389, DOI 10.1038/nrc801; Duffy MJ, 1996, ENZYME PROTEIN, V49, P85, DOI 10.1159/000468618; FEINBERG AP, 1983, BIOCHEM BIOPH RES CO, V111, P47, DOI 10.1016/S0006-291X(83)80115-6; GOELZ SE, 1985, SCIENCE, V228, P187, DOI 10.1126/science.2579435; GRAFF JR, 1995, CANCER RES, V55, P5195; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; GUO Y, 2002, J BIOL CHEM     0826; Guo YJ, 2000, FASEB J, V14, P1400, DOI 10.1096/fj.14.10.1400; HENDERSON BE, 1988, CANCER RES, V48, P246; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HIENERT G, 1988, J UROLOGY, V140, P1466, DOI 10.1016/S0022-5347(17)42074-X; Jarrard DF, 1997, GENE CHROMOSOME CANC, V19, P90, DOI 10.1002/(SICI)1098-2264(199706)19:2<90::AID-GCC4>3.0.CO;2-V; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; KIRCHHEIMER J, 1984, BIOCHIM BIOPHYS ACTA, V797, P256, DOI 10.1016/0304-4165(84)90129-6; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; OHTANIFUJITA N, 1993, ONCOGENE, V8, P1063; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Rabbani S A, 2001, Surg Oncol Clin N Am, V10, P393; Rabbani SA, 1998, INT J ONCOL, V12, P911; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; Slack A, 2002, J GENE MED, V4, P381, DOI 10.1002/jgm.288; Szyf M, 2002, METHODS, V27, P184, DOI 10.1016/S1046-2023(02)00073-7; SZYF M, 1994, TRENDS PHARMACOL SCI, V15, P233, DOI 10.1016/0165-6147(94)90317-4; Szyf M, 2001, PROG NUCLEIC ACID RE, V69, P47, DOI 10.1016/S0079-6603(01)69044-5; VANDERKWAST TH, 1991, INT J CANCER, V48, P189, DOI 10.1002/ijc.2910480206; VASSALLI JD, 1994, NATURE, V370, P14, DOI 10.1038/370014a0; VERDE P, 1988, NUCLEIC ACIDS RES, V16, P10699, DOI 10.1093/nar/16.22.10699; WATT PM, 2000, GENE CHROMOSOME CANC, V29, P371; Xing RH, 1999, INT J CANCER, V81, P443, DOI 10.1002/(SICI)1097-0215(19990505)81:3<443::AID-IJC19>3.0.CO;2-T; Xing RH, 1997, CANCER RES, V57, P3585; Xing RH, 1996, INT J CANCER, V67, P423, DOI 10.1002/(SICI)1097-0215(19960729)67:3<423::AID-IJC18>3.0.CO;2-8	37	78	89	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1081	1088		10.1096/fj.02-0973com	http://dx.doi.org/10.1096/fj.02-0973com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773490				2022-12-28	WOS:000183818000011
J	Gilroy, DW; Newson, J; Sawmynaden, PA; Willoughby, DA; Croxtall, JD				Gilroy, DW; Newson, J; Sawmynaden, PA; Willoughby, DA; Croxtall, JD			A novel role for phospholipase A(2) isoforms in the checkpoint control of acute inflammation	FASEB JOURNAL			English	Article						resolution; cyclooxygenase; lipoxygenase; arachidonic acid; eicosanoids	PLATELET-ACTIVATING-FACTOR; ARACHIDONIC-ACID RELEASE; PERITONEAL-MACROPHAGES; HUMAN-MONOCYTES; PHAGOCYTOSIS; BIOSYNTHESIS; CELLS; GLUCOCORTICOIDS; CYCLOOXYGENASE; NEUTROPHILS	Acute inflammation can be considered in terms of a series of checkpoints where each phase of cellular influx, persistence, and clearance is controlled by endogenous stop and go signals. It is becoming increasingly apparent that in addition to initiating the inflammatory response, eicosanoids may also mediate resolution. This suggests there are two phases of arachidonic acid release: one at onset for the generation of proinflammatory eicosanoids and one at resolution for the synthesis of proresolving eicosanoids. What is unclear is the identity of the phospholipase (PLA(2)) isoforms involved in this biphasic release of arachidonic acid. We show here that type VI iPLA(2) drives the onset of acute pleurisy through the synthesis of PGE(2), LTB4, PAF, and IL-1beta. However, during resolution there is a switch to a sequential induction of first sPLA(2) (types IIa and V) that mediates the release of PAY and lipoxin A, which, in turn, are responsible for the subsequent induction of type IV cPLA(2) that mediates the release of arachidonic acid for the synthesis of proresolving prostaglandins. This study is the first of its kind to address the respective roles of PLA(2) isoforms in acute resolving inflammation and to identify type VI iPLA(2) as a potentially selective target for the treatment of inflammatory diseases.	St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England; St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Biochem Pharmacol, London EC1M 6BQ, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Gilroy, DW (corresponding author), St Bartholomews & Royal London Sch Med & Dent, William Harvey Res Inst, Dept Expt Pathol, London EC1M 6BQ, England.	d.w.gilroy@qmul.ac.uk	Gilroy, Derek/AAP-7227-2020; Gilroy, Derek W/C-2588-2009	Gilroy, Derek/0000-0003-3476-0844; 				Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Balsinde J, 1996, J BIOL CHEM, V271, P31937, DOI 10.1074/jbc.271.50.31937; Balsinde J, 1997, J BIOL CHEM, V272, P16069, DOI 10.1074/jbc.272.26.16069; BONVENTRE JV, 1992, J AM SOC NEPHROL, V3, P128; BUSSOLINO F, 1989, J BIOL CHEM, V264, P21711; Choudhury QG, 2000, BRIT J PHARMACOL, V131, P255, DOI 10.1038/sj.bjp.0703573; CROXTALL JD, 1995, BIOCHEM PHARMACOL, V50, P465, DOI 10.1016/0006-2952(95)00156-T; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Goulding NJ, 1998, INFLAMM RES, V47, pS158; HOFFMAN T, 1988, J IMMUNOL, V140, P3912; HOPE WC, 1993, AGENTS ACTIONS, V39, pC39, DOI 10.1007/BF01972714; Ichinose F, 2002, J CLIN INVEST, V109, P1493, DOI 10.1172/JCI200214294; ICHINOSE M, 1994, CELL IMMUNOL, V156, P508, DOI 10.1006/cimm.1994.1194; KENNEDY BP, 1995, J BIOL CHEM, V270, P22378, DOI 10.1074/jbc.270.38.22378; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; LENNARTZ MR, 1993, J LEUKOCYTE BIOL, V54, P389, DOI 10.1002/jlb.54.5.389; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Nagase T, 2000, NAT IMMUNOL, V1, P42, DOI 10.1038/76897; NAKANO T, 1990, J BIOL CHEM, V265, P12745; Naraba H, 1998, J IMMUNOL, V160, P2974; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Nowatzke W, 1998, ENDOCRINOLOGY, V139, P4073, DOI 10.1210/en.139.10.4073; Reddy ST, 1997, J BIOL CHEM, V272, P3231, DOI 10.1074/jbc.272.6.3231; SERHAN CN, 1994, BBA-LIPID LIPID MET, V1212, P1, DOI 10.1016/0005-2760(94)90185-6; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; Takano T, 2000, PROSTAG OTH LIPID M, V60, P15, DOI 10.1016/S0090-6980(99)00033-7; The Joint Committee of the Medical Research Council and Nuffield Foundation on Clinical Trials of Cortisone, 1959, ANN RHEUM DIS, V18, P173; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Walev I, 2000, J IMMUNOL, V164, P5120, DOI 10.4049/jimmunol.164.10.5120; WILLIAMS KI, 1988, J PATHOL, V156, P101, DOI 10.1002/path.1711560204; Winstead MV, 2000, BBA-MOL CELL BIOL L, V1488, P28, DOI 10.1016/S1388-1981(00)00107-4; Wolf MJ, 1997, J BIOL CHEM, V272, P1522, DOI 10.1074/jbc.272.3.1522; Yedgar S, 2000, BBA-MOL CELL BIOL L, V1488, P182, DOI 10.1016/S1388-1981(00)00120-7	35	145	150	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					489	498		10.1096/fj.03-0837com	http://dx.doi.org/10.1096/fj.03-0837com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003994				2022-12-28	WOS:000220522800041
J	Louzada, PR; Lima, ACP; Mendonca-Silva, DL; Noel, F; De Mello, FG; Ferreira, ST				Louzada, PR; Lima, ACP; Mendonca-Silva, DL; Noel, F; De Mello, FG; Ferreira, ST			Taurine prevents the neurotoxicity of beta-amyloid and glutamate receptor agonists: activation of GABA receptors and possible implications for Alzheimer's disease and other neurological disorders	FASEB JOURNAL			English	Article						amyloid; neuroprotection	EXCITATORY AMINO-ACIDS; BLOOD-BRAIN-BARRIER; LIPID-PEROXIDATION; NEURONAL DEATH; HIPPOCAMPAL-NEURONS; CALCIUM HOMEOSTASIS; IN-VITRO; PEPTIDE; RETINA; EXCITOTOXICITY	Alzheimer's disease (AD) and several other neurological disorders have been linked to the overactivation of glutamatergic transmission and excitotoxicity as a common pathway of neuronal injury. The beta-amyloid peptide (Abeta) is centrally related to the pathogenesis of AD, and previous reports have demonstrated that the blockade of glutamate receptors prevents Abeta-induced neuronal death. We show that taurine, a beta-amino acid found at high concentrations in the brain, protects chick retinal neurons in culture against the neurotoxicity of Abeta and glutamate receptor agonists. The protective effect of taurine is not mediated by interaction with glutamate receptors, as demonstrated by binding studies using radiolabeled glutamate receptor ligands. The neuroprotective action of taurine is blocked by picrotoxin, an antagonist of GABA(A) receptors. GABA and the GABA(A) receptor agonists phenobarbital and melatonin also protect neurons against Abeta-induced neurotoxicity. These results suggest that activation of GABA receptors decreases neuronal vulnerability to excitotoxic damage and that pharmacological manipulation of the excitatory and inhibitory neurotransmitter tonus may protect neurons against a variety of insults. GABAergic transmission may represent a promising target for the treatment of AD and other neurological disorders in which excitotoxicity plays a relevant role.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Farmacol Basica & Clin, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Biofis Carlos Chagas Filho, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro	Ferreira, ST (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	ferreira@bioqmed.uf.br	Noël, François/C-3402-2009; Paula-Lima, Andrea/I-2537-2013; Ferreira, Sergio/AAZ-1576-2020; nikkhah, elham/M-6142-2017	Noël, François/0000-0001-6813-1347; Paula-Lima, Andrea/0000-0002-0466-7561; Ferreira, Sergio/0000-0001-7160-9866; 				Abel KM, 2003, NEUROPHARMACOLOGY, V44, P729, DOI 10.1016/S0028-3908(03)00073-X; Alvarez A, 1998, J NEUROSCI, V18, P3213; ARIAS C, 1995, J NEUROSCI RES, V41, P561, DOI 10.1002/jnr.490410416; Balla A, 2001, NEUROPSYCHOPHARMACOL, V25, P157, DOI 10.1016/S0893-133X(01)00230-5; Behrens PF, 2002, BRAIN, V125, P1908, DOI 10.1093/brain/awf180; BENRABH H, 1995, BRAIN RES, V692, P57, DOI 10.1016/0006-8993(95)00648-A; Birdsall T C, 1998, Altern Med Rev, V3, P128; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Butterfield DA, 2002, NEUROBIOL AGING, V23, P655; Cluskey S, 2001, J CLIN PATHOL-MOL PA, V54, P386; De Felice FG, 2001, FASEB J, V15, P1297, DOI 10.1096/fj.00-0676fje; del Olmo N, 2000, BRAIN RES, V864, P298, DOI 10.1016/S0006-8993(00)02211-3; DIFAZIO MC, 1992, NEUROLOGY, V42, P402, DOI 10.1212/WNL.42.2.402; El Idrissi A, 1999, J NEUROSCI, V19, P9459; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; Forloni G, 1997, J NEUROCHEM, V68, P319; FRANDSEN A, 1990, NEUROSCI LETT, V111, P233, DOI 10.1016/0304-3940(90)90374-I; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; Green AR, 2000, NEUROPHARMACOLOGY, V39, P1483, DOI 10.1016/S0028-3908(99)00233-6; GUIDOTTI A, 1972, J NEUROCHEM, V19, P431, DOI 10.1111/j.1471-4159.1972.tb01352.x; Harkany T, 2000, EUR J NEUROSCI, V12, P2735, DOI 10.1046/j.1460-9568.2000.00164.x; Hassel B, 2001, EPILEPSY RES, V43, P153, DOI 10.1016/S0920-1211(00)00196-0; Holden C, 2003, SCIENCE, V300, P1866, DOI 10.1126/science.300.5627.1866; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Jevtovic-Todorovic V, 2001, BRAIN RES, V913, P185, DOI 10.1016/S0006-8993(01)02800-1; JOHNSTON GAR, 1980, J NEUROCHEM, V34, P241, DOI 10.1111/j.1471-4159.1980.tb04650.x; Keller JN, 1997, NEUROSCIENCE, V80, P685, DOI 10.1016/S0306-4522(97)00065-1; KIEBURTZ KD, 1991, ARCH NEUROL-CHICAGO, V48, P1281, DOI 10.1001/archneur.1991.00530240087028; KOWALL NW, 1992, NEUROBIOL AGING, V13, P537, DOI 10.1016/0197-4580(92)90053-Z; LAUNDERBACK CM, 1999, LIFE SCI, V650, P1977; Lima ACP, 2003, NEUROTOX RES, V5, P323, DOI 10.1007/BF03033152; LIMA L, 1993, J NEUROCHEM, V60, P2153, DOI 10.1111/j.1471-4159.1993.tb03500.x; Lima L, 1998, J NEUROSCI RES, V53, P377, DOI 10.1002/(SICI)1097-4547(19980801)53:3<377::AID-JNR12>3.0.CO;2-2; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lombardini JB, 1996, ADV EXP MED BIOL, V403, P343; Loureiro-dos-Santos NE, 2001, J NEUROCHEM, V77, P1136, DOI 10.1046/j.1471-4159.2001.00330.x; Louzada PR, 2001, NEUROSCI LETT, V301, P59, DOI 10.1016/S0304-3940(01)01585-3; MARK RJ, 1995, NEUROBIOL AGING, V16, P187, DOI 10.1016/0197-4580(94)00150-2; Matsuyama Y, 1983, Prog Clin Biol Res, V125, P461; MATTSON MP, 1992, J NEUROSCI, V12, P376, DOI 10.1523/jneurosci.12-02-00376.1992; Mattson MP, 2003, NEUROMOL MED, V3, P65, DOI 10.1385/NMM:3:2:65; MCBRIDE WJ, 1980, FED PROC, V39, P2701; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; NAGELHUS EA, 1993, NEUROSCIENCE, V54, P615, DOI 10.1016/0306-4522(93)90233-6; Noda M, 1999, NEUROSCIENCE, V92, P1465, DOI 10.1016/S0306-4522(99)00036-6; O'Byrne MB, 2000, J NEUROCHEM, V74, P2087, DOI 10.1046/j.1471-4159.2000.0742087.x; OKAMOTO K, 1983, BRAIN RES, V259, P319, DOI 10.1016/0006-8993(83)91266-0; PIKE CJ, 1991, BRAIN RES, V563, P311, DOI 10.1016/0006-8993(91)91553-D; POMARA N, 1992, AM J PSYCHIAT, V149, P251; Rodrigues CMP, 2001, BIOCHEM BIOPH RES CO, V281, P468, DOI 10.1006/bbrc.2001.4370; Saransaari P, 1997, NEUROSCIENCE, V79, P847, DOI 10.1016/S0306-4522(97)00038-9; Schwartz-Bloom RD, 2000, NEUROSCIENCE, V98, P471, DOI 10.1016/S0306-4522(00)00144-5; Selkoe DJ, 1999, NATURE, V399, pA23, DOI 10.1038/399a023; TADOLINI B, 1995, BIOCHEM BIOPH RES CO, V213, P820, DOI 10.1006/bbrc.1995.2203; Tamai I, 1995, BIOCHEM PHARMACOL, V50, P1783, DOI 10.1016/0006-2952(95)02046-2; Velasco I, 2002, J NEUROSCI RES, V67, P406, DOI 10.1002/jnr.10114; Zhao P, 1999, NEUROSCI LETT, V268, P25, DOI 10.1016/S0304-3940(99)00373-0	57	182	191	1	30	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					511	518		10.1096/fj.03-0739com	http://dx.doi.org/10.1096/fj.03-0739com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003996				2022-12-28	WOS:000220522800043
J	Stolen, CM; Madanat, R; Marti, L; Kari, S; Yegutkin, GG; Sariola, H; Zorzano, A; Jalkanen, S				Stolen, CM; Madanat, R; Marti, L; Kari, S; Yegutkin, GG; Sariola, H; Zorzano, A; Jalkanen, S			Semicarbazide-sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like complications	FASEB JOURNAL			English	Article						vascular adhesion protein-1; amine oxidase (copper-containing); transgene; obesity; vascular complications	VASCULAR ADHESION PROTEIN-1; STIMULATE GLUCOSE-TRANSPORT; SMOOTH-MUSCLE CELLS; HYDROGEN-PEROXIDE; ADVANCED GLYCATION; HEART-FAILURE; ADIPOSE-CELLS; MELLITUS; PLASMA; RATS	Semicarbazide-sensitive amine oxidases (SSAO) are copper-containing enzymes that oxidatively deaminate primary amines to produce hydrogen peroxide, ammonium, and specific aldehydes. Vascular adhesion protein-1 (VAP-1) is a cell surface and soluble molecule that possesses SSAO activity. VAP-1 protein, SSAO activity, and SSAO reaction products are elevated in the serum of patients with diabetes, congestive heart failure, and specific inflammatory liver diseases. By expressing human VAP-1/SSAO on mouse endothelial cells and subsequently in the serum, and by chronically treating the transgenic mice for 15 months with a high-fat diet and a physiological substrate for SSAO, methylamine, the in vivo roles of SSAO were assessed. The VAP-1 transgene increased the mouse body mass index and subcutaneous abdominal fat pad weights in a manner independent of food consumption. The transgene together with increased SSAO substrate availability enhanced glucose uptake in an SSAO-dependent manner. The increased SSAO activity also led to diabetes-like complications, including advanced glycation end product formation, elevated blood pressure, altered atherosclerosis progression, and nephropathy. These findings suggest that, although manipulation of VAP-1/SSAO has potential to serve as a therapeutic treatment in insulin-resistant conditions, care must be taken to fully understand its impact on obesity and vascular damage.	Univ Turku, MediCity Res Lab, FIN-20520 Turku, Finland; Natl Publ Hlth Inst, Turku, Finland; Univ Barcelona, Fac Biol, Dept Bioquim & Biol Mol, Barcelona, Spain; Univ Helsinki, Inst Biotechnol, Dev Biol Res Program, FIN-00014 Helsinki, Finland	University of Turku; Finland National Institute for Health & Welfare; University of Barcelona; University of Helsinki	Stolen, CM (corresponding author), Univ Turku, MediCity Res Lab, Tykistokatu 6A, FIN-20520 Turku, Finland.	craig.stolen@utu.fi	Zorzano, Antonio/R-5479-2018; Stolen, Craig Michael/ACQ-2892-2022; Yegutkin, Gennady G./K-3815-2014	Stolen, Craig Michael/0000-0002-5725-463X; Yegutkin, Gennady G./0000-0001-6684-7982				Abella A, 2003, DIABETES, V52, P1004, DOI 10.2337/diabetes.52.4.1004; AIHAUD G, 1992, ANNU REV NUTR, V12, P207; Boomsma F, 1997, CARDIOVASC RES, V33, P387, DOI 10.1016/S0008-6363(96)00209-X; BOOMSMA F, 1995, CLIN SCI, V88, P675, DOI 10.1042/cs0880675; Boomsma F, 2000, EUR HEART J, V21, P1859, DOI 10.1053/euhj.2000.2176; Boomsma F, 1999, DIABETOLOGIA, V42, P233, DOI 10.1007/s001250051143; BOOR PJ, 1992, TOXICOLOGY, V73, P251, DOI 10.1016/0300-483X(92)90067-O; Brownlee M, 2000, METABOLISM, V49, P9, DOI 10.1016/S0026-0495(00)80078-5; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; Deng YL, 1999, J CHROMATOGR SCI, V37, P317, DOI 10.1093/chromsci/37.9.317; Deyl Z, 1999, J CHROMATOGR A, V836, P161, DOI 10.1016/S0021-9673(98)00887-5; El Hadri K, 2002, ARTERIOSCL THROM VAS, V22, P89, DOI 10.1161/hq0102.101550; ELLIOTT J, 1991, RES VET SCI, V50, P334, DOI 10.1016/0034-5288(91)90134-A; Enrique-Tarancon G, 1998, J BIOL CHEM, V273, P8025, DOI 10.1074/jbc.273.14.8025; Enrique-Tarancon G, 2000, BIOCHEM J, V350, P171, DOI 10.1042/0264-6021:3500171; Fontana E, 2001, BIOCHEM J, V356, P769, DOI 10.1042/0264-6021:3560769; FUJIHARA CK, 1992, DIABETES, V41, P286, DOI 10.2337/diabetes.41.3.286; Gronvall-Nordquist JLE, 2001, J DIABETES COMPLICAT, V15, P250, DOI 10.1016/S1056-8727(01)00151-9; GUMA A, 1988, BIOCHEM J, V253, P625, DOI 10.1042/bj2530625; HAYES BE, 1990, RES COMMUN CHEM PATH, V69, P71; He CJ, 1996, J CLIN INVEST, V97, P1242, DOI 10.1172/JCI118539; HELANDER A, 1987, BIOCHEM PHARMACOL, V36, P3981, DOI 10.1016/0006-2952(87)90467-9; Karadi I, 2002, CLIN CHIM ACTA, V323, P139, DOI 10.1016/S0009-8981(02)00189-4; KATUSIC ZS, 1993, AM J PHYSIOL, V264, pH859, DOI 10.1152/ajpheart.1993.264.3.H859; Kurkijarvi R, 2000, GASTROENTEROLOGY, V119, P1096, DOI 10.1053/gast.2000.18163; Kurkijarvi R, 1998, J IMMUNOL, V161, P1549; Lyles GA, 1996, INT J BIOCHEM CELL B, V28, P259, DOI 10.1016/1357-2725(95)00130-1; Mahadev K, 2001, J BIOL CHEM, V276, P48662, DOI 10.1074/jbc.M105061200; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; Marti L, 1998, J PHARMACOL EXP THER, V285, P342; Marti L, 2001, DIABETES, V50, P2061, DOI 10.2337/diabetes.50.9.2061; Mathys KC, 2002, BIOCHEM BIOPH RES CO, V297, P863, DOI 10.1016/S0006-291X(02)02293-3; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; Mercier N, 2001, BIOCHEM J, V358, P335, DOI 10.1042/0264-6021:3580335; Meszaros Z, 1999, EUR J DRUG METAB PH, V24, P299, DOI 10.1007/BF03190036; Meszaros Z, 1999, METABOLISM, V48, P113, DOI 10.1016/S0026-0495(99)90019-7; MILLS E, 1993, AM J PHYSIOL, V264, pR73, DOI 10.1152/ajpregu.1993.264.1.R73; Morin N, 2001, J PHARMACOL EXP THER, V297, P563; Muzykantov VR, 2001, J CONTROL RELEASE, V71, P1, DOI 10.1016/S0168-3659(01)00215-2; Rodriguez-Martinez MA, 1998, BRIT J PHARMACOL, V125, P1329, DOI 10.1038/sj.bjp.0702200; Salmi M, 2002, AM J PATHOL, V161, P2255, DOI 10.1016/S0002-9440(10)64501-4; SASSYPRIGENT C, 1995, LAB INVEST, V73, P64; Seiler N, 2002, NEUROCHEM INT, V41, P189, DOI 10.1016/S0197-0186(02)00041-4; Vidrio H, 2000, GEN PHARMACOL-VASC S, V35, P195, DOI 10.1016/S0306-3623(01)00106-9; Wautier JL, 2001, DIABETES METAB, V27, P535; Yang M, 2002, BIOTECHNOL PROGR, V18, P129, DOI 10.1021/bp0101334; Yang ZW, 1998, EUR J PHARMACOL, V344, P169, DOI 10.1016/S0014-2999(97)01576-8; YOUNG BA, 1995, KIDNEY INT, V47, P935, DOI 10.1038/ki.1995.139; YU PH, 1990, J PHARM PHARMACOL, V42, P882, DOI 10.1111/j.2042-7158.1990.tb07048.x; Yu PH, 1997, DIABETOLOGIA, V40, P1243, DOI 10.1007/s001250050816	50	94	105	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					702	+		10.1096/fj.03-0562fje	http://dx.doi.org/10.1096/fj.03-0562fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977883				2022-12-28	WOS:000220425000023
J	Nikawa, T; Ishidoh, K; Hirasaka, K; Ishihara, I; Ikemoto, M; Kano, M; Kominami, E; Nonaka, I; Ogawa, T; Adams, GR; Baldwin, KM; Yasui, N; Kishi, K; Takeda, S				Nikawa, T; Ishidoh, K; Hirasaka, K; Ishihara, I; Ikemoto, M; Kano, M; Kominami, E; Nonaka, I; Ogawa, T; Adams, GR; Baldwin, KM; Yasui, N; Kishi, K; Takeda, S			Skeletal muscle gene expression in space-flown rats	FASEB JOURNAL			English	Article						spaceflight; tail-suspension; denervation; microarray analysis; rat skeletal muscle	SPACEFLIGHT; MODEL; DEGRADATION; ACTIVATION; ATROPHY	Skeletal muscles are vulnerable to marked atrophy under microgravity. This phenomenon is due to the transcriptional alteration of skeletal muscle cells to weightlessness. To further investigate this issue at a subcellular level, we examined the expression of similar to26,000 gastrocnemius muscle genes in space-flown rats by DNA microarray analysis. Comparison of the changes in gene expression among spaceflight, tail-suspended, and denervated rats revealed that such changes were unique after spaceflight and not just an extension of simulated weightlessness. The microarray data showed two spaceflight-specific gene expression patterns: 1) imbalanced expression of mitochondrial genes with disturbed expression of cytoskeletal molecules, including putative mitochondria-anchoring proteins, A-kinase anchoring protein, and cytoplasmic dynein, and 2) up-regulated expression of ubiquitin ligase genes, MuRF-1, Cbl-b, and Siah-1A, which are rate-limiting enzymes of muscle protein degradation. Distorted expression of cytoskeletal genes during spaceflight resulted in dislocation of the mitochondria in the cell. Several oxidative stress-inducible genes were highly expressed in the muscle of spaceflight rats. We postulate that mitochondrial dislocation during spaceflight has deleterious effects on muscle fibers, leading to atrophy in the form of insufficient energy provision for construction and leakage of reactive oxygen species from the mitochondria.	Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan; Juntendo Univ, Sch Med, Dept Biochem, Tokyo 113, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mol Therapy, Tokyo, Japan; Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Ultrastruct Res, Tokyo, Japan; Univ Tokushima, Sch Med, Dept Orthopaed, Tokushima 7708503, Japan; Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92717 USA	Tokushima University; Juntendo University; National Center for Neurology & Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan; Tokushima University; University of California System; University of California Irvine	Nikawa, T (corresponding author), Univ Tokushima, Sch Med, Dept Nutr, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	nikawa@nutr.med.tokushima-u.ac.jp	Hirasaka, Katsuya/AAJ-7371-2021; Kominami, Eiki/D-3802-2009; Hirasaka, Katsuya/J-5283-2019	Hirasaka, Katsuya/0000-0003-2645-8450; Ikemoto-Uezumi, Madoka/0000-0003-2771-9851				Adams GR, 2000, J APPL PHYSIOL, V88, P904, DOI 10.1152/jappl.2000.88.3.904; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; CARLSON BM, 1977, TSITOLOGIYA, V39, P965; CARPENTER S, 1984, PATHOLOGY SKELETAL M, P149; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; CHOMCZYNSKI P, 1995, BIOTECHNIQUES, V19, P942; Cogoli A., 1989, LIFE SCI RES SPACE, V1105, P49; Gustafsson T, 1999, AM J PHYSIOL-HEART C, V276, pH679, DOI 10.1152/ajpheart.1999.276.2.H679; Hammond TG, 1999, NAT MED, V5, P359, DOI 10.1038/7331; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1097/00005768-200301000-00016; Ikemoto M, 2001, FASEB J, V15, P1279, DOI 10.1096/fj.00-0629fje; INOBE M, J APPL PHYSL, V92, P1936; JIANG B, 1993, J APPL PHYSIOL, V74, P527, DOI 10.1152/jappl.1993.74.2.527; KONDO H, 1992, AM J PHYSIOL, V262, pE583, DOI 10.1152/ajpendo.1992.262.5.E583; Lewis ML, 2001, FASEB J, V15, P1783, DOI 10.1096/fj.00-0820fje; MOREY ER, 1979, BIOSCIENCE, V29, P168, DOI 10.2307/1307797; Morey-Holton ER, 2002, J APPL PHYSIOL, V92, P1367, DOI 10.1152/japplphysiol.00969.2001; Musacchia X J, 1988, Exerc Sport Sci Rev, V16, P61; NOLTE J, 1972, J HISTOCHEM CYTOCHEM, V20, P567, DOI 10.1177/20.8.567; Pollard TD, 2003, NATURE, V422, P741, DOI 10.1038/nature01598; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; RILEY DA, 1990, FASEB J, V4, P84, DOI 10.1096/fasebj.4.1.2153085; van der Geld CWM, 1999, INT J COMPUT FLUID D, V13, P1, DOI 10.1080/10618569908940887; VIHKO V, 1978, HISTOCHEMISTRY, V57, P237, DOI 10.1007/BF00492083; Weller B, 1999, NEUROMUSCULAR DISORD, V9, P208, DOI 10.1016/S0960-8966(98)00130-8; Wheeler TC, 2002, J BIOL CHEM, V277, P10273, DOI 10.1074/jbc.M107857200	27	151	166	1	23	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					522	+		10.1096/fj.03-0419fje	http://dx.doi.org/10.1096/fj.03-0419fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14715702				2022-12-28	WOS:000188829300031
J	Iliev, AI; Stringaris, AK; Nau, R; Neumann, H				Iliev, AI; Stringaris, AK; Nau, R; Neumann, H			Neuronal injury mediated via stimulation of microglial toll-like receptor-9 (TLR9)	FASEB JOURNAL			English	Article						microglia, neurons; toll-like receptor-9; CpG-DNA; neurite damage; neuroinflammation; meningitis; TNF-alpha; NO	NITRIC-OXIDE; BACTERIAL-DNA; NEURODEGENERATIVE DISEASE; MULTIPLE-SCLEROSIS; INNATE IMMUNITY; AXONAL INJURY; CPG MOTIFS; ACTIVATION; CELLS; NEUROTOXICITY	Innate immune cells express toll-like receptor-9 (TLR9) and respond to unmethylated, CG dinucleotide motif-rich DNA released from bacteria during infection or endogenous cells during autoimmune tissue injury. Oligonucleotides containing CG dinucleotide (CpG-DNA) mimic the effect of unmethylated DNA and stimulate TLR9. CpG-DNA was cytotoxic to neurons in organotypic brain cultures. Neurotoxicity of CpG-DNA was mediated via microglial cells and started primarily from neurites as determined by time-lapse imaging of enhanced green fluorescent protein (EGFP)-transfected neurons. Cultured brain microglial cells expressed TLR9 and responded to CpG-DNA by production of the inflammatory mediators nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha). Blockade of NO synthase and TNF-alpha prevented damage of neurites and neurotoxicity of CpG-DNA. The data suggest that stimulation of microglia via TLR9 and subsequent release of NO and TNF-alpha is a major source of neurotoxicity in bacterial and autoimmune brain tissue injury.	Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; European Neurosci Inst Gottingen, Neuroimmunol Unit, D-37073 Gottingen, Germany	University of Gottingen	Nau, R (corresponding author), Univ Gottingen, Dept Neurol, Robert Koch Str 40, D-37075 Gottingen, Germany.	rnau@gwdg.de	Nau, Roland/F-8234-2015; Stringaris, Argyris/N-1135-2017; Neumann, Harald/A-9718-2010; Iliev, Asparouh/D-2222-2015	Neumann, Harald/0000-0002-5071-5202; 				Bal-Price A, 2001, J NEUROSCI, V21, P6480; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Bottcher T, 2003, NEUROSCI LETT, V344, P17, DOI 10.1016/S0304-3940(03)00404-X; CHAO CC, 1992, J IMMUNOL, V149, P2736; Chao CC, 1995, BRAIN BEHAV IMMUN, V9, P355, DOI 10.1006/brbi.1995.1033; Dalpke AH, 2002, J IMMUNOL, V168, P4854, DOI 10.4049/jimmunol.168.10.4854; DAWSON TM, 1994, J NEUROSCI, V14, P5147; DAWSON VL, 1994, NEUROPHARMACOLOGY, V33, P1425, DOI 10.1016/0028-3908(94)90045-0; Deng GM, 2001, J IMMUNOL, V167, P4616, DOI 10.4049/jimmunol.167.8.4616; Gerber J, 2001, EUR J CLIN MICROBIOL, V20, P490; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Ii M, 1996, BRAIN RES, V720, P93, DOI 10.1016/0006-8993(96)00156-4; Kingham PJ, 1999, J NEUROCHEM, V73, P538, DOI 10.1046/j.1471-4159.1999.0730538.x; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; Lehnardt S, 2003, P NATL ACAD SCI USA, V100, P8514, DOI 10.1073/pnas.1432609100; Malipiero U, 1999, EUR J IMMUNOL, V29, P3053, DOI 10.1002/(SICI)1521-4141(199910)29:10<3053::AID-IMMU3053>3.0.CO;2-I; Medana IM, 2002, AM J PATHOL, V160, P655, DOI 10.1016/S0002-9440(10)64885-7; Nau R, 2002, TRENDS NEUROSCI, V25, P38, DOI 10.1016/S0166-2236(00)02024-5; Neumann H, 1998, P NATL ACAD SCI USA, V95, P5779, DOI 10.1073/pnas.95.10.5779; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Neumann H, 2002, J NEUROSCI, V22, P854, DOI 10.1523/JNEUROSCI.22-03-00854.2002; Nguyen MD, 2002, NAT REV NEUROSCI, V3, P216, DOI 10.1038/nrn752; Perry VH, 2003, NAT REV NEUROSCI, V4, P103, DOI 10.1038/nrn1032; Peterson JW, 2001, ANN NEUROL, V50, P389, DOI 10.1002/ana.1123; Ronaghy A, 2002, J IMMUNOL, V168, P51, DOI 10.4049/jimmunol.168.1.51; Schluesener HJ, 2001, J NEUROIMMUNOL, V113, P89, DOI 10.1016/S0165-5728(00)00428-8; Sparwasser T, 1997, EUR J IMMUNOL, V27, P1671, DOI 10.1002/eji.1830270712; Takeshita S, 2001, NEUROREPORT, V12, P3029, DOI 10.1097/00001756-200110080-00010; Vinuesa CG, 2002, NATURE, V416, P595, DOI 10.1038/416595a; Wagner H, 1999, ADV IMMUNOL, V73, P329, DOI 10.1016/S0065-2776(08)60790-7; Wyss-Coray T, 2002, NEURON, V35, P419, DOI 10.1016/S0896-6273(02)00794-8	33	140	145	2	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					412	+		10.1096/fj.03-0670fje	http://dx.doi.org/10.1096/fj.03-0670fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688201				2022-12-28	WOS:000188067500007
J	Bezard, E; Baufreton, J; Owens, G; Crossman, AR; Dudek, H; Taupignon, A; Brotchie, JM				Bezard, E; Baufreton, J; Owens, G; Crossman, AR; Dudek, H; Taupignon, A; Brotchie, JM			Sonic hedgehog is a neuromodulator in the adult subthalamic nucleus	FASEB JOURNAL			English	Article						patched; Parkinson's disease; basal ganglia; rat; macaque	NEURONS IN-VITRO; PRIMATE MODELS; BASAL GANGLIA; HIGH-AFFINITY; PATCHED GENE; CELLS; EXPRESSION; RECEPTORS; INDUCTION; TRANSPORT	It is well established that members of the hedgehog family are involved in tissue patterning during development. We herein show that sonic hedgehog signaling molecules are differentially regulated by dopamine depletion in the basal ganglia of adult animals and specifically that sonic hedgehog levels are reduced in an animal model of Parkinson's disease. In addition, we show that sonic hedgehog protein inhibits electrical activity in the subthalamic nucleus, a key element of basal ganglia, within minutes of application. As the subthalamic nucleus is overactive in parkinsonism, we suggest that enhancement of sonic hedgehog signaling in the subthalamic nucleus may be of therapeutic value in Parkinson's disease.	Univ Victor Segalen, Basal Gang, F-33076 Bordeaux, France; Univ Victor Segalen, CNRS, UMR 5543, F-33076 Bordeaux, France; Univ Manchester, Sch Biol Sci, Div Neurosci, Manchester Movement Disorder Lab, Manchester M13 9PT, Lancs, England; Motac Neurosci Ltd, Manchester M15 6SE, Lancs, England; Curis Inc, Cambridge, MA USA; Toronto Western Hosp, Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada	UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Manchester; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Bezard, E (corresponding author), Univ Victor Segalen, Basal Gang, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	erwan.bezard@umr5543.u-bordeaux2.fr	Bezard, Erwan/A-8173-2008; Bezard, Erwan/ABD-5153-2021	Bezard, Erwan/0000-0002-0410-4638; Brotchie, Jonathan/0000-0003-2337-0816; Baufreton, Jerome/0000-0002-2623-6375; Taupignon, Anne/0000-0002-4662-7971				Baufreton J, 2001, J NEUROPHYSIOL, V86, P75, DOI 10.1152/jn.2001.86.1.75; Baufreton J, 2003, J NEUROSCI, V23, P816; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; Beurrier C, 1999, J NEUROSCI, V19, P599, DOI 10.1523/jneurosci.19-02-00599.1999; Bevan MD, 2002, J NEUROPHYSIOL, V87, P1348, DOI 10.1152/jn.00582.2001; Bevan MD, 2000, J NEUROPHYSIOL, V83, P3169, DOI 10.1152/jn.2000.83.5.3169; Bevan MD, 2002, TRENDS NEUROSCI, V25, P525, DOI 10.1016/S0166-2236(02)02235-X; Bezard E, 2001, J NEUROSCI, V21, P6853, DOI 10.1523/JNEUROSCI.21-17-06853.2001; Bezard E, 2001, NEUROSCIENCE, V103, P117, DOI 10.1016/S0306-4522(00)00546-7; Bezard E., 2001, FASEB J, DOI [10.1096: fj.00-0637fje, DOI 10.1096FJ.00-0637FJE]; Carstea ED, 1997, SCIENCE, V277, P228, DOI 10.1126/science.277.5323.228; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; Emond P, 1997, J MED CHEM, V40, P1366, DOI 10.1021/jm960795d; FENWICK EM, 1982, J PHYSIOL-LONDON, V331, P577, DOI 10.1113/jphysiol.1982.sp014393; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gross CE, 1999, PROG NEUROBIOL, V59, P509, DOI 10.1016/S0301-0082(99)00015-5; Guerineau NC, 1997, J PHYSIOL-LONDON, V500, P487, DOI 10.1113/jphysiol.1997.sp022035; Guilloteau D, 1998, NUCL MED BIOL, V25, P331, DOI 10.1016/S0969-8051(97)00224-2; Hahn H, 1996, J BIOL CHEM, V271, P12125, DOI 10.1074/jbc.271.21.12125; Henry B, 1999, EXP NEUROL, V155, P204, DOI 10.1006/exnr.1998.6996; Huang Z, 1996, CELL, V86, P411, DOI 10.1016/S0092-8674(00)80114-2; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Loftus SK, 1997, SCIENCE, V277, P232, DOI 10.1126/science.277.5323.232; Magill PJ, 2000, J NEUROSCI, V20, P820, DOI 10.1523/JNEUROSCI.20-02-00820.2000; MANEUF YP, 1995, BRAIN RES, V683, P102, DOI 10.1016/0006-8993(95)00358-W; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; Miao NN, 1997, J NEUROSCI, V17, P5891; MITCHELL IJ, 1989, NEUROSCIENCE, V32, P213, DOI 10.1016/0306-4522(89)90120-6; Motoyama J, 1998, NAT GENET, V18, P104, DOI 10.1038/ng0298-104; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NIKAIDO H, 1992, SCIENCE, V258, P936, DOI 10.1126/science.1279804; SANGER F, 1977, NATURE, V265, P687, DOI 10.1038/265687a0; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Takabatake T, 1997, FEBS LETT, V410, P485, DOI 10.1016/S0014-5793(97)00645-5; Traiffort E, 1999, EUR J NEUROSCI, V11, P3199, DOI 10.1046/j.1460-9568.1999.00777.x; Traiffort E, 2001, EUR J NEUROSCI, V14, P839, DOI 10.1046/j.0953-816x.2001.01708.x; vandenHeuvel M, 1996, NATURE, V382, P547, DOI 10.1038/382547a0; Wallace VA, 1999, DEVELOPMENT, V126, P2901; WANG MZ, 1995, NAT MED, V1, P1184, DOI 10.1038/nm1195-1184	42	24	25	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2337	+		10.1096/fj.03-0291fje	http://dx.doi.org/10.1096/fj.03-0291fje			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525941				2022-12-28	WOS:000186343300011
J	Stenham, DR; Campbell, JD; Sansom, MSP; Higgins, CF; Kerr, ID; Linton, KJ				Stenham, DR; Campbell, JD; Sansom, MSP; Higgins, CF; Kerr, ID; Linton, KJ			An atomic detail model for the human ATP binding cassette transporter P-glycoprotein derived from disulphide cross-linking and homology modeling	FASEB JOURNAL			English	Article						multidrug resistance; ABC transporter; membrane protein structure; ABCB1	RETRACTED ARTICLE. SEE; ABC TRANSPORTER; INTRAHEPATIC CHOLESTASIS; TRANSMEMBRANE SEGMENTS; CLOSED CONFORMATION; ELECTRON-MICROSCOPY; ESCHERICHIA-COLI; CATALYTIC CYCLE; NUCLEOTIDE; GENE	The multidrug resistance P-glycoprotein mediates the extrusion of chemotherapeutic drugs from cancer cells. Characterization of the drug binding and ATPase activities of the protein have made it the paradigm ATP binding cassette (ABC) transporter. P-glycoprotein has been imaged at low resolution by electron cryo-microscopy and extensively analyzed by disulphide cross-linking, but a high resolution structure solved ab initio remains elusive. Homology models of P-glycoprotein were generated using the structure of a related prokaryotic ABC transporter, the lipid A transporter MsbA, as a template together with structural data describing the dimer interface of the nucleotide binding domains (NBDs). The first model, which maintained the NBD:transmembrane domain (TMD) interface of MsbA, did not satisfy previously published cross-linking data. This suggests that either P-glycoprotein has a very different structure from MsbA or that the published E. coli MsbA structure does not reflect a physiological state. To distinguish these alternatives, we mapped the interface between the two TMDs of P-glycoprotein experimentally by chemical cross-linking of introduced triple-cysteine residues. Based on these data, a plausible atomic model of P-glycoprotein could be generated using the MsbA template, if the TMDs of MsbA are reoriented with respect to the NBDs. This model will be important for understanding the mechanism of P-glycoprotein and other ABC transporters.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, MRC, Ctr Clin Sci, London W12 0NN, England; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England	University of Nottingham; Imperial College London; University of Oxford	Kerr, ID (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.	ian.kerr@nottingham.ac.uk; kenneth.linton@csc.mrc.ac.uk	Sansom, Mark S.P./C-5157-2009; Kerr, Ian D/B-3803-2015	Sansom, Mark S.P./0000-0001-6360-7959; Kerr, Ian D/0000-0002-7544-8454				Allikmets R, 1997, NAT GENET, V15, P236, DOI 10.1038/ng0397-236; Blott EJ, 1999, EMBO J, V18, P6800, DOI 10.1093/emboj/18.23.6800; Campbell JD, 2003, BIOCHEMISTRY-US, V42, P3666, DOI 10.1021/bi027337t; Capener CE, 2000, BIOPHYS J, V78, P2929, DOI 10.1016/S0006-3495(00)76833-0; Chang G, 2001, SCIENCE, V293, P1793, DOI 10.1126/science.293.5536.1793; Chang G, 2003, J MOL BIOL, V330, P419, DOI 10.1016/S0022-2836(03)00587-4; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; Dixon PH, 2000, HUM MOL GENET, V9, P1209, DOI 10.1093/hmg/9.8.1209; Fetsch EE, 2002, P NATL ACAD SCI USA, V99, P9685, DOI 10.1073/pnas.152204499; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kerr ID, 2002, BBA-BIOMEMBRANES, V1561, P47, DOI 10.1016/S0304-4157(01)00008-9; Lee JY, 2002, J BIOL CHEM, V277, P40125, DOI 10.1074/jbc.M206871200; Locher KP, 2002, SCIENCE, V296, P1091, DOI 10.1126/science.1071142; Loo TW, 1997, J BIOL CHEM, V272, P20986, DOI 10.1074/jbc.272.34.20986; Loo TW, 2000, J BIOL CHEM, V275, P5253, DOI 10.1074/jbc.275.8.5253; Loo TW, 2002, J BIOL CHEM, V277, P41303, DOI 10.1074/jbc.C200484200; Loo TW, 2002, P NATL ACAD SCI USA, V99, P3511, DOI 10.1073/pnas.022049799; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Martin C, 2000, MOL PHARMACOL, V58, P624, DOI 10.1124/mol.58.3.624; Mourez M, 1997, EMBO J, V16, P3066, DOI 10.1093/emboj/16.11.3066; Mullenbach R, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.5.e70; Pascaud C, 1998, BIOCHEM J, V333, P351, DOI 10.1042/bj3330351; Qu Q, 2001, BIOCHEMISTRY-US, V40, P1413, DOI 10.1021/bi002035h; RIORDAN JR, 1989, SCIENCE, V245, P1066; Rodriguez R, 1998, BIOINFORMATICS, V14, P523, DOI 10.1093/bioinformatics/14.6.523; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Rosenberg MF, 1997, J BIOL CHEM, V272, P10685; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sansom MSP, 1998, BIOCHEM SOC T, V26, P509, DOI 10.1042/bst0260509; Sauna ZE, 2000, P NATL ACAD SCI USA, V97, P2515, DOI 10.1073/pnas.97.6.2515; Seigneuret M, 2003, J BIOL CHEM, V278, P30115, DOI 10.1074/jbc.M302443200; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Smith PC, 2002, MOL CELL, V10, P139, DOI 10.1016/S1097-2765(02)00576-2; Sorgen PL, 2002, P NATL ACAD SCI USA, V99, P14037, DOI 10.1073/pnas.182552199; Strautnieks SS, 1998, NAT GENET, V20, P233, DOI 10.1038/3034; Taylor AM, 2001, BRIT J PHARMACOL, V134, P1609, DOI 10.1038/sj.bjp.0704400; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	41	118	119	1	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2287	+		10.1096/fj.03-0107fje	http://dx.doi.org/10.1096/fj.03-0107fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563687				2022-12-28	WOS:000186343300030
J	Hsiai, TK; Cho, SK; Wong, PK; Ing, M; Salazar, A; Sevanian, A; Navab, M; Demer, LL; Ho, CM				Hsiai, TK; Cho, SK; Wong, PK; Ing, M; Salazar, A; Sevanian, A; Navab, M; Demer, LL; Ho, CM			Monocyte recruitment to endothelial cells in response to oscillatory shear stress	FASEB JOURNAL			English	Article						micro-electromechanical systems (MEMS); cell tracking velocimetry; shear stress sensors; endothelial cells; monocytes	CAROTID BIFURCATION; PULSATILE FLOW; ATHEROSCLEROSIS; HEMODYNAMICS; EXPRESSION; DYNAMICS; ADHESION; ERYTHROCYTES; MECHANISMS; LEUKOCYTES	Leukocyte recruitment to endothelial cells is a critical event in inflammatory responses. The spatial, temporal gradients of shear stress, topology, and outcome of cellular interactions that underlie these responses have so far been inferred from static imaging of tissue sections or studies of statically cultured cells. In this report, we developed micro-electromechanical systems (MEMS) sensors, comparable to a single endothelial cell (EC) in size, to link real-time shear stress with monocyte/EC binding kinetics in a complex flow environment, simulating the moving and unsteady separation point at the arterial bifurcation with high spatial and temporal resolution. In response to oscillatory shear stress (tau) at +/- 2.6 dyn/cm(2) at a time-averaged shear stress (tau(ave)) = 0 and 0.5 Hz, individual monocytes displayed unique to-and-fro trajectories undergoing rolling, binding, and dissociation with other monocyte, followed by solid adhesion on EC. Our study quantified individual monocyte/EC binding kinetics in terms of displacement and velocity profiles. Oscillatory flow induces up-regulation of adhesion molecules and cytokines to mediate monocyte/EC interactions over a dynamic range of shear stress +/- 2.6 dyn/cm(2) (P = 0.50, n = 10).	Univ So Calif, Sch Engn, Dept Biomed Engn, Los Angeles, CA 90089 USA; Univ So Calif, Sch Engn, Div Cardiovasc Med, Los Angeles, CA USA; Keck Sch Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Engn & Appl Sci, Dept Mech & Aerosp Engn, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90024 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of Southern California	Hsiai, TK (corresponding author), Univ So Calif, Sch Engn, Dept Biomed Engn, Olin Hall Engn 500, Los Angeles, CA 90089 USA.	hsiai@usc.edu	Wong, Pak Kin/A-7974-2012; Ho, Chih-Ming/I-6537-2012; Demer, Linda L/I-5770-2013	Wong, Pak Kin/0000-0001-7388-2110; Demer, Linda L/0000-0002-9618-6895; Ho, Chih-Ming/0000-0001-7369-5446	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL083015, R01HL118650, T32HL007895, K08HL068689] Funding Source: NIH RePORTER; NHLBI NIH HHS [K08 HL068689-01A1, R01 HL118650, T32 HL007895, HL07895, R01 HL083015, K08 HL068689] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593; [Anonymous], 1989, MEASUREMENT WALL SHE; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Chu Y, 2002, ARTERIOSCL THROM VAS, V22, P611, DOI 10.1161/01.ATV.0000012663.85364.FA; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; FOGELMAN AM, 1988, J LIPID RES, V29, P1243; Frangos JA, 1996, BIOCHEM BIOPH RES CO, V224, P660, DOI 10.1006/bbrc.1996.1081; FUNG YC, 1993, J BIOMECH ENG-T ASME, V115, P1, DOI 10.1115/1.2895465; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; Hsiai TK, 2002, ANN BIOMED ENG, V30, P646, DOI 10.1114/1.1484222; Hsiai TK, 2001, ARTERIOSCL THROM VAS, V21, P1770, DOI 10.1161/hq1001.097104; HUANG JB, 1995, P IEEE INSTR MEAS C; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Kitayama J, 2000, CELL IMMUNOL, V203, P39, DOI 10.1006/cimm.2000.1671; Ku DN, 1997, ANNU REV FLUID MECH, V29, P399, DOI 10.1146/annurev.fluid.29.1.399; KU DN, 1985, ARTERIOSCLEROSIS, V5, P293, DOI 10.1161/01.ATV.5.3.293; Liu C, 1999, J MICROELECTROMECH S, V8, P90; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Marschel P, 2002, ANN BIOMED ENG, V30, P333, DOI 10.1114/1.1475342; Melder RJ, 2000, MICROVASC RES, V59, P316, DOI 10.1006/mvre.1999.2223; MOTOMIYA M, 1984, STROKE, V15, P50, DOI 10.1161/01.STR.15.1.50; PEERSEN E, 1997, EUR J VASC ENDOVASC, V13, P4439; Raffel M., 1998, EXP FLUID MECH; Ravensbergen J, 1998, ARTERIOSCL THROM VAS, V18, P708, DOI 10.1161/01.ATV.18.5.708; Rosenfeld ME, 2002, ARTERIOSCL THROM VAS, V22, P361, DOI 10.1161/hq0302.104847; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SCHMIDSCHONBEIN GW, 1980, MICROVASC RES, V19, P45, DOI 10.1016/0026-2862(80)90083-7; Shanmugan K.S., 1988, RANDOM SIGNALS DETEC; Steinman DA, 2002, MAGN RESON MED, V47, P149, DOI 10.1002/mrm.10025; Taylor AD, 1996, BIOPHYS J, V71, P3488, DOI 10.1016/S0006-3495(96)79544-9; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Walker NJ, 2002, SCIENCE, V296, P557, DOI 10.1126/science.296.5567.557; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	39	112	114	1	17	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1648	1657		10.1096/fj.02-1064com	http://dx.doi.org/10.1096/fj.02-1064com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958171	Green Accepted			2022-12-28	WOS:000185925100039
J	Pai, R; Nakamura, T; Moon, WS; Tarnawski, AS				Pai, R; Nakamura, T; Moon, WS; Tarnawski, AS			Prostaglandins promote colon cancer cell invasion; signaling by cross-talk between two distinct growth factor receptors	FASEB JOURNAL			English	Article						EGFR; Met-R; beta-catenin; uPAR; PGE(2)	BETA-CATENIN; COLORECTAL-CANCER; CARCINOMA CELLS; PLASMINOGEN-ACTIVATOR; EGF RECEPTOR; EXPRESSION; E-2; METASTASIS; INVASIVENESS; PROGRESSION	Colorectal cancer is the second most frequent cancer in the Western world, often lethal when invasion and/or metastasis occur. In addition to hepatocyte growth factor (HGF), colon cancer invasion may be driven by prostaglandins, especially the E-2 series (PGE(2)), generated by the cyclooxygenase-2 (Cox-2) enzyme. While concentration of PGE2 as well as expression of Cox-2, HGF receptor (c-Met-R), epidermal growth factor receptor (EGFR), and beta-catenin are all dramatically increased in colon cancers and implicated in their growth and invasion, the precise role of PGE2 in the latter process remains unclear. Here we provide evidence that PGE(2) transactivates c-Met-R (contingent upon functional EGFR), increases tyrosine phosphorylation and nuclear accumulation of beta-catenin, and induces urokinase-type plasminogen activator receptor ( uPAR) mRNA expression. This is accompanied by increased beta-catenin association with c-Met-R and enhanced colon cancer cell invasiveness. Inactivation of EGFR and c-Met-R significantly reduced PGE(2)-induced cancer cell invasiveness. Clinical relevance of these findings is confirmed by our immunohistochemical studies demonstrating that cancer cells in the invasive front overexpress Cox-2, c-Met-R, and beta-catenin. Our findings explain a functional relationship between prostaglandins, EGFR, and c-Met-R in colon cancer growth and invasion.	Dept Vet Affairs Med Ctr, Med Serv, Gastroenterol Sect 111G, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Osaka Univ, Grad Sch Med, Osaka, Japan	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; Osaka University	Pai, R (corresponding author), Dept Vet Affairs Med Ctr, Med Serv, Gastroenterol Sect 111G, 5901 E 7th St, Long Beach, CA 90822 USA.	rpai@uci.edu.com						Adam L, 2001, CANCER RES, V61, P81; ALEXANDER N, 2002, AM J PATHOL, V160, P389; Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; Bergstrom JD, 2000, EXP CELL RES, V259, P293, DOI 10.1006/excr.2000.4967; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Chen WS, 2001, INT J CANCER, V91, P894, DOI 10.1002/1097-0215(200102)9999:9999<894::AID-IJC1146>3.3.CO;2-R; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; DuBois RN, 1996, J GASTROENTEROL, V31, P898, DOI 10.1007/BF02358623; Eguchi S, 1998, J BIOL CHEM, V273, P8890, DOI 10.1074/jbc.273.15.8890; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; GANESH S, 1994, LANCET, V344, P401, DOI 10.1016/S0140-6736(94)91427-3; Hao XP, 1997, VIRCHOWS ARCH, V431, P167, DOI 10.1007/s004280050084; Hiscox S, 1999, ANTICANCER RES, V19, P509; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Levy GN, 1997, FASEB J, V11, P234, DOI 10.1096/fasebj.11.4.9068612; Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595; Ozgul C, 1997, Acta Physiol Hung, V85, P121; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Prescott SM, 1996, CELL, V87, P783, DOI 10.1016/S0092-8674(00)81983-2; PYKE C, 1991, AM J PATHOL, V138, P1059; Scheving LA, 2002, BIOCHEM BIOPH RES CO, V290, P197, DOI 10.1006/bbrc.2001.6157; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Tomioka D, 2001, CANCER RES, V61, P7518; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Yang VW, 2000, PROSTAG OTH LIPID M, V60, P83, DOI 10.1016/S0090-6980(99)00054-4	32	154	167	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1640	1647		10.1096/fj.02-1011com	http://dx.doi.org/10.1096/fj.02-1011com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958170				2022-12-28	WOS:000185925100038
J	Jansson, PA; Pellme, F; Hammarstedt, A; Sandqvist, M; Brekke, H; Caidahl, K; Forsberg, M; Volkmann, R; Carvalho, E; Funahashi, T; Matsuzawa, Y; Wiklund, O; Yang, XL; Taskinen, MR; Smith, U				Jansson, PA; Pellme, F; Hammarstedt, A; Sandqvist, M; Brekke, H; Caidahl, K; Forsberg, M; Volkmann, R; Carvalho, E; Funahashi, T; Matsuzawa, Y; Wiklund, O; Yang, XL; Taskinen, MR; Smith, U			A novel cellular marker of insulin resistance and early atherosclerosis in humans is related to impaired fat cell differentiation and low adiponectin	FASEB JOURNAL			English	Article						type 2 diabetes; insulin signaling; adipose tissue; macroangiopathy; insulin	DEPENDENT DIABETES-MELLITUS; CORONARY HEART-DISEASE; COMPLEMENT-RELATED PROTEIN; INTIMA-MEDIA THICKNESS; METABOLIC SYNDROME; ARTERY DISEASE; PROINSULIN; SENSITIVITY; EXPRESSION; MICE	The epidemic increase in type 2 diabetes can be prevented only if markers of risk can be identified and used for early intervention. We examined the clinical phenotype of individuals characterized by normal or low IRS-1 protein expression in fat cells as well as the potential molecular mechanisms related to the adipose tissue. Twenty-five non-obese individuals with low or normal IRS-1 expression in subcutaneous abdominal fat cells were extensively characterized and the results compared with 71 carefully matched subjects with or without a known genetic predisposition for type 2 diabetes. In contrast to the commonly used risk marker, known heredity for diabetes, low cellular IRS-1 identified individuals who were markedly insulin resistant, had high proinsulin and insulin levels, and exhibited evidence of early atherosclerosis measured as increased intima media thickness in the carotid artery bulb. Circulating levels of adiponectin were also significantly reduced. Gene analyses of fat cells in a parallel study showed attenuated expression of several genes related to fat cell differentiation ( adiponectin, aP2, PPARgamma, and lipoprotein lipase) in the group of individuals characterized by a low IRS-1 expression and insulin resistance. A low IRS-1 expression in fat cells is a marker of insulin resistance and risk for type 2 diabetes and is associated with evidence of early vascular complications. Impaired adipocyte differentiation, including low gene expression and circulating levels of adiponectin, can provide a link between the cellular marker and the in vivo phenotype.	Univ Gothenburg, Sahlgrenska Acad, Lundberg Lab Diabet Res, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Nutr, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Clin Physiol, Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden; Univ Helsinki, Dept Med, FIN-00014 Helsinki, Finland; Osaka Univ, Dept Internal Med & Mol Sci, Suita, Osaka 565, Japan	University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Gothenburg; University of Helsinki; Osaka University	Smith, U (corresponding author), Univ Gothenburg, Sahlgrens Univ Hosp, Sahlgrenska Acad, Dept Internal Med,Lundberg Lab Diabet Res, SE-41345 Gothenburg, Sweden.	ulf.smith@medic.gu.se	Taskinen, Marja-Riitta/AAN-5432-2020; Carvalho, Eugenia/AAV-6868-2021	Taskinen, Marja-Riitta/0000-0002-6229-3588; Carvalho, Eugenia/0000-0001-6264-3632				ADAMS MR, 1995, CIRCULATION, V92, P2127, DOI 10.1161/01.CIR.92.8.2127; Alberti KGMM, 1998, DIABETIC MED, V15, P539, DOI 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S; Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Axelsen M, 1999, ANN INTERN MED, V131, P27, DOI 10.7326/0003-4819-131-1-199907060-00006; BAVENHOLM P, 1995, CIRCULATION, V92, P1422, DOI 10.1161/01.CIR.92.6.1422; BECKNIELSEN H, 1994, J CLIN INVEST, V94, P1714, DOI 10.1172/JCI117518; Carvalho E, 1999, FASEB J, V13, P2173, DOI 10.1096/fasebj.13.15.2173; Carvalho Eugenia, 2001, FASEB Journal, V15, P1101; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Combs TP, 2002, ENDOCRINOLOGY, V143, P998, DOI 10.1210/endo.143.3.8662; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; ERIKSSON J, 1989, NEW ENGL J MED, V321, P337, DOI 10.1056/NEJM198908103210601; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; GLAGOV S, 1988, ARCH PATHOL LAB MED, V112, P1018; Haffner SM, 1998, STROKE, V29, P1498, DOI 10.1161/01.STR.29.8.1498; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hammarstedt A, 2003, BIOCHEM BIOPH RES CO, V301, P578, DOI 10.1016/S0006-291X(03)00014-7; Hanley AJG, 2002, DIABETES, V51, P1263, DOI 10.2337/diabetes.51.4.1263; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Howard G, 1996, CIRCULATION, V93, P1809, DOI 10.1161/01.CIR.93.10.1809; Hulthe J, 1997, STROKE, V28, P1189, DOI 10.1161/01.STR.28.6.1189; Isomaa B, 2001, DIABETES CARE, V24, P683, DOI 10.2337/diacare.24.4.683; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; Laakso M, 2001, J INTERN MED, V249, P225, DOI 10.1046/j.1365-2796.2001.00789.x; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Ouchi N, 2001, CIRCULATION, V103, P1057, DOI 10.1161/01.CIR.103.8.1057; Reaven GM, 1996, CIRCULATION, V93, P1780, DOI 10.1161/01.CIR.93.10.1780; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Rondinone CM, 1997, P NATL ACAD SCI USA, V94, P4171, DOI 10.1073/pnas.94.8.4171; SMITH U, 1972, J LIPID RES, V13, P822; STEIL GM, 1993, DIABETES, V42, P250, DOI 10.2337/diabetes.42.2.250; Tuomilehto Jaakko, 2001, New England Journal of Medicine, V344, P1343, DOI 10.1056/NEJM200105033441801; Wendelhag I, 1997, STROKE, V28, P2195, DOI 10.1161/01.STR.28.11.2195; WIKSTRAND J, 1992, ARTERIOSCLER THROMB, V12, P114, DOI 10.1161/01.ATV.12.1.114; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Zethelius B, 2002, CIRCULATION, V105, P2153, DOI 10.1161/01.CIR.0000015855.04844.E7; Zimmet P, 2001, NATURE, V414, P782, DOI 10.1038/414782a	40	91	95	2	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1434	1440		10.1096/fj.02-1132com	http://dx.doi.org/10.1096/fj.02-1132com			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890697				2022-12-28	WOS:000185345100036
J	Berberat, PO; Katori, M; Kaczmarek, E; Anselmo, D; Lassman, C; Ke, B; Shen, X; Busuttil, RW; Yamashita, K; Csizmadia, E; Tyagi, S; Otterbein, LE; Brouard, S; Tobiasch, E; Bach, FH; Kupiec-Weglinski, JW; Soares, MP				Berberat, PO; Katori, M; Kaczmarek, E; Anselmo, D; Lassman, C; Ke, B; Shen, X; Busuttil, RW; Yamashita, K; Csizmadia, E; Tyagi, S; Otterbein, LE; Brouard, S; Tobiasch, E; Bach, FH; Kupiec-Weglinski, JW; Soares, MP			Heavy chain ferritin acts as an anti-apoptotic gene that protects livers from ischemia-reperfusion injury	FASEB JOURNAL			English	Article						heme oxygenase-1; IRI; H-ferritin	NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; ADENOVIRUS-MEDIATED EXPRESSION; ENDOTHELIAL-CELL ACTIVATION; HEME OXYGENASE-1; ISCHEMIA/REPERFUSION INJURY; NEUTROPHIL INFILTRATION; LIPID-PEROXIDATION; RAT; PREVENTS	Heme oxygenase-1 (HO-1) is induced under a variety of pro-oxidant conditions such as those associated with ischemia-reperfusion injury (IRI) of transplanted organs. HO-1 cleaves the heme porphyrin ring releasing Fe2+, which induces the expression of the Fe2+ sequestering protein ferritin. By limiting the ability of Fe2+ to participate in the generation of free radicals through the Fenton reaction, ferritin acts as an anti-oxidant. We have previously shown that HO-1 protects transplanted organs from IRI. We have linked this protective effect with the anti-apoptotic action of HO-1. Whether the iron-binding properties of ferritin contributed to the protective effect of HO-1 was not clear. We now report that recombinant adenovirus mediated overexpression of the ferritin heavy chain (H-ferritin) gene protects rat livers from IRI and prevents hepatocellular damage upon transplantation into syngeneic recipients. The protective effect of H-ferritin is associated with the inhibition of endothelial cell and hepatocyte apoptosis in vivo. H-ferritin protects cultured endothelial cells from apoptosis induced by a variety of stimuli. These findings unveil the anti-apoptotic function of H-ferritin and suggest that H-ferritin can be used in a therapeutic manner to prevent liver IRI and thus maximize the organ donor pool used for transplantation.	Harvard Univ, Sch Med,Dept Surg, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, Boston, MA 02215 USA; Univ Calif Los Angeles, Dumont Transplant Ctr, David Geffen Sch Med, Los Angeles, CA USA; Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Harvard Univ, Sch Med,Dept Surg, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.	msoares@caregroup.harvard.edu	Soares, Miguel P/G-4188-2011; brouard, sophie c/Q-1285-2016	Soares, Miguel/0000-0002-9314-4833; Ke, Bibo/0000-0002-1885-1538				Amersi F, 1999, J CLIN INVEST, V104, P1631, DOI 10.1172/JCI7903; Amersi F, 2002, AM J TRANSPLANT, V2, P600, DOI 10.1034/j.1600-6143.2002.20704.x; Amersi F, 2001, TRANSPLANTATION, V71, P112, DOI 10.1097/00007890-200101150-00018; Anrather J, 1997, J CLIN INVEST, V99, P763, DOI 10.1172/JCI119222; BALLA G, 1992, J BIOL CHEM, V267, P18148; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Blydt-Hansen TD, 2003, J AM SOC NEPHROL, V14, P745, DOI 10.1097/01.ASN.0000050760.87113.25; Bowie AG, 1997, J BIOL CHEM, V272, P25941, DOI 10.1074/jbc.272.41.25941; Brouard S, 2002, J BIOL CHEM, V277, P17950, DOI 10.1074/jbc.M108317200; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; CLAVIEN PA, 1992, TRANSPLANTATION, V53, P957, DOI 10.1097/00007890-199205000-00001; COZZI A, 1990, FEBS LETT, V277, P119, DOI 10.1016/0014-5793(90)80823-2; EISENSTEIN RS, 1991, P NATL ACAD SCI USA, V88, P688, DOI 10.1073/pnas.88.3.688; Farmer D. G., 2000, TRANSPLANT REV, V14, P106, DOI DOI 10.1053/TR.2000.4651; FENTON HGH, 1894, J CHEM SOC LOND; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; Graham F L, 1992, Biotechnology, V20, P363; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; JAESCHKE H, 1990, FASEB J, V4, P3355, DOI 10.1096/fasebj.4.15.2253850; JUCKETT MB, 1995, AM J PATHOL, V147, P782; KAMADA N, 1979, TRANSPLANTATION, V28, P47, DOI 10.1097/00007890-197907000-00011; Katori M, 2002, TRANSPLANTATION, V73, P287, DOI 10.1097/00007890-200201270-00023; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MCGRORY WJ, 1988, VIROLOGY, V163, P614, DOI 10.1016/0042-6822(88)90302-9; MULLANE KM, 1985, J PHARMACOL METHOD, V14, P157, DOI 10.1016/0160-5402(85)90029-4; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; She HY, 2002, AM J PHYSIOL-GASTR L, V283, pG719, DOI 10.1152/ajpgi.00108.2002; SHIBAHARA S, 1993, J BIOCHEM-TOKYO, V113, P214, DOI 10.1093/oxfordjournals.jbchem.a124028; Soares MP, 2002, ANTIOXID REDOX SIGN, V4, P321, DOI 10.1089/152308602753666370; Soares MP, 1998, J IMMUNOL, V161, P4572; Soares MP, 2001, IMMUNOL REV, V184, P275, DOI 10.1034/j.1600-065x.2001.1840124.x; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Suttner DM, 1999, AM J PHYSIOL-LUNG C, V276, pL443, DOI 10.1152/ajplung.1999.276.3.L443; SUZUKI S, 1993, TRANSPLANTATION, V55, P1265; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tenhunen R, 1969, Trans Assoc Am Physicians, V82, P363; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013	42	169	182	0	15	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1724	+		10.1096/fj.03-0229fje	http://dx.doi.org/10.1096/fj.03-0229fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958189	Bronze			2022-12-28	WOS:000184471600017
J	Quast, T; Wehner, S; Kirfel, G; Jaeger, K; De Luca, M; Herzog, V				Quast, T; Wehner, S; Kirfel, G; Jaeger, K; De Luca, M; Herzog, V			sAPP as a regulator of dendrite motility and melanin release in epidermal melanocytes and melanoma cells	FASEB JOURNAL			English	Article						beta-amyloid precursor protein; marker protein; whole mount epidermis	AMYLOID PRECURSOR PROTEIN; ALZHEIMERS-DISEASE; MESSENGER-RNA; STIMULATING HORMONE; AXONAL-TRANSPORT; RAT-TISSUES; GROWTH; SKIN; DOMAIN; BINDING	Numerous factorsincludingultraviolet(UV)radiation and growth factors regulate the specific function of epidermal melanocytes. A recently discovered epidermal growth factor is sAPP, the soluble N-terminal ectodomain of the beta-amyloid precursor protein(APP). Using whole mount preparations of isolated human epidermis,we detected a small population of basal cells, which expressed exceptionally highlevelsofAPP.Thesecellswereidentifiedasmelanocytes,which,similar to keratinocytes and neuronal cells, expressed the three APP isoforms 695,751,and 770. They differed in their expression pattern from that of neuronal cells by expressing onlylowlevelsofAPP695.Melanocytesandmelanomacellsinvitroreleased,in addition to keratinocytes,large quantities of sAPP. Because of its growth factor function,we studied possible effects of sAPP on melanocytes. Recombinants APPstronglyincreasedlamellipodiaactivityatdendritictips,an effect that coincided with increased release of melanin particles. Our observations point to the possible use of APP as an immunocytochemical marker for melanocytes. They suggest that sAPP derived from keratinocytes and/or melanocytes belongs to a family of factors operating in the paracrine and/or autocrine regulation of melanocyte function.	Univ Bonn, Inst Cell Biol, D-53121 Bonn, Germany; Univ Bonn, Bonner Forum Biomed, D-53121 Bonn, Germany; Marien Hosp, D-50321 Bruhl, Germany; Fdn Banca Occhi Veneto, I-30171 Venice, Italy	University of Bonn; University of Bonn; St. Marien Hospital	Herzog, V (corresponding author), Univ Bonn, Inst Cell Biol, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.	Herzog@uni-bonn.de	De Luca, Michele/N-5883-2014; Wehner, Sven/X-6326-2019	De Luca, Michele/0000-0002-0850-8445; Wehner, Sven/0000-0002-8632-7631				Berson JF, 2001, MOL BIOL CELL, V12, P3451, DOI 10.1091/mbc.12.11.3451; BOLOGNIA JL, 1988, J AM ACAD DERMATOL, V19, P217, DOI 10.1016/S0190-9622(88)70168-1; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; DELUCA M, 1993, J CELL SCI, V105, P1079; DELUCA M, 1994, KERATINOCYTE HDB, P95; FITZPATRICK T B, 1963, Dermatol Wochenschr, V147, P481; GILCHREST BA, 1979, ANN INTERN MED, V91, P17, DOI 10.7326/0003-4819-91-1-17; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GORDON PR, 1989, J INVEST DERMATOL, V92, P565, DOI 10.1111/1523-1747.ep12709595; GREEN H, 1979, P NATL ACAD SCI USA, V76, P5665, DOI 10.1073/pnas.76.11.5665; HARA M, 1995, J INVEST DERMATOL, V105, P744, DOI 10.1111/1523-1747.ep12325522; Hara M, 2000, J INVEST DERMATOL, V114, P438, DOI 10.1046/j.1523-1747.2000.00894.x; Hearing VJ, 1999, J INVEST DERM SYMP P, V4, P24, DOI 10.1038/sj.jidsp.5640176; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; Heber S, 2000, J NEUROSCI, V20, P7951; Hinz B, 1999, EXP CELL RES, V251, P234, DOI 10.1006/excr.1999.4541; HIROBE T, 1978, J CELL SCI, V33, P371; Hoffmann J, 2000, EUR J CELL BIOL, V79, P905, DOI 10.1078/0171-9335-00117; HOLBROOK KA, 1989, ANAT EMBRYOL, V180, P443, DOI 10.1007/BF00305119; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; JIMBOW K, 1976, J INVEST DERMATOL, V67, P72, DOI 10.1111/1523-1747.ep12512500; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1990, BIOCHEM BIOPH RES CO, V166, P1192, DOI 10.1016/0006-291X(90)90992-V; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kirfel G, 2002, EUR J CELL BIOL, V81, P664, DOI 10.1078/0171-9335-00284; Kummer C, 2002, EXP CELL RES, V280, P222, DOI 10.1006/excr.2002.5631; LACOUR JP, 1992, J CELL PHYSIOL, V151, P287, DOI 10.1002/jcp.1041510210; LEVINE N, 1991, JAMA-J AM MED ASSOC, V266, P2730, DOI 10.1001/jama.266.19.2730; Luger TA, 1998, ANN NY ACAD SCI, V840, P381, DOI 10.1111/j.1749-6632.1998.tb09577.x; Marks MS, 2001, NAT REV MOL CELL BIO, V2, P738, DOI 10.1038/35096009; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; ORTONNE JP, 1990, J INT MED RES, V18, pC8; Perez RG, 1997, J NEUROSCI, V17, P9407; Pietrzik CU, 1998, P NATL ACAD SCI USA, V95, P1770, DOI 10.1073/pnas.95.4.1770; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; Raucher D, 2000, J CELL BIOL, V148, P127, DOI 10.1083/jcb.148.1.127; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Rossjohn J, 1999, NAT STRUCT BIOL, V6, P327; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; Schmitz A, 2002, HISTOCHEM CELL BIOL, V117, P171, DOI 10.1007/s00418-001-0351-5; Scott GA, 1998, J INVEST DERMATOL, V111, P243, DOI 10.1046/j.1523-1747.1998.00276.x; SISODIA SS, 1993, J NEUROSCI, V13, P3136; SMALL DH, 1994, J NEUROSCI, V14, P2117; SZABO G, 1967, PHILOS T R SOC LONDO, P252; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; Virador VM, 2001, FASEB J, V15, P105, DOI 10.1096/fj.01-0518fje; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; Whiteman DC, 1999, ARCH DERMATOL RES, V291, P511, DOI 10.1007/s004030050446; YAMAMOTO O, 1994, PIGM CELL RES, V7, P158, DOI 10.1111/j.1600-0749.1994.tb00044.x; YOSHIKAI S, 1990, GENE, V87, P257, DOI 10.1016/0378-1119(90)90310-N	54	30	34	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1739	+		10.1096/fj.02-1059fje	http://dx.doi.org/10.1096/fj.02-1059fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958194				2022-12-28	WOS:000184471600028
J	Hinoi, E; Fujimori, S; Yoneda, Y				Hinoi, E; Fujimori, S; Yoneda, Y			Modulation of cellular differentiation by N-methyl-D-aspartate receptors in osteoblasts	FASEB JOURNAL			English	Article						glutamate; CBFA1; osteocalcin; alkaline phosphatase; Ca2+ accumulation	IONOTROPIC GLUTAMATE RECEPTORS; NICOTINIC ACETYLCHOLINE-RECEPTOR; CULTURED CALVARIAL OSTEOBLASTS; TRANSCRIPTION FACTOR CBFA1; PIG MYENTERIC PLEXUS; RAT ADRENAL-MEDULLA; BONE-RESORPTION; CLEIDOCRANIAL DYSPLASIA; BINDING-SITE; EXPRESSION	N-Methyl-D-aspartate (NMDA) receptors for the central neurotransmitter L-glutamate (Glu) have been shown to be present in both osteoblasts and osteoclasts. Sustained exposure to the NMDA channel antagonist dizocilpine (MK-801) significantly prevented increases in both alkaline phosphatase activity and Ca2+ accumulation in a concentration-dependent manner in osteoblasts cultured for 7-28 days in vitro (DIV), without significantly affecting cell survivability. Osteocalcin expression was markedly reduced in the presence of MK-801 in osteoblasts cultured for 28 DIV. Both an NMDA domain antagonist and a glycine domain antagonist similarly prevented Ca2+ accumulation in osteoblasts exposed for 28 consecutive DIV. MK-801 was effective in significantly inhibiting Ca2+ accumulation determined at 28 DIV in osteoblast s exposed before 7 DIV but was in effective in cells exposed after 11-21 DIV. Sustained exposure to MK-801 significantly inhibited DNA binding activity and expression of corebinding factor alpha-1 (CBFA1) in osteoblasts exposed after 7 DIV up to 28 DIV, but not in those exposed before 7 DIV. These results suggest that heteromeric NMDA receptor channels may be function ally expressed to regulate mechanisms underlying cellular differentiation rather than proliferation and/or maturation through modulation of expression of CBFA1 in cultured rat calvarial osteoblasts.	Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, Kanazawa, Ishikawa 9200934, Japan	Kanazawa University	Yoneda, Y (corresponding author), Kanazawa Univ, Grad Sch Nat Sci & Technol, Mol Pharmacol Lab, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.	yyoneda@anet.ne.jp	Yoneda, Yukio/ABI-1864-2020	Yoneda, Yukio/0000-0002-4624-177X				AAS P, 1989, EUR J PHARMACOL, V164, P93, DOI 10.1016/0014-2999(89)90235-5; AMADOR M, 1991, SYNAPSE, V7, P207, DOI 10.1002/syn.890070305; Arias HR, 2001, MOL PHARMACOL, V59, P1051, DOI 10.1124/mol.59.5.1051; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; Chenu C, 1998, BONE, V22, P295, DOI 10.1016/S8756-3282(97)00295-0; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Ducy P, 2000, SCIENCE, V289, P1501, DOI 10.1126/science.289.5484.1501; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Fujimori S, 2002, BIOCHEM BIOPH RES CO, V293, P1445, DOI 10.1016/S0006-291X(02)00405-9; Genever PG, 2001, FASEB J, V15, P1586, DOI 10.1096/fj.00-0594fje; GOVITRAPONG P, 1986, J PINEAL RES, V3, P223, DOI 10.1111/j.1600-079X.1986.tb00745.x; Gu YC, 2000, J BIOL CHEM, V275, P34252, DOI 10.1074/jbc.M004520200; Harada H, 1999, J BIOL CHEM, V274, P6972, DOI 10.1074/jbc.274.11.6972; Hinoi E, 2001, BIOCHEM BIOPH RES CO, V281, P341, DOI 10.1006/bbrc.2001.4355; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V294, P1177, DOI 10.1016/S0006-291X(02)00578-8; Hinoi E, 2002, J NEUROSCI RES, V68, P36, DOI 10.1002/jnr.10202; Hinoi E, 2002, BRAIN RES, V943, P112, DOI 10.1016/S0006-8993(02)02726-9; Hinoi E, 2002, BIOCHEM BIOPH RES CO, V297, P452, DOI 10.1016/S0006-291X(02)02223-4; Hinoi E, 2001, NEUROCHEM INT, V38, P539, DOI 10.1016/S0197-0186(00)00115-7; HOHMANN EL, 1986, SCIENCE, V232, P868, DOI 10.1126/science.3518059; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Huggett J, 2000, FEBS LETT, V485, P13, DOI 10.1016/S0014-5793(00)02175-X; INAGAKI N, 1995, FASEB J, V9, P686, DOI 10.1096/fasebj.9.8.7768362; Itzstein C, 2001, J CELL BIOCHEM, V82, P134, DOI 10.1002/jcb.1114; Jochum W, 2000, NAT MED, V6, P980, DOI 10.1038/79676; KIYAMA H, 1993, MOL BRAIN RES, V19, P262, DOI 10.1016/0169-328X(93)90039-R; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; KRISTENSEN P, 1993, FEBS LETT, V332, P14, DOI 10.1016/0014-5793(93)80472-7; Laketic-Ljubojevic I, 1999, BONE, V25, P631, DOI 10.1016/S8756-3282(99)00224-0; LUZZI S, 1988, BRIT J PHARMACOL, V95, P1271, DOI 10.1111/j.1476-5381.1988.tb11764.x; Lynch DR, 2001, CURR DRUG TARGETS, V2, P215, DOI 10.2174/1389450013348434; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; Miyamoto Y, 2002, J NEUROSCI, V22, P2335, DOI 10.1523/JNEUROSCI.22-06-02335.2002; MORONI F, 1986, NEUROSCI LETT, V68, P57, DOI 10.1016/0304-3940(86)90229-6; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Patton AJ, 1998, BONE, V22, P645, DOI 10.1016/S8756-3282(98)00061-1; Peet NM, 1999, FASEB J, V13, P2179, DOI 10.1096/fasebj.13.15.2179; RAMOA AS, 1990, J PHARMACOL EXP THER, V254, P71; Sabatakos G, 2000, NAT MED, V6, P985, DOI 10.1038/79683; Serre CM, 1999, BONE, V25, P623, DOI 10.1016/S8756-3282(99)00215-X; SHANNON HE, 1989, J PHARMACOL EXP THER, V251, P518; Skerry TM, 2001, CURR PHARM DESIGN, V7, P737, DOI 10.2174/1381612013397771; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; Teitelbaum SL, 2000, SCIENCE, V289, P1504, DOI 10.1126/science.289.5484.1504; THURKRAL V, 1997, NEUROSCIENCE, V79, P411; Tintut Y, 1999, J BIOL CHEM, V274, P28875, DOI 10.1074/jbc.274.41.28875; Villalobos C, 1996, FASEB J, V10, P654, DOI 10.1096/fasebj.10.5.8621065; WANG ZQ, 1995, CANCER RES, V55, P6244; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Yatsushiro S, 2000, J NEUROCHEM, V75, P288, DOI 10.1046/j.1471-4159.2000.0750288.x; YONEDA Y, 1986, BRAIN RES, V383, P387, DOI 10.1016/0006-8993(86)90046-6; Yoneda Y, 2001, PROG NEUROBIOL, V63, P697, DOI 10.1016/S0301-0082(00)00036-8; YONEDA Y, 1986, Neuroscience Research, V3, P430, DOI 10.1016/0168-0102(86)90034-9	54	85	87	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1532	+		10.1096/fj.02-0820fje	http://dx.doi.org/10.1096/fj.02-0820fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824297				2022-12-28	WOS:000183818000015
J	Bennett, JJ; Adusumilli, P; Petrowsky, H; Burt, BM; Roberts, G; Delman, KA; Zager, JS; Chou, TC; Fong, YM				Bennett, JJ; Adusumilli, P; Petrowsky, H; Burt, BM; Roberts, G; Delman, KA; Zager, JS; Chou, TC; Fong, YM			Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma(1)34.5 deleted oncolytic herpes virus (G207)	FASEB JOURNAL			English	Article						chemotherapy; gastric cancer; gene therapy; herpes simplex virus; HSV	SQUAMOUS-CELL CARCINOMA; SIMPLEX-VIRUS; INTRAPERITONEAL CHEMOTHERAPY; PREMATURE SHUTOFF; PROTEIN-SYNTHESIS; LIVER METASTASES; GROWTH ARREST; GENE-THERAPY; CANCER; REPLICATION	Oncolytic viruses used for gene therapy have been genetically modified to selectively target tumor cells while sparing normal host tissue. The multimutant virus G207 has been attenuated by inactivation of viral ribonucleotide reductase and by deletion of both viral gamma(1)34.5 genes. Deletion of gamma(1)34.5 greatly decreases the neurovirulence of this mutant virus but also reduces its antitumor efficacy. The mammalian homologue to the gamma(1)34.5 gene product is the GADD34 protein. This protein can functionally substitute for the gamma(1)34.5 gene and is also up-regulated during DNA damage. We postulated that combining use of the chemotherapy agent mitomycin C (MMC) with G207 will selectively up-regulate GADD34 in tumor that may complement the gamma(1)34.5 gene deletion and augment viral antitumor efficacy. This hypothesis was tested in human gastric cells in vitro and in vivo. Using both the isobologram method and combination-index method of Chou-Talalay, significant synergism was demonstrated between MMC and G207. As a result of such synergism, a dose-reduction for each agent can be accomplished over a wide range of drug-effect levels without sacrificing tumor cell kill. Northern blot analysis confirmed that expression of GADD34 mRNA was increased by MMC treatment. SiRNA directed at GADD34 decreased MMC-associated enhancement of viral proliferation and resulted in decreased viral synergy with MMC. These data indicate that induction of GADD34 selectively restores the virulent phenotype of the deleted gene in G207 and thus provides a cellular basis for the combined use of DNA-damaging agents and gamma(1)34.5 HSV mutants in the treatment of cancer.	Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Div, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Mol Pharmacol & Therapeut Program, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Fong, YM (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Surg, Hepatobiliary Div, 1275 York Ave, New York, NY 10021 USA.	Fongy@mskcc.org	Chou, Ting-Chao/AAA-7881-2020; Petrowsky, Henrik/J-6377-2019; Chou, Ting-Chao/B-4111-2009	Chou, Ting-Chao/0000-0002-3340-1594; Petrowsky, Henrik/0000-0001-5744-0531; Chou, Ting-Chao/0000-0002-3340-1594	NATIONAL CANCER INSTITUTE [R01CA072632, R01CA080982] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 76416, R01 CA 72632, R01 R01CA/DK80982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Advani SJ, 1998, GENE THER, V5, P160, DOI 10.1038/sj.gt.3300546; Aghi M, 1999, CANCER RES, V59, P3861; Andreansky S, 1998, GENE THER, V5, P121, DOI 10.1038/sj.gt.3300550; Bao JJ, 1996, HUM GENE THER, V7, P355, DOI 10.1089/hum.1996.7.3-355; Bennett JJ, 2000, J MOL MED-JMM, V78, P166, DOI 10.1007/s001090000092; Carew JF, 1999, HUM GENE THER, V10, P1599, DOI 10.1089/10430349950017608; Carroll NM, 1997, J SURG RES, V69, P413, DOI 10.1006/jsre.1997.5089; Carroll NM, 1996, ANN SURG, V224, P323, DOI 10.1097/00000658-199609000-00008; Chahlavi Ali, 1999, Neoplasia (New York), V1, P162, DOI 10.1038/sj.neo.7900016; CHOU J, 1990, SCIENCE, V250, P1262, DOI 10.1126/science.2173860; CHOU J, 1995, P NATL ACAD SCI USA, V92, P10516, DOI 10.1073/pnas.92.23.10516; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; CHOU J, DOSE EFFECT ANAL MIC; CHOU J, 1991, QUANTITATION SYNERGI, P223; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Chou TC, 1991, SYNERGISM ANTAGONISM, P61; CHU DZJ, 1989, CANCER, V63, P364, DOI 10.1002/1097-0142(19890115)63:2<364::AID-CNCR2820630228>3.0.CO;2-V; Chung RY, 1999, J VIROL, V73, P7556, DOI 10.1128/JVI.73.9.7556-7564.1999; Coukos G, 2000, CANCER GENE THER, V7, P275, DOI 10.1038/sj.cgt.7700130; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; GOLDSTEIN DJ, 1988, J VIROL, V62, P196, DOI 10.1128/JVI.62.1.196-205.1988; GUNDERSON LL, 1982, INT J RADIAT ONCOL, V8, P1, DOI 10.1016/0360-3016(82)90377-7; He B, 1996, J VIROL, V70, P84, DOI 10.1128/JVI.70.1.84-90.1996; Hollander MC, 1997, J BIOL CHEM, V272, P13731, DOI 10.1074/jbc.272.21.13731; HUBER BE, 1991, P NATL ACAD SCI USA, V88, P8039, DOI 10.1073/pnas.88.18.8039; KELSEN D, 1999, SEMIN ONCOL, V23, P379; Khuri FR, 2000, NAT MED, V6, P879, DOI 10.1038/78638; KOOBY DA, 1999, FASEB J, V6, P499; Kramm CM, 1997, HUM GENE THER, V8, P2057, DOI 10.1089/hum.1997.8.17-2057; Lamont JP, 2000, ANN SURG ONCOL, V7, P588, DOI 10.1007/BF02725338; Markert JM, 2000, GENE THER, V7, P867, DOI 10.1038/sj.gt.3301205; MINETA T, 1995, NAT MED, V1, P938, DOI 10.1038/nm0995-938; Rosen HR, 1998, J CLIN ONCOL, V16, P2733, DOI 10.1200/JCO.1998.16.8.2733; Toda M, 1998, HUM GENE THER, V9, P2177, DOI 10.1089/hum.1998.9.15-2177; Toda M, 1998, J IMMUNOL, V160, P4457; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; VERWEIJ J, 1990, Anti-Cancer Drugs, V1, P5, DOI 10.1097/00001813-199010000-00002; Walker JR, 1999, HUM GENE THER, V10, P2237, DOI 10.1089/10430349950017211; WILKE H, 1990, SEMIN ONCOL, V17, P61; WISBECK WM, 1986, RADIOTHER ONCOL, V7, P13, DOI 10.1016/S0167-8140(86)80120-7; Wong RJ, 2001, HUM GENE THER, V12, P253, DOI 10.1089/10430340150218396; YAZAKI T, 1995, CANCER RES, V55, P4752; Yoon SS, 2000, FASEB J, V14, P301, DOI 10.1096/fasebj.14.2.301; Yu WS, 1998, AM SURGEON, V64, P1104; ZHAN QM, 1994, MOL CELL BIOL, V14, P2361, DOI 10.1128/MCB.14.4.2361	45	60	65	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1001	+		10.1096/fj.02-1080fje	http://dx.doi.org/10.1096/fj.02-1080fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059970				2022-12-28	WOS:000221108800021
J	Recchia, A; Debetto, P; Negro, A; Guidolin, D; Skaper, SD; Giusti, P				Recchia, A; Debetto, P; Negro, A; Guidolin, D; Skaper, SD; Giusti, P			alpha-synuclein and Parkinson's Disease	FASEB JOURNAL			English	Review						alpha synuclein aggregation; dopaminergic neurons; animal models of Parkinson's disease	MULTIPLE SYSTEM ATROPHY; LEWY BODIES; IN-VITRO; OXIDATIVE STRESS; ANIMAL-MODELS; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; AUTONOMIC FAILURE; GAMMA-SYNUCLEIN; NERVOUS-SYSTEM	Alpha-synuclein (alpha-syn) is a small soluble protein expressed primarily at presynaptic terminals in the central nervous system. Interest in alpha-syn has increased dramatically after the discovery of a relationship between its dysfunction and several neurodegenerative diseases, including Parkinson's disease (PD). The physiological functions of alpha-syn remain to be fully defined, although recent data suggest a role in regulating membrane stability and neuronal plasticity. Various trigger factors, either environmental or genetic, can lead to a cascade of events involving misfolding or loss of normal function of alpha-syn. In dopaminergic neurons, this may promote a vicious cycle in which elevation in cytoplasmic dopamine, oxidative stress, alpha-syn dysfunction, and disruption of vesicle function lead to dopaminergic cell loss and PD. Alpha-Syn dysfunction appears to be a common feature of all forms of PD. The mechanism by which alpha-syn induces neuronal cell toxicity may invoke multiple pathways, such as aggregation or interaction with other proteins and molecules, including synphilin-1, chaperone 14-3-3 protein, and dopamine itself. This complexity has hindered the development of models to study PD. The available animal models of PD, each present distinct advantages and limits. Findings to date suggest that alpha-syn-based models represent a paradigm, which is closest to the human pathology.	Univ Padua, Dept Pharmacol & Anesthesiol, I-35131 Padua, Italy; Univ Padua, Ctr Ric Biotecnol Innovat, I-35131 Padua, Italy; Univ Padua, Dept Human Anat & Physiol, I-35131 Padua, Italy; GlaxoSmithKlin Res & Dev Ltd, Neurol & GI Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England	University of Padua; University of Padua; University of Padua; GlaxoSmithKline	Giusti, P (corresponding author), Univ Padua, Dept Pharmacol & Anesthesiol, Largo E Meneghetti 2, I-35131 Padua, Italy.			NEGRO, ALESSANDRO/0000-0003-3142-7632; Guidolin, Diego/0000-0003-2133-3552; GIUSTi, Pietro/0000-0001-9352-4046				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Arai K, 2000, NEUROSCI LETT, V296, P171, DOI 10.1016/S0304-3940(00)01623-2; Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Berg D, 2001, J NEUROCHEM, V79, P225, DOI 10.1046/j.1471-4159.2001.00608.x; BERRIOS GE, 1995, BRIT J PSYCHIAT, V166, P789, DOI 10.1192/bjp.166.6.789; Betarbet R, 2002, BIOESSAYS, V24, P308, DOI 10.1002/bies.10067; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; BOSTON PF, 1982, J NEUROCHEM, V38, P1475, DOI 10.1111/j.1471-4159.1982.tb07928.x; Burn DJ, 2001, J CLIN PATHOL-MOL PA, V54, P419; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chen YG, 1997, J CELL BIOL, V138, P495, DOI 10.1083/jcb.138.3.495; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Ciechanover A, 2001, NAT MED, V7, P1108, DOI 10.1038/nm1001-1108; Clayton DF, 1999, J NEUROSCI RES, V58, P120, DOI 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.3.CO;2-5; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dawson TM, 2003, J CLIN INVEST, V111, P145, DOI 10.1172/JCI200317575; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Dluzen D E, 2000, J Gend Specif Med, V3, P36; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Ellis CE, 2001, J BIOL CHEM, V276, P3879, DOI 10.1074/jbc.M010316200; Forman MS, 2002, AM J PATHOL, V160, P1725, DOI 10.1016/S0002-9440(10)61119-4; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; FU H, 2000, PHARMACOL TOXICOL, V40, P617; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Galvin JE, 1999, P NATL ACAD SCI USA, V96, P13450, DOI 10.1073/pnas.96.23.13450; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; George JM, 2002, GENOME BIOL, V3; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; GIBB WRG, 1988, J NEUROL NEUROSUR PS, V51, P745, DOI 10.1136/jnnp.51.6.745; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Gomez-Tortosa E, 1999, NEUROLOGY, V53, P1284, DOI 10.1212/WNL.53.6.1284; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Ilic T, 1998, Vojnosanit Pregl, V55, P463; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Jones DC, 2000, J NEUROCHEM, V74, P2296, DOI 10.1046/j.1471-4159.2000.0742296.x; Junn E, 2002, NEUROSCI LETT, V320, P146, DOI 10.1016/S0304-3940(02)00016-2; Kahle PJ, 2002, J NEUROCHEM, V82, P449, DOI 10.1046/j.1471-4159.2002.01020.x; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kim TD, 2002, BIOCHEMISTRY-US, V41, P13782, DOI 10.1021/bi026284c; Kirik D, 2002, J NEUROSCI, V22, P2780, DOI 10.1523/JNEUROSCI.22-07-02780.2002; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee MK, 2001, CLIN NEUROSCI RES, V1, P456, DOI 10.1016/S1566-2772(01)00024-X; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Lo Bianco C, 2002, P NATL ACAD SCI USA, V99, P10813, DOI 10.1073/pnas.152339799; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; MAROTEAUX L, 1988, J NEUROSCI, V8, P2804; McKeith Ian G, 2003, Semin Clin Neuropsychiatry, V8, P46; McLean PJ, 2002, NEUROSCI LETT, V323, P219, DOI 10.1016/S0304-3940(02)00154-4; Mochizuki A, 2002, ACTA NEUROPATHOL, V104, P534, DOI 10.1007/s00401-002-0582-0; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; NAKAJO S, 1994, MOL BRAIN RES, V27, P81, DOI 10.1016/0169-328X(94)90187-2; Nakamura T, 2001, BIOCHEM BIOPH RES CO, V280, P1085, DOI 10.1006/bbrc.2000.4253; NCNAUGHT K, 2003, EXP NEUROL, V179, P38; NCNAUGHT KS, 2002, NEUROREPORT, V13, P1437; Negro A, 2001, FASEB J, V15, P210, DOI 10.1096/fj.01-0517fje; Newell KL, 1999, J NEUROPATH EXP NEUR, V58, P1263, DOI 10.1097/00005072-199912000-00007; Nussbaum RL, 2003, NEW ENGL J MED, V348, P2588; Okochi M, 2000, J BIOL CHEM, V275, P390, DOI 10.1074/jbc.275.1.390; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Ostrerova-Golts N, 2000, J NEUROSCI, V20, P6048, DOI 10.1523/JNEUROSCI.20-16-06048.2000; Park SM, 2002, J BIOL CHEM, V277, P28512, DOI 10.1074/jbc.M111971200; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Polymeropoulos MH, 2000, ANN NY ACAD SCI, V920, P28; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Rabinovic AD, 2000, NEUROSCIENCE, V101, P67, DOI 10.1016/S0306-4522(00)00293-1; Rajagopalan S, 2001, MECH AGEING DEV, V122, P1499, DOI 10.1016/S0047-6374(01)00283-4; RIEDERER P, 1989, J NEUROCHEM, V52, P515, DOI 10.1111/j.1471-4159.1989.tb09150.x; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; Saito Y, 2000, J NEUROL SCI, V177, P48, DOI 10.1016/S0022-510X(00)00337-3; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Siderowf A, 2003, ANN INTERN MED, V138, P651, DOI 10.7326/0003-4819-138-8-200304150-00013; Simard M, 2001, INT J GERIATR PSYCH, V16, P311; Slavotinek AM, 2001, TRENDS GENET, V17, P528, DOI 10.1016/S0168-9525(01)02413-1; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; SPILLANTINI MG, 1995, GENOMICS, V27, P379, DOI 10.1006/geno.1995.1063; Spillantini MG, 1999, ACTA NEUROPATHOL, V97, P585, DOI 10.1007/s004010051034; Suh YH, 2002, PHARMACOL REV, V54, P469, DOI 10.1124/pr.54.3.469; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; TANNER CM, 1992, OCCUP MED, V7, P503; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Uversky VN, 2002, FEBS LETT, V522, P9, DOI 10.1016/S0014-5793(02)02883-1; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Warner TT, 2003, ANN NEUROL, V53, pS16, DOI 10.1002/ana.10487; West A, 2002, AM J MED GENET, V114, P584, DOI 10.1002/ajmg.10525; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zigmond MJ, 2002, PARKINSONISM RELAT D, V8, P389, DOI 10.1016/S1353-8020(02)00019-6; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	111	220	235	0	26	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					617	626		10.1096/fj.03-0338rev	http://dx.doi.org/10.1096/fj.03-0338rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054084				2022-12-28	WOS:000221108800032
J	Wright, GL; Hanlon, P; Amin, K; Steenbergen, C; Murphy, E; Arcasoy, MO				Wright, GL; Hanlon, P; Amin, K; Steenbergen, C; Murphy, E; Arcasoy, MO			Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury	FASEB JOURNAL			English	Article						ATP; myocardium; signal transduction	PROTECTS; APOPTOSIS; NEURONS; GENE; RECOVERY; HYPOXIA	Erythropoietin (EPO), the principal hematopoietic cytokine that regulates mammalian erythropoiesis, exhibits diverse cellular effects in non-hematopoietic tissues. The physiologic functions of EPO are mediated by its specific cell-surface receptor EPOR. In this study, we demonstrate EPOR expression in adult rat cardiac myocytes and examine the direct effects of EPO on the heart to investigate whether recombinant EPO may exert an acute cardioprotective effect during ischemia-reperfusion injury. To determine whether EPO is cardioprotective, isolated rat hearts were perfused for 10 min in the Langendorff-mode with Krebs-Henseleit buffer in the absence or presence of brief recombinant EPO treatment while left-ventricular-developed pressure (LVDP) was measured continuously to assess contractile function. The hearts were then subjected to 20 min of normothermic global ischemia followed by 25 min of reperfusion. The post-ischemic recovery of LVDP in the untreated control hearts was 26 +/- 5% of their baseline LVDP, whereas hearts pretreated with EPO exhibited significantly improved post-ischemic recovery to 57 +/- 7%. We used P-31 nuclear magnetic resonance (NMR) spectroscopy to determine whether modulation of intracellular pH and/or high-energy phosphate levels during ischemia contributed to EPO-mediated cardioprotection. These experiments revealed that the rapid cardioprotective effect of EPO during ischemia-reperfusion injury was associated with preservation of ATP levels in the ischemic myocardium.	Duke Univ, Sch Med, Dept Med, Div Hematol, Durham, NC 27710 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA; SRI Int, Biosci Div, Menlo Pk, CA 94025 USA; Duke Univ, Sch Med, Dept Pathol, Durham, NC 27706 USA	Duke University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); SRI International; Duke University	Arcasoy, MO (corresponding author), Duke Univ, Sch Med, Dept Med, Div Hematol, DUMC Box 3912, Durham, NC 27710 USA.	arcas001@mc.duke.edu		Amin, Khalid/0000-0001-8992-8419	NHLBI NIH HHS [R01 HL039752, R01-HL-39752] Funding Source: Medline; NIDDK NIH HHS [R21-DK-65065] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039752] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK065065] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES010004] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ANAGNOSTOU A, 1990, P NATL ACAD SCI USA, V87, P5978, DOI 10.1073/pnas.87.15.5978; ANAGNOSTOU A, 1994, P NATL ACAD SCI USA, V91, P3974, DOI 10.1073/pnas.91.9.3974; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Cai ZQ, 2003, CIRCULATION, V108, P79, DOI 10.1161/01.CIR.0000078635.89229.8A; Calvillo L, 2003, P NATL ACAD SCI USA, V100, P4802, DOI 10.1073/pnas.0630444100; Celik M, 2002, P NATL ACAD SCI USA, V99, P2258, DOI 10.1073/pnas.042693799; Chen J, 2003, AM J PHYSIOL-HEART C, V285, pH2657, DOI 10.1152/ajpheart.00557.2003; Chong ZZ, 2002, CIRCULATION, V106, P2973, DOI 10.1161/01.CIR.0000039103.58920.1F; DANDREA AD, 1993, BLOOD, V82, P46, DOI 10.1182/blood.V82.1.46.bloodjournal82146; DANDREA AD, 1909, CELL, V68, P388; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; GANOTE CE, 1985, AM J PATHOL, V120, P129; Gorio A, 2002, P NATL ACAD SCI USA, V99, P9450, DOI 10.1073/pnas.142287899; Haroon ZSA, 2003, AM J PATHOL, V163, P993, DOI 10.1016/S0002-9440(10)63459-1; Henry D H, 1995, Curr Opin Hematol, V2, P118; JONES SS, 1990, BLOOD, V76, P31; Junk AK, 2002, P NATL ACAD SCI USA, V99, P10659, DOI 10.1073/pnas.152321399; Juul SE, 1998, EARLY HUM DEV, V52, P235, DOI 10.1016/S0378-3782(98)00030-9; KRANTZ SB, 1991, BLOOD, V77, P419; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; LIU ZY, 1994, DEV BIOL, V166, P159, DOI 10.1006/dbio.1994.1304; Moon C, 2003, P NATL ACAD SCI USA, V100, P11612, DOI 10.1073/pnas.1930406100; Morishita E, 1997, NEUROSCIENCE, V76, P105, DOI 10.1016/s0306-4522(96)00306-5; MURRY CE, 1990, CIRC RES, V66, P913, DOI 10.1161/01.RES.66.4.913; PAFFETTLUGASSY N, 2002, BLOOD, V100, P2277; Parsa CJ, 2003, J CLIN INVEST, V112, P999, DOI 10.1172/JCI200318200; Ribatti D, 1999, BLOOD, V93, P2627, DOI 10.1182/blood.V93.8.2627.408k21_2627_2636; Rizzo JD, 2002, BLOOD, V100, P2303, DOI 10.1182/blood-2002-06-1767; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; Schneider S, 2001, AM J PHYSIOL-HEART C, V280, pH499; Siren AL, 2001, P NATL ACAD SCI USA, V98, P4044, DOI 10.1073/pnas.051606598; STEENBERGEN C, 1993, CIRC RES, V72, P112, DOI 10.1161/01.RES.72.1.112; Stuckmann I, 2003, DEV BIOL, V255, P334, DOI 10.1016/S0012-1606(02)00078-7; Suzuki N, 2002, BLOOD, V100, P2279, DOI 10.1182/blood-2002-01-0124; Tramontano AF, 2003, BIOCHEM BIOPH RES CO, V308, P990, DOI 10.1016/S0006-291X(03)01503-1; Wald MR, 1996, J CELL PHYSIOL, V167, P461, DOI 10.1002/(SICI)1097-4652(199606)167:3<461::AID-JCP10>3.3.CO;2-N; WINKELMANN JC, 1990, BLOOD, V76, P24; WOLFE CL, 1993, CIRCULATION, V87, P881, DOI 10.1161/01.CIR.87.3.881; Wu H, 1999, DEVELOPMENT, V126, P3597; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Yasuda Y, 1998, J BIOL CHEM, V273, P25381, DOI 10.1074/jbc.273.39.25381; Yu XB, 2002, DEVELOPMENT, V129, P505; Yu XB, 2001, BLOOD, V98, P475, DOI 10.1182/blood.V98.2.475	43	191	202	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					1031	+		10.1096/fj.03-1289fje	http://dx.doi.org/10.1096/fj.03-1289fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059965				2022-12-28	WOS:000221108800016
J	Francois, H; Placier, S; Flamant, M; Tharaux, PL; Chansel, D; Dussaule, JC; Chatziantoniou, C				Francois, H; Placier, S; Flamant, M; Tharaux, PL; Chansel, D; Dussaule, JC; Chatziantoniou, C			Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition	FASEB JOURNAL			English	Article						renal fibrosis; collagen; hypertension; endothelin	NITRIC-OXIDE SYNTHESIS; ANGIOTENSIN-II; HYPERTENSIVE-RATS; KINASE ACTIVATION; TRANSGENIC MICE; COLLAGEN GENE; EGF RECEPTOR; EXPRESSION; TRANSACTIVATION; HYPERTROPHY	Hypertension is frequently associated with the development of renal vascular and glomerular fibrosis. The purpose of the present study was to investigate whether epidermal growth factor receptor (EGFR) activation participates in the development of renal fibrosis and to test if blockade of EGFR activation would have therapeutic effects. Experiments were performed during nitric oxide (NO) deficiency-induced hypertension in rats (L-NAME model). After 4 weeks of L-NAME treatment, animals developed hypertension associated to deterioration of renal structure and function. Over the same period, EGFR was activated twofold within glomeruli. This activation was accompanied by increased activity of the mitogen-activated protein kinase (MAPK) p42/p44 pathway and exaggerated collagen I expression. Gefitinib, an EGFR-tyrosine kinase inhibitor, given concomitantly with L-NAME, normalized MAPK activation and collagen I expression and prevented the decline of renal function and the development of fibrosis. Since endothelin mediates the L-NAME-induced fibrogenesis, the endothelin-EGFR interaction was tested in transgenic mice expressing luciferase under the control of collagen I-alpha2 promoter: In renal cortex of these animals, the endothelin-induced collagen I gene activity was inhibited by an EGFR-phosphorylation inhibitor. These results provide the first evidence that EGFR activation plays an important role in the progression of renal vascular and glomerular fibrosis.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 06, UFR St Antoine, Physiol Lab, AP HP, F-75012 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); UDICE-French Research Universities; Sorbonne Universite	Chatziantoniou, C (corresponding author), INSERM, U489, F-75020 Paris, France.	christos.chatziantoniou@tnn.ap-hop-paris.fr	Chatziantoniou, Christos/L-2501-2016; Tharaux, Pierre-Louis/A-9155-2009	Tharaux, Pierre-Louis/0000-0002-6062-5905; Francois, Helene/0000-0001-7436-9554				ABBOUD HE, 1995, ANNU REV PHYSIOL, V57, P297; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bancroft J, 1982, THEORY PRACTICE HIST, P131; Boffa JJ, 1999, CIRCULATION, V100, P1901, DOI 10.1161/01.CIR.100.18.1901; Boffa JJ, 2003, J AM SOC NEPHROL, V14, P1132, DOI 10.1097/01.ASN.0000060574.38107.3B; BouGharios G, 1996, J CELL BIOL, V134, P1333, DOI 10.1083/jcb.134.5.1333; Bouriquet N, 1996, HYPERTENSION, V27, P382, DOI 10.1161/01.HYP.27.3.382; Brenner BM, 2001, NEW ENGL J MED, V345, P861, DOI 10.1056/NEJMoa011161; Brilla CG, 1996, HYPERTENSION, V28, P269, DOI 10.1161/01.HYP.28.2.269; BRILLA CG, 1991, CIRC RES, V69, P107, DOI 10.1161/01.RES.69.1.107; Buist A, 1998, BIOCHEM BIOPH RES CO, V251, P6, DOI 10.1006/bbrc.1998.9405; Chatziantoniou C, 1998, J CLIN INVEST, V101, P2780, DOI 10.1172/JCI2132; CRAWFORD DC, 1994, CIRC RES, V74, P727, DOI 10.1161/01.RES.74.4.727; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Flamant M, 2002, FASEB J, V16, P327, DOI 10.1096/fj.02-0115fje; Floege J, 1999, AM J PATHOL, V154, P169, DOI 10.1016/S0002-9440(10)65263-7; FLOEGE J, 1995, MINER ELECTROL METAB, V21, P271; Johnson DH, 2003, LUNG CANCER, V41, pS23, DOI 10.1016/S0169-5002(03)00136-3; Ju HS, 1996, MOL CELL BIOCHEM, V164, P231, DOI 10.1007/BF00408663; LI JS, 1994, HYPERTENSION, V24, P183, DOI 10.1161/01.HYP.24.2.183; Mendelsohn J, 2000, CLIN CANCER RES, V6, P747; Michel JB, 1996, J CARDIOVASC PHARM, V28, P142, DOI 10.1097/00005344-199607000-00021; Mizuno S, 1998, J CLIN INVEST, V101, P1827, DOI 10.1172/JCI1709; Moreau P, 1997, CIRCULATION, V96, P1593, DOI 10.1161/01.CIR.96.5.1593; Murasawa S, 1998, CIRC RES, V82, P1338, DOI 10.1161/01.RES.82.12.1338; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Richards WG, 1998, J CLIN INVEST, V101, P935, DOI 10.1172/JCI2071; Ruperez M, 2003, AM J PATHOL, V163, P1937, DOI 10.1016/S0002-9440(10)63552-3; Saito Y, 2001, J MOL CELL CARDIOL, V33, P3, DOI 10.1006/jmcc.2000.1272; Strutz F, 2000, KIDNEY INT, V57, P1521, DOI 10.1046/j.1523-1755.2000.00997.x; Suzuki H, 2003, CANCER RES, V63, P5054; Swaisland H, 2001, CLIN PHARMACOKINET, V40, P297, DOI 10.2165/00003088-200140040-00005; Takemoto M, 1997, J CLIN INVEST, V99, P278, DOI 10.1172/JCI119156; Terzi F, 2000, J CLIN INVEST, V106, P225, DOI 10.1172/JCI8315; Tharaux PL, 1999, CIRCULATION, V99, P2185, DOI 10.1161/01.CIR.99.16.2185; Vargas GA, 2000, KIDNEY INT, V57, P1426, DOI 10.1046/j.1523-1755.2000.00987.x; Wakeling AE, 2002, CANCER RES, V62, P5749; Weber KT, 2000, CIRCULATION, V102, P1342, DOI 10.1161/01.CIR.102.12.1342; WOLF G, 1991, KIDNEY INT, V39, P401, DOI 10.1038/ki.1991.52; YOSHIOKA K, 1990, J PATHOL, V162, P141, DOI 10.1002/path.1711620207; Zatz R, 1998, HYPERTENSION, V32, P958, DOI 10.1161/01.HYP.32.6.958	41	98	101	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					926	+		10.1096/fj.03-0702fje	http://dx.doi.org/10.1096/fj.03-0702fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033924				2022-12-28	WOS:000220522800008
J	Lombardo, F; Komatsu, D; Hadjiargyrou, M				Lombardo, F; Komatsu, D; Hadjiargyrou, M			Molecular cloning and characterization of Mustang, a novel nuclear protein expressed during skeletal development and regeneration	FASEB JOURNAL			English	Article						fracture; repair; healing; novel; gene	MEDIATED TRANSCRIPTIONAL REPRESSION; FRACTURE REPAIR; GROUCHO; PHOSPHORYLATION; GROWTH; MATRIX	Bone regeneration occurs as a series of events that requires temporal and spatial orchestration of numerous cell types guided by the transcriptional activity of thousands of genes, as recently demonstrated by our laboratory. Using the rat femoral fracture model, bioinformatics, cloning, expression assays, fusion proteins, and transfection, we report on the identification and characterization of one such differentially expressed gene, termed Mustang (musculoskeletal temporally activated novel gene). Mustang encodes for an 82 amino acid nuclear protein with no homology to any known protein family. However, other species homologues (mouse, human, cow) were identified within EST (expressed sequence tag) databases. Nuclear localization was confirmed using a GFP-Mustang fusion protein. Using in situ hybridization, Mustang expression was localized to differentiating periosteal osteogenic cells, proliferating chondrocytes, and osteoblasts of the fracture callus. Unlike adult tissues, developing embryos abundantly express Mustang, especially in mesenchymal condensations of limbs, vertebral perichondrium, and mesenchymal cells of the intervertebral discs. Although the precise function of Mustang is unknown, its unique pattern of expression during bone development and regeneration, absence in adult tissues (except skeletal muscle and tendon), and nuclear localization suggest that Mustang is involved in the development and regeneration of the mammalian musculoskeletal system.	SUNY Stony Brook, Dept Biomed Engn, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Orthopaed, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hadjiargyrou, M (corresponding author), SUNY Stony Brook, Dept Biomed Engn, Psychol A Bldg, Stony Brook, NY 11794 USA.	Michael.Hadjiargyrou@sunysb.edu	Hadjiargyrou, Michael/H-7191-2018	Hadjiargyrou, Michael/0000-0001-8927-2333				BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Einhorn TA, 1998, CLIN ORTHOP RELAT R, pS7; Ferguson C, 1999, MECH DEVELOP, V87, P57, DOI 10.1016/S0925-4773(99)00142-2; Ferguson CM, 1998, ANN NY ACAD SCI, V857, P33, DOI 10.1111/j.1749-6632.1998.tb10105.x; GARMAN R, 2001, ANN BIOMED ENG, V29, pS89; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Hadjiargyrou M, 2002, J BIOL CHEM, V277, P30177, DOI 10.1074/jbc.M203171200; Hadjiargyrou M, 1998, BIOCHEM BIOPH RES CO, V249, P879, DOI 10.1006/bbrc.1998.9167; Hadjiargyrou M, 2001, BONE, V29, P149, DOI 10.1016/S8756-3282(01)00489-6; Hadjiargyrou M, 2000, J BONE MINER RES, V15, P1014, DOI 10.1359/jbmr.2000.15.6.1014; Javed A, 2000, J CELL SCI, V113, P2221; JINGUSHI S, 1992, J BONE MINER RES, V7, P1045; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; Nuthall HN, 2002, J BIOL CHEM, V277, P51049, DOI 10.1074/jbc.M111660200; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; SANDBERG MM, 1993, CLIN ORTHOP RELAT R, P292; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Vortkamp A, 1998, MECH DEVELOP, V71, P65, DOI 10.1016/S0925-4773(97)00203-7; Zhi J, 2001, J BONE MINER RES, V16, P1994, DOI 10.1359/jbmr.2001.16.11.1994	24	35	38	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					52	61		10.1096/fj.03-0521com	http://dx.doi.org/10.1096/fj.03-0521com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718386				2022-12-28	WOS:000188829300039
J	Hein, TW; Zhang, CH; Wang, W; Chang, CI; Thengchaisri, N; Kuo, L				Hein, TW; Zhang, CH; Wang, W; Chang, CI; Thengchaisri, N; Kuo, L			Ischemia-reperfusion selectively impairs nitric oxide-mediated dilation in coronary arterioles: counteracting role of arginase	FASEB JOURNAL			English	Article						endothelium; ischemia; L-arginine; microcirculation; vasodilation	ENDOTHELIUM-DEPENDENT RELAXATION; MYOCARDIAL-ISCHEMIA; L-ARGININE; EXPRESSION; INJURY; CELLS; INFARCTION; SYNTHASE; ALPHA; DYSFUNCTION	A reduction in L-arginine availability has been implicated in the impairment of endothelium-dependent nitric oxide (NO)-mediated vasodilation by ischemia-reperfusion (I/R). However, the mechanisms contributing to dysregulation of the L-arginine pool remain unknown. Because endothelial cells can metabolize L-arginine via two major enzymes, that is, NO synthase (NOS) and arginase, we hypothesized that up-regulation of arginase during I/R reduces L-arginine availability to NOS and thus impairs NO-mediated vasodilation. To test this hypothesis, a local I/R was produced in the porcine heart by occlusion of a small branch of left anterior descending artery for 30 min, followed by reperfusion for 90 min. Arterioles (60-110 mum) isolated from non-ischemic and ischemic regions of subepicardium were cannulated and pressurized without flow for in vitro study. Vessels from both regions developed similar levels of basal tone. Although the dilation of I/R vessels to endothelium-independent agonist sodium nitroprusside was not altered, the endothelium-dependent NO-mediated dilations to adenosine and serotonin were attenuated. I/R not only inhibited arteriolar production of NO but also increased arteriolar arginase activity. Arginase inhibitor alpha-difluoromethylornithine enhanced NO production/dilation in normal vessels and also restored the NO-mediated function in I/R vessels. Treating I/R vessels with L-arginine also restored vasodilations. Immunohistochemical data revealed that I/R upregulated arginase but down-regulated NOS expression in the arteriolar endothelium. Pretreating the animals with protein synthesis inhibitor cycloheximide prevented I/R-induced arginase upregulation and also preserved NO-mediated vascular function. These results suggest that one mechanism by which I/R inhibits NO-mediated arteriolar dilation is through increased arginase activity, which limits the availability of L-arginine to NOS for NO production. In addition, the inability of arginase blockade or L-arginine supplementation to completely restore vasodilatory function may be attributable to the down-regulation of endothelial NOS expression.	Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Kuo, L (corresponding author), Texas A&M Univ Syst Hlth Sci Ctr, Coll Med, Cardiovasc Res Inst, Dept Med Physiol, College Stn, TX 77843 USA.	LKUO@tamu.edu	Thengchaisri, Naris/AAN-3260-2020	Thengchaisri, Naris/0000-0003-0815-0743; Kuo, Lih/0000-0002-4912-6910				Abd-El-Aleem SA, 2000, J PATHOL, V191, P434, DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH654>3.0.CO;2-S; BOLTON JE, 1977, J ENDOCRINOL, V74, P213, DOI 10.1677/joe.0.0740213; Bruch-Gerharz D, 2003, AM J PATHOL, V162, P203, DOI 10.1016/S0002-9440(10)63811-4; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988, DOI 10.1152/ajpheart.1996.271.5.H1988; Carden DL, 2000, J PATHOL, V190, P255, DOI 10.1002/(SICI)1096-9896(200002)190:3<255::AID-PATH526>3.0.CO;2-6; Corraliza I, 2002, J RHEUMATOL, V29, P2261; Domoki F, 1999, AM J PHYSIOL-HEART C, V277, pH1113, DOI 10.1152/ajpheart.1999.277.3.H1113; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Frangogiannis NG, 1998, CIRCULATION, V98, P699, DOI 10.1161/01.CIR.98.7.699; Frangogiannis NG, 2002, CARDIOVASC RES, V53, P31, DOI 10.1016/S0008-6363(01)00434-5; Hein TW, 1998, CIRC RES, V83, P404, DOI 10.1161/01.RES.83.4.404; Hein TW, 1999, CIRC RES, V85, P634, DOI 10.1161/01.RES.85.7.634; Hein TW, 2000, AM J PHYSIOL-HEART C, V278, pH175, DOI 10.1152/ajpheart.2000.278.1.H175; Hesse M, 2001, J IMMUNOL, V167, P6533, DOI 10.4049/jimmunol.167.11.6533; ITO H, 1992, CIRCULATION, V85, P1699, DOI 10.1161/01.CIR.85.5.1699; Ito H, 1996, CIRCULATION, V93, P1993, DOI 10.1161/01.CIR.93.11.1993; Jenkinson CP, 1996, COMP BIOCHEM PHYS B, V114, P107, DOI 10.1016/0305-0491(95)02138-8; Kalweit GA, 2001, J THORAC CARDIOV SUR, V122, P1011, DOI 10.1067/mtc.2001.115158; Kanno S, 2000, CIRCULATION, V101, P2742, DOI 10.1161/01.CIR.101.23.2742; Katusic ZS, 2001, AM J PHYSIOL-HEART C, V281, pH981, DOI 10.1152/ajpheart.2001.281.3.H981; KU DD, 1982, SCIENCE, V218, P576, DOI 10.1126/science.7123259; KUO L, 1991, AM J PHYSIOL, V261, pH1706, DOI 10.1152/ajpheart.1991.261.6.H1706; KUO L, 1988, AM J PHYSIOL, V255, pH1558, DOI 10.1152/ajpheart.1988.255.6.H1558; Kupatt C, 1999, CIRC RES, V84, P392, DOI 10.1161/01.RES.84.4.392; LAWSON DL, 1990, FREE RADICAL BIO MED, V8, P373, DOI 10.1016/0891-5849(90)90103-P; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; LEFER AM, 1991, CHEST, V100, pS160; Moali C, 2000, BIOCHEMISTRY-US, V39, P8208, DOI 10.1021/bi992992v; Moudgil R, 2002, CAN J CARDIOL, V18, P1107; Nelin LD, 2001, AM J PHYSIOL-LUNG C, V281, pL1232, DOI 10.1152/ajplung.2001.281.5.L1232; Porembska Z, 2003, CLIN CHIM ACTA, V328, P105, DOI 10.1016/S0009-8981(02)00391-1; QUILLEN JE, 1990, CIRCULATION, V82, P586, DOI 10.1161/01.CIR.82.2.586; Roe MT, 2001, J AM COLL CARDIOL, V37, P9, DOI 10.1016/S0735-1097(00)01101-3; Sakata Y, 1997, AM HEART J, V133, P616, DOI 10.1016/S0002-8703(97)70162-5; Selamnia M, 1998, BIOCHEM PHARMACOL, V55, P1241, DOI 10.1016/S0006-2952(97)00572-8; Shimizu Y, 2002, J AM COLL CARDIOL, V40, P1347, DOI 10.1016/S0735-1097(02)02158-7; SMIRNOV VN, 1974, CIRC RES, V35, P58; Tiefenbacher CP, 1996, CIRCULATION, V94, P1423, DOI 10.1161/01.CIR.94.6.1423; Trouba KJ, 2002, ANTIOXID REDOX SIGN, V4, P665, DOI 10.1089/15230860260220175; TSAO PS, 1990, CIRCULATION, V82, P1402, DOI 10.1161/01.CIR.82.4.1402; VANWYLEN DGL, 1994, CIRCULATION, V89, P2283, DOI 10.1161/01.CIR.89.5.2283; Waddington SN, 1998, BIOCHEM BIOPH RES CO, V247, P84, DOI 10.1006/bbrc.1998.8755; Wei LH, 2000, AM J PHYSIOL-CELL PH, V279, pC248, DOI 10.1152/ajpcell.2000.279.1.C248; WEYRICH AS, 1992, CIRCULATION, V86, P279, DOI 10.1161/01.CIR.86.1.279; WU GY, 1995, AM J PHYSIOL-HEART C, V269, pH1312, DOI 10.1152/ajpheart.1995.269.4.H1312; Xu Y, 2000, HYPERTENSION, V36, P506, DOI 10.1161/01.HYP.36.4.506; Yang BC, 1997, CIRCULATION, V96, P922; Zhang CH, 2001, FASEB J, V15, P1264, DOI 10.1096/fj.00-0681fje	48	142	142	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2328	+		10.1096/fj.03-0115fje	http://dx.doi.org/10.1096/fj.03-0115fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563685				2022-12-28	WOS:000186343300028
J	John, AE; Lukacs, NW; Berlin, AA; Palecanda, A; Bargatze, RF; Stoolman, LM; Nagy, JO				John, AE; Lukacs, NW; Berlin, AA; Palecanda, A; Bargatze, RF; Stoolman, LM; Nagy, JO			Discovery of a potent nanoparticle P-selectin antagonist with anti-inflammatory effects in allergic airway disease	FASEB JOURNAL			English	Article						selectin inhibitor; asthma; eosinophil; lung	LOW-MOLECULAR-WEIGHT; COCKROACH ALLERGEN; ENDOTHELIAL-CELLS; CHILDHOOD ASTHMA; IN-VIVO; ADHESION; EXPRESSION; RECRUITMENT; INHIBITION; HYPERREACTIVITY	The severity of allergic asthma is dependent, in part, on the intensity of peribronchial inflammation. P-selectin is known to play a role in the development of allergen-induced peribronchial inflammation and airway hyperreactivity. Selective inhibitors of P-selectin-mediated leukocyte endothelial-cell interactions may therefore attenuate the inflammatory processes associated with allergic airway disease. Novel P-selectin inhibitors were created using a polyvalent polymer nanoparticle capable of displaying multiple synthetic, low molecular weight ligands. By assembling a particle that presents an array of groups, which as monomers interact with only low affinity, we created a construct that binds extremely efficiently to P-selectin. The ligands acted as mimetics of the key binding elements responsible for the high-avidity adhesion of P-selectin to the physiologic ligand, PSGL-1. The inhibitors were initially evaluated using an in vitro shear assay system in which interactions between circulating cells and P-selectin-coated capillary tubes were measured. The nanoparticles were shown to preferentially bind to selectins expressed on activated endothelial cells. We subsequently demonstrated that nanoparticles displaying P-selectin blocking arrays were functionally active in vivo, significantly reducing allergen-induced airway hyperreactivity and peribronchial eosinophilic inflammation in a murine model of asthma.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; LigoCyte Pharmaceut Inc, Bozeman, MT 59718 USA	University of Michigan System; University of Michigan	Lukacs, NW (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine, Ann Arbor, MI 48109 USA.	nlukacs@umich.edu	Lukacs, Nicholas W/ABH-5583-2020	John, Alison/0000-0002-0453-3221	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R44AI043789, R43AI043789] Funding Source: NIH RePORTER; NIAID NIH HHS [R44 AI043789, R43 AI043789-01, R44 AI043789-03, R44 AI043789-04, R44 AI043789-02] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Asher MI, 1998, EUR RESPIR J, V12, P315; BARGATZE RF, 1994, J IMMUNOL, V152, P5814; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bendas G, 1998, Pharm Acta Helv, V73, P19, DOI 10.1016/S0031-6865(97)00043-5; Bless NM, 1998, AM J PATHOL, V153, P1113, DOI 10.1016/S0002-9440(10)65655-6; Broide DH, 1998, AM J RESP CELL MOL, V18, P218, DOI 10.1165/ajrcmb.18.2.2829; Bruehl RE, 2001, BIOCHEMISTRY-US, V40, P5964, DOI 10.1021/bi002921s; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; DeSanctis GT, 1997, J APPL PHYSIOL, V83, P681, DOI 10.1152/jappl.1997.83.3.681; Edwards BS, 2000, J IMMUNOL, V165, P404, DOI 10.4049/jimmunol.165.1.404; Eppihimer MJ, 1996, CIRC RES, V79, P560, DOI 10.1161/01.RES.79.3.560; Galustian C, 2002, IMMUNOLOGY, V105, P350, DOI 10.1046/j.1365-2567.2002.01369.x; Hartert T V, 2000, Curr Opin Pulm Med, V6, P4, DOI 10.1097/00063198-200001000-00002; Hicks AER, 2002, FASEB J, V16, P1461, DOI 10.1096/fj.02-0075fje; Ikami T, 1998, CHEM PHARM BULL, V46, P797; Kaila N, 2002, MED RES REV, V22, P566, DOI 10.1002/med.10018; Kaila N, 2001, BIOORGAN MED CHEM, V9, P801, DOI 10.1016/S0968-0896(00)00298-4; Kessner S, 2001, BBA-BIOMEMBRANES, V1514, P177, DOI 10.1016/S0005-2736(01)00368-6; Knibbs RN, 1998, J IMMUNOL, V161, P6305; Koenig A, 1998, J CLIN INVEST, V101, P877, DOI 10.1172/JCI1509; Kurokawa K, 2000, BIOORG MED CHEM LETT, V10, P1827, DOI 10.1016/S0960-894X(00)00358-9; LEY K, 1991, AM J PHYSIOL, V260, pH1667, DOI 10.1152/ajpheart.1991.260.5.H1667; Lukacs NW, 2002, J IMMUNOL, V169, P2120, DOI 10.4049/jimmunol.169.4.2120; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Marinier A, 2001, BIOORGAN MED CHEM, V9, P1395, DOI 10.1016/S0968-0896(01)00015-3; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Nishida Y, 2000, BIOMACROMOLECULES, V1, P68, DOI 10.1021/bm990011o; Ohta S, 2001, INFLAMM RES, V50, P544, DOI 10.1007/PL00000232; PERRY MA, 1991, J CLIN INVEST, V87, P1798, DOI 10.1172/JCI115200; Pochechueva TV, 2002, CHEM BIOL, V9, P757, DOI 10.1016/S1074-5521(02)00157-6; R. New, 1990, LIPOSOMES A PRACTICA, P33; RINGSDORF H, 1988, ANGEW CHEM INT EDIT, V27, P113, DOI 10.1002/anie.198801131; Romano S J, 2001, Curr Opin Investig Drugs, V2, P907; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Schon MP, 2002, NAT MED, V8, P366, DOI 10.1038/nm0402-366; Sears P, 1999, ANGEW CHEM INT EDIT, V38, P2301; Shapiro GG, 2002, PEDIATR PULM, V33, P47, DOI 10.1002/ppul.10029; SIMANEK EE, 1998, ANGEW CHEM INT EDIT, V38, P2300; Skoner DP, 2002, PEDIATRICS, V109, P381; Slee DH, 2001, J MED CHEM, V44, P2094, DOI 10.1021/jm000508c; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Spragg DD, 1997, P NATL ACAD SCI USA, V94, P8795, DOI 10.1073/pnas.94.16.8795; Stahn R, 2001, CELL MOL LIFE SCI, V58, P141, DOI 10.1007/PL00000774; Symon FA, 1996, J IMMUNOL, V157, P1711; Tang MLK, 2001, PULM PHARMACOL THER, V14, P203, DOI 10.1006/pupt.2001.0293; TEDDER TF, 1995, FASEB J, V9, P866, DOI 10.1096/fasebj.9.10.7542213; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wolber FM, 1997, AM J PATHOL, V151, P1715; Woltmann G, 2000, BLOOD, V95, P3146	52	50	59	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2296	+		10.1096/fj.03-0166fje	http://dx.doi.org/10.1096/fj.03-0166fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563683	Green Accepted, Green Submitted			2022-12-28	WOS:000186343300024
J	Boelaert, K; Tannahill, LA; Bulmer, JN; Kachilele, S; Chan, SY; Kim, D; Gittoes, NJL; Franklyn, JA; Kilby, MD; Mccabe, CJ				Boelaert, K; Tannahill, LA; Bulmer, JN; Kachilele, S; Chan, SY; Kim, D; Gittoes, NJL; Franklyn, JA; Kilby, MD; Mccabe, CJ			A potential role for PTTG/securin in the developing human fetal brain	FASEB JOURNAL			English	Article						embryonic expression; proliferation; NT-2	TUMOR-TRANSFORMING GENE; FIBROBLAST-GROWTH-FACTOR; NORMAL HUMAN-TISSUES; CHROMATID SEPARATION; HIPPOCAMPAL-NEURONS; PITUITARY-TUMORS; CEREBRAL-CORTEX; THYROID-HORMONE; NERVOUS-SYSTEM; C-MYC	Human securin, known also as PTTG, has established oncogenic and cell cycle regulatory functions. PTTG/securin transforms cells in vitro, inhibits sister chromatid separation, and regulates secretion of fibroblast growth factor-2. FGF-2 is a key regulator of CNS development and PTTG/securin expression has been reported in murine fetal brain. We examined the expression and function of securin and FGF-2 in the developing human fetal brain and in a fetal neuronal cell line (NT 2). Securin expression was significantly reduced in first and second trimester fetal cerebral cortex compared with adult cerebral cortex, where immunocytochemistry revealed intense securin staining in neuronal cell bodies. FGF-2 protein was concordantly lower in fetal cortex, whereas pretranslational expression of PTTG binding factor (PBF) was not significantly altered in fetal brain compared with adult. PCNA expression demonstrated that high securin levels in adult cortex were associated with absent cell proliferation. In NT-2 cells, securin stimulated FGF-2 expression, which could be abrogated by a carboxyl-terminal mutation. Low transient expression of securin resulted in a significant proliferative effect, whereas high levels of securin expression inhibited cell turnover. We propose a potential role for human PTTG/securin in modulating cell proliferation and FGF-2 expression during human neurogenesis.	Univ Birmingham, Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; Univ Birmingham, Queen Elizabeth Hosp, Div Reprod & Child Hlth, Birmingham B15 2TH, W Midlands, England; Univ Newcastle Upon Tyne, Royal Victoria Infirm, Dept Pathol, Sch Clin & Lab Sci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	University of Birmingham; University of Birmingham; Newcastle University - UK	Mccabe, CJ (corresponding author), Univ Birmingham, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	mccabcjz@bham.ac.uk	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/AAW-9704-2020; Chan, Shiao/C-8347-2011	FRCPI, Mark D Kilby MB BS DSc MD FRCOG/0000-0001-9987-4223; Chan, Shiao-Yng/0000-0002-3530-3023				Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Chan S, 2002, DEV BRAIN RES, V138, P109, DOI 10.1016/S0165-3806(02)00459-5; Chien WW, 2000, J BIOL CHEM, V275, P19422, DOI 10.1074/jbc.M910105199; Ciruna BG, 1997, DEVELOPMENT, V124, P2829; CORDONCARDO C, 1990, LAB INVEST, V63, P832; Dono R, 1998, EMBO J, V17, P4213, DOI 10.1093/emboj/17.15.4213; ECKENSTEIN FP, 1994, J NEUROBIOL, V25, P1467; FURTH ME, 1987, ONCOGENE, V1, P47; Ghosh MM, 1995, BIOREMED SER, V3, P15; Gittoes NJL, 1997, J CLIN ENDOCR METAB, V82, P1960, DOI 10.1210/jc.82.6.1960; Gonzalez AM, 1996, PEDIATR RES, V39, P375, DOI 10.1203/00006450-199603000-00001; Heaney AP, 1999, NAT MED, V5, P1317, DOI 10.1038/15275; Heaney AP, 2001, J CLIN ENDOCR METAB, V86, P5025, DOI 10.1210/jc.86.10.5025; HERN WM, 1984, OBSTET GYNECOL, V63, P26; HIRVONEN H, 1990, ONCOGENE, V5, P1787; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; Ishikawa H, 2001, J CLIN ENDOCR METAB, V86, P867, DOI 10.1210/jc.86.2.867; Kakar SS, 2001, J HISTOCHEM CYTOCHEM, V49, P1537, DOI 10.1177/002215540104901207; Lemaitre JM, 1996, ADV CANCER RES, V70, P95, DOI 10.1016/S0065-230X(08)60873-8; McCabe CJ, 2003, CLIN ENDOCRINOL, V58, P141, DOI 10.1046/j.1365-2265.2003.01598.x; McCabe CJ, 2002, J CLIN ENDOCR METAB, V87, P4238, DOI 10.1210/jc.2002-020309; MYERS C, 1991, AM J REPROD IMMUNOL, V25, P133, DOI 10.1111/j.1600-0897.1991.tb01081.x; Nakagawara A, 2001, CANCER LETT, V169, P107, DOI 10.1016/S0304-3835(01)00530-4; NURCOMBE V, 1993, SCIENCE, V260, P103, DOI 10.1126/science.7682010; Ortega S, 1998, P NATL ACAD SCI USA, V95, P5672, DOI 10.1073/pnas.95.10.5672; PAVELIC K, 1991, International Journal of Developmental Biology, V35, P209; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; PETROSKI RE, 1991, DEV BIOL, V147, P1, DOI 10.1016/S0012-1606(05)80002-8; *POLK REP, 1998, REV GUID RES US FET; Qian XM, 1997, NEURON, V18, P81, DOI 10.1016/S0896-6273(01)80048-9; Ramos-Morales F, 2000, ONCOGENE, V19, P403, DOI 10.1038/sj.onc.1203320; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; SCHMUTZLER RK, 1992, HUM REPROD, V7, P25, DOI 10.1093/humrep/7.suppl_1.25; Tarabykin V, 2000, MECH DEVELOP, V92, P301, DOI 10.1016/S0925-4773(00)00243-4; VICARIOABEJON C, 1995, NEURON, V15, P105, DOI 10.1016/0896-6273(95)90068-3; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; WEISE B, 1993, J NEUROSCI RES, V34, P442, DOI 10.1002/jnr.490340409; Yu R, 2000, MOL ENDOCRINOL, V14, P1137, DOI 10.1210/me.14.8.1137; Yu R, 2001, BRAIN PATHOL, V11, P328; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	44	39	40	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1631	1639		10.1096/fj.02-0948com	http://dx.doi.org/10.1096/fj.02-0948com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958169				2022-12-28	WOS:000185925100037
J	Song, LT; Mandecki, W; Goldman, E				Song, LT; Mandecki, W; Goldman, E			Expression of non-open reading frames isolated from phage display due to translation reinitiation	FASEB JOURNAL			English	Article						E. coli protein synthesis; internal initiation of translation; non-ORF expression; UGA stop codons	REPRESSOR MESSENGER-RNA; ESCHERICHIA-COLI; PROTEIN-SYNTHESIS; PEPTIDE LIBRARY; BINDING-SITE; INITIATION; RIBOSOME; SEQUENCE; BACTERIOPHAGE-T4; ACCURACY	An unusual 38 codon sequence was previously isolated from a random peptide library by binding to growth hormone binding protein in phage display. This sequence, "H10," and several variants did not contain open reading frames, but expressed a beta-galactosidase reporter 10 - 40% as well as control in both the original reading frame from phage display and the frame - 1 to it. Inspection of the sequence suggested that expression in the - 1 frame resulted from initiation at a downstream ATG in that frame, present in H10 and its variants, subsequently confirmed by site-directed mutagenesis. Unexpectedly, mutagenesis of that out-of-frame downstream ATG also increased expression in the original non-open reading frame by two- to threefold, creating a TTG codon adjacent to an existing in-frame TTG codon, suggesting downstream translational reinitiation at a putative TTG start. We undertook an extensive site-directed mutagenesis approach and report that this hypothesis is almost certainly correct. Features required for this reinitiation include an upstream translation start and a stop that can even be a suppressed amber codon 22 nucleotides further downstream from the restart. Replacing the TTG with ATG increases expression only twofold. Reinitiation occurs in either of two reading frames in this sequence.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Newark, NJ 07101 USA; Pharmaseq Inc, Monmouth Jct, NJ USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Goldman, E (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, 225 Warren St,POB 1709, Newark, NJ 07101 USA.	egoldman@umdnj.edu	Song, Liting/F-3724-2011	Song, Liting/0000-0001-9789-7616				ADHIN MR, 1990, J MOL BIOL, V213, P811, DOI 10.1016/S0022-2836(05)80265-7; Andre A, 2000, FEBS LETT, V468, P73, DOI 10.1016/S0014-5793(00)01198-4; BARRICK D, 1994, NUCLEIC ACIDS RES, V22, P1287, DOI 10.1093/nar/22.7.1287; BERKHOUT B, 1985, GENE, V37, P171, DOI 10.1016/0378-1119(85)90270-7; Carcamo J, 1998, P NATL ACAD SCI USA, V95, P11146, DOI 10.1073/pnas.95.19.11146; CURRAN JF, 1986, P NATL ACAD SCI USA, V83, P6538, DOI 10.1073/pnas.83.17.6538; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; GAO WW, 1995, J MOL BIOL, V251, P210, DOI 10.1006/jmbi.1995.0428; Gesteland RF, 1996, ANNU REV BIOCHEM, V65, P741, DOI 10.1146/annurev.bi.65.070196.003521; Goldman E, 2000, FASEB J, V14, P603, DOI 10.1096/fasebj.14.3.603; Gutkina NI, 2002, BIOCHEM BIOPH RES CO, V298, P37, DOI 10.1016/S0006-291X(02)02392-6; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; MANLEY JL, 1978, J MOL BIOL, V125, P449, DOI 10.1016/0022-2836(78)90310-8; MATTESON RJ, 1991, NUCLEIC ACIDS RES, V19, P3499, DOI 10.1093/nar/19.13.3499; Miller J. H, 1972, EXPT MOL GENETICS; NAPOLI C, 1981, J MOL BIOL, V149, P433, DOI 10.1016/0022-2836(81)90480-0; NELSON M, 1992, METHOD ENZYMOL, V216, P279; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; RINGQUIST S, 1992, MOL MICROBIOL, V6, P1219, DOI 10.1111/j.1365-2958.1992.tb01561.x; Sambrook J., 2002, MOL CLONING LAB MANU; Sasaki J, 2000, P NATL ACAD SCI USA, V97, P1512, DOI 10.1073/pnas.010426997; SHINEDLING S, 1987, J MOL BIOL, V195, P471, DOI 10.1016/0022-2836(87)90176-8; SIPLEY J, 1993, P NATL ACAD SCI USA, V90, P2315, DOI 10.1073/pnas.90.6.2315; SPANJAARD RA, 1989, NUCLEIC ACIDS RES, V17, P5501, DOI 10.1093/nar/17.14.5501; STEEGE DA, 1977, P NATL ACAD SCI USA, V74, P4163, DOI 10.1073/pnas.74.10.4163; Stenstrom CM, 2002, GENE, V288, P1, DOI 10.1016/S0378-1119(02)00501-2; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Yu JS, 2001, MOL MICROBIOL, V42, P821, DOI 10.1046/j.1365-2958.2001.02681.x; Zemsky J, 2002, GENE EXPRESSION, V10, P109	31	4	4	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					1674	1681		10.1096/fj.03-0105com	http://dx.doi.org/10.1096/fj.03-0105com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958174				2022-12-28	WOS:000185925100042
J	Shao, CL; Furusawa, Y; Kobayashi, Y; Funayama, T; Wada, S				Shao, CL; Furusawa, Y; Kobayashi, Y; Funayama, T; Wada, S			Bystander effect induced by counted high-LET particles in confluent human fibroblasts: a mechanistic study	FASEB JOURNAL			English	Article						microbeam; micronucleus; gap junction; reactive oxygen species	TISSUE-CULTURE MODEL; ALPHA-PARTICLES; MAMMALIAN-CELLS; INTERCELLULAR COMMUNICATION; LOW FLUENCES; IONIZING-RADIATION; GAMMA-IRRADIATION; MICROBEAM; SINGLE; INDUCTION	The possible mechanism of a radiation-induced bystander response was investigated by using a high-LET heavy particle microbeam, which allows selected cells to be individually hit with precise numbered particles. Even when only a single cell within the confluent culture was hit by one particle of Ar-40 (similar to1260 keV/mum) or Ne-20 (similar to380 keV/mum), a 1.4-fold increase of micronuclei (MN) was detected demonstrating a bystander response. When the number of targeted cells increased, the number of MN biphasically increased; however, the efficiency of MN induction per targeted cell markedly decreased. When 49 cells in the culture were individually hit by 1 to 4 particles, the production of MN in the irradiated cultures were similar to2-fold higher than control levels but independent of the number and LET of the particles. MN induction in the irradiated-culture was partly reduced by treatment with DMSO, a scavenger of reactive oxygen species (ROS), and was almost fully suppressed by the mixture of DMSO and PMA, an inhibitor of gap junctional intercellular communication (GJIC). Accordingly, both ROS and GJIC contribute to the above-mentioned bystander response and GJIC may play an essential role by mediating the release of soluble biochemical factors from targeted cells.	Natl Inst Radiol Sci, Heavy Ion Radiobiol Res Grp, Chiba 2638555, Japan; Japan Atom Energy Res Inst, Takasaki Radiat Chem Res Estab, Biotechnol Lab, Takasaki, Gumma 3701201, Japan	National Institutes for Quantum Science & Technology; Japan Atomic Energy Agency	Furusawa, Y (corresponding author), Natl Inst Radiol Sci, Heavy Ion Radiobiol Res Grp, 4-9-1 Anagawa, Chiba 2638555, Japan.	Shao@gci.ac.uk; Furusawa@nirs.go.jp	Furusawa, Yoshiya/A-4487-2012	Furusawa, Yoshiya/0000-0003-4213-7331; Shao, Chunlin/0000-0001-9336-9912; /0000-0003-4250-4269				Azzam EI, 1998, RADIAT RES, V150, P497, DOI 10.2307/3579865; Azzam EI, 2001, P NATL ACAD SCI USA, V98, P473, DOI 10.1073/pnas.011417098; Azzam EI, 2000, CANCER RES, V60, P2623; Belyakov OV, 2001, BRIT J CANCER, V84, P674, DOI 10.1054/bjoc.2000.1665; Bishayee A, 1999, RADIAT RES, V152, P88, DOI 10.2307/3580054; Bishayee A, 2001, RADIAT RES, V155, P335, DOI 10.1667/0033-7587(2001)155[0335:FRIAGJ]2.0.CO;2; Deshpande A, 1996, RADIAT RES, V145, P260, DOI 10.2307/3578980; Ehrhart EJ, 1997, FASEB J, V11, P991, DOI 10.1096/fasebj.11.12.9337152; ELFOULY MH, 1987, EXP CELL RES, V168, P422, DOI 10.1016/0014-4827(87)90014-0; EWING D, 1991, RADIAT RES, V126, P187, DOI 10.2307/3577817; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; FENECH M, 1993, ENVIRON HEALTH PERSP, V101, P101, DOI 10.2307/3431708; Folkard M, 1997, INT J RADIAT BIOL, V72, P375, DOI 10.1080/095530097143158; Folkard M, 2001, RADIAT RES, V156, P796, DOI 10.1667/0033-7587(2001)156[0796:AFUXRM]2.0.CO;2; Folkard M, 1997, INT J RADIAT BIOL, V72, P387, DOI 10.1080/095530097143167; Furusawa Y, 2000, RADIAT RES, V154, P485, DOI 10.1667/0033-7587(2000)154[0485:IOAAHC]2.0.CO;2; Hei TK, 1997, P NATL ACAD SCI USA, V94, P3765, DOI 10.1073/pnas.94.8.3765; *ICRP, 1994, ANN ICRP, V24, P1; Iyer R, 2000, CANCER RES, V60, P1290; Iyer R, 2000, ARCH BIOCHEM BIOPHYS, V376, P14, DOI 10.1006/abbi.1999.1684; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; Little JB, 2000, CARCINOGENESIS, V21, P397, DOI 10.1093/carcin/21.3.397; Matsumoto H, 2001, RADIAT RES, V155, P387, DOI 10.1667/0033-7587(2001)155[0387:IORBAN]2.0.CO;2; Mothersill C, 1998, RADIAT RES, V149, P256, DOI 10.2307/3579958; Mothersill C, 2001, RADIAT RES, V155, P759, DOI 10.1667/0033-7587(2001)155[0759:RIBEPH]2.0.CO;2; Nagasawa H, 2002, CANCER RES, V62, P2531; NAGASAWA H, 1992, CANCER RES, V52, P6394; Narayanan PK, 1997, CANCER RES, V57, P3963; Prise KM, 1998, INT J RADIAT BIOL, V74, P793, DOI 10.1080/095530098141087; Randers-Pehrson G, 2001, RADIAT RES, V156, P210, DOI 10.1667/0033-7587(2001)156[0210:TCUSIM]2.0.CO;2; Seymour C B, 1997, Radiat Oncol Investig, V5, P106, DOI 10.1002/(SICI)1520-6823(1997)5:3<106::AID-ROI4>3.0.CO;2-1; Shao C, 2002, INT J RADIAT BIOL, V78, P837, DOI 10.1080/09553000210149786; Shao CL, 1999, RADIAT ENVIRON BIOPH, V38, P105, DOI 10.1007/s004110050145; Shao CL, 2001, J RADIAT RES, V42, P305, DOI 10.1269/jrr.42.305; Sonveaux P, 2002, FASEB J, V16, P1979, DOI 10.1096/fj.02-0487fje; Wu LJ, 1999, P NATL ACAD SCI USA, V96, P4959, DOI 10.1073/pnas.96.9.4959; Zhou HN, 2000, P NATL ACAD SCI USA, V97, P2099, DOI 10.1073/pnas.030420797; Zhou HN, 2001, P NATL ACAD SCI USA, V98, P14410, DOI 10.1073/pnas.251524798	38	111	126	2	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1422	1427		10.1096/fj.02-1115com	http://dx.doi.org/10.1096/fj.02-1115com			6	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890695				2022-12-28	WOS:000185345100034
J	Andringa, G; Lam, KY; Chegary, M; Wang, X; Chase, TN; Bennett, MC				Andringa, G; Lam, KY; Chegary, M; Wang, X; Chase, TN; Bennett, MC			Tissue trans glutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease	FASEB JOURNAL			English	Article						crosslinking; protein aggregation; human; brain; substantia nigra	ALZHEIMERS-DISEASE; BODY FORMATION; LEWY BODIES; TRANSGLUTAMINASE; PROTEIN; FIBRINOGEN; MEMBRANE; STABILIZATION; AGGREGATION; PATHOLOGY	In Parkinson's disease (PD), conformational changes in the alpha-synuclein monomer precede the formation of Lewy bodies. We examined postmortem PD and undiseased (control) substantia nigra for evidence of pathological crosslinking of alpha-synuclein by tissue transglutaminase (tTG) using immunohistochemistry, immunoprecipitation, and Western blot. Consistent with previous reports, we found that both tTG and its substrate-characteristic N-epsilon-(gamma-glutamyl)-lysine crosslink are increased in PD nigral dopamine neurons. Furthermore, both the tTG protein and its substrate crosslink coprecipitated with alpha-synuclein in extracts of PD substantia nigra. Unexpectedly, the isodipeptide crosslink was detected in the alpha-synuclein monomer as well as in higher molecular mass oligomers of alpha-synuclein. Although the intramolecularly crosslinked alpha-synuclein monomer was present in control tissue, it was highly enriched in PD substantia nigra. Conversely, significantly less uncrosslinked alpha-synuclein remained in the postimmunoprecipitate lysate of PD tissue than in control. Crosslinked alpha-synuclein, formed at the expense of the total alpha-synuclein monomer, correlated with disease progression. These results demonstrate that much of the alpha-synuclein monomer in PD nigra is crosslinked by tTG and thus may be functionally impaired. This modification appears to be an early step in PD pathogenesis, preceding the aggregation of alpha-synuclein in Lewy bodies.	Natl Inst Neurol Disorders & Stroke, Expt Therapeut Branch, NIH, Bethesda, MD 20892 USA; Blanchette Rockefeller Neurosci Inst, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Chase, TN (corresponding author), Natl Inst Neurol Disorders & Stroke, Expt Therapeut Branch, NIH, Bldg 10,Room 5C-103, Bethesda, MD 20892 USA.	Chaset@ninds.nih.gov			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002265] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Braak H, 1998, PROG BRAIN RES, V117, P267; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BUDZYNSKI AZ, 1986, CRC CR REV ONCOL-HEM, V6, P97, DOI 10.1016/S1040-8428(86)80019-1; CALNE DB, 1992, ANN NEUROL S, V32, P125; CHEN MH, 1996, HELICOBACTER, V1, P271; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; DUDEK SM, 1993, J NEUROCHEM, V61, P1159, DOI 10.1111/j.1471-4159.1993.tb03636.x; Festoff BW, 2002, J NEUROCHEM, V81, P708, DOI 10.1046/j.1471-4159.2002.00850.x; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Gai WP, 2000, EXP NEUROL, V166, P324, DOI 10.1006/exnr.2000.7527; Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HIRSCH E, 1988, NATURE, V334, P345, DOI 10.1038/334345a0; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Leng Y, 2001, J BIOL CHEM, V276, P28212, DOI 10.1074/jbc.M011121200; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Monsonego A, 1997, J BIOL CHEM, V272, P3724, DOI 10.1074/jbc.272.6.3724; MURTHY SNP, 1990, P NATL ACAD SCI USA, V87, P9679, DOI 10.1073/pnas.87.24.9679; Murthy SNP, 2000, P NATL ACAD SCI USA, V97, P44, DOI 10.1073/pnas.97.1.44; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Norlund MA, 1999, BRAIN RES, V851, P154, DOI 10.1016/S0006-8993(99)02179-4; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pronin AN, 2000, J BIOL CHEM, V275, P26515, DOI 10.1074/jbc.M003542200; Schneider JA, 2002, J HISTOCHEM CYTOCHEM, V50, P99, DOI 10.1177/002215540205000111; Shults CW, 1997, ANN NEUROL, V42, P261, DOI 10.1002/ana.410420221; van der Goot FG, 1997, ELECTROPHORESIS, V18, P2689, DOI 10.1002/elps.1150181426; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	39	106	107	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					932	+		10.1096/fj.03-0829fje	http://dx.doi.org/10.1096/fj.03-0829fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001552				2022-12-28	WOS:000220522800031
J	Ma, WC; Li, DY; Sun, F; Kleiman, NJ; Spector, A				Ma, WC; Li, DY; Sun, F; Kleiman, NJ; Spector, A			The effect of stress withdrawal on gene expression and certain biochemical and cell biological properties of peroxide-conditioned cell lines	FASEB JOURNAL			English	Article						microarrays; hydrogen peroxide; tertiary butyl hydroperoxide; GSH-S-transferase; catalase; cataract	LENS EPITHELIAL-CELLS; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; LIPID-PEROXIDATION; AQUEOUS-HUMOR; RABBIT LENS; SEQUENCE DATABASES; INDUCED CATARACT; UP-REGULATION; H2O2	Maturity onset cataract is a disease that afflicts > 25% of the U.S. population over 65. Oxidative stress is believed to be a major factor in the development of this disease and peroxides are suspected to be prominent stressing agents. To elucidate mechanisms involved in the protection of cells against oxidative stress, immortal murine lens epithelial cells (alphaTN4-1) have been conditioned to survive lethal concentrations of either tertiary butyl hydroperoxide, TBOOH (a lipid peroxide prototype) (T cells), or H2O2 (H cells). It was found that T cells survived exposure to H2O2 but H cells were killed by TBOOH. In this communication, biological characteristics of the T cells are reported. It is shown that the T cell's ability to survive TBOOH is lost if the cells are grown in the absence of this peroxide (denoted as T- cells). By comparing the differential gene expression of 12,422 genes and ESTs from T and T- and the unconditioned control cells, 16 genes were found that may account for the loss of resistance to TBOOH. They include 5 glutathione-S-transferases, superoxide dismutase 1, zeta crystallin, a NADPH quinone reductase, as well as genes involved in detoxifying aldehydes, controlling iron metabolism, and degrading toxic lipoproteins.	Columbia Univ Coll Phys & Surg, Dept Ophthalmol, New York, NY 10032 USA	Columbia University	Spector, A (corresponding author), Columbia Univ Coll Phys & Surg, Dept Ophthalmol, 630 W 168th St, New York, NY 10032 USA.	as42@columbia.edu	Kleiman, Norman J/B-9745-2008	Kleiman, Norman J/0000-0002-4725-998X				ALIN P, 1985, FEBS LETT, V179, P267, DOI 10.1016/0014-5793(85)80532-9; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Augusteyn R., 1981, MECH CATARACT FORMAT, P72; BABIZHAEV MA, 1986, BIOFIZIKA+, V31, P109; Babizhayev MA, 1996, BBA-MOL BASIS DIS, V1315, P87, DOI 10.1016/0925-4439(95)00091-7; BHUYAN DK, 1992, INVEST OPHTH VIS SCI, V33, P798; BHUYAN KC, 1986, LIFE SCI, V38, P1463, DOI 10.1016/0024-3205(86)90559-X; BHUYAN KC, 1981, IRCS MED SCI-BIOCHEM, V9, P126; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Choudhary S, 2003, INVEST OPHTH VIS SCI, V44, P2675, DOI 10.1167/iovs.02-0965; Delamere NA, 1998, INVEST OPHTH VIS SCI, V39, P763; FERRARA P, 1993, TECHNIQUES PROTEIN C, V4, P379; GARCIACASTINEIRAS S, 1992, EXP EYE RES, V55, P9, DOI 10.1016/0014-4835(92)90086-8; GIBLIN FJ, 1990, EXP EYE RES, V50, P795, DOI 10.1016/0014-4835(90)90130-M; Goswami S, 2003, INVEST OPHTH VIS SCI, V44, P2084, DOI 10.1167/iovs.02-0882; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; HIGUCHI R, 1993, BIO-TECHNOL, V11, P1026, DOI 10.1038/nbt0993-1026; Kantorow M, 1998, INVEST OPHTH VIS SCI, V39, P2344; Krysan K, 2002, INVEST OPHTH VIS SCI, V43, P1876; KUPFER C, 1994, PRINCIPLES PRACTICE, P1249; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI D, 2003, IN PRESS EXP EYE RES; Li DWC, 1997, MOL CELL BIOCHEM, V173, P59, DOI 10.1023/A:1006828402225; Ma WC, 2003, EXP EYE RES, V77, P711, DOI 10.1016/j.exer.2003.08.004; MANN M, 1993, BIOL MASS SPECTROM, V22, P338, DOI 10.1002/bms.1200220605; MATSUDA H, 1981, EXP EYE RES, V33, P253, DOI 10.1016/S0014-4835(81)80049-8; Matsui H, 2003, INVEST OPHTH VIS SCI, V44, P3467, DOI 10.1167/iovs.02-0830; OYSTER CW, 1995, HUMAN EYE STRUCTURE; RAMACHANDRAN S, 1991, EXP EYE RES, V53, P503, DOI 10.1016/0014-4835(91)90167-D; Reddy VN, 2001, INVEST OPHTH VIS SCI, V42, P3247; Smith B J, 1994, Methods Mol Biol, V32, P23; Spector A, 1996, EXP EYE RES, V62, P521, DOI 10.1006/exer.1996.0063; Spector A, 1998, INVEST OPHTH VIS SCI, V39, P1188; SPECTOR A, 1981, EXP EYE RES, V33, P673, DOI 10.1016/S0014-4835(81)80107-8; SPECTOR A, 1995, EXP EYE RES, V60, P471, DOI 10.1016/S0014-4835(05)80062-4; SPECTOR A, 1995, FASEB J, V9, P1173, DOI 10.1096/fasebj.9.12.7672510; SPECTOR A, 1995, EXP EYE RES, V60, P483, DOI 10.1016/S0014-4835(05)80063-6; SPECTOR A, 1984, INVEST OPHTH VIS SCI, V25, P130; SPECTOR A, 1993, CURR EYE RES, V12, P163, DOI 10.3109/02713689308999484; Spector A, 2002, INVEST OPHTH VIS SCI, V43, P3251; Spector A, 2001, EXP EYE RES, V72, P533, DOI 10.1006/exer.2001.0980; Spector A, 2000, INVEST OPHTH VIS SCI, V41, P832; Spector A, 2000, J OCUL PHARMACOL TH, V16, P193, DOI 10.1089/jop.2000.16.193; Spector A., 1991, OXIDATIVE STRESS OXI, P529; STARK WJ, 1989, ARCH OPHTHALMOL-CHIC, V107, P1441, DOI 10.1001/archopht.1989.01070020515030; *VIS RES, 1998, 1999 2002 REP NAT AD, P59; WANG KY, 1994, J BIOL CHEM, V269, P13601; Yang YS, 2002, INVEST OPHTH VIS SCI, V43, P434; ZIGLER JS, 1989, FREE RADICAL BIO MED, V7, P499	50	15	16	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					480	488		10.1096/fj.03-0732com	http://dx.doi.org/10.1096/fj.03-0732com			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003993				2022-12-28	WOS:000220522800040
J	Spijker, S; Houtzager, SWJ; de Gunst, MCM; de Boer, WPH; Schoffelmeer, ANM; Smit, AB				Spijker, S; Houtzager, SWJ; de Gunst, MCM; de Boer, WPH; Schoffelmeer, ANM; Smit, AB			Morphine exposure and abstinence define specific stages of gene expression in the rat nucleus accumbens	FASEB JOURNAL			English	Article						real-time quantitative PCR; gene expression profiling; sensitization; addiction; natural withdrawal; bioinformatics	MESSENGER-RNA EXPRESSION; AMPHETAMINE-REGULATED TRANSCRIPT; RECEPTOR DOWN-REGULATION; C-FOS GENE; DOPAMINE-RECEPTOR; BEHAVIORAL SENSITIZATION; MOLECULAR-MECHANISMS; LOCOMOTOR-ACTIVITY; CHRONIC COCAINE; BRAIN	Intermittent exposure to addictive drugs causes long-lasting changes in responsiveness to these substances due to persistent molecular and cellular alterations within the meso-corticolimbic system. In this report, we studied the expression profiles of 159 genes in the rat nucleus accumbens during morphine exposure (14 days, 10 mg/kg s.c.) and drug-abstinence ( 3 weeks). We used real-time quantitative PCR to monitor gene expression after establishing its sensitivity and resolution to resolve small changes in expression for genes in various abundance classes. Morphine-exposure (5 time points) and subsequent abstinence ( 6 time points) induced phase-specific temporal gene expression of distinct functional groups of genes, for example, short-term homeostatic responses. Opiate withdrawal appeared to be a new stimulus in terms of gene expression and mediates a marked wave of gene repression. Prolonged abstinence resulted in persistently changed expression levels of genes involved in neuronal outgrowth and re-wiring. Our findings substantiate the hypothesis that this new gene program, initiated upon morphine-withdrawal, may subserve long-term neuronal plasticity involved in the persistent behavioral consequences of repeated drug-exposure.	Free Univ Amsterdam, Dept Mol & Cellular Neurobiol, Grad Sch Neurosci Amsterdam, Neurosci Res Inst, NL-1081 HV Amsterdam, Netherlands; Free Univ Amsterdam, Fac Sci, Dept Math, NL-1081 HV Amsterdam, Netherlands; Vrije Univ Amsterdam, Med Ctr, Dept Med Oncol, NL-1007 MB Amsterdam, Netherlands; Free Univ Amsterdam, Med Ctr, Dept Med Pharmacol, NL-1081 BT Amsterdam, Netherlands	University of Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam; Vrije Universiteit Amsterdam	Spijker, S (corresponding author), Free Univ Amsterdam, Dept Mol & Cellular Neurobiol, Grad Sch Neurosci Amsterdam, Neurosci Res Inst, De Boelelaan 1085, NL-1081 HV Amsterdam, Netherlands.	sspijker@bio.vu.nl	Smit, August B/E-8410-2011; Spijker, Sabine/F-2300-2011	Spijker, Sabine/0000-0002-6814-2019				Baca SM, 1998, BRAIN RES, V797, P55, DOI 10.1016/S0006-8993(98)00343-6; BASHEER R, 1993, J NEUROSCI RES, V36, P551, DOI 10.1002/jnr.490360507; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; BOER D, 2001, P 2 INT C SYST BIOL, P69; Carlezon WA, 1999, SYNAPSE, V31, P256, DOI 10.1002/(SICI)1098-2396(19990315)31:4<256::AID-SYN3>3.0.CO;2-E; Castella P, 2000, MOL CELL BIOL, V20, P6170, DOI 10.1128/MCB.20.16.6170-6183.2000; Castella P, 1999, J NEUROSCI RES, V56, P229, DOI 10.1002/(SICI)1097-4547(19990501)56:3<229::AID-JNR2>3.0.CO;2-Z; Cha XY, 1997, J NEUROSCI, V17, P6864; COLE RL, 1995, NEURON, V14, P813, DOI 10.1016/0896-6273(95)90225-2; Crespo JA, 2002, ANN NY ACAD SCI, V965, P78; Douglass J, 1996, GENE, V169, P241, DOI 10.1016/0378-1119(96)88651-3; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Evans SJ, 2002, EUR J NEUROSCI, V16, P409, DOI 10.1046/j.1460-9568.2002.02097.x; FOSNAUGH JS, 1995, J NEUROCHEM, V64, P2377; Gao PP, 2000, J NEUROSCI RES, V60, P427, DOI 10.1002/(SICI)1097-4547(20000515)60:4<427::AID-JNR1>3.3.CO;2-4; Georges F, 2000, EUR J NEUROSCI, V12, P4475, DOI 10.1046/j.0953-816X.2000.01334.x; Georges F, 1999, EUR J NEUROSCI, V11, P481, DOI 10.1046/j.1460-9568.1999.00462.x; Gomes BA, 2002, PHARMACOL BIOCHEM BE, V72, P273, DOI 10.1016/S0091-3057(01)00757-2; GRAYBIEL AM, 1990, P NATL ACAD SCI USA, V87, P6912, DOI 10.1073/pnas.87.17.6912; Grimm JW, 2001, NATURE, V412, P141, DOI 10.1038/35084134; Guzowski JF, 2000, J NEUROSCI, V20, P3993; Harlan RE, 1998, MOL NEUROBIOL, V16, P221, DOI 10.1007/BF02741385; Hoek RM, 1997, P NATL ACAD SCI USA, V94, P14072, DOI 10.1073/pnas.94.25.14072; Horger BA, 1999, J NEUROSCI, V19, P4110; HURD YL, 1992, MOL BRAIN RES, V16, P97, DOI 10.1016/0169-328X(92)90198-K; HYMAN C, 1994, J NEUROSCI, V14, P335; Jacobs EH, 2002, FASEB J, V16, P1961, DOI 10.1096/fj.02-0272fje; Jang CG, 2000, BRAIN RES BULL, V52, P217, DOI 10.1016/S0361-9230(00)00261-6; Janis LS, 1999, J NEUROSCI, V19, P4962; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; Kalivas PW, 1999, SYNAPSE, V33, P153, DOI 10.1002/(SICI)1098-2396(199908)33:2<153::AID-SYN5>3.0.CO;2-N; Kimmel HL, 2000, J PHARMACOL EXP THER, V294, P784; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kuhar MJ, 1999, TRENDS NEUROSCI, V22, P316, DOI 10.1016/S0166-2236(98)01377-0; LIU JL, 1994, P NATL ACAD SCI USA, V91, P8537, DOI 10.1073/pnas.91.18.8537; Lu WX, 1997, SYNAPSE, V26, P269, DOI 10.1002/(SICI)1098-2396(199707)26:3<269::AID-SYN8>3.0.CO;2-5; LYFORD GL, 1995, NEURON, V14, P433, DOI 10.1016/0896-6273(95)90299-6; Mackler SA, 2000, J NEUROSCI, V20, P6210, DOI 10.1523/JNEUROSCI.20-16-06210.2000; Martin G, 1999, J NEUROSCI, V19, P9081, DOI 10.1523/JNEUROSCI.19-20-09081.1999; Muller PY, 2002, BIOTECHNIQUES, V32, P1372; Nadon R, 2002, TRENDS GENET, V18, P265, DOI 10.1016/S0168-9525(02)02665-3; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pierce RC, 1996, J NEUROSCI, V16, P1550; Przewlocka B, 1995, EUR NEUROPSYCHOPHARM, V5, P465; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Ranaldi R, 2000, PSYCHOPHARMACOLOGY, V151, P192, DOI 10.1007/s002130000480; Robinson TE, 1999, SYNAPSE, V33, P160; SCHOFFELMEER ANM, 1995, EUR J PHARMACOL, V286, P311, DOI 10.1016/0014-2999(95)00588-7; Self DW, 1998, J NEUROSCI, V18, P1848; SELF DW, 1995, ANNU REV NEUROSCI, V18, P463, DOI 10.1146/annurev.neuro.18.1.463; Steward O, 1998, NEURON, V21, P741, DOI 10.1016/S0896-6273(00)80591-7; TJON GHK, 1995, EUR J PHARMACOL, V283, P169, DOI 10.1016/0014-2999(95)00319-G; Turchan J, 1997, NEUROPEPTIDES, V31, P24, DOI 10.1016/S0143-4179(97)90015-9; van Kesteren RE, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-16-j0004.2001; Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493; Vanderschuren LJMJ, 1997, PSYCHOPHARMACOLOGY, V131, P115, DOI 10.1007/s002130050273; Walters CL, 2000, NEUROPSYCHOPHARMACOL, V23, P307, DOI 10.1016/S0893-133X(00)00113-5; Wang JH, 1997, J CLIN NEUROPHYSIOL, V14, P264, DOI 10.1097/00004691-199707000-00002; WANG JQ, 1995, BRAIN RES, V673, P262, DOI 10.1016/0006-8993(94)01422-E; Wise RA, 1996, CURR OPIN NEUROBIOL, V6, P243, DOI 10.1016/S0959-4388(96)80079-1; WISE RA, 1987, PSYCHOL REV, V94, P469, DOI 10.1037/0033-295X.94.4.469; Yoburn BC, 2003, SYNAPSE, V47, P109, DOI 10.1002/syn.10149; Yue Y, 1999, J NEUROSCI, V19, P2090	66	55	56	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					848	+		10.1096/fj.03-0612fje	http://dx.doi.org/10.1096/fj.03-0612fje			28	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033927				2022-12-28	WOS:000220522800011
J	Barberis, D; Artigiani, S; Casazza, A; Corso, S; Giordano, S; Love, CA; Jones, EY; Comoglio, PM; Tamagnone, L				Barberis, D; Artigiani, S; Casazza, A; Corso, S; Giordano, S; Love, CA; Jones, EY; Comoglio, PM; Tamagnone, L			Plexin signaling hampers integrin-based adhesion, leading to Rho-kinase independent cell rounding, and inhibiting lamellipodia extension and cell motility	FASEB JOURNAL			English	Article						semaphorin; migration; axon guidance	GROWTH CONE COLLAPSE; SEMAPHORIN RECEPTOR; AXON GUIDANCE; ACTIVE RAC; DISTINCT REQUIREMENTS; SUBSTRATE ADHESION; PDZ-RHOGEF; FAMILY; TRANSMEMBRANE; MIGRATION	Plexins encode receptors for semaphorins, molecular signals guiding cell migration, and axon pathfinding. The mechanisms mediating plexin function are poorly understood. Plexin activation in adhering cells rapidly leads to retraction of cellular processes and cell rounding ("cell collapse"). Here we show that, unexpectedly, this response does not require the activity of Rho-ependent kinase (ROCK) nor the contraction of F-actin cables. Interestingly, integrin-based focal adhesive structures are disassembled within minutes upon plexin activation; this is followed by actin depolymerization and, eventually, by cellular collapse. We also show that plexin activation hinders cell attachment to adhesive substrates, blocks the extension of lamellipodia, and thereby inhibits cell migration. We conclude that plexin signaling uncouples cell substrate-adhesion from cytoskeletal dynamics required for cell migration and axon extension.	Univ Turin, IRCC, Inst Canc Res & Treatment, Sch Med, I-10060 Candiolo, TO, Italy; Canc Res UK Receptor Struct Grp, Oxford OX3 7BN, England	IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin; Cancer Research UK	Tamagnone, L (corresponding author), Univ Turin, IRCC, Inst Canc Res & Treatment, Sch Med, SP 142, I-10060 Candiolo, TO, Italy.	luca.tamagnone@ircc.it	Jones, Yvonne/J-2293-2016; Love, Christopher/E-3503-2012; Jones, Yvonne/N-8111-2019; Tamagnone, Luca/J-8948-2018; GIORDANO, Silvia/J-9858-2018	Jones, Yvonne/0000-0002-3834-1893; Jones, Yvonne/0000-0002-3834-1893; Tamagnone, Luca/0000-0002-2884-7946; Comoglio, Paolo/0000-0002-7056-5328; GIORDANO, Silvia/0000-0003-1854-1086; CORSO, Simona/0000-0002-5069-1503	Telethon [E.1129] Funding Source: Medline	Telethon(Fondazione Telethon)		Adelsman MA, 1999, MOL BIOL CELL, V10, P2861, DOI 10.1091/mbc.10.9.2861; Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Artigiani S, 2003, J BIOL CHEM, V278, P10094, DOI 10.1074/jbc.M210156200; Atwal JK, 2003, J NEUROSCI, V23, P7602; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Behar O, 1999, P NATL ACAD SCI USA, V96, P13501, DOI 10.1073/pnas.96.23.13501; Brown CB, 2001, DEVELOPMENT, V128, P3071; Castellani V, 2002, CURR OPIN NEUROBIOL, V12, P532, DOI 10.1016/S0959-4388(02)00357-4; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; DAVIS SJ, 1990, J BIOL CHEM, V265, P10410; Delaire S, 2001, J IMMUNOL, V166, P4348, DOI 10.4049/jimmunol.166.7.4348; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Driessens MHE, 2002, FEBS LETT, V529, P168, DOI 10.1016/S0014-5793(02)03323-9; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Eickholt BJ, 1999, DEVELOPMENT, V126, P2181; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FAN JH, 1995, NEURON, V14, P263, DOI 10.1016/0896-6273(95)90284-8; Feiner L, 2001, DEVELOPMENT, V128, P3061; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Giordano S, 2002, NAT CELL BIOL, V4, P720, DOI 10.1038/ncb843; Harlow E, 1998, ANTIBODIES LAB MANUA; Hu HL, 2001, NEURON, V32, P39, DOI 10.1016/S0896-6273(01)00453-6; Jin Z, 1997, J NEUROSCI, V17, P6256; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kikutani H, 2003, NAT REV IMMUNOL, V3, P159, DOI 10.1038/nri1003; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kuhn TB, 1999, J NEUROSCI, V19, P1965; LUO YL, 1993, CELL, V75, P217, DOI 10.1016/0092-8674(93)80064-L; Maddox AS, 2003, J CELL BIOL, V160, P255, DOI 10.1083/jcb.200207130; Maestrini E, 1996, P NATL ACAD SCI USA, V93, P674, DOI 10.1073/pnas.93.2.674; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; Mikule K, 2002, J NEUROSCI, V22, P4932, DOI 10.1523/JNEUROSCI.22-12-04932.2002; Mills J, 2003, J NEUROSCI, V23, P1638; Offterdinger M, 2003, J CELL PHYSIOL, V195, P260, DOI 10.1002/jcp.10237; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Pasterkamp RJ, 2003, CURR OPIN NEUROBIOL, V13, P79, DOI 10.1016/S0959-4388(03)00003-5; Perrot V, 2002, J BIOL CHEM, V277, P43115, DOI 10.1074/jbc.M206005200; Rohm B, 2000, FEBS LETT, V486, P68, DOI 10.1016/S0014-5793(00)02240-7; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Serini G, 2003, NATURE, V424, P391, DOI 10.1038/nature01784; Spassky N, 2002, J NEUROSCI, V22, P5992; Stockton RA, 2001, MOL BIOL CELL, V12, P1937, DOI 10.1091/mbc.12.7.1937; Swiercz JM, 2002, NEURON, V35, P51, DOI 10.1016/S0896-6273(02)00750-X; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; Tamagnone L, 2000, TRENDS CELL BIOL, V10, P377, DOI 10.1016/S0962-8924(00)01816-X; Terman JR, 2002, CELL, V109, P887, DOI 10.1016/S0092-8674(02)00794-8; Vikis HG, 2000, P NATL ACAD SCI USA, V97, P12457, DOI 10.1073/pnas.220421797; Vikis HG, 2002, GENE DEV, V16, P836, DOI 10.1101/gad.966402; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Winberg ML, 1998, CELL, V95, P903, DOI 10.1016/S0092-8674(00)81715-8; Zhou FQ, 2002, J CELL BIOL, V157, P839, DOI 10.1083/jcb.200112014	60	99	99	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					592	+		10.1096/fj.03-0957fje	http://dx.doi.org/10.1096/fj.03-0957fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734633	Green Accepted			2022-12-28	WOS:000188829300019
J	Fassbender, K; Walter, S; Kuhl, S; Landmann, R; Ishii, K; Bertsch, T; Stalder, AK; Muehlhauser, F; Liu, Y; Ulmer, AJ; Rivest, S; Lentschat, A; Gulbins, E; Jucker, M; Staufenbiel, M; Brechtel, K; Walter, J; Multhaup, G; Penke, B; Adachi, Y; Hartmann, T; Beyreuther, K				Fassbender, K; Walter, S; Kuhl, S; Landmann, R; Ishii, K; Bertsch, T; Stalder, AK; Muehlhauser, F; Liu, Y; Ulmer, AJ; Rivest, S; Lentschat, A; Gulbins, E; Jucker, M; Staufenbiel, M; Brechtel, K; Walter, J; Multhaup, G; Penke, B; Adachi, Y; Hartmann, T; Beyreuther, K			The LPS receptor (CD14) links innate immunity with Alzheimer's disease	FASEB JOURNAL			English	Article						AD; lipopolysaccharide; A beta	CENTRAL-NERVOUS-SYSTEM; AMYLOID-BETA; LIPOPOLYSACCHARIDE LPS; MICROGLIAL CELLS; MOUSE MODEL; ACTIVATION; EXPRESSION; PATHOLOGY; BINDING; ENDOTOXIN	To rapidly respond to invading microorganisms, humans call on their innate immune system. This occurs by microbe-detecting receptors, such as CD14, that activate immune cells to eliminate the pathogens. Here, we link the lipopolysaccharide receptor CD14 with Alzheimer's disease, a severe neurodegenerative disease resulting in dementia. We demonstrate that this key innate immunity receptor interacts with fibrils of Alzheimer amyloid peptide. Neutralization with antibodies against CD14 and genetic deficiency for this receptor significantly reduced amyloid peptide induced microglial activation and microglial toxicity. The observation of strongly enhanced microglial expression of the LPS receptor in brains of animal models of Alzheimer's disease indicates a clinical relevance of these findings. These data suggest that CD14 may significantly contribute to the overall neuroinflammatory response to amyloid peptide, highlighting the possibility that the enormous progress currently being made in the field of innate immunity could be extended to research on Alzheimer's disease.	Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany; Heidelberg Univ, Ctr Mol Biol, D-69120 Heidelberg, Germany; Univ Basel Hosp, Dept Res, Div Infect Dis, CH-4031 Basel, Switzerland; Heidelberg Univ, Dept Clin Chem, D-68167 Mannheim, Germany; Univ Basel Hosp, Div Neuropathol, CH-4031 Basel, Switzerland; Novartis Inst BioMed Res, Basel, Switzerland; Borstel Res Ctr, Ctr Med & Biosci, D-23845 Borstel, Germany; St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Univ Laval, Mol Endocrinol Lab, Quebec City, PQ PQ G1V 4G2, Canada; Albert Szent Gyorgyi Med Univ, Dept Med Chem, H-6720 Szeged, Hungary; Tokyo Univ Pharm & Life Sci, Sch Pharm, Tokyo 1920392, Japan	University of Gottingen; Ruprecht Karls University Heidelberg; University of Basel; Ruprecht Karls University Heidelberg; University of Basel; Novartis; Forschungszentrum Borstel; St Jude Children's Research Hospital; Laval University; Szeged University; Tokyo University of Pharmacy & Life Sciences	Fassbender, K (corresponding author), Univ Gottingen, Dept Neurol, D-37075 Gottingen, Germany.	klaus.fassbender@med.uni-goettingen.de	Hartmann, Tobias/AAB-8297-2022; Ishii, Ken J/B-1685-2012; Gulbins, Erich/L-6989-2014	Ishii, Ken J/0000-0002-6728-3872; Gulbins, Erich/0000-0002-3117-1342; Hartmann, Tobias/0000-0001-7481-6430; Fassbender, Klaus/0000-0003-3596-868X; Walter, Silke/0000-0002-1176-2911; Rivest, Serge/0000-0002-6082-770X			We thank M. Freeman and D. Golenbock (Boston) for providing CD14-/- mice and Y. Imai(Kodaira, Japan) for providing the iba1 mAb	Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bendelac A, 2000, CURR OPIN IMMUNOL, V12, P11, DOI 10.1016/S0952-7915(99)00044-8; Beschorner R, 2002, ACTA NEUROPATHOL, V103, P541, DOI 10.1007/s00401-001-0503-7; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; El Khoury JB, 2003, J EXP MED, V197, P1657, DOI 10.1084/jem.20021546; ElKhoury J, 1996, NATURE, V382, P716; Fassbender K, 2001, P NATL ACAD SCI USA, V98, P5856, DOI 10.1073/pnas.081620098; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Goodwin JL, 1997, BRAIN RES, V768, P279, DOI 10.1016/S0006-8993(97)00653-7; Hamann L, 2000, EUR J IMMUNOL, V30, P211, DOI 10.1002/1521-4141(200001)30:1<211::AID-IMMU211>3.3.CO;2-F; HAMPTON RY, 1991, NATURE, V352, P342, DOI 10.1038/352342a0; Haziot A, 1996, IMMUNITY, V4, P407, DOI 10.1016/S1074-7613(00)80254-X; in 't Veld BA, 2001, NEW ENGL J MED, V345, P1515, DOI 10.1056/NEJMoa010178; Ishii K, 2000, FASEB J, V14, P1485, DOI 10.1096/fj.14.11.1485; Kaisho T, 2001, NATURE, V414, P701, DOI 10.1038/414701a; KIRKLAND TN, 1993, J BIOL CHEM, V268, P24818; Laflamme N, 2001, FASEB J, V15, P155, DOI 10.1096/fj.00-0339com; Lim GP, 2000, J NEUROSCI, V20, P5709, DOI 10.1523/JNEUROSCI.20-15-05709.2000; Mackenzie IRA, 1998, NEUROLOGY, V50, P986, DOI 10.1212/WNL.50.4.986; McGeer PL, 1996, NEUROLOGY, V47, P425, DOI 10.1212/WNL.47.2.425; MEDA L, 1995, NATURE, V374, P647, DOI 10.1038/374647a0; Nagaoka I, 2001, J IMMUNOL, V167, P3329, DOI 10.4049/jimmunol.167.6.3329; Perera PY, 2001, J IMMUNOL, V166, P574, DOI 10.4049/jimmunol.166.1.574; ROGERS J, 1992, P NATL ACAD SCI USA, V89, P10016, DOI 10.1073/pnas.89.21.10016; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SEDGWICK JD, 1991, P NATL ACAD SCI USA, V88, P7438, DOI 10.1073/pnas.88.16.7438; Sellati TJ, 1998, J IMMUNOL, V160, P5455; Sheng JG, 1997, ACTA NEUROPATHOL, V94, P1, DOI 10.1007/s004010050664; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Yates SL, 2000, J NEUROCHEM, V74, P1017, DOI 10.1046/j.1471-4159.2000.0741017.x; Younkin SG, 2001, NAT MED, V7, P18, DOI 10.1038/83292	36	259	276	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					203	205		10.1096/fj.03-0364fje	http://dx.doi.org/10.1096/fj.03-0364fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597556				2022-12-28	WOS:000188829300074
J	Hardaker, EL; Bacon, AM; Carlson, K; Roshak, AK; Foley, JJ; Schmidt, DB; Buckley, PT; Comegys, M; Panettieri, RA; Sarau, HM; Belmonte, KE				Hardaker, EL; Bacon, AM; Carlson, K; Roshak, AK; Foley, JJ; Schmidt, DB; Buckley, PT; Comegys, M; Panettieri, RA; Sarau, HM; Belmonte, KE			Regulation of TNF-alpha and IFN-gamma induced CXCL10 expression: participation of the airway smooth muscle in the pulmonary inflammatory response in chronic obstructive pulmonary disease	FASEB JOURNAL			English	Article						chemokines; inflammation; respiratory; NF-kappa B	NECROSIS-FACTOR-ALPHA; CHEMOKINE RECEPTOR CXCR3; INDUCIBLE PROTEIN-10; INTERFERON-GAMMA; T-LYMPHOCYTES; PERIPHERAL AIRWAYS; GENE-EXPRESSION; I-TAC; CELLS; IP-10	The chemokine CXCL 10 is produced by many inflammatory cells found in the diseased lung and has been implicated in the pathogenesis of chronic obstructive pulmonary disease (COPD). The present study demonstrates elevated CXCL10 protein in the lungs of COPD patients, which appears histologically in airway smooth muscle (hASM). In primary cultured hASM cells taken from normal donors, CXCL10 protein expression was induced by IFN-gamma and TNF-alpha., cytokines reported as elevated in COPD, and a synergistic response was obtained when they were combined. TNF-alpha. stimulation of hASM enhanced accumulation of CXCL10 mRNA, indicating regulation at the transcriptional level, while IFN-gamma stimulation resulted in a smaller accumulation of CXCL10 mRNA. When these cytokines were applied simultaneously, an additive effect was obtained. TNF-alpha-induced CXCL 10 expression in hASM was dependent on NFkappaB activation, and a salicylanilide NF kappa B inhibitor blocked the CXCL10 expression. In contrast, IFN-gamma stimulation resulted in transient NF kappa B activation, and the inhibitor had little effect on CXCL 10 expression. When these cytokines were added simultaneously, NF kappa B was activated earlier and lasted longer, and the effect was blocked by the inhibitor. These data demonstrate a potential active role for hASM in pulmonary inflammatory diseases such as COPD by producing CXCL10.	GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, King Of Prussia, PA 19406 USA; Univ Penn, Med Ctr, Pulm Allergy & Crit Care Div, Philadelphia, PA 19104 USA	GlaxoSmithKline; University of Pennsylvania	Belmonte, KE (corresponding author), GlaxoSmithKline Inc, Ctr Excellence Drug Discovery, King Of Prussia, PA 19406 USA.	Kristen.E.Belmonte@GSK.com	panettieri, reynold/AAG-9485-2019		Airways Biology Institute at the University of Pennsylvania GlaxoSmithKline; National Institutes of Health [HL-67663]	Airways Biology Institute at the University of Pennsylvania GlaxoSmithKline; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	The authors wish to thank Andrew Eszterhas in Dr. Reynold Panettieri's laboratory (University of Pennsylvania) for the primary cultured hASM cells, GlaxoSmithKline employee Roseanna Frankowski for assistance with the immunohistochemistry methods, and James F. Callahan for his guidance regarding use of the NF-kB inhibitor. This work was supported by the Airways Biology Institute at the University of Pennsylvania in cooperation with a grant from GlaxoSmithKline and a grant from the National Institutes of Health (HL-67663 to R. A. Panettieri, Jr.).	Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794, DOI 10.1165/ajrcmb.23.6.4184; Barnes PJ, 2000, CHEST, V117, P10; Boorsma DM, 1998, ARCH DERMATOL RES, V290, P335, DOI 10.1007/s004030050314; Bukowski RM, 1999, CLIN CANCER RES, V5, P2780; CALLAHAN JF, 2000, KEYSTONE S, V369; CALLAHAN JF, 1999, Patent No. 9965449; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Carayol N, 2002, AM J RESP CELL MOL, V26, P341, DOI 10.1165/ajrcmb.26.3.4684; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixon AE, 2000, AM J PHYSIOL-LUNG C, V279, pL592, DOI 10.1152/ajplung.2000.279.3.L592; Ebert LM, 2001, J IMMUNOL, V166, P4870, DOI 10.4049/jimmunol.166.8.4870; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; Frangogiannis NG, 2000, CELL TISSUE RES, V302, P365, DOI 10.1007/s004410000274; Gasperini S, 1999, J IMMUNOL, V162, P4928; Hamerman JA, 2001, J IMMUNOL, V167, P2227, DOI 10.4049/jimmunol.167.4.2227; HayGlass KT, 2000, IMMUNOPHARMACOLOGY, V48, P283, DOI 10.1016/S0162-3109(00)00225-3; Hozumi A, 2001, AM J PHYSIOL-LUNG C, V281, pL1444, DOI 10.1152/ajplung.2001.281.6.L1444; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530, DOI 10.1164/ajrccm.153.2.8564092; Kronke M, 1992, Immunol Ser, V56, P189; Lamkhioued B, 2000, AM J RESP CRIT CARE, V162, P723, DOI 10.1164/ajrccm.162.2.9901080; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; LUSTER AD, 1985, NATURE, V315, P672, DOI 10.1038/315672a0; Majumder S, 1998, J IMMUNOL, V161, P4736; Majumder S, 1998, J NEUROSCI RES, V54, P169, DOI 10.1002/(SICI)1097-4547(19981015)54:2<169::AID-JNR5>3.0.CO;2-C; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; Neville Lewis F., 1997, Cytokine and Growth Factor Reviews, V8, P207, DOI 10.1016/S1359-6101(97)00015-4; OSBORN L, 1989, P NATL ACAD SCI USA, V86, P2336, DOI 10.1073/pnas.86.7.2336; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Piali L, 1998, EUR J IMMUNOL, V28, P961, DOI 10.1002/(SICI)1521-4141(199803)28:03<961::AID-IMMU961>3.0.CO;2-4; Platanias LC, 1999, EXP HEMATOL, V27, P1583, DOI 10.1016/S0301-472X(99)00109-5; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rabin RL, 1999, J IMMUNOL, V162, P3840; Ren XD, 2002, SHOCK, V17, P513, DOI 10.1097/00024382-200206000-00013; Romagnani P, 2002, J AM SOC NEPHROL, V13, P53, DOI 10.1681/ASN.V13153; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822, DOI 10.1164/ajrccm.157.3.9709027; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Saetta M, 1999, AM J RESP CRIT CARE, V160, pS17, DOI 10.1164/ajrccm.160.supplement_1.6; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sarau HM, 1999, MOL PHARMACOL, V56, P657, DOI 10.1124/mol.56.3.657; Sauty A, 1999, J IMMUNOL, V162, P3549; SCHUTZE S, 1992, SEMIN ONCOL, V19, P16; Soejima K, 2001, J IMMUNOL, V167, P6576, DOI 10.4049/jimmunol.167.11.6576; Soler N, 1999, EUR RESPIR J, V14, P1015, DOI 10.1183/09031936.99.14510159; Tan JQ, 2000, BLOOD, V96, P1230, DOI 10.1182/blood.V96.4.1230.h8001230_1230_1238; Tensen CP, 1999, J INVEST DERMATOL, V112, P716, DOI 10.1046/j.1523-1747.1999.00581.x; Wang XK, 1996, J BIOL CHEM, V271, P24286, DOI 10.1074/jbc.271.39.24286	49	96	100	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					191	193		10.1096/fj.03-0170fje	http://dx.doi.org/10.1096/fj.03-0170fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597565				2022-12-28	WOS:000188829300070
J	Jerkic, M; Rivas-Elena, JV; Prieto, M; Carron, R; Sanz-Rodriguez, F; Perez-Barriocanal, F; Rodriguez-Barbero, A; Bernabeu, C; Lopez-Novoa, IM				Jerkic, M; Rivas-Elena, JV; Prieto, M; Carron, R; Sanz-Rodriguez, F; Perez-Barriocanal, F; Rodriguez-Barbero, A; Bernabeu, C; Lopez-Novoa, IM			Endoglin regulates nitric oxide-dependent vasodilatation	FASEB JOURNAL			English	Article						endoglin haploinsufficiency; vascular tone; eNOS expression	HEREDITARY HEMORRHAGIC TELANGIECTASIA; GROWTH-FACTOR-BETA; HUMAN ENDOTHELIAL-CELLS; CELLULAR-RESPONSES; MESANGIAL CELLS; ANGIOTENSIN-II; UP-REGULATION; EXPRESSION; RECEPTOR; MICE	Endoglin is a membrane glycoprotein that plays an important role in cardiovascular development and angiogenesis. We examined the role of endoglin in the control of vascular tone by measuring nitric oxide (NO)-dependent vasodilation in haploinsufficient mice (Eng(+/-)) and their Eng(+/+) littermates. The vasodilatory effect of acetylcholine, bradykinin, and sodium nitroprusside was assessed in anesthetized mice; in isolated, perfused hindlimbs; and in aortic rings. The substantial hypotensive and vasodilatory response induced by acetylcholine and bradykinin in Eng(+/+) was markedly reduced in Eng(+/-) mice. Both kinds of animals had similar responses to sodium nitroprusside, suggesting that the deficient vasodilatory effect is not due to a NO response impairment. Urinary and plasma concentrations of nitrites, a NO metabolite, were lower in Eng(+/-) than in Eng(+/+) mice. The levels of endothelial nitric oxide synthase (eNOS) in kidneys and femoral arteries were about half in Eng(+/-) than in Eng(+/+) mice and were also reduced in primary cultures of aortic endothelial cells from Eng(+/-) compared with those from Eng(+/+) mice. Furthermore, overexpression or suppression of endoglin in cultured cells induced a marked increase or decrease in the protein levels of eNOS, respectively. Thus, our results in vivo and in vitro demonstrate a relationship between endoglin and NO-dependent vasodilation mediated by the regulation of eNOS expression.	Univ Salamanca, Dept Fisiol & Farmacol, Edificio Dept, Inst Reina Sofia Invest Nefrol, Salamanca 37007, Spain; CSIC, Ctr Invest Biol, E-28040 Madrid, Spain	University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Lopez-Novoa, IM (corresponding author), Univ Salamanca, Dept Fisiol & Farmacol, Edificio Dept, Inst Reina Sofia Invest Nefrol, Campus Miguel Unamuno, Salamanca 37007, Spain.	jmlnovoa@usal.es	Lopez-Novoa, Jose M/A-3672-2008; Sanz-Rodriguez, Francisco/AAK-8388-2020; Prieto, Marta/H-2539-2014; Rodriguez-Barbero, Alicia/A-7583-2017; Bernabeu, Carmelo/L-3226-2014; Bernabeu, Carmelo/P-4662-2019; Prieto, Marta/A-5445-2016	Rodriguez-Barbero, Alicia/0000-0002-6774-7147; Bernabeu, Carmelo/0000-0002-1563-6162; Bernabeu, Carmelo/0000-0002-1563-6162; Prieto, Marta/0000-0002-2540-4461; Rosalia, Carron/0000-0003-4445-2255; Lopez-Novoa, Jose M./0000-0002-6211-7269				Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 2000, TRENDS CARDIOVAS MED, V10, P279, DOI 10.1016/S1050-1738(01)00062-7; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; BRAVERMAN IM, 1990, J INVEST DERMATOL, V95, P422, DOI 10.1111/1523-1747.ep12555569; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; Coleman HA, 2001, J PHYSIOL-LONDON, V531, P359, DOI 10.1111/j.1469-7793.2001.0359i.x; Diez-Marques L, 2002, BBA-MOL BASIS DIS, V1587, P36, DOI 10.1016/S0925-4439(02)00051-0; Gonzalez-Santiago L, 2002, CIRC RES, V90, P539, DOI 10.1161/01.RES.0000012445.68979.9D; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; GUYTON AC, 1996, TXB MED PHYSL, P200; Inoue T, 1995, MATER SCI RES INT, V1, P1; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2003, J CELL SCI, V116, P2677, DOI 10.1242/jcs.00470; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Li DY, 2001, HYPERTENSION, V38, P1062, DOI 10.1161/hy1101.092971; Marchetti J, 2001, BRIT J PHARMACOL, V132, P749, DOI 10.1038/sj.bjp.0703851; MARCHUK DA, 2001, METABOLIC MOL BASES, V4, P5419; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; NICOSIA RF, 1990, LAB INVEST, V63, P115; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Relou IAM, 1998, TISSUE CELL, V30, P525, DOI 10.1016/S0040-8166(98)80032-3; RISAU W, 1995, FASEB J, V9, P926, DOI 10.1096/fasebj.9.10.7615161; Rodriguez-Barbero A, 2001, BIOCHEM BIOPH RES CO, V282, P142, DOI 10.1006/bbrc.2001.4526; Rodriguez-Pena A, 2002, HYPERTENSION, V40, P713, DOI 10.1161/01.HYP.0000037429.73954.27; Shovlin CL, 1999, THORAX, V54, P714, DOI 10.1136/thx.54.8.714; Torsney E, 2003, CIRCULATION, V107, P1653, DOI 10.1161/01.CIR.0000058170.92267.00; Valdivielso JM, 2001, AM J PHYSIOL-REG I, V280, pR771, DOI 10.1152/ajpregu.2001.280.3.R771; Valdivielso JM, 1999, AM J PHYSIOL-REG I, V276, pR1718, DOI 10.1152/ajpregu.1999.276.6.R1718; ZANCHI A, 1995, CARDIOVASC RES, V30, P122	33	130	135	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					609	+		10.1096/fj.03-0197fje	http://dx.doi.org/10.1096/fj.03-0197fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734648				2022-12-28	WOS:000188829300014
J	Morale, MC; Serra, PA; Delogu, MR; Migheli, R; Rocchitta, G; Tirolo, C; Caniglia, S; Testa, N; L'Episcopo, F; Gennuso, F; Scoto, GM; Barden, N; Miele, E; Desole, MS; Marchetti, B				Morale, MC; Serra, PA; Delogu, MR; Migheli, R; Rocchitta, G; Tirolo, C; Caniglia, S; Testa, N; L'Episcopo, F; Gennuso, F; Scoto, GM; Barden, N; Miele, E; Desole, MS; Marchetti, B			Glucocorticoid receptor deficiency increases vulnerability of the nigrostriatal dopaminergic system: critical role of glial nitric oxide	FASEB JOURNAL			English	Article						Parkinson's disease (PD); inflammation; hypothalamic-pituitary-adrenocortical (UPA) axis; astroglial inducible nitric oxide synthase (iNOS); neuroprotection	CENTRAL-NERVOUS-SYSTEM; KAPPA-B-ALPHA; GENE-EXPRESSION; PARKINSONS-DISEASE; IMMUNE FUNCTION; AUTOIMMUNE ENCEPHALOMYELITIS; SELECTIVE-INHIBITION; INDUCED APOPTOSIS; LHRH NEURONS; MPTP MODEL	Glucocorticoids (GCs) exert via glucocorticoid receptors (GRs) potent anti-inflammatory and immunosuppressive effects. Emerging evidence indicates that an inflammatory process is involved in dopaminergic nigro-striatal neuronal loss in Parkinson's disease. We here report that the GR deficiency of transgenic (Tg) mice expressing GR antisense RNA from early embryonic life has a dramatic impact in "programming" the vulnerability of doparninergic neurons to 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). The GR deficiency of Tg mice exacerbates MPTP-induced toxicity to doparninergic neurons, as revealed by both severe loss of tyrosine hydroxylase positive nigral neurons and sharp decreases in striatal levels of dopamine and its metabolites. In addition, the late increase in dopamine oxidative metabolism and ascorbic acid oxidative status in GR-deficient mice was far greater than in wild-type (Wt) mice. Inducible nitric oxide synthase (iNOS) was sharply increased in activated astrocytes, macrophages/microglia of GR-deficient as compared with Wt mice. Moreover, GR-deficient microglia produced three- to fourfold higher nitrite levels than Wt mice; these increases preceded the loss of doparninergic function and were resistant to GR the inhibitory effect of GC, pointing to peroxynitrites as candidate neurotoxic effectors. The NOS inhibitor N-6-(1-iminoethyl)-L-lysine normalized vulnerability of Tg mice, thus establishing a novel link between genetic impairment of GR function and vulnerability to MPTP.	IRCCS, OASI Inst Res & Care Mental Retardat & Brain Aging, I-94018 Troina, EN, Italy; Univ Sassari, Fac Med, Dept Pharmacol, I-07100 Sassari, Italy; Univ Catania, Fac Pharm, Dept Pharmacol, Catania, Italy; Univ Laval, Dept Anat & Physiol, Quebec City, PQ, Canada; Univ Laval, CHUL, Res Ctr, Quebec City, PQ, Canada	IRCCS Oasi Maria SS; University of Sassari; University of Catania; Laval University; Laval University	Marchetti, B (corresponding author), IRCCS, OASI Inst Res & Care Mental Retardat & Brain Aging, Via Conte Ruggero 73, I-94018 Troina, EN, Italy.	bianca.marchetti@oasi.en.it	Rocchitta, Gaia/HHM-8002-2022; Caniglia, Salvatore/D-1001-2017; L'Episcopo, Francesca/K-4602-2016; Morale, Maria Concetta/D-5847-2017; Tirolo, Cataldo/C-9929-2017; Nunzio, Testa/D-8023-2017; Marchetti, Bianca Maria/K-4623-2016; Caniglia, Salvatore/D-1001-2017	Caniglia, Salvatore/0000-0002-9416-8458; L'Episcopo, Francesca/0000-0003-3292-9677; Morale, Maria Concetta/0000-0003-0624-7234; Tirolo, Cataldo/0000-0003-1747-8134; Nunzio, Testa/0000-0002-4024-2325; Marchetti, Bianca Maria/0000-0002-9287-8448; Gennuso, Florinda/0000-0001-5635-4973; MIGHELI, Rossana/0000-0001-5520-5511; SERRA, Pier Andrea/0000-0003-2401-5146; ROCCHITTA, Gaia Giovanna Maria/0000-0002-4319-4197; Caniglia, Salvatore/0000-0003-1238-6193	Italian Ministry of Health; Italian Ministry of Research (MURST); OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy; Medical Research Council of Canada;  [RF-2002]	Italian Ministry of Health(Ministry of Health, Italy); Italian Ministry of Research (MURST)(Ministry of Education, Universities and Research (MIUR)); OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy; Medical Research Council of Canada(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 	The authors wish to thank the Italian Ministry of Health (Strategic Research Project RF-2002, conv. n. 189), Italian Ministry of Research (MURST), OASI (IRCCS) Institution for Research and Care on Mental Retardation and Brain Aging Troina (EN) Italy, and The Medical Research Council of Canada for support of this project. M.C.M. and P.A.S. share the first authorship.	AHBON E, 2000, P NATL ACAD SCI USA, V97, P14726; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; ARNELLE DR, 1995, ARCH BIOCHEM BIOPHYS, V318, P279, DOI 10.1006/abbi.1995.1231; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Avola R, 2000, INT J DEV NEUROSCI, V18, P743, DOI 10.1016/S0736-5748(00)00052-6; Bakker JM, 2000, J IMMUNOL, V165, P5932, DOI 10.4049/jimmunol.165.10.5932; Barden N, 1997, NEUROENDOCRINOLOGY, V66, P212, DOI 10.1159/000127240; BARNES PJ, 1993, TRENDS PHARMACOL SCI, V14, P436, DOI 10.1016/0165-6147(93)90184-L; Barthwal MK, 2001, REDOX REP, V6, P297, DOI 10.1179/135100001101536436; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Bogdan C, 1998, J EXP MED, V187, P1361, DOI 10.1084/jem.187.9.1361; Bye N, 1998, NEUROREPORT, V9, P1179, DOI 10.1097/00001756-199804200-00040; Bye N, 2001, NEUROSCIENCE, V105, P853, DOI 10.1016/S0306-4522(01)00236-6; Chrousos GP, 2000, ANN NY ACAD SCI, V917, P38, DOI 10.1111/j.1749-6632.2000.tb05371.x; COHEN J, 1991, LANCET, V338, P736, DOI 10.1016/0140-6736(91)91453-2; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; De Groot CJA, 2001, MICROSC RES TECHNIQ, V54, P34, DOI 10.1002/jemt.1118; De Vera ME, 1997, AM J PHYSIOL-GASTR L, V273, pG1290, DOI 10.1152/ajpgi.1997.273.6.G1290; DEGROOT CJA, 1989, IMMUNOBIOLOGY, V179, P314, DOI 10.1016/S0171-2985(89)80038-5; Dehmer T, 2000, J NEUROCHEM, V74, P2213, DOI 10.1046/j.1471-4159.2000.0742213.x; DEKLOET ER, 1987, PSYCHONEUROENDOCRINO, V12, P83, DOI 10.1016/0306-4530(87)90040-0; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; Drew PD, 2000, BRAIN RES BULL, V52, P391, DOI 10.1016/S0361-9230(00)00275-6; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Galigniana MD, 1999, MOL PHARMACOL, V55, P317, DOI 10.1124/mol.55.2.317; Gallo F, 2000, SYNAPSE, V36, P233, DOI 10.1002/(SICI)1098-2396(20000615)36:4<233::AID-SYN1>3.0.CO;2-I; Gallo F, 2000, J NEUROENDOCRINOL, V12, P941, DOI 10.1046/j.1365-2826.2000.00554.x; GIULIAN D, 1993, GLIA, V7, P102, DOI 10.1002/glia.440070116; Hantraye P, 1996, NAT MED, V2, P1017, DOI 10.1038/nm0996-1017; Ho A, 1998, J NEUROSCI, V18, P5614; Iravani MM, 2002, NEUROSCIENCE, V110, P49, DOI 10.1016/S0306-4522(01)00562-0; Ito K, 2001, FASEB J, V15, pA473; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; Jenner P, 1996, NEUROLOGY, V47, pS161, DOI 10.1212/WNL.47.6_Suppl_3.161S; Karanth S, 1997, ENDOCRINOLOGY, V138, P3476, DOI 10.1210/en.138.8.3476; Kielian T, 2003, J NEUROSCI RES, V71, P315, DOI 10.1002/jnr.10501; Kitraki E, 1996, NEUROENDOCRINOLOGY, V63, P305, DOI 10.1159/000126971; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Laflamme N, 1997, J MOL NEUROSCI, V8, P165, DOI 10.1007/BF02736831; LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561; Lapchak PA, 1998, MOVEMENT DISORD, V13, P49; Levecque C, 2003, HUM MOL GENET, V12, P79, DOI 10.1093/hmg/ddg009; Liberatore GT, 1999, NAT MED, V5, P1403; Linthorst ACE, 1999, EUR J NEUROSCI, V11, P178, DOI 10.1046/j.1460-9568.1999.00425.x; Linthorst ACE, 2000, EUR J NEUROSCI, V12, P283, DOI 10.1046/j.1460-9568.2000.00878.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marchetti B, 2001, BRAIN RES REV, V37, P259, DOI 10.1016/S0165-0173(01)00130-8; Marchetti B, 2002, J IMMUNOL, V168, P5848, DOI 10.4049/jimmunol.168.11.5848; Marchetti B, 2000, ANN NY ACAD SCI, V917, P678; MARCHETTI B, 1994, ANN NY ACAD SCI, V719, P308, DOI 10.1111/j.1749-6632.1994.tb56839.x; MARCHETTI B, 1932, 32 ANN M SOC NEUR MI; McCann SM, 2003, CURR PHARM DESIGN, V9, P381, DOI 10.2174/1381612033391766; McCann SM, 1998, ANN NY ACAD SCI, V840, P174, DOI 10.1111/j.1749-6632.1998.tb09561.x; McCann SM, 1997, NEUROIMMUNOMODULAT, V4, P98, DOI 10.1159/000097327; McCartney-Francis NL, 2001, J IMMUNOL, V166, P2734, DOI 10.4049/jimmunol.166.4.2734; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; McEwen BS, 1998, NEW ENGL J MED, V338, P171, DOI 10.1056/NEJM199801153380307; MCGEER EG, 1995, NEURODEGENER DIS, P277; Meaney MJ, 1996, DEV NEUROSCI-BASEL, V18, P49, DOI 10.1159/000111395; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; MORALE MC, 1995, ENDOCRINOLOGY, V136, P3949, DOI 10.1210/en.136.9.3949; Morale MC, 2001, IMMUNOL CELL BIOL, V79, P400, DOI 10.1046/j.1440-1711.2001.01030.x; Nichols NR, 2001, BRAIN RES REV, V37, P273, DOI 10.1016/S0165-0173(01)00131-X; Noack H, 1998, GLIA, V23, P285, DOI 10.1002/(SICI)1098-1136(199808)23:4<285::AID-GLIA1>3.0.CO;2-2; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; Przedborski S, 1996, P NATL ACAD SCI USA, V93, P4565, DOI 10.1073/pnas.93.10.4565; Reichardt HM, 2000, MOL CELL BIOL, V20, P9009, DOI 10.1128/MCB.20.23.9009-9017.2000; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Ruuls SR, 1996, CLIN EXP IMMUNOL, V103, P467; Sacedon R, 1999, J NEUROIMMUNOL, V98, P157, DOI 10.1016/S0165-5728(99)00091-0; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Serra PA, 2002, J BIOL CHEM, V277, P34451, DOI 10.1074/jbc.M202099200; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; SIMONS SS, 1995, METHOD ENZYMOL, V251, P406; Snyder SH, 1996, NAT MED, V2, P965, DOI 10.1038/nm0996-965; STEC I, 1994, J PSYCHIAT RES, V28, P1, DOI 10.1016/0022-3956(94)90031-0; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Tanaka J, 1997, GLIA, V20, P23, DOI 10.1002/(SICI)1098-1136(199705)20:1<23::AID-GLIA3>3.3.CO;2-U; TIPTON KF, 1993, J NEUROCHEM, V61, P1191, DOI 10.1111/j.1471-4159.1993.tb13610.x; Tolwani RJ, 1999, LAB ANIM SCI, V49, P363; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0; TRIARHOU LC, 1988, J NEUROCYTOL, V17, P221, DOI 10.1007/BF01674209; UHL GR, 1985, LANCET, V1, P956; WESTERINK BHC, 1982, J NEUROCHEM, V38, P680, DOI 10.1111/j.1471-4159.1982.tb08685.x; Willenborg DO, 1999, J IMMUNOL, V163, P5278; Wu CH, 2001, NEUROSCI RES, V40, P235, DOI 10.1016/S0168-0102(01)00231-0; Wu DC, 2002, J NEUROSCI, V22, P1763, DOI 10.1523/JNEUROSCI.22-05-01763.2002; Zhou XL, 2000, J BIOL CHEM, V275, P21241, DOI 10.1074/jbc.M904498199	90	56	56	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					164	166		10.1096/fj.03-0501fje	http://dx.doi.org/10.1096/fj.03-0501fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630699				2022-12-28	WOS:000188829300062
J	Zisch, AH; Lutolf, MP; Ehrbar, M; Raeber, GP; Rizzi, SC; Davies, N; Schmokel, H; Bezuidenhout, D; Djonov, V; Zilla, P; Hubbell, JA				Zisch, AH; Lutolf, MP; Ehrbar, M; Raeber, GP; Rizzi, SC; Davies, N; Schmokel, H; Bezuidenhout, D; Djonov, V; Zilla, P; Hubbell, JA			Cell-demanded release of VEGF from synthetic, biointeractive cell-ingrowth matrices for vascularized tissue growth	FASEB JOURNAL			English	Article						therapeutic angiogenesis; VEGF; bioactive polymers; controlled release; tissue engineering; scaffold; PEG	HEPARIN-BINDING DOMAIN; ENDOTHELIAL-CELLS; CHORIOALLANTOIC MEMBRANE; EXTRACELLULAR MATRICES; FACTOR DELIVERY; HYDROGELS; ANGIOGENESIS; EXPRESSION; DEGRADATION; MYOCARDIUM	Local, controlled induction of angiogenesis remains a challenge that limits tissue engineering approaches to replace or restore diseased tissues. We present a new class of bioactive synthetic hydrogel matrices based on poly(ethylene glycol) (PEG) and synthetic peptides that exploits the activity of vascular endothelial growth factor (VEGF) alongside the base matrix functionality for cellular ingrowth, that is, induction of cell adhesion by pendant RGD-containing peptides and provision of cell-mediated remodeling by cross-linking matrix metalloproteinase substrate peptides. By using a Michael-type addition reaction, we incorporated variants of VEGF(121) and VEGF(165) covalently within the matrix, available for cells as they invade and locally remodel the material. The functionality of the matrix-conjugated VEGF was preserved and was critical for in vitro endothelial cell survival and migration within the matrix environment. Consistent with a scheme of locally restricted availability of VEGF, grafting of these VEGF-modified hydrogel matrices atop the chick chorioallontoic membrane evoked strong new blood vessel formation precisely at the area of graft-membrane contact. When implanted subcutaneously in rats, these VEGF-containing matrices were completely remodeled into native, vascularized tissue. This type of synthetic, biointeractive matrix with integrated angiogenic growth factor activity, presented and released only upon local cellular demand, could become highly useful in a number of clinical healing applications of local therapeutic angiogenesis.	Swiss Fed Inst Technol Zurich ETHZ, Inst Biomed Engn, CH-8044 Zurich, Switzerland; Swiss Fed Inst Technol Zurich ETHZ, Dept Mat Sci, CH-8044 Zurich, Switzerland; Univ Zurich, CH-8006 Zurich, Switzerland; Univ Cape Town, Cape Heart Ctr, Dept Cardiothorac Surg, ZA-7700 Rondebosch, South Africa; Univ Bern, Inst Anat, CH-3012 Bern, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University of Cape Town; University of Bern	Zisch, AH (corresponding author), Swiss Fed Inst Technol Zurich ETHZ, Inst Biomed Engn, Moussonstr 18, CH-8044 Zurich, Switzerland.	andreas.zisch@mat.ethz.ch	Davies, Neil Hamer/B-1366-2008; Ehrbar, Martin/F-4578-2012; Hubbell, Jeffrey A/A-9266-2008; Bezuidenhout, Deon/B-8656-2009; Lutolf, Matthias P/E-5914-2010	Davies, Neil Hamer/0000-0003-0432-4515; Ehrbar, Martin/0000-0003-2707-4870; Hubbell, Jeffrey A/0000-0003-0276-5456; Bezuidenhout, Deon/0000-0001-8052-7491; Djonov, Valentin/0000-0002-5062-1169				Arras M, 1998, NAT BIOTECHNOL, V16, P159, DOI 10.1038/nbt0298-159; AUERBACH R, 1974, DEV BIOL, V41, P391, DOI 10.1016/0012-1606(74)90316-9; Baumgartner I, 1998, CIRCULATION, V97, P1114, DOI 10.1161/01.CIR.97.12.1114; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; BIKFALVI A, 1991, J CELL PHYSIOL, V149, P50, DOI 10.1002/jcp.1041490108; Birkenhager R, 1996, BIOCHEM J, V316, P703, DOI 10.1042/bj3160703; Djonov V, 2000, CIRC RES, V86, P286, DOI 10.1161/01.RES.86.3.286; EDELMAN ER, 1991, BIOMATERIALS, V12, P619, DOI 10.1016/0142-9612(91)90107-L; Elbert DL, 2001, BIOMACROMOLECULES, V2, P430, DOI 10.1021/bm0056299; Elbert DL, 2001, J CONTROL RELEASE, V76, P11, DOI 10.1016/S0168-3659(01)00398-4; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, NAT MED, V5, P1359, DOI 10.1038/70928; Halstenberg S, 2002, BIOMACROMOLECULES, V3, P710, DOI 10.1021/bm015629o; Hariawala MD, 1996, J SURG RES, V63, P77, DOI 10.1006/jsre.1996.0226; Henry TD, 2001, AM HEART J, V142, P872, DOI 10.1067/mhj.2001.118471; Hern DL, 1998, J BIOMED MATER RES, V39, P266, DOI 10.1002/(SICI)1097-4636(199802)39:2<266::AID-JBM14>3.0.CO;2-B; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; HOUCK KA, 1992, J BIOL CHEM, V267, P26031; Keck RG, 1997, ARCH BIOCHEM BIOPHYS, V344, P103, DOI 10.1006/abbi.1997.0145; Keyt BA, 1996, J BIOL CHEM, V271, P7788, DOI 10.1074/jbc.271.13.7788; Kim TK, 2002, J PHARM PHARMACOL, V54, P897, DOI 10.1211/002235702760089009; King TW, 2000, J BIOMED MATER RES, V51, P383, DOI 10.1002/1097-4636(20000905)51:3<383::AID-JBM12>3.0.CO;2-D; Kipshidze N, 2000, TEX HEART I J, V27, P196; Kuhl PR, 1996, NAT MED, V2, P1022, DOI 10.1038/nm0996-1022; Lazarous DF, 1997, CARDIOVASC RES, V36, P78, DOI 10.1016/S0008-6363(97)00142-9; Lee KY, 2000, NATURE, V408, P998, DOI 10.1038/35050141; Lee RJ, 2000, CIRCULATION, V102, P898; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li WL, 2000, J CELL SCI, V113, P1525; Lutolf MP, 2003, BIOMACROMOLECULES, V4, P713, DOI 10.1021/bm025744e; Lutolf MP, 2003, ADV MATER, V15, P888, DOI 10.1002/adma.200304621; Lutolf MP, 2001, BIOCONJUGATE CHEM, V12, P1051, DOI 10.1021/bc015519e; Lutolf MR, 2003, NAT BIOTECHNOL, V21, P513, DOI 10.1038/nbt818; Mann BK, 2001, BIOMATERIALS, V22, P3045, DOI 10.1016/S0142-9612(01)00051-5; Mann BK, 2001, BIOMATERIALS, V22, P439, DOI 10.1016/S0142-9612(00)00196-4; Morpurgo M, 1996, BIOCONJUGATE CHEM, V7, P363, DOI 10.1021/bc9600224; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Post MJ, 2001, CARDIOVASC RES, V49, P522, DOI 10.1016/S0008-6363(00)00216-9; Richardson TP, 2001, NAT BIOTECHNOL, V19, P1029, DOI 10.1038/nbt1101-1029; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V69, P149, DOI 10.1016/S0168-3659(00)00296-0; Sakiyama-Elbert SE, 2000, J CONTROL RELEASE, V65, P389, DOI 10.1016/S0168-3659(99)00221-7; Sakiyama-Elbert SE, 2001, FASEB J, V15, P1300, DOI 10.1096/fj.00-0564fje; Schumacher B, 1998, CIRCULATION, V97, P645, DOI 10.1161/01.CIR.97.7.645; Sheridan MH, 2000, J CONTROL RELEASE, V64, P91, DOI 10.1016/S0168-3659(99)00138-8; Wang C, 1999, NATURE, V397, P417, DOI 10.1038/17092; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; West JL, 1999, MACROMOLECULES, V32, P241, DOI 10.1021/ma981296k; WILTING J, 1993, CELL TISSUE RES, V274, P163, DOI 10.1007/BF00327997; Wilting J, 1996, DEV BIOL, V176, P76, DOI 10.1006/dbio.1996.9993; Wissink MJB, 2000, J CONTROL RELEASE, V64, P103, DOI 10.1016/S0168-3659(99)00145-5; Woessner JF, 2002, MATRIX METALLOPROTEI; Zisch AH, 2001, J CONTROL RELEASE, V72, P101, DOI 10.1016/S0168-3659(01)00266-8	55	406	423	0	126	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2260	+		10.1096/fj.02-1041fje	http://dx.doi.org/10.1096/fj.02-1041fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563693				2022-12-28	WOS:000186343300021
J	Chen-Konak, L; Guetta-Shubin, Y; Yahav, H; Salit-Salit, A; Zilberman, M; Binah, O; Resnick, N				Chen-Konak, L; Guetta-Shubin, Y; Yahav, H; Salit-Salit, A; Zilberman, M; Binah, O; Resnick, N			Transcriptional and post-translation regulation of the Tie1 receptor by fluid shear stress changes in vascular endothelial cells	FASEB JOURNAL			English	Article						vascular endothelium; biomechanical forces; vascular restructuring; shear stress response element	TYROSINE KINASE TIE; SIGNALING PATHWAYS; GENE-EXPRESSION; BLOOD-VESSELS; GROWTH; ARTERIOGENESIS; SURVIVAL; ROLES; VEGF; FLOW	The interaction between the vascular endothelium and hemodynamic forces (and more specifically, fluid shear stress), induced by the flow of blood, plays a major role in vascular remodeling and in new blood vessels formation via a process termed arteriogenesis. Tiel is an orphan tyrosine kinase receptor expressed almost exclusively in endothelial cells and is required for normal vascular development and maintenance. The present study demonstrates that Tiel expression is rapidly down-regulated in endothelial cells exposed to shear stress, and more so to shear stress changes. This down-regulation is accompanied by a rapid cleavage of Tiel and binding of the cleaved Tiel 45 kDa endodomain to Tie2. The rapid cleavage of Tiel is followed by a transcriptional down-regulation in response to shear stress. The activity of the Tiel promoter is suppressed by shear stress and by tumor necrosis factor a,. Shear stress-induced transcriptional suppression of Tiel is mediated by a negative shear stress response element, localized in a region of 250 by within the promoter. The rapid down-regulation of Tiel by shear stress changes and its rapid binding to Tie2 may be required for destabilization of endothelial cells in order to initiate the process of vascular restructuring.	Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Anat & Cell Biol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Interdepartmental Program Biotechnol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Physiol, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Resnick, N (corresponding author), Technion Israel Inst Technol, Rappaport Family Inst Res Med Sci, Dept Anat & Cell Biol, POB 9697, IL-31096 Haifa, Israel.	nresnick@rics.bwh.harvard.edu		Binah, Ofer/0000-0002-0468-8530				Ando J, 1996, BIOCHEM BIOPH RES CO, V225, P347, DOI 10.1006/bbrc.1996.1178; ANDO J, 1994, AM J PHYSIOL, V267, pC679, DOI 10.1152/ajpcell.1994.267.3.C679; ANDO J, 1995, ANN NY ACAD SCI, V748, P148; ANDO J, 1995, ANN NY ACAD SCI, V748, P156; Boutet SC, 2001, BIOCHEM J, V360, P23, DOI 10.1042/0264-6021:3600023; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Buschmann I, 2000, J PATHOL, V190, P338, DOI 10.1002/(SICI)1096-9896(200002)190:3<338::AID-PATH594>3.0.CO;2-7; Calvert JT, 1999, HUM MOL GENET, V8, P1279, DOI 10.1093/hmg/8.7.1279; Carmeliet, 1999, Curr Interv Cardiol Rep, V1, P322; Carmeliet P, 2000, ANN NY ACAD SCI, V902, P249; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2001, NAT BIOTECHNOL, V19, P1019, DOI 10.1038/nbt1101-1019; Carmeliet P., 2000, ANN NY ACAD SCI, V902, P62; Chen KD, 1999, J BIOL CHEM, V274, P18393, DOI 10.1074/jbc.274.26.18393; Christensen RA, 2002, J CELL BIOCHEM, V85, P505, DOI 10.1002/jcb.10148; Clark ER, 1918, AM J ANAT, V23, P37, DOI 10.1002/aja.1000230103; Davies PF, 1997, J VASC RES, V34, P208, DOI 10.1159/000159224; Deindl E, 2001, CIRC RES, V89, P779, DOI 10.1161/hh2101.098613; Egginton S, 2001, CARDIOVASC RES, V49, P634, DOI 10.1016/S0008-6363(00)00282-0; Fujikawa K, 1999, J VASC RES, V36, P272, DOI 10.1159/000025655; Garcia-Cardena G, 2001, P NATL ACAD SCI USA, V98, P4478, DOI 10.1073/pnas.071052598; Gimbrone MA, 2000, ANN NY ACAD SCI, V902, P230; Herzog S, 2002, AM J PHYSIOL-HEART C, V283, pH2012, DOI 10.1152/ajpheart.00257.2002; Iljin K, 2002, FASEB J, V16, P1764, DOI 10.1096/fj.01-1043com; Iljin K, 1999, FASEB J, V13, P377, DOI 10.1096/fasebj.13.2.377; Jones N, 2001, EMBO REP, V2, P438, DOI 10.1093/embo-reports/kve093; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; Kontos CD, 2002, MOL CELL BIOL, V22, P1704, DOI 10.1128/MCB.22.6.1704-1713.2002; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; KORHONEN J, 1995, BLOOD, V86, P1828, DOI 10.1182/blood.V86.5.1828.bloodjournal8651828; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; LANGILLE BL, 1986, ARTERIOSCLEROSIS, V6, P146, DOI 10.1161/01.ATV.6.2.146; Loughna S, 2001, MATRIX BIOL, V20, P319, DOI 10.1016/S0945-053X(01)00149-4; Loughna S, 2001, MOL CELL, V7, P233, DOI 10.1016/S1097-2765(01)00171-X; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Marron MB, 2000, ADV EXP MED BIOL, V476, P35; McCarthy MJ, 1999, LAB INVEST, V79, P889; McCarthy MJ, 1998, FEBS LETT, V423, P334, DOI 10.1016/S0014-5793(98)00122-7; McCormick SM, 2001, P NATL ACAD SCI USA, V98, P8955, DOI 10.1073/pnas.171259298; Meeson A, 1996, DEVELOPMENT, V122, P3929; Meeson AP, 1999, DEVELOPMENT, V126, P1407; MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895; Niu XL, 2002, J BIOL CHEM, V277, P31768, DOI 10.1074/jbc.M203995200; PARTANEN J, 1992, MOL CELL BIOL, V12, P1698, DOI 10.1128/MCB.12.4.1698; Partanen J, 1996, DEVELOPMENT, V122, P3013; Puri MC, 1999, DEVELOPMENT, V126, P4569; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; REMUZZI A, 1984, BIORHEOLOGY, V21, P617; Resnick N, 2000, CURR OPIN LIPIDOL, V11, P167, DOI 10.1097/00041433-200004000-00010; RESNICK N, 2003, IN PRESS PROG BIOPHY; Risau W, 1995, ANNU REV CELL DEV BI, V11, P73, DOI 10.1146/annurev.cb.11.110195.000445; SATO TN, 1993, P NATL ACAD SCI USA, V90, P9355, DOI 10.1073/pnas.90.20.9355; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Schaper W, 1999, CARDIOVASC RES, V43, P835, DOI 10.1016/S0008-6363(99)00191-1; Schaper W, 2001, CIRCULATION, V104, P1994, DOI 10.1161/circ.104.17.1994; Scholz Dimitri, 2001, Angiogenesis, V4, P247, DOI 10.1023/A:1016094004084; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5; Tallquist MD, 1999, ONCOGENE, V18, P7917, DOI 10.1038/sj.onc.1203216; Tsiamis AC, 2002, MICROVASC RES, V63, P149, DOI 10.1006/mvre.2001.2377; van Royen N, 2002, FASEB J, V16, P432, DOI 10.1096/fj.01-0563fje; van Royen N, 2001, CARDIOVASC RES, V49, P543, DOI 10.1016/S0008-6363(00)00206-6; van Royen N, 2001, J NUCL CARDIOL, V8, P687, DOI 10.1067/mnc.2001.118924; Vikkula M, 1996, CELL, V87, P1181, DOI 10.1016/S0092-8674(00)81814-0; Wang YX, 2002, AM J PHYSIOL-CELL PH, V283, pC1540, DOI 10.1152/ajpcell.00222.2002; Ward NL, 2002, SEMIN CELL DEV BIOL, V13, P19, DOI 10.1006/scdb.2001.0288; Wong AL, 1997, CIRC RES, V81, P567, DOI 10.1161/01.RES.81.4.567; Yabkowitz R, 1999, BLOOD, V93, P1969, DOI 10.1182/blood.V93.6.1969.406k14_1969_1979; Yabkowitz R, 1997, BLOOD, V90, P706, DOI 10.1182/blood.V90.2.706.706_706_715	71	43	44	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2121	+		10.1096/fj.02-1151fje	http://dx.doi.org/10.1096/fj.02-1151fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500555				2022-12-28	WOS:000185925100004
J	Simon, MT; Pauloin, A; Normand, G; Lieu, HT; Mouly, H; Pivert, G; Carnot, F; Tralhao, JG; Brechot, C; Christa, L				Simon, MT; Pauloin, A; Normand, G; Lieu, HT; Mouly, H; Pivert, G; Carnot, F; Tralhao, JG; Brechot, C; Christa, L			HIP/PAP stimulates liver regeneration after partial hepatectomy and combines mitogenic and anti-apoptotic functions through the PKA signaling pathway	FASEB JOURNAL			English	Article						HIP/PAP/Reg-2; c-type lectin; TNF-alpha; PKA	PANCREATITIS-ASSOCIATED PROTEIN; HEPATIC PROGENITOR CELLS; PRIMARY HEPATOCYTES; TRANSGENIC MICE; MOUSE-LIVER; OVAL CELLS; PAP-I; EXPRESSION; ACTIVATION; INTESTINE	The HIP/PAP (=human Reg-2) C-type lectin encoding gene is activated in primary liver cancers. In normal liver, the protein is undetectable in normal mature hepatocytes and found only in some ductular cells, representing potential hepatic progenitor cells. The aim of this study was to examine the consequences of human HIP/PAP expression in the liver of transgenic mice. We demonstrated that HIP/PAP stimulated liver regeneration after partial hepatectomy. To further investigate the enhanced liver regeneration observed in vivo, primary cultures of hepatocytes were used to evaluate the mitogenic and anti-apoptotic properties of HIP/PAP. HIP/PAP increased hepatocyte DNA synthesis and protected hepatocytes against TNF-alpha plus actinomycin-D-induced apoptosis. HIP/PAP anti-apoptotic effects against TNF-alpha were clearly demonstrated when protein kinase A activity was specifically inhibited by KT5720, and HIP/PAP stimulated PKA-dependent phosphorylation of the proapoptotic Bad protein at Ser-112, suggesting that HIP/PAP may compete with cAMP to stimulate PKA activity. Overall, our results led us to propose a new role for a C-type lectin, HIP/PAP, as a hepatic cytokine that combines mitogenic and anti-apoptotic functions regarding hepatocytes, and consequently acts as a growth factor in vivo to enhance liver regeneration.	Univ Paris 05, Necker pasteur Inst, INSERM, U370, F-75742 Paris 15, France; INRA, Jouy En Josas, France; Hop Necker Enfants Malad, Serv Anatomopathol, Paris, France; Hop Europeen Georges Pompidou, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; INRAE; UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Christa, L (corresponding author), Univ Paris 05, Necker pasteur Inst, INSERM, U370, 156 Rue Vaugirard, F-75742 Paris 15, France.	christa@necker.fr	Normand, Guillaume/A-1975-2010	Normand, Guillaume/0000-0003-1228-3813; Tralhao, Jose/0000-0002-5641-6975				Abergel C, 1999, ACTA CRYSTALLOGR D, V55, P1487, DOI 10.1107/S0907444999007969; Akahani S, 1997, CANCER RES, V57, P5272; Akhurst B, 2001, HEPATOLOGY, V34, P519, DOI 10.1053/jhep.2001.26751; Alison M, 1998, J HEPATOL, V29, P676, DOI 10.1016/S0168-8278(98)80165-7; Bernerd F, 1999, P NATL ACAD SCI USA, V96, P11329, DOI 10.1073/pnas.96.20.11329; Christa L, 1996, AM J PHYSIOL-GASTR L, V271, pG993, DOI 10.1152/ajpgi.1996.271.6.G993; Christa L, 1999, AM J PATHOL, V155, P1525, DOI 10.1016/S0002-9440(10)65468-5; Christa L, 2000, EUR J BIOCHEM, V267, P1665, DOI 10.1046/j.1432-1327.2000.01159.x; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; FACTOR VM, 1994, AM J PATHOL, V145, P409; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Fausto Nelson, 1994, P1501; Fladmark KE, 1997, BIOCHEM BIOPH RES CO, V232, P20, DOI 10.1006/bbrc.1997.6214; FU XX, 1988, J VIROL, V62, P3422, DOI 10.1128/JVI.62.9.3422-3430.1988; Harada H, 1999, MOL CELL, V3, P413, DOI 10.1016/S1097-2765(00)80469-4; Hatano E., 2002, AM J PHYSIOL-GASTR L, V282, pG1357; Higgins GM, 1931, ARCH PATHOL, V12, P186; KLAUNIG JE, 1981, IN VITRO CELL DEV B, V17, P913; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LASSERRE C, 1992, CANCER RES, V52, P5089; Lasserre C, 1999, AM J PATHOL, V154, P1601, DOI 10.1016/S0002-9440(10)65413-2; LEIST M, 1994, J IMMUNOL, V153, P1778; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Libbrecht L, 2001, AM J SURG PATHOL, V25, P1388, DOI 10.1097/00000478-200111000-00006; Livesey FJ, 1997, NATURE, V390, P614, DOI 10.1038/37615; Malka D, 2000, GASTROENTEROLOGY, V119, P816, DOI 10.1053/gast.2000.16491; Montalto G, 1998, ONCOLOGY-BASEL, V55, P421, DOI 10.1159/000011889; Moucadel V, 2001, EUR J CELL BIOL, V80, P156, DOI 10.1078/0171-9335-00148; Nishimune H, 2000, NAT CELL BIOL, V2, P906, DOI 10.1038/35046558; Ortiz EM, 1998, GASTROENTEROLOGY, V114, P808, DOI 10.1016/S0016-5085(98)70595-5; Petersen BE, 1998, HEPATOLOGY, V27, P1030, DOI 10.1002/hep.510270419; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; RENTON KW, 1978, MOL PHARMACOL, V14, P672; Roskams T, 1998, J HEPATOL, V29, P455, DOI 10.1016/S0168-8278(98)80065-2; Sell S, 1998, HEPATOLOGY, V27, P317, DOI 10.1002/hep.510270202; Sirica A. E., 1997, BILIARY PANCREATIC D, P229; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Webster CRL, 1998, HEPATOLOGY, V27, P1324, DOI 10.1002/hep.510270519; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737	41	71	76	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1441	1450		10.1096/fj.02-1013com	http://dx.doi.org/10.1096/fj.02-1013com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12890698				2022-12-28	WOS:000185345100037
J	Andriamampandry, C; Taleb, O; Viry, S; Muller, C; Humbert, JP; Gobaille, S; Aunis, D; Maitre, M				Andriamampandry, C; Taleb, O; Viry, S; Muller, C; Humbert, JP; Gobaille, S; Aunis, D; Maitre, M			Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate	FASEB JOURNAL			English	Article						receptor for neuromodulator; drug of abuse; GHB; sleep regulation	SUCCINIC SEMI-ALDEHYDE; REGIONAL-DISTRIBUTION; HYDROXYCROTONIC ACID; GUINEA-PIG; SUPERFAMILY; SITES; SLEEP; LOCALIZATION; EXPRESSION; NARCOLEPSY	gamma-Hydroxybutyrate (GHB) is an endogenous neuromodulator with therapeutical applications in anesthesia, sleep disorders, and drug addiction. We report the cloning of a GHB receptor from a rat hippocampal cDNA library. This receptor has a molecular mass of 56 kDa and belongs to the seven-transmembrane receptor family. The peptidic sequence has no significant homology with any known receptor, including GABA(B) receptors. Its mRNA is restricted to the brain and is particularly abundant in the hippocampus, cortex, striatum, thalamus, olfactory bulbs, and cerebellum, matching the distribution of GHB binding sites in rat brain. Southern blot revealed the presence of homologous sequences in several species including the human. Binding assays on transfected CHO cells showed a dissociation constant (K-d) of 426 nM for GHB and no affinity for GABA, baclofen, or glutamate. In patch-clamp experiments, transfected CHO cells revealed a functional G-protein-coupled receptor as demonstrated by GTP-gamma-S-induced irreversible activation. Application of 0.1-15 muM GHB specifically induced an inward current at negative membrane potentials that was not reproduced by application of baclofen (10 muM). CGP-55845, a GABAB receptor antagonist, did not inhibit the GHB-induced response nor did the GHB receptor antagonist NCS-382, suggesting that the GHB receptor system includes several subtypes.	Fac Med Strasbourg, Inst Chim Biol, F-67085 Strasbourg, France; Fac Med Strasbourg, INSERM, U575, F-67085 Strasbourg, France	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Maitre, M (corresponding author), Fac Med Strasbourg, Inst Chim Biol, 11 Rue Humann, F-67085 Strasbourg, France.	maitre@neurochem.u-strasbg.fr	Maitre, Michel/J-9974-2016; Dominique, Aunis/W-1419-2019; Taleb, Omar/K-1457-2016	Maitre, Michel/0000-0003-1478-4806; Taleb, Omar/0000-0003-2407-0380				Andriamampandry C, 1998, BIOCHEM J, V334, P43, DOI 10.1042/bj3340043; APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BENAVIDES J, 1982, LIFE SCI, V30, P953, DOI 10.1016/0024-3205(82)90624-5; Bourguignon JJ, 2000, ALCOHOL, V20, P227, DOI 10.1016/S0741-8329(99)00086-5; BRUGGER F, 1993, EUR J PHARMACOL, V235, P153, DOI 10.1016/0014-2999(93)90836-7; CASH CD, 1979, J NEUROCHEM, V33, P1169, DOI 10.1111/j.1471-4159.1979.tb05261.x; Cash CD, 1996, NEUROSCI LETT, V209, P25, DOI 10.1016/0304-3940(96)12589-1; CHIN MY, 1992, WESTERN J MED, V156, P380; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Colombo G, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P150, DOI 10.4324/9780203300992_chapter_9; Crunelli V, 2002, GAMMA-HYDROXYBUTYRATE: MOLECULAR, FUNCTIONAL, AND CLINICAL ASPECTS, P75, DOI 10.4324/9780203300992_chapter_5; DOHERTY JD, 1978, J PHARMACOL EXP THER, V207, P130; Friedman J, 1996, NEUROLOGY, V46, P469, DOI 10.1212/WNL.46.2.469; GALLIMBERTI L, 1989, LANCET, V2, P787; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HARRIS NC, 1989, NEUROSCIENCE, V31, P363, DOI 10.1016/0306-4522(89)90380-1; HECHLER V, 1992, BRAIN RES, V572, P345, DOI 10.1016/0006-8993(92)90498-X; HECHLER V, 1990, NEUROSCI LETT, V110, P204, DOI 10.1016/0304-3940(90)90812-N; HECHLER V, 1993, J PHARMACOL EXP THER, V264, P1406; KALINYAK JE, 1987, J BIOL CHEM, V262, P460; Kemmel V, 1998, NEUROSCIENCE, V86, P989, DOI 10.1016/S0306-4522(98)00085-2; LABORIT G, 1980, AGRESSOLOGIE, V21, P189; LABORIT H, 1964, INT J NEUROPHARMACOL, V3, P433; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; MAITRE M, 1990, J PHARMACOL EXP THER, V255, P657; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAITRE M, 1994, EUR J PHARMACOL, V256, P211, DOI 10.1016/0014-2999(94)90248-8; MAMELAK M, 1986, SLEEP, V9, P285, DOI 10.1093/sleep/9.1.285; Maniatis T., 1982, MOL CLONING; OLPE HR, 1979, EUR J PHARMACOL, V53, P359, DOI 10.1016/0014-2999(79)90460-6; PRITCHETT DB, 1988, EMBO J, V7, P4135, DOI 10.1002/j.1460-2075.1988.tb03308.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROTH RH, 1970, BIOCHEM PHARMACOL, V19, P3013, DOI 10.1016/0006-2952(70)90087-0; RUMIGNY JF, 1981, J NEUROCHEM, V36, P1433, DOI 10.1111/j.1471-4159.1981.tb00583.x; RUMIGNY JF, 1981, FEBS LETT, V134, P96, DOI 10.1016/0014-5793(81)80559-5; SCHARF MB, 1985, J CLIN PSYCHIAT, V46, P222; Scharf MB, 1998, J RHEUMATOL, V25, P1986; SCRIMA L, 1990, SLEEP, V13, P479, DOI 10.1093/sleep/13.6.479; Sincock PM, 1997, J HISTOCHEM CYTOCHEM, V45, P515, DOI 10.1177/002215549704500404; SNEAD OC, 1994, BRAIN RES, V659, P147, DOI 10.1016/0006-8993(94)90874-5; Snead OC, 2000, J NEUROCHEM, V75, P1986, DOI 10.1046/j.1471-4159.2000.0751986.x; SNEAD OC, 1991, NEUROPHARMACOLOGY, V30, P161, DOI 10.1016/0028-3908(91)90199-L; SNEAD OC, 1981, DEV BRAIN RES, V1, P579; SNEAD OC, 1984, BIOCHEM PHARMACOL, V33, P2587; Stell IM, 1996, BRIT MED J, V313, P424; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; VAYER P, 1988, NEUROSCI LETT, V87, P99, DOI 10.1016/0304-3940(88)90152-8; VAYER P, 1988, NEUROCHEM INT, V12, P53, DOI 10.1016/0197-0186(88)90148-9; VAYER P, 1985, BIOCHEM PHARMACOL, V34, P2401, DOI 10.1016/0006-2952(85)90804-4	51	92	100	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1691	+		10.1096/fj.02-0846fje	http://dx.doi.org/10.1096/fj.02-0846fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958178				2022-12-28	WOS:000184471600011
J	Schulz, R; Gres, P; Skyschally, A; Duschin, A; Belosjorow, S; Konietzka, I; Heusch, G				Schulz, R; Gres, P; Skyschally, A; Duschin, A; Belosjorow, S; Konietzka, I; Heusch, G			Ischemic preconditioning preserves connexin 43 phosphorylation during sustained ischemia in pig hearts in vivo	FASEB JOURNAL			English	Article						protein kinases; reperfusion; preconditioning	ACTIVATED PROTEIN-KINASE; JUNCTION UNCOUPLER HEPTANOL; INFARCT SIZE-REDUCTION; GAP-JUNCTIONS; INTERCELLULAR COMMUNICATION; MAPK ACTIVATION; PKC-EPSILON; CHANNEL; CONDUCTANCE; CARDIOPROTECTION	During myocardial ischemia, connexin 43 (Cx43) is dephosphorylated in vitro, and the subsequent opening of gap junctions formed by two opposing Cx43 hexamers was suggested to propagate ischemia/reperfusion injury. Reduction of infarct size (IS) by ischemic preconditioning (IP) involves activation of protein kinase C (PKC) and p38 mitogen activated protein kinase (MAPK), both of which can phosphorylate Cx43. We now studied in anesthetized pigs whether IP impacts on Cx43 phosphorylation by measuring the density of non-phosphorylated and total Cx43 (confocal laser) during normoperfusion and 90-min ischemia in non-preconditioned and preconditioned hearts. Co-localization of PKCalpha, p38MAPKalpha and p38MAPKbeta with Cx43 and the activity of p38MAPK were assessed. IP by 10 min ischemia and 15 min reperfusion reduced IS. Non-phosphorylated Cx43 remained unchanged during ischemia in preconditioned hearts, while it increased from 35+/-3 to 75+/-8 AU (P<0.05) in non-preconditioned hearts. Co-localization of PKC alpha, p38MAPK alpha and p38MAPK beta with Cx43 during ischemia increased only in preconditioned hearts. While the ischemia-induced increase in p38MAPK alpha activity was comparable in preconditioned and non-preconditioned hearts, p38MAPK beta activity was increased only in preconditioned hearts. Blockade of p38MAPK by SB203580 attenuated the IS-reduction and the increased p38MAPK-Cx43 co-localization by IP. We conclude that IP increases co-localization of protein kinases with Cx43 and preserves phosphorylation of Cx43 during ischemia.	Univ Klinikum Essen, Zentrum Innere Med, Inst Pathophysiol, D-45122 Essen, Germany	University of Duisburg Essen	Schulz, R (corresponding author), Univ Klinikum Essen, Zentrum Innere Med, Inst Pathophysiol, Hufelandstr 55, D-45122 Essen, Germany.	rainer_schulz@uni-essen.de	Heusch, Gerd/ABE-6675-2020; Schulz, Rainer/ABD-5069-2021	Schulz, Rainer/0000-0003-3017-0476				Baines CP, 2002, CIRC RES, V90, P390, DOI 10.1161/01.RES.0000012702.90501.8D; Baines CP, 1997, J MOL CELL CARDIOL, V29, P207, DOI 10.1006/jmcc.1996.0265; Barancik M, 2000, J CARDIOVASC PHARM, V35, P474, DOI 10.1097/00005344-200003000-00019; Barker RJ, 2002, CIRC RES, V91, P556, DOI 10.1161/01.RES.0000036861.37203.2F; Beardslee MA, 2000, CIRC RES, V87, P656, DOI 10.1161/01.RES.87.8.656; Behrends M, 2000, AM J PHYSIOL-HEART C, V279, pH1111, DOI 10.1152/ajpheart.2000.279.3.H1111; BEYER EC, 1989, J CELL BIOL, V108, P595, DOI 10.1083/jcb.108.2.595; Bowling N, 2001, J MOL CELL CARDIOL, V33, P789, DOI 10.1006/jmcc.2000.1349; BRANDES RP, 2000, BRIT J PHARMACOL, V136, P709; BURT JM, 1988, AM J PHYSIOL, V254, pH1206, DOI 10.1152/ajpheart.1988.254.6.H1206; CAMERON SJ, 2002, CIRCULATION S2, V106; Cleveland JC, 1997, J MOL CELL CARDIOL, V29, P175, DOI 10.1006/jmcc.1996.0262; Daleau P, 2001, CAN J PHYSIOL PHARM, V79, P371, DOI 10.1139/cjpp-79-5-371; Das DK, 1999, MOL CELL BIOCHEM, V196, P59, DOI 10.1023/A:1006966128795; Doble BW, 2000, CIRC RES, V86, P293, DOI 10.1161/01.RES.86.3.293; EkVitorin JF, 1996, BIOPHYS J, V71, P1273, DOI 10.1016/S0006-3495(96)79328-1; Erdbrugger W, 1997, BRIT J PHARMACOL, V120, P177, DOI 10.1038/sj.bjp.0700877; Garcia-Dorado D, 2002, CARDIOVASC RES, V55, P456, DOI 10.1016/S0008-6363(02)00441-8; GarciaDorado D, 1997, CIRCULATION, V96, P3579; Giepmans BNG, 2001, J BIOL CHEM, V276, P8544, DOI 10.1074/jbc.M005847200; Gysembergh A, 2001, CARDIOVASC PATHOL, V10, P13, DOI 10.1016/S1054-8807(00)00056-9; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Kumar S, 1999, BIOCHEM BIOPH RES CO, V263, P825, DOI 10.1006/bbrc.1999.1454; Kwak BR, 1996, MOL CELL BIOCHEM, V157, P93; Ladilov Y, 2002, AM J PHYSIOL-HEART C, V283, pH1092, DOI 10.1152/ajpheart.00318.2001; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAU AF, 1991, J MOL CELL CARDIOL, V23, P659, DOI 10.1016/0022-2828(91)90975-R; Li GH, 2002, CARDIOVASC PATHOL, V11, P158, DOI 10.1016/S1054-8807(02)00102-3; Lin R, 2001, J CELL BIOL, V154, P815, DOI 10.1083/jcb.200102027; LUCCHESI BR, 1998, DIALOGUES CARDIOVASC, V3, P3; Michel MC, 2001, N-S ARCH PHARMACOL, V363, P245, DOI 10.1007/s002100000363; Morley GE, 1997, J CARDIOVASC ELECTR, V8, P939, DOI 10.1111/j.1540-8167.1997.tb00856.x; Petrich BG, 2002, CIRC RES, V91, P640, DOI 10.1161/01.RES.0000035854.11082.01; Ping PP, 2002, J CLIN INVEST, V109, P499, DOI 10.1172/JCI200213200; Ping PP, 2001, CIRC RES, V88, P59, DOI 10.1161/01.RES.88.1.59; Polontchouk L, 2001, FASEB J, V15, P87, DOI 10.1096/fj.01-0381fje; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; SAEZ JC, 1986, P NATL ACAD SCI USA, V83, P2473, DOI 10.1073/pnas.83.8.2473; Saurin AT, 2000, FASEB J, V14, P2237, DOI 10.1096/fj.99-0671com; Schneider S, 2001, AM J PHYSIOL-HEART C, V280, pH499; Schulz R, 2001, CARDIOVASC RES, V52, P181, DOI 10.1016/S0008-6363(01)00384-4; Schulz R, 2002, CARDIOVASC RES, V55, P690, DOI 10.1016/S0008-6363(02)00319-X; Schwanke U, 2002, AM J PHYSIOL-HEART C, V283, pH1740, DOI 10.1152/ajpheart.00442.2002; Shimizu N, 1998, CARDIOVASC RES, V38, P116, DOI 10.1016/S0008-6363(97)00327-1; Skyschally A, 2003, AM J PHYSIOL-HEART C, V284, pH698, DOI 10.1152/ajpheart.00693.2002; SPRAY DC, 1985, AM J PHYSIOL, V248, pH753, DOI 10.1152/ajpheart.1985.248.6.H753; SPRAY DC, 1990, AM J PHYSIOL, V258, pC195, DOI 10.1152/ajpcell.1990.258.2.C195; TAKENSKWAK BR, 1992, PFLUG ARCH EUR J PHY, V422, P198, DOI 10.1007/BF00370421; Toyofuku T, 1999, CIRC RES, V85, P672, DOI 10.1161/01.RES.85.8.672; van Veen TAB, 2001, CARDIOVASC RES, V51, P217, DOI 10.1016/S0008-6363(01)00324-8; Vondriska TM, 2001, AM J PHYSIOL-HEART C, V280, pH1434, DOI 10.1152/ajpheart.2001.280.4.H1434; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; Weinbrenner C, 1998, CIRCULATION, V98, P899, DOI 10.1161/01.CIR.98.9.899; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	56	143	155	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAY	2003	17	8					1355	+		10.1096/fj.02-0975fje	http://dx.doi.org/10.1096/fj.02-0975fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759340				2022-12-28	WOS:000183165000021
J	Jeneson, JAL; Bruggeman, FJ				Jeneson, JAL; Bruggeman, FJ			Robust homeostatic control of quadriceps pH during natural locomotor activity in man	FASEB JOURNAL			English	Article						acid-base balance; exercise; skeletal muscle; cellular energetics; (31P) NMR spectroscopy; coresponse analysis	SARCOPLASMIC-RETICULUM; MUSCLE BIOENERGETICS; EXERCISE; PHOSPHOCREATINE; SPECTROSCOPY; RESPIRATION; METABOLITES; BLOOD; CELLS	It is generally thought that intracellular pH (pH(i)) of skeletal muscle falls at least 0.5 units during intense activity, but evidence on natural (i.e., voluntary, two-legged (2L)) locomotor activity in man has exclusively come from invasive studies of upper leg muscle. Here, noninvasive P-31 nuclear magnetic resonance spectroscopy (P-31 NMRS) was used to study human quadriceps muscle energetics and pH(i) during incremental bicycling exercise to exhaustion in six normally active subjects. Cellular energy charge (CEC; [PCr]/([PCr]+[ P-i])) linearly (r 0.90) dropped 83 +/- 3% during ramp exercise to exhaustion from 0.92 +/- 0.01 at rest to 0.16 +/- 0.03 at maximal sustained work rate (WR) (166 +/- 17 W; range: 108-223 W). Surprisingly, pH(i) likewise dropped linearly (r 0.82) no more than 0.2 units over the entire range of WR between rest and maximal (pH(i) 7.08+/-0.01 and 6.84+/-0.02, respectively). But after termination of exercise pH(i) dropped rapidly to textbook acidic values of 6.6 explaining classic biopsy results. Comparative coresponse analysis of pH(i) and CEC changes during 2L-vs. 1L-cycling showed that homeostatic control of quadriceps pHi during bicycling is robust and unique to natural locomotor exercise. These results highlight the robustness of the integrative set of physicochemical and physiological control mechanisms in acid-base balance during natural locomotor activity in man.	Univ Utrecht, Sch Vet Med, Dept Physiol, Div Pathobiol, NL-3508 TD Utrecht, Netherlands; Vrije Univ Amsterdam, Biocentrum, Dept Mol Cell Physiol, Amsterdam, Netherlands	Utrecht University; Vrije Universiteit Amsterdam	Jeneson, JAL (corresponding author), Univ Utrecht, Sch Vet Med, Dept Physiol, Div Pathobiol, Androclus Gebouw,Yalelaan 1, NL-3508 TD Utrecht, Netherlands.	j.jeneson@vet.uu.nl	Bruggeman, Frank/AAS-8371-2020; Bruggeman, Frank/C-4356-2015	Bruggeman, Frank/0000-0002-0255-4766; Bruggeman, Frank/0000-0002-0255-4766				ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; CHANCE B, 1980, P NATL ACAD SCI-BIOL, V77, P7430, DOI 10.1073/pnas.77.12.7430; FABIATO A, 1978, J PHYSIOL-LONDON, V276, P233, DOI 10.1113/jphysiol.1978.sp012231; FITTS RH, 1996, HDB PHYSL, V12, P1158; GRAHAM RA, 1994, AM J PHYSIOL, V266, pR638, DOI 10.1152/ajpregu.1994.266.2.R638; HARRIS RC, 1977, J APPL PHYSIOL, V43, P852, DOI 10.1152/jappl.1977.43.5.852; HASSELBACH W, 1983, ANNU REV PHYSIOL, V45, P325, DOI 10.1146/annurev.ph.45.030183.001545; HERMANSEN L, 1972, J APPL PHYSIOL, V32, P304, DOI 10.1152/jappl.1972.32.3.304; Hochachka PW, 1997, J EXP BIOL, V200, P381; Hofmeyr JHS, 1996, J THEOR BIOL, V182, P371, DOI 10.1006/jtbi.1996.0176; JENESON JAL, 1995, AM J PHYSIOL-CELL PH, V268, pC1474, DOI 10.1152/ajpcell.1995.268.6.C1474; JENSENURSTAD M, 1994, EUR J APPL PHYSIOL, V69, P189, DOI 10.1007/BF01094787; JOHNSON RL, 1996, HDB PHYSL, V12, P515; KAMMERMEIER H, 1987, J MOL CELL CARDIOL, V19, P115, DOI 10.1016/S0022-2828(87)80550-3; Kardos A, 2000, CIRCULATION, V101, P2716, DOI 10.1161/01.CIR.101.23.2716; Kemper WF, 2001, P NATL ACAD SCI USA, V98, P723, DOI 10.1073/pnas.011387598; Kushmerick MJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1739, DOI 10.1152/ajpcell.1997.272.5.C1739; LEJEMTEL TH, 1986, CIRCULATION, V74, P245, DOI 10.1161/01.CIR.74.2.245; MAGNUSSON G, 1994, ACTA PHYSIOL SCAND, V150, P353, DOI 10.1111/j.1748-1716.1994.tb09699.x; METZGER JM, 1990, J PHYSIOL-LONDON, V428, P751, DOI 10.1113/jphysiol.1990.sp018239; MEYER RA, 1988, AM J PHYSIOL, V254, pC548, DOI 10.1152/ajpcell.1988.254.4.C548; RADDA GK, 1986, SCIENCE, V233, P640, DOI 10.1126/science.3726553; RICHARDSON RS, 1995, J CLIN INVEST, V96, P1916, DOI 10.1172/JCI118237; RODENBURG JB, 1994, J APPL PHYSIOL, V77, P1021, DOI 10.1152/jappl.1994.77.2.1021; SAHLIN K, 1976, PFLUG ARCH EUR J PHY, V367, P143, DOI 10.1007/BF00585150; Taylor D J, 1983, Mol Biol Med, V1, P77; WASSERMAN K, 1994, AM J PHYSIOL, V266, pE519, DOI 10.1152/ajpendo.1994.266.4.E519; WASSERMAN K, 1986, HDB PHYSL 2 3, V2, P595; WIENER DH, 1986, J AM COLL CARDIOL, V7, P793, DOI 10.1016/S0735-1097(86)80338-2	29	19	19	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	APR	2004	18	6					1010	+		10.1096/fj.03-0762fje	http://dx.doi.org/10.1096/fj.03-0762fje			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15059964				2022-12-28	WOS:000221108800015
J	Bellenger, J; Bellenger, S; Clement, L; Mandard, S; Diot, C; Poisson, JP; Narce, M				Bellenger, J; Bellenger, S; Clement, L; Mandard, S; Diot, C; Poisson, JP; Narce, M			A new hypotensive polyunsaturated fatty acid dietary combination regulates oleic acid accumulation by suppression of stearoyl CoA desaturase 1 gene expression in the SHR model of genetic hypertension	FASEB JOURNAL			English	Article						hepatocyte; SCD-1; PUFA; dietary regulation	ELEMENT-BINDING PROTEIN-1; DELTA-6-DESATURASE ACTIVITY; DOCOSAHEXAENOIC ACID; LIPID-COMPOSITION; LIVER-MICROSOMES; RAT; SYNTHASE; TRANSCRIPTION; CHOLESTEROL; N-3	Polyunsaturated fatty acids (PUFA) are known to repress SCD-1 gene expression, key enzyme of monounsaturated fatty acid biosynthesis. Alterations of the monounsaturated/saturated fatty acids ratio have been implicated in various diseases related to the metabolic syndrome, including hypertension. We previously evidenced that lipogenesis end-products accumulated in spontaneously hypertensive rats (SHR), and that a dietary combination of n-6/n-3 PUFA had hypotensive effects. Our present objective was to test the hypothesis that these SHR liver lipid disorders might be modulated, in response to this hypotensive combination, by changes in SCD-1 expression and activity. So we studied, in hepatocytes, SCD-1 transcription by Northern blotting, as well as plasma and liver fatty acid composition by gas-liquid chromatography. Liver SCD-1 gene expression was suppressed by 50%, and in different lipid classes, relative abundance of stearic and oleic acids decreased. Consequently, the Delta9 desaturation index, calculated from the ratio of oleic vs. stearic acids, decreased. In addition, the level of circulating saturated fatty acids decreased when one of oleic acids increased. These data provided evidence that the tested hypotensive PUFA combination reverses the high monounsaturated/saturated fatty acids ratio associated to hypertension in SHR, via a regulation monounsaturated fatty acid relative abundance by repression of SCD-1 gene.	Univ Bourgogne, Fac Sci Gabriel, IFR Qual Aliments 92, UPRES Lipides & Nutr EA 2422, F-21000 Dijon, France; Univ Bourgogne, CESG, CNRS, ENSBANA FRE2328, Dijon, France; Univ Wageningen & Res Ctr, Wageningen, Netherlands; Unite Mixte Rech INRA ENSA Genet Anim, Rennes, France	Universite de Bourgogne; Centre National de la Recherche Scientifique (CNRS); Institut Agro; AgroSup Dijon; Universite de Bourgogne; Wageningen University & Research; INRAE; Institut Agro; Agrocampus Ouest	Narce, M (corresponding author), Univ Bourgogne, Fac Sci Gabriel, IFR Qual Aliments 92, UPRES Lipides & Nutr EA 2422, 6 Blvd Gabriel, F-21000 Dijon, France.	Michel.Narce@u-bourgogne.fr	Diot, Christian/AAE-2514-2020; Mandard, Stéphane/J-4800-2019; BELLENGER, Jerome/AAC-9423-2022	Diot, Christian/0000-0001-9525-6401; Mandard, Stéphane/0000-0002-7298-821X; BELLENGER, Jerome/0000-0001-8643-6195; Narce, Michel/0000-0002-9986-6247; Bellenger, Sandrine/0000-0002-4593-5454				Attie AD, 2002, J LIPID RES, V43, P1899, DOI 10.1194/jlr.M200189-JLR200; BELLENGER J, 2003, IN PRESS 5 WORLD C E; Bellenger-Germain S, 2002, LIPIDS, V37, P561, DOI 10.1007/s11745-002-0933-z; BLAKE WL, 1990, J NUTR, V120, P1727, DOI 10.1093/jn/120.12.1727; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHRISTIANSEN EN, 1991, BIOCHIM BIOPHYS ACTA, V1082, P57, DOI 10.1016/0005-2760(91)90299-W; CLARKE SD, 1993, PROG LIPID RES, V32, P139, DOI 10.1016/0163-7827(93)90013-M; Delachambre MC, 1998, LIPIDS, V33, P795, DOI 10.1007/s11745-998-0272-0; Engler MM, 1999, P SOC EXP BIOL MED, V221, P32, DOI 10.1046/j.1525-1373.1999.d01-51.x; Engler MM, 2000, LIPIDS, V35, P1011, DOI 10.1007/s11745-000-0612-0; Foretz M, 1999, BIOCHEM J, V341, P371, DOI 10.1042/0264-6021:3410371; Foucher C, 1997, J HYPERTENS, V15, P863, DOI 10.1097/00004872-199715080-00010; GARG ML, 1988, J NUTR, V118, P661, DOI 10.1093/jn/118.6.661; GARG ML, 1988, BIOCHEM J, V249, P351, DOI 10.1042/bj2490351; Glazier AN, 2002, MAMM GENOME, V13, P108, DOI 10.1007/s00335-001-2132-9; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; Kim H, 2003, J BIOCHEM MOL BIOL, V36, P258; LANDSCHULZ KT, 1994, BIOCHEM BIOPH RES CO, V200, P763, DOI 10.1006/bbrc.1994.1516; MILLANVOYEVANBRUSSEL E, 1994, AM J HYPERTENS, V7, P953; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Miyazaki M, 2001, J LIPID RES, V42, P1018; Moon YS, 2002, J LIPID RES, V43, P691; Nakamura MT, 2000, J NUTR, V130, P1561, DOI 10.1093/jn/130.6.1561; Narce M, 1997, BIOCHIMIE, V79, P135, DOI 10.1016/S0300-9084(97)81505-2; NARCE M, 1995, PROSTAG LEUKOTR ESS, V53, P59, DOI 10.1016/0952-3278(95)90084-5; NARCE M, 1992, BRIT J NUTR, V68, P627, DOI 10.1079/BJN19920121; NARCE M, 1995, MOL CELL BIOCHEM, V152, P7; Ntambi JM, 1999, J LIPID RES, V40, P1549; NTAMBI JM, 1992, J BIOL CHEM, V267, P10925; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Perona JS, 2000, LIFE SCI, V66, P521, DOI 10.1016/S0024-3205(99)00622-0; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Sessler AM, 1998, J NUTR, V128, P923, DOI 10.1093/jn/128.6.923; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SINGER P, 1990, KLIN WOCHENSCHR, V68, P40; SLOVER HT, 1979, J AM OIL CHEM SOC, V56, P933, DOI 10.1007/BF02674138; Teran-Garcia M, 2002, BIOCHEM BIOPH RES CO, V290, P1295, DOI 10.1006/bbrc.2002.6341; Triboulot C, 2001, J NUTR, V131, P2364, DOI 10.1093/jn/131.9.2364; Waters KM, 1996, LIPIDS, V31, pS33, DOI 10.1007/BF02637047; WILSON MD, 1990, J NUTR, V120, P544, DOI 10.1093/jn/120.6.544; Worgall TS, 1998, J BIOL CHEM, V273, P25537, DOI 10.1074/jbc.273.40.25537; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yahagi N, 1999, J BIOL CHEM, V274, P35840, DOI 10.1074/jbc.274.50.35840	49	36	37	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					773	+		10.1096/fj.03-0950fje	http://dx.doi.org/10.1096/fj.03-0950fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977874				2022-12-28	WOS:000220425000014
J	Amiry-Moghaddam, M; Xue, R; Haug, FM; Neely, JD; Bhardwaj, A; Agre, P; Adams, ME; Froehner, SC; Mori, S; Ottersen, OP				Amiry-Moghaddam, M; Xue, R; Haug, FM; Neely, JD; Bhardwaj, A; Agre, P; Adams, ME; Froehner, SC; Mori, S; Ottersen, OP			Alpha syntrophin deletion removes the perivascular but not the endothelial pool of aquaporin-4 at the blood-brain barrier and delays the development of brain edema in an experimental model of acute hyponatremia	FASEB JOURNAL			English	Article						brain edema; AQP4; water channel; endothelia; blood-brain-barrier; syntrophin	WATER CHANNEL PROTEIN; CEREBELLAR INFARCTION; EXPRESSION; MICE; STROKE; CELLS; VASOPRESSIN; MANAGEMENT; TRANSPORT; MOUSE	The formation of brain edema, commonly occurring as a potentially lethal complication of acute hyponatremia, is delayed following knockout of the water channel aquaporin-4 (AQP4). Here we show by high-resolution immunogold analysis of the blood-brain-barrier that AQP4 is expressed in brain endothelial cells as well as in the perivascular membranes of astrocyte endfeet. A selective removal of perivascular AQP4 by alpha-syntrophin deletion delays the buildup of brain edema (assessed by Diffusion-weighted MRI) following water intoxication, despite the presence of a normal complement of endothelial AQP4. This indicates that the perivascular membrane domain, which is peripheral to the endothelial blood-brain barrier, may control the rate of osmotically driven water entry. This study is also the first to demonstrate that the time course of edema development differs among brain regions, probably reflecting differences in aquaporin-4 distribution. The resolution of the molecular basis and subcellular site of osmotically driven brain water uptake should help design new therapies for acute brain edema.	Univ Oslo, Ctr Mol Biol & Neurosci, N-0317 Oslo, Norway; Univ Oslo, Inst Basic Med Sci, Dept Anat, N-0317 Oslo, Norway; Johns Hopkins Univ, Sch Med, Dept Radiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med & Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA	University of Oslo; University of Oslo; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; University of Washington; University of Washington Seattle	Ottersen, OP (corresponding author), Univ Oslo, Ctr Mol Biol & Neurosci, POB 1105 Blindern, N-0317 Oslo, Norway.	o.p.ottersen@basalmed.uio.no		Amiry-Moghaddam, Mahmood/0000-0003-1071-1247; Haug, Finn-Mogens Smejda/0000-0002-8814-3035				Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Agre P, 1997, BIOL CELL, V89, P255, DOI 10.1016/S0248-4900(97)83377-1; AMARENCO P, 1990, NEUROLOGY, V40, P1383, DOI 10.1212/WNL.40.9.1383; AMARENCO P, 1990, NEUROCHIRURGIE, V36, P234; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P2106, DOI 10.1073/pnas.0437946100; BAIN PG, 1986, LANCET, V2, P634; Cadnapaphornchai MA, 2000, AM J MED, V109, P688, DOI 10.1016/S0002-9343(00)00622-7; Fraser CL, 1997, AM J MED, V102, P67, DOI 10.1016/S0002-9343(96)00274-4; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Goto S, 2002, STROKE, V33, P1101, DOI 10.1161/01.STR.0000014203.65693.1E; HISE MA, 1979, EUR NEUROL, V18, P328, DOI 10.1159/000115097; KASE CS, 1993, STROKE, V24, P76, DOI 10.1161/01.STR.24.1.76; Ko SBH, 1999, BIOCHEM MOL BIOL INT, V47, P309; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655, DOI 10.1152/ajpcell.1995.269.3.C655; MENZIES WF, 1893, BRAIN, V15, P436; MORI S, 1995, MAGNET RESON MED, V33, P41, DOI 10.1002/mrm.1910330107; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; Nielsen S, 1997, J NEUROSCI, V17, P171; Niermann H, 2001, J NEUROSCI, V21, P3045, DOI 10.1523/JNEUROSCI.21-09-03045.2001; Oster JR, 1999, ARCH INTERN MED, V159, P333, DOI 10.1001/archinte.159.4.333; Pasantes-Morales H, 2002, ARCH MED RES, V33, P237, DOI 10.1016/S0188-4409(02)00353-3; Shi NY, 2001, P NATL ACAD SCI USA, V98, P12754, DOI 10.1073/pnas.221450098; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; Takumi Y, 1999, NAT NEUROSCI, V2, P618, DOI 10.1038/10172; Vajda Z, 2002, P NATL ACAD SCI USA, V99, P13131, DOI 10.1073/pnas.192457099; Xue R, 2001, MAGNET RESON MED, V46, P183, DOI 10.1002/mrm.1174	29	189	204	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					542	+		10.1096/fj.03-0869fje	http://dx.doi.org/10.1096/fj.03-0869fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734638				2022-12-28	WOS:000188829300016
J	Erber, R; Thurnher, A; Katsen, AD; Groth, G; Kerger, H; Hammes, HP; Menger, MD; Ullrich, A; Vajkoczy, P				Erber, R; Thurnher, A; Katsen, AD; Groth, G; Kerger, H; Hammes, HP; Menger, MD; Ullrich, A; Vajkoczy, P			Combined inhibition of VEGF- and PDGF-signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms	FASEB JOURNAL			English	Article						angiogenesis; glioma; resistance; tyrosine kinase inhibitors; vessel maturation	GROWTH-FACTOR RECEPTOR; ANGIOGENESIS IN-VIVO; SMOOTH-MUSCLE-CELLS; TRANSDUCTION PATHWAY; TYROSINE KINASES; BLOOD-VESSELS; TIE2 RECEPTOR; PHASE-I; ANGIOPOIETIN-1; EXPRESSION	Destruction of existing tumor blood vessels may be achieved by targeting vascular endothelial growth factor (VEGF) signaling, which mediates not only endothelial cell proliferation but also endothelial cell survival. In this study, however, intravital microscopy failed to demonstrate that targeting of VEGFR-2 (by the tyrosine kinase inhibitor SU5416) induces significant regression of experimental tumor blood vessels. Immunohistochemistry, electron microscopy, expression analyses, and in situ hybridization provide evidence that this resistance of tumor blood vessels to VEGFR-2 targeting is conferred by pericytes that stabilize blood vessels and provide endothelial cell survival signals via the Ang-1/Tie2 pathway. In contrast, targeting VEGFR-2 plus the platelet-derived growth factor receptor (PDGFR)-beta system (PDGFR-beta) signaling (by SU6668) rapidly forced 40% of tumor blood vessels into regression, rendering these tumors hypoxic as shown by phosphorescence quenching. TUNEL staining, electron microscopy, and apoptosis blocking experiments suggest that VEGFR-2 plus PDGFR-beta targeting enforced tumor blood vessel regression by inducing endothelial cell apoptosis. We further show that this is achieved by an interference with pericyte-endothelial cell interaction. This study provides novel insights into the mechanisms of how 1) pericytes may provide escape strategies to anti-angiogenic therapies and 2) novel concepts that target not only endothelial cells but also pericyte-associated pathways involved in vascular stabilization and maturation exert potent anti-vascular effects.	Heidelberg Univ, Fac Med, Dept Neurosurg, D-6800 Mannheim, Germany; Univ Saarland, Inst Clin & Expt Surg, D-6650 Homburg, Germany; Heidelberg Univ, Fac Med, Vth Med Clin, Dept Anesthesiol & Intens Care Med, D-6800 Mannheim, Germany; Max Planck Inst Biochem, Dept Mol Biol, D-82152 Martinsried, Germany	Ruprecht Karls University Heidelberg; Saarland University; Ruprecht Karls University Heidelberg; Max Planck Society	Vajkoczy, P (corresponding author), Heidelberg Univ, Klinikum Mannheim, Dept Neurosurg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany.	peter.vajkoczy@nch.ma.uni-heidelberg.de	Hammes, Hans-Peter/S-3719-2019; Erber, Ralf/AAF-3002-2020; Erber, Ralf/B-6790-2008					Abramsson A, 2002, CIRCULATION, V105, P112, DOI 10.1161/hc0102.101437; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Benjamin LE, 1997, P NATL ACAD SCI USA, V94, P8761, DOI 10.1073/pnas.94.16.8761; Benjamin LE, 1999, J CLIN INVEST, V103, P159, DOI 10.1172/JCI5028; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Chekenya M, 2002, NEUROPATH APPL NEURO, V28, P367, DOI 10.1046/j.1365-2990.2002.00412.x; Daemen MARC, 1999, J CLIN INVEST, V104, P541, DOI 10.1172/JCI6974; Darland DC, 1999, J CLIN INVEST, V103, P157, DOI 10.1172/JCI6127; Drevs J, 2000, CANCER RES, V60, P4819; Fong TAT, 1999, CANCER RES, V59, P99; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Hawighorst T, 2002, AM J PATHOL, V160, P1381, DOI 10.1016/S0002-9440(10)62565-5; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Herbst RS, 2002, J CLIN ONCOL, V20, P3792, DOI 10.1200/JCO.2002.11.061; Hirschi KK, 1998, J CELL BIOL, V141, P805, DOI 10.1083/jcb.141.3.805; Jayson GC, 2002, J NATL CANCER I, V94, P1484, DOI 10.1093/jnci/94.19.1484; Katsen AD, 1998, VIRCHOWS ARCH, V433, P75, DOI 10.1007/s004280050219; Kerbel RS, 2001, CANCER METAST REV, V20, P79, DOI 10.1023/A:1013172910858; Kerger H, 1996, AM J PHYSIOL-HEART C, V270, pH827, DOI 10.1152/ajpheart.1996.270.3.H827; Kerger H, 2003, MICROVASC RES, V65, P32, DOI 10.1016/S0026-2862(02)00027-4; Kim I, 2000, CIRC RES, V86, P24, DOI 10.1161/01.RES.86.1.24; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Laird AD, 2000, CANCER RES, V60, P4152; Laird AD, 2002, FASEB J, V16, DOI 10.1096/fj.01-0700com; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; Mendel DB, 2000, CLIN CANCER RES, V6, P4848; Menter DG, 2002, EXPERT OPIN INV DRUG, V11, P1749, DOI 10.1517/13543784.11.12.1749; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Morikawa S, 2002, AM J PATHOL, V160, P985, DOI 10.1016/S0002-9440(10)64920-6; NEHLS V, 1992, CELL TISSUE RES, V270, P469, DOI 10.1007/BF00645048; NICOSIA RF, 1995, LAB INVEST, V73, P658; Park YS, 2003, MICROVASC RES, V65, P125, DOI 10.1016/S0026-2862(02)00035-3; Prewett M, 1999, CANCER RES, V59, P5209; Reinmuth N, 2001, FASEB J, V15, P1239, DOI 10.1096/fj.00-0693fje; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SCHLINGEMANN RO, 1990, AM J PATHOL, V136, P1393; Schramm R, 2003, TRANSPLANTATION, V75, P239, DOI 10.1097/01.TP.0000040869.19883.4A; St Croix B, 2000, SCIENCE, V289, P1197; STEWART PA, 1991, INT J RADIAT BIOL, V60, P125, DOI 10.1080/09553009114551701; STEWART PA, 1985, ACTA NEUROPATHOL, V67, P96, DOI 10.1007/BF00688129; Sundberg C, 2002, LAB INVEST, V82, P387, DOI 10.1038/labinvest.3780433; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Vajkoczy P, 1999, INT J DEV NEUROSCI, V17, P557, DOI 10.1016/S0736-5748(99)00021-0; Vajkoczy P, 1998, J CEREBR BLOOD F MET, V18, P510, DOI 10.1097/00004647-199805000-00006; Vajkoczy P, 2000, NEOPLASIA, V2, P53, DOI 10.1038/sj.neo.7900062; Vajkoczy P, 2002, J CLIN INVEST, V109, P777, DOI 10.1172/JCI200214105; Vajkoczy Peter, 1999, Neoplasia (New York), V1, P31, DOI 10.1038/sj.neo.7900006; Wanner GA, 1999, FASEB J, V13, P1239, DOI 10.1096/fasebj.13.10.1239; WESSELING P, 1995, J NEUROPATH EXP NEUR, V54, P304, DOI 10.1097/00005072-199505000-00003	54	492	530	0	20	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					338	340		10.1096/fj.03-0271fje	http://dx.doi.org/10.1096/fj.03-0271fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657001				2022-12-28	WOS:000188067500023
J	Shan, SQ; Robson, ND; Cao, YT; Qiao, T; Li, CY; Kontos, CD; Garcia-Blanco, M; Dewhirst, MW				Shan, SQ; Robson, ND; Cao, YT; Qiao, T; Li, CY; Kontos, CD; Garcia-Blanco, M; Dewhirst, MW			Responses of vascular endothelial cells to angiogenic signaling are important for tumor cell survival	FASEB JOURNAL			English	Article						murine mammary carcinoma; murine melanoma; basic fibroblast growth factor; soluble Tie-2; green fluorescence protein	FIBROBLAST-GROWTH-FACTOR; SKIN WINDOW CHAMBERS; FACTOR RECEPTORS; TIE2 RECEPTOR; IN-VIVO; EXPRESSION; ANGIOPOIETIN-1; CANCER; VEGF; INHIBITION	Neoplastic cells overexpress several angiogenic cytokines, which stimulate neovascularization. Whether the responses of the host endothelial cells to these signaling molecules affect tumor cells during early tumorigenesis has not been investigated. We investigated pre-angiogenic tumor cell survival and angiogenesis initiation by two murine tumor lines (4T1 mammary carcinoma and B16 melanoma), which constitutively expressed GFP, in dorsal skin-fold window chambers of mice treated with extracellular domain of Tie-2 (ExTek) or bFGF. ExTek reduced tumor cell survival, retarded tumor growth, and inhibited angiogenesis onset compared with controls. bFGF increased tumor cell survival and promoted earlier angiogenesis and tumor growth. Neither bFGF nor ExTek affected cell proliferation in vitro. RT-PCR showed mRNA expression of bFGF receptor 2 (FGFR2)IIIB, which does not bind bFGF efficiently, by 4T1 cells and B16 cells express FGFR1 but not FGFR2. B16 cells expressed angiopoietin (Ang) 2, but neither cell line expresses Ang1. Both tumor lines express VEGF. These findings suggested that effects of bFGF and ExTek on tumor cell survival and angiogenesis were not due to direct action but were instead a result of paracrine factors secreted by endothelial cells. These subsequent signals form endothelial cells promote early survival and proliferation of disseminated tumor cells before onset of angiogenesis.	Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Dewhirst, MW (corresponding author), Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA.	dewhirst@radonc.duke.edu	Dewhirst, Mark/Q-1302-2019; Li, Chuan-Yuan/H-4148-2013	Dewhirst, Mark/0000-0003-3459-6546; Kontos, Christopher/0000-0002-8056-3115				Abe Mayumi, 2001, Angiogenesis, V4, P289, DOI 10.1023/A:1016018617152; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BOOCOCK CA, 1995, JNCI-J NATL CANCER I, V87, P506, DOI 10.1093/jnci/87.7.506; Browder T, 2000, CANCER RES, V60, P1878; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Da Silva-Azevedo L, 2002, BIOCHEM BIOPH RES CO, V297, P1270, DOI 10.1016/S0006-291X(02)02370-7; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Dow JK, 2000, UROLOGY, V55, P800, DOI 10.1016/S0090-4295(00)00457-X; DUBOIS NA, 1991, EXP CELL RES, V196, P302, DOI 10.1016/0014-4827(91)90265-V; Folkman J, 2000, JNCI-J NATL CANCER I, V92, P94, DOI 10.1093/jnci/92.2.94; Folkman J, 2001, SCIENCE, V293, P227, DOI 10.1126/science.1062892; Friedl P, 1997, CANCER RES, V57, P2061; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; GOTO F, 1993, LAB INVEST, V69, P508; Graeven U, 2001, CANCER RES, V61, P7282; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; INGBER D, 1991, J CELL BIOCHEM, V47, P236, DOI 10.1002/jcb.240470309; Jackson MW, 2002, CANCER RES, V62, P854; Kumar-Singh S, 1999, J PATHOL, V189, P72, DOI 10.1002/(SICI)1096-9896(199909)189:1<72::AID-PATH401>3.0.CO;2-0; Laurie R, 2001, LIBRARY, V2, P83, DOI 10.1093/library/2.1.83; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, CELL GROWTH DIFFER, V9, P49; Lin PN, 1997, J CLIN INVEST, V100, P2072, DOI 10.1172/JCI119740; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Masood R, 1997, P NATL ACAD SCI USA, V94, P979, DOI 10.1073/pnas.94.3.979; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Peters KG, 1998, BRIT J CANCER, V77, P51, DOI 10.1038/bjc.1998.8; POLVERINI PJ, 1991, ASSAY PURIFICATION N, V198; RAK JW, 1995, ANTI-CANCER DRUG, V6, P3, DOI 10.1097/00001813-199502000-00001; Riedel F, 2000, HEAD NECK-J SCI SPEC, V22, P183, DOI 10.1002/(SICI)1097-0347(200003)22:2<183::AID-HED11>3.0.CO;2-R; Rofstad EK, 2000, CANCER RES, V60, P4932; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; Segall JE, 1996, CLIN EXP METASTAS, V14, P61, DOI 10.1007/BF00157687; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SHAN S, 1997, BRIT J CANCER, V46, P429; Shan SQ, 2001, CLIN CANCER RES, V7, P2590; Siemeister G, 1999, CANCER RES, V59, P3185; STAVRI GT, 1995, CIRCULATION, V92, P11, DOI 10.1161/01.CIR.92.1.11; Stratmann A, 1998, AM J PATHOL, V153, P1459, DOI 10.1016/S0002-9440(10)65733-1; Thurston G, 2000, NAT MED, V6, P460, DOI 10.1038/74725; White RR, 2003, P NATL ACAD SCI USA, V100, P5028, DOI 10.1073/pnas.0831159100; YAYON A, 1992, EMBO J, V11, P1885, DOI 10.1002/j.1460-2075.1992.tb05240.x; Yuan HT, 1999, J AM SOC NEPHROL, V10, P1722	51	32	33	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					326	+		10.1096/fj.03-0765fje	http://dx.doi.org/10.1096/fj.03-0765fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688196				2022-12-28	WOS:000188067500002
J	Soudais, C; Skander, N; Kremer, EJ				Soudais, C; Skander, N; Kremer, EJ			Long-term in vivo transduction of neurons throughout the rat central nervous system using novel helper-dependent CAV-2 vectors	FASEB JOURNAL			English	Article						adenovirus; gutless; gene therapy; neurodegenerative disorders; canine	CAPACITY ADENOVIRAL VECTORS; VIRAL CODING SEQUENCES; MEDIATED GENE-TRANSFER; BASAL NUCLEUS; CANINE ADENOVIRUS; SENILE DEMENTIA; PARKINSONS-DISEASE; PACKAGING SIGNAL; THERAPY; MEYNERT	Numerous genetic and environmental causes, variable pathophysiologies, and the blood-brain barrier create a formidable challenge for the study and treatment of neurodegenerative diseases affecting the central nervous system. Although there are many intracellular strategies to address neurodegeneration, for example, which transgene to use, one fundamental criterion for the long-term survival of neurons may be their genetic modification. Here, we describe the generation and in vivo efficacy of helper-dependent canine adenovirus (CAV-2) vectors that preferentially transduced neurons and efficiently trafficked via axonal retrograde transport. We used a flexible strategy and the synergy between Cre/loxP and nonlethal packaging-defective helper vectors to generate high titer helper-dependent vector stocks. One year after striatal injections in the rat brain, we found stable, high-level expression in striatal neurons, similar to50% of the dopaminergic neurons of the substantia nigra, and the cholinergic neurons in the basal nuclei of Meynert. Due to the intrinsic properties of helper-dependent CAV-2 vectors (27-kb cloning capacity; low preexisting, innate, and induced immunogenicity; retrograde transport; and long-term transgene expression), they will aid fundamental and applied studies in neurobiology. Moreover, helper-dependent CAV-2 vectors may be clinically relevant for the treatment of many neurodegenerative diseases.	CNRS, UMR 5535, IGMM, F-34293 Montpellier, France; Fac Med Necker enfants malad, INSERM, U550, F-75015 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Kremer, EJ (corresponding author), CNRS, UMR 5535, IGMM, IFR 122,1919 Route de Mende, F-34293 Montpellier, France.	kremer@igm.cnrs-mop.fr	Kremer, EJ/P-9838-2019; Kremer, Eric J/D-3734-2013; soudais, claire/F-9756-2016	Kremer, EJ/0000-0001-6114-7530; soudais, claire/0000-0002-4387-6649				AKLI S, 1993, NAT GENET, V3, P224, DOI 10.1038/ng0393-224; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Amalfitano Andrea, 2002, Current Gene Therapy, V2, P111, DOI 10.2174/1566523024605618; ANDERS K H, 1990, Pediatric Neurosurgery, V16, P316, DOI 10.1159/000120551; Bergen K, 1997, COPEIA, P275, DOI 10.2307/1447747; BOTH GW, 2002, ADENOVIRAL VECTORS G, P447; Brooks AI, 2002, P NATL ACAD SCI USA, V99, P6216, DOI 10.1073/pnas.082011999; Chartier C, 1996, J VIROL, V70, P4805, DOI 10.1128/JVI.70.7.4805-4810.1996; Chillon M, 2001, HUM GENE THER, V12, P1815, DOI 10.1089/104303401750476302; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Ehrengruber MU, 2002, MOL NEUROBIOL, V26, P183, DOI 10.1385/MN:26:2-3:183; FLOMENBERG P, 1995, J INFECT DIS, V171, P1090, DOI 10.1093/infdis/171.5.1090; GLUZMAN Y, 1983, J VIROL, V45, P91, DOI 10.1128/JVI.45.1.91-103.1983; Greber UF, 2002, CELL MOL LIFE SCI, V59, P608, DOI 10.1007/s00018-002-8453-3; Hartigan-O'Connor D, 2002, HUM GENE THER, V13, P519, DOI 10.1089/10430340252809810; Hartigan-O'Connor D, 2002, METHOD ENZYMOL, V346, P224; Hehir KM, 1996, J VIROL, V70, P8459, DOI 10.1128/JVI.70.12.8459-8467.1996; Hsich G, 2002, HUM GENE THER, V13, P579, DOI 10.1089/10430340252837198; Keriel A, 2003, M S-MED SCI, V19, P1048, DOI 10.1051/medsci/200319111048; Kilgard M, 2003, NEURON, V38, P678, DOI 10.1016/S0896-6273(03)00327-1; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Kochanek S, 1996, P NATL ACAD SCI USA, V93, P5731, DOI 10.1073/pnas.93.12.5731; Kochanek S, 2001, CURR OPIN MOL THER, V3, P454; Korczyn A. D., 2001, J NEUROL S3, V248, P1, DOI DOI 10.1007/PL00022916; Kremer EJ, 2000, J VIROL, V74, P505, DOI 10.1128/JVI.74.1.505-512.2000; KREMER EJ, 2004, IN PRESS J GENE MED; Lilley C. E., 2001, Current Gene Therapy, V1, P339, DOI 10.2174/1566523013348346; Loser P, 1998, J VIROL, V72, P180; Loser Peter, 2002, Curr Gene Ther, V2, P161, DOI 10.2174/1566523024605555; Lowenstein PR, 2002, TRENDS IMMUNOL, V23, P23, DOI 10.1016/S1471-4906(01)02063-4; Lowenstein PR, 2002, METHOD ENZYMOL, V346, P292; Martinez-Serrano A, 2000, NAT MED, V6, P483, DOI 10.1038/74918; Mittereder N, 1996, J VIROL, V70, P7498, DOI 10.1128/JVI.70.11.7498-7509.1996; Morante-Oria J, 2003, P NATL ACAD SCI USA, V100, P12468, DOI 10.1073/pnas.1633692100; Morsy MA, 1998, P NATL ACAD SCI USA, V95, P7866, DOI 10.1073/pnas.95.14.7866; Morsy MA, 1999, MOL MED TODAY, V5, P18, DOI 10.1016/S1357-4310(98)01376-8; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; Ng P, 2002, J VIROL, V76, P4181, DOI 10.1128/JVI.76.9.4181-4189.2002; O'Neal VK, 2000, MOL MED, V6, P179, DOI 10.1007/BF03402113; Oorschot DE, 1996, J COMP NEUROL, V366, P580, DOI 10.1002/(SICI)1096-9861(19960318)366:4<580::AID-CNE3>3.0.CO;2-0; Parks RJ, 1996, P NATL ACAD SCI USA, V93, P13565, DOI 10.1073/pnas.93.24.13565; Passini MA, 2002, J NEUROSCI, V22, P6437; PEARSON RCA, 1983, BRAIN RES, V289, P375, DOI 10.1016/0006-8993(83)90046-X; PEARSON RCA, 1983, BRAIN RES, V261, P321, DOI 10.1016/0006-8993(83)90637-6; Reddy PS, 2002, MOL THER, V5, P63, DOI 10.1006/mthe.2001.0510; ROSSOR MN, 1982, NEUROSCI LETT, V28, P217, DOI 10.1016/0304-3940(82)90155-0; Sandig V, 2000, P NATL ACAD SCI USA, V97, P1002, DOI 10.1073/pnas.97.3.1002; Sapolsky RM, 2003, NAT REV NEUROSCI, V4, P61, DOI 10.1038/nrn1006; Sato M, 2002, GENE THER, V9, P472, DOI 10.1038/sj.gt.3301668; Schiedner G, 2002, J VIROL, V76, P1600, DOI 10.1128/JVI.76.4.1600-1609.2002; ShammahLagnado SJ, 1996, J COMP NEUROL, V376, P489, DOI 10.1002/(SICI)1096-9861(19961216)376:3<489::AID-CNE10>3.0.CO;2-H; Shu SY, 2003, J NEUROSCI RES, V71, P751, DOI 10.1002/jnr.10518; Soudais C, 2000, J VIROL, V74, P10639, DOI 10.1128/JVI.74.22.10639-10649.2000; Soudais C, 2001, FASEB J, V15, P2283, DOI 10.1096/fj.01-0321fje; Soudais C, 2001, MOL THER, V3, P631, DOI 10.1006/mthe.2001.0263; Stripecke R, 1999, GENE THER, V6, P1305, DOI 10.1038/sj.gt.3300951; TAGLIAVINI F, 1984, ACTA NEUROL SCAND, V70, P20; TAGLIAVINI F, 1983, ACTA NEUROPATHOL, V61, P157, DOI 10.1007/BF00697397; TAGLIAVINI F, 1983, LANCET, V1, P469; TAGLIAVINI F, 1985, ACTA NEUROPATHOL, V66, P127, DOI 10.1007/BF00688687; Tsuchiya K, 2002, NEUROPATHOLOGY, V22, P77, DOI 10.1046/j.1440-1789.2002.00429.x; Worgall S, 1997, HUM GENE THER, V8, P1675, DOI 10.1089/hum.1997.8.14-1675	63	89	92	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					391	+		10.1096/fj.03-0438fje	http://dx.doi.org/10.1096/fj.03-0438fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688208				2022-12-28	WOS:000188067500014
J	Quaranta, MG; Mattioli, B; Spadaro, F; Straface, E; Giordani, L; Ramoni, C; Malorni, W; Viora, M				Quaranta, MG; Mattioli, B; Spadaro, F; Straface, E; Giordani, L; Ramoni, C; Malorni, W; Viora, M			HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells	FASEB JOURNAL			English	Article						ATDS immunopathogenesis; exogenous Nef; signal transduction; cytoskeleton rearrangement	HUMAN-IMMUNODEFICIENCY-VIRUS; NF-KAPPA-B; CYTOTOXIC T-LYMPHOCYTES; HUMAN IMMUNE-RESPONSE; TYPE-1 NEF; IMMUNOLOGICAL SYNAPSE; CHEMOKINE PRODUCTION; ACTIN CYTOSKELETON; DOWN-REGULATION; EXOGENOUS NEF	The accessory HIV-1 Nef protein plays a key role in AIDS pathogenesis. We recently demonstrated that exogenous Nef triggers phenotypic and functional differentiation of immature dendritic cells (DCs). Here we investigated whether the Nef-induced DC differentiation occurs with morphological remodeling and have focused on the interference of Nef in the signaling pathways that regulates DC maturation. We found that exogenous Nef enters immature DCs, promoting their functional and morphological differentiation. Specifically, Nef promotes interleukin (IL) -12 release, which closely fits with nuclear factor (NF) -kappaB activation. Nef induces rearrangement of actin microfilaments, leading to uropod and ruffle formation. Moreover, Nef increases the capacity of DCs to form clusters with allogeneic CD4(+) T cells, improving immunological synapse formation. Searching for molecules involved in Nef-triggered signaling pathways driving the DC maturation, we found that Nef targets Vav and promotes its tyrosine phosphorylation, associated with its nucleus-to-cytoplasm redistribution. This has a direct effect on Vav guanine nucleotide exchange factor activity for the small GTPase Racl. We hypothesize that targeting Vav, Nef modulates both early signaling events (such as cytoskeletal rearrangement) and delayed responses (such as transcriptional regulation), promoting DC differentiation. Our results highlight how Nef may enhance T lymphocyte activation, thus fostering virus dissemination, manipulating the DC arm of the immune response.	Ist Super Sanita, Dept Immunol, I-00161 Rome, Italy; Ist Super Sanita, Dept Ultrastruct, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); Istituto Superiore di Sanita (ISS)	Viora, M (corresponding author), Ist Super Sanita, Dept Immunol, Viale Regina Elena 299, I-00161 Rome, Italy.	viora@iss.it	Malorni, Walter/G-5874-2016; Spadaro, Francesca/M-7512-2017	Spadaro, Francesca/0000-0002-6610-350X; Quaranta, Maria Giovanna/0000-0002-1077-1488; malorni, walter/0000-0002-1223-7000				Al-Alwan MM, 2001, J IMMUNOL, V166, P1452, DOI 10.4049/jimmunol.166.3.1452; Andrieu M, 2001, AIDS RES HUM RETROV, V17, P1365, DOI 10.1089/08892220152596623; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Burns S, 2001, BLOOD, V98, P1142, DOI 10.1182/blood.V98.4.1142; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; CHEINGSONGPOPOV R, 1990, AIDS RES HUM RETROV, V6, P1099, DOI 10.1089/aid.1990.6.1099; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Engering A, 2002, BLOOD, V100, P1780, DOI 10.1182/blood-2001-12-0179; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; Fackler OT, 1997, EUR J BIOCHEM, V247, P843, DOI 10.1111/j.1432-1033.1997.00843.x; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; Federico M, 2001, BLOOD, V98, P2752, DOI 10.1182/blood.V98.9.2752; Frank I., 2002, Current Molecular Medicine (Hilversum), V2, P229, DOI 10.2174/1566524024605716; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Giordani L, 2000, CLIN EXP IMMUNOL, V122, P358, DOI 10.1046/j.1365-2249.2000.01388.x; GRANELLIPIPERNO A, 1995, P NATL ACAD SCI USA, V92, P10944, DOI 10.1073/pnas.92.24.10944; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Houlard M, 2002, J EXP MED, V195, P1115, DOI 10.1084/jem.20011701; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kobayashi M, 2001, J IMMUNOL, V167, P3585, DOI 10.4049/jimmunol.167.7.3585; Kohleisen B, 2001, J NEUROVIROL, V7, P52; Kranewitter WJ, 2001, CELL MOTIL CYTOSKEL, V49, P154, DOI 10.1002/cm.1029; LUCCHIARI M, 1994, INT IMMUNOL, V6, P1739, DOI 10.1093/intimm/6.11.1739; LucchiariHartz M, 1996, INT IMMUNOL, V8, P577, DOI 10.1093/intimm/8.4.577; Manninen A, 2002, J EXP MED, V195, P1023, DOI 10.1084/jem.20012039; Messmer D, 2002, J IMMUNOL, V169, P4172, DOI 10.4049/jimmunol.169.8.4172; Messmer D, 2002, AIDS RES HUM RETROV, V18, P1043, DOI 10.1089/08892220260235407; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Ouaaz F, 2002, IMMUNITY, V16, P257, DOI 10.1016/S1074-7613(02)00272-8; Pandori MW, 1996, J VIROL, V70, P4283, DOI 10.1128/JVI.70.7.4283-4290.1996; PANTALEO G, 1993, NATURE, V362, P355, DOI 10.1038/362355a0; Papkalla A, 2002, J VIROL, V76, P8455, DOI 10.1128/JVI.76.16.8455-8459.2002; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Peters JH, 1996, IMMUNOL TODAY, V17, P273, DOI 10.1016/0167-5699(96)80544-5; Piguet V, 1999, REV MED VIROL, V9, P111, DOI 10.1002/(SICI)1099-1654(199904/06)9:2&lt;111::AID-RMV245&gt;3.0.CO;2-P; Quaranta MG, 1999, EXP CELL RES, V250, P112, DOI 10.1006/excr.1999.4494; Quaranta MG, 2002, EXP CELL RES, V275, P243, DOI 10.1006/excr.2002.5497; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Romero F, 1996, CELL SIGNAL, V8, P545, DOI 10.1016/S0898-6568(96)00118-0; Romero F, 1996, MOL CELL BIOL, V16, P37; Saksela Kalle, 1997, Frontiers in Bioscience, V2, pD606; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schwartz O, 1996, NAT MED, V2, P338, DOI 10.1038/nm0396-338; Sewell AK, 2001, TRENDS IMMUNOL, V22, P173, DOI 10.1016/S1471-4906(01)01866-X; Shutt DC, 2000, CELL MOTIL CYTOSKEL, V46, P200, DOI 10.1002/1097-0169(200007)46:3<200::AID-CM5>3.0.CO;2-M; Sims TN, 2002, IMMUNOL REV, V186, P100, DOI 10.1034/j.1600-065X.2002.18610.x; Sol-Foulon N, 2002, IMMUNITY, V16, P145, DOI 10.1016/S1074-7613(02)00260-1; Steinman R. M, 1999, FUNDAMENTAL IMMUNOLO, P547; STEINMAN RM, 1999, DENDRITIC CELLS BIOL, P421; Swetman CA, 2002, EUR J IMMUNOL, V32, P2074, DOI 10.1002/1521-4141(200207)32:7<2074::AID-IMMU2074>3.0.CO;2-S; Tobiume M, 2002, AIDS RES HUM RETROV, V18, P461, DOI 10.1089/088922202753614227; Torres BA, 1996, AIDS, V10, P1042, DOI 10.1097/00002030-199610090-00017; Varin A, 2003, J BIOL CHEM, V278, P2219, DOI 10.1074/jbc.M209622200; Verhasselt B, 1999, BLOOD, V94, P2809, DOI 10.1182/blood.V94.8.2809.420k11_2809_2818; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Welker R, 1996, VIROLOGY, V219, P228, DOI 10.1006/viro.1996.0240; West MA, 2000, CURR BIOL, V10, P839, DOI 10.1016/S0960-9822(00)00595-9; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317	66	60	61	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2025	2036		10.1096/fj.03-0272com	http://dx.doi.org/10.1096/fj.03-0272com			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597672				2022-12-28	WOS:000186961200039
J	Lambert, V; Wielockx, B; Munaut, C; Galopin, C; Jost, M; Itoh, T; Werb, Z; Baker, A; Libert, C; Krell, HW; Foidart, JM; Noel, A; Rakic, JM				Lambert, V; Wielockx, B; Munaut, C; Galopin, C; Jost, M; Itoh, T; Werb, Z; Baker, A; Libert, C; Krell, HW; Foidart, JM; Noel, A; Rakic, JM			MMP-2 and MMP-9 synergize in promoting choroidal neovascularization	FASEB JOURNAL			English	Article						matrix metalloproteinase; CNV; age-related macular degeneration	ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; SORSBYS FUNDUS DYSTROPHY; RETINAL-PIGMENT EPITHELIUM; MATRIX METALLOPROTEINASES; TISSUE INHIBITORS; FIBRINOLYTIC-ACTIVITY; MACULAR DEGENERATION; ANGIOGENESIS; MICE	Matrix metalloproteinase 2 (MMP-2) and MMP-9 are increased in human choroidal neovascularization (CNV) occurring during the exudative most aggressive form of age-related macular degeneration (AMD), but their precise role and potential interactions remain unclear. To address the question of MMP-2 and MMP-9 functions, mice deficient in the expression of MMP-2 (MMP-2 KO), MMP-9 (MMP-9 KO), and both MMP-2 and MMP-9 (MMP-2,9 KO) with their corresponding wild-type mice (WT) underwent CNV induction by laser-induced rupture of the Bruch's membrane. Both the incidence and the severity of CNV were strongly attenuated in double deficient compared with single gene deficient mice or corresponding WT controls. The reduced neovascularization was accompanied by fibrinogen/fibrin accumulation. Furthermore, overexpression of the endogenous MMP inhibitors TIMP-1 or TIMP-2 (delivered by adenoviral vectors) in WT mice or daily injection of a synthetic and gelatinase selective MMP inhibitor (Ro 26-2853) significantly decreased the pathological reaction. These findings suggest that MMP-2 and MMP-9 may cooperate in the development of AMD and that their selective inhibition represents an alternative strategy for the treatment of choroidal neovascularization.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Flanders Interuniv Inst Biotechnol, Dept Mol Biol, Ghent, Belgium; Univ Ghent, B-9000 Ghent, Belgium; Shionogi & Co Ltd, Shionogi Inst Med Sci, Osaka, Japan; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Bristol, Bristol Royal Infirm, Bristol Heart Inst, Bristol BS2 8HW, Avon, England; Roche Diagnost GmbH, Pharma Res Penzberg, D-82372 Penzberg, Germany; Univ Hosp, Dept Ophthalmol, B-4000 Liege, Belgium	University of Liege; Ghent University; Shionogi & Company Limited; University of California System; University of California San Francisco; Bristol Royal Infirmary; University of Bristol; Roche Holding; University of Liege	Foidart, JM (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Pathol Tower B23, B-4000 Liege, Belgium.	jmfoidart@ulg.ac.be	Baker, Andy/AAO-5250-2021; Libert, Claude/A-6504-2010; Wielockx, Ben/AAC-6854-2020; Munaut, Carine/K-8138-2019	Baker, Andy/0000-0003-1441-5576; Wielockx, Ben/0000-0002-4923-2596; Noel, Agnes/0000-0002-7670-6179				Arlt M, 2002, CANCER RES, V62, P5543; Baker AH, 1998, J CLIN INVEST, V101, P1478, DOI 10.1172/JCI1584; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Berglin L, 2003, INVEST OPHTH VIS SCI, V44, P403, DOI 10.1167/iovs.02-0180; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Campochiaro PA, 2000, J CELL PHYSIOL, V184, P301, DOI 10.1002/1097-4652(200009)184:3<301::AID-JCP3>3.0.CO;2-H; Carmeliet P, 1997, NAT GENET, V17, P439, DOI 10.1038/ng1297-439; Carmeliet P, 1997, CIRCULATION, V96, P3180, DOI 10.1161/01.CIR.96.9.3180; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Das A, 1999, INVEST OPHTH VIS SCI, V40, P809; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fine SL, 2000, NEW ENGL J MED, V342, P483, DOI 10.1056/NEJM200002173420707; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Itoh T, 1997, J BIOL CHEM, V272, P22389, DOI 10.1074/jbc.272.36.22389; Itoh T, 2002, J IMMUNOL, V169, P2643, DOI 10.4049/jimmunol.169.5.2643; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kadonosono K, 1999, AM J OPHTHALMOL, V128, P382, DOI 10.1016/S0002-9394(99)00135-X; Krzystolik MG, 2002, ARCH OPHTHALMOL-CHIC, V120, P338; Kvanta A, 2000, CURR EYE RES, V21, P684, DOI 10.1076/0271-3683(200009)21:3;1-R;FT684; Lambert V, 2002, AM J PATHOL, V161, P1247, DOI 10.1016/S0002-9440(10)64401-X; Lambert V, 2001, FASEB J, V15, P1021, DOI 10.1096/fj.00-0393com; Lein M, 2002, ONCOGENE, V21, P2089, DOI 10.1038/sj.onc.1205267; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Lijnen HR, 2002, BIOCHEMISTRY-MOSCOW+, V67, P92, DOI 10.1023/A:1013908332232; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Lund LR, 1999, EMBO J, V18, P4645, DOI 10.1093/emboj/18.17.4645; Majid MA, 2002, FEBS LETT, V529, P281, DOI 10.1016/S0014-5793(02)03359-8; Manes S, 1999, J BIOL CHEM, V274, P6935, DOI 10.1074/jbc.274.11.6935; Mori K, 2002, INVEST OPHTH VIS SCI, V43, P2428; Munaut C, 1995, INVAS METAST, V15, P169; Ogata N, 2002, INVEST OPHTH VIS SCI, V43, P1168; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Pagenstecher A, 2000, AM J PATHOL, V157, P197, DOI 10.1016/S0002-9440(10)64531-2; Pepper MS, 2001, ARTERIOSCL THROM VAS, V21, P1104, DOI 10.1161/hq0701.093685; Qi JH, 2002, J BIOL CHEM, V277, P13394, DOI 10.1074/jbc.M110870200; Rakic JM, 2003, INVEST OPHTH VIS SCI, V44, P1732, DOI 10.1167/iovs.02-0809; Schwesinger C, 2001, AM J PATHOL, V158, P1161, DOI 10.1016/S0002-9440(10)64063-1; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Steen B, 1998, INVEST OPHTH VIS SCI, V39, P2194; Takahashi T, 2000, AM J OPHTHALMOL, V130, P774, DOI 10.1016/S0002-9394(00)00772-8; VanNewkirk MR, 2000, OPHTHALMOLOGY, V107, P1593, DOI 10.1016/S0161-6420(00)00175-5; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WEBER BHF, 1994, NAT GENET, V8, P352, DOI 10.1038/ng1294-352; Yamada E, 2001, HISTOL HISTOPATHOL, V16, P87, DOI 10.14670/HH-16.87	50	137	152	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2290	+		10.1096/fj.03-0113fje	http://dx.doi.org/10.1096/fj.03-0113fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563686	Green Submitted			2022-12-28	WOS:000186343300026
J	Merkler, D; Oertle, T; Buss, A; Pinschewer, DD; Schnell, L; Bareyre, FM; Kerschensteiner, M; Buddeberg, BS; Schwab, ME				Merkler, D; Oertle, T; Buss, A; Pinschewer, DD; Schnell, L; Bareyre, FM; Kerschensteiner, M; Buddeberg, BS; Schwab, ME			Rapid induction of autoantibodies against Nogo-A and MOG in the absence of an encephalitogenic T cell response: implication for immunotherapeutic approaches in neurological diseases	FASEB JOURNAL			English	Article						reticulon; EAE; CNS; immunization	MYELIN OLIGODENDROCYTE GLYCOPROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; SPINAL-CORD-INJURY; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; AMYLOID-BETA-PEPTIDE; MULTIPLE-SCLEROSIS; NEURITE OUTGROWTH; AXON REGENERATION; CLASS-II; EXPERIMENTAL STROKE	Vaccinations against various antigens of the central nervous system (CNS) are gaining increasing interest as a therapeutic approach in a variety of neurological diseases such as spinal cord injury, ischemic stroke, Alzheimer disease, or spongiform encephalopathy. In the present work, the time window after spinal cord injury allowing potentially therapeutic antibody to penetrate the damaged blood-brain barrier (BBB) was measured by intravenous injection of a monoclonal anti-Nogo-A antibody. Although an influx of Nogo antibodies at the lesion site was detectable up to 2 wk after injury, a significant decrease in BBB permeability was noticed within the first week. Clearly, therefore, a vaccination protocol with a rapid antibody response is required for acute therapeutic interventions after CNS trauma. We designed a conjugate vaccine paradigm with particular focus on the safety and the kinetics of the antibody response. As antigen targets, we used Nogo-A and the strongly encephalitogenic myelin-oligodendrocyte glycoprotein (MOG). Intrasplenic autoimmunization of rats with a Nogo-A-specific region fused to the Tetanus toxin C-fragment (TTC) resulted in a fast IgM response against Nogo-A. A specific switch to IgG was observed as soon as 4-7 days after intrasplenic immunization in TTC-primed animals. In spite of the induction of a specific IgG response after intrasplenic immunization, no signs of experimental autoimmune disease (EAE) or inflammatory infiltrates on histological examinations were observable. In contrast to subcutaneous immunization with MOG, in vitro cytokine secretion assays (IL-2, IL-10, and IFN-gamma) did not reveal activation of MOG-specific T cells after intrasplenic immunization. Our findings have critical implications for future strategies in the development of safe and efficient therapeutic vaccines for neurological diseases.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Hosp, Inst Expt Immunol, Zurich, Switzerland	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Zurich; University Zurich Hospital	Merkler, D (corresponding author), Univ Gottingen, Inst Neuropathol, Robert Koch Str 40, D-37075 Gottingen, Germany.	merkler@med.uni-goettingen.de	Schwab, Martin E/B-6818-2016; Merkler, Doron/N-9157-2016	Merkler, Doron/0000-0002-0247-2007; Pinschewer, Daniel/0000-0002-1594-3189				Adelmann M, 1995, J NEUROIMMUNOL, V63, P17, DOI 10.1016/0165-5728(95)00124-7; AMOR S, 1994, J IMMUNOL, V153, P4349; Bard F, 2000, NAT MED, V6, P916, DOI 10.1038/78682; Bourquin C, 2000, EUR J IMMUNOL, V30, P3663; BREGMAN BS, 1995, NATURE, V378, P498, DOI 10.1038/378498a0; Casetta I, 2000, Neurol Sci, V21, pS839, DOI 10.1007/s100720070022; Check E, 2002, NATURE, V415, P462, DOI 10.1038/415462a; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; During MJ, 2000, SCIENCE, V287, P1453, DOI 10.1126/science.287.5457.1453; Fogdell-Hahn A, 2000, TISSUE ANTIGENS, V55, P140, DOI 10.1034/j.1399-0039.2000.550205.x; Frank M, 1998, J NEUROSCI, V18, P4901; Fritschy JM, 1998, J COMP NEUROL, V390, P194; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; Gray D, 1996, IMMUNOL REV, V150, P45, DOI 10.1111/j.1600-065X.1996.tb00695.x; Hauben E, 2000, J NEUROSCI, V20, P6421, DOI 10.1523/JNEUROSCI.20-17-06421.2000; Hauben E, 2001, P NATL ACAD SCI USA, V98, P15173, DOI 10.1073/pnas.011585298; Heppner FL, 2001, SCIENCE, V294, P178, DOI 10.1126/science.1063093; Herzog A, 1997, J NEUROSCI METH, V72, P57, DOI 10.1016/S0165-0270(96)00156-2; Huang DW, 1999, NEURON, V24, P639, DOI 10.1016/S0896-6273(00)81118-6; Iglesias A, 2001, GLIA, V36, P220, DOI 10.1002/glia.1111; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jones TB, 2002, J NEUROSCI, V22, P2690, DOI 10.1523/JNEUROSCI.22-07-02690.2002; Koller MF, 2002, J NEUROIMMUNOL, V132, P113, DOI 10.1016/S0165-5728(02)00316-8; KUMAR A, 1992, J IMMUNOL, V148, P1499; MARTIN R, 1995, CRIT REV CL LAB SCI, V32, P121, DOI 10.3109/10408369509084683; Medaglini D, 2001, VACCINE, V19, P1931, DOI 10.1016/S0264-410X(00)00434-5; Merkler D, 2001, J NEUROSCI, V21, P3665, DOI 10.1523/JNEUROSCI.21-10-03665.2001; Munch G, 2002, J NEURAL TRANSM, V109, P1081, DOI 10.1007/s007020200091; Nicoll JAR, 2003, NAT MED, V9, P448, DOI 10.1038/nm840; Ochsenbein AF, 2000, J IMMUNOL, V164, P6296, DOI 10.4049/jimmunol.164.12.6296; Oertle T, 2003, J NEUROSCI, V23, P5393; OLERUP O, 1991, TISSUE ANTIGENS, V38, P1, DOI 10.1111/j.1399-0039.1991.tb02029.x; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Peretz D, 2001, NATURE, V412, P739, DOI 10.1038/35089090; Pot C, 2002, J CELL BIOL, V159, P29, DOI 10.1083/jcb.200206068; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHNELL L, 1990, NATURE, V343, P269, DOI 10.1038/343269a0; Sicotte M, 2003, MOL CELL NEUROSCI, V23, P251, DOI 10.1016/S1044-7431(03)00053-8; Singleton J A, 2000, MMWR CDC Surveill Summ, V49, P39; Stefferl A, 1999, J IMMUNOL, V163, P40; Storch MK, 1998, BRAIN PATHOL, V8, P681, DOI 10.1111/j.1750-3639.1998.tb00194.x; TANNO H, 1992, J NEUROTRAUM, V9, P21, DOI 10.1089/neu.1992.9.21; VALMORI D, 1992, J IMMUNOL, V149, P717; WEKERLE H, 1994, ANN NEUROL, V36, pS47, DOI 10.1002/ana.410360714; Wiessner C, 2003, J CEREBR BLOOD F MET, V23, P154, DOI 10.1097/01.WCB.0000040400.30600.AF; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1990, ANNU REV IMMUNOL, V8, P579, DOI 10.1146/annurev.iy.08.040190.003051; Zhang Y, 2001, J NEUROIMMUNOL, V114, P168, DOI 10.1016/S0165-5728(01)00242-9	50	27	27	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2275	+		10.1096/fj.02-1203fje	http://dx.doi.org/10.1096/fj.02-1203fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563689				2022-12-28	WOS:000186343300017
J	Schrauwen, P; Hoeks, J; Schaart, G; Kornips, E; Binas, B; van de Vusse, GJ; van Bilsen, M; Luiken, JJFP; Coort, SLM; Glatz, JFC; Saris, WHM; Hesselinkt, MKC				Schrauwen, P; Hoeks, J; Schaart, G; Kornips, E; Binas, B; van de Vusse, GJ; van Bilsen, M; Luiken, JJFP; Coort, SLM; Glatz, JFC; Saris, WHM; Hesselinkt, MKC			Uncoupling protein 3 as a mitochondrial fatty acid anion exporter	FASEB JOURNAL			English	Article						UCP3; fatty acid transport; mitochondria; high-fat diet	MESSENGER-RNA EXPRESSION; HUMAN SKELETAL-MUSCLE; BINDING PROTEIN; WEIGHT-REDUCTION; UP-REGULATION; MICE LACKING; UCP3; METABOLISM; OXIDATION; OBESITY	In contrast to UCP1, the primary function of UCP3 is not the dissipation of energy. Rather, several lines of evidence suggest that UCP3 is related to cellular long-chain fatty acid homeostasis. If long-chain fatty acids enter the mitochondrial matrix in their non-esterified form, they cannot be metabolized and may exert deleterious effects. To test the feasibility that UCP3 exports fatty acid anions, we systematically interfered at distinct steps in the fatty acid metabolism pathway, thereby creating conditions in which the entry of (non-esterified) fatty acids into the mitochondrial matrix is enhanced. First, reducing the cellular fatty acid binding capacity, known to increase cytosolic concentrations of non-esterified fatty acids, up-regulated UCP3 5.3-fold. Second, inhibition of mitochondrial entry of esterified long-chain fatty acids up-regulated UCP3 by 1.9-fold. Third, high-fat diets, to increase mitochondrial supply of nonesterified long-chain fatty acids exceeding oxidative capacity, up-regulated UCP3 twofold. However, feeding a similar amount of medium-chain fatty acids, which can be oxidized inside the mitochondrial matrix and therefore do not need to be exported from the matrix, did not affect UCP3 protein levels. These data are compatible with a physiological function of UCP3 in facilitating outward transport of long-chain fatty acid anions, which cannot be oxidized, from the mitochondrial matrix.	Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, Dept Movement Sci, Nutr & Toxicol Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands; Maastricht Univ, CARIM, Dept Physiol, NL-6200 MD Maastricht, Netherlands; Max Delbruck Ctr Mol Med, Dept Hypertens Res, Berlin, Germany	Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Maastricht University; Maastricht University Medical Centre (MUMC); Helmholtz Association; Max Delbruck Center for Molecular Medicine	Schrauwen, P (corresponding author), Maastricht Univ, Dept Human Biol, Nutr & Toxicol Res Inst Maastricht, POB 616, NL-6200 MD Maastricht, Netherlands.	p.schrauwen@hb.unimaas.nl	Coort, Susan/ABF-1021-2021; van Bilsen, Marc/E-8342-2016	Hoeks, Joris/0000-0002-0265-0870; schrauwen, patrick/0000-0002-0973-847X				Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Bachmann OP, 2001, DIABETES, V50, P2579, DOI 10.2337/diabetes.50.11.2579; Bezaire V, 2001, AM J PHYSIOL-ENDOC M, V281, pE975, DOI 10.1152/ajpendo.2001.281.5.E975; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; Boss O, 1998, FASEB J, V12, P335, DOI 10.1096/fasebj.12.3.335; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Glatz JFC, 1996, PROG LIPID RES, V35, P243, DOI 10.1016/S0163-7827(96)00006-9; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; GREENBERGER NJ, 1969, NEW ENGL J MED, V280, P1045, DOI 10.1056/NEJM196905082801906; Hamilton JA, 1999, DIABETES, V48, P2255, DOI 10.2337/diabetes.48.12.2255; Hesselink MKC, 2003, J CLIN INVEST, V111, P479, DOI 10.1172/JCI16653; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; JEZEK P, 1994, J BIOL CHEM, V269, P26184; Jezek P, 1998, BBA-BIOENERGETICS, V1365, P319, DOI 10.1016/S0005-2728(98)00084-X; Kelley DE, 2002, DIABETES, V51, P2944, DOI 10.2337/diabetes.51.10.2944; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liang P, 1997, DIABETES, V46, P920, DOI 10.2337/diabetes.46.5.920; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Samec S, 1998, FASEB J, V12, P715, DOI 10.1096/fasebj.12.9.715; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; SCHOLTE HR, 1979, J NEUROL SCI, V40, P39, DOI 10.1016/0022-510X(79)90007-8; Schrauwen P, 2000, DIABETOLOGIA, V43, P1408, DOI 10.1007/s001250051547; Schrauwen P, 1999, INT J OBESITY, V23, P966, DOI 10.1038/sj.ijo.0801026; Schrauwen P, 2001, DIABETES, V50, P2870, DOI 10.2337/diabetes.50.12.2870; Schrauwen P, 2001, FASEB J, V15, P2497, DOI 10.1096/fj.01-0400hyp; Schrauwen P, 2001, INT J OBESITY, V25, P449, DOI 10.1038/sj.ijo.0801566; Schrauwen P, 2002, AM J PHYSIOL-ENDOC M, V282, pE11, DOI 10.1152/ajpendo.2002.282.1.E11; Skulachev VP, 1999, J BIOENERG BIOMEMBR, V31, P431, DOI 10.1023/A:1005492205984; Tsuboyama-Kasaoka N, 1998, BIOCHEM BIOPH RES CO, V247, P498, DOI 10.1006/bbrc.1998.8818; VANDERVUSSE GJ, 1995, J APPL PHYSIOL, V78, P1839, DOI 10.1152/jappl.1995.78.5.1839; VEERKAMP JH, 1993, MOL CELL BIOCHEM, V123, P101, DOI 10.1007/BF01076480; Vidal-Puig A, 1999, OBES RES, V7, P133, DOI 10.1002/j.1550-8528.1999.tb00694.x; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VONDERVUSSE GJ, 1996, HDB PHYSL INTEGRATIO, P952; Weigle DS, 1998, DIABETES, V47, P298, DOI 10.2337/diabetes.47.2.298	36	98	99	1	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2272	+		10.1096/fj.03-0515fje	http://dx.doi.org/10.1096/fj.03-0515fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525936	Green Submitted			2022-12-28	WOS:000186343300015
J	Hurtado, O; De Cristobal, J; Sanchez, V; Lizasoain, I; Cardenas, A; Pereira, MP; Colado, MI; Leza, JC; Lorenzo, P; Moro, MA				Hurtado, O; De Cristobal, J; Sanchez, V; Lizasoain, I; Cardenas, A; Pereira, MP; Colado, MI; Leza, JC; Lorenzo, P; Moro, MA			Inhibition of glutamate release by delaying ATP fall accounts for neuroprotective effects of antioxidants in experimental stroke	FASEB JOURNAL			English	Article						cerebral infarct; MCAO; reactive oxygen species	MITOCHONDRIAL RESPIRATORY-CHAIN; OXYGEN-GLUCOSE DEPRIVATION; FOCAL CEREBRAL-ISCHEMIA; RAT FOREBRAIN SLICES; HIPPOCAMPAL SLICES; BRAIN ISCHEMIA; HYDROGEN-PEROXIDE; FREE-RADICALS; GERBIL BRAIN; NITRIC-OXIDE	Excitotoxic neuronal injury related to excessive glutamate release is believed to play a key role in the pathogenesis of focal cerebral ischemia. Reversal of neuronal glutamate transporters caused by ATP fall and subsequent imbalance of membrane ionic gradients accounts for most glutamate release after cerebral ischemia. ATP synthesis from oxidative phosphorylation derives from the coupled functioning of the mitochondrial respiratory chain (MRC) and the ATP synthase; interestingly, the MRC is one of the main sites of cellular reactive oxygen species (ROS) generation even in physiological circumstances. Hence, we have studied the effect of the antioxidants glutathione, superoxide dismutase, and alpha-tocopherol on infarct outcome, brain ATP, and glutamate levels after permanent middle cerebral artery occlusion (MCAO) in Fischer rats; we have also characterized the actions of antioxidants on MRC complexes. Our results show that intraperitoneal administration of antioxidants 2 h before MCAO enhances ATP synthesis and causes a neuroprotective effect concomitant to inhibition of ischemia-induced increase in brain glutamate. Antioxidants also increased mitochondrial ATP and MRC complex I-III activity and respiration, suggesting that these actions are due to removal of the inhibition caused by endogenous ROS on MRC. These findings may possess important therapeutic repercussions in the management of ischemic stroke.	Univ Complutense Madrid, Fac Med, Dept Farmacol, E-28040 Madrid, Spain	Complutense University of Madrid	Moro, MA (corresponding author), Univ Complutense Madrid, Fac Med, Dept Farmacol, E-28040 Madrid, Spain.	neurona@med.ucm.es	HURTADO, OLIVIA/E-7248-2012; Moro, María Ángeles/K-6396-2014; Pereira, Marta/L-3208-2014; Lizasoain, Ignacio/K-9844-2014; Pereira, Marta/ABF-7999-2020	HURTADO, OLIVIA/0000-0001-5735-7092; Moro, María Ángeles/0000-0003-1010-8237; Pereira, Marta/0000-0002-9347-957X; Lizasoain, Ignacio/0000-0002-6028-7379; Pereira, Marta/0000-0002-9347-957X; LEZA, JUAN CARLOS/0000-0002-9901-0094				ALLEN KL, 1995, J NEUROCHEM, V64, P2222; ALMEIDA A, 1995, J NEUROCHEM, V65, P1698; BEAL MF, 1992, FASEB J, V6, P3338, DOI 10.1096/fasebj.6.15.1464368; Bickler PE, 1996, J NEUROCHEM, V67, P1463; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; CADENAS E, 1977, ARCH BIOCHEM BIOPHYS, V180, P248, DOI 10.1016/0003-9861(77)90035-2; Caplan LR, 2002, ARCH NEUROL-CHICAGO, V59, P703, DOI 10.1001/archneur.59.5.703; Cardenas A, 2000, N-S ARCH PHARMACOL, V362, P208, DOI 10.1007/s002100000286; Castillo J, 1997, LANCET, V349, P79, DOI 10.1016/S0140-6736(96)04453-4; Castillo J, 1996, STROKE, V27, P1060, DOI 10.1161/01.STR.27.6.1060; Chamorro A, 2002, STROKE, V33, P1048, DOI 10.1161/hs0402.105927; Chan PH, 2001, J CEREBR BLOOD F MET, V21, P2, DOI 10.1097/00004647-200101000-00002; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; DAVALOS A, 1999, CURRENT REV CEREBROV, P149; De Cristobal J, 2002, NEUROREPORT, V13, P217, DOI 10.1097/00001756-200202110-00009; De Cristobal J, 2002, STROKE, V33, P261, DOI 10.1161/hs0102.101299; De Cristobal J, 2001, J NEUROCHEM, V79, P456, DOI 10.1046/j.1471-4159.2001.00600.x; De Keyser J, 1999, TRENDS NEUROSCI, V22, P535, DOI 10.1016/S0166-2236(99)01463-0; FLOYD RA, 1990, FASEB J, V4, P2587, DOI 10.1096/fasebj.4.9.2189775; Galeffi F, 2000, J NEUROCHEM, V75, P1242, DOI 10.1046/j.1471-4159.2000.0751242.x; GEY KF, 1993, CLIN INVESTIGATOR, V71, P3, DOI 10.1007/BF00210955; Gilgun-Sherki Y, 2002, PHARMACOL REV, V54, P271, DOI 10.1124/pr.54.2.271; GOLDBERG MP, 2002, STROKE TRIALS DIRECT; Halliwell B, 2001, DRUG AGING, V18, P685, DOI 10.2165/00002512-200118090-00004; Halliwell B, 1989, FREE RADICALS BIOL M, VUK; HILL HD, 1988, ANAL BIOCHEM, V170, P203, DOI 10.1016/0003-2697(88)90109-1; Hunter AJ, 2000, NEUROPHARMACOLOGY, V39, P806, DOI 10.1016/S0028-3908(99)00262-2; Jabaudon D, 2000, P NATL ACAD SCI USA, V97, P5610, DOI 10.1073/pnas.97.10.5610; KASS IS, 1989, J PHYSIOL-LONDON, V413, P1; Keller JN, 1998, J NEUROSCI, V18, P687; KING TE, 1966, ADV ENZYMOL RAMB, V28, P155; KUHN W, 1995, STROKE, V26, P1959; Largeron M, 2001, EUR J PHARMACOL, V424, P189, DOI 10.1016/S0014-2999(01)01152-9; Lees KR, 2000, BRIT MED BULL, V56, P401, DOI 10.1258/0007142001903049; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; MADL JE, 1993, J NEUROSCI, V13, P4429; Manev H, 1996, FASEB J, V10, P1546, DOI 10.1096/fasebj.10.13.8940301; MONYER H, 1990, NEURON, V5, P121, DOI 10.1016/0896-6273(90)90302-V; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; Moro MA, 2000, NEUROPHARMACOLOGY, V39, P1309, DOI 10.1016/S0028-3908(99)00226-9; Murakami K, 1998, J NEUROSCI, V18, P205; Oberle S, 1998, CIRC RES, V82, P1016, DOI 10.1161/01.RES.82.9.1016; Paxinos G., 1986, RAT BRAIN STEREOTAXI, V2nd; PEKOE G, 1982, AGENTS ACTIONS, V12, P232, DOI 10.1007/BF01965152; PELLEGRINIGIAMPIETRO DE, 1990, J NEUROSCI, V10, P1035, DOI 10.1523/jneurosci.10-03-01035.1990; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; RAGAN CI, 1987, MITOCHONDRIA PRACTIC, P153; Riepe MW, 1997, STROKE, V28, P2006, DOI 10.1161/01.STR.28.10.2006; Rossi DJ, 2000, NATURE, V403, P316, DOI 10.1038/35002090; Santos MS, 1996, STROKE, V27, P941, DOI 10.1161/01.STR.27.5.941; SCHAPIRA AHV, 1994, MITOCHONDRIA DNA PRO, P241; Skaper SD, 1998, FASEB J, V12, P725, DOI 10.1096/fasebj.12.9.725; VANJAARSVELD H, 1994, RES COMMUN MOL PATH, V86, P287; WHARTON DC, 1968, J BIOL CHEM, V243, P702	56	50	53	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2082	+		10.1096/fj.02-1086fje	http://dx.doi.org/10.1096/fj.02-1086fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500556				2022-12-28	WOS:000185925100003
J	Laurent, M; Martinerie, C; Thibout, H; Hoffman, MP; Verrecchia, F; Le Bouc, Y; Mauviel, A; Kleinman, HK				Laurent, M; Martinerie, C; Thibout, H; Hoffman, MP; Verrecchia, F; Le Bouc, Y; Mauviel, A; Kleinman, HK			NOVH increases MMP3 expression and cell migration in glioblastoma cells via a PDGFR-alpha-dependent mechanism	FASEB JOURNAL			English	Article						CCN family; macroarray; metalloprotease; PDGF receptors	TISSUE GROWTH-FACTOR; IMMEDIATE-EARLY GENE; SMOOTH-MUSCLE-CELLS; MATRIX METALLOPROTEINASES; ENDOTHELIAL-CELLS; WILMS-TUMORS; FACTOR-BETA; PRODUCT; FAMILY; DOMAIN	Nephroblastoma overexpressed gene (NOV) is highly expressed in the nervous system. We investigated its biological activity by expressing the human NOV gene ( NOVH) in a human glioblastoma cell line that is negative for NOVH and by analyzing four clones with different levels of NOVH expression. There was no difference in cell proliferation between the NOVH-expressing cell lines, but there was increased cell adhesion and migration that correlated with increasing NOVH expression. Gene expression profiling was used to investigate the mechanisms by which NOVH expression regulated cell activity. We identified two induced genes in NOVH-expressing cells that are involved in cell migration: matrix metalloprotease (MMP) 3 and platelet-derived growth factor receptor (PDGFR)-alpha. Our studies show that PDGFR-alpha induced MMP3 gene expression and increased cell proliferation and cell migration upon stimulation by platelet-derived growth factor (PDGF)-AA. We also show that the induction of MMP3 in cells expressing NOVH is potentiated by either cell density, serum, or PDGF-BB. Thus, expression of NOVH in glioblastoma cells triggers a cascade of gene expression resulting in increased cell adhesion and migration.	Hop St Antoine, INSERM,U515, Proliferat Differenciat & Proc Tumoraux Batim, F-75012 Paris, France; NIDCR, NIH, Bethesda, MD 20814 USA; Hop St Louis, INSERM, U32, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Laurent, M (corresponding author), Hop St Antoine, INSERM,U515, Proliferat Differenciat & Proc Tumoraux Batim, 184 Rue Fbg St Antoine,Batiment Kourilsky, F-75012 Paris, France.	laurent@st-antoine.inserm.fr	MAUVIEL, Alain/F-6251-2013; Verrecchia, Franck/G-5535-2018	Verrecchia, Franck/0000-0003-4920-2554	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000707] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000707] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; BRADHAM DM, 1991, J CELL BIOL, V114, P1285, DOI 10.1083/jcb.114.6.1285; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; BRUNNER A, 1991, DNA CELL BIOL, V10, P293, DOI 10.1089/dna.1991.10.293; Burren CP, 1999, J CLIN ENDOCR METAB, V84, P1096; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chevalier G, 1998, AM J PATHOL, V152, P1563; DARVILLE MI, 1992, NUCLEIC ACIDS RES, V20, P3575, DOI 10.1093/nar/20.14.3575; Ellis PD, 2000, ARTERIOSCL THROM VAS, V20, P1912, DOI 10.1161/01.ATV.20.8.1912; Fan WH, 2002, J BIOL CHEM, V277, P9800, DOI 10.1074/jbc.M111213200; FEDDERSEN RM, 1992, NEURON, V9, P955, DOI 10.1016/0896-6273(92)90247-B; Frazier KS, 1997, INT J BIOCHEM CELL B, V29, P153, DOI 10.1016/S1357-2725(96)00127-6; Glukhova L, 2001, CANCER GENET CYTOGEN, V130, P105, DOI 10.1016/S0165-4608(01)00477-0; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; Inoki I, 2001, FASEB J, V15, P219, DOI 10.1096/fj.01-0332fje; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Kirstein M, 1996, J BIOL CHEM, V271, P18231, DOI 10.1074/jbc.271.30.18231; Kocialkowski S, 2001, ANAT EMBRYOL, V203, P417, DOI 10.1007/s004290100177; Lafont J, 2002, J BIOL CHEM, V277, P41220, DOI 10.1074/jbc.M204405200; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Liu CL, 1999, GENE, V238, P471, DOI 10.1016/S0378-1119(99)00364-9; Lopez-Bermejo A, 2000, ENDOCRINOLOGY, V141, P4072, DOI 10.1210/en.141.11.4072; Mahiou J, 1998, BIOCHEM J, V330, P1051, DOI 10.1042/bj3301051; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; Manara MC, 2002, AM J PATHOL, V160, P849, DOI 10.1016/S0002-9440(10)64908-5; Martinerie C, 1997, J CLIN PATHOL-MOL PA, V50, P310, DOI 10.1136/mp.50.6.310; MARTINERIE C, 1994, ONCOGENE, V9, P2729; Martinerie C, 2001, J CLIN ENDOCR METAB, V86, P3929, DOI 10.1210/jc.86.8.3929; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; Nakanishi T, 2000, ENDOCRINOLOGY, V141, P264, DOI 10.1210/endo.141.1.7267; Perbal B, 1999, P NATL ACAD SCI USA, V96, P869, DOI 10.1073/pnas.96.3.869; QUINONES S, 1989, J BIOL CHEM, V264, P8339; RAFF MC, 1988, NATURE, V333, P562, DOI 10.1038/333562a0; Sakamoto K, 2002, J BIOL CHEM, V277, P29399, DOI 10.1074/jbc.M203727200; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P123; Scholz G, 1996, MOL CELL BIOL, V16, P481; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Su BY, 1998, CR ACAD SCI III-VIE, V321, P883, DOI 10.1016/S0764-4469(99)80002-X; Su BY, 2001, J CLIN PATHOL-MOL PA, V54, P184, DOI 10.1136/mp.54.3.184; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; WENXIN L, 1996, J CLIN PATHOL-MOL PA, V49, pM91; WESTPHAL M, 1987, EXP CELL BIOL, V55, P152; Wong M, 1997, DEV BIOL, V192, P492, DOI 10.1006/dbio.1997.8766; Woodard AS, 1998, J CELL SCI, V111, P469	45	42	45	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1919	+		10.1096/fj.02-1023fje	http://dx.doi.org/10.1096/fj.02-1023fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519668				2022-12-28	WOS:000185345100013
J	Robenek, MJ; Schlattmann, K; Zimmer, KP; Plenz, G; Troyer, D; Robenek, H				Robenek, MJ; Schlattmann, K; Zimmer, KP; Plenz, G; Troyer, D; Robenek, H			Cholesterol transporter caveolin-1 transits the lipid bilayer during intracellular cycling	FASEB JOURNAL			English	Article						intracellular transport; membrane leaflet; endocytotic pathway; lipid droplets	PROTEIN TRANSLOCATION; MEMBRANE; DOMAINS; IDENTIFICATION; COMPLEX; MEDIATE	Caveolin-1, a major protein of cell surface invaginations called caveolae, is currently believed to cycle between the plasma membrane and intracellular compartments via the endocytotic pathway, at least for part of its itinerary. We studied the distribution of caveolin-1 in cell membranes, using ultrathin cryosections and freeze-fracture immunolabeling and found this protein not only in the cytoplasmic leaflet of the plasma membrane, but also in the exoplasmic leaflet of all intracellular membranes. This sidedness implies that caveolin-1 switches from one membrane leaflet to the other somewhere on its way through the cell and rules out the classic mechanism of endocytotic membrane budding and fusion for caveolin-1 intracellular trafficking. Underlying the sidedness of caveolin-1 may be a fundamental, hitherto unrecognized, mechanism by which proteins transit membranes.	Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, D-48149 Munster, Germany; Univ Munster, Univ Childrens Hosp, D-4400 Munster, Germany; Univ Munster, Dept Thorac & Cardiovasc Surg, D-4400 Munster, Germany; Univ Munster, Dept Cardiol & Angiol, D-4400 Munster, Germany	University of Munster; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Munster; University of Munster; University of Munster	Robenek, MJ (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Dept Cell Biol & Ultrastruct Res, Domagkstr 3, D-48149 Munster, Germany.	robenek@uni-muenster.de	Zimmer, Klaus-Peter/AAY-9261-2020; Zimmer, Klaus-Peter/AAY-9351-2020					Agarraberes FA, 2001, BBA-BIOMEMBRANES, V1513, P1, DOI 10.1016/S0304-4157(01)00005-3; BRANTON D, 1975, SCIENCE, V190, P54, DOI 10.1126/science.1166299; CONRAD PA, 1995, J CELL BIOL, V131, P1421, DOI 10.1083/jcb.131.6.1421; Couet J, 2001, ADV DRUG DELIVER REV, V49, P223, DOI 10.1016/S0169-409X(01)00139-9; Das K, 1999, J BIOL CHEM, V274, P18721, DOI 10.1074/jbc.274.26.18721; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; FUJIMOTO K, 1995, J CELL SCI, V108, P3443; Ikonen E, 2000, TRAFFIC, V1, P212, DOI 10.1034/j.1600-0854.2000.010303.x; Liu PS, 1999, NAT CELL BIOL, V1, P369, DOI 10.1038/14067; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Machleidt T, 2000, J CELL BIOL, V148, P17, DOI 10.1083/jcb.148.1.17; Matveev S, 2001, ADV DRUG DELIVER REV, V49, P237, DOI 10.1016/S0169-409X(01)00138-7; Nichols BJ, 2002, NAT CELL BIOL, V4, P374, DOI 10.1038/ncb787; Okamoto T, 1998, J BIOL CHEM, V273, P5419, DOI 10.1074/jbc.273.10.5419; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Rapoport TA, 1999, BIOL CHEM, V380, P1143, DOI 10.1515/BC.1999.145; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; Schlegel A, 2000, J BIOL CHEM, V275, P21605, DOI 10.1074/jbc.M002558200; SHOTTON DM, 1995, RAPID FREEZING FREEZ, P1; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Thyberg J, 2002, J HISTOCHEM CYTOCHEM, V50, P185, DOI 10.1177/002215540205000206; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van Deurs B, 2003, TRENDS CELL BIOL, V13, P92, DOI 10.1016/S0962-8924(02)00039-9; van Meer G, 2001, J CELL BIOL, V152, pF29, DOI 10.1083/jcb.152.5.F29	27	21	21	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1940	+		10.1096/fj.03-0008fje	http://dx.doi.org/10.1096/fj.03-0008fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923065				2022-12-28	WOS:000185345100015
J	Guo, Z; Shao, LF; Feng, XS; Reid, K; Marderstein, E; Nakao, A; Geller, DA				Guo, Z; Shao, LF; Feng, XS; Reid, K; Marderstein, E; Nakao, A; Geller, DA			A critical role for C/EBP beta binding to the AABS promoter response element in the human iNOS gene	FASEB JOURNAL			English	Article						iNOS; nitric oxide; cytokines; AABS; C/EBP beta	NITRIC-OXIDE SYNTHASE; FACTOR-KAPPA-B; INTERFERON-GAMMA; TRANSCRIPTIONAL REGULATION; NUCLEAR-FACTOR; CYTOKINE INDUCTION; MOLECULAR-CLONING; PROTEIN-BETA; EXPRESSION; CELLS	The human iNOS (hiNOS) gene is expressed in a tissue-specific manner, but the molecular basis for this regulation has not been elucidated. Here, we show that liver cell-specific hiNOS gene activation involves protein-DNA binding to an A-activator binding site (AABS) located at -192 nucleotides in the hiNOS promoter region. Mutation of this site in the -7.2 kb hiNOS promoter construct inhibited basal hiNOS promoter activity in primary rat hepatocytes (77%), and two human liver cell lines, AKN-1 (63%) and HepG2 (60%), but had no significant effect on basal hiNOS activity in three non-hepatic human cell types. Interestingly, mutation of AABS significantly abrogated cytokine-induced promoter activity in all cell types. C/EBPbeta transcription factor bound to AABS by gel shift assay. Overexpression of C/EBPbeta active form (LAP) increased hiNOS basal promoter activity similar to sixfold in liver cells, but had minimal effect in non-hepatic cells. In contrast, overexpression of the transcriptional inhibitor (LIP) strongly suppressed both basal and cytokine-inducible promoter activity. These data show that the cis-acting AABS DNA element mediates liver-specific basal hiNOS promoter activity through binding of the trans-acting C/EBPbeta factor. Further, C/EBPbeta binding to AABS functions as a "switchpoint" that is necessary for cytokine-inducible hiNOS gene expression in all cell types examined.	Univ Pittsburgh, Starzl Transplant Inst, Dept Surg, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Geller, DA (corresponding author), Univ Pittsburgh, Starzl Transplant Inst, Dept Surg, 3459 5th Ave,UPMC Montefiore,7 South, Pittsburgh, PA 15213 USA.	gellerda@msx.upmc.edu						AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CHARTRAIN NA, 1994, J BIOL CHEM, V269, P6765; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DREWES T, 1991, NUCLEIC ACIDS RES, V19, P6383, DOI 10.1093/nar/19.23.6383; Eberhardt W, 1996, BIOCHEM BIOPH RES CO, V223, P752, DOI 10.1006/bbrc.1996.0968; Feng XS, 2002, P NATL ACAD SCI USA, V99, P14212, DOI 10.1073/pnas.212306199; Ganster RW, 2001, P NATL ACAD SCI USA, V98, P8638, DOI 10.1073/pnas.151239498; Gao JJ, 1997, J BIOL CHEM, V272, P1226, DOI 10.1074/jbc.272.2.1226; GELLER DA, 1995, J IMMUNOL, V155, P4890; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; KALING M, 1991, MOL CELL BIOL, V11, P93, DOI 10.1128/MCB.11.1.93; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; Kolyada AY, 1996, BIOCHEM BIOPH RES CO, V220, P600, DOI 10.1006/bbrc.1996.0449; Kolyada AY, 2001, MOL MED, V7, P329, DOI 10.1007/BF03402216; Kroncke KD, 1998, CLIN EXP IMMUNOL, V113, P147; Kunz D, 1996, P NATL ACAD SCI USA, V93, P255, DOI 10.1073/pnas.93.1.255; LECLAIR KP, 1992, P NATL ACAD SCI USA, V89, P8145, DOI 10.1073/pnas.89.17.8145; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MANCHADO C, 1994, BIOCHEM J, V302, P695, DOI 10.1042/bj3020695; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; Mellott JK, 2001, AM J PHYSIOL-LUNG C, V280, pL390, DOI 10.1152/ajplung.2001.280.3.L390; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; Nussler AK, 1999, IN VITRO CELL DEV-AN, V35, P190, DOI 10.1007/s11626-999-0026-4; NUSSLER AK, 1992, J EXP MED, V176, P261, DOI 10.1084/jem.176.1.261; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; Ratovitski EA, 1999, J BIOL CHEM, V274, P30250, DOI 10.1074/jbc.274.42.30250; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Sakitani K, 1998, GENES CELLS, V3, P321, DOI 10.1046/j.1365-2443.1998.00193.x; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Welm AL, 1999, MOL CELL BIOL, V19, P1695; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779	38	30	32	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1718	+		10.1096/fj.02-1172fje	http://dx.doi.org/10.1096/fj.02-1172fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958187				2022-12-28	WOS:000184471600029
J	Ortega-Velazquez, R; Marques, ML; Ruiz-Torres, MP; Gonzalez-Rubio, M; Rodriguez-Puyol, M; Puyol, DR				Ortega-Velazquez, R; Marques, ML; Ruiz-Torres, MP; Gonzalez-Rubio, M; Rodriguez-Puyol, M; Puyol, DR			Arg-Gly-Asp-Ser peptide stimulates transforming growth factor-beta 1 transcription and secretion through integrin activation	FASEB JOURNAL			English	Article						RGD-containing peptides; fibronectin; extracellular matrix components secretion; integrin-linked kinase; tyrosine phosphorylation	GROWTH-FACTOR-BETA; GLYCOGEN-SYNTHASE KINASE; EXTRACELLULAR-MATRIX; LINKED KINASE; CELL-ADHESION; TYROSINE PHOSPHORYLATION; TGF-BETA; APOPTOSIS; RGD; PINCH	Extracellular matrix (ECM) components, through specific peptide motifs such as Arg-Gly-Asp (RGD), interact with integrins and can modify the behavior of cells. Transforming growth factor-beta1 (TGF-beta1) is the main cytokine involved in the synthesis of ECM proteins. We analyzed the effect of a RGD-containing peptide, as Arg-Gly-Asp-Ser (RGDS), on the regulation of TGF-beta1 secretion in cultured human mesangial cells. We found that RGDS increased mRNA expression and secretion of TGF-beta1 by stimulating the TGF-beta1 gene promoter. This effect was dependent on the interaction of RGDS with integrins. We evaluated the signaling pathways implicated in TGF-beta1 production by analyzing the effect of RGDS on kinase-related integrins. RGDS stimulated tyrosine phosphorylation as well as integrin-linked kinase (ILK) activity. However, tyrosine kinase inhibitors did not prevent the RGDS effect. In contrast, the inhibition of ILK by cell transfection with a kinase dead-ILK completely abolished the increased TGF-beta1 secretion and promoter activity in the presence of RGDS. Thus RGDS modulates the secretion of TGF-beta1, probably through increased synthesis by interacting with integrins and activating ILK. This supports a role for ECM components in the regulation of their own secretion.	Univ Alcala de Henares, Dept Physiol, Alcala De Henares, Spain; Univ Alcala de Henares, Dept Med, Alcala De Henares, Spain; Hosp Principe de Asturias, Nephrol Sect, Alcala De Henares, Spain; Inst Reina Sofia Invest Nefrol, Alcala De Henares, Spain	Universidad de Alcala; Universidad de Alcala; Prince of Asturias University Hospital	Puyol, DR (corresponding author), Univ Alcala De Henares, Fac Med, Dept Fisiol, Carretera Barcelona,Km 33-600, Madrid 28880, Spain.	diego.rodriguez@uah.es	Ruiz-Torres, María/I-1985-2017; Puyol, Diego Rodriguez/AAG-9752-2020; Puyol, Manuel Rodriguez/AAG-7049-2020	Ruiz-Torres, María/0000-0003-1640-7326; Puyol, Diego Rodriguez/0000-0002-9125-9311; Puyol, Manuel Rodriguez/0000-0002-5230-6664; Ortega-Velazquez, Rocio/0000-0003-3254-6641; Ortega-Velazquez, Rocio/0000-0002-2804-4908				BORDER WA, 1992, J CLIN INVEST, V90, P1, DOI 10.1172/JCI115821; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Buckley CD, 1999, NATURE, V397, P534, DOI 10.1038/17409; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Dedhar S, 1999, TRENDS CELL BIOL, V9, P319, DOI 10.1016/S0962-8924(99)01612-8; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; DSOUZA SE, 1991, TRENDS BIOCHEM SCI, V16, P246, DOI 10.1016/0968-0004(91)90096-E; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GonzalezRubio M, 1996, KIDNEY INT, V50, P164, DOI 10.1038/ki.1996.299; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Hedin U, 1997, ARTERIOSCL THROM VAS, V17, P1977, DOI 10.1161/01.ATV.17.10.1977; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI200214685; Iglesias-de la Cruz MC, 2001, KIDNEY INT, V59, P87, DOI 10.1046/j.1523-1755.2001.00469.x; Iglesias-de la Cruz MC, 2000, EXP NEPHROL, V8, P97; Ilic D, 1997, J CELL SCI, V110, P401; Kagami S, 2000, KIDNEY INT, V58, P1088, DOI 10.1046/j.1523-1755.2000.00266.x; Kawata Y, 1998, J BIOL CHEM, V273, P16905, DOI 10.1074/jbc.273.27.16905; Li FG, 1999, J CELL SCI, V112, P4589; Lutgens E, 2002, ARTERIOSCL THROM VAS, V22, P975, DOI 10.1161/01.ATV.0000019729.39500.2F; Marchand-Brynaert J, 1999, BIOMATERIALS, V20, P1773, DOI 10.1016/S0142-9612(99)00072-1; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; MIGITA K, 1994, J IMMUNOL, V153, P3457; Monno R, 2001, J AM SOC NEPHROL, V12, P891, DOI 10.1681/ASN.V125891; Mooney A, 1999, AM J PATHOL, V155, P599, DOI 10.1016/S0002-9440(10)65155-3; MOONEY DJ, 1994, MOL BIOL CELL, V5, P1281, DOI 10.1091/mbc.5.12.1281; Moreno-Manzano V, 2000, BIOCHEM BIOPH RES CO, V277, P293, DOI 10.1006/bbrc.2000.3654; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; Schaller MD, 2001, BBA-MOL CELL RES, V1540, P1, DOI 10.1016/S0167-4889(01)00123-9; SHARMA K, 1994, AM J PHYSIOL, V266, pF829, DOI 10.1152/ajprenal.1994.266.6.F829; STERZEL RB, 1993, KIDNEY INT, V43, pS26; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077	38	36	38	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1529	+		10.1096/fj.02-0785fje	http://dx.doi.org/10.1096/fj.02-0785fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824296				2022-12-28	WOS:000183818000035
J	Fedarko, NS; Jain, A; Karadag, A; Fisher, LW				Fedarko, NS; Jain, A; Karadag, A; Fisher, LW			Three small integrin-binding ligand N-linked glycoproteins (SIBLINGs) bind and activate specific matrix metalloproteinases	FASEB JOURNAL			English	Article						bone sialoprotein; osteopontin; dentin matrix protein 1	BONE SIALOPROTEIN; OSTEOPONTIN EXPRESSION; BREAST-CANCER; CELLS; PROSTATE; GROWTH; PROTEIN-1; MIGRATION; EVASION	Matrix metalloproteinases (MMPs) are critical for development, wound healing, and for the progression of cancer. It is generally accepted that MMPs are secreted in a latent form (proMMP) and are activated only upon removal of their inhibitory propeptides. This report shows that three members of the SIBLING (Small, Integrin-Binding LIgand, N-linked Glycoprotein) family can specifically bind (K(d)approximate tonM) and activate three different MMPs. Binding of SIBLING to their corresponding proMMPs is associated with structural changes as indicated by quenching of intrinsic tryptophan fluorescence, increased susceptibility to plasmin cleavage, and decreased inhibition by specific natural and synthetic inhibitors. Activation includes both making the proMMPs enzymatically active and the reactivation of the TIMP (tissue inhibitors of MMP) inhibited MMPs. Bone sialoprotein specifically binds proMMP-2 and active MMP-2, while osteopontin binds proMMP-3 and active MMP-3, and dentin matrix protein-1 binds proMMP-9 and active MMP-9. Both pro and active MMP-SIBLING complexes are disrupted by the abundant serum protein, complement Factor H, thereby probably limiting SIBLING-mediated activation to regions immediately adjacent to sites of secretion in vivo. These data suggest that the SIBLING family offers an alternative method of controlling the activity of at least three MMPs.	Johns Hopkins Univ, Sch Med, Dept Med, Div Geriatr, Baltimore, MD 21224 USA; Natl Inst Dent & Craniofacial Res, Craniofacial & Skeletal Dis Branch, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	Johns Hopkins University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Fedarko, NS (corresponding author), Room 5B-79 JHAAC,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ndarko@jhmi.edu		Fedarko, Neal/0000-0001-6055-6279	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000074] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000074] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bellahcene A, 2000, CIRC RES, V86, P885, DOI 10.1161/01.RES.86.8.885; Bellahcene A, 1996, INT J CANCER, V69, P350; BELLAHCENE A, 1994, CANCER RES, V54, P2823; Bellahcene A, 1997, CALCIFIED TISSUE INT, V61, P183, DOI 10.1007/s002239900320; Bellahcene A, 1998, THYROID, V8, P637, DOI 10.1089/thy.1998.8.637; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIANCO P, 1991, CALCIFIED TISSUE INT, V49, P421, DOI 10.1007/BF02555854; Chambers AF, 1996, LUNG CANCER-J IASLC, V15, P311, DOI 10.1016/0169-5002(95)00595-1; Chaplet M, 2003, J BONE MINER RES, V18, P1506, DOI 10.1359/jbmr.2003.18.8.1506; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Fedarko NS, 2000, J BIOL CHEM, V275, P16666, DOI 10.1074/jbc.M001123200; Fisher LW, 2001, BIOCHEM BIOPH RES CO, V280, P460, DOI 10.1006/bbrc.2000.4146; Freije JMP, 2003, ADV EXP MED BIOL, V532, P91; Hirama M, 2003, CANCER LETT, V198, P107, DOI 10.1016/S0304-3835(03)00286-6; Jain A, 2002, J BIOL CHEM, V277, P13700, DOI 10.1074/jbc.M110757200; Koeneman KS, 1999, PROSTATE, V39, P246; MacDougall M, 1998, AM J DENT, V11, pS11; MacDougall M, 1996, CONNECT TISSUE RES, V35, P267, DOI 10.3109/03008209609029200; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Sugiura Y, 1998, CANCER RES, V58, P2209; Takano S, 2000, BRIT J CANCER, V82, P1967; Tiniakos DG, 1998, HUM PATHOL, V29, P1250, DOI 10.1016/S0046-8177(98)90253-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tuck AB, 2000, J CELL BIOCHEM, V78, P465, DOI 10.1002/1097-4644(20000901)78:3<465::AID-JCB11>3.0.CO;2-C; Tuck AB, 1998, INT J CANCER, V79, P502, DOI 10.1002/(SICI)1097-0215(19981023)79:5<502::AID-IJC10>3.0.CO;2-3; Tunio GM, 1998, ARCH PATHOL LAB MED, V122, P1087; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Waltregny D, 1998, J NATL CANCER I, V90, P1000, DOI 10.1093/jnci/90.13.1000; Woessner JF, 1998, BIOL EXTRAC, P1; Wu Y, 2000, BRIT J CANCER, V83, P156; Yu AE, 1998, BIOL EXTRAC, P85; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	32	168	174	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					734	+		10.1096/fj.03-0966fje	http://dx.doi.org/10.1096/fj.03-0966fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766790				2022-12-28	WOS:000220425000041
J	Artwohl, M; Roden, M; Waldhausl, W; Freudenthaler, A; Baumgartner-Parzer, SM				Artwohl, M; Roden, M; Waldhausl, W; Freudenthaler, A; Baumgartner-Parzer, SM			Free fatty acids trigger apoptosis and inhibit cell cycle progression in human vascular endothelial cells	FASEB JOURNAL			English	Article						endothelial dysfunction; vascular complications; diabetes	NF-KAPPA-B; OXIDATIVE STRESS; LINOLEIC-ACID; OLEIC-ACID; INSULIN-RESISTANCE; INDUCE APOPTOSIS; GLUCOSE; ACTIVATION; PROTEIN; EXPRESSION	Plasma free fatty acid (FFA) concentrations are increased in states of insulin resistance and impair endothelial function. Because the underlying mechanisms are largely unknown, we examined selected, purified FFAs. (100.300 mu mol/l, 24.48 h) action on apoptosis, cell cycle distribution, and associated gene/protein expression in human umbilical vein endothelial cells (HUVECs). Stearic acid, but not oleic acid, time and concentration dependently increased endothelial apoptosis by fivefold (n=6, P<0.01), whereas polyunsaturated FFAs (PUFAs; linoleic, gamma-linolenic, and arachidonic acid) exerted proapoptotic activity only at 300 mu mol/l (P<0.05). Proapoptotic FFA action increased with FFAs' number of double bonds and with protein expression of the apoptosis promotor bak. The G(0)/G(1) cell cycle arrest (n=6, P<0.05) induced by stearic acid (+14%) and PUFAs (+30%) is reflected by up-regulation of p21(WAF-1/Cip1). In addition, all FFAs concentration dependently reduced (P<0.05) gene/protein expression of clusterin (-54%), NF-kappa B's inhibitor, I kappa B alpha (-50%), endothelin-1 (-44%), and endothelial NO synthase (-44%). Plasma samples obtained from individuals with elevated plasma FFAs (372 +/- 22 mu mol/l) increased endothelial apoptosis by 4.2-fold (P<0.001, n=10) compared with intraindividually matched low plasma FFA (56 +/- 21 mu mol/l) conditions, underlining the results obtained by defined FFA stimulation. In conclusion, FFA structure differently affects endothelial cell proliferation and apoptosis, both representing key factors in the development of micro- and macrovascular dysfunction.	Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria	University of Vienna	Baumgartner-Parzer, SM (corresponding author), Univ Vienna, Dept Internal Med 3, Div Endocrinol & Metab, A-1090 Vienna, Austria.	sabina.baumgartner-parzer@akh-wien.ac.at	Roden, Michael/AAD-3843-2019		European foundation for the study of diabetes (EFSD); Austrian Science Fonds [P 15656]; Austrian National Bank [10510]	European foundation for the study of diabetes (EFSD); Austrian Science Fonds(Austrian Science Fund (FWF)); Austrian National Bank	The study was supported in part by the European foundation for the study of diabetes (EFSD 2002) and the Austrian Science Fonds (P 15656) and the Jubilaumsfondsprojekt No.10510 of the Austrian National Bank.	Akimoto S, 2000, CIRC RES, V86, P185, DOI 10.1161/01.RES.86.2.185; Aoki M, 2001, HYPERTENSION, V38, P48, DOI 10.1161/01.HYP.38.1.48; Artwohl M, 2003, DIABETES, V52, P1240, DOI 10.2337/diabetes.52.5.1240; Artwohl M, 2002, INT J OBESITY, V26, P577, DOI 10.1038/sj.ijo.0801947; Artwohl M, 2000, BRIT J PHARMACOL, V131, P1577, DOI 10.1038/sj.bjp.0703660; BATES EJ, 1995, ATHEROSCLEROSIS, V116, P247, DOI 10.1016/0021-9150(95)05553-9; Baumgartner-Parzer SM, 2001, EXP CLIN ENDOCR DIAB, V109, pS166, DOI 10.1055/s-2001-18579; BAUMGARTNERPARZER SM, 1995, DIABETES, V44, P1323, DOI 10.2337/diabetes.44.11.1323; BODEN G, 1994, J CLIN INVEST, V93, P2438, DOI 10.1172/JCI117252; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Carluccio MA, 1999, ARTERIOSCL THROM VAS, V19, P220, DOI 10.1161/01.ATV.19.2.220; Chung BH, 1998, ATHEROSCLEROSIS, V141, P321; CRISSMAN HA, 1995, CELL GROWTH APOPTOSI, P21; DAVDA RK, 1995, HYPERTENSION, V26, P764, DOI 10.1161/01.HYP.26.5.764; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Dimmeler S, 2000, CIRC RES, V87, P434; Dimmeler S, 2002, CURR OPIN LIPIDOL, V13, P531, DOI 10.1097/00041433-200210000-00009; Dresner A, 1999, J CLIN INVEST, V103, P253, DOI 10.1172/JCI5001; Eitel K, 2003, DIABETES, V52, P991, DOI 10.2337/diabetes.52.4.991; Evans JL, 2003, DIABETES, V52, P1, DOI 10.2337/diabetes.52.1.1; Fagot-Campagna A, 1998, INT J EPIDEMIOL, V27, P808, DOI 10.1093/ije/27.5.808; Henning B, 2001, J AM COLL NUTR, V20, P97, DOI 10.1080/07315724.2001.10719021; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; Humphreys DT, 1999, J BIOL CHEM, V274, P6875, DOI 10.1074/jbc.274.11.6875; Im EO, 2001, CANCER LETT, V163, P83, DOI 10.1016/S0304-3835(00)00671-6; Jiang WG, 1998, BIOCHEM BIOPH RES CO, V244, P414, DOI 10.1006/bbrc.1998.8288; KASTAN MB, 1991, CANCER RES, V51, P6304; Kiessling F, 2000, BASIC RES CARDIOL, V95, P299, DOI 10.1007/s003950070049; Lupi R, 2002, DIABETES, V51, P1437, DOI 10.2337/diabetes.51.5.1437; Mackness B, 1997, ARTERIOSCL THROM VAS, V17, P1233, DOI 10.1161/01.ATV.17.7.1233; Massaro M, 2002, NUTR METAB CARDIOVAS, V12, P42; Meerarani P, 2000, AM J CLIN NUTR, V71, P81; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Nilsson L, 1998, ARTERIOSCL THROM VAS, V18, P1679, DOI 10.1161/01.ATV.18.11.1679; OPIE LH, 1963, NEW ENGL J MED, V268, P757, DOI 10.1056/NEJM196304042681404; Outinen PA, 1999, BLOOD, V94, P959, DOI 10.1182/blood.V94.3.959.415k20_959_967; Pleiner J, 2002, J CLIN ENDOCR METAB, V87, P2913, DOI 10.1210/jc.87.6.2913; REAVEN GM, 1988, DIABETES, V37, P1020, DOI 10.2337/diabetes.37.8.1020; Roden M, 1996, J CLIN INVEST, V97, P2859, DOI 10.1172/JCI118742; Roden M, 1999, DIABETES, V48, P358, DOI 10.2337/diabetes.48.2.358; Romeo G, 2002, DIABETES, V51, P2241, DOI 10.2337/diabetes.51.7.2241; Sata M, 2000, HYPERTENSION, V36, P83, DOI 10.1161/01.HYP.36.1.83; Shichiri M, 1997, HYPERTENSION, V30, P1198, DOI 10.1161/01.HYP.30.5.1198; SHULMAN GI, 2000, J CLIN INVEST, V106, P171, DOI DOI 10.1172/JCI10583; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S, DOI 10.1093/ajcn/70.3.560s; Sivamurthy N, 2001, SURGERY, V130, P204, DOI 10.1067/msy.2001.115823; Steinberg HO, 1997, J CLIN INVEST, V100, P1230, DOI 10.1172/JCI119636; Steinberg HO, 2000, DIABETES, V49, P1231, DOI 10.2337/diabetes.49.7.1231; Steinberg HO, 2002, DIABETOLOGIA, V45, P623, DOI 10.1007/s00125-002-0800-2; Stingl H, 2002, OBES RES, V10, P1111, DOI 10.1038/oby.2002.151; Surette ME, 1999, CARCINOGENESIS, V20, P757, DOI 10.1093/carcin/20.5.757; Toborek M, 1997, J LIPID RES, V38, P2155; Urbich C, 2000, CIRCULATION, V101, P352, DOI 10.1161/01.CIR.101.4.352; WALDHAUSL WK, 2000, CURR OPIN ENDOCRINOL, V71, P211; Warren MC, 2000, FREE RADICAL BIO MED, V29, P537, DOI 10.1016/S0891-5849(00)00353-1; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wong SCC, 2001, J PATHOL, V194, P35, DOI 10.1002/path.838; Yam D, 1996, ISRAEL J MED SCI, V32, P1134; Young VM, 1998, METABOLISM, V47, P566, DOI 10.1016/S0026-0495(98)90241-4	62	129	143	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					146	148		10.1096/fj.03-0301fje	http://dx.doi.org/10.1096/fj.03-0301fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597560				2022-12-28	WOS:000188829300056
J	Ermak, G; Cheadle, C; Becker, KG; Harris, CD; Davies, KJA				Ermak, G; Cheadle, C; Becker, KG; Harris, CD; Davies, KJA			DSCR1 (Adapt78) modulates expression of SOD1	FASEB JOURNAL			English	Article						calcipressin 1; sod 1; oxidative stress; Down's syndrome	CU/ZN-SUPEROXIDE DISMUTASE; SYNDROME CRITICAL REGION; CALCINEURIN A-ALPHA; DOWN-SYNDROME; GENE-EXPRESSION; GLUTATHIONE-PEROXIDASE; OXIDATIVE STRESS; MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; INHIBITS CALCINEURIN	DSCR1(Adapt78) is a stress responsive gene that can be induced by multiple stresses. We have previously demonstrated that acute DSCR1(Adapt78) overexpression can transiently protect cells against oxidative stress and calcium-mediated stresses, while its chronic overexpression is associated with neurofibrillary tangles, Alzheimer disease, and Down's syndrome. It seems that a delicate balance of DSCR1(Adapt78) expression is maintained in cells, and this gene can have either protective or damaging effects, depending on both its level and duration of expression. The mechanisms by which DSCR1(Adapt78) can protect or harm cells are poorly understood. Here, we tried to identify pathways and targets affected by the DSCR1(Adapt78) gene using regulated expression of DSCR1(Adapt78) in PC-12 cells, followed by microarray analysis of mRNAs from these cells. We found that DSCR1(Adapt78) expression stimulates SOD1 (intracellular Cu,Zn superoxide dismutase) gene expression and increased sod 1 enzyme activity. Previous studies have indicated that sod 1 can either protect or damage cells, depending on its levels. Our findings suggest that sod 1 may also be involved in both the acute protective and the chronic damaging effects of DSCR1(Adapt78) expression. These data also have importance for our understanding of Down's syndrome, Alzheimer's disease, and other human pathologies.	Univ So Calif, Ethel Percy Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Div Mol & Computat Biol, Los Angeles, CA 90089 USA; NIA, DNA Array Unit, Res Resources Branch, NIH, Baltimore, MD 21224 USA	University of Southern California; University of Southern California; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Davies, KJA (corresponding author), Univ So Calif, Ethel Percy Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	kelvin@usc.edu		Davies, Kelvin/0000-0001-7790-3003; Becker, Kevin/0000-0002-6794-6656	NIA NIH HHS [AG16256] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016256] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANNEREN KG, 1987, PEDIATR RES, V21, P88, DOI 10.1203/00006450-198701000-00019; Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; Barrett T, 2001, RESTOR NEUROL NEUROS, V18, P127; BROOKSBANK BWL, 1984, DEV BRAIN RES, V16, P37, DOI 10.1016/0165-3806(84)90060-9; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CEBALLOS I, 1991, FREE RADICAL RES COM, V12-3, P571; Cheadle C, 2003, J MOL DIAGN, V5, P73, DOI 10.1016/S1525-1578(10)60455-2; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crawford DR, 1997, ARCH BIOCHEM BIOPHYS, V342, P6, DOI 10.1006/abbi.1997.0109; CUNNINGHAM KW, 1994, J CELL BIOL, V124, P351, DOI 10.1083/jcb.124.3.351; Davies KJA, 2001, BIOFACTORS, V15, P91, DOI 10.1002/biof.5520150208; DEHAAN JB, 1995, BIOCHEM MOL BIOL INT, V35, P1281; deHaan JB, 1996, HUM MOL GENET, V5, P283, DOI 10.1093/hmg/5.2.283; Ermak G, 2002, FASEB J, V16, DOI 10.1096/fj.01-0846com; Ermak G, 2002, DRUG TODAY, V38, P509, DOI 10.1358/dot.2002.38.7.704681; Ermak G, 2002, MOL IMMUNOL, V38, P713, DOI 10.1016/S0161-5890(01)00108-0; Ermak G, 2001, J BIOL CHEM, V276, P38787, DOI 10.1074/jbc.M102829200; FLOHE L, 1984, METHOD ENZYMOL, V105, P93; Fuentes JJ, 2000, HUM MOL GENET, V9, P1681, DOI 10.1093/hmg/9.11.1681; Fuentes JJ, 1997, GENOMICS, V44, P358, DOI 10.1006/geno.1997.4866; GRONER Y, 1994, BIOMED PHARMACOTHER, V48, P231, DOI 10.1016/0753-3322(94)90138-4; Gulesserian T, 2001, J INVEST MED, V49, P41, DOI 10.2310/6650.2001.34089; Honig LS, 2000, AM J MED, V108, P317, DOI 10.1016/S0002-9343(00)00291-6; Hughes SM, 1998, CURR BIOL, V8, pR892, DOI 10.1016/S0960-9822(07)00554-4; Kayyali US, 1997, J NEUROCHEM, V68, P1668; Krebs J, 1998, BIOMETALS, V11, P375, DOI 10.1023/A:1009226316146; Leahy KP, 1999, ARCH BIOCHEM BIOPHYS, V368, P67, DOI 10.1006/abbi.1998.1059; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Mayne M, 2001, J VIROL, V75, P11641, DOI 10.1128/JVI.75.23.11641-11650.2001; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strippoli P, 2000, GENOMICS, V64, P252, DOI 10.1006/geno.2000.6127; THASE ME, 1984, BIOL PSYCHIAT, V19, P571; Torsdottir G, 2001, PHARMACOL TOXICOL, V89, P320, DOI 10.1034/j.1600-0773.2001.d01-168.x; Vawter MP, 2001, BRAIN RES BULL, V55, P641, DOI 10.1016/S0361-9230(01)00522-6; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Yang J, 2002, INT FED INFO PROC, V87, P61; Zhuo M, 1999, P NATL ACAD SCI USA, V96, P4650, DOI 10.1073/pnas.96.8.4650	43	26	29	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					62	69		10.1096/fj.03-0451com	http://dx.doi.org/10.1096/fj.03-0451com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718387				2022-12-28	WOS:000188829300040
J	Erol, E; Kumar, LS; Cline, GW; Shulman, GI; Kelly, DP; Binas, B				Erol, E; Kumar, LS; Cline, GW; Shulman, GI; Kelly, DP; Binas, B			Liver fatty acid-binding protein is required for high rates of hepatic fatty acid oxidation but not for the action of PPAR-alpha in fasting mice	FASEB JOURNAL			English	Article						lipid metabolism; gene expression	PROLIFERATOR-ACTIVATED RECEPTORS; PEROXISOME PROLIFERATORS; EXPRESSION; GENE; MITOCHONDRIAL; CHOLESTEROL; TRANSPORT; LACKING; MURINE; ALTER	Liver fatty acid binding protein (L-FABP) has been proposed to limit the availability of long-chain fatty acids (LCFA) for oxidation and for peroxisome proliferator-activated receptor alpha (PPAR-alpha), a fatty acid binding transcription factor that determines the capacity of hepatic fatty acid oxidation. Here, we used L-FABP null mice to test this hypothesis. Under fasting conditions, this mutation reduced beta-hydroxybutyrate (BHB) plasma levels as well as BHB release and palmitic acid oxidation by isolated hepatocytes. However, the capacity for ketogenesis was not reduced: BHB plasma levels were restored by octanoate injection; BHB production and palmitic acid oxidation were normal in liver homogenates; and hepatic expression of key PPAR-alpha. target (MCAD, mitochondrial HMG CoA synthase, ACO, CYP4A3) and other (CPTI, LCAD) genes of mitochondrial and extramitochondrial LCFA oxidation and ketogenesis remained at wild-type levels. During standard diet, mitochondrial HMG CoA synthase mRNA was selectively reduced in L-FABP null liver. These results suggest that under fasting conditions, hepatic L-FABP contributes to hepatic LCFA oxidation and ketogenesis by a nontranscriptional mechanism, whereas L-FABP can activate ketogenic gene expression in fed mice. Thus, the mechanisms whereby L-FABP affects fatty acid oxidation may vary with physiological condition.	Texas A&M Univ, Coll Vet Med, Dept Pathobiol, College Stn, TX 77843 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, Howard Hughes Med Inst, New Haven, CT USA; Washington Univ, Sch Med, Cardiovasc Res Ctr, St Louis, MO USA	Texas A&M University System; Texas A&M University College Station; Howard Hughes Medical Institute; Yale University; Washington University (WUSTL)	Binas, B (corresponding author), Texas A&M Univ, Coll Vet Med, Dept Pathobiol, Raymond Stotzer Pkwy, College Stn, TX 77843 USA.	bbinas@cvm.tamu.edu	Shulman, Gerald I./P-7176-2019	Shulman, Gerald I./0000-0003-1529-5668	NIDDK NIH HHS [R01 DK040936] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040936] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AYTE J, 1990, P NATL ACAD SCI USA, V87, P3874, DOI 10.1073/pnas.87.10.3874; Binas B, 1999, FASEB J, V13, P805, DOI 10.1096/fasebj.13.8.805; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; Chao H, 2003, J LIPID RES, V44, P72, DOI 10.1194/jlr.M200191-JLR200; Coleman RA, 2002, J NUTR, V132, P2123, DOI 10.1093/jn/132.8.2123; Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491; Frolov A, 1997, BIOCHEMISTRY-US, V36, P6545, DOI 10.1021/bi970205t; HAINLINE BE, 1993, BIOCHIM BIOPHYS ACTA, V1216, P460, DOI 10.1016/0167-4781(93)90015-6; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; Hertzel AV, 2000, TRENDS ENDOCRIN MET, V11, P175; Huang H, 2002, J BIOL CHEM, V277, P29139, DOI 10.1074/jbc.M202923200; Hung DY, 2003, AM J PHYSIOL-GASTR L, V284, pG423, DOI 10.1152/ajpgi.00328.2002; KAIKAUS RM, 1993, MOL CELL BIOCHEM, V123, P93, DOI 10.1007/BF01076479; Kersten S, 1999, J CLIN INVEST, V103, P1489, DOI 10.1172/JCI6223; Le May C, 2000, FEBS LETT, V475, P163, DOI 10.1016/S0014-5793(00)01648-3; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Leone TC, 1999, P NATL ACAD SCI USA, V96, P7473, DOI 10.1073/pnas.96.13.7473; Linden D, 2002, J BIOL CHEM, V277, P23044, DOI 10.1074/jbc.M110416200; Luxon BA, 1996, AM J PHYSIOL-GASTR L, V271, pG113, DOI 10.1152/ajpgi.1996.271.1.G113; Luxon BA, 1997, AM J PHYSIOL-CELL PH, V273, pC859, DOI 10.1152/ajpcell.1997.273.3.C859; Madden CR, 2000, J VIROL, V74, P5266, DOI 10.1128/JVI.74.11.5266-5272.2000; Martin GG, 2003, J BIOL CHEM, V278, P21429, DOI 10.1074/jbc.M300287200; McArthur MJ, 1999, J LIPID RES, V40, P1371; MCGARRY JD, 1980, ANNU REV BIOCHEM, V49, P395, DOI 10.1146/annurev.bi.49.070180.002143; Murphy EJ, 1996, BBA-LIPID LIPID MET, V1301, P191, DOI 10.1016/0005-2760(96)00024-0; Neschen S, 2002, AM J PHYSIOL-ENDOC M, V282, pE395, DOI 10.1152/ajpendo.00414.2001; Newberry EP, 2003, J BIOL CHEM, V278, P51664, DOI 10.1074/jbc.M309377200; OCKNER RK, 1979, J CLIN INVEST, V64, P172, DOI 10.1172/JCI109437; Sambrook J., 2001, MOL CLONING LAB MANU; Schaap FG, 1999, CIRC RES, V85, P329, DOI 10.1161/01.RES.85.4.329; Storch J, 2000, BBA-MOL CELL BIOL L, V1486, P28, DOI 10.1016/S1388-1981(00)00046-9; Tan NS, 2002, MOL CELL BIOL, V22, P5114, DOI 10.1128/MCB.22.14.5114-5127.2002; VEERKAMP JH, 1986, BIOCHIM BIOPHYS ACTA, V875, P301, DOI 10.1016/0005-2760(86)90180-3; Watanabe K, 2000, J BIOL CHEM, V275, P22293, DOI 10.1074/jbc.M000248200; Wolfrum C, 1999, BBA-MOL CELL BIOL L, V1437, P194, DOI 10.1016/S1388-1981(99)00008-6; Wolfrum C, 2000, BIOCHEMISTRY-US, V39, P1469, DOI 10.1021/bi991638u; Wolfrum C, 1999, J LIPID RES, V40, P708; Wolfrum C, 2001, P NATL ACAD SCI USA, V98, P2323, DOI 10.1073/pnas.051619898	38	84	85	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					347	+		10.1096/fj.03-0330fje	http://dx.doi.org/10.1096/fj.03-0330fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656998				2022-12-28	WOS:000188067500019
J	Philp, D; Nguyen, M; Scheremeta, B; St-Surin, S; Villa, AM; Orgel, A; Kleinman, HK; Elkin, M				Philp, D; Nguyen, M; Scheremeta, B; St-Surin, S; Villa, AM; Orgel, A; Kleinman, HK; Elkin, M			Thymosin beta(4) increases hair growth by activation of hair follicle stem cells	FASEB JOURNAL			English	Article						matrix metalloproteinase-2; clonogenic keratinocytes	VEIN ENDOTHELIAL-CELLS; FACTOR HGF ACTIVATOR; RAT VIBRISSA; IN-VIVO; BETA-4; BULGE; SKIN; COLLAGEN; ANAGEN; MATRIX	Thymosin beta(4), a 43-amino acid polypeptide that is an important mediator of cell migration and differentiation, also promotes angiogenesis and wound healing. Here, we report that thymosin beta(4) stimulates hair growth in normal rats and mice. A specific subset of hair follicular keratinocytes in mouse skin expresses thymosin beta(4) in a highly coordinated manner during the hair growth cycle. These keratinocytes originate in the hair follicle bulge region, a niche for skin stem cells. Rat vibrissa follicle clonogenic keratinocytes, closely related, if not identical, to the bulge-residing stem cells, were isolated and their migration and differentiation increased in the presence of nanomolar concentrations of thymosin beta(4). Expression and secretion of the extracellular matrix-degrading enzyme matrix metalloproteinase-2 were increased by thymosin beta(4). Thus, thymosin beta(4) accelerates hair growth, in part, due to its effect on critical events in the active phase of the hair follicle cycle, including promoting the migration of stem cells and their immediate progeny to the base of the follicle, differentiation, and extracellular matrix remodeling.	NICHHD, Cell Biol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Kleinman, HK (corresponding author), NIDCR, Cell Biol Sect, NIH, Bldg 30,Room 433,30 Convent Dr,MSC 4370, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bao L, 1998, CLIN EXP METASTAS, V16, P227, DOI 10.1023/A:1006540824969; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; BARRANDON Y, 1987, P NATL ACAD SCI USA, V84, P2302, DOI 10.1073/pnas.84.8.2302; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Cotsarelis G, 1997, AM J PATHOL, V151, P1505; Frohm M, 1996, EUR J BIOCHEM, V237, P86, DOI 10.1111/j.1432-1033.1996.0086n.x; Fuchs E, 1995, ANNU REV CELL DEV BI, V11, P123, DOI 10.1146/annurev.cb.11.110195.001011; GRANT DS, 1995, J CELL SCI, V108, P3685; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; JAHODA CAB, 1992, J ANAT, V181, P47; Janes SM, 2002, J PATHOL, V197, P479, DOI 10.1002/path.1156; Jensen UB, 1999, DEVELOPMENT, V126, P2409; Karelina TV, 2000, J INVEST DERMATOL, V114, P371, DOI 10.1046/j.1523-1747.2000.00886.x; KOBAYASHI K, 1993, P NATL ACAD SCI USA, V90, P7391, DOI 10.1073/pnas.90.15.7391; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Lee YR, 2001, J DERMATOL SCI, V25, P156, DOI 10.1016/S0923-1811(00)00124-9; Lindner G, 2000, FASEB J, V14, P319, DOI 10.1096/fasebj.14.2.319; LINK RE, 1990, J INVEST DERMATOL, V95, P202, DOI 10.1111/1523-1747.ep12478002; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Lyle S, 1998, J CELL SCI, V111, P3179; Lyle S, 1999, J INVEST DERM SYMP P, V4, P296, DOI 10.1038/sj.jidsp.5640233; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Oh IS, 2002, BIOCHEM BIOPH RES CO, V296, P401, DOI 10.1016/S0006-291X(02)00888-4; Oshima H, 2001, CELL, V104, P233, DOI 10.1016/S0092-8674(01)00208-2; PAUS R, 1989, LAB INVEST, V60, P365; PAUS R, 1990, BRIT J DERMATOL, V122, P777, DOI 10.1111/j.1365-2133.1990.tb06266.x; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Roy P, 2001, J CELL BIOL, V153, P1035, DOI 10.1083/jcb.153.5.1035; SCANDURRO AB, 1995, J INVEST DERMATOL, V105, P177, DOI 10.1111/1523-1747.ep12317089; Shapiro J, 1998, DERMATOL CLIN, V16, P341, DOI 10.1016/S0733-8635(05)70017-6; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2002, CURR EYE RES, V24, P268, DOI 10.1076/ceyr.24.4.268.8414; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; Stetler-Stevenson WG, 2001, SEMIN CANCER BIOL, V11, P143, DOI 10.1006/scbi.2000.0365; SUN TT, 1991, J INVEST DERMATOL, V96, pS77, DOI 10.1111/1523-1747.ep12471959; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; WEINBERG WC, 1990, DIFFERENTIATION, V45, P168, DOI 10.1111/j.1432-0436.1990.tb00470.x; WILSON C, 1994, DIFFERENTIATION, V55, P127, DOI 10.1046/j.1432-0436.1994.5520127.x; WILSON CL, 1994, SKIN PHARMACOL, V7, P8; Yamazaki M, 1999, J INVEST DERM SYMP P, V4, P312, DOI 10.1038/sj.jidsp.5640236; Yano K, 2001, J CLIN INVEST, V107, P409, DOI 10.1172/JCI11317; Young JD, 1999, NAT MED, V5, P1424; YUSPA SH, 1993, J INVEST DERMATOL, V101, pS27, DOI 10.1111/1523-1747.ep12362567	46	90	93	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					385	+		10.1096/fj.03-0244fje	http://dx.doi.org/10.1096/fj.03-0244fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657002				2022-12-28	WOS:000188067500024
J	Radtke, C; Akiyama, Y; Brokaw, J; Lankford, KL; Wewetzer, K; Fodor, WL; Kocsis, JD				Radtke, C; Akiyama, Y; Brokaw, J; Lankford, KL; Wewetzer, K; Fodor, WL; Kocsis, JD			Remyelination of the nonhuman primate spinal cord by transplantation of H-transferase transgenic adult pig olfactory ensheathing cells	FASEB JOURNAL			English	Article						OEC; HT; transplantation	SCHWANN-CELLS; AXONAL REGENERATION; GLIA; EXPRESSION; CONDUCTION; RECOVERY; BULB	Olfactory ensheathing cells (OECs) have been shown to mediate remyelination and to stimulate axonal regeneration in a number of in vivo rodent spinal cord studies. However, whether OECs display similar properties in the primate model has not been tested so far. In the present study, we thus transplanted highly-purified OECs isolated from transgenic pigs expressing the alpha1,2 fucosyltransferase gene (H-transferase or HT) gene into a demyelinated lesion of the African green monkey spinal cord. Four weeks posttransplantation, robust remyelination was found in 62.5% of the lesion sites, whereas there was virtually no remyelination in the nontransplanted controls. This together with the immunohistochemical demonstration of the grafted cells within the lesioned area confirmed that remyelination was indeed achieved by OECs. Additional in vitro assays demonstrated 1) that the applied cell suspension consisted of >98% OECs, 2) that the majority of the cells expressed the transgene, and 3) that expression of the HT gene reduced complement activation more than twofold compared with the nontransgenic control. This is the first demonstration that xenotransplantation of characterized OECs into the primate spinal cord results in remyelination.	Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06516 USA; Vet Affairs Med Ctr, Neurosci Res Ctr, West Haven, CT 06516 USA; Alex Pharmaceut Inc, Cheshire, CT 06410 USA; Hannover Med Sch, CTR Anat, D-3000 Hannover, Germany	Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Hannover Medical School	Kocsis, JD (corresponding author), Yale Univ, Sch Med, Neurosci Res Ctr 127A, VAMC, West Haven, CT 06516 USA.	william.fodor@uconn.edu	Messier, Claude/A-2322-2008; Radtke, Christine/M-2927-2013; Radtke, Christine/B-8491-2018	Messier, Claude/0000-0002-4791-1763; Radtke, Christine/0000-0001-6877-5038	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043432, P50NS010174, F05NS010174] Funding Source: NIH RePORTER; NICHD NIH HHS [R44 HD095784] Funding Source: Medline; NINDS NIH HHS [R01 NS043432-05, P50 NS010174-290027, R01 NS043432, F05 NS010174] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Auchincloss H, 1998, ANNU REV IMMUNOL, V16, P433, DOI 10.1146/annurev.immunol.16.1.433; Barnett SC, 2000, BRAIN, V123, P1581, DOI 10.1093/brain/123.8.1581; BERTHOLD CH, PHYSL PATHOBIOLOGY A, P3; Chen SC, 1997, ANN NY ACAD SCI, V831, P350; CHUAH MI, 1991, J NEUROSCI RES, V29, P172, DOI 10.1002/jnr.490290206; CICCHETTI F, 2002, XENOTRANSPLANTATION, V9, P1; Costa C, 2002, XENOTRANSPLANTATION, V9, P45, DOI 10.1034/j.1399-3089.2002.0o142.x; Costa C, 1999, FASEB J, V13, P1762, DOI 10.1096/fasebj.13.13.1762; Deacon T, 1997, NAT MED, V3, P350, DOI 10.1038/nm0397-350; FODOR WL, 1994, P NATL ACAD SCI USA, V91, P11153, DOI 10.1073/pnas.91.23.11153; Franklin RJM, 1996, GLIA, V17, P217, DOI 10.1002/(SICI)1098-1136(199607)17:3<217::AID-GLIA4>3.0.CO;2-Y; GALILI U, 1991, P NATL ACAD SCI USA, V88, P7401, DOI 10.1073/pnas.88.16.7401; Imaizumi T, 2000, BRAIN RES, V854, P70, DOI 10.1016/S0006-8993(99)02285-4; Imaizumi T, 1998, J NEUROSCI, V18, P6176; Imaizumi T, 2000, NAT BIOTECHNOL, V18, P949, DOI 10.1038/79432; ISACSON O, 1995, NAT MED, V1, P1189, DOI 10.1038/nm1195-1189; Kato T, 2000, GLIA, V30, P209, DOI 10.1002/(SICI)1098-1136(200005)30:3<209::AID-GLIA1>3.0.CO;2-8; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; Li Y, 1998, J NEUROSCI, V18, P10514; Lu J, 2002, BRAIN, V125, P14, DOI 10.1093/brain/awf014; McCurry KR, 1997, HUM IMMUNOL, V58, P91, DOI 10.1016/S0198-8859(97)00229-2; PIXLEY SK, 1992, GLIA, V5, P269, DOI 10.1002/glia.440050405; Ramon-Cueto A, 2000, NEURON, V25, P425, DOI 10.1016/S0896-6273(00)80905-8; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; Ramon-Cueto A, 1998, BRAIN RES BULL, V46, P175, DOI 10.1016/S0361-9230(97)00463-2; Smith PM, 2002, EXP NEUROL, V176, P402, DOI 10.1006/exnr.2002.7936; Takami T, 2002, J NEUROSCI, V22, P6670; Watanabe E, 1998, CELL TRANSPLANT, V7, P239, DOI 10.1016/S0963-6897(98)00011-6; Wewetzer K, 2002, CELL TISSUE RES, V309, P337, DOI 10.1007/s00441-002-0607-y	29	72	83	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					335	+		10.1096/fj.03-0214fje	http://dx.doi.org/10.1096/fj.03-0214fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657003	Green Accepted			2022-12-28	WOS:000188067500034
J	Lanigan, TM; Liu, A; Huang, YZ; Mei, L; Margolis, B; Guan, KL				Lanigan, TM; Liu, A; Huang, YZ; Mei, L; Margolis, B; Guan, KL			Human homologue of Drosophila CNK interacts with Ras effector proteins Raf and Rlf	FASEB JOURNAL			English	Article							MAP KINASE ACTIVATION; KSR-1 GENE ENCODES; SIGNAL-TRANSDUCTION; C-ELEGANS; CELL-TRANSFORMATION; GROWTH-FACTOR; PATHWAY; BINDING; MEK; SCAFFOLD	Connector enhancer of KSR (CNK) is a multidomain protein that participates in Ras signaling in Drosophila eye development. In this report we identify the human homologue of CNK, termed CNK2A, and a truncated alternatively spliced variant, CNK2B. We characterize CNK2 phosphorylation, membrane localization, and interaction with Ras effector molecules. Our results show that MAPK signaling appears to play a role in the phosphorylation of CNK2 in vivo. CNK2 is found in both membrane and cytoplasmic fractions of the cell. In MDCK cells, full-length CNK2 is localized to the lateral plasma membrane. Consistent with previous reports, we show CNK2 interacts with Raf. CNK2 interaction was mapped to the regulatory and kinase domains of Raf, as well as to the carboxyl-terminal half of CNK2. CNK2 also interacts with the Ral signaling components, Ral GTPase, and the Ral-GDS family member R1f. CNK2 interaction was mapped to the GEF domain of R1f. The ability of CNK2 to interact with both Ras effector proteins Raf and R1f suggests that CNK2 may integrate signals between MAPK and Ral pathways through a complex interplay of components.	Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Alabama, Dept Neurobiol, Birmingham, AL USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama, Dept Phys Med & Rehabil, Birmingham, AL 35294 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Guan, KL (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu	Mei, Lin/G-8755-2012		NIA NIH HHS [5T32AG00114-17] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anselmo AN, 2002, J BIOL CHEM, V277, P5940, DOI 10.1074/jbc.M110498200; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; Cacace AM, 1999, MOL CELL BIOL, V19, P229; Denouel-Galy A, 1998, CURR BIOL, V8, P46, DOI 10.1016/S0960-9822(98)70019-3; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; Huang YZ, 2000, NEURON, V26, P443, DOI 10.1016/S0896-6273(00)81176-9; Joneson T, 1998, J BIOL CHEM, V273, P7743, DOI 10.1074/jbc.273.13.7743; JULLIENFLORES V, 1995, J BIOL CHEM, V270, P22473, DOI 10.1074/jbc.270.38.22473; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; KORNFELD K, 1995, CELL, V83, P903, DOI 10.1016/0092-8674(95)90206-6; Li WQ, 2000, GENE DEV, V14, P895; Michaud NR, 1997, P NATL ACAD SCI USA, V94, P12792, DOI 10.1073/pnas.94.24.12792; Mirey G, 2003, MOL CELL BIOL, V23, P1112, DOI 10.1128/MCB.23.3.1112-1124.2003; Morrison DK, 2001, J CELL SCI, V114, P1609; Muller J, 2001, MOL CELL, V8, P983, DOI 10.1016/S1097-2765(01)00383-5; Prober DA, 2002, GENE DEV, V16, P2286, DOI 10.1101/gad.991102; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Roy F, 2002, GENE DEV, V16, P427, DOI 10.1101/gad.962902; Schaeffer HJ, 1998, SCIENCE, V281, P1668, DOI 10.1126/science.281.5383.1668; Sieburth DS, 1998, CELL, V94, P119, DOI 10.1016/S0092-8674(00)81227-1; Stewart S, 1999, MOL CELL BIOL, V19, P5523; Sugimoto T, 1998, EMBO J, V17, P1717, DOI 10.1093/emboj/17.6.1717; SUNDARAM M, 1995, CELL, V83, P889, DOI 10.1016/0092-8674(95)90205-8; Sundaram M, 1996, BIOESSAYS, V18, P473, DOI 10.1002/bies.950180609; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Therrien M, 1999, P NATL ACAD SCI USA, V96, P13259, DOI 10.1073/pnas.96.23.13259; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; Therrien M, 1998, CELL, V95, P343, DOI 10.1016/S0092-8674(00)81766-3; Verheijen MHG, 1999, ONCOGENE, V18, P4435, DOI 10.1038/sj.onc.1202834; WASSARMAN DA, 1995, CURR OPIN GENET DEV, V5, P44, DOI 10.1016/S0959-437X(95)90052-7; Waters SB, 1996, J BIOL CHEM, V271, P18224, DOI 10.1074/jbc.271.30.18224; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wolthuis RMF, 1997, EMBO J, V16, P6748, DOI 10.1093/emboj/16.22.6748; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Xing HM, 1997, CURR BIOL, V7, P294, DOI 10.1016/S0960-9822(06)00152-7; Yao I, 1999, J BIOL CHEM, V274, P11889, DOI 10.1074/jbc.274.17.11889; Yao I, 2000, BIOCHEM BIOPH RES CO, V270, P538, DOI 10.1006/bbrc.2000.2475; Yu W, 1998, CURR BIOL, V8, P56, DOI 10.1016/S0960-9822(98)70020-X; ZHENG CF, 1994, J BIOL CHEM, V269, P19947	43	42	44	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					2048	2060		10.1096/fj.02-1096com	http://dx.doi.org/10.1096/fj.02-1096com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597674	Green Submitted			2022-12-28	WOS:000186961200041
J	Tai, CH; Boraud, T; Bezard, E; Bioulac, B; Gross, C; Benazzouz, A				Tai, CH; Boraud, T; Bezard, E; Bioulac, B; Gross, C; Benazzouz, A			Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata	FASEB JOURNAL			English	Article						Parkinson's disease; extracellular recordings; basal ganglia; cytochrome oxidase	DEEP BRAIN-STIMULATION; ADVANCED PARKINSONS-DISEASE; MPTP-TREATED MONKEY; GLOBUS-PALLIDUS; ELECTRICAL-STIMULATION; PARS RETICULATA; DOPAMINE NEURONS; STN STIMULATION; BASAL GANGLIA; CELL-BODIES	High-frequency stimulation (HFS) of the subthalamic nucleus (STN) has been shown to produce a dramatic alleviation of motor symptoms in patients with advanced Parkinson's disease. Its functional mechanism, however, remains obscure. We used extracellular recording and in situ cytochrome oxidase (Col) mRNA hybridization to investigate the effects of HFS of the STN on neuronal activity of the STN and the substantia nigra reticulata (SNr) in normal rats and rats with 6-hydroxydopamine (6-OHDA) lesion of the substantia nigra compacta (SNc). To allow detection of spikes and analysis of firing activity, artifacts recorded during stimulation were scaled down using a template subtraction method. In both normal and lesioned rats, the activity of a majority of STN neurons was inhibited during stimulation. In the SNr, HFS also induced an inhibition of the activity of a majority of neurons in normal and lesioned rats. In situ hybridization histochemistry confirmed these results in that it showed a significant decrease in levels of Col mRNA expression in the STN and SNr in both normal and lesioned rats during stimulation. These data afford an interesting insight into the functional mechanism of deep brain stimulation and support the hypothesis that HFS exerts an inhibitory influence on STN neuronal firing.	Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, F-33076 Bordeaux, France; Natl Taiwan Univ Hosp, Dept Neurol, Taipei, Taiwan; Natl Taiwan Univ, Coll Med, Taipei 10018, Taiwan	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Benazzouz, A (corresponding author), Univ Victor Segalen, Basal Gang, Neurophysiol Lab, CNRS,UMR 5543, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	Abdelhamid.Benazzouz@umr5543.u-bordeaux2.fr	Bezard, Erwan/A-8173-2008; Boraud, Thomas/A-6260-2008; Benazzouz, Abdelhamid/E-5050-2016; Bezard, Erwan/ABD-5153-2021	Bezard, Erwan/0000-0002-0410-4638; Tai, Chun-Hwei/0000-0002-3493-8879				ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AZIZ TZ, 1992, BRIT J NEUROSURG, V6, P575, DOI 10.3109/02688699209002375; BENABID AL, 1994, STEREOT FUNCT NEUROS, V62, P76, DOI 10.1159/000098600; Benazzouz A, 2000, NEUROREPORT, V11, P1593, DOI 10.1097/00001756-200005150-00043; BENAZZOUZ A, 1995, NEUROSCI LETT, V189, P77, DOI 10.1016/0304-3940(95)11455-6; Benazzouz A, 2000, NEUROLOGY, V55, pS13; Benazzouz A, 1996, MOVEMENT DISORD, V11, P627, DOI 10.1002/mds.870110606; BENAZZOUZ A, 1993, EUR J NEUROSCI, V5, P382, DOI 10.1111/j.1460-9568.1993.tb00505.x; Benazzouz A, 2000, NEUROSCIENCE, V99, P289, DOI 10.1016/S0306-4522(00)00199-8; BERGMAN H, 1994, J NEUROPHYSIOL, V72, P507, DOI 10.1152/jn.1994.72.2.507; BERGMAN H, 1990, SCIENCE, V249, P1436, DOI 10.1126/science.2402638; Beurrier C, 2001, J NEUROPHYSIOL, V85, P1351, DOI 10.1152/jn.2001.85.4.1351; Bevan MD, 1999, J NEUROSCI, V19, P7617, DOI 10.1523/JNEUROSCI.19-17-07617.1999; Bezard E, 1999, EUR J NEUROSCI, V11, P2167, DOI 10.1046/j.1460-9568.1999.00627.x; BEZARD E, 2001, FASEB J, V10, P1096; Boraud T, 1996, NEUROSCI LETT, V215, P17, DOI 10.1016/S0304-3940(96)12943-8; Boraud T, 1998, BRAIN RES, V787, P157, DOI 10.1016/S0006-8993(97)01563-1; BURBAUD P, 1995, EXP BRAIN RES, V105, P48; CANTERAS NS, 1990, BRAIN RES, V513, P43, DOI 10.1016/0006-8993(90)91087-W; Dostrovsky JO, 2000, J NEUROPHYSIOL, V84, P570, DOI 10.1152/jn.2000.84.1.570; Dostrovsky JO, 2002, MOVEMENT DISORD, V17, pS63, DOI 10.1002/mds.10143; FUJIMOTO K, 1993, BRAIN RES, V609, P185, DOI 10.1016/0006-8993(93)90872-K; Gao GM, 1997, NEUROREPORT, V8, P2601, DOI 10.1097/00001756-199707280-00036; Guridi J, 1996, BRAIN, V119, P1717, DOI 10.1093/brain/119.5.1717; HAMMOND C, 1978, BRAIN RES, V151, P235, DOI 10.1016/0006-8993(78)90881-8; Hashimoto T, 2003, J NEUROSCI, V23, P1916; Hassani OK, 1996, NEUROSCIENCE, V72, P105, DOI 10.1016/0306-4522(95)00535-8; HOLLERMAN JR, 1990, BRAIN RES, V533, P203, DOI 10.1016/0006-8993(90)91341-D; Kaneoke Y, 1996, J NEUROSCI METH, V68, P211, DOI 10.1016/0165-0270(96)00081-7; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; Levy R, 2001, BRAIN, V124, P2105, DOI 10.1093/brain/124.10.2105; Limousin P, 1997, ANN NEUROL, V42, P283, DOI 10.1002/ana.410420303; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LIMOUSIN P, 1995, MOVEMENT DISORD, V10, P672, DOI 10.1002/mds.870100523; Lisman JE, 1997, TRENDS NEUROSCI, V20, P38, DOI 10.1016/S0166-2236(96)10070-9; MILLER WC, 1987, ADV BEHAV BIOL, V32, P415; Moro E, 2002, NEUROLOGY, V59, P706, DOI 10.1212/WNL.59.5.706; Mouroux M, 1997, NEUROSCIENCE, V81, P387, DOI 10.1016/S0306-4522(97)00110-3; Ni ZG, 2001, BRAIN RES, V899, P142, DOI 10.1016/S0006-8993(01)02219-3; Ni ZG, 2001, SYNAPSE, V40, P145, DOI 10.1002/syn.1036.abs; Nowak LG, 1998, EXP BRAIN RES, V118, P477, DOI 10.1007/s002210050304; Nowak LG, 1998, EXP BRAIN RES, V118, P489, DOI 10.1007/s002210050305; Paxinos G., 1996, RAT BRAIN STEREOTAXI; ROBLEDO P, 1990, BRAIN RES, V518, P47, DOI 10.1016/0006-8993(90)90952-8; Salin P, 2002, J NEUROSCI, V22, P5137, DOI 10.1523/JNEUROSCI.22-12-05137.2002; Tehovnik EJ, 1996, J NEUROSCI METH, V65, P1, DOI 10.1016/0165-0270(95)00131-X; Vila M, 2000, EUR J NEUROSCI, V12, P337, DOI 10.1046/j.1460-9568.2000.00901.x; Windels F, 2000, EUR J NEUROSCI, V12, P4141, DOI 10.1046/j.1460-9568.2000.00296.x; WINDELS F, 2002, SOC NEUROSCIENCE WAS	50	195	202	1	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					1820	1830		10.1096/fj.03-0163com	http://dx.doi.org/10.1096/fj.03-0163com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14519661				2022-12-28	WOS:000186343300036
J	Bornstein, SR; Yoshida-Hiroi, M; Sotiriou, S; Levine, M; Hartwig, HG; Nussbaum, RL; Eisenhofer, G				Bornstein, SR; Yoshida-Hiroi, M; Sotiriou, S; Levine, M; Hartwig, HG; Nussbaum, RL; Eisenhofer, G			Impaired adrenal catecholamine system function in mice with deficiency of the ascorbic acid transporter (SVCT2)	FASEB JOURNAL			English	Article						SVCT2; ascorbic acid; catecholamines; norepinephrine; epinephrine; dopamine; adrenal gland; sympathetic nervous system	CORTICOTROPIN-RELEASING HORMONE; VITAMIN-C TRANSPORT; CHROMAFFIN CELLS; BIOSYNTHESIS; SECRETION; GLAND	Ascorbic acid ( vitamin C) is a cofactor required in catecholamine synthesis for conversion of dopamine to norepinephrine by dopamine beta-hydroxylase. Mutant mice lacking the plasma membrane ascorbic acid transporter (SVCT2) have severely reduced tissue levels of ascorbic acid and die after birth. We therefore investigated whether these mice might have impaired synthesis of catecholamines. Levels of catecholamines in brain were unaffected by SVCT2 deficiency. In heart, the only evidence for impaired dopamine beta-hydroxylase activity was a twofold increase in tissue dopamine. An influence of the deficiency on tissue catecholamines was most prominent in the adrenals where norepinephrine was decreased by 50% and epinephrine, by 81%. On the ultrastructural level, adrenal chromaffin cells in SVCT2 null mice showed depletion of catecholamine storage vesicles, increased amounts of rough endoplasmic reticulum, signs of apoptosis, and increased glycogen storage. Decreased plasma levels of corticosterone indicated additional effects of the deficiency on adrenal cortical function. These data show that deranged catecholamine system function in SVCT2 null mice is largely restricted to the adrenal medulla and cannot account for the lethality in these animals. The data, however, establish a crucial role for ascorbic acid in adrenal chromaffin cell function.	Univ Dusseldorf, Dept Endocrinol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Anat, D-40225 Dusseldorf, Germany; NINDS, Clin Neurocardiol Sect, NIH, Bethesda, MD 20892 USA; NHGRI, Genet Dis Res Branch, NIH, Bethesda, MD 20892 USA; NIDDKD, Mol & Clin Nutr Sect, NIH, Bethesda, MD 20892 USA	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Bornstein, SR (corresponding author), Univ Dusseldorf, Dept Endocrinol, Moorenstr 5, D-40225 Dusseldorf, Germany.	stefan.bornstein@uni-duesseldorf.de	Eisenhofer, Graeme/AAU-9829-2021	Eisenhofer, Graeme/0000-0002-8601-9903	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000169] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK054506, Z01DK054506] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bland ML, 2000, P NATL ACAD SCI USA, V97, P14488, DOI 10.1073/pnas.97.26.14488; Bornstein SR, 1999, FASEB J, V13, P1185, DOI 10.1096/fasebj.13.10.1185; Bornstein SR, 2000, P NATL ACAD SCI USA, V97, P14742, DOI 10.1073/pnas.97.26.14742; BORNSTEIN SR, 1992, ANAT RECORD, V234, P255, DOI 10.1002/ar.1092340212; BORNSTEIN SR, 1990, CELL TISSUE RES, V260, P161, DOI 10.1007/BF00297501; DANIELS AJ, 1982, SCIENCE, V216, P737, DOI 10.1126/science.7079733; Daruwala R, 1999, FEBS LETT, V460, P480, DOI 10.1016/S0014-5793(99)01393-9; DILIBERTO EJ, 1991, AM J CLIN NUTR, V54, pS1163, DOI 10.1093/ajcn/54.6.1163s; Ehrhart-Bornstein M, 1998, ENDOCR REV, V19, P101, DOI 10.1210/er.19.2.101; EIPPER BA, 1991, AM J CLIN NUTR, V54, pS1153, DOI 10.1093/ajcn/54.6.1153s; EISENHOFER G, 1986, CLIN CHEM, V32, P2030; GHADIALLY FN, 1997, ULTRASTRUCT PATHOL, V2, P1013; LEVINE M, 1985, VITAM HORM, V42, P1; LEVINE M, 1985, J BIOL CHEM, V260, P2942; Liang WJ, 2001, MOL MEMBR BIOL, V18, P87, DOI 10.1080/09687680120706; Merke DP, 2000, NEW ENGL J MED, V343, P1362, DOI 10.1056/NEJM200011093431903; MORITA K, 1985, J BIOL CHEM, V260, P5112; Nussdorfer G G, 1986, Int Rev Cytol, V98, P1; RUSSELL JT, 1985, J BIOL CHEM, V260, P226; Sotiriou S, 2002, NAT MED, V8, P514, DOI 10.1038/nm0502-514; Stratakis C A, 2000, J Med Genet, V37, pE20, DOI 10.1136/jmg.37.9.e20; THOMAS SA, 1995, NATURE, V374, P643, DOI 10.1038/374643a0; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; TVELD AMI, 1988, AM J HYPERTENS, V1, P231, DOI 10.1093/ajh/1.3.231; Vincent S., 2002, CLIN AUTON RES, V12, P144; Wang JF, 2000, J HYDROMETEOROL, V1, P267, DOI 10.1175/1525-7541(2000)001<0267:TIOODO>2.0.CO;2; Wolkersdorfer GW, 1996, ENDOCR RES, V22, P411, DOI 10.3109/07435809609043727; Wolkersdorfer GW, 1996, J CLIN ENDOCR METAB, V81, P4129, DOI 10.1210/jc.81.11.4129; WURTMAN RJ, 1965, SCIENCE, V150, P1464, DOI 10.1126/science.150.3702.1464; WURTMAN RJ, 1966, J BIOL CHEM, V241, P2301	30	55	62	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1928	+		10.1096/fj.02-1167fje	http://dx.doi.org/10.1096/fj.02-1167fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897061				2022-12-28	WOS:000185345100019
J	Breuil, V; Schmid-Antomarchi, H; Schmid-Alliana, A; Rezzonico, R; Euller-Ziegler, L; Rossi, B				Breuil, V; Schmid-Antomarchi, H; Schmid-Alliana, A; Rezzonico, R; Euller-Ziegler, L; Rossi, B			The receptor activator of nuclear factor (NF)kappa B ligand (RANKL) is a new chemotactic factor for human monocytes	FASEB JOURNAL			English	Article						migration; CD14+; MonoMac6 cell line; osteoprotegerin	TUMOR-NECROSIS-FACTOR; OSTEOPROTEGERIN LIGAND; T-CELLS; OSTEOCLAST DIFFERENTIATION; RHEUMATOID-ARTHRITIS; BONE LOSS; KAPPA-B; FAMILY; EXPRESSION; CYTOKINE	Bone resorption is regulated by the immune system, where receptor activator of nuclear factor (NF)kappaB ligand (RANKL), a new member of the tumor-necrosis factor family, may contribute to pathological conditions. Due to the role of RANKL in the maturation of monocyte-derived osteoclasts, we hypothesized that RANKL could exert chemotactic properties toward monocytic cells. Our results demonstrate that RANKL induces the migration of MonoMac-6 monocytic cells as well as human freshly isolated total peripheral blood mononuclear cells (PBMC) and CD14(+) purified PBMC. RANKL induces the migration of MonoMac-6 cells in a dose-dependent manner and with an efficacy similar to MCP-1. After an 8-h incubation, the soluble form of RANKL (sRANKL) started to exhibit a chemoattractive effect on MonoMac-6 cells, with an increased effect observed up to 24 h. RANKL elicits an additive chemotactic effect to MCP-1. Furthermore, addition of the RANKL decoy receptor osteoprotegerin in the lower well or RANKL in the upper well abrogates the RANKL-induced migration of MonoMac-6 cells, hallmarking a true specific activity. RNase protection assay experiments indicate that exposure of MonoMac-6 cells to RANKL had no significant effect on the expression of a variety of chemokines, known to attract monocytes. This study provides evidence that RANKL behaves as a chemotactic factor for monocytic cells, emphazing the cross-talk between bone and immune systems.	Fac Med Pasteur, INSERM, Unit 364, IFR 50, F-06107 Nice 2, France; Archet Hosp, Dept Rheumatol, F-06200 Nice, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice	Rossi, B (corresponding author), Fac Med Pasteur, INSERM, Unit 364, IFR 50, Ave Valombrose, F-06107 Nice 2, France.	rossi@unice.fr	SCHMID-ALLIANA, Annie/P-4366-2016; REZZONICO, Roger/N-9626-2016	SCHMID-ALLIANA, Annie/0000-0003-2321-7408; REZZONICO, Roger/0000-0002-8460-1641				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Cambien B, 2001, BLOOD, V97, P359, DOI 10.1182/blood.V97.2.359; Collin-Osdoby P, 2001, J BIOL CHEM, V276, P20659, DOI 10.1074/jbc.M010153200; Dougall WC, 1999, GENE DEV, V13, P2412, DOI 10.1101/gad.13.18.2412; Goldring SR, 2000, ARTHRITIS RES, V2, P33, DOI 10.1186/ar67; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Haynes DR, 2003, RHEUMATOLOGY, V42, P123, DOI 10.1093/rheumatology/keg047; Hofbauer LC, 2000, J BONE MINER RES, V15, P2, DOI 10.1359/jbmr.2000.15.1.2; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; JIANG YL, 1992, J IMMUNOL, V148, P2423; Kim D, 2000, J EXP MED, V192, P1467, DOI 10.1084/jem.192.10.1467; Kong YY, 1999, NATURE, V402, P304, DOI 10.1038/35005552; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 2001, ARTHRITIS RHEUM, V44, P1003, DOI 10.1002/1529-0131(200105)44:5<1003::AID-ANR179>3.0.CO;2-#; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lader CS, 2001, BRIT J HAEMATOL, V112, P430, DOI 10.1046/j.1365-2141.2001.02437.x; Lorenzo J, 2000, J CLIN INVEST, V106, P749, DOI 10.1172/JCI11089; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; McGowan NWA, 2001, ENDOCRINOLOGY, V142, P1678, DOI 10.1210/en.142.4.1678; MING WJ, 1987, J IMMUNOL, V138, P1469; Muller WA, 2001, J EXP MED, V194, pF47, DOI 10.1084/jem.194.9.f47; Nosaka K, 2002, BLOOD, V99, P634, DOI 10.1182/blood.V99.2.634; Parfitt AM, 1998, BONE, V23, P491, DOI 10.1016/S8756-3282(98)00140-9; Parfitt AM, 2000, BONE, V26, P319, DOI 10.1016/S8756-3282(00)80937-0; Speden DJ, 2002, J RHEUMATOL, V29, P516; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Takami M, 1999, CELL TISSUE RES, V298, P327, DOI 10.1007/s004419900092; Takayanagi H, 2000, NATURE, V408, P600, DOI 10.1038/35046102; Tsou CL, 2001, J BIOL CHEM, V276, P44622, DOI 10.1074/jbc.M107327200; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	35	49	50	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1751	+		10.1096/fj.02-1188fje	http://dx.doi.org/10.1096/fj.02-1188fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958198				2022-12-28	WOS:000184471600003
J	Herrmann, J; Gulati, R; Napoli, C; Woodrum, JE; Lerman, LO; Rodriguez-Porcel, M; Sica, V; Simari, RD; Ciechanover, A; Lerman, A				Herrmann, J; Gulati, R; Napoli, C; Woodrum, JE; Lerman, LO; Rodriguez-Porcel, M; Sica, V; Simari, RD; Ciechanover, A; Lerman, A			Oxidative stress-related increase in ubiquitination in early coronary atherogenesis	FASEB JOURNAL			English	Article						coronary artery disease; proteasome; ubiquitin	FACTOR-KAPPA-B; OXIDIZED PROTEINS; ENDOTHELIAL FUNCTION; PROTEASOME PATHWAY; DEGRADATION; 20S; ACTIVATION; HYPERCHOLESTEROLEMIA; IMMUNOREACTIVITY; ACCUMULATION	The ubiquitin-proteasome system (UPS) is involved in the removal of damaged proteins and the activation of transcription factors, such as nuclear-factor-kappaB. Recent reports, however, questioned the functional activity of the UPS under conditions of increased oxidative stress, such as experimental hypercholesterolemia, which was the objective of our study. Pigs were placed on a normal chow diet (N) or on a hypercholesterolemic diet without (HC) or with vitamin C and E supplementation (HC+VIT) for 12 weeks. Compared with N, plasma concentration of total cholesterol increased in both HC and HC+VIT [76 +/- 21 vs. 400 +/- 148 (P<0.05) and 329 +/- 102 (P<0.05) mg/dL], whereas increase in lipid peroxidation, as assessed by LDL-malondialdehyde plasma concentration, was found in HC but not in HC+VIT [6.6 +/- 0.7 vs. 8.5 +/- 0.3 (P<0.05) and 6.8 +/- 0.7 nmol/mg protein]. In comparison with N, the level of ubiquitin conjugates in the coronary artery, as assessed by immunoblotting, increased by 42% in HC but not in HC+VIT and was localized predominantly to media vascular smooth muscle cells by immunostaining. There was no difference in proteasome proteolytic activity among the study groups. These results demonstrate that the UPS is functionally active in early atherogenesis despite increase in oxidative stress with important repercussions in the pathophysiology and therapy of cardiovascular diseases.	Mayo Clin, Div Cardiovasc Dis, Rochester, MN USA; Mayo Clin, Div Hypertens, Rochester, MN USA; Univ Naples Federico II, Dept Med & Clin Pathol, Naples, Italy; Technion Israel Inst Technol, Rappaport Inst Res Med Sci, Haifa, Israel	Mayo Clinic; Mayo Clinic; University of Naples Federico II; Technion Israel Institute of Technology	Lerman, A (corresponding author), Mayo Clin & Mayo Fdn, Div Cardiovasc Dis, 200 1st St SW, Rochester, MN 55905 USA.	lerman.amir@mayo.edu	Ciechanover, Aaron J/C-9166-2017; Lerman, Lilach/M-4962-2017	Napoli, Claudio/0000-0002-5455-555X				Adam PJ, 1997, CARDIOVASC RES, V33, P416, DOI 10.1016/S0008-6363(96)00220-9; Adamo AM, 1999, J NEUROSCI RES, V55, P523, DOI 10.1002/(SICI)1097-4547(19990215)55:4<523::AID-JNR12>3.0.CO;2-Q; AEBI H, 1984, METHOD ENZYMOL, V105, P121; ALLAIN CC, 1974, CLIN CHEM, V20, P470; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bulteau AL, 2001, J BIOL CHEM, V276, P30057, DOI 10.1074/jbc.M100142200; Ciechanover A, 2000, J CELL BIOCHEM, P40; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; Davies KJA, 2001, BIOCHIMIE, V83, P301, DOI 10.1016/S0300-9084(01)01250-0; Davies SS, 2002, FASEB J, V16, P715, DOI 10.1096/fj.01-0696fje; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; De Nigris F, 2001, ANTIOXID REDOX SIGN, V3, P1119, DOI 10.1089/152308601317203620; de Nigris F, 2001, BIOCHEM BIOPH RES CO, V281, P945, DOI 10.1006/bbrc.2001.4431; FigueiredoPereira ME, 1997, MOL BIOL REP, V24, P35, DOI 10.1023/A:1006848405975; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; Friguet B, 2002, METHOD ENZYMOL, V353, P253; Grune T, 1997, FASEB J, V11, P526, DOI 10.1096/fasebj.11.7.9212076; Herrmann J, 2002, J AM COLL CARDIOL, V40, P1919, DOI 10.1016/S0735-1097(02)02564-0; HERSHKO A, 1986, J BIOL CHEM, V261, P1992; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; Igarashi Masahiko, 1994, Artery, V21, P256; Ishii T, 1999, FREE RADICAL RES, V31, P351, DOI 10.1080/10715769900300921; JahngenHodge J, 1997, J BIOL CHEM, V272, P28218, DOI 10.1074/jbc.272.45.28218; Kikuchi J, 2000, ARTERIOSCL THROM VAS, V20, P128, DOI 10.1161/01.ATV.20.1.128; Kornitzer D, 2000, J CELL PHYSIOL, V182, P1, DOI 10.1002/(SICI)1097-4652(200001)182:1<1::AID-JCP1>3.0.CO;2-V; LOWE J, 1993, BRAIN PATHOL, V3, P55, DOI 10.1111/j.1750-3639.1993.tb00726.x; Meiners S, 2002, CIRCULATION, V105, P483, DOI 10.1161/hc0402.102951; Napoli C, 2001, MAYO CLIN PROC, V76, P619; Okada K, 1999, J BIOL CHEM, V274, P23787, DOI 10.1074/jbc.274.34.23787; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Peterson TE, 1999, BIOCHEM BIOPH RES CO, V265, P722, DOI 10.1006/bbrc.1999.1738; Reinheckel T, 1998, BIOCHEM J, V335, P637, DOI 10.1042/bj3350637; Ritchie NE, 1998, CIRCULATION, V98, P1707, DOI 10.1161/01.CIR.98.17.1707; Rodriguez-Porcel M, 2002, CARDIOVASC RES, V53, P1010, DOI 10.1016/S0008-6363(01)00535-1; Rodriguez-Porcel M, 2001, J AM COLL CARDIOL, V37, P608, DOI 10.1016/S0735-1097(00)01139-6; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; Shang F, 2001, EXP EYE RES, V73, P229, DOI 10.1006/exer.2001.1029; Shang F, 1997, J BIOL CHEM, V272, P23086, DOI 10.1074/jbc.272.37.23086; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Wilson SH, 2002, ATHEROSCLEROSIS, V160, P147, DOI 10.1016/S0021-9150(01)00546-9; Wilson SH, 2000, ATHEROSCLEROSIS, V148, P23, DOI 10.1016/S0021-9150(99)00211-7; Wilson SH, 2001, ARTERIOSCL THROM VAS, V21, P122, DOI 10.1161/01.ATV.21.1.122	42	47	52	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1730	+		10.1096/fj.02-0841fje	http://dx.doi.org/10.1096/fj.02-0841fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958191				2022-12-28	WOS:000184471600001
J	Oertle, T; Klinger, M; Stuermer, CAO; Schwab, ME				Oertle, T; Klinger, M; Stuermer, CAO; Schwab, ME			A reticular rhapsody: phylogenic evolution and nomenclature of the RTN/Nogo gene family	FASEB JOURNAL			English	Article						reticulon; intron loss; endoplasmic reticulum	MYELIN-ASSOCIATED GLYCOPROTEIN; FUNCTIONAL-CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; DIFFERENTIAL EXPRESSION; GENOMIC ORGANIZATION; NEURITE OUTGROWTH; NOGO-A; PROTEIN; IDENTIFICATION; RECEPTOR	Reticulon (RTN) genes code for a family of proteins relatively recently described in higher vertebrates. The four known mammalian paralogues (RTN1, - 2, - 3, and - 4/Nogo) have homologous carboxyl termini with two characteristic large hydrophobic regions. Except for RTN4-A/Nogo-A, thought to be an inhibitor for neurite outgrowth, restricting the regenerative capabilities of the mammalian CNS after injury, the functions of other family members are largely unknown. The overall occurrence of RTNs in different phyla and the evolution of the RTN gene family have hitherto not been analyzed. Here we expound data showing that the RTN family has arisen during early eukaryotic evolution potentially concerted to the establishment of the endomembrane system. Over 250 reticulon-like (RTNL) genes were identified in deeply diverging eukaryotes, fungi, plants, and animals. A systematic nomenclature for all identified family members is introduced. The analysis of exon-intron arrangements and of protein homologies allowed us to isolate key steps in the history of these genes. Our data corroborate the hypothesis that present RTNs evolved from an intron-rich reticulon ancestor mainly by the loss of different introns in diverse phyla. We also present evidence that the exceptionally large RTN4-A-specific exon 3, which harbors a potent neurite growth inhibitory region, may have arisen de novo similar to 350 MYA during transition to land vertebrates. These data emphasize on the one hand the universal role of reticulons in the eukaryotic system and on the other hand the acquisition of putative new functions through acquirement of novel amino-terminal exons.	Univ Zurich, Brain Res Inst, CH-8057 Zurich, Switzerland; Swiss Fed Inst Technol, Dept Biol, CH-8057 Zurich, Switzerland; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	University of Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; University of Konstanz	Oertle, T (corresponding author), Univ Zurich, Brain Res Inst, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	oertle@hifo.unizh.ch	Schwab, Martin E/B-6818-2016					Abi-Rached L, 2002, NAT GENET, V31, P100, DOI 10.1038/ng855; Bapteste E, 2002, P NATL ACAD SCI USA, V99, P1414, DOI 10.1073/pnas.032662799; BASTMEYER M, 1991, J NEUROSCI, V11, P626; BEATTIE MS, 1990, J NEUROBIOL, V21, P1108, DOI 10.1002/neu.480210714; Becker T, 1998, J NEUROSCI, V18, P5789; Burchett SA, 2002, J BIOL CHEM, V277, P22156, DOI 10.1074/jbc.M202254200; Canestro C, 2002, J MOL EVOL, V54, P81, DOI 10.1007/s00239-001-0020-2; Chen MS, 2000, NATURE, V403, P434, DOI 10.1038/35000219; Dacks JB, 2001, CELL, V107, P419, DOI 10.1016/S0092-8674(01)00584-0; De Souza SJ, 1998, P NATL ACAD SCI USA, V95, P5094, DOI 10.1073/pnas.95.9.5094; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; Doolittle RF, 1996, SCIENCE, V271, P470, DOI 10.1126/science.271.5248.470; FINK GR, 1987, CELL, V49, P5, DOI 10.1016/0092-8674(87)90746-X; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fragaki K, 2001, VACCINE, V19, P1701, DOI 10.1016/S0264-410X(00)00398-4; GAY GD, 1994, PROTEIN ENG, V7, P103; Godoy C, 1996, YEAST, V12, P983, DOI 10.1002/(SICI)1097-0061(199608)12:10<983::AID-YEA2>3.0.CO;2-D; GrandPre T, 2000, NATURE, V403, P439, DOI 10.1038/35000226; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hamada N, 2002, CELL MOL BIOL, V48, P163; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huber AB, 2002, J NEUROSCI, V22, P3553; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Iwahashi J, 2002, BIOCHEM BIOPH RES CO, V293, P698, DOI 10.1016/S0006-291X(02)00282-6; KAUSHIK R, 2002, ANN DROS RES C, V43, pC186; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; Li Q, 2001, ONCOGENE, V20, P3929, DOI 10.1038/sj.onc.1204536; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; Llopart A, 2002, P NATL ACAD SCI USA, V99, P8121, DOI 10.1073/pnas.122570299; Moreira EF, 1999, GENOMICS, V58, P73, DOI 10.1006/geno.1999.5807; Morin X, 2001, P NATL ACAD SCI USA, V98, P15050, DOI 10.1073/pnas.261408198; Niederost B, 2002, J NEUROSCI, V22, P10368; Oertle T, 2003, ONCOGENE, V22, P1390, DOI 10.1038/sj.onc.1206278; Oertle T, 2003, J MOL BIOL, V325, P299, DOI 10.1016/S0022-2836(02)01179-8; OERTLE T, 2003, IN PRESS J NEUROSCI; Patthy L, 1999, GENE, V238, P103, DOI 10.1016/S0378-1119(99)00228-0; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Roebroek AJM, 1998, GENOMICS, V51, P98, DOI 10.1006/geno.1997.5175; ROEBROEK AJM, 1993, J BIOL CHEM, V268, P13439; Roebroek AJM, 1996, GENOMICS, V32, P191, DOI 10.1006/geno.1996.0105; Schwab ME, 1996, PHYSIOL REV, V76, P319, DOI 10.1152/physrev.1996.76.2.319; Senden NHM, 1996, EUR J CELL BIOL, V69, P197; Sipiczki M, 2000, GENOME BIOL, V1, DOI [10.1186/gb-2000-1-2-reviews1011, DOI 10.1186/GB-2000-1-2-REVIEWS1011]; Spring J, 1997, FEBS LETT, V400, P2, DOI 10.1016/S0014-5793(96)01351-8; Suffia I, 2000, INFECT IMMUN, V68, P630, DOI 10.1128/IAI.68.2.630-636.2000; Tagami S, 2000, ONCOGENE, V19, P5736, DOI 10.1038/sj.onc.1203948; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VANDEVELDE HJK, 1994, J CELL SCI, V107, P2403; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; WANNER M, 1995, J NEUROSCI, V15, P7500; Wendland B, 2001, NAT CELL BIOL, V3, pE133, DOI 10.1038/35078592; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WOOD MR, 1979, SCIENCE, V206, P344, DOI 10.1126/science.482943; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724	55	139	157	0	13	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1238	1247		10.1096/fj.02-1166hyp	http://dx.doi.org/10.1096/fj.02-1166hyp			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832288	Green Submitted			2022-12-28	WOS:000184471600035
J	Titos, E; Claria, J; Planaguma, A; Lopez-Parra, M; Villamor, N; Parrizas, M; Carrio, A; Miquel, R; Jimenez, W; Arroyo, V; Rivera, F; Rodes, J				Titos, E; Claria, J; Planaguma, A; Lopez-Parra, M; Villamor, N; Parrizas, M; Carrio, A; Miquel, R; Jimenez, W; Arroyo, V; Rivera, F; Rodes, J			Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis	FASEB JOURNAL			English	Article						hepatic inflammation; sinusoidal liver cells; arachidonic acid metabolites	LEUKOTRIENE-SYNTHESIS; CANCER CELLS; CYSTEINYL LEUKOTRIENES; HL-60 CELLS; LUNG-CANCER; IN-VITRO; PROLIFERATION; INJURY; SURVIVAL; MACROPHAGES	The existence of an increased number of Kupffer cells is recognized as critical in the initiation of the inflammatory cascade leading to liver fibrosis. Because 5-lipoxygenase(5-LO) is a key regulator of cell growth and survival, in the current investigation we assessed whether inhibition of the 5-LO pathway would reduce the excessive number of Kupffer cells and attenuate inflammation and fibrosis in experimental liver disease. Kupffer cells were the only liver cell type endowed with a metabolically active 5-LO pathway(i.e., expressed mRNAs for 5-LO,5-LO-activating protein[FLAP], and leukotriene [LT] C-4 synthase and generated LnTB(4) and cysteinyl-LTs). Both the selective 5-LO inhibitor AA861 and the FLAP inhibitor BAY-X-1005 markedly reduced the number of Kupffer cells in culture. The antiproliferative properties of AA861 and BAY-X-1005 were associated with the occurrence of condensed nuclei, fragmented DNA,and changes in DNA content and cell cycle frequency distribution consistent with anapoptotic process. In vivo, in carbon tetrachloride-treated rats,BAY-X-1005 had a significant antifibrotic effect and reduced liver damage and the hepatic content of hydroxyproline. Together,these findings indicate a novel mechanism by which inactivation of the 5-LO pathway could disrupt the sequence of events leading to liver inflammation and fibrosis.	Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Hormonal Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Hematopathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Pathol Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Genet Lab, E-08036 Barcelona, Spain; Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Claria, J (corresponding author), Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, DNA Unit, 170 Barcelona, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Parrizas, Marcelina/AAS-3629-2021; Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019; Claria, Joan/M-7772-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Claria, Joan/0000-0003-4333-7749; Jimenez, Wladimiro/0000-0002-9376-0214; Parrizas, Marcelina/0000-0003-1296-8302; Carrio, Ana/0000-0002-8394-2321				Alric L, 2000, INFLAMM RES, V49, P700, DOI 10.1007/s000110050649; Anderson KM, 1998, ANTICANCER RES, V18, P791; Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BAUD L, 1987, J IMMUNOL, V138, P1190; BAUD L, 1985, J CLIN INVEST, V76, P374, DOI 10.1172/JCI111972; BOUWENS L, 1984, HEPATOLOGY, V4, P213, DOI 10.1002/hep.1840040208; BOUWENS L, 1986, HEPATOLOGY, V6, P718, DOI 10.1002/hep.1840060430; Brown SB, 1996, J CELL BIOCHEM, V60, P246, DOI 10.1002/(SICI)1097-4644(19960201)60:2<246::AID-JCB9>3.0.CO;2-X; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Claria J, 1999, ASCITES AND RENAL DYSFUNCTION IN LIVER DISEASE, P379; CROFTON RW, 1978, J EXP MED, V148, P1, DOI 10.1084/jem.148.1.1; Datta K, 1999, BIOCHEM J, V340, P371, DOI 10.1042/0264-6021:3400371; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; DIJKSTRA CD, 1985, IMMUNOLOGY, V54, P589; Ding XZ, 1999, BIOCHEM BIOPH RES CO, V261, P218, DOI 10.1006/bbrc.1999.1012; Dittmann KH, 1998, LEUKEMIA RES, V22, P49, DOI 10.1016/S0145-2126(97)00132-X; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Frey T, 1997, CYTOMETRY, V28, P253, DOI 10.1002/(SICI)1097-0320(19970701)28:3<253::AID-CYTO10>3.0.CO;2-O; Friedman SL, 2000, J BIOL CHEM, V275, P2247, DOI 10.1074/jbc.275.4.2247; Fukai F, 1996, CELL BIOL INT, V20, P423, DOI 10.1006/cbir.1996.0053; FUKAI F, 1993, ARCH BIOCHEM BIOPHYS, V305, P378, DOI 10.1006/abbi.1993.1435; GEERTS A, 1988, J HEPATOL, V6, P50, DOI 10.1016/S0168-8278(88)80461-6; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Ghosh J, 1997, BIOCHEM BIOPH RES CO, V235, P418, DOI 10.1006/bbrc.1997.6799; GRESSNER AM, 1994, ANN BIOL CLIN-PARIS, V52, P205; HOEDEMAKERS RMJ, 1994, HEPATOLOGY, V19, P666, DOI 10.1002/hep.1840190318; KEPPLER D, 1988, SEMIN LIVER DIS, V8, P357, DOI 10.1055/s-2008-1040557; King MA, 2000, CYTOMETRY, V40, P10, DOI 10.1002/(SICI)1097-0320(20000501)40:1<10::AID-CYTO2>3.0.CO;2-F; Kondo K, 1998, THROMB HAEMOSTASIS, V79, P635; Lee E, 1999, AM J RESP CRIT CARE, V160, P2079, DOI 10.1164/ajrccm.160.6.9903136; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881, DOI 10.1164/ajrccm.161.6.9907054; LEPLEY RA, 1994, J BIOL CHEM, V269, P24163; Luckey SW, 2001, EXP MOL PATHOL, V71, P226, DOI 10.1006/exmp.2001.2399; MULLERPEDDINGHAUS R, 1993, J PHARMACOL EXP THER, V267, P51; Ou D, 2001, CANCER LETT, V166, P223, DOI 10.1016/S0304-3835(01)00411-6; PASQUALE D, 1993, EXP HEMATOL, V21, P1361; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229, DOI 10.1164/ajrccm.165.2.2104050; Planaguma A, 2002, FASEB J, V16, P1937, DOI 10.1096/fj.02-0224fje; Provost P, 1999, P NATL ACAD SCI USA, V96, P1881, DOI 10.1073/pnas.96.5.1881; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Shimada K, 1998, HEPATOLOGY, V28, P1275, DOI 10.1002/hep.510280516; Tang DG, 1996, P NATL ACAD SCI USA, V93, P5241, DOI 10.1073/pnas.93.11.5241; THOMPSON WD, 1980, J PATHOL, V130, P65, DOI 10.1002/path.1711300202; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; TSUKUI T, 1992, J LEUKOCYTE BIOL, V52, P383, DOI 10.1002/jlb.52.4.383; Uz T, 2001, EUR J PHARMACOL, V418, P15, DOI 10.1016/S0014-2999(01)00924-4; Walker JL, 2002, AM J PHYSIOL-HEART C, V282, pH585, DOI 10.1152/ajpheart.00003.2001; WINWOOD PJ, 1993, SEMIN LIVER DIS, V13, P50, DOI 10.1055/s-2007-1007337; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P470	54	63	66	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1745	+		10.1096/fj.02-1157fje	http://dx.doi.org/10.1096/fj.02-1157fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958196				2022-12-28	WOS:000184471600025
J	Duff, SE; Li, CG; Garland, JM; Kumar, S				Duff, SE; Li, CG; Garland, JM; Kumar, S			CD105 is important for angiogenesis: evidence and potential applications	FASEB JOURNAL			English	Review						HHT1; tumor prognosis; cancer	HEREDITARY HEMORRHAGIC TELANGIECTASIA; GROWTH-FACTOR-BETA; HUMAN SOLID TUMORS; ENDOGLIN MONOCLONAL-ANTIBODIES; VASCULAR ENDOTHELIAL-CELLS; BINDING PROTEIN ENDOGLIN; ARG-GLY-ASP; BREAST-CARCINOMA; PROGNOSTIC-SIGNIFICANCE; CELLULAR-RESPONSES	Angiogenesis is the propelling force for tumor growth and metastasis, and antiangiogenic therapy represents one of the most promising modalities for cancer treatment. CD105 (endoglin) is a proliferation-associated and hypoxia-inducible protein abundantly expressed in angiogenic endothelial cells (EC). It is a receptor for transforming growth factor (TGF) -beta1 and -beta3 and modulates TGF-beta signaling by interacting with TGF-beta receptors I and/or II. Immunohistochemistry studies have revealed that CD105 is strongly expressed in blood vessels of tumor tissues. Intratumoral microvessel density (MVD) determined using antibodies to CD105 has been found to be an independent prognostic indicator, wherein increased MVD correlates with shorter survival. CD105 is able to be shed into the circulation, with elevated levels detected in patients with various types of cancer and positively correlated with tumor metastasis. Tangible evidence of its proangiogenic role comes from knockout studies in which CD105 null mice die in utero as a result of impaired angiogenesis in the yolk sac and heart defects. The potential usefulness of CD105 for tumor imaging has been evaluated in tumor-bearing mice and dogs that have shown the rapid accumulation of radiolabeled anti-CD105 monoclonal antibody in the tumors with a high tumor-to-background ratio. The anti-CD105 antibody conjugated with immunotoxins and immunoradioisotopes efficiently suppressed/abrogated tumor growth in murine models bearing breast and colon carcinoma without any significant systemic side effects. Immunoscintigraphy in patients with renal cell carcinomas has shown specific localization of Tc-99(m)-labeled CD105 mab in tumor endothelial cells. Thus, CD105 is a promising vascular target that can be used for tumor imaging, prognosis, and bears therapeutic potential in patients with solid tumors and other angiogenic diseases.	Univ Manchester, Sch Med, Dept Pathol, Manchester M13 9PT, Lancs, England	University of Manchester	Kumar, S (corresponding author), Univ Manchester, Sch Med, Dept Pathol, Manchester M13 9PT, Lancs, England.	MDDPSSK2@FS1.SCG.MAN.AC.UK	Duff, Sarah E/AAW-3795-2021					Abdalla SA, 2000, HUM MOL GENET, V9, P1227, DOI 10.1093/hmg/9.8.1227; Adam PJ, 1998, BIOCHEM BIOPH RES CO, V247, P33, DOI 10.1006/bbrc.1998.8734; Akagi K, 2002, SURGERY, V131, pS109, DOI 10.1067/msy.2002.119361; Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Balza E, 2001, INT J CANCER, V94, P579, DOI 10.1002/ijc.1505; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Bloemendal HJ, 1999, EUR J CLIN INVEST, V29, P802; Bodey B, 1998, ANTICANCER RES, V18, P1485; Bodey B, 1998, ANTICANCER RES, V18, P3621; Botella LM, 2001, J BIOL CHEM, V276, P34486, DOI 10.1074/jbc.M011611200; Bourdeau A, 2001, AM J PATHOL, V158, P2011, DOI 10.1016/S0002-9440(10)64673-1; Bourdeau A, 2000, TRENDS CARDIOVAS MED, V10, P279, DOI 10.1016/S1050-1738(01)00062-7; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Bredow S, 2000, EUR J CANCER, V36, P675, DOI 10.1016/S0959-8049(99)00335-4; Brekken RA, 2002, INT J CANCER, V100, P123, DOI 10.1002/ijc.10462; Brewer CA, 2000, OBSTET GYNECOL, V96, P224, DOI 10.1016/S0029-7844(00)00864-4; BUHRING HJ, 1991, LEUKEMIA, V5, P841; Burrows FJ, 1995, CLIN CANCER RES, V1, P1623; CHEIFETZ S, 1992, J BIOL CHEM, V267, P19027; de Caestecker MP, 2000, JNCI-J NATL CANCER I, V92, P1388, DOI 10.1093/jnci/92.17.1388; FERNANDEZRUIZ E, 1993, CYTOGENET CELL GENET, V64, P204, DOI 10.1159/000133576; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608; Fonsatti E, 2000, CLIN CANCER RES, V6, P2037; Freemont AJ, 2002, J PATHOL, V197, P281, DOI 10.1002/path.1107; GOUGOS A, 1988, J IMMUNOL, V141, P1934; GOUGOS A, 1988, J IMMUNOL, V141, P1925; GOUGOS A, 1992, INT IMMUNOL, V4, P83, DOI 10.1093/intimm/4.1.83; Graulich W, 1999, GENE, V227, P55, DOI 10.1016/S0378-1119(98)00585-X; Guerrero-Esteo M, 1999, EUR J CELL BIOL, V78, P614, DOI 10.1016/S0171-9335(99)80046-6; Guerrero-Esteo M, 2002, J BIOL CHEM, V277, P29197, DOI 10.1074/jbc.M111991200; Haitjema T, 1996, ARCH INTERN MED, V156, P714, DOI 10.1001/archinte.156.7.714; HORAK ER, 1992, LANCET, V340, P1120, DOI 10.1016/0140-6736(92)93150-L; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kay NE, 2002, LEUKEMIA, V16, P911, DOI 10.1038/sj.leu.2402467; Kumar P, 1996, J PATHOL, V178, P363, DOI 10.1002/(SICI)1096-9896(199604)178:4<363::AID-PATH491>3.0.CO;2-8; Kumar S, 1999, CANCER RES, V59, P856; LASTRES P, 1992, EUR J IMMUNOL, V22, P393, DOI 10.1002/eji.1830220216; LASTRES P, 1994, BIOCHEM J, V301, P765, DOI 10.1042/bj3010765; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; Letamendia A, 1998, J BIOL CHEM, V273, P33011, DOI 10.1074/jbc.273.49.33011; Li CG, 2001, J NATL CANCER I, V93, P555, DOI 10.1093/jnci/93.7.555; Li CG, 2000, INT J CANCER, V89, P122, DOI 10.1002/(SICI)1097-0215(20000320)89:2<122::AID-IJC4>3.0.CO;2-M; Li CG, 2000, FASEB J, V14, P55, DOI 10.1096/fasebj.14.1.55; Li DY, 1999, SCIENCE, V284, P1534, DOI 10.1126/science.284.5419.1534; Lindmark G, 1996, J CLIN ONCOL, V14, P461, DOI 10.1200/JCO.1996.14.2.461; Matsuno F, 1999, CLIN CANCER RES, V5, P371; Matsuno H, 2002, J RHEUMATOL, V29, P890; MCALLISTER KA, 1994, NAT GENET, V8, P345, DOI 10.1038/ng1294-345; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; PAGE DL, 1995, HUM PATHOL, V26, P1173, DOI 10.1016/0046-8177(95)90188-4; Paquet ME, 2001, HUM MOL GENET, V10, P1347, DOI 10.1093/hmg/10.13.1347; Pece-Barbara N, 1999, HUM MOL GENET, V8, P2171, DOI 10.1093/hmg/8.12.2171; Pichuantes S, 1997, TISSUE ANTIGENS, V50, P265, DOI 10.1111/j.1399-0039.1997.tb02870.x; QUACKENBUSH EJ, 1985, J IMMUNOL, V134, P1276; Ribatti D, 1998, CLIN RHEUMATOL, V17, P115, DOI 10.1007/BF01452256; Rius C, 1998, BLOOD, V92, P4677; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Sanchez-Elsner T, 2002, J BIOL CHEM, V277, P43799, DOI 10.1074/jbc.M207160200; Seon BK, 1997, CLIN CANCER RES, V3, P1031; Seon BK, 2002, INT J CANCER, V99, P310, DOI 10.1002/ijc.10378; Shovlin CL, 1997, THROMB HAEMOSTASIS, V78, P145; Shyu KG, 2002, CARDIOVASC RES, V54, P576, DOI 10.1016/S0008-6363(02)00259-6; SRIVASTAVA A, 1988, AM J PATHOL, V133, P419; STJACQUES S, 1994, ENDOCRINOLOGY, V134, P2645, DOI 10.1210/en.134.6.2645; Tabata M, 1999, INT J CANCER, V82, P737, DOI 10.1002/(SICI)1097-0215(19990827)82:5<737::AID-IJC18>3.3.CO;2-#; Takahashi N, 2001, CLIN CANCER RES, V7, P524; Takahashi N, 2001, CANCER RES, V61, P7846; Tanaka F, 2001, CLIN CANCER RES, V7, P3410; Tanigawa N, 1997, BRIT J CANCER, V75, P566, DOI 10.1038/bjc.1997.99; Van de Kerkhof PCM, 1998, ACTA DERM-VENEREOL, V78, P19; Vermeulen PB, 1996, EUR J CANCER, V32A, P2474, DOI 10.1016/S0959-8049(96)00379-6; WANG JM, 1994, J NATL CANCER I, V86, P386, DOI 10.1093/jnci/86.5.386; WANG JM, 1993, INT J CANCER, V54, P363, DOI 10.1002/ijc.2910540303; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WILKSTROM P, 2002, PROSTATE, P268	80	417	470	0	37	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					984	992		10.1096/fj.02-0634rev	http://dx.doi.org/10.1096/fj.02-0634rev			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773481				2022-12-28	WOS:000183818000002
J	Haase, H; Pagel, I; Khalina, Y; Zacharzowsky, U; Person, V; Lutsch, G; Petzhold, D; Kott, M; Schaper, J; Morano, I				Haase, H; Pagel, I; Khalina, Y; Zacharzowsky, U; Person, V; Lutsch, G; Petzhold, D; Kott, M; Schaper, J; Morano, I			The carboxyl-terminal ahnak domain induces actin bundling and stabilizes muscle contraction	FASEB JOURNAL			English	Article						protein-protein interaction; muscle contractility; myocytes	DESMOYOKIN/AHNAK PROTEIN; TRANSLOCATION; MEMBRANE; TARGET	Ahnak, a 700 kDa protein, is expressed in a variety of cells and has been implicated in different cell-type-specific functions. In the human heart, we observed an endogenous carb oxyl-terminal 72 kDa ahnak fragment that copurified with myofibrillar proteins. Immunocytochemistry combined with confocal microscopy localized this fragment to the intercalated discs and close to the Z-line of cardiomyocytes. No endogenous myofibrillar ahnak fragment was observed in the skeletal muscle. We elucidated the role of the recombinant carb oxyl-terminal ahnak fragment (ahnak-C2) in actin filament organization and in the function of muscle fibers. Addition of ahnak-C2 to actin filaments induced filament bundling into paracrystalline-like structures as revealed by electron microscopy. Incubation of demembranated skeletal muscle fibers with ahnak-C2 attenuated the decline in isometric force development upon repeated contraction-relaxation cycles. Our results suggest that the carboxyl-terminal ahnak domain exerts a stabilizing effect on muscle contractility via its interaction with actin of thin filaments.	Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Humboldt Univ, Charite, Franz Volhard Clin, D-13125 Berlin, Germany; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Russia; Max Planck Inst Physiol & Clin Res, D-61231 Bad Nauheim, Germany; Humboldt Univ, Charite, Johannes Muller Inst Physiol, D-13125 Berlin, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; Max Planck Society; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haase, H (corresponding author), Max Delbruck Ctr Mol Med, Robert Rossle Str 10, D-13092 Berlin, Germany.	haase@mdc-berlin.de						BEHLKE J, 1991, FEBS LETT, V288, P119, DOI 10.1016/0014-5793(91)81016-2; BLANCHARD A, 1989, J MUSCLE RES CELL M, V10, P280, DOI 10.1007/BF01758424; Borgonovo B, 2002, NAT CELL BIOL, V4, P955, DOI 10.1038/ncb888; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; Gentil BJ, 2003, J HISTOCHEM CYTOCHEM, V51, P339, DOI 10.1177/002215540305100309; Gentil BJ, 2001, J BIOL CHEM, V276, P23253, DOI 10.1074/jbc.M010655200; Gregorio CC, 1997, CELL STRUCT FUNCT, V22, P191, DOI 10.1247/csf.22.191; Haase H, 1999, FASEB J, V13, P2161, DOI 10.1096/fasebj.13.15.2161; HASHIMOTO T, 1995, EXP CELL RES, V217, P258, DOI 10.1006/excr.1995.1085; Hohaus A, 2002, FASEB J, V16, DOI 10.1096/fj.01-0855com; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kingsley PD, 2001, DEV GROWTH DIFFER, V43, P133; Kreis T., 1993, GUIDEBOOK CYTOSKELET; LU MH, 1992, J CELL BIOL, V117, P1007, DOI 10.1083/jcb.117.5.1007; MORANO I, 1995, CIRC RES, V76, P720, DOI 10.1161/01.RES.76.5.720; Nie ZZ, 2000, J INVEST DERMATOL, V114, P1044, DOI 10.1046/j.1523-1747.2000.00949.x; PARDEE JD, METHODS ENZYMOLOGY, V85, P164; PERSECHINI A, 1985, J BIOL CHEM, V260, P7951; Sekiya F, 1999, J BIOL CHEM, V274, P13900, DOI 10.1074/jbc.274.20.13900; She BR, 2002, EXP CELL RES, V273, P34, DOI 10.1006/excr.2001.5435; SHTIVELMAN E, 1993, J CELL BIOL, V120, P625, DOI 10.1083/jcb.120.3.625; SHTIVELMAN E, 1992, P NATL ACAD SCI USA, V89, P5472, DOI 10.1073/pnas.89.12.5472; SOLARO RJ, 1971, BIOCHIM BIOPHYS ACTA, V245, P259, DOI 10.1016/0005-2728(71)90033-8; Sussman J, 2001, J CELL BIOL, V154, P1019, DOI 10.1083/jcb.200105121; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2	25	33	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					839	+		10.1096/fj.03-0446fje	http://dx.doi.org/10.1096/fj.03-0446fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001564				2022-12-28	WOS:000220522800029
J	Lapointe, N; St-Hilaire, M; Martinoli, MG; Blanchet, J; Gould, P; Rouillard, C; Cicchetti, F				Lapointe, N; St-Hilaire, M; Martinoli, MG; Blanchet, J; Gould, P; Rouillard, C; Cicchetti, F			Rotenone induces non-specific central nervous system and systemic toxicity	FASEB JOURNAL			English	Article						Parkinson's disease; basal ganglia; pesticide; neurotoxicity; inflammation	ENVIRONMENTAL RISK-FACTORS; PARKINSONS-DISEASE; DOPAMINERGIC-NEURONS; ELDERLY CANADIANS; ALPHA-SYNUCLEIN; NGFI-B; EXPRESSION; NURR1; EXPOSURE; MOUSE	We investigated the dopaminergic (DA) neuronal degeneration in animals subjected to systemic treatment of rotenone via subcutaneous delivery. Behavioral observations revealed a hypokinetic period in rats sacrificed at 3 and 5 days, and dystonic episodes in animals sacrificed at 8 days. Less than 20% of the total number of animals given rotenone depicted brain lesions after 8 days of treatment, as demonstrated by a significant loss of DA fibers in the striatum, but not of DA nigral neurons. Tyrosine hydroxylase-negative striatal territories were characterized by postsynaptic toxicity as demonstrated by a decreased number of interneurons labeled for choline acetyltransferase, NADPH-diaphorase, parvalbumin, and projection neurons labeled for calbindin and nerve growth factor inducible-B (NGFI-B). Post-synaptic neurodegeneration was demonstrated further by abundant striatal staining for Fluoro-Jade. Decrease in the nuclear orphan receptor Nurr1 expression was the only significant change observed at the level of the substantia nigra. Autopsy reports confirmed that animals suffered from severe digestion problems. These data suggest that hypokinesia observed between 3 and 5 days is the result of general health problems rather than a specific motor deficit associated to Parkinson's disease (PD) symptoms. Overall, the effects of rotenone toxicity are widespread, and subcutaneous administration of this toxin does not provide the neuropathological and behavioral basis for a relevant and reliable PD model.	CHU Laval, Ctr Rech Neurosci, Ste Foy, PQ G1V 4G2, Canada; Univ Laval, Dept Med, Ste Foy, PQ G1K 7P4, Canada; Univ Quebec Trois Rivieres, Dept Chim Biol, Trois Rivieres, PQ G9A 5H7, Canada; Hop Enfants Jesus, Serv Anatomopathol & Cytol, Quebec City, PQ G1J 1Z4, Canada	Laval University; Laval University; University of Quebec; University of Quebec Trois Rivieres; Laval University	Cicchetti, F (corresponding author), CHU Laval, Ctr Rech Neurosci, RC-9800,2705 Blvd Laurier, Ste Foy, PQ G1V 4G2, Canada.	Francesca.Cicchetti@crchul.ulaval.ca	Rouillard, Claude/A-1310-2008; Rouillard, Claude/G-9127-2017	Rouillard, Claude/0000-0003-4210-9330; Martinoli, Maria-Grazia/0000-0003-2551-1950; Cicchetti, Francesca/0000-0001-5490-1961				Alam M, 2002, BEHAV BRAIN RES, V136, P317, DOI 10.1016/S0166-4328(02)00180-8; AQUILONIUS SM, 1986, ACTA NEUROL SCAND, V74, P379; Backman C, 1999, BRAIN RES, V851, P125, DOI 10.1016/S0006-8993(99)02149-6; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Beaudry G, 2000, J NEUROCHEM, V75, P1694, DOI 10.1046/j.1471-4159.2000.0751694.x; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BUTTERFIELD PG, 1993, NEUROLOGY, V43, P1150, DOI 10.1212/WNL.43.6.1150; CHATURVEDI S, 1995, CAN J NEUROL SCI, V22, P232, DOI 10.1017/S0317167100039901; Cicchetti F, 2000, BRAIN RES REV, V34, P80, DOI 10.1016/S0165-0173(00)00039-4; Cicchetti F, 1998, SYNAPSE, V30, P284, DOI 10.1002/(SICI)1098-2396(199811)30:3<284::AID-SYN6>3.3.CO;2-D; Corasaniti MT, 1998, PHARMACOL TOXICOL, V83, P1, DOI 10.1111/j.1600-0773.1998.tb01434.x; Dawson TM, 2002, NEURON, V35, P219, DOI 10.1016/S0896-6273(02)00780-8; Ferrante RJ, 1997, BRAIN RES, V753, P157, DOI 10.1016/S0006-8993(97)00008-5; FERRANTE RJ, 1991, J NEUROSCI, V11, P3877; Gabrielson KL, 2001, AM J PATHOL, V159, P1507, DOI 10.1016/S0002-9440(10)62536-9; Giasson BI, 2000, NAT NEUROSCI, V3, P1227, DOI 10.1038/81737; Gorell JM, 1998, NEUROLOGY, V50, P1346, DOI 10.1212/WNL.50.5.1346; Gorell JM, 1999, NEUROTOXICOLOGY, V20, P239; GRAEBER MB, 1993, ACTA NEUROPATHOL, V86, P179, DOI 10.1007/BF00334886; GRAEBER MB, 1990, J NEUROIMMUNOL, V27, P121, DOI 10.1016/0165-5728(90)90061-Q; GREENAMYRE J, 2002, SOC NEUR ABST, V32, P314; HEIKKILA RE, 1985, LIFE SCI, V36, P231, DOI 10.1016/0024-3205(85)90064-5; HIER DB, 1977, ANN NEUROL, V1, P152, DOI 10.1002/ana.410010209; Hirsch EC, 1998, ANN NEUROL, V44, pS115, DOI 10.1002/ana.410440717; Hoglinger GU, 2003, J NEUROCHEM, V84, P491, DOI 10.1046/j.1471-4159.2003.01533.x; IMAIZUMI Y, 1995, ACTA NEUROL SCAND, V91, P311, DOI 10.1111/j.1600-0404.1995.tb07013.x; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Kilburn KH, 1999, ENVIRON RES, V81, P92, DOI 10.1006/enrs.1998.3971; Kim KS, 2003, J NEUROCHEM, V85, P622, DOI 10.1046/j.1471-4159.2003.01671.x; Langlois MC, 2001, NEUROSCIENCE, V106, P117, DOI 10.1016/S0306-4522(01)00248-2; Le W, 1999, J NEUROCHEM, V73, P2218; Lee MA, 2002, NEUROSCI LETT, V333, P74, DOI 10.1016/S0304-3940(02)00981-3; Liou HH, 1997, NEUROLOGY, V48, P1583, DOI 10.1212/WNL.48.6.1583; Manning-Bog AB, 2002, J BIOL CHEM, V277, P1641, DOI 10.1074/jbc.C100560200; MARKING LL, 1988, INVESTIGATIONS FISH, V94, P1; McCormack AL, 2002, NEUROBIOL DIS, V10, P119, DOI 10.1006/nbdi.2002.0507; McCrank E, 1996, CAN J NEUROL SCI, V23, P157, DOI 10.1017/S0317167100038932; Nishino H, 2000, J NEUROTRAUM, V17, P251, DOI 10.1089/neu.2000.17.251; Perier C, 2003, TRENDS NEUROSCI, V26, P345, DOI 10.1016/S0166-2236(03)00144-9; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264; RIVEST S, 1994, J NEUROENDOCRINOL, V6, P101, DOI 10.1111/j.1365-2826.1994.tb00559.x; Saucedo-Cardenas O, 1998, P NATL ACAD SCI USA, V95, P4013, DOI 10.1073/pnas.95.7.4013; SCHERERSINGLER U, 1983, J NEUROSCI METH, V9, P229, DOI 10.1016/0165-0270(83)90085-7; Schmued LC, 1997, BRAIN RES, V751, P37, DOI 10.1016/S0006-8993(96)01387-X; Seidler A, 1996, NEUROLOGY, V46, P1275, DOI 10.1212/WNL.46.5.1275; Sherer TB, 2003, EXP NEUROL, V179, P9, DOI 10.1006/exnr.2002.8072; St-Hilaire M, 2003, NEUROBIOL DIS, V14, P98, DOI 10.1016/S0969-9961(03)00081-0; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thiffault C, 2000, BRAIN RES, V885, P283, DOI 10.1016/S0006-8993(00)02960-7; Vila M, 2001, P NATL ACAD SCI USA, V98, P2837, DOI 10.1073/pnas.051633998; WINDHOLZ M, 1976, MERCK INDEX ENCY CHE, V1071; ZAYED J, 1990, CAN J NEUROL SCI, V17, P286, DOI 10.1017/S0317167100030584; Zetterstrom RH, 1997, SCIENCE, V276, P248, DOI 10.1126/science.276.5310.248	54	140	145	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					717	+		10.1096/fj.03-0677fje	http://dx.doi.org/10.1096/fj.03-0677fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14766796				2022-12-28	WOS:000220425000043
J	Garrison, HH; Gerbi, SA; Kincade, PW				Garrison, HH; Gerbi, SA; Kincade, PW			In an era of scientific opportunity, are there opportunities for biomedical scientists?	FASEB JOURNAL			English	Article						NIH; training; postdoctoral; employment	EDUCATION	Has the dramatic growth in the NIH budget affected the training and production of biomedical Ph.D.s? Examination of new survey data reveals surprising findings. Despite the need for an increased workforce to carry out the expansion in biomedical research, there has not been an increase in new U.S. doctorates awarded, and time-to-degree in the biomedical sciences is no longer increasing. Furthermore, both the frequency and length of postdoctoral appointments are decreasing for U.S. biomedical science recipients. There has been, however, continued growth in the number of foreign postdoctorals. Industrial employment of biomedical scientists continues to increase, but there has been only modest growth in tenured or tenure-track academic jobs.	Federat Amer Soc Expt Biol, Bethesda, MD 20814 USA; Brown Univ, Div Biol & Med, Providence, RI 02912 USA; Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA	Brown University; Oklahoma Medical Research Foundation	Garrison, HH (corresponding author), Federat Amer Soc Expt Biol, 9650 Rockville Pike, Bethesda, MD 20814 USA.	hgarrison@opa.faseb.org		Garrison, Howard/0000-0001-9455-3527				*FED AM SOC EXP BI, 1997, GRAD ED CONS C REP; Freeman R, 2001, SCIENCE, V294, P2293, DOI 10.1126/science.1067477; Garrison HH, 1998, FASEB J, V12, P139, DOI 10.1096/fasebj.12.2.139; Gerbi SA, 2001, SCIENCE, V292, P1489, DOI 10.1126/science.1059268; GOLDMAN CA, 2001, PH D FACTORY TRAININ; Hecker DE, 2001, MON LABOR REV, V124, P57; Kennedy D, 2002, SCIENCE, V298, P323, DOI 10.1126/science.298.5592.323; Marincola E, 1998, SCIENCE, V281, P645, DOI 10.1126/science.281.5377.645; *NAT POSTD ASS, 2003, POL REC NAT I HLTH; *NAT RES COUNC, 1994, FUND YOUNG INV BIOL; *NAT SCI FDN, 2003, GRAD STUD POSTD SCI; National Research Council, 1998, TRENDS EARL CAR LIF; *NIH, 2003, NIH STAT RESP ADDR N; *PHARM RES MAN ASS, 2002, IND PROF; The National Research Council, 2000, ADDR NAT CHANG NEEDS; Zumeta W, 2002, ISSUES SCI TECHNOL, V19, P36	16	14	14	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2169	2173		10.1096/fj.03-0836life	http://dx.doi.org/10.1096/fj.03-0836life			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14525935				2022-12-28	WOS:000188067500035
J	Sredni, B; Gal, R; Cohen, IJ; Dazard, JE; Givol, D; Gafter, U; Motro, B; Eliyahu, S; Albeck, M; Lander, HM; Kalechman, Y				Sredni, B; Gal, R; Cohen, IJ; Dazard, JE; Givol, D; Gafter, U; Motro, B; Eliyahu, S; Albeck, M; Lander, HM; Kalechman, Y			Hair growth induction by the tellurium immunomodulator AS101: association with delayed terminal differentiation of follicular keratinocytes and ras-dependent up-regulation of KGF expression	FASEB JOURNAL			English	Article						KGF; hair; P21(waf); P21(ras); AS101	PROTECTIVE ROLE; MURINE MODEL; TNF-ALPHA; MICE; MOUSE; NUDE; SKIN; COMBINATION; ALOPECIA; PROTEIN	The synthetic immunomodulator AS101 {ammonium trichloro(dioxoethylene-o,o')tellurate} was previously found to protect cancer patients from chemotherapy-induced bone marrow toxicity and alopecia. Here we show that AS101 induces hair growth in nude and normal mice. AS101 possesses the dual ability to both induce anagen and retard spontaneous catagen in the C57BL/6 mouse model. Anagen induced by AS101 is mediated by keratinocyte growth factor (KGF), as it is abrogated both in nude mice co-treated with AS101 plus neutralizing anti KGF antibodies and in AS101-treated transgenic mice expressing a dominant-negative KGF receptor transgene in basal keratinocytes. AS101 up-regulates KGF expression by activating the ras signaling pathway in cultured fibroblasts. AS101-induced delayed catagen is associated with inhibition of terminal differentiation marker expression both in nude and C57BL/6 mice epidermal follicular keratinocytes and in cultures of primary mouse follicular keratinocytes induced to differentiate. This activity is associated with relatively sustained elevation of p21(waf). Delayed expression of terminal differentiation markers was not induced by AS101 in follicular keratinocytes from p21(waf) knockout mice. Because similar results were obtained with cultures of primary human keratinocytes and fibroblasts, preliminary case report studies revealed substantial hair growth when AS101 was topically applied on three adolescents who had remained alopeciac 1-2 years after chemotherapy. The results emphasize the unique mode of action of AS101 and highlight its potential clinical use for treating certain types of alopecia.	Bar Ilan Univ, Fac Life Sci, CAIR Inst, IL-52900 Ramat Gan, Israel; Rabin Med Ctr, Dept Pathol, IL-49372 Petah Tiqwa, Israel; Rabin Med Ctr, Dept Nephrol, IL-49372 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Rabin Med Ctr, Schneider Childrens Med Ctr Israel, Inst Pediat Hematol Oncol, IL-49372 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cornell Univ, Coll Med, Dept Biochem, New York, NY USA	Bar Ilan University; Rabin Medical Center; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Cornell University	Sredni, B (corresponding author), Bar Ilan Univ, Fac Life Sci, CAIR Inst, IL-52900 Ramat Gan, Israel.	srednib@mail.biu.ac.il	Cohen, Ian/H-3358-2013; /ABF-8487-2022					ANDERSON TD, 1993, INT REV EXP PATHOL, V34, P9; Andreadis ST, 2001, FASEB J, V15, P898, DOI 10.1096/fj.00-0324com; Botchkareva NV, 2000, AM J PATHOL, V156, P1041, DOI 10.1016/S0002-9440(10)64972-3; BRISSETT JL, 1966, GENE DEV, V10, P2212; CAIRNS JI, 1989, J INVEST DERMATOL, V92, P410; CAMPBELLBURK SL, 1995, METHOD ENZYMOL, V255, P3; DANILENKO DM, 1995, AM J PATHOL, V147, P145; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DUCROS DL, 1993, J INVEST DERMATOL, V101, pS106, DOI 10.1111/1523-1747.ep12363020; FLANAGAN SP, 1966, GENET RES, V8, P295, DOI 10.1017/S0016672300010168; Frank J, 1999, NATURE, V398, P473, DOI 10.1038/18997; FUCHS E, 1993, J CELL SCI, P197; Guo LF, 1996, GENE DEV, V10, P165, DOI 10.1101/gad.10.2.165; Hines MD, 1996, J BIOL CHEM, V271, P6245, DOI 10.1074/jbc.271.11.6245; JINDO T, 1994, J INVEST DERMATOL, V103, P306, DOI 10.1111/1523-1747.ep12394731; Kalechman Y, 1997, J IMMUNOL, V159, P2658; KALECHMAN Y, 1995, BLOOD, V85, P1555, DOI 10.1182/blood.V85.6.1555.bloodjournal8561555; Kalechman Y, 1996, J IMMUNOL, V156, P1101; KALECHMAN Y, 1993, CANCER RES, V53, P5962; Kalechman Y, 2000, INT J CANCER, V86, P281, DOI 10.1002/(SICI)1097-0215(20000415)86:2<281::AID-IJC20>3.0.CO;2-X; Kalechman Y, 2002, J IMMUNOL, V169, P384, DOI 10.4049/jimmunol.169.1.384; KALECHMAN Y, 1991, CANCER RES, V51, P1499; KALECHMAN Y, 1990, J IMMUNOL, V145, P1512; KOPFMAIER P, 1990, ACTA ANAT, V139, P178; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; Lindner G, 1997, AM J PATHOL, V151, P1601; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; Pantelouris E M, 1973, Differentiation, V1, P437, DOI 10.1111/j.1432-0436.1973.tb00143.x; Paus R, 1996, ARCH DERMATOL RES, V288, P408, DOI 10.1007/s004030050072; Paus R, 1999, J INVEST DERM SYMP P, V4, P338, DOI 10.1038/sj.jidsp.5640241; Paus R, 1999, NEW ENGL J MED, V341, P491, DOI 10.1056/NEJM199908123410706; PAUS R, 1996, CURR OPIN DERMATOL, V3, P248; Paus Ralf, 1998, Journal of Dermatology (Tokyo), V25, P793; Rosenquist TA, 1996, DEV DYNAM, V205, P379, DOI 10.1002/(SICI)1097-0177(199604)205:4<379::AID-AJA2>3.0.CO;2-F; SREDNI B, 1987, NATURE, V330, P173, DOI 10.1038/330173a0; Sredni B, 1996, J NATL CANCER I, V88, P1276, DOI 10.1093/jnci/88.18.1276; SREDNI B, 1995, J CLIN ONCOL, V13, P2342, DOI 10.1200/JCO.1995.13.9.2342; Sredni B, 1996, INT J CANCER, V65, P97, DOI 10.1002/(SICI)1097-0215(19960103)65:1<97::AID-IJC17>3.0.CO;2-F; Stenn KS, 1996, DERMATOL CLIN, V14, P543, DOI 10.1016/S0733-8635(05)70383-1; Strassmann G, 1997, CELL IMMUNOL, V176, P180, DOI 10.1006/cimm.1997.1087; TANIGAKI N, 1990, ARCH DERMATOL RES, V282, P402, DOI 10.1007/BF00372092; TERRELL TG, 1993, INT REV EXP PATHOL, V34, P43; WERNER S, 1994, SCIENCE, V266, P819, DOI 10.1126/science.7973639; WYSOLMERSKI JJ, 1994, P NATL ACAD SCI USA, V91, P1133, DOI 10.1073/pnas.91.3.1133	45	42	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					400	+		10.1096/fj.03-0552fje	http://dx.doi.org/10.1096/fj.03-0552fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656992				2022-12-28	WOS:000188067500031
J	Rouzaud, F; Annereau, JP; Valencia, JC; Costin, GE; Hearing, VJ				Rouzaud, F; Annereau, JP; Valencia, JC; Costin, GE; Hearing, VJ			Regulation of melanocortin 1 receptor expression at the mRNA and protein levels by its natural agonist and antagonist	FASEB JOURNAL			English	Article						promoter; 5 ' untranslated region (5 ' UTR); melanocyte; translation	MELANOCYTE-STIMULATING-HORMONE; AGOUTI SIGNALING PROTEIN; TRANSLATIONAL CONTROL; POINT MUTATIONS; MSH RECEPTORS; IN-VITRO; GENES; INITIATION; CELLS; HYPOTHALAMUS	Five melanocortin receptors, which form a subfamily of G protein-coupled receptors, are expressed in mammalian tissues and regulate such diverse physiological processes as pigmentation, adrenal function, energy homeostasis, feeding efficiency, and sebaceous gland lipid production, as well as immune and sexual function. Pigmentation in mammals is stimulated by alpha-melanocyte stimulating hormone (MSH), which binds to the melanocortin 1 receptor (Mclr) and induces an activation of melanogenic enzymes through stimulation of adenylate cyclase and protein kinase A. The antagonist agouti signal protein (ASP) interacts with the Mclr and blocks its stimulation by MSH. We examined the influence of ASP or MSH on Mclr gene expression, and we report that both ligands influence the Mclr 5' promoter structure in distinct manners. Our study further shows that MSH regulates Mclr function at both the mRNA and protein levels, whereas ASP acts only on its translation.	NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hearing, VJ (corresponding author), NCI, Cell Biol Lab, NIH, Bldg 37,Room 1B25, Bethesda, MD 20892 USA.	hearingv@nih.gov			DIVISION OF BASIC SCIENCES - NCI [Z01BC009100] Funding Source: NIH RePORTER	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Malek ZA, 2001, J CELL SCI, V114, P1019; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; Bray GA, 2000, NATURE, V404, P672, DOI 10.1038/35007544; Broberger C, 1998, J COMP NEUROL, V402, P460; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; CHAKRABORTY A, 1995, J INVEST DERMATOL, V105, P655, DOI 10.1111/1523-1747.ep12324134; CHAKRABORTY AK, 1992, BIOCHEM BIOPH RES CO, V188, P1325, DOI 10.1016/0006-291X(92)91376-2; CONE RD, 1993, MELANOTROPIC PEPTIDE, P342; COSTIN GE, 2003, IN PRESS J CELL SCI; Curry JD, 2001, BRIT J HAEMATOL, V115, P826, DOI 10.1046/j.1365-2141.2001.03190.x; Davuluri RV, 2000, GENOME RES, V10, P1807, DOI 10.1101/gr.GR-1460R; Elias CF, 1998, J COMP NEUROL, V402, P442, DOI 10.1002/(SICI)1096-9861(19981228)402:4<442::AID-CNE2>3.0.CO;2-R; Furumura M, 1998, P NATL ACAD SCI USA, V95, P7374, DOI 10.1073/pnas.95.13.7374; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; GESCHWIND II, 1966, ENDOCRINOLOGY, V79, P1165, DOI 10.1210/endo-79-6-1165; Haskell-Luevano C, 1999, ENDOCRINOLOGY, V140, P1408, DOI 10.1210/en.140.3.1408; HINNEBUSCH AG, 1990, TRENDS BIOCHEM SCI, V15, P148, DOI 10.1016/0968-0004(90)90215-W; Huang QH, 1999, AM J PHYSIOL-REG I, V276, pR864, DOI 10.1152/ajpregu.1999.276.3.R864; HUNT G, 1995, J ENDOCRINOL, V147, pR1, DOI 10.1677/joe.0.147R001; JACKSON IJ, 1993, NATURE, V362, P587, DOI 10.1038/362587a0; Jean S, 2001, BBA-GENE STRUCT EXPR, V1522, P89, DOI 10.1016/S0167-4781(01)00326-8; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1994, BIOCHIMIE, V76, P815, DOI 10.1016/0300-9084(94)90182-1; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LU DS, 1994, NATURE, V371, P799, DOI 10.1038/371799a0; MacNeil DJ, 2002, EUR J PHARMACOL, V450, P91, DOI 10.1016/S0014-2999(02)01989-1; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; MOUNTJOY KG, 1992, SCIENCE, V257, P1248, DOI 10.1126/science.1325670; Ollmann MM, 1997, SCIENCE, V278, P135, DOI 10.1126/science.278.5335.135; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; ROBBINS LS, 1993, CELL, V72, P827, DOI 10.1016/0092-8674(93)90572-8; Sakai C, 1997, EMBO J, V16, P3544, DOI 10.1093/emboj/16.12.3544; Scott MC, 2002, PIGM CELL RES, V15, P433, DOI 10.1034/j.1600-0749.2002.02051.x; Searle A.G., 1968, COMP GENETICS COAT C; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; Siegrist W, 1997, J RECEPT SIGNAL TR R, V17, P75, DOI 10.3109/10799899709036595; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; Slominski A, 2000, PHYSIOL REV, V80, P979, DOI 10.1152/physrev.2000.80.3.979; SMITH AI, 1988, ENDOCR REV, V9, P159, DOI 10.1210/edrv-9-1-159; Suzuki I, 1997, J INVEST DERMATOL, V108, P838, DOI 10.1111/1523-1747.ep12292572; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; Toyofuku K, 2001, FASEB J, V15, P2149, DOI 10.1096/fj.01-0216com; Valencia JC, 2001, J INVEST MED, V49, P421, DOI 10.2310/6650.2001.33787; Vergoni AV, 1999, EUR J PHARMACOL, V369, P11, DOI 10.1016/S0014-2999(99)00045-X; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; Wickens M, 1997, CURR OPIN GENET DEV, V7, P220, DOI 10.1016/S0959-437X(97)80132-3; Yang YK, 1999, MOL ENDOCRINOL, V13, P148, DOI 10.1210/me.13.1.148; ZUCKER M, 1999, ALGORITHMS THERMODYN	52	36	37	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2154	+		10.1096/fj.03-0206fje	http://dx.doi.org/10.1096/fj.03-0206fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500544				2022-12-28	WOS:000185925100010
J	Hertig, A; Berrou, J; Allory, Y; Breton, L; Commo, F; De Beauregard, MAC; Carmeliet, P; Rondeau, E				Hertig, A; Berrou, J; Allory, Y; Breton, L; Commo, F; De Beauregard, MAC; Carmeliet, P; Rondeau, E			Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta	FASEB JOURNAL			English	Article						antiglomerular basement membrane disease; thrombin; fibrinolysis; serpins; Th1 cells	INDUCED PULMONARY-FIBROSIS; CRESCENTIC GLOMERULONEPHRITIS; MICE; NEPHRITIS; SYSTEM; GENE; GENERATION; PREVENTS; PROTECTS; RECEPTOR	Type 1 plasminogen activator inhibitor (PAI-1) is the primary inhibitor of tissue-type plasminogen activator (tPA) and urokinase-type plasminogen activator (uPA). Whereas PAI-1 is not expressed in normal kidneys, it is strongly induced in glomerular diseases and thus could promote the local accumulation of fibrin. To study the role of PAI-1 in the development of inflammatory glomerular injury, passive antiglomerular basement membrane (GBM) glomerulonephritis (GN) was induced in PAI-1 knockout mice and in wild-type mice of the same genetic background. Unexpectedly, PAI-1 deficiency was associated with an early and severe exacerbation of glomerular injury: Infiltration by CD4 T cells, proportion of fibrinous crescents, and renal function impairment were significantly more pronounced in PAI-1 -/- mice. Interestingly, activation of transforming growth factor (TGF)-beta, which is known to be dependent on the PA/plasmin system in vitro, was dramatically enhanced in the kidneys in the absence of PAI-1. Moreover, administration of neutralizing antibodies against TGF-beta significantly attenuated the disease in PAI-1 -/- mice. This suggests that the poor outcome of GN in PAI-1 -/- mice is consecutive to an uncontrolled activation of TGF-beta and confers PAI-1 with a new, immunomodulatory role.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Hop Tenon, Assoc Claude Bernard, F-75020 Paris, France; Hop Tenon, Dept Pathol, F-75020 Paris, France; Hop Tenon, Dept Nephrol A, F-75020 Paris, France; Flanders Interuniv Inst Biotechnol, Ctr Transgene Technol & Gene Therapy, Louvain, Belgium	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite	Rondeau, E (corresponding author), INSERM, U489, 4 Rue Chine, F-75020 Paris, France.	eric.rondeau@tnn.ap-hop-paris.fr	Carmeliet, Peter/AAQ-5140-2020	Carmeliet, Peter/0000-0001-7961-1821				CARMELIET P, 1993, J CLIN INVEST, V92, P2746, DOI 10.1172/JCI116892; Cunningham MA, 2000, J EXP MED, V191, P455, DOI 10.1084/jem.191.3.455; Dewerchin M, 2001, THROMB HAEMOSTASIS, V86, P640; Drew AF, 2001, AM J PHYSIOL-RENAL, V281, pF1157, DOI 10.1152/ajprenal.0002.2001; Eddy AA, 2002, AM J PHYSIOL-RENAL, V283, pF209, DOI 10.1152/ajprenal.00032.2002; Eitzman DT, 2000, BLOOD, V96, P4212; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; FENG LL, 1993, J AM SOC NEPHROL, V3, P1753; FOUQUERAY B, 1996, J AM SOC NEPHROL, V7, P1968; Godar S, 1999, EUR J IMMUNOL, V29, P1004, DOI 10.1002/(SICI)1521-4141(199903)29:03<1004::AID-IMMU1004>3.0.CO;2-Q; GRAINGER DJ, 1994, NATURE, V370, P460, DOI 10.1038/370460a0; Haraguchi M, 2001, KIDNEY INT, V59, P2146, DOI 10.1046/j.1523-1755.2001.00729.x; Hattori N, 2000, J CLIN INVEST, V106, P1341, DOI 10.1172/JCI10531; Kanamaru Y, 2001, J IMMUNOL, V166, P2818, DOI 10.4049/jimmunol.166.4.2818; Kitching AR, 2000, HISTOL HISTOPATHOL, V15, P993, DOI 10.14670/HH-15.993; Kitching AR, 1997, J EXP MED, V185, P963, DOI 10.1084/jem.185.5.963; Lelongt B, 2001, J EXP MED, V193, P793, DOI 10.1084/jem.193.7.793; Luttun A, 2002, ARTERIOSCL THROM VAS, V22, P499, DOI 10.1161/hq0302.104529; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; MAKINO H, 1988, KIDNEY INT, V34, P195, DOI 10.1038/ki.1988.165; Marty I, 2001, J CLIN INVEST, V107, P631, DOI 10.1172/JCI11064; McCormick LL, 1999, J IMMUNOL, V163, P5693; NEALE TJ, 1988, LANCET, V2, P421; Oda T, 2001, KIDNEY INT, V60, P587, DOI 10.1046/j.1523-1755.2001.030002587.x; Rerolle JP, 2000, KIDNEY INT, V58, P1841, DOI 10.1046/j.1523-1755.2000.00355.x; RIFKIN DB, 1990, CELL DIFFER DEV, V32, P313, DOI 10.1016/0922-3371(90)90045-X; RONDEAU E, 1990, CLIN NEPHROL, V33, P55; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; VILLAMEDIANA LM, 1990, KIDNEY INT, V38, P956, DOI 10.1038/ki.1990.297; Xu YC, 1996, KIDNEY INT, V50, P2011, DOI 10.1038/ki.1996.523; Yang JW, 2002, J CLIN INVEST, V110, P1525, DOI 10.1172/JC1200216219; ZOJA C, 1990, LAB INVEST, V62, P34	32	51	55	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1904	+		10.1096/fj.03-0084fje	http://dx.doi.org/10.1096/fj.03-0084fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897066				2022-12-28	WOS:000185345100024
J	Liu, ZJ; Snyder, R; Soma, A; Shirakawa, T; Ziober, BL; Fairman, RM; Herlyn, M; Velazquez, OC				Liu, ZJ; Snyder, R; Soma, A; Shirakawa, T; Ziober, BL; Fairman, RM; Herlyn, M; Velazquez, OC			VEGF-A and alpha(V)beta(3) integrin synergistically rescue angiogenesis via N-Ras and PI3-K signaling in human microvascular endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; VEGF-A; alpha(V)beta(3) integrin; N-Ras; PI3-K	GROWTH-FACTOR; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; HUMAN-MELANOMA; ACTIVATION; TRANSDUCTION; PATHWAY; BINDING; RAF-1; AKT	We recently showed that normal fibroblasts mediate capillary-like differentiation of human microvascular endothelial cells (HMVEC) in a 3-D angiogenesis model. Here, we show that a collaborative effect of VEGF-A and alpha(v)beta(3) integrin is critical in fibroblast-mediated angiogenesis because enhancement of both VEGF production by fibroblasts and beta(3) integrin expression in HMVEC can rescue capillary-like endothelial differentiation under reduced serum conditions. To investigate the downstream signaling mechanisms, we compared N-Ras and Rho/Rac/Cdc42, as well as phosphatidylinositol 3-kinase (PI3-K) and Akt, for their involvement in the capillary-like network formation. The dominant-negative mutant of N-Ras (N-Ras(N17)), but not the mutants of Rho/Rac/Cdc42, suppressed network formation. Overexpression of a constitutively active form of PI3-K rescued the network formation, which was inhibited by a dominant-negative beta(3) integrin; however, an active form of Akt failed to rescue the inhibition but induced a phenotypic change in HMVEC. Moreover, PI3-K is a downstream target of N-Ras because it could be coimmunoprecipitated with N-Ras, and its active form could rescue the inhibitory effect of N-Ras (N17). Thus, our data indicate the existence of N-Ras- and PI3-K-dependent but Rho/Rac/Cdc42- and Akt-independent signaling mechanisms for the synergistic effect of VEGF-A and alpha(v)beta(3) on fibroblast-mediated microvascular network formation.	Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Otorhinolaryngol, Philadelphia, PA 19104 USA	University of Pennsylvania; The Wistar Institute; University of Pennsylvania	Velazquez, OC (corresponding author), Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA.	omaida.velazquez@uphs.upenn.edu						Amerongen GPV, 2001, ARTERIOSCL THROM VAS, V21, P300, DOI 10.1161/01.ATV.21.3.300; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bialkowska K, 2000, J CELL BIOL, V151, P685, DOI 10.1083/jcb.151.3.685; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Cullen PJ, 2001, CURR BIOL, V11, pR342, DOI 10.1016/S0960-9822(01)00189-0; Downward J, 1997, ADV SEC MESS PHOSPH, V31, P1; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ferrara N, 1999, CURR TOP MICROBIOL, V237, P1; Garcia JGN, 2001, J CLIN INVEST, V108, P689, DOI 10.1172/JCI12450; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; Hsu MY, 1998, AM J PATHOL, V153, P1435, DOI 10.1016/S0002-9440(10)65730-6; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; IMCKE E, 1991, ARCH DERMATOL RES, V283, P149, DOI 10.1007/BF00372054; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; KIKUCHI A, 1994, MOL CELL BIOL, V14, P7483, DOI 10.1128/MCB.14.11.7483; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Liu ZJ, 1998, MOL CELL BIOL, V18, P3445, DOI 10.1128/MCB.18.6.3445; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Meadows KN, 2001, J BIOL CHEM, V276, P49289, DOI 10.1074/jbc.M108069200; Meier F, 2000, AM J PATHOL, V156, P193, DOI 10.1016/S0002-9440(10)64719-0; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nesbit M, 1999, ONCOGENE, V18, P6469, DOI 10.1038/sj.onc.1203066; Olson MF, 2000, SEMIN IMMUNOL, V12, P63, DOI 10.1006/smim.2000.0208; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; Ridley AJ, 2001, FEBS LETT, V498, P168, DOI 10.1016/S0014-5793(01)02481-4; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; SHATTIL SJ, 1995, THROMB HAEMOSTASIS, V74, P149; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Soga N, 2001, EXP CELL RES, V269, P73, DOI 10.1006/excr.2001.5295; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; VAN AL, 1993, P NATL ACAD SCI USA, V90, P6213; Velazquez OC, 2002, FASEB J, V16, P1316, DOI 10.1096/fj.01-1011fje; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	60	29	31	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1931	+		10.1096/fj.02-1171fje	http://dx.doi.org/10.1096/fj.02-1171fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	14519669				2022-12-28	WOS:000185345100008
J	Moccia, F; Lim, D; Nusco, GA; Ercolano, E; Santella, L				Moccia, F; Lim, D; Nusco, GA; Ercolano, E; Santella, L			NAADP activates a Ca2+ current that is dependent on F-actin cytoskeleton	FASEB JOURNAL			English	Article						Ca2+ imaging; electrophysiology; nicotinic acid adenine dinucleotide phosphate	ADENINE-DINUCLEOTIDE PHOSPHATE; CYCLIC ADP-RIBOSE; PANCREATIC BETA-CELLS; INOSITOL TRISPHOSPHATE; STARFISH OOCYTES; INTRACELLULAR CA2+; ASCIDIAN OOCYTES; CALCIUM-RELEASE; FERTILIZATION; CHANNELS	Nicotinic acid adenine dinucleotide phosphate (NAADP) is involved in the Ca2+ response observed at fertilization in several species, including starfish. In this study, we have employed Ca2+ imaging and the single-electrode voltage-clamp technique to investigate whether the NAADP-mediated Ca2+ entry discovered in our laboratory in starfish oocytes was underlain by a membrane current and whether the response to NAADP required an intact cytoskeleton. Uncaging of preinjected NAADP evoked a cortical Ca2+ flash that was followed by the spreading of the wave to the remainder of the cell. No Ca2+ increase was detected in Ca2+-free sea water. Under voltage-clamp conditions, the photoliberation of NAADP activated an inward rectifying membrane current, which reversed at potentials more positive than + 50 mV and was abolished by removal of Ca2+ but not of Na+. The current was affected by preincubation with verapamil, SK& F 96356, and thapsigargin but not by preinjection of heparin, 8-NH2- cyclic ADP-ribose, or both antagonists. The membrane current and the Ca2+ wave were inhibited by latrunculin-A and jasplakinolide, which depolymerize and stabilize actin cytoskeleton, respectively. These data offer the first demonstration that NAADP initiates a Ca2+ sweep by activating a Ca2+-permeable membrane current that requires an intact F-actin cytoskeleton as other Ca2+-permeable currents, such as I-CRAC and I-ARC.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy	Stazione Zoologica Anton Dohrn di Napoli	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, Villa Comunale, I-80121 Naples, Italy.	santella@szn.it	Santella, Luigia/AAM-3524-2020; Moccia, Francesco/AAX-6447-2020; Lim, Dmitry/H-9101-2012	Santella, Luigia/0000-0001-7159-0499; Moccia, Francesco/0000-0003-0010-0098; 				Albrieux M, 1998, J BIOL CHEM, V273, P14566, DOI 10.1074/jbc.273.23.14566; Bak J, 2002, BIOCHEM BIOPH RES CO, V295, P806, DOI 10.1016/S0006-291X(02)00761-1; Bak J, 2001, CURR BIOL, V11, P987, DOI 10.1016/S0960-9822(01)00269-X; Baumann O, 2001, NEUROSCI LETT, V306, P181, DOI 10.1016/S0304-3940(01)01900-0; Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Berridge G, 2002, J BIOL CHEM, V277, P43717, DOI 10.1074/jbc.M203224200; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Billington RA, 2002, J PHYSIOL-LONDON, V544, P107, DOI 10.1113/jphysiol.2002.030098; Bozem M, 2000, CELL CALCIUM, V28, P73, DOI 10.1054/ceca.2000.0133; Brailoiu E, 2001, MOL PHARMACOL, V60, P718; Cancela JM, 1999, NATURE, V398, P74, DOI 10.1038/18032; Cancela JM, 2000, EMBO J, V19, P2549, DOI 10.1093/emboj/19.11.2549; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Carlier MF, 1997, J MOL BIOL, V269, P459, DOI 10.1006/jmbi.1997.1062; Churchill GC, 2003, CURR BIOL, V13, P125, DOI 10.1016/S0960-9822(03)00002-2; Churchill GC, 2001, EMBO J, V20, P2666, DOI 10.1093/emboj/20.11.2666; Churchill GC, 2002, CELL, V111, P703, DOI 10.1016/S0092-8674(02)01082-6; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Genazzani AA, 1997, BRIT J PHARMACOL, V121, P1489, DOI 10.1038/sj.bjp.0701295; Gerasimenko J, 2003, BIOCHEM SOC T, V31, P76, DOI 10.1042/bst0310076; Glogauer M, 1997, J CELL SCI, V110, P11; Hille B., 1992, IONIC CHANNELS EXCIT; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Inoue I, 2002, J PHYSIOL-LONDON, V541, P769, DOI 10.1113/jphysiol.2002.019638; JOHNSON BD, 1993, NEURON, V10, P797, DOI 10.1016/0896-6273(93)90196-X; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Lader AS, 1999, AM J PHYSIOL-CELL PH, V277, pC1277, DOI 10.1152/ajpcell.1999.277.6.C1277; LANSMAN JB, 1983, J PHYSIOL-LONDON, V345, P353, DOI 10.1113/jphysiol.1983.sp014982; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; Lee HC, 2000, J CELL SCI, V113, P4413; Lim D, 2002, FASEB J, V16, P1050, DOI 10.1096/fj.02-0021com; Lim D, 2001, FASEB J, V15, P2257, DOI 10.1096/fj.01-0157com; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; MIYAZAKI S, 1979, DEV BIOL, V70, P327, DOI 10.1016/0012-1606(79)90031-9; MIYAZAKI SI, 1975, J PHYSIOL-LONDON, V246, P55, DOI 10.1113/jphysiol.1975.sp010880; MOCCIA F, 2003, IN PRESS PFLUGERS AR; Nusco GA, 2002, BIOCHEM BIOPH RES CO, V290, P1015, DOI 10.1006/bbrc.2001.6286; Patel S, 2003, BIOESSAYS, V25, P430, DOI 10.1002/bies.10276; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Rueckschloss U, 2001, J PHYSIOL-LONDON, V537, P363, DOI 10.1111/j.1469-7793.2001.00363.x; Sabala P, 2002, BIOCHEM BIOPH RES CO, V296, P484, DOI 10.1016/S0006-291X(02)00893-8; Santella L, 2000, J BIOL CHEM, V275, P8301, DOI 10.1074/jbc.275.12.8301; Vazquez G, 2002, EMBO J, V21, P4531, DOI 10.1093/emboj/cdf467; Wang YJ, 2002, BIOCHEM J, V363, P117, DOI 10.1042/0264-6021:3630117; Wilding M, 1998, AM J PHYSIOL-CELL PH, V275, pC1277, DOI 10.1152/ajpcell.1998.275.5.C1277	48	58	61	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1907	+		10.1096/fj.03-0178fje	http://dx.doi.org/10.1096/fj.03-0178fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12923070				2022-12-28	WOS:000185345100004
J	Hansen, HP; Recke, A; Reineke, U; von Tresckow, B; Borchmann, P; von Strandmann, EP; Lange, H; Lemke, H; Engert, A				Hansen, HP; Recke, A; Reineke, U; von Tresckow, B; Borchmann, P; von Strandmann, EP; Lange, H; Lemke, H; Engert, A			Ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5	FASEB JOURNAL			English	Article						shedding regulation; TACE; metalloproteinase; TNFR superfamily	ALPHA-CONVERTING-ENZYME; NECROSIS-FACTOR-ALPHA; REED-STERNBERG CELLS; HODGKINS-DISEASE; EXTRACELLULAR DOMAINS; MONOCLONAL-ANTIBODY; LYMPHOID-CELLS; TNF RECEPTORS; LIGAND; EXPRESSION	Tumor necrosis factor (TNF)-alpha converting enzyme ( TACE) is responsible for the ectodomain release of various membrane proteins by proteolytic cleavage in close proximity to the cell membrane. Despite the wide spectrum of possible substrates, selective cleavage can be achieved by substrate cross-linking. To explore the underlying mechanism, we studied the TACE-mediated shedding of CD30. Whereas the constitutive release of the soluble ectodomain of CD30 (sCD30) from the lymphoma cell line Karpas 299 was enhanced by most anti-CD30 antibodies, it was inhibited by antibodies Ber-H2 and Ki-4. On the basis of the recognized epitopes, shedding seemed to depend on the availability of the cysteine-rich domains (CRD) 2 and 5 of the CD30 ectodomain. CRD2 and 5 have almost identical amino acid sequences and are localized distant from the TACE-targeted cleavage site. Soluble CD30, the product of this enzyme reaction, did not inhibit, but on the contrary, it stimulated CD30 shedding in a CRD2/5-dependent manner. This process could also be induced by CRD2/5-derived peptides but not by a CRD1-derived control peptide. This example of a product-activation was CD30 selective since other TACE substrates such as TNFR1 or TNF-alpha were not affected. These data suggest that CD30 shedding is stimulated by an elevated local availability of CRD2 or 5, possibly by forming a docking station for the releasing enzyme through substrate aggregation.	Univ Hosp Cologne, Dept Internal Med 1, LFI, D-50924 Cologne, Germany; Univ Kiel, Dept Biochem, Kiel, Germany; Jerini AG, Berlin, Germany	University of Cologne; University of Kiel; Shire Pharmaceuticals Limited	Hansen, HP (corresponding author), Univ Hosp Cologne, Dept Internal Med 1, LFI, Ebene 4,Room 703,Joseph Stelzmann Str 9, D-50924 Cologne, Germany.	h.hansen@uni-koeln.de	Recke, Andreas/C-8963-2009	Recke, Andreas/0000-0002-7674-1804				Althoff K, 2000, EUR J BIOCHEM, V267, P2624, DOI 10.1046/j.1432-1327.2000.01278.x; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; DELLO SP, 2002, BIOL CHEM, V383, P69; Doedens JR, 2003, BIOCHEM BIOPH RES CO, V308, P331, DOI 10.1016/S0006-291X(03)01381-0; Dong LY, 2003, J MOL RECOGNIT, V16, P28, DOI 10.1002/jmr.605; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; GRUSS HJ, 1994, BLOOD, V83, P2045; HANSEN HP, 1995, INT J CANCER, V63, P750, DOI 10.1002/ijc.2910630524; Hansen HP, 2000, J IMMUNOL, V165, P6703, DOI 10.4049/jimmunol.165.12.6703; Hargreaves PG, 2002, EUR J IMMUNOL, V32, P163, DOI 10.1002/1521-4141(200201)32:1<163::AID-IMMU163>3.0.CO;2-T; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Horie R, 1998, SEMIN IMMUNOL, V10, P457, DOI 10.1006/smim.1998.0156; Horie R, 2002, ONCOGENE, V21, P2493, DOI 10.1038/sj.onc.1205337; HORNLOHRENS O, 1995, INT J CANCER, V60, P539, DOI 10.1002/ijc.2910600419; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Maskos K, 1998, P NATL ACAD SCI USA, V95, P3408, DOI 10.1073/pnas.95.7.3408; McDermott MF, 1999, CELL, V97, P133, DOI 10.1016/S0092-8674(00)80721-7; Molina MA, 2001, CANCER RES, V61, P4744; Pang S, 2001, BIOCHEM J, V358, P185, DOI 10.1042/0264-6021:3580185; Pinckard JK, 1997, J IMMUNOL, V158, P3869; PORTEU F, 1994, J BIOL CHEM, V269, P2834; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; Sadhukhan R, 1998, P NATL ACAD SCI USA, V95, P138, DOI 10.1073/pnas.95.1.138; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; STEIN H, 1985, BLOOD, V66, P848; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Wiley SR, 1996, J IMMUNOL, V157, P3635	31	27	27	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					893	+		10.1096/fj.03-0901fje	http://dx.doi.org/10.1096/fj.03-0901fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033921				2022-12-28	WOS:000220522800005
J	Ho, L; Qin, WP; Pompl, PN; Xiang, ZM; Wang, J; Zhao, Z; Peng, YZ; Cambareri, G; Rocher, A; Mobbs, CV; Hof, PR; Pasinetti, GM				Ho, L; Qin, WP; Pompl, PN; Xiang, ZM; Wang, J; Zhao, Z; Peng, YZ; Cambareri, G; Rocher, A; Mobbs, CV; Hof, PR; Pasinetti, GM			Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						diabetes; glycogen synthase kinase; beta-amyloid; insulin-degrading enzyme	DEGRADING ENZYME; PRECURSOR PROTEIN; BETA-PROTEIN; IN-VIVO; VASCULAR FACTORS; FOLLOW-UP; MICE; BRAIN; DEMENTIA; POPULATION	Recent epidemiological evidence indicates that insulin resistance, a proximal cause of Type II diabetes [ a non-insulin dependent form of diabetes mellitus (NIDDM)], is associated with an increased relative risk for Alzheimer's disease (AD). In this study we examined the role of dietary conditions leading to NIDDM-like insulin resistance on amyloidosis in Tg2576 mice, which model AD-like neuropathology. We found that diet-induced insulin resistance promoted amyloidogenic beta-amyloid (Abeta) Abeta(1-40) and Abeta(1-42) peptide generation in the brain that corresponded with increased gamma-secretase activities and decreased insulin degrading enzyme (IDE) activities. Moreover, increased Abeta production also coincided with increased AD-type amyloid plaque burden in the brain and impaired performance in a spatial water maze task. Further exploration of the apparent interrelationship of insulin resistance to brain amyloidosis revealed a functional decrease in insulin receptor (IR)-mediated signal transduction in the brain, as suggested by decreased IR beta-subunit (IRbeta) Y-1162/1163 autophosphorylation and reduced phosphatidylinositol 3 (PI3)-kinase/pS(473)-AKT/Protein kinase (PK)-B in these same brain regions. This latter finding is of particular interest given the known inhibitory role of AKT/PKB on glycogen synthase kinase (GSK)-3alpha activity, which has previously been shown to promote Abeta peptide generation. Most interestingly, we found that decreased pS(21)-GSK-3alpha and pS(9)-GSK-3alpha phosphorylation, which is an index of GSK activation, positively correlated with the generation of brain C-terminal fragment (CTF)-gamma cleavage product of amyloid precursor protein, an index of gamma-secretase activity, in the brain of insulin-resistant relative to normoglycemic Tg2576 mice. Our study is consistent with the hypothesis that insulin resistance may be an underlying mechanism responsible for the observed increased relative risk for AD neuropathology, and presents the first evidence to suggest that IR signaling can influence Abeta production in the brain.	CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Kastor Neurobiol Aging Labs, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Fishberg Res Ctr Neurobiol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Geriatr & Adult Dev, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Adv Imaging Program, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Pasinetti, GM (corresponding author), CUNY Mt Sinai Sch Med, Dept Psychiat, Neuroinflammat Res Labs, Box 1230,1 Gustave L Levy Pl, New York, NY 10029 USA.	giulio.pasinetti@mssm.edu		Pasinetti, Giulio/0000-0002-1524-5196; Mobbs, Charles/0000-0002-5815-8711				Barber AJ, 2001, J BIOL CHEM, V276, P32814, DOI 10.1074/jbc.M104738200; Bussiere T, 2002, NEUROSCIENCE, V112, P75, DOI 10.1016/S0306-4522(02)00056-8; Callahan MJ, 2001, AM J PATHOL, V158, P1173, DOI 10.1016/S0002-9440(10)64064-3; CARR TP, 1993, CLIN BIOCHEM, V26, P39, DOI 10.1016/0009-9120(93)90015-X; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Di Iorio A, 1999, AGING CLIN EXP RES, V11, P345, DOI 10.1007/BF03339811; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Gasparini L, 2001, J NEUROSCI, V21, P2561, DOI 10.1523/JNEUROSCI.21-08-02561.2001; Gibbs RB, 2003, J NEUROSCI RES, V74, P637, DOI 10.1002/jnr.10811; Grant W B, 1999, J Alzheimers Dis, V1, P197; Hebert LE, 2003, ARCH NEUROL-CHICAGO, V60, P1119, DOI 10.1001/archneur.60.8.1119; Hof PR, 2000, J COMP NEUROL, V420, P113, DOI 10.1002/(SICI)1096-9861(20000424)420:1<113::AID-CNE8>3.0.CO;2-N; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; Iivonen H, 2003, BEHAV BRAIN RES, V141, P207, DOI 10.1016/S0166-4328(02)00369-8; Johnston AM, 2003, FEBS LETT, V546, P32, DOI 10.1016/S0014-5793(03)00438-1; Kawarabayashi T, 2001, J NEUROSCI, V21, P372, DOI 10.1523/JNEUROSCI.21-02-00372.2001; Kilander L, 1998, HYPERTENSION, V31, P780, DOI 10.1161/01.HYP.31.3.780; Kim JJ, 2002, GROWTH HORM IGF RES, V12, P84, DOI 10.1054/ghir.2002.0265; King DL, 2002, PHYSIOL BEHAV, V75, P627, DOI 10.1016/S0031-9384(02)00639-X; Leibson CL, 1997, AM J EPIDEMIOL, V145, P301; Levin-Allerhand J A, 2002, J Nutr Health Aging, V6, P315; Makimura Hideo, 2003, BMC Physiol, V3, P4, DOI 10.1186/1472-6793-3-4; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Meyer JS, 2000, ANN NY ACAD SCI, V903, P411, DOI 10.1111/j.1749-6632.2000.tb06393.x; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Molteni R, 2002, NEUROSCIENCE, V112, P803, DOI 10.1016/S0306-4522(02)00123-9; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; *NAT I DIAB DIG KI, 2002, NAT DIAB STAT FACT S; Nimchinsky EA, 2000, J COMP NEUROL, V416, P112, DOI 10.1002/(SICI)1096-9861(20000103)416:1<112::AID-CNE9>3.0.CO;2-K; Pansari K, 2002, INT J CLIN PRACT, V56, P197; Pedersen WA, 1999, J MOL NEUROSCI, V13, P159, DOI 10.1385/JMN:13:1-2:159; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Petot GJ, 2003, METABOLISM, V52, P279, DOI 10.1053/meta.2003.50066; Phiel CJ, 2003, NATURE, V423, P435, DOI 10.1038/nature01640; Pyorala M, 2000, ARTERIOSCL THROM VAS, V20, P538, DOI 10.1161/01.ATV.20.2.538; Rajala RVS, 2002, J BIOL CHEM, V277, P43319, DOI 10.1074/jbc.M206355200; Refolo LM, 2000, NEUROBIOL DIS, V7, P321, DOI 10.1006/nbdi.2000.0304; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Shearman MS, 2000, BIOCHEMISTRY-US, V39, P8698, DOI 10.1021/bi0005456; Shie FS, 2002, NEUROREPORT, V13, P455, DOI 10.1097/00001756-200203250-00019; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Stolk RP, 1997, DIABETES CARE, V20, P792, DOI 10.2337/diacare.20.5.792; Takeda K, 2003, J ENDOCRINOL, V176, P237, DOI 10.1677/joe.0.1760237; Tandrup T, 1997, J MICROSC-OXFORD, V186, P108, DOI 10.1046/j.1365-2818.1997.2070765.x; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Xiang ZM, 2002, GENE EXPRESSION, V10, P271, DOI 10.3727/000000002783992352	49	493	522	1	33	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					902	+		10.1096/fj.03-0978fje	http://dx.doi.org/10.1096/fj.03-0978fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033922				2022-12-28	WOS:000220522800006
J	Kobayashi, S; Sawano, A; Nojima, Y; Shibuya, M; Maru, Y				Kobayashi, S; Sawano, A; Nojima, Y; Shibuya, M; Maru, Y			The c-Cb1/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1)	FASEB JOURNAL			English	Article						endocytosis; ubiquitination; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; DEPENDENT DOWN-REGULATION; TYROSINE KINASE; FACTOR RECEPTOR; NEGATIVE REGULATION; CBL; BINDING; FLK-1/KDR; NEPHRIN; FAMILY	Vascular endothelial growth factor (VEGF) and its receptors are key regulators of angiogenesis and are potential targets in cancer therapy. Here we report the down-regulation of activated VEGF receptor (VEGFR)-1/Flt-1 by endocytosis and proteolytic degradation. VEGF stimulation induced a ternary complex of Flt-1, c-Cbl, and CD2AP. Substitution of tyrosine 1333 in Flt-1 with phenylalanine (Y1333F) impaired its binding to c-Cbl. In a transient expression system, VEGF stimulated colocalization of Flt-1, CD2AP, and c-Cbl in endocytic vesicles. This colocalization was significantly impaired by an inhibitor of VEGFR kinase SU5416, the Y1333F mutation in Flt-1, or by a dominant negative form of CD2AP. In Flt-1-overexpressing NIH3T3 cells, expression of the wild-type CD2AP enhanced VEGF-stimulated internalization as well as ubiquitination of Flt-1 whereas that of a mutated form of either CD2AP or c-Cbl failed to do so. These results suggest that the c-Cbl/CD2AP complex binds to activated Flt-1 and plays a crucial role in its endocytosis and subsequent degradation.	Tokyo Womens Med Univ Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan; Univ Tokyo, Inst Med Sci, Div Genet, Minato Ku, Tokyo, Japan; Gunma Univ, Sch Med, Dept Internal Med 3, Gunma, Japan	University of Tokyo; Gunma University	Maru, Y (corresponding author), Tokyo Womens Med Univ Sch Med, Dept Pharmacol, Shinjuku Ku, Tokyo 1628666, Japan.	ymaru@research.twmu.ac.jp		Sakaue-Sawano, Asako/0000-0002-6975-0390				Autiero M, 2003, NAT MED, V9, P936, DOI 10.1038/nm884; Baulida J, 1996, J BIOL CHEM, V271, P5251; Cormont M, 2003, TRAFFIC, V4, P97, DOI 10.1034/j.1600-0854.2003.40205.x; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dustin ML, 1998, CELL, V94, P667, DOI 10.1016/S0092-8674(00)81608-6; Duval M, 2003, J BIOL CHEM, V278, P20091, DOI 10.1074/jbc.M301410200; Farsad K, 2001, J CELL BIOL, V155, P193, DOI 10.1083/jcb.200107075; Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669; Fong TAT, 1999, CANCER RES, V59, P99; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; HENDRIK G, 2001, J BIOL CHEM, V276, P3222; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003; Ito N, 1998, J BIOL CHEM, V273, P23410, DOI 10.1074/jbc.273.36.23410; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Kirsch KH, 1999, P NATL ACAD SCI USA, V96, P6211, DOI 10.1073/pnas.96.11.6211; LeCouter J, 2003, SCIENCE, V299, P890, DOI 10.1126/science.1079562; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Maru Y, 2000, EUR J CELL BIOL, V79, P130, DOI 10.1078/S0171-9335(04)70015-1; Maru Y, 2001, BBA-MOL CELL RES, V1540, P147, DOI 10.1016/S0167-4889(01)00127-6; Miyake S, 1999, J BIOL CHEM, V274, P16619, DOI 10.1074/jbc.274.23.16619; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Sawano A, 1997, BIOCHEM BIOPH RES CO, V238, P487, DOI 10.1006/bbrc.1997.7327; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Shih NY, 2001, AM J PATHOL, V159, P2303, DOI 10.1016/S0002-9440(10)63080-5; Shih NY, 1999, SCIENCE, V286, P312, DOI 10.1126/science.286.5438.312; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; YAMANE A, 1994, ONCOGENE, V9, P2683	32	74	79	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					929	+		10.1096/fj.03-0767fje	http://dx.doi.org/10.1096/fj.03-0767fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15001553				2022-12-28	WOS:000220522800032
J	Langen, RCJ; Van der Velden, JLJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, YMW				Langen, RCJ; Van der Velden, JLJ; Schols, AMWJ; Kelders, MCJM; Wouters, EFM; Janssen-Heininger, YMW			Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization	FASEB JOURNAL			English	Article						MyoD; nuclear factor kappa B; protein stability; muscle regeneration	OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC HEART-FAILURE; RAT SKELETAL-MUSCLE; SATELLITE CELLS; KAPPA-B; REGULATORY FACTORS; INDUCED EXPRESSION; VARIANT SYNTHESIS; KINASE-ACTIVITY; WEIGHT-LOSS	Tumor necrosis factor alpha (TNFalpha) has been implicated as a mediator of muscle wasting through nuclear factor kappa B (NF-kappaB) -dependent inhibition of myogenic differentiation. The aim of the present study was to identify the regulatory molecule(s) of myogenesis targeted by TNFalpha/NF-kappaB signaling. TNFalpha interfered with cell cycle exit and repressed the accumulation of transcripts encoding muscle-specific genes in differentiating C2C12 myoblasts. Overexpression of a p65 (RelA) mutant lacking the transcriptional activation domain attenuated the TNFalpha-mediated inhibition of muscle-specific gene transcription. The ability of muscle regulatory factor MyoD to induce muscle-specific transcription in 10T1/2 fibroblasts was also disrupted by wild-type p65, demonstrating that NF-kappaB transcriptional activity interferes with the function of MyoD. Inhibition of muscle-specific gene expression by TNFalpha was restored by overexpression of MyoD, whereas endogenous MyoD protein abundance and stability were reduced by TNFalpha through increased proteolysis of MyoD by the ubiquitin proteasome pathway. Last, the inhibitory effects of TNFalpha on myogenic differentiation were demonstrated in a mouse model of skeletal muscle regeneration, in which TNFalpha caused a delay in myoblast cell cycle exit. These results implicate that TNFalpha inhibits myogenic differentiation through destabilizing MyoD protein in a NF-kappaB-dependent manner, which interferes with skeletal muscle regeneration and may contribute to muscle wasting.	Maastricht Univ, Dept Resp Med, NL-6202 AZ Maastricht, Netherlands; Univ Vermont, Dept Pathol, Burlington, VT 05405 USA	Maastricht University; University of Vermont	Langen, RCJ (corresponding author), Maastricht Univ, Dept Resp Med, POB 5800, NL-6202 AZ Maastricht, Netherlands.	r.langen@pul.unimaas.nl	Wouters, Emiel/ABD-6200-2021	van der Velden, Jos/0000-0002-2451-3180				Anker SD, 1997, LANCET, V349, P1050, DOI 10.1016/S0140-6736(96)07015-8; Anker SD, 1997, LANCET, V349, P1258; Argiles JM, 1999, MED RES REV, V19, P223, DOI 10.1002/(SICI)1098-1128(199905)19:3<223::AID-MED3>3.0.CO;2-N; BELEC L, 1995, J ACQ IMMUN DEF SYND, V8, P212; Bodine SC, 2001, SCIENCE, V294, P1704, DOI 10.1126/science.1065874; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buck M, 1996, EMBO J, V15, P1753, DOI 10.1002/j.1460-2075.1996.tb00524.x; Cornelison DDW, 2000, DEV BIOL, V224, P122, DOI 10.1006/dbio.2000.9682; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453, DOI 10.1164/ajrccm.150.5.7952575; Duguez S, 2003, AM J PHYSIOL-ENDOC M, V285, pE206, DOI 10.1152/ajpendo.00331.2002; FONG Y, 1989, AM J PHYSIOL, V256, P659; GARCIAMARTINEZ C, 1993, FEBS LETT, V323, P211, DOI 10.1016/0014-5793(93)81341-V; Gomes MD, 2001, P NATL ACAD SCI USA, V98, P14440, DOI 10.1073/pnas.251541198; Gonen H, 1996, J BIOL CHEM, V271, P302, DOI 10.1074/jbc.271.1.302; GUO K, 1995, MOL CELL BIOL, V15, P3823; Guttridge DC, 2000, SCIENCE, V289, P2363, DOI 10.1126/science.289.5488.2363; Guttridge DC, 1999, MOL CELL BIOL, V19, P5785; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Hatoum Ossama Abu, 1998, Molecular and Cellular Biology, V18, P5670; Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534; Kami K, 2002, J HISTOCHEM CYTOCHEM, V50, P1579, DOI 10.1177/002215540205001202; KOTLER DP, 1989, AM J CLIN NUTR, V50, P444, DOI 10.1093/ajcn/50.3.444; Langen RCJ, 2003, IN VITRO CELL DEV-AN, V39, P163; Langen RCJ, 2002, AM J PHYSIOL-CELL PH, V283, pC714, DOI 10.1152/ajpcell.00418.2001; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Layne MD, 1999, EXP CELL RES, V249, P177, DOI 10.1006/excr.1999.4465; Li YP, 2003, FASEB J, V17, P1048, DOI 10.1096/fj.02-0759com; Li YP, 2003, AM J PHYSIOL-CELL PH, V285, pC370, DOI 10.1152/ajpcell.00453.2002; Lingbeck JM, 2003, J BIOL CHEM, V278, P1817, DOI 10.1074/jbc.M208815200; LLOVERA M, 1994, FEBS LETT, V338, P311, DOI 10.1016/0014-5793(94)80290-4; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; Mitchell PO, 2001, AM J PHYSIOL-CELL PH, V281, pC1706, DOI 10.1152/ajpcell.2001.281.5.C1706; Munz B, 2002, MOL CELL BIOL, V22, P5879, DOI 10.1128/MCB.22.16.5879-5886.2002; Nakashima J, 1998, CLIN CANCER RES, V4, P1743; Puri PL, 2000, J CELL PHYSIOL, V185, P155, DOI 10.1002/1097-4652(200011)185:2<155::AID-JCP1>3.0.CO;2-Z; Reynaud EG, 1999, MOL CELL BIOL, V19, P7621; RUDNICKI MA, 1993, CELL, V75, P1351, DOI 10.1016/0092-8674(93)90621-V; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791, DOI 10.1164/ajrccm.157.6.9705017; Smith HK, 2001, J APPL PHYSIOL, V90, P1407, DOI 10.1152/jappl.2001.90.4.1407; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Szalay K, 1997, EUR J CELL BIOL, V74, P391; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; Thaloor D, 1999, AM J PHYSIOL-CELL PH, V277, pC320, DOI 10.1152/ajpcell.1999.277.2.C320; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Vary TC, 1996, SHOCK, V6, P13, DOI 10.1097/00024382-199607000-00004; Wanek LJ, 2000, ANAT REC, V258, P176; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; WU RS, 1982, CELL, V31, P367, DOI 10.1016/0092-8674(82)90130-1; WUNSCH AM, 1987, DEV BIOL, V119, P94, DOI 10.1016/0012-1606(87)90210-7; Zhao SP, 1997, INT J CARDIOL, V58, P257, DOI 10.1016/S0167-5273(96)02873-2	51	234	247	0	11	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	FEB	2004	18	2					227	237		10.1096/fj.03-0251com	http://dx.doi.org/10.1096/fj.03-0251com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769817				2022-12-28	WOS:000220425000003
J	Zhang, T; He, XH; Tsang, TC; Harris, DT				Zhang, T; He, XH; Tsang, TC; Harris, DT			SING: a novel strategy for identifying tumor-specific, cytotoxic T lymphocyte-recognized tumor antigens	FASEB JOURNAL			English	Article						tumor antigens; NFAT; GFP; signal transduction	SIGNAL-TRANSDUCTION; CHIMERIC RECEPTORS; EXPRESSION CLONING; CELLS; IDENTIFICATION; IMMUNOTHERAPY; GENE; ACTIVATION; PATHWAYS	Traditional methods for identifying T cell-recognized tumor antigens (Ags) are laborious and time-consuming. In an attempt to simplify the procedure, a novel strategy, SING ((SI) under bar gnal transduction molecule-mediated, (N) under bar FAT-controlled, (g) under bar FP expression) was established as a direct approach for cloning T cell-recognized tumor Ags. In the SING system, a mouse T cell line (BW5147) was transduced with a chimeric H-2K(b) construct containing T cell-signaling domains and a green fluorescent protein (GFP) reporter gene under the transcriptional control of nuclear factor of activated T cells (NFAT). The resultant BW5147 cells were named BS cells. This cell line could "sense" TCR stimulation through the T cell-signaling domains after coculture with Ag-specific T cells and then become fluorescent (expressing green fluorescence protein, GFP(+)) in the presence of Ag peptides. The interaction between BS cells and Ag-specific T cells could be enhanced by addition of costimulatory signals. Currently, BS cells have been optimized to "sense" TCR stimulation after being pulsed with the relevant peptides at concentrations as low as 10(-9) M. Endogenous Ag-expressing BS cells could also become fluorescent after coculture with Ag-specific T cells. Our results provide a proof of principle for using the SING system to directly isolate Ag-expressing BS cells from BS cell repertoires, which are retrovirally transduced with tumor-derived cDNA libraries. Once tumor Ag-marked BS cells are identified, the sequences encoding tumor Ags could be easily retrieved by PCR amplification of the genomic DNA using vector-specific primers.	Univ Arizona, Dept Microbiol & Immunol, Gene Therapy Grp, Tucson, AZ 85721 USA	University of Arizona	Harris, DT (corresponding author), Univ Arizona, Dept Microbiol & Immunol, Gene Therapy Grp, Tucson, AZ 85721 USA.	davidh@u.arizona.edu		Zhang, Tong/0000-0002-9657-5129				Aarnoudse CA, 2002, INT J CANCER, V99, P7, DOI 10.1002/ijc.10317; BRICHARD V, 1993, J EXP MED, V178, P489, DOI 10.1084/jem.178.2.489; Clavreul A, 2000, MOL IMMUNOL, V37, P571, DOI 10.1016/S0161-5890(00)00085-7; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; DePlaen E, 1997, METHODS, V12, P125, DOI 10.1006/meth.1997.0462; FALO LD, 1995, NAT MED, V1, P649, DOI 10.1038/nm0795-649; Finney HM, 1998, J IMMUNOL, V161, P2791; FISK B, 1995, J EXP MED, V181, P2109, DOI 10.1084/jem.181.6.2109; Geiger TL, 2001, BLOOD, V98, P2364, DOI 10.1182/blood.V98.8.2364; Hooijberg E, 2000, BLOOD, V96, P459; KARTTUNEN J, 1991, P NATL ACAD SCI USA, V88, P3972, DOI 10.1073/pnas.88.9.3972; KARTTUNEN J, 1992, P NATL ACAD SCI USA, V89, P6020, DOI 10.1073/pnas.89.13.6020; Kataoka T, 1996, J IMMUNOL, V156, P3678; LI X, 1999, CELL, V96, P1; Lord GM, 1999, IMMUNOL TODAY, V20, P33, DOI 10.1016/S0167-5699(98)01379-6; Morris EC, 2003, CLIN EXP IMMUNOL, V131, P1, DOI 10.1046/j.1365-2249.2003.02055.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rosenberg SA, 2001, NATURE, V411, P380, DOI 10.1038/35077246; Rosenberg SA, 1999, IMMUNITY, V10, P281, DOI 10.1016/S1074-7613(00)80028-X; Uenaka A, 2001, Cancer Immun, V1, P8; Underhill DM, 1999, J EXP MED, V190, P1909, DOI 10.1084/jem.190.12.1909; van der Merwe PA, 2003, ANNU REV IMMUNOL, V21, P659, DOI 10.1146/annurev.immunol.21.120601.141036; vanOers NSC, 1996, J EXP MED, V183, P1053, DOI 10.1084/jem.183.3.1053; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Zhang T, 2003, J HEMATOTH STEM CELL, V12, P123, DOI 10.1089/152581603321210208	25	6	6	1	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					600	+		10.1096/fj.03-0881fje	http://dx.doi.org/10.1096/fj.03-0881fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734636				2022-12-28	WOS:000188829300005
J	Baudhuin, LM; Jiang, Y; Zaslavsky, A; Ishii, I; Chun, J; Xu, Y				Baudhuin, LM; Jiang, Y; Zaslavsky, A; Ishii, I; Chun, J; Xu, Y			S1P(3)-mediated Akt activation and crosstalk with platelet-derived growth factor receptor (PDGFR)	FASEB JOURNAL			English	Article						sphingosine-1-phosphate; mouse embryonic fibroblasts; GPCR	PROTEIN-COUPLED RECEPTOR; NITRIC-OXIDE PRODUCTION; SPHINGOSINE 1-PHOSPHATE; LYSOPHOSPHATIDIC ACID; PHOSPHOLIPASE-D; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; CELL-PROLIFERATION; ENDOTHELIAL-CELLS; SPHINGOSINE-1-PHOSPHATE	Akt plays a pivotal role in cell survival and tumorigenesis. We investigated the potential interaction between sphingosine-1-phosphate (S1P) and platelet-derived growth factor (PDGF) in the Akt signaling pathway. Using mouse embryonic fibroblasts (MEFs) from S1P receptor knockout mice, we show here that S1P3 was required for S473 phosphorylation of Akt by S1P. In addition, S1P-stimulated activation of Akt, but not ERK, was blocked by a PDGF receptor (PDGFR)-specific inhibitor, AG1296, suggesting a S1P3-mediated specific crosstalk between the Akt signaling pathways of SIP and PDGFR in MEFs. We investigated this crosstalk under different conditions and found that both Akt and ERK activation induced by S1P, but not lysophosphatidic acid (LPA), in BEY ovarian cancer cells required PDGFR but not epidermal growth factor receptor (EGFR) or insulin-like growth factor-I receptor (IGFR). Importantly, S1P induced a G(i)-dependent tyrosine phosphorylation of PDGFR in BEY cells. This dependence on PDGFR in SIP-induced Akt activation was also observed in A2780, T47D, and HMEC-1 cells (which express S1P(3)), but not in PC-3 or GI-101A cells (which do not express S1P(3)), further supporting that S1P(3) mediates the crosstalk between S1P and PDGFR. This is the first report demonstrating a unique interaction between S1P(3) and PDGFR, in addition to demonstrating a specific role for S1P(3) in SIP-induced Akt activation.	Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Natl Inst Neurosci, Dept Mol Genet, Tokyo 1878502, Japan; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Cleveland Clin Fdn, Dept Obstet & Gynecol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; University System of Ohio; Cleveland State University; National Center for Neurology & Psychiatry - Japan; Scripps Research Institute; Cleveland Clinic Foundation	Xu, Y (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	xuy@ccf.org	Chun, Jerold/Y-4670-2019	Ishii, Isao/0000-0002-5367-205X				Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; An SZ, 2000, J BIOL CHEM, V275, P288, DOI 10.1074/jbc.275.1.288; Banno Y, 1999, J BIOL CHEM, V274, P27385, DOI 10.1074/jbc.274.39.27385; Banno Y, 2003, BIOCHEM J, V369, P363, DOI 10.1042/BJ20021368; Banno Y, 2001, J BIOL CHEM, V276, P35622, DOI 10.1074/jbc.M105673200; Baudhuin LM, 2002, MOL PHARMACOL, V62, P660, DOI 10.1124/mol.62.3.660; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Davaille J, 2002, J BIOL CHEM, V277, P37323, DOI 10.1074/jbc.M202798200; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Hobson JP, 2001, SCIENCE, V291, P1800, DOI 10.1126/science.1057559; Im DS, 2000, BIOCHEM BIOPH RES CO, V279, P139, DOI 10.1006/bbrc.2000.3933; Ishii I, 2001, J BIOL CHEM, V276, P33697, DOI 10.1074/jbc.M104441200; Ishii I, 2002, J BIOL CHEM, V277, P25152, DOI 10.1074/jbc.M200137200; Kluk MJ, 2003, FEBS LETT, V533, P25, DOI 10.1016/S0014-5793(02)03742-0; Kluk MJ, 2002, BBA-MOL CELL BIOL L, V1582, P72, DOI 10.1016/S1388-1981(02)00139-7; Kluk MJ, 2001, CIRC RES, V89, P496, DOI 10.1161/hh1801.096338; Kou RQ, 2002, BIOCHEMISTRY-US, V41, P4982, DOI 10.1021/bi016017r; Kwon YG, 2001, J BIOL CHEM, V276, P10627, DOI 10.1074/jbc.M011449200; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Lee MJ, 2001, MOL CELL, V8, P693, DOI 10.1016/S1097-2765(01)00324-0; Liu AX, 1998, CANCER RES, V58, P2973; Liu YJ, 2000, J CLIN INVEST, V106, P951, DOI 10.1172/JCI10905; Marte BM, 1997, TRENDS BIOCHEM SCI, V22, P355, DOI 10.1016/S0968-0004(97)01097-9; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Panetti TS, 2002, BBA-MOL CELL BIOL L, V1582, P190, DOI 10.1016/S1388-1981(02)00155-5; Pyne S, 2002, BBA-MOL CELL BIOL L, V1582, P121, DOI 10.1016/S1388-1981(02)00146-4; Rosenfeldt HM, 2001, FASEB J, V15, P2649, DOI 10.1096/fj.01-0523com; Siehler S, 2002, BBA-MOL CELL BIOL L, V1582, P94, DOI 10.1016/S1388-1981(02)00142-7; Sledz CA, 2003, NAT CELL BIOL, V5, P834, DOI 10.1038/ncb1038; Spiegel S, 2000, BBA-MOL CELL BIOL L, V1484, P107, DOI 10.1016/S1388-1981(00)00010-X; Takuwa Y, 2002, BBA-MOL CELL BIOL L, V1582, P112, DOI 10.1016/S1388-1981(02)00145-2; Uhlenbrock K, 2002, CELL SIGNAL, V14, P941, DOI 10.1016/S0898-6568(02)00041-4; Van Brocklyn JR, 2000, BLOOD, V95, P2624; Waters C, 2003, J BIOL CHEM, V278, P6282, DOI 10.1074/jbc.M208560200; Weiner JA, 1999, P NATL ACAD SCI USA, V96, P5233, DOI 10.1073/pnas.96.9.5233; Yang AH, 2002, BBA-MOL CELL BIOL L, V1582, P197, DOI 10.1016/S1388-1981(02)00172-5; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598	40	67	74	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					341	+		10.1096/fj.03-0302fje	http://dx.doi.org/10.1096/fj.03-0302fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657000				2022-12-28	WOS:000188067500028
J	Koshikawa, N; Schenk, S; Moeckel, G; Sharabi, A; Miyazaki, K; Gardner, H; Zent, R; Quaranta, V				Koshikawa, N; Schenk, S; Moeckel, G; Sharabi, A; Miyazaki, K; Gardner, H; Zent, R; Quaranta, V			Proteolytic processing of laminin-5 by MT1-MMP in tissues and its effects on epithelial cell morphology	FASEB JOURNAL			English	Article						matrix metalloproteinase; MT1-MMP KO mouse; extracellular matrix; cell migration; laminin-5 gamma 2	MATRIX METALLOPROTEINASES; GAMMA-2 CHAIN; MT-MMPS; MEMBRANE; KIDNEY; ALPHA-6-BETA-4; EXPRESSION; INTEGRINS; KERATINOCYTES; MORPHOGENESIS	The extracellular matrix macromolecule laminin-5 (Ln-5) is converted by matrix metalloproteinases (MMP) MT1-MMP and MMP-2 into a migration-promoting substrate in vitro. We now report that cleavage of Ln-5 by MT1-MMP occurs in vivo and affects epithelial tissue organization and probably Ln-5 turnover. In MT1-MMP knockout (KO) mice, the kidneys showed increased levels of total Ln-5 gamma2 subunit, but significantly reduced amounts of gamma2', an amino-terminal truncated proteolytic form of gamma2. The kidney tubular epithelia of KO animals were poorly differentiated, a phenotype reminiscent of human congenital mixed hypoplastic/dysplastic disorders. To establish a better link between Ln-5 proteolytic cleavage and epithelial morphology, MT1-MMP expression was reconstituted by transfection of MT1-MMP into a Ln-5 positive, MT1-MMP deficient epithelial cell line. MT1-MMP transfectants demonstrated increased levels of processed Ln-5 gamma2 chain and enhanced spreading on Ln-5, but not fibronectin. Recombinant MT1-MMP cleaved gamma2 constructs in vitro at a known in vivo gamma2 gamma2' processing site. These results strongly indicate that Ln-5 is a physiological substrate of MT1-MMP in vivo. Proteolytic processing of gamma2 subunit by MT1-MMP may influence Ln-5 turnover in epithelial basement membranes and affect epithelial morphogenesis.	Vanderbilt Univ, Med Ctr, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Ctr Matrix Biol, Nashville, TN 37232 USA; Scripps Res Inst, La Jolla, CA USA; Vanderbilt Univ, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vet Affairs Hosp, Nashville, TN USA; Yokohama City Univ, Kihara Inst Biol Res, Div Cell Biol, Yokohama, Kanagawa 232, Japan	Vanderbilt University; Vanderbilt University; Scripps Research Institute; Vanderbilt University; Vanderbilt University; Yokohama City University	Quaranta, V (corresponding author), Vanderbilt Univ, Med Ctr, Dept Canc Biol, 771 Preston Bldg, Nashville, TN 37232 USA.	vito.quaranta@vanderbilt.edu	Koshikawa, Naohiko/S-7306-2017; Quaranta, Vito/G-6512-2016	Koshikawa, Naohiko/0000-0002-4539-888X; Quaranta, Vito/0000-0001-7491-8672; Sharabi, Andrew/0000-0003-2075-1197; Moeckel, Gilbert/0000-0002-6059-0837				Airenne T, 2000, CELL TISSUE RES, V300, P129, DOI 10.1007/s004410050054; Amano S, 2000, J BIOL CHEM, V275, P22728, DOI 10.1074/jbc.M002345200; Baker SE, 1996, J CELL SCI, V109, P2509; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CARTER DA, 1991, RESTOR NEUROL NEUROS, V3, P65, DOI 10.3233/RNN-1991-3203; CARTER WG, 1990, J CELL BIOL, V111, P3141, DOI 10.1083/jcb.111.6.3141; Cosgrove D, 1996, GENE DEV, V10, P2981, DOI 10.1101/gad.10.23.2981; De Arcangelis A, 2000, TRENDS GENET, V16, P389, DOI 10.1016/S0168-9525(00)02074-6; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Engvall E, 1996, J CELL BIOCHEM, V61, P493; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Gilles C, 2001, J CELL SCI, V114, P2967; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Kanwar YS, 1999, AM J PHYSIOL-RENAL, V277, pF934, DOI 10.1152/ajprenal.1999.277.6.F934; Kinoh H, 1996, J CELL SCI, V109, P953; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Kreidberg JA, 1996, DEVELOPMENT, V122, P3537; MARINKOVICH MP, 1992, J BIOL CHEM, V267, P17900; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miosge N, 2002, ANAT EMBRYOL, V205, P355, DOI 10.1007/s00429-002-0256-7; MIYAZAKI K, 1993, P NATL ACAD SCI USA, V90, P11767, DOI 10.1073/pnas.90.24.11767; Mizushima H, 1998, HORM RES, V50, P7, DOI 10.1159/000053118; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; Pirila E, 2003, BIOCHEM BIOPH RES CO, V303, P1012, DOI 10.1016/S0006-291X(03)00452-2; Plopper GE, 1998, BREAST CANCER RES TR, V51, P57, DOI 10.1023/A:1006086218174; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; RYAN MC, 1994, J BIOL CHEM, V269, P22779; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Schenk S, 2003, J CELL BIOL, V161, P197, DOI 10.1083/jcb.200208145; Shofuda K, 1997, J BIOL CHEM, V272, P9749; SILVA FG, 1993, ARCH PATHOL LAB MED, V117, P1233; STRONGIN AY, 1993, J BIOL CHEM, V268, P14033; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; TRUONG LD, 1988, HISTOCHEMISTRY, V90, P51, DOI 10.1007/BF00495707; UITTO J, 1994, J INVEST DERMATOL, V103, pS39, DOI 10.1111/1523-1747.ep12398967; Uitto J, 1996, MOL BIOL REP, V23, P35, DOI 10.1007/BF00357071; Utani A, 2001, J BIOL CHEM, V276, P28779, DOI 10.1074/jbc.M101420200; VAILLY J, 1994, EUR J BIOCHEM, V219, P209, DOI 10.1111/j.1432-1033.1994.tb19932.x; Veitch DP, 2003, J BIOL CHEM, V278, P15661, DOI 10.1074/jbc.M210588200; Wahlgren J, 2003, J ORAL PATHOL MED, V32, P100, DOI 10.1034/j.1600-0714.2003.00075.x; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; YURCHENCO PD, 1994, CURR OPIN CELL BIOL, V6, P674, DOI 10.1016/0955-0674(94)90093-0; Zent R, 2001, DEV BIOL, V238, P289, DOI 10.1006/dbio.2001.0391	45	60	62	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					364	+		10.1096/fj.03-0584fje	http://dx.doi.org/10.1096/fj.03-0584fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688206				2022-12-28	WOS:000188067500012
J	Lou, YR; Laaksi, I; Syvala, H; Blauer, M; Tammela, TLJ; Ylikomi, T; Tuohimaa, P				Lou, YR; Laaksi, I; Syvala, H; Blauer, M; Tammela, TLJ; Ylikomi, T; Tuohimaa, P			25-hydroxyvitamin D-3 is an active hormone in human primary prostatic stromal cells	FASEB JOURNAL			English	Article						fibroblast; prostate cancer; cell proliferation; 25-hydroxyvitamin D-3 24-hydroxylase; 25-hydroxyvitamin D-3 1 alpha-hydroxylase	1-ALPHA-HYDROXYLASE GENE-EXPRESSION; VITAMIN-D; 1,25-DIHYDROXYVITAMIN D-3; ALPHA-HYDROXYLASE; IN-VITRO; CANCER; CALCITRIOL; INHIBITION; CLONING; GROWTH	According to the present paradigm, 1alpha,25-dihydroxyvitamin D-3 [1alpha,25-(OH)(2)D-3] is a biologically active hormone; whereas 25-hydroxyvitamin D-3 (25OHD(3)) is regarded as a prohormone activated through the action of 25-hydroxyvitamin D-3 1alpha-hydroxylase (1alpha-hydroxylase). Although the role of vitamin D-3 in the regulation of growth and differentiation of prostatic epithelial cells has been well studied, its action and metabolism in prostatic stroma are still largely unknown. We investigated the effects of 25OHD(3) and 1alpha,25-(OH)(2)D-3 on two human stromal primary cultures termed P29SN and P32S. In a cell proliferation assay, 25OHD(3) was found at physiological concentrations of 100-250 nM to inhibit the growth of both primary cultures, whereas 1alpha,25-(OH)(2)D-3 at a pharmacological concentration of 10 nM exhibited the growth-inhibitory effects on P29SN cells but not on P32S cells. Quantitative real-time RT-PCR analysis revealed that both 25OHD(3) and 1alpha,25-(OH)(2)D-3 induced 25-hydroxyvitamin D-3 24-hydroxylase (24-hydroxylase) mRNA in a dose- and time-dependent manner. By inhibiting 1alpha-hydroxylase and/or 24-hydroxylase enzyme activities, the induction of 24-hydroxylase mRNA by 250 nM 25OHD(3) was clearly enhanced, suggesting that 1alpha-hydroxylation is not a prerequisite for the hormonal activity of 25OHD(3). Altogether our results suggest that 25OHD(3) at a high but physiological concentration acts as an active hormone with respect to vitamin D-3 responsive gene regulation and suppression of cell proliferation.	Univ Tampere, Sch Med, Dept Anat, FIN-33014 Tampere, Finland; Univ Tampere, Sch Med, Dept Cell Biol, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Tampere Univ Hosp, Dept Urol, Tampere, Finland	Tampere University; Tampere University; Tampere University; Tampere University Hospital; Tampere University; Tampere University Hospital	Lou, YR (corresponding author), Univ Tampere, Sch Med, Dept Anat, FIN-33014 Tampere, Finland.	loyalo@uta.fi	Lou, Yan-Ru/K-4348-2012; Lou, Yan-Ru/AAX-4008-2020	Lou, Yan-Ru/0000-0001-7717-6010; Lou, Yan-Ru/0000-0001-7717-6010				Ahonen MH, 2000, CANCER CAUSE CONTROL, V11, P847, DOI 10.1023/A:1008923802001; Barreto AM, 2000, CANCER EPIDEM BIOMAR, V9, P265; Bland R, 1999, ENDOCRINOLOGY, V140, P2027, DOI 10.1210/en.140.5.2027; Bland R, 2001, KIDNEY INT, V60, P1277, DOI 10.1046/j.1523-1755.2001.00966.x; BOUILLON R, 1995, ENDOCR REV, V16, P200, DOI 10.1210/er.16.2.200; Brenza HL, 2000, ARCH BIOCHEM BIOPHYS, V381, P143, DOI 10.1006/abbi.2000.1970; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Chen TC, 2003, J CELL BIOCHEM, V88, P315, DOI 10.1002/jcb.10342; Cunha GR, 2002, DIFFERENTIATION, V70, P473, DOI 10.1046/j.1432-0436.2002.700902.x; CUNHA GR, 1987, ENDOCR REV, V8, P338, DOI 10.1210/edrv-8-3-338; DOKOH S, 1983, ENDOCRINOLOGY, V112, P200, DOI 10.1210/endo-112-1-200; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gross C, 1998, J UROLOGY, V159, P2035, DOI 10.1016/S0022-5347(01)63236-1; Harant H, 2000, J CELL BIOCHEM, V78, P112, DOI 10.1002/(SICI)1097-4644(20000701)78:1<112::AID-JCB10>3.0.CO;2-7; Hawkins GA, 2002, PROSTATE, V53, P175, DOI 10.1002/pros.10144; HINE TJ, 1994, ANN CLIN BIOCHEM, V31, P31, DOI 10.1177/000456329403100105; Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073; Hsu JY, 2001, CANCER RES, V61, P2852; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Kivineva M, 1998, J STEROID BIOCHEM, V66, P121, DOI 10.1016/S0960-0760(98)00054-5; Konety BR, 2000, J UROLOGY, V164, P1812, DOI 10.1016/S0022-5347(05)67112-1; Konety BR, 1996, CELL GROWTH DIFFER, V7, P1563; Krill D, 1999, UROLOGY, V54, P171, DOI 10.1016/S0090-4295(99)00103-X; KUENG W, 1989, ANAL BIOCHEM, V182, P16, DOI 10.1016/0003-2697(89)90710-0; Lokeshwar BL, 1999, CANCER EPIDEM BIOMAR, V8, P241; Mantell DJ, 2000, CIRC RES, V87, P214, DOI 10.1161/01.RES.87.3.214; Miller GJ, 1995, CLIN CANCER RES, V1, P997; Monkawa T, 2000, KIDNEY INT, V58, P559, DOI 10.1046/j.1523-1755.2000.00202.x; Monkawa T, 1997, BIOCHEM BIOPH RES CO, V239, P527, DOI 10.1006/bbrc.1997.7508; OHYAMA Y, 1993, BIOCHEMISTRY-US, V32, P76, DOI 10.1021/bi00052a011; Olumi AF, 1998, CANCER RES, V58, P4525; Olumi AF, 1999, CANCER RES, V59, P5002; Osborn J L, 1995, Urol Oncol, V1, P195, DOI 10.1016/1078-1439(95)00061-5; Peehl DM, 1997, EXP CELL RES, V232, P208, DOI 10.1006/excr.1997.3525; PEEHL DM, 1994, CANCER RES, V54, P805; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; REINHARDT TA, 1984, J CLIN ENDOCR METAB, V58, P91, DOI 10.1210/jcem-58-1-91; Schuster I, 2001, STEROIDS, V66, P409, DOI 10.1016/S0039-128X(00)00159-8; Schwartz GG, 1997, CANCER EPIDEM BIOMAR, V6, P727; SIMPSON RU, 1980, P NATL ACAD SCI-BIOL, V77, P5822, DOI 10.1073/pnas.77.10.5822; SKOWRONSKI RJ, 1995, ENDOCRINOLOGY, V136, P20, DOI 10.1210/en.136.1.20; Smith DC, 1999, CLIN CANCER RES, V5, P1339; StArnaud R, 1997, J BONE MINER RES, V12, P1552, DOI 10.1359/jbmr.1997.12.10.1552; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; TURNBULL H, 1982, CLIN CHIM ACTA, V120, P65, DOI 10.1016/0009-8981(82)90078-X; Vieth R, 1999, AM J CLIN NUTR, V69, P842; Ylikomi T, 2002, VITAM HORM, V64, P357, DOI 10.1016/S0083-6729(02)64010-5; Zehnder D, 1999, J AM SOC NEPHROL, V10, P2465; Zehnder D, 2001, J CLIN ENDOCR METAB, V86, P888, DOI 10.1210/jc.86.2.888; Zierold C, 2003, J CELL BIOCHEM, V88, P234, DOI 10.1002/jcb.10341	51	71	73	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					332	+		10.1096/fj.03-0140fje	http://dx.doi.org/10.1096/fj.03-0140fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14657005				2022-12-28	WOS:000188067500033
J	Veikkola, T; Lohela, M; Ikenberg, K; Makinen, T; Korff, T; Saaristo, A; Petrova, T; Jeltsch, M; Augustin, HG; Alitalo, K				Veikkola, T; Lohela, M; Ikenberg, K; Makinen, T; Korff, T; Saaristo, A; Petrova, T; Jeltsch, M; Augustin, HG; Alitalo, K			Intrinsic versus micro environmental regulation of lymphatic endothelial cell phenotype and function	FASEB JOURNAL			English	Article						LEC; VEGFR-3; VEGFR-2; pericyte; SMC	SMOOTH-MUSCLE CELLS; GROWTH-FACTOR RECEPTOR-3; VASCULAR DEVELOPMENT; TRANSGENIC MICE; MESSENGER-RNA; VEGF-C; BLOOD; ANGIOGENESIS; ANGIOPOIETIN-2; EXPRESSION	Vascular endothelial cells are characterized by a high degree of functional and phenotypic plasticity, which is controlled both by their pericellular microenvironment and their intracellular gene expression programs. To gain further insight into the mechanisms regulating the endothelial cell phenotype, we have compared the responses of lymphatic endothelial cells (LECs) and blood vascular endothelial cells (BECs) to vascular endothelial growth factors (VEGFs). VEGFR-3-specific signals are sufficient for LEC but not BEC proliferation, as shown by the ability of the specific ligand VEGF-C156S to stimulate cell cycle entry only in LECs. On the other hand, we found that VEGFR-3 stimulation did not induce LEC cell shape changes typical of VEGFR-2-stimulated LECs, indicating receptor-specific differences in the cytoskeletal responses. Genes induced via VEGFR-2 also differed between BECs and LECs: angiopoietin-2 (Ang-2) was induced via VEGFR-2 in BECs and LECs, but the smooth muscle cell (SMC) chemoattractant BMP-2 was induced only in BECs. Both BECs and LECs were able to promote SMC chemotaxis, but contact with SMCs led to down-regulation of VEGFR-3 expression in BECs in a 3-dimensional coculture system. This was consistent with the finding that VEGFR-3 is down-regulated in vivo at sites of endothelial cell-pericyte/smooth muscle cell contacts. Collectively, these data show intrinsic cell-specific differences of BEC and LEC responses to VEGFs and identify a pericellular regulatory mechanism for VEGFR-3 down-regulation in endothelial cells.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland; Tumor Biol Ctr, Dept Vasc Biol & Angiogenesis Res, D-79106 Freiburg, Germany	University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Alitalo, K (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.	Kari.Alitalo@helsinki.fi	Alitalo, Kari K/J-5013-2014; Augustin, Hellmut/AAA-5246-2020; Jeltsch, Michael/I-5340-2012; Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014	Alitalo, Kari K/0000-0002-7331-0902; Augustin, Hellmut/0000-0002-7173-4242; Jeltsch, Michael/0000-0003-2890-7790; Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257				ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; Bouletreau PJ, 2002, PLAST RECONSTR SURG, V109, P2384, DOI 10.1097/00006534-200206000-00033; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Carmeliet P, 2000, NAT MED, V6, P389, DOI 10.1038/74651; Darland DC, 2001, CURR TOP DEV BIOL, V52, P107, DOI 10.1016/S0070-2153(01)52010-4; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ferrara N, 2001, Am J Physiol Cell Physiol, V280, pC1358; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Galetti TP, 2002, EUR UROL SUPPL, V1, P3; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; GERHARDT H, 2003, IN PRESS J CELL BIOL; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Holash J, 1999, ONCOGENE, V18, P5356, DOI 10.1038/sj.onc.1203035; Huang YQ, 2002, BLOOD, V99, P1646, DOI 10.1182/blood.V99.5.1646; IIVANAINEN E, 2003, IN PRESS FASEB J; Iljin K, 2002, FASEB J, V16, P1764, DOI 10.1096/fj.01-1043com; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Jussila L, 1998, CANCER RES, V58, P1599; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Korff T, 2001, FASEB J, V15, P447, DOI 10.1096/fj.00-0139com; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; Mandriota SJ, 1998, CIRC RES, V83, P852, DOI 10.1161/01.RES.83.8.852; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Oh SJ, 1997, DEV BIOL, V188, P96, DOI 10.1006/dbio.1997.8639; Partanen TA, 2001, MICROSC RES TECHNIQ, V55, P108, DOI 10.1002/jemt.1162; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Petrova TV, 2002, EMBO J, V21, P4593, DOI 10.1093/emboj/cdf470; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Teichert-Kuliszewska K, 2001, CARDIOVASC RES, V49, P659, DOI 10.1016/S0008-6363(00)00231-5; Veikkola T, 2001, EMBO J, V20, P1223, DOI 10.1093/emboj/20.6.1223; Willette RN, 1999, J VASC RES, V36, P120, DOI 10.1159/000025634	36	64	65	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	NOV	2003	17	14					2006	2013		10.1096/fj.03-0179com	http://dx.doi.org/10.1096/fj.03-0179com			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597670				2022-12-28	WOS:000186961200037
J	Bellini, MH; Peroni, CN; Bartolini, P				Bellini, MH; Peroni, CN; Bartolini, P			Increases in weight of growth hormone-deficient and immunodeficient (lit/scid) dwarf mice after grafting of hGH-secreting, primary human keratinocytes	FASEB JOURNAL			English	Article						gene therapy; retroviral vector; in vivo secretion; GH circulatory level	HUMAN EPIDERMAL-CELLS; GENE-THERAPY; STEM-CELLS; CULTURED EPITHELIUM; RETROVIRAL VECTORS; ESCHERICHIA-COLI; IN-VITRO; EXPRESSION; PROSPECTS; PROTEINS	Primary human keratinocytes, stably transduced with the human growth hormone (hGH) gene (under control of the retroviral LTR promoter) and selected via geneticin secreted as much as 7 mug hGH/10(6) cells/day. Their grafting onto immunodeficient dwarf mice (lit/scid) led to hGH levels in the circulation that did not go below 0.2-0.3 ng/ml during a 12 day period (peak value, 1.5 ng/ml at 4 h). This phenomenon was associated with a body weight increase of the grafted animals (0.060 g/animal/day) significantly higher (P<0.01) than that of controls (0.023 g/animal/day). This is the first report describing successful utilization of immunodeficient dwarf mice (lit/scid) in keratinocyte-based hGH gene therapy.	Univ Sao Paulo, IPEN CNEN, Dept Biotechnol, BR-05508900 Sao Paulo, Brazil	Comissao Nacional de Energia Nuclear (CNEN); Instituto de Pesquisas Energeticas e Nucleares (IPEN); Universidade de Sao Paulo	Bartolini, P (corresponding author), Univ Sao Paulo, IPEN CNEN, Dept Biotechnol, Ave Professor Lineu Prestes 2242,Cidade Univ, BR-05508900 Sao Paulo, Brazil.	pbartoli@ipen.br	Peroni, Cibele/D-5020-2012					BARRANDON Y, 1988, J INVEST DERMATOL, V91, P315, DOI 10.1111/1523-1747.ep12475646; BELLINI MH, 1993, ENDOCRINOLOGY, V132, P2051, DOI 10.1210/en.132.5.2051; Bellini MH, 1998, J ENDOCRINOL INVEST, V21, P1; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CRYSTAL RG, 1995, SCIENCE, V270, P404, DOI 10.1126/science.270.5235.404; Deitel K, 2002, J SURG ONCOL, V81, P75, DOI 10.1002/jso.10136; DELUCA M, 1989, BURNS, V15, P303, DOI 10.1016/0305-4179(89)90007-7; DeLuca M, 1997, GENE THER, V4, P381, DOI 10.1038/sj.gt.3300434; FENJVES ES, 1994, HUM GENE THER, V5, P1241, DOI 10.1089/hum.1994.5.10-1241; GERRARD AJ, 1993, NAT GENET, V3, P180, DOI 10.1038/ng0293-180; GOEDDEL DV, 1979, NATURE, V281, P544, DOI 10.1038/281544a0; GRAY GL, 1985, GENE, V39, P247, DOI 10.1016/0378-1119(85)90319-1; He X, 1998, GENE THER, V5, P537, DOI 10.1038/sj.gt.3300622; JENSEN UB, 1994, J INVEST DERMATOL, V103, P391, DOI 10.1111/1523-1747.ep12395402; Kolodka TM, 1998, P NATL ACAD SCI USA, V95, P4356, DOI 10.1073/pnas.95.8.4356; Krueger GG, 1999, P ASSOC AM PHYSICIAN, V111, P198, DOI 10.1046/j.1525-1381.1999.99225.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPKER JH, 1983, GENE, V24, P281, DOI 10.1016/0378-1119(83)90088-4; Mathor MB, 1996, P NATL ACAD SCI USA, V93, P10371, DOI 10.1073/pnas.93.19.10371; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; MORGAN JR, 1987, SCIENCE, V237, P1476; OCONNOR NE, 1981, LANCET, V1, P75; PEETERS S, 1977, ENDOCRINOLOGY, V101, P1164, DOI 10.1210/endo-101-4-1164; Pellegrini G, 1998, MED BIOL ENG COMPUT, V36, P778, DOI 10.1007/BF02518885; RHEINWALD JG, 1975, CELL, V6, P317, DOI 10.1016/0092-8674(75)90183-X; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RIBELA MTCP, 1993, J IMMUNOL METHODS, V159, P269, DOI 10.1016/0022-1759(93)90166-5; Taichman LB, 1999, P ASSOC AM PHYSICIAN, V111, P206, DOI 10.1046/j.1525-1381.1999.99226.x; TEUMER J, 1990, FASEB J, V4, P3245, DOI 10.1096/fasebj.4.14.2227214; Wang XM, 1997, P NATL ACAD SCI USA, V94, P219, DOI 10.1073/pnas.94.1.219	31	14	14	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2322	+		10.1096/fj.03-0018fje	http://dx.doi.org/10.1096/fj.03-0018fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525947				2022-12-28	WOS:000186343300001
J	Jong, YJI; Ford, SR; Seehra, K; Malave, VB; Baenziger, NL				Jong, YJI; Ford, SR; Seehra, K; Malave, VB; Baenziger, NL			Alzheimer's disease skin fibroblasts selectively express a bradykinin signaling pathway mediating tau protein Ser phosphorylation	FASEB JOURNAL			English	Article						signal transduction; receptor modulation; phosphorylation cascade; rotein kinase C; Down's syndrome	AMYLOID PRECURSOR PROTEIN; KINASE-C-ALPHA; PATHOLOGICAL-CHANGES; EDINGER-WESTPHAL; BETA-PROTEIN; HEAD-INJURY; IN-VITRO; RECEPTORS; NEURONS; BRAIN	Increased Ser phosphorylation of tau microtubule-associated protein in the brain is an early feature of Alzheimer's disease (AD) that precedes progression of the disease to frank neuronal disruption. We demonstrate that bradykinin (BK) B-2 receptor activation leads to selective Ser phosphorylation of tau in skin fibroblasts from persons who have or will develop AD due to Presenilin 1 mutations or Trisomy 21, but not in skin fibroblasts from normal individuals at any age. The increased signal transduction in AD fibroblasts that culminates in tau Ser phosphorylation reflects modification of the G protein-coupled BK B2 receptors themselves. Both the BK B2 receptor modification and BK-mediated tau Ser phosphorylation are dependent on activation of protein kinase C and can be detected in fibroblasts from persons with Trisomy 21 two decades before the characteristic onset of AD. This dysregulated signaling cascade in AD may thus be expressed throughout life as an aberrant pathway in peripheral tissues more accessible than brain for molecular analysis. The sites of greatest BK B2 receptor expression in brain overlap with those areas displaying the earliest pathology in the course of AD, suggesting that BK receptor pathway dysfunction may be a molecular signature yielding information about the pathogenesis of AD.	Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA	Washington University (WUSTL)	Baenziger, NL (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, 660 S Euclid Ave,Campus Box 8108, St Louis, MO 63110 USA.	baenzign@thalamus.wustl.edu						Augustinack JC, 2002, ACTA NEUROPATHOL, V103, P26, DOI 10.1007/s004010100423; BAENZIGER NL, 1992, EUR J CELL BIOL, V58, P71; BAENZIGER NL, 1994, J BIOL CHEM, V269, P14892; BECHERER PR, 1982, CELL, V30, P243, DOI 10.1016/0092-8674(82)90030-7; Blaukat A, 2000, MOL CELL BIOL, V20, P6837, DOI 10.1128/MCB.20.18.6837-6848.2000; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Braak H, 1997, NEUROBIOL AGING, V18, P351, DOI 10.1016/S0197-4580(97)00056-0; Buee-Scherrer V, 2002, FEBS LETT, V515, P151, DOI 10.1016/S0014-5793(02)02460-2; CAPORASO GL, 1992, P NATL ACAD SCI USA, V89, P3055, DOI 10.1073/pnas.89.7.3055; Chen Er-Yun, 2000, Journal of Comparative Neurology, V427, P1; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; CORREA FMA, 1979, P NATL ACAD SCI USA, V76, P1489, DOI 10.1073/pnas.76.3.1489; Couto LB, 1998, BRIT J PHARMACOL, V125, P1578, DOI 10.1038/sj.bjp.0702209; Dalemar LR, 1996, EUR J CELL BIOL, V69, P236; Dendorfer A, 1997, BRIT J PHARMACOL, V122, P1585, DOI 10.1038/sj.bjp.0701547; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; El-Dahr SS, 2000, PHYSIOL GENOMICS, V3, P121, DOI 10.1152/physiolgenomics.2000.3.3.121; Favit A, 1998, P NATL ACAD SCI USA, V95, P5562, DOI 10.1073/pnas.95.10.5562; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; FOWLER CJ, 1995, MOL CELL BIOCHEM, V149, P287, DOI 10.1007/BF01076590; FUJIWARA Y, 1989, LIFE SCI, V44, P1645, DOI 10.1016/0024-3205(89)90481-5; Gasparini L, 1998, FASEB J, V12, P17, DOI 10.1096/fasebj.12.1.17; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; Hensley K, 1999, J NEUROCHEM, V72, P2053, DOI 10.1046/j.1471-4159.1999.0722053.x; Hoozemans JJM, 2002, J NEUROPATH EXP NEUR, V61, P678, DOI 10.1093/jnen/61.8.678; HUANG HM, 1995, J NEUROCHEM, V64, P761; INNIS RB, 1981, P NATL ACAD SCI-BIOL, V78, P2630, DOI 10.1073/pnas.78.4.2630; JOACHIM CL, 1989, NATURE, V341, P226, DOI 10.1038/341226a0; Jong YJI, 2002, INT IMMUNOPHARMACOL, V2, P1833, DOI 10.1016/S1567-5769(02)00168-6; JONG YJI, 1993, P NATL ACAD SCI USA, V90, P10994, DOI 10.1073/pnas.90.23.10994; KATZMAN R, 1991, FASEB J, V5, P278, DOI 10.1096/fasebj.5.3.2001787; Ladner CJ, 1996, J NEUROPATH EXP NEUR, V55, P924, DOI 10.1097/00005072-199608000-00008; LEVESQUE L, 1995, BRIT J PHARMACOL, V116, P1673, DOI 10.1111/j.1476-5381.1995.tb16390.x; MASLIAH E, 1991, J NEUROSCI, V11, P2759; Mitchell TW, 2002, ANN NEUROL, V51, P182, DOI 10.1002/ana.10086; Murone C, 1997, J COMP NEUROL, V381, P203, DOI 10.1002/(SICI)1096-9861(19970505)381:2<203::AID-CNE7>3.0.CO;2-7; Nicoll JAR, 1996, ANN NY ACAD SCI, V777, P271, DOI 10.1111/j.1749-6632.1996.tb34431.x; Noble W, 2003, NEURON, V38, P555, DOI 10.1016/S0896-6273(03)00259-9; Parvizi J, 2000, ANN NEUROL, V48, P344, DOI 10.1002/1531-8249(200009)48:3<344::AID-ANA9>3.3.CO;2-J; Parvizi J, 1998, NEUROREPORT, V9, P4151, DOI 10.1097/00001756-199812210-00028; PERRY DC, 1984, J NEUROCHEM, V43, P1072, DOI 10.1111/j.1471-4159.1984.tb12846.x; Pizard A, 1998, J BIOL CHEM, V273, P1309, DOI 10.1074/jbc.273.3.1309; Price JL, 1999, ANN NEUROL, V45, P358, DOI 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X; Qi Y, 2003, BIOCHEMISTRY-US, V42, P1042, DOI 10.1021/bi0267590; Raidoo DM, 1996, IMMUNOPHARMACOLOGY, V33, P104, DOI 10.1016/0162-3109(96)00021-5; Raidoo DM, 1997, J NEUROIMMUNOL, V77, P39, DOI 10.1016/S0165-5728(97)00048-9; Raidoo DM, 1998, PHARMACOL THERAPEUT, V79, P105, DOI 10.1016/S0163-7258(98)00011-4; Rapoport M, 2002, P NATL ACAD SCI USA, V99, P6364, DOI 10.1073/pnas.092136199; RASMUSSON DX, 1995, BRAIN INJURY, V9, P213, DOI 10.3109/02699059509008194; Saito Y, 2000, NEUROLOGY, V55, P1727, DOI 10.1212/WNL.55.11.1727; Schupf N, 2002, BRIT J PSYCHIAT, V180, P405, DOI 10.1192/bjp.180.5.405; Scinto LFM, 1999, ACTA NEUROPATHOL, V97, P557, DOI 10.1007/s004010051031; Scinto LFM, 2001, NEUROBIOL AGING, V22, P729, DOI 10.1016/S0197-4580(01)00235-4; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; SHERRINGTON R, 1995, NATURE, V375, P754, DOI 10.1038/375754a0; Shi B, 1998, NEUROENDOCRINOLOGY, V67, P209, DOI 10.1159/000054316; Shibayama Y, 1999, CLIN IMMUNOL, V90, P89, DOI 10.1006/clim.1998.4621; Shima K, 1977, Nihon Yakurigaku Zasshi, V73, P237; Sironi JJ, 1998, FEBS LETT, V436, P471, DOI 10.1016/S0014-5793(98)01185-5; SLACK BE, 1993, J BIOL CHEM, V268, P21097; SNIDER RM, 1984, J NEUROCHEM, V43, P1749, DOI 10.1111/j.1471-4159.1984.tb06104.x; Steiner H, 1998, J BIOL CHEM, V273, P32322, DOI 10.1074/jbc.273.48.32322; STERANKA LR, 1988, P NATL ACAD SCI USA, V85, P3245, DOI 10.1073/pnas.85.9.3245; Stieler JT, 2001, NEUROREPORT, V12, P3969, DOI 10.1097/00001756-200112210-00023; Van Hoesen GW, 2000, ANN NY ACAD SCI, V911, P254; Van Hoesen GW, 2000, CEREB CORTEX, V10, P243, DOI 10.1093/cercor/10.3.243; Vogt BA, 1998, EXP NEUROL, V153, P8, DOI 10.1006/exnr.1998.6852; Zhang DQ, 1998, BRAIN RES, V811, P161, DOI 10.1016/S0006-8993(98)00935-4; Zhao WQ, 2002, NEUROBIOL DIS, V11, P166, DOI 10.1006/nbdi.2002.0520; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x	71	19	19	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2319	+		10.1096/fj.02-1147fje	http://dx.doi.org/10.1096/fj.02-1147fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563691				2022-12-28	WOS:000186343300023
J	Berger, P; Girodet, PO; Begueret, H; Ousova, O; Perng, DW; Marthan, R; Walls, AF; de Lara, JMT				Berger, P; Girodet, PO; Begueret, H; Ousova, O; Perng, DW; Marthan, R; Walls, AF; de Lara, JMT			Tryptase-stimulated human airway smooth muscle cells induce cytokine synthesis and mast cell chemotaxis	FASEB JOURNAL			English	Article						asthma; protease-activated receptor; transforming growth factor beta 1; stem cell factor	GROWTH-FACTOR-BETA; BRONCHOALVEOLAR LAVAGE FLUID; HUMAN-LUNG FIBROBLASTS; BRONCHIAL-ASTHMA; T-HELPER-2 CYTOKINES; ACTIVATED RECEPTOR-2; MESSENGER-RNA; EXPRESSION; RELEASE; CORTICOSTEROIDS	Asthmatic patients have higher numbers of mast cells in the smooth muscle layer of airways than normal subjects. Human airway smooth muscle cells (HASMCs) are a source of various cytokines including transforming growth factor beta1 (TGF-beta1), which is chemotactic for mast cells. We have thus examined the potential for interaction between HASMCs and mast cells and have investigated, in particular, the hypothesis that after stimulation, HASMCs can induce mast cell chemotaxis through the production of cytokines. Supernatants of HASMCs treated with the major mast cell product tryptase had increased chemotactic activity for the HMC-1 mast cell line. The effect depended on an intact catalytic site for tryptase and could be induced by a peptide agonist for protease activated receptor 2. Chemotactic activity was related to the synthesis of TGF-beta1 by HASMCs and, to a lesser extent, to stem cell factor. The number of mast cells within the smooth muscle layer of asthmatic patients was closely related to TGF-beta1 expression by smooth muscle. HASMCs may thus be able to stimulate the accumulation of mast cells, and these cells may, in turn, stimulate the secretion of chemotactic factors by HASMCs.	Univ Bordeaux 2, Lab Physiol Cellulaire Resp, INSERM, E0356, F-33076 Bordeaux, France; Southampton Gen Hosp, Immunopharmacol Grp, Southampton SO16 6YD, Hants, England; CHU Bordeaux, Hop Haut Leveque, Serv Malad Resp, F-33604 Pessac, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite de Bordeaux; University of Southampton; CHU Bordeaux	de Lara, JMT (corresponding author), Univ Bordeaux 2, Lab Physiol Cellulaire Resp, INSERM, E0356, 146 Rue Leo Saignat, F-33076 Bordeaux, France.	manuel.tunondelara@u-bordeaux2.fr	Berger, Patrick/D-8779-2012	Berger, Patrick/0000-0003-4702-0343; Marthan, Roger/0000-0001-5412-5712; Walls, Andrew/0000-0003-4803-4595; Girodet, Pierre-Olivier/0000-0002-9298-9711				Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123, DOI 10.1164/ajrccm.155.3.9116997; Berger P, 2001, J APPL PHYSIOL, V91, P1372, DOI 10.1152/jappl.2001.91.3.1372; Berger P, 1999, EUR RESPIR J, V14, P1394, DOI 10.1183/09031936.99.14613949; Berger P, 2001, J APPL PHYSIOL, V91, P995, DOI 10.1152/jappl.2001.91.2.995; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804, DOI 10.1164/ajrccm.154.6.8970374; Bohm SK, 1996, BIOCHEM J, V314, P1009; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BROWN JK, 1995, CHEST, V107, pS95, DOI 10.1378/chest.107.3_Supplement.95S; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369, DOI 10.1152/ajplung.2001.281.6.L1369; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; Coutts A, 2001, AM J PHYSIOL-LUNG C, V280, pL999, DOI 10.1152/ajplung.2001.280.5.L999; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951, DOI 10.1164/ajrccm.158.6.9803053; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863, DOI 10.1164/ajrccm/142.4.863; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933, DOI 10.1164/ajrccm.159.6.9805039; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22, DOI 10.1152/ajplung.1999.277.1.L22; He S, 1998, J PHARMACOL EXP THER, V286, P289; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; Hoshino M, 1998, THORAX, V53, P21, DOI 10.1136/thx.53.1.21; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83, DOI 10.1164/ajrccm/144.1.83; John M, 1998, AM J RESP CELL MOL, V18, P84, DOI 10.1165/ajrcmb.18.1.2813; John M, 1997, J IMMUNOL, V158, P1841; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kim YK, 1997, J ALLERGY CLIN IMMUN, V100, P389, DOI 10.1016/S0091-6749(97)70254-9; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; MATTOLI S, 1995, BIOCHEM BIOPH RES CO, V209, P316, DOI 10.1006/bbrc.1995.1505; McKay S, 1998, AM J RESP CELL MOL, V18, P823, DOI 10.1165/ajrcmb.18.6.2924; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326, DOI 10.1165/ajrcmb.17.3.2733; NILSSON G, 1994, J IMMUNOL, V153, P3717; Olsson N, 2000, J LEUKOCYTE BIOL, V67, P350, DOI 10.1002/jlb.67.3.350; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313, DOI 10.1152/ajplung.2001.281.6.L1313; PESCI A, 1993, AM REV RESPIR DIS, V147, P684, DOI 10.1164/ajrccm/147.3.684; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pype JL, 1999, AM J RESP CELL MOL, V21, P528, DOI 10.1165/ajrcmb.21.4.3660; RAGHU G, 1989, AM REV RESPIR DIS, V140, P95, DOI 10.1164/ajrccm/140.1.95; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642, DOI 10.1164/ajrccm.156.2.9605065; SCHWARTZ LB, 1986, J BIOL CHEM, V261, P7372; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591, DOI 10.1164/ajrccm.156.2.9609066; WALLS AF, 1990, CLIN EXP ALLERGY, V20, P581, DOI 10.1111/j.1365-2222.1990.tb03153.x; WENZEL SE, 1988, AM REV RESPIR DIS, V137, P1002, DOI 10.1164/ajrccm/137.5.1002	44	135	140	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2139	+		10.1096/fj.03-0041fje	http://dx.doi.org/10.1096/fj.03-0041fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500550				2022-12-28	WOS:000185925100012
J	Wersinger, C; Prou, D; Vernier, P; Sidhu, A				Wersinger, C; Prou, D; Vernier, P; Sidhu, A			Modulation of dopamine transporter function by alpha-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress	FASEB JOURNAL			English	Article						Parkinson's disease; synucleinopathies; MPP+; neurodegeneration; Lewy bodies	MULTIPLE-SYSTEM ATROPHY; CORTICAL LEWY BODIES; PARKINSONS-DISEASE; WILD-TYPE; NACP/ALPHA-SYNUCLEIN; NEURONAL CELLS; PROTEIN; PATHOGENESIS; MUTATIONS; INCLUSIONS	Human alpha-synuclein accumulates in dopaminergic neurons as intraneuronal inclusions, Lewy bodies, which are characteristic of idiopathic Parkinson's disease (PD). Here, we suggest that modulation of the functional activity of the dopamine transporter (DAT) by alpha-synuclein may be a key factor in the preferential degeneration of mesencephalic dopamine (DA)- synthesizing neurons in PD. In cotransfected Ltk-, HEK 293, and SK-N-MC cells, alpha-synuclein induced a 35% decrease in [H-3] DA uptake. Biotinylated DAT levels were decreased by 40% in cotransfected cells relative to cells expressing only DAT. DAT was colocalized with alpha-synuclein in mesencephalic neurons and cotransfected Ltk- cells. Coimmunoprecipitation studies showed the existence of a complex between alpha-synuclein and DAT, in specific rat brain regions and cotransfected cells, through specific amino acid motifs of both proteins. The attenuation of DAT function by alpha-synuclein was cytoprotective, because DA-mediated oxidative stress and cell death were reduced in cotransfected cells. The neurotoxin MPP+ (1-methyl-4-phenylpyridinium), oxidative stress, or impairment of cell adhesion ablated the alpha-synuclein-mediated inhibition of DAT activity, which caused increased uptake of DA and increased biotinylated DAT levels, in both mesencephalic neurons and cotransfected cells. These studies suggest a novel normative role for alpha-synuclein in regulating DA synaptic availability and homeostasis, which is relevant to the pathophysiology of PD.	Georgetown Univ, Dept Pediat, Washington, DC 20007 USA; CNRS, Inst Neurobiol Alfred Fessard, F-91198 Gif Sur Yvette, France	Georgetown University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Sidhu, A (corresponding author), Lab Mol Neurochem, Res Bldg,Room W222,3970 Reservoir Rd NW, Washington, DC 20007 USA.	sidhua@georgetown.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X				Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Alim MA, 2002, J BIOL CHEM, V277, P2112, DOI 10.1074/jbc.M102981200; Baba M, 1998, AM J PATHOL, V152, P879; Blum D, 2001, PROG NEUROBIOL, V65, P135, DOI 10.1016/S0301-0082(01)00003-X; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Chan P, 1998, NEUROLOGY, V50, P1136, DOI 10.1212/WNL.50.4.1136; Chen NH, 2000, EUR J PHARMACOL, V405, P329, DOI 10.1016/S0014-2999(00)00563-X; Ciliax BJ, 1999, J COMP NEUROL, V409, P38, DOI 10.1002/(SICI)1096-9861(19990621)409:1<38::AID-CNE4>3.0.CO;2-1; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; D'Andrea MR, 2001, NEUROSCI LETT, V306, P137, DOI 10.1016/S0304-3940(01)01811-0; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; Ebadi M, 2001, BIOL SIGNAL RECEPT, V10, P224; Eells JB, 2003, CURR MED CHEM, V10, P857, DOI 10.2174/0929867033457700; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Gai WP, 1998, LANCET, V352, P547, DOI 10.1016/S0140-6736(05)79256-4; Goedert M, 1998, MOL PSYCHIATR, V3, P462, DOI 10.1038/sj.mp.4000458; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Hashimoto M, 1999, NEUROREPORT, V10, P717, DOI 10.1097/00001756-199903170-00011; Hashimoto M, 2002, J BIOL CHEM, V277, P11465, DOI 10.1074/jbc.M111428200; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; Jensen PH, 1999, J BIOL CHEM, V274, P25481, DOI 10.1074/jbc.274.36.25481; Jensen PH, 2000, J BIOL CHEM, V275, P21500, DOI 10.1074/jbc.M000099200; Kahle PJ, 2000, ANN NY ACAD SCI, V920, P33; Kawamata H, 2001, J NEUROCHEM, V77, P929, DOI 10.1046/j.1471-4159.2001.00301.x; Kholodilov NG, 1999, NEUROSCI LETT, V275, P105, DOI 10.1016/S0304-3940(99)00740-5; Kholodilov NG, 1999, J NEUROCHEM, V73, P2586, DOI 10.1046/j.1471-4159.1999.0732586.x; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lavedan C, 1998, GENOME RES, V8, P871, DOI 10.1101/gr.8.9.871; Lee FJS, 2001, FASEB J, V15, P916, DOI 10.1096/fj.00-0334com; Lee M, 2001, J NEUROCHEM, V76, P998, DOI 10.1046/j.1471-4159.2001.00149.x; Lippa CF, 1999, ANN NEUROL, V45, P353, DOI 10.1002/1531-8249(199903)45:3<353::AID-ANA11>3.0.CO;2-4; LODER MK, 2003, IN PRESS J BIOL CHEM; Lotharius J, 2002, HUM MOL GENET, V11, P2395, DOI 10.1093/hmg/11.20.2395; Lotharius J, 2002, NAT REV NEUROSCI, V3, P932, DOI 10.1038/nrn983; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; Mori F, 2002, BRAIN RES, V941, P118, DOI 10.1016/S0006-8993(02)02643-4; Mouradian MM, 2002, NEUROLOGY, V58, P179, DOI 10.1212/WNL.58.2.179; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Nelson N, 1998, J NEUROCHEM, V71, P1785; Payton JE, 2001, MOL BRAIN RES, V95, P138, DOI 10.1016/S0169-328X(01)00257-1; Perez RG, 2002, J NEUROSCI, V22, P3090, DOI 10.1523/JNEUROSCI.22-08-03090.2002; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Pristupa ZB, 1998, SYNAPSE, V30, P79, DOI 10.1002/(SICI)1098-2396(199809)30:1<79::AID-SYN10>3.3.CO;2-I; Prou D, 2001, J CELL SCI, V114, P3517; Przedborski S, 2001, J NEUROCHEM, V76, P637, DOI 10.1046/j.1471-4159.2001.00174.x; Seo JH, 2002, FASEB J, V16, P1826, DOI 10.1096/fj.02-0041fje; Sharma N, 2001, AM J PATHOL, V159, P339, DOI 10.1016/S0002-9440(10)61700-2; Sidhu A, 1998, J NEUROCHEM, V70, P2459; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 2000, ANN NY ACAD SCI, V920, P16; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Stefanis L, 2001, J NEUROSCI, V21, P9549, DOI 10.1523/JNEUROSCI.21-24-09549.2001; Stephan A, 2002, HIPPOCAMPUS, V12, P55, DOI 10.1002/hipo.10006; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, ARCH NEUROL-CHICAGO, V55, P151, DOI 10.1001/archneur.55.2.151; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Wersinger C, 2003, NEUROSCI LETT, V340, P189, DOI 10.1016/S0304-3940(03)00097-1; Wersinger C, 2003, NEUROSCI LETT, V342, P124, DOI 10.1016/S0304-3940(03)00212-X; WERSINGER C, 2003, IN PRESS MOL CELL NE; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Zahniser NR, 2001, PHARMACOL THERAPEUT, V92, P21, DOI 10.1016/S0163-7258(01)00158-9; Zourlidou A, 2003, NEUROSCI LETT, V340, P234, DOI 10.1016/S0304-3940(03)00081-8	72	116	117	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2151	+		10.1096/fj.03-0152fje	http://dx.doi.org/10.1096/fj.03-0152fje			30	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958153				2022-12-28	WOS:000185925100029
J	Sasson, R; Dantes, A; Tajima, K; Amsterdam, A				Sasson, R; Dantes, A; Tajima, K; Amsterdam, A			Novel genes modulated by FSH in normal and immortalized FSH-responsive cells: new insights into the mechanism of FSH action	FASEB JOURNAL			English	Article						ovary; apoptosis; DNA microarray; granzyme; steroidogenesis; human granulosa cells	FOLLICLE-STIMULATING-HORMONE; ENDOTHELIAL GROWTH-FACTOR; IN-VITRO FERTILIZATION; HUMAN GRANULOSA-CELLS; OVARIAN HYPERSTIMULATION SYNDROME; PROTEIN-TYROSINE-PHOSPHATASE; HUMAN CHORIONIC-GONADOTROPIN; PROSTATIC ACID-PHOSPHATASE; FACTOR BINDING PROTEIN-3; GRANZYME-B INHIBITOR	Follicle-stimulating hormone (FSH) controls the development of follicle-enclosed oocytes in the mammalian ovary by interacting with specific receptors located exclusively on granulosa cells. Its biological activity involves stimulation of intercellular communication, intracellular signaling, and up-regulation of steroidogenesis; the entire spectrum of genes regulated by FSH is not yet fully characterized. We have established monoclonal rat FSH-responsive granulosa cell lines that express FSH receptors at 20-fold higher rates than with primary cells, and thus increased the probability of yielding a distinct spectrum of genes modulated by FSH. Using Affymetrix DNA microarrays, we discovered 11 genes not reported earlier to be upregulated by FSH and 9 genes not reported earlier to be down-regulated by FSH. Modulation of signal transduction associated with G-protein signaling, phosphorylation of proteins, and intracellular-extracellular ion balance was suggested by up-regulation of decay accelerating factor GPI-form precursor (DAF), membrane interacting protein RGS16, protein tyrosine phosphatase ( PTPase), oxidative stress-inducible protein tyrosine phosphatase (OSIPTPase), and downregulation of rat prostatic acid phosphatase (rPAP), Na+, K+-ATPase, and protein phosphatase 1beta. Elevation in granzyme-like proteins 1 and 3, and natural killer (NK) cell protease 1 (NKP-1) along with reduction in carboxypeptidase E indicates possible FSH-mediated preparation of the cells for apoptosis. Upregulation of vascular endothelial growth factors indicates the ability of FSH to produce angiogenic factors upon their maturation; whereas, reduction in insulin-like growth factor binding protein (IGFBP3) indicates its increased potential to promote p53-induced apoptosis. Striking similarities in FSH modulation of gene expression were found in primary cultures of human granulosa cells obtained from IVF patients although these cells expressed only 1% of FSH receptor compared with immortalized rat cells, as indicated by microarray technique, which probably is in the normal range of expression of this receptor in nontransformed cells. These findings should increase our understanding of the mechanism of FSH action in stimulating development of the ovarian follicular cells, of intracellular and intercellular communication, and of increasing the potential of ovarian follicular cells to undergo apoptosis during the process of selection of the dominant follicle.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Amsterdam, A (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	abraham.amsterdam@weizmann.ac.il						AHARONI D, 1995, EXP CELL RES, V218, P271, DOI 10.1006/excr.1995.1156; Aharoni D, 1997, CURR BIOL, V7, P43, DOI 10.1016/S0960-9822(06)00026-1; ALBERTINI DF, 1974, J CELL BIOL, V63, P234, DOI 10.1083/jcb.63.1.234; Almog B, 2001, MOL CELL ENDOCRINOL, V183, P179, DOI 10.1016/S0303-7207(01)00543-3; Amato G, 1999, FERTIL STERIL, V72, P454, DOI 10.1016/S0015-0282(99)00288-5; AMSTERDAM A, 1988, P NATL ACAD SCI USA, V85, P7582, DOI 10.1073/pnas.85.20.7582; Amsterdam A, 1999, TRENDS ENDOCRIN MET, V10, P255, DOI 10.1016/S1043-2760(99)00164-2; AMSTERDAM A, 1989, TRENDS BIOCHEM SCI, V14, P377, DOI 10.1016/0968-0004(89)90012-1; Amsterdam A, 1997, ENDOCR REV, V18, P435, DOI 10.1210/er.18.4.435; AMSTERDAM A, 1992, BIOL REPROD, V46, P513, DOI 10.1095/biolreprod46.4.513; Amsterdam A, 2002, MOL CELL ENDOCRINOL, V187, P69, DOI 10.1016/S0303-7207(01)00701-8; AMSTERDAM A, 1987, ENDOCR REV, V8, P309, DOI 10.1210/edrv-8-3-309; AMSTERDAM A, 1975, J CELL BIOL, V67, P894, DOI 10.1083/jcb.67.3.894; AMSTERDAM A, 1976, J CELL SCI, V21, P93; Amsterdam A., 1993, OVARY, P487; Barkan D, 1999, ENDOCRINOLOGY, V140, P1731, DOI 10.1210/en.140.4.1731; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Bladergroen BA, 2001, J IMMUNOL, V166, P3218, DOI 10.4049/jimmunol.166.5.3218; Breckwoldt M, 1996, MOL HUM REPROD, V2, P391, DOI 10.1093/molehr/2.6.391; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; COHEN PTW, 1988, FEBS LETT, V232, P17, DOI 10.1016/0014-5793(88)80378-8; CONN G, 1990, P NATL ACAD SCI USA, V87, P2628, DOI 10.1073/pnas.87.7.2628; Cool DR, 1998, MOL CELL ENDOCRINOL, V139, P7, DOI 10.1016/S0303-7207(98)00081-1; Del Razo LM, 2001, TOXICOL APPL PHARM, V177, P132, DOI 10.1006/taap.2001.9291; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; Enskog A, 2001, EUR J OBSTET GYN R B, V96, P196, DOI 10.1016/S0301-2115(00)00460-7; EVA C, 1992, FEBS LETT, V314, P285, DOI 10.1016/0014-5793(92)81490-D; Faigle W, 2000, MOL BIOL CELL, V11, P3485, DOI 10.1091/mbc.11.10.3485; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; Fritz S, 2001, J CLIN ENDOCR METAB, V86, P349, DOI 10.1210/jc.86.1.349; GEBAUER H, 1978, BIOL REPROD, V18, P350, DOI 10.1095/biolreprod18.3.350; Ghersi G, 2001, PEPTIDES, V22, P453, DOI 10.1016/S0196-9781(01)00340-0; Gonzalez-Robayna IJ, 2000, MOL ENDOCRINOL, V14, P1283, DOI 10.1210/me.14.8.1283; GRIGORENKO VG, 1994, FEBS LETT, V342, P278, DOI 10.1016/0014-5793(94)80516-4; Grosse J, 2000, BIOL REPROD, V63, P643, DOI 10.1095/biolreprod63.2.643; HANUKOGLU I, 1990, J CELL BIOL, V111, P1373, DOI 10.1083/jcb.111.4.1373; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4688, DOI 10.1210/en.139.11.4688; Hosokawa K, 1998, ENDOCRINOLOGY, V139, P4679, DOI 10.1210/en.139.11.4679; KERENTAL I, 1993, MOL CELL ENDOCRINOL, V95, pR1, DOI 10.1016/0303-7207(93)90042-I; KERENTAL I, 1995, EXP CELL RES, V218, P283, DOI 10.1006/excr.1995.1157; KerenTal I, 1997, MOL CELL ENDOCRINOL, V127, P49, DOI 10.1016/S0303-7207(96)03989-5; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; Leo CP, 2001, BIOL REPROD, V65, P269, DOI 10.1095/biolreprod65.1.269; Lin MF, 2001, J UROLOGY, V166, P1943, DOI 10.1016/S0022-5347(05)65725-4; Liu HC, 2001, FERTIL STERIL, V75, P947, DOI 10.1016/S0015-0282(01)01706-X; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Lucas AD, 2001, AM J PATHOL, V158, P855, DOI 10.1016/S0002-9440(10)64034-5; Miwa T, 2000, IMMUNOGENETICS, V51, P129, DOI 10.1007/s002510050021; Morohashi KI, 1996, FASEB J, V10, P1569, DOI 10.1096/fasebj.10.14.9002548; Nagai Y, 1999, J BIOL CHEM, V274, P11053, DOI 10.1074/jbc.274.16.11053; Neulen J, 1998, MOL HUM REPROD, V4, P203, DOI 10.1093/molehr/4.3.203; OMURA T, 1995, J STEROID BIOCHEM, V53, P19, DOI 10.1016/0960-0760(95)00036-Y; Pham CTN, 1999, P NATL ACAD SCI USA, V96, P8627, DOI 10.1073/pnas.96.15.8627; Pierce SB, 2001, GENE DEV, V15, P672, DOI 10.1101/gad.867301; PLATE KH, 1993, CANCER RES, V53, P5822; Rajasekaran SA, 2001, MOL BIOL CELL, V12, P279, DOI 10.1091/mbc.12.2.279; RENNERT H, 1991, BIOCHEMISTRY-US, V30, P11280, DOI 10.1021/bi00111a013; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Rizk B, 1997, HUM REPROD UPDATE, V3, P255, DOI 10.1093/humupd/3.3.255; Robker RL, 2000, STEROIDS, V65, P559, DOI 10.1016/S0039-128X(00)00114-8; Sasson R, 2002, J CLIN ENDOCR METAB, V87, P3441, DOI 10.1210/jc.87.7.3441; Sasson R, 2002, BIOCHEM BIOPH RES CO, V294, P51, DOI 10.1016/S0006-291X(02)00431-X; Sasson R, 2001, ENDOCRINOLOGY, V142, P802, DOI 10.1210/en.142.2.802; Schams D, 2001, EXP CLIN ENDOCR DIAB, V109, P155, DOI 10.1055/s-2001-14839; SHASTRI N, 1993, J IMMUNOL, V150, P2724; SHI LF, 1992, J EXP MED, V175, P553, DOI 10.1084/jem.175.2.553; SHUKOVSKI L, 1995, ENDOCRINOLOGY, V136, P2889, DOI 10.1210/en.136.7.2889; SIDHU J, 1993, CANCER, V72, P1673, DOI 10.1002/1097-0142(19930901)72:5<1673::AID-CNCR2820720530>3.0.CO;2-G; Sommersberg B, 2000, BIOL REPROD, V63, P1661, DOI 10.1095/biolreprod63.6.1661; Spicer LJ, 1999, DOMEST ANIM ENDOCRIN, V16, P19, DOI 10.1016/S0739-7240(98)00049-6; SUH BS, 1992, J CELL BIOL, V119, P439, DOI 10.1083/jcb.119.2.439; SUH BS, 1990, ENDOCRINOLOGY, V127, P2489; Sun JR, 1997, J BIOL CHEM, V272, P15434, DOI 10.1074/jbc.272.24.15434; Tajima K, 2002, MOL HUM REPROD, V8, P48, DOI 10.1093/molehr/8.1.48; Tao JC, 2001, J BIOL CHEM, V276, P29520, DOI 10.1074/jbc.M103721200; Terranova PF, 1997, AM J REPROD IMMUNOL, V37, P50; Tripp RA, 2001, NAT IMMUNOL, V2, P732, DOI 10.1038/90675; Wang GQ, 2001, J EXP MED, V194, P1325, DOI 10.1084/jem.194.9.1325; Wen XY, 2001, MAMM GENOME, V12, P129, DOI 10.1007/s003350010256; ZUNINO SJ, 1990, J IMMUNOL, V144, P2001	80	78	82	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUL	2003	17	10					1256	1266		10.1096/fj.02-0740com	http://dx.doi.org/10.1096/fj.02-0740com			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832290				2022-12-28	WOS:000184471600037
J	Taylor, NA; Van de Ven, WJM; Creemers, JWM				Taylor, NA; Van de Ven, WJM; Creemers, JWM			Curbing activation: proprotein convertases in homeostasis and pathology	FASEB JOURNAL			English	Review						knockout mice; human patients; viral and bacterial infection; Alzheimer's disease; inhibitors	NEUROENDOCRINE PROTEIN 7B2; FAMILIAL BRITISH DEMENTIA; PROSAAS-DERIVED PEPTIDES; EBOLA-VIRUS GLYCOPROTEIN; PROHORMONE CONVERTASE; PROCESSING ENZYME; GENE-EXPRESSION; SMALL-CELL; NULL MICE; FUR GENE	The proprotein convertases (PCs) are a seven-member family of endoproteases that activate proproteins by cleavage at basic motifs. Expression patterns for individual PCs vary widely, and all cells express several members. The list of substrates activated by PCs has grown to include neuropeptides, peptide hormones, growth and differentiation factors, receptors, enzymes, adhesion molecules, blood coagulation factors, plasma proteins, viral coat proteins, and bacterial toxins. It has become clear that the PC family plays a crucial role in a variety of physiological processes and is involved in the pathology of diseases such as cancer, viral infection, and Alzheimer's disease. Recent studies using PC inhibitors have demonstrated their potential as therapeutic targets. Despite the avalanche of in vitro data, the physiological role of individual PCs has remained largely elusive. Recently, however, knockout mouse models have been developed for furin, PC1, PC2, PC4, PC6B, LPC, and PACE4, and human patients with PC1 deficiency have been identified. The phenotypes range from undetectable to early embryonic lethality. The major lesson learned from these studies is that specific PC - substrate pairs do exist, but that there is substantial redundancy for the majority of substrates. To some extent, redundancy may be cell type and even species dependent.	Katholieke Univ Leuven, Dept Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	KU Leuven	Creemers, JWM (corresponding author), Katholieke Univ Leuven, Dept Human Genet, Mol Oncol Lab, Gasthuisberg O-N 6,Herestr 49, B-3000 Louvain, Belgium.	john.creemers@med.kuleuven.ac.be						Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Allen RG, 2001, J NEUROSCI, V21, P5864, DOI 10.1523/JNEUROSCI.21-16-05864.2001; Anderson ED, 2002, J BIOL CHEM, V277, P12879, DOI 10.1074/jbc.M108740200; ANDERSON GD, 1993, PAC J MATH, V160, P1; Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Apletalina EV, 2000, BIOCHEM BIOPH RES CO, V267, P940, DOI 10.1006/bbrc.1999.2060; Balyasnikova IV, 2002, BIOCHEM J, V362, P585, DOI 10.1042/0264-6021:3620585; Basak A, 2001, J BIOL CHEM, V276, P32720, DOI 10.1074/jbc.M104064200; Bassi DE, 2000, MOL CARCINOGEN, V28, P63, DOI 10.1002/1098-2744(200006)28:2<63::AID-MC1>3.3.CO;2-3; Bassi DE, 2001, P NATL ACAD SCI USA, V98, P10326, DOI 10.1073/pnas.191199198; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BEAMER WG, 1976, J ENDOCRINOL, V71, P37, DOI 10.1677/joe.0.0710037; Beauregard KE, 2000, CELL MICROBIOL, V2, P251, DOI 10.1046/j.1462-5822.2000.00052.x; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BENJANNET S, 1991, P NATL ACAD SCI USA, V88, P3564, DOI 10.1073/pnas.88.9.3564; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Berman Y, 2000, J NEUROCHEM, V75, P1763, DOI 10.1046/j.1471-4159.2000.0751763.x; Berthet V, 2000, J BIOL CHEM, V275, P33308, DOI 10.1074/jbc.M004834200; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Blobel CP, 2000, REV REPROD, V5, P75, DOI 10.1530/revreprod/5.2.75; Boheler KR, 2002, CIRC RES, V91, P189, DOI 10.1161/01.RES.0000027865.61704.32; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; Cameron A, 2000, J BIOL CHEM, V275, P36741, DOI 10.1074/jbc.M003848200; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Cheng M, 1997, INT J CANCER, V71, P966, DOI 10.1002/(SICI)1097-0215(19970611)71:6<966::AID-IJC10>3.3.CO;2-A; Constam DB, 1996, J CELL BIOL, V134, P181, DOI 10.1083/jcb.134.1.181; Constam DB, 2000, GENE DEV, V14, P1146; CREEMERS JWM, 1995, J BIOL CHEM, V270, P2695, DOI 10.1074/jbc.270.6.2695; CREEMERS JWM, 1992, FEBS LETT, V300, P82, DOI 10.1016/0014-5793(92)80169-H; CREEMERS JWM, 1993, J BIOL CHEM, V268, P21826; Creemers JWM, 2001, J BIOL CHEM, V276, P4211, DOI 10.1074/jbc.M006947200; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; Dahlen JR, 1998, J BIOL CHEM, V273, P1851, DOI 10.1074/jbc.273.4.1851; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; Decroly E, 1997, FEBS LETT, V405, P68, DOI 10.1016/S0014-5793(97)00156-7; Decroly E, 1996, J BIOL CHEM, V271, P30442, DOI 10.1074/jbc.271.48.30442; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Feng Y, 2001, NEUROSCIENCE, V105, P469, DOI 10.1016/S0306-4522(01)00200-7; Fortenberry Y, 2002, J BIOL CHEM, V277, P5175, DOI 10.1074/jbc.M104531200; Fugere M, 2002, J BIOL CHEM, V277, P7648, DOI 10.1074/jbc.M107467200; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; Furuta M, 1998, J BIOL CHEM, V273, P3431, DOI 10.1074/jbc.273.6.3431; Furuta M, 1997, P NATL ACAD SCI USA, V94, P6646, DOI 10.1073/pnas.94.13.6646; Furuta M, 2001, J BIOL CHEM, V276, P27197, DOI 10.1074/jbc.M103362200; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; Gordon VM, 1997, INFECT IMMUN, V65, P3370, DOI 10.1128/IAI.65.8.3370-3375.1997; Gu ML, 1996, INFECT IMMUN, V64, P524, DOI 10.1128/IAI.64.2.524-527.1996; Hagaman JR, 1998, P NATL ACAD SCI USA, V95, P2552, DOI 10.1073/pnas.95.5.2552; HALLENBERGER S, 1992, NATURE, V360, P358, DOI 10.1038/360358a0; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Hubbard FC, 1997, CANCER RES, V57, P5226; Hwang JR, 2001, J NEUROCHEM, V79, P437, DOI 10.1046/j.1471-4159.2001.00594.x; Jackson RS, 1997, NAT GENET, V16, P303, DOI 10.1038/ng0797-303; Jean F, 2000, P NATL ACAD SCI USA, V97, P2864, DOI 10.1073/pnas.050504297; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Kangas H, 2002, AMYLOID, V9, P83, DOI 10.3109/13506120208995240; Khatib AM, 2002, AM J PATHOL, V160, P1921, DOI 10.1016/S0002-9440(10)61140-6; Khatib AM, 2001, J BIOL CHEM, V276, P30686, DOI 10.1074/jbc.M101725200; Kim SH, 2002, J BIOL CHEM, V277, P1872, DOI 10.1074/jbc.M108739200; Kim SH, 1999, NAT NEUROSCI, V2, P984, DOI 10.1038/14783; Lanoue E, 2001, ENDOCRINOLOGY, V142, P4141, DOI 10.1210/en.142.9.4141; Laurent V, 2002, P NATL ACAD SCI USA, V99, P3087, DOI 10.1073/pnas.261715099; Leitlein J, 2001, J IMMUNOL, V166, P7238, DOI 10.4049/jimmunol.166.12.7238; Li M, 1999, NEUROENDOCRINOLOGY, V69, P217, DOI 10.1159/000054422; Li M, 2000, ENDOCRINOLOGY, V141, P3723, DOI 10.1210/en.141.10.3723; Li M, 2000, ANN NY ACAD SCI, V921, P333; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P7780, DOI 10.1021/bi00023a027; LINDBERG I, 1995, BIOCHEMISTRY-US, V34, P5486, DOI 10.1021/bi00016a020; LIPKIND G, 1995, J BIOL CHEM, V270, P13277, DOI 10.1074/jbc.270.22.13277; Lipkind GM, 1998, P NATL ACAD SCI USA, V95, P7310, DOI 10.1073/pnas.95.13.7310; Lissitzky JC, 2000, BIOCHEM J, V346, P133, DOI 10.1042/0264-6021:3460133; Lowe LA, 2001, DEVELOPMENT, V128, P1831; Mahloogi H, 2002, CARCINOGENESIS, V23, P565, DOI 10.1093/carcin/23.4.565; Maisner A, 2000, J GEN VIROL, V81, P441, DOI 10.1099/0022-1317-81-2-441; Mbikay M, 1997, BRIT J CANCER, V75, P1509, DOI 10.1038/bjc.1997.258; Mbikay M, 1997, P NATL ACAD SCI USA, V94, P6842, DOI 10.1073/pnas.94.13.6842; McKee ML, 1999, BIOCHEMISTRY-US, V38, P16507, DOI 10.1021/bi991308+; Meerabux J, 1996, CANCER RES, V56, P448; Mercapide J, 2002, CLIN CANCER RES, V8, P1740; Miranda L, 1996, P NATL ACAD SCI USA, V93, P7695, DOI 10.1073/pnas.93.15.7695; MOLLOY SS, 1994, EMBO J, V13, P18, DOI 10.1002/j.1460-2075.1994.tb06231.x; Mori K, 1999, J BIOCHEM-TOKYO, V125, P627, DOI 10.1093/oxfordjournals.jbchem.a022329; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; Neumann G, 2002, J VIROL, V76, P406, DOI 10.1128/JVI.76.1.406-410.2002; North WG, 1998, PEPTIDES, V19, P1743, DOI 10.1016/S0196-9781(98)00130-2; Nour N, 2003, J BIOL CHEM, V278, P2886, DOI 10.1074/jbc.M208009200; OHNISHI Y, 1994, J VIROL, V68, P4075, DOI 10.1128/JVI.68.6.4075-4079.1994; ORAHILLY S, 1995, NEW ENGL J MED, V333, P1386, DOI 10.1056/NEJM199511233332104; Paquet L, 1996, J NEUROSCI, V16, P964; Polette M, 1998, INT J BIOCHEM CELL B, V30, P1195, DOI 10.1016/S1357-2725(98)00083-1; Qian YM, 2000, J BIOL CHEM, V275, P23596, DOI 10.1074/jbc.M001583200; Rancourt SL, 1997, DEV GENET, V21, P75, DOI 10.1002/(SICI)1520-6408(1997)21:1&lt;75::AID-DVG9&gt;3.0.CO;2-5; Rehfeld JF, 2002, FEBS LETT, V510, P89, DOI 10.1016/S0014-5793(01)03234-3; RHODES CJ, 1992, J BIOL CHEM, V267, P22719; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; ROEBROEK AJM, 1992, J BIOL CHEM, V267, P17208; Roebroek AJM, 1998, DEVELOPMENT, V125, P4863; Rounseville MP, 2000, J MOL ENDOCRINOL, V25, P121, DOI 10.1677/jme.0.0250121; Sarac MS, 2002, INFECT IMMUN, V70, P7136, DOI 10.1128/IAI.70.12.7136-7139.2002; Sayah M, 2001, J NEUROCHEM, V76, P1833, DOI 10.1046/j.1471-4159.2001.00165.x; SCHALKEN JA, 1987, J CLIN INVEST, V80, P1545, DOI 10.1172/JCI113240; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Seidah NG, 1998, ANN NY ACAD SCI, V839, P9, DOI 10.1111/j.1749-6632.1998.tb10727.x; Seidel B, 1998, DNA CELL BIOL, V17, P1017, DOI 10.1089/dna.1998.17.1017; Shintani N, 2002, REGUL PEPTIDES, V109, P45, DOI 10.1016/S0167-0115(02)00169-6; Siezen RJ, 1997, PROTEIN SCI, V6, P501; SPENCE MJ, 1995, SOMAT CELL MOLEC GEN, V21, P1, DOI 10.1007/BF02255818; STEINER DF, 1967, SCIENCE, V157, P697, DOI 10.1126/science.157.3789.697; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; Sucic JF, 1999, BIOCHEM J, V339, P639, DOI 10.1042/0264-6021:3390639; TAKAHASHI S, 1995, J BIOL CHEM, V270, P26565, DOI 10.1074/jbc.270.44.26565; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; THOMAS L, 1991, P NATL ACAD SCI USA, V88, P5297, DOI 10.1073/pnas.88.12.5297; Ulloa L, 2001, J BIOL CHEM, V276, P21387, DOI 10.1074/jbc.M006933200; vandeLoo JWHP, 1997, J BIOL CHEM, V272, P27116, DOI 10.1074/jbc.272.43.27116; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; Viale A, 1999, J BIOL CHEM, V274, P6536, DOI 10.1074/jbc.274.10.6536; Villeneuve P, 2002, J NEUROCHEM, V82, P783, DOI 10.1046/j.1471-4159.2002.00988.x; Vishnuvardhan D, 2000, BIOCHEM BIOPH RES CO, V273, P188, DOI 10.1006/bbrc.2000.2915; Volchkov VE, 1998, P NATL ACAD SCI USA, V95, P5762, DOI 10.1073/pnas.95.10.5762; Wang J, 2001, DIABETES, V50, P534, DOI 10.2337/diabetes.50.3.534; WATANABE M, 1995, J VIROL, V69, P3206, DOI 10.1128/JVI.69.5.3206-3210.1995; Webb GC, 2002, DIABETES, V51, P398, DOI 10.2337/diabetes.51.2.398; Westphal CH, 1999, CELL, V96, P689, DOI 10.1016/S0092-8674(00)80579-6; YI Z, 1993, J BIOL CHEM, V268, P5615; Zambon MC, 2001, REV MED VIROL, V11, P227, DOI 10.1002/rmv.319; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913; Zhou A, 1998, J BIOL CHEM, V273, P11107, DOI 10.1074/jbc.273.18.11107; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10299, DOI 10.1073/pnas.162352799; Zhu XR, 2002, P NATL ACAD SCI USA, V99, P10293, DOI 10.1073/pnas.162352599	135	170	193	0	12	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1215	1227		10.1096/fj.02-0831rev	http://dx.doi.org/10.1096/fj.02-0831rev			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12832286				2022-12-28	WOS:000184471600033
J	Blaber, SI; Ciric, B; Christophi, GP; Bernett, MJ; Blaber, M; Rodriguez, M; Scarisbrick, IA				Blaber, SI; Ciric, B; Christophi, GP; Bernett, MJ; Blaber, M; Rodriguez, M; Scarisbrick, IA			Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease	FASEB JOURNAL			English	Article						experimental autoimmune encephalomyelitis; myelin; inflammation; injury; enzyme	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MYELENCEPHALON-SPECIFIC PROTEASE; RAT SPINAL-CORD; MULTIPLE-SCLEROSIS; SERINE-PROTEASE; ZYME/PROTEASE M/NEUROSIN; ALZHEIMERS-DISEASE; BIOCHEMICAL-CHARACTERIZATION	Kallikrein 6 (K6, MSP) is a newly identified member of the Kallikrein family of serine proteases that is preferentially expressed in the adult central nervous system (CNS). We have previously demonstrated that K6 is abundantly expressed by inflammatory cells at sites of CNS inflammation and demyelination in animal models of multiple sclerosis (MS) and in human MS lesions. To test the hypothesis that this novel enzyme is a mediator of pathogenesis in CNS inflammatory disease, we have evaluated whether autonomously generated K6 antibodies alter the clinicopathological course of disease in murine proteolipid protein139-151-induced experimental autoimmune encephalomyelitis (PLP139-151 EAE). We demonstrate that immunization of mice with recombinant K6 generates antibodies that block K6 enzymatic activity in vitro, including the breakdown of myelin basic protein (MBP), and that K6-immunized mice exhibit significantly delayed onset and severity of clinical deficits. Reduced clinical deficits were reflected in significantly less spinal cord pathology and meningeal inflammation and in reduced Th1 cellular responses in vivo and in vitro. These data demonstrate for the first time that K6 participates in enzymatic cascades mediating CNS inflammatory disease and that this unique enzyme may represent a novel therapeutic target for the treatment of progressive inflammatory disorders, including MS.	Florida State Univ, Dept Chem & Biochem, Inst Mol Biophys, Tallahassee, FL 32306 USA; Mayo Clin & Mayo Grad Sch Med, Program Mol Neurosci, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Neurol, Rochester, MN 55905 USA; Mayo Clin & Mayo Grad Sch Med, Dept Phys Med & Rehabil, Rochester, MN 55905 USA	State University System of Florida; Florida State University; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Scarisbrick, IA (corresponding author), Mayo Clin & Mayo Fdn, Dept Neurol, 428 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.	Scarisbrick.Isobel@Mayo.edu	Blaber, Michael/E-7478-2011; Blaber, Michael/N-1083-2019; Blaber, Michael/ABA-5031-2021	Blaber, Michael/0000-0002-6856-1643; Rodriguez, Moses/0000-0001-6328-6497				Anisowicz A, 1996, MOL MED, V2, P624, DOI 10.1007/BF03401646; Bauer J, 1995, GLIA, V15, P437, DOI 10.1002/glia.440150407; Begolka WS, 1998, J IMMUNOL, V161, P4437; Bernett MJ, 2002, J BIOL CHEM, V277, P24562, DOI 10.1074/jbc.M202392200; Bever CT, 1999, NEUROLOGY, V53, P1380, DOI 10.1212/WNL.53.7.1380; Blaber SI, 2002, BIOCHEMISTRY-US, V41, P1165, DOI 10.1021/bi015781a; BROSNAN CF, 1981, J IMMUNOL, V126, P614; Brown PD, 2000, EXPERT OPIN INV DRUG, V9, P2167, DOI 10.1517/13543784.9.9.2167; Brundula V, 2002, BRAIN, V125, P1297, DOI 10.1093/brain/awf133; Diamandis EP, 2000, CLIN BIOCHEM, V33, P663, DOI 10.1016/S0009-9120(00)00185-5; Diamandis EP, 2000, CLIN BIOCHEM, V33, P579, DOI 10.1016/S0009-9120(00)00182-X; GIJBELS K, 1994, J CLIN INVEST, V94, P2177, DOI 10.1172/JCI117578; Harvey TJ, 2000, J BIOL CHEM, V275, P37397, DOI 10.1074/jbc.M004525200; HEWSON AK, 1995, INFLAMM RES, V44, P345, DOI 10.1007/BF01796266; HUITINGA I, 1995, CLIN EXP IMMUNOL, V100, P344; KRONER H, 1997, J EXP MED, V186, P1585; LEONARD JP, 1995, J EXP MED, V181, P381, DOI 10.1084/jem.181.1.381; Little SP, 1997, J BIOL CHEM, V272, P25135, DOI 10.1074/jbc.272.40.25135; Matsui H, 2000, J BIOL CHEM, V275, P11050, DOI 10.1074/jbc.275.15.11050; Meier N, 1999, BIOCHEM BIOPH RES CO, V258, P374, DOI 10.1006/bbrc.1999.0600; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; MILLER SD, 1994, IMMUNOL TODAY, V15, P356, DOI 10.1016/0167-5699(94)90173-2; Norga K, 1995, INFLAMM RES, V44, P529, DOI 10.1007/BF01757357; Okui A, 2001, NEUROREPORT, V12, P1345, DOI 10.1097/00001756-200105250-00011; PANITCH HS, 1987, NEUROLOGY, V37, P1097, DOI 10.1212/WNL.37.7.1097; Petersen DM, 2002, AM J EVAL, V23, P55, DOI 10.1177/109821400202300106; Petraki CD, 2001, J HISTOCHEM CYTOCHEM, V49, P1431, DOI 10.1177/002215540104901111; PIERCE M, 1989, J HISTOTECHNOL, V12, P35; RACKE MK, 1994, J EXP MED, V180, P1961, DOI 10.1084/jem.180.5.1961; Ransohoff RM, 1997, J LEUKOCYTE BIOL, V62, P645, DOI 10.1002/jlb.62.5.645; RODRIGUEZ M, 1988, J IMMUNOL, V140, P2950; Romanic AM, 1997, LAB INVEST, V76, P11; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; Scarisbrick IA, 2000, GLIA, V30, P219, DOI 10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2; Scarisbrick IA, 2002, BRAIN, V125, P1283, DOI 10.1093/brain/awf142; Scarisbrick IA, 2001, J COMP NEUROL, V431, P347; Scarisbrick IA, 1997, J NEUROSCI, V17, P8156; Sellebjerg F, 2000, EUR J NEUROL, V7, P281, DOI 10.1046/j.1468-1331.2000.00074.x; Shimizu-Okabe C, 2001, NEUROREPORT, V12, P2747, DOI 10.1097/00001756-200108280-00031; Theien BE, 2001, J CLIN INVEST, V107, P995, DOI 10.1172/JCI11717; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; Tran EH, 1998, J IMMUNOL, V161, P3767; von Budingen HC, 2002, P NATL ACAD SCI USA, V99, P8207, DOI 10.1073/pnas.122092499; Weller RO, 1996, BRAIN PATHOL, V6, P275, DOI 10.1111/j.1750-3639.1996.tb00855.x; Yamashiro K, 1997, BBA-GENE STRUCT EXPR, V1350, P11, DOI 10.1016/S0167-4781(96)00187-X; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yousef GM, 1999, GENOMICS, V62, P251, DOI 10.1006/geno.1999.6012; Yousef GM, 2001, ENDOCR REV, V22, P184, DOI 10.1210/er.22.2.184	48	85	90	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3					920	+		10.1096/fj.03-1212fje	http://dx.doi.org/10.1096/fj.03-1212fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033932				2022-12-28	WOS:000220522800017
J	Fadeel, B; Orrenius, S; Pervaiz, S				Fadeel, B; Orrenius, S; Pervaiz, S			Buried alive: a novel approach to cancer treatment	FASEB JOURNAL			English	Article						cancer cells; apoptosis; scavenger receptors; phagocytosis; cell clearance	CELL-DEATH; CLEARANCE; PHOSPHATIDYLSERINE; APOPTOSIS; AUTOANTIGENS; PHAGOCYTOSIS; STRESS	The heightened interest in the development of novel anti-cancer drugs that trigger apoptotic death in cancer cells stems from the fact that immediately upon execution of the death signal, the corpse is efficiently removed via specific recruitment of phagocytic cells. This prevents spilling of cellular contents and the associated inflammatory response, a likely scenario during necrotic death. Recent evidence has established that phagocytic removal of apoptotic cells is a function of ligand-receptor interaction, whereby the ligand(s) for the scavenger receptor(s) of phagocytic cells is/are specifically expressed on apoptosing cells. Therefore, by implication, enhancing this ligand-receptor interaction could be an alternate means for removing unwanted cells. Here we present a provocative hypothesis that circumvents the need for chemotherapy-induced apoptosis in cancer cells. According to our model, cancer cells need not die in order to be removed by scavenger cells, but could still be effectively phagocytosed provided the cell surface expression of specific molecules that strongly engage phagocytic cells is sufficiently enhanced. In other words, inducing the expression of "eat me" signals on cancer cells could be a novel approach to "bury alive" these unwanted cells without the untoward effects of chemotherapy-induced apoptosis.	Natl Univ Singapore, Fac Med, Dept Physiol, NUS Grad Sch Integrat Sci & Engn, Singapore 117548, Singapore; Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	National University of Singapore; Karolinska Institutet	Pervaiz, S (corresponding author), Natl Univ Singapore, Fac Med, Dept Physiol, NUS Grad Sch Integrat Sci & Engn, MD9 03-06, Singapore 117548, Singapore.	phssp@nus.edu.sg	Pervaiz, Shazib/C-4188-2015					Bergsmedh A, 2001, P NATL ACAD SCI USA, V98, P6407, DOI 10.1073/pnas.101129998; Brown S, 2002, NATURE, V418, P200, DOI 10.1038/nature00811; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; Casiano CA, 1996, J EXP MED, V184, P765, DOI 10.1084/jem.184.2.765; FADEEL B, 2003, IN PRESS CELL MOL LI; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Herr I, 2001, BLOOD, V98, P2603, DOI 10.1182/blood.V98.9.2603; Hoeppner DJ, 2001, NATURE, V412, P202, DOI 10.1038/35084103; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; Mevorach D, 1998, J EXP MED, V188, P387, DOI 10.1084/jem.188.2.387; Pervaiz S, 2002, CURR PHARM DESIGN, V8, P1723, DOI 10.2174/1381612023394025; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; SCHROIT AJ, 1985, J BIOL CHEM, V260, P5131	18	14	18	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					1	4		10.1096/fj.03-0510hyp	http://dx.doi.org/10.1096/fj.03-0510hyp			4	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14718381				2022-12-28	WOS:000188829300034
J	Gomez-Ambrosi, J; Catalan, V; Diez-Caballero, A; Martinez-Cruz, LA; Gil, MJ; Garcia-Foncillas, J; Cienfuegoas, JA; Salvador, J; Mato, JM; Fruhbeck, G				Gomez-Ambrosi, J; Catalan, V; Diez-Caballero, A; Martinez-Cruz, LA; Gil, MJ; Garcia-Foncillas, J; Cienfuegoas, JA; Salvador, J; Mato, JM; Fruhbeck, G			Gene expression profile of omental adipose tissue in human obesity	FASEB JOURNAL			English	Article						adipocytes; DNA microarrays; lipolysis; metabolism	BODY-MASS INDEX; QUANTITATIVE-TRAIT LOCI; AUTOSOMAL GENOMIC SCAN; LDL RECEPTOR; WIDE SCAN; FAT; LEPTIN; ADIPOGENESIS; LIPOLYSIS; INSULIN	The aim of the present study was to gain in sight into the pathophysiology of obesity by comparing the pattern of gene expression of omental adipose tissue of obese and lean volunteers using DNA microarrays. Omental adipose tissue biopsies were obtained by laparoscopic surgery from six male patients (44.2 +/- 6.3 yr). RNA was extracted and pooled for the obese (BMI: 37.3 +/- 2.5 kg/m2) and lean (BMI: 23.4 +/- 0.8 kg/m2) groups. From the total number of genes analyzed (1,152 well-characterized human genes), 41% were expressed at sufficient levels in human adipose tissue for detection in the microarray experiments, finding that 89 genes were up-regulated while 64 were down-regulated at least twofold in the omental adipose tissue obtained from obese patients. We found a general tendency to blunt lipolysis inducer genes and a global down-regulation of genes encoding growth factors. Moreover, an up-regulation in the expression of several mitogen-activated protein kinases (MAPKs) was observed. The down-regulation of genes involved in lipolysis activation may be involved in the etiopathogenesis of obesity. In addition, down-regulation of grow th factors and the up-regulation of MAPKs may indicate an attempt to restrain adipocyte proliferation and differentiation. Furthermore, obesity is accompanied by an altered expression in omental adipose tissue of genes involved not only in energy homeostasis but also in quite diverse biological functions, such as immune response. The genomic approach underlines the importance of adipose tissue beyond energy metabolism.	Clin Univ Navarra, Dept Endocrinol, Pamplona 31008, Spain; Clin Univ Navarra, Metabol Res Lab, Pamplona, Spain; Clin Univ Navarra, Lab Biotechnol, Pamplona 31008, Spain; Clin Univ Navarra, Dept Surg, Pamplona, Spain; Clin Univ Navarra, Dept Biochem, Pamplona, Spain; Univ Navarra, Appl Med Res Ctr, Lab Proteom Genom & Bioinform, Pamplona, Spain	University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra; University of Navarra	Fruhbeck, G (corresponding author), Clin Univ Navarra, Dept Endocrinol, Pamplona 31008, Spain.	gfruhbeck@unav.es	Catalan, Victoria/H-3566-2017; MATO, JOSE/A-5187-2011; Gómez-Ambrosi, Javier/D-2984-2017; Garcia-Foncillas, Jesus/E-6857-2010; Martinez-Cruz, Luis Alfonso/G-2285-2011	Catalan, Victoria/0000-0002-7513-7509; MATO, JOSE/0000-0003-1264-3153; Gómez-Ambrosi, Javier/0000-0001-5601-1604; Martinez-Cruz, Luis Alfonso/0000-0002-5856-9377; J, Garcia-Foncillas/0000-0002-7591-8006				Arner P, 1999, INT J OBESITY, V23, P10, DOI 10.1038/sj.ijo.0800789; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bonora E, 2000, DIABETES CARE, V23, P57, DOI 10.2337/diacare.23.1.57; Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Chagnon YC, 2001, J APPL PHYSIOL, V90, P1777, DOI 10.1152/jappl.2001.90.5.1777; Chagnon YC, 1997, OBES RES, V5, P115, DOI 10.1002/j.1550-8528.1997.tb00651.x; Charriere G, 2003, J BIOL CHEM, V278, P9850, DOI 10.1074/jbc.M210811200; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Clement Karine, 2002, Am J Pharmacogenomics, V2, P177, DOI 10.2165/00129785-200202030-00003; Comuzzie AG, 1997, NAT GENET, V15, P273, DOI 10.1038/ng0397-273; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Feitosa MF, 2002, AM J HUM GENET, V70, P72, DOI 10.1086/338144; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Fruhbeck G, 2001, FASEB J, V15, P1996, DOI 10.1096/fj.00-0829hyp; Fruhbeck G, 2003, DIABETOLOGIA, V46, P143, DOI 10.1007/s00125-003-1053-4; Fruhbeck G, 2001, FASEB J, V15, P333, DOI 10.1096/fj.00-0249com; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; Gabrielsson BG, 2002, OBES RES, V10, P608, DOI 10.1038/oby.2002.83; Gabrielsson BL, 2000, OBES RES, V8, P374, DOI 10.1038/oby.2000.45; Gregoire FM, 1998, PHYSIOL REV, V78, P783, DOI 10.1152/physrev.1998.78.3.783; Hager J, 1998, NAT GENET, V20, P304, DOI 10.1038/3123; Hanson RL, 1998, AM J HUM GENET, V63, P1130, DOI 10.1086/302061; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jagoe RT, 2002, FASEB J, V16, P1697, DOI 10.1096/fj.02-0312com; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kopelman PG, 2000, NATURE, V404, P635, DOI 10.1038/35007508; LAFONTAN M, 1993, J LIPID RES, V34, P1057; Lembertas AV, 1997, J CLIN INVEST, V100, P1240, DOI 10.1172/JCI119637; LONNQVIST F, 1995, NAT MED, V1, P950, DOI 10.1038/nm0995-950; Mamo JCL, 2001, AM J PHYSIOL-ENDOC M, V281, pE626, DOI 10.1152/ajpendo.2001.281.3.E626; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI [10.1001/jama.289.1.76, DOI 10.1001/JAMA.289.1.76]; Montagne CT, 2000, DIABETES, V49, P883, DOI 10.2337/diabetes.49.6.883; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Nadler ST, 2001, J NUTR, V131, P2078, DOI 10.1093/jn/131.8.2078; Nieman DC, 1996, INT J OBESITY, V20, P353; Norman RA, 1998, AM J HUM GENET, V62, P659, DOI 10.1086/301758; Olofsson B, 1996, J BIOL CHEM, V271, P19310, DOI 10.1074/jbc.271.32.19310; Perusse L, 2001, DIABETES, V50, P614, DOI 10.2337/diabetes.50.3.614; Rankinen T, 2002, OBES RES, V10, P196, DOI 10.1038/oby.2002.30; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Samartin S, 2001, NUTR RES, V21, P243, DOI 10.1016/S0271-5317(00)00255-4; Sarzani R, 1996, J ENDOCRINOL INVEST, V19, P581; Sato T, 2003, BIOCHEM BIOPH RES CO, V300, P167, DOI 10.1016/S0006-291X(02)02774-2; Schreyer SA, 2002, AM J PHYSIOL-ENDOC M, V282, pE207, DOI 10.1152/ajpendo.2002.282.1.E207; Sengenes C, 2000, FASEB J, V14, P1345, DOI 10.1096/fj.14.10.1345; Serradeil-Le Gal C, 2000, FEBS LETT, V475, P150, DOI 10.1016/S0014-5793(00)01649-5; Soukas A, 2001, J BIOL CHEM, V276, P34167, DOI 10.1074/jbc.M104421200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Stone S, 2002, AM J HUM GENET, V70, P1459, DOI 10.1086/340670; VALET P, 1990, J CLIN INVEST, V85, P291, DOI 10.1172/JCI114425; van der Kallen CJH, 2000, INT J OBESITY, V24, P1381, DOI 10.1038/sj.ijo.0801412; WEIGLE DS, 1994, FASEB J, V8, P302, DOI 10.1096/fasebj.8.3.8143936; Wells JCK, 2001, INT J OBESITY, V25, P1161, DOI 10.1038/sj.ijo.0801634; Weyer C, 2001, MOL GENET METAB, V72, P231, DOI 10.1006/mgme.2001.3147; Yang YS, 2003, BIOCHEM BIOPH RES CO, V300, P839, DOI 10.1016/S0006-291X(02)02843-7; Yang YS, 2002, ENDOCRINE, V18, P57, DOI 10.1385/ENDO:18:1:57	58	124	131	1	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					215	+		10.1096/fj.03-0591fje	http://dx.doi.org/10.1096/fj.03-0591fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630696	Green Submitted			2022-12-28	WOS:000188829300046
J	Swevers, L; Kravariti, L; Ciolfi, S; Xenou-Kokoletsi, M; Ragoussis, N; Smagghe, G; Nakagawa, Y; Mazomenos, B; Iatrou, K				Swevers, L; Kravariti, L; Ciolfi, S; Xenou-Kokoletsi, M; Ragoussis, N; Smagghe, G; Nakagawa, Y; Mazomenos, B; Iatrou, K			A cell-based high-throughput screening system for detecting ecdysteroid agonists and antagonists in plant extracts and libraries of synthetic compounds	FASEB JOURNAL			English	Article						20-hydroxyecdysone; insect cell line; lepidopteran cells; silkworm; Bombyx mori; green fluorescent protein; ecdysone response; chemical libraries	QUANTITATIVE STRUCTURE-ACTIVITY; INSECT GROWTH-REGULATORS; N-ACETYLGLUCOSAMINE INCORPORATION; DROSOPHILA ECDYSONE RECEPTOR; CYTOPLASMIC ACTIN GENE; BOMBYX-MORI; SPODOPTERA-FRUGIPERDA; CULTURED INTEGUMENT; LARVICIDAL ACTIVITY; BIOLOGICAL-ACTIVITY	Screening systems for ecdysteroid mimetic or antiecdysteroid substances in plant extracts or libraries of synthetic compounds are commonly based on the observation of morphological and/or growth responses in insect cell lines. Because these responses are slow and require careful monitoring, existing screening systems are considered limited regarding their applicability to analysis in high-throughput (HT) formats. Here we describe the generation of transformed silkmoth (Bombyx mori) cell lines that respond to the addition of ecdysone-like substances through the expression of the green fluorescent protein (GFP) and the appearance of green fluorescence. Because tests consist of three simple steps, i.e., 1) distribution of transformed cells in microtiter plates; 2) addition of compounds/extracts at different concentrations; and 3) quantification of fluorescence intensity by a fluorescence plate reader, they can be performed quickly and be easily adapted to a HT format. The generated reporter cell lines are used for the screening of extracts from available plant collections for the presence of compounds with ecdysone mimetic or antagonistic activities as well as for monitoring subsequent activity during enrichment and purification steps. The same cell lines are also used here for the determination of structure-activity relationships among available synthetic dibenzoylhydrazine derivatives. Finally, for the identified agonists, we show that their activity as determined by the cell-based screening assays parallels their bioactivity in growth inhibition and toxicity assays carried out on live insects.	Natl Ctr Sci Res Demokritos, Inst Biol, Athens 15310, Greece; Vioryl SA, Athens 14564, Greece; Univ Ghent, Lab Agrozool, B-9000 Ghent, Belgium; Kyoto Univ, Grad Sch Agr, Kyoto 6068502, Japan	National Centre of Scientific Research "Demokritos"; Ghent University; Kyoto University	Swevers, L (corresponding author), Natl Ctr Sci Res Demokritos, Inst Biol, POB 60228, Athens 15310, Greece.	swevers@bio.demokritos.gr; iatrou@bio.demokritos.gr	Kravariti, Lara/AAM-6512-2021; Smagghe, Guy/AAE-8914-2019	Smagghe, Guy/0000-0001-8334-3313	General Secretariat of Science and Technology, Greek Ministry of Development [98BI-26]	General Secretariat of Science and Technology, Greek Ministry of Development	We thank Drs. G. R. Carlson and T. Dhadialla for the generous gift of RH-5992, RH-2485, RH-0345, and RH-5849; Dr. M. Koelle (Stanford University) for the gift of the pMK43.2 reporter vector; Dr. P. J. Farrell (University of Calgary) for help and advice during the construction of the Bm5/ERE.gfp cell lines; Grace Wong for help with the determination of promoter strength determinations through CAT assays of transfected cells; and Laurie Robertson (Flow Cytometry Facility, Department of Biochemistry and Molecular Biology, University of Calgary) for the flow cytometry analyses. This work was supported by grant No 98BI-26 of the General Secretariat of Science and Technology, Greek Ministry of Development.	ADLER JH, 1995, LIPIDS, V30, P257, DOI 10.1007/BF02537830; ANTONIEWSKI C, 1993, INSECT BIOCHEM MOLEC, V23, P105, DOI 10.1016/0965-1748(93)90088-A; BERGAMASCO R., 1980, PROGR ECDYSONE RES, P299; Cespedes CL, 2000, J AGR FOOD CHEM, V48, P1903, DOI 10.1021/jf990443q; CHERBAS L, 1991, GENE DEV, V5, P120, DOI 10.1101/gad.5.1.120; CHERBAS L, 1980, ROUX ARCH DEV BIOL, V189, P1, DOI 10.1007/BF00848562; CLEMENT CY, 1993, INSECT BIOCHEM MOLEC, V23, P187, DOI 10.1016/0965-1748(93)90100-7; Dhadialla TS, 1998, ANNU REV ENTOMOL, V43, P545, DOI 10.1146/annurev.ento.43.1.545; Dinan L, 1997, BIOCHEM J, V327, P643, DOI 10.1042/bj3270643; Dinan L, 2001, PHYTOCHEMISTRY, V57, P325, DOI 10.1016/S0031-9422(01)00078-4; Dinan L, 2001, CELL MOL LIFE SCI, V58, P321, DOI 10.1007/PL00000859; DREVET JR, 1994, J BIOL CHEM, V269, P10660; Eystathioy T, 2001, MECH DEVELOP, V103, P107, DOI 10.1016/S0925-4773(01)00335-5; Farrell PJ, 1998, BIOTECHNOL BIOENG, V60, P656, DOI 10.1002/(SICI)1097-0290(19981220)60:6<656::AID-BIT2>3.0.CO;2-9; Farrell PJ, 2000, PROTEINS, V41, P144, DOI 10.1002/1097-0134(20001001)41:1<144::AID-PROT160>3.3.CO;2-8; GRACE TDC, 1967, NATURE, V216, P613, DOI 10.1038/216613a0; Ha DS, 1996, MOL BIOCHEM PARASIT, V77, P57, DOI 10.1016/0166-6851(96)02580-7; Harmatha J, 1997, ARCH INSECT BIOCHEM, V35, P219, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<219::AID-ARCH20>3.3.CO;2-Z; Harmatha J, 2002, INSECT BIOCHEM MOLEC, V32, P181, DOI 10.1016/S0965-1748(01)00099-6; Jayaprakasha GK, 1997, PHYTOCHEMISTRY, V44, P843, DOI 10.1016/S0031-9422(96)00589-4; JOHNSON R, 1992, VIROLOGY, V190, P815, DOI 10.1016/0042-6822(92)90919-G; Keith MBA, 2000, BIOTECHNIQUES, V28, P148, DOI 10.2144/00281rr03; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOOLMAN J, 1989, ECDYSONE CHEMISTRY M; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; Lu M, 1997, J BIOL CHEM, V272, P30724, DOI 10.1074/jbc.272.49.30724; Mange A, 1997, J MOL BIOL, V265, P266, DOI 10.1006/jmbi.1996.0734; MOUNIER N, 1986, BIOCHIMIE, V68, P1053, DOI 10.1016/S0300-9084(86)80179-1; Nakagawa Y, 1999, PESTIC SCI, V55, P909, DOI 10.1002/(SICI)1096-9063(199909)55:9&lt;909::AID-PS34&gt;3.0.CO;2-G; NAKAGAWA Y, 1995, STEROIDS, V60, P401, DOI 10.1016/0039-128X(94)00065-K; Nakagawa Y, 1998, PESTIC SCI, V53, P267, DOI 10.1002/(SICI)1096-9063(199808)53:4&lt;267::AID-PS765&gt;3.0.CO;2-U; Nakagawa Y, 2002, PEST MANAG SCI, V58, P131, DOI 10.1002/ps.429; Nakagawa Y, 2001, PEST MANAG SCI, V57, P858, DOI 10.1002/ps.376; Nijhout H.F., 1994, INSECT HORMONES; OIKAWA N, 1994, PESTIC BIOCHEM PHYS, V48, P135, DOI 10.1006/pest.1994.1014; OIKAWA N, 1994, PESTIC SCI, V41, P139, DOI 10.1002/ps.2780410210; OIKAWA N, 1993, PESTIC BIOCHEM PHYS, V47, P165, DOI 10.1006/pest.1993.1075; QUACK S, 1995, EUR J ENTOMOL, V92, P341; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; Ruberto G, 2002, J AGR FOOD CHEM, V50, P6766, DOI 10.1021/jf020607u; Sarker SD, 1997, ARCH INSECT BIOCHEM, V35, P211, DOI 10.1002/(SICI)1520-6327(1997)35:1/2<211::AID-ARCH19>3.3.CO;2-X; Sawada Y, 2003, PEST MANAG SCI, V59, P49, DOI 10.1002/ps.606; Schmelz EA, 2002, ARCH INSECT BIOCHEM, V51, P204, DOI 10.1002/arch.10062; Smagghe G, 1999, ARCH INSECT BIOCHEM, V41, P42, DOI 10.1002/(SICI)1520-6327(1999)41:1&lt;42::AID-ARCH7&gt;3.0.CO;2-H; SMAGGHE G, 1995, EUR J ENTOMOL, V92, P333; Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530; Suresh G, 2002, J AGR FOOD CHEM, V50, P4484, DOI 10.1021/jf025534t; Suzuki S, 1996, GEN COMP ENDOCR, V104, P129, DOI 10.1006/gcen.1996.0155; SWEVERS L, 1995, INSECT BIOCHEM MOLEC, V25, P857, DOI 10.1016/0965-1748(95)00024-P; Swevers L, 1996, INSECT BIOCHEM MOLEC, V26, P217, DOI 10.1016/0965-1748(95)00097-6; Tazima Y, 1978, SILKWORM IMPORTANT L; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; Wang SF, 1998, J BIOL CHEM, V273, P27531, DOI 10.1074/jbc.273.42.27531; WING KD, 1988, SCIENCE, V241, P470, DOI 10.1126/science.241.4864.470; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; YOUNG NJ, 1993, GEN COMP ENDOCR, V90, P183, DOI 10.1006/gcen.1993.1073	56	55	59	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					134	136		10.1096/fj.03-0627fje	http://dx.doi.org/10.1096/fj.03-0627fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630695				2022-12-28	WOS:000188829300051
J	Falciatori, I; Borsellino, G; Haliassos, N; Boitani, C; Corallini, S; Battistini, L; Bernardi, G; Stefanini, M; Vicini, E				Falciatori, I; Borsellino, G; Haliassos, N; Boitani, C; Corallini, S; Battistini, L; Bernardi, G; Stefanini, M; Vicini, E			Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis	FASEB JOURNAL			English	Article						spermatogenesis; germ cell transplantation; seminiferous epithelium wave	GLYCOPROTEIN GENE LEADS; BONE-MARROW-CELLS; C-KIT; SELF-RENEWAL; GERM-CELLS; DYE EFFLUX; EXPRESSION; SPERMATOGENESIS; TRANSPLANTATION; COLONIZATION	In mammals, spermatogenesis is maintained by spermatogonial stem cells (SSC). In their niche, SSC divide to self-maintain and to produce a transit-amplifying population that eventually enters the meiotic cycle to give rise to spermatozoa. The low number of SSC and the lack of specific markers hinder their isolation and enrichment. Stem cells in several adult tissues can be identified by using their verapamil-sensitive Hoechst dye-effluxing properties, which define the characteristic "side population" (SP). Here we show, by multicolor flow cytometric analysis, that immature mouse testis contains a "side-population" (T-SP), which is Sca-l(pos), Ep-CAM(pos), EE2 (pos), alpha6-integrin (pos), and alphav-integrin(neg). A 13-fold enrichment in SSC activity was observed when sorted T-SP cells from ROSA 26 mice were transplanted in busulfan-treated mouse testis. Whereas an incomplete range of spermatogenic stages was encountered two months after transplantation of unsorted testicular cells, the transplantation of T-SP cells generated all associations of mouse germ cells representing the full range of spermatogenic stages. These data suggest that Hoechst staining and cell sorting might provide a novel approach to SSC enrichment in mammals.	Univ Roma La Sapienza, Dept Histol & Med Embryol, I-00161 Rome, Italy; Santa Lucia Fdn Sci Inst IRCCS, Neuroimmunol & Flor Cytometry Unit, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Rome, Italy	Sapienza University Rome; IRCCS Santa Lucia; University of Rome Tor Vergata	Vicini, E (corresponding author), Univ Roma La Sapienza, Dept Histol & Med Embryol, Via Antonio Scarpa 14, I-00161 Rome, Italy.	elena.vicini@uniroma1.it	Battistini, luca/ABE-1882-2021; Borsellino, Giovanna/K-3074-2016; Haliasos, Nikolaos/G-6352-2010; Battistini, Luca/D-6920-2014	Borsellino, Giovanna/0000-0002-4227-6481; Battistini, Luca/0000-0002-6488-4891; Vicini, Elena/0000-0003-0399-0145; Haliasos, Nikolaos/0000-0003-3204-1483				Anderson R, 1999, J REPROD FERTIL, V116, P379, DOI 10.1530/jrf.0.1160379; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BRINSTER RL, 1994, P NATL ACAD SCI USA, V91, P11298, DOI 10.1073/pnas.91.24.11298; Bunting KD, 2000, BLOOD, V96, P902, DOI 10.1182/blood.V96.3.902.015k40_902_909; Bunting KD, 1998, BLOOD, V92, P2269, DOI 10.1182/blood.V92.7.2269.2269_2269_2279; De Rooij DG, 2000, J ANDROL, V21, P776; Dobrinski I, 1999, MOL REPROD DEV, V53, P142, DOI 10.1002/(SICI)1098-2795(199906)53:2&lt;142::AID-MRD3&gt;3.0.CO;2-O; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Ivanova NB, 2002, SCIENCE, V298, P601, DOI 10.1126/science.1073823; Kanatsu-Shinohara M, 2003, BIOL REPROD, V68, P1801, DOI 10.1095/biolreprod.102.012575; KLEIN J, 1986, NATURAL HIST MAJOR H, P152; KOSHIMIZU U, 1995, MOL REPROD DEV, V40, P221, DOI 10.1002/mrd.1080400211; Kubota H, 2003, P NATL ACAD SCI USA, V100, P6487, DOI 10.1073/pnas.0631767100; McLean DJ, 2002, BIOL REPROD, V66, P1374, DOI 10.1095/biolreprod66.5.1374; Meng XJ, 2000, SCIENCE, V287, P1489, DOI 10.1126/science.287.5457.1489; Morena AR, 1996, J ANDROL, V17, P708; Nagano M, 1999, BIOL REPROD, V60, P1429, DOI 10.1095/biolreprod60.6.1429; OAKBERG EF, 1956, AM J ANAT, V99, P507, DOI 10.1002/aja.1000990307; Ogawa T, 2003, BIOL REPROD, V68, P316, DOI 10.1095/biolreprod.102.004549; Ogawa T, 1997, INT J DEV BIOL, V41, P111; Ohta H, 2000, DEVELOPMENT, V127, P2125; Ohta H, 2000, DEV GROWTH DIFFER, V42, P105; Ramalho-Santos M, 2002, SCIENCE, V298, P597, DOI 10.1126/science.1072530; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Russell L. D., 1990, HISTOLOGICAL HISTOPA; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; SCHINKEL AH, 1994, CELL, V77, P491, DOI 10.1016/0092-8674(94)90212-7; Schrans-Stassen BHGJ, 1999, ENDOCRINOLOGY, V140, P5894, DOI 10.1210/en.140.12.5894; Shinohara T, 2000, DEV BIOL, V220, P401, DOI 10.1006/dbio.2000.9655; Shinohara T, 2001, P NATL ACAD SCI USA, V98, P6186, DOI 10.1073/pnas.111158198; Shinohara T, 2000, P NATL ACAD SCI USA, V97, P8346, DOI 10.1073/pnas.97.15.8346; Shinohara T, 2000, INT J ANDROL, V23, P89, DOI 10.1046/j.1365-2605.2000.00025.x; SMIT JJM, 1993, CELL, V75, P451, DOI 10.1016/0092-8674(93)90380-9; SORRENTINO V, 1991, ONCOGENE, V6, P149; Spradling A, 2001, NATURE, V414, P98, DOI 10.1038/35102160; Storms RW, 2000, BLOOD, V96, P2125; TEGELENBOSCH RAJ, 1993, MUTAT RES, V290, P193; VANDERIJN M, 1989, P NATL ACAD SCI USA, V86, P4634; Varnum-Finney B, 2000, NAT MED, V6, P1278, DOI 10.1038/81390; Ventela S, 2002, BIOL REPROD, V66, P1422, DOI 10.1095/biolreprod66.5.1422; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689; Zhou CS, 2001, BMC BIOCHEM, V2, DOI 10.1186/1471-2091-2-7; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999	46	87	96	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					376	+		10.1096/fj.03-0744fje	http://dx.doi.org/10.1096/fj.03-0744fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14688197				2022-12-28	WOS:000188067500003
J	Romano, M; Claria, J				Romano, M; Claria, J			Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy	FASEB JOURNAL			English	Review						arachidonic acid; cancer; cyclooxygenase and lipoxygenase inhibitors; eicosanoids	ENDOTHELIAL GROWTH-FACTOR; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; LEUKOTRIENE B-4 RECEPTOR; ARACHIDONIC-ACID; INTESTINAL POLYPOSIS; NUCLEAR-LOCALIZATION; PHOSPHOLIPASE A(2); DUAL INHIBITORS; GENE-EXPRESSION	Cyclooxygenase (COX) and lipoxygenase (LO) metabolic pathways are emerging as key regulators of cell proliferation and neo-angiogenesis. COX and LO inhibitors are being investigated as potential anticancer drugs and results from clinical trials seem to be encouraging. In this article we will review evidence of COX-2 and 5-LO involvement in cancer pathobiology, propose a model of integrated control of cell proliferation by these enzymes, and discuss the pharmacologic implications of this model. -Romano, M., Claria, J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy.	Univ G DAnnunzio, Dipartimento Sci Biomed, Mol Med Lab, CeSI, I-66013 Chieti, Italy; Univ Barcelona, Hosp Clin, Inst Invest Biomed August Pi & Sunyer, DNA Unit, E-08036 Barcelona, Spain	G d'Annunzio University of Chieti-Pescara; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Romano, M (corresponding author), Univ G DAnnunzio, Dipartimento Sci Biomed, Mol Med Lab, CeSI, Via Vestini 31, I-66013 Chieti, Italy.	mromano@unich.it	Romano, Mario/I-7986-2012; Claria, Joan/M-7772-2019	Romano, Mario/0000-0001-8512-1458; Claria, Joan/0000-0003-4333-7749				Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Avis IM, 1996, J CLIN INVEST, V97, P806, DOI 10.1172/JCI118480; Bailie MB, 1996, J IMMUNOL, V157, P5221; Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Barbey S, 2002, BIOORG MED CHEM LETT, V12, P779, DOI 10.1016/S0960-894X(02)00013-6; BOADO RJ, 1992, P NATL ACAD SCI USA, V89, P9044, DOI 10.1073/pnas.89.19.9044; BORGEAT P, 1976, J BIOL CHEM, V251, P7816; BRUNGS M, 1995, P NATL ACAD SCI USA, V92, P107, DOI 10.1073/pnas.92.1.107; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Chan G, 1999, CANCER RES, V59, P991; Chan K, 2003, J MACH LEARN RES, V3, P99, DOI 10.1162/153244303768966120; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; Chulada PC, 2000, CANCER RES, V60, P4705; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Danz H, 2002, PLANTA MED, V68, P152, DOI 10.1055/s-2002-20252; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Drazen JM, 1999, P ASSOC AM PHYSICIAN, V111, P547, DOI 10.1046/j.1525-1381.1999.t01-1-99242.x; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Elder DJE, 1997, CLIN CANCER RES, V3, P1679; Fiorucci S, 2001, BIOCHEM PHARMACOL, V62, P1433, DOI 10.1016/S0006-2952(01)00747-X; FitzGerald GA, 2001, NEW ENGL J MED, V345, P433, DOI 10.1056/NEJM200108093450607; Fujita H, 2002, PROSTATE, V53, P232, DOI 10.1002/pros.10152; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; FUNK CD, 1991, FASEB J, V5, P2304, DOI 10.1096/fasebj.5.9.1907252; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Halushka MK, 2003, CLIN PHARMACOL THER, V73, P122, DOI 10.1067/mcp.2003.1; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; HECKER M, 1995, BASIC CLIN PHARM, P290; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Hong SH, 1999, CANCER RES, V59, P2223; Hoper MM, 1997, AM J RESP CELL MOL, V17, P748; Horizoe T, 1998, INFLAMM RES, V47, P375, DOI 10.1007/s000110050347; HOSHIKO S, 1990, P NATL ACAD SCI USA, V87, P9073, DOI 10.1073/pnas.87.23.9073; Hosoi T, 2002, J BIOL CHEM, V277, P31459, DOI 10.1074/jbc.M203194200; Hsi LC, 2002, J BIOL CHEM, V277, P40549, DOI 10.1074/jbc.M203522200; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Inagaki M, 2000, J MED CHEM, V43, P2040, DOI 10.1021/jm9906015; JONES DA, 1993, J BIOL CHEM, V268, P9049; Jones SM, 2002, J BIOL CHEM, V277, P38550, DOI 10.1074/jbc.M206070200; KARGMAN S, 1992, J CELL BIOL, V119, P1701, DOI 10.1083/jcb.119.6.1701; Kawamori T, 1998, CANCER RES, V58, P409; Kirkpatrick K, 2002, CURR MED RES OPIN, V18, P237, DOI 10.1185/030079902125000633; Koki AT, 2002, PROSTAG LEUKOTR ESS, V66, P13, DOI 10.1054/plef.2001.0335; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lam BK, 2000, AM J RESP CRIT CARE, V161, pS16, DOI 10.1164/ajrccm.161.supplement_1.ltta-4; Lin HJ, 2002, CANCER EPIDEM BIOMAR, V11, P1305; Liu XH, 2002, J BIOL CHEM, V277, P50081, DOI 10.1074/jbc.M201095200; Lynch KR, 1999, NATURE, V399, P789; Masferrer JL, 2000, CANCER RES, V60, P1306; Morita I, 2002, PROSTAG OTH LIPID M, V68-9, P165, DOI 10.1016/S0090-6980(02)00029-1; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Muller-Decker K, 1999, INT J COLORECTAL DIS, V14, P212, DOI 10.1007/s003840050213; Murono S, 2001, P NATL ACAD SCI USA, V98, P6905, DOI 10.1073/pnas.121016998; Narumiya S, 2001, J CLIN INVEST, V108, P25, DOI 10.1172/JCI200113455; Nie D, 1998, CANCER RES, V58, P4047; Ohd JF, 2003, GASTROENTEROLOGY, V124, P57, DOI 10.1053/gast.2003.50011; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Piazza GA, 1997, CANCER RES, V57, P2452; Pouliot M, 1996, EUR J BIOCHEM, V238, P250, DOI 10.1111/j.1432-1033.1996.0250q.x; Prescott SM, 2000, J CLIN INVEST, V105, P1511, DOI 10.1172/JCI10241; QIAO L, 1995, BIOCHIM BIOPHYS ACTA, V128, P215; RADMARK O, 1984, J BIOL CHEM, V259, P2339; Rao CV, 1996, CANCER RES, V56, P532; RIGAS B, 1993, J LAB CLIN MED, V122, P518; RIGAU J, 1991, ANN INTERN MED, V115, P952, DOI 10.7326/0003-4819-115-12-952; Rocca B, 2002, P NATL ACAD SCI USA, V99, P7634, DOI 10.1073/pnas.112202999; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Seed MP, 1997, CANCER RES, V57, P1625; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; SERHAN CN, 1995, J LIPID MEDIAT CELL, V12, P293, DOI 10.1016/0929-7855(95)00035-O; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Shureiqi I, 2001, CANCER RES, V61, P4879; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Spencer AG, 1998, J BIOL CHEM, V273, P9886, DOI 10.1074/jbc.273.16.9886; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Tanabe T, 2002, PROSTAG OTH LIPID M, V68-9, P95, DOI 10.1016/S0090-6980(02)00024-2; TAY A, 1994, GENOMICS, V23, P718, DOI 10.1006/geno.1994.1569; Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252; Tries S, 2002, INFLAMM RES, V51, P135, DOI 10.1007/PL00000285; Trifan OC, 2002, CANCER RES, V62, P5778; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; TSUKADA T, 1986, BIOCHEM BIOPH RES CO, V140, P832, DOI 10.1016/0006-291X(86)90709-6; Tucker ON, 1999, CANCER RES, V59, P987; Uhl J, 2002, J BIOL CHEM, V277, P4374, DOI 10.1074/jbc.M107665200; Vadlamudi R, 1999, ONCOGENE, V18, P305, DOI 10.1038/sj.onc.1202307; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	100	195	206	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	NOV	2003	17	14					1986	1995		10.1096/fj.03-0053rev	http://dx.doi.org/10.1096/fj.03-0053rev			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	750AA	14597668				2022-12-28	WOS:000186961200035
J	Lawrence, KM; Scarabelli, TM; Turtle, L; Chanalaris, A; Townsend, PA; Carroll, CJ; Hubank, M; Stephanou, A; Knight, RA; Latchman, DS				Lawrence, KM; Scarabelli, TM; Turtle, L; Chanalaris, A; Townsend, PA; Carroll, CJ; Hubank, M; Stephanou, A; Knight, RA; Latchman, DS			Urocortin protects cardiac myocytes from ischemia/reperfusion injury by attenuating calcium insensitive phospholipase A(2) gene expression	FASEB JOURNAL			English	Article						urocortin; ischaemia; reperfusion; bromoenol lactone; cardioprotection; lysophosphatidylcholine	CORTICOTROPIN-RELEASING-FACTOR; MAPK-DEPENDENT PATHWAY; REPERFUSION INJURY; ISCHEMIC-INJURY; TIME-COURSE; LYSOPHOSPHATIDYLCHOLINE; HEART; MYOCARDIUM; CHANNELS; METABOLITE	We have used Affymetrix gene chip technology to look for changes in gene expression caused by a 24 h exposure of rat primary neonatal cardiac myocytes to the cardioprotective agent urocortin. We observed a 2.5-fold down-regulation at both the mRNA and protein levels of a specific calcium-insensitive phospholipase A(2) enzyme. Levels of lysophosphatidylcholine, a toxic metabolite of phospholipase A(2), were lowered by 30% in myocytes treated with urocortin for 24 h and by 50% with the irreversible iPLA(2) inhibitor bromoenol lactone compared with controls. Both 4 h ischemia and ischemia followed by 24 h reperfusion caused a significant increase in lysophosphatidylcholine concentration compared with controls. When these myocytes were pretreated with urocortin, the ischemia-induced increase in lysophosphatidylcholine concentration was significantly lowered. Moreover, co-incubation of cardiac myocytes with urocortin, or the specific phospholipase A(2) inhibitor bromoenol lactone, reduces the cytotoxicity produced by lysophosphatidylcholine or ischemia/reperfusion. Similarly, in the intact heart ex vivo we found that cardiac damage measured by infarct size was significantly increased when lysophoshatidylcholine was applied during ischemia, compared with ischemia alone, and that pre-treatment with both urocortin and bromoenol lactone reversed the increase in infarct size. This, to our knowledge, is the first study linking the cardioprotective effect of urocortin to a decrease in a specific enzyme protein and a subsequent decrease in the concentration of its cardiotoxic metabolite.	UCL, Inst Child Hlth, Med Mol Biol Unit, London WC1N 1EH, England; Royal Brompton Hosp, Natl Heart & Lung Inst, London, England	University of London; University College London; Imperial College London; Royal Brompton Hospital	Lawrence, KM (corresponding author), UCL, Inst Child Hlth, Med Mol Biol Unit, 30 Guilford St, London WC1N 1EH, England.	k.lawrence@ich.ucl.ac.uk	Chanalaris, Anastasios/A-5620-2008; Hubank, Michael JF/C-1837-2008; Carroll, Christopher/AAJ-6185-2021; Carroll, Christopher/AAV-8023-2021; Townsend, Paul/AAF-8234-2020	Hubank, Michael JF/0000-0002-2901-0742; Carroll, Christopher/0000-0002-2814-6955; Chanalaris, Anastasios/0000-0002-8884-6750; Townsend, Paul/0000-0001-8956-9508; Turtle, Lance/0000-0002-0778-1693				Brar BK, 2000, J BIOL CHEM, V275, P8508, DOI 10.1074/jbc.275.12.8508; Brar BK, 2002, J ENDOCRINOL, V172, P283, DOI 10.1677/joe.0.1720283; Brar BK, 2002, J MOL CELL CARDIOL, V34, P483, DOI 10.1006/jmcc.2002.1529; Brar BK, 1999, MOL CELL ENDOCRINOL, V158, P55, DOI 10.1016/S0303-7207(99)00183-5; BURNASHEV NA, 1989, PFLUG ARCH EUR J PHY, V415, P124, DOI 10.1007/BF00373151; BURNASHEV NA, 1991, J MOL CELL CARDIOL, V23, P23, DOI 10.1016/0022-2828(91)90020-M; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; COLE WC, 1991, CIRC RES, V69, P571, DOI 10.1161/01.RES.69.3.571; CORR PB, 1995, HERZ, V20, P156; Cummings BS, 2000, J PHARMACOL EXP THER, V294, P793; Daleau P, 1999, J MOL CELL CARDIOL, V31, P1391, DOI 10.1006/jmcc.1999.0973; Donaldson CJ, 1996, ENDOCRINOLOGY, V137, P2167, DOI 10.1210/en.137.5.2167; EDDLESTONE GT, 1995, AM J PHYSIOL-CELL PH, V268, pC181, DOI 10.1152/ajpcell.1995.268.1.C181; GROSS GJ, 1995, BASIC RES CARDIOL, V90, P85, DOI 10.1007/BF00789438; Hashizume H, 1997, JPN HEART J, V38, P11; Itoh K, 1998, BASIC RES CARDIOL, V93, P23, DOI 10.1007/s003950050058; Latchman DS, 2002, INT J BIOCHEM CELL B, V34, P907, DOI 10.1016/S1357-2725(02)00011-0; Latchman DS, 2001, TRENDS CARDIOVAS MED, V11, P167, DOI 10.1016/S1050-1738(01)00093-7; Lawrence KM, 2002, CIRCULATION, V106, P1556, DOI 10.1161/01.CIR.0000028424.02525.AE; LOVENBERG TW, 1995, ENDOCRINOLOGY, V136, P4139, DOI 10.1210/en.136.9.4139; LUNBAEK JA, 1994, J GEN PHYSIOL, V104, P645; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; Okosi A, 1998, NEUROPEPTIDES, V32, P167, DOI 10.1016/S0143-4179(98)90033-6; Scarabelli TM, 1999, J IMMUNOL METHODS, V228, P23, DOI 10.1016/S0022-1759(99)00090-3; Schulman D, 2002, AM J PHYSIOL-HEART C, V283, pH1481, DOI 10.1152/ajpheart.01089.2001; Sedlis SP, 1997, CORONARY ARTERY DIS, V8, P19, DOI 10.1097/00019501-199701000-00003; SHAIKH NA, 1981, CIRC RES, V49, P316, DOI 10.1161/01.RES.49.2.316; SHIZUME H, 1997, JPN HEART J, V38, P11; Stephanou A, 1998, J MOL CELL CARDIOL, V30, P849, DOI 10.1006/jmcc.1998.0651; UNDROVINAS AI, 1992, CIRC RES, V71, P1231, DOI 10.1161/01.RES.71.5.1231; VAUGHAN J, 1995, NATURE, V378, P287, DOI 10.1038/378287a0; WALKER DM, 1993, CARDIOVASC RES, V27, P962, DOI 10.1093/cvr/27.6.962; Wang JX, 2001, CIRCULATION, V104, P2645, DOI 10.1161/hc4701.100513; Watson CL, 1997, CIRC RES, V81, P387, DOI 10.1161/01.RES.81.3.387; WOLF RA, 1985, J BIOL CHEM, V260, P7295	35	44	46	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2313	+		10.1096/fj.02-0832fje	http://dx.doi.org/10.1096/fj.02-0832fje			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563694				2022-12-28	WOS:000186343300029
J	Shiraishi, M; Wang, XM; Walsh, MP; Kargacin, G; Loutzenhiser, K; Loutzenhiser, R				Shiraishi, M; Wang, XM; Walsh, MP; Kargacin, G; Loutzenhiser, K; Loutzenhiser, R			Myosin heavy chain expression in renal afferent and efferent arterioles: relationship to contractile kinetics and function	FASEB JOURNAL			English	Article						renal microcirculation; angiotensin II; MHC-A; MHC-B; vascular smooth muscle	SMOOTH-MUSCLE MYOSIN; ISOFORM EXPRESSION; SHORTENING VELOCITY; ANGIOTENSIN-II; DIVERSITY; INSERT; KIDNEY	The physiological role of smooth muscle myosin heavy chain (MHC) isoform diversity is poorly understood. The expression of MHC-B, which contains an insert at the ATP binding pocket, has been linked to enhanced contractile kinetics. We recently reported that the renal afferent arteriole exhibits an unusually rapid myogenic response and that its kinetic features allow this vessel to modulate tone in response to alterations in systolic blood pressure. In the present study, we examined MHC expression patterns in renal afferent and efferent arterioles. These two vessels regulate glomerular inflow and outflow resistances and control the pressure within the intervening glomerular capillaries (PGC). Whereas the afferent arteriole must respond rapidly to increases in blood pressure, the efferent arteriole plays a distinctly different role, maintaining a tonic elevation in outflow resistance to preserve function when renal perfusion is compromised. Using RT-PCR, Western analysis, and immunofluorescence imaging of intact isolated arterioles, we found that the afferent arteriole predominantly expresses the MHC-B isoform, whereas the efferent arteriole expresses only the slower-cycling MHC-A isoform. We examined the kinetics of angiotensin II- and norepinephrine-induced vasoconstriction and found that the afferent arteriole responds similar to3-fold faster than the efferent arteriole. Our findings thus point to the renal microcirculation as a unique and important example of smooth muscle adaptation in regard to MHC isoform expression and physiological function.	Univ Calgary, Fac Med, Smooth Muscle Res Grp, Calgary, AB T2N 4N1, Canada	University of Calgary	Loutzenhiser, R (corresponding author), Univ Calgary, Fac Med, Smooth Muscle Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	rloutzen@ucalgary.ca		Shiraishi, Mitsuya/0000-0001-7737-0075				BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; Babu GJ, 2000, MICROSC RES TECHNIQ, V50, P532, DOI 10.1002/1097-0029(20000915)50:6<532::AID-JEMT10>3.0.CO;2-E; Babu GJ, 2001, NAT CELL BIOL, V3, P1025, DOI 10.1038/ncb1101-1025; BIDANI AK, 1987, AM J PHYSIOL, V252, pF1003, DOI 10.1152/ajprenal.1987.252.6.F1003; DiSanto ME, 1997, AM J PHYSIOL-CELL PH, V272, pC1532, DOI 10.1152/ajpcell.1997.272.5.C1532; Eddinger TJ, 2001, AM J PHYSIOL-CELL PH, V280, pC309, DOI 10.1152/ajpcell.2001.280.2.C309; GROSCHELSTEWART U, 1985, CELL TISSUE RES, V241, P399, DOI 10.1007/BF00217186; Hansen PB, 2001, CIRC RES, V89, P630, DOI 10.1161/hh1901.097126; HODGE TP, 1992, J CELL BIOL, V118, P1085, DOI 10.1083/jcb.118.5.1085; HOSTETTER TH, 1982, AM J MED, V72, P375, DOI 10.1016/0002-9343(82)90490-9; HRICIK DE, 1983, NEW ENGL J MED, V308, P373, DOI 10.1056/NEJM198302173080706; KELLEY CA, 1992, J BIOL CHEM, V267, P2127; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KIMURA K, 1995, KIDNEY INT, V48, P372, DOI 10.1038/ki.1995.305; KUROO M, 1989, J BIOL CHEM, V264, P18272; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauzon AM, 1998, J MUSCLE RES CELL M, V19, P825, DOI 10.1023/A:1005489501357; Loutzenhiser K, 2000, CIRC RES, V87, P551, DOI 10.1161/01.RES.87.7.551; LOUTZENHISER R, 1989, AM J PHYSIOL, V257, pF561, DOI 10.1152/ajprenal.1989.257.4.F561; Loutzenhiser R, 1997, AM J PHYSIOL-RENAL, V273, pF307, DOI 10.1152/ajprenal.1997.273.2.F307; Loutzenhiser R, 2002, CIRC RES, V90, P1316, DOI 10.1161/01.RES.0000024262.11534.18; LOUTZENHISER R, 1990, CALCIUM ANTAGONISTS, P33; Low RB, 1999, AM J RESP CELL MOL, V20, P651, DOI 10.1165/ajrcmb.20.4.3050; Meer DP, 1997, AM J PHYSIOL-CELL PH, V273, pC1259; Navar LG, 1996, PHYSIOL REV, V76, P425, DOI 10.1152/physrev.1996.76.2.425; NEURINGER JR, 1993, AM J KIDNEY DIS, V22, P98, DOI 10.1016/S0272-6386(12)70174-9; Rovner AS, 1997, J MUSCLE RES CELL M, V18, P103, DOI 10.1023/A:1018689102122; Salomonsson M, 1999, AM J PHYSIOL-RENAL, V276, pF700, DOI 10.1152/ajprenal.1999.276.5.F700; SOMLYO AP, 1990, ANNU REV PHYSIOL, V52, P857; Tang LL, 2000, CIRC RES, V86, P663, DOI 10.1161/01.RES.86.6.663; Wetzel U, 1998, CIRC RES, V83, P204, DOI 10.1161/01.RES.83.2.204; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; White SL, 1998, AM J PHYSIOL-CELL PH, V275, pC581, DOI 10.1152/ajpcell.1998.275.2.C581	33	24	24	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2284	+		10.1096/fj.03-0096fje	http://dx.doi.org/10.1096/fj.03-0096fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14563688				2022-12-28	WOS:000186343300019
J	Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y				Strayer, A; Wu, ZX; Christen, Y; Link, CD; Luo, Y			Expression of the small heat-shock protein Hsp-16-2 in Caenorhabditis elegans is suppressed by Ginkgo biloba extract EGb 761	FASEB JOURNAL			English	Article						GFP reporter; ROS; oxidative stress	OXIDATIVE STRESS; GENE-EXPRESSION; DOUBLE-BLIND; RANDOMIZED-TRIAL; EGB 761(R); ALPHA; HSP27; PHOSPHORYLATION; INTERLEUKIN-1; ACCUMULATION	EGb 761, a standardized extract of Ginkgo biloba leaves, has been shown to have antioxidative properties. We have previously demonstrated that EGb 761 increases stress resistance and mean life span in the model organism Caenorhabditis elegans. In this study, the molecular mechanism of EGb 761 on alleviating effects of oxidative stress is further investigated using transgenic C. elegans expressing a jellyfish green fluorescent protein (GFP)-tagged inducible small heat-shock protein gene (hsp-16-2). The expression of hsp-16-2 induced by the pro-oxidant juglone and by heat shock was significantly suppressed by 86% and 33%, respectively, in the transgenic nematode fed with EGb 761. These effects of EGb 761 correlate with its ability to increase mean survival rate of the nematode in response to acute oxidative and thermal stresses, as well as to attenuate the basal levels of hydrogen peroxide in the organism. Thus, we interpret the suppression of hsp-16-2/GFP expression as an indication that EGb 761 decreases cellular stress resulting from exogenous treatments, therefore leading to a decreased transcriptional induction of the reporter transgene. These results support the hypothesis that EGb 761 augments the natural antistress system of C. elegans, thus increasing stress resistance and life span.	Univ So Mississippi, Dept Biol Sci, Hattiesburg, MS 39406 USA; Beaufour Ipsen, Paris, France; Univ Colorado, Inst Behav Genet, Boulder, CO 80309 USA	University of Southern Mississippi; Ipsen; University of Colorado System; University of Colorado Boulder	Luo, Y (corresponding author), Univ So Mississippi, Dept Biol Sci, 2609 W 4th St, Hattiesburg, MS 39406 USA.	yuan.luo@usm.edu						Butterfield DA, 1999, LIFE SCI, V65, P1883, DOI 10.1016/S0024-3205(99)00442-7; Butterfield DA, 1997, P NATL ACAD SCI USA, V94, P674, DOI 10.1073/pnas.94.2.674; Chao SH, 2001, NUCLEIC ACIDS RES, V29, P767, DOI 10.1093/nar/29.3.767; Christen Y, 2002, CELL MOL BIOL, V48, P601; CHRISTEN Y, 2000, OXIDAT STRESS DIS, V5, P411; Curtis-Prior P, 1999, J PHARM PHARMACOL, V51, P535, DOI 10.1211/0022357991772817; DeFeudis F.V., 1998, GINKGO BILOBA EXTRAC; DeFeudis FV, 2002, DRUG DEVELOP RES, V57, P214, DOI 10.1002/ddr.10151; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Ganzera M, 2001, CHEM PHARM BULL, V49, P1170, DOI 10.1248/cpb.49.1170; GUESDON F, 1993, J BIOL CHEM, V268, P4236; GuhaThakurta D, 2002, GENOME RES, V12, P701, DOI 10.1101/gr.228902; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HASSAN HM, 1979, ARCH BIOCHEM BIOPHYS, V196, P385, DOI 10.1016/0003-9861(79)90289-3; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kato K, 2002, FASEB J, V16, P1432, DOI 10.1096/fj.02-0129fje; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; LARSEN PL, 1993, P NATL ACAD SCI USA, V90, P8905, DOI 10.1073/pnas.90.19.8905; Le Bars PL, 2000, DEMENT GERIATR COGN, V11, P230, DOI 10.1159/000017242; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; Leroux MR, 1997, J BIOL CHEM, V272, P24646, DOI 10.1074/jbc.272.39.24646; Link CD, 1999, CELL STRESS CHAPERON, V4, P235, DOI 10.1379/1466-1268(1999)004<0235:DOOSRI>2.3.CO;2; Link CD, 2003, NEUROBIOL AGING, V24, P397, DOI 10.1016/S0197-4580(02)00224-5; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Luo Y, 2001, J ALZHEIMERS DIS, V3, P401, DOI 10.3233/JAD-2001-3407; Mehlen P, 1996, J BIOL CHEM, V271, P16510, DOI 10.1074/jbc.271.28.16510; Mehlen P, 1997, J BIOL CHEM, V272, P31657, DOI 10.1074/jbc.272.50.31657; Mix JA, 2002, HUM PSYCHOPHARM CLIN, V17, P267, DOI 10.1002/hup.412; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Rogalla T, 1999, J BIOL CHEM, V274, P18947, DOI 10.1074/jbc.274.27.18947; ROYALL JA, 1993, ARCH BIOCHEM BIOPHYS, V302, P348, DOI 10.1006/abbi.1993.1222; Schutte A, 2001, TRANSPLANT P, V33, P3724, DOI 10.1016/S0041-1345(01)02520-9; Smith JV, 2002, CELL MOL BIOL, V48, P699; SMITH JV, 2003, IN PRESS J ALZHEIMER, V4; Solomon PR, 2002, JAMA-J AM MED ASSOC, V288, P835, DOI 10.1001/jama.288.7.835; Soulie C, 2002, CELL MOL BIOL, V48, P641; Taricani L, 2001, NUCLEIC ACIDS RES, V29, P3030, DOI 10.1093/nar/29.14.3030; Valdez MM, 2002, EUR J BIOCHEM, V269, P1806, DOI 10.1046/j.1432-1033.2002.02812.x; Wadsworth TL, 2001, BIOCHEM PHARMACOL, V62, P963, DOI 10.1016/S0006-2952(01)00734-1; Walker GA, 2001, J GERONTOL A-BIOL, V56, pB281, DOI 10.1093/gerona/56.7.B281; Ward CP, 2002, PHARMACOL BIOCHEM BE, V72, P913, DOI 10.1016/S0091-3057(02)00768-2; Watanabe CMH, 2001, P NATL ACAD SCI USA, V98, P6577, DOI 10.1073/pnas.111126298; Westman J, 2000, AMINO ACIDS, V19, P339, DOI 10.1007/s007260070065; Winter JC, 1998, PHYSIOL BEHAV, V63, P425, DOI 10.1016/S0031-9384(97)00464-2; Wu ZX, 2002, CELL MOL BIOL, V48, P725; Yatin SM, 1999, NEUROBIOL AGING, V20, P325	46	108	116	0	27	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2305	+		10.1096/fj.03-0376fje	http://dx.doi.org/10.1096/fj.03-0376fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525938				2022-12-28	WOS:000186343300010
J	Ylikarppa, R; Eklund, L; Sormunen, R; Kontiola, AI; Utriainen, A; Maatta, M; Fukai, N; Olsen, BR; Pihlajaniemi, T				Ylikarppa, R; Eklund, L; Sormunen, R; Kontiola, AI; Utriainen, A; Maatta, M; Fukai, N; Olsen, BR; Pihlajaniemi, T			Lack of type XVIII collagen results in anterior ocular defects	FASEB JOURNAL			English	Article						anterior eye segment defects; basement membranes; iris; ciliary body	HEPARAN-SULFATE PROTEOGLYCAN; BASEMENT-MEMBRANE ZONES; INTRAOCULAR-PRESSURE; KNOBLOCH-SYNDROME; DBA/2J MICE; ENDOGENOUS INHIBITOR; TUMOR-GROWTH; IRIS ATROPHY; RIEG1 GENE; PAX6 GENE	Mice lacking type XVIII collagen have defects in the posterior part of the eye, including delayed regression of the hyaloid vasculature and poor outgrowth of the retinal vessels. We report here that these mice also have a fragile iris and develop atrophy of the ciliary body. The irises of Coll8al(-/-) mice can be seen to adhere to the lens and cornea. After the pupils begin to function, the double layer of epithelial cells separates at the apical cell contacts, leading to defoliation of its posterior pigment epithelial cell layer, and extracellular material begins to accumulate in the basement membrane zones of the iris. In contrast to the iris epithelia, where no clear signs of cellular atrophy were detected, the lack of type XVIII collagen resulted in atrophy of the pigmented epithelial cells of the ciliary body, and there were also ultrastructural abnormalities in the basement membrane zones. These changes did not lead to chronically elevated intraocular pressures, however. Our results indicate that type XVIII collagen is needed for the integrity of the epithelial basement membranes of the iris and the ciliary body and that its gene should therefore be taken into account as a new potential cause of anterior segment disorders in the eye.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, Oulu 90014, Finland; Univ Oulu, Dept Med Biochem & Mol Biol, Oulu 90014, Finland; Univ Oulu, Dept Pathol, Oulu 90014, Finland; Univ Helsinki, Cent Hosp, Dept Ophthalmol, Helsinki, Finland; Univ Helsinki Hosp, Dept Ophthalmol, Helsinki, Finland; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA	University of Oulu; University of Oulu; University of Oulu; University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Harvard University; Harvard Medical School	Pihlajaniemi, T (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, Oulu 90014, Finland.	taina.pihlajaniemi@oulu.fi		Pihlajaniemi, Taina/0000-0002-1664-9045				Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Alward WLM, 2000, AM J OPHTHALMOL, V130, P107, DOI 10.1016/S0002-9394(00)00525-0; Anderson MG, 2002, NAT GENET, V30, P81, DOI 10.1038/ng794; Avila MY, 2001, INVEST OPHTH VIS SCI, V42, P1841; Azuma N, 1999, AM J HUM GENET, V65, P656, DOI 10.1086/302529; Chang B, 1999, NAT GENET, V21, P405, DOI 10.1038/7741; Danias J, 2003, INVEST OPHTH VIS SCI, V44, P1138, DOI 10.1167/iovs.02-0553; Dong SC, 2003, J BIOL CHEM, V278, P1700, DOI 10.1074/jbc.M209276200; Doward W, 1999, J MED GENET, V36, P152; FREDDO TF, 1984, INVEST OPHTH VIS SCI, V25, P1094; Freddo TF, 1996, MICROSC RES TECHNIQ, V33, P369, DOI 10.1002/(SICI)1097-0029(19960401)33:5<369::AID-JEMT1>3.0.CO;2-J; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Gould DB, 1997, AM J HUM GENET, V61, P765; Gould DB, 2002, HUM MOL GENET, V11, P1185, DOI 10.1093/hmg/11.10.1185; Halfter W, 1998, J BIOL CHEM, V273, P25404, DOI 10.1074/jbc.273.39.25404; John SWM, 1997, INVEST OPHTH VIS SCI, V38, P249; John SWM, 1998, INVEST OPHTH VIS SCI, V39, P951; Kawashima H, 2003, J BIOL CHEM, V278, P13069, DOI 10.1074/jbc.M212244200; Knobloch WH, 1971, J PEDIATR OPHTHALMOL, V8, P181; Kontiola AI, 2001, EXP EYE RES, V73, P781, DOI 10.1006/exer.2001.1088; Kulak SC, 1998, HUM MOL GENET, V7, P1113, DOI 10.1093/hmg/7.7.1113; Lin YF, 2001, DEVELOPMENT, V128, P1573; Mears AJ, 1998, AM J HUM GENET, V63, P1316, DOI 10.1086/302109; Miosge N, 1999, FASEB J, V13, P1743, DOI 10.1096/fasebj.13.13.1743; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Nishimura DY, 1998, NAT GENET, V19, P140, DOI 10.1038/493; OH SP, 1994, P NATL ACAD SCI USA, V91, P4229, DOI 10.1073/pnas.91.10.4229; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; PASSOSBUENO MR, 1994, AM J MED GENET, V52, P170, DOI 10.1002/ajmg.1320520209; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; Rehn M, 1996, SEMIN CELL DEV BIOL, V7, P673, DOI 10.1006/scdb.1996.0082; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Savinova OV, 2001, BMC GENET, V2, DOI 10.1186/1471-2156-2-12; Sertie AL, 2000, HUM MOL GENET, V9, P2051, DOI 10.1093/hmg/9.13.2051; Shields MB., 1987, TXB OF GLAUCOMA; Smith RS, 2000, PATHOLOGY OF GENETICALLY ENGINEERED MICE, P217; Sniderman LC, 2000, AM J MED GENET, V90, P146, DOI 10.1002/(SICI)1096-8628(20000117)90:2<146::AID-AJMG11>3.3.CO;2-Q; Sonoda S, 2000, GRAEF ARCH CLIN EXP, V238, P552, DOI 10.1007/s004170000124; Suzuki OT, 2002, AM J HUM GENET, V71, P1320, DOI 10.1086/344695; Tomono Y, 2002, CELL STRUCT FUNCT, V27, P9, DOI 10.1247/csf.27.9; Traboulsi E., 1998, GENETIC DIS EYE	41	57	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2257	+		10.1096/fj.02-1001fje	http://dx.doi.org/10.1096/fj.02-1001fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525950				2022-12-28	WOS:000186343300002
J	Fuchs, M; Hilfiker, A; Kaminski, K; Hilfiker-Kleiner, D; Guener, Z; Klein, G; Podewski, E; Schieffer, B; Rose-John, S; Drexler, H				Fuchs, M; Hilfiker, A; Kaminski, K; Hilfiker-Kleiner, D; Guener, Z; Klein, G; Podewski, E; Schieffer, B; Rose-John, S; Drexler, H			Role of interleukin-6 for left ventricular remodeling and survival after experimental myocardial infarction	FASEB JOURNAL			English	Article						interleukins; mice, knock out; Jak Stat; heart; infarct size	LEUKEMIA-INHIBITORY FACTOR; CARDIAC MYOCYTES; HEART-FAILURE; JAK/STAT PATHWAY; ANGIOTENSIN-II; CYTOKINE EXPRESSION; ACTIVATION; RAT; RECEPTOR; GP130	Circulating levels of interleukin (IL)-6 are elevated after myocardial infarction (MI) and associated with increased morbidity and mortality. Its myocardial expression post-MI suggests a pathophysiological role in this condition. To explore the role of endogenous IL-6, we analyzed MI size, left ventricular (LV) remodeling, and mortality after permanent coronary ligation in IL-6 knockout mice (IL-6(-/-)) and wild-type controls (WT). Six weeks after MI, IL-6(-/-) and WT had similar mortality rates, MI sizes, LV remodeling, and LV dysfunction in vivo, determined by catheterization. Infarct size 24 h post-MI, shown by 2,3,5-triphenyltetrazolium chloride (TTC) staining, was similar at 24 h. Treatment with exogenous IL-6 did not alter MI size in WT. Infarction resulted in marked phosphorylation of STAT3, without differences between genotypes. Leukemia inhibitory factor (LIF) protein was increased 48 h post-MI in IL-6(-/-), and angiotensin II and AT(1) receptor (AT(1)R) protein were strongly increased in IL-6(-/-\) baseline and post-MI, suggesting compensatory up- regulation. Lack of IL-6 does not affect long-term MI size or LV function, remodeling, and survival. In mice lacking IL-6, other members of the IL-6 family such as LIF and other factors signaling via JAK/STAT such as angiotensin may act in a compensatory manner to activate the JAK/STAT pathway, thereby maintaining STAT3 phosphorylation, which is crucial for the cellular effects of IL-6 cytokines.	Hannover Med Sch, D-30625 Hannover, Germany; Univ Kiel, Dept Biochem, Kiel, Germany	Hannover Medical School; University of Kiel	Drexler, H (corresponding author), Hannover Med Sch, Carl Neuberg Str 1, D-30625 Hannover, Germany.	drexler.helmut@mh-hannover.de	Kaminski, Karol A./J-4515-2014; Rose-John, Stefan/A-7998-2010	Kaminski, Karol A./0000-0002-9465-2581; Rose-John, Stefan/0000-0002-7519-3279				Clark WM, 2000, STROKE, V31, P1715, DOI 10.1161/01.STR.31.7.1715; Deten A, 2002, CARDIOVASC RES, V55, P329, DOI 10.1016/S0008-6363(02)00413-3; FINKEL MS, 1992, SCIENCE, V257, P387, DOI 10.1126/science.1631560; Gwechenberger M, 1999, CIRCULATION, V99, P546, DOI 10.1161/01.CIR.99.4.546; Hilfiker A, 2002, CIRCULATION, V106, P254, DOI 10.1161/01.CIR.0000021426.87274.62; Hirota H, 1999, CELL, V97, P189, DOI 10.1016/S0092-8674(00)80729-1; HIROTA H, 1995, P NATL ACAD SCI USA, V92, P4862, DOI 10.1073/pnas.92.11.4862; Jones KD, 2001, GYNAECOL ENDOSC, V10, P281, DOI 10.1046/j.1365-2508.2001.00461.x; Korte T, 2002, J INTERV CARD ELECTR, V6, P121, DOI 10.1023/A:1015359332161; KUKIELKA GL, 1995, CIRCULATION, V92, P1866, DOI 10.1161/01.CIR.92.7.1866; KUKIELKA GL, 1993, J CLIN INVEST, V92, P1504, DOI 10.1172/JCI116729; Li BS, 1997, AM J PHYSIOL-HEART C, V273, pH2508, DOI 10.1152/ajpheart.1997.273.5.H2508; Lutgens E, 1999, CARDIOVASC RES, V41, P586, DOI 10.1016/S0008-6363(98)00216-8; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; Matsui H, 1996, RES COMMUN MOL PATH, V93, P149; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Nemoto S, 2002, AM J PHYSIOL-HEART C, V282, pH2316, DOI 10.1152/ajpheart.00763.2001; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Ono K, 1998, CIRCULATION, V98, P149, DOI 10.1161/01.CIR.98.2.149; Pan J, 1997, CIRC RES, V81, P611, DOI 10.1161/01.RES.81.4.611; PFEFFER MA, 1979, CIRC RES, V44, P503, DOI 10.1161/01.RES.44.4.503; TorreAmione G, 1996, J AM COLL CARDIOL, V27, P1201, DOI 10.1016/0735-1097(95)00589-7; Tsutamoto T, 1998, J AM COLL CARDIOL, V31, P391, DOI 10.1016/S0735-1097(97)00494-4; VANDAM M, 1993, J BIOL CHEM, V268, P15285; Wang F, 2001, CIRCULATION, V103, P1296; Wollert KC, 1999, CARDIOVASC RES, V43, P838, DOI 10.1016/S0008-6363(99)00145-5; Wollert KC, 1997, CIRCULATION, V95, P1910; YAMAWAKI S, 1995, ELS APPL ELECT MAT, V6, P91; YOUKER K, 1992, J CLIN INVEST, V89, P602, DOI 10.1172/JCI115626; Yue P, 1998, AM J PHYSIOL-HEART C, V275, pH250, DOI 10.1152/ajpheart.1998.275.1.H250	30	110	117	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2118	+		10.1096/fj.03-0331fje	http://dx.doi.org/10.1096/fj.03-0331fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958147				2022-12-28	WOS:000185925100028
J	Philp, D; Huff, T; Gho, YS; Hannappel, E; Kleinman, HK				Philp, D; Huff, T; Gho, YS; Hannappel, E; Kleinman, HK			The actin binding site on thymosin beta(4) promotes angiogenesis	FASEB JOURNAL			English	Article						beta-thymosin; angiogenic activity; 5 kDa polypeptide; G-actin	DEOXYNUCLEOTIDYL TRANSFERASE-ACTIVITY; ENDOTHELIAL-CELLS; IN-VIVO; PEPTIDE; EXPRESSION; TRANSGLUTAMINASE; METASTASIS; MOTILITY; CANCER; LINES	Thymosin beta(4) is a ubiquitous 43 amino acid, 5 kDa polypeptide that is an important mediator of cell proliferation, migration, and differentiation. It is the most abundant member of the beta-thymosin family in mammalian tissue and is regarded as the main G-actin sequestering peptide. Thymosin beta(4) is angiogenic and can promote endothelial cell migration and adhesion, tubule formation, aortic ring sprouting, and angiogenesis. It also accelerates wound healing and reduces inflammation when applied in dermal wound-healing assays. Using naturally occurring thymosin beta(4), proteolytic fragments, and synthetic peptides, we find that a seven amino acid actin binding motif of thymosin beta(4) is essential for its angiogenic activity. Migration assays with human umbilical vein endothelial cells and vessel sprouting assays using chick aortic arches show that thymosin beta(4) and the actin-binding motif of the peptide display near-identical activity at similar to50 nM, whereas peptides lacking any portion of the actin motif were inactive. Furthermore, adhesion to thymosin beta(4) was blocked by this seven amino acid peptide demonstrating it as the major thymosin beta(4) cell binding site on the molecule. The adhesion and sprouting activity of thymosin beta(4) was inhibited with the addition of 5-50 nM soluble actin. These results demonstrate that the actin binding motif of thymosin beta(4) is an essential site for its angiogenic activity.	NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA; Univ Erlangen Nurnberg, Inst Biochem, Erlangen, Germany; Kyung Hee Univ, Grad Sch E W Med Sci, Yongin, South Korea	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); University of Erlangen Nuremberg; Kyung Hee University	Kleinman, HK (corresponding author), NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, 30-433 30 Convent Dr,MSC-4370, Bethesda, MD 20892 USA.	hkleinman@dir.nidcr.nih.gov			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000230] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Auerbach R, 2000, CANCER METAST REV, V19, P167, DOI 10.1023/A:1026574416001; Bao L, 1998, CLIN EXP METASTAS, V16, P227, DOI 10.1023/A:1006540824969; Bao LR, 1996, NAT MED, V2, P1322, DOI 10.1038/nm1296-1322; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; FFOLKMAN J, 1992, SEMIN CANCER BIOL, P89; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Gho YS, 1997, CANCER RES, V57, P3733; Gho YS, 2002, J BIOL CHEM, V277, P9690, DOI 10.1074/jbc.M105526200; Gho YS, 1997, J BIOL CHEM, V272, P24294, DOI 10.1074/jbc.272.39.24294; GMORIANU J, 1993, P NATL ACAD SCI USA, V90, P3815; Grant D S, 1999, Angiogenesis, V3, P125, DOI 10.1023/A:1009041911493; GRANT DS, 1995, J CELL SCI, V108, P3685; HALL AK, 1991, INT J CANCER, V48, P672, DOI 10.1002/ijc.2910480507; HANNAPPEL E, 1985, ARCH BIOCHEM BIOPHYS, V240, P236, DOI 10.1016/0003-9861(85)90028-1; HU GF, 1993, BIOCHEM BIOPH RES CO, V197, P682, DOI 10.1006/bbrc.1993.2533; HU GF, 1994, P NATL ACAD SCI USA, V91, P12096, DOI 10.1073/pnas.91.25.12096; HU GF, 1993, P NATL ACAD SCI USA, V90, P1217, DOI 10.1073/pnas.90.4.1217; HU SK, 1981, MOL CELL BIOCHEM, V41, P49; Huff T, 2001, INT J BIOCHEM CELL B, V33, P205, DOI 10.1016/S1357-2725(00)00087-X; Huff T, 2002, FASEB J, V16, DOI 10.1096/fj.01-0713com; HUFF T, 1995, EUR J BIOCHEM, V230, P650; Huff T, 1999, FEBS LETT, V464, P14, DOI 10.1016/S0014-5793(99)01670-1; Huff T, 1997, ANAL CHIM ACTA, V352, P239, DOI 10.1016/S0003-2670(97)00133-5; Kobayashi T, 2002, AM J PATHOL, V160, P869, DOI 10.1016/S0002-9440(10)64910-3; Koutrafouri V, 2001, BBA-GEN SUBJECTS, V1568, P60, DOI 10.1016/S0304-4165(01)00200-8; LOW TLK, 1981, P NATL ACAD SCI-BIOL, V78, P1162, DOI 10.1073/pnas.78.2.1162; Malinda KM, 1999, J INVEST DERMATOL, V113, P364, DOI 10.1046/j.1523-1747.1999.00708.x; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; OLSON KA, 1995, P NATL ACAD SCI USA, V92, P442, DOI 10.1073/pnas.92.2.442; Philp D, 2003, WOUND REPAIR REGEN, V11, P19, DOI 10.1046/j.1524-475X.2003.11105.x; REICHERT A, 1994, FEBS LETT, V347, P247, DOI 10.1016/0014-5793(94)00551-6; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SAFER D, 1991, J BIOL CHEM, V266, P4029; Salcedo R, 2001, J IMMUNOL, V166, P7571, DOI 10.4049/jimmunol.166.12.7571; Sosne G, 2002, EXP EYE RES, V74, P293, DOI 10.1006/exer.2001.1125; Sosne G, 2001, EXP EYE RES, V72, P605, DOI 10.1006/exer.2000.0985; XU GJ, 1982, P NATL ACAD SCI-BIOL, V79, P4006, DOI 10.1073/pnas.79.13.4006; YAMAMOTO T, 1993, BIOCHEM BIOPH RES CO, V193, P706, DOI 10.1006/bbrc.1993.1682; Young JD, 1999, NAT MED, V5, P1424	40	109	124	0	7	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2103	+		10.1096/fj.03-0121fje	http://dx.doi.org/10.1096/fj.03-0121fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	14500546				2022-12-28	WOS:000185925100014
J	Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ				Rogers, MS; Rohan, RM; Birsner, AE; D'Amato, RJ			Genetic loci that control vascular endothelial growth factor-induced angiogenesis	FASEB JOURNAL			English	Article						quantitative trait locus; QTL; corneal neovascularization recombinant inbred; BXD	QUANTITATIVE TRAIT LOCI; TUMOR ANGIOGENESIS; PERMEABILITY FACTOR; IN-VITRO; MOUSE; CELLS; MICE; NEOVASCULARIZATION; EXPRESSION; GENOME	Angiogenesis is regulated by the balance between angiogenic stimulators and inhibitors. Numerous reports have demonstrated that tumors induce aggressive angiogenesis by upregulating the production of angiogenesis stimulating growth factors to overcome the baseline levels of endogenous inhibitors. However, the possibility of large differences in the host's responsiveness to angiogenic factors has been largely overlooked. Using the corneal micropocket neovascularization assay, we have observed >10-fold differences in responsiveness to either basic fibroblast growth factor (bFGF) or vascular endothelial growth factor (VEGF) among various mouse strains. The inheritance pattern observed for these traits supported a QTL (quantitative trait locus) approach to mapping the genes responsible for the differences in angiogenic responsiveness. To overcome variability in the assay, we used recombinant inbred lines to map this phenotype. In the BXD series of recombinant inbred mouse strains, we have mapped the regions responsible for regulating VEGF-induced angiogenesis using both composite interval mapping and multiple interval mapping. Both approaches link VEGF responsiveness to regions on chromosomes 2 (near D2Mit6) and 10 (near D10Mit20). Candidate angiogenesis-related genes in these regions include those for collagen XVIII/endostatin, matrix metalloproteinase 11, integrin beta(2), prostaglandin D2 synthase, and interleukin-1 receptor antagonist.	Childrens Hosp, Dept Surg, Div Surg Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	D'Amato, RJ (corresponding author), Childrens Hosp, Dept Surg, Div Surg Res, 300 Longwood Ave, Boston, MA 02115 USA.	robert.damato@tch.harvard.edu	Rogers, Michael S/A-9814-2009; Rogers, Michael/AAE-2217-2019	Rogers, Michael S/0000-0002-5250-8434; Rogers, Michael/0000-0002-5250-8434				Balasubramanian SP, 2002, BRIT J CANCER, V87, P1057, DOI 10.1038/sj.bjc.6600625; Blake JA, 2002, NUCLEIC ACIDS RES, V30, P113, DOI 10.1093/nar/30.1.113; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brockmann GA, 2001, FASEB J, V15, P978, DOI 10.1096/fj.00-0391com; Brockmann GA, 2000, GENOME RES, V10, P1941, DOI 10.1101/gr.GR1499R; Cherrington JM, 2000, ADV CANCER RES, V79, P1, DOI 10.1016/S0065-230X(00)79001-4; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; CLAUSS M, 1990, J EXP MED, V172, P1535, DOI 10.1084/jem.172.6.1535; Coxon A, 2002, ARTHRITIS RHEUM, V46, P2604, DOI 10.1002/art.10546; DIETRICH WF, 1993, CELL, V75, P631, DOI 10.1016/0092-8674(93)90484-8; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Erb MH, 2002, CURR EYE RES, V24, P245, DOI 10.1076/ceyr.24.4.245.8412; Gao YL, 2000, CIRC RES, V87, P739, DOI 10.1161/01.RES.87.9.739; Gupta AR, 2001, J GENE MED, V3, P252, DOI 10.1002/1521-2254(200105/06)3:3<252::AID-JGM185>3.0.CO;2-S; Iughetti P, 2001, CANCER RES, V61, P7375; Jackson AU, 2002, J GERONTOL A-BIOL, V57, pB9, DOI 10.1093/gerona/57.1.B9; Jansen RC, 1996, TRENDS PLANT SCI, V1, P89, DOI 10.1016/S1360-1385(96)80040-9; Kao CH, 1999, GENETICS, V152, P1203; Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905; LANDER ES, 1989, GENETICS, V121, P185; Lee WH, 1999, ENDOCRINE, V11, P181, DOI 10.1385/ENDO:11:2:181; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; Loughnan MS, 1996, AUST NZ J OPHTHALMOL, V24, P289, DOI 10.1111/j.1442-9071.1996.tb01596.x; Mariotti M, 2000, J BIOL CHEM, V275, P24047, DOI 10.1074/jbc.M001928200; McLaren J, 2000, HUM REPROD UPDATE, V6, P45, DOI 10.1093/humupd/6.1.45; Miller RA, 2002, J GERONTOL A-BIOL, V57, pB3, DOI 10.1093/gerona/57.1.B3; MINTZ B, 1975, P NATL ACAD SCI USA, V72, P3585, DOI 10.1073/pnas.72.9.3585; Rohan RM, 2000, FASEB J, V14, P871, DOI 10.1096/fasebj.14.7.871; Rowse GJ, 1998, CANCER RES, V58, P2675; Rupnick MA, 2002, P NATL ACAD SCI USA, V99, P10730, DOI 10.1073/pnas.162349799; Seghezzi G, 1998, J CELL BIOL, V141, P1659, DOI 10.1083/jcb.141.7.1659; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Smith SK, 2001, BRIT J OBSTET GYNAEC, V108, P777, DOI 10.1111/j.1471-0528.2001.00211.x; Taba Y, 2000, CIRC RES, V86, P967, DOI 10.1161/01.RES.86.9.967; Taomoto M, 2000, INVEST OPHTH VIS SCI, V41, P230; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Watson CJ, 2000, CYTOKINE, V12, P1232, DOI 10.1006/cyto.2000.0692; ZENG ZB, 1994, GENETICS, V136, P1457; ZENG ZB, 1993, P NATL ACAD SCI USA, V90, P10972, DOI 10.1073/pnas.90.23.10972; ZENG ZB, 1994, P 5 WORLD C GEN APPL, V22, P65; Zorick TS, 2001, EUR J HUM GENET, V9, P811, DOI 10.1038/sj.ejhg.5200721	43	48	48	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2112	+		10.1096/fj.03-0246fje	http://dx.doi.org/10.1096/fj.03-0246fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958152				2022-12-28	WOS:000185925100019
J	Kim, W; Moon, SO; Sung, MJ; Kim, SH; Lee, S; So, JN; Park, SK				Kim, W; Moon, SO; Sung, MJ; Kim, SH; Lee, S; So, JN; Park, SK			Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells	FASEB JOURNAL			English	Article						angiogenesis; ERK	SMOOTH-MUSCLE CELLS; HUMAN ENDOMETRIUM; SURVIVAL FACTOR; GROWTH-FACTOR; EXPRESSION; SECRETION; RECEPTOR; PEPTIDE; ANGIOPOIETIN-1; MECHANISMS	Adrenomedullin ( AM) is a multifunctional peptide in human pheochromocytoma. To evaluate whether AM could be an angiogenic factor, we examined its effect on kinases and angiogenic processes. AM induced tyrosine phosphorylation of Akt and mitogen-activated protein kinase ( MAPK)/extracellular signal-regulated kinase1/2 (ERK1/2) by using distinct signaling pathways in human umbilical vein endothelial cells (HUVECs). AM also phosphorylated focal adhesion kinase, and phosphatidylinositol 3'-kinase inhibitor inhibited AM-induced focal adhesion kinase phosphorylation. Pretreatment with high concentrations of AM(22-52), a putative AM receptor antagonist, partially suppressed AM-induced phosphorylation of Akt, ERK1/2, and focal adhesion kinase. AM and vascular endothelial growth factor produced increases in DNA synthesis and migration in HUVECs. AM induced tube formation in HUVECs, and its effect was inhibited by pretreatment with phosphatidylinositol 3'-kinase inhibitor or ERK1/2 inhibitor. AM induced sprouting in porcine pulmonary arterial endothelial cells and promoted neovessel formation in a mouse Matrigel plug assay. Inhibitors of phosphatidylinositol 3'- kinase and ERK1/2 inhibited AM-induced endothelial sprouting in vitro and angiogenesis in vivo. AM exerts angiogenic activity through activation of Akt, MAPK, and focal adhesion kinase in endothelial cells.	Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Inst Clin Med, Chonju 560180, South Korea; Woosuk Univ, Dept Biotechnol, Chonju, South Korea	Jeonbuk National University; Woosuk University	Park, SK (corresponding author), Chonbuk Natl Univ, Sch Med, Dept Internal Med, Res Inst Clin Med, 634-1 Keum Am Dong, Chonju 560180, South Korea.	parksk@moak.chonbuk.ac.kr	Kim, Won/F-1643-2018	Kim, Won/0000-0003-1068-1455				Abe K, 2000, FERTIL STERIL, V74, P141, DOI 10.1016/S0015-0282(00)00585-9; ABEDI H, 1995, CARDIOVASC RES, V30, P544, DOI 10.1016/0008-6363(95)00092-5; BEAN AJ, 1994, FASEB J, V8, P630, DOI 10.1096/fasebj.8.9.8005390; Cameron VA, 2002, AM J PHYSIOL-ENDOC M, V282, pE139, DOI 10.1152/ajpendo.2002.282.1.E139; Caron KM, 2001, P NATL ACAD SCI USA, V98, P615, DOI 10.1073/pnas.021548898; Cuttitta F, 2002, MICROSC RES TECHNIQ, V57, P110, DOI 10.1002/jemt.10059; Dimmeler S, 2000, CIRC RES, V86, P4, DOI 10.1161/01.RES.86.1.4; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; FREDERICK J, 1998, MATRIX METALLOPROTEI, P1; Fujita Y, 2002, INT J UROL, V9, P285, DOI 10.1046/j.1442-2042.2002.00469.x; Grant D S, 1997, EXS, V79, P317; Hay D L, 2001, Trends Pharmacol Sci, V22, P57, DOI 10.1016/S0165-6147(00)01617-5; Hinson JP, 2000, ENDOCR REV, V21, P138, DOI 10.1210/er.21.2.138; HORIO T, 1995, CIRC RES, V77, P660, DOI 10.1161/01.RES.77.4.660; Kamitani S, 1999, FEBS LETT, V448, P111, DOI 10.1016/S0014-5793(99)00358-0; Kano H, 1996, J HYPERTENS, V14, P209, DOI 10.1097/00004872-199602000-00009; Kato H, 1997, ENDOCRINOLOGY, V138, P2615, DOI 10.1210/en.138.6.2615; Kim I, 2000, CIRC RES, V86, P952, DOI 10.1161/01.RES.86.9.952; Kim W, 2002, APOPTOSIS, V7, P527, DOI 10.1023/A:1020695110648; Kim YM, 2002, J BIOL CHEM, V277, P6799, DOI 10.1074/jbc.M109434200; KITAMURA K, 1993, BIOCHEM BIOPH RES CO, V192, P553, DOI 10.1006/bbrc.1993.1451; Kitamura K, 2002, MICROSC RES TECHNIQ, V57, P3, DOI 10.1002/jemt.10052; KLAGSBRUN M, 1991, ANNU REV PHYSIOL, V53, P217, DOI 10.1146/annurev.physiol.53.1.217; Lee MS, 2001, CANCER RES, V61, P3290; Lee S, 2003, FASEB J, V17, pA326, DOI 10.1096/fj.02-0570fje; McLatchie LM, 1998, NATURE, V393, P333, DOI 10.1038/30666; Minamino N, 2002, MICROSC RES TECHNIQ, V57, P28, DOI 10.1002/jemt.10048; Nikitenko LL, 2000, MOL HUM REPROD, V6, P811, DOI 10.1093/molehr/6.9.811; Oehler MK, 2002, ONCOGENE, V21, P2815, DOI 10.1038/sj.onc.1205374; Papapetropoulos A, 1999, LAB INVEST, V79, P213; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; SAKATA J, 1994, FEBS LETT, V352, P105, DOI 10.1016/0014-5793(94)00928-7; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SUGO S, 1994, BIOCHEM BIOPH RES CO, V201, P1160, DOI 10.1006/bbrc.1994.1827; SUGO S, 1994, BIOCHEM BIOPH RES CO, V203, P719, DOI 10.1006/bbrc.1994.2241; Takahashi T, 1999, ONCOGENE, V18, P2221, DOI 10.1038/sj.onc.1202527; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zhao Y, 1998, ONCOGENE, V16, P409, DOI 10.1038/sj.onc.1201768	40	109	112	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2003	17	11					1937	+		10.1096/fj.02-1209fje	http://dx.doi.org/10.1096/fj.02-1209fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	721YB	12897063				2022-12-28	WOS:000185345100021
J	Greco, M; Villani, G; Mazzucchelli, F; Bresolin, N; Papa, S; Attardi, G				Greco, M; Villani, G; Mazzucchelli, F; Bresolin, N; Papa, S; Attardi, G			Marked aging-related decline in efficiency of oxidative phosphorylation in human skin fibroblasts	FASEB JOURNAL			English	Article						fetal fibroblasts; mitochondrial respiration; cytochrome c oxidase	CYTOCHROME-C-OXIDASE; MITOCHONDRIAL-DNA; RESPIRATORY-CHAIN; SKELETAL-MUSCLE; HUMAN-CELLS; IN-VIVO; WILD-TYPE; AGE; MUTATION; LIVER	An extensive analysis has been carried out of mitochondrial biochemical and bioenergetic properties of fibroblasts, mostly skin-derived, from a large group of subjects ranging in age between 20 wk fetal and 103 yr. A striking age-related change observed in a fundamental process underlying mitochondrial biogenesis and function was the very significant decrease in rate of mitochondrial protein synthesis in individuals above 40 yr. The analysis of endogenous respiration rate revealed a significant decrease in the age range from 40 to 90 yr and a tendency to uncoupling in the samples from subjects above 60 year. A surprising finding was the occurrence of a subgroup of individuals greater than or equal to90 yr old whose skin fibroblasts exhibited an exceptionally high respiration rate. This high rate was not due to respiration uncoupling, rather pointing to a compensatory phenomenon, not involving an increase in mtDNA content, in the corresponding skin fibroblast populations, or, possibly, to a selection of a different cell type secondary to more extensive dermal atrophy. The most important aging-related phenotypic effects observed were those that affected the cell oxidative phosphorylation (OX-PHOS) capacity. These were, in particular, the very significant reduction in the ratio of uncoupled to oligomycin-inhibited endogenous respiration observed in intact fibroblasts, which pointed to a decrease with donor's age in the control of respiration by the mitochondrial membrane potential, the very significant decrease in efficiency of OX-PHOS, as determined by novel in situ measurements of P:O ratios, and, consistent with these results, the very significant reduction in the respiratory control ratios. These findings clearly pointed to a dramatic mitochondrial dysfunction, which would lead to a decrease in ATP synthesis rate, with the observed decline in mitochondrial protein synthesis rate being a likely contributing factor. These observations have important implications for understanding the biology of aging, as well as the pathogenesis of aging-related degenerative diseases.	CALTECH, Div Biol, Pasadena, CA 91125 USA; Univ Milan, Inst Clin Neurol, Osped Maggiore Policlin, I-20122 Milan, Italy; Univ Bari, Dept Med Biochem & Biol, I-70124 Bari, Italy	California Institute of Technology; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; Universita degli Studi di Bari Aldo Moro	Attardi, G (corresponding author), CALTECH, Div Biol, 156-29, Pasadena, CA 91125 USA.	attardi@caltech.edu		Bresolin, Nereo/0000-0001-6694-3595; Papa, Sergio/0000-0002-4417-1763				Allen RG, 1997, J BIOL CHEM, V272, P24805, DOI 10.1074/jbc.272.40.24805; Attardi G, 2002, MITOCHONDRION, V2, P27, DOI 10.1016/S1567-7249(02)00032-6; Barazzoni R, 2000, J BIOL CHEM, V275, P3343, DOI 10.1074/jbc.275.5.3343; BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2; Boffoli D, 1996, BBA-MOL BASIS DIS, V1315, P66, DOI 10.1016/0925-4439(95)00107-7; BOWLING AC, 1993, J NEUROCHEM, V60, P1964, DOI 10.1111/j.1471-4159.1993.tb13430.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; Cuezva JM, 1997, J BIOENERG BIOMEMBR, V29, P365, DOI 10.1023/A:1022450831360; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; Hagen TM, 1997, P NATL ACAD SCI USA, V94, P3064, DOI 10.1073/pnas.94.7.3064; HAYASHI JI, 1994, J BIOL CHEM, V269, P6878; Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601; KING MP, 1988, CELL, V52, P811, DOI 10.1016/0092-8674(88)90423-0; KUNTZ WS, 2000, J BIOL CHEM, V275, P27741; KUNZ D, 1995, BIOCHEM MOL MED, V54, P105, DOI 10.1006/bmme.1995.1015; Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891; Lenaz G, 2000, BBA-BIOENERGETICS, V1459, P397, DOI 10.1016/S0005-2728(00)00177-8; Michikawa Y, 1999, Somat Cell Mol Genet, V25, P333, DOI 10.1023/A:1019972500785; Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774; MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9; MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167; MULLERHOCKER J, 1993, VIRCHOWS ARCH A, V422, P7, DOI 10.1007/BF01605127; Papa S, 1996, BBA-BIOENERGETICS, V1276, P87, DOI 10.1016/0005-2728(96)00077-1; REIS RJS, 1983, J BIOL CHEM, V258, P9078; TORII K, 1992, AM J RESP CELL MOL, V6, P88, DOI 10.1165/ajrcmb/6.1.88; TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0; Ventura B, 2002, BBA-BIOENERGETICS, V1553, P249, DOI 10.1016/S0005-2728(01)00246-8; Villani G, 1998, J BIOL CHEM, V273, P31829, DOI 10.1074/jbc.273.48.31829; Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166; Villani G, 2001, METHOD CELL BIOL, V65, P119, DOI 10.1016/S0091-679X(01)65007-6; Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com; Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499; YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164; YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699	38	82	84	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1706	+		10.1096/fj.02-1009fje	http://dx.doi.org/10.1096/fj.02-1009fje			26	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958183				2022-12-28	WOS:000184471600007
J	Yang, CW; Li, C; Jung, JY; Shin, SJ; Choi, BS; Lim, SW; Sun, BK; Kim, YS; Kim, J; Chang, YS; Bang, BK				Yang, CW; Li, C; Jung, JY; Shin, SJ; Choi, BS; Lim, SW; Sun, BK; Kim, YS; Kim, J; Chang, YS; Bang, BK			Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney	FASEB JOURNAL			English	Article						renal ischemia-reperfusion; erythropoietin; apoptosis; stress kinase; heat shock protein 70	DELAYED GRAFT FUNCTION; HEAT-SHOCK; KINASE ACTIVATION; ACUTE REJECTION; CYCLOSPORINE-A; MAP KINASES; APOPTOSIS; ISCHEMIA/REPERFUSION; HEAT-SHOCK-PROTEIN-70; EXPRESSION	Improving the ability of the kidney to tolerate ischemic injury has important implications. We investigated the effect of recombinant human erythropoietin (rHuEPO) treatment on subsequent ischemia/reperfusion (I/R) injury and evaluated the role of heat shock protein (HSP) 70 in rHuEPO-induced renal protection. rHuEPO (3000 U/kg) was administered 24 h before I/R injury, and rats were killed at 24, 48, and 72 h after I/R injury. Pretreatment of rHuEPO resulted in the following: i) decreased serum creatinine level; ii) decreased tubular cell apoptosis and necrosis, measured by DNA fragmentation analysis and TUNEL staining and histomorphological criteria; iii) decreased tubular cell proliferation as determined by proliferating cell nuclear antigen expression; iv) increased bcl-2 protein and decreased caspase 3 activity; and v) decreased JNK expression. rHuEPO treatment increased HSP70 expression in a dose-dependent manner in normal rat kidneys, and inhibition of HSP70 expression by quercetin eliminated the renoprotective effect of rHuEPO in ischemic kidneys. Our study demonstrates that rHuEPO has a protective effect on subsequent I/R injury and that this effect is associated with induction of HSP70. Our study provides a new avenue for therapy to prevent renal damage after I/R injury.	Catholic Univ Korea, Dept Anat, Cell Death Dis Res Ctr, Seoul 137040, South Korea; Catholic Univ Korea, Cell Death Dis Res Ctr, Dept Internal Med, Coll Med, Seoul, South Korea; YanBian Univ, Coll Med, Affiliated Hosp, Nephrol & Dialysis Unit, JiLan 133000, Peoples R China	Catholic University of Korea; Catholic University of Korea; Yanbian University	Kim, J (corresponding author), Catholic Univ Korea, Dept Anat, Cell Death Dis Res Ctr, 505 Banpo Dong, Seoul 137040, South Korea.	jinkim@catholic.ac.kr		JUNG, JU YOUNG/0000-0002-6355-5738				Bernaudin M, 1999, J CEREBR BLOOD F MET, V19, P643, DOI 10.1097/00004647-199906000-00007; Blondeau N, 2002, NEUROSCIENCE, V109, P231, DOI 10.1016/S0306-4522(01)00473-0; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Chong ZZ, 2002, J CEREBR BLOOD F MET, V22, P503, DOI 10.1097/00004647-200205000-00001; Di Mari JF, 1999, AM J PHYSIOL-RENAL, V277, pF195, DOI 10.1152/ajprenal.1999.277.2.F195; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Gabai VL, 1998, FEBS LETT, V438, P1, DOI 10.1016/S0014-5793(98)01242-3; Gabai VL, 1997, J BIOL CHEM, V272, P18033, DOI 10.1074/jbc.272.29.18033; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Hayashi Y, 2002, CIRCULATION, V106, P2601, DOI 10.1161/01.CIR.0000035651.72240.07; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Ikeyama S, 2001, J HEPATOL, V35, P53, DOI 10.1016/S0168-8278(01)00053-8; Ishizaka N, 2002, HYPERTENSION, V39, P122, DOI 10.1161/hy1201.096818; JAATTELA M, 1992, EMBO J, V11, P3507, DOI 10.1002/j.1460-2075.1992.tb05433.x; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Kaushal GP, 1998, AM J PHYSIOL-RENAL, V274, pF587, DOI 10.1152/ajprenal.1998.274.3.F587; Kelly KJ, 2001, KIDNEY INT, V59, P1798, DOI 10.1046/j.1523-1755.2001.0590051798.x; Kim J, 1999, J AM SOC NEPHROL, V10, P1; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Madamanchi NR, 2001, ARTERIOSCL THROM VAS, V21, P321, DOI 10.1161/01.ATV.21.3.321; McLaren AJ, 1999, CLIN TRANSPLANT, V13, P266, DOI 10.1034/j.1399-0012.1999.130308.x; Mehta A, 2002, MOL CELL BIOCHEM, V240, P19, DOI 10.1023/A:1020675721351; MESTRIL R, 1994, J CLIN INVEST, V93, P759, DOI 10.1172/JCI117030; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MORIN R L, 1990, P1; Nemoto T, 2001, KIDNEY INT, V59, P246, DOI 10.1046/j.1523-1755.2001.00485.x; Nogae S, 1998, J AM SOC NEPHROL, V9, P620; Oberbauer R, 2001, J LAB CLIN MED, V138, P343, DOI 10.1067/mlc.2001.118926; Park KM, 2001, J BIOL CHEM, V276, P11870, DOI 10.1074/jbc.M007518200; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; PLUMIER JCL, 1995, J CLIN INVEST, V95, P1854, DOI 10.1172/JCI117865; Ruscher K, 2002, J NEUROSCI, V22, P10291, DOI 10.1523/jneurosci.22-23-10291.2002; Sadamoto Y, 1998, BIOCHEM BIOPH RES CO, V253, P26, DOI 10.1006/bbrc.1998.9748; Sakanaka M, 1998, P NATL ACAD SCI USA, V95, P4635, DOI 10.1073/pnas.95.8.4635; SANFILIPPO F, 1984, TRANSPLANTATION, V38, P643, DOI 10.1097/00007890-198412000-00019; Sesti F, 2002, GYNECOL OBSTET INVES, V54, P1, DOI 10.1159/000064688; TROPPMANN C, 1995, TRANSPLANTATION, V59, P962, DOI 10.1097/00007890-199504150-00007; Uddin S, 2000, BIOCHEM BIOPH RES CO, V275, P16, DOI 10.1006/bbrc.2000.3266; Vairano M, 2002, EUR J NEUROSCI, V16, P584, DOI 10.1046/j.1460-9568.2002.02125.x; VANES A, 1983, TRANSPLANTATION, V36, P255; VAZIRI ND, 1994, AM J PHYSIOL, V266, pF360, DOI 10.1152/ajprenal.1994.266.3.F360; VENKATACHALAM MA, 1978, KIDNEY INT, V14, P31, DOI 10.1038/ki.1978.87; Wang JG, 2002, MULTIBODY SYST DYN, V7, P145, DOI 10.1023/A:1014491204982; Wang XX, 2002, J NEUROCHEM, V83, P1094, DOI 10.1046/j.1471-4159.2002.01224.x; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAMAMOTO K, 1984, AM J PATHOL, V116, P253; Yang CW, 2003, TRANSPLANTATION, V75, P20, DOI 10.1097/01.TP.0000040002.12912.65; Yang CW, 2001, TRANSPLANTATION, V72, P1753; Yang CW, 2001, EXP NEPHROL, V9, P284; Yin TG, 1997, J BIOL CHEM, V272, P19943, DOI 10.1074/jbc.272.32.19943; Ysebaert DK, 1997, TRANSPLANT P, V29, P2348, DOI 10.1016/S0041-1345(97)00396-5	52	202	229	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2003	17	10					1754	+		10.1096/fj.02-1191fje	http://dx.doi.org/10.1096/fj.02-1191fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	706TR	12958199				2022-12-28	WOS:000184471600018
J	Bartoli, M; Platt, DH; Lemtalsi, T; Gu, XL; Brooks, SE; Marrero, MB; Caldwell, RB				Bartoli, M; Platt, DH; Lemtalsi, T; Gu, XL; Brooks, SE; Marrero, MB; Caldwell, RB			VEGF differentially activates STAT3 in microvascular endothelial cells	FASEB JOURNAL			English	Article						VEGFR2; angiogenesis	GROWTH-FACTOR; SIGNAL TRANSDUCER; EXPRESSION; ANGIOGENESIS; PROLIFERATION; INDUCTION; HYPOXIA	Increased VEGF expression is found in several pathologies characterized by abnormal angiogenesis. Previous studies have shown that the transcription factor STAT3 mediates VEGF gene transcription and its activation. In this study, Western analysis and confocal immunocytochemistry were used to examine STAT3 activation in retinal microvascular endothelial cells (BREC). We found that VEGF rapidly induces STAT3 tyrosine phosphorylation and nuclear translocation. Immunoprecipitation studies also showed that VEGF forms a complex with VEGFR2 only in BREC and not in aortic macrovascular endothelial cells (BAEC). In addition, quantitative real-time RT-PCR analysis of VEGF-induced VEGF expression showed a significant increase in specific mRNA formation only in BREC and not in BAEC, and this effect was significantly reduced by antisense-mediated reduction of STAT3 expression. Furthermore, studies conducted in human dermal microvascular endothelial cells (HDMEC) showed that, in this endothelial cell type, VEGF autocrine expression is also accompanied by STAT3 activation as in BREC. In this study we showed that VEGF can differentially induce STAT3 activation in micro-versus macro-vascular endothelial cells and that this effect is linked to VEGFR2/STAT3 complex formation, which correlates with VEGF autocrine ability to stimulate its own gene expression.	Med Coll Georgia, Vasc Biol Ctr, Dept Pathol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Cellular Biol & Anat, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Med Coll Georgia, Dept Ophthalmol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University; University System of Georgia; Augusta University	Bartoli, M (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Dept Pathol, CB3209,1459 Laney Walker Blvd, Augusta, GA 30912 USA.	mbartoli@mail.mcg.edu		Caldwell, Ruth/0000-0003-0168-0354				Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Bromberg J, 2002, J CLIN INVEST, V109, P1139, DOI 10.1172/JCI200215617; Castilla MA, 1999, CIRC RES, V85, P1132; Duh E, 1999, DIABETES, V48, P1899, DOI 10.2337/diabetes.48.10.1899; DVORAK HF, 1995, INT ARCH ALLERGY IMM, V107, P233, DOI 10.1159/000236988; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043; Hess DC, 2000, STROKE, V31, P1179, DOI 10.1161/01.STR.31.5.1179; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Jans DA, 1998, BIOESSAYS, V20, P400, DOI 10.1002/(SICI)1521-1878(199805)20:5<400::AID-BIES7>3.0.CO;2-R; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Jove R, 2000, ONCOGENE, V19, P2466, DOI 10.1038/sj.onc.1203549; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy DE, 2002, J CLIN INVEST, V109, P1143, DOI 10.1172/JCI200215650; Mui ALF, 1999, CELL MOL LIFE SCI, V55, P1547, DOI 10.1007/s000180050394; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Nakamura M, 2002, PATHOL INT, V52, P331, DOI 10.1046/j.1440-1827.2002.01367.x; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Osugi T, 2002, J BIOL CHEM, V277, P6676, DOI 10.1074/jbc.M108246200; Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje; Schaefer LK, 2002, ONCOGENE, V21, P2058, DOI 10.1038/sj.onc.1205263; Sehgal PB, 2002, J BIOL CHEM, V277, P12067, DOI 10.1074/jbc.M200018200; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Valdembri D, 2001, FASEB J, V15, P225, DOI 10.1096/fj.01-0633fje; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4	32	139	145	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1562	+		10.1096/fj.02-1084fje	http://dx.doi.org/10.1096/fj.02-1084fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824281				2022-12-28	WOS:000183818000016
J	Land, A; Zonneveld, D; Braakman, I				Land, A; Zonneveld, D; Braakman, I			Folding of HIV-1 Envelope glycoprotein involves extensive isomerization of disulfide bonds and conformation-dependent leader peptide cleavage	FASEB JOURNAL			English	Article						gp120; gp160; endoplasmic reticulum; signal sequence; protein processing	IMMUNODEFICIENCY-VIRUS TYPE-1; PANCREATIC TRYPSIN-INHIBITOR; N-ACETYLGLUCOSAMINIDASE-F; ENDOPLASMIC-RETICULUM; SIGNAL-SEQUENCE; TRANSMEMBRANE GLYCOPROTEIN; INFLUENZA HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; QUALITY-CONTROL; VACCINIA VIRUS	Human immunodeficiency virus binds and enters cells via the Envelope glycoprotein gp160 at its surface. In infected cells, gp160 is found not only on the plasma membrane but also in the endoplasmic reticulum (ER). Our aim was to establish rate-determining steps in the maturation process of gp160, using a radioactive pulse-chase approach. We found that gp160 has an intricate folding process: disulfide bonds start to form during synthesis but undergo extensive isomerization until the correct native conformation is reached. Removal of the leader peptide critically depends on formation of at least some disulfide bonds in subunit gp120 during folding. Envelope folds extremely slowly and therefore resides in the ER longer than other proteins, but the yield of properly folded molecules is high and degradation is undetectable. The large quantity of gp160 in the ER hence is a result of its slow transit through this compartment. We show here that newly synthesized HIV-1 Envelope glycoprotein apparently follows a slow but high-yield folding path in which co- and post-translational formation of disulfide bonds in gp120, disulfide isomerization and conformation dependent removal of the leader sequence are determining and intertwined events.	Univ Utrecht, Dept Bioorgan Chem 1, NL-3584 CH Utrecht, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Biochem, NL-1105 AZ Amsterdam, Netherlands	Utrecht University; University of Amsterdam; Academic Medical Center Amsterdam	Braakman, I (corresponding author), Univ Utrecht, Dept Bioorgan Chem 1, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	I.Braakman@chem.uu.nl		Braakman, Ineke/0000-0003-1592-4364				ALLAN JS, 1985, SCIENCE, V228, P1091, DOI 10.1126/science.2986290; ALLEN S, 1995, J BIOL CHEM, V270, P4797, DOI 10.1074/jbc.270.9.4797; Benham AM, 2000, CRIT REV BIOCHEM MOL, V35, P433, DOI 10.1080/10409230091169258; BERMAN PW, 1988, J VIROL, V62, P3135, DOI 10.1128/JVI.62.9.3135-3142.1988; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CREIGHTON TE, 1977, J MOL BIOL, V113, P275, DOI 10.1016/0022-2836(77)90142-5; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Das AT, 1999, VIROLOGY, V263, P55, DOI 10.1006/viro.1999.9898; Dettenhofer M, 2001, J BIOL CHEM, V276, P5985, DOI 10.1074/jbc.M008933200; DOMS RW, 1993, VIROLOGY, V193, P545, DOI 10.1006/viro.1993.1164; EARL PL, 1991, J VIROL, V65, P2047, DOI 10.1128/JVI.65.4.2047-2055.1991; ELBEIN AD, 1984, CRC CR REV BIOCH MOL, V16, P21, DOI 10.3109/10409238409102805; ELDER JH, 1982, P NATL ACAD SCI-BIOL, V79, P4540, DOI 10.1073/pnas.79.15.4540; Ellgaard L, 2001, CURR OPIN CELL BIOL, V13, P431, DOI 10.1016/S0955-0674(00)00233-7; FENNIE C, 1989, J VIROL, V63, P639, DOI 10.1128/JVI.63.2.639-646.1989; FENOUILLET E, 1995, J GEN VIROL, V76, P1509, DOI 10.1099/0022-1317-76-6-1509; FUERST TR, 1989, J MOL BIOL, V206, P333, DOI 10.1016/0022-2836(89)90483-X; HALLENBERGER S, 1993, VIROLOGY, V193, P510, DOI 10.1006/viro.1993.1156; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; High S, 2000, FEBS LETT, V476, P38, DOI 10.1016/S0014-5793(00)01666-5; KIENY MP, 1986, BIO-TECHNOL, V4, P790, DOI 10.1038/nbt0986-790; KOZARSKY K, 1989, J ACQ IMMUN DEF SYND, V2, P163; LAEMMLI UK, 1970, J MOL BIOL, V49, P99, DOI 10.1016/0022-2836(70)90379-7; Land A, 2001, BIOCHIMIE, V83, P783, DOI 10.1016/S0300-9084(01)01314-1; LEONARD CK, 1990, J BIOL CHEM, V265, P10373; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; LI Y, 1993, J VIROL, V67, P584, DOI 10.1128/JVI.67.1.584-588.1993; Li Y, 2000, VIROLOGY, V272, P417, DOI 10.1006/viro.2000.0357; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; LYKO F, 1995, J BIOL CHEM, V270, P19873, DOI 10.1074/jbc.270.34.19873; Martoglio B, 1997, EMBO J, V16, P6636, DOI 10.1093/emboj/16.22.6636; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; Moulard M, 1999, VIRUS RES, V60, P55, DOI 10.1016/S0168-1702(99)00002-7; Otteken A, 1996, J VIROL, V70, P3407, DOI 10.1128/JVI.70.6.3407-3415.1996; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1995, J BIOL CHEM, V270, P18051, DOI 10.1074/jbc.270.30.18051; PAL R, 1989, P NATL ACAD SCI USA, V86, P3384, DOI 10.1073/pnas.86.9.3384; Rehm A, 2001, EMBO J, V20, P1573, DOI 10.1093/emboj/20.7.1573; Rothenberg SM, 2001, J VIROL, V75, P11851, DOI 10.1128/JVI.75.23.11851-11862.2001; Salzwedel K, 1999, J VIROL, V73, P2469, DOI 10.1128/JVI.73.3.2469-2480.1999; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; STEIN BS, 1990, J BIOL CHEM, V265, P2640; STEUBE K, 1985, BIOCHEMISTRY-US, V24, P5587, DOI 10.1021/bi00341a045; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; Tarentino A L, 1978, Methods Enzymol, V50, P574; TATU U, 1995, EMBO J, V14, P1340, DOI 10.1002/j.1460-2075.1995.tb07120.x; WAINHOBSON S, 1985, CELL, V40, P9, DOI 10.1016/0092-8674(85)90303-4; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WEISSMAN JS, 1992, P NATL ACAD SCI USA, V89, P9900, DOI 10.1073/pnas.89.20.9900; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580	56	78	81	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1058	1067		10.1096/fj.02-0811com	http://dx.doi.org/10.1096/fj.02-0811com			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12773488	Green Submitted			2022-12-28	WOS:000183818000009
J	Woods, CC; Banks, KE; Gruener, R; DeLuca, D				Woods, CC; Banks, KE; Gruener, R; DeLuca, D			Loss of T cell precursors after spaceflight and exposure to vector-averaged gravity	FASEB JOURNAL			English	Article						fetal thymus organ culture; microgravity; clinostat	POSITIVE NONLYMPHOID CELLS; THYMUS ORGAN-CULTURES; PRE-TCR; IMMUNOLOGICAL SYNAPSE; MURINE THYMOCYTES; BONE-MARROW; FETAL; DIFFERENTIATION; ACTIVATION; CLINOROTATION	Using fetal thymus organ culture (FTOC), we examined the effects of spaceflight and vector-averaged gravity on T cell development. Under both conditions, the development of T cells was significantly attenuated. Exposure to spaceflight for 16 days resulted in a loss of precursors for CD4(+), CD8(+), and CD4(+) CD8(+) T cells in a rat/mouse xenogeneic co-culture. A significant decrease in the same precursor cells, as well as a decrease in CD4(-)CD8(-) T cell precursors, was also observed in a murine C57BL/6 FTOC after rotation in a clinostat to produce a vector-averaged microgravity-like environment. The block in T cell development appeared to occur between the pre-T cell and CD4(+)CD8(+) T cell stage. These data indicate that gravity plays a decisive role in the development of T cells.	Univ Arizona, Dept Microbiol & Immunol, Tucson, AZ 85724 USA; Univ Arizona, Dept Physiol, Tucson, AZ USA	University of Arizona; University of Arizona	DeLuca, D (corresponding author), Univ Arizona, Dept Microbiol & Immunol, 1501 N Campbell,POB 245049, Tucson, AZ 85724 USA.	deluca@u.arizona.edu						Basson MA, 2000, IMMUNOL TODAY, V21, P509, DOI 10.1016/S0167-5699(00)01711-4; Carleton M, 2002, J IMMUNOL, V168, P1649, DOI 10.4049/jimmunol.168.4.1649; Congdon CC, 1996, J APPL PHYSIOL, V81, P172, DOI 10.1152/jappl.1996.81.1.172; Cooper D, 2001, IN VITRO CELL DEV-AN, V37, P63; DELUCA D, 1995, J IMMUNOL METHODS, V178, P13, DOI 10.1016/0022-1759(94)00236-P; DELUCA D, 1986, J IMMUNOL, V136, P430; DELUCA D, 1986, J IMMUNOL, V137, P1435; DEUGNIER MA, 1990, EUR J IMMUNOL, V20, P2075, DOI 10.1002/eji.1830200928; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; FUCHS BB, 1993, J LEUKOCYTE BIOL, V54, P245, DOI 10.1002/jlb.54.3.245; GODFREY DI, 1993, IMMUNOL TODAY, V14, P547, DOI 10.1016/0167-5699(93)90186-O; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; GROVE DS, 1995, EXP CELL RES, V219, P102, DOI 10.1006/excr.1995.1210; Gruener R, 1994, Biol Sci Space, V8, P79; Hailman E, 2002, IMMUNITY, V16, P839, DOI 10.1016/S1074-7613(02)00326-6; Haks MC, 1999, SEMIN IMMUNOL, V11, P23, DOI 10.1006/smim.1998.0153; Hashemi BB, 1999, FASEB J, V13, P2071, DOI 10.1096/fasebj.13.14.2071; Horneck G, 1999, MUTAT RES-FUND MOL M, V430, P221, DOI 10.1016/S0027-5107(99)00133-5; Klaus DM, 1998, ADV SPACE RES, V21, P1315, DOI 10.1016/S0273-1177(97)00404-3; Kobayashi K, 2000, BIOCHEM BIOPH RES CO, V279, P258, DOI 10.1006/bbrc.2000.3945; Kruisbeek AM, 2000, IMMUNOL TODAY, V21, P637, DOI 10.1016/S0167-5699(00)01744-8; Kuo YP, 2002, J NEUROIMMUNOL, V130, P140, DOI 10.1016/S0165-5728(02)00220-5; Leitenberg D, 2001, SEMIN IMMUNOL, V13, P129, DOI 10.1006/smim.2000.0304; Malissen B, 1996, CURR OPIN IMMUNOL, V8, P383, DOI 10.1016/S0952-7915(96)80129-4; MANDEL TE, 1978, IMMUNOLOGY, V35, P317; MATSUMOTO K, 1991, IMMUNOLOGY, V72, P20; Middlebrook AJ, 2002, J IMMUNOL, V169, P2915, DOI 10.4049/jimmunol.169.6.2915; Nickerson CA, 2000, INFECT IMMUN, V68, P3147, DOI 10.1128/IAI.68.6.3147-3152.2000; Petrie HT, 2000, J IMMUNOL, V165, P3094, DOI 10.4049/jimmunol.165.6.3094; Saint-Ruf C, 2000, NATURE, V406, P524, DOI 10.1038/35020093; Sarkar D, 2000, J BONE MINER RES, V15, P489, DOI 10.1359/jbmr.2000.15.3.489; Shao H, 1999, J IMMUNOL, V163, P603; Strollo F, 1999, ADV SPACE B, V7, P99, DOI 10.1016/S1569-2574(08)60008-8; SUSHKOV FV, 1983, KOSM BIOL AVIAK MED+, V17, P56; Tabourn B, 1999, IN VITRO CELL DEV-AN, V35, P4; Taylor G R, 1997, Adv Space Biol Med, V6, P1, DOI 10.1016/S1569-2574(08)60076-3; TAYLOR GR, 1993, J LEUKOCYTE BIOL, V54, P179, DOI 10.1002/jlb.54.3.179; Trobridge PA, 2001, J IMMUNOL, V166, P809, DOI 10.4049/jimmunol.166.2.809; WALTENBERGER J, 1998, ANGIOGENESIS, V2, P115; Wilkinson B, 2001, CELL IMMUNOL, V211, P86, DOI 10.1006/cimm.2001.1827; YEOMAN H, 1993, P NATL ACAD SCI USA, V90, P10778, DOI 10.1073/pnas.90.22.10778; Zipris D, 2001, CELL MOL BIOL, V47, P65	42	26	32	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUN	2003	17	9					1526	+		10.1096/fj.02-0749fje	http://dx.doi.org/10.1096/fj.02-0749fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	12824295				2022-12-28	WOS:000183818000042
J	Laposa, RR; Henderson, JT; Wells, PG				Laposa, RR; Henderson, JT; Wells, PG			Tetracycline-dependent regulation of formamidopyrimidine DNA glycosylase in transgenic mice conditionally reduces oxidative DNA damage in vivo	FASEB JOURNAL			English	Article						DNA repair; oxidative stress; brain	BASE EXCISION-REPAIR; MAMMALIAN-CELLS; ESCHERICHIA-COLI; ALZHEIMERS-DISEASE; OGG1 PROTEIN; SACCHAROMYCES-CEREVISIAE; CHEMICAL TERATOGENESIS; GENE-EXPRESSION; 8-HYDROXYGUANINE; 8-OXOGUANINE	8-Oxo-deoxyguanosine (8-oxo-dG) is a pervasive oxidative DNA lesion formed by endogenous oxidative stress and enhanced by drugs and environmental chemicals. This lesion results in transcriptional errors and mutations and is linked to neurodegeneration, teratogenesis, cancer, and other pathologies. We demonstrate that the neonatal central nervous system of transgenic mice carrying the tetracycline-regulable DNA repair gene formamidopyrimidine DNA glycosylase (fpg) has a 50% reduction in 8-oxo-dG levels. This enhanced DNA repair is suppressed by treatment with doxycycline. For the first time, this murine model permits the level of a specific DNA oxidation product to be regulated in a temporally and spatially specific manner, allowing its role as a primary or secondary factor in neurodegenerative disease to be determined in vivo.	Univ Toronto, Fac Pharm, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Pharmacol, Toronto, ON, Canada	University of Toronto; University of Toronto	Wells, PG (corresponding author), Univ Toronto, Fac Pharm, 19 Russell St, Toronto, ON M5S 2S2, Canada.	pg.wells@utoronto.ca						ACKLANDBERGLUND CE, 1995, BIOTECHNIQUES, V18, P196; Alam ZI, 1997, J NEUROCHEM, V69, P1196, DOI 10.1046/j.1471-4159.1997.69031196.x; Alamo MJP, 1998, NUCLEIC ACIDS RES, V26, P5199, DOI 10.1093/nar/26.22.5199; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Ames Bruce N., 1995, Microbiologia (Madrid), V11, P305; Asami S, 1996, CANCER RES, V56, P2546; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; Boiteux S, 1999, BIOCHIMIE, V81, P59, DOI 10.1016/S0300-9084(99)80039-X; Boiteux S, 1998, FREE RADICAL RES, V29, P487, DOI 10.1080/10715769800300541; Cappelli E, 2000, CARCINOGENESIS, V21, P1135, DOI 10.1093/carcin/21.6.1135; CUSSAC C, 1996, NUCLEIC ACIDS RES, V24, P1772; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Friedberg EC, 2000, MUTAT RES-DNA REPAIR, V459, P243, DOI 10.1016/S0921-8777(00)00006-9; Gabbita SP, 1998, J NEUROCHEM, V71, P2034, DOI 10.1046/j.1471-4159.1998.71052034.x; Gill RD, 1996, CANCER RES, V56, P3721; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Guibourt N, 2000, BIOCHEMISTRY-US, V39, P1716, DOI 10.1021/bi992262n; HALL J, 1993, INT J CANCER, V54, P728, DOI 10.1002/ijc.2910540504; Hollenbach S, 1999, CARCINOGENESIS, V20, P1863, DOI 10.1093/carcin/20.9.1863; Jaruga P, 1996, NUCLEIC ACIDS RES, V24, P1389, DOI 10.1093/nar/24.8.1389; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; LAVAL F, 1994, NUCLEIC ACIDS RES, V22, P4943, DOI 10.1093/nar/22.23.4943; Le Page F, 2000, P NATL ACAD SCI USA, V97, P8397, DOI 10.1073/pnas.140137297; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Lovell MA, 2000, BRAIN RES, V855, P116, DOI 10.1016/S0006-8993(99)02335-5; Lyras L, 1997, J NEUROCHEM, V68, P2061; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Minowa O, 2000, P NATL ACAD SCI USA, V97, P4156, DOI 10.1073/pnas.050404497; Moallem SA, 1998, DEVELOPMENT, V125, P3225; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; Nicol CJ, 2000, FASEB J, V14, P111, DOI 10.1096/fasebj.14.1.111; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; QUIN H, 1997, J BIOCHEM BIOPH METH, V36, P63; Rosenquist TA, 1997, P NATL ACAD SCI USA, V94, P7429, DOI 10.1073/pnas.94.14.7429; Sarao R, 1998, TRANSGENIC RES, V7, P421, DOI 10.1023/A:1008837410485; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; Viswanathan A, 1998, J BIOL CHEM, V273, P21276, DOI 10.1074/jbc.273.33.21276; Wells PG, 1996, CRIT REV BIOCHEM MOL, V31, P1, DOI 10.3109/10409239609110574; WILSON DM, 1998, DNA REPAIR PROKARYOT; Winn LM, 1997, FREE RADICAL BIO MED, V22, P607, DOI 10.1016/S0891-5849(96)00340-1; YAMAMOTO F, 1992, JPN J CANCER RES, V83, P351, DOI 10.1111/j.1349-7006.1992.tb00114.x; [No title captured]	45	7	7	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1343	+		10.1096/fj.02-0689fje	http://dx.doi.org/10.1096/fj.02-0689fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759334				2022-12-28	WOS:000183165000019
J	Fogli, S; Nieri, P; Breschi, MC				Fogli, S; Nieri, P; Breschi, MC			The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage	FASEB JOURNAL			English	Review						doxorubicin; NO; apoptosis; cardioprotection	DOXORUBICIN-INDUCED APOPTOSIS; IRON REGULATORY PROTEIN-1; CYTOCHROME-C RELEASE; FACTOR-KAPPA-B; CARDIOMYOCYTE APOPTOSIS; MEDIATED APOPTOSIS; MITOCHONDRIAL RESPIRATION; CYTOSOLIC FRACTIONS; RYANODINE RECEPTOR; LIPID-PEROXIDATION	Anthracycline antibiotics are potent antitumor agents whose activity is severely limited by a cumulative dose-dependent chronic cardiotoxicity that results from the summation of multiple biochemical pathways of cellular damage, which ultimately yields to disruption of myocardiocyte integrity and loss of cardiac function. Nitric oxide (NO) is a key molecule involved in the pathophysiology of heart; dysregulation of activity of NO synthases (NOSs) and of NO metabolism seems to be a common feature in various cardiac diseases. The contribution of NO to anthracycline cardiac damage is suggested by evidence demonstrating anthracycline-mediated induction of NOS expression and NO release in heart and the ability of NOSs to promote anthracycline redox cycling to produce reactive oxygen species (ROS), including O-2(-) center dot and H2O2. Overproduction of ROS and NO yields to reactive nitrogen species, particularly the powerful oxidant molecule peroxynitrite (ONOO-), which may produce the marked reduction of cardiac contractility. This review focuses on the anthracycline-mediated deregulation of NO network and presents an unifying viewpoint of the main molecular mechanisms involved in the pathogenesis of anthracycline cardiotoxicity, including iron, free radicals, and novel mechanistic notions on cardiac ceramide signaling and apoptosis. The data presented in the literature encourage the development of strategies of pharmacological manipulation of NO metabolism to be used as a novel approach to the prevention of cardiotoxicity induced by anthracyclines.	Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, PI-56126 Pisa, Italy	University of Pisa	Fogli, S (corresponding author), Univ Pisa, Dept Psychiat Neurobiol Pharmacol & Biotechnol, Via Bonanno 6, PI-56126 Pisa, Italy.	s.fogli@do.med.unipi.it	Fogli, Stefano/AAC-1939-2019; Nieri, Paola/K-5814-2016; Fogli, Stefano/G-8324-2011; Fogli, Stefano/AAB-5874-2022	Fogli, Stefano/0000-0002-7845-2598				Adderley SR, 1999, J BIOL CHEM, V274, P5038, DOI 10.1074/jbc.274.8.5038; Aldieri E, 2002, TOXICOL APPL PHARM, V185, P85, DOI 10.1006/taap.2002.9527; Andrieu-Abadie N, 1999, FASEB J, V13, P1501, DOI 10.1096/fasebj.13.12.1501; Arola OJ, 2000, CANCER RES, V60, P1789; Arstall MA, 1999, CIRC RES, V85, P829, DOI 10.1161/01.RES.85.9.829; Balligand JL, 1997, ARTERIOSCL THROM VAS, V17, P1846, DOI 10.1161/01.ATV.17.10.1846; Berry C, 2001, AM J PHYSIOL-HEART C, V281, pH2337, DOI 10.1152/ajpheart.2001.281.6.H2337; Bishopric Nanette H., 2001, Current Opinion in Pharmacology, V1, P141, DOI 10.1016/S1471-4892(01)00032-7; BOSE R, 1995, CELL, V82, P405, DOI 10.1016/0092-8674(95)90429-8; Brown GC, 2002, FREE RADICAL BIO MED, V33, P1440, DOI 10.1016/S0891-5849(02)01112-7; Brunner F, 2001, CIRCULATION, V104, P3097, DOI 10.1161/hc5001.101966; Cairo G, 2002, BIOCHEMISTRY-US, V41, P7435, DOI 10.1021/bi025756k; Champion HC, 2003, HEART FAIL REV, V8, P35, DOI 10.1023/A:1022142904202; Childs AC, 2002, CANCER RES, V62, P4592; DANESI R, 1992, CANCER CHEMOTH PHARM, V29, P261, DOI 10.1007/BF00685942; Danesi R, 2002, CLIN PHARMACOKINET, V41, P431, DOI 10.2165/00003088-200241060-00004; Davis KL, 2001, ANNU REV PHARMACOL, V41, P203, DOI 10.1146/annurev.pharmtox.41.1.203; DEBELDER AJ, 1993, LANCET, V341, P84, DOI 10.1016/0140-6736(93)92559-C; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Di Paola M, 2000, BIOCHEMISTRY-US, V39, P6660, DOI 10.1021/bi9924415; DOROSHOW JH, 1983, CANCER RES, V43, P460; Doursout MF, 2001, J CARDIOVASC PHARM, V37, P349, DOI 10.1097/00005344-200104000-00001; Dowd NP, 2001, J CLIN INVEST, V108, P585, DOI 10.1172/JCI11334; Gambliel HA, 2002, BIOCHEM BIOPH RES CO, V291, P433, DOI 10.1006/bbrc.2002.6380; Garner AP, 1999, CANCER RES, V59, P1929; Garratt AN, 2003, TRENDS CARDIOVAS MED, V13, P80, DOI 10.1016/S1050-1738(02)00231-1; Gunther MR, 1997, J BIOL CHEM, V272, P17086, DOI 10.1074/jbc.272.27.17086; Gutierrez JA, 1997, J PHARMACOL EXP THER, V282, P1643; Haenen GRMM, 1997, BIOCHEM BIOPH RES CO, V236, P591, DOI 10.1006/bbrc.1997.7016; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Haywood GA, 1996, CIRCULATION, V93, P1087, DOI 10.1161/01.CIR.93.6.1087; Henaff M, 2001, FASEB J, V15, P99, DOI 10.1096/fj.01-0389fje; Ing DJ, 1999, CIRC RES, V84, P21; Jensen BV, 1996, LANCET, V347, P297, DOI 10.1016/S0140-6736(96)90469-9; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; Kang YJ, 2000, J BIOL CHEM, V275, P13690, DOI 10.1074/jbc.275.18.13690; Kelly RA, 1996, CIRC RES, V79, P363, DOI 10.1161/01.RES.79.3.363; KEUNG EC, 1991, J CLIN INVEST, V87, P2108, DOI 10.1172/JCI115241; Koglin J, 1999, CIRCULATION, V99, P836, DOI 10.1161/01.CIR.99.6.836; Kotamraju S, 2002, J BIOL CHEM, V277, P17179, DOI 10.1074/jbc.M111604200; Krainock R, 2001, J NEUROCHEM, V78, P552, DOI 10.1046/j.1471-4159.2001.00420.x; Kumar D, 2001, ANTIOXID REDOX SIGN, V3, P135, DOI 10.1089/152308601750100641; Kunisada K, 2002, CARDIOVASC RES, V53, P936, DOI 10.1016/S0008-6363(01)00506-5; Kwok JC, 2002, MOL PHARMACOL, V62, P888, DOI 10.1124/mol.62.4.888; Laurent G, 2001, BLOOD, V98, P913, DOI 10.1182/blood.V98.4.913; LAURINDO FRM, 1991, CIRCULATION, V83, P1705, DOI 10.1161/01.CIR.83.5.1705; LEANDRO J, 1994, AM J CARDIOL, V74, P1152, DOI 10.1016/0002-9149(94)90470-7; LEFER AM, 1991, FASEB J, V5, P2029, DOI 10.1096/fasebj.5.7.2010056; Levade T, 2001, CIRC RES, V89, P957, DOI 10.1161/hh2301.100350; Lewis NP, 1996, CIRCULATION, V93, P720, DOI 10.1161/01.CIR.93.4.720; Lipshultz SE, 1996, J CLIN ONCOL, V14, P328, DOI 10.1200/JCO.1996.14.2.328; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Maczewski M, 2003, EUR J PHARMACOL, V461, P139, DOI 10.1016/S0014-2999(03)01302-5; Maestre N, 2001, CANCER RES, V61, P2558; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Massion P B, 2001, Curr Opin Crit Care, V7, P323, DOI 10.1097/00075198-200110000-00003; Menna P, 2002, CHEM RES TOXICOL, V15, P1179, DOI 10.1021/tx020055+; Mihm MJ, 2002, BRIT J PHARMACOL, V135, P581, DOI 10.1038/sj.bjp.0704495; Minotti G, 1996, J CLIN INVEST, V98, P650, DOI 10.1172/JCI118836; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2001, CANCER RES, V61, P8422; MINOTTI G, 1995, J CLIN INVEST, V95, P1595, DOI 10.1172/JCI117833; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; Monneret C, 2001, EUR J MED CHEM, V36, P483, DOI 10.1016/S0223-5234(01)01244-2; Mostafa AM, 1999, RES COMMUN MOL PATH, V106, P193; Mungrue Imran N, 2002, Heart Fail Rev, V7, P407, DOI 10.1023/A:1020762401408; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Nakamura T, 2000, CIRCULATION, V102, P572; Negoro S, 2001, CIRCULATION, V103, P555, DOI 10.1161/01.CIR.103.4.555; Neuss M, 2001, CARDIOVASC DRUG THER, V15, P507, DOI 10.1023/A:1013715704835; OLSON RD, 1990, FASEB J, V4, P3076, DOI 10.1096/fasebj.4.13.2210154; Onody A, 2003, FEBS LETT, V536, P35, DOI 10.1016/S0014-5793(03)00006-1; Pacher P, 2003, CIRCULATION, V107, P896, DOI 10.1161/01.CIR.0000048192.52098.DD; Pacher P, 2002, J PHARMACOL EXP THER, V300, P862, DOI 10.1124/jpet.300.3.862; Pai VB, 2000, DRUG SAFETY, V22, P263, DOI 10.2165/00002018-200022040-00002; Pascale C, 2002, LANCET, V359, P1153, DOI 10.1016/S0140-6736(02)08135-7; PEDERSENBJERGAARD J, 1992, LEUKEMIA RES, V16, P1057, DOI 10.1016/0145-2126(92)90043-7; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; Rabkin SW, 2002, NITRIC OXIDE-BIOL CH, V7, P229, DOI 10.1016/S1089-8603(02)00115-5; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; Ramachandran A, 2002, FREE RADICAL BIO MED, V33, P1465, DOI 10.1016/S0891-5849(02)01142-5; Ruvolo PP, 1999, J BIOL CHEM, V274, P20296, DOI 10.1074/jbc.274.29.20296; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Saeki K, 2002, LIFE SCI, V70, P2377, DOI 10.1016/S0024-3205(02)01524-2; Sawyer DB, 2002, CIRCULATION, V105, P1551, DOI 10.1161/01.CIR.0000013839.41224.1C; Sayed-Ahmed MM, 2001, PHARMACOL TOXICOL, V89, P140, DOI 10.1034/j.1600-0773.2001.d01-148.x; Schwertz H, 2002, PROTEOMICS, V2, P988, DOI 10.1002/1615-9861(200208)2:8<988::AID-PROT988>3.0.CO;2-#; Seidman A, 2002, J CLIN ONCOL, V20, P1215, DOI 10.1200/JCO.20.5.1215; Shadle SE, 2000, BIOCHEM PHARMACOL, V60, P1435, DOI 10.1016/S0006-2952(00)00458-5; Shen JG, 2000, BBA-MOL BASIS DIS, V1500, P217, DOI 10.1016/S0925-4439(99)00109-X; Shinmura K, 2002, CIRC RES, V90, P602, DOI 10.1161/01.RES.0000012202.52809.40; Shioji K, 2002, CIRCULATION, V106, P1403, DOI 10.1161/01.CIR.0000027817.55925.B4; Sun XH, 2002, EXP BIOL MED, V227, P652, DOI 10.1177/153537020222700815; Tan Dun-Xian, 2002, Current Topics in Medicinal Chemistry, V2, P181, DOI 10.2174/1568026023394443; Thomas DD, 2002, P NATL ACAD SCI USA, V99, P12691, DOI 10.1073/pnas.202312699; Turko IV, 2002, PHARMACOL REV, V54, P619, DOI 10.1124/pr.54.4.619; van Acker FAA, 2001, CLIN CANCER RES, V7, P1378; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; Vaziri ND, 2000, HYPERTENSION, V36, P957, DOI 10.1161/01.HYP.36.6.957; Wang GW, 2001, J PHARMACOL EXP THER, V298, P461; Wang GX, 2001, EUR J PHARMACOL, V423, P99, DOI 10.1016/S0014-2999(01)01096-2; Weinstein DM, 2000, J PHARMACOL EXP THER, V294, P396; Wojtacki J, 2000, Med Sci Monit, V6, P411; Wong SCY, 1998, CIRCULATION, V98, P100, DOI 10.1161/01.CIR.98.2.100; Xu KY, 1999, P NATL ACAD SCI USA, V96, P657, DOI 10.1073/pnas.96.2.657; Xu L, 1998, SCIENCE, V279, P234, DOI 10.1126/science.279.5348.234; Zhou S, 2001, TOXICOL APPL PHARM, V175, P60, DOI 10.1006/taap.2001.9230; Zhou SY, 2001, CANCER RES, V61, P771	110	95	107	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	APR	2004	18	6					664	675		10.1096/fj.03-0724rev	http://dx.doi.org/10.1096/fj.03-0724rev			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	816KM	15054088				2022-12-28	WOS:000221108800036
J	Chung, L; Ng, YC				Chung, L; Ng, YC			Altered expression of apoptosis-related proteins in aged skeletal muscle	FASEB JOURNAL			English	Meeting Abstract	Experimental Biology 2004 Meeting	APR 17-21, 2004	Washington, DC						Penn State Univ, Milton S Hershey Med Ctr, Coll Med, Hershey, PA 17033 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health				Rader, Christoph/0000-0001-9955-3454					0	17	24	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR 23	2004	18	4		S			A345	A345		10.1096/fj.03-0586fje	http://dx.doi.org/10.1096/fj.03-0586fje			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806ZA	14688205				2022-12-28	WOS:000220470601661
J	Chen, LX; Zeng, Y; Yang, HP; Lee, TD; French, SW; Corrales, FJ; Garcia-Trevijano, ER; Avila, MA; Mato, JM; Lu, SC				Chen, LX; Zeng, Y; Yang, HP; Lee, TD; French, SW; Corrales, FJ; Garcia-Trevijano, ER; Avila, MA; Mato, JM; Lu, SC			Impaired liver regeneration in mice lacking methionine adenosyltransferase 1A	FASEB JOURNAL			English	Article						S-adenosylmethionine; partial hepatectomy; cyclin D1; hepatocyte growth factor	NITRIC-OXIDE SYNTHASE; ADENOSYL-L-METHIONINE; NF-KAPPA-B; S-ADENOSYLMETHIONINE; RAT HEPATOCYTES; KINASE CASCADE; FACTOR-ALPHA; EXPRESSION; PROLIFERATION; GROWTH	Methionine adenosyltransferase (MAT) is an essential enzyme because it catalyzes the formation of S-adenosylmethionine (SAMe), the principal biological methyl donor. Of the two genes that encode MAT, MAT1A is mainly expressed in adult liver and MAT2A is expressed in all extrahepatic tissues. Mice lacking MAT1A have reduced hepatic SAMe content and spontaneously develop hepatocellular carcinoma. The current study examined the influence of chronic hepatic SAMe deficiency on liver regeneration. Despite having higher baseline hepatic staining for proliferating cell nuclear antigen, MAT1A knockout mice had impaired liver regeneration after partial hepatectomy (PH) as determined by bromodeoxyuridine incorporation. This can be explained by an inability to up-regulate cyclin D1 after PH in the knockout mice. Upstream signaling pathways involved in cyclin D1 activation include nuclear factor kappaB (NFkappaB), the c-Jun-N-terminal kinase (JNK), extracellular signal-regulated kinases (ERKs), and signal transducer and activator of transcription-3 (STAT-3). At baseline, JNK and ERK are more activated in the knockouts whereas NFkappaB and STAT-3 are similar to wild-type mice. Following PH, early activation of these pathways occurred, but although they remained increased in wildtype mice, c-jun and ERK phosphorylation fell progressively in the knockouts. Hepatic SAMe levels fell progressively following PH in wild-type mice but remained unchanged in the knockouts. In culture, MAT1A knockout hepatocytes have higher baseline DNA synthesis but failed to respond to the mitogenic effect of hepatocyte growth factor. Taken together, our findings define a critical role for SAMe in ERK signaling and cyclin D1 regulation during regeneration and suggest chronic hepatic SAMe depletion results in loss of responsiveness to mitogenic signals.	Univ So Calif, Sch Med,Res Ctr Liver Dis,Dept Med, UCLA Res Ctr Alcohol Liver & Pancreat Dis, Div Gastrointestinal & Liver Dis, Los Angeles, CA 90033 USA; Harbor UCLA Res & Educ Inst, Dept Pathol, Torrance, CA 90502 USA; Univ Navarra, Fdn Invest Med Aplicada, E-31080 Pamplona, Spain; CIC Biogune, Metabol Unit, Derio 48160, Bizkaia, Spain	University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of Navarra; CIC bioGUNE	Lu, SC (corresponding author), Univ So Calif, Sch Med,Res Ctr Liver Dis,Dept Med, UCLA Res Ctr Alcohol Liver & Pancreat Dis, Div Gastrointestinal & Liver Dis, HMR Bldg 415,2011 Zonal Ave, Los Angeles, CA 90033 USA.	shellylu@usc.edu	Lu, Shelly/AAH-5937-2021; MATO, JOSE/A-5187-2011; Avila, Matias A/Y-6342-2019; Ruiz García-Trevijano, Elena R./ABE-1014-2021	Lu, Shelly/0000-0003-2128-5407; MATO, JOSE/0000-0003-1264-3153; Avila, Matias A/0000-0001-6570-3557; Ruiz García-Trevijano, Elena R./0000-0002-3985-1270; Corrales, Fernando/0000-0002-0231-5159				Assy N, 1997, J HEPATOL, V26, P945, DOI 10.1016/S0168-8278(97)80266-8; Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Coqueret O, 2002, GENE, V299, P35, DOI 10.1016/S0378-1119(02)01055-7; Factor VM, 1997, HEPATOLOGY, V26, P1434; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; Garcia-Trevijano ER, 2002, GASTROENTEROLOGY, V122, P1355, DOI 10.1053/gast.2002.33020; Higgins GM, 1931, ARCH PATHOL, V12, P186; Horvath B, 2002, BRAIN RES, V955, P260, DOI 10.1016/S0006-8993(02)03364-4; Huang YF, 1998, BONE, V23, P327, DOI 10.1016/S8756-3282(98)00115-X; Huang ZZ, 1998, AM J PHYSIOL-GASTR L, V275, pG14, DOI 10.1152/ajpgi.1998.275.1.G14; KINSELL LW, 1947, SCIENCE, V106, P589, DOI 10.1126/science.106.2763.589; KONE BC, 1995, AM J PHYSIOL-RENAL, V269, pF718, DOI 10.1152/ajprenal.1995.269.5.F718; LATASA MU, 2001, FASEB J, DOI DOI 10.1096/FJ.00-0556FJE; Li W, 2002, J BIOL CHEM, V277, P28411, DOI 10.1074/jbc.M202807200; Lu SC, 2001, P NATL ACAD SCI USA, V98, P5560, DOI 10.1073/pnas.091016398; Majano PL, 2001, J HEPATOL, V35, P692, DOI 10.1016/S0168-8278(01)00208-2; MARTINDUCE C, 1988, HEPATOLOGY, V8, P65; Martinez-Chantar ML, 2002, FASEB J, V16, P1292, DOI 10.1096/fj.02-0078fje; Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev; Nelsen CJ, 2003, J BIOL CHEM, V278, P3656, DOI 10.1074/jbc.M209374200; Newberne P M, 1986, Adv Exp Med Biol, V206, P223; Nomura J, 2003, LIFE SCI, V72, P2117, DOI 10.1016/S0024-3205(03)00070-5; Paneda C, 2002, HEPATOLOGY, V35, P1381, DOI 10.1053/jhep.2002.32538; PASCALE RM, 1991, ANTICANCER RES, V11, P1617; Santamaria E, 2003, P NATL ACAD SCI USA, V100, P3065, DOI 10.1073/pnas.0536625100; Schwabe RF, 2003, HEPATOLOGY, V37, P824, DOI 10.1053/jhep.2003.50135; SHIVAPURKAR N, 1986, CARCINOGENESIS, V8, P615; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; Tombes RM, 1998, BIOCHEM J, V330, P1451; VENDEMIALE G, 1989, SCAND J GASTROENTERO, V24, P407, DOI 10.3109/00365528909093067; Yang HP, 2003, J BIOL CHEM, V278, P50887, DOI 10.1074/jbc.M307600200; Yang SQ, 2001, HEPATOLOGY, V34, P694, DOI 10.1053/jhep.2001.28054	33	61	65	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					914	+		10.1096/fj.03-1204fje	http://dx.doi.org/10.1096/fj.03-1204fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033934	Green Submitted			2022-12-28	WOS:000220522800014
J	Frigeri, A; Nicchia, GP; Balena, R; Nico, B; Svelto, M				Frigeri, A; Nicchia, GP; Balena, R; Nico, B; Svelto, M			Aquaporins in skeletal muscle: reassessment of the functional role of aquaporin-4	FASEB JOURNAL			English	Article						mdx mouse; muscular dystrophy; muscle swelling; AQP4; AQP1	WATER CHANNEL; VOLUME CHANGES; MULLER CELLS; EXPRESSION; LOCALIZATION; TRANSPORT; FIBERS; TEMPERATURE; ASTROCYTES; MOLECULES	Aquaporin-4 (AQP4) is the major water channel of the neuromuscular system, but its physiological function in both perivascular astrocytes and skeletal muscle sarcolemma is unclear. The purpose of this study was to assess the following in skeletal muscle: a) the expression of all cloned water cannels; b) the functional role of AQP4 using sarcolemma vesicles purified by means of several fractionation methods, and c) the functional effect of AQP4 reduction in mdx mice, the animal model of Duchenne muscular dystrophy (DMD). Immunofluorescence and immunoblot experiments performed with affinity purified antibodies revealed that only AQP1 and AQP4 are expressed in mouse skeletal muscle: AQP1 in endothelial cells of continuous capillaries and AQP4 on the plasma membrane of muscle fiber. Plasma membrane vesicle purification was performed with a procedure extensively used to purify and characterize dystrophin-associated proteins (DAPs) from rabbit skeletal muscle. Western blot analysis showed strong co-enrichment of the analyzed DAPs and AQP4, indicating that the membrane vesicle preparation was highly enriched in sarcolemma. Stopped-flow light-scattering measurements showed high osmotic water permeability of sarcolemma vesicles (similar to150 mum/s) compatible with the AQP-mediated pathway for water movement. Sarcolemma vesicles prepared from mdx mice revealed, in parallel with AQP4 disappearance from the plasma membrane, a strong reduction in water permeability compared with wild-type mice. Altogether, these results demonstrate high AQP4-mediated water permeability of the skeletal muscle sarcolemma. Expression of sarcolemmal AQP4 together with that of vascular AQP1 may be responsible for the fast water transfer from the blood into the muscle during intense activity. These data imply an important role for aquaporins in skeletal muscle physiology as well as an involvement of AQP4 in the molecular alterations that occur in the muscle of DMD patients.	Univ Bari, Dipartimento Fisiol Gen & Ambientale, I-70126 Bari, Italy; Univ Bari, Ctr Excellence Comparat Gen CEGBA, I-70126 Bari, Italy; Univ Bari, Dept Human Anat, I-70124 Bari, Italy	Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro; Universita degli Studi di Bari Aldo Moro	Frigeri, A (corresponding author), Univ Bari, Dipartimento Fisiol Gen & Ambientale, Via Amendola 165-A, I-70126 Bari, Italy.	a.frigeri@biologia.uniba.it	frigeri, Antonio/AAC-6336-2022; Svelto, Maria/P-6186-2014	Frigeri, Antonio/0000-0002-5284-2934; Svelto, Maria/0000-0002-5584-9541				Adams ME, 2001, J CELL BIOL, V155, P113, DOI 10.1083/jcb.200106158; Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; Crosbie RH, 2002, FASEB J, V16, P943, DOI 10.1096/fj.01-0327com; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Frigeri A, 1998, J CLIN INVEST, V102, P695, DOI 10.1172/JCI2545; Frigeri A, 2002, FASEB J, V16, P1120, DOI 10.1096/fj.01-0797fje; FRIGERI A, 1995, J CELL SCI, V108, P2993; Frigeri A, 2001, FASEB J, V15, P90, DOI 10.1096/fj.00-0260com; Frigeri A, 2001, FASEB J, V15, P1282, DOI 10.1096/fj.00-0525fje; FRIGERI A, 1997, J PHYSL P, V504, P40; GRIMDITCH GK, 1985, AM J PHYSIOL, V249, pE398, DOI 10.1152/ajpendo.1985.249.4.E398; HAMILTON MT, 1993, AM J PHYSIOL, V265, pR1318, DOI 10.1152/ajpregu.1993.265.6.R1318; Hwang SM, 2002, EXP MOL MED, V34, P69, DOI 10.1038/emm.2002.10; LANNERGREN J, 1990, J PHYSIOL-LONDON, V420, pP116; Li J, 2002, INVEST OPHTH VIS SCI, V43, P573; LIDINGER MI, 1994, AM J PHYSIOL, V266, pR1896; LUNDVALL J, 1972, ACTA PHYSIOL SCAND, V85, P258, DOI 10.1111/j.1748-1716.1972.tb05259.x; MA TH, 1993, J BIOL CHEM, V268, P22756; MA TH, 1994, AM J PHYSIOL, V266, pC189, DOI 10.1152/ajpcell.1994.266.1.C189; Marinelli RA, 2003, J BIOL CHEM, V278, P43157, DOI 10.1074/jbc.M305899200; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MENKE A, 1995, J CELL SCI, V108, P727; Nagelhus EA, 1999, GLIA, V26, P47, DOI 10.1002/(SICI)1098-1136(199903)26:1<47::AID-GLIA5>3.0.CO;2-5; Nagelhus EA, 1998, J NEUROSCI, V18, P2506; Neely JD, 2001, P NATL ACAD SCI USA, V98, P14108, DOI 10.1073/pnas.241508198; NEERING IR, 1991, BIOPHYS J, V59, P926, DOI 10.1016/S0006-3495(91)82306-2; Newman Eric A., 1995, P717; Nicchia GP, 2003, FASEB J, V17, P1508, DOI 10.1096/fj.02-1183fje; Nicchia GP, 2001, J HISTOCHEM CYTOCHEM, V49, P1547, DOI 10.1177/002215540104901208; Nicchia GP, 2000, GLIA, V31, P29, DOI 10.1002/(SICI)1098-1136(200007)31:1<29::AID-GLIA30>3.0.CO;2-3; NIELSEN S, 1993, P NATL ACAD SCI USA, V90, P7275, DOI 10.1073/pnas.90.15.7275; Nielsen S, 2002, PHYSIOL REV, V82, P205, DOI 10.1152/physrev.00024.2001; NOTH J, 1974, J MEMBRANE BIOL, V17, P367, DOI 10.1007/BF01870192; OHLENDIECK K, 1991, J CELL BIOL, V112, P135, DOI 10.1083/jcb.112.1.135; OLBRICH KC, 1997, J PHYSL P, V504, P40; Rapp G, 1998, BIOPHYS J, V75, P2984, DOI 10.1016/S0006-3495(98)77739-2; SJOGAARD G, 1985, AM J PHYSIOL, V248, pR190, DOI 10.1152/ajpregu.1985.248.2.R190; SRETER FA, 1963, AM J PHYSIOL, V205, P1290, DOI 10.1152/ajplegacy.1963.205.6.1290; TAYLOR SR, 1992, ADV EXP MED BIOL, V311, P91; TROMBITAS K, 1993, J MUSCLE RES CELL M, V14, P573, DOI 10.1007/BF00141554; Vaghy PL, 1998, FEBS LETT, V431, P125, DOI 10.1016/S0014-5793(98)00738-8; VANHEESWIJK MP, 1998, J MEMBRANE BIOL, V92, P183; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Wakayama Y, 2002, HISTOCHEM J, V34, P331, DOI 10.1023/A:1023382609541; Ward DS, 1996, AM J PHYSIOL-REG I, V271, pR1682, DOI 10.1152/ajpregu.1996.271.6.R1682; WATSON PD, 1993, AM J PHYSIOL, V265, pH1869, DOI 10.1152/ajpheart.1993.265.6.H1869; WATSON PD, 1993, AM J PHYSIOL, V264, pR790, DOI 10.1152/ajpregu.1993.264.4.R790; WOLF MB, 1985, AM J PHYSIOL, V249, pH792, DOI 10.1152/ajpheart.1985.249.4.H792; WOLF MB, 1989, AM J PHYSIOL, V256, pH282, DOI 10.1152/ajpheart.1989.256.1.H282; Yang BX, 2000, AM J PHYSIOL-CELL PH, V278, pC1108, DOI 10.1152/ajpcell.2000.278.6.C1108; Yokota T, 2000, P JPN ACAD B-PHYS, V76, P22, DOI 10.2183/pjab.76.22	51	76	77	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					905	+		10.1096/fj.03-0987fje	http://dx.doi.org/10.1096/fj.03-0987fje			17	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033928				2022-12-28	WOS:000220522800012
J	Johnson, JD; Kuang, SH; Misler, S; Polonsky, KS				Johnson, JD; Kuang, SH; Misler, S; Polonsky, KS			Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion	FASEB JOURNAL			English	Article						diabetes; calcium stores; exocytosis; basal hyperinsulinemia; CD38	CYCLIC ADP-RIBOSE; CA2+-INDUCED CA2+ RELEASE; GROWTH-HORMONE RELEASE; CALCIUM STORES; EXOCYTOSIS; MOBILIZATION; GONADOTROPIN; ACTIVATION; CAFFEINE; CHANNELS	It is clear that pancreatic beta-cell dysfunction, including basal hyperinsulinemia and reduced insulin release in response to glucose, is a key determinant of disease progression in type 2 diabetes, but the underlying molecular defects are not known. In diabetes, the expression and function of ryanodine receptor (RyR) Ca2+ release channels are reduced. The present studies were undertaken to define the subcellular location and role of RyR in the control of stimulated and basal insulin release from human pancreatic beta cells. Using confocal microscopy, we observed RyR immunoreactivity in a vesicular pattern. RyRs did not colocalize with insulin secretory granules but partially colocalized with endosomes. Direct activation with nanomolar concentrations of ryanodine evoked increases in cytosolic Ca2+ that were coupled to transient insulin release. Insulin release stimulated by 1 nM ryanodine was sensitive to BAPTA-AM preincubation but independent of thapsigargin-sensitive endoplasmic reticulum ( ER) Ca2+ pools. Blocking RyRs with micromolar concentrations of ryanodine led to BAPTA-resistant insulin release that was not associated with an increase in cytosolic Ca2+, which implicated alterations in luminal Ca2+. However, neither Ca2+ signals nor insulin release stimulated by glucose was blocked by 10-50 muM ryanodine, which suggests that the CD38/cyclic ADP-ribose/RyR pathway is not a primary mechanism of glucose action in nontransformed beta cells. We provide the first evidence that RyRs directly control insulin secretion in primary beta cells. Unexpectedly, stimulation of insulin secretion by ryanodine occurs independently of glucose and by two mechanisms, including a novel cytosolic Ca2+-independent mechanism likely involving changes in Ca2+ within the lumens of non-ER organelles, such as endosomes.	Washington Univ, Sch Med, Dept Internal Med, Div Metab, St Louis, MO 63110 USA	Washington University (WUSTL)	Polonsky, KS (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Metab, St Louis, MO 63110 USA.	jim@jimjohnson.ca; polonsky@im.wustl.edu	Johnson, James/B-3919-2008	Johnson, James/0000-0002-7523-9433; Kuang, Shihuan/0000-0001-9180-3180				Bell GI, 2001, NATURE, V414, P788, DOI 10.1038/414788a; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; Gerasimenko OV, 1996, CELL, V84, P473, DOI 10.1016/S0092-8674(00)81292-1; Graves TK, 2003, ENDOCRINOLOGY, V144, P3565, DOI 10.1210/en.2002-0104; Han WP, 1999, J NEUROSCI, V19, P900; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; Hong K, 2000, NATURE, V403, P93, DOI 10.1038/47507; ISLAM MS, 1995, BIOCHEM J, V306, P679, DOI 10.1042/bj3060679; Islam MS, 2002, DIABETES, V51, P1299, DOI 10.2337/diabetes.51.5.1299; Islam MS, 1998, P NATL ACAD SCI USA, V95, P6145, DOI 10.1073/pnas.95.11.6145; Johnson JD, 2000, MOL CELL ENDOCRINOL, V165, P139, DOI 10.1016/S0303-7207(00)00252-5; Johnson JD, 2003, J CLIN INVEST, V111, P1147, DOI 10.1172/JCI200316537; Johnson JD, 2003, J NEUROENDOCRINOL, V15, P204, DOI 10.1046/j.1365-2826.2003.00977.x; Johnson JD, 2002, P NATL ACAD SCI USA, V99, P14566, DOI 10.1073/pnas.222099799; Johnson JD, 2002, J NEUROENDOCRINOL, V14, P144, DOI 10.1046/j.0007-1331.2001.00756.x; Johnson JD, 2002, AM J PHYSIOL-CELL PH, V282, pC635, DOI 10.1152/ajpcell.00044.2001; Johnson JD, 2002, AM J PHYSIOL-ENDOC M, V282, pE810, DOI 10.1152/ajpendo.00038.2001; Johnson JD, 2000, MOL CELL ENDOCRINOL, V170, P15, DOI 10.1016/S0303-7207(00)00338-5; Johnson JD, 2000, BIOCHEM CELL BIOL, V78, P217, DOI 10.1139/bcb-78-3-217; Kahn SE, 2003, DIABETOLOGIA, V46, P3, DOI 10.1007/s00125-002-1009-0; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kang GX, 2001, J PHYSIOL-LONDON, V536, P375, DOI 10.1111/j.1469-7793.2001.0375c.xd; KATO I, 1995, J BIOL CHEM, V270, P30045, DOI 10.1074/jbc.270.50.30045; Kato I, 1999, J BIOL CHEM, V274, P1869, DOI 10.1074/jbc.274.4.1869; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Masumiya H, 2001, J BIOL CHEM, V276, P39727, DOI 10.1074/jbc.M106557200; Meissner G, 2002, FRONT BIOSCI, V7, pD2072, DOI 10.2741/meissner; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; MISLER S, 1992, DIABETES, V41, P662, DOI 10.2337/diabetes.41.6.662; Mitchell KJ, 2003, J BIOL CHEM, V278, P11057, DOI 10.1074/jbc.M210257200; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; Nakagaki I, 2000, PFLUG ARCH EUR J PHY, V440, P828, DOI 10.1007/s004240000372; Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Scheenen WJJM, 1998, J BIOL CHEM, V273, P19002, DOI 10.1074/jbc.273.30.19002; Sun W, 2003, J CELL BIOL, V162, P125, DOI 10.1083/jcb.200302083; Tengholm A, 1998, DIABETES, V47, P1224, DOI 10.2337/diabetes.47.8.1224; Tengholm A, 2000, CELL CALCIUM, V27, P43, DOI 10.1054/ceca.1999.0087; Tse FT, 1999, BIOESSAYS, V21, P861, DOI 10.1002/(SICI)1521-1878(199910)21:10<861::AID-BIES8>3.0.CO;2-9; Webb DL, 1996, J BIOL CHEM, V271, P19074, DOI 10.1074/jbc.271.32.19074; Yang HT, 2002, P NATL ACAD SCI USA, V99, P9225, DOI 10.1073/pnas.142651999; Yin Y, 2002, J PHYSIOL-LONDON, V539, P409, DOI 10.1013/jphysiol.2001.012943	43	67	72	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	MAR	2004	18	3					878	+		10.1096/fj.03-1280fje	http://dx.doi.org/10.1096/fj.03-1280fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15033925				2022-12-28	WOS:000220522800009
J	Patlak, M				Patlak, M			From viper's venom to drug design: treating hypertension	FASEB JOURNAL			English	Editorial Material																			0	25	28	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAR	2004	18	3								10.1096/fj.03-1398bkt	http://dx.doi.org/10.1096/fj.03-1398bkt			1	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	807TC	15003987				2022-12-28	WOS:000220522800034
J	Jin, KL; Mao, XO; Cottrell, B; Schilling, B; Xie, L; Row, RH; Sun, YJ; Peel, A; Childs, J; Gendeh, G; Gibson, BW; Greenberg, DA				Jin, KL; Mao, XO; Cottrell, B; Schilling, B; Xie, L; Row, RH; Sun, YJ; Peel, A; Childs, J; Gendeh, G; Gibson, BW; Greenberg, DA			Proteomic and immunochemical characterization of a role for stathmin in adult neurogenesis	FASEB JOURNAL			English	Article						doublecortin; migration; ischemia; proteomics	DIFFERENTIAL GEL-ELECTROPHORESIS; MICROTUBULE-ASSOCIATED PROTEIN; GENE-EXPRESSION; SUBVENTRICULAR ZONE; MICROARRAY ANALYSIS; OLFACTORY SYSTEM; UP-REGULATION; RAT-BRAIN; IN-VITRO; PHOSPHOPROTEIN	Stathmin is a developmentally regulated cytosolic protein expressed at high levels in the brain. Two-dimensional differential in-gel electrophoresis and mass spectroscopy of proteins expressed in immature and mature cultures from embryonic rat cerebral cortex identified stathmin among several differentially expressed proteins, consistent with a possible role in neurogenesis. Stathmin immunohistochemistry in adult rodent brain revealed prominent expression in neuroproliferative zones and neuronal migration pathways, a pattern that resembles the expression of doublecortin, which is implicated in neuronal migration. Stathmin immunoreactivity was also associated with neurons undergoing ectopic chain migration into the ischemic striatum and cerebral cortex following focal cerebral ischemia. Reducing the expression of stathmin or doublecortin with an antisense oligonucleotide inhibited the migration of new neurons from the subventricular zone to the olfactory bulb via the rostral migratory stream. These results suggest a role for stathmin in the migration of newborn neurons in the adult brain.	Buck Inst Age Res, Novato, CA 94945 USA; Univ Calif San Francisco, San Francisco, CA 94143 USA; Amersham Biosci, Piscataway, NJ USA	Buck Institute for Research on Aging; University of California System; University of California San Francisco	Greenberg, DA (corresponding author), Buck Inst Age Res, 8001 Redwood Blvd, Novato, CA 94945 USA.	dgreenberg@buckinstitute.org			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044921] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021980] Funding Source: NIH RePORTER; NIA NIH HHS [AG21980] Funding Source: Medline; NINDS NIH HHS [NS44921] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; BAYER SA, 1991, J COMP NEUROL, V307, P499, DOI 10.1002/cne.903070312; Bayer Shirley A., 1995, P1041; Betarbet R, 1996, CELL TRANSPLANT, V5, P165, DOI 10.1016/0963-6897(95)02042-X; Brauer AU, 2001, NEUROSCIENCE, V102, P515, DOI 10.1016/S0306-4522(00)00471-1; Cameron HA, 1998, J NEUROBIOL, V36, P287, DOI 10.1002/(SICI)1097-4695(199808)36:2<287::AID-NEU13>3.3.CO;2-E; Camoletto P, 1997, NEUROREPORT, V8, P2825, DOI 10.1097/00001756-199709080-00004; Cardinaux JR, 1997, MOL BRAIN RES, V51, P220, DOI 10.1016/S0169-328X(97)00241-6; Cheng HW, 1997, NEUROREPORT, V8, P3691, DOI 10.1097/00001756-199712010-00007; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; de Rouvroit CL, 2001, MECH DEVELOP, V105, P47, DOI 10.1016/S0925-4773(01)00396-3; des Portes V, 1998, HUM MOL GENET, V7, P1063, DOI 10.1093/hmg/7.7.1063; Feng YY, 2001, NAT REV NEUROSCI, V2, P408, DOI 10.1038/35077559; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; Francis F, 1999, NEURON, V23, P247, DOI 10.1016/S0896-6273(00)80777-1; Geschwind DH, 2001, NEURON, V29, P325, DOI 10.1016/S0896-6273(01)00209-4; Gharbi S, 2002, MOL CELL PROTEOMICS, V1, P91, DOI 10.1074/mcp.T100007-MCP200; Gleeson JG, 1999, NEURON, V23, P257, DOI 10.1016/S0896-6273(00)80778-3; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; Gritti A, 1996, J NEUROSCI, V16, P1091; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Hofmann MH, 1999, J NEUROSCI METH, V88, P27, DOI 10.1016/S0165-0270(99)00007-2; Jin K, 2002, J CLIN INVEST, V110, P311, DOI 10.1172/JCI200215251; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin K, 2002, NEUROCHEM RES, V27, P1105, DOI 10.1023/A:1020913123054; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Jin KL, 2002, J NEUROSCI, V22, P5365; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; Liedtke W, 2002, AM J PATHOL, V160, P469, DOI 10.1016/S0002-9440(10)64866-3; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Luo YQ, 2002, J NEUROCHEM, V83, P1481, DOI 10.1046/j.1471-4159.2002.01260.x; LUSKIN MB, 1993, NEURON, V11, P173, DOI 10.1016/0896-6273(93)90281-U; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Morales AV, 1998, EUR J NEUROSCI, V10, P3237, DOI 10.1046/j.1460-9568.1998.00332.x; Mori N, 2002, J NEUROSCI RES, V70, P264, DOI 10.1002/jnr.10353; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pellier-Monnin V, 2001, J COMP NEUROL, V433, P239, DOI 10.1002/cne.1138; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; PESCHANSKI M, 1993, J COMP NEUROL, V337, P655, DOI 10.1002/cne.903370410; Rakic P, 1996, P NATL ACAD SCI USA, V93, P9218, DOI 10.1073/pnas.93.17.9218; RAY J, 1993, P NATL ACAD SCI USA, V90, P3602, DOI 10.1073/pnas.90.8.3602; Rousselot P, 1997, J COMP NEUROL, V385, P415; ROWLANDS DC, 1995, LAB INVEST, V72, P100; Ruepp SU, 2002, TOXICOL SCI, V65, P135, DOI 10.1093/toxsci/65.1.135; Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062; SOBEL A, 1989, J BIOL CHEM, V264, P3765; Soriano MA, 2000, J CEREBR BLOOD F MET, V20, P1045, DOI 10.1097/00004647-200007000-00004; Suzuki T, 1999, BRAIN RES, V816, P457, DOI 10.1016/S0006-8993(98)01179-2; Teramoto T, 2003, J CLIN INVEST, V111, P1125, DOI 10.1172/JCI200317170; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Tonge R, 2001, PROTEOMICS, V1, P377; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Von Eggeling F, 2001, INT J MOL MED, V8, P373; Yan JX, 2002, PROTEOMICS, V2, P1682, DOI 10.1002/1615-9861(200212)2:12<1682::AID-PROT1682>3.0.CO;2-Y; Zhou G, 2002, MOL CELL PROTEOMICS, V1, P117, DOI 10.1074/mcp.M100015-MCP200	59	76	82	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					287	299		10.1096/fj.03-0973com	http://dx.doi.org/10.1096/fj.03-0973com			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14769823				2022-12-28	WOS:000220425000009
J	Romeo, G; Frangioni, JV; Kazlauskas, A				Romeo, G; Frangioni, JV; Kazlauskas, A			Profilin acts downstream of LDL to mediate diabetic endothelial cell dysfunction	FASEB JOURNAL			English	Article						diabetic macrovascular disease; ICAM-1; phage-display; profilin-1	CORONARY-HEART-DISEASE; GROWTH-FACTOR; IN-VIVO; ADHESION MOLECULES; GENE-EXPRESSION; MESANGIAL CELLS; PROTEIN; ATHEROSCLEROSIS; INSULIN; PHOSPHORYLATION	The changes occurring at the luminal surface of endothelial cells in diabetes and their relevance to endothelial dysfunction are poorly characterized in vivo. In this study, we developed an integrated strategy to discover cell surface proteins associated with diabetes and to test their role in endothelial dysfunction. First, a peptide phage display library was screened over the endothelial surface of the intact aorta or in retinal endothelial cells from diabetic and control rats. Then, we purified profilin-1 as a binding partner for one of the diabetic aorta-specific phage. Profilin was increased in the aortic endothelium of human diabetic individuals and streptozotocin-diabetic rats. Furthermore, overexpressing profilin in rat aortic endothelial cells triggered 3 indicators of endothelial dysfunction: increased apoptosis, elevated expression of ICAM-1, and decreased phosphorylation of the vasodilator-stimulated phosphoprotein, a marker for nitric oxide signaling. The changes in ICAM-1 and vasodilator-stimulated phosphoprotein were recapitulated in the diabetic aorta in vivo. LDL and oxysterols elevated profilin in cultured aortic endothelial cells. Interference with the de novo synthesis of profilin abrogated the LDL-mediated increase in ICAM-1 expression. Finally, profilin expression was markedly elevated in atherosclerotic plaques. These data indicate that profilin contributes to endothelial dysfunction in a pathway that is downstream of LDL.	Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Ctr, Boston, MA USA	Harvard University; Harvard Medical School; Schepens Eye Research Institute; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Kazlauskas, A (corresponding author), Harvard Univ, Sch Med, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.	Kazlauskas@vision.eri.harvard.edu						Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Barreiro O, 2002, J CELL BIOL, V157, P1233, DOI 10.1083/jcb.200112126; Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570; Boeri D, 2001, DIABETES, V50, P1432, DOI 10.2337/diabetes.50.6.1432; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; Cheng KS, 2001, CHINESE J ASTRON AST, V1, P1, DOI 10.1088/1009-9271/1/1/1; Clarkson MR, 2002, J BIOL CHEM, V277, P9707, DOI 10.1074/jbc.M109172200; Coppolino MG, 2001, J CELL SCI, V114, P4307; Cosentino F, 1998, J CARDIOVASC PHARM, V32, pS54; Dardik R, 2002, THROMB HAEMOSTASIS, V88, P1047; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; DOUKAS J, 1993, J IMMUNOL, V150, P1036; Folsom AR, 1999, DIABETES CARE, V22, P1077, DOI 10.2337/diacare.22.7.1077; Frangioni JV, 2000, NAT BIOTECHNOL, V18, P1080, DOI 10.1038/80280; Gelderloos JA, 1998, J BIOL CHEM, V273, P5908, DOI 10.1074/jbc.273.10.5908; Gerhardinger C, 1998, AM J PATHOL, V152, P1453; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hwang SJ, 1997, CIRCULATION, V96, P4219; JOHNSTONE MT, 1993, CIRCULATION, V88, P2510, DOI 10.1161/01.CIR.88.6.2510; Jude EB, 2001, DIABETES CARE, V24, P1433, DOI 10.2337/diacare.24.8.1433; KLEIN R, 1994, ARCH INTERN MED, V154, P2169, DOI 10.1001/archinte.154.19.2169; Lambrechts A, 1997, EMBO J, V16, P484, DOI 10.1093/emboj/16.3.484; Lim MJ, 2001, MICROVASC RES, V62, P366, DOI 10.1006/mvre.2001.2355; Lim SC, 1999, DIABETES CARE, V22, P1865, DOI 10.2337/diacare.22.11.1865; Miyamoto K, 1999, P NATL ACAD SCI USA, V96, P10836, DOI 10.1073/pnas.96.19.10836; Mizutani M, 1996, J CLIN INVEST, V97, P2883, DOI 10.1172/JCI118746; Moldovan NI, 1997, CURR BIOL, V7, P24, DOI 10.1016/S0960-9822(06)00024-8; Morigi M, 1998, J CLIN INVEST, V101, P1905, DOI 10.1172/JCI656; Oelze M, 2000, CIRC RES, V87, P999, DOI 10.1161/01.RES.87.11.999; Ory DS, 1996, P NATL ACAD SCI USA, V93, P11400, DOI 10.1073/pnas.93.21.11400; Park' L, 1998, NAT MED, V4, P1025, DOI 10.1038/2012; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; Podesta F, 2000, AM J PATHOL, V156, P1025, DOI 10.1016/S0002-9440(10)64970-X; Pugliese G, 1997, J AM SOC NEPHROL, V8, P406; REINHARD M, 1995, EMBO J, V14, P1583, DOI 10.1002/j.1460-2075.1995.tb07146.x; Rohde LE, 1998, ARTERIOSCL THROM VAS, V18, P1765, DOI 10.1161/01.ATV.18.11.1765; Sakai J, 1998, J BIOL CHEM, V273, P5785, DOI 10.1074/jbc.273.10.5785; Smolenski A, 1998, J BIOL CHEM, V273, P20029, DOI 10.1074/jbc.273.32.20029; Soriano FG, 2001, NAT MED, V7, P108, DOI 10.1038/83241; Steinberg HO, 1996, J CLIN INVEST, V97, P2601, DOI 10.1172/JCI118709; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tamura M, 2000, J AM SOC NEPHROL, V11, P423, DOI 10.1681/ASN.V113423; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8; Voss SD, 2002, ANAL BIOCHEM, V308, P364, DOI 10.1016/S0003-2697(02)00268-3; Witke W, 1998, EMBO J, V17, P967, DOI 10.1093/emboj/17.4.967	48	31	34	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	FEB	2004	18	2					725	+		10.1096/fj.03-0841fje	http://dx.doi.org/10.1096/fj.03-0841fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	806HM	14977885				2022-12-28	WOS:000220425000025
J	Alcouffe, J; Therville, N; Segui, B; Nazzal, D; Blaes, N; Salvayre, R; Thomsen, M; Benoist, H				Alcouffe, J; Therville, N; Segui, B; Nazzal, D; Blaes, N; Salvayre, R; Thomsen, M; Benoist, H			Expression of membrane-bound and soluble FasL in Fas- and FADD-dependent T lymphocyte apoptosis induced by mildly oxidized LDL	FASEB JOURNAL			English	Article						lipoproteins; ROS; MAPK; ceramide; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; ACTIVATED PROTEIN-KINASE; OXLDL-INDUCED APOPTOSIS; ENDOTHELIAL-CELLS; LIGAND EXPRESSION; ATHEROSCLEROTIC LESIONS; DOWN-REGULATION; DEATH; CERAMIDE	Apoptosis plays an essential role in atherosclerosis. Oxidized low-density lipoproteins (oxLDL) and activated T lymphocytes are present in atherosclerotic lesions, and we have previously reported that oxLDL induce apoptosis of activated T lymphocytes. We now show that this is preceded by an increase of Fas and FasL expression. Fas and FasL overexpression was dependent on reactive oxygen species (ROS) production as well as ERK and JNK activation. In addition, oxLDL triggered an early production of soluble FasL by T lymphocytes. Blocking anti-Fas antibody or Fas-Fc protein, but also antioxidant molecules and inhibitors of ERK and JNK, decreased oxLDL-mediated apoptosis. Moreover, PHA-activated murine lymphocytes lacking a functional Fas receptor were partially resistant to oxLDL. Finally, Jurkat T cells deficient for FADD, an adaptor protein required for Fas signaling, resisted oxLDL-induced apoptosis. OxLDL triggered caspase 8 and 3 activation as well as ceramide production in PHA-activated lymphocytes and in Jurkat cells. Caspase activation was completely impaired in FADD-deficient cells, but ceramide production was not affected. Altogether, our results highlight the putative role of both membrane-bound and soluble FasL in oxLDL-induced Fas and FADD-dependent apoptosis of T lymphocytes and suggest an involvement of ROS, ERK, and JNK in this process.	CHU Rangueil, INSERM U466, F-31059 Toulouse 9, France; Univ Toulouse 3, Toulouse, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Benoist, H (corresponding author), CHU Rangueil, INSERM U466, 1 Ave Jean Poulhes,TSA 50032, F-31059 Toulouse 9, France.	hbenoist@toulouse.inserm.fr	Blaes, Nelly/M-1468-2018; Ségui, Bruno/O-8957-2014; Therville, Nicole/P-2371-2014; Thomsen, Mogens/B-7651-2011; Benoist, Hervé/P-2927-2014	Ségui, Bruno/0000-0002-6119-1889; Therville, Nicole/0000-0002-7068-1361; Thomsen, Mogens/0000-0002-4546-0129; 	Universite Paul Sabatier-Toulouse 3; Association pour la Recherche contre le Cancer (ARC)	Universite Paul Sabatier-Toulouse 3; Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR))	We thank Dr. Olivier Cuvillier and Pr. Thierry Levade for helpful discussions; Dr. Sophie Koutouzov for the gift of C3H-MRL-Faslpr mice; and Stephane Carpentier, Patricia Clave, and Sylvain Lagorce for excellent technical assistance. This work was supported by grants from the Universite Paul Sabatier-Toulouse 3 and the Association pour la Recherche contre le Cancer (ARC).	Alcouffe J, 1999, J LIPID RES, V40, P1200; AUGE N, 1995, BIOCHEM J, V309, P1015, DOI 10.1042/bj3091015; Ayroldi E, 1999, BLOOD, V94, P3456, DOI 10.1182/blood.V94.10.3456.422k33_3456_3467; Benoist Herve, 2002, Subcell Biochem, V36, P123; Bjorkerud B, 1996, ARTERIOSCL THROM VAS, V16, P416, DOI 10.1161/01.ATV.16.3.416; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; Caspar-Bauguil S, 1998, BIOCHEM J, V330, P659, DOI 10.1042/bj3300659; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Deigner HP, 2001, FASEB J, V15, P807, DOI 10.1096/fj.15.3.807; Devadas S, 2002, J EXP MED, V195, P59, DOI 10.1084/jem.20010659; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; DREW AF, 1995, ARTERIOSCL THROM VAS, V15, P1563, DOI 10.1161/01.ATV.15.10.1563; Esaki T, 2000, NITRIC OXIDE-BIOL CH, V4, P561, DOI 10.1006/niox.2000.0311; Escargueil-Blanc I, 1998, J BIOL CHEM, V273, P27389, DOI 10.1074/jbc.273.42.27389; EscargueilBlanc I, 1997, ARTERIOSCL THROM VAS, V17, P331, DOI 10.1161/01.ATV.17.2.331; ESCARGUEILBLANC I, 1994, FASEB J, V8, P1075, DOI 10.1096/fasebj.8.13.7926374; Faris M, 1998, J IMMUNOL, V160, P134; FROSTEGARD J, 1990, P NATL ACAD SCI USA, V87, P904, DOI 10.1073/pnas.87.3.904; Geng YJ, 1998, CIRCULATION, V98, P48; Huang Y, 2001, ATHEROSCLEROSIS, V156, P119, DOI 10.1016/S0021-9150(00)00638-9; Janssen O, 2000, CELL TISSUE RES, V301, P85, DOI 10.1007/s004419900155; Juo P, 1999, CELL GROWTH DIFFER, V10, P797; KAPUSCINSKI J, 1977, ANAL BIOCHEM, V83, P252, DOI 10.1016/0003-2697(77)90533-4; Kavurma MM, 2003, CELL DEATH DIFFER, V10, P36, DOI 10.1038/sj.cdd.4401179; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; KLEINDIENST R, 1993, AM J PATHOL, V142, P1927; Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859; Lee TS, 2001, AM J PHYSIOL-CELL PH, V280, pC709, DOI 10.1152/ajpcell.2001.280.3.C709; Li DY, 1998, AM J PHYSIOL-HEART C, V275, pH568, DOI 10.1152/ajpheart.1998.275.2.H568; Mallat Z, 2000, BRIT J PHARMACOL, V130, P947, DOI 10.1038/sj.bjp.0703407; Martinez-Lorenzo MJ, 1999, J IMMUNOL, V163, P1274; MartinezLorenzo MJ, 1996, IMMUNOLOGY, V89, P511, DOI 10.1046/j.1365-2567.1996.d01-782.x; MCMURRAY HF, 1993, J CLIN INVEST, V92, P1004, DOI 10.1172/JCI116605; NAGATA S, 1995, IMMUNOL TODAY, V16, P39, DOI 10.1016/0167-5699(95)80069-7; Napoli C, 2000, FASEB J, V14, P1996, DOI 10.1096/fj.99-0986com; Napoli C, 2001, J CELL BIOCHEM, V82, P674, DOI 10.1002/jcb.1198; Negre-Salvayre A, 2002, METHOD ENZYMOL, V352, P62; NEGRESALVAYRE A, 1992, PHOTOCHEM PHOTOBIOL, V55, P197, DOI 10.1111/j.1751-1097.1992.tb04228.x; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; Okura T, 2002, J HYPERTENS, V20, P895, DOI 10.1097/00004872-200205000-00024; RAJAVASHISTH TB, 1995, ARTERIOSCL THROM VAS, V15, P1591, DOI 10.1161/01.ATV.15.10.1591; REID VC, 1993, ATHEROSCLEROSIS, V98, P17, DOI 10.1016/0021-9150(93)90219-K; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 1998, J BIOL CHEM, V273, P33103, DOI 10.1074/jbc.273.50.33103; Sata M, 1998, J CLIN INVEST, V102, P1682, DOI 10.1172/JCI3531; Schneider DB, 2000, ARTERIOSCL THROM VAS, V20, P298, DOI 10.1161/01.ATV.20.2.298; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shimizu M, 1999, J IMMUNOL, V162, P7350; vanParijs L, 1996, CURR OPIN IMMUNOL, V8, P355, DOI 10.1016/S0952-7915(96)80125-7; VANVELDHOVEN PP, 1992, BIOCHEM BIOPH RES CO, V187, P209, DOI 10.1016/S0006-291X(05)81480-9; Vindelov L, 1990, Methods Cell Biol, V33, P127; WICK G, 1995, IMMUNOL TODAY, V16, P27, DOI 10.1016/0167-5699(95)80067-0; WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499; Xu XP, 1999, CIRCULATION, V99, P993, DOI 10.1161/01.CIR.99.8.993; YAGI K, 1987, CHEM PHYS LIPIDS, V45, P337, DOI 10.1016/0009-3084(87)90071-5; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017; Zhou XH, 1996, AM J PATHOL, V149, P359	62	24	26	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					122	124		10.1096/fj.02-0808fje	http://dx.doi.org/10.1096/fj.02-0808fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630709				2022-12-28	WOS:000188829300047
J	Chau, CH; Shum, DKY; Li, H; Pei, J; Lui, YY; Wirthlin, L; Chan, YS; Xu, XM				Chau, CH; Shum, DKY; Li, H; Pei, J; Lui, YY; Wirthlin, L; Chan, YS; Xu, XM			Chondroitinase ABC enhances axonal regrowth through Schwann cell-seeded guidance channels after spinal cord injury	FASEB JOURNAL			English	Article						chondroitin sulfates; regeneration; transplantation; Schwann cells	ADULT-RAT BRAIN; SULFATE PROTEOGLYCANS; TRANSPLANTS SUPPORT; FUNCTIONAL RECOVERY; SCIATIC-NERVES; CNS AXONS; IN-VIVO; REGENERATION; GROWTH; EXPRESSION	Grafting of Schwann cell-seeded channels into hemisected adult rat thoracic spinal cords has been tested as a strategy to bridge the injured cord. Despite success in guiding axonal growth into the graft, regeneration across the distal graft-host interface into the host spinal cord was limited. We hypothesized that chondroitin sulfate (CS) glycoforms deposited at the gliotic front of the interface constitute a molecular barrier to axonal growth into the host cord. Because CS glycoforms deposited by purified astrocytes in vitro were removable by digestion with chondroitinase ABC, we attempted to achieve likewise by infusion of the enzyme to the host side of the interface. By I month post-treatment, significant numbers of regenerating axons crossed an interface that was subdued in macrophage/microglia reaction and decreased in CS-immunopositivity. The axons extended as far into the caudal cord as 5 mm, in contrast to nil in vehicle-infused controls. Fascicular organizations of axon-Schwann cell units within the regenerated tissue cable were better-preserved in enzyme-treated cords than in vehicle-infused controls. We conclude that CS glycoforms deposited during gliosis at the distal graft-host interface could be cleared by the in vivo action of chondroitinase ABC to improve prospects of axonal regeneration into the host spinal cord.	Univ Hong Kong, Dept Biochem, Fac Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Dept Physiol, Fac Med, Hong Kong, Hong Kong, Peoples R China; St Louis Univ, Sch Med, Dept Anat & Neurobio, St Louis, MO 63104 USA; Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, Louisville, KY 40292 USA	University of Hong Kong; University of Hong Kong; Saint Louis University; University of Louisville	Xu, XM (corresponding author), Univ Louisville, Sch Med, Dept Neurol Surg, Kentucky Spinal Cord Injury Res Ctr, 511 S Floyd St,MDR 616, Louisville, KY 40292 USA.	shumdkhk@hkucc.hku.hk; xmxu0001@gwise.louisville.edu		Xu, Xiao-ming/0000-0002-7229-0081; Chan, Ying Shing/0000-0002-6228-1595	National Institutes of Health [NS36350]; International Spinal Research Trust; Daniel Heumann Fund for Spinal Cord Research; Hong Kong Research Grants Council [HKU328/93M, HKU7355/00M]; Croucher Foundation Fellowship	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); International Spinal Research Trust; Daniel Heumann Fund for Spinal Cord Research; Hong Kong Research Grants Council(Hong Kong Research Grants Council); Croucher Foundation Fellowship	We wish to thank Xiaobin Lu for helpful technical assistance. This work was supported by grants from National Institutes of Health NS36350, International Spinal Research Trust, and The Daniel Heumann Fund for Spinal Cord Research (to XMX), Hong Kong Research Grants Council HKU328/93M and HKU7355/00M (to DKYS) and a Croucher Foundation Fellowship (to CHC).	ANDERSON DK, 1995, BRAIN PATHOL, V5, P451, DOI 10.1111/j.1750-3639.1995.tb00624.x; BALENTINE JD, 1978, LAB INVEST, V39, P236; Bamber NI, 2001, EUR J NEUROSCI, V13, P257, DOI 10.1046/j.1460-9568.2001.01387.x; BLIGHT AR, 1994, NEUROSCIENCE, V60, P263, DOI 10.1016/0306-4522(94)90220-8; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Bregman BS, 2002, PROG BRAIN RES, V137, P257; BUNGE MB, 1994, EXP NEUROL, V127, P76, DOI 10.1006/exnr.1994.1082; Bunge R P, 1997, Adv Neurol, V72, P305; Chau CH, 1999, EUR J NEUROSCI, V11, P1914, DOI 10.1046/j.1460-9568.1999.00615.x; Cheng H, 1996, SCIENCE, V273, P510, DOI 10.1126/science.273.5274.510; Cheng HL, 1997, J CELL PHYSIOL, V171, P161; Couchman JR, 1996, J BIOL CHEM, V271, P9595, DOI 10.1074/jbc.271.16.9595; Coumans JV, 2001, J NEUROSCI, V21, P9334, DOI 10.1523/JNEUROSCI.21-23-09334.2001; Diener PS, 1998, J NEUROSCI, V18, P779; Diener PS, 1998, J NEUROSCI, V18, P763; Dihne M, 2001, BRAIN RES, V902, P178, DOI 10.1016/S0006-8993(01)02378-2; DUSART I, 1994, EUR J NEUROSCI, V6, P712, DOI 10.1111/j.1460-9568.1994.tb00983.x; ECCLESTON PA, 1990, EUR J NEUROSCI, V2, P985, DOI 10.1111/j.1460-9568.1990.tb00011.x; Erickson AC, 2000, J HISTOCHEM CYTOCHEM, V48, P1291, DOI 10.1177/002215540004801001; Fitch MT, 1999, J NEUROSCI, V19, P8182; Franzen R, 1998, J NEUROSCI RES, V51, P316, DOI 10.1002/(SICI)1097-4547(19980201)51:3<316::AID-JNR5>3.0.CO;2-J; GHIRNIKAR RS, 1995, GLIA, V14, P145, DOI 10.1002/glia.440140209; GRILLNER S, 1975, PHYSIOL REV, V55, P247, DOI 10.1104/pp.55.2.247; Guest JD, 1997, EXP NEUROL, V148, P502, DOI 10.1006/exnr.1997.6693; Haas CA, 1999, J NEUROSCI, V19, P9953; JAKEMAN LB, 1991, J COMP NEUROL, V307, P311, DOI 10.1002/cne.903070211; Jones LL, 2002, J NEUROSCI, V22, P4611, DOI 10.1523/JNEUROSCI.22-11-04611.2002; Jones LL, 2002, J NEUROSCI, V22, P2792, DOI 10.1523/JNEUROSCI.22-07-02792.2002; KATO M, 1987, J BIOL CHEM, V262, P7180; KUNKELBAGDEN E, 1992, EXP NEUROL, V116, P40, DOI 10.1016/0014-4886(92)90174-O; Kwon BK, 2002, P NATL ACAD SCI USA, V99, P3246, DOI 10.1073/pnas.052308899; Li Y, 1997, SCIENCE, V277, P2000, DOI 10.1126/science.277.5334.2000; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; McKeon RJ, 1999, J NEUROSCI, V19, P10778, DOI 10.1523/JNEUROSCI.19-24-10778.1999; MCKEON RJ, 1995, EXP NEUROL, V136, P32, DOI 10.1006/exnr.1995.1081; Moon LDF, 2003, J NEUROSCI RES, V71, P23, DOI 10.1002/jnr.10449; Moon LDF, 2001, NAT NEUROSCI, V4, P465, DOI 10.1038/87415; OUDEGA M, 1994, EXP NEUROL, V129, P194, DOI 10.1006/exnr.1994.1161; Plant GW, 2001, MOL CELL NEUROSCI, V17, P471, DOI 10.1006/mcne.2000.0948; Ramon-Cueto A, 1998, J NEUROSCI, V18, P3803; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; Shum DKY, 1996, J NEUROSCI RES, V46, P465, DOI 10.1002/(SICI)1097-4547(19961115)46:4<465::AID-JNR8>3.0.CO;2-E; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Thon N, 2000, EUR J NEUROSCI, V12, P2547, DOI 10.1046/j.1460-9568.2000.00109.x; TONA A, 1993, J NEUROSCI RES, V36, P191, DOI 10.1002/jnr.490360209; Tuszynski MH, 1999, J NEUROTRAUM, V16, P523, DOI 10.1089/neu.1999.16.523; Ughrin YM, 2003, J NEUROSCI, V23, P175; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Wassnehove-McCarthy DJ, 1999, J BIOL CHEM, V274, P25004, DOI 10.1074/jbc.274.35.25004; WILLIAMS LR, 1987, EXP NEUROL, V95, P743, DOI 10.1016/0014-4886(87)90313-X; Xu XM, 1999, EUR J NEUROSCI, V11, P1723, DOI 10.1046/j.1460-9568.1999.00591.x; Xu XM, 1997, J NEUROCYTOL, V26, P1, DOI 10.1023/A:1018557923309; XU XM, 1995, J COMP NEUROL, V351, P145, DOI 10.1002/cne.903510113; XU XM, 1995, EXP NEUROL, V134, P261, DOI 10.1006/exnr.1995.1056; Yan P, 1999, J NEUROSCI, V19, P9355; Yick LW, 2000, NEUROREPORT, V11, P1063, DOI 10.1097/00001756-200004070-00032; Zhang ZY, 1997, EXP NEUROL, V143, P141, DOI 10.1006/exnr.1996.6355; Zuo J, 1998, EXP NEUROL, V154, P654, DOI 10.1006/exnr.1998.6951	59	154	162	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					194	196		10.1096/fj.03-0196fje	http://dx.doi.org/10.1096/fj.03-0196fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14630702				2022-12-28	WOS:000188829300071
J	Courtemanche, C; Huang, AC; Elson-Schwab, I; Kerry, N; Ng, BY; Ames, BN				Courtemanche, C; Huang, AC; Elson-Schwab, I; Kerry, N; Ng, BY; Ames, BN			Folate deficiency and ionizing radiation cause DNA breaks in primary human lymphocytes: a comparison	FASEB JOURNAL			English	Article						DNA damage; nutrition; ionizing radiation; microarray; cancer risk	P53-REGULATED GENE-EXPRESSION; FOLIC-ACID; IN-VITRO; EXCISION-REPAIR; URACIL MISINCORPORATION; GENOMIC STABILITY; HOMOCYSTEINE CONCENTRATIONS; PLASMA HOMOCYSTEINE; BIOLOGIC RESPONSES; ADAPTIVE RESPONSE	DNA double-strand breaks, the most serious DNA lesion caused by ionizing radiation, are also caused by several vitamin or mineral deficiencies, such as for folate. Primary human lymphocytes were either irradiated or cultured at different levels of folate deficiency to assess cell proliferation, apoptosis, cell cycle, DNA breaks, and changes in gene expression. Both radiation and folate deficiency decreased cell proliferation and induced DNA breaks, apoptosis, and cell cycle arrest. Levels of folate deficiency commonly found resulted in effects similar to those caused by 1 Gy of radiation, a relatively high dose. Though both radiation and folate deficiency caused DNA breaks, they affected the expression of different genes. Radiation activated excision and DNA double-strand break repair genes and repressed mitochondrially encoded genes. Folate deficiency activated base and nucleotide excision repair genes and repressed folate-related genes. No DNA double-strand break repair gene was activated by folate deficiency. These findings suggest that a diet poor in folate may pose a risk of DNA damage comparable to that of a relatively high dose of radiation. Our results also suggest that research on biological effects of low-dose radiation should take into account the nutritional status of the subjects, because folate deficiency could confound the effects of low-dose radiation.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute; University of California System; University of California Berkeley	Ames, BN (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.	bames@chori.org			fellowship from the Conseil de Recherches Medicales (CRM) du Canada; U.S. Department of Energy [DE-FG03-00ER62943]; National Foundation for Cancer Research [00-CHORI]; National Institute of Environmental Health Sciences Center [P30-ES0186]	fellowship from the Conseil de Recherches Medicales (CRM) du Canada; U.S. Department of Energy(United States Department of Energy (DOE)); National Foundation for Cancer Research; National Institute of Environmental Health Sciences Center(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Eric Winstall and John Nides for critical reading of the manuscript, Jay Tong and Bruce Sun from AllCells for providing the human lymphocytes, and the microarray team at Operon Technologies for their help. C.C. was supported by a fellowship from the Conseil de Recherches Medicales (CRM) du Canada. This work was supported by the U.S. Department of Energy (DE-FG03-00ER62943), the National Foundation for Cancer Research (00-CHORI), and the National Institute of Environmental Health Sciences Center (P30-ES0186).	Ames BN, 1998, TOXICOL LETT, V103, P5, DOI 10.1016/S0378-4274(98)00282-3; AMES BN, 1995, P NATL ACAD SCI USA, V92, P5258, DOI 10.1073/pnas.92.12.5258; Ames BN, 2002, NAT REV CANCER, V2, P694, DOI 10.1038/nrc886; Amundson SA, 2001, RADIAT RES, V156, P657, DOI 10.1667/0033-7587(2001)156[0657:IOGEAA]2.0.CO;2; Andersson SGE, 1998, TRENDS MICROBIOL, V6, P263, DOI 10.1016/S0966-842X(98)01312-2; Aspinwall R, 1997, P NATL ACAD SCI USA, V94, P109, DOI 10.1073/pnas.94.1.109; BAILEY LB, 2001, PRES KNOWL IN PRESS; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Blount BC, 1997, P NATL ACAD SCI USA, V94, P3290, DOI 10.1073/pnas.94.7.3290; BRANDA RF, 1993, CANCER RES, V53, P5401; Branda RF, 2001, MUTAT RES-FUND MOL M, V473, P51, DOI 10.1016/S0027-5107(00)00138-X; Bronstrup A, 1998, AM J CLIN NUTR, V68, P1104; CHEN ATL, 1989, ENVIRON MOL MUTAGEN, V13, P319, DOI 10.1002/em.2850130407; Choi SW, 2000, J NUTR, V130, P129, DOI 10.1093/jn/130.2.129; Choi SW, 1998, GUT, V43, P93, DOI 10.1136/gut.43.1.93; *COMM BIOL EFF ION, HEALTH EF E IN PRESS; Cravo ML, 1998, AM J GASTROENTEROL, V93, P2060, DOI 10.1111/j.1572-0241.1998.00592.x; Crott JW, 2001, CARCINOGENESIS, V22, P1019, DOI 10.1093/carcin/22.7.1019; Duan W, 2002, J NEUROCHEM, V80, P101, DOI 10.1046/j.0022-3042.2001.00676.x; Duthie SJ, 2000, NUTR CANCER, V37, P245, DOI 10.1207/S15327914NC372_18; Duthie SJ, 1998, FASEB J, V12, P1491, DOI 10.1096/fasebj.12.14.1491; EVERSON RB, 1988, JNCI-J NATL CANCER I, V80, P525, DOI 10.1093/jnci/80.7.525; Feinendegen LE, 2001, J NUCL MED, V42, p17N; Fenech M, 2001, MUTAT RES-FUND MOL M, V475, P57, DOI 10.1016/S0027-5107(01)00079-3; FENECH M, 1986, MUTAT RES, V161, P193, DOI 10.1016/0027-5107(86)90010-2; Fenech M, 2002, MUTAT RES-FUND MOL M, V504, P131, DOI 10.1016/S0027-5107(02)00086-6; Fenech M, 2001, MUTAT RES-FUND MOL M, V475, P1, DOI 10.1016/S0027-5107(01)00069-0; Fenech M, 2001, MUTAT RES-FUND MOL M, V480, P51, DOI 10.1016/S0027-5107(01)00168-3; Fenech MF, 1997, CARCINOGENESIS, V18, P1329, DOI 10.1093/carcin/18.7.1329; Ford BN, 2001, RADIAT RES, V156, P668, DOI 10.1667/0033-7587(2001)156[0668:GERILC]2.0.CO;2; Gourabi H, 1998, MUTAGENESIS, V13, P475, DOI 10.1093/mutage/13.5.475; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hoel DG, 1998, HEALTH PHYS, V75, P241, DOI 10.1097/00004032-199809000-00002; Huang RFS, 1999, J NUTR, V129, P25, DOI 10.1093/jn/129.1.25; Iyer R, 2002, MUTAT RES-FUND MOL M, V503, P1, DOI 10.1016/S0027-5107(02)00068-4; Izeradjene K, 2001, INT IMMUNOL, V13, P85, DOI 10.1093/intimm/13.1.85; Jacob RA, 1998, J NUTR, V128, P1204, DOI 10.1093/jn/128.7.1204; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Jenner TJ, 2001, RADIAT RES, V156, P590, DOI 10.1667/0033-7587(2001)156[0590:COBLTR]2.0.CO;2; Jhaveri MS, 2001, MOL PHARMACOL, V60, P1288, DOI 10.1124/mol.60.6.1288; Joiner MC, 2001, INT J RADIAT ONCOL, V49, P379, DOI 10.1016/S0360-3016(00)01471-1; Kavanagh BD, 1995, CLIN CANCER RES, V1, P1557; Konopacka M, 2001, MUTAT RES-GEN TOX EN, V491, P1, DOI 10.1016/S1383-5718(00)00133-9; Koury MJ, 2000, BLOOD, V96, P3249; Krokan HE, 2000, FEBS LETT, V476, P73, DOI 10.1016/S0014-5793(00)01674-4; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; Longley DB, 2002, CANCER RES, V62, P2644; Maluf SW, 2001, ENVIRON MOL MUTAGEN, V38, P311, DOI 10.1002/em.10029; Malyapa RS, 1998, RADIAT RES, V149, P396, DOI 10.2307/3579703; MASUTANI C, 1994, EMBO J, V13, P1831, DOI 10.1002/j.1460-2075.1994.tb06452.x; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; OLINSKI R, 1995, FREE RADICAL BIO MED, V18, P807, DOI 10.1016/0891-5849(94)00171-F; OLIVE PL, 1992, EXP CELL RES, V198, P259, DOI 10.1016/0014-4827(92)90378-L; Pollycove M, 2001, J NUCL MED, V42, p26N; Popanda O, 2003, INT J RADIAT ONCOL, V55, P1216, DOI 10.1016/S0360-3016(02)04415-2; Prise KM, 1998, INT J RADIAT BIOL, V74, P173, DOI 10.1080/095530098141564; Ravanat JL, 2002, CARCINOGENESIS, V23, P1911, DOI 10.1093/carcin/23.11.1911; Rydberg B, 2002, P NATL ACAD SCI USA, V99, P16654, DOI 10.1073/pnas.262591699; SchmidtUllrich RK, 1997, ONCOGENE, V15, P1191, DOI 10.1038/sj.onc.1201275; SHADLEY JD, 1987, RADIAT RES, V111, P511, DOI 10.2307/3576936; Suzuki K, 2001, CANCER RES, V61, P5396; Trenz K, 2002, MUTAT RES-FUND MOL M, V500, P89, DOI 10.1016/S0027-5107(01)00300-1; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; Voehringer DW, 2000, P NATL ACAD SCI USA, V97, P2680, DOI 10.1073/pnas.97.6.2680; Wallock LM, 2001, FERTIL STERIL, V75, P252, DOI 10.1016/S0015-0282(00)01697-6; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; Wolff S, 1998, ENVIRON HEALTH PERSP, V106, P277, DOI 10.2307/3433927; Xu B, 2002, MOL CELL BIOL, V22, P1049, DOI 10.1128/MCB.22.4.1049-1059.2002; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhao RB, 2000, GENE DEV, V14, P981; Zhu WY, 2001, CELL BIOL INT, V25, P1261, DOI 10.1006/cbir.2001.0811	74	73	75	1	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					209	211		10.1096/fj.03-0382fje	http://dx.doi.org/10.1096/fj.03-0382fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597554				2022-12-28	WOS:000188829300076
J	Devy, L; de Groot, FMH; Blacher, S; Hajitou, A; Beusker, PH; Scheeren, HW; Foidart, JM; Noel, A				Devy, L; de Groot, FMH; Blacher, S; Hajitou, A; Beusker, PH; Scheeren, HW; Foidart, JM; Noel, A			Plasmin-activated doxorubicin prodrugs containing a spacer reduce tumor growth and angiogenesis without systemic toxicity	FASEB JOURNAL			English	Article						angiogenesis; proteases; anthracycline prodrugs; anticancer therapy	SENSITIVE DIPEPTIDE PRODRUGS; HUMAN COLON-CANCER; IN-VIVO; ANTICANCER PRODRUGS; IV COLLAGENASES; CELL-LINES; MATRIX; ANTHRACYCLINES; CHEMOTHERAPY; MONOTHERAPY	To generate doxorubicin (Dox) specifically at the tumor site, the chemotherapeutic agent was incorporated into a prodrug by linkage to a peptide specifically recognized by plasmin, which is overproduced in many cancers. ST-9905, which contains an elongated self-elimination spacer, is activated more rapidly in vitro by plasmin than is ST-9802. Prodrug activation in vitro depended on the level of urokinase produced by tumor cells and was inhibited by aprotinin, a plasmin inhibitor. Comparison of equimolar concentrations of ST-9905, ST-9802, and Dox in EF43.fgf-4 and MCF7 models revealed that both prodrugs, in sharp contrast to Dox, displayed antiproliferative and antiangiogenic activities without discernible toxicity. Although MCF7 cells are poor urokinase producers in vitro, prodrug efficacy in this model may be explained by production of plasmin by tumor-infiltrating host cells. Mice treated with equitoxic concentrations (maximum tolerated doses) of prodrugs showed 100% survival and negligible body weight loss, in contrast to results after Dox treatment. ST-9905 was substantially more effective than ST9802 and induced similar tumor growth inhibition as Dox but without apparent toxicity. This finding may be explained by the elongated spacer, which facilitates enzymatic prodrug activation. These data validate both the use of elongated spacers in vivo and the concept of targeting anticancer prodrugs to tumor-associated plasmin.	Univ Liege, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Syntarga BV, NL-6525 ED Nijmegen, Netherlands; Univ Nijmegen, Dept Organ Chem, NSR Ctr Mol Struct Design & Synth, Nijmegen, Netherlands	University of Liege; Radboud University Nijmegen	Noel, A (corresponding author), Univ Liege, Lab Tumor & Dev Biol, Tour Pathol B23, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be		Noel, Agnes/0000-0002-7670-6179; Hajitou, Amin/0000-0003-1119-5686				Bajou K, 2002, INT J CANCER, V100, P501, DOI 10.1002/ijc.10487; Bosslet K, 1998, CANCER RES, V58, P1195; Bugge TH, 1997, BLOOD, V90, P4522; CARL PL, 1981, J MED CHEM, V24, P479, DOI 10.1021/jm00137a001; CHAKRAVARTY PK, 1983, J MED CHEM, V26, P638, DOI 10.1021/jm00359a004; Damen EWP, 2001, EXPERT OPIN THER PAT, V11, P651, DOI 10.1517/13543776.11.4.651; de Groot FMH, 2001, J ORG CHEM, V66, P8815, DOI 10.1021/jo0158884; de Groot FMH, 2001, CURR MED CHEM, V8, P1093; de Groot FMH, 1999, J MED CHEM, V42, P5277, DOI 10.1021/jm9910472; DeFeo-Jones D, 2000, NAT MED, V6, P1248, DOI 10.1038/81351; DOROSHOW JH, 1986, BIOCHEM BIOPH RES CO, V135, P330, DOI 10.1016/0006-291X(86)90981-2; Dubowchik GM, 1999, PHARMACOL THERAPEUT, V83, P67, DOI 10.1016/S0163-7258(99)00018-2; Dubowchik GM, 1998, BIOORG MED CHEM LETT, V8, P3347, DOI 10.1016/S0960-894X(98)00610-6; Dubowchik GM, 1998, BIOORG MED CHEM LETT, V8, P3341, DOI 10.1016/S0960-894X(98)00609-X; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Foekens JA, 2000, CANCER RES, V60, P636; Garsky VM, 2001, J MED CHEM, V44, P4216, DOI 10.1021/jm0101996; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Hajitou A, 1998, ONCOGENE, V17, P2059, DOI 10.1038/sj.onc.1202126; Hajitou A, 2001, CANCER RES, V61, P3450; Heymans S, 1999, NAT MED, V5, P1135, DOI 10.1038/13459; Khan SR, 2000, PROSTATE, V45, P80, DOI 10.1002/1097-0045(20000915)45:1<80::AID-PROS10>3.0.CO;2-Q; Kratz F, 2001, BIOORG MED CHEM LETT, V11, P2001, DOI 10.1016/S0960-894X(01)00354-7; Liu SH, 2003, P NATL ACAD SCI USA, V100, P657, DOI 10.1073/pnas.0236849100; Monte M, 1997, EUR J CANCER, V33, P676, DOI 10.1016/S0959-8049(96)00506-0; NOEL A, 1993, MATRIX, V13, P267, DOI 10.1016/S0934-8832(11)80021-1; Noel A, 2001, Surg Oncol Clin N Am, V10, P417; NOEL A, 1994, PATHOL RES PRACT, V190, P934; POURREAUSCHNEIDER N, 1989, J NATL CANCER I, V81, P259, DOI 10.1093/jnci/81.4.259; PYKE C, 1993, AM J PATHOL, V142, P359; PYKE C, 1994, HISTOPATHOLOGY, V24, P131, DOI 10.1111/j.1365-2559.1994.tb01291.x; Rio Marie-Christine, 1998, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V192, P253; Sounni NE, 2002, FASEB J, V16, P555, DOI 10.1096/fj.01-0790com; Sweatman Trevor W., 1997, P113; TESORIERE L, 1994, J PHARMACOL EXP THER, V269, P430; THAYER WS, 1988, BIOCHEM PHARMACOL, V37, P2189, DOI 10.1016/0006-2952(88)90580-1; Trouet A, 2001, CANCER RES, V61, P2843	37	35	46	0	14	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					565	+		10.1096/fj.03-0462fje	http://dx.doi.org/10.1096/fj.03-0462fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734647				2022-12-28	WOS:000188829300009
J	Gaus, K; Kritharides, L; Schmitz, G; Boettcher, A; Drobnik, W; Langmann, T; Quinn, CM; Death, A; Dean, RT; Jessup, W				Gaus, K; Kritharides, L; Schmitz, G; Boettcher, A; Drobnik, W; Langmann, T; Quinn, CM; Death, A; Dean, RT; Jessup, W			Apolipoprotein A-1 interaction with plasma membrane lipid rafts controls cholesterol export from macrophages	FASEB JOURNAL			English	Article						efflux; foam cell; reverse cholesterol transport; ABCA1; atherosclerosis	LOW-DENSITY-LIPOPROTEIN; HUMAN THP-1 MACROPHAGES; CASSETTE TRANSPORTER 1; A-I; CELLULAR CHOLESTEROL; FOAM CELLS; ENDOPLASMIC-RETICULUM; PHOSPHOLIPID EFFLUX; LOADED MACROPHAGES; CAVEOLAE MEMBRANE	Cholesterol efflux to apolipoprotein A-1 (apoA-1) from cholesterol-loaded macrophages is an important anti -atheroscl erotic mechanism in reverse cholesterol transport. We recently provided kinetic evidence for two distinct pathways for cholesterol efflux to apoA-1 [Gaus et al. (2001) Biochemistry 40, 9363]. Cholesterol efflux from two membrane pools occurs sequentially with different kinetics; a small pool rapidly effluxed over the first hour, followed by progressive release from a major, slow efflux pool over several hours. In the present study, we propose that the rapid and slow cholesterol efflux pools represent cholesterol derived from lipid raft and nonraft domains of the plasma membrane, respectively. We provide direct evidence that apoA-1 binds to both lipid raft and nonraft domains of the macrophage plasma membrane. Conditions that selectively deplete plasma membrane lipid raft cholesterol, such as incorporation of 7-ketocholesterol or rapid exposure to cyclodextrins, block apoA-1 binding to these domains but also inhibit cholesterol efflux from the major, slow pool. We propose that cholesterol exported to apoA-1 from this major slow efflux pool derives from nonraft regions of the plasma membrane but that the interaction of apoA-1 with lipid rafts is necessary to stimulate this efflux.	Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Macrophage Biol Grp, Sydney, NSW 2052, Australia; Concord Hosp, Dept Cardiol, Concord, NSW, Australia; Univ Regensburg, Inst Clin Chem & Lab Med, D-93042 Regensburg, Germany; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Canberra, Belconnen, ACT 2616, Australia	University of New South Wales Sydney; Concord Repatriation General Hospital; University of Regensburg; University of Sydney; University of Canberra	Jessup, W (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Vasc Res, Macrophage Biol Grp, Sydney, NSW 2052, Australia.	w.jessup@unsw.edu.au	Kritharides, Leonard/AAQ-2720-2020; Langmann, Thomas/HHZ-9814-2022	Langmann, Thomas/0000-0001-6826-529X; Gaus, Katharina/0000-0002-8009-9658; Dean, Roger Thornton/0000-0002-8859-8902; Schmitz, Gerd/0000-0002-1325-1007				Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Babitt J, 1997, J BIOL CHEM, V272, P13242, DOI 10.1074/jbc.272.20.13242; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Bortnick AE, 2000, J BIOL CHEM, V275, P28634, DOI 10.1074/jbc.M003407200; Brown AJ, 1999, ATHEROSCLEROSIS, V142, P1, DOI 10.1016/S0021-9150(98)00196-8; Brown AJ, 1996, J LIPID RES, V37, P320; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Costet P, 2000, J BIOL CHEM, V275, P28240; Drobnik W, 2002, TRAFFIC, V3, P268, DOI 10.1034/j.1600-0854.2002.030404.x; Feng B, 2002, J BIOL CHEM, V277, P43271, DOI 10.1074/jbc.M207532200; Fielding PE, 2000, BIOCHEMISTRY-US, V39, P14113, DOI 10.1021/bi0004192; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; Gargalovic P, 2003, J LIPID RES, V44, P11, DOI 10.1194/jlr.R200005-JLR200; Gaus K, 2001, BIOCHEMISTRY-US, V40, P9363, DOI 10.1021/bi010323n; Gaus K, 2001, BIOCHEMISTRY-US, V40, P13002, DOI 10.1021/bi010833h; Gelissen IC, 1998, BIOCHEM J, V331, P231, DOI 10.1042/bj3310231; Gelissen IC, 1999, J LIPID RES, V40, P1636; Gelissen IC, 1996, J BIOL CHEM, V271, P17852, DOI 10.1074/jbc.271.30.17852; Gillotte KL, 1998, J LIPID RES, V39, P1918; Gillotte KL, 1999, J BIOL CHEM, V274, P2021, DOI 10.1074/jbc.274.4.2021; Gillotte-Taylor K, 2002, J BIOL CHEM, V277, P11811, DOI 10.1074/jbc.M108268200; Graf GA, 1999, J BIOL CHEM, V274, P12043, DOI 10.1074/jbc.274.17.12043; Graham A, 1996, ATHEROSCLEROSIS, V120, P135, DOI 10.1016/0021-9150(95)05695-5; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hayden JM, 2002, J LIPID RES, V43, P26; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kritharides L, 1998, ARTERIOSCL THROM VAS, V18, P1589, DOI 10.1161/01.ATV.18.10.1589; KRITHARIDES L, 1995, ARTERIOSCL THROM VAS, V15, P276, DOI 10.1161/01.ATV.15.2.276; KRITHARIDES L, 1993, ANAL BIOCHEM, V213, P79, DOI 10.1006/abio.1993.1389; Kruth HS, 2001, J LIPID RES, V42, P1492; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; MANDER EL, 1994, BBA-LIPID LIPID MET, V1212, P80, DOI 10.1016/0005-2760(94)90192-9; MATTSSON L, 1993, J CLIN INVEST, V92, P1759, DOI 10.1172/JCI116764; Matveev S, 1999, J LIPID RES, V40, P1647; Mendez AJ, 1997, J LIPID RES, V38, P1807; Mendez AJ, 2001, J BIOL CHEM, V276, P3158, DOI 10.1074/jbc.M007717200; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Ostermeyer AG, 2001, J CELL BIOL, V152, P1071, DOI 10.1083/jcb.152.5.1071; Pike LJ, 2002, BIOCHEMISTRY-US, V41, P2075, DOI 10.1021/bi0156557; Rees D, 1999, J BIOL CHEM, V274, P27925, DOI 10.1074/jbc.274.39.27925; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Saito H, 1997, J LIPID RES, V38, P287; Schuck S, 2003, P NATL ACAD SCI USA, V100, P5795, DOI 10.1073/pnas.0631579100; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; Sviridov D, 1996, J BIOL CHEM, V271, P33277, DOI 10.1074/jbc.271.52.33277; van Reyk DM, 1999, J LEUKOCYTE BIOL, V66, P557, DOI 10.1002/jlb.66.4.557; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200; Yancey PG, 2003, ARTERIOSCL THROM VAS, V23, P712, DOI 10.1161/01.ATV.0000057572.97137.DD	58	83	86	0	9	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					574	+		10.1096/fj.03-0486fje	http://dx.doi.org/10.1096/fj.03-0486fje			27	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734645				2022-12-28	WOS:000188829300011
J	Strowski, MZ; Cramer, T; Schafer, G; Juttner, S; Walduck, A; Schipani, E; Kemmner, W; Wessler, S; Wunder, C; Weber, M; Meyer, TF; Wiedenmann, B; Jons, T; Naumann, M; Hocker, M				Strowski, MZ; Cramer, T; Schafer, G; Juttner, S; Walduck, A; Schipani, E; Kemmner, W; Wessler, S; Wunder, C; Weber, M; Meyer, TF; Wiedenmann, B; Jons, T; Naumann, M; Hocker, M			Helicobacter pylori stimulates host vascular endothelial growth factor-A (vegf-A) gene expression via MEK/ERK-dependent activation of Sp1 and Sp3	FASEB JOURNAL			English	Article						angiogenesis; Sp1/Sp3 transcription factors; gastric epithelial cells	CAG PATHOGENICITY ISLAND; HISTIDINE-DECARBOXYLASE PROMOTER; GASTRIC-CANCER; TRANSCRIPTIONAL ACTIVATION; OXIDATIVE STRESS; EPITHELIAL-CELLS; PROTEIN-KINASE; FACTOR-ALPHA; ANGIOGENESIS; BINDING	VEGF-A is a key regulator of inflammatory and tumor-associated angiogenesis. H. pylori plays a critical role in the pathogenesis of benign and malignant gastric diseases. It has been suggested that H. pylori infection is associated with activation of host angiogenesis, however, underlying mechanisms as well as angiogenic growth factors activated by the bacterium have not yet been identified. Therefore, we investigated the influence of the bacterium on VEGF-A as a candidate host target gene in vivo and in vitro. We show that H. pylori potently up-regulates production and release of VEGF-A protein as well as vegf-A mRNA levels, and we provide strong evidence that enhanced recruitment of SpI and Sp3 transcription factors to two proximal GC-rich vegf-A promoter elements mediates H. pylori-triggered vegf-A gene expression. In addition, H. pylori infection increased the transactivating capacity of both SpI and Sp3, which suggests additional mechanism(s) of vegf-A gene regulation by the bacterium. Signaling studies identified the MEK>ERK1/-2 kinase cascade as principal host signaling pathway mediating H. pylori-stimulated vegf-A transcription. By identifying H. pylori as potent activator of vegf-A gene expression and characterization of underlying molecular mechanisms, our results provide novel insights into pathways linking the bacterium to host angiogenesis and may help to develop strategies to influence vegf-A gene expression in the setting of H. pylori infection.	Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Charite, Sekt Mol Hepatol & Gastroenterol, D-13353 Berlin, Germany; Max Planck Inst Infekt Biol, Berlin, Germany; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Unit, Boston, MA USA; Free Univ Berlin, Klinikum Rudolf Virchow, Robert Rossle Klin, D-13122 Berlin, Germany; Max Delbruck Ctr, Berlin, Germany; Otto Von Guericke Univ, Inst Expt Innere Med, Magdeburg, Germany; Univ Med Berlin, Inst Anat, Charite, Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Max Planck Society; Harvard University; Harvard Medical School; Massachusetts General Hospital; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Otto von Guericke University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Hocker, M (corresponding author), Univ Med Berlin, Med Klin Schwerpunkt Hepatol & Gastroenterol, Charite, Sekt Mol Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	hoecker@charite.de	Wunder, Christian/K-8542-2017; Naumann, Michael/B-5285-2011; Meyer, Thomas F. F/J-2485-2013; Wessler, Silja/C-6309-2015; Cramer, Thorsten/S-2479-2016	Wunder, Christian/0000-0001-9091-0080; Naumann, Michael/0000-0002-8060-2313; Meyer, Thomas F. F/0000-0002-6120-8679; Wessler, Silja/0000-0001-7011-6162; Cramer, Thorsten/0000-0002-6462-239X; Wiedenmann, Bertram/0000-0002-7890-2552; Walduck, Anna/0000-0002-9624-4370	Bundesministerium fur Bildung und Forschung (BMBF) [NBLIII-Schnittstellenlabor Tumormetastasierung]; Deutsche Forschungsgemeinschaft (DFG) [HO1288/6-1, Na292/6-2]; DFG-Graduiertenkolleg [GRK276]; Max-Planck-Gesellschaft(Tandemprojekt-Initiative)	Bundesministerium fur Bildung und Forschung (BMBF)(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); DFG-Graduiertenkolleg(German Research Foundation (DFG)); Max-Planck-Gesellschaft(Tandemprojekt-Initiative)	Grant support of M. H. was provided by the Bundesministerium fur Bildung und Forschung (BMBF; Grant NBLIII-Schnittstellenlabor Tumormetastasierung), the Deutsche Forschungsgemeinschaft (DFG; HO1288/6-1), the DFG-Graduiertenkolleg GRK276, and the Max-Planck-Gesellschaft(Tandemprojekt-Initiative). M. N. was supported by the DFG (Na292/6-2). We express our gratitude to M. Cobb, C. Vinson, M. Karin, and G. Suske for providing plasmid DNA.	Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Alroy I, 1999, MOL CELL BIOL, V19, P1961; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; CORREA P, 1995, CRIT REV FOOD SCI, V35, P59, DOI 10.1080/10408399509527687; Cox JM, 2001, INFECT IMMUN, V69, P6970, DOI 10.1128/IAI.69.11.6970-6980.2001; CRABTREE JE, 1998, DIG DIS SCI S, V43, P46; DVORAK HF, 1995, AM J PATHOL, V146, P1029; Ernst P, 1999, ALIMENT PHARM THER, V13, P13, DOI 10.1046/j.1365-2036.1999.00003.x; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; Gille J, 1997, EMBO J, V16, P750, DOI 10.1093/emboj/16.4.750; Glocker E, 1998, INFECT IMMUN, V66, P2346, DOI 10.1128/IAI.66.5.2346-2348.1998; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Houghton J, 2002, J GASTROEN HEPATOL, V17, P495, DOI 10.1046/j.1440-1746.2002.02770.x; Innocenti M, 2002, INFECT IMMUN, V70, P4581, DOI 10.1128/IAI.70.8.4581-4590.2002; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jones MK, 1999, NAT MED, V5, P1418; Jones MK, 2001, GASTROENTEROLOGY, V121, P1040, DOI 10.1053/gast.2001.29308; Kanai T, 1998, INT J CANCER, V77, P933, DOI 10.1002/(SICI)1097-0215(19980911)77:6<933::AID-IJC23>3.0.CO;2-0; Keates S, 1999, J IMMUNOL, V163, P5552; Kempf VAJ, 2001, CELL MICROBIOL, V3, P623, DOI 10.1046/j.1462-5822.2001.00144.x; KOLCH W, 1995, BREAST CANCER RES TR, V36, P139, DOI 10.1007/BF00666036; Lee K, 1996, ENDOCRINOLOGY, V137, P5109, DOI 10.1210/en.137.11.5109; Lucas B, 2001, INFECT IMMUN, V69, P1714, DOI 10.1128/IAI.69.3.1714-1721.2001; Maeda K, 1999, CANCER, V86, P566, DOI 10.1002/(SICI)1097-0142(19990815)86:4<566::AID-CNCR4>3.0.CO;2-1; Maulik N, 2002, FREE RADICAL BIO MED, V33, P1047, DOI 10.1016/S0891-5849(02)01005-5; Megraud F, 2001, DIGEST DIS, V19, P99, DOI 10.1159/000050662; Milanini J, 1998, J BIOL CHEM, V273, P18165, DOI 10.1074/jbc.273.29.18165; Naumann M, 2001, INT J MED MICROBIOL, V291, P299, DOI 10.1078/1438-4221-00133; Naumann M, 1999, J BIOL CHEM, V274, P31655, DOI 10.1074/jbc.274.44.31655; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Raychowdhury R, 2002, MOL ENDOCRINOL, V16, P2802, DOI 10.1210/me.2001-0292; Ross S, 2002, MOL CELL, V10, P831, DOI 10.1016/S1097-2765(02)00682-2; Ryuto M, 1996, J BIOL CHEM, V271, P28220, DOI 10.1074/jbc.271.45.28220; Sapetschnig A, 2002, EMBO J, V21, P5206, DOI 10.1093/emboj/cdf510; Schafer G, 2003, J BIOL CHEM, V278, P8190, DOI 10.1074/jbc.M211999200; Scheiman JM, 1999, AM J MED, V106, P222, DOI 10.1016/S0002-9343(98)00393-3; Shi Q, 2001, CANCER RES, V61, P4143; Shih SC, 2002, AM J PATHOL, V161, P35, DOI 10.1016/S0002-9440(10)64154-5; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki N, 1998, J PHYSIOL PHARMACOL, V49, P515; Takahashi Y, 1996, CLIN CANCER RES, V2, P1679; Thiel G, 2000, BBA-GENE STRUCT EXPR, V1493, P289, DOI 10.1016/S0167-4781(00)00207-4; van der Flier M, 2000, INFECT IMMUN, V68, P4792, DOI 10.1128/IAI.68.8.4792-4794.2000; Wessler S, 2002, FASEB J, V16, P417, DOI 10.1096/fj.01-0766fje; Wessler S, 2000, J BIOL CHEM, V275, P3629, DOI 10.1074/jbc.275.5.3629; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	47	60	62	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					218	220		10.1096/fj.03-0055fje	http://dx.doi.org/10.1096/fj.03-0055fje			3	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14597566				2022-12-28	WOS:000188829300078
J	Stuart, JA; Karahalil, B; Hogue, BA; Souza-Pinto, NC; Bohr, VA				Stuart, JA; Karahalil, B; Hogue, BA; Souza-Pinto, NC; Bohr, VA			Mitochondrial and nuclear DNA base excision repair are affected differently by caloric restriction	FASEB JOURNAL			English	Article						OGG1; UDG; AP endonuclease; dietary restriction; aging; mitochondria	RAT-LIVER MITOCHONDRIA; OXIDATIVE DAMAGE; DIETARY RESTRICTION; POLYMERASE-GAMMA; LIFE-SPAN; AGE; STRESS; BRAIN; MUSCLE; MODEL	Aging is strongly correlated with the accumulation of oxidative damage in DNA, particularly in mitochondria. Oxidative damage to both mitochondrial and nuclear DNA is repaired by the base excision repair (BER) pathway. The "mitochondrial theory of aging" suggests that aging results from declining mitochondrial function, due to high loads of damage and mutation in mitochondrial DNA (mtDNA). Restriction of caloric intake is the only intervention so far proven to slow the aging rate. However, the molecular mechanisms underlying such effects are still unclear. We used caloric-restricted (CR) mice to investigate whether lifespan extension is associated with changes in mitochondrial BER activities. Mice were divided into two groups, receiving 100% (PF) or 60% (CR) of normal caloric intake, a regime that extends mean lifespan by similar to40% in CR mice. Mitochondria isolated from CR mice had slightly higher uracil (UDG) and oxoguanine DNA glycosylase (OGGI) activities but marginally lower abasic endonuclease and polymerase gamma gap-filling activities, although these differences were tissue-specific. Uracil-initiated BER synthesis incorporation activities were significantly lower in brain and kidney from CR mice but marginally enhanced in liver. However, nuclear repair synthesis activities were increased by CR, indicating differential regulation of BER in the two compartments. The results indicate that a general up-regulation of mitochondrial BER does not occur in CR.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Bohr, VA (corresponding author), 5600 Nathan Shock Dr,Box 1, Baltimore, MD 21224 USA.	vbohr@nih.gov	Souza-Pinto, Nadja/T-3050-2019; Souza-Pinto, Nadja C./C-3462-2013; Karahalil, Bensu/AFU-8097-2022; Bohr, Vilhelm/AAP-5931-2020	Souza-Pinto, Nadja/0000-0003-4206-964X; Souza-Pinto, Nadja C./0000-0003-4206-964X; 	NATIONAL INSTITUTE ON AGING [Z01AG000733, ZIAAG000733] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348; Barja G, 2000, FASEB J, V14, P312, DOI 10.1096/fasebj.14.2.312; Cabelof DC, 2003, DNA REPAIR, V2, P295, DOI 10.1016/S1568-7864(02)00219-7; Chen DX, 2003, J CEREBR BLOOD F MET, V23, P88, DOI 10.1097/01.WCB.0000039286.37737.19; CHUNG MH, 1992, FREE RADICAL BIO MED, V12, P523, DOI 10.1016/0891-5849(92)90105-P; Cortopassi GA, 1996, MECH AGEING DEV, V91, P211, DOI 10.1016/S0047-6374(96)01788-5; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; de Souza-Pinto NC, 2001, FREE RADICAL BIO MED, V30, P916, DOI 10.1016/S0891-5849(01)00483-X; Drew B, 2003, AM J PHYSIOL-REG I, V284, pR474, DOI 10.1152/ajpregu.00455.2002; Frossi B, 2002, J CELL PHYSIOL, V193, P180, DOI 10.1002/jcp.10159; Golden TR, 2001, MECH AGEING DEV, V122, P1577, DOI 10.1016/S0047-6374(01)00288-3; Gredilla R, 2001, FASEB J, V15, P1589, DOI 10.1096/fj.00-0764fje; HARMAN D, 1994, AGE, V17, P119, DOI 10.1007/BF02435819; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HART RW, 1974, P NATL ACAD SCI USA, V71, P2169, DOI 10.1073/pnas.71.6.2169; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; Hursting SD, 2003, ANNU REV MED, V54, P131, DOI 10.1146/annurev.med.54.101601.152156; Kang CM, 1998, FREE RADICAL BIO MED, V24, P148, DOI 10.1016/S0891-5849(97)00204-9; Karahalil B, 2002, FASEB J, V16, P1895, DOI 10.1096/fj.02-0463com; Lass A, 1998, FREE RADICAL BIO MED, V25, P1089, DOI 10.1016/S0891-5849(98)00144-0; Lee CM, 1997, FREE RADICAL BIO MED, V22, P1259, DOI 10.1016/S0891-5849(96)00546-1; Lenaz G, 1998, BBA-BIOENERGETICS, V1366, P53, DOI 10.1016/S0005-2728(98)00120-0; Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Lopez-Torres M, 2002, FREE RADICAL BIO MED, V32, P882, DOI 10.1016/S0891-5849(02)00773-6; Mattson MP, 2002, PHYSIOL REV, V82, P637, DOI 10.1152/physrev.00004.2002; Melov S, 1999, MUTAT RES-DNA REPAIR, V434, P233, DOI 10.1016/S0921-8777(99)00031-2; Melov S, 1997, NUCLEIC ACIDS RES, V25, P974, DOI 10.1093/nar/25.5.974; Nyaga Simon G, 2002, Methods Mol Biol, V197, P227, DOI 10.1385/1-59259-284-8:227; Ogihara M, 2002, EXP MOL PATHOL, V73, P234, DOI 10.1006/exmp.2002.2442; PINZ KG, 1995, J BIOL CHEM, V270, P9202, DOI 10.1074/jbc.270.16.9202; Sokhansanj BA, 2002, NUCLEIC ACIDS RES, V30, P1817, DOI 10.1093/nar/30.8.1817; St-Pierre J, 2002, J BIOL CHEM, V277, P44784, DOI 10.1074/jbc.M207217200; WERAARCHAKUL N, 1989, EXP CELL RES, V181, P197, DOI 10.1016/0014-4827(89)90193-6	34	79	85	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2004	18	1					595	+		10.1096/fj.03-0890fje	http://dx.doi.org/10.1096/fj.03-0890fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	772EX	14734635	Green Submitted			2022-12-28	WOS:000188829300012
J	Schmitz, ML; Bacher, S; Dienz, O				Schmitz, ML; Bacher, S; Dienz, O			NF-kappa B activation pathways induced by T cell costimulation	FASEB JOURNAL			English	Review						IKK; Vav; PKC theta	KINASE-C-THETA; IMMUNOLOGICAL SYNAPSE; PKC-THETA; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; RECEPTOR SIGNALS; MEMBRANE RAFTS; IKK-GAMMA; PROTEIN; RECRUITMENT	Analysis of knockout mice and of T cells deficient for individual signaling proteins allowed the identification of novel members of the costimulation-induced NF-kappaB activation pathway while biochemical approaches started to unveil their functional mechanisms. These results show that NF-kappaB activation depends on an early wave of tyrosine phosphorylation that allows the inducible formation of multiprotein complexes containing several proteins required for NF-kappaB activation: adaptor proteins including Src homology 2 domain-containing leukocyte phosphoprotein 76 (SLP76) and proteins with enzymatic activity, such as phospholipase C (PLC) gamma and the exchange factor Vav1. While Vav1 contributes to Rac-dependent reorganization of the actin cytoskeleton, activated PLCgamma1 generates the protein kinase C (PKC) activator diacylglycerol. In T cells, the novel PKC isoform PKCtheta is indispensable for NF-kappaB activation and its enzymatic activity depends on recruitment to the immunological synapse. Downstream from PKCtheta, the caspase recruitment domain (CARD) proteins CARD11/CARMA1 and BcIl0 relay T cell receptor-derived signals to the IkappaB kinase (IKK) complex. Many members of the NF-kappaB activation cascade, including the IKKs, are either constitutively or inducibly translocated to the lipid raft fraction, showing a highly organized spatial distribution of these NF-kappaB activating proteins.	Univ Bern, Dept Chem & Biochem, CH-3012 Bern, Switzerland; Univ Vermont, Dept Med, Immunobiol Program, Burlington, VT USA	University of Bern; University of Vermont	Schmitz, ML (corresponding author), Univ Bern, Dept Chem & Biochem, Freiestr 3, CH-3012 Bern, Switzerland.	Lienhard.Schmitz@ibc.unibe.ch	Schmitz, M. Lienhard/D-9328-2017	Schmitz, M. Lienhard/0000-0002-6984-7192				ANDERSON MT, 1994, P NATL ACAD SCI USA, V91, P11527, DOI 10.1073/pnas.91.24.11527; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; Berridge MJ, 1997, CRIT REV IMMUNOL, V17, P155, DOI 10.1615/CritRevImmunol.v17.i2.30; Bertin J, 2001, J BIOL CHEM, V276, P11877, DOI 10.1074/jbc.M010512200; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bock BC, 2000, J BIOL CHEM, V275, P14231, DOI 10.1074/jbc.275.19.14231; Bromley SK, 2001, NAT IMMUNOL, V2, P1159, DOI 10.1038/ni737; Cao YJ, 2002, EMBO J, V21, P4809, DOI 10.1093/emboj/cdf499; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; Dienz O, 2000, J BIOL CHEM, V275, P24547, DOI 10.1074/jbc.C000177200; Dienz O, 2003, J IMMUNOL, V170, P365, DOI 10.4049/jimmunol.170.1.365; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Dustin ML, 2000, NAT IMMUNOL, V1, P23, DOI 10.1038/76877; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; Gaide O, 2002, NAT IMMUNOL, V3, P836, DOI 10.1038/ni830; Gaide O, 2001, FEBS LETT, V496, P121, DOI 10.1016/S0014-5793(01)02414-0; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; Guiet C, 2000, J CELL BIOL, V148, P1131, DOI 10.1083/jcb.148.6.1131; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 2000, MOL CELL BIOL, V20, P2556, DOI 10.1128/MCB.20.7.2556-2568.2000; Herndon TM, 2001, J IMMUNOL, V166, P5654, DOI 10.4049/jimmunol.166.9.5654; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Hughes K, 2001, J BIOL CHEM, V276, P36008, DOI 10.1074/jbc.M106125200; Isakov N, 2002, ANNU REV IMMUNOL, V20, P761, DOI 10.1146/annurev.immunol.20.100301.064807; Iwashima M, 2002, P NATL ACAD SCI USA, V99, P4544, DOI 10.1073/pnas.082647499; Kane LP, 2002, TRENDS IMMUNOL, V23, P413, DOI 10.1016/S1471-4906(02)02264-0; Kane LP, 2002, MOL CELL BIOL, V22, P5962, DOI 10.1128/MCB.22.16.5962-5974.2002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Krawczyk C, 2001, TRENDS CELL BIOL, V11, P212, DOI 10.1016/S0962-8924(01)01981-X; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Lin X, 2000, MOL CELL BIOL, V20, P2933, DOI 10.1128/MCB.20.8.2933-2940.2000; Lin X, 1999, IMMUNITY, V10, P271, DOI 10.1016/S1074-7613(00)80027-8; Matsumoto M, 2002, J IMMUNOL, V169, P1151, DOI 10.4049/jimmunol.169.3.1151; Monks CRF, 1997, NATURE, V385, P83, DOI 10.1038/385083a0; Ng PWP, 2001, ONCOGENE, V20, P4484, DOI 10.1038/sj.onc.1204513; Peters RT, 2000, MOL CELL, V5, P513, DOI 10.1016/S1097-2765(00)80445-1; Plyte S, 2000, ONCOGENE, V19, P1529, DOI 10.1038/sj.onc.1203451; Pomerantz JL, 2002, EMBO J, V21, P5184, DOI 10.1093/emboj/cdf505; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Poyet JL, 2001, J BIOL CHEM, V276, P3183, DOI 10.1074/jbc.C000792200; Reynolds LF, 2002, J EXP MED, V195, P1103, DOI 10.1084/jem.20011663; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Ruland J, 2001, CELL, V104, P33, DOI 10.1016/S0092-8674(01)00189-1; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEDWICK CE, 2002, SCI STKE, pRE2; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; Thome M, 2002, CURR BIOL, V12, pR45, DOI 10.1016/S0960-9822(01)00668-6; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Villalba M, 2002, J CELL BIOL, V157, P253, DOI 10.1083/jcb.200201097; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; Walk SF, 1998, EUR J IMMUNOL, V28, P2265, DOI 10.1002/(SICI)1521-4141(199808)28:08<2265::AID-IMMU2265>3.0.CO;2-P; Wang DH, 2002, NAT IMMUNOL, V3, P830, DOI 10.1038/ni824; Wang Y, 2001, CHINESE J ELECTRON, V10, P276; Weil R, 2003, IMMUNITY, V18, P13, DOI 10.1016/S1074-7613(02)00506-X; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Zhang GL, 2000, J ENDOTOXIN RES, V6, P453, DOI 10.1179/096805100101532414; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1	63	55	58	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	DEC	2003	17	15					2187	2193		10.1096/fj.02-1100rev	http://dx.doi.org/10.1096/fj.02-1100rev			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	763GX	14656980				2022-12-28	WOS:000188067500039
J	Kupershmidt, S; Yang, ICH; Hayashi, K; Wei, J; Chanthaphaychith, S; Petersen, CI; Johns, DC; George, AL; Roden, DM; Balser, JR				Kupershmidt, S; Yang, ICH; Hayashi, K; Wei, J; Chanthaphaychith, S; Petersen, CI; Johns, DC; George, AL; Roden, DM; Balser, JR			I-Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines	FASEB JOURNAL			English	Article						HERG; potassium channel; gating; pharmacology; arrhythmia; electrophysiology	RECTIFIER K+-CURRENT; LONG QT SYNDROME; OPEN-CHANNEL BLOCK; POTASSIUM CHANNEL; HERG; DOFETILIDE; CURRENTS; RECTIFICATION; ARRHYTHMIA; INACTIVATION	The cardiac potassium channel encoded by the human ether-a-go-go related gene (HERG) is blocked by a diverse array of common therapeutic compounds. Even transient exposure to such agents may provoke the life-threatening cardiac arrhythmia torsades de pointes in some, but not all, individuals. Although the molecular and genetic factors predicting such wide variability in drug response remain unclear, known sequence variations within the coding region of HERG do not explain the adverse drug response in many cases. Although other proteins can modulate HERG function, no studies have identified protein partners capable of limiting the pharmacological sensitivity of HERG. Here we show that KCR1, a protein identified previously in rat cerebellum, is a plasma membrane-associated protein expressed at the RNA level in the human heart and can be immunoprecipitated with HERG. Functionally, KCR1 reduces the sensitivity of HERG to classic proarrhythmic HERG blockers (sotalol, quinidine, dofetilide) in both cardiac and noncardiac cell lines. We propose that KCR1, when coupled to HERG, may limit the sensitivity of HERG to proarrhythmic drug blockade and may be a rational target for modifying the proarrhythmic effects of otherwise clinically useful compounds.	Vanderbilt Univ, Sch Med, Dept Anesthesiol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Johns Hopkins Univ, Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Johns Hopkins University	Kupershmidt, S (corresponding author), Vanderbilt Univ, Sch Med, Dept Anesthesiol, 554 Preston Res Bldg, Nashville, TN 37232 USA.	sabina.kupershmidt@vanderbilt.edu	Kupershmidt, Sabina/AAO-5464-2021; Roden, Dan/ABD-5412-2021	Kupershmidt, Sabina/0000-0002-8119-2723; 				Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; BALSER JR, 1991, CIRC RES, V69, P519, DOI 10.1161/01.RES.69.2.519; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Burda P, 1998, GLYCOBIOLOGY, V8, P455, DOI 10.1093/glycob/8.5.455; CARMELIET E, 1992, J PHARMACOL EXP THER, V262, P809; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Fiset C, 1996, J MOL CELL CARDIOL, V28, P1085, DOI 10.1006/jmcc.1996.0100; Gong JP, 1999, SCIENCE, V285, P1565, DOI 10.1126/science.285.5433.1565; Hoshi N, 1998, J BIOL CHEM, V273, P23080, DOI 10.1074/jbc.273.36.23080; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; JURKIEWICZ NK, 1993, CIRC RES, V72, P75, DOI 10.1161/01.RES.72.1.75; Kagan A, 2002, EMBO J, V21, P1889, DOI 10.1093/emboj/21.8.1889; Keating MT, 1996, SCIENCE, V272, P681, DOI 10.1126/science.272.5262.681; Kiehn J, 1996, CIRCULATION, V94, P2572, DOI 10.1161/01.CIR.94.10.2572; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; McDonald TV, 1997, NATURE, V388, P289, DOI 10.1038/40882; Roden DM, 1998, PACE, V21, P1029, DOI 10.1111/j.1540-8159.1998.tb00148.x; RODEN DM, 1993, AM J CARDIOL, V72, pB44, DOI 10.1016/0002-9149(93)90040-J; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1990, J GEN PHYSIOL, V96, P195, DOI 10.1085/jgp.96.1.195; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Sesti F, 2000, P NATL ACAD SCI USA, V97, P10613, DOI 10.1073/pnas.180223197; Sheng M, 1996, CURR OPIN NEUROBIOL, V6, P602, DOI 10.1016/S0959-4388(96)80091-2; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Snyders DJ, 1996, MOL PHARMACOL, V49, P949; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 1997, NAT GENET, V17, P338, DOI 10.1038/ng1197-338; Teschemacher AG, 1999, BRIT J PHARMACOL, V128, P479, DOI 10.1038/sj.bjp.0702800; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Weerapura M, 2002, J PHYSIOL-LONDON, V540, P15, DOI 10.1113/jphysiol.2001.013296; Weinshenker D, 1999, J NEUROSCI, V19, P9831; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Yang T, 1997, CIRC RES, V80, P782; YANG T, 1995, CIRC RES, V77, P1246, DOI 10.1161/01.RES.77.6.1246; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	42	40	46	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2263	+		10.1096/fj.02-1057fje	http://dx.doi.org/10.1096/fj.02-1057fje			19	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525949				2022-12-28	WOS:000186343300005
J	Luquet, S; Lopez-Soriano, J; Holst, D; Fredenrich, A; Melki, J; Rassoulzadegan, M; Grimaldi, PA				Luquet, S; Lopez-Soriano, J; Holst, D; Fredenrich, A; Melki, J; Rassoulzadegan, M; Grimaldi, PA			Peroxisome proliferator-activated receptor delta controls muscle development and oxydative capability	FASEB JOURNAL			English	Article						muscle development; lipid metabolism; hyperplasia; fiber typing; Cre-Lox transgenesis	SKELETAL-MUSCLE; PPAR-DELTA; TRANSGENE EXPRESSION; FATTY-ACIDS; STEM-CELLS; MICE; GAMMA; ADIPOSE; GROWTH; MOUSE	Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors exerting several functions in development and metabolism. The physiological functions of PPARdelta remain elusive. By using a CRE-Lox recombination approach, we generated an animal model for muscle-specific PPARdelta overexpression to investigate the role of PPARdelta in this tissue. Muscle-specific PPARdelta overexpression results in a profound change in fiber composition due to hyperplasia and/or shift to more oxidative fiber and, as a consequence, leads to the increase of both enzymatic activities and genes implicated in oxidative metabolism. These changes in muscle are accompanied by a reduction of body fat mass, mainly due to a large reduction of adipose cell size. Furthermore, we demonstrate that endurance exercise promotes an accumulation of PPARdelta protein in muscle of wild-type animals. Collectively, these results suggest that PPARdelta plays an important role in muscle development and adaptive response to environmental changes, such as training exercise. They strongly support the idea that activation of PPARdelta could be beneficial in prevention of metabolic disorders, such as obesity or type 2 diabetes.	Univ Nice, Ctr Biochim, INSERM, U470, F-06108 Nice 2, France; Hop Louis Pasteur, Serv Diabetol Endocrinol, F-06002 Nice, France; Genopole, INSERM, EMI 9913, F-91057 Evry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; CHU Nice; Genopole; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Grimaldi, PA (corresponding author), Univ Nice, Ctr Biochim, INSERM, U470, Parc Valrose, F-06108 Nice 2, France.	grimaldi@unice.fr	Luquet, serge/AAT-1809-2021; Rassoulzadegan, Minoo/O-7939-2016; Lopez-Soriano, Joaquin/AAB-7459-2019	Luquet, serge/0000-0001-8668-6645; Lopez-Soriano, Joaquin/0000-0002-5374-2222				Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900; AMRI EZ, 1995, J BIOL CHEM, V270, P2367, DOI 10.1074/jbc.270.5.2367; Barton ER, 2002, J CELL BIOL, V157, P137, DOI 10.1083/jcb.200108071; Bastie C, 2000, J BIOL CHEM, V275, P38768, DOI 10.1074/jbc.M006450200; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chawla A, 2003, P NATL ACAD SCI USA, V100, P1268, DOI 10.1073/pnas.0337331100; Cifuentes-Diaz C, 2001, J CELL BIOL, V152, P1107, DOI 10.1083/jcb.152.5.1107; Escher P, 2000, MUTAT RES-FUND MOL M, V448, P121, DOI 10.1016/S0027-5107(99)00231-6; Giuili G, 2002, EMBO REP, V3, P753, DOI 10.1093/embo-reports/kvf149; Hertz R, 1996, EUR J BIOCHEM, V235, P242, DOI 10.1111/j.1432-1033.1996.00242.x; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; ISHIHARA A, 1991, EUR J APPL PHYSIOL, V62, P211, DOI 10.1007/BF00643744; Jehl-Pietri C, 2000, BIOCHEM J, V350, P93, DOI 10.1042/0264-6021:3500093; Kelley G, 1996, J APPL PHYSIOL, V81, P1584, DOI 10.1152/jappl.1996.81.4.1584; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Leibowitz MD, 2000, FEBS LETT, V473, P333, DOI 10.1016/S0014-5793(00)01554-4; LeRoith D, 1995, ANN NY ACAD SCI, V766, P402, DOI 10.1111/j.1749-6632.1995.tb26689.x; Lim H, 1999, GENE DEV, V13, P1561, DOI 10.1101/gad.13.12.1561; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; McCall GE, 1996, J APPL PHYSIOL, V81, P2004, DOI 10.1152/jappl.1996.81.5.2004; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; Miniou P, 1999, NUCLEIC ACIDS RES, V27, DOI 10.1093/nar/27.19.e27; Musaro A, 2001, NAT GENET, V27, P195, DOI 10.1038/84839; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Niwa H, 1998, GENE DEV, V12, P2048, DOI 10.1101/gad.12.13.2048; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Oliver WR, 2001, P NATL ACAD SCI USA, V98, P5306, DOI 10.1073/pnas.091021198; Park BH, 2001, P NATL ACAD SCI USA, V98, P2598, DOI 10.1073/pnas.051630998; Peters JM, 2000, MOL CELL BIOL, V20, P5119, DOI 10.1128/MCB.20.14.5119-5128.2000; Poirier H, 2001, BIOCHEM J, V355, P481, DOI 10.1042/0264-6021:3550481; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; SEELBACH JD, 1985, INT J OBESITY, V9, P11; Spiegelman BM, 2000, INT J OBESITY, V24, pS8, DOI 10.1038/sj.ijo.0801492; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Yamauchi T, 2001, J BIOL CHEM, V276, P41245, DOI 10.1074/jbc.M103241200	38	413	435	0	36	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2003	17	13					2299	+		10.1096/fj.03-0269fje	http://dx.doi.org/10.1096/fj.03-0269fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	739KH	14525942				2022-12-28	WOS:000186343300012
J	Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E				Varani, K; Abbracchio, MP; Cannella, M; Cislaghi, G; Giallonardo, P; Mariotti, C; Cattabriga, E; Cattabeni, F; Borea, PA; Squitieri, F; Cattaneo, E			Aberrant A(2A) receptor function in peripheral blood cells in Huntington's disease	FASEB JOURNAL			English	Article						A(2A) adenosine receptor; blood circulating cells; Huntington's disease; biomarker	ADENOSINE RECEPTORS; LIGAND-BINDING; BIOCHEMICAL-CHARACTERIZATION; NEURODEGENERATIVE DISEASE; MEMBRANES; LYMPHOCYTES; MECHANISM; STRIATUM; SYSTEMS; MODELS	A(2A) adenosine receptors specifically found on striatal medium spiny neurons play a major role in sensory motor function and may also be involved in neuropsychiatric and neurodegenerative disorders. One hypothesis concerning Huntington's disease (HD) proposes that an imbalance of the cortico-striatal pathway, due to the mutation in the HD gene, leads to striatal vulnerability. An A(2A) receptor dysfunction has been previously demonstrated in striatal cells engineered to express mutant huntingtin. Here we tested whether a similar dysfunction (i.e., the binding and functional parameters of A(2A) adenosine receptors) is present in peripheral blood cells (platelets, lymphocytes, and neutrophils) of subjects carrying the mutant gene. This study involved 48 heterozygous and three homozygous patients compared with 58 healthy subjects. Moreover, we selected seven at-risk mutation carriers. A(2A) receptor density and function are substantially increased in peripheral blood cells from both patients and subjects at the presymptomatic stage. In the neutrophils of the three homozygous HD subjects receptor dysfunction was higher than in heterozygotes. These data indicate the existence of an aberrant A(2A) receptor phenotype in the peripheral blood cells of subjects carrying the HD mutation. Future studies will assess whether this parameter can be exploited as a peripheral biomarker of Huntington's disease.	IRCCS Neuromed, Neurogenet Unit, I-86077 Pozzilli, IS, Italy; Univ Ferrara, Dept Clin & Expt Med, Pharmacol Unit, I-44100 Ferrara, Italy; Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Fornaroli Hosp, Neurol Sect, Magenta, MI, Italy; IRCCS C Besta, Neurogenet Sect, Milan, Italy	IRCCS Neuromed; University of Ferrara; University of Milan; University of Milan	Squitieri, F (corresponding author), IRCCS Neuromed, Neurogenet Unit, Local Camerelle, I-86077 Pozzilli, IS, Italy.	neurogen@neuromed.it; elena.cattaneo@unimi.it	Squitieri, Ferdinando/N-1852-2019; Cannella, Milena/G-8291-2011; Mariotti, Caterina/AAP-9425-2021; Abbracchio, Maria Pia/B-9342-2014	Squitieri, Ferdinando/0000-0002-7397-1727; Mariotti, Caterina/0000-0003-2405-3564; Abbracchio, Maria Pia/0000-0002-7833-3388; CANNELLA, Milena/0000-0001-6284-9374; CATTANEO, ELENA/0000-0002-0755-4917	Telethon [GGP02185] Funding Source: Medline	Telethon(Fondazione Telethon)		Abbracchio MP, 1999, ANN NY ACAD SCI, V890, P79, DOI 10.1111/j.1749-6632.1999.tb07983.x; Barbanti P, 2000, CEPHALALGIA, V20, P15, DOI 10.1046/j.1468-2982.2000.00001.x; BENJAMIN CM, 1994, AM J HUM GENET, V55, P606; BLUM D, 2003, LANCET, V362, P366; Cannella M, 2001, NEUROL SCI, V22, P55, DOI 10.1007/s100720170044; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 1999, PHILOS T R SOC B, V354, P981, DOI 10.1098/rstb.1999.0449; Di Luca M, 1998, ARCH NEUROL-CHICAGO, V55, P1195, DOI 10.1001/archneur.55.9.1195; Draper N.R., 1998, APPL REGRESSION ANAL, P79; FERRE S, 1993, J NEUROSCI, V13, P5402, DOI 10.1523/JNEUROSCI.13-12-05402.1993; FREDHOLM BB, 1994, PHARMACOL REV, V46, P143; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Ilani T, 2001, P NATL ACAD SCI USA, V98, P625, DOI 10.1073/pnas.021535398; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P456, DOI 10.1016/S0165-6147(97)90683-0; Kieburtz K, 1996, MOVEMENT DISORD, V11, P136, DOI 10.1002/mds.870110204; Lawrence AD, 1998, BRAIN, V121, P1343, DOI 10.1093/brain/121.7.1343; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MAGGI R, 1993, PHARMACOL RES, V28, P351, DOI 10.1006/phrs.1993.1137; MARTINEZMIR MI, 1991, NEUROSCIENCE, V42, P697, DOI 10.1016/0306-4522(91)90038-P; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PARSONS B, 1995, J NEUROCHEM, V65, P2057; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Rovati GE, 1998, TRENDS PHARMACOL SCI, V19, P365; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Seubert CN, 2000, ANESTHESIOLOGY, V92, P567, DOI 10.1097/00000542-200002000-00041; Sipione S, 2001, MOL NEUROBIOL, V23, P21; Squitieri F, 2001, BRAIN RES BULL, V56, P233, DOI 10.1016/S0361-9230(01)00648-7; SQUITIERI F, 1994, HUM MOL GENET, V3, P2103, DOI 10.1093/hmg/3.12.2103; Squitieri F, 2003, BRAIN, V126, P946, DOI 10.1093/brain/awg077; Ujfalusi A, 1998, LIFE SCI, V64, pPL19, DOI 10.1016/S0024-3205(98)00547-5; Varani K, 2000, MOL PHARMACOL, V57, P968; Varani K, 1998, BRIT J PHARMACOL, V123, P1723, DOI 10.1038/sj.bjp.0701758; Varani K, 1996, BRIT J PHARMACOL, V117, P1693, DOI 10.1111/j.1476-5381.1996.tb15341.x; Varani K, 1999, BRIT J CLIN PHARMACO, V47, P167, DOI 10.1046/j.1365-2125.1999.00866.x; Varani K, 2003, FASEB J, V17, P2148, DOI 10.1096/fj.03-0079fje; Varani K, 2001, FASEB J, V15, P1245, DOI 10.1096/fj.00-0730fje; Varani K, 1997, BRIT J PHARMACOL, V122, P386, DOI 10.1038/sj.bjp.0701378; Vonsattel JPG, 1998, J NEUROPATH EXP NEUR, V57, P369	39	122	126	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2003	17	12					2148	+		10.1096/fj.03-0079fje	http://dx.doi.org/10.1096/fj.03-0079fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	732DG	12958155				2022-12-28	WOS:000185925100018
J	Nahoum, V; Gangloff, A; Shi, R; Lin, SX				Nahoum, V; Gangloff, A; Shi, R; Lin, SX			How estrogen-specific proteins discriminate estrogens from androgens: A common steroid-binding site architecture	FASEB JOURNAL			English	Article						"sandwich-like" structure; estrogen-specific; estrogen receptor; 17 beta-HSD1; estrogen sulfotransferase; convergent evolution	HUMAN 17-BETA-HYDROXYSTEROID DEHYDROGENASE; CRYSTAL-STRUCTURE; HUMAN-BREAST; ESTRADIOL; RECEPTOR; CANCER; C-19-DELTA-5-STEROIDS; 17-BETA-ESTRADIOL; SULFOTRANSFERASE; INTRACRINOLOGY	Steroid hormones play an essential role in a wide range of physiological and pathological processes, such as growth, metabolism, aging, and hormone-sensitive cancers. Estrogens are no exception and influence growth, differentiation, and functioning of many target tissues, such as the mammary gland, uterus, hypothalamus, pituitary, bone, and liver. Although very similar in structure, each steroid class (i.e., estrogens, androgens, progestins, mineral corticoids, or glucocorticoids) is responsible for distinct physiological processes. To permit specific biological responses for a given steroid class, specific proteins are responsible for steroid bioactivation, action, and inactivation, yet they have low or no affinity to other classes. Estrogens make no exception and possess their own set of related proteins. To understand the molecular basis underlying estrogen recognition from other steroids, structural features of estrogen-specific proteins were analyzed along with their ability to discriminate between steroid hormones belonging to different classes. Hence, the study of all estrogen-specific proteins for which an atomic structure has been determined demonstrated that a common steroid-binding pocket architecture is shared by these proteins. This architecture is composed of the following elements: i) a glutamate residue acting as a proton acceptor coupled with a proton donor that interact with the steroid O3; ii) a proton donor (His or Ser) that interacts with O17; iii) a highly conserved sandwich-like structure providing steric hindrance and preventing C19 steroid from binding; and iv) several amino acid residues interacting with the C18. As these different estrogen-specific proteins are not related in overall sequence, the inference is that the steroid binding site in these proteins has originated by convergent evolution.	CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, Quebec City, PQ G1V 4G2, Canada; Univ Laval, Quebec City, PQ, Canada	Laval University; Laval University	Lin, SX (corresponding author), CHU Laval, Res Ctr, Oncol & Mol Endocrinol Res Ctr, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sxlin@crchul.ulaval.ca		Gangloff, Anne/0000-0002-6848-6559; Nahoum, Virginie/0000-0003-3125-6618; Lin, Sheng-Xiang/0000-0001-9149-375X				AAKVAAG A, 1990, CANCER RES, V50, P7806; ADAMS JB, 1985, MOL CELL ENDOCRINOL, V41, P1, DOI 10.1016/0303-7207(85)90138-8; Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Ekena K, 1998, J BIOL CHEM, V273, P693, DOI 10.1074/jbc.273.2.693; Gangloff A, 2002, FASEB J, V16, P274, DOI 10.1096/fj.02-0397fje; Gangloff A, 2001, BIOCHEM J, V356, P269, DOI 10.1042/0264-6021:3560269; Han Q, 2000, J BIOL CHEM, V275, P1105, DOI 10.1074/jbc.275.2.1105; Huang YW, 2001, MOL ENDOCRINOL, V15, P2010, DOI 10.1210/me.15.11.2010; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Katzenellenbogen B S, 1979, Recent Prog Horm Res, V35, P259; KATZENELLENBOGEN BS, 1980, ANNU REV PHYSIOL, V42, P17, DOI 10.1146/annurev.ph.42.030180.000313; LABRIE F, 1991, MOL CELL ENDOCRINOL, V78, pC113, DOI 10.1016/0303-7207(91)90116-A; Lamminmaki U, 2001, J BIOL CHEM, V276, P36687, DOI 10.1074/jbc.M102367200; Mazza C, 1998, J BIOL CHEM, V273, P8145, DOI 10.1074/jbc.273.14.8145; Monnet C, 2002, J MOL BIOL, V315, P699, DOI 10.1006/jmbi.2001.5284; MURDOCK GL, 1988, BIOCHEMISTRY-US, V27, P4452, DOI 10.1021/bi00412a036; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; POULIN R, 1986, CANCER RES, V46, P4933; Puranen T, 1997, MOL ENDOCRINOL, V11, P77, DOI 10.1210/me.11.1.77; READ LD, 1991, CHARACTERIZATION REG; Sarrel P.M., 1994, SCI MED, V1, P44; Sasano H, 2000, ONCOLOGY-BASEL, V59, P5, DOI 10.1159/000055281; SIMARD J, 1988, MOL CELL ENDOCRINOL, V55, P233, DOI 10.1016/0303-7207(88)90138-4; SIMARD J, 1987, J STEROID BIOCHEM, V26, P539, DOI 10.1016/0022-4731(87)90005-7; Suzuki T, 2000, BRIT J CANCER, V82, P518; Trinh CH, 1997, STRUCTURE, V5, P937, DOI 10.1016/S0969-2126(97)00247-5; Yue W, 1998, CANCER RES, V58, P927	31	36	36	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1334	+		10.1096/fj.02-0524fje	http://dx.doi.org/10.1096/fj.02-0524fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	12759331				2022-12-28	WOS:000183165000013
J	Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M				Catalano, A; Caprari, P; Soddu, S; Procopio, A; Romano, M			5-Lipoxygenase antagonizes genotoxic stress-induced apoptosis by altering p53 nuclear trafficking	FASEB JOURNAL			English	Article; Proceedings Paper	8th International Conference on Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases	SEP, 2003	Chicago, IL			eicosanoids; mesothelioma	CANCER-THERAPY; MALIGNANT MESOTHELIOMA; LEUKOTRIENE SYNTHESIS; CELL-SURVIVAL; EXPRESSION; PROTEIN; CYCLOOXYGENASE-2; OVEREXPRESSION; BIOSYNTHESIS; LINES	5-Lipoxygenase (5-LO) promotes cancer cell proliferation and survival by unclear mechanisms. Here, we show that 5-LO expression and activity were induced by genotoxic agents in a p53-independent manner and antagonized p53- or genotoxic drug-induced apoptosis in a variety of cancer cells. 5-LO inhibited p53- governed transactivation of the pro-apoptotic genes bax and pig3 but not of p21(WAF1/CIP1) or mdm2. This may be explained by 5-LO capability to inhibit the binding of p53 to promyelocytic leukemia protein (PML) and p53 subnuclear relocalization into PML-nuclear bodies in response to genotoxic stress. Interestingly, 5-LO activity appears to be involved in nuclear retention and inactivation of wild-type p53 in malignant mesothelioma cells. In these cells, genetic or pharmacological inhibition of 5-LO enabled suppression of in vitro tumorigenicity by low doses of chemotherapeutic drugs. Together, these results uncover novel functions of 5-LO and contribute to the understanding of 5-LO involvement in tumor progression. Moreover, they provide a rationale to the therapeutic use of 5-LO inhibitors to enhance cancer chemosensitivity in selected tumors.	Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, I-60131 Ancona, Italy; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Rome, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Dept Biomed Sci, Chieti, Italy; Gabriele DAnnunzio Univ Fdn, CeSI, Aging Res Ctr, Chieti, Italy; NCI, Neural Dev Grp, Mouse Canc Genet Program, Frederick, MD 21701 USA	Marche Polytechnic University; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; G d'Annunzio University of Chieti-Pescara; G d'Annunzio University of Chieti-Pescara; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Catalano, A (corresponding author), Univ Politecn Marche, Dipartimento Patol Mol & Terapie Innovat, Via Ranieri, I-60131 Ancona, Italy.	catgfp@yahoo.it	Soddu, Silvia/K-2467-2018; Procopio, Antonio Domenico/AAB-2451-2021; Soddu, Silvia/ABH-6774-2020; Romano, Mario/I-7986-2012	Soddu, Silvia/0000-0001-8526-0044; Procopio, Antonio Domenico/0000-0001-6897-8724; Soddu, Silvia/0000-0001-8526-0044; Romano, Mario/0000-0001-8512-1458				Avis I, 2001, FASEB J, V15, P2007, DOI 10.1096/fj.00-0866fje; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Catalano A, 2004, CRIT REV ONCOL HEMAT, V50, P101, DOI 10.1016/j.critrevonc.2003.10.001; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Catalano A, 2001, AM J PATHOL, V159, P721, DOI 10.1016/S0002-9440(10)61743-9; Chen XS, 1998, J BIOL CHEM, V273, P31237, DOI 10.1074/jbc.273.47.31237; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Ghosh J, 1998, P NATL ACAD SCI USA, V95, P13182, DOI 10.1073/pnas.95.22.13182; GIACCIA AJ, 1998, GENE DEV, V14, P2015; GOETZL EJ, 1995, FASEB J, V9, P1051, DOI 10.1096/fasebj.9.11.7649404; Gupta S, 2001, CANCER-AM CANCER SOC, V91, P737, DOI 10.1002/1097-0142(20010215)91:4<737::AID-CNCR1059>3.0.CO;2-F; Han JA, 2002, EMBO J, V21, P5635, DOI 10.1093/emboj/cdf591; Hennig R, 2002, AM J PATHOL, V161, P421, DOI 10.1016/S0002-9440(10)64198-3; Hong SH, 1999, CANCER RES, V59, P2223; Liu CH, 2001, J BIOL CHEM, V276, P18563, DOI 10.1074/jbc.M010787200; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Peters-Golden M, 2000, AM J RESP CRIT CARE, V161, pS36, DOI 10.1164/ajrccm.161.supplement_1.ltta-8; Prives C, 1999, J PATHOL, V187, P112; REID GK, 1990, J BIOL CHEM, V265, P19818; Romano M, 2003, FASEB J, V17, P1986, DOI 10.1096/fj.03-0053rev; Romano M, 2001, FASEB J, V15, P2326, DOI 10.1096/fj.01-0150com; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Toschi E, 2000, J INVEST DERMATOL, V114, P1188, DOI 10.1046/j.1523-1747.2000.00000.x; Vivo C, 2003, BRIT J CANCER, V88, P388, DOI 10.1038/sj.bjc.6600736; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Woo CH, 2000, J BIOL CHEM, V275, P32357, DOI 10.1074/jbc.M005638200	35	102	104	0	2	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2004	18	12					1740	+		10.1096/fj.04-2258fje	http://dx.doi.org/10.1096/fj.04-2258fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	15375079	Green Published			2022-12-28	WOS:000224243200022
